5,018 Matching Annotations
  1. Nov 2020
    1. Reviewer #3:

      This manuscript reports results from an eye tracking study of humans walking in natural terrain. These eye movements together with images simultaneously obtained by a head-fixed camera are used to calculate optic flow fields as seen by the retina and as seen by the head-fixed camera. Next, the structure of these flow fields is described. It is noted that this structure is somewhat stable in the retinal image, due to compensatory gaze stabilisation reflexes, but varies wildly in the head-centric image. Then, the authors estimate the focus of expansion in the head-centric flow and argue that it cannot be used for locomotor control, because it also varies wildly during walking. In a second, more theoretical section of the manuscript, they calculate retinal flow for a movement over an artificial ground plane, given the locomotor and eye movements recorded previously. They describe the structure of the retinal flow and compute the distribution of curl and divergence across the retina as well as in a projection onto the ground plane. They argue that curl around the fovea and the location of the maximum of divergence can be used to estimate the direction of walking relative to the direction of gaze and in relation to the ground plane.

      I really like the experimental part of the study. However, I see fundamental issues in the theoretical part, in the general framing of the presentation, and in misrepresentations of previous literature.

      The simultaneous measurement of head-centric image and gaze with sufficient temporal resolution to calculate retinal flow during natural walking provides a beautiful demonstration of retinal flow fields, and confirms many known aspects of retinal flow. The calculation of head-centric flow from the head camera images provides a compelling, though not unexpected, demonstration that the FOE in head-centric flow is not useful for locomotor control. It is not unexpected since one of the most well-known issues in optic flow is that the FoE is destroyed when self-motion contains rotational components (Regan and Beverley, 1982, Warren and Hannon, 1990, Lappe et al. 1999). Although this is often presented as an issue of eye movements in retinal flow, it applies to all rotations and combinations of rotations that exist on top of any translational motion of the observer. Thus, the oscillatory bounce and sway motion of the head during walking is expected to render any use of the FOE in a head-centric image futile.

      Yet, the first part of the manuscript is very much framed as a critique of the idea of a stable FoE in head-centric flow, presuming that this is what previous researchers commonly believed. This argument contains a logical fallacy. Previous research argued that there is no FoE in retinal flow because of eye rotations (e.g. Warren and Hannon, 1990). This does not predict, inversely, that there is an FoE in head-centric flow. In fact, it does not provide any prediction on head-centric flow. The authors often suggest that a stable FoE in head-centric flow is tacitly implied, commonly believed, etc without providing reference. In fact, the only paper I know that specifically proposed a head-centric representation of heading is by van den Berg and Beintema (1997).

      Instead, the fundamental problem of heading perception is to estimate self-motion from retinal flow when the self-motion that generates retinal flow combines all kinds of translations and rotations. The present study shows, consistent with much of the prior literature, that the patterns of retinal flow are sufficiently stable and informative to obtain the direction of one's travel in a retinal frame of reference, and, via projection, with respect to the ground plane. This is due to the stabilising gaze reflexes that keep motion small near the fovea and produce (in case of a ground plane) a spiralling pattern of retinal flow. This is well known from theoretical and lab studies (e.g. Warren and Hannon, 1990, Lappe et al., 1998, Niemann et al., 1999, Lappe et al. 1999) and, to repeat, beautifully shown for the natural situation in the present data. The presentation should link back to this work rather than trying to shoot down purported mechanisms that are obviously invalid.

      The second part of the manuscript presents a theoretical analysis of the retinal flow for locomotion across a ground plane under gaze stabilisation. This has two components: (a) the structure of the retinal flow and the utility of gaze stabilisation, and (b) ways to recover information about self-motion from the retinal flow. Both aspects have a long history of research that is neglected in the present manuscript. The essential circular structure of the retinal flow during gaze stabilisation is long known (Warren and Hannon, 1990, van den Berg, 1996, Lappe et al., 1998, Lappe et al. 1999). Detailed analyses of the statistical structure of retinal flow during gaze stabilisation have shown the impact and utility of gaze stabilisation (Calow et al., 2004; Calow and Lappe, 2007; Roth and Black, 2007) and provided links to properties of neurons in the visual system (Calow and Lappe, 2008). These studies included simulated motions of the head during walking, as in the current manuscript, and extended to natural scenes other than a simple ground plane.

      Given the structure of the retinal flow during gaze stabilisation the central question is how to recover information about self-motion from it. The authors investigate a proposal originally made by Koenderink and van Doorn (1976; 1984) that relies on estimates of curl and divergence in the visual field. They propose that locomotor heading may be determined directly in retinotopic coordinates (l. 314). This is true, but it fails to mention that other models of heading perception during gaze stabilisation similarly determine heading in retinotopic coordinates (e.g. Lappe and Rauschecker, 1993; Perrone and Stone, 1994; Royden, 1997). In fact, as outlined above, the mathematical problem of self-motion estimation is typically presented in retinal (or camera) coordinates (e.g. Longuet-Higgins and Prazdny, 1980). The problem with the divergence model in comparison to the other models above is threefold. First, it really only works for a plane, not in other environments. Second, it requires a local estimate of divergence at each position in the visual field. The alternative models above combine information across the visual field and are therefore much more robust against noise in the flow. One would need to see whether the estimate of the divergence distribution is sufficient to work with the natural flow fields. Third, being a local measure it requires a dense flow field while heading estimation from retinal flow is known to work with sparse flow fields (Warren and Hannon, 1990). Thus, the theoretical part of the manuscript should either provide proof that the maximum of divergence is superior to these other models or broaden the view to include these models as possibilities to estimate self motion from retinal flow.

      The case is similar for the use of curl. It is true that the rotational or spiral pattern around the fovea in retinal flow provides information about the direction of self motion with respect to the direction of gaze, as has been noted many times before. This structure is used by many models of heading estimation. However, curl is, like divergence, a local property and thus not as robust as models that use the entire flow field. It may be interesting to note that neurons in optic flow responsive areas of the monkey brain can pick up this rotational pattern and respond to it in consistency with their preference for self-motion across a plane (Bremmer et al., 2010; Kaminiarz et al. 2014).

      I think what the authors may want to draw more attention to is the dynamics of the retinal flow and the associated self-motion in retinal (or plane projection) coordinates. The movies provide compelling illustrations of how the direction of heading (or the divergence maximum, if you want to focus on that) sways back and forth on the retina and on the plane with each step. This requires that the analysis of retinal flow (and the estimation of self-motion) has to be fast and dynamic, or maybe should include some form of temporal prediction or filtering. Work on the dynamics of retinal flow perception has indeed shown that heading estimation can work with very brief flow fields (Bremmer et al. 2017), that the brain focuses on instantaneous flow fields (Paolini et al. 2000) and that short presentations sometime provide better heading estimates than long presentations (Grigo and Lappe, 1999). The temporal dynamics of retinal flow is an underappreciated problem that could be more in the focus of the present study.

      Additional specific comments:

      Footnote on page 2: It is not only VOR but also OKN (Lappe et al., 1998, Niemann et al., 1999) that stabilises gaze in optic flow fields.

      Line 55: Natural translation and acceleration patterns of the head have been considered by (Cutting et al., 1992; Palmisano et al. 2000; Calow and Lappe, 2007, 2008; Bossard et al., 2016)

      Line 59: The statement is misleading that the key assumption behind work on the rotation problem is that the removal of the rotational component of flow will return a translational flow field with a stable FoE. Only one class of models, those using differential motion parallax (Rieger and Lawton, 1985, Royden, 1997) explicitly constructs a translational flow field and aims to locate the FoE in that field. Other models (Koenderink and van Doorn, 1976, 1984; Lappe and Rauschecker, 1993; Perrone and Stone, 1994) do not subtract the rotation but estimate heading in retinal coordinates from the combined retinal flow. This also applies to line 109.

      Last paragraph on page 5: Measures of eye movement during walking in natural terrain were also taken by Calow and Lappe (2008) and 't Hart and Einhäuser (2012).

      Lines 140 to 163: This paragraph is problematic and misleading as pointed out before.

      Line 193: The lack of stability is expected, as outlined above. The use of a straight line motion in psychophysical experiments reflects an experimental choice to investigate the rotation problem in retinal flow, not an implicit assumption that bodily motion is usually along a straight line.

      Line 200: That gaze stabilization may be an important component in understanding the use of optic flow patterns has also long been assumed (Lappe and Rauschecker, 1993; 1994; 1995; Perrone and Stone, 1994; Glennerster et al. 2001; Angelaki and Hess, 2005; Pauwels et al., 2007).

      Line 314: Locomotor heading may be determined directly in retinotopic coordinates. Yes, and this is precisely what the above mentioned models do.

      Line 334: What is meant by "robust" here? The videos seem to show simulated flow for a ground plane, not the real flow from any of the terrains. It is not clear whether the features can be extracted from the real terrain retinal flow.

      First paragraph on page 15: This is an important discussion about the dynamics of retinal flow in conjunction with the dynamics of the gait cycle. It should be expanded and better balanced with respect to previous work and other models. It is true that any simple inference of an FoE would not work. However, models that estimate heading (not FoE) in the retinal reference frame would be consistent with the discussion. Oscillations of the head during walking affect the location of the divergence maximum and curl as much as the direction of heading in retinal coordinates. In fact, the videos nicely show how these variables oscillate with each step. This applies to all retinal flow analyses, and is a problem for any model. It requires a dynamical analysis. The speed of neural computations is an issue, of course, but it applies to divergence and curl in the same way as to other models. There is some indication, however, that neural computations on optic flow are fast, deal with instantaneous flow fields, and respond consistently to natural (spiral) retinal flow, as described above.

      Line 393: This paragraph is misleading in suggesting that naturally occurring flow fields have not been used in psychophysical and electrophysiological experiments.

      Line 516: This has been done by Bremmer et al. (2010) and Kaminiarz et al. (2014). Their results are consistent with computing heading directly in a retinal reference frame as predicted by several models of retinal flow analysis (e.g. Lappe et al. 1999).

      References:

      Angelaki, D. E. and Hess, B. J. M. (2005). Self-motion-induced eye movements: effects an visual acuity and navigation. Nat. Rev. Neurosci., 6:966-976.

      Bossard, M., Goulon, C., and Mestre, D. R. (2016). Viewpoint oscillation improves the perception of distance travelled based on optic flow. J Vis, 16(15):4.

      Bremmer, F., Kubischik, M., Pekel, M., Hoffmann, K. P., and Lappe, M. (2010). Visual selectivity for heading in monkey area MST. Exp. Brain Res., 200(1):51-60.

      Calow, D., Krüger, N., Wörgötter, F., and Lappe, M. (2004). Statistics of optic flow for self-motion through natural scenes. In Ilg, U., Bülthoff, H. H., and Mallot, H. A., editors, Dynamic Perception, Workshop of the GI Section 'Computer Vision', pages 133-138, Berlin. Akademische Verlagsgesellschaft Aka GmbH.

      Calow, D. and Lappe, M. (2007). Local statistics of retinal optic flow for self- motion through natural sceneries. Network, 18(4):343-374.

      Calow, D. and Lappe, M. (2008). Efficient encoding of natural optic flow. Network Comput. Neural Syst., 19(3):183-212.

      Cutting, J. E., Springer, K., Braren, P. A., and Johnson, S. H. (1992). Wayfinding on foot from information in retinal, not optical, flow. J. Exp. Psychol. Gen., 121(1):41-72.

      Grigo, A. and Lappe, M. (1999). Dynamical use of different sources of information in heading judgments from retinal flow. JOSA A, 16(9):2079-2091.

      't Hart, B. M. and Einhäuser, W. (2012). Mind the step: complementary effects of an implicit task on eye and head movements in real-life gaze allocation. Exp. Brain Res., 223(2):233-249.

      Kaminiarz, A., Schlack, A., Hoffmann, K.-P., Lappe, M., and Bremmer, F. (2014). Visual selectivity for heading in the macaque ventral intraparietal area. J. Neurophys. 112(10):2470-80

      Lappe, M., Pekel, M., and Hoffmann, K. P. (1998). Optokinetic eye movements elicited by radial optic flow in the macaque monkey. J. Neurophysiol., 79(3):1461-1480.

      Lappe, M. and Rauschecker, J. P. (1993). A neural network for the processing of optic flow from ego-motion in man and higher mammals. Neural Comp., 5(3):374-391.

      Lappe, M. and Rauschecker, J. P. (1994). Heading detection from optic flow. Nature, 369(6483):712-713.

      Lappe, M. and Rauschecker, J. P. (1995). Motion anisotropies and heading detection. Biol. Cybern., 72(3):261-277.

      Niemann, T., Lappe, M., Büscher, A., and Hoffmann, K. P. (1999). Ocular responses to radial optic flow and single accelerated targets in humans. Vision Res., 39(7):1359-1371.

      Pauwels, K., Lappe, M., and Hulle, M. M. (2007). Fixation as a mechanism for stabilization of short image sequences. Int. J. Comp. Vis., 72(1):67-78.

      Perrone, J. A. and Stone, L. S. (1994). A model of self-motion estimation within primate extrastriate visual cortex. Vision Res., 34(21):2917-2938.

      Regan, D. and Beverley, K. I. (1982). How do we avoid confounding the direction we are looking and the direction we are moving? Science, 215:194-196.

      Rieger, J. H. and Lawton, D. T. (1985). Processing differential image motion. J. Opt. Soc. Am. A, 2(2):354-360.

      Roth, S. and Black, M. J. (2007). On the spatial statistics of optical flow. Int. J. Comp. Vis., 74(1):33-50.

      Royden, C. S. (1997). Mathematical analysis of motion-opponent mechanisms used in the determination of heading and depth. J. Opt. Soc. Am. A, 14(9):2128-2143.

      van den Berg, A. V. (1996). Judgements of heading. Vision Res., 36(15):2337-2350.

      van den Berg, A. V. and Beintema, J. A. (1997). Motion templates with eye velocity gain fields for transformation of retinal to head centric flow. NeuroReport, 8(4):835-840.

  2. Oct 2020
    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Please note that the authors have provided a formatted PDF version of this rebuttal, including additional figures and references, via the Open Science Framework: https://osf.io/5acqp/

      Reviewer #1

      This is an interesting and thorough study characterising human iPSC with hetero or homozygous mutation in pi3k pathway that lead to its hyper-activation. They prove that the increased stemness results from enhanced autocrine responsiveness to TGF signalling pathway. The main conclusions are well supported by the presented data. Cutting edge tools and bioinformatic analysis are adequately applied. I have only one important point:

      1) Western blot based validation of TGF pathway activation in wt and mutant iPSCs will be helpful to strengthen the results based on bioinformatic data.

      AUTHORS’ RESPONSE__:__ We thank the Reviewer for the positive evaluation of our work.

      Functional validation of the signalling hypothesis is indeed important, and we did in fact already present supportive data. Current evidence suggests that SMAD2 is the main transcription factor mediating actions of the TGFb/NODAL pathway in an early developmental context [1,2], and we have shown increased phosphorylation of SMAD2 (S465/S467) in PIK3CAH1047R/H1047R iPSCs using RPPA in the two datasets shown in Fig.2.

      We have attempted to demonstrate increased NODAL protein directly in PIK3CAH1047R/H1047R cells, but have been unsuccessful due to poor signal on immunoblotting. We thus opted for functional testing of our hypothesis using the experiment presented in Fig. 5, wherein TGFb (a surrogate for NODAL) is removed from the culture medium. Human iPSCs depend strictly on TGFb/NODAL for maintenance of NANOG expression and thus pluripotency [3,4]. Upon exclusion of TGFb/NODAL from the culture medium of normal human iPSCs, the early responses (prior to overt differentiation) are expected to be: (A) decreased NODAL expression, due to well-established autoregulation [2], then (B) a decrease in NANOG and ultimately POU5F1 (OCT3/4) mRNA levels (see also Introduction, lines 80-90). The evidence in Fig. 5 that PIK3CAH1047R/H1047R fail to exhibit these responses upon exogenous TGFb/NODAL removal supports the notion that these cells autonomously sustain TGFb/NODAL signalling.

      For improved clarity, we have also added the following information to the revised manuscript:

      lines 202-205: “This is consistent with strong NODAL mRNA upregulation and increased pSMAD2 (S465/S467) in PIK3CAH1047R/H1047R iPSCs in the current study (Dataset S2 and RPPA data in Fig. 2, respectively), and with prior evidence of activation of the NODAL/TGFb pathway in homozygous PIK3CAH1047R iPSCs.”

      Reviewer #2

      In this manuscript, Madsen et al have investigated the role of heterozygous versus homozygous PIK3CAH1047R gain-of-function mutation at maintaining stemness of induced pluripotent stem cells (iPSCs). The authors have performed high-depth RNAseq, proteomic, and RPPA analyses to show that biallelic PIK3CA alterations induce stronger activation of the PI3K signaling axis, compared to monoallelic mutations. The authors claim that a higher PI3K signaling dose activates the NODAL/TGF-b pathway, which in turn supports stemness in an autocrine fashion. These are important findings, however, the manuscript and its conclusions can be improved.

      AUTHORS’ RESPONSE__:__ We thank the Reviewer for acknowledging the importance of the work and for their constructive suggestions for improvements.

      The authors have described the role of PIK3CAH-1047R gain-of-function mutation in cancer and overgrowth syndromes. However, cancer associated somatic mutations in PIK3CA are mostly heterozygous. Similarly, PIK3CA related overgrowth syndromes (PROS) are caused by post-zygotic mosaic PIK3CA activating mutation. As such, the relevance of homozygous PIK3CA alterations to these pathological conditions is unclear. The authors should elaborate on the biological implications of their findings.

      AUTHORS’ RESPONSE__:__ We disagree with the Reviewer’s comment which implies that homozygous PIK3CA mutations are not relevant to many cancers. In our previous work [5], we provided evidence that many human cancers harbour multiple PIK3CA mutant alleles. Specifically, among cancers with a unique PIK3CA mutation, approximately 50% exhibit multiple copies according to allele copy number analysis. We further demonstrated that a substantial proportion of cancers have multiple different PIK3CA variants or additional oncogenic ‘hits’ within the pathway. These findings have been supported by other recent high-profile papers [6–8]. Such multiple alterations increase activity of the PI3K pathway beyond the level seen with heterozygosity alone [5,6]. This substantial body of literature renders our PIK3CAH1047R iPSC model system highly relevant for studying disease-relevant, dose-dependent oncogenic PIK3CA activation.

      The Reviewer is correct, however, that PROS is caused by postzygotic heterozygous PIK3CA mutations almost exclusively. Observations in homozygous cells are therefore not directly relevant to the pathogenesis of PROS. On the other hand, the heterozygous cells are closely relevant, being human, carefully matched with isogenic controls, and unperturbed by further manipulations such as artificial immortalisation. Our prior studies demonstrated no clear phenotypes in heterozygous cells in the iPSC differentiation paradigm, despite the rock solid causal nature of heterozygous mutations in PROS. This negative finding, surprising given the dramatic PROS phenotypes, is very important in understanding how best to create disease-relevant PROS models. One intent of the current study was to increase the sensitivity of our transcriptomic analysis, and to combine this with proteomic studies to determine if heterozygous cells really do not exhibit a phenotype. We now show that there are indeed faint echoes in heterozygous cells of the dramatic changes in homozygous cells. We believe that the human growth phenotype is a summative consequence of such small differences in growth behaviours sustained over months and years, highlighting how subtle difference in signalling can lead to dramatic human growth consequences across the lifecourse. Similar observations were also recently made following systematic analyses of oncogenic RAS mutations [9]. The new information we present about heterozygous PIK3CAH1047R cells, while much less “showy” than the cancer-relevant behavious of homozygous cells, we thus contend is very important for understanding of the PROS phenotype and its experimental modelling. To emphasise this point, we have added the following statements to the abstract and discussion, respectively.

      • lines 56-57: “This work illustrates the importance of allele dosage and expression when artificial systems are used to model human genetic disease caused by activating PIK3CA mutations.”
      • lines 104-106: “We discuss the implications of our findings for understanding and modelling developmental disorders and cancers driven by genetic PI3K activation.”
      • lines 333-340: “Finally, our observations are important for future studies seeking to model human PIK3CA-related diseases. The modest changes observed in heterozygous PIK3CAH1047R cells, in sharp contrast to the radical transcriptional alterations in homozygous cells, emphasise the importance of careful allele dose titration when artificial overexpression systems are used to model disorders caused by genetic PIK3CA activation. Our findings in heterozygous cells are also a reminder that very small effect sizes in cellular systems may summate and result in major human phenotypes over a life course. That such minor changes are found in a cellular study of a rare and severe disorder emphasises the challenges of modelling much more subtle disease susceptibility conferred by GWAS-detected genetic associations, where cellular effect sizes are likely to be smaller still.”

        The role of biallelic PIK3CA mutation is reminiscent of compound mutations in PIK3CA which have also been shown to increase PI3K signaling output. However, double PIK3CA mutations confer enhanced sensitivity to PI3K inhibition (Toska et al. Science 2019). Could the authors kindly speculate on this discrepancy.

      AUTHORS’ RESPONSE: We emphasise first that PIK3CAH1047R/H1047R cells do respond to BYL719 at the signalling level, as demonstrated previously [5] and in the manuscript (revised Figure S5; see also additional Western blot below). Our point is that the cells have undergone a switch to self-sustained stemness. That is, while PIK3CA activation was the driver of the initial change in cell state, the induced stemness phenotype is no longer reversed by removal of that trigger, with our data suggesting that this is now driven by self-sustained TGFb/NODAL signalling. This is in line with the role of this pathway in the maintenance of the pluripotent state. We speculate that this may be important in a cancer context where surviving stem cells may permit cancer persistence after toxic therapies, even if short term growth of tumours is reduced by agents such as PI3K inhibitors.

      Our data are not directly comparable to prior cellular data, for example in Vasan et al. [6], due to: (a) use of different cell model system and (b) assessment of different functional responses. We would also sound some methodological notes of caution re some of the prior studies alluded to, as potentially confounding differences in growth rate in the cells studied was not corrected for. It is well-established that IC50 and Emax values depend on cell division rates, and failure to correct for this can result in artefactual correlations between genotype and drug sensitivity (see, e.g., Hafner et al. Nature Methods 2016: “Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs” [10]**).

      Similarly, the p110 alpha specific inhibitor, alpelisib, is highly effective against PIK3CA-mutant ER+ breast cancer and PROS. As such, the clinical relevance of the insensitivity of homozygous PIK3CA mutation to PI3K inhibitors is unclear.

      AUTHORS’ RESPONSE__:__ Efficacy of Alpelisib in PROS is currently supported only by unregistered observational studies, but is nevertheless striking. It is not relevant to our findings in homozygous cells, as the Reviewer has previously observed, however.

      As for cancer, in a randomised phase 3 trial that compared Alpelisib/BYL719 with fulvestrant to fulvestrant alone, the overall response (irrespective of PIK3CA mutant status) was indeed greater with the combination treatment (26.6 % vs 12.8 %), with a hazard ratio of 0.65 (95% CI, 0.5 to 0.85) in patients with PIK3CA-mutant caners versus a hazard ratio of 0.85 (95% CI, 0.58 to 1.25) in those without a PIK3CA mutation [11]. This trial demonstrated the utility of additional PIK3CA mutant-centric stratification, but a substantial proportion of patients with PIK3CA-mutant tumours (>50%) did not benefit from the BYL719 and fulvestrant combination [11]. However, these observations are not directly relevant to this manuscript and are instead included in a separate manuscript focused on PI3K signalling and stemness in human breast cancers (preprint [12]**).

      Figure 2: The authors have performed RPPA analysis in the presence of 100 nM BYL719. Alpelisib is commonly used at 1 uM concentration for in-vitro experiments, and has a cMax of ~5 uM. We suggest the authors perform western blot analysis to confirm the results of RPPA.

      AUTHORS’ RESPONSE__:__ We carefully chose the optimal concentration of BYL719 to preserve inhibitor selectivity, and to avoid undue toxicity and confounding off-target effects, rather than copying the dose “commonly used”. The Cmax is not relevant to our use of BYL719 in the current study as a precise tool compound. We refer the Reviewer to the known pharmacological characteristics of this compound [13,14]. According to available evidence, it is only a selective PI3Kα inhibitor at concentrations 250 nM (Table below adapted from Ref. **[13]; for formatted version, please see PDF version: https://osf.io/ecmhr/)

      Enzyme

      In vitro IC50 for NVP-BYL719 (nM)

      PI3Kα

      4.6 +/- 0.4

      PI3Kα-H1047R

      4.8 +/- 0.4

      PI3K**b

      1156 +/- 77

      PI3K**d

      290 +/- 180

      PI3K**g

      250 +/- 140

      PI4K**b

      571 +/- 42

      We have previously demonstrated (Fig. 2C in Ref. [5]) that 100 nM BYL719 is sufficient to restore pAKT (S473) levels in both heterozygous and homozygous PIK3CAH1047R to levels observed in WT cells. This is consistent with the RPPA data reported in the current work (Fig. 2B). Of note, while 500 nM BYL719 completely ablates pAKT irrespective of genotype, we previously noted substantial toxicity [5], precluding use of this or higher doses of BYL719 in our model system. This is in line with a recent Nature Cell Biology study by Yilmaz et al. ([15]) which demonstrated the essential growth-promoting role of the PI3K pathway in human pluripotent stem cells; Yilmaz et al. also demonstrate that compared to somatic cells (fibroblasts), human pluripotent stem cells suffer dramatic effects on growth/survival in response to Torin1/rapamycin [15], overall suggesting that this cell type is exquisitely sensitive to inhibition of the PI3K/AKT/mTOR pathway.

      In the present study we have also confirmed that 250 nM BYL719, used for Fig. 5 experiments, has worked as expected at the level of pAKT (S473) as shown in the below Western blot (see also revised Fig. S5; please access PDF version to view Western blot: https://osf.io/ecmhr/)

      Figures 3 and 4: The authors should expand their RNAseq analysis to demonstrate enrichment of stemness and TGFb signaling in homozygous mutant cells compared to heterozygous cells.

      AUTHORS’ RESPONSE__:__ We thank the Reviewer for this suggestion. The unsupervised MDS plot (Fig. 1A) clearly demonstrates the overlap between wild-type and heterozygous cells, strongly suggesting functional concordance and consistent differences to homozygous counterparts. Indeed, the below count table illustrates that the majority of differentially expressed genes in homozygous versus wild-type cells are also differentially expressed in homozygous versus heterozygous cells, including the direction of the change (please access the PDF version for formatted table: https://osf.io/ecmhr/)

      Comparison

      Differentially expressed gene count

      HOMvsWT

      5644

      HOMvsHET

      5764

      HOMvsWT AND HOMvsHET

      4825 (2300 upregulated; 2525 downregulated; 1 discordant)

      We have now performed additional fast gene set enrichment analyses (fgsea; shown below - please access PDF version to view figure: https://osf.io/ecmhr/) using the R package fgsea ([16]) and 14 of the Broad Institute’s 50 Hallmark Gene Set Collection [17], including manual addition of the PLURINET signature [18]. The 14 gene sets were chosen based on their relevance to answering the Reviewer’s question as well as their connection to PI3K signalling. Fold changes for all expressed genes were included in the analyses, without further thresholding in order to minimise bias.

      The results for homozygous vs wild-type comparisons are concordant with our upstream regulator analyses using IPA; as expected, TGFb signalling and PI3K signalling are among the top positively enriched (NES > 1) in comparison between homozygous and heterozygous cells. Unsurprisingly, however, the strength of the enrichments are lower when comparing the two PIK3CAH1047R genotypes.

      We are not convinced that including these surplus data will add value to the manuscript and its main message, however we will leave this decision to the discretion of the Editor (please also refer to our response to the subsequent question from Reviewer 2). Moreover, these data will remain visible in the publicly available rebuttal document.

      The authors should confirm the results of pathway analysis in vitro to show that homozygous PIK3CA mutation confers increased stemness compared to heterozygous mutation.

      AUTHORS’ RESPONSE__:__ This was a key finding in our previous publication [5]. The aim of the current study was to interrogate this phenomenon further through high-depth transcriptomic/signalling analyses.

      Figure 5: Kindly provide direct evidence demonstrating that increased PIK3CA signaling output induces NODAL expression in this experimental setting.

      AUTHORS’ RESPONSE__:__ We have consistently demonstrated increased NODAL mRNA expression (RNAseq data, Fig. S4 and Ref. [5]). Unfortunately, we have been unsuccessful in attempts to obtain good quality immunoblots for NODAL protein in PIK3CAH1047R/H1047R cells (as noted in response to Reviewer 1). We note, in fact, that such documentation of NODAL protein levels, while not unprecedented, is fairly rare.

      Also, please normalize gene expression data to WT cells so it is easy to visualize the changes in NODAL and NANOG expression in homozygous and heterozygous mutants compared to WT iPSCs.

      AUTHORS’ RESPONSE__:__ It is arithmetically more precise to normalise to the highest expression (i.e. that of PIK3CAH1047R/H1047R cells) – thereby avoiding artificial inflation of fold-changes when normalising to very low levels of expression. Ultimately, the relative levels calculated – and the increased expression of NODAL in PIK3CAH1047R/H1047R cells – are identical visually. Only the entirely arbitrary units change. Thus we do not deem normalisation to WT to be necessary or to add value to the analysis.

      Kindly quantify Fig. S5.

      AUTHORS’ RESPONSE__:__ These brightfield micrographs were taken as part of routine practice to monitor cell health during maintenance and experimentation, and are suboptimal for direct quantitation due to uneven illumination background and lack of whole-well imaging. Nevertheless, we have now undertaken quantification as the Reviewer suggests, using individual images taken during independent experimental replicates. The results have been added to Fig. S5 and support our assertion that 250 nM BYL719 had a growth inhibitory effect in homozygous PIK3CAH1047R iPSCs. All raw images and associated data have been uploaded to the Open Science Framework (https://osf.io/hbf7x/). The following short method section detailing the image analysis algorithm has also been included in the revised supplementary material:

      “Colony size quantitation from light micrographs

      Routine cell culture light micrographs were acquired on an EVOS FL digital inverted microscope (AMF4300, Thermo Fisher Scientific) using the 4X or 10X objective (final magnification 40X and 100X, respectively). For quantitation, 4X images were used for colony segmentation with Definiens Developer XD software. Background was detected using a contrast threshold; for this each pixel was compared to those in the surrounding 24 pixels (i.e. a 5x5 pixel box), and pixels with low contrast (between -50 and +50) were classified as background. Remaining pixels were classified as colonies, and any holes (pixels that were not initially classified as being part of the colony due to low contrast) were filled. Edges of the resulting colonies were smoothened by shrinking and then growing the colonies by 2 pixels. Finally, colonies less than 2000 pixels in size were reclassified as background. The area of the resulting colonies could then be measured and averaged over each field of view.”

      Reviewer #3

      In this manuscript by Madsen et al., a comparison of the transcriptome and proteome in heterozygous and homozygous PIK3CAH1047R human pluripotent stem cells mutants is presented. The authors demonstrate marked alterations in expression at both the protein and RNA level of homozygous mutants compared to wildtype, while heterozygous lines exhibit only minor changes. Multiple analytical approaches are employed to investigate network alterations, leading the authors to suggest a TGFβ-mediated rewiring of key pluripotent genes to induce a state of sustained stemness. Madsen et al. conclude with a set of experiments to functionally implicate NODAL/TGFβ autocrine signalling in PIK3CAH1047R dose-dependent stemness. The key conclusions are not convincing. While the unbiased omics approach sets up this study well, the study suffers from a lack of convincing functional assays (cell biological assays) to test their model and tease apart a phenotype for the het cells. More robust functional experiments are required to support the finding the NODAL/TGFβ signalling mediates the self-sustained stemness, particularly because this is the major novel finding distinguished from the authors previous work.

      AUTHORS’ RESPONSE__:__ We thank the Reviewer for their detailed critique. Our perspective on the robustness and novelty of our findings diverges from that of the Reviewer, however, as we elaborate on in more detail below.

      While the authors present a comprehensive omics investigation into alterations between wild type, homozygous, and heterozygous mutants, the critical functional experiments are lacking. In Figure 5, the authors seek to support the role of TGFβ in mediated stemness in the homozygous mutants, however, are not able to directly deplete TGFβ due to technical limitations of the culture conditions. Consequentially, the experiments are primarily built on the use of NODAL withdrawal and stimulation. The data presented thus implicate NODAL in the stemness phenotype, but it's not obvious TGFβ is substantially involved, particularly considering the inhibitor subsequently employed also inhibits NODAL type 1 receptors.

      AUTHORS’ RESPONSE__:__ NODAL and TGFb activate shared signalling pathways downstream from their respective receptors, and indeed they (as well as Activin) can be used interchangeably in stem cell culture, which is common practice [19–21]. Commercially available Essential 8/TeSR-E8 is supplemented with TGFb not NODAL; therefore the factor we have removed is TGFb, prior to any controlled introduction of NODAL (based on strong upregulation of its mRNA in PIK3CAH1047R/H1047R). Any residual TGFb-like ligands will be contributed by Matrigel as outlined in the text (lines 247-251). It is well-established that “NODAL/TGFb signalling” denotes signalling through SMAD2/3/4 (as opposed to BMP signalling through SMAD1/5/8), and this is how we use the term throughout the manuscript. Accordingly, it is functional activation of the “NODAL/TGFb signalling pathway” that we investigate (see also response to Reviewer 1, p.1).

      In summary, we seek not to make a distinct point about TGFb, but rather refer to NODAL/TGFb signalling as a matter of biochemical correctness. For clarity, we now replace mentions of “TGFb signalling” with “NODAL/TGFb signalling” throughout the revised manuscript. We have also revised the legend for Figure 3 to make this clearer.

      Furthermore, there is a paucity of readouts for stemness. For example, a more convincing narrative would include additional expression markers of the core pluripotency network (e.g. OCT4, SOX2, etc.) as well as functional readouts (e.g. NODAL withdrawal and assessment of differentiation) after NODAL stimulation/depletion and comparing across genotypes. Overall, the primary conclusions of this work are not well-evidence by the presented data and the authors should consider additional functional experiments or reframing the narrative.

      AUTHORS’ RESPONSE__:__ We chose the current strategy because we wanted to capture the earliest changes after depletion of NODAL/TGFb/ signalling, prior to any signalling rewiring triggered by differentiation. In fact, we believe that a strength of this study is our observation of differences in critical stemness markers in spite of the short time course. To aid non-expert readers we offered a primer on stemness genes and rationale for the markers chosen in the existing introduction (lines 80-90).

      We have further assessed additional stemness and differentiation marker genes in two independent homozygous PIK3CAH1047R cell lines using a high-throughput pluripotent stem cell scorecard (Fig. S4). This replicates the effect on cell marker genes documented by RT-qPCR in Fig.5, while also showing additional reductions in genes that were upregulated in homozygous PIK3CAH1047R cells (MYC, GDF3, FGF4) and which have previously been shown to be highly expressed in pluripotent stem cells (we have now added this additional clarification to the legend of Fig. S4) [22]. Despite the short term treatment, these data also show that no other treatment but SB431542 is capable of triggering expression of early neuroectoderm markers (CDH9, MAP2 and PAPLN) [23], prior to overt morphological changes in the cultures (Fig. S5; higher resolution images are also available via The Open Science Framework: https://osf.io/hbf7x/). Neuroectodermal gene expression is expected upon inhibition of TGFb signalling in human pluripotent stem cells [24,25].

      A key conclusion of this study is there is a dose-dependent stemness phenotype. As this is not explicitly defined, to this reader, it would imply a graded response between wild type, heterozygotes, and homozygotes in the phenotypic and molecular characteristics. However, as is noted particularly in the omics components of the manuscript, there is in fact "near-binary" alteration in the assayed characteristics. Again, this should be qualified more explicitly, but it is more consistent with the data, which suggests the heterozygotes behave very similarly to the wild types, while homozygotes have substantial alterations. I would suggest the authors consider renaming their descriptions, removing "near-binary" and "dose-dependent" to something like "dose-threshold." This suggests after X threshold of oncogenic PI3K signalling, substantial alterations occur; under this threshold (e.g. hets), changes are marginal. In the event however that there may be a more "dose-dependent" effect, I would expect the transcriptomic and proteomic changes observed in the heterozygous cell lines should be seen in the homozygous cell lines (of which they are likely in greater in magnitude in addition to other changes).

      AUTHORS’ RESPONSE__:__ This appears to us to be largely a matter of semantics. In talking of “dose dependency” we were certainly not implying a graded affect (as the Reviewer points out, our are findings are far from this, suggesting a sharp threshold of dose which triggers widespread changes), and indeed nothing in these words strictly suggests this interpretation. Nevertheless we are sensitive to the fact of the Reviewer’s interpretation of the term, and mindful that this might be shared by other readers. On the other hand talking of a “near-binary” effect seems to us to be an accurate description of our findings. We have edited the manuscript to minimise ambiguity with the following changes:

      • line 49 “dose” replaced with “strength”: “We demonstrate signalling rewiring as a function of oncogenic PI3K signalling strength, and provide experimental evidence that self-sustained stemness is causally related to enhanced autocrine NODAL/TGFb
      • line 102: “This work provides in-depth characterisation of the near-binary PI3K signalling effects seen in hPSCs ….”
      • lines 195, 198, 317: inserted “allele dose-dependent We would also like to take issue with the case that the Reviewer seems to be making that a more graded change in gene expression across heterozygotes and homozygotes is to be expected. As mentioned in the manuscript (lines 206-210), there is evidence for NODAL/TGFb pathway activation in heterozygous cells. Nevertheless given the known temporal, context- and dose-dependent effects of this pathway [1,2,26,27] and, importantly, the widely described biological properties of developmental systems (featuring positive feedback loops, bistability and hysteresis; see Ref. [28,29]), we have no reason to expect that transcriptomic and proteomic changes observed in homozygous cell lines will be reproduced in heterozygous cell lines.

      The manuscript would benefit from more direct comparisons between the heterozygotes and homozygotes.

      AUTHORS’ RESPONSE__:__ Please refer to the additional data provided in response to a similar question by Reviewer 2.

      Further to the above point, as the marginal phenotype observed in heterozygotes is a critical point in this paper, the authors would benefit from including heterozygote lines in the functional experiments presented in Fig 5. Inclusion of the hets in these experiments would instill confidence in this reader that the marginal molecular alterations characterized at the proteomic and transcriptomic level is reflected in the lack of functional stemness-sustaining behaviour.

      AUTHORS’ RESPONSE__:__ The lack of stemness-sustaining behaviour in the heterozygous clones was demonstrated across multiple different experiments in our previous work, and further functional studies of early differentiation in these cells seemed a poor use of resource and very unlikely to give useful insights. Given the major disease phenotype associated with the same genetic change (PROS), the relative lack of phenotype in heterozygous cells was surprising and holds obvious implications for disease modelling (see also response to Reviewer 2, pp.2-3), and for how model systems are “calibrated” against human developmental disease. The aim of the current work was to:

        • Determine whether increasing the depth of signalling and transcriptomic analyses would unmask small but important changes in heterozygous mutants that might have been missed in prior studies (i.e. we actively aimed to increase the power of the study for identification of subtle changes) and *
        • To characterise in greater depth the signalling and transcriptional changes underpinning the robust threshold effect observed for self-sustained stemness driven by PIK3CAH1047R/H1047R. We would further observe that PROS does not feature obvious qualititative errors in tissue specification, but rather excessive growth of more or less normally differentiated tissues. We conceptualise this as reflecting a small incremental growth advantage in normally differented tissues of certain lineages that summates to create a major disease phenotype over months and years.*

      Thus, without the functional and mechanistic experiments alluded to above, the claims/ conclusions are speculative. In particular, the cancer narrative is irrelevant to the study. Considering both the lack of conclusive differentiation experiments or relevant breast cancer experiments, the discussion on differentiation therapy for breast cancer should be removed.

      AUTHORS’ RESPONSE__:__ The reference to cancer links to a computational study of human breast cancers where we specifically looked at the relationship between strength of PI3K signalling and ‘stemness’ [12], both measured using established transcriptional indices. We have included the bioRxiv reference in our revised manuscript (see l.337). While there is an element of speculation in this cancer observation, we do feel it is important and grounded in this and the BioRXiv study, and would prefer to maintain it. However, if editors take a different view it can be removed.

      Reproducibility is a concern for this study. The authors should perform more replicates on their experiments (focusing on technical replicates of the lines employed to discern technical vs biological variability). A challenge in reading this manuscript is understanding which replicates were used for which experiments, and whether they are technical or biological (i.e. different lines). While some of the figure legends note this information, it would be helpful to provide clarity throughout the text. In addition, it should be noted that some experiments (e.g. the RPPA analysis in Fig 2B and Fig S3B) show substantial variability between replicates, but because it appears only a single technical replicate from two different cell lines was used, it is impossible to distinguish whether the variability is of a biological or technical nature. The authors would do well to focus on collecting more technical replicates of fewer biological replicates, and then expand to include more biological replicates if initial biological variation is observed.

      AUTHORS’ RESPONSE__:__ We strenuously disagree with the Reviewer on this point. Throughout this manuscript, we have been transparent and thorough in reporting how experiments were performed, including the number of both biological and technical replicates. Representative examples include:

      Legend to Figure 2A (RPPA dataset in growth-replete conditions): “The data are based on 10 wild-type cultures (3 clones), 5 PIK3CAWT/H1047R cultures (3 clones) and 7 PIK3CAH1047R/H1047R cultures (2 clones) as indicated.”

      Legend to Figure 5: “The data are from two independent experiments, with each treatment applied to triplicate cultures of three wild-type and two homozygous iPSC clones.

      Specifically to address the RPPA studies, and as is clear from the Figure 2 legend, we initially performed RPPA analyses in growth factor-replete conditions with extensive technical and biological replication, arguing against the Reviewer’s point. To aid interpretation, we opted for summarising this large dataset in Venn diagrams (following extensive limma-based statistical analysis, including correction for multiple comparisons and sample interdependence as advised in Ref. [30]). If the Reviewer deems it valuable, we could include a heatmap overview as shown below:

      [To view figure, please access PDF version of this rebuttal on https://osf.io/ecmhr/]

      We took the view that the above representation, while comprehensive, is not particularly informative to the reader. All individual data points for both total and phosphoproteins – with and without normalisation – are plotted as part of separate barplots in the accompanying RNotebook (https://osf.io/d9tca/). These clearly demonstrate that the technical and biological variability in canonical PI3K signalling responses at the level of AKT and immediately downstream of AKT is very low. The same applies to the increased phosphorylation of SMAD2 (S465/S467) in PIK3CAH1047R iPSCs. We include two examples below, and would be happy to include the link to the above RNotebook in the respective Figure legend if the Reviewer deems this helpful.

      [To view figure, please access PDF version of this rebuttal on https://osf.io/ecmhr/]

      The interpretation of the second RPPA experiment (Fig. 2B) in growth factor-depleted conditions is focused entirely on these responses due to their consistency across both datasets (further supported by low-throughput signalling analyses in the previous PNAS publication).

      We had made all raw data and guided analysis scripts for the above RPPA dataset publicly available, and the same is true for all original data as highlighted in the Materials & Methods section. Thus we strongly believe that readers have the opportunity to assess our work and reproduce our analyses/conclusions fully should they wish to do so.

      • Finally, we noted in the initial PNAS paper describing these models that we derived and worked with up to 10 independent homozygous PIK3CAH1047R clones, as well as with 3 and 4 independent heterozygous and wild-type clones, respectively. This exceeds the common use of 2 clones (if at all mentioned) in many similar studies in the stem cell literature (e.g. Ref. [31–34]). In our view, derivation of more than two independent clones is crucial for reproducibility in gene editing studies given substantial variability arising from genetic drift [35,36]. We have consistently shown the phenotypic robustness of our mutant clones across the two studies; note, for example, the low technical and biological variability in both heterozygous and homozygous mutants in the transcriptomic data in Fig. 1A. As noted in the manuscript, the high-depth RNAseq data analysis was performed in different clones and independently of the RNAseq reported in Ref. [5], yet yields highly similar results and confirms transcriptional rewiring of PIK3CAH1047R/H1047R iPSCs.*

      Throughout the text, the authors frequently reference their previous study in PNAS and often the lines of what is novel in this paper vs. reproduction of previous findings is blurred. The authors would benefit from reducing the frequency of referencing their previous study and focusing on emphasizing the novelty of the present findings.

      AUTHORS’ RESPONSE__:__ We have carefully reviewed all instances of citation of our previous study in the manuscript and have reduced their numbers to improve focus on the current findings as suggested. As noted above, however, the current study builds closely upon the findings of the previous work, and referring to these to put the current work in context is important. Indeed, this is reflected in some of the reviewers’ collective comments and questions which are answered by the prior study. We have carefully reviewed the places in which we have cited our previous study and note that except for 2 citations in the Introduction and 3 more in the Discussion, all remaining citations are in the context of linking new and old data, which we believe is important for clarity as suggested by the reviewers. However, if editors take a different view we can minimise this and reduce the number of citations.

      Without functional assays to complement and test their models, this manuscript is not a significant advance.

      AUTHORS’ RESPONSE__:__ While we take the Reviewer’s point that further studies could have strengthened robustness of the evidence supporting a mediating role of NODAL/TGFb signalling in PI3K-driven stemness, we think this assertion is far too sweeping, and neglects numerous facets of the study of use and interest to several fields (as agreed by the other reviewers). To recapitulate some key points of interest/use of this study:

      • Using a carefully derived PIK3CAH1047R iPSC model system and pharmacologically relevant doses of a recently approved PI3Ka-selective inhibitor, we demonstrate that the efficacy of the latter can depend on the strength of PI3K pathway activation and phenotype under investigation – despite expected downregulation of PI3K signalling by Alpelisib, the stemness phenotype is not reversed.
      • We link this to self-sustained TGFb signalling in cells with strong PI3K activation by homozygous PIK3CAH1047R The link between the two pathways and the underlying rewiring are likely to be relevant in other contexts, as observed recently in a breast epithelial model system [37]. Given similarity between human pluripotent stem cells and cancer cells, our findings are of wider relevance.
      • Aberrant PI3K activation has been associated with numerous pathologies, so it is important for the field to have well-characterised model systems with endogenous expression of one of the most common PIK3CA mutations. Our thorough characterisation of PIK3CAH1047R iPSCs validates one such model.
      • To our knowledge, this is the first study to provide a comprehensive and integrated characterisation of isoform-specific PI3K signalling and transcriptomic changes in human pluripotent stem cells. This is important because current knowledge of PI3K signalling in human PSCs is largely based on extrapolation of findings from mouse embryonic stem cells, with many previous studies relying on high concentrations of the non-specific pan-PI3K inhibitor LY294002 (the use of which has been discouraged by the PI3K signalling community [38]).

        I believe the narrative was written for pluripotent stem cell biologists but without robust functional and quantitative cell biological assays to test their models, I don't anticipate stem cell biologists will be very interested.

      AUTHORS’ RESPONSE__:__ The Reviewer is incorrect in his/her assertion about the target audience. PI3K signalling plays a key role in numerous disease and physiological processes as well as in development, and is of broad interest to cancer biologists, genetecists, rare disease biologists, biochemists, cell signallers, and endocrinologists among many others. Indeed we started with a primary focus on disease modelling (cancer, PROS) rather than stem cell biology, but because our findings are significant for the role of PI3K in stem cell biology as well as for these diseases, we aimed to make findings accessible across many of these readers. We refer the Reviewer to our previous response with regards to the significance of this work.

      **Minor Comments:**

      Consider adding gridlines to the MDS plots for clarity of read

      AUTHORS’ RESPONSE__:__ This is a matter of taste, and as we honestly can not see how it would enhance appreciation of the very clear clustering, we have decided to leave the plot in its current form.

      In Fig S2, some of the in-figure labelling is incorrect

      AUTHORS’ RESPONSE__:__ We thank the Reviewer for spotting this. We believe the labelling error to be corrected now and we have further tried to streamline the plot headings, but please do let us know if there is something else which we may have missed.

      In Fig S1C, the authors note poor correlation in the heterozygotes between this and a previous study. It would be helpful to qualify this discrepancy, as it is potentially concerning.

      AUTHORS’ RESPONSE__: The sensitivity to detect differential gene expression is high for large fold changes (as seen in PIK3CAH1047R/H1047R mutants) in transcriptomic studies, but declines rapidly for fold changes in expression lines 126-131: “The magnitudes of gene expression changes in PIK3CAH1047R/H1047R cells correlated strongly with our previous findings (Spearman’s rho = 0.74, p WT/H1047R iPSCs (Fig. S1C), as expected given the smaller number and lower magnitude of observed gene expression changes in heterozygous cells, and the lower depth of previous transcriptomic studies__.”*

      Line 208, the authors state that the small p-value for the homozygotes is suggestive of a dose-dependent effect. This is not the case; it simply suggests a greater probability of the effect being non-random.

      AUTHORS’ RESPONSE__:__ The Reviewer is formally correct, and we apologise for the imprecision of our language. Nevertheless biological effect size is pertinent to the p value determined, and so our statement, while requiring an inductive leap from the reader, is not wholly invalid. To tidy this up and improve precision we have reworded as follows:

      lines 215-217: “This is in keeping with the much lower effect size in heterozygous cells, and consistent with a critical role for the TGFbeta pathway in mediating the allele dose-dependent effect of PIK3CAH1047R in human iPSCs.”

      What does the height in Fig 4B correspond to? It would perhaps be of value to scale nodes based on the significance value.

      AUTHORS’ RESPONSE__:__ 4B illustrates hierarchical clustering of the module eigengenes - the height corresponds to similarity of gene expression. We clarify this in the revised manuscript.

      References

      1 Lee, K. L. et al. (2011) Graded Nodal/Activin signaling titrates conversion of quantitative phospho-Smad2 levels into qualitative embryonic stem cell fate decisions. PLoS Genet. 7.

      2 Hill, C. S. (2018) Spatial and temporal control of NODAL signaling. Curr. Opin. Cell Biol. 51, 50–57.

      3 Xu, R. H. et al. (2008) NANOG is a Direct Target of TGFβ/Activin-Mediated SMAD Signaling in Human ESCs. Cell Stem Cell 3, 196–206.

      4 Vallier, L. et al. (2009) Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. Development 136, 1339–49.

      5 Madsen, R. R. et al. (2019) Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner. Proc. Natl. Acad. Sci. 116, 8380–8389.

      6 Vasan, N. et al. (2019) Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science (80-. ). 366, 714–723.

      7 Saito, Y. et al. (2020) Landscape and function of multiple mutations within individual oncogenes. Nature 582, 95–99.

      8 Gorelick, A. N. et al. (2020) Phase and context shape the function of composite oncogenic mutations. Nature.

      9 Gillies, T. et al. (2020) Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway 1–19.

      10 Hafner, M. et al. (2016) Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521–527.

      11 André, F. et al. (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929–1940.

      12 Madsen, R. R. et al. (2020) Relationship between stemness and transcriptionally-inferred PI3K activity in human breast cancer. bioRxiv 2020.07.09.195974.

      13 Fritsch, C. et al. (2014) Characterization of the novel and specific PI3Ka inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther. 13, 1117–1129.

      14 Furet, P. et al. (2013) Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorganic Med. Chem. Lett.

      15 Yilmaz, A. et al. (2018) Defining essential genes for human pluripotent stem cells by CRISPR–Cas9 screening in haploid cells. Nat. Cell Biol. 20, 610–619.

      16 Sergushichev, A. A. (2016) An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. bioRxiv 060012.

      17 Liberzon, A. et al. (2015) The Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst. 1, 417–425.

      18 Müller, F. J. et al. (2008) Regulatory networks define phenotypic classes of human stem cell lines. Nature 455, 401–405.

      19 James, D. et al. (2005) TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 132, 1273–82.

      20 Vallier, L. et al. (2005) Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J. Cell Sci. 118, 4495–4509.

      21 Chen, G. et al. (2011) Chemically defined conditions for human iPSC derivation and culture. Nat. Methods 8, 424–429.

      22 Adewumi, O. et al. (2007) Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat. Biotechnol. 25, 803–816.

      23 Tsankov, A. M. et al. (2015) A qPCR ScoreCard quantifies the differentiation potential of human pluripotent stem cells. Nat. Biotechnol. 33, 1–15.

      24 Smith, J. R. et al. (2008) Inhibition of Activin/Nodal signaling promotes specification of human embryonic stem cells into neuroectoderm. Dev. Biol. 313, 107–117.

      25 Vallier, L. et al. (2004) Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. Dev. Biol. 275, 403–421.

      26 Sorre, B. et al. (2014) Encoding of temporal signals by the TGF-β Pathway and implications for embryonic patterning. Dev. Cell 30, 334–342.

      27 David, C. J. and Massagué, J. (2018) Contextual determinants of TGFβ action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19, 1–17.

      28 Alon, U. (2007) Network motifs: theory and experimental approaches. Nat. Rev. Genet. 8, 450–461.

      29 Sonnen, K. F. and Aulehla, A. (2014) Dynamic signal encoding-From cells to organisms. Semin. Cell Dev. Biol. 34, 91–98.

      30 Germain, P. L. and Testa, G. (2017) Taming Human Genetic Variability: Transcriptomic Meta-Analysis Guides the Experimental Design and Interpretation of iPSC-Based Disease Modeling. Stem Cell Reports 8, 1784–1796.

      31 Wang, L. et al. (2017) GCN5 Regulates FGF Signaling and Activates Selective MYC Target Genes during Early Embryoid Body Differentiation. Stem Cell Reports 10, 287–299.

      32 Zeng, H. et al. (2016) An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery. Cell Stem Cell 0, 1660–1669.

      33 Ho, L. et al. (2015) ELABELA Is an Endogenous Growth Factor that Sustains hESC Self-Renewal via the PI3K/AKT Pathway. Cell Stem Cell 17, 435–447.

      34 Roudnicky, F. et al. (2019) Modeling the effects of severe metabolic disease by genome editing of HPSC-derived endothelial cells reveals an inflammatory phenotype. Int. J. Mol. Sci. 20, 1–10.

      35 Veres, A. et al. (2014) Low incidence of Off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 15, 27–30.

      36 Ben-David, U. et al. (2018) Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560, 325–330.

      37 Katsuno, Y. et al. (2019) Chronic TGF-b exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Sci. Signal. 12, eaau8544.

      38 Manning, B. D. and Toker, A. (2017) AKT/PKB Signaling: Navigating the Network. Cell 169, 381–405.

    1. Author Response

      We thank the Editor of eLife f or kindly considering our manuscript for publication and for soliciting three peer reviews. We note that the reviews were positive for the most part. We sincerely believe that the key criticisms arise regrettably from a seeming misunderstanding of the motivation and context of our work – one that we hoped was a candid presentation of available data for tarantulas and the methods used. We provide detailed responses to the reviewers’ concerns below. We further note that our manuscript has since been published with minimal changes (Foley et al. 2020 Proceedings of the Royal Society B 287: 20201688, doi:10.1098/rspb.2020.1688).

      Tarantulas belong to an enigmatic and charismatic group with a nearly cosmopolitan distribution and intriguingly show vivid coloration despite being mostly nocturnal/ crepuscular. Using a robust phylogeny based on a comprehensive transcriptomic dataset that includes nearly all theraphosid subfamilies (except Selenogyrinae), we performed both discrete and continuous ancestral state reconstructions of blue and green coloration in tarantulas using modern phylogenetic methods. Using phylogenetic correlation tests, we evaluated various possible functions for blue and green coloration, for instance aposematism and crypsis. Our results suggest green coloration is likely used in crypsis, while blue (and green) coloration show no correlation with urtication, stridulation or arboreality. Our findings also support a single ancestral origin of blue in tarantulas with losses being more frequent than gains, while green color has evolved multiple independent times but never lost. We comparatively assessed opsin expression from the transcriptomic data across tarantulas to understand the functional significance of blue and green coloration. Our opsin homolog network shows that tarantulas possess a rather diverse suite of regular arthropod opsins than previously appreciated.

      While color vision in (jumping) spiders is relatively well studied, to the best of our knowledge, this is the first study to comparatively consider the identity of opsin expression across tarantulas, and in relation to the evolution of coloration. Our study challenges current belief (e.g., Morehouse et al. 2017 doi: 10.1086/693977 and references therein; Hsiung et al. 2015 doi: 10.1126/sciadv.1500709) that tarantulas are incapable of perceiving colors, at least from a molecular perspective and suggests a role for sexual selection in their evolution. This also adds to the growing body of knowledge on the complexity of arthropod visual systems (e.g., see Futahashi et al. 2015 doi:10.1073/pnas.1424670112, Hill et al. 2002 doi:10.1126/science.1076196).

      In short, we believe our results are timely and pertinent broadly to sensory biologists, behavioural ecologists and evolutionary biologists as it is an exhortation for sorely needed behavioural and sensory experiments to understand proximate use of vivid coloration in this enigmatic group.

      Summary:

      This study offers some interesting data and ideas on colour evolution in tarantulas, building upon previous work on this topic. However, the reviewers judged that the insights are too taxon-specific and that several key conclusions are too speculative. There were also concerns about the methodology for trait scoring from photographs that the authors might consider going forward.

      Reviewer #1:

      This study investigates the evolution of blue and green setae colouration in tarantulas using phylogenetic analyses and trait values calculated from photographs. It argues that (i) green colouration has evolved in association with arboreality, and thus crypsis, and (ii) blue colouration is an ancestral trait lost and gained several times in tarantula evolution, possibly under sexual selection. It also uses transcriptome data to identify opsin homologs, as indirect evidence that tarantulas may have colour vision.

      Otherwise, a few comments:

      1) Given that data is limited for the family (only 25% of genera could be included in this study), it seemed a shame not to discuss further the variation in colour and habit within genera. Based on Figure 1 and supplementary tables, the majority of "blue" genera contain a mix of blue and not-blue (and not-photographed) species. Does this mean that blue has been lost many more times in recent evolutionary history? And how often are "losses" on your tree likely to be the result of insufficient sampling for the genus (i.e. you happen not to have sampled the blue species)?

      First, the taxa in our robust and well-resolved phylogeny are representative of the major lineages within Theraphosidae, i.e., we have sampled nearly all theraphosid subfamilies (except Selenogyrinae). Our ideal is also to work with a more complete genus-level molecular phylogeny and corresponding color dataset for theraphosidae. However, this group is generally not well represented in museum collections (let alone in digitized collections), while the pet trade is focussed on only a select number of taxa. While we appreciate the reviewer’s concern that adding more taxa and corresponding data could potentially change the results, we believe that with a strong backbone phylogeny recovering the major branches, the results should not change all that much (For instance, cf. Hackett et al. 2008 10.1126/science.1157704 vs. Prum et al. 2016 10.1038/nature19417, where the initial Hackett et al. backbone is robust to increased sampling). Although the way trait losses are concentrated towards the tip suggests that using a genus-level phylogeny would perhaps show a few more recent trait losses, but unlikely to contradict an ancient origin of blue coloration at the base of this group, especially given the way the outgroups are polarized (i.e., outgroups also exhibit blue).

      2) A key conclusion of the study is that sexual selection should not be discarded as a possible explanation for spider colour. However, there is very little detail given in the discussion to build this case. Do these spiders have mating displays that might plausibly include visual signals? How common are sexually-selected colours in spiders generally? Where on the body is the blue coloration (in cases where it is not whole body)? I also missed whether the images used are of males or females or both, or how many species show sexual dimorphism in colouration (mentioned briefly in the Discussion, but not summarised for species or genera).

      We agree with the reviewer that we should have provided more information regarding sexual dichromatism in tarantulas, and on the images we used in the study (whether male/female). However, the location of blue coloration varies wildly with species – some species have blue chelicerae, blue abdomens, or blue carapaces while others are entirely blue. We also know very little about mating (and selection, if any) strategies in tarantulas, let alone the sensory ecology of this group. However, there is intriguing anecdotal information from one species (Aphonopelma) that they can be active as early as 4pm (Shillington 2002 Canadian J. Zoology, 80: 251-259, doi: 10.1139/z01-227), while some species show an intensification of color upon maturation, often a hallmark of sexual selection. Indeed, we believe that our work will incite broad interest on these intriguing questions.

      3) A quick scroll through the amazing images on Rick West's site suggests that oranges and red/pinks are not rare in tarantulas. Perhaps the data is just not available, but it would be good to mention somewhere the rationale behind the blue/green focus, rather than examining all colours.

      We agree. However, in the present study, we focused on blue and green colors because the data is readily available and we wanted to build upon the previous work by Hsiung et al 2015. Given that violet/blue and likely also some green coloration are structural in origin (Saranathan et al. 2015 Nano Letters, doi: 10.1021/acs.nanolett.5b0020; Hsiung et al. 2015), these hues are unlikely to fade or vary between individuals unlike diet acquired pigmentary coloration. Hence, these colors perhaps better lend themselves to analyses using digital photographs.

      I suggest defining stridulating / urticating setae for non-specialist readers. I had to look these up to understand that they were involved in defence.

      We thank the reviewer for this suggestion.

      I notice the Rick West website says species IDs should not be made from photos alone. Is there a risk of misidentification for any photos?

      We understand the reviewer’s concern. However, Rick West is an experienced arachnologist and quite knowledgeable in tarantula systematics and taxonomy (see https://www.tarantupedia.com/researchers/rick-c-west), which is why we endeavoured to use his website as extensively as possible without resorting to photos from hobbyists. We further validated the IDs with field guides, when in doubt.

      The Results section would benefit from some more clear statements of key results. For example, phrases like "AIC values to assess the relationships between greenness and arboreality are reported in Table 3" could be replaced instead with a summary statement indicating what this table shows.

      We agree and thank the reviewer for this suggestion.

      In the Figure 1 caption I think there is a typo: 'the proportions of species with images that possess blue colouration (grey = no available images)" but should this say "grey = not blue"?

      We apologize for the confusion. This is not a typo – this is in relation to Trichopelma, for which no images of described species were available, and so we cannot conclude that none of the taxa are blue/green.

      142 - the lengthy discussion here of whether there is one or more mechanisms by which blue is produced in tarantulas, and the detailed criticism of Hsuing SEMs, seems a bit out of place given that the current study does not investigate the proximate mechanism of blue colouration but merely its presence.

      We respectfully disagree. The core support for Hsiung et al.’s (2015) argument against sexual selection as a driver of color evolution in tarantulas comes from their structural diagnoses of the nanostructures responsible for the violet/blue structural coloration and their subsequent argument that a diversity of divergent nanostructures rather than convergence argues against sexual selection. While it is true that we did not investigate the proximate mechanism of blue coloration here, one of us (Saranathan et al. 2015) has already done so elsewhere. It appears that in insects and spiders, the bulk of the nanostructural diversity is across families and not within.

      Table S6 - It is not clear to me how the values for predicted N orthologs were calculated.

      This is mentioned in line 354 of our methods – “Per the ‘moderate’ criteria from the Alliance of Genome Resources (55), hits may be considered orthologous if three or more of the twelve tools in their suite converge upon that result”.

      The Table S7 caption states: "A * indicates currently undescribed species with blue or green colour that can be confidently attributed to corresponding genus. However, as the described species exhibit no blue or green colour, we conservatively scored these as 0." Is this a conservative approach though? If they have been confidently assigned to genus, I don't understand why they would not be included.

      This refers to the cases where a hitherto undescribed species possesses the blue or green color. However, even though the species has not formally been described, its placement in the genus is not in question. We have not included such undescribed species in our tabulated number of species per genus, as it is difficult to express any such undescribed species as a fraction of the total number of species in that genus.

      Reviewer #2:

      This paper presents a broad-ranging overview of tarantula visual pigments in relationship with the color of the spiders. The paper is interesting, well-written and presented, and will inspire further study into the visual and spectral characteristics of the genus.

      We thank the reviewer for her/his/their kind words.

      First a minor remark, Terakita and many others distinguish between opsin, being the protein part of the visual pigment molecule and intact light-sensing, so-called opsin-based pigment, often generalized as a rhodopsin. The statement of line 65, 'convert light photons to electrochemical signals through a signalling cascade' is according to that view strictly not correct. Furthermore, the presence of opsins in transcriptomes may be telling, but it is not at all sure that they are expressed in the eyes, if at all. As the authors well know, in many animal species some of the opsins are expressed elsewhere. It may be informative to mention that.

      We thank the reviewer for this clarification. As for the regions of opsin expression, we very much agree – were it not for constraints of sample availability, we would also have preferred to sequence only the eyes and brain of various tarantulas that were all exposed to similar lighting conditions. However, we encouragingly see that our “leg only” transcriptomes have far fewer (often no) opsins as compared to the whole-body data.

      The blueness or greenness feature prominently in the paper, but the criteria used for determining to which class a spider belongs are not at all sure. The Color Survey and Supplementary Table S2 refer to Birdspiders.com, but that requires a donation; not very welcoming. The other used sources are also not readily giving the insight or overview which material was sampled. I therefore think that the paper would considerably gain in palatability by adding a few exemplary photographs as well as measured spectra. Of course, I am inclined to trust the authors, but I would not immediately take color photographs from the web as the best material for assessing color data with 4-digit accuracy. Furthermore, the accessible photographs do not always show nice, uniform colors, so it might be sensible to mention which body part was used to score the animals. And finally, using CIE metric might infer to many readers that the spiders are presumably trichromatic, like us. Any further evidence?

      We refer to the detailed description of our method for scoring blue or green coloration in tarantulas (l. 277-303). Briefly, we calculated ΔE (CIE 1976) difference values using between the images of each taxa against a suitable reference (average of green leaves, or Haplopelma lividum, the bluest taxa in our survey based on the b value of its images). We use the ΔE Lab values to perform quantitative ancestral state reconstruction, while we use ΔE b (for blue) and ΔE a (for green) to discretize the data for understanding trait gains and losses.

      BirdSpiders.com only requires one to enter names of genera as search terms in order to see photos that we used. However, we agree could have provided some photos of exemplars. We do realise that using pictures is not ideal, as opposed to reflectance spectrophotometry (our ideal as well), which is why we limited ourselves to a single reputable source (BirdSpiders.com) for consistent images, whenever possible. However, acquiring sample material and reflectance of tarantulas is challenging. This group is generally not well represented in museum collections (let along in digitized collections), while the pet trade is focussed on only a select number of taxa and doing field work to collect specimens is fraught with moral and ethical issues (e.g., see https://www.nytimes.com/2019/04/01/science/poaching-wildlife-scientists.html). This study nevertheless represents a substantial improvement upon a recent high-profile work that used the OSX “color picker” function (Hsiung et al. 2015).

      Indeed, available evidence on tarantula vision (including our opsin sequences) suggests tarantulas are likely trichromats (Dahl and Granda 1989 J. Arachnol., Morehouse et al. 2017) similar to jumping spiders (e.g., Zurek et al. 2015, doi: 10.1016/j.cub.2015.03.033), so we consider CIE as an appropriate color space for a putative tristimulus system in tarantulas (see also our response to Reviewer 3). Again, this underscores the need for future studies on the sensory biology and psychophysics of this enigmatic group.

      Reviewer #3:

      This neat paper continues the story of structural colour evolution in a group that is rarely appreciated for their ornamentation. The study uses colour & ecological data to model their evolution in a comparative framework, and also synthesises transcriptomic data to estimate the presence and diversity of opsins in the group. The main findings are that the tarantulas are ancestrally 'blue' and that green colouration has arisen repeatedly and seems to follow transitions to arboreality, along with evidence of perhaps underappreciated opsin diversity in the group. It's well-written and engaging, and a useful addition to our understanding of this developing story. I just have a few concerns around methods and the interpretation of results, however, which I feel need some further consideration.

      We thank the reviewer for his/her/their kind words.

      As the authors discuss in detail, this work in many ways parallels that of Hsiung et al. (2015). The two studies seem to agree in the broad-brush conclusions, which is interesting (and promising, for our understanding of the question), though their results conflict in significant ways too. Differences in methodology are an obvious cause, and they are particularly important in studies such as this in which the starting conditions (e.g. the assumed phylogeny or decisions around mapping of traits) so significantly shape outcomes. The current study uses a more recent and robust phylogeny, which is great, and the authors also emphasise their use of quantitative methods to assign colour traits (blue/green), unlike Hsiung et al.

      We thank the reviewer for his/her/their appreciation.

      1) This latter point is my main area of methodological concern, and I am not currently convinced that it is as useful or objective as is suggested. One issue is that the photographs are unstandardised in several dimensions, which will render the extracted values quite unreliable. I know the authors have considered this (as discussed in their supplement), but ultimately I don't believe you can reliably compare colour estimates from such diverse sources. Issues include non-standardised lighting conditions, alternate white-balancing algorithms, artefacts introduced through image compression, differences in the spectral sensitivities of camera models, no compensation for non-linear scaling of sensor outputs (which would again differ with camera models and even lenses), and so on (the works of Martin Stevens, Jolyon Troscianko, Jair Garcia, Adrian Dyer offer good discussion of these and related challenges). Some effort is made to minimise adverse effects, such as excluding the L dimension when calculating some colour distances, but even then the consequences are overstated since the outputs of camera sensors scale non-linearly with intensity, and so non-standardised lighting will still affect chromatic channels (a & b values). So with these factors at play, it becomes very difficult to know whether identified colour differences are a consequence of genuine differences in colouration, or simply differences in white balancing or some other feature of the photographs themselves.

      We thank the reviewer for his/her/their carefully considered thoughts and for drawing our attention to the work of Martin Stevens, Jolyon Troscianko, Jair Garcia, and Adrian Dyer in this regard (e.g. Stevens et al. 2007 Biol. J. Linn. Soc. Lond., doi: 10.1111/j.1095-8312.2007.00725.x). These are fair points raised by the reviewer. We are indeed aware that there are clear drawbacks in working solely with photographs from online sources as opposed to optical reflectance data (our ideal), but we are sure that the reviewer appreciates how challenging it is to source specimens of tarantulas. It is for this reason that we restricted ourselves to photographs from mostly only 1 reputable source (BirdSpiders.com). Furthermore, this is why we chose a perceptual model that permits device independent color representation, one that lets us separate chromatic variables from brightness, keeping in mind the underlying assumptions. However, some recent research suggests that CIELab space can perform reasonably well as compared to the latest algorithms for illuminant-invariant color spaces (Chong et al. 2008 ACM Transactions on Graphics, doi: 10.1145/1360612.1360660). Please also see our response below (to point #2) and also to Reviewer #2 above.

      Given the dearth of tarantula specimens and in the absence of spectrometry, future work will have to try and acquire uncompressed original images (with EXIF data) and could perform image processing such as homomorphic filtering and adaptive histogram equalization (Pizer et al. 1987 Computer Vision, Graphics, and Image Processing; Gonzalez and Woods 2018 Digital Image Processing, Pearson) in order to further mitigate artefacts such as those arising from differences in illumination, especially if using images from a diversity of sources.

      2) The justification for some related decisions are also unclear to me. The CIE-76 colour distance is used, and is described as 'conservative'. But it is not so much conservative as it is an inaccurate model of human colour sensation. It fails to account for perceptual non-uniformity and actually overestimates colour differences between highly chromatic colours (like saturated blues). The authors note they preferred this to CIE-2000, which is a much better measure in terms of accuracy, because the latter was too permissive (line 300). I understand the problem, and appreciate their honesty, but this decision seems very arbitrary. If the goal is to quantitatively estimate colour differences according to human viewers, then the metric which best estimates our perceptual abilities would strike me as most appropriate. Also, the fact that all species would be classified as 'blue' using the CIE-2000, when some of them are obviously not blue by simply looking at them, is consistent with the kinds of image-processing issues noted above. I only focus on this general point because it is offered as a key advance on previous work (L 40-41), but I don't think that is clearly the case (though I agree that the scoring methods of Hsiung et al. are quite vague). I'm generally in favour of this sort of quantitative approach, but here I wonder if it wouldn't be simpler and more defensible to just ask some humans to classify images of spiders as either 'blue' or 'green', since that seems to be the end-goal anyway.

      We agree that CIE 1976 is an inaccurate model of “human color sensation,” but at the same time the degree of their applicability or lack thereof to non-human tristimulus visual systems is not clear. In any case, the digital photographs do not preserve UV information anyway. We hasten to add CIE 1976 is still widely used in color science and engineering research for its simplicity and perceptual uniformity, as a simple Google Scholar search would attest. We believe that the reviewer is perhaps mistaken as to our motivation for choosing the CIE 1976 and the exact nature of the shortcomings of the CIE 1976 model, which it turns out to be an unintended advantage. Our goal was not, as the reviewer suggests, to just “quantitatively estimate color differences according to human viewers,” but to do so in a device independent fashion given the constraints of working with already available digital images, and for a putative trichromat visual system. Given there are technically no limits for a and b values in the CIE 76 space, color patches with high values of chroma are computed to have too strong a difference than in actual fact (Hill et al. 1997 ACM Transactions on Graphics, 16, 109-154). This is precisely the kind of situation that we do not face here, as we are essentially comparing shades of blue rather than for instance, chromatic contrasts between saturated blue vs. green or blue vs. red. Moreover, we only use the rectilinear rather than the polar coordinate representation of the colors (in other words, we do not compute the psychometric correlates, chroma Cab, or the hue angle hab). Contrary to the reviewer’s assertion that the CIE 1976 “overestimates color differences between highly chromatic colors (like saturated blues),” a quick perusal of Table S3 affirms that a comparison of highly saturated blues such as between our “standard” H. lividum and Poecilotheria metallica reveals they are quite close in terms of chromatic contrasts (i.e., small E values). Moreover, CIE 1994 and subsequent revisions rely on a von Kries-type transformation to account for non-uniformity of the perceptual space, but as the reviewer is well aware, without an accurate idea of the illumination conditions, use of CIE 2000 is not justified.

      Lastly, we are sure the reviewer appreciates that asking humans to manually score the colors of images (e.g. Hsiung et al. 2015) is neither reproducible nor enables quantitative analyses of trait evolution.

      3) L26-27, 53-56, 171-176: This is a more minor point than the above, but some of the discussion and logic around hypothesised functions could be elaborated upon, given it's presented as a motivating aim of the text (52-56). The challenge with a group like this, as the authors clearly know, is that essentially none of the ecological and behavioural work necessary to identify function(s) hasn't been done yet, so there are serious limitations on what might be inferred from purely comparative analyses at this stage. The (very interesting!) link between green colouration and arboreality is hypothesised and interpreted as evidence for crypsis, for example, but the link is not so straightforward. Light in a dense forest understory is quite often greenish (e.g. see Endler's work on terrestrial light environments) including at night which, when striking a specular, structurally-coloured green could make for a highly conspicuous colour pattern - especially achromatically (which is what nocturnal visual predators would often be relying on). This is particularly true if the substrate is brown rotten leaves or dirt, in which case they could shine like a beacon. Conversely, if the blue is sufficiently saturated and spectrally offset from the substrate it could be quite achromatically cryptic at dusk or night. To really answer these questions demands information on the viewers, viewing conditions, visual environment etc. The point being that it is a bit too simplistic to observe that, to a human, spiders are green and leaves on the forest floor may be green, and so suggest crypsis as the likely function (abstract L 22-23). So inferences around visual function(s) could either be toned down in places given the evidence at hand or shored up with further detail (though I'm not sure how much is available).

      We agree. Indeed, we are limited by the absence of rigorous behavioural studies. With this in mind, we have already made every effort to tone down and emphasize that our results might point towards a given function, but we do not claim it outright. It is our fervent hope that these findings will form the basis for future behavioural studies by giving researchers a starting point to test their hypotheses.

      We would like to point out that the association we uncovered is actually between arboreal taxa and the presence of green coloration and not as the reviewer says “spiders are green and leaves on forest floor may be green.” These taxa live in natural crevices on trees, shrubs and essentially spend their lives arboreally. Also, green coloration in tarantulas need not be structural in origin (see e.g., Saranathan et al. 2015) and this is why to test for crypsis against foliage, we used (pigmentary) leaves as the representative model for comparison to tarantula green colors. Although, certain lycaenid butterflies (Saranathan et al. 2010 10.1073/pnas.0909616107; Michielsen et al. 2010 10.1098/rsif.2009.0352), for instance, use structural coloration to better aid in crypsis against foliage.

      Minor comments:

      • I'm not familiar enough with with methods for creating homolog networks to comment in detail, but the use of BLASTing existing opsin sequences against transcriptomes seems straightforward enough. As do the methods for phylogenetic reconstruction.

      We agree this is straightforward.

      • L48: What constitutes a 'representative' species? And how reasonable is it to assign a value for such a labile trait to an entire genus? I understand we can only do our best of course and simplifications need to be made, but I can imagine many cases among insects (e.g. among butterflies and flies) where genus-level assignments would be meaningless due to the immense diversity of structural colouration among species (including in terms of simple presence/absence).

      Please see our response to Reviewer 2 above.

      • Line 168: Wouldn't this speak against a sexual function? Only in a tentative way of course, but the presence of conspicuous structural colouration in juveniles, which is absent in adults, would suggest a non-sexual origin to me.

      The reviewer’s inference is incorrect. We do not suggest that blue coloration is present in juveniles but absent in adults, but only that such conspicuous colors already appear in the penultimate moult right before the male creates a sperm web and is ready for mating.

    2. Reviewer #3:

      This neat paper continues the story of structural colour evolution in a group that is rarely appreciated for their ornamentation. The study uses colour & ecological data to model their evolution in a comparative framework, and also synthesises transcriptomic data to estimate the presence and diversity of opsins in the group. The main findings are that the tarantulas are ancestrally 'blue' and that green colouration has arisen repeatedly and seems to follow transitions to arboreality, along with evidence of perhaps underappreciated opsin diversity in the group. It's well-written and engaging, and a useful addition to our understanding of this developing story. I just have a few concerns around methods and the interpretation of results, however, which I feel need some further consideration.

      As the authors discuss in detail, this work in many ways parallels that of Hsiung et al. (2015). The two studies seem to agree in the broad-brush conclusions, which is interesting (and promising, for our understanding of the question), though their results conflict in significant ways too. Differences in methodology are an obvious cause, and they are particularly important in studies such as this in which the starting conditions (e.g. the assumed phylogeny or decisions around mapping of traits) so significantly shape outcomes. The current study uses a more recent and robust phylogeny, which is great, and the authors also emphasise their use of quantitative methods to assign colour traits (blue/green), unlike Hsiung et al.

      1) This latter point is my main area of methodological concern, and I am not currently convinced that it is as useful or objective as is suggested. One issue is that the photographs are unstandardised in several dimensions, which will render the extracted values quite unreliable. I know the authors have considered this (as discussed in their supplement), but ultimately I don't believe you can reliably compare colour estimates from such diverse sources. Issues include non-standardised lighting conditions, alternate white-balancing algorithms, artefacts introduced through image compression, differences in the spectral sensitivities of camera models, no compensation for non-linear scaling of sensor outputs (which would again differ with camera models and even lenses), and so on (the works of Martin Stevens, Jolyon Troscianko, Jair Garcia, Adrian Dyer offer good discussion of these and related challenges). Some effort is made to minimise adverse effects, such as excluding the L dimension when calculating some colour distances, but even then the consequences are overstated since the outputs of camera sensors scale non-linearly with intensity, and so non-standardised lighting will still affect chromatic channels (a & b values). So with these factors at play, it becomes very difficult to know whether identified colour differences are a consequence of genuine differences in colouration, or simply differences in white balancing or some other feature of the photographs themselves.

      2) The justification for some related decisions are also unclear to me. The CIE-76 colour distance is used, and is described as 'conservative'. But it is not so much conservative as it is an inaccurate model of human colour sensation. It fails to account for perceptual non-uniformity and actually overestimates colour differences between highly chromatic colours (like saturated blues). The authors note they preferred this to CIE-2000, which is a much better measure in terms of accuracy, because the latter was too permissive (line 300). I understand the problem, and appreciate their honesty, but this decision seems very arbitrary. If the goal is to quantitatively estimate colour differences according to human viewers, then the metric which best estimates our perceptual abilities would strike me as most appropriate. Also, the fact that all species would be classified as 'blue' using the CIE-2000, when some of them are obviously not blue by simply looking at them, is consistent with the kinds of image-processing issues noted above. I only focus on this general point because it is offered as a key advance on previous work (L 40-41), but I don't think that is clearly the case (though I agree that the scoring methods of Hsiung et al. are quite vague). I'm generally in favour of this sort of quantitative approach, but here I wonder if it wouldn't be simpler and more defensible to just ask some humans to classify images of spiders as either 'blue' or 'green', since that seems to be the end-goal anyway.

      3) L26-27, 53-56, 171-176: This is a more minor point than the above, but some of the discussion and logic around hypothesised functions could be elaborated upon, given it's presented as a motivating aim of the text (52-56). The challenge with a group like this, as the authors clearly know, is that essentially none of the ecological and behavioural work necessary to identify function(s) hasn't been done yet, so there are serious limitations on what might be inferred from purely comparative analyses at this stage. The (very interesting!) link between green colouration and arboreality is hypothesised and interpreted as evidence for crypsis, for example, but the link is not so straightforward. Light in a dense forest understory is quite often greenish (e.g. see Endler's work on terrestrial light environments) including at night which, when striking a specular, structurally-coloured green could make for a highly conspicuous colour pattern - especially achromatically (which is what nocturnal visual predators would often be relying on). This is particularly true if the substrate is brown rotten leaves or dirt, in which case they could shine like a beacon. Conversely, if the blue is sufficiently saturated and spectrally offset from the substrate it could be quite achromatically cryptic at dusk or night. To really answer these questions demands information on the viewers, viewing conditions, visual environment etc. The point being that it is a bit too simplistic to observe that, to a human, spiders are green and leaves on the forest floor may be green, and so suggest crypsis as the likely function (abstract L 22-23). So inferences around visual function(s) could either be toned down in places given the evidence at hand or shored up with further detail (though I'm not sure how much is available).

      Minor comments:

      -I'm not familiar enough with with methods for creating homolog networks to comment in detail, but the use of BLASTing existing opsin sequences against transcriptomes seems straightforward enough. As do the methods for phylogenetic reconstruction.

      -L48: What constitutes a 'representative' species? And how reasonable is it to assign a value for such a labile trait to an entire genus? I understand we can only do our best of course and simplifications need to be made, but I can imagine many cases among insects (e.g. among butterflies and flies) where genus-level assignments would be meaningless due to the immense diversity of structural colouration among species (including in terms of simple presence/absence).

      -Line 168: Wouldn't this speak against a sexual function? Only in a tentative way of course, but the presence of conspicuous structural colouration in juveniles, which is absent in adults, would suggest a non-sexual origin to me.

    1. Reviewer #2:

      The authors employed a clever experimental paradigm to investigate how the brain integrates visual information to reach a decision on the familiarity of a presented face. Eighteen subjects performed an EEG experiment while they were presented with images of themselves, close friends, famous individuals, or unfamiliar individuals. They were required to perform a 2AFC task to decide on the familiarity of the image (familiar/unfamiliar). The authors report behavioral differences in accuracy and reaction times depending on the task difficulty (more or less degraded images) and depending on the familiarity of the face, with self and personally familiar faces being recognized more easily and faster. Some of these behavioral differences were reflected in brain activity as evaluated by ERPs, decoding, and RSA analyses. Adopting a novel RSA-based connectivity method, the authors claim that under conditions with limited visual information (more degraded images), top-down effects from frontal areas to occipital areas are stronger than in conditions with increased visual information (less degraded images).

      The main question of this work is of interest and important in the face processing literature. The paradigm is clever and has the potential to address the question of interest. However, I have strong concerns about the methods, as well as some issues with the interpretation and framework in which the authors place the results of this work.

      Methods:

      1) There is little information about single-subject results or effect sizes, except for behavioral results. Only the mean values across subjects are reported with significance values (however, the reader cannot be sure about this as it is not explicitly mentioned anywhere). It's unclear from the description of the methods how data from different subjects were pooled for group analysis. Similarly, it's unclear how the null distributions were generated across subjects for permutation testing.

      2) Different analyses use either correct trials only or both incorrect and correct trials, without any clear rationale of why this is warranted. This is especially important in a task with highly different accuracy values depending on the conditions of interest. Figure 1B shows different levels of behavioral accuracy depending on coherence levels, while Figure 1D shows different levels of accuracy depending on familiarity type. This is very interesting, but it creates challenges for the analysis of brain data.

      On the one hand, if only correct trials are selected for the analysis (as in the decoding results), then different conditions will have a different number of trials. In turn, this will change the distribution of samples into classes, it will change the theoretical chance level, and it will change the levels of noise for estimates of central tendency. For example, the difference in decoding results between different familiarity types in Figure 3B could potentially be driven by a different number of trials belonging to each of the subclasses of familiarity.

      On the other hand, if both correct and incorrect trials are selected for the analysis (as in the RSA analysis), then results are confounded by potentially different brain processes that take place for correct and incorrect trials. Consider that in a 2AFC task, participants can be correct in one way only (correct classification), while they can be incorrect in many ways (slow RT, low attention level, or true misclassification). Given this experimental paradigm, I think the more straightforward approach would be to analyze correct and incorrect trials separately for all analyses and report both results. This would limit confounding effects in the interpretation of the data.

      3) For the decoding analyses, I find it suboptimal (and potentially problematic) to use a binary classifier (familiar vs. unfamiliar) to investigate a multiclass problem (levels of familiarity). A better approach would be to run a 4-way classification from the beginning, and then use this classifier to generate a 2-way classifier. This approach would preserve the actual structure of the data, which is divided into four classes of interest and not only two. In addition, I cannot tell from the methods whether the labels were permuted appropriately for permutation testing. Since there is a different number of trials in each class, the label permutation should maintain the same proportion of trials in each class to preserve the original structure and generate an appropriate null distribution (Etzel, 2015; Etzel & Braver, 2013; Nichols & Holmes, 2002)

      4) It's unclear to me what the brain-behavior correlation analysis is meant to represent (Figure 3C) when the decoding analysis is performed on correct trials only, while behavioral accuracy is (necessarily) computed on all trials. In addition, I am left to wonder whether the overall within-subject behavioral accuracy is predicted by (or correlates with) the overall decoding accuracy across timepoints based on within-subject brain data. If such an effect exists, then the more complicated, time-varying analysis would be warranted. However, this analysis should be reported with individual subject's results to highlight the effect size of such a correlation. Finally, I would suggest the authors move some of the text describing this analysis from the methods to the main text. I find the description in the main text to be particularly opaque and much clearer in the methods section.

      5) It's unclear how the RSA results were pooled across subjects. In addition, these analyses used both correct and incorrect trials. I don't see why these analyses cannot be performed on correct and incorrect trials separately by sub-selecting rows and columns of the RDMs for each subject. This would make the interpretation of the results much more straightforward. These results are now confounded by whether the image was correctly or incorrectly classified by the participant.

      6) I'm not convinced the partial correlation results with low-level visual features are sufficient to account for the effect of visual differences. These differences necessarily exist when using pictures of famous people with less staged pictures of friends and other individuals. I'd like to know how much each image class can be predicted by image statistics alone either by mimicking the experiment using a classifier or by training a classifier to distinguish familiarity type on the actual images. This would quantify whether the familiarity of the person can be decoded simply based on low-level visual properties (such as luminance values from pixel intensities), or from more biologically inspired features that simulate early visual cortex, such as HMAX features or the first layer of a general recognition visual DNN.

      7) I find the proposed connectivity method quite interesting, but I'm highly concerned whenever a method is developed and tested in a single dataset to support the main hypothesis. I realize it is hard to obtain a real "ground truth" dataset to test this method, especially in our global condition. However, I would be more confident in this method if it were applied to some simulated data to show that it can recover the simulated feedforward/feedback dynamics with different amounts of noise in the dataset. In addition, especially for this analysis, differences between correct and incorrect trials should be analyzed. Otherwise, the interesting findings in Figure 4D could be confounded by a different number of correct trials in each of the coherence levels (with more incorrect trials for the 22% condition).

      Interpretation:

      8) Throughout the manuscript, I find the description of the visual pathway and the face processing network to be too simplified. It is described with a simple distinction into "peri-occipital" and "peri-frontal" areas, and a dichotomy between feed-forward/feed-back connection. While EEG cannot afford a more precise spatial resolution, I think both the introduction and the discussion should place the results of this manuscript within the broader and more precise knowledge we have about the visual system and the face processing system. For example, how do these results fit within the framework of (familiar) face processing (Duchaine & Yovel, 2015; Freiwald et al., 2016; Haxby et al., 2000; Visconti di Oleggio Castello et al., 2017)?

      While I agree that the evidence for top-down effects from frontal areas in visual recognition is substantial (as the seminal work by Moshe Bar and others has shown), recurrent and feedback connections exist much earlier in the pathway (Kravitz et al., 2013). These recurrent connections have been shown to play a role in tasks with occluded images as well (Tang et al., 2018), which has similarities with the task presented in this manuscript. Thus, for this task, do we really need to assume a contribution from frontal areas? Could it be more easily explained by these recurrent connections in occipital and temporal areas alone? I think the discussion should present a more precise (and nuanced) description of the visual pathway and the face processing network, rather than a simplified dichotomy between frontal/occipital areas.

      References:

      Duchaine, B., & Yovel, G. (2015). A Revised Neural Framework for Face Processing. Annual Review of Vision Science, 1(1), 393-416.

      Etzel, J. A. (2015). MVPA Permutation Schemes: Permutation Testing for the Group Level. 2015 International Workshop on Pattern Recognition in NeuroImaging, 65-68.

      Etzel, J. A., & Braver, T. S. (2013). MVPA Permutation Schemes: Permutation Testing in the Land of Cross-Validation. 2013 International Workshop on Pattern Recognition in Neuroimaging, 140-143.

      Freiwald, W., Duchaine, B., & Yovel, G. (2016). Face Processing Systems: From Neurons to Real-World Social Perception. Annual Review of Neuroscience, 39(1), 325-346.

      Haxby, J. V., Hoffman, E. A., & Gobbini, M. I. (2000). The distributed human neural system for face perception. Trends in Cognitive Sciences, 4(6), 223-233.

      Kravitz, D. J., Saleem, K. S., Baker, C. I., Ungerleider, L. G., & Mishkin, M. (2013). The ventral visual pathway: an expanded neural framework for the processing of object quality. Trends in Cognitive Sciences, 17(1), 26-49.

      Nichols, T. E., & Holmes, A. P. (2002). Nonparametric permutation tests for functional neuroimaging: a primer with examples. Human Brain Mapping, 15(1), 1-25.

      Tang, H., Schrimpf, M., Lotter, W., Moerman, C., Paredes, A., Ortega Caro, J., Hardesty, W., Cox, D., & Kreiman, G. (2018). Recurrent computations for visual pattern completion. Proceedings of the National Academy of Sciences of the United States of America. https://doi.org/10.1073/pnas.1719397115

      Visconti di Oleggio Castello, M., Halchenko, Y. O., Swaroop Guntupalli, J., Gors, J. D., & Gobbini, M. I. (2017). The neural representation of personally familiar and unfamiliar faces in the distributed system for face perception. In Sci. Rep. (Issue 1, p. 138297). https://doi.org/10.1038/s41598-017-12559-1

    2. Reviewer #1:

      In this manuscript the authors report a study investigating the "neural familiarity spectrum" of face recognition. The authors used a paradigm via which stimuli (i.e. facial identities with varied levels of familiarity) were gradually revealed. In general, I entirely agree that the previous overemphasis of and/or arguing "for a dominance of feed-forward processing" ought to be replaced by a more "nuanced view". In my opinion, the constraints imposed by our methodological choices, which ultimately determine the nature of our observations, also need to be humbly considered. I commend the authors for their efforts and their well-written, interesting manuscript, which I believe represents a valuable and needed contribution to the field of face cognition and beyond.

      Major Points:

      Throughout the manuscript references are warranted to a number of studies that have:

      (i) Used similar approaches to a) decelerate the categorization process and b) investigate representations across time by applying uni-/multivariate analyses that were stimulus onset and/or reaction time aligned (eg, Carlson et al., 2006; Jiang et al., 2011; Ramon et al., 2015; Quek et al., 2018)

      (ii) Have reported findings related to frontal contributions towards familiar face recognition (numerous EEG studies by Caharel and colleagues, and Ramon et al. (2010, 2015) What I am missing is an explicit discussion of the challenging effect of expectations related to identities (as well as specific images since observers provided stimuli themselves). The authors discuss the role of perceptual difficulty and familiarity level, but the latter is in fact confounded with expectations of the specific to-be-presented identities that moreover appear in the context of the active (vs. orthogonal) task, both of which increase signal strength. (Note: this is not a critique and applies to all studies using personally familiar identities - especially those that have used a relatively small number of identities).

      In light of this, I believe that statements related to the dominance of "feed-forward flow" in relation to perceptual difficulty should be more nuanced. Examples include:

      -"perceptual difficulty and the level of familiarity influence the neural representation of familiar faces and the degree to which peri-frontal neural networks contribute to familiar face recognition"

      -"We observed that the direction of information flow is influenced by the familiarity of the stimulus"

      Level of familiarity and perceptual difficulty are correlated in the present study, as well as most studies precisely because observers know who will be seen. Therefore, one could argue that the expectations, not the level of familiarity per se determine "the involvement of peri-frontal cognitive areas in familiar face recognition". (cf. Huang et al., (2017) and Ramon & Gobbini (2018) for a discussion).

      Related to this aspect and relevant for the analyses is the different number of trials across categories (3x as many unfamiliar face trials vs. each of the familiar ones). How was this dealt with statistically (cf. also stats reported in Figure 2) and were Ss informed about the ratio beforehand? Given the provision of self and personally familiar images, the task could also be considered a n-identity search task (cf. Besson et al., 2017), as they match sensory inputs to one of n possible known vs. an unknown number of unfamiliar identities / events. (To illustrate, the effects of expectations can determine the degree to which recovery from neural adaptation is observed across different face-preferential regions using the same task; e.g. Rotshtein et al, 2005, Nat Neurosci vs. Ramon et al., 2010, EJN)

      The authors list "levels of categorization [...], task difficulty [...] and perceptual difficulty [...]" as potentially affecting "the complex interplay of feed-forward and feedback mechanisms in the brain" (l.442). I agree and point towards further relevant papers to be cited that additionally investigate the impact of expectations or "decisional space" on categorical decisions in the healthy as well as impaired brain (eg Ramon, 2018, Cogn Neuropsychol; Ramon et al., 2019, Cognition; Ramon et al., 2019, Cogn Neuropsychol).

      To summarize, can "accumulation of sensory evidence in the brain across the time course of stimulus presentation" (l.267) and "the strength of incoming perceptual evidence and the familiarity of the face stimulus" considered to determine the direction of information processing be distinguished from the effect of expectations that potentially increases over time? (This is naturally non-existent for unfamiliar stimuli, for which no "domination of feed-forward flow of information" was found).

    1. Author Response

      We thank the editors and reviewers for taking the time to assess our paper. We note that the reviewers seemed generally supportive of the paper, including noting that the paper addressed important questions. For context, we reiterate here our main findings:

      • a prefrontal cortex population encodes the past and the present in its joint activity, but solves the interference problem by encoding all features on independent axes for their past and their present.
      • This encoding would in principle allow upstream regions to independently access representations of the past and present in mPfC populations. We go on to show this happens: we show that only the encoding of the present, and not the past, is reactivated in sleep after training.

      In this context, the main editorial objection that we “did not control for potential confounding of behavioral variables” is not explained in the reviews; we also note that there were no “concerns about the analytical methods used” that were pertinent to our main findings. We are thus unclear about the basis for rejection.

      We respond below to the main points of each reviewer; their suggestions on terminology and of separating literature citations on rodent and primate PfC are being given due consideration.

      Reviewer #1:

      Maggi and Humphries examined how the coding of the present and past choices in the medial prefrontal cortex (mPFC) of the rats during a Y-maze task overlaps and whether they can be reliably distinguished. They found that the neural signals related to the animal's choice in the present and past are distinct and as a result they can be recalled separately, for example, during post-training sleep. Although these are very important questions and an interesting set of analyses have been applied, the results in this report are not entirely convincing, because the analyses did not successfully exclude some alternative hypotheses.

      1) The authors analyzed the signals related to the choice, light cue, and outcome separately, and this is possible because the relationship between the animal's choices and cues were decoupled by testing the animals under at least two different rules. There were a total of 4 alternative rules and different sessions included different subsets of these rules. It is possible that at least some results reported in this paper might vary depending on which of these results were tested. For example, rules might affect how the animals learned the task. Therefore, the authors should provide more detailed information about how often different rules were used to collect the neural data reported in this paper, and whether any of the results change according to the rules used in a given session.

      In the paper we did examine mPfC encoding in the trials under the two qualitatively distinct types of rule (direction-based i.e. egocentric, and cue-based i.e. allocentric), and showed that encoding of the direction, light, and outcome occurred in both rule types (figure 1e). We gave the number of sessions for those rules in the legend for Figure 1e. (We could equally decode all 3 features in direction-based and cue-based rule sessions in the inter-trial interval as well, see Maggi et al 2018, Figure 9). Thus we compared the decoding vectors across all rule-types.

      Only 8 sessions contained more than 1 rule, in the sessions in which the rule was switched. In the full analysis underlying this paper, we had also separately examined the decoding in these 8 rule-switch sessions, and found equally good decoding of direction, choice, and cue. As the paper was already dense - see e.g. Reviewer 3’s comments - we elected to not show this null result in the current version of the manuscript - it is available in version 1 of this preprint - but it can be restored if desired.

      2) The authors claim that the neural coding identified in this study does not depend on the signals in individual neurons by showing comparable results after removing the neurons with significant modulations. This logic is flawed, because the neurons without "significant" modulations might still include meaningful signals due to type II errors. Furthermore, if individual neurons carry absolutely no signals, how can a population of neurons still encode any signals? This might suggest some kind of joint coding, and the authors should not merely implicate such a possibility without more thorough tests.

      The joint coding of information by a population of neurons is the basis for the whole paper, and is tested extensively: for example, Figure 1 is about establishing that joint coding exists in mPfC. Our point on lines 91-95 was simply to show that the decoding could not be trivially explained by one or two neurons that reliably and strongly differed in the firing rates between different labels (e.g. between left or right choice of direction). To do so, we found sessions in which there were neurons with significantly detectable tuning to the task feature, omitted those sessions, and then looked at the performance of the feature decoding in the remaining sessions - and found it was just as good. Indeed, our point is precisely that it is possible for individual neurons to carry no signals detectable by classic significance testing (potentially due to Type II errors), yet for the population to be able to perfectly encode the information.

      The explanation is simply that most, and sometimes all, individual neurons do not consistently covary their firing with the changes in a feature (e.g. choose left and choose right trials) across every trial of a session. In other words, no neuron need consistently participate in encoding information. But so long as when a neuron does change its firing it does consistently vary with the feature, then across a population there are enough intermittently participating neurons on a given trial to always decode the information.

      3) The authors analyzed the activity divided into 5 different epochs, where the position #3 corresponds to a choice point and #5 corresponds to the reward site. Therefore, it is surprising that the reliable outcome signals begin to emerge from the position #3 (i.e., choice point). Is this a false positive?

      No, this replicated a common finding of outcome-predictive signals in prefrontal cortex; e.g. Daw, N. D., O’Doherty, J. P., Dayan, P., Seymour, B. & Dolan, R. J. Cortical substrates for exploratory decisions in humans. Nature 441, 876–879 (2006).

      Fellows, L. K. Advances in understanding ventromedial prefrontal function: the accountant joins the executive. Neurology 68, 991–995 (2007).

      Sul, J. H., Kim, H., Huh, N., Lee, D. & Jung, M. W. Distinct roles of rodent orbitofrontal and medial prefrontal cortex in decision making. Neuron 66, 449–460 (2010).

      Kaplan, R. et al. The neural representation of prospective choice during spatial planning and decisions. PLoS Biol. 15, e1002588 (2017).

      We will add these references to the next version of the manuscript.

      4) The authors report that there is retrospective coding, i.e., no coding of the choice in the previous. By contrast, during the intertrial interval (while the animal's returning to the start position), the signals related to the "past" choice were still present but different from how this information was coding earlier during the trial. This is not surprising since during the intertrial interval, the animal's movement direction is opposite compared to that during the trial, so this coding change could reflect the animal's sensory environment. Whether the brain encodes the past and previous events using different coding schemes or not cannot be tested with such confounding.

      We note that the reviewer’s objection here only relates to the choice of arm direction, whereas we showed independent encoding of all three features: direction, outcome, and cue position. We can thus test how the past and present are differently encoded because we showed they are both encoded in the same set of neurons. We showed at length both here (Figure 2a&c, Supplementary Figure 5a) and in Maggi et al 2018 (Figs 5-6 and accompanying supplementary figures) that we could decode the past events from the population activity during the inter-trial interval. The information of the trial and the inter-trial interval can be decoded from the same neurons, so the question is: how can the same neurons encode both the present and the past?

      One interpretation of the reviewer’s comments is that they are concerned about the possible confounding of movement direction between the trial and the following inter-trial interval. Namely, that the turn directions are guaranteed to be opposite: e.g a left turn into the left-hand arm on the trial would mean a right-hand turn on the return journey of the inter-trial interval. However, that would mean the feature labels would be exactly complementary e.g. trial =[L L R L R] and ITI = [R R L R L]. So if the population was encoding the direction choice the same way in both the trial and ITI, then using the trial’s decoder of direction to decode direction choice in the ITI should result in a performance of 1-[proportion of correctly classified trials], meaning the classifier would be significantly below chance (and vice-versa for using the inter-trial interval’s decoder for the trials). However, we find the cross-decoding performs at chance (Fig 2).

      5) The authors tested whether the coding of present and past events is consistent using a transfer (cross-decoding) analysis. However, this is based on simply correlation, and does not exclude the possibility that neurons changing their activity similarly according to (for example) the animal's choice might also change their baseline activity between the two periods (as revealed by the analysis of "population activity" in Figure 3) or might additionally encode different variables. In this case, decoding based on simple correlation might not reveal consistent coding that might be present.

      It is unclear what the referee means by the cross-decoding analysis being “based on simple correlation”. The decoder is trained on vectors of firing rates (cf Figure 1b). The decoder assigns high weights to neurons whose activity differs most strongly between the two labels (e.g. left and right choice of direction). So a change in “baseline”, presumably meaning the average firing rate of a neuron across all trials or all ITIs, would not alter the decoder outcome. In addition to the two cross-decoding tests, we also showed the independent encoding by: (a) The angles formed by the decoding vectors trained solely on the trials and solely on the ITIs (Fig 2d-f) (b) The independence of the population rate vectors between trials and ITIs (Fig 3). Indeed, the change in population rates between trials and ITIs shown in Figure 3 is exactly those predicted by the cross-decoding results, as explained on pg 7.

      Reviewer #2:

      The study by Maggi and Humphries re-examines data by Peyrache et al. (2009), which the authors have themselves analysed previously (Maggi et al., 2018), recorded , in rat prelimbic/infralimbic cortex (see comment below on terminology). In particular, they look at the relationship between decoding of task events during performance of a trial, and during the subsequent intertrial interval. (n.b. in this study, unlike in many studies, the ITI is considerably longer than the trial period). They find that although task-relevant information can be decoded during these two periods, the information is encoded in orthogonal subspaces during trials ('the present') and ITIs ('the past'). They build on this to examine how information is encoded during sleep following training (vs a pre-training control period). They find that only the trial subspaces are reactivated during sleep, not the ITI subspaces, and more so if the rat received a higher rate of average reward.

      On the whole, I found this an interesting paper with a clear set of findings, and well-analysed data. Although the advance in some ways an incremental one on previous studies of sleep/replay, and on the authors' previous analyses of this dataset, the study will undoubtedly be of interest to researchers who are interested in consolidation of past experience during sleep. In particular, the study benefits from being able to look for two different types of information ('past' and 'present' decoders) in the same sleep recording sessions. There were a few things that I felt the authors could address:

      1) For the cross-decoding analysis in figure 2 b, it is not entirely clear from the main text which part of the trial and ITI coding is being used here. It seems to me like a more useful way of showing the cross-decoding analysis would be to show the 10x10 matrix of cross decoding accuracy for each of the 5 maze positions in both trials and ITIs. This is, I think, different from what the analysis in figure 3g is trying to show (which plots the classification error after dimensionality reduction to a 2D space).

      As we strived to explain in the text, for the cross-decoding analysis we used the decoder trained on the firing rates across the entire trial and separately across the entire ITI, in order to arrive at the most stable decoding vectors. We did not show the cross-decoding for the full 5x5 matrix of positions, as the results would be quite noisy. Nevertheless, this is a constructive suggestion, and we will add this analysis. (And indeed the analysis in Figure 3 already shows that the population activity is separable in 1 or 2 dimensions between the trials and ITIs at each maze position, so we would expect the decoder weight vectors to also be independent).

      2) It was surprising to me that the authors do not mention the finding in figure 4e anywhere in the abstract or introduction. It makes the reactivation story far more compelling if it can be linked to a change in behaviour during the preceding trials. I think this finding would benefit from not being buried deep in the results section.

      We are happy to make this result clearer. Our main finding is of the independent coding, and this result in Fig 4e does not speak directly to the independent coding results, but rather is a lovely little result to support the hypothesis that there really is reactivation of the population vectors in sleep. Because it did not speak to the main thrust of the paper, it was omitted from the abstract given the constraints on the number of words (150).

      3) The finding in figure 5 seems slightly extra-ordinary. It suggests that reactivation decoding during sleep is reliable even if very long bins of activity are used to calculate the firing rate (e.g. up to 10s). Does this relationship ever break down? Presumably with the sleep data, it would be possible to extend bins up to 1 minute, 5 minutes, etc. If there is still more reactivation at these extremely long time-bin lengths, does this mean that these neurons are essentially more persistently active? One possible way to test for this might be to project the data recorded during sleep through the classifier weights, and then calculate the autocorrelation function of this projected data (e.g. Murray et al., Nat Neuro 2014) - if this activity becomes more persistent, the shape of the ACF may change post-training.

      An excellent question. Rather than persistent activity, we interpreted the consistency of reactivation across orders of magnitude time-scales as showing that the correlations between the neurons were roughly consistent; and thus when active tended to be active in roughly the same relative order. Support for this comes from the findings in Appendix Fig A4e - the correlation matrix between neurons in the trial was more consistently found in post than pre-session sleep.

      Reviewer #3:

      This article asks the question if within trial (present) and ITI (past) task parameters are encoded in mPFC, and how encoding during these two trial epochs are encoded. They claim that firing in mPFC reflects past and present, but population encoding of past and present are independent. Further they show that the present is reactivated during sleep, not the past.

      On the face of it, this seems like an interesting paper. It is novel in that ITI encoding would be highly related to what was going on in the trial. The sleep finding is also interesting but I don't quite get the distinction between present and past for sleep. That could use some clarification.

      1) I'm not an expert in regards to this type of analysis, but throughout I was left with the feeling that I would prefer at least some single neuron data and firing rate analysis to complement the highly computational analysis, which frankly, was difficult to understand or critique by somebody who is not an expert.

      The goal of the paper is to assess the population coding in PfC of the same events in the past and the present. Indeed, as reported in the paper, we found 25-39 sessions which had no single neuron tuning at all to a given event in a trial (such as the choice of maze arm).

      2) I would have liked to see more analysis of firing correlations with behavior. It seems to me if animals were doing different things during the trial and the ITI, then it might not be a surprise that there is independent encoding.

      3) I also wonder if the finding is solely dependent on the task (which is poorly described). It seems like there should be independent coding of past and present in this circumstance because they do not feed into each other, and behavior during one is independent of behavior in the other.

      4) Relatedly, the authors suggest that independent encoding can explain how the brain resolves interference between past and present, but in this task there was no interference between past and present, and the authors do not show that when there is more or less dependent encoding that there is more or less interference. Without it is unclear how to know how important this finding is as it relates to performance and general mPFC function.

      We deal with these points together, as they are all on the behaviour in the trial and inter-trial interval in the task. Yes, the behaviour in the trial is independent of that in the inter-trial interval, so there is no “interference” of behaviour. But that is not of relevance to what is encoded in the PfC. The Introduction and Discussion both point out that the problem is interference of the encoding itself: the encoding of the past and present exists, as we show at length, so the question is: how can it co-exist in the same neurons? We indeed ask if there is no “interference” in the encoding simply because activity in the inter-trial interval is just a memory trace of activity in the trial, and rule that out.

      We cannot address when there is “more or less dependent” encoding, because the results are what they are: there is independent encoding of the same events (Figure 2).

      The task is described in detail in the Methods (pgs 20-21).

      5) Could activity reflect what the animal predicts will happen on the next trial, or what they are planning to do? It wasn't clear if that was examined.

      Whether activity in the inter-trial interval predicted what will happen in the next trial was examined in detail in Maggi et al 2018 (Fig 6), and shown here in Figure 2g. We found no encoding of the following trial’s choices, except for a very niche occurrence: an above chance decoding of the next trial’s direction choice when the rat had returned to the start position, during a learning session, and for a direction rule. In other words, as it turned to start the next trial, so there was decoding of the upcoming choice of arm.

    1. Reviewer #3:

      The study by Mangeol et al. aims to dissect the localisations, interactions and hierarchical order of apical protein complexes crucial to the generation and maintenance of epithelial polarity in epithelial tissues.

      They analyse by super-resolution microscopy (STORM) three different mature epithelia, human and mouse intestine as well as mature Caco-2 cells in culture. Using immunofluorescence labeling of endogenous proteins, they compare individual components to markers of tight junctions, to each other and to the actin cytoskeleton. They identify defined clusters in defined sub regions of the apical domain of the analysed cells, raising interesting questions for future analyses.

      The subject matter of the study, the generation and maintenance of epithelial polarity and the role of apical polarity complexes, is clearly a very important one, especially as most organ systems are epithelial in nature. And despite decades of study, many questions are still unresolved.

      The imaging performed in this study is skilful and beautifully presented. The imaging achieving, according to the authors, an isotropic resolution of about 80nm is impressive. Because of this great gain in resolution compared to other studies of similar components I have a couple of technical questions or comments:

      1) I would very much appreciate some comments or thoughts on the fact that polarity proteins were revealed using antibodies. Antibodies are in the range of 10-15nm in length, so with an isotropic resolution of 80 nm, this might have to be taken into account when using primary and secondary antibodies to reveal proteins. In particular, monoclonal versus polyclonal antibodies might have differing effects on localisation precision.

      2) The authors use rather high concentrations of detergent (1% SDS or 1% Triton X-100) for permeabilisation according to their protocols. Are they not worried that this might affect tissue integrity and protein distribution?

      The authors rightly point out where their study fits within what has been attempted by other labs previously in order to understand and dissect apical polarity complex function. They clearly define interesting aspects, such as PALS1-PATJ and aPKC-PAR6 forming independent clusters, and the lack of colocalisation and thus maybe association with Crumbs3. In contrast to the last sentence statement of their abstract 'This organization at the nanoscale level significantly simplifies our view on how polarity proteins could cooperate to drive and maintain cell polarity.' I cannot yet see what these results simplify about our understanding of apical polarity complexes and even more so what the authors' new model is of how the complexes work. This needs to be spelt out more clearly, please. And I would also point out that, in part, other studies have pointed in the same direction. The recent paper by the Ludwig lab (Tan et al. 2020 Current Biology 30, 2791-2804) points in part in a similar direction, identifying a vertebrate 'marginal zone' similar to the one already known from invertebrate epithelia, as well as identifying basal to this an apical and basal tight junction area. Furthermore, as the authors themselves discuss in the discussion, the 'splitting away' of Par3 has been observed in Drosophila epithelia (embryonic, follicle cells and eye disc), and should maybe be introduced already at an earlier point of the paper. Furthermore, papers by Wang et al. and Dickinson et al., that also analyse PAR complex clustering should be cited and mentioned in the introduction/discussion (Wang, S.-C., Low, T. Y. F., Nishimura, Y., Gole, L., Yu, W., & Motegi, F. (2017). Cortical forces and CDC-42 control clustering of PAR proteins for Caenorhabditis elegans embryonic polarization. Nature Cell Biology, 19(8), 988-995. http://doi.org/10.1016/S0960-9822(99)80042-6; Dickinson, D. J., Schwager, F., Pintard, L., Gotta, M., & Goldstein, B. (2017). A Single-Cell Biochemistry Approach Reveals PAR Complex Dynamics during Cell Polarization, 1-42. http://doi.org/10.1016/j.devcel.2017.07.024).

      I am also a bit confused by the analysis presented in Figure 5 with regards to colocalisation of components with apical F-actin structures and the deduction from these and the EM data that some components, aPKC/Par6, localise to 'the first row of' microvilli near junctions whilst PALS1-PATJ localise near the base of said microvilli. How would localisation to the apical plasma membrane outside of or within microvilli be restricted to only the ones near junctions? There is not only F-actin in microvilli but also all over and near the apical cortex, so what distinguished the ability of aPKC/PAR6 to bind to actin in microvilli? The PATJ knock-down results are interesting, and I agree suggestive of some interaction between the complexes and actin organisation. But without further analyses as to what other components might be affected in their localisation in this situation, it is hard to judge whether the effect on actin is a direct or rather indirect one, so I am unsure as to what these images add without more in depth follow-up.

      Some more specific comments:

      Figure 1: It would be good to show and demonstrate that Occludin and ZO-1 labeling are completely interchangeable in terms of localisation precision.

      Figure 3: I do understand the authors' rationale for analysing the localisation in the orientation (planar versus apical-basal) that reveals the largest distance, but it would be good to nonetheless show the other orientation for completeness (maybe as supplementary).

    1. King, Martin Luther. “Letter to Birmingham.” Received by Bishop C. C. J. Carpenter, Bishop Joseph A. Durick, Rabbi Milton L. Grafman, Bishop Nolan B. Harmon, Rev. George H. Murray, Rev. Edward Ramage, Rev. Earl Stallings, Birmingham City Jail, 16 Apr. 1963, Birmingham, Alabama. Livingston, Donovan, director. Donovan Livingston’s Harvard Graduate School of Education Student Speech. Youtube, Harvard Graduate School of Education, 25 May 2016, youtu.be/9XGUpKITeJM.

      I see two out of the three sources here.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      We would like to express our appreciation for both the Editors’ and Reviewers’ efforts as essential contributions to the peer review process. We highly value the Reviewers’ constructive critique of our manuscript#RC-2020_00434R entitled “A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.__” __

      We appreciate the Reviewers’ thoughtful consideration of our work and feel their critiques and recommendations have significantly improved our manuscript. Taken together, we believe the additional data, clarification of data presentation, and revised discussion address the heart of the Reviewers’ previous concerns. Thus we feel the work is ready for reconsideration and will be an impactful addition to the literature appropriate for publication. Below we provide a breakdown and a point by point response to previous review critiques.

      Thank you for your attention. We look forward to your response.

      Best Wishes,

      Brian Kraemer, PhD ▪ Associate Director for Research Geriatric Research Education and Clinical Center ▪ Veterans Affairs Puget Sound Health Care System ▪ Research Professor ▪ Departments of Medicine, Psychiatry and Behavioral Sciences, and Pathology ▪ University of Washington ▪ 1660 South Columbian Way ▪ Seattle, WA 98108 ▪ Phone 206-277-1071 ▪ www.kraemerlab.uw.edu

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      In this manuscript, Baker et al. report the screening of a collection of ~6,070 drugs for their inhibitory activity against the enzymatic activity of the SARS-SoV-2 Mpro protein in vitro using two peptide substrates. 50 compounds with activity against Mpro were identified and tested for their dose-dependent effect in the same assay. Several hits were identified, among which are approved drugs that target the HCV protease.

      Indeed, there is an urgent need for effective drugs for SARS-CoV-2 infection, and high throughput screenings can discover novel candidates. However, the novelty of this work is quite limited, as former screens have been published with the same target using the same substrates. Moreover, as discussed below the translational impact of the hits discussed is also quite limited, particularly in the absence of antiviral data. Lastly, there are several overstatements in the write up and it will require major editing.

      **Major comments:**

      1. Were there any positive controls previously shown to potently inhibit the SARS-CoV-2 Mpro included in the screen (e.g. ebselen)? How did these perform in this assay? When first designing our protease assay, we did use ebselen as the initial control. Ebselen showed low potency in all our in our assays and was not considered as a positive control subsequently. It should be noted that Ebselen failed to work against multiple substrates. It is possible that our buffer conditions prevented Ebselen activity. See data plotted below. After identifying boceprevir as a potent inhibitor, it was used in all subsequent assays as a positive control.

      It will be helpful if the authors would provide info re the 50 hits from prior screens conducted with this library of compounds - how promiscuous are they across screens? How toxic in cell based assays?

      We have updated the table to provide additional useful information as well as a footnote explaining statuses. The compounds in the Broad repurposing library are generally non-toxic and information about them can be found here: https://clue.io/repurposing

      The translational potential of the findings appears to be limited. The calculated IC50s for these drugs in the Mpro assay are very high (10-1000 fold higher) relative to their IC50 in an enzymatic assay involving the HCV protease (Boceprevir: IC50 = 0.95 μM vs. 0.084 μM in HCV), Ciluprevir (IC50 = 20.77 μM vs. 0.0087 in HCV), Telaprevir (IC50 = 15.25 μM vs.0.050 μM in HCV) (https://aac.asm.org/content/aac/57/12/6236.full.pdf ). In the absence of antiviral data, the main statement of the manuscript that "the work presented here supports the rapid evaluation of previous HCV NS3/4A inhibitors for repurposing as a COVID-19 therapy." is thus an overstatement. Even is there is some activity, since likely to be limited, as with the HIV protease inhibitors, its chances to elicit a meaningful clinical effect is low. Moreover, when used in monotherapy, some of these protease inhibitors have a very low genetic barrier to resistance.

      We have reworked the discussion to incorporate these concerns and limitations of our results.

      There are additional inaccurate or overstatements - e.g. line 61 "Probably the most successful approved antivirals are protease inhibitors such as atazanavir for HIV-1 and simeprevir for hepatitis C. [reviewed in 10 and 11]."

      We have reworded this statement: (Page 4, Lines 61-62)

      “There is precedence for targeting the protease, as this approach has been successful in treating both HIV-1 and hepatitis C (10,11).”

      The manuscript requires editing - e.g. structure of sentences, commas, spacing (including in the abstract) etc.

      The manuscript has been re-proofed throughout (see tracked changes version of manuscript)

      What is the take home message? The statement "Taken together this work suggests previous large-scale commercial drug development initiatives targeting hepatitis C NS3/4A viral protease should be revisited because some previous lead compounds may be more potent against SARS-CoV-2 Mpro than Boceprevir and suitable for rapid repurposing." is unclear.

      The take home message of the manuscript is that HCV-targeting protease inhibitors have potential in blocking the SARS-Cov2 protease and a more thorough analysis of the space is needed. As the reviewer pointed out, the identified hits boceprevir and narlaprevir are less potent when targeting the SARS-Cov2 protease as compared to the HCV protease. However, we believe this work does show the potential for screening HCV-targeting protease inhibitors that may not have made it to the clinic. For instance, Boceprevir or Narlaprevir analogs may be even more potent against Mrpo. Further, we believe that these compounds would benefit from further optimization through medicinal chemistry.

      We have expanded the discussion to incorporate issues brought up here and in point 3.

      Reviewer #1 (Significance (Required)):

      Limited. As discussed above

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      SARS-CoV-2 pandemic causing serious health crisis globally. There are no specific medicine or vaccines to contain this virus currently. To address this issue, the authors developed one efficient fluorescent Mpro assay system and screened ~6070 previous used drugs in this article. Several compounds with activity against SARS-CoV-2 Mpro in vitro were founded. Most hits are hepatitis C NS3/4A protease inhibitors with fair IC50 value. Besides, the authors found that most identified compounds in in silico screen lack activity against Mpro in kinetic protease assays.

      These research results are well proved and reproducible. But there are two minor questions I present below:

      1. In your Mpro assay optimization process you said substrate MCA-AVLQSGFR-K(Dnp)- K-NH2 had drastically lower rates of Mpro catalyzed hydrolysis and were not considered further in your assay development. And in your Fig.1 I saw extremely low RFU changes. But several nice inhibitors were screened using this substrate that was reported in April. Can you explain this result? The substrates used in our assay appear to be much more efficiently cleaved at least with our buffer conditions and Mpro concentrations tested. Variables including recombinant Mpro purity and activity, differences in assay buffer, reader sensitivity may all play a role, but our best guess is that the substrate identified by Marcin Drag’s group (https://doi.org/10.1101/2020.04.29.068890), is more readily cleaved by Mpro. Although screening with other reported substrates is feasible given previous results, we believe the Ac-Abu-Tle-Leu-Gln-AFC to be superior for use in high throughput screening because of its superior cleavage kinetics yielding an improved signal to background ratio for HTS.

      To exclude inhibitors possibly acting as aggregators, a detergent-based control should do at the same time when you do IC50 value measurement.

      Compound aggregation is a concern, and our assays were all run with detergent in the buffer. Our buffer composition was 20mM Tris pH 7.8, 150mM NaCl, 1mM EDTA, 1mM DTT, 0.05% Triton X-100.

      Reviewer #2 (Significance (Required)):

      Nice work but the significance of this article is losing now. Most screened hits are reported in the last serval months. Some inhibitor complex structures have been published or released on Protein Data Bank. The novelty is missing. I suggest the authors add more results and resubmit it again.

      **Referees Cross-commenting**

      I agree with the other two reviewers' comments. The significance of this work is losing but still has something interest. I think it can be published in the lower-impact journal if they complete our suggestions

      We concur with both reviewers that demonstration of antiviral activity would strengthen the impact of the manuscript. However, this work remains outside of the scope of feasibility at our institution. We believe that our screen and hit identification can stand on their own until further translational work can be completed.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      In this report, Baker et al. show that four inhibitors of hepatitis C virus (HCV) NS3/4 protease (ciluprevir, boceprevir, narlaprevir and telaprevir) are also effective inhibitors of the SARS-CoV-2 main protease (Mpro) in enzymatic assays, with lower IC50 values for narlaprevir and boceprevir (around 1 µM in their assay conditions). HCV NS3/4 inhibitors were identified after screening a library of >6,000 compounds of the Broad Institute, including approved drugs. Screening was done with fluorometric proteolytic assays.

      Experiments have been apparently well-done and results are sound. The manuscript needs editing.

      Reviewer #3 (Significance (Required)):

      Experiments have been apparently well-done and results are sound. However, this is a limited study since there are no data obtained in cell culture and a comparison of IC50 values of the selected drugs against HCV and SARS-CoV-2 proteases is missing. It is difficult to infer whether the drugs would be equally effective against SARS-CoV-2 than against HCV, and otherwise, how much should the doses increase in order to have a therapeutic effect.

      The manuscript needs editing (see below) and the Discussion is poor. The results reported by authors are not new, and a discussion of the effects of HCV inhibitors on SARS-CoV-2 replication, based on previous publications is necessary to provide the appropriate context for the study.

      Here are some references on Covid-19 and HCV inhibitors, that in my opinion should be considered for discussion and proper citation. As correctly pointed out by Baker and co- workers, docking studies should be considered with caution, though.

      We appreciate the feedback and have now reworked and expanded the discussion to incorporate reviewer #1 and #3 comments and suggestions.

      1: Ghahremanpour MM, Tirado-Rives J, Deshmukh M, Ippolito JA, Zhang CH, de Vaca IC, Liosi ME, Anderson KS, Jorgensen WL. Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. bioRxiv [Preprint]. 2020 Aug 28:2020.08.28.271957. doi: 10.1101/2020.08.28.271957. PMID: 32869018; PMCID: PMC7457600.

      2: Sacco MD, Ma C, Lagarias P, Gao A, Townsend JA, Meng X, Dube P, Zhang X, Hu Y, Kitamura N, Hurst B, Tarbet B, Marty MT, Kolocouris A, Xiang Y, Chen Y, Wang J. Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L. bioRxiv [Preprint]. 2020 Jul 27:2020.07.27.223727. doi: 10.1101/2020.07.27.223727. PMID: 32766590; PMCID: PMC7402059.

      3: Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, Zhang X, Tarbet B, Marty MT, Chen Y, Wang J. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2viral replication by targeting the viral main protease. Cell Res. 2020 Aug;30(8):678-692. doi: 10.1038/s41422-020-0356-z. Epub 2020 Jun 15. PMID: 32541865; PMCID: PMC7294525.

      4: Ke YY, Peng TT, Yeh TK, Huang WZ, Chang SE, Wu SH, Hung HC, Hsu TA, Lee SJ, Song JS, Lin WH, Chiang TJ, Lin JH, Sytwu HK, Chen CT. Artificial intelligence approach fighting COVID-19 with repurposing drugs. Biomed J. 2020 May 15:S2319- 4170(20)30049-4. doi: 10.1016/j.bj.2020.05.001. Epub ahead of print. PMID: 32426387; PMCID: PMC7227517.

      5: Elzupir AO. Inhibition of SARS-CoV-2 main protease 3CLpro by means of α-ketoamide and pyridone-containing pharmaceuticals using in silico molecular docking. J Mol Struct. 2020 Dec 15;1222:128878. doi: 10.1016/j.molstruc.2020.128878. Epub 2020 Jul 10.

      PMID: 32834113; PMCID: PMC7347502.

      Additional computational studies:

      1: Hosseini FS, Amanlou M. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. Life Sci. 2020 Aug 8;258:118205. doi:10.1016/j.lfs.2020.118205. Epub ahead of print. PMID: 32777300; PMCID:PMC7413873.

      2: Hakmi M, Bouricha EM, Kandoussi I, Harti JE, Ibrahimi A. Repurposing of known anti- virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis. Bioinformation. 2020 Apr 30;16(4):301-306. doi:10.6026/97320630016301.

      PMID: 32773989; PMCID: PMC7392094.

      3: Chtita S, Belhassan A, Aouidate A, Belaidi S, Bouachrine M, Lakhlifi T. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking Screening. Comb Chem High Throughput Screen. 2020 Jul 30. doi:10.2174/1386207323999200730205447. Epub ahead of print. PMID: 32748740.

      4: Alamri MA, Tahir Ul Qamar M, Mirza MU, Bhadane R, Alqahtani SM, Muneer I, Froeyen M, Salo-Ahen OMH. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro. J Biomol Struct Dyn. 2020 Jun 24:1-13. doi:10.1080/07391102.2020.1782768. Epub ahead of print. PMID: 32579061; PMCID:PMC7332866.

      5: Bafna K, Krug RM, Montelione GT. Structural Similarity of SARS-CoV2 Mpro and HCV NS3/4A Proteases Suggests New Approaches for Identifying Existing Drugs Useful as COVID-19 Therapeutics. ChemRxiv [Preprint]. 2020 Apr 21. doi: 10.26434/chemrxiv.12153615. PMID: 32511291; PMCID: PMC7263768.

      6: Eleftheriou P, Amanatidou D, Petrou A, Geronikaki A. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS- CoV-2 Virus. Molecules. 2020 May 29;25(11):2529. doi:10.3390/molecules25112529.

      PMID: 32485894; PMCID: PMC7321236.

      7: Wang J. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study. J Chem Inf Model. 2020 Jun 22;60(6):3277-3286. doi: 10.1021/acs.jcim.0c00179. Epub 2020 May 4. PMID: 32315171; PMCID: PMC7197972.

      8: Chen YW, Yiu CB, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. 2020 Feb 21;9:129. doi: 10.12688/f1000research.22457.2. PMID: 32194944; PMCID: PMC7062204.

      Minor comments:

      We appreciate the time that the reviewer has taken to address grammatical changes and have addressed each throughout the manuscript with tracked changes.

      p.2, line 26: > appears as an attractive

      Manuscript edited

      p.2, line 27: > we show that the existing

      Manuscript edited

      p.2, line 33: > separate numbers and units, eg. 1.10 µM (this is a persisting error that should be corrected throughout the whole ms)

      Manuscript edited

      p.4, line 44: SARS virus should be referred as to SARS-CoV-1 throughout the whole manuscript. MERS-CoV is the name of the virus causing MERS

      Manuscript edited

      p.4, lines 61-62: > the selection of the specific compounds seems to be arbitrary... why atazanavir and not darunavir or other? The sentence should be rewritten.

      Rewritten as: “There is precedence for targeting the protease, as this approach has been successful in treating both HIV-1 and hepatitis C.”

      p.6, line 100: Citing Fig. 2B before completing the description of Fig. 1 is distracting. Authors should think of a better way to describe their results.

      This was a mistake and should have cited Fig 1B. Thank you for catching this.

      p.7, line 116: It is not clear what "10m-20,810" means

      This has been clarified to state: “ΔRFU at 10 minutes = 20,810 relative fluorescence units”

      p.7, lines 125-126: These sentences belong to an introduction, not appropriate in results section.

      We have removed these sentences.

      Figure 2. Part A is not necessary in results (ok for introduction). Black and purple dots in part B is not a good choice since they are difficult to distinguish, maybe orange and black is better.

      We have removed panel A, expanded the size of panel B and changed the color.

      Table 1: Status should be explained in a footnote (i.e the distinction between launched, P2/P3, phase 2, preclinical is not clear).

      The one compound indicated in P2/P3 development is now Phase 3 and the table has been updated. We have added a footnote:

      *Launched = compound approved for humans, though may only be approved for veterinary use in some countries

      Discussion. I think that subheadings are not necessary.

      Subheadings have been removed from the discussion.

      **Referees cross-commenting** I agree with reviewer no. 1 on the limited interest of the study. However, it could be published in a specialized lower-impact journal after addressing issues raised by reviewers 2 and 3 (likely to be completed in less than a month)

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      In this report, Baker et al. show that four inhibitors of hepatitis C virus (HCV) NS3/4 protease (ciluprevir, boceprevir, narlaprevir and telaprevir) are also effective inhibitors of the SARS-CoV-2 main protease (Mpro) in enzymatic assays, with lower IC50 values for narlaprevir and boceprevir (around 1 µM in their assay conditions). HCV NS3/4 inhibitors were identified after screening a library of >6,000 compounds of the Broad Institute, including approved drugs. Screening was done with fluorometric proteolytic assays.

      Experiments have been apparently well-done and results are sound. The manuscript needs editing.

      Significance

      Experiments have been apparently well-done and results are sound. However, this is a limited study since there are no data obtained in cell culture and a comparison of IC50 values of the selected drugs against HCV and SARS-CoV-2 proteases is missing. It is difficult to infer whether the drugs would be equally effective against SARS-CoV-2 than against HCV, and otherwise, how much should the doses increase in order to have a therapeutic effect. The manuscript needs editing (see below) and the Discussion is poor. The results reported by authors are not new, and a discussion of the effects of HCV inhibitors on SARS-CoV-2 replication, based on previous publications is necessary to provide the appropriate context for the study. Here are some references on Covid-19 and HCV inhibitors, that in my opinion should be considered for discussion and proper citation. As correctly pointed out by Baker and co-workers, docking studies should be considered with caution, though.

      1: Ghahremanpour MM, Tirado-Rives J, Deshmukh M, Ippolito JA, Zhang CH, de Vaca IC, Liosi ME, Anderson KS, Jorgensen WL. Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. bioRxiv [Preprint]. 2020 Aug 28:2020.08.28.271957. doi: 10.1101/2020.08.28.271957. PMID: 32869018; PMCID: PMC7457600.

      2: Sacco MD, Ma C, Lagarias P, Gao A, Townsend JA, Meng X, Dube P, Zhang X, Hu Y, Kitamura N, Hurst B, Tarbet B, Marty MT, Kolocouris A, Xiang Y, Chen Y, Wang J. Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M<sup>pro</sup> and cathepsin L. bioRxiv [Preprint]. 2020 Jul 27:2020.07.27.223727. doi: 10.1101/2020.07.27.223727. PMID: 32766590; PMCID: PMC7402059.

      3: Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, Zhang X, Tarbet B, Marty MT, Chen Y, Wang J. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020 Aug;30(8):678-692. doi: 10.1038/s41422-020-0356-z. Epub 2020 Jun 15. PMID: 32541865; PMCID: PMC7294525.

      4: Ke YY, Peng TT, Yeh TK, Huang WZ, Chang SE, Wu SH, Hung HC, Hsu TA, Lee SJ, Song JS, Lin WH, Chiang TJ, Lin JH, Sytwu HK, Chen CT. Artificial intelligence approach fighting COVID-19 with repurposing drugs. Biomed J. 2020 May 15:S2319-4170(20)30049-4. doi: 10.1016/j.bj.2020.05.001. Epub ahead of print. PMID: 32426387; PMCID: PMC7227517.

      5: Elzupir AO. Inhibition of SARS-CoV-2 main protease 3CLpro by means of α-ketoamide and pyridone-containing pharmaceuticals using in silico molecular docking. J Mol Struct. 2020 Dec 15;1222:128878. doi: 10.1016/j.molstruc.2020.128878. Epub 2020 Jul 10. PMID: 32834113; PMCID: PMC7347502.

      Additional computational studies:

      1: Hosseini FS, Amanlou M. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. Life Sci. 2020 Aug 8;258:118205. doi:10.1016/j.lfs.2020.118205. Epub ahead of print. PMID: 32777300; PMCID:PMC7413873.

      2: Hakmi M, Bouricha EM, Kandoussi I, Harti JE, Ibrahimi A. Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis. Bioinformation. 2020 Apr 30;16(4):301-306. doi:10.6026/97320630016301. PMID: 32773989; PMCID: PMC7392094.

      3: Chtita S, Belhassan A, Aouidate A, Belaidi S, Bouachrine M, Lakhlifi T. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking Screening. Comb Chem High Throughput Screen. 2020 Jul 30. doi:10.2174/1386207323999200730205447. Epub ahead of print. PMID: 32748740.

      4: Alamri MA, Tahir Ul Qamar M, Mirza MU, Bhadane R, Alqahtani SM, Muneer I, Froeyen M, Salo-Ahen OMH. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL<sup>pro</sup>. J Biomol Struct Dyn. 2020 Jun 24:1-13. doi:10.1080/07391102.2020.1782768. Epub ahead of print. PMID: 32579061; PMCID:PMC7332866.

      5: Bafna K, Krug RM, Montelione GT. Structural Similarity of SARS-CoV2 M<sup>pro</sup> and HCV NS3/4A Proteases Suggests New Approaches for Identifying Existing Drugs Useful as COVID-19 Therapeutics. ChemRxiv [Preprint]. 2020 Apr 21. doi: 10.26434/chemrxiv.12153615. PMID: 32511291; PMCID: PMC7263768.

      6: Eleftheriou P, Amanatidou D, Petrou A, Geronikaki A. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. Molecules. 2020 May 29;25(11):2529. doi:10.3390/molecules25112529. PMID: 32485894; PMCID: PMC7321236.

      7: Wang J. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study. J Chem Inf Model. 2020 Jun 22;60(6):3277-3286. doi: 10.1021/acs.jcim.0c00179. Epub 2020 May 4. PMID: 32315171; PMCID: PMC7197972.

      8: Chen YW, Yiu CB, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL <sup>pro</sup>) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. 2020 Feb 21;9:129. doi: 10.12688/f1000research.22457.2. PMID: 32194944; PMCID: PMC7062204.

      Minor comments:

      p.2, line 26: > appears as an attractive

      p.2, line 27: > we show that the existing

      p.2, line 33: > separate numbers and units, eg. 1.10 µM (this is a persisting error that should be corrected throughout the whole ms)

      p.4, line 44: SARS virus should be referred as to SARS-CoV-1 throughout the whole manuscript. MERS-CoV is the name of the virus causing MERS

      p.4, lines 61-62: > the selection of the specific compounds seems to be arbitrary... why atazanavir and not darunavir or other? The sentence should be rewritten.

      p.6, line 100: Citing Fig. 2B before completing the description of Fig. 1 is distracting. Authors should think of a better way to describe their results.

      p.7, line 116: It is not clear what "10m-20,810" means

      p.7, lines 125-126: These sentences belong to an introduction, not appropriate in results section.

      Figure 2. Part A is not necessary in results (ok for introduction). Black and purple dots in part B is not a good choice since they are difficult to distinguish, maybe orange and black is better.

      Table 1: Status should be explained in a footnote (i.e the distinction between launched, P2/P3, phase 2, preclinical is not clear).

      Discussion. I think that subheadings are not necessary.

      Referees cross-commenting

      I agree with reviewer no. 1 on the limited interest of the study. However, it could be published in a specialized lower-impact journal after addressing issues raised by reviewers 2 and 3 (likely to be completed in less than a month)

    1. SciScore for 10.1101/2020.10.14.335893: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Mice 296 were male, age-matched, and grouped for SARS-CoV-2 infection or IAV and SARS-CoV- 297 2 co-infection.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">270 Rabbit monoclonal antibody against ACE2 (Abclonal, A4612, 1:1000)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>A4612</div> <div>suggested: (ABclonal Cat# A4612, RRID:AB_2863309)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mouse monoclonal 271 antibody against SARS-CoV Nucleoprotein (Sino Biological, 40143-MM05, 1:1000)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antibody against SARS-CoV Nucleoprotein ( Sino Biological , 40143-MM05</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The primary antibodies used 278 in this study were rabbit polyclonal antibody against ACE2 for immunofluorescence (Sino 279 Biological, 10108-T26) and anti-influenza virus-NP (kindly provided by Prof.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ACE2</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-influenza virus-NP</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">281 Alexa Fluor M555, Invitrogen) and DAPI (Beyotime, C1002), were admitted afterward Peroxidase-conjugated secondary antibodies according to standard protocols.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>C1002</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">200 The 293T, A549, Huh-7, MDCK, and Vero E6, WI-38, WI-38 VA-13, and BEAS-2B were 201 obtained from ATCC and maintained in Dulbecco’s modified Eagle’s medium (DMEM; 202 Gibco) supplemented with 10% foetal bovine serum (FBS), Calu-3 (ATCC) was 203 maintained in DMEM supplemented with 20% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Huh-7</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>WI-38</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>BEAS-2B</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Calu-3</div> <div>suggested: BCRJ Cat# 0264, RRID:CVCL_0609)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">NCI-H292(ATCC) was maintained 204 with RPMI-1640 (Gibco) supplemented with 20% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NCI-H292</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To produce 226 pseudotyped VSV-ΔG-Luc/mCherry bearing SARS-CoV-2 spike protein (pSARS-CoV-2), 227 Vero E6 cells were seeded in 10 cm dish and transfected simultaneously with 15 μg SARS- 228 CoV-2-S-Δ18 plasmid by Lipofectamine 3000 (Thermo).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Forty-eight hours post- 229 transfection, 150 µl pseudotyped VSV-ΔG bearing VSV-G protein were used to infect Vero 230 E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero 230</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">458 (J-L) WT A549, and IFNAR-/-A549 cells were infected with WSN at MOI 0.1 for 12 hours, 459 cells were then infected with pSARS-CoV-2 for another 24 hours followed by measuring 460 luciferase activity and mRNA expression levels of indicated genes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IFNAR-/-A549</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">464 A549 cells were infected with A/WSN/33 at indicated MOIs.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>A549</div> <div>suggested: NCI-DTP Cat# A549, RRID:CVCL_0023)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( A-C) P values are from 480 unpaired One-way ANOVA. * 482 (A) MDCK cells were pre-infected with WSN (MOI=0.1), H1N1(MOI=1), or H3N2 483 (MOI=1) for 12 hours and were then infected with pSARS-CoV-2 for another 24 hours 484 followed by measuring luciferase activity.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MDCK</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">284 ACE2 knocking-down cells 285 Two sgRNAs targeting the hACE2 gene were designed under the protocol in 286 http://chopchop.cbu.uib.no and commercially synthesized to clone in lenti-Cas9-blast 287 vector (kindly provided by Prof. Hongbing Shu).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>http://chopchop.cbu.uib.no</div> <div>suggested: (CHOPCHOP, RRID:SCR_015723)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293 Mice 294 The K18 hACE2 transgenic mice purchased from Gempharmatech were housed in ABSL- 295 3 pathogen-free facilities under 12-h light-dark cycles with access to food and water.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Gempharmatech</div> <div>suggested: (GemPharmatech, RRID:SCR_017239)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. Reviewer #1:

      General assessment:

      In this paper, Davidson et al. characterize the neural correlates of visual disappearance during perceptual filling-in (PFI) using steady-state visual evoked potentials (SSVEPs). They show that target disappearance actually leads to an increase rather than to a decrease of the target SNR. This finding is potentially of importance. However, the current version of the manuscript does not provide enough details regarding the underlying assumptions and neural mechanisms. The results should also be better described, interpreted and compared to the existing literature. I list my most substantive concerns below.

      Substantive concerns:

      1) I was a bit frustrated to see that almost no discussion about the neural mechanisms underlying the results is provided. It seems important to better explain the cortical processes involved (e.g. the authors could compare more carefully their results with those obtained in macaque electrophysiology by De Weerd et al. 1995).

      To go further along this direction, one possibility would also be to analyse the SNRs at the intermodulation frequencies (I see in supplementary figure 3 that responses at F2-F1 = 5Hz are significantly above noise). This would permit to characterize and discuss the interactions between the neural responses corresponding to the processing of the targets and to the surround (see e.g. Appelbaum et al., 2008).

      2) When I read the whole manuscript, I had the feeling that the analysis of the SNR change latencies (which is currently described in the supplements) would deserve to be more documented and to appear in the main document. The finding that changes in background SNR precede changes in target SNR is an important result which clarifies the temporal sequence of neural activations. That would also be nice if the authors could determine when the SNR change corresponding to the inter-modulation product (e.g. at F2-F1) appears (see my first point above).

      3) To better characterize the difference between the responses to PFI vs to phenomenally matched disappearances (PMD) and support the claim that target-SNR decreases rather than increases during PMD (l. 170), that would be great to show the target-SNR changes around button press (i.e. the equivalent of figure 2 b & e) for PMD.

      4) The target disappearance during PFI is associated with an increase of SNR and therefore, SSVEPs in this case do not reflect conscious perception. But does it necessarily imply that this target-SNR increase reflects attention instead? The authors base their interpretation on previous studies (Lou, 1999; De Weerd et al., 2006) where attending to target feature increased PFI probability (which I think is not exactly equivalent to the PFI magnitude reported here) and also on the correlation they found between target-SNR and evoked alpha. However, these are indirect evidences and in their experimental protocol, attention was not directly manipulated (as e.g. in Morgan et al., 1996 or Müller et al., 2006). I would suggest being a little bit more cautious with this interpretation in the manuscript.

      5) Before this study, other groups looked at the dissociation between attention and perceptual awareness (among others, see e.g. Wyart & Tallon-Baudry, 2008; 2009; Koivisto et al., 2009; Norman et al., 2013). A deeper review of the existing literature on this topic (in the introduction and/or discussion) would permit to better understand what is already known and also to provide leads for future investigations.

    1. tѲѲˢ*"θ"˹Ѳ+ FѲ#1Ѳ"'Ѳ#ѲѲ"ѲѲѲLѲ1ѲB+ɇѲ^Ѳ15̪<

      I feel as though this is a continuity throughout history; it is harder for those who are privileged to understand and want to help those without power. That is not to say that people who are privileged always ignore social issues such as this, but it is much easier to ignore something that is not perceived to be directly tied to you.

    1. Energy democracy must also address global inequalities.Inthe case of climate change, the international trade union movement has consistently supported the principle of ‘common but differentiated responsibilities’ (or CBDR), This principle is foundin the UNFCCC and in the Kyoto Protocol. There are two considerations in the application of the CBDR principle: (a) the C U M U L A T I V Eresponsibility of countries for the problem (historical as well as current responsibility); (b) the A B I L I T Yof counties to deal with the problem in technical and economic ter

      A global perspective

    1. 1. I will primarily use the terms “medical-ly assisted dying” and “medical assistance in dying” in an attempt to remain somewhat neutral throughout this paper, although I will sometimes use the term “euthanasia” when speaking of the European context.2. “Terminology of Assisted Dying,” Death with Dignity, https://www.death-withdignity.org/terminology/, accessed September 13, 2017.3. K. Butler, “Aid in Dying or Assisted Suicide? What to Do When Every Phrase Is Fraught,” Center for Health Journalism Member Blog, October 26, 2015, https://www.centerforhealthjournalism.org/2015/10/23/aid-dying-or-assisted-suicide-what-do-when-neutral-terms-can%E2%80%99t-be-found.4. The push away from using the term “physician-assisted suicide” is not unique, in that much of the politics surrounding the movement to legalize medical aid in dy-ing has come in the form of battles related to terminology (for instance, proponents advocate for “the right to die” and “self-deliverance,” while critics often classify the act as “murder”).5. American Association of Suicidology, “Statement of the American Association of Suicidology: ‘Suicide’ Is Not the Same as ‘Physician Aid in Dying,’” 2017, https://ohiooptions.org/wp-content/uploads/2016/02/AAS-PAD-Statement-Approved-10.30.17-ed-10-30-17.pdf.6. Ibid., 1.7. Ibid., 4. 8. This reflects the debate around medi-cal aid in dying particular to the context of the United States, where this distinc-tion carries a lot of weight. In Belgium, the Netherlands, and Switzerland, where those requesting medical aid in dying are not required to have a terminal illness, the distance between requests for medically assisted deaths as a result of psychological suffering and those related to physical suf-fering is often less apparent. Canada is still debating how this distinction will shake out, as there is ambiguity in the current law where those eligible for medical aid in dying must be suffering from a “griev-ous and irremediable medical condition” and death must be “reasonably foreseeable” (Government of Canada, Bill C-14: An Act to Amend the Criminal Code and to Make Related Amendments to Other Acts [Medical Assistance in Dying], S. C. 2016, c. 3). The analysis within this article is not meant to be specific to a country or region but takes inspiration from current logical debates particular to the United States.9. While the American Association of Suicidology statement argues that there are fifteen features that distinguish suicide and medically assisted death, I do not con-sider all of these because several of the fea-tures highlighted (such as safeguards built into death with dignity laws in the United States) are not universal or have a somewhat accidental relationship to the acts them-selves. 10. H. Hjelmeland and B. L. Knizek, “Why We Need Qualitative Research in Suicidology,” Suicide and Life-Threatening Behavior 40, no. 1 (2010): 74-80; M. Gavin and A. Rogers, “Narratives of Suicide in Psychological Autopsy: Bringing Lay Knowledge Back In,” Journal of Mental Health 15, no. 2 (2009): 135-44. I ac-knowledge that relying on the accounts of those who have survived suicide attempts is inherently limited. As articulated by Scott Fitzpatrick, “Although personal stories of suicide confer certain privileges and ben-efits on survivors of suicide attempts, they also manifest and normalize particular ways of thinking, acting, and communicating that have considerable ethical and political force in shaping the ways suicidal behavior is understood, the ways it is subjectively experienced, and the ways it is responded to” (S. J. Fitzpatrick, “Ethical and Politica

      Easy to use and comprehend ...

    2. Implications of the Turn to Stories in Suicide Prevention,” Philosophy, Psychiatry, & Psychology 23, no. 3 [2016]: 265-76, at 267.) Of course, there are limitations to re-search that excludes such voices as well.11. Y. Y. W. Mak, G. Elwyn, and I. G. Finlay, “Patients’ Voices Are Needed in Debates on Euthanasia,” BMJ 327 (2003): 213.12. Butler, “Aid in Dying or Assisted Suicide?” 13. See David Hume’s essay “On Suicide” for an extended critique of the stance that suicide is immoral as a result of the sanctity of life (chap. 1 in Essays on Suicide and the Immortality of the Soul [Blackmask Online, 2001]).14. “Glossary of Terms,” Death with Dignity, https://www.deathwithdignity.org/assisted-dyingglossary/, accessed February 6, 2018.15. These words from E. J. Lieberman in Psychiatric News, August 4, 2006, are quoted in “Terminology of Assisted Dying,” Death with Dignity, https://www.deathwithdig-nity.org/terminology/, accessed September 13, 2017. A related difference that has been put forward is that suicide is much more violent than medically assisted dy-ing (American Association of Suicidology, “Statement of the American Association of Suicidology”; D. C. Leven and T. E. Quill, “The Clinical, Ethical and Legislative Case for Medical Aid in Dying in New York,” New York State Bar Association Health Law Journal 22, no. 3 (2017): 27-29. This claim is difficult to evaluate because one’s method of suicide is significantly predicted by the ac-cessibility of different means (C. W. Barber and M. J. Miller, “Reducing a Suicidal Person’s Access to Lethal Means of Suicide,” American Journal of Preventive Medicine 47, no. 3 [2014]: S264-S272; M. Eddleston et al., “Choice of Poison for Intentional Self-Poisoning in Rural Sri Lanka,” Clinical Toxicology 44, no. 3 [2006]: 283-86.) For example, while suicide by firearms account-ed for over 50 percent of cases of suicide in the United States in 2012, in the United Kingdom, where firearms are less prevalent, only 1.8 percent of suicides were caused by firearms in 2011 (“Suicide Statistics,” Lost All Hope, http://lostallhope.com/suicide-statistics, accessed February 6, 2018).16. L. W., “A Terminally Ill Patient’s Right to Die,” Write the World, March 18, 2016, https://writetheworld.com/groups/1/shared/11180/version/26139.17. T. R. Simon et al., “Characteristics of Impulsive Suicide Attempts and Attempters,” Suicide and Life-Threatening Behavior 32 (2001): 49-59. 18. D. E. Klonsky and A. M. May, “The Three-Step Theory (3ST): A New Theory of Suicide Rooted in the ‘Ideation-to-Action’ Framework,” International Journal of Cognitive Therapy 8, no. 2 (2015): 114-29; M. Liotta, C. Mento, and S. Settineri, “Seriousness and Lethality of Attempted Suicide: A Systematic Review,” Aggression and Violent Behavior 21 (2015): 97-109.19. T. R. Simon and A. E. Crosby, “Suicide Planning among High School Students Who Report Attempting Suicide,” Suicide and Life-Threatening Behavior 30, no. 3 (2000): 213-21.20. R. Lakeman and M. Fitzgerald, “How People Live with or Get Over Being Suicidal: A Review of Qualitative Studies,” Journal of Advanced Nursing 64, no. 2 (2008): 114-26, at 123.21. L. Thienpont et al., “Euthanasia Requests, Procedures and Outcomes for 100 Belgian Patients Suffering from Psychiatric Disorders: A Retrospective, Descriptive Study,” BMJ Open 5, no. 7 (2015): doi:10.1136/bmjopen-2014-007454.22. M. Verhofstadt, L. Thienpont, and G. Y. Peters, “When Unbearable Suffering Incites Psychiatric Patients to Request Euthanasia: Qualitative Study,” British Journal of Psychiatry 211, no. 4 (2017): 238-45, at 241. While medically assisted dying is not impulsive in one sense, given that a required waiting period acts as a safeguard to ensure that individuals take the time to consider their decision before ending their lives, the act itself can take place quite im-pulsively once the substance has been ob-tained, particularly in the United States, where a physician is not required to be pres-ent and a final attestation is not required (except in California).23. “Patients’ Rights to Self-Determination at the End of Life,” American Public Health Association, October 28, 2008, https://www.apha.org/policies-and-advocacy/public-health-policy-statements/policy-database/2014/07/29/13/28/pa-tients-rights-to-self-determination-at-the-end-of-life.24. R. K. Farberman, “Terminal Illness and Hastened Death Requests: The Important Role of the Mental Health Professional,” Professional Psychology Research and Practice 28 (1997): 544-47, quoted in Working Group on Assisted Suicide and End of Life Decisions, Report to the Board of Directors (Washington, DC: American Psychological Association, 2000). 25. American Association of Suicidology “Statement of the American Association of Suicidology,” 3. 26. E. Chesney, G. M. Goodwin, and S. Fazel, “Risks of All-Cause and Suicide Mortality in Mental Disorders: A Meta-review,” World Psychiatry 13, no. 2 (2014): 153-60; J. Cavanagh et al., “Psychological Autopsy Studies of Suicide: A Systematic Review,” Psychological Medicine 33, no. 3 (2003): 395-405.27. H. Kincaid, “DSM Applications to Young Children: Are There Really Bipolar and Depressed Two-Year-Olds?,” in Extraordinary Science and Psychiatry: Responses to the Crisis in Mental Health Research, ed. J. Poland and Ş. Tekin (Cambridge, MA: MIT Press, 2017), 267-92.28. Fitzpatrick, “Ethical and Political Implications of the Turn to Stories,” 269.29. Gavin and Rogers, “Narratives of Suicide in Psychological Autopsy,” 135.30. See H. Maung, “Voluntary Euthanasia and Borderline Personality Disorder: Is the Wish to Die Necessarily a Symptom of the Illness?” (unpublished) for a fascinating discussion of whether or not a causal relationship between a psychiatric disorder and the wish to die necessarily ren-ders that wish invalid.31. A. Maier-Clayton, “As a Person with Mental Illness, Here’s Why I Support Medically Assisted Death,” Globe and Mail,May 8, 2016.32. In 2017, after years of advocating for legalizing medical aid in dying in Canada for those suffering psychologically, as he was, Maier-Clayton did in fact end his life by suicide.33. S. A. Irwin, “Psychiatric Issues in Palliative Care: Recognition of Depression in Patients Enrolled in Hospice Care,” Journal of Palliative Medicine 11, no. 2 (2008): 158-63.34. B. Kelly et al., “Factors Associated with the Wish to Hasten Death: A Study of Patients with Terminal Illness,” Psychological Medicine 33, no. 1 (2003): 75-81; K. G. Wilson et al., “Desire for Euthanasia or Physician-Assisted Suicide in Palliative Cancer Care,” Health Psychology 26, no. 3 (2007): 314-23. 35. L. S. Dugdale and D. Callahan, “Assisted Death and the Public Good,” Southern Medical Journal 110, no. 9 (2017): 559-61, citing evidence from D. L. Rosenstein, “Depression and End-of-Life Care for Patients with Cancer,” Dialogues in Clinical Neuroscience 13, no. 1 (2011): 101-8.36. Farberman, “Terminal Illness and Hastened Death Requests,” 545.37. H. M. Chochinov et al., “Will to Live in the Terminally Ill,” Lancet 354 (1999): 816-19.38. D. W. Kissane, “The Contribution of Demoralization to End of Life Decision-Making,” Hastings Center Report 34, no. 4 (2004): 21-31.39. “Terminology of Assisted Dying,” California Death with Dignity, http://cali-forniadeathwithdignity.org/terminology/, accessed September 13, 2017.40. American Association of Suicidology, “Statement of the American Association of Suicidology.”41. S. O’Neill, “‘Assisted Suicide’ or ‘Aid in Dying?’ The Semantic Battle over SB 128,” Southern California Public Radio, 89.3KPCC, https://www.scpr.org/

      ... easily navigatalbe ...

    3. 42HASTINGS CENTER REPORTJanuary-February 2020news/2015/06/04/52187/assisted-suicide-or-aid-in-dying-the-semantic-batt/. There are interesting parallels here between this discussion and past debates surrounding whether the withdrawal of medical treat-ment constitutes suicide (for example, William Bartling’s living will read, “While I have no wish to die, I find intolerable the living conditions forced upon me by my deteriorating lungs, heart and blood ves-sel systems and find intolerable my being continuously connected to this ventilator” [William Francis Bartling et al., Plaintiffs and Appellants, v. Glendale Adventist Medical Center et al., Defendants and Respondents: Court of Appeal, Second District, Division 5, California, 1986]). Thank you to an anonymous reviewer for pointing this out. 42. Butler, “Aid in Dying or Assisted Suicide?”43. “Terminology of Assisted Dying,” California Death with Dignity, http://cali-forniadeathwithdignity.org/terminology/. 44. Ibid.45. M. Dees et al., “Unbearable Suffering of Patients with a Request for Euthanasia or Physician-Assisted Suicide: An Integrative Review,” Psycho-Oncology 19, no. 4 (2010): 339-52; W. Breitbart, B. D. Rosenfeld, and S. D. Passik, “Interest in Physician-Assisted Suicide among Ambulatory HIV-Infected Patients,” American Journal of Psychiatry153, no. 2 (1996): 238-42; A. Chapple et al., “What People Close to Death Say about Euthanasia and Assisted Suicide: A Qualitative Study,” Journal of Medical Ethics32, no. 12 (2006): 706-10. 46. S. J. Cash et al., “Adolescent Suicide Statements on MySpace,” Cyberpsychology, Behavior, and Social Networking 16, no. 3 (2013): 166-74; S. A. Kidd and M. J. Kral, “Suicide and Prostitution among Street Youth: A Qualitative Analysis,” Adolescence 37 (2002): 411-30; Lakeman and Fitzgerald, “How People Live with or Get Over Being Suicidal”; D. H. Rosen, “Suicide Survivors: A Follow-Up Study of Persons Who Survived Jumping from the Golden Gate and San Francisco–Oakland Bay Bridges,” Western Journal of Medicine122, no. 4 (1975): 289-94.47. Lakeman and Fitzgerald, “How People Live with or Get Over Being Suicidal.”48. L. Ganzini, E. R. Goy, and S. K. Dobscha, “Oregonians’ Reasons for Requesting Physician Aid in Dying,” Archives of Internal Medicine 169, no. 5 (2009): 489-92; Dugdale and Callahan, “Assisted Death and the Public Good”; Breitbart, Rosenfeld, and Passik, “Interest in Physician-Assisted Suicide among Ambulatory HIV-Infected Patients.” 49. C. Gamondi, M. Pott, and S. Payne, “Families’ Experiences with Patients Who Died after Assisted Suicide: A Retrospective Interview Study in Southern Switzerland,” Annals of Oncology 24, no. 6 (2013): 1639-44, at 1641.50. J. V. Lavery et al., “Origins of the Desire for Euthanasia and Assisted Suicide in People with HIV-1 or AIDS: A Qualitative Study,” Lancet 358 (2001): 362-67; Dees, “Unbearable Suffering”; Breitbart, Rosenfeld, and Passik, “Interest in Physician-Assisted Suicide among Ambulatory HIV-Infected Patients”; Mak, “Patients’ Voices”; S. Gibson et al., “The Impact of Participating in Suicide Research Online,” Suicide and Life-Threatening Behavior 44, no. 4 (2014): 372-83; Kidd and Kral, “Suicide and Prostitution among Street Youth”; M. J. Player et al., “What Interrupts Suicide Attempts in Men: A Qualitative Study,” PloS One 10, no. 6 (2015): e0128180; M. Elliott, D. E. Naphan, and B. L. Kohlenberg, “Suicidal Behavior during Economic Hard Times,” International Journal of Social Psychiatry61, no. 5 (2014): 492-97; J. K. Chan, H. Kirkpatrick, and J. Brasch, “The Reasons to Go On Living Project: Stories of Recovery after a Suicide Attempt,” Qualitative Research in Psychology 14, no. 3 (2017): 350-73. 51. Chan, Kirkpatrick, and Brasch, “The Reasons to Go On Living Project,” story 56. 52. Lavery et al., “Origins of the Desire for Euthanasia,” 364.53. R. Berghmans, G. Widdershoven, and I. Widdershoven-Heerding, “Physician-Assisted Suicide in Psychiatry and Loss of Hope,” International Journal of Law and Psychiatry 36, no. 5 (2013): 436-43, at 436. 54. M. Henick, “Why People with Mental Illness Shouldn’t Have Access to Medically Assisted Death,” Globe and Mail,May 8, 2016. 55. B. D. Kelly and D. M. McLoughlin. “Euthanasia, Assisted Suicide and Psychiatry: A Pandora’s Box,” British Journal of Psychiatry 181, no. 4 (2002): 278-79, at 279.56. Joey Olszewski, “I Survived a Suicide Attempt,” in D. L. Stage, “Live through This,” https://www.livethroughthis.org/, accessed February 16, 2018.57. This question overlaps significantly with the question of how much is enough suffering to justify approving an individual’s request for a medically assisted death, or at what point is suffering unbearable. I have chosen to frame it in terms of hopeless-ness rather than suffering here because I see hope as a central factor underlying intu-itions regarding the difference between psy-chological and physical suffering, but this discussion overlaps in important ways with questions related to how we define unbear-able suffering. 58. T. Sheldon, “Being ‘Tired of Life’ Is Not Grounds for Euthanasia,” BMJ 326, no. 7380 (2003): 71.59. A. Picard, “The Mentally Ill Must Be Part of the Assisted-Dying Debate,” Globe and Mail, April 17, 2017.60. S. Hughes, “Adam Maier-Clayton’s Controversial Right-to-Die Campaign,” BBC, http://www.bbc.com/news/world-us-canada-40546632, accessed February 8, 2018.61. Kissane, “The Contribution of Demoralization.” 62. Thienpont, “Euthanasia Requests, Procedures and Outcomes.”63. M. Gupta et al., “Exploring the Psychological Suffering of a Person Requesting Medical Assistance in Dying,” Medical Assistance in Dying Research Group, Department of Psychiatry, CHUM Research Centre, August 2017, http://www.cmq.org/pdf/outils-fin-de-vie/exploring-psychological-suffering.pdf?t=1535846400024.64. L. Saad, “U.S. Support for Euthanasia Hinges on How It’s Described,” http://news.gallup.com/poll/162815/support-euthanasia-hinges-described.aspx, accessed February 15, 2018.65. J. Wood and J. McCarthy, “Majority of Americans Remain Supportive of Euthanasia,” http://news.gallup.com/poll/211928/majority-americans-remain-sup-portive-euthanasia.aspx, accessed February 15, 2018.66. D. A. Jones and D. Paton, “How Does Legalization of Physician-Assisted Suicide Affect Rates of Suicide?,” Southern Medical Journal 108, no. 10 (2015): 599-604. 67. A. Kheriaty, “Social Contagion Effects of Physician-Assisted Suicide: Commentary on ‘How Does Legalization of Physician-Assisted Suicide Affect Rates of Suicide?’,” Southern Medical Journal 108, no. 10 (2015): 605-6. 68. Dugdale and Callahan, “Assisted Death and the Public Good,” at 559.69. Verhofstadt, Thienpont, and Peters, “When Unbearable Suffering Incites Psychiatric Patients,” 241.70. L. Ganzini et al., “Mental Health Outcomes of Family Members of Oregonians Who Request Physician Aid in Dying,” Journal of Pain and Symptom Management 38, no. 6 (2009): 807-15; N. B. Swarte et al., “Effects of Euthanasia on the Bereaved Family and Friends: A Cross Sectional Study,” BMJ 327 (2003): 189.71. Thienpont et al., “Euthanasia Requests, Procedures and Outcomes,” 7.72. Ibid., 5. A significantly smaller per-centage of individuals with terminal illness whose requests for medical aid in dying are granted actually take the prescription in order to die; in 2015, only 135 out of 208 individuals (62 percent) who received

      ... very organized ...

    Annotators

    1. Reviewer #2:

      The manuscript describes new cryo-EM, biochemistry, and genetic data on the structure and function of the COPII coat. Several new discoveries are reported including the discovery of an extra density near the dimerization region of Sec13/31, and "extra rods" of Sec13/31 that also bind near the dimerization region. Additionally, they showed new interactions between the Sec31 C-terminal unstructured region and Sec23 that appear to bridge multiple Sec23 molecules. Finally, they increased the resolution of the Sec23/24 region of their structure compared to their previous studies and were able to resolve a previously unresolved L-loop in Sec23 that makes contact with Sar1. Most of their structural observations were nicely backed up with biochemical and genetic experiments which give confidence in their structural observations. Overall the paper is well-written and the conclusions justified. However, this is the third iteration of structure determination of the COPII coat on membrane with essentially the same preparation and methods. Each time, there has been an incremental increase in resolution and new discoveries, but the impact of the present study is deemed to be modest. The science is good and appropriate for a specialized journal. Areas of specific concern are described below.

      1) The abstract should be re-written with a better description of the work.

      2) Line 166 - "Surprisingly, this mutant was capable of tubulating GUVs". This experiment gets to one of the fundamental unknown questions in COPII vesiculation. It is not clear what components are driving the membrane remodeling and at what stages during vesicle formation. Isn't it possible that the tubulation activity the authors observe in vitro is not being driven at all by Sec13/31 but rather Sec23/24-Sar1? Their Sec31ΔCTD data supports this idea because it lacks a clear ordered outer coat despite making tubules. An interesting experiment would be to see if tubules form in the absence of all of Sec13/31 except the disordered domain of Sec31 that the authors suggest crosslinks adjacent Sec23/24s.

      3) Line 191 - "Inspecting cryo-tomograms of these tubules revealed no lozenge pattern for the outer 192 coat" - this phrasing is vague. The reviewer thinks that what they mean is that there is a lack of order for the Sec13/31 layer. Please clarify.

      4) Line 198 - "unambiguously confirming this density corresponds to 199 the CTD." This only confirms that it is the CTD if that were the only change and the Sec13/31 lattice still formed. Another possibility is that it is density from other Sec13/31 that only appears when the lattice is formed such as the "extra rods". One possibility is that the density is from the extra rods. The reviewer agrees that their interpretation is indeed the most likely, but it is not unambiguous. The authors should consider cross-linking mass spectrometry.

      5) In the Sec31ΔCTD section, the authors should comment on why ΔCTD is so deleterious to oligomer organization in yeast when cages form so abundantly in preparations of human Sec13/31 ΔC (Paraan et al 2018).

      6) The data is good for the existence of the "extra rods", but significance and importance of them is not clear. How can these extra densities be distinguished from packing artifacts due to imperfections in the helical symmetry.

      7) Figure 5 is very hard to interpret and should be redone. Panels B and C are particularly hard to interpret.

      8) The features present in Sec23/24 structure do not reflect the reported resolution of 4.7 Å. It seems that the resolution is overestimated.

      9) Lines 315/316 - "We have combined cryo-tomography with biochemical and genetic assays to obtain a complete picture of the assembled COPII coat at unprecedented resolution (Fig. 7)." Figure 7 is a schematic model/picture; the authors should reference a different figure or rephrase the sentence.

    1. Relación entre datos y conocimiento.

      Waagmeester, A., Stupp, G., Burgstaller-Muehlbacher, S., Good, B. M., Griffith, M., Griffith, O. L., Hanspers, K., Hermjakob, H., Hudson, T. S., Hybiske, K., Keating, S. M., Manske, M., Mayers, M., Mietchen, D., Mitraka, E., Pico, A. R., Putman, T., Riutta, A., Queralt-Rosinach, N., Schriml, L. M., … Su, A. I. (2020). Wikidata as a knowledge graph for the life sciences. eLife, 9, e52614. https://doi.org/10.7554/eLife.52614

    2. Waagmeester, A., Stupp, G., Burgstaller-Muehlbacher, S., Good, B. M., Griffith, M., Griffith, O. L., Hanspers, K., Hermjakob, H., Hudson, T. S., Hybiske, K., Keating, S. M., Manske, M., Mayers, M., Mietchen, D., Mitraka, E., Pico, A. R., Putman, T., Riutta, A., Queralt-Rosinach, N., Schriml, L. M., … Su, A. I. (2020). Wikidata as a knowledge graph for the life sciences. eLife, 9, e52614. https://doi.org/10.7554/eLife.52614

      En este artículo se da la importancia que ha tenido Wikidata para poder organizar información pertinente a genómica, proteómica, compuestos químicos y enfermedades.

    1. 3.1.1 Anamnese en lichamelijk onderzoek Het diagnostische proces begint natuurlijk met een goede anamnese en een degelijk lichamelijk onderzoek. Een goede anamnese levert al een waarschijnlijkheidsdiagnose die in ongeveer 80% van de gevallen blijkt te kloppen. Dat betekent dus goed luisteren en gericht vragen. Daarna volgt het lichamelijk onderzoek, waarbij verschillende zaken kunnen opvallen zoals bleekheid (anemie), uremische huidskleur, geur uit de mond. Grote of kleine bloeduitstortingen kunnen op een verhoogde bloedingsneiging wijzen. Tekenen van overvulling (overhydratie) zijn bijvoorbeeld oedeem, een verhoogde veneuze druk, hoge bloeddruk en kortademigheid (dyspnoe) door het uittreden van vocht in de longen. Bij een nefrotisch syndroom is er vaak veel oedeem zonder een verhoogde veneuze druk. Aan het hart kunnen geruisen (souffles) worden gehoord. Pericardwrijven duidt op uremische pericarditis. Meer dan twee harttonen (galopritme) past bij decompensatio cordis. Bij vocht in de longen (longoedeem) kunnen met de stethoscoop crepitaties over de longvelden worden gehoord. De lever kan vergroot zijn en soms is de milt te voelen. Bij pyelonefritis (nierbekkenontsteking) is er slagpijn in de nierloges en ook cystenieren zijn meestal te voelen. Polyneuropathie geeft gestoorde reflexen en stoornissen in de sensibiliteit, die met een speld en een watje kunnen worden vastgesteld. En zo zijn nog meer bevindingen mogelijk. Het verdient aanbeveling om de normaalwaarden van de belangrijkste bepalingen in bloed en urine te kennen. Deze zijn in ieder ziekenhuis via het laboratorium verkrijgbaar. 3.1.2 Onderzoek van urine Onderzoek van de urine is natuurlijk belangrijk. Allereerst kijkt men naar de kleur. Geconcentreerde urine is donker, waterige urine heeft een lichtgele kleur. Bij een gestoorde nierfunctie zal de urine minder geconcentreerd zijn. De kleur van de urine kan verder worden beïnvloed door kleurstoffen uit voeding en medicamenten. Het soortelijk gewicht wordt bepaald door de hoeveelheid in de urine opgeloste stoffen. Osmolariteit De geconcentreerdheid of osmolariteit van de urine kan gemeten worden. Osmolariteit is in feite een maat voor de hoeveelheid opgeloste deeltjes in de urine (zie ook paragraaf 1.2.2). De osmolariteit van het plasma bedraagt 290 milliosmol/l. Ongeconcentreerde urine heeft een lagere osmolariteit dan plasma, geconcentreerde urine een hogere. De osmolariteit kan stijgen tot 1000 milliosmol/l en meer. De geconcentreerdheid van de urine kan ook worden geschat door het soortelijk gewicht van de urine te meten. Urine met dezelfde osmolariteit als plasma heeft een soortelijk gewicht van 1010. In geconcentreerde urine kan deze waarde stijgen tot ongeveer 1030. pH Gewoonlijk is urine zuur, met een zuurgraad (pH) van 4 tot 6. Bij urineweginfecties door bacteriën die urease maken (dat ureum splitst), wordt ammoniumcarbonaat gevormd, waardoor de urine alkalisch wordt. Eiwit Proteïnurie (eiwit in de urine) is een belangrijk symptoom van vooral glomerulaire nieraandoeningen. Het belangrijkste eiwit dat dan in de urine gaat lekken is albumine. De meeste diagnostische dipsticks die eiwit in de urine aantonen, reageren op albumine. Bij vroege schade aan de glomeruli door diabetes mellitus of hypertensie treedt al minimale verhoging op van de uitscheiding van albumine in de urine. Dit wordt microalbuminurie genoemd. Er zijn speciale bepalingsmethoden ontwikkeld om microalbuminurie in de urine aan te tonen. Gezonde mensen hebben geen proteïnurie. Glucose Glucose in de urine wijst meestal op het bestaan van suikerziekte (diabetes mellitus). Ook kan de glucosedrempel, het vermogen van de nieren om glucose na filtratie in de tubuli terug te resorberen, verlaagd zijn. Dit kan optreden bij nieraandoeningen die vooral de functie van de proximale tubuluscellen beschadigen. Hemoglobine, myoglobine en bilirubine Hemoglobine kan in de urine komen wanneer er sprake is van intravasale hemolyse. Erytrocyten gaan kapot in de bloedbaan, waarbij hemoglobine vrij in de circulatie komt en via filtratie kan terechtkomen in de urine. Dit kan bijvoorbeeld optreden na een ‘verkeerde’ bloedtransfusie, of bij een ernstige malaria-aanval. Ook het spiereiwit myoglobine kan onder pathologische omstandigheden in de urine voorkomen, bijvoorbeeld als de spieren ernstig beschadigd worden bij een trauma. Dit ziektebeeld heet rabdomyolyse. Beide ziektebeelden kunnen leiden tot acute nierinsufficiëntie, omdat beide eiwitten toxisch kunnen zijn. Er kan acute tubulusnecrose optreden. Onder beide omstandigheden zal de urine roodbruin van kleur worden en is een stickje dat hemoglobine in de urine aantoont, positief. Een hemastix zal echter ook positief zijn als er intacte erytrocyten in de urine zitten. Men moet een test op erytrocyten met een stickje dus altijd combineren met het bekijken van een urinesediment (zie verder). Verder is er in de urine (direct) bilirubine te vinden als er sprake is van een stuwingsicterus. De urine wordt dan geelbruin van kleur. Sediment Bij iedere verdenking op een nieraandoening moet het urinesediment (figuur 3.1) microscopisch onderzocht worden. Het vinden van erytrocytencilinders bewijst met zekerheid dat het in de urine gevonden bloed afkomstig is uit de nieren. Behalve erytrocyten en verschillende soorten cilinders, kunnen in het sediment ook leukocyten, bacteriën, epitheelcellen en kristallen worden gevonden. Bij verdenking op een maligne aandoening, vooral in de afvoerende urinewegen, kan cytologisch onderzoek van de urine nodig zijn. Figuur 3.1 Urinesediment met een erytrocytencilinder × Bacteriën Bij de aanwezigheid van bacteriën kan men een gramgekleurd preparaat maken en een bacteriologische kweek inzetten. Cilinders zijn eiwitafgietsels van de tubuli. Hyaliene cilinders zijn doorzichtig en kunnen normaal in geconcentreerde urine voorkomen. Korrelcilinders bevatten resten van cellen en ook die kunnen sporadisch in normale urine voorkomen. Als het er echter veel zijn, duidt dit op nierpathologie. 24-uursurine Het verzamelen van de urine gedurende 24 uur en het bepalen daarin van het creatininegehalte is de basis voor het berekenen van een endogene creatinineklaring (zie ook paragraaf 1.2.9). Ook de uitscheiding van eiwit en natrium in de 24-uursurine kan belangrijke informatie opleveren. Een eiwituitscheiding van meer dan 1 gram per 24 uur past alleen bij een glomerulonefritis. Een natriumgehalte van 10 mmol of minder is een belangrijke aanwijzing voor het bestaan van een prerenale nierinsufficiëntie. Bestaat er echter bij een acute nierinsufficiëntie een natriumconcentratie van rond 75 mmol zonder dat diuretica zijn toegediend, dan wijst dit op een acute tubulusnecrose. Beter is nog om een fractionele natriumexcretie (FENA) uit te rekenen, waarbij de natriumexcretie wordt berekend gerelateerd aan de creatinine-excretie. Dit kan ook op een portie urine. Een FENA > 1% wijst dan op acute tubulusnecrose. 3.1.3 Onderzoek van bloed Creatinine Het serumcreatinine kan worden gebruikt als maat voor de nierfunctie, maar dit kent beperkingen. Creatinine wordt geproduceerd door de spieren. De hoogte van het creatinine in het bloed is niet alleen afhankelijk van het uitscheidend vermogen van de nieren, maar ook van de spiermassa van de patiënt. Het serumcreatinine is vooral te gebruiken voor het eenvoudig vervolgen van de nierfunctie van een patiënt als deze verder metabool stabiel is. Daarbij is het belangrijk te weten dat het serumcreatinine doorgaans pas gaat stijgen als de glomerulaire filtratiesnelheid onder de 60 ml/min is gedaald. Bij patiënten op de intensive care die lange tijd beademd worden, neemt de spiermassa en dus de creatinineproductie af, zodat men bij een laag serumcreatinine ten onrechte kan denken dat de nierfunctie goed is of aan het verbeteren. Zie verder paragraaf 1.2.9. Elektrolyten, ureum, albumine Natrium, kalium, chloor, calcium, bicarbonaat, fosfaat en magnesium kunnen in hun concentraties gestoord raken bij een gestoorde nierfunctie. Het ureumgehalte in het bloed zal bij nierinsufficiëntie stijgen en moet worden gecontroleerd om bij te hoog oplopen de indicatie tot nierfunctievervangende behandeling te kunnen stellen. Ook het urinezuur, normaal 0,12 tot 0,42 mmol/l, zal bij een gestoorde nierfunctie verhoogd zijn in het bloed. De bepaling van het gehalte aan totaal eiwit en serumalbumine is van belang bij alle patiënten die een eiwitverlies hebben dan wel in een katabole toestand verkeren. Zie verder paragraaf 3.3. Immunologisch onderzoek Immunologisch onderzoek van het bloed is van belang bij de diagnostiek van glomerulonefritiden. Men bepaalt bijvoorbeeld de ANA-serologie (antinucleaire antilichamen) en als deze positief is het anti-ds-DNA, met eventueel nog andere antistoffen bij SLE (systemische lupus erythematodes). Bij de ziekte van Wegener is de ANCA (antineutrofiele cytoplasmatische antistof) positief. De complementfactoren C3 en C4 zijn vaak verlaagd bij SLE, maar ook bij sommige andere vormen van glomerulonefritis. Virologie, bacteriologie, parasitologie Sommige nierziekten zijn geassocieerd met of worden veroorzaakt door een infectie met een bacterie, virus of parasiet. In verband met besmettingsgevaar en preventie daarvan is het verder belangrijk om van iedere patiënt die behandeld wordt of gaat worden met hemodialyse de status ten aanzien van hepatitis B, hepatitis C en hiv te kennen. 3.1.4 Beeldvormend onderzoek Echografie De echografie werkt met hoogfrequente geluidsgolven van 1,5 tot 8 MHz. Daarbij wordt gebruikgemaakt van het verschijnsel dat dit geluid door verschillende weefselstructuren anders wordt weerkaatst of geabsorbeerd. De weerkaatsing wordt opgevangen door een detector en met behulp van elektronica omgezet in een zichtbaar beeld. De nieren laten zich goed afbeelden doordat de buitenkant een bepaalde weerkaatsing geeft, het nierweefsel een andere en het pyelum nóg een andere. Met echografie kan heel goed een stuwing van de afvoerende urinewegen worden opgespoord of uitgesloten. Ook krijgt men een indruk van de grootte van de nieren. Heel belangrijk is de echografie geworden bij de diagnose van congenitale cystenieren. Stenen kunnen, mits ze niet te klein zijn, worden gezien omdat ze een slagschaduw geven. Tumoren zijn soms zichtbaar door een andere weerkaatsing, of omdat de nier een afwijkende vorm heeft. Ten slotte is het zinvol een nierbiopsie te verrichten met behulp van echografie
    1. y the most complex substance. The most complex substance is the one with the largest number of different atoms, which is C7H16C7H16C_7H_{16}. We will assume initially that the final balanced chemical equation contains 1 molecule or formula unit of this substance. 2. Adjust the coefficients. a. Because one molecule of n-heptane contains 7 carbon atoms, we need 7 CO2 molecules, each of which contains 1 carbon atom, on the right side: C7H16(l)+O2(g)→7–CO2(g)+H2O(g)C7H16(l)+O2(g)→7_CO2(g)+H2O(g)\ce{C7H16 (l) + O2 (g) → } \underline{7} \ce{CO2 (g) + H2O (g) } \nonumber 7 carbon atoms on both reactant and product sides b. Because one molecule of n-heptane contains 16 hydrogen atoms, we need 8 H2O molecules, each of which contains 2 hydrogen atoms, on the right side: C7H16(l)+O2(g)→7CO2(g)+8–H2O(g)C7H16(l)+O2(g)→7CO2(g)+8_H2O(g)\ce{C7H16 (l) + O2 (g) → 7 CO2 (g) + } \underline{8} \ce{H2O (g) } \nonumber 16 hydrogen atoms on both reactant and product sides 3. Balance polyatomic ions as a unit. There are no polyatomic ions to be considered in this reaction. 4. Balance the remaining atoms. The carbon and hydrogen atoms are now balanced, but we have 22 oxygen atoms on the right side and only 2 oxygen atoms on the left. We can balance the oxygen atoms by adjusting the coefficient in front of the least complex substance, O2, on the reactant side: C7H16(l)+11–––O2(g)→7CO2(g)+8H2O(g)C7H16(l)+11_O2(g)→7CO2(g)+8H2O(g)\ce{C7H16 (l) + }\underline{11} \ce{ O2 (g) → 7 CO2 (g) + 8H2O (g) } \nonumber 22 oxygen atoms on both reactant and product sides 5. Check your work. The equation is now balanced, and there are no fractional coefficients: there are 7 carbon atoms, 16 hydrogen atoms, and 22 oxygen atoms on each side. Always check to be sure that a chemical equation is balanced.

      STUDY

    1. SciScore for 10.1101/2020.09.29.319061: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">The study plan and procedures were approved by the internal ethical review board, which is complied with local ethical regulation.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Safety and efficacy in mice A total number of 50 BALB/c swiss albino mice (male and female) of 6-8 weeks old, were selected randomly and isolated 5 days before immunization.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">No treatment randomization and blinding methods were used in the study and sample sizes were determined by the resource equation method.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Target amplification Nasopharyngeal and oropharyngeal swab sample were collected from a COVID-19 positive male patient.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The immobilization procedure was performed by using running buffer HBS-EP, pH 7.4 (GE Healthcare, USA). samples containing 1 µL mouse serum each were analyzed using surface plasmon resonance (SPR) technology to analyze the binding affinity of the antibody pool.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SPR</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Intracellular cytokine staining of cells were stained with following antibodies with maintaining supplier’s instructions: V500 anti-mouse CD45 (BD Bioscience, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse CD45</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Alexa Fluor® 594 conjugate secondary antibody (ThermoFisher, USA), in-house developed TNF alpha fusion protein, anti Fc primary antibody (ThermoFisher, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti Fc</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IL-2 and Il-6 titer ELISA plate (Corning) was coated with 1µg/mL IL-2 polyclonal antibody (ThermoFisher, USA) in Dulbecco’s phosphate-buffered saline (DPBS) (ThermoFisher, USA) for 2 hours at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IL-2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing for 3 times, the plate was again incubated with Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP conjugate (ThermoFisher, USA) for 50 min at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-Mouse IgG</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To check whether the immunization have generated antibody pool spanning for the whole antigen or for any specific domain (S1 or S2), we have chosen surface plasmon resonance (SPR) experiment.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>S1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>S2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In-vitro neutralization ACE2 overexpressing HEK293 cell (Innoprot, Spain) were seeded in a two 96 well TC treated plate at a concentration of 2.2 × 104 cells per well and overnight incubation was performed.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>HEK293</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Safety and efficacy in mice A total number of 50 BALB/c swiss albino mice (male and female) of 6-8 weeks old, were selected randomly and isolated 5 days before immunization.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>BALB/c swiss albino</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Immunogenicity The immunogenicity of BANCOVID was evaluated in BALB/c mice, post administration to the quadriceps muscle.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>BALB/c</div> <div>suggested: RRID:IMSR_ORNL:BALB/cRl)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Amplified S-gene and polymerase chain reaction (PCR) engineered pET31b(+) (Novagen, Germany) bacterial expression vector were amplified using 0570F and 0571R primers, excised and extracted from agarose gel using GeneJET Gel Extraction and DNA Cleanup Micro Kit (ThermoFisher, USA), using Clustal alignment was Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/) identified (data not shown) using EMBOSS showed Cons and assembled together using NEBuilder® HiFi DNA Assembly Master Mix (NEB, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>https://www.ebi.ac.uk/Tools/msa/clustalo/</div> <div>suggested: (Clustal Omega, RRID:SCR_001591)</div> </div> <div style="margin-bottom:8px"> <div>EMBOSS</div> <div>suggested: (EMBOSS, RRID:SCR_008493)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mRNA production mRNA synthesis The in-vitro (IVT) mRNA synthesis reaction was performed using MEGAscript™ T7 Transcription Kit (ThermoFisher, USA), and Ribonucleotide Solution Set (NEB, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MEGAscript™</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cellular immunogenicity SARS-CoV-2 surface glycoprotein peptide mapping SARS-CoV-2 Spike S1+S2 ECD His recombinant protein (Sino Biological, China), S2 ECD- His Recombinant Protein (Sino Biological, China), and RBD-His Recombinant Protein (Sino Biological, China) were digested and purified according to ThermoFisher Pierce Trypsin Protease, MS grade instructions (supplementary method 2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ThermoFisher Pierce Trypsin Protease</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After getting raw data from mass spectrometry system, data analysis was performed in BioPharma Finder (ThermoFisher, USA) using variable parameters to get confident data, and then data were combined in one map to visualize complete fragmentation (supplementary figure 6).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>BioPharma Finder</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">On the other hand, full length SARS-CoV-2 surface glycoprotein was digested computationally (ExPASy PeptideMass: https://web.expasy.org/peptide_mass/) via trypsin (supplementary figure 7)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ExPASy</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After hours, cell events were acquired using an FACS Lyric (BD Biosciences), followed by FlowJo software (FlowJo LLC, Ashland, OR) analysis (supplementary figure 8, 9, 10).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap used on page 40. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. Why Are Finland’s Schools Successful? The country’s achievements in education have other nations, especially the United States, doing their homework <img src="https://thumbs-prod.si-cdn.com/thzZYTv2Evhq3x8iHdcaakihfVE=/800x600/filters:no_upscale()/https://public-media.si-cdn.com/filer/cd/ee/cdee1c82-f8e3-4de4-983e-8599d4485745/finland-smiles-wr.jpg" alt="Kirkkojarvi School" itemprop="image"> "This is what we do every day," says Kirkkojarvi Comprehensive School principal Kari Louhivuori, "prepare kids for life." (Stuart Conway) By LynNell Hancock Smithsonian Magazine | Subscribe September 2011 AddThis Sharing ButtonsShare to FacebookFacebookShare to TwitterTwitterShare to RedditReddit78Share to PinterestPinterest997Share to LinkedInLinkedInShare to FlipboardFlipboardShare to EmailEmailShare to PrintPrintShare to MoreAddThis934 It was the end of term at Kirkkojarvi Comprehensive School in Espoo, a sprawling suburb west of Helsinki, when Kari Louhivuori, a veteran teacher and the school’s principal, decided to try something extreme—by Finnish standards. One of his sixth-grade students, a Kosovo-Albanian boy, had drifted far off the learning grid, resisting his teacher’s best efforts. The school’s team of special educators—including a social worker, a nurse and a psychologist—convinced Louhivuori that laziness was not to blame. So he decided to hold the boy back a year, a measure so rare in Finland it’s practically obsolete. function dispatchComscoreLoadedEvent(){ let event = new Event('MPlayerComscoreLoaded'); window.dispatchEvent(event); } !function(e){var t={};function n(r){if(t[r])return t[r].exports;var i=t[r]={i:r,l:!1,exports:{}};return e[r].call(i.exports,i,i.exports,n),i.l=!0,i.exports}n.m=e,n.c=t,n.d=function(e,t,r){n.o(e,t)||Object.defineProperty(e,t,{enumerable:!0,get:r})},n.r=function(e){"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},n.t=function(e,t){if(1&t&&(e=n(e)),8&t)return e;if(4&t&&"object"===typeof e&&e&&e.__esModule)return e;var r=Object.create(null);if(n.r(r),Object.defineProperty(r,"default",{enumerable:!0,value:e}),2&t&&"string"!=typeof e)for(var i in e)n.d(r,i,function(t){return e[t]}.bind(null,i));return r},n.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return n.d(t,"a",t),t},n.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},n.p="",n(n.s=68)}([function(e,t){e.exports=function(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}},function(e,t){e.exports=function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}},function(e,t){function n(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}e.exports=function(e,t,r){return t&&n(e.prototype,t),r&&n(e,r),e}},function(e,t){e.exports=function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}},function(e,t,n){e.exports=n(47)},function(e,t){function n(t){return e.exports=n=Object.setPrototypeOf?Object.getPrototypeOf:function(e){return e.__proto__||Object.getPrototypeOf(e)},n(t)}e.exports=n},function(e,t,n){"use strict";var r=n(21),i=Object.prototype.toString;function o(e){return"[object Array]"===i.call(e)}function a(e){return"undefined"===typeof e}function s(e){return null!==e&&"object"===typeof e}function u(e){return"[object Function]"===i.call(e)}function c(e,t){if(null!==e&&"undefined"!==typeof e)if("object"!==typeof e&&(e=[e]),o(e))for(var n=0,r=e.length;n<r;n++)t.call(null,e[n],n,e);else for(var i in e)Object.prototype.hasOwnProperty.call(e,i)&&t.call(null,e[i],i,e)}e.exports={isArray:o,isArrayBuffer:function(e){return"[object ArrayBuffer]"===i.call(e)},isBuffer:function(e){return null!==e&&!a(e)&&null!==e.constructor&&!a(e.constructor)&&"function"===typeof e.constructor.isBuffer&&e.constructor.isBuffer(e)},isFormData:function(e){return"undefined"!==typeof FormData&&e instanceof FormData},isArrayBufferView:function(e){return"undefined"!==typeof ArrayBuffer&&ArrayBuffer.isView?ArrayBuffer.isView(e):e&&e.buffer&&e.buffer instanceof ArrayBuffer},isString:function(e){return"string"===typeof e},isNumber:function(e){return"number"===typeof e},isObject:s,isUndefined:a,isDate:function(e){return"[object Date]"===i.call(e)},isFile:function(e){return"[object File]"===i.call(e)},isBlob:function(e){return"[object Blob]"===i.call(e)},isFunction:u,isStream:function(e){return s(e)&&u(e.pipe)},isURLSearchParams:function(e){return"undefined"!==typeof URLSearchParams&&e instanceof URLSearchParams},isStandardBrowserEnv:function(){return("undefined"===typeof navigator||"ReactNative"!==navigator.product&&"NativeScript"!==navigator.product&&"NS"!==navigator.product)&&"undefined"!==typeof window&&"undefined"!==typeof document},forEach:c,merge:function e(){var t={};function n(n,r){"object"===typeof t[r]&&"object"===typeof n?t[r]=e(t[r],n):t[r]=n}for(var r=0,i=arguments.length;r<i;r++)c(arguments[r],n);return t},deepMerge:function e(){var t={};function n(n,r){"object"===typeof t[r]&&"object"===typeof n?t[r]=e(t[r],n):t[r]="object"===typeof n?e({},n):n}for(var r=0,i=arguments.length;r<i;r++)c(arguments[r],n);return t},extend:function(e,t,n){return c(t,function(t,i){e[i]=n&&"function"===typeof t?r(t,n):t}),e},trim:function(e){return e.replace(/^\s*/,"").replace(/\s*$/,"")}}},function(e,t){function n(e,t,n,r,i,o,a){try{var s=e[o](a),u=s.value}catch(c){return void n(c)}s.done?t(u):Promise.resolve(u).then(r,i)}e.exports=function(e){return function(){var t=this,r=arguments;return new Promise(function(i,o){var a=e.apply(t,r);function s(e){n(a,i,o,s,u,"next",e)}function u(e){n(a,i,o,s,u,"throw",e)}s(void 0)})}}},function(e,t,n){var r=n(48);e.exports=function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function");e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,writable:!0,configurable:!0}}),t&&r(e,t)}},function(e,t,n){var r=n(49),i=n(3);e.exports=function(e,t){return!t||"object"!==r(t)&&"function"!==typeof t?i(e):t}},function(e,t,n){var r=n(42),i=n(43),o=n(18),a=n(44);e.exports=function(e,t){return r(e)||i(e,t)||o(e,t)||a()}},function(e,t,n){var r=n(39),i=n(40),o=n(18),a=n(41);e.exports=function(e){return r(e)||i(e)||o(e)||a()}},function(e,t,n){var r=n(45);e.exports=function(e,t){if(null==e)return{};var n,i,o=r(e,t);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);for(i=0;i<a.length;i++)n=a[i],t.indexOf(n)>=0||Object.prototype.propertyIsEnumerable.call(e,n)&&(o[n]=e[n])}return o}},function(e,t,n){var r=n(50);function i(t,n,o){return"undefined"!==typeof Reflect&&Reflect.get?e.exports=i=Reflect.get:e.exports=i=function(e,t,n){var i=r(e,t);if(i){var o=Object.getOwnPropertyDescriptor(i,t);return o.get?o.get.call(n):o.value}},i(t,n,o||t)}e.exports=i},function(e,t,n){"use strict";e.exports=n(36)},function(e,t,n){"use strict";var r=n(14),i={childContextTypes:!0,contextType:!0,contextTypes:!0,defaultProps:!0,displayName:!0,getDefaultProps:!0,getDerivedStateFromError:!0,getDerivedStateFromProps:!0,mixins:!0,propTypes:!0,type:!0},o={name:!0,length:!0,prototype:!0,caller:!0,callee:!0,arguments:!0,arity:!0},a={$$typeof:!0,compare:!0,defaultProps:!0,displayName:!0,propTypes:!0,type:!0},s={};function u(e){return r.isMemo(e)?a:s[e.$$typeof]||i}s[r.ForwardRef]={$$typeof:!0,render:!0,defaultProps:!0,displayName:!0,propTypes:!0},s[r.Memo]=a;var c=Object.defineProperty,l=Object.getOwnPropertyNames,d=Object.getOwnPropertySymbols,p=Object.getOwnPropertyDescriptor,f=Object.getPrototypeOf,h=Object.prototype;e.exports=function e(t,n,r){if("string"!==typeof n){if(h){var i=f(n);i&&i!==h&&e(t,i,r)}var a=l(n);d&&(a=a.concat(d(n)));for(var s=u(t),y=u(n),g=0;g<a.length;++g){var v=a[g];if(!o[v]&&(!r||!r[v])&&(!y||!y[v])&&(!s||!s[v])){var m=p(n,v);try{c(t,v,m)}catch(b){}}}}return t}},function(e,t,n){"use strict";(function(e,r){var i,o=n(29);i="undefined"!==typeof self?self:"undefined"!==typeof window?window:"undefined"!==typeof e?e:r;var a=Object(o.a)(i);t.a=a}).call(this,n(37),n(38)(e))},function(e,t){e.exports=function(e,t){(null==t||t>e.length)&&(t=e.length);for(var n=0,r=new Array(t);n<t;n++)r[n]=e[n];return r}},function(e,t,n){var r=n(17);e.exports=function(e,t){if(e){if("string"===typeof e)return r(e,t);var n=Object.prototype.toString.call(e).slice(8,-1);return"Object"===n&&e.constructor&&(n=e.constructor.name),"Map"===n||"Set"===n?Array.from(e):"Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n)?r(e,t):void 0}}},function(e,t){var n,r,i=e.exports={};function o(){throw new Error("setTimeout has not been defined")}function a(){throw new Error("clearTimeout has not been defined")}function s(e){if(n===setTimeout)return setTimeout(e,0);if((n===o||!n)&&setTimeout)return n=setTimeout,setTimeout(e,0);try{return n(e,0)}catch(t){try{return n.call(null,e,0)}catch(t){return n.call(this,e,0)}}}!function(){try{n="function"===typeof setTimeout?setTimeout:o}catch(e){n=o}try{r="function"===typeof clearTimeout?clearTimeout:a}catch(e){r=a}}();var u,c=[],l=!1,d=-1;function p(){l&&u&&(l=!1,u.length?c=u.concat(c):d=-1,c.length&&f())}function f(){if(!l){var e=s(p);l=!0;for(var t=c.length;t;){for(u=c,c=[];++d<t;)u&&u[d].run();d=-1,t=c.length}u=null,l=!1,function(e){if(r===clearTimeout)return clearTimeout(e);if((r===a||!r)&&clearTimeout)return r=clearTimeout,clearTimeout(e);try{r(e)}catch(t){try{return r.call(null,e)}catch(t){return r.call(this,e)}}}(e)}}function h(e,t){this.fun=e,this.array=t}function y(){}i.nextTick=function(e){var t=new Array(arguments.length-1);if(arguments.length>1)for(var n=1;n<arguments.length;n++)t[n-1]=arguments[n];c.push(new h(e,t)),1!==c.length||l||s(f)},h.prototype.run=function(){this.fun.apply(null,this.array)},i.title="browser",i.browser=!0,i.env={},i.argv=[],i.version="",i.versions={},i.on=y,i.addListener=y,i.once=y,i.off=y,i.removeListener=y,i.removeAllListeners=y,i.emit=y,i.prependListener=y,i.prependOnceListener=y,i.listeners=function(e){return[]},i.binding=function(e){throw new Error("process.binding is not supported")},i.cwd=function(){return"/"},i.chdir=function(e){throw new Error("process.chdir is not supported")},i.umask=function(){return 0}},function(e,t){!function(){"use strict";if("object"===typeof window)if("IntersectionObserver"in window&&"IntersectionObserverEntry"in window&&"intersectionRatio"in window.IntersectionObserverEntry.prototype)"isIntersecting"in window.IntersectionObserverEntry.prototype||Object.defineProperty(window.IntersectionObserverEntry.prototype,"isIntersecting",{get:function(){return this.intersectionRatio>0}});else{var e=window.document,t=[];r.prototype.THROTTLE_TIMEOUT=100,r.prototype.POLL_INTERVAL=null,r.prototype.USE_MUTATION_OBSERVER=!0,r.prototype.observe=function(e){if(!this._observationTargets.some(function(t){return t.element==e})){if(!e||1!=e.nodeType)throw new Error("target must be an Element");this._registerInstance(),this._observationTargets.push({element:e,entry:null}),this._monitorIntersections(e.ownerDocument),this._checkForIntersections()}},r.prototype.unobserve=function(e){this._observationTargets=this._observationTargets.filter(function(t){return t.element!=e}),this._unmonitorIntersections(e.ownerDocument),0==this._observationTargets.length&&this._unregisterInstance()},r.prototype.disconnect=function(){this._observationTargets=[],this._unmonitorAllIntersections(),this._unregisterInstance()},r.prototype.takeRecords=function(){var e=this._queuedEntries.slice();return this._queuedEntries=[],e},r.prototype._initThresholds=function(e){var t=e||[0];return Array.isArray(t)||(t=[t]),t.sort().filter(function(e,t,n){if("number"!=typeof e||isNaN(e)||e<0||e>1)throw new Error("threshold must be a number between 0 and 1 inclusively");return e!==n[t-1]})},r.prototype._parseRootMargin=function(e){var t=(e||"0px").split(/\s+/).map(function(e){var t=/^(-?\d*\.?\d+)(px|%)$/.exec(e);if(!t)throw new Error("rootMargin must be specified in pixels or percent");return{value:parseFloat(t[1]),unit:t[2]}});return t[1]=t[1]||t[0],t[2]=t[2]||t[0],t[3]=t[3]||t[1],t},r.prototype._monitorIntersections=function(t){var n=t.defaultView;if(n&&-1==this._monitoringDocuments.indexOf(t)){var r=this._checkForIntersections,a=null,s=null;if(this.POLL_INTERVAL?a=n.setInterval(r,this.POLL_INTERVAL):(i(n,"resize",r,!0),i(t,"scroll",r,!0),this.USE_MUTATION_OBSERVER&&"MutationObserver"in n&&(s=new n.MutationObserver(r)).observe(t,{attributes:!0,childList:!0,characterData:!0,subtree:!0})),this._monitoringDocuments.push(t),this._monitoringUnsubscribes.push(function(){var e=t.defaultView;e&&(a&&e.clearInterval(a),o(e,"resize",r,!0)),o(t,"scroll",r,!0),s&&s.disconnect()}),t!=(this.root&&this.root.ownerDocument||e)){var u=d(t);u&&this._monitorIntersections(u.ownerDocument)}}},r.prototype._unmonitorIntersections=function(t){var n=this._monitoringDocuments.indexOf(t);if(-1!=n){var r=this.root&&this.root.ownerDocument||e;if(!this._observationTargets.some(function(e){var n=e.element.ownerDocument;if(n==t)return!0;for(;n&&n!=r;){var i=d(n);if((n=i&&i.ownerDocument)==t)return!0}return!1})){var i=this._monitoringUnsubscribes[n];if(this._monitoringDocuments.splice(n,1),this._monitoringUnsubscribes.splice(n,1),i(),t!=r){var o=d(t);o&&this._unmonitorIntersections(o.ownerDocument)}}}},r.prototype._unmonitorAllIntersections=function(){var e=this._monitoringUnsubscribes.slice(0);this._monitoringDocuments.length=0,this._monitoringUnsubscribes.length=0;for(var t=0;t<e.length;t++)e[t]()},r.prototype._checkForIntersections=function(){var e=this._rootIsInDom(),t=e?this._getRootRect():{top:0,bottom:0,left:0,right:0,width:0,height:0};this._observationTargets.forEach(function(r){var i=r.element,o=s(i),a=this._rootContainsTarget(i),u=r.entry,c=e&&a&&this._computeTargetAndRootIntersection(i,o,t),l=r.entry=new n({time:window.performance&&performance.now&&performance.now(),target:i,boundingClientRect:o,rootBounds:t,intersectionRect:c});u?e&&a?this._hasCrossedThreshold(u,l)&&this._queuedEntries.push(l):u&&u.isIntersecting&&this._queuedEntries.push(l):this._queuedEntries.push(l)},this),this._queuedEntries.length&&this._callback(this.takeRecords(),this)},r.prototype._computeTargetAndRootIntersection=function(t,n,r){if("none"!=window.getComputedStyle(t).display){for(var i=n,o=l(t),c=!1;!c&&o;){var d=null,p=1==o.nodeType?window.getComputedStyle(o):{};if("none"==p.display)return null;if(o==this.root||9==o.nodeType)if(c=!0,o==this.root||o==e)d=r;else{var f=l(o),h=f&&s(f),y=f&&this._computeTargetAndRootIntersection(f,h,r);h&&y?(o=f,d=u(h,y)):(o=null,i=null)}else{var g=o.ownerDocument;o!=g.body&&o!=g.documentElement&&"visible"!=p.overflow&&(d=s(o))}if(d&&(i=a(d,i)),!i)break;o=o&&l(o)}return i}},r.prototype._getRootRect=function(){var t;if(this.root)t=s(this.root);else{var n=e.documentElement,r=e.body;t={top:0,left:0,right:n.clientWidth||r.clientWidth,width:n.clientWidth||r.clientWidth,bottom:n.clientHeight||r.clientHeight,height:n.clientHeight||r.clientHeight}}return this._expandRectByRootMargin(t)},r.prototype._expandRectByRootMargin=function(e){var t=this._rootMarginValues.map(function(t,n){return"px"==t.unit?t.value:t.value*(n%2?e.width:e.height)/100}),n={top:e.top-t[0],right:e.right+t[1],bottom:e.bottom+t[2],left:e.left-t[3]};return n.width=n.right-n.left,n.height=n.bottom-n.top,n},r.prototype._hasCrossedThreshold=function(e,t){var n=e&&e.isIntersecting?e.intersectionRatio||0:-1,r=t.isIntersecting?t.intersectionRatio||0:-1;if(n!==r)for(var i=0;i<this.thresholds.length;i++){var o=this.thresholds[i];if(o==n||o==r||o<n!==o<r)return!0}},r.prototype._rootIsInDom=function(){return!this.root||c(e,this.root)},r.prototype._rootContainsTarget=function(t){return c(this.root||e,t)&&(!this.root||this.root.ownerDocument==t.ownerDocument)},r.prototype._registerInstance=function(){t.indexOf(this)<0&&t.push(this)},r.prototype._unregisterInstance=function(){var e=t.indexOf(this);-1!=e&&t.splice(e,1)},window.IntersectionObserver=r,window.IntersectionObserverEntry=n}function n(e){this.time=e.time,this.target=e.target,this.rootBounds=e.rootBounds,this.boundingClientRect=e.boundingClientRect,this.intersectionRect=e.intersectionRect||{top:0,bottom:0,left:0,right:0,width:0,height:0},this.isIntersecting=!!e.intersectionRect;var t=this.boundingClientRect,n=t.width*t.height,r=this.intersectionRect,i=r.width*r.height;this.intersectionRatio=n?Number((i/n).toFixed(4)):this.isIntersecting?1:0}function r(e,t){var n=t||{};if("function"!=typeof e)throw new Error("callback must be a function");if(n.root&&1!=n.root.nodeType)throw new Error("root must be an Element");this._checkForIntersections=function(e,t){var n=null;return function(){n||(n=setTimeout(function(){e(),n=null},t))}}(this._checkForIntersections.bind(this),this.THROTTLE_TIMEOUT),this._callback=e,this._observationTargets=[],this._queuedEntries=[],this._rootMarginValues=this._parseRootMargin(n.rootMargin),this.thresholds=this._initThresholds(n.threshold),this.root=n.root||null,this.rootMargin=this._rootMarginValues.map(function(e){return e.value+e.unit}).join(" "),this._monitoringDocuments=[],this._monitoringUnsubscribes=[]}function i(e,t,n,r){"function"==typeof e.addEventListener?e.addEventListener(t,n,r||!1):"function"==typeof e.attachEvent&&e.attachEvent("on"+t,n)}function o(e,t,n,r){"function"==typeof e.removeEventListener?e.removeEventListener(t,n,r||!1):"function"==typeof e.detatchEvent&&e.detatchEvent("on"+t,n)}function a(e,t){var n=Math.max(e.top,t.top),r=Math.min(e.bottom,t.bottom),i=Math.max(e.left,t.left),o=Math.min(e.right,t.right),a=o-i,s=r-n;return a>=0&&s>=0&&{top:n,bottom:r,left:i,right:o,width:a,height:s}||null}function s(e){var t;try{t=e.getBoundingClientRect()}catch(n){}return t?(t.width&&t.height||(t={top:t.top,right:t.right,bottom:t.bottom,left:t.left,width:t.right-t.left,height:t.bottom-t.top}),t):{top:0,bottom:0,left:0,right:0,width:0,height:0}}function u(e,t){var n=t.top-e.top,r=t.left-e.left;return{top:n,left:r,height:t.height,width:t.width,bottom:n+t.height,right:r+t.width}}function c(e,t){for(var n=t;n;){if(n==e)return!0;n=l(n)}return!1}function l(t){var n=t.parentNode;return 9==t.nodeType&&t!=e?d(t):n&&11==n.nodeType&&n.host?n.host:n&&n.assignedSlot?n.assignedSlot.parentNode:n}function d(e){try{return e.defaultView&&e.defaultView.frameElement||null}catch(t){return null}}}()},function(e,t,n){"use strict";e.exports=function(e,t){return function(){for(var n=new Array(arguments.length),r=0;r<n.length;r++)n[r]=arguments[r];return e.apply(t,n)}}},function(e,t,n){"use strict";var r=n(6);function i(e){return encodeURIComponent(e).replace(/%40/gi,"@").replace(/%3A/gi,":").replace(/%24/g,"$").replace(/%2C/gi,",").replace(/%20/g,"+").replace(/%5B/gi,"[").replace(/%5D/gi,"]")}e.exports=function(e,t,n){if(!t)return e;var o;if(n)o=n(t);else if(r.isURLSearchParams(t))o=t.toString();else{var a=[];r.forEach(t,function(e,t){null!==e&&"undefined"!==typeof e&&(r.isArray(e)?t+="[]":e=[e],r.forEach(e,function(e){r.isDate(e)?e=e.toISOString():r.isObject(e)&&(e=JSON.stringify(e)),a.push(i(t)+"="+i(e))}))}),o=a.join("&")}if(o){var s=e.indexOf("#");-1!==s&&(e=e.slice(0,s)),e+=(-1===e.indexOf("?")?"?":"&")+o}return e}},function(e,t,n){"use strict";e.exports=function(e){return!(!e||!e.__CANCEL__)}},function(e,t,n){"use strict";(function(t){var r=n(6),i=n(57),o={"Content-Type":"application/x-www-form-urlencoded"};function a(e,t){!r.isUndefined(e)&&r.isUndefined(e["Content-Type"])&&(e["Content-Type"]=t)}var s={adapter:function(){var e;return"undefined"!==typeof XMLHttpRequest?e=n(25):"undefined"!==typeof t&&"[object process]"===Object.prototype.toString.call(t)&&(e=n(25)),e}(),transformRequest:[function(e,t){return i(t,"Accept"),i(t,"Content-Type"),r.isFormData(e)||r.isArrayBuffer(e)||r.isBuffer(e)||r.isStream(e)||r.isFile(e)||r.isBlob(e)?e:r.isArrayBufferView(e)?e.buffer:r.isURLSearchParams(e)?(a(t,"application/x-www-form-urlencoded;charset=utf-8"),e.toString()):r.isObject(e)?(a(t,"application/json;charset=utf-8"),JSON.stringify(e)):e}],transformResponse:[function(e){if("string"===typeof e)try{e=JSON.parse(e)}catch(t){}return e}],timeout:0,xsrfCookieName:"XSRF-TOKEN",xsrfHeaderName:"X-XSRF-TOKEN",maxContentLength:-1,validateStatus:function(e){return e>=200&&e<300},headers:{common:{Accept:"application/json, text/plain, */*"}}};r.forEach(["delete","get","head"],function(e){s.headers[e]={}}),r.forEach(["post","put","patch"],function(e){s.headers[e]=r.merge(o)}),e.exports=s}).call(this,n(19))},function(e,t,n){"use strict";var r=n(6),i=n(58),o=n(22),a=n(60),s=n(63),u=n(64),c=n(26);e.exports=function(e){return new Promise(function(t,l){var d=e.data,p=e.headers;r.isFormData(d)&&delete p["Content-Type"];var f=new XMLHttpRequest;if(e.auth){var h=e.auth.username||"",y=e.auth.password||"";p.Authorization="Basic "+btoa(h+":"+y)}var g=a(e.baseURL,e.url);if(f.open(e.method.toUpperCase(),o(g,e.params,e.paramsSerializer),!0),f.timeout=e.timeout,f.onreadystatechange=function(){if(f&&4===f.readyState&&(0!==f.status||f.responseURL&&0===f.responseURL.indexOf("file:"))){var n="getAllResponseHeaders"in f?s(f.getAllResponseHeaders()):null,r={data:e.responseType&&"text"!==e.responseType?f.response:f.responseText,status:f.status,statusText:f.statusText,headers:n,config:e,request:f};i(t,l,r),f=null}},f.onabort=function(){f&&(l(c("Request aborted",e,"ECONNABORTED",f)),f=null)},f.onerror=function(){l(c("Network Error",e,null,f)),f=null},f.ontimeout=function(){var t="timeout of "+e.timeout+"ms exceeded";e.timeoutErrorMessage&&(t=e.timeoutErrorMessage),l(c(t,e,"ECONNABORTED",f)),f=null},r.isStandardBrowserEnv()){var v=n(65),m=(e.withCredentials||u(g))&&e.xsrfCookieName?v.read(e.xsrfCookieName):void 0;m&&(p[e.xsrfHeaderName]=m)}if("setRequestHeader"in f&&r.forEach(p,function(e,t){"undefined"===typeof d&&"content-type"===t.toLowerCase()?delete p[t]:f.setRequestHeader(t,e)}),r.isUndefined(e.withCredentials)||(f.withCredentials=!!e.withCredentials),e.responseType)try{f.responseType=e.responseType}catch(b){if("json"!==e.responseType)throw b}"function"===typeof e.onDownloadProgress&&f.addEventListener("progress",e.onDownloadProgress),"function"===typeof e.onUploadProgress&&f.upload&&f.upload.addEventListener("progress",e.onUploadProgress),e.cancelToken&&e.cancelToken.promise.then(function(e){f&&(f.abort(),l(e),f=null)}),void 0===d&&(d=null),f.send(d)})}},function(e,t,n){"use strict";var r=n(59);e.exports=function(e,t,n,i,o){var a=new Error(e);return r(a,t,n,i,o)}},function(e,t,n){"use strict";var r=n(6);e.exports=function(e,t){t=t||{};var n={},i=["url","method","params","data"],o=["headers","auth","proxy"],a=["baseURL","url","transformRequest","transformResponse","paramsSerializer","timeout","withCredentials","adapter","responseType","xsrfCookieName","xsrfHeaderName","onUploadProgress","onDownloadProgress","maxContentLength","validateStatus","maxRedirects","httpAgent","httpsAgent","cancelToken","socketPath"];r.forEach(i,function(e){"undefined"!==typeof t[e]&&(n[e]=t[e])}),r.forEach(o,function(i){r.isObject(t[i])?n[i]=r.deepMerge(e[i],t[i]):"undefined"!==typeof t[i]?n[i]=t[i]:r.isObject(e[i])?n[i]=r.deepMerge(e[i]):"undefined"!==typeof e[i]&&(n[i]=e[i])}),r.forEach(a,function(r){"undefined"!==typeof t[r]?n[r]=t[r]:"undefined"!==typeof e[r]&&(n[r]=e[r])});var s=i.concat(o).concat(a),u=Object.keys(t).filter(function(e){return-1===s.indexOf(e)});return r.forEach(u,function(r){"undefined"!==typeof t[r]?n[r]=t[r]:"undefined"!==typeof e[r]&&(n[r]=e[r])}),n}},function(e,t,n){"use strict";function r(e){this.message=e}r.prototype.toString=function(){return"Cancel"+(this.message?": "+this.message:"")},r.prototype.__CANCEL__=!0,e.exports=r},function(e,t,n){"use strict";function r(e){var t,n=e.Symbol;return"function"===typeof n?n.observable?t=n.observable:(t=n("observable"),n.observable=t):t="@@observable",t}n.d(t,"a",function(){return r})},function(e,t,n){"use strict";(function(e){n.d(t,"a",function(){return f});var r=function(){for(var e=0,t=0,n=arguments.length;t<n;t++)e+=arguments[t].length;var r=Array(e),i=0;for(t=0;t<n;t++)for(var o=arguments[t],a=0,s=o.length;a<s;a++,i++)r[i]=o[a];return r},i=function(){return function(e,t,n){this.name=e,this.version=t,this.os=n,this.type="browser"}}(),o=function(){return function(t){this.version=t,this.type="node",this.name="node",this.os=e.platform}}(),a=function(){return function(e,t,n,r){this.name=e,this.version=t,this.os=n,this.bot=r,this.type="bot-device"}}(),s=function(){return function(){this.type="bot",this.bot=!0,this.name="bot",this.version=null,this.os=null}}(),u=function(){return function(){this.type="react-native",this.name="react-native",this.version=null,this.os=null}}(),c=/(nuhk|Googlebot|Yammybot|Openbot|Slurp|MSNBot|Ask\ Jeeves\/Teoma|ia_archiver)/,l=3,d=[["aol",/AOLShield\/([0-9\._]+)/],["edge",/Edge\/([0-9\._]+)/],["edge-ios",/EdgiOS\/([0-9\._]+)/],["yandexbrowser",/YaBrowser\/([0-9\._]+)/],["kakaotalk",/KAKAOTALK\s([0-9\.]+)/],["samsung",/SamsungBrowser\/([0-9\.]+)/],["silk",/\bSilk\/([0-9._-]+)\b/],["miui",/MiuiBrowser\/([0-9\.]+)$/],["beaker",/BeakerBrowser\/([0-9\.]+)/],["edge-chromium",/Edg\/([0-9\.]+)/],["chromium-webview",/(?!Chrom.*OPR)wv\).*Chrom(?:e|ium)\/([0-9\.]+)(:?\s|$)/],["chrome",/(?!Chrom.*OPR)Chrom(?:e|ium)\/([0-9\.]+)(:?\s|$)/],["phantomjs",/PhantomJS\/([0-9\.]+)(:?\s|$)/],["crios",/CriOS\/([0-9\.]+)(:?\s|$)/],["firefox",/Firefox\/([0-9\.]+)(?:\s|$)/],["fxios",/FxiOS\/([0-9\.]+)/],["opera-mini",/Opera Mini.*Version\/([0-9\.]+)/],["opera",/Opera\/([0-9\.]+)(?:\s|$)/],["opera",/OPR\/([0-9\.]+)(:?\s|$)/],["ie",/Trident\/7\.0.*rv\:([0-9\.]+).*\).*Gecko$/],["ie",/MSIE\s([0-9\.]+);.*Trident\/[4-7].0/],["ie",/MSIE\s(7\.0)/],["bb10",/BB10;\sTouch.*Version\/([0-9\.]+)/],["android",/Android\s([0-9\.]+)/],["ios",/Version\/([0-9\._]+).*Mobile.*Safari.*/],["safari",/Version\/([0-9\._]+).*Safari/],["facebook",/FBAV\/([0-9\.]+)/],["instagram",/Instagram\s([0-9\.]+)/],["ios-webview",/AppleWebKit\/([0-9\.]+).*Mobile/],["ios-webview",/AppleWebKit\/([0-9\.]+).*Gecko\)$/],["searchbot",/alexa|bot|crawl(er|ing)|facebookexternalhit|feedburner|google web preview|nagios|postrank|pingdom|slurp|spider|yahoo!|yandex/]],p=[["iOS",/iP(hone|od|ad)/],["Android OS",/Android/],["BlackBerry OS",/BlackBerry|BB10/],["Windows Mobile",/IEMobile/],["Amazon OS",/Kindle/],["Windows 3.11",/Win16/],["Windows 95",/(Windows 95)|(Win95)|(Windows_95)/],["Windows 98",/(Windows 98)|(Win98)/],["Windows 2000",/(Windows NT 5.0)|(Windows 2000)/],["Windows XP",/(Windows NT 5.1)|(Windows XP)/],["Windows Server 2003",/(Windows NT 5.2)/],["Windows Vista",/(Windows NT 6.0)/],["Windows 7",/(Windows NT 6.1)/],["Windows 8",/(Windows NT 6.2)/],["Windows 8.1",/(Windows NT 6.3)/],["Windows 10",/(Windows NT 10.0)/],["Windows ME",/Windows ME/],["Open BSD",/OpenBSD/],["Sun OS",/SunOS/],["Chrome OS",/CrOS/],["Linux",/(Linux)|(X11)/],["Mac OS",/(Mac_PowerPC)|(Macintosh)/],["QNX",/QNX/],["BeOS",/BeOS/],["OS/2",/OS\/2/]];function f(t){return t?y(t):"undefined"===typeof document&&"undefined"!==typeof navigator&&"ReactNative"===navigator.product?new u:"undefined"!==typeof navigator?y(navigator.userAgent):"undefined"!==typeof e&&e.version?new o(e.version.slice(1)):null}function h(e){return""!==e&&d.reduce(function(t,n){var r=n[0],i=n[1];if(t)return t;var o=i.exec(e);return!!o&&[r,o]},!1)}function y(e){var t=h(e);if(!t)return null;var n=t[0],o=t[1];if("searchbot"===n)return new s;var u=o[1]&&o[1].split(/[._]/).slice(0,3);u?u.length<l&&(u=r(u,function(e){for(var t=[],n=0;n<e;n++)t.push("0");return t}(l-u.length))):u=[];var d=u.join("."),f=function(e){for(var t=0,n=p.length;t<n;t++){var r=p[t],i=r[0],o=r[1],a=o.exec(e);if(a)return i}return null}(e),y=c.exec(e);return y&&y[1]?new a(n,d,f,y[1]):new i(n,d,f)}}).call(this,n(19))},function(e,t){function n(){return e.exports=n=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},n.apply(this,arguments)}e.exports=n},function(e,t,n){e.exports=n(52)},function(e,t,n){e.exports=n(34)()},function(e,t,n){"use strict";var r=n(35);function i(){}function o(){}o.resetWarningCache=i,e.exports=function(){function e(e,t,n,i,o,a){if(a!==r){var s=new Error("Calling PropTypes validators directly is not supported by the `prop-types` package. Use PropTypes.checkPropTypes() to call them. Read more at http://fb.me/use-check-prop-types");throw s.name="Invariant Violation",s}}function t(){return e}e.isRequired=e;var n={array:e,bool:e,func:e,number:e,object:e,string:e,symbol:e,any:e,arrayOf:t,element:e,elementType:e,instanceOf:t,node:e,objectOf:t,oneOf:t,oneOfType:t,shape:t,exact:t,checkPropTypes:o,resetWarningCache:i};return n.PropTypes=n,n}},function(e,t,n){"use strict";e.exports="SECRET_DO_NOT_PASS_THIS_OR_YOU_WILL_BE_FIRED"},function(e,t,n){"use strict";var r="function"===typeof Symbol&&Symbol.for,i=r?Symbol.for("react.element"):60103,o=r?Symbol.for("react.portal"):60106,a=r?Symbol.for("react.fragment"):60107,s=r?Symbol.for("react.strict_mode"):60108,u=r?Symbol.for("react.profiler"):60114,c=r?Symbol.for("react.provider"):60109,l=r?Symbol.for("react.context"):60110,d=r?Symbol.for("react.async_mode"):60111,p=r?Symbol.for("react.concurrent_mode"):60111,f=r?Symbol.for("react.forward_ref"):60112,h=r?Symbol.for("react.suspense"):60113,y=r?Symbol.for("react.suspense_list"):60120,g=r?Symbol.for("react.memo"):60115,v=r?Symbol.for("react.lazy"):60116,m=r?Symbol.for("react.block"):60121,b=r?Symbol.for("react.fundamental"):60117,O=r?Symbol.for("react.responder"):60118,_=r?Symbol.for("react.scope"):60119;function S(e){if("object"===typeof e&&null!==e){var t=e.$$typeof;switch(t){case i:switch(e=e.type){case d:case p:case a:case u:case s:case h:return e;default:switch(e=e&&e.$$typeof){case l:case f:case v:case g:case c:return e;default:return t}}case o:return t}}}function E(e){return S(e)===p}t.AsyncMode=d,t.ConcurrentMode=p,t.ContextConsumer=l,t.ContextProvider=c,t.Element=i,t.ForwardRef=f,t.Fragment=a,t.Lazy=v,t.Memo=g,t.Portal=o,t.Profiler=u,t.StrictMode=s,t.Suspense=h,t.isAsyncMode=function(e){return E(e)||S(e)===d},t.isConcurrentMode=E,t.isContextConsumer=function(e){return S(e)===l},t.isContextProvider=function(e){return S(e)===c},t.isElement=function(e){return"object"===typeof e&&null!==e&&e.$$typeof===i},t.isForwardRef=function(e){return S(e)===f},t.isFragment=function(e){return S(e)===a},t.isLazy=function(e){return S(e)===v},t.isMemo=function(e){return S(e)===g},t.isPortal=function(e){return S(e)===o},t.isProfiler=function(e){return S(e)===u},t.isStrictMode=function(e){return S(e)===s},t.isSuspense=function(e){return S(e)===h},t.isValidElementType=function(e){return"string"===typeof e||"function"===typeof e||e===a||e===p||e===u||e===s||e===h||e===y||"object"===typeof e&&null!==e&&(e.$$typeof===v||e.$$typeof===g||e.$$typeof===c||e.$$typeof===l||e.$$typeof===f||e.$$typeof===b||e.$$typeof===O||e.$$typeof===_||e.$$typeof===m)},t.typeOf=S},function(e,t){var n;n=function(){return this}();try{n=n||new Function("return this")()}catch(r){"object"===typeof window&&(n=window)}e.exports=n},function(e,t){e.exports=function(e){if(!e.webpackPolyfill){var t=Object.create(e);t.children||(t.children=[]),Object.defineProperty(t,"loaded",{enumerable:!0,get:function(){return t.l}}),Object.defineProperty(t,"id",{enumerable:!0,get:function(){return t.i}}),Object.defineProperty(t,"exports",{enumerable:!0}),t.webpackPolyfill=1}return t}},function(e,t,n){var r=n(17);e.exports=function(e){if(Array.isArray(e))return r(e)}},function(e,t){e.exports=function(e){if("undefined"!==typeof Symbol&&Symbol.iterator in Object(e))return Array.from(e)}},function(e,t){e.exports=function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}},function(e,t){e.exports=function(e){if(Array.isArray(e))return e}},function(e,t){e.exports=function(e,t){if("undefined"!==typeof Symbol&&Symbol.iterator in Object(e)){var n=[],r=!0,i=!1,o=void 0;try{for(var a,s=e[Symbol.iterator]();!(r=(a=s.next()).done)&&(n.push(a.value),!t||n.length!==t);r=!0);}catch(u){i=!0,o=u}finally{try{r||null==s.return||s.return()}finally{if(i)throw o}}return n}}},function(e,t){e.exports=function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}},function(e,t){e.exports=function(e,t){if(null==e)return{};var n,r,i={},o=Object.keys(e);for(r=0;r<o.length;r++)n=o[r],t.indexOf(n)>=0||(i[n]=e[n]);return i}},function(e,t){},function(e,t,n){var r=function(e){"use strict";var t,n=Object.prototype,r=n.hasOwnProperty,i="function"===typeof Symbol?Symbol:{},o=i.iterator||"@@iterator",a=i.asyncIterator||"@@asyncIterator",s=i.toStringTag||"@@toStringTag";function u(e,t,n){return Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}),e[t]}try{u({},"")}catch(M){u=function(e,t,n){return e[t]=n}}function c(e,t,n,r){var i=t&&t.prototype instanceof g?t:g,o=Object.create(i.prototype),a=new C(r||[]);return o._invoke=function(e,t,n){var r=d;return function(i,o){if(r===f)throw new Error("Generator is already running");if(r===h){if("throw"===i)throw o;return D()}for(n.method=i,n.arg=o;;){var a=n.delegate;if(a){var s=P(a,n);if(s){if(s===y)continue;return s}}if("next"===n.method)n.sent=n._sent=n.arg;else if("throw"===n.method){if(r===d)throw r=h,n.arg;n.dispatchException(n.arg)}else"return"===n.method&&n.abrupt("return",n.arg);r=f;var u=l(e,t,n);if("normal"===u.type){if(r=n.done?h:p,u.arg===y)continue;return{value:u.arg,done:n.done}}"throw"===u.type&&(r=h,n.method="throw",n.arg=u.arg)}}}(e,n,a),o}function l(e,t,n){try{return{type:"normal",arg:e.call(t,n)}}catch(M){return{type:"throw",arg:M}}}e.wrap=c;var d="suspendedStart",p="suspendedYield",f="executing",h="completed",y={};function g(){}function v(){}function m(){}var b={};b[o]=function(){return this};var O=Object.getPrototypeOf,_=O&&O(O(R([])));_&&_!==n&&r.call(_,o)&&(b=_);var S=m.prototype=g.prototype=Object.create(b);function E(e){["next","throw","return"].forEach(function(t){u(e,t,function(e){return this._invoke(t,e)})})}function w(e,t){var n;this._invoke=function(i,o){function a(){return new t(function(n,a){!function n(i,o,a,s){var u=l(e[i],e,o);if("throw"!==u.type){var c=u.arg,d=c.value;return d&&"object"===typeof d&&r.call(d,"__await")?t.resolve(d.__await).then(function(e){n("next",e,a,s)},function(e){n("throw",e,a,s)}):t.resolve(d).then(function(e){c.value=e,a(c)},function(e){return n("throw",e,a,s)})}s(u.arg)}(i,o,n,a)})}return n=n?n.then(a,a):a()}}function P(e,n){var r=e.iterator[n.method];if(r===t){if(n.delegate=null,"throw"===n.method){if(e.iterator.return&&(n.method="return",n.arg=t,P(e,n),"throw"===n.method))return y;n.method="throw",n.arg=new TypeError("The iterator does not provide a 'throw' method")}return y}var i=l(r,e.iterator,n.arg);if("throw"===i.type)return n.method="throw",n.arg=i.arg,n.delegate=null,y;var o=i.arg;return o?o.done?(n[e.resultName]=o.value,n.next=e.nextLoc,"return"!==n.method&&(n.method="next",n.arg=t),n.delegate=null,y):o:(n.method="throw",n.arg=new TypeError("iterator result is not an object"),n.delegate=null,y)}function T(e){var t={tryLoc:e[0]};1 in e&&(t.catchLoc=e[1]),2 in e&&(t.finallyLoc=e[2],t.afterLoc=e[3]),this.tryEntries.push(t)}function A(e){var t=e.completion||{};t.type="normal",delete t.arg,e.completion=t}function C(e){this.tryEntries=[{tryLoc:"root"}],e.forEach(T,this),this.reset(!0)}function R(e){if(e){var n=e[o];if(n)return n.call(e);if("function"===typeof e.next)return e;if(!isNaN(e.length)){var i=-1,a=function n(){for(;++i<e.length;)if(r.call(e,i))return n.value=e[i],n.done=!1,n;return n.value=t,n.done=!0,n};return a.next=a}}return{next:D}}function D(){return{value:t,done:!0}}return v.prototype=S.constructor=m,m.constructor=v,v.displayName=u(m,s,"GeneratorFunction"),e.isGeneratorFunction=function(e){var t="function"===typeof e&&e.constructor;return!!t&&(t===v||"GeneratorFunction"===(t.displayName||t.name))},e.mark=function(e){return Object.setPrototypeOf?Object.setPrototypeOf(e,m):(e.__proto__=m,u(e,s,"GeneratorFunction")),e.prototype=Object.create(S),e},e.awrap=function(e){return{__await:e}},E(w.prototype),w.prototype[a]=function(){return this},e.AsyncIterator=w,e.async=function(t,n,r,i,o){void 0===o&&(o=Promise);var a=new w(c(t,n,r,i),o);return e.isGeneratorFunction(n)?a:a.next().then(function(e){return e.done?e.value:a.next()})},E(S),u(S,s,"Generator"),S[o]=function(){return this},S.toString=function(){return"[object Generator]"},e.keys=function(e){var t=[];for(var n in e)t.push(n);return t.reverse(),function n(){for(;t.length;){var r=t.pop();if(r in e)return n.value=r,n.done=!1,n}return n.done=!0,n}},e.values=R,C.prototype={constructor:C,reset:function(e){if(this.prev=0,this.next=0,this.sent=this._sent=t,this.done=!1,this.delegate=null,this.method="next",this.arg=t,this.tryEntries.forEach(A),!e)for(var n in this)"t"===n.charAt(0)&&r.call(this,n)&&!isNaN(+n.slice(1))&&(this[n]=t)},stop:function(){this.done=!0;var e=this.tryEntries[0].completion;if("throw"===e.type)throw e.arg;return this.rval},dispatchException:function(e){if(this.done)throw e;var n=this;function i(r,i){return s.type="throw",s.arg=e,n.next=r,i&&(n.method="next",n.arg=t),!!i}for(var o=this.tryEntries.length-1;o>=0;--o){var a=this.tryEntries[o],s=a.completion;if("root"===a.tryLoc)return i("end");if(a.tryLoc<=this.prev){var u=r.call(a,"catchLoc"),c=r.call(a,"finallyLoc");if(u&&c){if(this.prev<a.catchLoc)return i(a.catchLoc,!0);if(this.prev<a.finallyLoc)return i(a.finallyLoc)}else if(u){if(this.prev<a.catchLoc)return i(a.catchLoc,!0)}else{if(!c)throw new Error("try statement without catch or finally");if(this.prev<a.finallyLoc)return i(a.finallyLoc)}}}},abrupt:function(e,t){for(var n=this.tryEntries.length-1;n>=0;--n){var i=this.tryEntries[n];if(i.tryLoc<=this.prev&&r.call(i,"finallyLoc")&&this.prev<i.finallyLoc){var o=i;break}}o&&("break"===e||"continue"===e)&&o.tryLoc<=t&&t<=o.finallyLoc&&(o=null);var a=o?o.completion:{};return a.type=e,a.arg=t,o?(this.method="next",this.next=o.finallyLoc,y):this.complete(a)},complete:function(e,t){if("throw"===e.type)throw e.arg;return"break"===e.type||"continue"===e.type?this.next=e.arg:"return"===e.type?(this.rval=this.arg=e.arg,this.method="return",this.next="end"):"normal"===e.type&&t&&(this.next=t),y},finish:function(e){for(var t=this.tryEntries.length-1;t>=0;--t){var n=this.tryEntries[t];if(n.finallyLoc===e)return this.complete(n.completion,n.afterLoc),A(n),y}},catch:function(e){for(var t=this.tryEntries.length-1;t>=0;--t){var n=this.tryEntries[t];if(n.tryLoc===e){var r=n.completion;if("throw"===r.type){var i=r.arg;A(n)}return i}}throw new Error("illegal catch attempt")},delegateYield:function(e,n,r){return this.delegate={iterator:R(e),resultName:n,nextLoc:r},"next"===this.method&&(this.arg=t),y}},e}(e.exports);try{regeneratorRuntime=r}catch(i){Function("r","regeneratorRuntime = r")(r)}},function(e,t){function n(t,r){return e.exports=n=Object.setPrototypeOf||function(e,t){return e.__proto__=t,e},n(t,r)}e.exports=n},function(e,t){function n(t){return"function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?e.exports=n=function(e){return typeof e}:e.exports=n=function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},n(t)}e.exports=n},function(e,t,n){var r=n(5);e.exports=function(e,t){for(;!Object.prototype.hasOwnProperty.call(e,t)&&null!==(e=r(e)););return e}},function(e){e.exports=JSON.parse('{"name":"mplayer","version":"4.0.13","description":"minute media player","author":"minute media","private":true,"scripts":{"start":"yarn compile && PORT=2001 per-env","start:production":"npm run -s serve","start:development":"npm run -s dev","build":"preact build --no-prerender","serve":"preact build && serve build --single","dev":"preact watch","lint":"./node_modules/.bin/eslint --cache --ext .js,.ts,.tsx ./src/.","test":"jest","compile":"webpack","compile:production":"NODE_ENV=production webpack","compile:qa":"NODE_ENV=qa webpack"},"devDependencies":{"@babel/cli":"^7.8.4","@babel/core":"^7.8.4","@babel/plugin-proposal-class-properties":"^7.8.3","@babel/plugin-transform-react-jsx":"^7.8.3","@babel/plugin-transform-runtime":"^7.9.0","@babel/preset-env":"^7.8.4","@babel/preset-react":"^7.8.3","@babel/preset-typescript":"^7.8.3","@typescript-eslint/eslint-plugin":"^2.10.0","@typescript-eslint/parser":"^2.10.0","eslint":"^6.7.2","eslint-config-mm":"git+https://github.com/FTBpro/eslint-config-mm.git#v3.1","eslint-loader":"3.0.2","identity-obj-proxy":"^3.0.0","jest":"^24.9.0","jest-emotion":"^10.0.32","jest-preset-preact":"^1.0.0","per-env":"^1.0.2","preact-cli":"^3.0.0-rc.6","react":"^16.13.1","react-dom":"^16.13.1","serve":"^11.1.0"},"dependencies":{"@emotion/core":"^10.0.28","axios":"^0.19.2","babel-loader":"^8.0.6","detect-browser":"^5.1.0","emotion":"^10.0.27","enzyme":"^3.11.0","enzyme-adapter-preact-pure":"^2.2.0","hls.js":"^0.13.2","intersection-observer":"^0.8.0","jest-enzyme":"^7.1.2","jest-junit":"^10.0.0","preact":"^10.0.1","preact-render-to-string":"^5.1.8","react-redux":"^7.2.0","react-svg-loader":"^3.0.3","redux":"^4.0.5","redux-thunk":"^2.3.0","terser-webpack-plugin":"1.2.3","webpack":"^4.41.6","webpack-cli":"^3.3.11"}}')},function(e,t,n){"use strict";var r=n(6),i=n(21),o=n(53),a=n(27);function s(e){var t=new o(e),n=i(o.prototype.request,t);return r.extend(n,o.prototype,t),r.extend(n,t),n}var u=s(n(24));u.Axios=o,u.create=function(e){return s(a(u.defaults,e))},u.Cancel=n(28),u.CancelToken=n(66),u.isCancel=n(23),u.all=function(e){return Promise.all(e)},u.spread=n(67),e.exports=u,e.exports.default=u},function(e,t,n){"use strict";var r=n(6),i=n(22),o=n(54),a=n(55),s=n(27);function u(e){this.defaults=e,this.interceptors={request:new o,response:new o}}u.prototype.request=function(e){"string"===typeof e?(e=arguments[1]||{}).url=arguments[0]:e=e||{},(e=s(this.defaults,e)).method?e.method=e.method.toLowerCase():this.defaults.method?e.method=this.defaults.method.toLowerCase():e.method="get";var t=[a,void 0],n=Promise.resolve(e);for(this.interceptors.request.forEach(function(e){t.unshift(e.fulfilled,e.rejected)}),this.interceptors.response.forEach(function(e){t.push(e.fulfilled,e.rejected)});t.length;)n=n.then(t.shift(),t.shift());return n},u.prototype.getUri=function(e){return e=s(this.defaults,e),i(e.url,e.params,e.paramsSerializer).replace(/^\?/,"")},r.forEach(["delete","get","head","options"],function(e){u.prototype[e]=function(t,n){return this.request(r.merge(n||{},{method:e,url:t}))}}),r.forEach(["post","put","patch"],function(e){u.prototype[e]=function(t,n,i){return this.request(r.merge(i||{},{method:e,url:t,data:n}))}}),e.exports=u},function(e,t,n){"use strict";var r=n(6);function i(){this.handlers=[]}i.prototype.use=function(e,t){return this.handlers.push({fulfilled:e,rejected:t}),this.handlers.length-1},i.prototype.eject=function(e){this.handlers[e]&&(this.handlers[e]=null)},i.prototype.forEach=function(e){r.forEach(this.handlers,function(t){null!==t&&e(t)})},e.exports=i},function(e,t,n){"use strict";var r=n(6),i=n(56),o=n(23),a=n(24);function s(e){e.cancelToken&&e.cancelToken.throwIfRequested()}e.exports=function(e){return s(e),e.headers=e.headers||{},e.data=i(e.data,e.headers,e.transformRequest),e.headers=r.merge(e.headers.common||{},e.headers[e.method]||{},e.headers),r.forEach(["delete","get","head","post","put","patch","common"],function(t){delete e.headers[t]}),(e.adapter||a.adapter)(e).then(function(t){return s(e),t.data=i(t.data,t.headers,e.transformResponse),t},function(t){return o(t)||(s(e),t&&t.response&&(t.response.data=i(t.response.data,t.response.headers,e.transformResponse))),Promise.reject(t)})}},function(e,t,n){"use strict";var r=n(6);e.exports=function(e,t,n){return r.forEach(n,function(n){e=n(e,t)}),e}},function(e,t,n){"use strict";var r=n(6);e.exports=function(e,t){r.forEach(e,function(n,r){r!==t&&r.toUpperCase()===t.toUpperCase()&&(e[t]=n,delete e[r])})}},function(e,t,n){"use strict";var r=n(26);e.exports=function(e,t,n){var i=n.config.validateStatus;!i||i(n.status)?e(n):t(r("Request failed with status code "+n.status,n.config,null,n.request,n))}},function(e,t,n){"use strict";e.exports=function(e,t,n,r,i){return e.config=t,n&&(e.code=n),e.request=r,e.response=i,e.isAxiosError=!0,e.toJSON=function(){return{message:this.message,name:this.name,description:this.description,number:this.number,fileName:this.fileName,lineNumber:this.lineNumber,columnNumber:this.columnNumber,stack:this.stack,config:this.config,code:this.code}},e}},function(e,t,n){"use strict";var r=n(61),i=n(62);e.exports=function(e,t){return e&&!r(t)?i(e,t):t}},function(e,t,n){"use strict";e.exports=function(e){return/^([a-z][a-z\d\+\-\.]*:)?\/\//i.test(e)}},function(e,t,n){"use strict";e.exports=function(e,t){return t?e.replace(/\/+$/,"")+"/"+t.replace(/^\/+/,""):e}},function(e,t,n){"use strict";var r=n(6),i=["age","authorization","content-length","content-type","etag","expires","from","host","if-modified-since","if-unmodified-since","last-modified","location","max-forwards","proxy-authorization","referer","retry-after","user-agent"];e.exports=function(e){var t,n,o,a={};return e?(r.forEach(e.split("\n"),function(e){if(o=e.indexOf(":"),t=r.trim(e.substr(0,o)).toLowerCase(),n=r.trim(e.substr(o+1)),t){if(a[t]&&i.indexOf(t)>=0)return;a[t]="set-cookie"===t?(a[t]?a[t]:[]).concat([n]):a[t]?a[t]+", "+n:n}}),a):a}},function(e,t,n){"use strict";var r=n(6);e.exports=r.isStandardBrowserEnv()?function(){var e,t=/(msie|trident)/i.test(navigator.userAgent),n=document.createElement("a");function i(e){var r=e;return t&&(n.setAttribute("href",r),r=n.href),n.setAttribute("href",r),{href:n.href,protocol:n.protocol?n.protocol.replace(/:$/,""):"",host:n.host,search:n.search?n.search.replace(/^\?/,""):"",hash:n.hash?n.hash.replace(/^#/,""):"",hostname:n.hostname,port:n.port,pathname:"/"===n.pathname.charAt(0)?n.pathname:"/"+n.pathname}}return e=i(window.location.href),function(t){var n=r.isString(t)?i(t):t;return n.protocol===e.protocol&&n.host===e.host}}():function(){return!0}},function(e,t,n){"use strict";var r=n(6);e.exports=r.isStandardBrowserEnv()?{write:function(e,t,n,i,o,a){var s=[];s.push(e+"="+encodeURIComponent(t)),r.isNumber(n)&&s.push("expires="+new Date(n).toGMTString()),r.isString(i)&&s.push("path="+i),r.isString(o)&&s.push("domain="+o),!0===a&&s.push("secure"),document.cookie=s.join("; ")},read:function(e){var t=document.cookie.match(new RegExp("(^|;\\s*)("+e+")=([^;]*)"));return t?decodeURIComponent(t[3]):null},remove:function(e){this.write(e,"",Date.now()-864e5)}}:{write:function(){},read:function(){return null},remove:function(){}}},function(e,t,n){"use strict";var r=n(28);function i(e){if("function"!==typeof e)throw new TypeError("executor must be a function.");var t;this.promise=new Promise(function(e){t=e});var n=this;e(function(e){n.reason||(n.reason=new r(e),t(n.reason))})}i.prototype.throwIfRequested=function(){if(this.reason)throw this.reason},i.source=function(){var e;return{token:new i(function(t){e=t}),cancel:e}},e.exports=i},function(e,t,n){"use strict";e.exports=function(e){return function(t){return e.apply(null,t)}}},function(e,t,n){"use strict";n.r(t);var r={};n.r(r),n.d(r,"render",function(){return B}),n.d(r,"hydrate",function(){return H}),n.d(r,"createElement",function(){return b}),n.d(r,"h",function(){return b}),n.d(r,"Fragment",function(){return S}),n.d(r,"createRef",function(){return _}),n.d(r,"isValidElement",function(){return a}),n.d(r,"Component",function(){return E}),n.d(r,"cloneElement",function(){return q}),n.d(r,"createContext",function(){return W}),n.d(r,"toChildArray",function(){return R}),n.d(r,"__u",function(){return U}),n.d(r,"options",function(){return o});var i={};n.r(i),n.d(i,"useState",function(){return te}),n.d(i,"useReducer",function(){return ne}),n.d(i,"useEffect",function(){return re}),n.d(i,"useLayoutEffect",function(){return ie}),n.d(i,"useRef",function(){return oe}),n.d(i,"useImperativeHandle",function(){return ae}),n.d(i,"useMemo",function(){return se}),n.d(i,"useCallback",function(){return ue}),n.d(i,"useContext",function(){return ce}),n.d(i,"useDebugValue",function(){return le}),n.d(i,"useErrorBoundary",function(){return de});var o,a,s,u,c,l,d,p=n(0),f=n.n(p),h={},y=[],g=/acit|ex(?:s|g|n|p|$)|rph|grid|ows|mnc|ntw|ine[ch]|zoo|^ord|itera/i;function v(e,t){for(var n in t)e[n]=t[n];return e}function m(e){var t=e.parentNode;t&&t.removeChild(e)}function b(e,t,n){var r,i,o,a=arguments,s={};for(o in t)"key"==o?r=t[o]:"ref"==o?i=t[o]:s[o]=t[o];if(arguments.length>3)for(n=[n],o=3;o<arguments.length;o++)n.push(a[o]);if(null!=n&&(s.children=n),"function"==typeof e&&null!=e.defaultProps)for(o in e.defaultProps)void 0===s[o]&&(s[o]=e.defaultProps[o]);return O(e,s,r,i,null)}function O(e,t,n,r,i){var a={type:e,props:t,key:n,ref:r,__k:null,__:null,__b:0,__e:null,__d:void 0,__c:null,constructor:void 0,__v:i};return null==i&&(a.__v=a),null!=o.vnode&&o.vnode(a),a}function _(){return{current:null}}function S(e){return e.children}function E(e,t){this.props=e,this.context=t}function w(e,t){if(null==t)return e.__?w(e.__,e.__.__k.indexOf(e)+1):null;for(var n;t<e.__k.length;t++)if(null!=(n=e.__k[t])&&null!=n.__e)return n.__e;return"function"==typeof e.type?w(e):null}function P(e){var t,n;if(null!=(e=e.__)&&null!=e.__c){for(e.__e=e.__c.base=null,t=0;t<e.__k.length;t++)if(null!=(n=e.__k[t])&&null!=n.__e){e.__e=e.__c.base=n.__e;break}return P(e)}}function T(e){(!e.__d&&(e.__d=!0)&&s.push(e)&&!A.__r++||c!==o.debounceRendering)&&((c=o.debounceRendering)||u)(A)}function A(){for(var e;A.__r=s.length;)e=s.sort(function(e,t){return e.__v.__b-t.__v.__b}),s=[],e.some(function(e){var t,n,r,i,o,a,s;e.__d&&(a=(o=(t=e).__v).__e,(s=t.__P)&&(n=[],(r=v({},o)).__v=r,i=L(s,o,r,t.__n,void 0!==s.ownerSVGElement,null,n,null==a?w(o):a),x(n,o),i!=a&&P(o)))})}function C(e,t,n,r,i,o,a,s,u,c){var l,d,p,f,g,v,b,_=r&&r.__k||y,E=_.length;for(u==h&&(u=null!=a?a[0]:E?w(r,0):null),n.__k=[],l=0;l<t.length;l++)if(null!=(f=n.__k[l]=null==(f=t[l])||"boolean"==typeof f?null:"string"==typeof f||"number"==typeof f?O(null,f,null,null,f):Array.isArray(f)?O(S,{children:f},null,null,null):null!=f.__e||null!=f.__c?O(f.type,f.props,f.key,null,f.__v):f)){if(f.__=n,f.__b=n.__b+1,null===(p=_[l])||p&&f.key==p.key&&f.type===p.type)_[l]=void 0;else for(d=0;d<E;d++){if((p=_[d])&&f.key==p.key&&f.type===p.type){_[d]=void 0;break}p=null}g=L(e,f,p=p||h,i,o,a,s,u,c),(d=f.ref)&&p.ref!=d&&(b||(b=[]),p.ref&&b.push(p.ref,null,f),b.push(d,f.__c||g,f)),null!=g?(null==v&&(v=g),u=D(e,f,p,_,a,g,u),c||"option"!=n.type?"function"==typeof n.type&&(n.__d=u):e.value=""):u&&p.__e==u&&u.parentNode!=e&&(u=w(p))}if(n.__e=v,null!=a&&"function"!=typeof n.type)for(l=a.length;l--;)null!=a[l]&&m(a[l]);for(l=E;l--;)null!=_[l]&&U(_[l],_[l]);if(b)for(l=0;l<b.length;l++)j(b[l],b[++l],b[++l])}function R(e,t){return t=t||[],null==e||"boolean"==typeof e||(Array.isArray(e)?e.some(function(e){R(e,t)}):t.push(e)),t}function D(e,t,n,r,i,o,a){var s,u,c;if(void 0!==t.__d)s=t.__d,t.__d=void 0;else if(i==n||o!=a||null==o.parentNode)e:if(null==a||a.parentNode!==e)e.appendChild(o),s=null;else{for(u=a,c=0;(u=u.nextSibling)&&c<r.length;c+=2)if(u==o)break e;e.insertBefore(o,a),s=a}return void 0!==s?s:o.nextSibling}function M(e,t,n){"-"===t[0]?e.setProperty(t,n):e[t]=null==n?"":"number"!=typeof n||g.test(t)?n:n+"px"}function I(e,t,n,r,i){var o,a;if(i&&"className"==t&&(t="class"),"style"===t)if("string"==typeof n)e.style=n;else{if("string"==typeof r&&(e.style=r=""),r)for(t in r)n&&t in n||M(e.style,t,"");if(n)for(t in n)r&&n[t]===r[t]||M(e.style,t,n[t])}else"o"===t[0]&&"n"===t[1]?(o=t!==(t=t.replace(/Capture$/,"")),(a=t.toLowerCase())in e&&(t=a),t=t.slice(2),e.l||(e.l={}),e.l[t]=n,n?r||e.addEventListener(t,k,o):e.removeEventListener(t,k,o)):"list"!==t&&"tagName"!==t&&"form"!==t&&"type"!==t&&"size"!==t&&"download"!==t&&"href"!==t&&!i&&t in e?e[t]=null==n?"":n:"function"!=typeof n&&"dangerouslySetInnerHTML"!==t&&(t!==(t=t.replace(/xlink:?/,""))?null==n||!1===n?e.removeAttributeNS("http://www.w3.org/1999/xlink",t.toLowerCase()):e.setAttributeNS("http://www.w3.org/1999/xlink",t.toLowerCase(),n):null==n||!1===n&&!/^ar/.test(t)?e.removeAttribute(t):e.setAttribute(t,n))}function k(e){this.l[e.type](o.event?o.event(e):e)}function N(e,t,n){var r,i;for(r=0;r<e.__k.length;r++)(i=e.__k[r])&&(i.__=e,i.__e&&("function"==typeof i.type&&i.__k.length>1&&N(i,t,n),t=D(n,i,i,e.__k,null,i.__e,t),"function"==typeof e.type&&(e.__d=t)))}function L(e,t,n,r,i,a,s,u,c){var l,d,p,f,h,y,g,m,b,O,_,w=t.type;if(void 0!==t.constructor)return null;(l=o.__b)&&l(t);try{e:if("function"==typeof w){if(m=t.props,b=(l=w.contextType)&&r[l.__c],O=l?b?b.props.value:l.__:r,n.__c?g=(d=t.__c=n.__c).__=d.__E:("prototype"in w&&w.prototype.render?t.__c=d=new w(m,O):(t.__c=d=new E(m,O),d.constructor=w,d.render=F),b&&b.sub(d),d.props=m,d.state||(d.state={}),d.context=O,d.__n=r,p=d.__d=!0,d.__h=[]),null==d.__s&&(d.__s=d.state),null!=w.getDerivedStateFromProps&&(d.__s==d.state&&(d.__s=v({},d.__s)),v(d.__s,w.getDerivedStateFromProps(m,d.__s))),f=d.props,h=d.state,p)null==w.getDerivedStateFromProps&&null!=d.componentWillMount&&d.componentWillMount(),null!=d.componentDidMount&&d.__h.push(d.componentDidMount);else{if(null==w.getDerivedStateFromProps&&m!==f&&null!=d.componentWillReceiveProps&&d.componentWillReceiveProps(m,O),!d.__e&&null!=d.shouldComponentUpdate&&!1===d.shouldComponentUpdate(m,d.__s,O)||t.__v===n.__v){d.props=m,d.state=d.__s,t.__v!==n.__v&&(d.__d=!1),d.__v=t,t.__e=n.__e,t.__k=n.__k,d.__h.length&&s.push(d),N(t,u,e);break e}null!=d.componentWillUpdate&&d.componentWillUpdate(m,d.__s,O),null!=d.componentDidUpdate&&d.__h.push(function(){d.componentDidUpdate(f,h,y)})}d.context=O,d.props=m,d.state=d.__s,(l=o.__r)&&l(t),d.__d=!1,d.__v=t,d.__P=e,l=d.render(d.props,d.state,d.context),d.state=d.__s,null!=d.getChildContext&&(r=v(v({},r),d.getChildContext())),p||null==d.getSnapshotBeforeUpdate||(y=d.getSnapshotBeforeUpdate(f,h)),_=null!=l&&l.type==S&&null==l.key?l.props.children:l,C(e,Array.isArray(_)?_:[_],t,n,r,i,a,s,u,c),d.base=t.__e,d.__h.length&&s.push(d),g&&(d.__E=d.__=null),d.__e=!1}else null==a&&t.__v===n.__v?(t.__k=n.__k,t.__e=n.__e):t.__e=V(n.__e,t,n,r,i,a,s,c);(l=o.diffed)&&l(t)}catch(e){t.__v=null,o.__e(e,t,n)}return t.__e}function x(e,t){o.__c&&o.__c(t,e),e.some(function(t){try{e=t.__h,t.__h=[],e.some(function(e){e.call(t)})}catch(e){o.__e(e,t.__v)}})}function V(e,t,n,r,i,o,a,s){var u,c,l,d,p,f=n.props,g=t.props;if(i="svg"===t.type||i,null!=o)for(u=0;u<o.length;u++)if(null!=(c=o[u])&&((null===t.type?3===c.nodeType:c.localName===t.type)||e==c)){e=c,o[u]=null;break}if(null==e){if(null===t.type)return document.createTextNode(g);e=i?document.createElementNS("http://www.w3.org/2000/svg",t.type):document.createElement(t.type,g.is&&{is:g.is}),o=null,s=!1}if(null===t.type)f!==g&&e.data!==g&&(e.data=g);else{if(null!=o&&(o=y.slice.call(e.childNodes)),l=(f=n.props||h).dangerouslySetInnerHTML,d=g.dangerouslySetInnerHTML,!s){if(null!=o)for(f={},p=0;p<e.attributes.length;p++)f[e.attributes[p].name]=e.attributes[p].value;(d||l)&&(d&&l&&d.__html==l.__html||(e.innerHTML=d&&d.__html||""))}(function(e,t,n,r,i){var o;for(o in n)"children"===o||"key"===o||o in t||I(e,o,null,n[o],r);for(o in t)i&&"function"!=typeof t[o]||"children"===o||"key"===o||"value"===o||"checked"===o||n[o]===t[o]||I(e,o,t[o],n[o],r)})(e,g,f,i,s),d?t.__k=[]:(u=t.props.children,C(e,Array.isArray(u)?u:[u],t,n,r,"foreignObject"!==t.type&&i,o,a,h,s)),s||("value"in g&&void 0!==(u=g.value)&&u!==e.value&&I(e,"value",u,f.value,!1),"checked"in g&&void 0!==(u=g.checked)&&u!==e.checked&&I(e,"checked",u,f.checked,!1))}return e}function j(e,t,n){try{"function"==typeof e?e(t):e.current=t}catch(e){o.__e(e,n)}}function U(e,t,n){var r,i,a;if(o.unmount&&o.unmount(e),(r=e.ref)&&(r.current&&r.current!==e.__e||j(r,null,t)),n||"function"==typeof e.type||(n=null!=(i=e.__e)),e.__e=e.__d=void 0,null!=(r=e.__c)){if(r.componentWillUnmount)try{r.componentWillUnmount()}catch(e){o.__e(e,t)}r.base=r.__P=null}if(r=e.__k)for(a=0;a<r.length;a++)r[a]&&U(r[a],t,n);null!=i&&m(i)}function F(e,t,n){return this.constructor(e,n)}function B(e,t,n){var r,i,a;o.__&&o.__(e,t),i=(r=n===l)?null:n&&n.__k||t.__k,e=b(S,null,[e]),a=[],L(t,(r?t:n||t).__k=e,i||h,h,void 0!==t.ownerSVGElement,n&&!r?[n]:i?null:t.childNodes.length?y.slice.call(t.childNodes):null,a,n||h,r),x(a,e)}function H(e,t){B(e,t,l)}function q(e,t,n){var r,i,o,a=arguments,s=v({},e.props);for(o in t)"key"==o?r=t[o]:"ref"==o?i=t[o]:s[o]=t[o];if(arguments.length>3)for(n=[n],o=3;o<arguments.length;o++)n.push(a[o]);return null!=n&&(s.children=n),O(e.type,s,r||e.key,i||e.ref,null)}function W(e,t){var n={__c:t="__cC"+d++,__:e,Consumer:function(e,t){return e.children(t)},Provider:function(e,n,r){return this.getChildContext||(n=[],(r={})[t]=this,this.getChildContext=function(){return r},this.shouldComponentUpdate=function(e){this.props.value!==e.value&&n.some(T)},this.sub=function(e){n.push(e);var t=e.componentWillUnmount;e.componentWillUnmount=function(){n.splice(n.indexOf(e),1),t&&t.call(e)}}),e.children}};return n.Provider.__=n.Consumer.contextType=n}o={__e:function(e,t){for(var n,r;t=t.__;)if((n=t.__c)&&!n.__)try{if(n.constructor&&null!=n.constructor.getDerivedStateFromError&&(r=!0,n.setState(n.constructor.getDerivedStateFromError(e))),null!=n.componentDidCatch&&(r=!0,n.componentDidCatch(e)),r)return T(n.__E=n)}catch(t){e=t}throw e}},a=function(e){return null!=e&&void 0===e.constructor},E.prototype.setState=function(e,t){var n;n=null!=this.__s&&this.__s!==this.state?this.__s:this.__s=v({},this.state),"function"==typeof e&&(e=e(v({},n),this.props)),e&&v(n,e),null!=e&&this.__v&&(t&&this.__h.push(t),T(this))},E.prototype.forceUpdate=function(e){this.__v&&(this.__e=!0,e&&this.__h.push(e),T(this))},E.prototype.render=S,s=[],u="function"==typeof Promise?Promise.prototype.then.bind(Promise.resolve()):setTimeout,A.__r=0,l=h,d=0;var z,G,$,K=0,Y=[],Z=o.__r,X=o.diffed,J=o.__c,Q=o.unmount;function ee(e,t){o.__h&&o.__h(G,e,K||t),K=0;var n=G.__H||(G.__H={__:[],__h:[]});return e>=n.__.length&&n.__.push({}),n.__[e]}function te(e){return K=1,ne(ve,e)}function ne(e,t,n){var r=ee(z++,2);return r.t=e,r.__c||(r.__c=G,r.__=[n?n(t):ve(void 0,t),function(e){var t=r.t(r.__[0],e);r.__[0]!==t&&(r.__=[t,r.__[1]],r.__c.setState({}))}]),r.__}function re(e,t){var n=ee(z++,3);!o.__s&&ge(n.__H,t)&&(n.__=e,n.__H=t,G.__H.__h.push(n))}function ie(e,t){var n=ee(z++,4);!o.__s&&ge(n.__H,t)&&(n.__=e,n.__H=t,G.__h.push(n))}function oe(e){return K=5,se(function(){return{current:e}},[])}function ae(e,t,n){K=6,ie(function(){"function"==typeof e?e(t()):e&&(e.current=t())},null==n?n:n.concat(e))}function se(e,t){var n=ee(z++,7);return ge(n.__H,t)?(n.__H=t,n.__h=e,n.__=e()):n.__}function ue(e,t){return K=8,se(function(){return e},t)}function ce(e){var t=G.context[e.__c],n=ee(z++,9);return n.__c=e,t?(null==n.__&&(n.__=!0,t.sub(G)),t.props.value):e.__}function le(e,t){o.useDebugValue&&o.useDebugValue(t?t(e):e)}function de(e){var t=ee(z++,10),n=te();return t.__=e,G.componentDidCatch||(G.componentDidCatch=function(e){t.__&&t.__(e),n[1](e)}),[n[0],function(){n[1](void 0)}]}function pe(){Y.some(function(e){if(e.__P)try{e.__H.__h.forEach(he),e.__H.__h.forEach(ye),e.__H.__h=[]}catch(t){return e.__H.__h=[],o.__e(t,e.__v),!0}}),Y=[]}o.__r=function(e){Z&&Z(e),z=0;var t=(G=e.__c).__H;t&&(t.__h.forEach(he),t.__h.forEach(ye),t.__h=[])},o.diffed=function(e){X&&X(e);var t=e.__c;t&&t.__H&&t.__H.__h.length&&(1!==Y.push(t)&&$===o.requestAnimationFrame||(($=o.requestAnimationFrame)||function(e){var t,n=function(){clearTimeout(r),fe&&cancelAnimationFrame(t),setTimeout(e)},r=setTimeout(n,100);fe&&(t=requestAnimationFrame(n))})(pe))},o.__c=function(e,t){t.some(function(e){try{e.__h.forEach(he),e.__h=e.__h.filter(function(e){return!e.__||ye(e)})}catch(n){t.some(function(e){e.__h&&(e.__h=[])}),t=[],o.__e(n,e.__v)}}),J&&J(e,t)},o.unmount=function(e){Q&&Q(e);var t=e.__c;if(t&&t.__H)try{t.__H.__.forEach(he)}catch(e){o.__e(e,t.__v)}};var fe="function"==typeof requestAnimationFrame;function he(e){"function"==typeof e.u&&e.u()}function ye(e){e.u=e.__()}function ge(e,t){return!e||t.some(function(t,n){return t!==e[n]})}function ve(e,t){return"function"==typeof t?t(e):t}function me(e,t){for(var n in t)e[n]=t[n];return e}function be(e,t){for(var n in e)if("__source"!==n&&!(n in t))return!0;for(var r in t)if("__source"!==r&&e[r]!==t[r])return!0;return!1}function Oe(e){this.props=e}(Oe.prototype=new E).isPureReactComponent=!0,Oe.prototype.shouldComponentUpdate=function(e,t){return be(this.props,e)||be(this.state,t)};var _e=o.__b;o.__b=function(e){e.type&&e.type.__f&&e.ref&&(e.props.ref=e.ref,e.ref=null),_e&&_e(e)};var Se="undefined"!=typeof Symbol&&Symbol.for&&Symbol.for("react.forward_ref")||3911;var Ee=function(e,t){return e?R(R(e).map(t)):null},we={map:Ee,forEach:Ee,count:function(e){return e?R(e).length:0},only:function(e){var t=R(e);if(1!==t.length)throw"Children.only";return t[0]},toArray:R},Pe=o.__e;function Te(e){return e&&((e=me({},e)).__c=null,e.__k=e.__k&&e.__k.map(Te)),e}function Ae(e){return e&&(e.__v=null,e.__k=e.__k&&e.__k.map(Ae)),e}function Ce(){this.__u=0,this.t=null,this.__b=null}function Re(e){var t=e.__.__c;return t&&t.o&&t.o(e)}function De(){this.u=null,this.i=null}o.__e=function(e,t,n){if(e.then)for(var r,i=t;i=i.__;)if((r=i.__c)&&r.__c)return null==t.__e&&(t.__e=n.__e,t.__k=n.__k),r.__c(e,t.__c);Pe(e,t,n)},(Ce.prototype=new E).__c=function(e,t){var n=this;null==n.t&&(n.t=[]),n.t.push(t);var r=Re(n.__v),i=!1,o=function(){i||(i=!0,t.componentWillUnmount=t.__c,r?r(a):a())};t.__c=t.componentWillUnmount,t.componentWillUnmount=function(){o(),t.__c&&t.__c()};var a=function(){var e;if(!--n.__u)for(n.__v.__k[0]=Ae(n.state.o),n.setState({o:n.__b=null});e=n.t.pop();)e.forceUpdate()};n.__u++||n.setState({o:n.__b=n.__v.__k[0]}),e.then(o,o)},Ce.prototype.componentWillUnmount=function(){this.t=[]},Ce.prototype.render=function(e,t){return this.__b&&(this.__v.__k&&(this.__v.__k[0]=Te(this.__b)),this.__b=null),[b(S,null,t.o?null:e.children),t.o&&e.fallback]};var Me=function(e,t,n){if(++n[1]===n[0]&&e.i.delete(t),e.props.revealOrder&&("t"!==e.props.revealOrder[0]||!e.i.size))for(n=e.u;n;){for(;n.length>3;)n.pop()();if(n[1]<n[0])break;e.u=n=n[2]}};function Ie(e){return this.getChildContext=function(){return e.context},e.children}function ke(e){var t=this,n=e.l,r=b(Ie,{context:t.context},e.__v);t.componentWillUnmount=function(){var e=t.s.parentNode;e&&e.removeChild(t.s),U(t.v)},t.l&&t.l!==n&&(t.componentWillUnmount(),t.h=!1),e.__v?t.h?(n.__k=t.__k,B(r,n),t.__k=n.__k):(t.s=document.createTextNode(""),t.__k=n.__k,H("",n),n.appendChild(t.s),t.h=!0,t.l=n,B(r,n,t.s),n.__k=t.__k,t.__k=t.s.__k):t.h&&t.componentWillUnmount(),t.v=r}(De.prototype=new E).o=function(e){var t=this,n=Re(t.__v),r=t.i.get(e);return r[0]++,function(i){var o=function(){t.props.revealOrder?(r.push(i),Me(t,e,r)):i()};n?n(o):o()}},De.prototype.render=function(e){this.u=null,this.i=new Map;var t=R(e.children);e.revealOrder&&"b"===e.revealOrder[0]&&t.reverse();for(var n=t.length;n--;)this.i.set(t[n],this.u=[1,0,this.u]);return e.children},De.prototype.componentDidUpdate=De.prototype.componentDidMount=function(){var e=this;this.i.forEach(function(t,n){Me(e,n,t)})};var Ne=/^(?:accent|alignment|arabic|baseline|cap|clip(?!PathU)|color|fill|flood|font|glyph(?!R)|horiz|marker(?!H|W|U)|overline|paint|stop|strikethrough|stroke|text(?!L)|underline|unicode|units|v|vector|vert|word|writing|x(?!C))[A-Z]/;E.prototype.isReactComponent={};var Le="undefined"!=typeof Symbol&&Symbol.for&&Symbol.for("react.element")||60103;var xe=o.event;function Ve(e,t){e["UNSAFE_"+t]&&!e[t]&&Object.defineProperty(e,t,{get:function(){return this["UNSAFE_"+t]},set:function(e){this["UNSAFE_"+t]=e}})}o.event=function(e){xe&&(e=xe(e)),e.persist=function(){};var t=!1,n=!1,r=e.stopPropagation;e.stopPropagation=function(){r.call(e),t=!0};var i=e.preventDefault;return e.preventDefault=function(){i.call(e),n=!0},e.isPropagationStopped=function(){return t},e.isDefaultPrevented=function(){return n},e.nativeEvent=e};var je,Ue={configurable:!0,get:function(){return this.class}},Fe=o.vnode;o.vnode=function(e){e.$$typeof=Le;var t=e.type,n=e.props;if(t){var r;if(n.class!=n.className&&(Ue.enumerable="className"in n,null!=n.className&&(n.class=n.className),Object.defineProperty(n,"className",Ue)),"function"!=typeof t)for(r in n.defaultValue&&void 0!==n.value&&(n.value||0===n.value||(n.value=n.defaultValue),n.defaultValue=void 0),"select"===t&&n.multiple&&Array.isArray(n.value)&&(R(n.children).forEach(function(e){-1!=n.value.indexOf(e.props.value)&&(e.props.selected=!0)}),n.value=void 0),!0===n.download&&(n.download=""),n){var i=Ne.test(r);i&&(e.props[r.replace(/[A-Z0-9]/,"-$&").toLowerCase()]=n[r]),(i||null===n[r])&&(n[r]=void 0)}else t.prototype&&!t.prototype.p&&(t.prototype.p=!0,Ve(t.prototype,"componentWillMount"),Ve(t.prototype,"componentWillReceiveProps"),Ve(t.prototype,"componentWillUpdate"));!function(t){var n=e.type,r=e.props;if(r&&"string"==typeof n){var i={};for(var o in r)/^on(Ani|Tra|Tou)/.test(o)&&(r[o.toLowerCase()]=r[o],delete r[o]),i[o.toLowerCase()]=o;if(i.ondoubleclick&&(r.ondblclick=r[i.ondoubleclick],delete r[i.ondoubleclick]),i.onbeforeinput&&(r.onbeforeinput=r[i.onbeforeinput],delete r[i.onbeforeinput]),i.onchange&&("textarea"===n||"input"===n.toLowerCase()&&!/^fil|che|ra/i.test(r.type))){var a=i.oninput||"oninput";r[a]||(r[a]=r[i.onchange],delete r[i.onchange])}}}()}Fe&&Fe(e)};var Be=o.__r;o.__r=function(e){Be&&Be(e),je=e.__c};function He(e){return!!e&&e.$$typeof===Le}var qe=function(e,t){return e(t)},We={useState:te,useReducer:ne,useEffect:re,useLayoutEffect:ie,useRef:oe,useImperativeHandle:ae,useMemo:se,useCallback:ue,useContext:ce,useDebugValue:le,version:"16.8.0",Children:we,render:function(e,t,n){if(null==t.__k)for(;t.firstChild;)t.removeChild(t.firstChild);return B(e,t),"function"==typeof n&&n(),e?e.__c:null},hydrate:function(e,t,n){return H(e,t),"function"==typeof n&&n(),e?e.__c:null},unmountComponentAtNode:function(e){return!!e.__k&&(B(null,e),!0)},createPortal:function(e,t){return b(ke,{__v:e,l:t})},createElement:b,createContext:W,createFactory:function(e){return b.bind(null,e)},cloneElement:function(e){return He(e)?q.apply(null,arguments):e},createRef:_,Fragment:S,isValidElement:He,findDOMNode:function(e){return e&&(e.base||1===e.nodeType&&e)||null},Component:E,PureComponent:Oe,memo:function(e,t){function n(e){var n=this.props.ref,r=n==e.ref;return!r&&n&&(n.call?n(null):n.current=null),t?!t(this.props,e)||!r:be(this.props,e)}function r(t){return this.shouldComponentUpdate=n,b(e,t)}return r.displayName="Memo("+(e.displayName||e.name)+")",r.prototype.isReactComponent=!0,r.__f=!0,r},forwardRef:function(e){function t(t,n){var r=me({},t);return delete r.ref,e(r,(n=t.ref||n)&&("object"!=typeof n||"current"in n)?n:null)}return t.$$typeof=Se,t.render=t,t.prototype.isReactComponent=t.__f=!0,t.displayName="ForwardRef("+(e.displayName||e.name)+")",t},unstable_batchedUpdates:qe,StrictMode:S,Suspense:Ce,SuspenseList:De,lazy:function(e){var t,n,r;function i(i){if(t||(t=e()).then(function(e){n=e.default||e},function(e){r=e}),r)throw r;if(!n)throw t;return b(n,i)}return i.displayName="Lazy",i.__f=!0,i},__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED:{ReactCurrentDispatcher:{current:{readContext:function(e){return je.__n[e.__c].props.value}}}}},ze=(n(33),We.createContext(null));var Ge=function(e){e()},$e=function(){return Ge},Ke={notify:function(){}};var Ye=function(){function e(e,t){this.store=e,this.parentSub=t,this.unsubscribe=null,this.listeners=Ke,this.handleChangeWrapper=this.handleChangeWrapper.bind(this)}var t=e.prototype;return t.addNestedSub=function(e){return this.trySubscribe(),this.listeners.subscribe(e)},t.notifyNestedSubs=function(){this.listeners.notify()},t.handleChangeWrapper=function(){this.onStateChange&&this.onStateChange()},t.isSubscribed=function(){return Boolean(this.unsubscribe)},t.trySubscribe=function(){this.unsubscribe||(this.unsubscribe=this.parentSub?this.parentSub.addNestedSub(this.handleChangeWrapper):this.store.subscribe(this.handleChangeWrapper),this.listeners=function(){var e=$e(),t=null,n=null;return{clear:function(){t=null,n=null},notify:function(){e(function(){for(var e=t;e;)e.callback(),e=e.next})},get:function(){for(var e=[],n=t;n;)e.push(n),n=n.next;return e},subscribe:function(e){var r=!0,i=n={callback:e,next:null,prev:n};return i.prev?i.prev.next=i:t=i,function(){r&&null!==t&&(r=!1,i.next?i.next.prev=i.prev:n=i.prev,i.prev?i.prev.next=i.next:t=i.next)}}}}())},t.tryUnsubscribe=function(){this.unsubscribe&&(this.unsubscribe(),this.unsubscribe=null,this.listeners.clear(),this.listeners=Ke)},e}();var Ze=function(e){var t=e.store,n=e.context,r=e.children,i=se(function(){var e=new Ye(t);return e.onStateChange=e.notifyNestedSubs,{store:t,subscription:e}},[t]),o=se(function(){return t.getState()},[t]);re(function(){var e=i.subscription;return e.trySubscribe(),o!==t.getState()&&e.notifyNestedSubs(),function(){e.tryUnsubscribe(),e.onStateChange=null}},[i,o]);var a=n||ze;return We.createElement(a.Provider,{value:i},r)};function Xe(){return(Xe=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e}).apply(this,arguments)}function Je(e,t){if(null==e)return{};var n,r,i={},o=Object.keys(e);for(r=0;r<o.length;r++)n=o[r],t.indexOf(n)>=0||(i[n]=e[n]);return i}var Qe=n(15),et=n.n(Qe),tt=n(14),nt="undefined"!==typeof window&&"undefined"!==typeof window.document&&"undefined"!==typeof window.document.createElement?ie:re,rt=[],it=[null,null];function ot(e,t){var n=e[1];return[t.payload,n+1]}function at(e,t,n){nt(function(){return e.apply(void 0,t)},n)}function st(e,t,n,r,i,o,a){e.current=r,t.current=i,n.current=!1,o.current&&(o.current=null,a())}function ut(e,t,n,r,i,o,a,s,u,c){if(e){var l=!1,d=null,p=function(){if(!l){var e,n,p=t.getState();try{e=r(p,i.current)}catch(f){n=f,d=f}n||(d=null),e===o.current?a.current||u():(o.current=e,s.current=e,a.current=!0,c({type:"STORE_UPDATED",payload:{error:n}}))}};n.onStateChange=p,n.trySubscribe(),p();return function(){if(l=!0,n.tryUnsubscribe(),n.onStateChange=null,d)throw d}}}var ct=function(){return[null,0]};function lt(e,t){void 0===t&&(t={});var n=t,r=n.getDisplayName,i=void 0===r?function(e){return"ConnectAdvanced("+e+")"}:r,o=n.methodName,a=void 0===o?"connectAdvanced":o,s=n.renderCountProp,u=void 0===s?void 0:s,c=n.shouldHandleStateChanges,l=void 0===c||c,d=n.storeKey,p=void 0===d?"store":d,f=(n.withRef,n.forwardRef),h=void 0!==f&&f,y=n.context,g=void 0===y?ze:y,v=Je(n,["getDisplayName","methodName","renderCountProp","shouldHandleStateChanges","storeKey","withRef","forwardRef","context"]),m=g;return function(t){var n=t.displayName||t.name||"Component",r=i(n),o=Xe({},v,{getDisplayName:i,methodName:a,renderCountProp:u,shouldHandleStateChanges:l,storeKey:p,displayName:r,wrappedComponentName:n,WrappedComponent:t}),s=v.pure;var c=s?se:function(e){return e()};function d(n){var r=se(function(){var e=n.reactReduxForwardedRef,t=Je(n,["reactReduxForwardedRef"]);return[n.context,e,t]},[n]),i=r[0],a=r[1],s=r[2],u=se(function(){return i&&i.Consumer&&Object(tt.isContextConsumer)(We.createElement(i.Consumer,null))?i:m},[i,m]),d=ce(u),p=Boolean(n.store)&&Boolean(n.store.getState)&&Boolean(n.store.dispatch);Boolean(d)&&Boolean(d.store);var f=p?n.store:d.store,h=se(function(){return function(t){return e(t.dispatch,o)}(f)},[f]),y=se(function(){if(!l)return it;var e=new Ye(f,p?null:d.subscription),t=e.notifyNestedSubs.bind(e);return[e,t]},[f,p,d]),g=y[0],v=y[1],b=se(function(){return p?d:Xe({},d,{subscription:g})},[p,d,g]),O=ne(ot,rt,ct),_=O[0][0],S=O[1];if(_&&_.error)throw _.error;var E=oe(),w=oe(s),P=oe(),T=oe(!1),A=c(function(){return P.current&&s===w.current?P.current:h(f.getState(),s)},[f,_,s]);at(st,[w,E,T,s,A,P,v]),at(ut,[l,f,g,h,w,E,T,P,v,S],[f,g,h]);var C=se(function(){return We.createElement(t,Xe({},A,{ref:a}))},[a,t,A]);return se(function(){return l?We.createElement(u.Provider,{value:b},C):C},[u,C,b])}var f=s?We.memo(d):d;if(f.WrappedComponent=t,f.displayName=r,h){var y=We.forwardRef(function(e,t){return We.createElement(f,Xe({},e,{reactReduxForwardedRef:t}))});return y.displayName=r,y.WrappedComponent=t,et()(y,t)}return et()(f,t)}}function dt(e,t){return e===t?0!==e||0!==t||1/e===1/t:e!==e&&t!==t}function pt(e,t){if(dt(e,t))return!0;if("object"!==typeof e||null===e||"object"!==typeof t||null===t)return!1;var n=Object.keys(e),r=Object.keys(t);if(n.length!==r.length)return!1;for(var i=0;i<n.length;i++)if(!Object.prototype.hasOwnProperty.call(t,n[i])||!dt(e[n[i]],t[n[i]]))return!1;return!0}var ft=n(16),ht=function(){return Math.random().toString(36).substring(7).split("").join(".")},yt={INIT:"@@redux/INIT"+ht(),REPLACE:"@@redux/REPLACE"+ht(),PROBE_UNKNOWN_ACTION:function(){return"@@redux/PROBE_UNKNOWN_ACTION"+ht()}};function gt(e){if("object"!==typeof e||null===e)return!1;for(var t=e;null!==Object.getPrototypeOf(t);)t=Object.getPrototypeOf(t);return Object.getPrototypeOf(e)===t}function vt(e,t,n){var r;if("function"===typeof t&&"function"===typeof n||"function"===typeof n&&"function"===typeof arguments[3])throw new Error("It looks like you are passing several store enhancers to createStore(). This is not supported. Instead, compose them together to a single function.");if("function"===typeof t&&"undefined"===typeof n&&(n=t,t=void 0),"undefined"!==typeof n){if("function"!==typeof n)throw new Error("Expected the enhancer to be a function.");return n(vt)(e,t)}if("function"!==typeof e)throw new Error("Expected the reducer to be a function.");var i=e,o=t,a=[],s=a,u=!1;function c(){s===a&&(s=a.slice())}function l(){if(u)throw new Error("You may not call store.getState() while the reducer is executing. The reducer has already received the state as an argument. Pass it down from the top reducer instead of reading it from the store.");return o}function d(e){if("function"!==typeof e)throw new Error("Expected the listener to be a function.");if(u)throw new Error("You may not call store.subscribe() while the reducer is executing. If you would like to be notified after the store has been updated, subscribe from a component and invoke store.getState() in the callback to access the latest state. See https://redux.js.org/api-reference/store#subscribelistener for more details.");var t=!0;return c(),s.push(e),function(){if(t){if(u)throw new Error("You may not unsubscribe from a store listener while the reducer is executing. See https://redux.js.org/api-reference/store#subscribelistener for more details.");t=!1,c();var n=s.indexOf(e);s.splice(n,1),a=null}}}function p(e){if(!gt(e))throw new Error("Actions must be plain objects. Use custom middleware for async actions.");if("undefined"===typeof e.type)throw new Error('Actions may not have an undefined "type" property. Have you misspelled a constant?');if(u)throw new Error("Reducers may not dispatch actions.");try{u=!0,o=i(o,e)}finally{u=!1}for(var t=a=s,n=0;n<t.length;n++){(0,t[n])()}return e}return p({type:yt.INIT}),(r={dispatch:p,subscribe:d,getState:l,replaceReducer:function(e){if("function"!==typeof e)throw new Error("Expected the nextReducer to be a function.");i=e,p({type:yt.REPLACE})}})[ft.a]=function(){var e,t=d;return(e={subscribe:function(e){if("object"!==typeof e||null===e)throw new TypeError("Expected the observer to be an object.");function n(){e.next&&e.next(l())}return n(),{unsubscribe:t(n)}}})[ft.a]=function(){return this},e},r}function mt(e,t){var n=t&&t.type;return"Given "+(n&&'action "'+String(n)+'"'||"an action")+', reducer "'+e+'" returned undefined. To ignore an action, you must explicitly return the previous state. If you want this reducer to hold no value, you can return null instead of undefined.'}function bt(e,t){return function(){return t(e.apply(this,arguments))}}function Ot(e,t){if("function"===typeof e)return bt(e,t);if("object"!==typeof e||null===e)throw new Error("bindActionCreators expected an object or a function, instead received "+(null===e?"null":typeof e)+'. Did you write "import ActionCreators from" instead of "import * as ActionCreators from"?');var n={};for(var r in e){var i=e[r];"function"===typeof i&&(n[r]=bt(i,t))}return n}function _t(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}function St(e,t){var n=Object.keys(e);return Object.getOwnPropertySymbols&&n.push.apply(n,Object.getOwnPropertySymbols(e)),t&&(n=n.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n}function Et(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return 0===t.length?function(e){return e}:1===t.length?t[0]:t.reduce(function(e,t){return function(){return e(t.apply(void 0,arguments))}})}function wt(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return function(e){return function(){var n=e.apply(void 0,arguments),r=function(){throw new Error("Dispatching while constructing your middleware is not allowed. Other middleware would not be applied to this dispatch.")},i={getState:n.getState,dispatch:function(){return r.apply(void 0,arguments)}},o=t.map(function(e){return e(i)});return function(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?St(n,!0).forEach(function(t){_t(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):St(n).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}({},n,{dispatch:r=Et.apply(void 0,o)(n.dispatch)})}}}function Pt(e){return function(t,n){var r=e(t,n);function i(){return r}return i.dependsOnOwnProps=!1,i}}function Tt(e){return null!==e.dependsOnOwnProps&&void 0!==e.dependsOnOwnProps?Boolean(e.dependsOnOwnProps):1!==e.length}function At(e,t){return function(t,n){n.displayName;var r=function(e,t){return r.dependsOnOwnProps?r.mapToProps(e,t):r.mapToProps(e)};return r.dependsOnOwnProps=!0,r.mapToProps=function(t,n){r.mapToProps=e,r.dependsOnOwnProps=Tt(e);var i=r(t,n);return"function"===typeof i&&(r.mapToProps=i,r.dependsOnOwnProps=Tt(i),i=r(t,n)),i},r}}var Ct=[function(e){return"function"===typeof e?At(e):void 0},function(e){return e?void 0:Pt(function(e){return{dispatch:e}})},function(e){return e&&"object"===typeof e?Pt(function(t){return Ot(e,t)}):void 0}];var Rt=[function(e){return"function"===typeof e?At(e):void 0},function(e){return e?void 0:Pt(function(){return{}})}];function Dt(e,t,n){return Xe({},n,{},e,{},t)}var Mt=[function(e){return"function"===typeof e?function(e){return function(t,n){n.displayName;var r,i=n.pure,o=n.areMergedPropsEqual,a=!1;return function(t,n,s){var u=e(t,n,s);return a?i&&o(u,r)||(r=u):(a=!0,r=u),r}}}(e):void 0},function(e){return e?void 0:function(){return Dt}}];function It(e,t,n,r){return function(i,o){return n(e(i,o),t(r,o),o)}}function kt(e,t,n,r,i){var o,a,s,u,c,l=i.areStatesEqual,d=i.areOwnPropsEqual,p=i.areStatePropsEqual,f=!1;function h(i,f){var h=!d(f,a),y=!l(i,o);return o=i,a=f,h&&y?(s=e(o,a),t.dependsOnOwnProps&&(u=t(r,a)),c=n(s,u,a)):h?(e.dependsOnOwnProps&&(s=e(o,a)),t.dependsOnOwnProps&&(u=t(r,a)),c=n(s,u,a)):y?function(){var t=e(o,a),r=!p(t,s);return s=t,r&&(c=n(s,u,a)),c}():c}return function(i,l){return f?h(i,l):(s=e(o=i,a=l),u=t(r,a),c=n(s,u,a),f=!0,c)}}function Nt(e,t){var n=t.initMapStateToProps,r=t.initMapDispatchToProps,i=t.initMergeProps,o=Je(t,["initMapStateToProps","initMapDispatchToProps","initMergeProps"]),a=n(e,o),s=r(e,o),u=i(e,o);return(o.pure?kt:It)(a,s,u,e,o)}function Lt(e,t,n){for(var r=t.length-1;r>=0;r--){var i=t[r](e);if(i)return i}return function(t,r){throw new Error("Invalid value of type "+typeof e+" for "+n+" argument when connecting component "+r.wrappedComponentName+".")}}function xt(e,t){return e===t}function Vt(e){var t=void 0===e?{}:e,n=t.connectHOC,r=void 0===n?lt:n,i=t.mapStateToPropsFactories,o=void 0===i?Rt:i,a=t.mapDispatchToPropsFactories,s=void 0===a?Ct:a,u=t.mergePropsFactories,c=void 0===u?Mt:u,l=t.selectorFactory,d=void 0===l?Nt:l;return function(e,t,n,i){void 0===i&&(i={});var a=i,u=a.pure,l=void 0===u||u,p=a.areStatesEqual,f=void 0===p?xt:p,h=a.areOwnPropsEqual,y=void 0===h?pt:h,g=a.areStatePropsEqual,v=void 0===g?pt:g,m=a.areMergedPropsEqual,b=void 0===m?pt:m,O=Je(a,["pure","areStatesEqual","areOwnPropsEqual","areStatePropsEqual","areMergedPropsEqual"]),_=Lt(e,o,"mapStateToProps"),S=Lt(t,s,"mapDispatchToProps"),E=Lt(n,c,"mergeProps");return r(d,Xe({methodName:"connect",getDisplayName:function(e){return"Connect("+e+")"},shouldHandleStateChanges:Boolean(e),initMapStateToProps:_,initMapDispatchToProps:S,initMergeProps:E,pure:l,areStatesEqual:f,areOwnPropsEqual:y,areStatePropsEqual:v,areMergedPropsEqual:b},O))}}var jt=Vt();Ge=qe;var Ut={BORDER_RADIUS:{EXTRA_TINY:"1px",TINY:"2px",SMALL:"3px",MEDIUM:"4px"},COLORS:{BLACK:"#000000",WHITE:"#ffffff",TRANSPARENT:"transparent",GRADIENT_BLACK:"linear-gradient(to bottom, rgba(0, 0, 0, 0.63), rgba(0, 0, 0, 0.62) 19%, rgba(0, 0, 0, 0))",LIGHT_GRAY_TRANSPARENT:"rgba(255, 255, 255, 0.23)",GRAY_TRANSPARENT:"rgba(143, 143, 143, 0.46)",BLACK_TRANSPARENT:"rgba(0, 0, 0, 0.7)",BLACK_80_OPACITY:"rgba(0, 0, 0, 0.8)",BLUR_TRANSPARENT:"rgba(0, 0, 0, 0.48)",GRAY:"rgba(0, 0, 0, 0.35)",SELECTED:"rgba(255, 255, 255, 0.1)",SCROLL_BAR:"rgba(255, 255, 255, 0.64)",TRANSPARENT_30_OPACITY:"rgba(0, 0, 0, 0.31)"},TEXT_FONT_FAMILY:{LATO:"Lato"},FONT_SIZE:{EXTRA_TINY:"8px",TINY:"10px",EXTRA_SMALL:"12px",SMALL:"14px",MEDIUM:"18px"}},Ft="179px",Bt="269px",Ht="180px",qt="270px",Wt="300px",zt="301px",Gt="500px",$t="501px",Kt="800px",Yt="801px";function Zt(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Xt(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Zt(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Zt(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Jt=function e(t){return t&&t.length>0?t.reduce(function(t,n){return n?Array.isArray(n)?Xt(Xt({},t),e(n)):Xt(Xt({},t),n):t},{}):null},Qt=function(e){return function(t){t({type:"[CORE] change video tag status",payload:e})}},en=function(e){return function(t){t({type:"[CORE] update video current fragment position",payload:e})}},tn=function(e){return function(t){t({type:"[CORE] update video current position",payload:e})}},nn=function(e){return function(t){t({type:"[CORE] update video current buffered time",payload:e})}},rn=function(e){return function(t){t({type:"[CORE] update video current duration",payload:e})}},on=function(e,t){return function(n){n({type:"[COMMON] set pending video status",payload:{pendingStatusObject:{type:e,value:t}}})}},an=function(e){return function(t){t({type:"[COMMON] set mute video",payload:e})}},sn=function(e){return function(t){t({type:"[COMMON] set volume",payload:e})}},un=function(e){return function(t){t({type:"[CORE] change loading player status",payload:e})}},cn=function(e){return function(t){t({type:"[COMMON] show black screen with loader",payload:e})}},ln=function(e){return function(t){t({type:"[CORE] set player size",payload:e})}},dn=function(e){return function(t){t({type:"[COMMON] set error message",payload:e})}},pn={mediaData:function(e){return e.mediaData},playerData:function(e){return e.playerData},dependenciesLoadingStatus:function(e){return e.dependenciesLoadingStatus},brandingData:function(e){return e.brandingData},anchorOptions:function(e){return e.anchorOptions},semanticOptions:function(e){return e.semanticOptions},monetization:function(e){return e.monetization},userInteraction:function(e){return e.userInteraction},splitView:function(e){return e.splitView},discovery:function(e){return e.discovery}},fn=pn.playerData,hn={playerId:function(e){return fn(e).playerId},videoTagStatus:function(e){return fn(e).videoTagStatus},pendingVideoTagStatus:function(e){return fn(e).pendingVideoTagStatus},currentVideoTime:function(e){return fn(e).currentVideoTime},currentVideoTimeFragment:function(e){return fn(e).currentVideoTimeFragment},currentVideoDuration:function(e){return fn(e).currentVideoDuration},currentVideoBufferedTime:function(e){return fn(e).currentVideoBufferedTime},playerMode:function(e){return fn(e).playerMode},playerSettings:function(e){return fn(e).playerSettings},playbackMethod:function(e){return fn(e).playbackMethod},playerVisibility:function(e){return fn(e).playerVisibility},playerPlaceholderVisibility:function(e){return fn(e).playerPlaceholderVisibility},playerInstanceUniqId:function(e){return fn(e).playerInstanceUniqId},showBlackScreen:function(e){return fn(e).loader.showBlackScreen},playerSize:function(e){return fn(e).playerSize},errorMessage:function(e){return fn(e).errorMessage},loadingPlayer:function(e){return fn(e).loadingPlayer}},yn=hn.playerSettings,gn={volume:function(e){return yn(e).volume},muted:function(e){return yn(e).muted},quality:function(e){return yn(e).quality},speed:function(e){return yn(e).speed},selectedSettingsCategory:function(e){return yn(e).selectedSettingsCategory},fullscreen:function(e){return yn(e).fullscreen},pendingFullscreenRequest:function(e){return this.fullscreen(e).pendingFullscreenRequest},isFullscreenOn:function(e){return this.fullscreen(e).isFullscreenOn}},vn=function(e){return"".concat("mplayer-monetization-placeholder","-").concat(e)},mn=function(e){return"".concat("mplayer-player-placeholder","-").concat(e)},bn=function(e){return"".concat("mplayer-player-container","-").concat(e)},On=function(e){return"".concat("mplayer-controls-placeholder","-").concat(e)},_n=function(e){return"".concat("mplayer-split-view-placeholder","-").concat(e)},Sn=function(e){return"".concat("mplayer-discovery-placeholder","-").concat(e)},En=function(e){return"".concat("mplayer-content-video","-").concat(e)},wn=function(e){return"".concat("mplayer","-").concat("error-page-message","-").concat(e)},Pn=function(e){return"".concat("mplayer","-").concat("loader","-").concat(e)},Tn=function(e){return"".concat("mplayer","-").concat("mplayer-close-bar-placeholder","-").concat(e)},An=pn.mediaData,Cn={mediaId:function(e){return An(e).mediaId},mediaType:function(e){return An(e).mediaType},videoList:function(e){return An(e).videoList},videoData:function(e){return An(e).videoData},activeVideoIndex:function(e){return An(e).activeVideoIndex},mediaRequest:function(e){return An(e).mediaRequest},mediaLoadingError:function(e){return An(e).mediaLoadingError}},Rn=Cn.videoData,Dn={creator:function(e){return Rn(e).creator},description:function(e){return Rn(e).description},duration:function(e){return Rn(e).duration},externalId:function(e){return Rn(e).externalId},index:function(e){return Rn(e).index},mediaId:function(e){return Rn(e).mediaId},provider:function(e){return Rn(e).provider},sources:function(e){return Rn(e).sources},tags:function(e){return Rn(e).tags},thumbnail:function(e){return Rn(e).thumbnail},title:function(e){return Rn(e).title},showTitle:function(e){return Rn(e).showTitle}},Mn=n(11),In=n.n(Mn);function kn(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:[];return se(function(){return e.apply(void 0,In()(t))},[e,t])}var Nn={root:{height:"100%",left:0,display:"block",width:"100%"}},Ln=function(){return{playerStyle:[Nn.root]}},xn=n(30),Vn=Object(xn.a)(),jn=function(e){return"undefined"===typeof e},Un=function(e){return jn(e)||null===e||0===e.length},Fn=function(){return null!==navigator.userAgent.match(/(iPad)|(iPhone)|(iPod)|(android)|(webOS)/i)},Bn=function(){return"iOS"===Vn.os},Hn=function(e){return Math.floor(10*e)/10},qn=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"0";return parseInt(e,10)/1e3},Wn=function(e,t){return jn(e)||jn(t)?0:e>t?1:-1},zn=function(e,t){var n;return function(){for(var r=arguments.length,i=new Array(r),o=0;o<r;o++)i[o]=arguments[o];clearTimeout(n),n=setTimeout(function(){n=null,e(i)},t)}},Gn=function(e){var t=e.clientWidth*(9/16),n=e.clientHeight;return Math.abs(t-n)>2?t:n},$n=function(e){return function(e){return!e.dataLayer||Array.isArray(e.dataLayer)}(e)?"dataLayer":"mmVideoDataLayer"},Kn=function(e){var t=ue(e,arguments.length>1&&void 0!==arguments[1]?arguments[1]:[]);re(function(){t()},[t]),re(function(){var e=zn(t,150);return window.addEventListener("resize",e),function(){window.removeEventListener("resize",e)}},[t])},Yn=pn.splitView,Zn=function(e){return Yn(e).splitViewRatio},Xn={GENERAL_ERROR:"An error has occurred, please try again later",VIDEO_ERROR:"The video is currently unavailable"},Jn=jt(function(e,t){return{thumbnail:Dn.thumbnail(e),playerId:t.playerId,muted:gn.muted(e),volume:gn.volume(e),currentVideoTime:hn.currentVideoTime(e),playbackMethod:hn.playbackMethod(e),splitViewRatio:Zn(e),playerSize:hn.playerSize(e),isFullscreenOn:gn.isFullscreenOn(e),playerMode:hn.playerMode(e),speed:gn.speed(e)}},function(e){return Ot({updateVideoTagStatus:Qt,updateVideoTime:tn,updateVideoTimeFragment:en,changeLoadingPlayerStatus:un,showBlackScreenLoader:cn,updateVideoDuration:rn,updateMute:an,updateVolume:sn,updateCurrentVideoBufferedTime:nn,setPlayerSize:ln,onErrorMessage:dn},e)})(function(e){var t=e.thumbnail,n=e.playerId,r=e.updateVideoTagStatus,i=e.updateVideoTime,o=e.updateCurrentVideoBufferedTime,a=e.muted,s=e.volume,u=e.currentVideoTime,c=e.playbackMethod,l=e.changeLoadingPlayerStatus,d=e.showBlackScreenLoader,p=e.updateVideoDuration,f=e.updateMute,h=e.updateVolume,y=e.updateVideoTimeFragment,g=e.setPlayerSize,v=e.splitViewRatio,m=e.playerSize,O=e.isFullscreenOn,_=e.playerMode,S=e.onErrorMessage,E=e.speed,w=oe(null),P=!Un(v),T=kn(Ln,[]).playerStyle,A=document.getElementById(bn(n));re(function(){w.current.playbackRate=E},[E]),Kn(function(){if(!Un(A)){var e=function(e,t,n,r,i){var o=e.style.width;return n?"desktop"===r||"miniDesktop"===r||"stickyDesktop"===r?"extraLarge":"medium":"100%"===o?t:i&&o<=Bt?"extraSmall":i&&o>=qt&&o<=Wt?"small":o<=Ft?"extraSmall":o>=Ht&&o<=Wt?"small":o>=zt&&o<=Gt?"medium":o>=$t&&o<=Kt?"large":o>=Yt?"extraLarge":null}(A,m,O,_,P);Un(e)||g(e)}},[A,m,O,_,P,g]);var C="autoplay"===c?"":t;return b("video",{ref:w,style:Jt(T),key:En(n),id:En(n),onEnded:function(){r("complete")},onDurationChange:function(e){var t,n=e.target.duration;t=n,Number.isNaN(t)||"number"!==typeof t||p(n)},onTimeUpdate:function(e){var t=e.target.currentTime;y(t);var n=parseInt(t.toString(),10);n!==u&&i(n)},onVolumeChange:function(e){var t=e.target,n=t.volume,r=t.muted;n!==s&&h(n),a!==r&&f(r)},onPause:function(){r("paused")},onPlaying:function(){r("playing")},onError:function(){r("error"),S(Xn.VIDEO_ERROR)},onLoadStart:function(){l(!0),d(!0)},onCanPlayThrough:function(){l(!1),d(!1),S("")},onCanPlay:function(){l(!1),S("")},onWaiting:function(){l(!0)},onSeeking:function(){r("seeking")},onProgress:function(e){var t=e.target.buffered,n=t.length;n>0&&o(t.end(n-1))},volume:s,muted:a,poster:C,playsInline:!0,"webkit-playsinline":""},b("track",{kind:"captions"}))}),Qn=function(e){return function(t){t({type:"[CORE] update ima status",payload:e})}},er=function(e){return function(t){t({type:"[CORE] update hls status",payload:e})}},tr=function(){return{adBlockCheckerStyle:{backgroundColor:Ut.COLORS.TRANSPARENT,height:"1px",width:"1px"}}},nr=jt(null,function(e){return{onAdBlockDetected:function(){return Qn("blocked")(e)}}})(function(e){var t=oe(),n=kn(tr,[]).adBlockCheckerStyle;return re(function(){0!==t.current.clientHeight&&0!==t.current.clientWidth||(0,e.onAdBlockDetected)()},[e]),b("div",{ref:t},b("div",{class:"adBanner",style:n}))}),rr=n(10),ir=n.n(rr);n(20);var or={root:null,threshold:[0,.1,.2,.3,.4,.5,.6,.7,.8,.9,1],rootMargin:"0px"},ar=function(e){var t=e.id,n=e.updateContainerVisibility,r=e.shouldObserve,i=e.regularMode,o=e.stickyAnchorMode,a=e.children,s=e.style,u=e.isPlaceholder,c=e.splitViewRatio,l=e.className,d=oe(),p=te(null),f=ir()(p,2),h=f[0],y=f[1];return re(function(){null!==h&&h.observe(d.current)},[h]),re(function(){!function(e,t,n){e&&t(new IntersectionObserver(function(e){var t=e[0];n(t.intersectionRatio)},or))}(r,y,n)},[r,n]),Kn(function(){u?function(e,t){var n=e.parentElement.clientWidth;e.style.maxWidth="".concat(n,"px"),Un(t)?e.style.height="".concat(Gn(e),"px"):e.style.height="".concat(Gn(e)*(t/100),"px")}(d.current,c):function(e,t,n){t?(e.style.width="".concat(e.parentElement.clientWidth,"px"),e.style.height="".concat(e.parentElement.clientHeight,"px")):n&&(e.style.width="".concat(e.parentElement.clientWidth,"px"),e.style.height="".concat(e.parentElement.clientHeight+24,"px"))}(d.current,i,o)},[u,i,o]),b("div",{className:l,id:t,ref:d,style:s},a)};function sr(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function ur(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?sr(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):sr(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var cr={display:"flex",flexDirection:"row"},lr=(ur(ur({},cr),{},{justifyContent:"flex-end"}),ur(ur({},cr),{},{justifyContent:"center"})),dr=ur(ur({},cr),{},{justifyContent:"space-between"}),pr=(ur(ur({},dr),{},{alignItems:"baseline"}),ur(ur({},lr),{},{alignItems:"center"})),fr=ur(ur({},cr),{},{justifyContent:"flex-start"}),hr=(ur(ur({},fr),{},{alignItems:"center"}),ur(ur({},fr),{},{alignItems:"flex-end",flexWrap:"wrap"}),{display:"flex",flexDirection:"column"}),yr=(ur(ur({},hr),{},{justifyContent:"flex-start"}),ur(ur({},hr),{},{justifyContent:"center"})),gr=(ur(ur({},hr),{},{justifyContent:"flex-end",alignItems:"center"}),ur(ur({},yr),{},{alignItems:"center"}));function vr(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function mr(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?vr(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):vr(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var br=mr(mr({},hr),{},{position:"relative",background:Ut.COLORS.BLACK}),Or=pn.anchorOptions,_r=function(e){return Or(e).orientation},Sr=function(e){return Or(e).canClose},Er=function(e){return Or(e).anchorData},wr=function(e){return Er(e).anchorDisabledByUser},Pr=function(e){return Er(e).anchorStatus};function Tr(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Ar(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Tr(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Tr(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Cr=jt(function(e){return{shouldObserve:"lazyplay"===hn.playbackMethod(e)||"autoplay_when_viewable"===hn.playbackMethod(e),regularMode:"inactive"===Pr(e)||!Un(Zn(e)),stickyAnchorMode:"sticky"===_r(e)&&"active"===Pr(e)&&Sr(e),style:Ar({},mr({},br)),isPlaceholder:!1}},function(e){return{updateContainerVisibility:function(t){return function(e){return function(t){t({type:"[CORE] update player visibility",payload:e})}}(t)(e)}}})(ar);function Rr(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Dr(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Rr(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Rr(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Mr={width:"100%",clear:"both",margin:"16px 0"};function Ir(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function kr(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Ir(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Ir(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Nr=jt(function(e){return{shouldObserve:"sticky"!==_r(e),style:kr({},Dr({},Mr)),splitViewRatio:Zn(e),isPlaceholder:!0,className:"monti-placeholder-mm-player"}},function(e){return{updateContainerVisibility:function(t){return function(e){return function(t){t({type:"[CORE] update placeholder visibility",payload:e})}}(t)(e)}}})(ar),Lr=function(){return{monetizationStyle:{position:"absolute",width:"100%",top:"0",display:"none"}}},xr=function(e){var t=e.playerId,n=kn(Lr,[]).monetizationStyle,r=oe();return Kn(function(){console.log("the monetization parent element : ",r.current.parentElement),r.current.style.height="".concat(Gn(r.current.parentElement),"px")}),b("div",{id:vn(t),style:n,ref:r})};function Vr(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function jr(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Vr(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Vr(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Ur={position:"relative",color:Ut.COLORS.WHITE,fontFamily:Ut.TEXT_FONT_FAMILY.LATO,fontWeight:"bold",textAlign:"center",tiny:{fontSize:Ut.FONT_SIZE.EXTRA_TINY},big:{fontSize:Ut.FONT_SIZE.SMALL}},Fr={position:"relative",color:Ut.COLORS.WHITE,tiny:{height:"12px",width:"12px",marginBottom:"8px"},big:{height:"24px",width:"24px",marginBottom:"16px"}},Br=jr(jr({},gr),{},{width:"100%",height:"100%",position:"absolute",top:0,backdropFilter:"blur(3px)",webkitBackdropFilter:"blur(3px)",backgroundColor:Ut.COLORS.BLUR_TRANSPARENT}),Hr=function(e){var t="extraSmall"===e||"small"===e,n="medium"===e||"large"===e||"extraLarge"===e;return{errorMessageStyle:[Ur,t&&Ur.tiny,n&&Ur.big],iconStyle:[Fr,t&&Fr.tiny,n&&Fr.big],screenStyle:jr({},Br)}},qr=n(12),Wr=n.n(qr);function zr(){return(zr=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e}).apply(this,arguments)}function Gr(){return(Gr=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e}).apply(this,arguments)}function $r(){return($r=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e}).apply(this,arguments)}var Kr={CLOSE_FILL:function(e){e.styles;var t=Wr()(e,["styles"]);return We.createElement("svg",Gr({xmlns:"http://www.w3.org/2000/svg",viewBox:"0 0 24 24",width:"24",height:"24"},t),We.createElement("path",{fill:"none",d:"M0 0h24v24H0z"}),We.createElement("path",{d:"M12 10.586l4.95-4.95 1.414 1.414-4.95 4.95 4.95 4.95-1.414 1.414-4.95-4.95-4.95 4.95-1.414-1.414 4.95-4.95-4.95-4.95L7.05 5.636z",fill:"rgba(255,255,255,1)"}))},ERROR_WARNING_FILL:function(e){e.styles;var t=Wr()(e,["styles"]);return We.createElement("svg",zr({xmlns:"http://www.w3.org/2000/svg",viewBox:"0 0 24 24",width:"24",height:"24"},t),We.createElement("path",{fill:"none",d:"M0 0h24v24H0z"}),We.createElement("path",{d:"M12 22C6.477 22 2 17.523 2 12S6.477 2 12 2s10 4.477 10 10-4.477 10-10 10zm-1-7v2h2v-2h-2zm0-8v6h2V7h-2z",fill:"rgba(255,255,255,1)"}))},PLAY_BLUR:function(e){e.styles;var t=Wr()(e,["styles"]);return We.createElement("svg",$r({xmlns:"http://www.w3.org/2000/svg",viewBox:"0 0 60 60"},t),We.createElement("circle",{cx:"30",cy:"30",r:"30",fillRule:"evenodd",clipRule:"evenodd",fillOpacity:".35"}),We.createElement("path",{fill:"none",d:"M11 11h38v38H11z"}),We.createElement("path",{d:"M43.3 30.7L22.1 44.8c-.3.2-.7.2-1 0-.3-.2-.5-.5-.5-.9V15.8c0-.4.2-.7.5-.9.3-.2.7-.2 1 0L43.3 29c.3.2.4.5.4.8s-.2.7-.4.9z",fill:"currentColor"}))}},Yr=n(31),Zr=n.n(Yr);function Xr(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Jr(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Xr(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Xr(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Qr=Ut.COLORS.WHITE,ei=function(e,t){var n=function(e){return{root:Jr(Jr({},cr),{},{alignItems:"center",width:"fit-content",height:"fit-content",outline:"none",color:e}),focused:{outline:"".concat(Ut.COLORS.WHITE," solid 1px")}}}(t||Qr);return{iconStyle:[n.root,e&&n.focused]}},ti=function(e){var t=e.icon,n=e.style,r=e.onClick,i=e.onMouseEnter,o=e.onMouseLeave,a=e.onKeyDown,s=e.id,u=e.color,c=e.clickable,l=void 0===c||c,d=e.focusable,p=void 0===d||d,f=te(!1),h=ir()(f,2),y=h[0],g=h[1],v=te(!1),m=ir()(v,2),O=m[0],_=m[1],S=kn(ei,[O,u]).iconStyle,E=l?{onClick:r,onMouseEnter:i,onMouseLeave:o,onFocus:function(e){y||_(!0),jn(i)||i(e)},onBlur:function(){document.hasFocus()&&g(!1),_(!1)},onKeyDown:function(e){jn(a)||a(e),"Enter"!==e.key||jn(r)||r()},onMouseDown:function(){g(!0),_(!1)}}:{},w=p?{tabIndex:0}:{};return b("span",Zr()({id:s,style:Jt([S,n])},E,w),b(t,null))},ni=jt(function(e){return{playerSize:hn.playerSize(e),playerErrorMessage:hn.errorMessage(e),mediaErrorMessage:Cn.mediaLoadingError(e),playerUniqId:hn.playerInstanceUniqId(e)}})(function(e){var t,n=e.playerSize,r=e.playerErrorMessage,i=e.mediaErrorMessage,o=e.playerUniqId,a=kn(Hr,[n]),s=a.errorMessageStyle,u=a.iconStyle,c=a.screenStyle,l=r||i;return Un(r)&&Un(i)?null:b("div",{id:(t=o,"".concat("mplayer","-").concat("error-page","-").concat(t)),style:c},b(ti,{icon:Kr.ERROR_WARNING_FILL,style:Jt(u)}),b("div",{id:wn(o),style:Jt(s)},l))}),ri=function(e,t){var n=function(e){return{height:"100%",left:0,display:"block",width:"100%",position:"relative",splitView:{width:"".concat(e/(9/16),"px")}}}(e);return{playerWrapperStyle:[n,t&&n.splitView]}},ii=jt(function(e){return{splitViewRatio:Zn(e)}})(function(e){var t=e.splitViewRatio,n=e.children,r=oe(),i=te(null),o=ir()(i,2),a=o[0],s=o[1],u=!Un(t),c=kn(ri,[a,u]).playerWrapperStyle;return Kn(function(){s(r.current.parentElement.clientHeight)},[r]),b("div",{ref:r,style:Jt(c)},n)});function oi(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function ai(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?oi(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):oi(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var si=ai(ai({},cr),{},{position:"absolute",width:"100%",height:"100%"}),ui={width:"100%",height:"100%",position:"relative"},ci={display:"flex",position:"relative",flexGrow:"1"},li={position:"absolute",zIndex:"1",width:"100%",top:"0",height:"100%",pointerEvents:"none"},di={position:"absolute",zIndex:"2",width:"100%",top:"0",height:"100%",pointerEvents:"none"},pi=function(){return{splitViewWrapperStyle:ai({},si),playerAndControlsWrapperStyle:ai({},ui),splitViewPlaceholderStyle:ai({},ci),controlsPlaceholderStyle:ai({},li),discoveryPlaceholderStyle:ai({},di)}};function fi(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function hi(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?fi(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):fi(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var yi={position:"absolute",overflow:"hidden",backgroundColor:Ut.COLORS.GRAY_TRANSPARENT,borderRadius:Ut.BORDER_RADIUS.SMALL,height:"6px",small:{width:"120px",height:"4px"},medium:{width:"200px"},largeAndExtraLarge:{width:"220px"},splitView:{width:"120px",height:"4px"},error:{display:"none"}},gi=hi(hi({},pr),{},{width:"100%",height:"100%",position:"absolute",top:"0",backgroundColor:Ut.COLORS.TRANSPARENT,blackScreen:{backgroundColor:Ut.COLORS.BLACK}}),vi=function(e,t,n,r,i){var o,a=!Un(n),s="small"===e,u="medium"===e,c="large"===e||"extraLarge"===e,l=i||Ut.COLORS.WHITE,d=(o=l,{position:"relative",width:"100%",height:"6px",borderRadius:Ut.BORDER_RADIUS.SMALL,animationName:"loaderAnimation",animationDuration:"3.5s",animationIterationCount:"infinite",animationTimingFunction:"ease-in-out",backgroundColor:o,small:{height:"4px"},splitView:{height:"4px"}});return{loaderStyle:[yi,r&&yi.error,s&&yi.small,u&&yi.medium,c&&yi.largeAndExtraLarge,a&&yi.splitView],barStyle:[d,s&&d.small,a&&d.splitView],screenStyle:[gi,t&&gi.blackScreen]}},mi=pn.monetization,bi={continuePlayingWhileWaitingForAd:function(e){return mi(e).continuePlayingWhileWaitingForAd},midrolls:function(e){return mi(e).midrolls},prerollEnabled:function(e){return mi(e).prerollEnabled},vpaidMode:function(e){return mi(e).vpaidMode},adRequestTimeout:function(e){return mi(e).adRequestTimeout},adsData:function(e){return mi(e).adsData}},Oi=bi.adsData,_i={adTagUrlTemplate:function(e){return Oi(e).adTagUrlTemplate},adType:function(e){return Oi(e).adType},adStatus:function(e){return Oi(e).adStatus},pendingAdStatus:function(e){return Oi(e).pendingAdStatus},adErrorMessage:function(e){return Oi(e).adErrorMessage},adDuration:function(e){return Oi(e).adDuration},playedMidrolls:function(e){return Oi(e).playedMidrolls},adImpression:function(e){return Oi(e).adImpression},adOpportunity:function(e){return Oi(e).adOpportunity},isVastAd:function(e){return Oi(e).isVastAd},adCurrentTime:function(e){return Oi(e).adCurrentTime},adMuted:function(e){return Oi(e).adMuted},adVolume:function(e){return Oi(e).adVolume},currentAdTag:function(e){return Oi(e).currentAdTag},adUnit:function(e){return Oi(e).adUnit},slotNumber:function(e){return Oi(e).slotNumber},podNumber:function(e){return Oi(e).podNumber},loadingAd:function(e){return Oi(e).loadingAd}},Si=pn.brandingData,Ei=function(e){return Si(e).brandingColor},wi=jt(function(e){return{showBlackScreen:hn.showBlackScreen(e),playerSize:hn.playerSize(e),splitViewRatio:Zn(e),playerUniqId:hn.playerInstanceUniqId(e),playerErrorMessage:hn.errorMessage(e),mediaErrorMessage:Cn.mediaLoadingError(e),loadingPlayer:hn.loadingPlayer(e),loadingAd:_i.loadingAd(e),brandingColor:Ei(e)}})(function(e){var t,n=e.playerSize,r=e.showBlackScreen,i=e.splitViewRatio,o=e.playerUniqId,a=e.playerErrorMessage,s=e.mediaErrorMessage,u=e.loadingPlayer,c=e.loadingAd,l=e.brandingColor,d=!Un(a)||!Un(s),p=u||c,f=kn(vi,[n,r,i,d,l]),h=f.loaderStyle,y=f.barStyle,g=f.screenStyle;return p?b("div",{id:(t=o,"".concat("mplayer","-").concat("loader-page","-").concat(t)),style:Jt(g)},b("div",{id:Pn(o),style:Jt(h)},b("div",{style:Jt(y)}))):null}),Pi=function(e){var t=e.playerId,n=e.store,r=e.playerPosition,i=kn(pi,[]),o=i.splitViewWrapperStyle,a=i.playerAndControlsWrapperStyle,s=i.splitViewPlaceholderStyle,u=i.controlsPlaceholderStyle,c=i.discoveryPlaceholderStyle;return re(function(){!function(e){var t=document.createElement("link");t.setAttribute("href","https://fonts.googleapis.com/css2?family=Lato:wght@300;400&display=swap"),t.setAttribute("rel","stylesheet"),t.setAttribute("type","text/css"),e.appendChild(t)}(r),function(e){var t=document.createElement("style");t.type="text/css",t.textContent="@keyframes loaderAnimation {0% {left: -100%}49% {left: 100%}50% {left: 100%}100% {left: -100%}}",e.appendChild(t)}(r)},[r]),b(Ze,{store:n},b(Nr,{id:mn(t)},b(Cr,{id:bn(t)},b("div",{id:Tn(t)}),b("div",{style:a},b("div",{style:o},b(ii,null,b(Jn,{playerId:t}),b(xr,{playerId:t}),b(wi,null),b(nr,null)),b("div",{id:_n(t),style:s})),b("div",{id:On(t),style:u}),b("div",{id:Sn(t),style:c}),b(ni,null)))))},Ti=n(1),Ai=n.n(Ti),Ci=function e(){var t=this;Ai()(this,e),f()(this,"HLS_MAIN_SCRIPT","https://cdn.jsdelivr.net/npm/hls.js@0.9.1"),f()(this,"HLS_FALLBACK_SCRIPT","https://www.oo-syringe.com/newplayer/mplayer_hls_wrapper.0.0.0.js"),f()(this,"IMA_SCRIPT","https://imasdk.googleapis.com/js/sdkloader/ima3.js"),f()(this,"MMPLUS_CONTAINER_ID","GTM-PL4PD49"),f()(this,"MM_CONTAINER_ID","GTM-TCW5HW"),f()(this,"dependenciesCallbacks",void 0),f()(this,"imaLoadingStatus",""),f()(this,"hlsLoadingStatus",""),f()(this,"gtmLoaded",!1),f()(this,"addDependenciesCallback",function(e){t.dependenciesCallbacks.includes(e)||t.dependenciesCallbacks.push(e)}),f()(this,"isDependenciesReady",function(){return t.gtmLoaded&&"loading"!==t.getHLSLoadingStatus()&&"loading"!==t.getIMALoadingStatus()}),f()(this,"getIMALoadingStatus",function(){return t.imaLoadingStatus}),f()(this,"getHLSLoadingStatus",function(){return t.hlsLoadingStatus}),f()(this,"removeDependenciesCallback",function(e){t.dependenciesCallbacks.filter(function(t){return t===e})}),f()(this,"loadScript",function(e,t,n){var r=document.createElement("script");r.setAttribute("src",e),r.addEventListener("load",t),r.addEventListener("error",n),document.body.appendChild(r)}),f()(this,"onScriptLoaded",function(e){t.dependenciesCallbacks.forEach(function(t){t.onDependencyReady(e)})}),f()(this,"onScriptFailed",function(e,n){t.dependenciesCallbacks.forEach(function(t){t.onDependencyFailure(e,n)})}),f()(this,"onHlsScriptLoaded",function(){void 0!==window.Hls?t.onScriptLoaded("hls"):t.onHlsLoadError()}),f()(this,"onHlsLoadError",function(){t.loadScript(t.HLS_FALLBACK_SCRIPT,t.onMMhlsScriptLoaded,t.onMMHlsScriptFailure)}),f()(this,"onMMhlsScriptLoaded",function(){t.onScriptLoaded("hls")}),f()(this,"onMMHlsScriptFailure",function(e){t.onScriptFailed("hls",e)}),f()(this,"onImaLoadError",function(e){t.imaLoadingStatus="error",t.onScriptFailed("ima",e)}),f()(this,"onImaLoaded",function(){t.onScriptLoaded("ima"),t.imaLoadingStatus="success"}),f()(this,"shouldLoadMmGTM",function(){var e=window.google_tag_manager;return!e||!e[t.MMPLUS_CONTAINER_ID]&&!e[t.MM_CONTAINER_ID]}),f()(this,"loadGTMifNeeded",function(){if(t.shouldLoadMmGTM()){var e,n;try{e=window.parent,n=window.parent.document}catch(u){e=window,n=window.document}var r=$n(e),i="dataLayer"!==r?"&l=".concat(r):"";e[r]=e[r]||[],e[r].push({"gtm.start":(new Date).getTime(),event:"gtm.js"});var o=n.getElementsByTagName("script")[0],a=n.createElement("script");a.setAttribute("async",""),a.setAttribute("src","https://www.googletagmanager.com/gtm.js?id=GTM-PL4PD49".concat(i)),o.parentNode.insertBefore(a,o);var s=n.createElement("iframe");s.src="https://www.googletagmanager.com/ns.html?id=GTM-PL4PD49",s.height="0",s.width="0",s.style="display:none;visibility:hidden",n.body.appendChild(s),t.gtmLoaded=!0}}),f()(this,"loadHLS",function(){Bn()||"safari"===Vn.name?t.hlsLoadingStatus="no-need":(t.loadScript(t.HLS_MAIN_SCRIPT,t.onHlsScriptLoaded,t.onHlsLoadError),t.hlsLoadingStatus="loading")}),f()(this,"loadIMA",function(){t.loadScript(t.IMA_SCRIPT,t.onImaLoaded,t.onImaLoadError),t.imaLoadingStatus="loading"}),f()(this,"loadExternalDependencies",function(){""===t.getIMALoadingStatus()&&t.loadIMA(),""===t.getHLSLoadingStatus()&&t.loadHLS(),t.gtmLoaded||t.loadGTMifNeeded()}),this.dependenciesCallbacks=[]};f()(Ci,"instance",void 0),f()(Ci,"getInstance",function(){return Ci.instance||(Ci.instance=new Ci),Ci.instance});var Ri=function(e){return"".concat("mplayer-monetization-ad-container","-").concat(e)},Di=function(e){return"".concat("mplayer-monetization-safari-video-ad","-").concat(e)},Mi=jt(function(e){return{contentVideoTime:hn.currentVideoTime(e),playerUniqId:hn.playerInstanceUniqId(e)}})(function(e){var t=e.contentVideoTime,n=e.playerUniqId,r=oe();return re(function(){Un(r.current)||(r.current.currentTime=t)},[t]),b("video",{id:Di(n),ref:r,style:{backgroundColor:"rgb(0, 0, 0)",width:"100%",height:"100%"},title:"Advertisement",preload:"auto",muted:!0,playsInline:!0,"webkit-playsinline":""})});function Ii(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function ki(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Ii(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Ii(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Ni=jt(function(e,t){return ki(ki({},t),{},{adStatus:_i.adStatus(e)})})(function(e){var t=e.playerId,n=e.adStatus,r="playing"===n||"paused"===n;return re(function(){document.getElementById(vn(t)).style.display=r?"flex":"none"},[t,r]),b("div",{style:{width:"100%",height:"100%"}},b("div",{id:Ri(t),style:{height:"100%",width:"100%"}},Bn()&&b(Mi,null)))}),Li=function(e){var t=e.store,n=e.playerId;return b(Ze,{store:t},b(Ni,{playerId:n}))},xi=n(2),Vi=n.n(xi),ji=(n(46),function(){function e(t,n,r){Ai()(this,e),f()(this,"store",void 0),f()(this,"getDependenciesElements",void 0),f()(this,"oldState",void 0),f()(this,"unsubscribe",void 0),f()(this,"onChange",void 0),this.store=t,this.oldState=t.getState(),this.getDependenciesElements=n,this.unsubscribe=t.subscribe(this.onStateChanged.bind(this)),this.onChange=r}return Vi()(e,[{key:"stopSubscription",value:function(){this.unsubscribe(),this.oldState=null,this.getDependenciesElements=null,this.store=null,this.unsubscribe=null,this.onChange=null}},{key:"onStateChanged",value:function(){var e=this.store.getState(),t=this.getDependenciesElements(this.oldState),n=this.getDependenciesElements(e);t.every(function(e,t){return e===n[t]})||this.onChange(e),this.oldState=e}}]),e}()),Ui=pn.dependenciesLoadingStatus,Fi={loadingImaStatus:function(e){return Ui(e).loadingImaStatus},loadingHLSStatus:function(e){return Ui(e).loadingHLSStatus}},Bi=function(e){return"blocked"===Fi.loadingImaStatus(e)},Hi=function(e){return"playing"===e||"requested"===e||"loaded"===e||"paused"===e},qi=function(){function e(t,n){Ai()(this,e),f()(this,"videoTimeSubscriber",void 0),f()(this,"adsScheduler",void 0),this.videoTimeSubscriber=new ji(t,e.getVideoTimeDependencies,this.onVideoTimeChanged.bind(this)),this.adsScheduler=n}return Vi()(e,[{key:"onVideoTimeChanged",value:function(t){"seeking"!==hn.videoTagStatus(t)&&(e.shouldRequestAd(t)?this.adsScheduler.onPreAdTimeReached(e.getMidroll(t)):e.isOnAdTime(t)&&this.adsScheduler.onAdTimeReached())}}],[{key:"getVideoTimeDependencies",value:function(e){return[hn.currentVideoTime(e)]}},{key:"isTimeInPreAdRange",value:function(e,t){return t>=e&&e>=t-$i}},{key:"getNextSpecificMidrollTime",value:function(t,n){return-1!==t.indexOf(n)?n:t.find(function(t){return e.isTimeInPreAdRange(n,t)})}},{key:"getNextReocurringMidrollNumber",value:function(e,t){var n=t/e;return t%e===0?n:Math.ceil(n)}},{key:"getMidroll",value:function(t){var n=hn.currentVideoTime(t),r=bi.midrolls(t),i=r.every,o=r.on,a=Dn.mediaId(t);if(!Un(i)){var s=e.getNextReocurringMidrollNumber(i,n);return{currentTime:n,mediaId:a,midrollNumber:s,midrollTime:s*i}}if(!Un(o)){var u=e.getNextSpecificMidrollTime(o,n);return{midrollNumber:o.indexOf(u)+1,currentTime:n,midrollTime:u,mediaId:a}}return null}},{key:"isMidrollAlreadyPlayed",value:function(e,t){return-1!==e.indexOf(t)}},{key:"isMidrollReached",value:function(t){var n=hn.currentVideoTime(t),r=bi.midrolls(t),i=r.every,o=r.on,a=_i.playedMidrolls(t);if(!Un(i)&&n>0){var s=e.getNextReocurringMidrollNumber(i,n),u=s*i;return!this.isMidrollAlreadyPlayed(a,s)&&e.isTimeInPreAdRange(n,u)}if(!Un(o)){var c=e.getNextSpecificMidrollTime(o,n),l=o.indexOf(c)+1;return l>0&&!this.isMidrollAlreadyPlayed(a,l)}return!1}},{key:"shouldRequestAd",value:function(e){var t=_i.adStatus(e);return!Bi(e)&&!Hi(t)&&this.isMidrollReached(e)}},{key:"isOnAdTime",value:function(t){var n=hn.currentVideoTime(t),r=bi.midrolls(t),i=r.every,o=r.on,a=_i.playedMidrolls(t);if(Bi(t))return!1;if(!Un(i)){var s=e.getNextReocurringMidrollNumber(i,n);return 0!==n&&n%i===0&&!this.isMidrollAlreadyPlayed(a,s)}if(!Un(o)){var u=o.indexOf(n);return-1!==u&&!this.isMidrollAlreadyPlayed(a,u)}return!1}}]),e}(),Wi=function(){function e(t){var n=this;Ai()(this,e),f()(this,"referrerUrl",void 0),f()(this,"staticAdTag",void 0),f()(this,"generate",function(e,t){var r=encodeURIComponent(n.referrerUrl);return Un(n.staticAdTag)?n.adTagFromApi(e,r,t):n.parseAdTag(n.staticAdTag,e,r,t)}),this.staticAdTag=t,this.referrerUrl=window.location.href}return Vi()(e,[{key:"parseAdTag",value:function(t,n,r,i){var o=t.replace("##AdUnit##",e.parseAdName(n)).replace("##DESCRIPTION_URL_UNESC##",r).replace("##REFERRER_URL_UNESC##",encodeURIComponent(this.referrerUrl)).replace("##CACHEBUSTER##",e.cacheBuster(n)).replace("##MIDROLL_ORDER##",e.adIndexFromName(n));return o=e.replaceVideoId(o,"##VIDEO_ID##",i),o=e.addHacksToAdTag(o)}},{key:"adTagFromApi",value:function(e,t,n){try{var r=window.getVideoTag(t,e);return Un(r)?null:this.parseAdTag(r,e,t,n)}catch(i){return null}}}],[{key:"getCCPAConsent",value:function(t){try{var n="";return window.__uspapi&&window.__uspapi("getUSPData",1,function(e,t){t&&(n=e.uspString)}),e.setSearchParamToAdTag(t,"us_privacy",n)}catch(r){return t}}},{key:"replaceVideoId",value:function(e,t,n){return e.replace(t,n).replace(encodeURIComponent(t),n).replace(encodeURIComponent(encodeURIComponent(t)),n)}},{key:"cacheBuster",value:function(t){return"".concat((new Date).getTime()).concat(e.adIndexFromName(t))}},{key:"parseAdName",value:function(t){return t.startsWith("preroll")?"PR":"MR".concat(e.adIndexFromName(t))}},{key:"adIndexFromName",value:function(e){return e.replace(/[^\d]*/g,"")}}]),e}();f()(Wi,"setSearchParamToAdTag",function(e,t,n){var r=new URL(e),i=decodeURIComponent(n);return r.searchParams.set(t,i),r.href}),f()(Wi,"getSearchParamFromAdTag",function(e,t){return new URL(e).searchParams.get(t)}),f()(Wi,"addHacksToAdTag",function(e){var t=e,n=Wi.getSearchParamFromAdTag(t,"cust_params");if(!jn(window.mmAPSbids)&&!Un(n)){var r="".concat(window.mmAPSbids,"&").concat(n);t=Wi.setSearchParamToAdTag(t,"cust_params",r)}if(!jn(window.shouldPlayAdRules)){var i=window.shouldPlayAdRules?"1":"0";t=Wi.setSearchParamToAdTag(t,"ad_rule",i)}return t=Wi.getCCPAConsent(t)});var zi=function(){function e(t,n){Ai()(this,e),f()(this,"store",void 0),f()(this,"videoTagStatusSubscriber",void 0),f()(this,"adsScheduler",void 0),f()(this,"previousVideoTagStatus",void 0);var r=t.getState;this.store=t,this.adsScheduler=n,this.previousVideoTagStatus=hn.videoTagStatus(r()),this.videoTagStatusSubscriber=new ji(t,e.getVideoTagStatusDependencies,this.onVideoTagStatusChanged.bind(this))}return Vi()(e,[{key:"onVideoTagStatusChanged",value:function(t){var n=hn.videoTagStatus(t),r=_i.adStatus(t);"seeking"===this.previousVideoTagStatus&&(Hi(r)?this.adsScheduler.onSeekedWhileAdInProgress():e.isSeekedOverMidroll(t)&&this.adsScheduler.onSeekToAdOpportunity(e.getSeekedMidroll(t))),this.previousVideoTagStatus=n}}],[{key:"getVideoTagStatusDependencies",value:function(e){return[hn.videoTagStatus(e)]}},{key:"getClosestSkippedUnplayedMidroll",value:function(e,t){for(var n=t;n>0;n-=1)if(-1===e.indexOf(n))return n;return null}},{key:"getClosestLowerSeekedMidrollNumber",value:function(e,t){var n=In()(e).reverse().find(function(e){return e<=t});return e.indexOf(n)+1}},{key:"getSeekedSpecificMidroll",value:function(e,t,n,r){var i=this.getClosestLowerSeekedMidrollNumber(e,t),o=this.getClosestSkippedUnplayedMidroll(r,i);return{midrollNumber:o,currentTime:t,midrollTime:e[o-1],mediaId:n}}},{key:"isSeekedOverSpecificMidroll",value:function(e,t,n){if(jn(e))return!1;var r=this.getClosestLowerSeekedMidrollNumber(e,n);return null!==this.getClosestSkippedUnplayedMidroll(t,r)}},{key:"getSeekedReoccuringMidroll",value:function(e,t,n,r){var i=Math.floor(t/e),o=this.getClosestSkippedUnplayedMidroll(r,i);return{midrollTime:o*e,currentTime:t,midrollNumber:o,mediaId:n}}},{key:"isSeekedOverReoccuringMidroll",value:function(e,t,n){if(jn(e))return!1;var r=Math.floor(n/e);return null!==this.getClosestSkippedUnplayedMidroll(t,r)}},{key:"getSeekedMidroll",value:function(e){var t=_i.playedMidrolls(e),n=hn.currentVideoTime(e),r=bi.midrolls(e),i=r.every,o=r.on,a=Cn.mediaId(e);return this.isSeekedOverReoccuringMidroll(i,t,n)?this.getSeekedReoccuringMidroll(i,n,a,t):this.isSeekedOverSpecificMidroll(o,t,n)?this.getSeekedSpecificMidroll(o,n,a,t):null}},{key:"isSeekedOverMidroll",value:function(e){var t=_i.playedMidrolls(e),n=hn.currentVideoTime(e),r=bi.midrolls(e),i=r.every,o=r.on,a=o;return bi.prerollEnabled(e)&&(a=o.filter(function(e){return 0!==e})),this.isSeekedOverReoccuringMidroll(i,t,n)||this.isSeekedOverSpecificMidroll(a,t,n)}}]),e}(),Gi=function e(t,n){var r=this;Ai()(this,e),f()(this,"pendingAdStatusStoreSubscriber",void 0),f()(this,"adsScheduler",void 0),f()(this,"onPendingAdStatusChanged",function(e){var t=_i.pendingAdStatus(e).type,n=_i.adStatus(e);if("playPreroll"===t&&!Hi(n)){var i=Cn.activeVideoIndex(e),o=Dn.mediaId(e);r.adsScheduler.onPrerollReached(o,i+1)}}),this.adsScheduler=n,this.pendingAdStatusStoreSubscriber=new ji(t,e.getPendingAdStatusDependencies,this.onPendingAdStatusChanged.bind(this))};f()(Gi,"getPendingAdStatusDependencies",function(e){return[_i.pendingAdStatus(e)]});var $i=3,Ki=function e(t,n){var r=this;Ai()(this,e),f()(this,"videoTimeSubscriber",void 0),f()(this,"videoSeekSubscriber",void 0),f()(this,"adTagGenerator",void 0),f()(this,"monetization",void 0),f()(this,"lastRequestedMidroll",null),f()(this,"prerollScheduler",void 0),f()(this,"generateMidrollTag",function(e){var t="midroll".concat(e.midrollNumber);return r.adTagGenerator.generate(t,e.mediaId)}),f()(this,"generatePrerollTag",function(e,t){var n="preroll".concat(t);return r.adTagGenerator.generate(n,e)}),f()(this,"onAdTimeReached",function(){r.monetization.onMidrollAdOpportunity()}),f()(this,"onPreAdTimeReached",function(e){r.onPreMidrollAdOpportunity(e)}),f()(this,"onSeekToAdOpportunity",function(e){r.onPreMidrollAdOpportunity(e)}),f()(this,"isMidrollAlreadyRequested",function(e){return e.midrollNumber===r.lastRequestedMidroll.midrollNumber&&e.mediaId===r.lastRequestedMidroll.mediaId&&e.midrollTime===r.lastRequestedMidroll.midrollTime}),f()(this,"onPreMidrollAdOpportunity",function(e){if(Un(r.lastRequestedMidroll)||!r.isMidrollAlreadyRequested(e)){r.lastRequestedMidroll=e;var t=r.generateMidrollTag(e);r.monetization.onPreMidrollAdOpportunity(e,t)}}),f()(this,"onPrerollReached",function(e,t){var n=r.generatePrerollTag(e,t);r.monetization.onPrerollAdOpportunity(n)}),f()(this,"onSeekedWhileAdInProgress",function(){r.monetization.onMidrollAdOpportunity()});var i=t.getState;this.monetization=n,this.videoTimeSubscriber=new qi(t,this),this.videoSeekSubscriber=new zi(t,this),this.prerollScheduler=new Gi(t,this);var o=_i.adTagUrlTemplate(i());this.adTagGenerator=new Wi(o)},Yi=function(){function e(){Ai()(this,e)}return Vi()(e,null,[{key:"generateAdRequest",value:function(e,t,n){var r=new google.ima.AdsRequest;return r.adTagUrl=e,Fn()||r.setAdWillPlayMuted(t),r.vastLoadTimeout=n,r}}]),e}(),Zi=function(e){return function(t){t({type:"[MONETIZATION] change ad status",payload:e})}},Xi=function(e){return function(t){t({type:"[COMMON] set pending video status",payload:{pendingStatusObject:{type:e,value:""}}})}},Ji=function(e){return function(t){t({type:"[MONETIZATION] change loading ad status",payload:e})}},Qi=function(e){return function(t){t({type:"[MONETIZATION] update ad muted",payload:e})}},eo=function(e){return function(t){t({type:"[MONETIZATION] change ad volume",payload:e})}},to=function e(t,n,r,i,o){var a=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"IMAAdManager",void 0),f()(this,"adsLoader",void 0),f()(this,"adDisplayContainer",void 0),f()(this,"adVideoElement",void 0),f()(this,"videoPlayerElement",void 0),f()(this,"adContainerElement",void 0),f()(this,"anchorStatusStoreSubscriber",void 0),f()(this,"totalAdRequestMadeAmount",0),f()(this,"registerForWindowResize",function(){var e=zn(a.onResize.bind(a),80);window.addEventListener("resize",e)}),f()(this,"initMutationObserver",function(e){new MutationObserver(a.onResize).observe(e,{attributes:!0,childList:!1,subtree:!1})}),f()(this,"loadNewAd",function(e,t){var n=a.store.dispatch;a.clearOldAdManagerIfExist();var r=a.createAdRequest(e);try{a.validateAdRequestCorrectness(r),a.adsLoader.requestAds(r),function(e,t){return function(n){n({type:"[MONETIZATION] change ad tag",payload:{adTag:e,adUnit:t}})}}(e,t)(n),Zi("requested")(n),a.totalAdRequestMadeAmount+=1}catch(i){a.onAdError(a.getLoadingError(r))}}),f()(this,"playAd",function(){try{a.IMAAdManager.init(a.videoPlayerElement.clientWidth,a.videoPlayerElement.clientHeight,google.ima.ViewMode.NORMAL);try{a.IMAAdManager.start()}catch(e){return!1}return!0}catch(t){return a.onAdError(a.getPlayAdError("ad manager start error")),!1}}),f()(this,"clearOldAdManagerIfExist",function(){Un(a.IMAAdManager)||(a.IMAAdManager.destroy(),a.IMAAdManager=null)}),f()(this,"createAdLoader",function(e,t){var n=bi.vpaidMode(e);a.adsLoader=new google.ima.AdsLoader(t),a.adsLoader.getSettings().setDisableCustomPlaybackForIOS10Plus(!0),a.adsLoader.getSettings().setVpaidMode(google.ima.ImaSdkSettings.VpaidMode[n]),a.adsLoader.addEventListener(google.ima.AdsManagerLoadedEvent.Type.ADS_MANAGER_LOADED,a.onIMAAdsManagerLoaded.bind(a),!1,a),a.adsLoader.addEventListener(google.ima.AdErrorEvent.Type.AD_ERROR,a.onAdError.bind(a),!1,a)}),f()(this,"createAdRequest",function(e){var t=a.store.getState,n=gn.muted(t()),r=bi.adRequestTimeout(t());return Yi.generateAdRequest(e,n,r)}),f()(this,"validateAdRequestCorrectness",function(e){e&&e.adTagUrl&&decodeURIComponent(e.adTagUrl.replace(/\+/g," "))}),f()(this,"getLoadingError",function(e){var t=function(){return"bad ad request ".concat(JSON.stringify(e))};return{getError:function(){return{getMessage:t}}}}),f()(this,"getPlayAdError",function(e){var t=function(){return"play ad error: ".concat(JSON.stringify(e))};return{getError:function(){return{getMessage:t}}}}),f()(this,"setAdVolume",function(e){var t=a.store,n=t.getState,r=t.dispatch,i=gn.volume(n());Bn()||gn.muted(n())?(e.setVolume(0),Qi(!0)(r)):(e.setVolume(gn.volume(n())),eo(i)(r),Qi(!1)(r))}),f()(this,"createIMAAdManager",function(t){a.IMAAdManager=t.getAdsManager(a.adVideoElement,e.getAdsRenderingSettings()),a.setAdVolume(a.IMAAdManager)}),f()(this,"registerToAdManagerEvents",function(){a.IMAAdManager.addEventListener(google.ima.AdErrorEvent.Type.AD_ERROR,a.onAdError),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.CONTENT_PAUSE_REQUESTED,a.onContentPauseRequested),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.CONTENT_RESUME_REQUESTED,a.onContentResumeRequested),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.STARTED,a.onAdStarted),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.IMPRESSION,a.onAdImpression),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.SKIPPED,a.onAdSkipped),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.COMPLETE,a.onAdCompleted),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.PAUSED,a.onAdPaused),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.RESUMED,a.onAdStarted),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.AD_PROGRESS,a.onAdProgressChanged),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.VOLUME_CHANGED,a.onVolumeChanged),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.VOLUME_MUTED,a.onAdVolumeMutedChanged),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.ALL_ADS_COMPLETED,a.onAdCompleted)}),f()(this,"onIMAAdsManagerLoaded",function(e){var t=a.store.dispatch;a.createIMAAdManager(e),a.registerToAdManagerEvents(),Zi("loaded")(t)}),f()(this,"onAdError",function(e){var t=a.store.dispatch;!function(e){return function(t){t({type:"[MONETIZATION] change ad error",payload:e})}}(e.getError().getMessage())(t),Ji(!1),a.continuePlayingContent()}),f()(this,"onAdImpression",function(e){var t=a.store.dispatch,n=!e.getAd().g.vpaid;a.setPodInfo(e),function(e){e({type:"[MONETIZATION] increase ad impression counter"})}(t),function(e){return function(t){t({type:"[MONETIZATION] update is vast ad",payload:e})}}(n)(t)}),f()(this,"onVolumeChanged",function(e){var t=a.store.dispatch;eo(e.target.getVolume())(t)}),f()(this,"onAdVolumeMutedChanged",function(e){var t=a.store.dispatch;0===e.target.getVolume()?Qi(!0)(t):Qi(!1)(t)}),f()(this,"continuePlayingContent",function(){var e=a.store,t=e.getState,n=e.dispatch,r=hn.videoTagStatus(t());Xi("idle"===r?"play":"resume")(n)}),f()(this,"stopPlayingContent",function(){var e=a.store.dispatch;Xi("pause")(e)}),f()(this,"onContentPauseRequested",function(){a.stopPlayingContent()}),f()(this,"onContentResumeRequested",function(){a.continuePlayingContent()}),f()(this,"onAdPaused",function(){var e=a.store.dispatch;Zi("paused")(e)}),f()(this,"setPodInfo",function(e){var t=e&&e.getAd()&&e.getAd().getAdPodInfo();if(!Un(t)){var n=a.store.dispatch;!function(e,t){return function(n){n({type:"[MONETIZATION] change pod info",payload:{slotNumber:e,podNumber:t}})}}(t.getAdPosition(),a.totalAdRequestMadeAmount)(n)}}),f()(this,"onAdStarted",function(){var e=a.store,t=e.dispatch,n=e.getState,r=gn.volume(n());Zi("playing")(t),0===a.IMAAdManager.getVolume()?a.IMAAdManager.setVolume(0):window.shouldPlayAdRule||a.IMAAdManager.setVolume(r),a.onResize()}),f()(this,"onAdCompleted",function(){var e=a.store.dispatch;Zi("completed")(e)}),f()(this,"onAdSkipped",function(){var e=a.store.dispatch;Zi("skipped")(e)}),f()(this,"onResize",function(){Un(a.IMAAdManager)||(a.IMAAdManager.resize(a.videoPlayerElement.clientWidth,a.videoPlayerElement.clientHeight,google.ima.ViewMode.NORMAL),a.adContainerElement.style.height="".concat(a.videoPlayerElement.clientHeight,"px"))}),f()(this,"onAdProgressChanged",function(e){var t,n,r=a.store,i=r.dispatch,o=r.getState,s=e.getAdData().currentTime,u=e.getAdData().duration,c=_i.adDuration(o());(t=s,function(e){e({type:"[MONETIZATION] change ad current time",payload:t})})(i),c!==u&&(n=u,function(e){e({type:"[MONETIZATION] change ad duration",payload:n})})(i)}),f()(this,"onAnchorStatusChanged",function(){var e=a.store.getState;"processing"!==Pr(e())&&a.onResize()}),f()(this,"changeAdVolume",function(e){Un(a.IMAAdManager)||a.IMAAdManager.setVolume(e)}),f()(this,"changeAdMuted",function(e,t){Un(a.IMAAdManager)||(t?a.IMAAdManager.setVolume(0):a.IMAAdManager.setVolume(e))}),f()(this,"changeAdStatus",function(e){Un(a.IMAAdManager)||("playing"===e&&a.IMAAdManager.resume(),"paused"===e&&a.IMAAdManager.pause())});var s=t.getState;this.store=t,this.adVideoElement=r,this.videoPlayerElement=i,this.adContainerElement=n,this.adDisplayContainer=new google.ima.AdDisplayContainer(n,r),this.createAdLoader(s(),this.adDisplayContainer),this.adDisplayContainer.initialize(),this.anchorStatusStoreSubscriber=new ji(t,e.getAnchorDependencies,this.onAnchorStatusChanged.bind(this)),this.registerForWindowResize(),this.initMutationObserver(o)};f()(to,"getAdsRenderingSettings",function(){var e=new google.ima.AdsRenderingSettings;return e.restoreCustomPlaybackStateOnAdBreakComplete=!0,e.enablePreloading=!1,e.uiElements=[],e.loadVideoTimeout=15e3,e}),f()(to,"getAnchorDependencies",function(e){return[Pr(e)]});var no=function e(t,n,r,i,o,a){var s=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"playerId",void 0),f()(this,"adScheduler",void 0),f()(this,"adHandler",void 0),f()(this,"imaLoadingStatusSubscriber",void 0),f()(this,"adStatusSubscriber",void 0),f()(this,"videoTagStatusSubscriber",void 0),f()(this,"adContainer",void 0),f()(this,"adVideoElement",void 0),f()(this,"videoPlayerElement",void 0),f()(this,"playerContainer",void 0),f()(this,"pendingMidrollAdPlay",!1),f()(this,"pendingPrerollAdPlay",!1),f()(this,"pendingPrerollAdTag",null),f()(this,"pendingMidrollNumber",null),f()(this,"pendingAdStatusStoreSubscriber",void 0),f()(this,"adMutedStoreSubscriber",void 0),f()(this,"adVolumeStoreSubscriber",void 0),f()(this,"onMidrollAdOpportunity",function(){var e=s.store,t=e.dispatch,n=e.getState,r=_i.adStatus(n()),i=bi.continuePlayingWhileWaitingForAd(n());"loaded"===r?s.playAd(!0):"requested"===r&&(s.pendingMidrollAdPlay=!0,i||(Xi("pause")(t),Ji(!0)(t))),function(e){e({type:"[MONETIZATION] increase ad Opportunity counter"})}(t)}),f()(this,"onPrerollAdOpportunity",function(e){var t=s.store,n=t.getState,r=t.dispatch,i=Fi.loadingImaStatus(n());Un(s.adHandler)?"loading"!==i&&""!==i||(Ji(!0)(r),s.pendingPrerollAdPlay=!0,s.pendingPrerollAdTag=e):(s.pendingPrerollAdPlay=!0,Ji(!0)(r),s.adHandler.loadNewAd(e,"preroll"))}),f()(this,"onPreMidrollAdOpportunity",function(e,t){Un(s.adHandler)||(e.currentTime>=e.midrollTime&&(s.pendingMidrollAdPlay=!0),s.pendingMidrollNumber=e.midrollNumber,s.adHandler.loadNewAd(t,"midroll"))}),f()(this,"hasPendingAd",function(){return s.hasPendingMidrollAdPlay()||s.hasPendingPrerollAdPlay()}),f()(this,"onAdStatusChanged",function(e){var t=s.store.dispatch,n=_i.adStatus(e);"completed"===n&&Ji(!1)(t);var r=bi.continuePlayingWhileWaitingForAd(e),i=_i.loadingAd(e);"playing"!==n&&"error"!==n||r||!i||Ji(!1)(t),s.hasPendingAd()&&"loaded"===n?s.playAd(s.hasPendingMidrollAdPlay()):s.hasPendingAd()&&"error"===n?(Ji(!1),s.clearPendingMidroll(),s.clearPendingPreroll()):Hi(n)||(Ji(!1),function(e){e({type:"[MONETIZATION] clear ad data"})}(t))}),f()(this,"clearPendingMidroll",function(){s.pendingMidrollNumber=null,s.pendingMidrollAdPlay=!1}),f()(this,"clearPendingPreroll",function(){s.pendingPrerollAdPlay=!1,s.pendingPrerollAdTag=null}),f()(this,"onVideoTagStatusChanged",function(e){"complete"===hn.videoTagStatus(e)&&function(e){e({type:"[MONETIZATION] clear played midrolls"})}(s.store.dispatch)}),f()(this,"hasPendingMidrollAdPlay",function(){return s.pendingMidrollAdPlay}),f()(this,"hasPendingPrerollAdPlay",function(){return s.pendingPrerollAdPlay}),f()(this,"playAd",function(e){var t,n=s.store.dispatch,r=s.adHandler.playAd();e?((t=s.pendingMidrollNumber,function(e){e({type:"[MONETIZATION] add played midroll number",payload:t})})(n),s.clearPendingMidroll()):s.clearPendingPreroll(),r||(Ji(!1)(n),Xi("resume")(n))}),f()(this,"onIMALoadingStatusChanged",function(t){e.canUseIMA(t)&&(Un(s.adHandler)&&(s.adHandler=new to(s.store,s.adContainer,s.adVideoElement,s.videoPlayerElement,s.playerContainer)),s.hasPendingPrerollAdPlay()&&s.adHandler.loadNewAd(s.pendingPrerollAdTag,"preroll"))}),f()(this,"onPendingAdStatusChanged",function(){var e=s.store.getState,t=_i.pendingAdStatus(e()).type;switch(t){case"paused":case"playing":s.adHandler.changeAdStatus(t)}}),f()(this,"onAdMutedChanged",function(){var e=s.store.getState,t=_i.adMuted(e()),n=gn.volume(e());s.adHandler.changeAdMuted(n,t)}),f()(this,"onAdVolumeChanged",function(){var e=s.store.getState,t=_i.adVolume(e());s.adHandler.changeAdVolume(t)});var u=t.getState;this.store=t,this.playerId=n,this.adContainer=r,this.adVideoElement=i,this.videoPlayerElement=o,this.playerContainer=a,this.adScheduler=new Ki(t,this),this.adStatusSubscriber=new ji(t,e.getAdStatusDependencies,this.onAdStatusChanged.bind(this)),this.videoTagStatusSubscriber=new ji(t,e.getVideoTagStatusDependencies,this.onVideoTagStatusChanged.bind(this)),e.canUseIMA(u())?this.adHandler=new to(t,r,i,o,a):this.imaLoadingStatusSubscriber=new ji(t,e.getIMALoadingStatusDependencies,this.onIMALoadingStatusChanged.bind(this)),this.pendingAdStatusStoreSubscriber=new ji(t,e.getPendingAdStatusDependencies,this.onPendingAdStatusChanged.bind(this)),this.adMutedStoreSubscriber=new ji(t,e.getAdMutedDependencies,this.onAdMutedChanged.bind(this)),this.adVolumeStoreSubscriber=new ji(t,e.getAdVolumeDependencies,this.onAdVolumeChanged.bind(this))};f()(no,"getAdStatusDependencies",function(e){return[_i.adStatus(e)]}),f()(no,"getVideoTagStatusDependencies",function(e){return[hn.videoTagStatus(e)]}),f()(no,"getIMALoadingStatusDependencies",function(e){return[Fi.loadingImaStatus(e)]}),f()(no,"canUseIMA",function(e){return"success"===Fi.loadingImaStatus(e)}),f()(no,"getPendingAdStatusDependencies",function(e){return[_i.pendingAdStatus(e)]}),f()(no,"getAdMutedDependencies",function(e){return[_i.adMuted(e)]}),f()(no,"getAdVolumeDependencies",function(e){return[_i.adVolume(e)]});var ro=function(e,t){!function(e,t){var n=document.getElementById(vn(t));B(b(Li,{store:e,playerId:t}),n)}(e,t);var n=function(e){var t=Ri(e);return document.getElementById(t)}(t),r=function(e){var t=Bn()?Di(e):En(e);return document.getElementById(t)}(t),i=function(e){var t=En(e);return document.getElementById(t)}(t),o=function(e){var t=bn(e);return document.getElementById(t)}(t);return new no(e,t,n,r,i,o)},io=n(4),oo=n.n(io),ao=n(7),so=n.n(ao),uo=function(){function e(){Ai()(this,e),f()(this,"duration",void 0),f()(this,"position",void 0),f()(this,"previousPosition",void 0),f()(this,"loadTime",void 0),f()(this,"adOrder",void 0),f()(this,"adType",void 0),f()(this,"adDuration",void 0),f()(this,"errorMessage",void 0),f()(this,"adPodNumber",void 0),f()(this,"adSlotNumber",void 0)}return Vi()(e,[{key:"setDuration",value:function(e){return this.duration=e,this}},{key:"setPosition",value:function(e){return this.position=e,this}},{key:"setPreviousPosition",value:function(e){return this.previousPosition=e,this}},{key:"setLoadTime",value:function(e){return this.loadTime=e,this}},{key:"setAdOrder",value:function(e){return this.adOrder=e,this}},{key:"setAdType",value:function(e){return this.adType=e,this}},{key:"setAdDuration",value:function(e){return this.adDuration=e,this}},{key:"setErrorMessage",value:function(e){return this.errorMessage=e,this}},{key:"setAdPodNumber",value:function(e){return this.adPodNumber=e,this}},{key:"setAdSlotNumber",value:function(e){return this.adSlotNumber=e,this}},{key:"build",value:function(){var e=[];return jn(this.position)||e.push("video current position=".concat(Hn(this.position),"sec")),jn(this.duration)||e.push("video duration time=".concat(Hn(this.duration),"sec")),jn(this.loadTime)||e.push("video load time=".concat(this.loadTime,"milliseconds")),jn(this.previousPosition)||e.push("previous position=".concat(Hn(this.previousPosition),"sec")),jn(this.adOrder)||e.push("ad order=".concat(this.adOrder)),jn(this.adType)||e.push("ad type=".concat(this.adType)),jn(this.adDuration)||e.push("ad duration=".concat(Hn(Number(this.adDuration)),"sec")),jn(this.adPodNumber)||e.push("pod number=".concat(this.adPodNumber)),jn(this.adSlotNumber)||e.push("slot number=".concat(this.adSlotNumber)),jn(this.errorMessage)||e.push("error message=".concat(this.errorMessage)),e.join(";")}}]),e}(),co="mmPlus GTM data ready to GA",lo="mmPlus GTM event to GA",po={EMBED:"vplayer video player embed",FIRST_PLAY:"vplayer video first play",COMPLETION_25_PERCENTAGE:"vplayer video 25% complete",COMPLETION_50_PERCENTAGE:"vplayer video 50% complete",COMPLETION_75_PERCENTAGE:"vplayer video 75% complete",COMPLETION_90_PERCENTAGE:"vplayer video 90% complete",AD_BLOCK:"vplayer video ad block",AD_REQUEST:"vplayer video ad request",AD_IMPRESSION:"vplayer video ad impression",AD_ERROR:"vplayer video ad error",AD_VIEWABLE_IMPRESSION:"vplayer video ad viewable impression",AD_COMPLETE:"vplayer video ad complete",AD_SKIP:"vplayer video ad skip",AD_PAUSE:"vplayer video ad pause",VIDEO_COMPLETE:"vplayer video complete",FULLSCREEN_ON:"vplayer video fullscreen on",FULLSCREEN_OFF:"vplayer video fullscreen off",SEEK:"vplayer video position seeked",VIDEO_MUTE:"vplayer video mute",VIDEO_UNMUTE:"vplayer video unmute",CONTROLS_MUTE_OR_UNMUTE:"controls Mute/Unmute button click",CONTROLS_PLAY_OR_PAUSE:"controls Play/Pause button click",CONTROLS_FULLSCREEN:"controls Fullscreen button click",CONTROLS_NEXT_VIDEO:"controls Next Video button click",CONTROLS_SETTINGS:"controls Settings button click",MINI_PLAYER_CLOSE:"vplayer video miniplayer close",LOADING_CONTENT_ERROR:"vplayer video player error",PLAYER_ERROR:"vplayer general player error",CONTENT_VIEWABLE_IMPRESSION:"vplayer video content viewable impression"},fo="loading ad provider library failed",ho="mid",yo=function e(t,n){var r=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"analyticsEventsCallbacks",void 0),f()(this,"videoMuteSubscriber",void 0),f()(this,"videoFullscreenSubscriber",void 0),f()(this,"onMuteStateChanged",function(e){var t=gn.muted(e),n=hn.currentVideoTimeFragment(e),i=(new uo).setPosition(n).build(),o=t?po.VIDEO_MUTE:po.VIDEO_UNMUTE;r.analyticsEventsCallbacks.onEvent(o,i)}),f()(this,"onFullsScreenStateChanged",function(e){var t=gn.fullscreen(e),n=hn.currentVideoTimeFragment(e),i=(new uo).setPosition(n).build(),o=t?po.FULLSCREEN_ON:po.FULLSCREEN_OFF;r.analyticsEventsCallbacks.onEvent(o,i)}),this.store=t,this.analyticsEventsCallbacks=n,this.videoMuteSubscriber=new ji(t,e.getVideoMuteDependencies,this.onMuteStateChanged.bind(this)),this.videoFullscreenSubscriber=new ji(t,e.getVideoFullscreenDependencies,this.onFullsScreenStateChanged.bind(this))};f()(yo,"getVideoMuteDependencies",function(e){return[gn.muted(e)]}),f()(yo,"getVideoFullscreenDependencies",function(e){return[gn.fullscreen(e)]});var go=n(3),vo=n.n(go),mo=n(8),bo=n.n(mo),Oo=n(9),_o=n.n(Oo),So=n(5),Eo=n.n(So);n(20);var wo={root:null,threshold:.5,rootMargin:"0px"},Po=function(){function e(t,n,r){Ai()(this,e),f()(this,"store",void 0),f()(this,"observableElement",void 0),f()(this,"callback",void 0),f()(this,"isViewableTimeoutHandler",null),f()(this,"observer",void 0),f()(this,"didReport",!1),this.store=t,this.observableElement=n,this.callback=r,this.observer=new IntersectionObserver(this.onIntersecting.bind(this),wo)}return Vi()(e,[{key:"unobserve",value:function(){this.observer.unobserve(this.observableElement),this.clearIsViewableTimeout()}},{key:"observe",value:function(){this.observer.observe(this.observableElement)}},{key:"onPlay",value:function(){this.didReport||this.observe()}},{key:"onPause",value:function(){this.unobserve()}},{key:"onComplete",value:function(){this.didReport=!1,this.unobserve()}},{key:"onIntersecting",value:function(e){var t=e[0].isIntersecting;null===this.isViewableTimeoutHandler&&t?this.isViewableTimeoutHandler=setTimeout(this.notifyViewable.bind(this),2e3):this.clearIsViewableTimeout()}},{key:"clearIsViewableTimeout",value:function(){clearTimeout(this.isViewableTimeoutHandler),this.isViewableTimeoutHandler=null}},{key:"notifyViewable",value:function(){var e=this.store.getState;this.didReport=!0,this.callback(e()),this.unobserve()}}]),e}();function To(e){var t=function(){if("undefined"===typeof Reflect||!Reflect.construct)return!1;if(Reflect.construct.sham)return!1;if("function"===typeof Proxy)return!0;try{return Date.prototype.toString.call(Reflect.construct(Date,[],function(){})),!0}catch(e){return!1}}();return function(){var n,r=Eo()(e);if(t){var i=Eo()(this).constructor;n=Reflect.construct(r,arguments,i)}else n=r.apply(this,arguments);return _o()(this,n)}}var Ao=function(e){bo()(n,e);var t=To(n);function n(e,r,i){var o;return Ai()(this,n),o=t.call(this,e,r,i),f()(vo()(o),"videoTagStatusSubscriber",void 0),f()(vo()(o),"onVideoTagStatusChanged",function(e){var t=hn.videoTagStatus(e);"playing"===t?o.onPlay():"paused"===t||"seeking"===t?o.onPause():"complete"!==t&&"error"!==t||o.onComplete()}),o.videoTagStatusSubscriber=new ji(e,n.getVideoTagStatusDependencies,o.onVideoTagStatusChanged.bind(vo()(o))),o}return n}(Po);f()(Ao,"getVideoTagStatusDependencies",function(e){return[hn.videoTagStatus(e)]});var Co=function e(t,n,r,i){var o=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"videoTagStatusSubscriber",void 0),f()(this,"analyticsEventsCallbacks",void 0),f()(this,"videoViewableImpressionObserver",void 0),f()(this,"firstPlayReportedIndex",-1),f()(this,"loadingStartTime",-1),f()(this,"registerVideoCallbacksIdNeeded",function(e,t){"none"!==hn.playbackMethod(e)&&document.getElementById(En(t)).addEventListener("loadstart",o.onLoadStart.bind(o),{once:!0})}),f()(this,"onLoadStart",function(){o.loadingStartTime=Date.now()}),f()(this,"getFirstPlayLabel",function(e){var t=hn.currentVideoTimeFragment(e),n=hn.currentVideoDuration(e),r=-1===o.loadingStartTime?-1:Date.now()-o.loadingStartTime;return(new uo).setPosition(t).setLoadTime(r).setDuration(n).build()}),f()(this,"onVideoTagStatusChanged",function(e){var t=hn.videoTagStatus(e),n=Cn.activeVideoIndex(e);if(!(n===o.firstPlayReportedIndex)&&"playing"===t){o.firstPlayReportedIndex=n;var r=o.getFirstPlayLabel(e);o.analyticsEventsCallbacks.onEvent(po.FIRST_PLAY,r)}}),f()(this,"reportVideoViewableImpression",function(e){var t=hn.currentVideoTimeFragment(e),n=(new uo).setPosition(t).build();o.analyticsEventsCallbacks.onEvent(po.CONTENT_VIEWABLE_IMPRESSION,n)}),this.store=t,this.analyticsEventsCallbacks=n,this.videoViewableImpressionObserver=new Ao(t,r,this.reportVideoViewableImpression.bind(this)),this.videoTagStatusSubscriber=new ji(t,e.getVideoTagDependencies,this.onVideoTagStatusChanged.bind(this)),this.registerVideoCallbacksIdNeeded(t.getState(),i)};f()(Co,"getVideoTagDependencies",function(e){return[hn.videoTagStatus(e)]});var Ro=[25,50,75,90],Do=function(){function e(){Ai()(this,e),f()(this,"lastReportedPercentage",void 0),this.lastReportedPercentage=0}return Vi()(e,[{key:"clear",value:function(){this.lastReportedPercentage=0}},{key:"updateConsumption",value:function(e,t){var n=e.position,r=e.duration,i=Math.round(n/r*100);i>this.lastReportedPercentage&&this.notifyReportableConsumption(e,i,t)}},{key:"notifyReportableConsumption",value:function(e,t,n){var r=this;Ro.filter(function(e){return e>r.lastReportedPercentage&&e<=t}).forEach(function(t){return n(t,e.position,e.duration)}),this.lastReportedPercentage=t}}]),e}(),Mo=function(){function e(t,n){var r=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"analyticsEventsCallbacks",void 0),f()(this,"videoTimeSubscriber",void 0),f()(this,"videoTagStatusSubscriber",void 0),f()(this,"videoDataStoreSubscriber",void 0),f()(this,"percentageConsumption",void 0),f()(this,"previousVideoTagStatus",void 0),f()(this,"lastPlayedPosition",void 0),f()(this,"getVideoPercentageAction",function(e){switch(e){case 25:return po.COMPLETION_25_PERCENTAGE;case 50:return po.COMPLETION_50_PERCENTAGE;case 75:return po.COMPLETION_75_PERCENTAGE;case 90:return po.COMPLETION_90_PERCENTAGE;default:return""}}),f()(this,"onVideoTimeChanged",function(e){var t=hn.currentVideoDuration(e),n=hn.currentVideoTimeFragment(e);r.percentageConsumption.updateConsumption({position:n,duration:t},r.onVideoTimeReport.bind(r))}),f()(this,"onVideoTagStatusChanged",function(e){var t=hn.videoTagStatus(e),n=hn.currentVideoTimeFragment(e),i=hn.currentVideoDuration(e);if("seeking"===r.previousVideoTagStatus){var o=(new uo).setPosition(n).setPreviousPosition(r.lastPlayedPosition).build();r.analyticsEventsCallbacks.onEvent(po.SEEK,o)}else"seeking"===t&&(r.lastPlayedPosition=n);r.previousVideoTagStatus=t,"complete"===t&&r.onComplete(i)}),f()(this,"onVideoDataChanged",function(){r.percentageConsumption.clear()}),f()(this,"onComplete",function(e){var t=(new uo).setDuration(e).build();r.analyticsEventsCallbacks.onEvent(po.VIDEO_COMPLETE,t),r.percentageConsumption.clear()}),this.store=t,this.analyticsEventsCallbacks=n,this.videoTimeSubscriber=new ji(t,e.getVideoTimeDependencies,this.onVideoTimeChanged.bind(this)),this.videoTagStatusSubscriber=new ji(t,e.getVideoTagStatusDependencies,this.onVideoTagStatusChanged.bind(this)),this.videoDataStoreSubscriber=new ji(t,e.getVideoDataDependencies,this.onVideoDataChanged.bind(this)),this.percentageConsumption=new Do}return Vi()(e,[{key:"onVideoTimeReport",value:function(e,t,n){var r=this.getVideoPercentageAction(e),i=(new uo).setPosition(t).setDuration(n).build();this.analyticsEventsCallbacks.onEvent(r,i)}}]),e}();f()(Mo,"getVideoTimeDependencies",function(e){return[hn.currentVideoTime(e)]}),f()(Mo,"getVideoTagStatusDependencies",function(e){return[hn.videoTagStatus(e)]}),f()(Mo,"getVideoDataDependencies",function(e){return[Cn.videoData(e)]});var Io=function e(t,n,r,i){Ai()(this,e),f()(this,"store",void 0),f()(this,"timeEvents",void 0),f()(this,"videoSettingsEvents",void 0),f()(this,"videoTagStatusEvents",void 0),this.store=t,this.timeEvents=new Mo(t,n),this.videoSettingsEvents=new yo(t,n),this.videoTagStatusEvents=new Co(t,n,r,i)},ko=n(13),No=n.n(ko),Lo=function(){function e(){Ai()(this,e),f()(this,"batteryLevel","N/A"),f()(this,"batteryChargingState",!1),f()(this,"connectionSpeed","N/A"),f()(this,"connectionType","N/A"),this.setConnectionParams()}return Vi()(e,[{key:"setConnectionParams",value:function(){var e=this,t=navigator.connection||navigator.mozConnection||navigator.webkitConnection;t&&(this.updateConnectionParams(t.effectiveType,t.downlink),t.addEventListener("change",function(){return e.updateConnectionParams(t.effectiveType,t.downlink)}))}},{key:"updateConnectionParams",value:function(e,t){this.connectionType=e,this.connectionSpeed=t}},{key:"attach",value:function(){var e=so()(oo.a.mark(function e(){var t,n=this;return oo.a.wrap(function(e){for(;;)switch(e.prev=e.next){case 0:if(!navigator.getBattery){e.next=7;break}return e.next=3,navigator.getBattery();case 3:t=e.sent,this.updateBatteryParams(t.level,t.charging),t.ondischargingtimechange=function(e){return n.updateBatteryParams(e.target.level,e.target.charging)},t.onchargingtimechange=function(e){return n.updateBatteryParams(e.target.level,e.target.charging)};case 7:case"end":return e.stop()}},e,this)}));return function(){return e.apply(this,arguments)}}()},{key:"updateBatteryParams",value:function(e,t){this.batteryLevel="".concat(100*e),this.batteryChargingState=t}},{key:"getBatteryLevel",value:function(){return this.batteryLevel}},{key:"getBatteryChargingState",value:function(){return this.batteryChargingState}},{key:"getConnectionSpeed",value:function(){return this.connectionSpeed}},{key:"getConnectionType",value:function(){return this.connectionType}}]),e}(),xo=function(){"undefined"===typeof window["$$mm-analytics"]&&(window["$$mm-analytics"]={});var e=window;return"undefined"===typeof e["$$mm-analytics"].firstEmbed&&(e["$$mm-analytics"].firstEmbed=Date.now()),e["$$mm-analytics"].firstEmbed},Vo=function(){return"time in process=".concat(Date.now()-xo()," milliseconds")},jo=function(){function e(t,n){var r=this;Ai()(this,e),f()(this,"videoTag",null),f()(this,"deviceParams",void 0),f()(this,"trafficDomain",void 0),f()(this,"adTimeoutDuration",void 0),f()(this,"playbackMethod",void 0),f()(this,"configName",void 0),f()(this,"playerUniqKey",void 0),f()(this,"attach",so()(oo.a.mark(function e(){return oo.a.wrap(function(e){for(;;)switch(e.prev=e.next){case 0:return r.deviceParams=new Lo,e.next=3,r.deviceParams.attach();case 3:case"end":return e.stop()}},e)}))),f()(this,"translatePlaybackMethod",function(e){switch(e){case"lazyplay":return"scroll to play";case"autoplay":return"auto play";case"autoplay_when_viewable":return"auto play when viewable";case"none":return"click to play";default:return"none"}}),f()(this,"getAdTimeout",function(e){return e?"".concat(qn(e)," sec"):"none"}),f()(this,"getVideoTag",function(){return null===r.videoTag&&(r.videoTag=document.getElementById(En(r.playerUniqKey))),r.videoTag}),f()(this,"getUnitSize",function(){var e=r.getVideoTag();return null!==e?"".concat(e.clientWidth,":").concat(e.clientHeight):"none"}),f()(this,"getBatteryCharging",function(){return r.deviceParams.getBatteryChargingState()?"yes":"no"});var i=t.publisher_contribution,o=t.monetization,a=t.playback_method,s=t.config_name;this.playerUniqKey=n,this.trafficDomain=i,this.adTimeoutDuration=o&&o.ad_request_timeout?this.getAdTimeout(o.ad_request_timeout):"none",this.playbackMethod=this.translatePlaybackMethod(a),this.configName=s}return Vi()(e,[{key:"getDimensions",value:function(){return{mmPlusConfigName:this.configName,mmPlusPlaybackMethod:this.playbackMethod,mmPlusPrePvTimeInProcess:Vo(),mmPlusTrafficDomain:this.trafficDomain,mmPlusUnitSize:this.getUnitSize(),mmPlusUnitType:"video",mmPlusUserBatteryCharging:this.getBatteryCharging(),mmPlusUserBatteryLevel:this.deviceParams.getBatteryLevel(),mmPlusUserConnectionSpeed:this.deviceParams.getConnectionSpeed(),mmPlusUserConnectionType:this.deviceParams.getConnectionType(),mmPlusAdTimeoutDuration:this.adTimeoutDuration}}}]),e}();function Uo(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Fo(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Uo(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Uo(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}function Bo(e){var t=function(){if("undefined"===typeof Reflect||!Reflect.construct)return!1;if(Reflect.construct.sham)return!1;if("function"===typeof Proxy)return!0;try{return Date.prototype.toString.call(Reflect.construct(Date,[],function(){})),!0}catch(e){return!1}}();return function(){var n,r=Eo()(e);if(t){var i=Eo()(this).constructor;n=Reflect.construct(r,arguments,i)}else n=r.apply(this,arguments);return _o()(this,n)}}var Ho=function(e){bo()(n,e);var t=Bo(n);function n(e,r){var i,o;return Ai()(this,n),o=t.call(this,e,r),f()(vo()(o),"domain",void 0),f()(vo()(o),"getDimensions",function(){return Fo(Fo({},No()((i=vo()(o),Eo()(n.prototype)),"getDimensions",i).call(i)),{},{mmPlusDomain:o.domain})}),o.domain=window.location.hostname,o}return n}(jo);function qo(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Wo(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?qo(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):qo(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}function zo(e){var t=function(){if("undefined"===typeof Reflect||!Reflect.construct)return!1;if(Reflect.construct.sham)return!1;if("function"===typeof Proxy)return!0;try{return Date.prototype.toString.call(Reflect.construct(Date,[],function(){})),!0}catch(e){return!1}}();return function(){var n,r=Eo()(e);if(t){var i=Eo()(this).constructor;n=Reflect.construct(r,arguments,i)}else n=r.apply(this,arguments);return _o()(this,n)}}var Go=function(e){bo()(n,e);var t=zo(n);function n(e,r,i){var o;Ai()(this,n),o=t.call(this,i,r),f()(vo()(o),"store",void 0),f()(vo()(o),"playerUniqId",void 0),f()(vo()(o),"autoPlay",void 0),f()(vo()(o),"streamType",void 0),f()(vo()(o),"gaProperty",void 0),f()(vo()(o),"booleanToYesOrNo",function(e){return e?"yes":"no"}),f()(vo()(o),"getAspectRatio",function(e,t){var r=n.getCommonDenominator(e,t),i=t/r;return"".concat(e/r,":").concat(i)}),f()(vo()(o),"getUnitRadio",function(){var e=o.getVideoTag();if(null!==e){var t=e.clientWidth,n=e.clientHeight;return o.getAspectRatio(t,n)}return"none"}),f()(vo()(o),"getVideoDuration",function(e){var t=Dn.duration(e);return t?"".concat(t," sec"):"none"});var a=i.playback_method,s=i.content_type,u=i.ga_property;return o.store=e,o.playerUniqId=r,o.autoPlay=o.booleanToYesOrNo("none"!==a),o.streamType=s,o.gaProperty=u||o.trafficDomain,o}return Vi()(n,[{key:"getDimensions",value:function(){var e=this.store.getState;return Wo(Wo({},No()(Eo()(n.prototype),"getDimensions",this).call(this)),{},{mmPlusVideoPlayerId:this.playerUniqId,mmPlusUnitId:Dn.mediaId(e())||"none",mmPlusUnitTitle:Dn.title(e())||"none",mmPlusVideoAutoplay:this.autoPlay,mmPlusVideoDuration:this.getVideoDuration(e()),mmPlusVideoStreamType:this.streamType,mmPlusVideoPlaylistId:Cn.mediaId(e())||"none",mmPlusVideoMuted:this.booleanToYesOrNo(gn.muted(e())),mmPlusUnitTags:Dn.tags(e()).toString()||"none",mmPlusUnitOrderNumber:Cn.activeVideoIndex(e()),mmPlusTrafficReferrer:document.referrer,mmPlusUnitProvider:Dn.provider(e())||"none",mmPlusUnitCreator:Dn.creator(e())||"none",mmPlusUnitExternalId:Dn.externalId(e())||"none",mmPlusUnitRatio:this.getUnitRadio(),mmPlusGaProperty:this.gaProperty,mmPlusVideoPlayerType:"vplayer",mmPlusVideoThumbnailsOn:"none",mmPlusVideoClosedCaptionsOn:"none",mmPlusVideoRecommendationsVisible:"none"})}}]),n}(jo);function $o(e){var t=function(){if("undefined"===typeof Reflect||!Reflect.construct)return!1;if(Reflect.construct.sham)return!1;if("function"===typeof Proxy)return!0;try{return Date.prototype.toString.call(Reflect.construct(Date,[],function(){})),!0}catch(e){return!1}}();return function(){var n,r=Eo()(e);if(t){var i=Eo()(this).constructor;n=Reflect.construct(r,arguments,i)}else n=r.apply(this,arguments);return _o()(this,n)}}f()(Go,"getCommonDenominator",function(e,t){for(var n=e,r=t;r;){var i=r;r=n%r,n=i}return n});var Ko=function(e){bo()(n,e);var t=$o(n);function n(e,r,i){var o;return Ai()(this,n),o=t.call(this,e,r,i),f()(vo()(o),"adStatusSubscriber",void 0),f()(vo()(o),"onAdStatusChanged",function(e){var t=_i.adStatus(e);"playing"===t?o.onPlay():"paused"===t?o.onPause():Hi(t)||o.onComplete()}),o.adStatusSubscriber=new ji(e,n.getAdStatusDependencies,o.onAdStatusChanged.bind(vo()(o))),o}return n}(Po);f()(Ko,"getAdStatusDependencies",function(e){return[_i.adStatus(e)]});var Yo=function e(t,n,r){var i=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"analyticsCallback",void 0),f()(this,"adStatusSubscriber",void 0),f()(this,"adImpressionSubscriber",void 0),f()(this,"adProviderLoadingStatusSubscriber",void 0),f()(this,"adViewableImpressionObserver",void 0),f()(this,"initAdBlockChecker",function(t){""===Fi.loadingImaStatus(t.getState())?i.adProviderLoadingStatusSubscriber=new ji(t,e.getAdProviderLoadingStatusDependencies,i.onAdProviderLoadingStatusChanged.bind(i)):i.onAdProviderLoadingStatusChanged(t.getState())}),f()(this,"getAdOrderFromPlayedMidrolls",function(e){return e&&e.length>0?e[e.length-1]:0}),f()(this,"getFullAdLabel",function(e){var t=hn.currentVideoTimeFragment(e),n=_i.adDuration(e),r=_i.playedMidrolls(e),o=_i.slotNumber(e),a=_i.podNumber(e),s=i.getAdOrderFromPlayedMidrolls(r);return(new uo).setAdType(ho).setPosition(t).setAdDuration(n).setAdOrder(s).setAdSlotNumber(o).setAdPodNumber(a).build()}),f()(this,"reportAdBlock",function(){i.analyticsCallback.onEvent(po.AD_BLOCK)}),f()(this,"reportError",function(e){var t=(new uo).setErrorMessage(e).build();i.analyticsCallback.onEvent(po.PLAYER_ERROR,t)}),f()(this,"reportAdRequested",function(e){var t=hn.currentVideoTimeFragment(e),n=_i.playedMidrolls(e),r=i.getAdOrderFromPlayedMidrolls(n),o=(new uo).setPosition(t).setAdOrder(r).build();i.analyticsCallback.onEvent(po.AD_REQUEST,o)}),f()(this,"reportAdImpression",function(e){var t=i.getFullAdLabel(e);i.analyticsCallback.onEvent(po.AD_IMPRESSION,t)}),f()(this,"reportAdError",function(e){var t=_i.adErrorMessage(e),n=_i.slotNumber(e),r=_i.podNumber(e),o=(new uo).setAdType(ho).setErrorMessage(t).setAdPodNumber(r).setAdSlotNumber(n).build();i.analyticsCallback.onEvent(po.AD_ERROR,o)}),f()(this,"reportAdComplete",function(e){var t=i.getFullAdLabel(e);i.analyticsCallback.onEvent(po.AD_COMPLETE,t)}),f()(this,"reportAdSkipped",function(e){var t=i.getFullAdLabel(e);i.analyticsCallback.onEvent(po.AD_SKIP,t)}),f()(this,"reportAdPaused",function(e){var t=i.getFullAdLabel(e);i.analyticsCallback.onEvent(po.AD_PAUSE,t)}),f()(this,"reportAdViewableImpression",function(e){var t=hn.currentVideoTimeFragment(e),n=_i.adDuration(e),r=_i.slotNumber(e),o=_i.podNumber(e),a=(new uo).setPosition(t).setAdType(ho).setAdDuration(n).setAdPodNumber(o).setAdSlotNumber(r).build();i.analyticsCallback.onEvent(po.AD_VIEWABLE_IMPRESSION,a)}),f()(this,"onAdStatusChanged",function(e){var t=_i.adStatus(e);"requested"===t&&i.reportAdRequested(e),"error"===t&&i.reportAdError(e),"completed"===t&&i.reportAdComplete(e),"skipped"===t&&i.reportAdSkipped(e),"paused"===t&&i.reportAdPaused(e)}),f()(this,"onAdProviderLoadingStatusChanged",function(e){var t=Fi.loadingImaStatus(e);"blocked"===t?i.reportAdBlock():"error"===t&&i.reportError(fo)}),f()(this,"onAdImpressionChanged",function(e){i.reportAdImpression(e)}),this.store=t,this.analyticsCallback=n,this.adStatusSubscriber=new ji(t,e.getAdStatusDependencies,this.onAdStatusChanged.bind(this)),this.adImpressionSubscriber=new ji(t,e.getAdImpressionDependencies,this.onAdImpressionChanged.bind(this)),this.adViewableImpressionObserver=new Ko(t,r,this.reportAdViewableImpression.bind(this)),this.initAdBlockChecker(t)};f()(Yo,"getAdProviderLoadingStatusDependencies",function(e){return[Fi.loadingImaStatus(e)]}),f()(Yo,"getAdStatusDependencies",function(e){return[_i.adStatus(e)]}),f()(Yo,"getAdImpressionDependencies",function(e){return[_i.adImpression(e)]});var Zo=pn.userInteraction,Xo=function(e){return Zo(e).userInteractionType},Jo=function e(t,n){var r=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"analyticsCallbacks",void 0),f()(this,"userInteraction",void 0),f()(this,"getLabel",function(e){var t=hn.currentVideoTimeFragment(e);return(new uo).setPosition(t).build()}),f()(this,"reportMuteOrUnmute",function(e){r.analyticsCallbacks.onEvent(po.CONTROLS_MUTE_OR_UNMUTE,r.getLabel(e))}),f()(this,"reportFullscreen",function(e){r.analyticsCallbacks.onEvent(po.CONTROLS_FULLSCREEN,r.getLabel(e))}),f()(this,"reportPlayOrPause",function(e){r.analyticsCallbacks.onEvent(po.CONTROLS_PLAY_OR_PAUSE,r.getLabel(e))}),f()(this,"reportNextVideo",function(e){r.analyticsCallbacks.onEvent(po.CONTROLS_NEXT_VIDEO,r.getLabel(e))}),f()(this,"reportSettings",function(e){r.analyticsCallbacks.onEvent(po.CONTROLS_SETTINGS,r.getLabel(e))}),f()(this,"reportMiniPlayerClosed",function(e){r.analyticsCallbacks.onEvent(po.MINI_PLAYER_CLOSE,r.getLabel(e))}),f()(this,"onUserInteractionChanged",function(e){switch(Xo(e)){case"mute":case"unmute":r.reportMuteOrUnmute(e);break;case"fullscreen":r.reportFullscreen(e);break;case"play":case"pause":r.reportPlayOrPause(e);break;case"settings":r.reportSettings(e);break;case"nextVideo":r.reportNextVideo(e);break;case"closeMiniPlayer":r.reportMiniPlayerClosed(e)}}),this.store=t,this.analyticsCallbacks=n,this.userInteraction=new ji(t,e.getUserInteractionDependencies,this.onUserInteractionChanged.bind(this))};function Qo(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function ea(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Qo(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Qo(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}f()(Jo,"getUserInteractionDependencies",function(e){return[Xo(e)]});var ta=function e(t,n,r,i){var o=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"videoEventsReporter",void 0),f()(this,"monetizationEventsReporter",void 0),f()(this,"userInteractionReporter",void 0),f()(this,"eventCustomDimensions",void 0),f()(this,"dataLayer",null),f()(this,"attach",function(){var e=so()(oo.a.mark(function e(t,n,r){return oo.a.wrap(function(e){for(;;)switch(e.prev=e.next){case 0:return o.eventCustomDimensions=new Go(t,n,r),e.next=3,o.eventCustomDimensions.attach();case 3:return e.next=5,o.reportReady(t,n,r);case 5:o.reportEmbed();case 6:case"end":return e.stop()}},e)}));return function(t,n,r){return e.apply(this,arguments)}}()),f()(this,"initDataLayer",function(){var e;try{e=$n(window.parent)}catch(t){e=$n(window)}o.dataLayer=window[e]}),f()(this,"reportReady",function(){var e=so()(oo.a.mark(function e(t,n,r){var i;return oo.a.wrap(function(e){for(;;)switch(e.prev=e.next){case 0:return i=new Ho(r,n),e.next=3,i.attach();case 3:o.dataLayer.push(ea({event:co},i.getDimensions()));case 4:case"end":return e.stop()}},e)}));return function(t,n,r){return e.apply(this,arguments)}}()),f()(this,"reportEmbed",function(){o.onEvent(po.EMBED)}),f()(this,"onEvent",function(e,t,n,r){var i=r||o.eventCustomDimensions.getDimensions(),a=n||lo;o.dataLayer.push(ea(ea({event:a,mmPlusGA_event_action:e,mmPlusGA_event_label:t,mmPlusGA_event_category:"MMVideo"},i),{},{time:Date.now()}))}),this.store=t,this.initDataLayer(),this.videoEventsReporter=new Io(t,this,i,n),this.monetizationEventsReporter=new Yo(t,this,i),window.monetizationEventsReporter=this.monetizationEventsReporter,this.userInteractionReporter=new Jo(t,this),this.attach(t,n,r)},na=pn.discovery,ra=function(e){return na(e).nextVideo},ia=n(51).version,oa=function e(){var t=this;Ai()(this,e),f()(this,"controlsLoaded",void 0),f()(this,"loadInternalPlugins",function(e,n,r){var i=r.dev_config,o=e.getState,a=i&&!Un(i.pluginsPath)?i.pluginsPath:function(){try{return"https://www.oo-syringe.com/prod/players"}catch(w){return"./dist/bundle"}}();t.loadAnalyticsPlugin(e,n,r),t.loadActionsPlugin(n,a),t.loadMonetizationPlugin(e,n),t.loadControlsPlugin(n,a),t.loadAnchorPlugin(n,a),t.loadComscorePlugin(n,r,a),Sr(o())&&Un(Zn(o()))&&t.loadCloseBarPlugin(n,a),"none"!==ra(o())&&t.loadDiscoveryPlugin(n,a),Un(Zn(o()))||t.loadSplitViewPlugin(n,a)}),f()(this,"loadActionsPlugin",function(e,t){if(window.monti.dataset&&window.monti.dataset.plugins.actionsPlugin)window.monti.dataset.plugins.actionsPlugin(e);else{var n=document.createElement("script");n.setAttribute("type","text/javascript"),n.setAttribute("src","".concat(t,"/mplayer_actions_plugin.").concat(ia,".js")),n.addEventListener("load",function(){window.monti.dataset.plugins.actionsPlugin(e)}),n.addEventListener("error",function(){console.log("ACTIONS PLUGIN LOADER ERROR !")}),document.body.appendChild(n)}}),f()(this,"loadMonetizationPlugin",function(e,t){ro(e,t)}),f()(this,"loadControlsPlugin",function(e,t){if(window.monti.dataset&&window.monti.dataset.plugins.controlsPlugin)window.monti.dataset.plugins.controlsPlugin(e);else{var n=document.createElement("script");n.setAttribute("src","".concat(t,"/mplayer_controls_plugin.").concat(ia,".js")),n.setAttribute("type","text/javascript"),n.addEventListener("load",function(){window.monti.dataset.plugins.controlsPlugin(e)}),n.addEventListener("error",function(){console.log("CONTROLS PLUGIN LOADER ERROR !")}),document.body.appendChild(n)}}),f()(this,"loadAnchorPlugin",function(e,t){if(window.monti.dataset&&window.monti.dataset.plugins.anchorPlugin)window.monti.dataset.plugins.anchorPlugin(e);else{var n=document.createElement("script");n.setAttribute("src","".concat(t,"/mplayer_anchor_plugin.").concat(ia,".js")),n.setAttribute("type","text/javascript"),n.addEventListener("load",function(){window.monti.dataset.plugins.anchorPlugin(e)}),n.addEventListener("error",function(){console.log("ANCHOR PLUGIN LOADER ERROR !")}),document.body.appendChild(n)}}),f()(this,"loadSplitViewPlugin",function(e,t){if(window.monti.dataset&&window.monti.dataset.plugins.splitViewPlugin)window.monti.dataset.plugins.splitViewPlugin(e);else{var n=document.createElement("script");n.setAttribute("src","".concat(t,"/mplayer_split_view_plugin.").concat(ia,".js")),n.setAttribute("type","text/javascript"),n.addEventListener("load",function(){window.monti.dataset.plugins.splitViewPlugin(e)}),n.addEventListener("error",function(){console.log("SPLIT VIEW PLUGIN LOADER ERROR !")}),document.body.appendChild(n)}}),f()(this,"loadComscorePlugin",function(e,t,n){if(window.monti.dataset&&window.monti.dataset.plugins.comscorePlugin)window.monti.dataset.plugins.comscorePlugin(e,t);else{var r=document.createElement("script");r.setAttribute("src","".concat(n,"/mplayer_comscore_plugin.").concat(ia,".js")),r.setAttribute("type","text/javascript"),r.addEventListener("load",function(){window.monti.dataset.plugins.comscorePlugin(e,t)}),r.addEventListener("error",function(){console.log("COMSCORE PLUGIN LOADER ERROR !")}),document.body.appendChild(r)}}),f()(this,"loadAnalyticsPlugin",function(e,t,n){!function(e,t,n){var r=document.getElementById(bn(t));new ta(e,t,n,r)}(e,t,n)}),f()(this,"loadDiscoveryPlugin",function(e,t){if(window.monti.dataset&&window.monti.dataset.plugins.discoveryPlugin)window.monti.dataset.plugins.discoveryPlugin(e);else{var n=document.createElement("script");n.setAttribute("src","".concat(t,"/mplayer_discovery_plugin.").concat(ia,".js")),n.setAttribute("type","text/javascript"),n.addEventListener("load",function(){window.monti.dataset.plugins.discoveryPlugin(e)}),n.addEventListener("error",function(){console.log("DISCOVERY PLUGIN LOADER ERROR !")}),document.body.appendChild(n)}}),f()(this,"loadCloseBarPlugin",function(e,t){if(window.monti.dataset&&window.monti.dataset.plugins.closeBar)window.monti.dataset.plugins.closeBarPlugin(e);else{var n=document.createElement("script");n.setAttribute("src","".concat(t,"/mplayer_close_bar_plugin.").concat(ia,".js")),n.setAttribute("type","text/javascript"),n.addEventListener("load",function(){window.monti.dataset.plugins.closeBarPlugin(e)}),n.addEventListener("error",function(){console.log("CLOSE BAR PLUGIN LOADER ERROR !")}),document.body.appendChild(n)}}),this.controlsLoaded=!1};function aa(e){return function(t){var n=t.dispatch,r=t.getState;return function(t){return function(i){return"function"===typeof i?i(n,r,e):t(i)}}}}f()(oa,"instance",void 0),f()(oa,"getInstance",function(){return oa.instance||(oa.instance=new oa),oa.instance});var sa=aa();sa.withExtraArgument=aa;var ua=sa;function ca(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function la(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?ca(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):ca(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var da={loadingHLSStatus:"",loadingImaStatus:""};function pa(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function fa(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?pa(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):pa(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var ha={playerId:"",playerInstanceUniqId:null,playbackMethod:"none",videoTagStatus:"idle",pendingVideoTagStatus:{type:null,value:null},currentVideoTime:0,currentVideoTimeFragment:0,currentVideoBufferedTime:0,currentVideoDuration:0,playerMode:"desktop",playerVisibility:0,playerPlaceholderVisibility:0,playerSettings:{muted:!0,volume:.5,speed:1,quality:"Auto",selectedSettingsCategory:"",fullscreen:{pendingFullscreenRequest:"",isFullscreenOn:!1}},loader:{showBlackScreen:!1},playerSize:"",errorMessage:"",loadingPlayer:!1};function ya(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function ga(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?ya(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):ya(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var va={showVoltaxLogo:!0,brandingLogoSrc:"",brandingLogoUrl:"",brandingColor:null};function ma(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function ba(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?ma(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):ma(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Oa={orientation:"right",canClose:!0,anchorData:{anchorEnabled:!1,anchorDisabledByUser:!1,anchorStatus:"inactive"},closableAd:!0,continueStreaming:!1,anchoringAppearance:"below",stickyBelowClassName:"",width:"",closeAfter:10,margins:{top:10,bottom:10,left:10,right:10}};function _a(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Sa(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?_a(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):_a(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Ea,wa={continuePlayingWhileWaitingForAd:!1,midrolls:{},prerollEnabled:!1,vpaidMode:"ENABLED",adRequestTimeout:1e4,adsData:{podNumber:0,slotNumber:0,adType:null,adTagUrlTemplate:null,adErrorMessage:null,adDuration:0,adCurrentTime:0,adOrder:0,adStatus:"",pendingAdStatus:{type:""},playedMidrolls:[],adImpression:0,adOpportunity:0,isVastAd:!1,adMuted:!0,adVolume:.5,currentAdTag:null,adUnit:"",loadingAd:!1}},Pa=n(32),Ta=n.n(Pa);!function(e){e.POST="post",e.GET="get",e.DELETE="delete",e.PUT="put",e.PATCH="patch",e.HEAD="head",e.OPTIONS="options"}(Ea||(Ea={}));var Aa=function(){function e(){Ai()(this,e)}return Vi()(e,null,[{key:"preformRequest",value:function(e,t){return new Promise(function(n,r){Ta()({method:e,url:t}).then(function(e){var t=e.data;n(t)}).catch(function(e){r(e)})})}},{key:"preformGet",value:function(e){return this.preformRequest(Ea.GET,e)}}]),e}();f()(Aa,"HTTP_STATUS_CODES",{OK:200,UNAUTHORIZED:401,INTERNAL_SERVER_ERROR:500,BAD_REQUEST:400,NOT_FOUND:404,CONFLICT:409});var Ca=function(){function e(){Ai()(this,e)}return Vi()(e,null,[{key:"getSemanticPlaylistUrl",value:function(e,t,n){if(n&&!Un(n.semantic_url))return n.semantic_url;var r=function(e){for(var t="",n=0,r=0;r<e.length;r+=1)n=e.charCodeAt(r)+2,t+=String.fromCharCode(n);return encodeURIComponent(encodeURIComponent(t))}(e.split("?")[0]),i="".concat(function(){try{return"https://semantic-matching.minutemediaservices.com/semantic-feed"}catch(w){return"https://semantic-matching.minutemediaservices.com/semantic-feed"}}(),"/").concat(r),o="?";return Un(t.minimumDateFactor)||(i="".concat(i).concat(o,"minimum_date_factor=").concat(t.minimumDateFactor),o="&"),Un(t.tags)||(i="".concat(i).concat(o,"tags=").concat(t.tags),o="&"),Un(t.scopedKeywords)||(i="".concat(i).concat(o,"scoped_keywords=").concat(t.scopedKeywords),o="&"),Un(t.scannedElement)||Un(t.scannedElementType)||(i="".concat(i).concat(o,"article_container=").concat(function(e,t){switch(t){case"id":return"".concat("#").concat(e);case"className":return e.split(" ").map(function(e){return"".concat(".").concat(e)}).join("");default:return"".concat("").concat(e)}}(t.scannedElement,t.scannedElementType)),o="&"),Un(t.scanImagesOnPage)||(i="".concat(i).concat(o,"scan_images=").concat(String(t.scanImagesOnPage))),i}},{key:"getSpecificPlaylistUrl",value:function(e,t){return t&&!Un(t.playlist_url)?t.playlist_url:"".concat("https://vms-videos.minutemediaservices.com","/").concat(e,"/").concat(e,".json")}}]),e}(),Ra=function(e,t){var n=e.findIndex(function(e){return e.type===t});return n>=0?e[n].file:""},Da=function(){function e(){Ai()(this,e)}return Vi()(e,null,[{key:"getSemanticPlaylist",value:function(e,t){var n=window.location.href,r=Ca.getSemanticPlaylistUrl(n,e,t);return Aa.preformGet(r)}},{key:"getSpecificPlaylist",value:function(e,t){var n=Ca.getSpecificPlaylistUrl(e,t);return Aa.preformGet(n)}}]),e}();f()(Da,"getPromotedVideos",function(){var e=so()(oo.a.mark(function e(t){var n;return oo.a.wrap(function(e){for(;;)switch(e.prev=e.next){case 0:return n=t.map(function(e){return Da.getSpecificPlaylist(e).then(function(e){return e.data}).catch(function(){return[]})}),e.abrupt("return",new Promise(function(e){Promise.all(n).then(function(t){var n=t.reduce(function(e,t){return e.concat(t)},[]);n.length>0&&e(n)})}));case 2:case"end":return e.stop()}},e)}));return function(t){return e.apply(this,arguments)}}());var Ma=function(e,t){return function(n){n({type:"[CORE] load video request success",payload:e.data.map(function(e,n){return{mediaId:e.payload_id,tags:e.tags,sources:e.sources,duration:e.duration,thumbnail:e.image,title:t?e.title:"",description:e.description,creator:e.creator,provider:e.video_provider,externalId:e.external_id,index:n}})})}},Ia=function(e){return function(t){t({type:"[CORE] load video request error",payload:e})}},ka=function(e,t,n){return function(){var r=so()(oo.a.mark(function r(i){var o;return oo.a.wrap(function(r){for(;;)switch(r.prev=r.next){case 0:return i({type:"[CORE] load video request"}),r.prev=1,r.next=4,Da.getSpecificPlaylist(e,n);case 4:o=r.sent,Ma(o,t)(i),r.next=11;break;case 8:r.prev=8,r.t0=r.catch(1),Ia(Xn.GENERAL_ERROR)(i);case 11:case"end":return r.stop()}},r,null,[[1,8]])}));return function(e){return r.apply(this,arguments)}}()},Na=function(e,t,n){return function(){var r=so()(oo.a.mark(function r(i){var o,a;return oo.a.wrap(function(r){for(;;)switch(r.prev=r.next){case 0:if(i({type:"[CORE] load video request"}),o=[],r.prev=2,!(Array.isArray(e.promotedVideos)&&e.promotedVideos.length>0)){r.next=7;break}return r.next=6,Da.getPromotedVideos(e.promotedVideos);case 6:o=r.sent;case 7:return r.next=9,Da.getSemanticPlaylist(e,n);case 9:(a=r.sent).data=o.concat(a.data),Ma(a,t)(i),r.next=17;break;case 14:r.prev=14,r.t0=r.catch(2),o.length>0?Ma({data:o},t)(i):Ia(Xn.GENERAL_ERROR)(i);case 17:case"end":return r.stop()}},r,null,[[2,14]])}));return function(e){return r.apply(this,arguments)}}()},La=function(e,t){return function(n){n({type:"[CORE] set current video",payload:{index:e,videoData:t}})}};function xa(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Va(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?xa(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):xa(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var ja={activeVideoIndex:0,mediaType:"semantic",mediaId:"",loadingMedia:!1,mediaLoadingError:"",mediaRequest:{type:null,value:""},videoList:[],videoData:{mediaId:"",tags:[],sources:[],duration:0,thumbnail:"",title:"",showTitle:!0,description:"",creator:"",provider:"",externalId:"",index:0}};function Ua(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Fa(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Ua(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Ua(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Ba={promotedVideos:[],scannedElement:"",tags:"",scopedKeywords:"",minimumDateFactor:"",scannedElementType:null,scanImagesOnPage:!1};function Ha(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function qa(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Ha(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Ha(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Wa={userInteractionType:""};function za(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Ga(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?za(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):za(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var $a={splitViewRatio:null};function Ka(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Ya(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Ka(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Ka(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Za={nextVideo:"none",showUpNext:!1,showSkippableContent:!1},Xa=function(e){return"none"===e?"none":"up_next"===e?"upNext":"skippable_content"===e?"skippableContent":"none"},Ja=function(e){for(var t=Object.keys(e),n={},r=0;r<t.length;r++){var i=t[r];"function"===typeof e[i]&&(n[i]=e[i])}var o,a=Object.keys(n);try{!function(e){Object.keys(e).forEach(function(t){var n=e[t];if("undefined"===typeof n(void 0,{type:yt.INIT}))throw new Error('Reducer "'+t+"\" returned undefined during initialization. If the state passed to the reducer is undefined, you must explicitly return the initial state. The initial state may not be undefined. If you don't want to set a value for this reducer, you can use null instead of undefined.");if("undefined"===typeof n(void 0,{type:yt.PROBE_UNKNOWN_ACTION()}))throw new Error('Reducer "'+t+"\" returned undefined when probed with a random type. Don't try to handle "+yt.INIT+' or other actions in "redux/*" namespace. They are considered private. Instead, you must return the current state for any unknown actions, unless it is undefined, in which case you must return the initial state, regardless of the action type. The initial state may not be undefined, but can be null.')})}(n)}catch(s){o=s}return function(e,t){if(void 0===e&&(e={}),o)throw o;for(var r=!1,i={},s=0;s<a.length;s++){var u=a[s],c=n[u],l=e[u],d=c(l,t);if("undefined"===typeof d){var p=mt(u,t);throw new Error(p)}i[u]=d,r=r||d!==l}return(r=r||a.length!==Object.keys(e).length)?i:e}}({dependenciesLoadingStatus:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:da,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] update hls status":return la(la({},e),{},{loadingHLSStatus:t.payload});case"[CORE] update ima status":return la(la({},e),{},{loadingImaStatus:t.payload});default:return e}},playerData:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:ha,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":var n=t.payload;return fa({},function(e,t,n){var r=t.playback_method,i=t.player_id;return fa(fa({},e),{},{playbackMethod:Un(r)?e.playbackMethod:r,playerId:Un(i)?e.playerId:i,playerInstanceUniqId:n,playerMode:Fn()?"mobile":"desktop"})}(e,n.initiateParams,n.playerInstanceUniqId));case"[CORE] reset player data time params":return fa(fa({},e),{},{currentVideoTimeFragment:0,currentVideoBufferedTime:0,currentVideoDuration:0,currentVideoTime:0});case"[COMMON] set mute video":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{muted:t.payload})});case"[COMMON] set volume":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{volume:t.payload})});case"[COMMON] change selected settings category":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{selectedSettingsCategory:t.payload})});case"[COMMON] change settings speed":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{speed:t.payload})});case"[COMMON] change settings quality":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{quality:t.payload})});case"[COMMON] set fullscreen":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{fullscreen:fa(fa({},e.playerSettings.fullscreen),{},{isFullscreenOn:t.payload,pendingFullscreenRequest:""})})});case"[COMMON] set fullscreen request":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{fullscreen:fa(fa({},e.playerSettings.fullscreen),{},{pendingFullscreenRequest:t.payload})})});case"[COMMON] set pending video status":var r=t.payload.pendingStatusObject;return fa(fa({},e),{},{pendingVideoTagStatus:fa({},r)});case"[COMMON] set player mode":return fa(fa({},e),{},{playerMode:t.payload});case"[CORE] update video current fragment position":return fa(fa({},e),{},{currentVideoTimeFragment:t.payload});case"[CORE] update video current position":return fa(fa({},e),{},{currentVideoTime:t.payload});case"[CORE] update video current buffered time":return fa(fa({},e),{},{currentVideoBufferedTime:t.payload});case"[CORE] update video current duration":return fa(fa({},e),{},{currentVideoDuration:t.payload});case"[CORE] change video tag status":return fa(fa({},e),{},{videoTagStatus:t.payload});case"[CORE] update player visibility":return fa(fa({},e),{},{playerVisibility:t.payload});case"[CORE] update placeholder visibility":return fa(fa({},e),{},{playerPlaceholderVisibility:t.payload});case"[CORE] change loading player status":return fa(fa({},e),{},{loadingPlayer:t.payload});case"[COMMON] show black screen with loader":return fa(fa({},e),{},{loader:fa(fa({},e.loader),{},{showBlackScreen:t.payload})});case"[CORE] set player size":return fa(fa({},e),{},{playerSize:t.payload});case"[COMMON] set error message":return fa(fa({},e),{},{errorMessage:t.payload});default:return e}},brandingData:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:va,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return ga({},function(e,t){var n=t.powered_by_strip,r=t.brand_logo,i=t.brand_logo_click_url,o=t.brand_color;return ga(ga({},e),{},{showVoltaxLogo:Un(n)?e.showVoltaxLogo:n,brandingLogoSrc:Un(r)?e.brandingLogoSrc:r,brandingLogoUrl:Un(i)?e.brandingLogoUrl:i,brandingColor:Un(o)?e.brandingColor:o})}(e,t.payload.initiateParams));default:return e}},anchorOptions:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:Oa,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return ba({},function(e,t){var n=t.anchor_options;if(!Un(n)){var r=n.anchoring_appearance,i=n.can_close,o=n.closable_ad,a=n.close_after,s=n.continue_streaming,u=n.orientation,c=n.margins,l=n.sticky_below_class_name,d=n.width,p=Un(c)?e.margins:{top:Number.isInteger(c.top)?c.top:e.margins.top,bottom:Number.isInteger(c.bottom)?c.bottom:e.margins.bottom,left:Number.isInteger(c.left)?c.left:e.margins.left,right:Number.isInteger(c.right)?c.right:e.margins.right};return ba(ba({},e),{},{anchoringAppearance:r||e.anchoringAppearance,canClose:Un(i)?e.canClose:i,orientation:Un(u)?e.orientation:u,closableAd:Un(o)?e.closableAd:o,closeAfter:Un(a)?e.closeAfter:a,continueStreaming:Un(s)?e.continueStreaming:s,stickyBelowClassName:Un(l)?e.stickyBelowClassName:l,width:Un(d)?e.width:d,margins:p,anchorData:ba(ba({},e.anchorData),{},{anchorEnabled:!0})})}return e}(e,t.payload.initiateParams));case"[COMMON] set anchor enable":return ba(ba({},e),{},{anchorData:ba(ba({},e.anchorData),{},{anchorEnabled:t.payload})});case"[ANCHOR] update is anchor status":return ba(ba({},e),{},{anchorData:ba(ba({},e.anchorData),{},{anchorStatus:t.payload})});case"[COMMON] set anchor disabled by user":return ba(ba({},e),{},{anchorData:ba(ba({},e.anchorData),{},{anchorDisabledByUser:t.payload})});default:return e}},monetization:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:wa,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return Sa({},function(e,t){var n=t.monetization;if(Un(n))return e;var r=n.ad_tag,i=n.ad_type,o=n.vpaid_mode,a=n.ad_request_timeout,s=n.continue_content_play_while_waiting_for_ad,u=n.midrolls,c=u&&u.on&&u.on.sort(Wn),l=Un(s)?e.continuePlayingWhileWaitingForAd:s,d=c?c.indexOf(0):-1,p=-1!==d&&!l;return p&&(c=c.splice(d,1)),Sa(Sa({},e),{},{midrolls:Sa(Sa({},e.midrolls),{},{every:u&&u.every,on:c}),prerollEnabled:p,adRequestTimeout:Un(a)?e.adRequestTimeout:parseInt(a,10),vpaidMode:Un(o)?e.vpaidMode:o,continuePlayingWhileWaitingForAd:l,adsData:Sa(Sa({},e.adsData),{},{adType:Un(i)?e.adsData.adType:i,adTagUrlTemplate:Un(r)?e.adsData.adTagUrlTemplate:r})})}(e,t.payload.initiateParams));case"[COMMON] set new ad tag url template":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adTagUrlTemplate:t.payload})});case"[MONETIZATION] change ad status":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adStatus:t.payload,adErrorMessage:null})});case"[MONETIZATION] change ad tag":var n=t.payload,r=n.adUnit,i=n.adTag;return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{currentAdTag:i,adUnit:r})});case"[MONETIZATION] change pending ad status":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{pendingAdStatus:t.payload})});case"[MONETIZATION] change ad error":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adStatus:"error",adErrorMessage:t.payload})});case"[MONETIZATION] increase ad impression counter":var o=e.adsData.adImpression;return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adImpression:o+1})});case"[MONETIZATION] increase ad Opportunity counter":var a=e.adsData.adOpportunity;return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adOpportunity:a+1})});case"[MONETIZATION] add played midroll number":var s=e.adsData.playedMidrolls,u=In()(s);return u.push(t.payload),Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adOrder:t.payload,playedMidrolls:u})});case"[MONETIZATION] clear played midrolls":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{playedMidrolls:[]})});case"[MONETIZATION] clear ad data":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adOrder:0,currentAdTag:null,adDuration:0,adUnit:""})});case"[MONETIZATION] change ad duration":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adDuration:t.payload})});case"[MONETIZATION] update is vast ad":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{isVastAd:t.payload})});case"[MONETIZATION] change ad current time":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adCurrentTime:t.payload})});case"[MONETIZATION] update ad muted":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adMuted:t.payload})});case"[MONETIZATION] change ad volume":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adVolume:t.payload})});case"[MONETIZATION] change pod info":var c=t.payload,l=c.podNumber,d=c.slotNumber;return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{podNumber:l,slotNumber:d})});case"[MONETIZATION] change loading ad status":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{loadingAd:t.payload})});default:return e}},mediaData:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:ja,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return Va({},function(e,t){var n=t.content_type,r=t.media_id,i=t.display_title;return Va(Va({},e),{},{mediaType:Un(n)?e.mediaType:n,mediaId:Un(r)?e.mediaId:r,videoData:Va(Va({},e.videoData),{},{showTitle:!!Un(i)||i})})}(e,t.payload.initiateParams));case"[CORE] load video request":return Va(Va({},e),{},{loadingMedia:!0});case"[CORE] load video request success":return Va(Va({},e),{},{loadingMedia:!1,videoList:t.payload});case"[CORE] set current video":var n=t.payload,r=n.index,i=n.videoData;return Va(Va({},e),{},{activeVideoIndex:r,videoData:i});case"[CORE] load video request error":return Va(Va({},e),{},{loadingMedia:!1,mediaLoadingError:t.payload});case"[COMMON] media request":var o=t.payload.mediaRequestObject;return Va(Va({},e),{},{mediaRequest:Va({},o)});default:return e}},semanticOptions:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:Ba,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return Fa({},function(e,t){var n=t.semantic_options;if(Un(n))return e;var r=n.minimum_date_factor,i=n.promoted_videos,o=n.scan_images_on_page,a=n.scanned_element,s=n.scanned_element_type,u=n.scoped_keywords,c=n.tags;return Fa(Fa({},e),{},{minimumDateFactor:Un(r)?e.minimumDateFactor:r,promotedVideos:Un(i)?e.promotedVideos:i,scanImagesOnPage:Un(o)?e.scanImagesOnPage:o,scannedElement:Un(a)?e.scannedElement:a,scannedElementType:Un(s)?e.scannedElementType:s,scopedKeywords:Un(u)?e.scopedKeywords:u,tags:Un(c)?e.tags:c})}(e,t.payload.initiateParams));default:return e}},userInteraction:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:Wa,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[USER INTERACTION] change user interaction":return qa(qa({},e),{},{userInteractionType:t.payload});default:return e}},splitView:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:$a,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return Ga({},function(e,t){var n=t.anchor_options;if(!Un(n)){var r=n.split_view,i=n.split_view_ratio;return Ga(Ga({},e),{},{splitViewRatio:Un(r)||!r||Un(i)?e.splitViewRatio:i})}return e}(e,t.payload.initiateParams));default:return e}},discovery:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:Za,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return Ya({},function(e,t){var n=t.next_video;return Un(n)?e:Ya(Ya({},e),{},{nextVideo:Xa(n)})}(e,t.payload.initiateParams));case"[DISCOVERY] show up next":return Ya(Ya({},e),{},{showUpNext:t.payload});case"[DISCOVERY] show skippable content":return Ya(Ya({},e),{},{showSkippableContent:t.payload});default:return e}}}),Qa=[],es=!1,ts=function e(){return function(t){return function(n){if(es)return Qa.push(n),null;es=!0;var r=t(n);return es=!1,Qa.length>0&&e()(t)(Qa.shift()),r}}},ns=function(e){var t=[];if(function(e){return!Un(e)&&!Un(e.enable_redux_debugging)&&e.enable_redux_debugging}(e)){var n=window&&window.__REDUX_DEVTOOLS_EXTENSION__&&window.__REDUX_DEVTOOLS_EXTENSION__();"function"===typeof n&&t.push(n)}var r=Et.apply(void 0,[wt(ua,ts)].concat(t));return vt(Ja,r)},rs=function(){function e(t){Ai()(this,e),f()(this,"playerVisibilitySubscriber",void 0),f()(this,"videoTagStatusSubscriber",void 0),f()(this,"shouldPlayIfLazyplay",!0),f()(this,"shouldPlayIfAutoplayWhenViewable",!0),f()(this,"videoPausedByObserver",!1),this.store=t,this.playerVisibilitySubscriber=null,this.videoTagStatusSubscriber=null,this.playAccordingToPlaybackMethod()}return Vi()(e,[{key:"lazyplayHandler",value:function(e){hn.playerVisibility(e)>=.5&&(this.playVideo(),this.shouldPlayIfLazyplay=!1)}},{key:"autoplayWhenViewableHandler",value:function(e){hn.playerVisibility(e)>=.5?this.playVideo():this.pauseVideo()}},{key:"onPlayerVisibilityChanged",value:function(e){var t=hn.playbackMethod(e);"lazyplay"===t&&this.shouldPlayIfLazyplay&&this.lazyplayHandler(e),"autoplay_when_viewable"===t&&this.shouldPlayIfAutoplayWhenViewable&&this.autoplayWhenViewableHandler(e)}},{key:"onVideoTagStatusChanged",value:function(e){var t=hn.videoTagStatus(e);"paused"!==t||this.videoPausedByObserver||(this.shouldPlayIfAutoplayWhenViewable=!1),"playing"===t&&(this.shouldPlayIfAutoplayWhenViewable=!0,this.videoPausedByObserver=!1)}},{key:"initiatePlayerVisibilitySubscriber",value:function(){this.playerVisibilitySubscriber=new ji(this.store,e.getPlayerVisibilityDependencies,this.onPlayerVisibilityChanged.bind(this))}},{key:"initiateVideoTagStatusSubscriber",value:function(){this.videoTagStatusSubscriber=new ji(this.store,e.getVideoTagStatusDependencies,this.onVideoTagStatusChanged.bind(this))}},{key:"playVideo",value:function(){var e=this.store,t=e.dispatch,n=e.getState;"idle"===hn.videoTagStatus(n())?on("play")(t):on("resume")(t)}},{key:"pauseVideo",value:function(){var e=this.store,t=e.dispatch,n=e.getState;"paused"!==hn.videoTagStatus(n())&&(this.videoPausedByObserver=!0,on("pause")(t))}},{key:"playAccordingToPlaybackMethod",value:function(){var e=this.store,t=e.dispatch,n=(0,e.getState)();switch(hn.playbackMethod(n)){case"autoplay":this.playVideo();break;case"lazyplay":this.initiatePlayerVisibilitySubscriber();break;case"autoplay_when_viewable":this.initiatePlayerVisibilitySubscriber(),this.initiateVideoTagStatusSubscriber();break;case"none":an(!1)(t)}}}],[{key:"getPlayerVisibilityDependencies",value:function(e){return[hn.playerVisibility(e)]}},{key:"getVideoTagStatusDependencies",value:function(e){return[hn.videoTagStatus(e)]}}]),e}(),is=function(){function e(t,n,r,i){var o=this;Ai()(this,e),f()(this,"videoStatusSubscriber",void 0),f()(this,"videoListSubscriber",void 0),f()(this,"mediaRequestSubscriber",void 0),f()(this,"playerVisibilitySubscriber",void 0),f()(this,"playbackMethodManager",void 0),f()(this,"store",void 0),f()(this,"loadContent",function(e,t,n,r){o.loadMedia(t,n,r).then(function(){o.playbackMethodManager=new rs(e)})}),f()(this,"loadMedia",function(e,t,n){var r=o.store,i=r.dispatch,a=r.getState,s=Dn.showTitle(a());if("semantic"===e){var u=pn.semanticOptions(a());return Na(u,s,n)(i)}return ka(t,s,n)(i)}),this.store=t,this.videoStatusSubscriber=new ji(t,e.getVideoStatusDependencies,this.onVideoStatusChanged.bind(this)),this.videoListSubscriber=new ji(t,e.getVideoListDependencies,this.onVideoListChanged.bind(this)),this.mediaRequestSubscriber=new ji(t,e.getMediaRequestDependencies,this.onMediaRequestChanged.bind(this)),this.playerVisibilitySubscriber=null,this.loadContent(t,r,n,i)}return Vi()(e,null,[{key:"createInstance",value:function(t,n,r,i){return new e(t,n,r,i)}}]),Vi()(e,[{key:"playNextVideo",value:function(e){var t=this.store.dispatch,n=Cn.videoList(e),r=Cn.activeVideoIndex(e)+1;n.length>1&&r>=n.length&&(r=0),r<n.length&&(!function(e){e({type:"[CORE] reset player data time params"})}(t),La(r,n[r])(t),on("play")(t))}},{key:"playPreviousVideo",value:function(e){var t=this.store.dispatch,n=Cn.videoList(e),r=Cn.activeVideoIndex(e);if(r>0){var i=r-1;La(i,n[i])(t),on("play")(t)}}},{key:"onVideoStatusChanged",value:function(e){"complete"===hn.videoTagStatus(e)&&this.playNextVideo(e)}},{key:"onVideoListChanged",value:function(e){var t=this.store.dispatch,n=Cn.videoList(e);!jn(n)&&n.length>0&&La(0,n[0])(t)}},{key:"onMediaRequestChanged",value:function(e){var t=Cn.mediaRequest(e);switch(t.type){case"playNewVideo":this.loadMedia("specific",t.value);break;case"playNextVideo":this.playNextVideo(e);break;case"playPreviousVideo":this.playPreviousVideo(e)}}}],[{key:"getVideoStatusDependencies",value:function(e){return[hn.videoTagStatus(e)]}},{key:"getVideoListDependencies",value:function(e){return[Cn.videoList(e)]}},{key:"getMediaRequestDependencies",value:function(e){return[Cn.mediaRequest(e)]}}]),e}(),os=function e(t){var n=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"onDependencyFailure",function(e,t){console.log("onDependencyFailure",e,t);var r=n.store,i=r.dispatch,o=r.getState;switch(e){case"ima":"blocked"!==Fi.loadingImaStatus(o())&&Qn("error")(i);break;case"hls":er("error")(i)}}),f()(this,"onDependencyReady",function(e){var t=n.store.dispatch;switch(e){case"ima":Qn("success")(t);break;case"hls":er("success")(t)}}),this.store=t},as=function(e){return function(t){t({type:"[COMMON] set fullscreen",payload:e})}},ss=function(){function e(t,n){var r=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"videoTag",void 0),f()(this,"pendingFullscreenSubscriber",void 0),f()(this,"adStatusSubscriber",void 0),f()(this,"playerUniqId",void 0),f()(this,"onAdStatusChanged",function(e){var t=_i.adStatus(e),n=r.videoTag.webkitDisplayingFullscreen;"playing"===t&&Bn()&&n&&r.exitFullscreen(r.videoTag)}),f()(this,"isPlayerInFullscreen",function(){var e=document,t=Bn()?En(r.playerUniqId):bn(r.playerUniqId);return Un(e.fullscreenElement)?!Un(e.webkitFullscreenElement)&&0===e.webkitFullscreenElement.id.localeCompare(t):0===e.fullscreenElement.id.localeCompare(t)}),f()(this,"changePlayerWidth",function(e){r.videoTag.style.width=e?"100%":"auto"}),f()(this,"onFullscreenChanged",function(){var e=r.store.dispatch,t=r.isPlayerInFullscreen();r.changePlayerWidth(t),as(t)(e)}),f()(this,"onFullscreenChangedIos",function(){var e=r.store.dispatch,t=r.videoTag.webkitDisplayingFullscreen;t||on("resume")(e),r.changePlayerWidth(t),as(t)(e)}),f()(this,"onPendingFullscreenRequestChanged",function(e){var t=gn.pendingFullscreenRequest(e);"enter"===t?r.enterFullscreen(r.videoTag):"exit"===t&&r.exitFullscreen(r.videoTag)}),f()(this,"getFullScreenElement",function(e,t){var n=document.getElementById(bn(r.playerUniqId));return Bn()?t:e?document:n}),f()(this,"enterFullscreen",function(e){var t=r.getFullScreenElement(!1,e);Bn()?t.webkitEnterFullscreen():document.webkitExitFullscreen?t.webkitRequestFullscreen():document.webkitCancelFullScreen?t.webkitRequestFullScreen():document.mozCancelFullScreen?t.mozRequestFullScreen():document.msExitFullscreen&&t.msRequestFullscreen()}),f()(this,"exitFullscreen",function(e){var t=r.getFullScreenElement(!0,e);document.webkitExitFullscreen||Bn()?t.webkitExitFullscreen():document.webkitCancelFullScreen?t.webkitCancelFullScreen():document.mozCancelFullScreen?t.mozCancelFullScreen():document.msExitFullscreen&&t.msExitFullscreen()}),this.store=t,this.videoTag=document.getElementById(En(n)),this.playerUniqId=n,document.addEventListener("fullscreenchange",this.onFullscreenChanged.bind(this)),document.addEventListener("webkitfullscreenchange",this.onFullscreenChanged.bind(this)),Bn()&&(this.videoTag.addEventListener("webkitendfullscreen",this.onFullscreenChangedIos.bind(this)),this.videoTag.addEventListener("webkitbeginfullscreen",this.onFullscreenChangedIos.bind(this))),this.pendingFullscreenSubscriber=new ji(t,e.getPendingFullscreenDependencies,this.onPendingFullscreenRequestChanged.bind(this)),this.adStatusSubscriber=new ji(t,e.getAdStatusDependencies,this.onAdStatusChanged.bind(this))}return Vi()(e,null,[{key:"createInstance",value:function(t,n){return new e(t,n)}}]),Vi()(e,null,[{key:"getPendingFullscreenDependencies",value:function(e){return[gn.pendingFullscreenRequest(e)]}},{key:"getAdStatusDependencies",value:function(e){return[_i.adStatus(e)]}}]),e}();function us(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function cs(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?us(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):us(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var ls,ds=function(e){return function(e){return e&&window.monti.playerConfigs&&window.monti.playerConfigs[e]}(e)?function(e){return window.monti.playerConfigs[e]}(e):window.monti.playerConfigs?window.monti.playerConfigs&&window.monti.playerConfigs[Object.keys(window.monti.playerConfigs)[0]]:null},ps=function e(t){var n=this;Ai()(this,e),f()(this,"videoTag",void 0),f()(this,"isBufferError",void 0),f()(this,"hls",void 0),f()(this,"hlsSetup",function(e,t,r,i){n.initiateHls(e),n.loadHlsSource(e,t,r,i)}),f()(this,"detachMedia",function(){Un(n.hls)||(n.hls.detachMedia(),n.hls.destroy(),n.hls=null)}),f()(this,"initiateHls",function(e){n.hls=new e,n.hls.attachMedia(n.videoTag)}),f()(this,"loadHlsSource",function(e,t,r,i){n.hls.on(e.Events.MEDIA_ATTACHED,function(){n.hls.loadSource(t)}),n.hls.on(e.Events.ERROR,function(t,o){n.mapHlsToErrors(e,o,i),t.details===e.ErrorDetails.BUFFER_STALLED_ERROR&&(r(!0),n.isBufferError=!0)}),n.hls.on(e.Events.FRAG_BUFFERED,function(){n.isBufferError&&(r(!1),n.isBufferError=!1)})}),f()(this,"mapHlsToErrors",function(e,t,r){if(t.fatal)switch(t.type){case e.ErrorTypes.NETWORK_ERROR:r(Xn.GENERAL_ERROR),n.hls.startLoad();break;case e.ErrorTypes.MEDIA_ERROR:r(Xn.GENERAL_ERROR),n.hls.recoverMediaError();break;default:r(Xn.GENERAL_ERROR),n.hls.destroy()}}),this.hls=void 0,this.videoTag=t,this.isBufferError=!1},fs=function e(){var t=this;Ai()(this,e),f()(this,"videoStreaming",void 0),f()(this,"hlsLibrarySetup",function(e,n,r,i){Un(t.videoStreaming)||t.videoStreaming.detachMedia(),t.videoStreaming=new ps(e),t.videoStreaming.hlsSetup(ls,n,r,i)})};f()(fs,"shouldLoadVideoStreamingSrcDirectly",function(e,t,n){return"no-need"===n&&!(""===e.canPlayType("application/vnd.apple.mpegurl"))}),f()(fs,"shouldUseHlsLibrary",function(e,t){return"success"===t&&(ls=void 0!==window.Hls?Hls:mmHls).isSupported()}),f()(fs,"isValidHlsUrl",function(e){return!Un(e)&&!e.includes(".mp4")}),f()(fs,"suitableVideoSource",function(e,t,n){return fs.isValidHlsUrl(t)?fs.shouldUseHlsLibrary(t,n)?"m3u8 with hls":fs.shouldLoadVideoStreamingSrcDirectly(e,t,n)?"m3u8 directly":"loading"!==n?"mp4":"":"mp4"}),f()(fs,"loadHlsVideoDirectly",function(e,t){e.setAttribute("src",t),e.load()});var hs=function(e){return function(t){t({type:"[MONETIZATION] change pending ad status",payload:{type:e}})}},ys="video/mp4",gs="application/vnd.apple.mpegurl",vs=function(){function e(t,n){var r=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"videoTag",void 0),f()(this,"prerollEnabled",void 0),f()(this,"pendingVideoStatusSubscriber",void 0),f()(this,"videoStreamingManager",void 0),f()(this,"videoDataSubscriber",void 0),f()(this,"hlsLoadingStatusSubscriber",void 0),f()(this,"newVideoDataLoaded",void 0),f()(this,"onHlsLoadingStatusChanged",function(e){"success"===Fi.loadingHLSStatus(e)&&(r.newVideoDataLoaded=!0,r.onPendingVideoStatusChanged(e))}),f()(this,"onPendingVideoStatusChanged",function(e){var t=hn.pendingVideoTagStatus(e),n=Dn.sources(e),i=Fi.loadingHLSStatus(e),o="blocked"===Fi.loadingImaStatus(e);r.handlePendingVideoStatus(t,n,i,o)}),f()(this,"onVideoDataChanged",function(){r.newVideoDataLoaded=!0}),f()(this,"sendPrerollPlayRequest",function(){var e=r.store.dispatch;hs("playPreroll")(e)}),f()(this,"handlePlayRequest",function(e,t,n){var i=r.store.dispatch;if(e&&e.length>0){if(r.newVideoDataLoaded&&(r.loadVideoSource(r.videoTag,e,t),r.newVideoDataLoaded=!1,r.prerollEnabled&&!n))return void r.sendPrerollPlayRequest();r.videoTag.play().catch(function(e){return console.error("Error playing the video: ",e)})}else dn(Xn.VIDEO_ERROR)(i)}),f()(this,"handlePendingVideoStatus",function(e,t,n,i){switch(e.type){case"play":r.handlePlayRequest(t,n,i);break;case"resume":r.videoTag.play().catch(function(e){return console.error("Error resuming the video: ",e)});break;case"pause":r.videoTag.pause();break;case"replay":r.videoTag.currentTime=0,r.videoTag.play().catch(function(e){return console.error("Error replaying the video: ",e)});break;case"seekTo":r.videoTag.pause(),r.videoTag.currentTime=e.value}}),f()(this,"loadMp4Source",function(e,t,n){var r=Ra(t,ys);n.setAttribute("src",r),n.load()}),f()(this,"loadVideoSource",function(e,t,n){var i=r.store.dispatch,o=Ra(t,gs);switch(fs.suitableVideoSource(e,o,n)){case"mp4":r.loadMp4Source(n,t,e);break;case"m3u8 with hls":r.videoStreamingManager.hlsLibrarySetup(e,o,function(e){return un(e)(i)},function(e){return dn(e)(i)});break;case"m3u8 directly":fs.loadHlsVideoDirectly(e,o)}}),this.store=t;var i=t.getState;this.videoStreamingManager=new fs,this.videoTag=document.getElementById(En(n)),this.prerollEnabled=bi.prerollEnabled(i()),this.pendingVideoStatusSubscriber=new ji(t,e.getPendingVideoStatusDependencies,this.onPendingVideoStatusChanged.bind(this)),this.videoDataSubscriber=new ji(t,e.getVideoDataDependencies,this.onVideoDataChanged.bind(this)),this.hlsLoadingStatusSubscriber=new ji(t,e.getHLSLoadingStatusDependencies,this.onHlsLoadingStatusChanged.bind(this))}return Vi()(e,null,[{key:"createInstance",value:function(t,n){return new e(t,n)}}]),Vi()(e,null,[{key:"getHLSLoadingStatusDependencies",value:function(e){return[Fi.loadingHLSStatus(e)]}},{key:"getPendingVideoStatusDependencies",value:function(e){return[hn.pendingVideoTagStatus(e)]}},{key:"getVideoDataDependencies",value:function(e){return[Cn.videoData(e)]}}]),e}();function ms(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function bs(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?ms(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):ms(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Os={READY_EVENT:"ready",PLAY_EVENT:"play",PAUSE_EVENT:"pause",TIME_EVENT:"time",SEEK_EVENT:"seek",COMPLETE_EVENT:"complete",VOLUME_EVENT:"volume",MUTE_EVENT:"mute"},_s=Object.values(Os),Ss={FULLSCREEN_EVENT:"fullscreen",ANCHOR_STATUS_EVENT:"anchorStatusChanged",ANCHOR_CLOSED_EVENT:"anchorClosed"},Es={AD_PLAY_EVENT:"adPlay",AD_PAUSE_EVENT:"adPause",AD_RESUME_EVENT:"adResume",AD_COMPLETE_EVENT:"adComplete",AD_TIME_EVENT:"adTime",AD_MUTE_EVENT:"adMute",AD_SKIPPED_EVENT:"adSkipped",AD_ERROR_EVENT:"adError",AD_BLOCK_EVENT:"adBlock",AD_REQUEST_EVENT:"adRequest",AD_OPPORTUNITY_EVENT:"adOpportunity",AD_IMPRESSION_EVENT:"adImpression"},ws=Object.values(Es),Ps=Object.values(bs(bs(bs({},Os),Es),Ss)),Ts=function(){function e(t,n){var r=this;Ai()(this,e),f()(this,"eventsCallbacksHandler",void 0),f()(this,"store",void 0),f()(this,"videoStatusSubscriber",void 0),f()(this,"videoMuteSubscriber",void 0),f()(this,"videoVolumeSubscriber",void 0),f()(this,"videoTimeFragmentSubscriber",void 0),f()(this,"videoListStoreSubscriber",void 0),f()(this,"previousVideoTagStatus",void 0),f()(this,"startSeekTime",0),f()(this,"canHandleReady",function(e,t,n){if(t===Os.READY_EVENT){var r=Cn.videoList(e);if(Array.isArray(r)&&r.length>0)return n(),!0}return!1}),f()(this,"canBeHandled",function(e,t){var n=r.store.getState;return r.canHandleReady(n(),e,t)}),f()(this,"reportSeekEnd",function(e){var t={position:hn.currentVideoTimeFragment(e),offset:r.startSeekTime};r.eventsCallbacksHandler.onEvent(Os.SEEK_EVENT,t)}),f()(this,"onMuteStateChanged",function(e){var t=gn.muted(e);r.eventsCallbacksHandler.onEvent(Os.MUTE_EVENT,{state:t})}),f()(this,"onVolumeChanged",function(e){var t=gn.muted(e),n=gn.volume(e);r.eventsCallbacksHandler.onEvent(Os.VOLUME_EVENT,{level:t?0:n})}),f()(this,"onVideoTimeFragmentChanged",function(e){var t=hn.currentVideoTimeFragment(e),n=hn.currentVideoDuration(e);r.eventsCallbacksHandler.onEvent(Os.TIME_EVENT,{duration:n,position:t})}),f()(this,"onVideoListChanged",function(){r.eventsCallbacksHandler.onEvent(Os.READY_EVENT)}),this.store=t,this.eventsCallbacksHandler=n,this.videoStatusSubscriber=new ji(t,e.getVideoStatusDependencies,this.onVideoStatusChanged.bind(this)),this.videoMuteSubscriber=new ji(t,e.getVideoMuteDependencies,this.onMuteStateChanged.bind(this)),this.videoVolumeSubscriber=new ji(t,e.getVolumeDependencies,this.onVolumeChanged.bind(this)),this.videoTimeFragmentSubscriber=new ji(t,e.getVideoTimeDependencies,this.onVideoTimeFragmentChanged.bind(this)),this.videoListStoreSubscriber=new ji(t,e.getVideoListDependencies,this.onVideoListChanged.bind(this)),this.previousVideoTagStatus=hn.videoTagStatus(t.getState())}return Vi()(e,[{key:"onVideoStatusChanged",value:function(e){var t=hn.videoTagStatus(e);switch("seeking"===this.previousVideoTagStatus&&this.reportSeekEnd(e),t){case"paused":this.eventsCallbacksHandler.onEvent(Os.PAUSE_EVENT);break;case"seeking":this.startSeekTime=hn.currentVideoTimeFragment(e);break;case"complete":this.eventsCallbacksHandler.onEvent(Os.COMPLETE_EVENT);break;case"playing":this.eventsCallbacksHandler.onEvent(Os.PLAY_EVENT)}this.previousVideoTagStatus=t}}],[{key:"getVideoStatusDependencies",value:function(e){return[hn.videoTagStatus(e)]}}]),e}();f()(Ts,"getVideoMuteDependencies",function(e){return[gn.muted(e)]}),f()(Ts,"getVolumeDependencies",function(e){return[gn.volume(e)]}),f()(Ts,"getVideoTimeDependencies",function(e){return[hn.currentVideoTimeFragment(e)]}),f()(Ts,"getVideoListDependencies",function(e){return[Cn.videoList(e)]}),f()(Ts,"isContentEvent",function(e){return _s.some(function(t){return t===e})});var As=function e(t,n){var r=this;Ai()(this,e),f()(this,"eventsCallbacksHandler",void 0),f()(this,"store",void 0),f()(this,"fullscreenSubscriber",void 0),f()(this,"anchorStatusSubscriber",void 0),f()(this,"anchorDisabledByUserSubscriber",void 0),f()(this,"onFullscreenChanged",function(e){var t=gn.isFullscreenOn(e);r.eventsCallbacksHandler.onEvent(Ss.FULLSCREEN_EVENT,{state:t})}),f()(this,"onAnchorStatusChanged",function(e){var t="active"===Pr(e)?"activated":"deactivated";r.eventsCallbacksHandler.onEvent(Ss.ANCHOR_STATUS_EVENT,{state:t})}),f()(this,"onAnchorDisabledByUser",function(e){if(wr(e)){var t=hn.currentVideoTimeFragment(e);r.eventsCallbacksHandler.onEvent(Ss.ANCHOR_CLOSED_EVENT,{position:t})}}),this.store=t,this.eventsCallbacksHandler=n,this.fullscreenSubscriber=new ji(t,e.getFullscreenDependencies,this.onFullscreenChanged.bind(this)),this.anchorStatusSubscriber=new ji(t,e.getAnchorStatusDependencies,this.onAnchorStatusChanged.bind(this)),this.anchorDisabledByUserSubscriber=new ji(t,e.getAnchorDisabledByUserDependencies,this.onAnchorDisabledByUser.bind(this))};f()(As,"getFullscreenDependencies",function(e){return[gn.isFullscreenOn(e)]}),f()(As,"getAnchorStatusDependencies",function(e){return[Pr(e)]}),f()(As,"getAnchorDisabledByUserDependencies",function(e){return[wr(e)]});var Cs=function(){function e(t,n){var r=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"eventsCallbacksHandler",void 0),f()(this,"adStatusSubscriber",void 0),f()(this,"adImpressionSubscriber",void 0),f()(this,"adOpportunitySubscriber",void 0),f()(this,"adTimeSubscriber",void 0),f()(this,"adMuteSubscriber",void 0),f()(this,"adProviderLoadingStatusSubscriber",void 0),f()(this,"previousAdStatus",void 0),f()(this,"canBeHandled",function(e,t){var n=r.store.getState;switch(Fi.loadingImaStatus(n())){case"loading":return!1;case"success":case"error":return!0;case"blocked":return t(),!0;case"":default:return!1}}),f()(this,"onAdStatusChanged",function(e){var t=_i.adStatus(e),n=_i.currentAdTag(e);switch(t){case"requested":r.eventsCallbacksHandler.onEvent(Es.AD_REQUEST_EVENT,{tag:n});break;case"paused":r.eventsCallbacksHandler.onEvent(Es.AD_PAUSE_EVENT,{tag:n});break;case"completed":r.eventsCallbacksHandler.onEvent(Es.AD_COMPLETE_EVENT,{tag:n});break;case"skipped":r.eventsCallbacksHandler.onEvent(Es.AD_SKIPPED_EVENT,{tag:n});break;case"playing":"paused"===r.previousAdStatus?r.eventsCallbacksHandler.onEvent(Es.AD_RESUME_EVENT,{tag:n}):r.eventsCallbacksHandler.onEvent(Es.AD_PLAY_EVENT,{tag:n});break;case"error":var i=_i.adErrorMessage(e);r.eventsCallbacksHandler.onEvent(Es.AD_ERROR_EVENT,{tag:n,message:i})}r.previousAdStatus=t}),f()(this,"onAtTimeChanged",function(e){var t=_i.adCurrentTime(e),n=_i.currentAdTag(e),i=_i.adDuration(e);r.eventsCallbacksHandler.onEvent(Es.AD_TIME_EVENT,{position:t,tag:n,duration:i})}),f()(this,"onAdMuteChanged",function(e){var t=_i.adMuted(e);r.eventsCallbacksHandler.onEvent(Es.AD_MUTE_EVENT,{state:t})}),f()(this,"onAdProviderLoadingChanged",function(e){"blocked"===Fi.loadingImaStatus(e)&&r.eventsCallbacksHandler.onEvent(Es.AD_BLOCK_EVENT)}),f()(this,"onAdImpressionChanged",function(e){var t=_i.currentAdTag(e);r.eventsCallbacksHandler.onEvent(Es.AD_IMPRESSION_EVENT,{tag:t})}),f()(this,"onAdOpportunityChanged",function(e){var t=_i.currentAdTag(e);r.eventsCallbacksHandler.onEvent(Es.AD_OPPORTUNITY_EVENT,{tag:t})}),this.store=t,this.eventsCallbacksHandler=n,this.previousAdStatus=_i.adStatus(t.getState()),this.adStatusSubscriber=new ji(t,e.getAdStatusDependencies,this.onAdStatusChanged.bind(this)),this.adTimeSubscriber=new ji(t,e.getAdTimeDependencies,this.onAtTimeChanged.bind(this)),this.adMuteSubscriber=new ji(t,e.getAdMuteDependencies,this.onAdMuteChanged.bind(this)),this.adImpressionSubscriber=new ji(t,e.getAdImpressionDependencies,this.onAdImpressionChanged.bind(this)),this.adOpportunitySubscriber=new ji(t,e.getAdOpportunitySubscriberDependencies,this.onAdOpportunityChanged.bind(this)),this.adProviderLoadingStatusSubscriber=new ji(t,e.getAdProviderLoadingDependencies,this.onAdProviderLoadingChanged.bind(this))}return Vi()(e,null,[{key:"getAdStatusDependencies",value:function(e){return[_i.adStatus(e)]}},{key:"getAdTimeDependencies",value:function(e){return[_i.adCurrentTime(e)]}},{key:"getAdMuteDependencies",value:function(e){return[_i.adMuted(e)]}},{key:"getAdProviderLoadingDependencies",value:function(e){return[Fi.loadingImaStatus(e)]}}]),e}();f()(Cs,"isAdEvent",function(e){return ws.some(function(t){return t===e})}),f()(Cs,"getAdImpressionDependencies",function(e){return[_i.adImpression(e)]}),f()(Cs,"getAdOpportunitySubscriberDependencies",function(e){return[_i.adOpportunity(e)]});var Rs=function e(t){var n=this;Ai()(this,e),f()(this,"contentEvents",void 0),f()(this,"generalEvents",void 0),f()(this,"adEvents",void 0),f()(this,"subscribers",{}),f()(this,"onRegisterToEvent",function(e,t,r){n.isValidEvent(e)&&(Ts.isContentEvent(e)&&n.contentEvents.canBeHandled(e,t)||Cs.isAdEvent(e)&&n.adEvents.canBeHandled(e,t())||n.getEventSubscribersList(e).push({callback:t,once:r}))}),f()(this,"isValidEvent",function(e){return Ps.some(function(t){return t===e})}),f()(this,"getEventSubscribersList",function(e){return Array.isArray(n.subscribers[e])||(n.subscribers[e]=[]),n.subscribers[e]}),f()(this,"filterOutOnceCallbacks",function(e,t){n.subscribers[e]=t.filter(function(e){return!e.once})}),f()(this,"onEvent",function(e,t){var r=n.getEventSubscribersList(e);r.forEach(function(e){(0,e.callback)(t)}),n.filterOutOnceCallbacks(e,r)}),this.contentEvents=new Ts(t,this),this.generalEvents=new As(t,this),this.adEvents=new Cs(t,this)},Ds=function(){function e(t){Ai()(this,e),f()(this,"eventsHandler",void 0),this.eventsHandler=new Rs(t)}return Vi()(e,[{key:"on",value:function(e,t){this.eventsHandler.onRegisterToEvent(e,t,!1)}},{key:"once",value:function(e,t){this.eventsHandler.onRegisterToEvent(e,t,!0)}}]),e}();function Ms(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Is(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Ms(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Ms(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var ks=function(){var e=window.monti.dataset;return jn(e)?(e={players:{},preact:Is(Is({},r),i),store:{},plugins:{}},window.monti.dataset=e,e):e},Ns=function(e){var t=function(){var e=(new Date).getTime(),t=performance&&performance.now&&1e3*performance.now()||0;return"xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx".replace(/[xy]/g,function(n){var r=16*Math.random();return e>0?(r=(e+r)%16|0,e=Math.floor(e/16)):(r=(t+r)%16|0,t=Math.floor(t/16)),("x"===n?r:3&r|8).toString(16)})}(),n=function(e,t){var n=ns(e.dev_config),r=ks(),i=n.dispatch;return r.store[t]=n,function(e,t){return function(n){n({type:"[CORE] initiate store",payload:{initiateParams:e,playerInstanceUniqId:t}})}}(e,t)(i),n}(e,t);return function(e,t,n){B(b(Pi,{playerId:t,store:n,playerPosition:e}),e)}(e.player_pos,t,n),oa.getInstance().loadInternalPlugins(n,t,e),ss.createInstance(n,t),vs.createInstance(n,t),is.createInstance(n,e.media_id,e.content_type,e.dev_config),function(e){var t=e.dispatch;if(er(Ci.getInstance().getHLSLoadingStatus())(t),Qn(Ci.getInstance().getIMALoadingStatus())(t),!Ci.getInstance().isDependenciesReady()){var n=new os(e);Ci.getInstance().addDependenciesCallback(n)}}(n),function(e,t){ks().players[t]=new Ds(e)}(n,t),t},Ls=function(e){return console.log("player initiation start",e),new Promise(function(t,n){try{var r=function(e){var t=e.player_pos||document.currentScript.parentElement,n=e.media_id||e.content_id;return cs(cs({},e),{},{player_pos:t,media_id:n})}(function(e){var t=e.player_id,n=ds(t);return null===n?e:cs(cs({},e),n)}(e)),i=Ns(r);!function(e){var t=new CustomEvent("montiConfigLoaded",{detail:{playerKey:e}});window.dispatchEvent(t)}(i),t(i)}catch(o){console.error("Player initiation error",o),n(o)}})},xs=function(){return{initiate:Ls}};window.monti=xs,Ci.getInstance().loadExternalDependencies()}]); window.monti().initiate(Object.assign({player_pos: document.currentScript.parentElement}, {"is_conflicting_with_other_jw_players":false,"programmatic_play_with_sound_on_desktop":false,"referrer_id":"af93e181-b289-0560-a2bf-808e93bb05bc","width":"100","comscore_publisher_id":"18120612","monetization":{"ad_type":"static_tag","continue_content_play_while_waiting_for_ad":false,"strategy":"on_player_load","ad_request_timeout":"10000","midrolls":{"on":[0]},"vpaid_mode":"ENABLED","ad_tag":"https://pubads.g.doubleclick.net/gampad/ads?sz=400x300|640x480|480x270|640x360&iu=/175840252/MMPlus/smithsonianmag/Video&impl=s&gdfp_req=1&env=vp&output=vast&unviewed_position_start=1&url=##REFERRER_URL_UNESC##&description_url=##DESCRIPTION_URL_UNESC##&correlator=##CACHEBUSTER##&cust_params=mm_midroll%3D##MIDROLL_ORDER##%26video_ID%3D##VIDEO_ID##"},"sponsorship":false,"player_identifier":"mplayer","recommendation_id":null,"brand_color":"#FF9900","powered_by_strip":true,"platform":"buffy","type":"video","config_name":"MM+ | Smithsonianmag | Podding","player_id":"3v9g2u2f","playlist_id":"fSkmeWKF","playback_method":"autoplay","anchor_viewability_method":"none","player_version":"v4","playlist_type":"semantic","semantic_options":{"scan_images_on_page":true,"scanned_element":"","tags":"geogrophy,nature,animals,habitat,outdoors,science,history","minimum_date_factor":30,"scanned_element_type":"tag","scoped_keywords":"mentalfloss","promoted_videos":[]},"script_destination":"mm","publisher_contribution":"floor8","general_script_description":"","brand_logo":"","brand_logo_click_url":"","next_video":"none","uniq_key":"af93e181-b289-0560-a2bf-808e93bb05bc","content_id":"fSkmeWKF","content_type":"semantic"})); Finland has vastly improved in reading, math and science literacy over the past decade in large part because its teachers are trusted to do whatever it takes to turn young lives around. This 13-year-old, Besart Kabashi, received something akin to royal tutoring. “I took Besart on that year as my private student,” Louhivuori told me in his office, which boasted a Beatles “Yellow Submarine” poster on the wall and an electric guitar in the closet. When Besart was not studying science, geography and math, he was parked next to Louhivuori’s desk at the front of his class of 9- and 10-year- olds, cracking open books from a tall stack, slowly reading one, then another, then devouring them by the dozens. By the end of the year, the son of Kosovo war refugees had conquered his adopted country’s vowel-rich language and arrived at the realization that he could, in fact, learn. Years later, a 20-year-old Besart showed up at Kirkkojarvi’s Christmas party with a bottle of Cognac and a big grin. “You helped me,” he told his former teacher. Besart had opened his own car repair firm and a cleaning company. “No big fuss,” Louhivuori told me. “This is what we do every day, prepare kids for life.” This tale of a single rescued child hints at some of the reasons for the tiny Nordic nation’s staggering record of education success, a phenomenon that has inspired, baffled and even irked many of America’s parents and educators. Finnish schooling became an unlikely hot topic after the 2010 documentary film Waiting for “Superman” contrasted it with America’s troubled public schools. “Whatever it takes” is an attitude that drives not just Kirkkojarvi’s 30 teachers, but most of Finland’s 62,000 educators in 3,500 schools from Lapland to Turku—professionals selected from the top 10 percent of the nation’s graduates to earn a required master’s degree in education. Many schools are small enough so that teachers know every student. If one method fails, teachers consult with colleagues to try something else. They seem to relish the challenges. Nearly 30 percent of Finland’s children receive some kind of special help during their first nine years of school. The school where Louhivuori teaches served 240 first through ninth graders last year; and in contrast with Finland’s reputation for ethnic homogeneity, more than half of its 150 elementary-level students are immigrants—from Somalia, Iraq, Russia, Bangladesh, Estonia and Ethiopia, among other nations. “Children from wealthy families with lots of education can be taught by stupid teachers,” Louhivuori said, smiling. “We try to catch the weak students. It’s deep in our thinking.” Advertisement scroll for more The transformation of the Finns’ education system began some 40 years ago as the key propellent of the country’s economic recovery plan. Educators had little idea it was so successful until 2000, when the first results from the Programme for International Student Assessment (PISA), a standardized test given to 15-year-olds in more than 40 global venues, revealed Finnish youth to be the best young readers in the world. Three years later, they led in math. By 2006, Finland was first out of 57 countries (and a few cities) in science. In the 2009 PISA scores released last year, the nation came in second in science, third in reading and sixth in math among nearly half a million students worldwide. “I’m still surprised,” said Arjariita Heikkinen, principal of a Helsinki comprehensive school. “I didn’t realize we were that good.” In the United States, which has muddled along in the middle for the past decade, government officials have attempted to introduce marketplace competition into public schools. In recent years, a group of Wall Street financiers and philanthropists such as Bill Gates have put money behind private-sector ideas, such as vouchers, data-driven curriculum and charter schools, which have doubled in number in the past decade. President Obama, too, has apparently bet on compe­tition. His Race to the Top initiative invites states to compete for federal dollars using tests and other methods to measure teachers, a philosophy that would not fly in Finland. “I think, in fact, teachers would tear off their shirts,” said Timo Heikkinen, a Helsinki principal with 24 years of teaching experience. “If you only measure the statistics, you miss the human aspect.”

      The facts show that America has it all wrong in putting to much emphasis on national "data-driven" competition. These approaches take away from the unique aspects of each child.

    2. t was the end of term at Kirkkojarvi Comprehensive School in Espoo, a sprawling suburb west of Helsinki, when Kari Louhivuori, a veteran teacher and the school’s principal, decided to try something extreme—by Finnish standards. One of his sixth-grade students, a Kosovo-Albanian boy, had drifted far off the learning grid, resisting his teacher’s best efforts. The school’s team of special educators—including a social worker, a nurse and a psychologist—convinced Louhivuori that laziness was not to blame. So he decided to hold the boy back a year, a measure so rare in Finland it’s practically obsolete. function dispatchComscoreLoadedEvent(){ let event = new Event('MPlayerComscoreLoaded'); window.dispatchEvent(event); } !function(e){var t={};function n(r){if(t[r])return t[r].exports;var i=t[r]={i:r,l:!1,exports:{}};return e[r].call(i.exports,i,i.exports,n),i.l=!0,i.exports}n.m=e,n.c=t,n.d=function(e,t,r){n.o(e,t)||Object.defineProperty(e,t,{enumerable:!0,get:r})},n.r=function(e){"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},n.t=function(e,t){if(1&t&&(e=n(e)),8&t)return e;if(4&t&&"object"===typeof e&&e&&e.__esModule)return e;var r=Object.create(null);if(n.r(r),Object.defineProperty(r,"default",{enumerable:!0,value:e}),2&t&&"string"!=typeof e)for(var i in e)n.d(r,i,function(t){return e[t]}.bind(null,i));return r},n.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return n.d(t,"a",t),t},n.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},n.p="",n(n.s=68)}([function(e,t){e.exports=function(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}},function(e,t){e.exports=function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}},function(e,t){function n(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}e.exports=function(e,t,r){return t&&n(e.prototype,t),r&&n(e,r),e}},function(e,t){e.exports=function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}},function(e,t,n){e.exports=n(47)},function(e,t){function n(t){return e.exports=n=Object.setPrototypeOf?Object.getPrototypeOf:function(e){return e.__proto__||Object.getPrototypeOf(e)},n(t)}e.exports=n},function(e,t,n){"use strict";var r=n(21),i=Object.prototype.toString;function o(e){return"[object Array]"===i.call(e)}function a(e){return"undefined"===typeof e}function s(e){return null!==e&&"object"===typeof e}function u(e){return"[object Function]"===i.call(e)}function c(e,t){if(null!==e&&"undefined"!==typeof e)if("object"!==typeof e&&(e=[e]),o(e))for(var n=0,r=e.length;n<r;n++)t.call(null,e[n],n,e);else for(var i in e)Object.prototype.hasOwnProperty.call(e,i)&&t.call(null,e[i],i,e)}e.exports={isArray:o,isArrayBuffer:function(e){return"[object ArrayBuffer]"===i.call(e)},isBuffer:function(e){return null!==e&&!a(e)&&null!==e.constructor&&!a(e.constructor)&&"function"===typeof e.constructor.isBuffer&&e.constructor.isBuffer(e)},isFormData:function(e){return"undefined"!==typeof FormData&&e instanceof FormData},isArrayBufferView:function(e){return"undefined"!==typeof ArrayBuffer&&ArrayBuffer.isView?ArrayBuffer.isView(e):e&&e.buffer&&e.buffer instanceof ArrayBuffer},isString:function(e){return"string"===typeof e},isNumber:function(e){return"number"===typeof e},isObject:s,isUndefined:a,isDate:function(e){return"[object Date]"===i.call(e)},isFile:function(e){return"[object File]"===i.call(e)},isBlob:function(e){return"[object Blob]"===i.call(e)},isFunction:u,isStream:function(e){return s(e)&&u(e.pipe)},isURLSearchParams:function(e){return"undefined"!==typeof URLSearchParams&&e instanceof URLSearchParams},isStandardBrowserEnv:function(){return("undefined"===typeof navigator||"ReactNative"!==navigator.product&&"NativeScript"!==navigator.product&&"NS"!==navigator.product)&&"undefined"!==typeof window&&"undefined"!==typeof document},forEach:c,merge:function e(){var t={};function n(n,r){"object"===typeof t[r]&&"object"===typeof n?t[r]=e(t[r],n):t[r]=n}for(var r=0,i=arguments.length;r<i;r++)c(arguments[r],n);return t},deepMerge:function e(){var t={};function n(n,r){"object"===typeof t[r]&&"object"===typeof n?t[r]=e(t[r],n):t[r]="object"===typeof n?e({},n):n}for(var r=0,i=arguments.length;r<i;r++)c(arguments[r],n);return t},extend:function(e,t,n){return c(t,function(t,i){e[i]=n&&"function"===typeof t?r(t,n):t}),e},trim:function(e){return e.replace(/^\s*/,"").replace(/\s*$/,"")}}},function(e,t){function n(e,t,n,r,i,o,a){try{var s=e[o](a),u=s.value}catch(c){return void n(c)}s.done?t(u):Promise.resolve(u).then(r,i)}e.exports=function(e){return function(){var t=this,r=arguments;return new Promise(function(i,o){var a=e.apply(t,r);function s(e){n(a,i,o,s,u,"next",e)}function u(e){n(a,i,o,s,u,"throw",e)}s(void 0)})}}},function(e,t,n){var r=n(48);e.exports=function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function");e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,writable:!0,configurable:!0}}),t&&r(e,t)}},function(e,t,n){var r=n(49),i=n(3);e.exports=function(e,t){return!t||"object"!==r(t)&&"function"!==typeof t?i(e):t}},function(e,t,n){var r=n(42),i=n(43),o=n(18),a=n(44);e.exports=function(e,t){return r(e)||i(e,t)||o(e,t)||a()}},function(e,t,n){var r=n(39),i=n(40),o=n(18),a=n(41);e.exports=function(e){return r(e)||i(e)||o(e)||a()}},function(e,t,n){var r=n(45);e.exports=function(e,t){if(null==e)return{};var n,i,o=r(e,t);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);for(i=0;i<a.length;i++)n=a[i],t.indexOf(n)>=0||Object.prototype.propertyIsEnumerable.call(e,n)&&(o[n]=e[n])}return o}},function(e,t,n){var r=n(50);function i(t,n,o){return"undefined"!==typeof Reflect&&Reflect.get?e.exports=i=Reflect.get:e.exports=i=function(e,t,n){var i=r(e,t);if(i){var o=Object.getOwnPropertyDescriptor(i,t);return o.get?o.get.call(n):o.value}},i(t,n,o||t)}e.exports=i},function(e,t,n){"use strict";e.exports=n(36)},function(e,t,n){"use strict";var r=n(14),i={childContextTypes:!0,contextType:!0,contextTypes:!0,defaultProps:!0,displayName:!0,getDefaultProps:!0,getDerivedStateFromError:!0,getDerivedStateFromProps:!0,mixins:!0,propTypes:!0,type:!0},o={name:!0,length:!0,prototype:!0,caller:!0,callee:!0,arguments:!0,arity:!0},a={$$typeof:!0,compare:!0,defaultProps:!0,displayName:!0,propTypes:!0,type:!0},s={};function u(e){return r.isMemo(e)?a:s[e.$$typeof]||i}s[r.ForwardRef]={$$typeof:!0,render:!0,defaultProps:!0,displayName:!0,propTypes:!0},s[r.Memo]=a;var c=Object.defineProperty,l=Object.getOwnPropertyNames,d=Object.getOwnPropertySymbols,p=Object.getOwnPropertyDescriptor,f=Object.getPrototypeOf,h=Object.prototype;e.exports=function e(t,n,r){if("string"!==typeof n){if(h){var i=f(n);i&&i!==h&&e(t,i,r)}var a=l(n);d&&(a=a.concat(d(n)));for(var s=u(t),y=u(n),g=0;g<a.length;++g){var v=a[g];if(!o[v]&&(!r||!r[v])&&(!y||!y[v])&&(!s||!s[v])){var m=p(n,v);try{c(t,v,m)}catch(b){}}}}return t}},function(e,t,n){"use strict";(function(e,r){var i,o=n(29);i="undefined"!==typeof self?self:"undefined"!==typeof window?window:"undefined"!==typeof e?e:r;var a=Object(o.a)(i);t.a=a}).call(this,n(37),n(38)(e))},function(e,t){e.exports=function(e,t){(null==t||t>e.length)&&(t=e.length);for(var n=0,r=new Array(t);n<t;n++)r[n]=e[n];return r}},function(e,t,n){var r=n(17);e.exports=function(e,t){if(e){if("string"===typeof e)return r(e,t);var n=Object.prototype.toString.call(e).slice(8,-1);return"Object"===n&&e.constructor&&(n=e.constructor.name),"Map"===n||"Set"===n?Array.from(e):"Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n)?r(e,t):void 0}}},function(e,t){var n,r,i=e.exports={};function o(){throw new Error("setTimeout has not been defined")}function a(){throw new Error("clearTimeout has not been defined")}function s(e){if(n===setTimeout)return setTimeout(e,0);if((n===o||!n)&&setTimeout)return n=setTimeout,setTimeout(e,0);try{return n(e,0)}catch(t){try{return n.call(null,e,0)}catch(t){return n.call(this,e,0)}}}!function(){try{n="function"===typeof setTimeout?setTimeout:o}catch(e){n=o}try{r="function"===typeof clearTimeout?clearTimeout:a}catch(e){r=a}}();var u,c=[],l=!1,d=-1;function p(){l&&u&&(l=!1,u.length?c=u.concat(c):d=-1,c.length&&f())}function f(){if(!l){var e=s(p);l=!0;for(var t=c.length;t;){for(u=c,c=[];++d<t;)u&&u[d].run();d=-1,t=c.length}u=null,l=!1,function(e){if(r===clearTimeout)return clearTimeout(e);if((r===a||!r)&&clearTimeout)return r=clearTimeout,clearTimeout(e);try{r(e)}catch(t){try{return r.call(null,e)}catch(t){return r.call(this,e)}}}(e)}}function h(e,t){this.fun=e,this.array=t}function y(){}i.nextTick=function(e){var t=new Array(arguments.length-1);if(arguments.length>1)for(var n=1;n<arguments.length;n++)t[n-1]=arguments[n];c.push(new h(e,t)),1!==c.length||l||s(f)},h.prototype.run=function(){this.fun.apply(null,this.array)},i.title="browser",i.browser=!0,i.env={},i.argv=[],i.version="",i.versions={},i.on=y,i.addListener=y,i.once=y,i.off=y,i.removeListener=y,i.removeAllListeners=y,i.emit=y,i.prependListener=y,i.prependOnceListener=y,i.listeners=function(e){return[]},i.binding=function(e){throw new Error("process.binding is not supported")},i.cwd=function(){return"/"},i.chdir=function(e){throw new Error("process.chdir is not supported")},i.umask=function(){return 0}},function(e,t){!function(){"use strict";if("object"===typeof window)if("IntersectionObserver"in window&&"IntersectionObserverEntry"in window&&"intersectionRatio"in window.IntersectionObserverEntry.prototype)"isIntersecting"in window.IntersectionObserverEntry.prototype||Object.defineProperty(window.IntersectionObserverEntry.prototype,"isIntersecting",{get:function(){return this.intersectionRatio>0}});else{var e=window.document,t=[];r.prototype.THROTTLE_TIMEOUT=100,r.prototype.POLL_INTERVAL=null,r.prototype.USE_MUTATION_OBSERVER=!0,r.prototype.observe=function(e){if(!this._observationTargets.some(function(t){return t.element==e})){if(!e||1!=e.nodeType)throw new Error("target must be an Element");this._registerInstance(),this._observationTargets.push({element:e,entry:null}),this._monitorIntersections(e.ownerDocument),this._checkForIntersections()}},r.prototype.unobserve=function(e){this._observationTargets=this._observationTargets.filter(function(t){return t.element!=e}),this._unmonitorIntersections(e.ownerDocument),0==this._observationTargets.length&&this._unregisterInstance()},r.prototype.disconnect=function(){this._observationTargets=[],this._unmonitorAllIntersections(),this._unregisterInstance()},r.prototype.takeRecords=function(){var e=this._queuedEntries.slice();return this._queuedEntries=[],e},r.prototype._initThresholds=function(e){var t=e||[0];return Array.isArray(t)||(t=[t]),t.sort().filter(function(e,t,n){if("number"!=typeof e||isNaN(e)||e<0||e>1)throw new Error("threshold must be a number between 0 and 1 inclusively");return e!==n[t-1]})},r.prototype._parseRootMargin=function(e){var t=(e||"0px").split(/\s+/).map(function(e){var t=/^(-?\d*\.?\d+)(px|%)$/.exec(e);if(!t)throw new Error("rootMargin must be specified in pixels or percent");return{value:parseFloat(t[1]),unit:t[2]}});return t[1]=t[1]||t[0],t[2]=t[2]||t[0],t[3]=t[3]||t[1],t},r.prototype._monitorIntersections=function(t){var n=t.defaultView;if(n&&-1==this._monitoringDocuments.indexOf(t)){var r=this._checkForIntersections,a=null,s=null;if(this.POLL_INTERVAL?a=n.setInterval(r,this.POLL_INTERVAL):(i(n,"resize",r,!0),i(t,"scroll",r,!0),this.USE_MUTATION_OBSERVER&&"MutationObserver"in n&&(s=new n.MutationObserver(r)).observe(t,{attributes:!0,childList:!0,characterData:!0,subtree:!0})),this._monitoringDocuments.push(t),this._monitoringUnsubscribes.push(function(){var e=t.defaultView;e&&(a&&e.clearInterval(a),o(e,"resize",r,!0)),o(t,"scroll",r,!0),s&&s.disconnect()}),t!=(this.root&&this.root.ownerDocument||e)){var u=d(t);u&&this._monitorIntersections(u.ownerDocument)}}},r.prototype._unmonitorIntersections=function(t){var n=this._monitoringDocuments.indexOf(t);if(-1!=n){var r=this.root&&this.root.ownerDocument||e;if(!this._observationTargets.some(function(e){var n=e.element.ownerDocument;if(n==t)return!0;for(;n&&n!=r;){var i=d(n);if((n=i&&i.ownerDocument)==t)return!0}return!1})){var i=this._monitoringUnsubscribes[n];if(this._monitoringDocuments.splice(n,1),this._monitoringUnsubscribes.splice(n,1),i(),t!=r){var o=d(t);o&&this._unmonitorIntersections(o.ownerDocument)}}}},r.prototype._unmonitorAllIntersections=function(){var e=this._monitoringUnsubscribes.slice(0);this._monitoringDocuments.length=0,this._monitoringUnsubscribes.length=0;for(var t=0;t<e.length;t++)e[t]()},r.prototype._checkForIntersections=function(){var e=this._rootIsInDom(),t=e?this._getRootRect():{top:0,bottom:0,left:0,right:0,width:0,height:0};this._observationTargets.forEach(function(r){var i=r.element,o=s(i),a=this._rootContainsTarget(i),u=r.entry,c=e&&a&&this._computeTargetAndRootIntersection(i,o,t),l=r.entry=new n({time:window.performance&&performance.now&&performance.now(),target:i,boundingClientRect:o,rootBounds:t,intersectionRect:c});u?e&&a?this._hasCrossedThreshold(u,l)&&this._queuedEntries.push(l):u&&u.isIntersecting&&this._queuedEntries.push(l):this._queuedEntries.push(l)},this),this._queuedEntries.length&&this._callback(this.takeRecords(),this)},r.prototype._computeTargetAndRootIntersection=function(t,n,r){if("none"!=window.getComputedStyle(t).display){for(var i=n,o=l(t),c=!1;!c&&o;){var d=null,p=1==o.nodeType?window.getComputedStyle(o):{};if("none"==p.display)return null;if(o==this.root||9==o.nodeType)if(c=!0,o==this.root||o==e)d=r;else{var f=l(o),h=f&&s(f),y=f&&this._computeTargetAndRootIntersection(f,h,r);h&&y?(o=f,d=u(h,y)):(o=null,i=null)}else{var g=o.ownerDocument;o!=g.body&&o!=g.documentElement&&"visible"!=p.overflow&&(d=s(o))}if(d&&(i=a(d,i)),!i)break;o=o&&l(o)}return i}},r.prototype._getRootRect=function(){var t;if(this.root)t=s(this.root);else{var n=e.documentElement,r=e.body;t={top:0,left:0,right:n.clientWidth||r.clientWidth,width:n.clientWidth||r.clientWidth,bottom:n.clientHeight||r.clientHeight,height:n.clientHeight||r.clientHeight}}return this._expandRectByRootMargin(t)},r.prototype._expandRectByRootMargin=function(e){var t=this._rootMarginValues.map(function(t,n){return"px"==t.unit?t.value:t.value*(n%2?e.width:e.height)/100}),n={top:e.top-t[0],right:e.right+t[1],bottom:e.bottom+t[2],left:e.left-t[3]};return n.width=n.right-n.left,n.height=n.bottom-n.top,n},r.prototype._hasCrossedThreshold=function(e,t){var n=e&&e.isIntersecting?e.intersectionRatio||0:-1,r=t.isIntersecting?t.intersectionRatio||0:-1;if(n!==r)for(var i=0;i<this.thresholds.length;i++){var o=this.thresholds[i];if(o==n||o==r||o<n!==o<r)return!0}},r.prototype._rootIsInDom=function(){return!this.root||c(e,this.root)},r.prototype._rootContainsTarget=function(t){return c(this.root||e,t)&&(!this.root||this.root.ownerDocument==t.ownerDocument)},r.prototype._registerInstance=function(){t.indexOf(this)<0&&t.push(this)},r.prototype._unregisterInstance=function(){var e=t.indexOf(this);-1!=e&&t.splice(e,1)},window.IntersectionObserver=r,window.IntersectionObserverEntry=n}function n(e){this.time=e.time,this.target=e.target,this.rootBounds=e.rootBounds,this.boundingClientRect=e.boundingClientRect,this.intersectionRect=e.intersectionRect||{top:0,bottom:0,left:0,right:0,width:0,height:0},this.isIntersecting=!!e.intersectionRect;var t=this.boundingClientRect,n=t.width*t.height,r=this.intersectionRect,i=r.width*r.height;this.intersectionRatio=n?Number((i/n).toFixed(4)):this.isIntersecting?1:0}function r(e,t){var n=t||{};if("function"!=typeof e)throw new Error("callback must be a function");if(n.root&&1!=n.root.nodeType)throw new Error("root must be an Element");this._checkForIntersections=function(e,t){var n=null;return function(){n||(n=setTimeout(function(){e(),n=null},t))}}(this._checkForIntersections.bind(this),this.THROTTLE_TIMEOUT),this._callback=e,this._observationTargets=[],this._queuedEntries=[],this._rootMarginValues=this._parseRootMargin(n.rootMargin),this.thresholds=this._initThresholds(n.threshold),this.root=n.root||null,this.rootMargin=this._rootMarginValues.map(function(e){return e.value+e.unit}).join(" "),this._monitoringDocuments=[],this._monitoringUnsubscribes=[]}function i(e,t,n,r){"function"==typeof e.addEventListener?e.addEventListener(t,n,r||!1):"function"==typeof e.attachEvent&&e.attachEvent("on"+t,n)}function o(e,t,n,r){"function"==typeof e.removeEventListener?e.removeEventListener(t,n,r||!1):"function"==typeof e.detatchEvent&&e.detatchEvent("on"+t,n)}function a(e,t){var n=Math.max(e.top,t.top),r=Math.min(e.bottom,t.bottom),i=Math.max(e.left,t.left),o=Math.min(e.right,t.right),a=o-i,s=r-n;return a>=0&&s>=0&&{top:n,bottom:r,left:i,right:o,width:a,height:s}||null}function s(e){var t;try{t=e.getBoundingClientRect()}catch(n){}return t?(t.width&&t.height||(t={top:t.top,right:t.right,bottom:t.bottom,left:t.left,width:t.right-t.left,height:t.bottom-t.top}),t):{top:0,bottom:0,left:0,right:0,width:0,height:0}}function u(e,t){var n=t.top-e.top,r=t.left-e.left;return{top:n,left:r,height:t.height,width:t.width,bottom:n+t.height,right:r+t.width}}function c(e,t){for(var n=t;n;){if(n==e)return!0;n=l(n)}return!1}function l(t){var n=t.parentNode;return 9==t.nodeType&&t!=e?d(t):n&&11==n.nodeType&&n.host?n.host:n&&n.assignedSlot?n.assignedSlot.parentNode:n}function d(e){try{return e.defaultView&&e.defaultView.frameElement||null}catch(t){return null}}}()},function(e,t,n){"use strict";e.exports=function(e,t){return function(){for(var n=new Array(arguments.length),r=0;r<n.length;r++)n[r]=arguments[r];return e.apply(t,n)}}},function(e,t,n){"use strict";var r=n(6);function i(e){return encodeURIComponent(e).replace(/%40/gi,"@").replace(/%3A/gi,":").replace(/%24/g,"$").replace(/%2C/gi,",").replace(/%20/g,"+").replace(/%5B/gi,"[").replace(/%5D/gi,"]")}e.exports=function(e,t,n){if(!t)return e;var o;if(n)o=n(t);else if(r.isURLSearchParams(t))o=t.toString();else{var a=[];r.forEach(t,function(e,t){null!==e&&"undefined"!==typeof e&&(r.isArray(e)?t+="[]":e=[e],r.forEach(e,function(e){r.isDate(e)?e=e.toISOString():r.isObject(e)&&(e=JSON.stringify(e)),a.push(i(t)+"="+i(e))}))}),o=a.join("&")}if(o){var s=e.indexOf("#");-1!==s&&(e=e.slice(0,s)),e+=(-1===e.indexOf("?")?"?":"&")+o}return e}},function(e,t,n){"use strict";e.exports=function(e){return!(!e||!e.__CANCEL__)}},function(e,t,n){"use strict";(function(t){var r=n(6),i=n(57),o={"Content-Type":"application/x-www-form-urlencoded"};function a(e,t){!r.isUndefined(e)&&r.isUndefined(e["Content-Type"])&&(e["Content-Type"]=t)}var s={adapter:function(){var e;return"undefined"!==typeof XMLHttpRequest?e=n(25):"undefined"!==typeof t&&"[object process]"===Object.prototype.toString.call(t)&&(e=n(25)),e}(),transformRequest:[function(e,t){return i(t,"Accept"),i(t,"Content-Type"),r.isFormData(e)||r.isArrayBuffer(e)||r.isBuffer(e)||r.isStream(e)||r.isFile(e)||r.isBlob(e)?e:r.isArrayBufferView(e)?e.buffer:r.isURLSearchParams(e)?(a(t,"application/x-www-form-urlencoded;charset=utf-8"),e.toString()):r.isObject(e)?(a(t,"application/json;charset=utf-8"),JSON.stringify(e)):e}],transformResponse:[function(e){if("string"===typeof e)try{e=JSON.parse(e)}catch(t){}return e}],timeout:0,xsrfCookieName:"XSRF-TOKEN",xsrfHeaderName:"X-XSRF-TOKEN",maxContentLength:-1,validateStatus:function(e){return e>=200&&e<300},headers:{common:{Accept:"application/json, text/plain, */*"}}};r.forEach(["delete","get","head"],function(e){s.headers[e]={}}),r.forEach(["post","put","patch"],function(e){s.headers[e]=r.merge(o)}),e.exports=s}).call(this,n(19))},function(e,t,n){"use strict";var r=n(6),i=n(58),o=n(22),a=n(60),s=n(63),u=n(64),c=n(26);e.exports=function(e){return new Promise(function(t,l){var d=e.data,p=e.headers;r.isFormData(d)&&delete p["Content-Type"];var f=new XMLHttpRequest;if(e.auth){var h=e.auth.username||"",y=e.auth.password||"";p.Authorization="Basic "+btoa(h+":"+y)}var g=a(e.baseURL,e.url);if(f.open(e.method.toUpperCase(),o(g,e.params,e.paramsSerializer),!0),f.timeout=e.timeout,f.onreadystatechange=function(){if(f&&4===f.readyState&&(0!==f.status||f.responseURL&&0===f.responseURL.indexOf("file:"))){var n="getAllResponseHeaders"in f?s(f.getAllResponseHeaders()):null,r={data:e.responseType&&"text"!==e.responseType?f.response:f.responseText,status:f.status,statusText:f.statusText,headers:n,config:e,request:f};i(t,l,r),f=null}},f.onabort=function(){f&&(l(c("Request aborted",e,"ECONNABORTED",f)),f=null)},f.onerror=function(){l(c("Network Error",e,null,f)),f=null},f.ontimeout=function(){var t="timeout of "+e.timeout+"ms exceeded";e.timeoutErrorMessage&&(t=e.timeoutErrorMessage),l(c(t,e,"ECONNABORTED",f)),f=null},r.isStandardBrowserEnv()){var v=n(65),m=(e.withCredentials||u(g))&&e.xsrfCookieName?v.read(e.xsrfCookieName):void 0;m&&(p[e.xsrfHeaderName]=m)}if("setRequestHeader"in f&&r.forEach(p,function(e,t){"undefined"===typeof d&&"content-type"===t.toLowerCase()?delete p[t]:f.setRequestHeader(t,e)}),r.isUndefined(e.withCredentials)||(f.withCredentials=!!e.withCredentials),e.responseType)try{f.responseType=e.responseType}catch(b){if("json"!==e.responseType)throw b}"function"===typeof e.onDownloadProgress&&f.addEventListener("progress",e.onDownloadProgress),"function"===typeof e.onUploadProgress&&f.upload&&f.upload.addEventListener("progress",e.onUploadProgress),e.cancelToken&&e.cancelToken.promise.then(function(e){f&&(f.abort(),l(e),f=null)}),void 0===d&&(d=null),f.send(d)})}},function(e,t,n){"use strict";var r=n(59);e.exports=function(e,t,n,i,o){var a=new Error(e);return r(a,t,n,i,o)}},function(e,t,n){"use strict";var r=n(6);e.exports=function(e,t){t=t||{};var n={},i=["url","method","params","data"],o=["headers","auth","proxy"],a=["baseURL","url","transformRequest","transformResponse","paramsSerializer","timeout","withCredentials","adapter","responseType","xsrfCookieName","xsrfHeaderName","onUploadProgress","onDownloadProgress","maxContentLength","validateStatus","maxRedirects","httpAgent","httpsAgent","cancelToken","socketPath"];r.forEach(i,function(e){"undefined"!==typeof t[e]&&(n[e]=t[e])}),r.forEach(o,function(i){r.isObject(t[i])?n[i]=r.deepMerge(e[i],t[i]):"undefined"!==typeof t[i]?n[i]=t[i]:r.isObject(e[i])?n[i]=r.deepMerge(e[i]):"undefined"!==typeof e[i]&&(n[i]=e[i])}),r.forEach(a,function(r){"undefined"!==typeof t[r]?n[r]=t[r]:"undefined"!==typeof e[r]&&(n[r]=e[r])});var s=i.concat(o).concat(a),u=Object.keys(t).filter(function(e){return-1===s.indexOf(e)});return r.forEach(u,function(r){"undefined"!==typeof t[r]?n[r]=t[r]:"undefined"!==typeof e[r]&&(n[r]=e[r])}),n}},function(e,t,n){"use strict";function r(e){this.message=e}r.prototype.toString=function(){return"Cancel"+(this.message?": "+this.message:"")},r.prototype.__CANCEL__=!0,e.exports=r},function(e,t,n){"use strict";function r(e){var t,n=e.Symbol;return"function"===typeof n?n.observable?t=n.observable:(t=n("observable"),n.observable=t):t="@@observable",t}n.d(t,"a",function(){return r})},function(e,t,n){"use strict";(function(e){n.d(t,"a",function(){return f});var r=function(){for(var e=0,t=0,n=arguments.length;t<n;t++)e+=arguments[t].length;var r=Array(e),i=0;for(t=0;t<n;t++)for(var o=arguments[t],a=0,s=o.length;a<s;a++,i++)r[i]=o[a];return r},i=function(){return function(e,t,n){this.name=e,this.version=t,this.os=n,this.type="browser"}}(),o=function(){return function(t){this.version=t,this.type="node",this.name="node",this.os=e.platform}}(),a=function(){return function(e,t,n,r){this.name=e,this.version=t,this.os=n,this.bot=r,this.type="bot-device"}}(),s=function(){return function(){this.type="bot",this.bot=!0,this.name="bot",this.version=null,this.os=null}}(),u=function(){return function(){this.type="react-native",this.name="react-native",this.version=null,this.os=null}}(),c=/(nuhk|Googlebot|Yammybot|Openbot|Slurp|MSNBot|Ask\ Jeeves\/Teoma|ia_archiver)/,l=3,d=[["aol",/AOLShield\/([0-9\._]+)/],["edge",/Edge\/([0-9\._]+)/],["edge-ios",/EdgiOS\/([0-9\._]+)/],["yandexbrowser",/YaBrowser\/([0-9\._]+)/],["kakaotalk",/KAKAOTALK\s([0-9\.]+)/],["samsung",/SamsungBrowser\/([0-9\.]+)/],["silk",/\bSilk\/([0-9._-]+)\b/],["miui",/MiuiBrowser\/([0-9\.]+)$/],["beaker",/BeakerBrowser\/([0-9\.]+)/],["edge-chromium",/Edg\/([0-9\.]+)/],["chromium-webview",/(?!Chrom.*OPR)wv\).*Chrom(?:e|ium)\/([0-9\.]+)(:?\s|$)/],["chrome",/(?!Chrom.*OPR)Chrom(?:e|ium)\/([0-9\.]+)(:?\s|$)/],["phantomjs",/PhantomJS\/([0-9\.]+)(:?\s|$)/],["crios",/CriOS\/([0-9\.]+)(:?\s|$)/],["firefox",/Firefox\/([0-9\.]+)(?:\s|$)/],["fxios",/FxiOS\/([0-9\.]+)/],["opera-mini",/Opera Mini.*Version\/([0-9\.]+)/],["opera",/Opera\/([0-9\.]+)(?:\s|$)/],["opera",/OPR\/([0-9\.]+)(:?\s|$)/],["ie",/Trident\/7\.0.*rv\:([0-9\.]+).*\).*Gecko$/],["ie",/MSIE\s([0-9\.]+);.*Trident\/[4-7].0/],["ie",/MSIE\s(7\.0)/],["bb10",/BB10;\sTouch.*Version\/([0-9\.]+)/],["android",/Android\s([0-9\.]+)/],["ios",/Version\/([0-9\._]+).*Mobile.*Safari.*/],["safari",/Version\/([0-9\._]+).*Safari/],["facebook",/FBAV\/([0-9\.]+)/],["instagram",/Instagram\s([0-9\.]+)/],["ios-webview",/AppleWebKit\/([0-9\.]+).*Mobile/],["ios-webview",/AppleWebKit\/([0-9\.]+).*Gecko\)$/],["searchbot",/alexa|bot|crawl(er|ing)|facebookexternalhit|feedburner|google web preview|nagios|postrank|pingdom|slurp|spider|yahoo!|yandex/]],p=[["iOS",/iP(hone|od|ad)/],["Android OS",/Android/],["BlackBerry OS",/BlackBerry|BB10/],["Windows Mobile",/IEMobile/],["Amazon OS",/Kindle/],["Windows 3.11",/Win16/],["Windows 95",/(Windows 95)|(Win95)|(Windows_95)/],["Windows 98",/(Windows 98)|(Win98)/],["Windows 2000",/(Windows NT 5.0)|(Windows 2000)/],["Windows XP",/(Windows NT 5.1)|(Windows XP)/],["Windows Server 2003",/(Windows NT 5.2)/],["Windows Vista",/(Windows NT 6.0)/],["Windows 7",/(Windows NT 6.1)/],["Windows 8",/(Windows NT 6.2)/],["Windows 8.1",/(Windows NT 6.3)/],["Windows 10",/(Windows NT 10.0)/],["Windows ME",/Windows ME/],["Open BSD",/OpenBSD/],["Sun OS",/SunOS/],["Chrome OS",/CrOS/],["Linux",/(Linux)|(X11)/],["Mac OS",/(Mac_PowerPC)|(Macintosh)/],["QNX",/QNX/],["BeOS",/BeOS/],["OS/2",/OS\/2/]];function f(t){return t?y(t):"undefined"===typeof document&&"undefined"!==typeof navigator&&"ReactNative"===navigator.product?new u:"undefined"!==typeof navigator?y(navigator.userAgent):"undefined"!==typeof e&&e.version?new o(e.version.slice(1)):null}function h(e){return""!==e&&d.reduce(function(t,n){var r=n[0],i=n[1];if(t)return t;var o=i.exec(e);return!!o&&[r,o]},!1)}function y(e){var t=h(e);if(!t)return null;var n=t[0],o=t[1];if("searchbot"===n)return new s;var u=o[1]&&o[1].split(/[._]/).slice(0,3);u?u.length<l&&(u=r(u,function(e){for(var t=[],n=0;n<e;n++)t.push("0");return t}(l-u.length))):u=[];var d=u.join("."),f=function(e){for(var t=0,n=p.length;t<n;t++){var r=p[t],i=r[0],o=r[1],a=o.exec(e);if(a)return i}return null}(e),y=c.exec(e);return y&&y[1]?new a(n,d,f,y[1]):new i(n,d,f)}}).call(this,n(19))},function(e,t){function n(){return e.exports=n=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},n.apply(this,arguments)}e.exports=n},function(e,t,n){e.exports=n(52)},function(e,t,n){e.exports=n(34)()},function(e,t,n){"use strict";var r=n(35);function i(){}function o(){}o.resetWarningCache=i,e.exports=function(){function e(e,t,n,i,o,a){if(a!==r){var s=new Error("Calling PropTypes validators directly is not supported by the `prop-types` package. Use PropTypes.checkPropTypes() to call them. Read more at http://fb.me/use-check-prop-types");throw s.name="Invariant Violation",s}}function t(){return e}e.isRequired=e;var n={array:e,bool:e,func:e,number:e,object:e,string:e,symbol:e,any:e,arrayOf:t,element:e,elementType:e,instanceOf:t,node:e,objectOf:t,oneOf:t,oneOfType:t,shape:t,exact:t,checkPropTypes:o,resetWarningCache:i};return n.PropTypes=n,n}},function(e,t,n){"use strict";e.exports="SECRET_DO_NOT_PASS_THIS_OR_YOU_WILL_BE_FIRED"},function(e,t,n){"use strict";var r="function"===typeof Symbol&&Symbol.for,i=r?Symbol.for("react.element"):60103,o=r?Symbol.for("react.portal"):60106,a=r?Symbol.for("react.fragment"):60107,s=r?Symbol.for("react.strict_mode"):60108,u=r?Symbol.for("react.profiler"):60114,c=r?Symbol.for("react.provider"):60109,l=r?Symbol.for("react.context"):60110,d=r?Symbol.for("react.async_mode"):60111,p=r?Symbol.for("react.concurrent_mode"):60111,f=r?Symbol.for("react.forward_ref"):60112,h=r?Symbol.for("react.suspense"):60113,y=r?Symbol.for("react.suspense_list"):60120,g=r?Symbol.for("react.memo"):60115,v=r?Symbol.for("react.lazy"):60116,m=r?Symbol.for("react.block"):60121,b=r?Symbol.for("react.fundamental"):60117,O=r?Symbol.for("react.responder"):60118,_=r?Symbol.for("react.scope"):60119;function S(e){if("object"===typeof e&&null!==e){var t=e.$$typeof;switch(t){case i:switch(e=e.type){case d:case p:case a:case u:case s:case h:return e;default:switch(e=e&&e.$$typeof){case l:case f:case v:case g:case c:return e;default:return t}}case o:return t}}}function E(e){return S(e)===p}t.AsyncMode=d,t.ConcurrentMode=p,t.ContextConsumer=l,t.ContextProvider=c,t.Element=i,t.ForwardRef=f,t.Fragment=a,t.Lazy=v,t.Memo=g,t.Portal=o,t.Profiler=u,t.StrictMode=s,t.Suspense=h,t.isAsyncMode=function(e){return E(e)||S(e)===d},t.isConcurrentMode=E,t.isContextConsumer=function(e){return S(e)===l},t.isContextProvider=function(e){return S(e)===c},t.isElement=function(e){return"object"===typeof e&&null!==e&&e.$$typeof===i},t.isForwardRef=function(e){return S(e)===f},t.isFragment=function(e){return S(e)===a},t.isLazy=function(e){return S(e)===v},t.isMemo=function(e){return S(e)===g},t.isPortal=function(e){return S(e)===o},t.isProfiler=function(e){return S(e)===u},t.isStrictMode=function(e){return S(e)===s},t.isSuspense=function(e){return S(e)===h},t.isValidElementType=function(e){return"string"===typeof e||"function"===typeof e||e===a||e===p||e===u||e===s||e===h||e===y||"object"===typeof e&&null!==e&&(e.$$typeof===v||e.$$typeof===g||e.$$typeof===c||e.$$typeof===l||e.$$typeof===f||e.$$typeof===b||e.$$typeof===O||e.$$typeof===_||e.$$typeof===m)},t.typeOf=S},function(e,t){var n;n=function(){return this}();try{n=n||new Function("return this")()}catch(r){"object"===typeof window&&(n=window)}e.exports=n},function(e,t){e.exports=function(e){if(!e.webpackPolyfill){var t=Object.create(e);t.children||(t.children=[]),Object.defineProperty(t,"loaded",{enumerable:!0,get:function(){return t.l}}),Object.defineProperty(t,"id",{enumerable:!0,get:function(){return t.i}}),Object.defineProperty(t,"exports",{enumerable:!0}),t.webpackPolyfill=1}return t}},function(e,t,n){var r=n(17);e.exports=function(e){if(Array.isArray(e))return r(e)}},function(e,t){e.exports=function(e){if("undefined"!==typeof Symbol&&Symbol.iterator in Object(e))return Array.from(e)}},function(e,t){e.exports=function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}},function(e,t){e.exports=function(e){if(Array.isArray(e))return e}},function(e,t){e.exports=function(e,t){if("undefined"!==typeof Symbol&&Symbol.iterator in Object(e)){var n=[],r=!0,i=!1,o=void 0;try{for(var a,s=e[Symbol.iterator]();!(r=(a=s.next()).done)&&(n.push(a.value),!t||n.length!==t);r=!0);}catch(u){i=!0,o=u}finally{try{r||null==s.return||s.return()}finally{if(i)throw o}}return n}}},function(e,t){e.exports=function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}},function(e,t){e.exports=function(e,t){if(null==e)return{};var n,r,i={},o=Object.keys(e);for(r=0;r<o.length;r++)n=o[r],t.indexOf(n)>=0||(i[n]=e[n]);return i}},function(e,t){},function(e,t,n){var r=function(e){"use strict";var t,n=Object.prototype,r=n.hasOwnProperty,i="function"===typeof Symbol?Symbol:{},o=i.iterator||"@@iterator",a=i.asyncIterator||"@@asyncIterator",s=i.toStringTag||"@@toStringTag";function u(e,t,n){return Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}),e[t]}try{u({},"")}catch(M){u=function(e,t,n){return e[t]=n}}function c(e,t,n,r){var i=t&&t.prototype instanceof g?t:g,o=Object.create(i.prototype),a=new C(r||[]);return o._invoke=function(e,t,n){var r=d;return function(i,o){if(r===f)throw new Error("Generator is already running");if(r===h){if("throw"===i)throw o;return D()}for(n.method=i,n.arg=o;;){var a=n.delegate;if(a){var s=P(a,n);if(s){if(s===y)continue;return s}}if("next"===n.method)n.sent=n._sent=n.arg;else if("throw"===n.method){if(r===d)throw r=h,n.arg;n.dispatchException(n.arg)}else"return"===n.method&&n.abrupt("return",n.arg);r=f;var u=l(e,t,n);if("normal"===u.type){if(r=n.done?h:p,u.arg===y)continue;return{value:u.arg,done:n.done}}"throw"===u.type&&(r=h,n.method="throw",n.arg=u.arg)}}}(e,n,a),o}function l(e,t,n){try{return{type:"normal",arg:e.call(t,n)}}catch(M){return{type:"throw",arg:M}}}e.wrap=c;var d="suspendedStart",p="suspendedYield",f="executing",h="completed",y={};function g(){}function v(){}function m(){}var b={};b[o]=function(){return this};var O=Object.getPrototypeOf,_=O&&O(O(R([])));_&&_!==n&&r.call(_,o)&&(b=_);var S=m.prototype=g.prototype=Object.create(b);function E(e){["next","throw","return"].forEach(function(t){u(e,t,function(e){return this._invoke(t,e)})})}function w(e,t){var n;this._invoke=function(i,o){function a(){return new t(function(n,a){!function n(i,o,a,s){var u=l(e[i],e,o);if("throw"!==u.type){var c=u.arg,d=c.value;return d&&"object"===typeof d&&r.call(d,"__await")?t.resolve(d.__await).then(function(e){n("next",e,a,s)},function(e){n("throw",e,a,s)}):t.resolve(d).then(function(e){c.value=e,a(c)},function(e){return n("throw",e,a,s)})}s(u.arg)}(i,o,n,a)})}return n=n?n.then(a,a):a()}}function P(e,n){var r=e.iterator[n.method];if(r===t){if(n.delegate=null,"throw"===n.method){if(e.iterator.return&&(n.method="return",n.arg=t,P(e,n),"throw"===n.method))return y;n.method="throw",n.arg=new TypeError("The iterator does not provide a 'throw' method")}return y}var i=l(r,e.iterator,n.arg);if("throw"===i.type)return n.method="throw",n.arg=i.arg,n.delegate=null,y;var o=i.arg;return o?o.done?(n[e.resultName]=o.value,n.next=e.nextLoc,"return"!==n.method&&(n.method="next",n.arg=t),n.delegate=null,y):o:(n.method="throw",n.arg=new TypeError("iterator result is not an object"),n.delegate=null,y)}function T(e){var t={tryLoc:e[0]};1 in e&&(t.catchLoc=e[1]),2 in e&&(t.finallyLoc=e[2],t.afterLoc=e[3]),this.tryEntries.push(t)}function A(e){var t=e.completion||{};t.type="normal",delete t.arg,e.completion=t}function C(e){this.tryEntries=[{tryLoc:"root"}],e.forEach(T,this),this.reset(!0)}function R(e){if(e){var n=e[o];if(n)return n.call(e);if("function"===typeof e.next)return e;if(!isNaN(e.length)){var i=-1,a=function n(){for(;++i<e.length;)if(r.call(e,i))return n.value=e[i],n.done=!1,n;return n.value=t,n.done=!0,n};return a.next=a}}return{next:D}}function D(){return{value:t,done:!0}}return v.prototype=S.constructor=m,m.constructor=v,v.displayName=u(m,s,"GeneratorFunction"),e.isGeneratorFunction=function(e){var t="function"===typeof e&&e.constructor;return!!t&&(t===v||"GeneratorFunction"===(t.displayName||t.name))},e.mark=function(e){return Object.setPrototypeOf?Object.setPrototypeOf(e,m):(e.__proto__=m,u(e,s,"GeneratorFunction")),e.prototype=Object.create(S),e},e.awrap=function(e){return{__await:e}},E(w.prototype),w.prototype[a]=function(){return this},e.AsyncIterator=w,e.async=function(t,n,r,i,o){void 0===o&&(o=Promise);var a=new w(c(t,n,r,i),o);return e.isGeneratorFunction(n)?a:a.next().then(function(e){return e.done?e.value:a.next()})},E(S),u(S,s,"Generator"),S[o]=function(){return this},S.toString=function(){return"[object Generator]"},e.keys=function(e){var t=[];for(var n in e)t.push(n);return t.reverse(),function n(){for(;t.length;){var r=t.pop();if(r in e)return n.value=r,n.done=!1,n}return n.done=!0,n}},e.values=R,C.prototype={constructor:C,reset:function(e){if(this.prev=0,this.next=0,this.sent=this._sent=t,this.done=!1,this.delegate=null,this.method="next",this.arg=t,this.tryEntries.forEach(A),!e)for(var n in this)"t"===n.charAt(0)&&r.call(this,n)&&!isNaN(+n.slice(1))&&(this[n]=t)},stop:function(){this.done=!0;var e=this.tryEntries[0].completion;if("throw"===e.type)throw e.arg;return this.rval},dispatchException:function(e){if(this.done)throw e;var n=this;function i(r,i){return s.type="throw",s.arg=e,n.next=r,i&&(n.method="next",n.arg=t),!!i}for(var o=this.tryEntries.length-1;o>=0;--o){var a=this.tryEntries[o],s=a.completion;if("root"===a.tryLoc)return i("end");if(a.tryLoc<=this.prev){var u=r.call(a,"catchLoc"),c=r.call(a,"finallyLoc");if(u&&c){if(this.prev<a.catchLoc)return i(a.catchLoc,!0);if(this.prev<a.finallyLoc)return i(a.finallyLoc)}else if(u){if(this.prev<a.catchLoc)return i(a.catchLoc,!0)}else{if(!c)throw new Error("try statement without catch or finally");if(this.prev<a.finallyLoc)return i(a.finallyLoc)}}}},abrupt:function(e,t){for(var n=this.tryEntries.length-1;n>=0;--n){var i=this.tryEntries[n];if(i.tryLoc<=this.prev&&r.call(i,"finallyLoc")&&this.prev<i.finallyLoc){var o=i;break}}o&&("break"===e||"continue"===e)&&o.tryLoc<=t&&t<=o.finallyLoc&&(o=null);var a=o?o.completion:{};return a.type=e,a.arg=t,o?(this.method="next",this.next=o.finallyLoc,y):this.complete(a)},complete:function(e,t){if("throw"===e.type)throw e.arg;return"break"===e.type||"continue"===e.type?this.next=e.arg:"return"===e.type?(this.rval=this.arg=e.arg,this.method="return",this.next="end"):"normal"===e.type&&t&&(this.next=t),y},finish:function(e){for(var t=this.tryEntries.length-1;t>=0;--t){var n=this.tryEntries[t];if(n.finallyLoc===e)return this.complete(n.completion,n.afterLoc),A(n),y}},catch:function(e){for(var t=this.tryEntries.length-1;t>=0;--t){var n=this.tryEntries[t];if(n.tryLoc===e){var r=n.completion;if("throw"===r.type){var i=r.arg;A(n)}return i}}throw new Error("illegal catch attempt")},delegateYield:function(e,n,r){return this.delegate={iterator:R(e),resultName:n,nextLoc:r},"next"===this.method&&(this.arg=t),y}},e}(e.exports);try{regeneratorRuntime=r}catch(i){Function("r","regeneratorRuntime = r")(r)}},function(e,t){function n(t,r){return e.exports=n=Object.setPrototypeOf||function(e,t){return e.__proto__=t,e},n(t,r)}e.exports=n},function(e,t){function n(t){return"function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?e.exports=n=function(e){return typeof e}:e.exports=n=function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},n(t)}e.exports=n},function(e,t,n){var r=n(5);e.exports=function(e,t){for(;!Object.prototype.hasOwnProperty.call(e,t)&&null!==(e=r(e)););return e}},function(e){e.exports=JSON.parse('{"name":"mplayer","version":"4.0.13","description":"minute media player","author":"minute media","private":true,"scripts":{"start":"yarn compile && PORT=2001 per-env","start:production":"npm run -s serve","start:development":"npm run -s dev","build":"preact build --no-prerender","serve":"preact build && serve build --single","dev":"preact watch","lint":"./node_modules/.bin/eslint --cache --ext .js,.ts,.tsx ./src/.","test":"jest","compile":"webpack","compile:production":"NODE_ENV=production webpack","compile:qa":"NODE_ENV=qa webpack"},"devDependencies":{"@babel/cli":"^7.8.4","@babel/core":"^7.8.4","@babel/plugin-proposal-class-properties":"^7.8.3","@babel/plugin-transform-react-jsx":"^7.8.3","@babel/plugin-transform-runtime":"^7.9.0","@babel/preset-env":"^7.8.4","@babel/preset-react":"^7.8.3","@babel/preset-typescript":"^7.8.3","@typescript-eslint/eslint-plugin":"^2.10.0","@typescript-eslint/parser":"^2.10.0","eslint":"^6.7.2","eslint-config-mm":"git+https://github.com/FTBpro/eslint-config-mm.git#v3.1","eslint-loader":"3.0.2","identity-obj-proxy":"^3.0.0","jest":"^24.9.0","jest-emotion":"^10.0.32","jest-preset-preact":"^1.0.0","per-env":"^1.0.2","preact-cli":"^3.0.0-rc.6","react":"^16.13.1","react-dom":"^16.13.1","serve":"^11.1.0"},"dependencies":{"@emotion/core":"^10.0.28","axios":"^0.19.2","babel-loader":"^8.0.6","detect-browser":"^5.1.0","emotion":"^10.0.27","enzyme":"^3.11.0","enzyme-adapter-preact-pure":"^2.2.0","hls.js":"^0.13.2","intersection-observer":"^0.8.0","jest-enzyme":"^7.1.2","jest-junit":"^10.0.0","preact":"^10.0.1","preact-render-to-string":"^5.1.8","react-redux":"^7.2.0","react-svg-loader":"^3.0.3","redux":"^4.0.5","redux-thunk":"^2.3.0","terser-webpack-plugin":"1.2.3","webpack":"^4.41.6","webpack-cli":"^3.3.11"}}')},function(e,t,n){"use strict";var r=n(6),i=n(21),o=n(53),a=n(27);function s(e){var t=new o(e),n=i(o.prototype.request,t);return r.extend(n,o.prototype,t),r.extend(n,t),n}var u=s(n(24));u.Axios=o,u.create=function(e){return s(a(u.defaults,e))},u.Cancel=n(28),u.CancelToken=n(66),u.isCancel=n(23),u.all=function(e){return Promise.all(e)},u.spread=n(67),e.exports=u,e.exports.default=u},function(e,t,n){"use strict";var r=n(6),i=n(22),o=n(54),a=n(55),s=n(27);function u(e){this.defaults=e,this.interceptors={request:new o,response:new o}}u.prototype.request=function(e){"string"===typeof e?(e=arguments[1]||{}).url=arguments[0]:e=e||{},(e=s(this.defaults,e)).method?e.method=e.method.toLowerCase():this.defaults.method?e.method=this.defaults.method.toLowerCase():e.method="get";var t=[a,void 0],n=Promise.resolve(e);for(this.interceptors.request.forEach(function(e){t.unshift(e.fulfilled,e.rejected)}),this.interceptors.response.forEach(function(e){t.push(e.fulfilled,e.rejected)});t.length;)n=n.then(t.shift(),t.shift());return n},u.prototype.getUri=function(e){return e=s(this.defaults,e),i(e.url,e.params,e.paramsSerializer).replace(/^\?/,"")},r.forEach(["delete","get","head","options"],function(e){u.prototype[e]=function(t,n){return this.request(r.merge(n||{},{method:e,url:t}))}}),r.forEach(["post","put","patch"],function(e){u.prototype[e]=function(t,n,i){return this.request(r.merge(i||{},{method:e,url:t,data:n}))}}),e.exports=u},function(e,t,n){"use strict";var r=n(6);function i(){this.handlers=[]}i.prototype.use=function(e,t){return this.handlers.push({fulfilled:e,rejected:t}),this.handlers.length-1},i.prototype.eject=function(e){this.handlers[e]&&(this.handlers[e]=null)},i.prototype.forEach=function(e){r.forEach(this.handlers,function(t){null!==t&&e(t)})},e.exports=i},function(e,t,n){"use strict";var r=n(6),i=n(56),o=n(23),a=n(24);function s(e){e.cancelToken&&e.cancelToken.throwIfRequested()}e.exports=function(e){return s(e),e.headers=e.headers||{},e.data=i(e.data,e.headers,e.transformRequest),e.headers=r.merge(e.headers.common||{},e.headers[e.method]||{},e.headers),r.forEach(["delete","get","head","post","put","patch","common"],function(t){delete e.headers[t]}),(e.adapter||a.adapter)(e).then(function(t){return s(e),t.data=i(t.data,t.headers,e.transformResponse),t},function(t){return o(t)||(s(e),t&&t.response&&(t.response.data=i(t.response.data,t.response.headers,e.transformResponse))),Promise.reject(t)})}},function(e,t,n){"use strict";var r=n(6);e.exports=function(e,t,n){return r.forEach(n,function(n){e=n(e,t)}),e}},function(e,t,n){"use strict";var r=n(6);e.exports=function(e,t){r.forEach(e,function(n,r){r!==t&&r.toUpperCase()===t.toUpperCase()&&(e[t]=n,delete e[r])})}},function(e,t,n){"use strict";var r=n(26);e.exports=function(e,t,n){var i=n.config.validateStatus;!i||i(n.status)?e(n):t(r("Request failed with status code "+n.status,n.config,null,n.request,n))}},function(e,t,n){"use strict";e.exports=function(e,t,n,r,i){return e.config=t,n&&(e.code=n),e.request=r,e.response=i,e.isAxiosError=!0,e.toJSON=function(){return{message:this.message,name:this.name,description:this.description,number:this.number,fileName:this.fileName,lineNumber:this.lineNumber,columnNumber:this.columnNumber,stack:this.stack,config:this.config,code:this.code}},e}},function(e,t,n){"use strict";var r=n(61),i=n(62);e.exports=function(e,t){return e&&!r(t)?i(e,t):t}},function(e,t,n){"use strict";e.exports=function(e){return/^([a-z][a-z\d\+\-\.]*:)?\/\//i.test(e)}},function(e,t,n){"use strict";e.exports=function(e,t){return t?e.replace(/\/+$/,"")+"/"+t.replace(/^\/+/,""):e}},function(e,t,n){"use strict";var r=n(6),i=["age","authorization","content-length","content-type","etag","expires","from","host","if-modified-since","if-unmodified-since","last-modified","location","max-forwards","proxy-authorization","referer","retry-after","user-agent"];e.exports=function(e){var t,n,o,a={};return e?(r.forEach(e.split("\n"),function(e){if(o=e.indexOf(":"),t=r.trim(e.substr(0,o)).toLowerCase(),n=r.trim(e.substr(o+1)),t){if(a[t]&&i.indexOf(t)>=0)return;a[t]="set-cookie"===t?(a[t]?a[t]:[]).concat([n]):a[t]?a[t]+", "+n:n}}),a):a}},function(e,t,n){"use strict";var r=n(6);e.exports=r.isStandardBrowserEnv()?function(){var e,t=/(msie|trident)/i.test(navigator.userAgent),n=document.createElement("a");function i(e){var r=e;return t&&(n.setAttribute("href",r),r=n.href),n.setAttribute("href",r),{href:n.href,protocol:n.protocol?n.protocol.replace(/:$/,""):"",host:n.host,search:n.search?n.search.replace(/^\?/,""):"",hash:n.hash?n.hash.replace(/^#/,""):"",hostname:n.hostname,port:n.port,pathname:"/"===n.pathname.charAt(0)?n.pathname:"/"+n.pathname}}return e=i(window.location.href),function(t){var n=r.isString(t)?i(t):t;return n.protocol===e.protocol&&n.host===e.host}}():function(){return!0}},function(e,t,n){"use strict";var r=n(6);e.exports=r.isStandardBrowserEnv()?{write:function(e,t,n,i,o,a){var s=[];s.push(e+"="+encodeURIComponent(t)),r.isNumber(n)&&s.push("expires="+new Date(n).toGMTString()),r.isString(i)&&s.push("path="+i),r.isString(o)&&s.push("domain="+o),!0===a&&s.push("secure"),document.cookie=s.join("; ")},read:function(e){var t=document.cookie.match(new RegExp("(^|;\\s*)("+e+")=([^;]*)"));return t?decodeURIComponent(t[3]):null},remove:function(e){this.write(e,"",Date.now()-864e5)}}:{write:function(){},read:function(){return null},remove:function(){}}},function(e,t,n){"use strict";var r=n(28);function i(e){if("function"!==typeof e)throw new TypeError("executor must be a function.");var t;this.promise=new Promise(function(e){t=e});var n=this;e(function(e){n.reason||(n.reason=new r(e),t(n.reason))})}i.prototype.throwIfRequested=function(){if(this.reason)throw this.reason},i.source=function(){var e;return{token:new i(function(t){e=t}),cancel:e}},e.exports=i},function(e,t,n){"use strict";e.exports=function(e){return function(t){return e.apply(null,t)}}},function(e,t,n){"use strict";n.r(t);var r={};n.r(r),n.d(r,"render",function(){return B}),n.d(r,"hydrate",function(){return H}),n.d(r,"createElement",function(){return b}),n.d(r,"h",function(){return b}),n.d(r,"Fragment",function(){return S}),n.d(r,"createRef",function(){return _}),n.d(r,"isValidElement",function(){return a}),n.d(r,"Component",function(){return E}),n.d(r,"cloneElement",function(){return q}),n.d(r,"createContext",function(){return W}),n.d(r,"toChildArray",function(){return R}),n.d(r,"__u",function(){return U}),n.d(r,"options",function(){return o});var i={};n.r(i),n.d(i,"useState",function(){return te}),n.d(i,"useReducer",function(){return ne}),n.d(i,"useEffect",function(){return re}),n.d(i,"useLayoutEffect",function(){return ie}),n.d(i,"useRef",function(){return oe}),n.d(i,"useImperativeHandle",function(){return ae}),n.d(i,"useMemo",function(){return se}),n.d(i,"useCallback",function(){return ue}),n.d(i,"useContext",function(){return ce}),n.d(i,"useDebugValue",function(){return le}),n.d(i,"useErrorBoundary",function(){return de});var o,a,s,u,c,l,d,p=n(0),f=n.n(p),h={},y=[],g=/acit|ex(?:s|g|n|p|$)|rph|grid|ows|mnc|ntw|ine[ch]|zoo|^ord|itera/i;function v(e,t){for(var n in t)e[n]=t[n];return e}function m(e){var t=e.parentNode;t&&t.removeChild(e)}function b(e,t,n){var r,i,o,a=arguments,s={};for(o in t)"key"==o?r=t[o]:"ref"==o?i=t[o]:s[o]=t[o];if(arguments.length>3)for(n=[n],o=3;o<arguments.length;o++)n.push(a[o]);if(null!=n&&(s.children=n),"function"==typeof e&&null!=e.defaultProps)for(o in e.defaultProps)void 0===s[o]&&(s[o]=e.defaultProps[o]);return O(e,s,r,i,null)}function O(e,t,n,r,i){var a={type:e,props:t,key:n,ref:r,__k:null,__:null,__b:0,__e:null,__d:void 0,__c:null,constructor:void 0,__v:i};return null==i&&(a.__v=a),null!=o.vnode&&o.vnode(a),a}function _(){return{current:null}}function S(e){return e.children}function E(e,t){this.props=e,this.context=t}function w(e,t){if(null==t)return e.__?w(e.__,e.__.__k.indexOf(e)+1):null;for(var n;t<e.__k.length;t++)if(null!=(n=e.__k[t])&&null!=n.__e)return n.__e;return"function"==typeof e.type?w(e):null}function P(e){var t,n;if(null!=(e=e.__)&&null!=e.__c){for(e.__e=e.__c.base=null,t=0;t<e.__k.length;t++)if(null!=(n=e.__k[t])&&null!=n.__e){e.__e=e.__c.base=n.__e;break}return P(e)}}function T(e){(!e.__d&&(e.__d=!0)&&s.push(e)&&!A.__r++||c!==o.debounceRendering)&&((c=o.debounceRendering)||u)(A)}function A(){for(var e;A.__r=s.length;)e=s.sort(function(e,t){return e.__v.__b-t.__v.__b}),s=[],e.some(function(e){var t,n,r,i,o,a,s;e.__d&&(a=(o=(t=e).__v).__e,(s=t.__P)&&(n=[],(r=v({},o)).__v=r,i=L(s,o,r,t.__n,void 0!==s.ownerSVGElement,null,n,null==a?w(o):a),x(n,o),i!=a&&P(o)))})}function C(e,t,n,r,i,o,a,s,u,c){var l,d,p,f,g,v,b,_=r&&r.__k||y,E=_.length;for(u==h&&(u=null!=a?a[0]:E?w(r,0):null),n.__k=[],l=0;l<t.length;l++)if(null!=(f=n.__k[l]=null==(f=t[l])||"boolean"==typeof f?null:"string"==typeof f||"number"==typeof f?O(null,f,null,null,f):Array.isArray(f)?O(S,{children:f},null,null,null):null!=f.__e||null!=f.__c?O(f.type,f.props,f.key,null,f.__v):f)){if(f.__=n,f.__b=n.__b+1,null===(p=_[l])||p&&f.key==p.key&&f.type===p.type)_[l]=void 0;else for(d=0;d<E;d++){if((p=_[d])&&f.key==p.key&&f.type===p.type){_[d]=void 0;break}p=null}g=L(e,f,p=p||h,i,o,a,s,u,c),(d=f.ref)&&p.ref!=d&&(b||(b=[]),p.ref&&b.push(p.ref,null,f),b.push(d,f.__c||g,f)),null!=g?(null==v&&(v=g),u=D(e,f,p,_,a,g,u),c||"option"!=n.type?"function"==typeof n.type&&(n.__d=u):e.value=""):u&&p.__e==u&&u.parentNode!=e&&(u=w(p))}if(n.__e=v,null!=a&&"function"!=typeof n.type)for(l=a.length;l--;)null!=a[l]&&m(a[l]);for(l=E;l--;)null!=_[l]&&U(_[l],_[l]);if(b)for(l=0;l<b.length;l++)j(b[l],b[++l],b[++l])}function R(e,t){return t=t||[],null==e||"boolean"==typeof e||(Array.isArray(e)?e.some(function(e){R(e,t)}):t.push(e)),t}function D(e,t,n,r,i,o,a){var s,u,c;if(void 0!==t.__d)s=t.__d,t.__d=void 0;else if(i==n||o!=a||null==o.parentNode)e:if(null==a||a.parentNode!==e)e.appendChild(o),s=null;else{for(u=a,c=0;(u=u.nextSibling)&&c<r.length;c+=2)if(u==o)break e;e.insertBefore(o,a),s=a}return void 0!==s?s:o.nextSibling}function M(e,t,n){"-"===t[0]?e.setProperty(t,n):e[t]=null==n?"":"number"!=typeof n||g.test(t)?n:n+"px"}function I(e,t,n,r,i){var o,a;if(i&&"className"==t&&(t="class"),"style"===t)if("string"==typeof n)e.style=n;else{if("string"==typeof r&&(e.style=r=""),r)for(t in r)n&&t in n||M(e.style,t,"");if(n)for(t in n)r&&n[t]===r[t]||M(e.style,t,n[t])}else"o"===t[0]&&"n"===t[1]?(o=t!==(t=t.replace(/Capture$/,"")),(a=t.toLowerCase())in e&&(t=a),t=t.slice(2),e.l||(e.l={}),e.l[t]=n,n?r||e.addEventListener(t,k,o):e.removeEventListener(t,k,o)):"list"!==t&&"tagName"!==t&&"form"!==t&&"type"!==t&&"size"!==t&&"download"!==t&&"href"!==t&&!i&&t in e?e[t]=null==n?"":n:"function"!=typeof n&&"dangerouslySetInnerHTML"!==t&&(t!==(t=t.replace(/xlink:?/,""))?null==n||!1===n?e.removeAttributeNS("http://www.w3.org/1999/xlink",t.toLowerCase()):e.setAttributeNS("http://www.w3.org/1999/xlink",t.toLowerCase(),n):null==n||!1===n&&!/^ar/.test(t)?e.removeAttribute(t):e.setAttribute(t,n))}function k(e){this.l[e.type](o.event?o.event(e):e)}function N(e,t,n){var r,i;for(r=0;r<e.__k.length;r++)(i=e.__k[r])&&(i.__=e,i.__e&&("function"==typeof i.type&&i.__k.length>1&&N(i,t,n),t=D(n,i,i,e.__k,null,i.__e,t),"function"==typeof e.type&&(e.__d=t)))}function L(e,t,n,r,i,a,s,u,c){var l,d,p,f,h,y,g,m,b,O,_,w=t.type;if(void 0!==t.constructor)return null;(l=o.__b)&&l(t);try{e:if("function"==typeof w){if(m=t.props,b=(l=w.contextType)&&r[l.__c],O=l?b?b.props.value:l.__:r,n.__c?g=(d=t.__c=n.__c).__=d.__E:("prototype"in w&&w.prototype.render?t.__c=d=new w(m,O):(t.__c=d=new E(m,O),d.constructor=w,d.render=F),b&&b.sub(d),d.props=m,d.state||(d.state={}),d.context=O,d.__n=r,p=d.__d=!0,d.__h=[]),null==d.__s&&(d.__s=d.state),null!=w.getDerivedStateFromProps&&(d.__s==d.state&&(d.__s=v({},d.__s)),v(d.__s,w.getDerivedStateFromProps(m,d.__s))),f=d.props,h=d.state,p)null==w.getDerivedStateFromProps&&null!=d.componentWillMount&&d.componentWillMount(),null!=d.componentDidMount&&d.__h.push(d.componentDidMount);else{if(null==w.getDerivedStateFromProps&&m!==f&&null!=d.componentWillReceiveProps&&d.componentWillReceiveProps(m,O),!d.__e&&null!=d.shouldComponentUpdate&&!1===d.shouldComponentUpdate(m,d.__s,O)||t.__v===n.__v){d.props=m,d.state=d.__s,t.__v!==n.__v&&(d.__d=!1),d.__v=t,t.__e=n.__e,t.__k=n.__k,d.__h.length&&s.push(d),N(t,u,e);break e}null!=d.componentWillUpdate&&d.componentWillUpdate(m,d.__s,O),null!=d.componentDidUpdate&&d.__h.push(function(){d.componentDidUpdate(f,h,y)})}d.context=O,d.props=m,d.state=d.__s,(l=o.__r)&&l(t),d.__d=!1,d.__v=t,d.__P=e,l=d.render(d.props,d.state,d.context),d.state=d.__s,null!=d.getChildContext&&(r=v(v({},r),d.getChildContext())),p||null==d.getSnapshotBeforeUpdate||(y=d.getSnapshotBeforeUpdate(f,h)),_=null!=l&&l.type==S&&null==l.key?l.props.children:l,C(e,Array.isArray(_)?_:[_],t,n,r,i,a,s,u,c),d.base=t.__e,d.__h.length&&s.push(d),g&&(d.__E=d.__=null),d.__e=!1}else null==a&&t.__v===n.__v?(t.__k=n.__k,t.__e=n.__e):t.__e=V(n.__e,t,n,r,i,a,s,c);(l=o.diffed)&&l(t)}catch(e){t.__v=null,o.__e(e,t,n)}return t.__e}function x(e,t){o.__c&&o.__c(t,e),e.some(function(t){try{e=t.__h,t.__h=[],e.some(function(e){e.call(t)})}catch(e){o.__e(e,t.__v)}})}function V(e,t,n,r,i,o,a,s){var u,c,l,d,p,f=n.props,g=t.props;if(i="svg"===t.type||i,null!=o)for(u=0;u<o.length;u++)if(null!=(c=o[u])&&((null===t.type?3===c.nodeType:c.localName===t.type)||e==c)){e=c,o[u]=null;break}if(null==e){if(null===t.type)return document.createTextNode(g);e=i?document.createElementNS("http://www.w3.org/2000/svg",t.type):document.createElement(t.type,g.is&&{is:g.is}),o=null,s=!1}if(null===t.type)f!==g&&e.data!==g&&(e.data=g);else{if(null!=o&&(o=y.slice.call(e.childNodes)),l=(f=n.props||h).dangerouslySetInnerHTML,d=g.dangerouslySetInnerHTML,!s){if(null!=o)for(f={},p=0;p<e.attributes.length;p++)f[e.attributes[p].name]=e.attributes[p].value;(d||l)&&(d&&l&&d.__html==l.__html||(e.innerHTML=d&&d.__html||""))}(function(e,t,n,r,i){var o;for(o in n)"children"===o||"key"===o||o in t||I(e,o,null,n[o],r);for(o in t)i&&"function"!=typeof t[o]||"children"===o||"key"===o||"value"===o||"checked"===o||n[o]===t[o]||I(e,o,t[o],n[o],r)})(e,g,f,i,s),d?t.__k=[]:(u=t.props.children,C(e,Array.isArray(u)?u:[u],t,n,r,"foreignObject"!==t.type&&i,o,a,h,s)),s||("value"in g&&void 0!==(u=g.value)&&u!==e.value&&I(e,"value",u,f.value,!1),"checked"in g&&void 0!==(u=g.checked)&&u!==e.checked&&I(e,"checked",u,f.checked,!1))}return e}function j(e,t,n){try{"function"==typeof e?e(t):e.current=t}catch(e){o.__e(e,n)}}function U(e,t,n){var r,i,a;if(o.unmount&&o.unmount(e),(r=e.ref)&&(r.current&&r.current!==e.__e||j(r,null,t)),n||"function"==typeof e.type||(n=null!=(i=e.__e)),e.__e=e.__d=void 0,null!=(r=e.__c)){if(r.componentWillUnmount)try{r.componentWillUnmount()}catch(e){o.__e(e,t)}r.base=r.__P=null}if(r=e.__k)for(a=0;a<r.length;a++)r[a]&&U(r[a],t,n);null!=i&&m(i)}function F(e,t,n){return this.constructor(e,n)}function B(e,t,n){var r,i,a;o.__&&o.__(e,t),i=(r=n===l)?null:n&&n.__k||t.__k,e=b(S,null,[e]),a=[],L(t,(r?t:n||t).__k=e,i||h,h,void 0!==t.ownerSVGElement,n&&!r?[n]:i?null:t.childNodes.length?y.slice.call(t.childNodes):null,a,n||h,r),x(a,e)}function H(e,t){B(e,t,l)}function q(e,t,n){var r,i,o,a=arguments,s=v({},e.props);for(o in t)"key"==o?r=t[o]:"ref"==o?i=t[o]:s[o]=t[o];if(arguments.length>3)for(n=[n],o=3;o<arguments.length;o++)n.push(a[o]);return null!=n&&(s.children=n),O(e.type,s,r||e.key,i||e.ref,null)}function W(e,t){var n={__c:t="__cC"+d++,__:e,Consumer:function(e,t){return e.children(t)},Provider:function(e,n,r){return this.getChildContext||(n=[],(r={})[t]=this,this.getChildContext=function(){return r},this.shouldComponentUpdate=function(e){this.props.value!==e.value&&n.some(T)},this.sub=function(e){n.push(e);var t=e.componentWillUnmount;e.componentWillUnmount=function(){n.splice(n.indexOf(e),1),t&&t.call(e)}}),e.children}};return n.Provider.__=n.Consumer.contextType=n}o={__e:function(e,t){for(var n,r;t=t.__;)if((n=t.__c)&&!n.__)try{if(n.constructor&&null!=n.constructor.getDerivedStateFromError&&(r=!0,n.setState(n.constructor.getDerivedStateFromError(e))),null!=n.componentDidCatch&&(r=!0,n.componentDidCatch(e)),r)return T(n.__E=n)}catch(t){e=t}throw e}},a=function(e){return null!=e&&void 0===e.constructor},E.prototype.setState=function(e,t){var n;n=null!=this.__s&&this.__s!==this.state?this.__s:this.__s=v({},this.state),"function"==typeof e&&(e=e(v({},n),this.props)),e&&v(n,e),null!=e&&this.__v&&(t&&this.__h.push(t),T(this))},E.prototype.forceUpdate=function(e){this.__v&&(this.__e=!0,e&&this.__h.push(e),T(this))},E.prototype.render=S,s=[],u="function"==typeof Promise?Promise.prototype.then.bind(Promise.resolve()):setTimeout,A.__r=0,l=h,d=0;var z,G,$,K=0,Y=[],Z=o.__r,X=o.diffed,J=o.__c,Q=o.unmount;function ee(e,t){o.__h&&o.__h(G,e,K||t),K=0;var n=G.__H||(G.__H={__:[],__h:[]});return e>=n.__.length&&n.__.push({}),n.__[e]}function te(e){return K=1,ne(ve,e)}function ne(e,t,n){var r=ee(z++,2);return r.t=e,r.__c||(r.__c=G,r.__=[n?n(t):ve(void 0,t),function(e){var t=r.t(r.__[0],e);r.__[0]!==t&&(r.__=[t,r.__[1]],r.__c.setState({}))}]),r.__}function re(e,t){var n=ee(z++,3);!o.__s&&ge(n.__H,t)&&(n.__=e,n.__H=t,G.__H.__h.push(n))}function ie(e,t){var n=ee(z++,4);!o.__s&&ge(n.__H,t)&&(n.__=e,n.__H=t,G.__h.push(n))}function oe(e){return K=5,se(function(){return{current:e}},[])}function ae(e,t,n){K=6,ie(function(){"function"==typeof e?e(t()):e&&(e.current=t())},null==n?n:n.concat(e))}function se(e,t){var n=ee(z++,7);return ge(n.__H,t)?(n.__H=t,n.__h=e,n.__=e()):n.__}function ue(e,t){return K=8,se(function(){return e},t)}function ce(e){var t=G.context[e.__c],n=ee(z++,9);return n.__c=e,t?(null==n.__&&(n.__=!0,t.sub(G)),t.props.value):e.__}function le(e,t){o.useDebugValue&&o.useDebugValue(t?t(e):e)}function de(e){var t=ee(z++,10),n=te();return t.__=e,G.componentDidCatch||(G.componentDidCatch=function(e){t.__&&t.__(e),n[1](e)}),[n[0],function(){n[1](void 0)}]}function pe(){Y.some(function(e){if(e.__P)try{e.__H.__h.forEach(he),e.__H.__h.forEach(ye),e.__H.__h=[]}catch(t){return e.__H.__h=[],o.__e(t,e.__v),!0}}),Y=[]}o.__r=function(e){Z&&Z(e),z=0;var t=(G=e.__c).__H;t&&(t.__h.forEach(he),t.__h.forEach(ye),t.__h=[])},o.diffed=function(e){X&&X(e);var t=e.__c;t&&t.__H&&t.__H.__h.length&&(1!==Y.push(t)&&$===o.requestAnimationFrame||(($=o.requestAnimationFrame)||function(e){var t,n=function(){clearTimeout(r),fe&&cancelAnimationFrame(t),setTimeout(e)},r=setTimeout(n,100);fe&&(t=requestAnimationFrame(n))})(pe))},o.__c=function(e,t){t.some(function(e){try{e.__h.forEach(he),e.__h=e.__h.filter(function(e){return!e.__||ye(e)})}catch(n){t.some(function(e){e.__h&&(e.__h=[])}),t=[],o.__e(n,e.__v)}}),J&&J(e,t)},o.unmount=function(e){Q&&Q(e);var t=e.__c;if(t&&t.__H)try{t.__H.__.forEach(he)}catch(e){o.__e(e,t.__v)}};var fe="function"==typeof requestAnimationFrame;function he(e){"function"==typeof e.u&&e.u()}function ye(e){e.u=e.__()}function ge(e,t){return!e||t.some(function(t,n){return t!==e[n]})}function ve(e,t){return"function"==typeof t?t(e):t}function me(e,t){for(var n in t)e[n]=t[n];return e}function be(e,t){for(var n in e)if("__source"!==n&&!(n in t))return!0;for(var r in t)if("__source"!==r&&e[r]!==t[r])return!0;return!1}function Oe(e){this.props=e}(Oe.prototype=new E).isPureReactComponent=!0,Oe.prototype.shouldComponentUpdate=function(e,t){return be(this.props,e)||be(this.state,t)};var _e=o.__b;o.__b=function(e){e.type&&e.type.__f&&e.ref&&(e.props.ref=e.ref,e.ref=null),_e&&_e(e)};var Se="undefined"!=typeof Symbol&&Symbol.for&&Symbol.for("react.forward_ref")||3911;var Ee=function(e,t){return e?R(R(e).map(t)):null},we={map:Ee,forEach:Ee,count:function(e){return e?R(e).length:0},only:function(e){var t=R(e);if(1!==t.length)throw"Children.only";return t[0]},toArray:R},Pe=o.__e;function Te(e){return e&&((e=me({},e)).__c=null,e.__k=e.__k&&e.__k.map(Te)),e}function Ae(e){return e&&(e.__v=null,e.__k=e.__k&&e.__k.map(Ae)),e}function Ce(){this.__u=0,this.t=null,this.__b=null}function Re(e){var t=e.__.__c;return t&&t.o&&t.o(e)}function De(){this.u=null,this.i=null}o.__e=function(e,t,n){if(e.then)for(var r,i=t;i=i.__;)if((r=i.__c)&&r.__c)return null==t.__e&&(t.__e=n.__e,t.__k=n.__k),r.__c(e,t.__c);Pe(e,t,n)},(Ce.prototype=new E).__c=function(e,t){var n=this;null==n.t&&(n.t=[]),n.t.push(t);var r=Re(n.__v),i=!1,o=function(){i||(i=!0,t.componentWillUnmount=t.__c,r?r(a):a())};t.__c=t.componentWillUnmount,t.componentWillUnmount=function(){o(),t.__c&&t.__c()};var a=function(){var e;if(!--n.__u)for(n.__v.__k[0]=Ae(n.state.o),n.setState({o:n.__b=null});e=n.t.pop();)e.forceUpdate()};n.__u++||n.setState({o:n.__b=n.__v.__k[0]}),e.then(o,o)},Ce.prototype.componentWillUnmount=function(){this.t=[]},Ce.prototype.render=function(e,t){return this.__b&&(this.__v.__k&&(this.__v.__k[0]=Te(this.__b)),this.__b=null),[b(S,null,t.o?null:e.children),t.o&&e.fallback]};var Me=function(e,t,n){if(++n[1]===n[0]&&e.i.delete(t),e.props.revealOrder&&("t"!==e.props.revealOrder[0]||!e.i.size))for(n=e.u;n;){for(;n.length>3;)n.pop()();if(n[1]<n[0])break;e.u=n=n[2]}};function Ie(e){return this.getChildContext=function(){return e.context},e.children}function ke(e){var t=this,n=e.l,r=b(Ie,{context:t.context},e.__v);t.componentWillUnmount=function(){var e=t.s.parentNode;e&&e.removeChild(t.s),U(t.v)},t.l&&t.l!==n&&(t.componentWillUnmount(),t.h=!1),e.__v?t.h?(n.__k=t.__k,B(r,n),t.__k=n.__k):(t.s=document.createTextNode(""),t.__k=n.__k,H("",n),n.appendChild(t.s),t.h=!0,t.l=n,B(r,n,t.s),n.__k=t.__k,t.__k=t.s.__k):t.h&&t.componentWillUnmount(),t.v=r}(De.prototype=new E).o=function(e){var t=this,n=Re(t.__v),r=t.i.get(e);return r[0]++,function(i){var o=function(){t.props.revealOrder?(r.push(i),Me(t,e,r)):i()};n?n(o):o()}},De.prototype.render=function(e){this.u=null,this.i=new Map;var t=R(e.children);e.revealOrder&&"b"===e.revealOrder[0]&&t.reverse();for(var n=t.length;n--;)this.i.set(t[n],this.u=[1,0,this.u]);return e.children},De.prototype.componentDidUpdate=De.prototype.componentDidMount=function(){var e=this;this.i.forEach(function(t,n){Me(e,n,t)})};var Ne=/^(?:accent|alignment|arabic|baseline|cap|clip(?!PathU)|color|fill|flood|font|glyph(?!R)|horiz|marker(?!H|W|U)|overline|paint|stop|strikethrough|stroke|text(?!L)|underline|unicode|units|v|vector|vert|word|writing|x(?!C))[A-Z]/;E.prototype.isReactComponent={};var Le="undefined"!=typeof Symbol&&Symbol.for&&Symbol.for("react.element")||60103;var xe=o.event;function Ve(e,t){e["UNSAFE_"+t]&&!e[t]&&Object.defineProperty(e,t,{get:function(){return this["UNSAFE_"+t]},set:function(e){this["UNSAFE_"+t]=e}})}o.event=function(e){xe&&(e=xe(e)),e.persist=function(){};var t=!1,n=!1,r=e.stopPropagation;e.stopPropagation=function(){r.call(e),t=!0};var i=e.preventDefault;return e.preventDefault=function(){i.call(e),n=!0},e.isPropagationStopped=function(){return t},e.isDefaultPrevented=function(){return n},e.nativeEvent=e};var je,Ue={configurable:!0,get:function(){return this.class}},Fe=o.vnode;o.vnode=function(e){e.$$typeof=Le;var t=e.type,n=e.props;if(t){var r;if(n.class!=n.className&&(Ue.enumerable="className"in n,null!=n.className&&(n.class=n.className),Object.defineProperty(n,"className",Ue)),"function"!=typeof t)for(r in n.defaultValue&&void 0!==n.value&&(n.value||0===n.value||(n.value=n.defaultValue),n.defaultValue=void 0),"select"===t&&n.multiple&&Array.isArray(n.value)&&(R(n.children).forEach(function(e){-1!=n.value.indexOf(e.props.value)&&(e.props.selected=!0)}),n.value=void 0),!0===n.download&&(n.download=""),n){var i=Ne.test(r);i&&(e.props[r.replace(/[A-Z0-9]/,"-$&").toLowerCase()]=n[r]),(i||null===n[r])&&(n[r]=void 0)}else t.prototype&&!t.prototype.p&&(t.prototype.p=!0,Ve(t.prototype,"componentWillMount"),Ve(t.prototype,"componentWillReceiveProps"),Ve(t.prototype,"componentWillUpdate"));!function(t){var n=e.type,r=e.props;if(r&&"string"==typeof n){var i={};for(var o in r)/^on(Ani|Tra|Tou)/.test(o)&&(r[o.toLowerCase()]=r[o],delete r[o]),i[o.toLowerCase()]=o;if(i.ondoubleclick&&(r.ondblclick=r[i.ondoubleclick],delete r[i.ondoubleclick]),i.onbeforeinput&&(r.onbeforeinput=r[i.onbeforeinput],delete r[i.onbeforeinput]),i.onchange&&("textarea"===n||"input"===n.toLowerCase()&&!/^fil|che|ra/i.test(r.type))){var a=i.oninput||"oninput";r[a]||(r[a]=r[i.onchange],delete r[i.onchange])}}}()}Fe&&Fe(e)};var Be=o.__r;o.__r=function(e){Be&&Be(e),je=e.__c};function He(e){return!!e&&e.$$typeof===Le}var qe=function(e,t){return e(t)},We={useState:te,useReducer:ne,useEffect:re,useLayoutEffect:ie,useRef:oe,useImperativeHandle:ae,useMemo:se,useCallback:ue,useContext:ce,useDebugValue:le,version:"16.8.0",Children:we,render:function(e,t,n){if(null==t.__k)for(;t.firstChild;)t.removeChild(t.firstChild);return B(e,t),"function"==typeof n&&n(),e?e.__c:null},hydrate:function(e,t,n){return H(e,t),"function"==typeof n&&n(),e?e.__c:null},unmountComponentAtNode:function(e){return!!e.__k&&(B(null,e),!0)},createPortal:function(e,t){return b(ke,{__v:e,l:t})},createElement:b,createContext:W,createFactory:function(e){return b.bind(null,e)},cloneElement:function(e){return He(e)?q.apply(null,arguments):e},createRef:_,Fragment:S,isValidElement:He,findDOMNode:function(e){return e&&(e.base||1===e.nodeType&&e)||null},Component:E,PureComponent:Oe,memo:function(e,t){function n(e){var n=this.props.ref,r=n==e.ref;return!r&&n&&(n.call?n(null):n.current=null),t?!t(this.props,e)||!r:be(this.props,e)}function r(t){return this.shouldComponentUpdate=n,b(e,t)}return r.displayName="Memo("+(e.displayName||e.name)+")",r.prototype.isReactComponent=!0,r.__f=!0,r},forwardRef:function(e){function t(t,n){var r=me({},t);return delete r.ref,e(r,(n=t.ref||n)&&("object"!=typeof n||"current"in n)?n:null)}return t.$$typeof=Se,t.render=t,t.prototype.isReactComponent=t.__f=!0,t.displayName="ForwardRef("+(e.displayName||e.name)+")",t},unstable_batchedUpdates:qe,StrictMode:S,Suspense:Ce,SuspenseList:De,lazy:function(e){var t,n,r;function i(i){if(t||(t=e()).then(function(e){n=e.default||e},function(e){r=e}),r)throw r;if(!n)throw t;return b(n,i)}return i.displayName="Lazy",i.__f=!0,i},__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED:{ReactCurrentDispatcher:{current:{readContext:function(e){return je.__n[e.__c].props.value}}}}},ze=(n(33),We.createContext(null));var Ge=function(e){e()},$e=function(){return Ge},Ke={notify:function(){}};var Ye=function(){function e(e,t){this.store=e,this.parentSub=t,this.unsubscribe=null,this.listeners=Ke,this.handleChangeWrapper=this.handleChangeWrapper.bind(this)}var t=e.prototype;return t.addNestedSub=function(e){return this.trySubscribe(),this.listeners.subscribe(e)},t.notifyNestedSubs=function(){this.listeners.notify()},t.handleChangeWrapper=function(){this.onStateChange&&this.onStateChange()},t.isSubscribed=function(){return Boolean(this.unsubscribe)},t.trySubscribe=function(){this.unsubscribe||(this.unsubscribe=this.parentSub?this.parentSub.addNestedSub(this.handleChangeWrapper):this.store.subscribe(this.handleChangeWrapper),this.listeners=function(){var e=$e(),t=null,n=null;return{clear:function(){t=null,n=null},notify:function(){e(function(){for(var e=t;e;)e.callback(),e=e.next})},get:function(){for(var e=[],n=t;n;)e.push(n),n=n.next;return e},subscribe:function(e){var r=!0,i=n={callback:e,next:null,prev:n};return i.prev?i.prev.next=i:t=i,function(){r&&null!==t&&(r=!1,i.next?i.next.prev=i.prev:n=i.prev,i.prev?i.prev.next=i.next:t=i.next)}}}}())},t.tryUnsubscribe=function(){this.unsubscribe&&(this.unsubscribe(),this.unsubscribe=null,this.listeners.clear(),this.listeners=Ke)},e}();var Ze=function(e){var t=e.store,n=e.context,r=e.children,i=se(function(){var e=new Ye(t);return e.onStateChange=e.notifyNestedSubs,{store:t,subscription:e}},[t]),o=se(function(){return t.getState()},[t]);re(function(){var e=i.subscription;return e.trySubscribe(),o!==t.getState()&&e.notifyNestedSubs(),function(){e.tryUnsubscribe(),e.onStateChange=null}},[i,o]);var a=n||ze;return We.createElement(a.Provider,{value:i},r)};function Xe(){return(Xe=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e}).apply(this,arguments)}function Je(e,t){if(null==e)return{};var n,r,i={},o=Object.keys(e);for(r=0;r<o.length;r++)n=o[r],t.indexOf(n)>=0||(i[n]=e[n]);return i}var Qe=n(15),et=n.n(Qe),tt=n(14),nt="undefined"!==typeof window&&"undefined"!==typeof window.document&&"undefined"!==typeof window.document.createElement?ie:re,rt=[],it=[null,null];function ot(e,t){var n=e[1];return[t.payload,n+1]}function at(e,t,n){nt(function(){return e.apply(void 0,t)},n)}function st(e,t,n,r,i,o,a){e.current=r,t.current=i,n.current=!1,o.current&&(o.current=null,a())}function ut(e,t,n,r,i,o,a,s,u,c){if(e){var l=!1,d=null,p=function(){if(!l){var e,n,p=t.getState();try{e=r(p,i.current)}catch(f){n=f,d=f}n||(d=null),e===o.current?a.current||u():(o.current=e,s.current=e,a.current=!0,c({type:"STORE_UPDATED",payload:{error:n}}))}};n.onStateChange=p,n.trySubscribe(),p();return function(){if(l=!0,n.tryUnsubscribe(),n.onStateChange=null,d)throw d}}}var ct=function(){return[null,0]};function lt(e,t){void 0===t&&(t={});var n=t,r=n.getDisplayName,i=void 0===r?function(e){return"ConnectAdvanced("+e+")"}:r,o=n.methodName,a=void 0===o?"connectAdvanced":o,s=n.renderCountProp,u=void 0===s?void 0:s,c=n.shouldHandleStateChanges,l=void 0===c||c,d=n.storeKey,p=void 0===d?"store":d,f=(n.withRef,n.forwardRef),h=void 0!==f&&f,y=n.context,g=void 0===y?ze:y,v=Je(n,["getDisplayName","methodName","renderCountProp","shouldHandleStateChanges","storeKey","withRef","forwardRef","context"]),m=g;return function(t){var n=t.displayName||t.name||"Component",r=i(n),o=Xe({},v,{getDisplayName:i,methodName:a,renderCountProp:u,shouldHandleStateChanges:l,storeKey:p,displayName:r,wrappedComponentName:n,WrappedComponent:t}),s=v.pure;var c=s?se:function(e){return e()};function d(n){var r=se(function(){var e=n.reactReduxForwardedRef,t=Je(n,["reactReduxForwardedRef"]);return[n.context,e,t]},[n]),i=r[0],a=r[1],s=r[2],u=se(function(){return i&&i.Consumer&&Object(tt.isContextConsumer)(We.createElement(i.Consumer,null))?i:m},[i,m]),d=ce(u),p=Boolean(n.store)&&Boolean(n.store.getState)&&Boolean(n.store.dispatch);Boolean(d)&&Boolean(d.store);var f=p?n.store:d.store,h=se(function(){return function(t){return e(t.dispatch,o)}(f)},[f]),y=se(function(){if(!l)return it;var e=new Ye(f,p?null:d.subscription),t=e.notifyNestedSubs.bind(e);return[e,t]},[f,p,d]),g=y[0],v=y[1],b=se(function(){return p?d:Xe({},d,{subscription:g})},[p,d,g]),O=ne(ot,rt,ct),_=O[0][0],S=O[1];if(_&&_.error)throw _.error;var E=oe(),w=oe(s),P=oe(),T=oe(!1),A=c(function(){return P.current&&s===w.current?P.current:h(f.getState(),s)},[f,_,s]);at(st,[w,E,T,s,A,P,v]),at(ut,[l,f,g,h,w,E,T,P,v,S],[f,g,h]);var C=se(function(){return We.createElement(t,Xe({},A,{ref:a}))},[a,t,A]);return se(function(){return l?We.createElement(u.Provider,{value:b},C):C},[u,C,b])}var f=s?We.memo(d):d;if(f.WrappedComponent=t,f.displayName=r,h){var y=We.forwardRef(function(e,t){return We.createElement(f,Xe({},e,{reactReduxForwardedRef:t}))});return y.displayName=r,y.WrappedComponent=t,et()(y,t)}return et()(f,t)}}function dt(e,t){return e===t?0!==e||0!==t||1/e===1/t:e!==e&&t!==t}function pt(e,t){if(dt(e,t))return!0;if("object"!==typeof e||null===e||"object"!==typeof t||null===t)return!1;var n=Object.keys(e),r=Object.keys(t);if(n.length!==r.length)return!1;for(var i=0;i<n.length;i++)if(!Object.prototype.hasOwnProperty.call(t,n[i])||!dt(e[n[i]],t[n[i]]))return!1;return!0}var ft=n(16),ht=function(){return Math.random().toString(36).substring(7).split("").join(".")},yt={INIT:"@@redux/INIT"+ht(),REPLACE:"@@redux/REPLACE"+ht(),PROBE_UNKNOWN_ACTION:function(){return"@@redux/PROBE_UNKNOWN_ACTION"+ht()}};function gt(e){if("object"!==typeof e||null===e)return!1;for(var t=e;null!==Object.getPrototypeOf(t);)t=Object.getPrototypeOf(t);return Object.getPrototypeOf(e)===t}function vt(e,t,n){var r;if("function"===typeof t&&"function"===typeof n||"function"===typeof n&&"function"===typeof arguments[3])throw new Error("It looks like you are passing several store enhancers to createStore(). This is not supported. Instead, compose them together to a single function.");if("function"===typeof t&&"undefined"===typeof n&&(n=t,t=void 0),"undefined"!==typeof n){if("function"!==typeof n)throw new Error("Expected the enhancer to be a function.");return n(vt)(e,t)}if("function"!==typeof e)throw new Error("Expected the reducer to be a function.");var i=e,o=t,a=[],s=a,u=!1;function c(){s===a&&(s=a.slice())}function l(){if(u)throw new Error("You may not call store.getState() while the reducer is executing. The reducer has already received the state as an argument. Pass it down from the top reducer instead of reading it from the store.");return o}function d(e){if("function"!==typeof e)throw new Error("Expected the listener to be a function.");if(u)throw new Error("You may not call store.subscribe() while the reducer is executing. If you would like to be notified after the store has been updated, subscribe from a component and invoke store.getState() in the callback to access the latest state. See https://redux.js.org/api-reference/store#subscribelistener for more details.");var t=!0;return c(),s.push(e),function(){if(t){if(u)throw new Error("You may not unsubscribe from a store listener while the reducer is executing. See https://redux.js.org/api-reference/store#subscribelistener for more details.");t=!1,c();var n=s.indexOf(e);s.splice(n,1),a=null}}}function p(e){if(!gt(e))throw new Error("Actions must be plain objects. Use custom middleware for async actions.");if("undefined"===typeof e.type)throw new Error('Actions may not have an undefined "type" property. Have you misspelled a constant?');if(u)throw new Error("Reducers may not dispatch actions.");try{u=!0,o=i(o,e)}finally{u=!1}for(var t=a=s,n=0;n<t.length;n++){(0,t[n])()}return e}return p({type:yt.INIT}),(r={dispatch:p,subscribe:d,getState:l,replaceReducer:function(e){if("function"!==typeof e)throw new Error("Expected the nextReducer to be a function.");i=e,p({type:yt.REPLACE})}})[ft.a]=function(){var e,t=d;return(e={subscribe:function(e){if("object"!==typeof e||null===e)throw new TypeError("Expected the observer to be an object.");function n(){e.next&&e.next(l())}return n(),{unsubscribe:t(n)}}})[ft.a]=function(){return this},e},r}function mt(e,t){var n=t&&t.type;return"Given "+(n&&'action "'+String(n)+'"'||"an action")+', reducer "'+e+'" returned undefined. To ignore an action, you must explicitly return the previous state. If you want this reducer to hold no value, you can return null instead of undefined.'}function bt(e,t){return function(){return t(e.apply(this,arguments))}}function Ot(e,t){if("function"===typeof e)return bt(e,t);if("object"!==typeof e||null===e)throw new Error("bindActionCreators expected an object or a function, instead received "+(null===e?"null":typeof e)+'. Did you write "import ActionCreators from" instead of "import * as ActionCreators from"?');var n={};for(var r in e){var i=e[r];"function"===typeof i&&(n[r]=bt(i,t))}return n}function _t(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}function St(e,t){var n=Object.keys(e);return Object.getOwnPropertySymbols&&n.push.apply(n,Object.getOwnPropertySymbols(e)),t&&(n=n.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n}function Et(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return 0===t.length?function(e){return e}:1===t.length?t[0]:t.reduce(function(e,t){return function(){return e(t.apply(void 0,arguments))}})}function wt(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return function(e){return function(){var n=e.apply(void 0,arguments),r=function(){throw new Error("Dispatching while constructing your middleware is not allowed. Other middleware would not be applied to this dispatch.")},i={getState:n.getState,dispatch:function(){return r.apply(void 0,arguments)}},o=t.map(function(e){return e(i)});return function(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?St(n,!0).forEach(function(t){_t(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):St(n).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}({},n,{dispatch:r=Et.apply(void 0,o)(n.dispatch)})}}}function Pt(e){return function(t,n){var r=e(t,n);function i(){return r}return i.dependsOnOwnProps=!1,i}}function Tt(e){return null!==e.dependsOnOwnProps&&void 0!==e.dependsOnOwnProps?Boolean(e.dependsOnOwnProps):1!==e.length}function At(e,t){return function(t,n){n.displayName;var r=function(e,t){return r.dependsOnOwnProps?r.mapToProps(e,t):r.mapToProps(e)};return r.dependsOnOwnProps=!0,r.mapToProps=function(t,n){r.mapToProps=e,r.dependsOnOwnProps=Tt(e);var i=r(t,n);return"function"===typeof i&&(r.mapToProps=i,r.dependsOnOwnProps=Tt(i),i=r(t,n)),i},r}}var Ct=[function(e){return"function"===typeof e?At(e):void 0},function(e){return e?void 0:Pt(function(e){return{dispatch:e}})},function(e){return e&&"object"===typeof e?Pt(function(t){return Ot(e,t)}):void 0}];var Rt=[function(e){return"function"===typeof e?At(e):void 0},function(e){return e?void 0:Pt(function(){return{}})}];function Dt(e,t,n){return Xe({},n,{},e,{},t)}var Mt=[function(e){return"function"===typeof e?function(e){return function(t,n){n.displayName;var r,i=n.pure,o=n.areMergedPropsEqual,a=!1;return function(t,n,s){var u=e(t,n,s);return a?i&&o(u,r)||(r=u):(a=!0,r=u),r}}}(e):void 0},function(e){return e?void 0:function(){return Dt}}];function It(e,t,n,r){return function(i,o){return n(e(i,o),t(r,o),o)}}function kt(e,t,n,r,i){var o,a,s,u,c,l=i.areStatesEqual,d=i.areOwnPropsEqual,p=i.areStatePropsEqual,f=!1;function h(i,f){var h=!d(f,a),y=!l(i,o);return o=i,a=f,h&&y?(s=e(o,a),t.dependsOnOwnProps&&(u=t(r,a)),c=n(s,u,a)):h?(e.dependsOnOwnProps&&(s=e(o,a)),t.dependsOnOwnProps&&(u=t(r,a)),c=n(s,u,a)):y?function(){var t=e(o,a),r=!p(t,s);return s=t,r&&(c=n(s,u,a)),c}():c}return function(i,l){return f?h(i,l):(s=e(o=i,a=l),u=t(r,a),c=n(s,u,a),f=!0,c)}}function Nt(e,t){var n=t.initMapStateToProps,r=t.initMapDispatchToProps,i=t.initMergeProps,o=Je(t,["initMapStateToProps","initMapDispatchToProps","initMergeProps"]),a=n(e,o),s=r(e,o),u=i(e,o);return(o.pure?kt:It)(a,s,u,e,o)}function Lt(e,t,n){for(var r=t.length-1;r>=0;r--){var i=t[r](e);if(i)return i}return function(t,r){throw new Error("Invalid value of type "+typeof e+" for "+n+" argument when connecting component "+r.wrappedComponentName+".")}}function xt(e,t){return e===t}function Vt(e){var t=void 0===e?{}:e,n=t.connectHOC,r=void 0===n?lt:n,i=t.mapStateToPropsFactories,o=void 0===i?Rt:i,a=t.mapDispatchToPropsFactories,s=void 0===a?Ct:a,u=t.mergePropsFactories,c=void 0===u?Mt:u,l=t.selectorFactory,d=void 0===l?Nt:l;return function(e,t,n,i){void 0===i&&(i={});var a=i,u=a.pure,l=void 0===u||u,p=a.areStatesEqual,f=void 0===p?xt:p,h=a.areOwnPropsEqual,y=void 0===h?pt:h,g=a.areStatePropsEqual,v=void 0===g?pt:g,m=a.areMergedPropsEqual,b=void 0===m?pt:m,O=Je(a,["pure","areStatesEqual","areOwnPropsEqual","areStatePropsEqual","areMergedPropsEqual"]),_=Lt(e,o,"mapStateToProps"),S=Lt(t,s,"mapDispatchToProps"),E=Lt(n,c,"mergeProps");return r(d,Xe({methodName:"connect",getDisplayName:function(e){return"Connect("+e+")"},shouldHandleStateChanges:Boolean(e),initMapStateToProps:_,initMapDispatchToProps:S,initMergeProps:E,pure:l,areStatesEqual:f,areOwnPropsEqual:y,areStatePropsEqual:v,areMergedPropsEqual:b},O))}}var jt=Vt();Ge=qe;var Ut={BORDER_RADIUS:{EXTRA_TINY:"1px",TINY:"2px",SMALL:"3px",MEDIUM:"4px"},COLORS:{BLACK:"#000000",WHITE:"#ffffff",TRANSPARENT:"transparent",GRADIENT_BLACK:"linear-gradient(to bottom, rgba(0, 0, 0, 0.63), rgba(0, 0, 0, 0.62) 19%, rgba(0, 0, 0, 0))",LIGHT_GRAY_TRANSPARENT:"rgba(255, 255, 255, 0.23)",GRAY_TRANSPARENT:"rgba(143, 143, 143, 0.46)",BLACK_TRANSPARENT:"rgba(0, 0, 0, 0.7)",BLACK_80_OPACITY:"rgba(0, 0, 0, 0.8)",BLUR_TRANSPARENT:"rgba(0, 0, 0, 0.48)",GRAY:"rgba(0, 0, 0, 0.35)",SELECTED:"rgba(255, 255, 255, 0.1)",SCROLL_BAR:"rgba(255, 255, 255, 0.64)",TRANSPARENT_30_OPACITY:"rgba(0, 0, 0, 0.31)"},TEXT_FONT_FAMILY:{LATO:"Lato"},FONT_SIZE:{EXTRA_TINY:"8px",TINY:"10px",EXTRA_SMALL:"12px",SMALL:"14px",MEDIUM:"18px"}},Ft="179px",Bt="269px",Ht="180px",qt="270px",Wt="300px",zt="301px",Gt="500px",$t="501px",Kt="800px",Yt="801px";function Zt(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Xt(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Zt(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Zt(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Jt=function e(t){return t&&t.length>0?t.reduce(function(t,n){return n?Array.isArray(n)?Xt(Xt({},t),e(n)):Xt(Xt({},t),n):t},{}):null},Qt=function(e){return function(t){t({type:"[CORE] change video tag status",payload:e})}},en=function(e){return function(t){t({type:"[CORE] update video current fragment position",payload:e})}},tn=function(e){return function(t){t({type:"[CORE] update video current position",payload:e})}},nn=function(e){return function(t){t({type:"[CORE] update video current buffered time",payload:e})}},rn=function(e){return function(t){t({type:"[CORE] update video current duration",payload:e})}},on=function(e,t){return function(n){n({type:"[COMMON] set pending video status",payload:{pendingStatusObject:{type:e,value:t}}})}},an=function(e){return function(t){t({type:"[COMMON] set mute video",payload:e})}},sn=function(e){return function(t){t({type:"[COMMON] set volume",payload:e})}},un=function(e){return function(t){t({type:"[CORE] change loading player status",payload:e})}},cn=function(e){return function(t){t({type:"[COMMON] show black screen with loader",payload:e})}},ln=function(e){return function(t){t({type:"[CORE] set player size",payload:e})}},dn=function(e){return function(t){t({type:"[COMMON] set error message",payload:e})}},pn={mediaData:function(e){return e.mediaData},playerData:function(e){return e.playerData},dependenciesLoadingStatus:function(e){return e.dependenciesLoadingStatus},brandingData:function(e){return e.brandingData},anchorOptions:function(e){return e.anchorOptions},semanticOptions:function(e){return e.semanticOptions},monetization:function(e){return e.monetization},userInteraction:function(e){return e.userInteraction},splitView:function(e){return e.splitView},discovery:function(e){return e.discovery}},fn=pn.playerData,hn={playerId:function(e){return fn(e).playerId},videoTagStatus:function(e){return fn(e).videoTagStatus},pendingVideoTagStatus:function(e){return fn(e).pendingVideoTagStatus},currentVideoTime:function(e){return fn(e).currentVideoTime},currentVideoTimeFragment:function(e){return fn(e).currentVideoTimeFragment},currentVideoDuration:function(e){return fn(e).currentVideoDuration},currentVideoBufferedTime:function(e){return fn(e).currentVideoBufferedTime},playerMode:function(e){return fn(e).playerMode},playerSettings:function(e){return fn(e).playerSettings},playbackMethod:function(e){return fn(e).playbackMethod},playerVisibility:function(e){return fn(e).playerVisibility},playerPlaceholderVisibility:function(e){return fn(e).playerPlaceholderVisibility},playerInstanceUniqId:function(e){return fn(e).playerInstanceUniqId},showBlackScreen:function(e){return fn(e).loader.showBlackScreen},playerSize:function(e){return fn(e).playerSize},errorMessage:function(e){return fn(e).errorMessage},loadingPlayer:function(e){return fn(e).loadingPlayer}},yn=hn.playerSettings,gn={volume:function(e){return yn(e).volume},muted:function(e){return yn(e).muted},quality:function(e){return yn(e).quality},speed:function(e){return yn(e).speed},selectedSettingsCategory:function(e){return yn(e).selectedSettingsCategory},fullscreen:function(e){return yn(e).fullscreen},pendingFullscreenRequest:function(e){return this.fullscreen(e).pendingFullscreenRequest},isFullscreenOn:function(e){return this.fullscreen(e).isFullscreenOn}},vn=function(e){return"".concat("mplayer-monetization-placeholder","-").concat(e)},mn=function(e){return"".concat("mplayer-player-placeholder","-").concat(e)},bn=function(e){return"".concat("mplayer-player-container","-").concat(e)},On=function(e){return"".concat("mplayer-controls-placeholder","-").concat(e)},_n=function(e){return"".concat("mplayer-split-view-placeholder","-").concat(e)},Sn=function(e){return"".concat("mplayer-discovery-placeholder","-").concat(e)},En=function(e){return"".concat("mplayer-content-video","-").concat(e)},wn=function(e){return"".concat("mplayer","-").concat("error-page-message","-").concat(e)},Pn=function(e){return"".concat("mplayer","-").concat("loader","-").concat(e)},Tn=function(e){return"".concat("mplayer","-").concat("mplayer-close-bar-placeholder","-").concat(e)},An=pn.mediaData,Cn={mediaId:function(e){return An(e).mediaId},mediaType:function(e){return An(e).mediaType},videoList:function(e){return An(e).videoList},videoData:function(e){return An(e).videoData},activeVideoIndex:function(e){return An(e).activeVideoIndex},mediaRequest:function(e){return An(e).mediaRequest},mediaLoadingError:function(e){return An(e).mediaLoadingError}},Rn=Cn.videoData,Dn={creator:function(e){return Rn(e).creator},description:function(e){return Rn(e).description},duration:function(e){return Rn(e).duration},externalId:function(e){return Rn(e).externalId},index:function(e){return Rn(e).index},mediaId:function(e){return Rn(e).mediaId},provider:function(e){return Rn(e).provider},sources:function(e){return Rn(e).sources},tags:function(e){return Rn(e).tags},thumbnail:function(e){return Rn(e).thumbnail},title:function(e){return Rn(e).title},showTitle:function(e){return Rn(e).showTitle}},Mn=n(11),In=n.n(Mn);function kn(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:[];return se(function(){return e.apply(void 0,In()(t))},[e,t])}var Nn={root:{height:"100%",left:0,display:"block",width:"100%"}},Ln=function(){return{playerStyle:[Nn.root]}},xn=n(30),Vn=Object(xn.a)(),jn=function(e){return"undefined"===typeof e},Un=function(e){return jn(e)||null===e||0===e.length},Fn=function(){return null!==navigator.userAgent.match(/(iPad)|(iPhone)|(iPod)|(android)|(webOS)/i)},Bn=function(){return"iOS"===Vn.os},Hn=function(e){return Math.floor(10*e)/10},qn=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"0";return parseInt(e,10)/1e3},Wn=function(e,t){return jn(e)||jn(t)?0:e>t?1:-1},zn=function(e,t){var n;return function(){for(var r=arguments.length,i=new Array(r),o=0;o<r;o++)i[o]=arguments[o];clearTimeout(n),n=setTimeout(function(){n=null,e(i)},t)}},Gn=function(e){var t=e.clientWidth*(9/16),n=e.clientHeight;return Math.abs(t-n)>2?t:n},$n=function(e){return function(e){return!e.dataLayer||Array.isArray(e.dataLayer)}(e)?"dataLayer":"mmVideoDataLayer"},Kn=function(e){var t=ue(e,arguments.length>1&&void 0!==arguments[1]?arguments[1]:[]);re(function(){t()},[t]),re(function(){var e=zn(t,150);return window.addEventListener("resize",e),function(){window.removeEventListener("resize",e)}},[t])},Yn=pn.splitView,Zn=function(e){return Yn(e).splitViewRatio},Xn={GENERAL_ERROR:"An error has occurred, please try again later",VIDEO_ERROR:"The video is currently unavailable"},Jn=jt(function(e,t){return{thumbnail:Dn.thumbnail(e),playerId:t.playerId,muted:gn.muted(e),volume:gn.volume(e),currentVideoTime:hn.currentVideoTime(e),playbackMethod:hn.playbackMethod(e),splitViewRatio:Zn(e),playerSize:hn.playerSize(e),isFullscreenOn:gn.isFullscreenOn(e),playerMode:hn.playerMode(e),speed:gn.speed(e)}},function(e){return Ot({updateVideoTagStatus:Qt,updateVideoTime:tn,updateVideoTimeFragment:en,changeLoadingPlayerStatus:un,showBlackScreenLoader:cn,updateVideoDuration:rn,updateMute:an,updateVolume:sn,updateCurrentVideoBufferedTime:nn,setPlayerSize:ln,onErrorMessage:dn},e)})(function(e){var t=e.thumbnail,n=e.playerId,r=e.updateVideoTagStatus,i=e.updateVideoTime,o=e.updateCurrentVideoBufferedTime,a=e.muted,s=e.volume,u=e.currentVideoTime,c=e.playbackMethod,l=e.changeLoadingPlayerStatus,d=e.showBlackScreenLoader,p=e.updateVideoDuration,f=e.updateMute,h=e.updateVolume,y=e.updateVideoTimeFragment,g=e.setPlayerSize,v=e.splitViewRatio,m=e.playerSize,O=e.isFullscreenOn,_=e.playerMode,S=e.onErrorMessage,E=e.speed,w=oe(null),P=!Un(v),T=kn(Ln,[]).playerStyle,A=document.getElementById(bn(n));re(function(){w.current.playbackRate=E},[E]),Kn(function(){if(!Un(A)){var e=function(e,t,n,r,i){var o=e.style.width;return n?"desktop"===r||"miniDesktop"===r||"stickyDesktop"===r?"extraLarge":"medium":"100%"===o?t:i&&o<=Bt?"extraSmall":i&&o>=qt&&o<=Wt?"small":o<=Ft?"extraSmall":o>=Ht&&o<=Wt?"small":o>=zt&&o<=Gt?"medium":o>=$t&&o<=Kt?"large":o>=Yt?"extraLarge":null}(A,m,O,_,P);Un(e)||g(e)}},[A,m,O,_,P,g]);var C="autoplay"===c?"":t;return b("video",{ref:w,style:Jt(T),key:En(n),id:En(n),onEnded:function(){r("complete")},onDurationChange:function(e){var t,n=e.target.duration;t=n,Number.isNaN(t)||"number"!==typeof t||p(n)},onTimeUpdate:function(e){var t=e.target.currentTime;y(t);var n=parseInt(t.toString(),10);n!==u&&i(n)},onVolumeChange:function(e){var t=e.target,n=t.volume,r=t.muted;n!==s&&h(n),a!==r&&f(r)},onPause:function(){r("paused")},onPlaying:function(){r("playing")},onError:function(){r("error"),S(Xn.VIDEO_ERROR)},onLoadStart:function(){l(!0),d(!0)},onCanPlayThrough:function(){l(!1),d(!1),S("")},onCanPlay:function(){l(!1),S("")},onWaiting:function(){l(!0)},onSeeking:function(){r("seeking")},onProgress:function(e){var t=e.target.buffered,n=t.length;n>0&&o(t.end(n-1))},volume:s,muted:a,poster:C,playsInline:!0,"webkit-playsinline":""},b("track",{kind:"captions"}))}),Qn=function(e){return function(t){t({type:"[CORE] update ima status",payload:e})}},er=function(e){return function(t){t({type:"[CORE] update hls status",payload:e})}},tr=function(){return{adBlockCheckerStyle:{backgroundColor:Ut.COLORS.TRANSPARENT,height:"1px",width:"1px"}}},nr=jt(null,function(e){return{onAdBlockDetected:function(){return Qn("blocked")(e)}}})(function(e){var t=oe(),n=kn(tr,[]).adBlockCheckerStyle;return re(function(){0!==t.current.clientHeight&&0!==t.current.clientWidth||(0,e.onAdBlockDetected)()},[e]),b("div",{ref:t},b("div",{class:"adBanner",style:n}))}),rr=n(10),ir=n.n(rr);n(20);var or={root:null,threshold:[0,.1,.2,.3,.4,.5,.6,.7,.8,.9,1],rootMargin:"0px"},ar=function(e){var t=e.id,n=e.updateContainerVisibility,r=e.shouldObserve,i=e.regularMode,o=e.stickyAnchorMode,a=e.children,s=e.style,u=e.isPlaceholder,c=e.splitViewRatio,l=e.className,d=oe(),p=te(null),f=ir()(p,2),h=f[0],y=f[1];return re(function(){null!==h&&h.observe(d.current)},[h]),re(function(){!function(e,t,n){e&&t(new IntersectionObserver(function(e){var t=e[0];n(t.intersectionRatio)},or))}(r,y,n)},[r,n]),Kn(function(){u?function(e,t){var n=e.parentElement.clientWidth;e.style.maxWidth="".concat(n,"px"),Un(t)?e.style.height="".concat(Gn(e),"px"):e.style.height="".concat(Gn(e)*(t/100),"px")}(d.current,c):function(e,t,n){t?(e.style.width="".concat(e.parentElement.clientWidth,"px"),e.style.height="".concat(e.parentElement.clientHeight,"px")):n&&(e.style.width="".concat(e.parentElement.clientWidth,"px"),e.style.height="".concat(e.parentElement.clientHeight+24,"px"))}(d.current,i,o)},[u,i,o]),b("div",{className:l,id:t,ref:d,style:s},a)};function sr(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function ur(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?sr(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):sr(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var cr={display:"flex",flexDirection:"row"},lr=(ur(ur({},cr),{},{justifyContent:"flex-end"}),ur(ur({},cr),{},{justifyContent:"center"})),dr=ur(ur({},cr),{},{justifyContent:"space-between"}),pr=(ur(ur({},dr),{},{alignItems:"baseline"}),ur(ur({},lr),{},{alignItems:"center"})),fr=ur(ur({},cr),{},{justifyContent:"flex-start"}),hr=(ur(ur({},fr),{},{alignItems:"center"}),ur(ur({},fr),{},{alignItems:"flex-end",flexWrap:"wrap"}),{display:"flex",flexDirection:"column"}),yr=(ur(ur({},hr),{},{justifyContent:"flex-start"}),ur(ur({},hr),{},{justifyContent:"center"})),gr=(ur(ur({},hr),{},{justifyContent:"flex-end",alignItems:"center"}),ur(ur({},yr),{},{alignItems:"center"}));function vr(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function mr(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?vr(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):vr(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var br=mr(mr({},hr),{},{position:"relative",background:Ut.COLORS.BLACK}),Or=pn.anchorOptions,_r=function(e){return Or(e).orientation},Sr=function(e){return Or(e).canClose},Er=function(e){return Or(e).anchorData},wr=function(e){return Er(e).anchorDisabledByUser},Pr=function(e){return Er(e).anchorStatus};function Tr(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Ar(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Tr(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Tr(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Cr=jt(function(e){return{shouldObserve:"lazyplay"===hn.playbackMethod(e)||"autoplay_when_viewable"===hn.playbackMethod(e),regularMode:"inactive"===Pr(e)||!Un(Zn(e)),stickyAnchorMode:"sticky"===_r(e)&&"active"===Pr(e)&&Sr(e),style:Ar({},mr({},br)),isPlaceholder:!1}},function(e){return{updateContainerVisibility:function(t){return function(e){return function(t){t({type:"[CORE] update player visibility",payload:e})}}(t)(e)}}})(ar);function Rr(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Dr(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Rr(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Rr(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Mr={width:"100%",clear:"both",margin:"16px 0"};function Ir(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function kr(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Ir(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Ir(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Nr=jt(function(e){return{shouldObserve:"sticky"!==_r(e),style:kr({},Dr({},Mr)),splitViewRatio:Zn(e),isPlaceholder:!0,className:"monti-placeholder-mm-player"}},function(e){return{updateContainerVisibility:function(t){return function(e){return function(t){t({type:"[CORE] update placeholder visibility",payload:e})}}(t)(e)}}})(ar),Lr=function(){return{monetizationStyle:{position:"absolute",width:"100%",top:"0",display:"none"}}},xr=function(e){var t=e.playerId,n=kn(Lr,[]).monetizationStyle,r=oe();return Kn(function(){console.log("the monetization parent element : ",r.current.parentElement),r.current.style.height="".concat(Gn(r.current.parentElement),"px")}),b("div",{id:vn(t),style:n,ref:r})};function Vr(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function jr(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Vr(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Vr(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Ur={position:"relative",color:Ut.COLORS.WHITE,fontFamily:Ut.TEXT_FONT_FAMILY.LATO,fontWeight:"bold",textAlign:"center",tiny:{fontSize:Ut.FONT_SIZE.EXTRA_TINY},big:{fontSize:Ut.FONT_SIZE.SMALL}},Fr={position:"relative",color:Ut.COLORS.WHITE,tiny:{height:"12px",width:"12px",marginBottom:"8px"},big:{height:"24px",width:"24px",marginBottom:"16px"}},Br=jr(jr({},gr),{},{width:"100%",height:"100%",position:"absolute",top:0,backdropFilter:"blur(3px)",webkitBackdropFilter:"blur(3px)",backgroundColor:Ut.COLORS.BLUR_TRANSPARENT}),Hr=function(e){var t="extraSmall"===e||"small"===e,n="medium"===e||"large"===e||"extraLarge"===e;return{errorMessageStyle:[Ur,t&&Ur.tiny,n&&Ur.big],iconStyle:[Fr,t&&Fr.tiny,n&&Fr.big],screenStyle:jr({},Br)}},qr=n(12),Wr=n.n(qr);function zr(){return(zr=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e}).apply(this,arguments)}function Gr(){return(Gr=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e}).apply(this,arguments)}function $r(){return($r=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e}).apply(this,arguments)}var Kr={CLOSE_FILL:function(e){e.styles;var t=Wr()(e,["styles"]);return We.createElement("svg",Gr({xmlns:"http://www.w3.org/2000/svg",viewBox:"0 0 24 24",width:"24",height:"24"},t),We.createElement("path",{fill:"none",d:"M0 0h24v24H0z"}),We.createElement("path",{d:"M12 10.586l4.95-4.95 1.414 1.414-4.95 4.95 4.95 4.95-1.414 1.414-4.95-4.95-4.95 4.95-1.414-1.414 4.95-4.95-4.95-4.95L7.05 5.636z",fill:"rgba(255,255,255,1)"}))},ERROR_WARNING_FILL:function(e){e.styles;var t=Wr()(e,["styles"]);return We.createElement("svg",zr({xmlns:"http://www.w3.org/2000/svg",viewBox:"0 0 24 24",width:"24",height:"24"},t),We.createElement("path",{fill:"none",d:"M0 0h24v24H0z"}),We.createElement("path",{d:"M12 22C6.477 22 2 17.523 2 12S6.477 2 12 2s10 4.477 10 10-4.477 10-10 10zm-1-7v2h2v-2h-2zm0-8v6h2V7h-2z",fill:"rgba(255,255,255,1)"}))},PLAY_BLUR:function(e){e.styles;var t=Wr()(e,["styles"]);return We.createElement("svg",$r({xmlns:"http://www.w3.org/2000/svg",viewBox:"0 0 60 60"},t),We.createElement("circle",{cx:"30",cy:"30",r:"30",fillRule:"evenodd",clipRule:"evenodd",fillOpacity:".35"}),We.createElement("path",{fill:"none",d:"M11 11h38v38H11z"}),We.createElement("path",{d:"M43.3 30.7L22.1 44.8c-.3.2-.7.2-1 0-.3-.2-.5-.5-.5-.9V15.8c0-.4.2-.7.5-.9.3-.2.7-.2 1 0L43.3 29c.3.2.4.5.4.8s-.2.7-.4.9z",fill:"currentColor"}))}},Yr=n(31),Zr=n.n(Yr);function Xr(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Jr(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Xr(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Xr(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Qr=Ut.COLORS.WHITE,ei=function(e,t){var n=function(e){return{root:Jr(Jr({},cr),{},{alignItems:"center",width:"fit-content",height:"fit-content",outline:"none",color:e}),focused:{outline:"".concat(Ut.COLORS.WHITE," solid 1px")}}}(t||Qr);return{iconStyle:[n.root,e&&n.focused]}},ti=function(e){var t=e.icon,n=e.style,r=e.onClick,i=e.onMouseEnter,o=e.onMouseLeave,a=e.onKeyDown,s=e.id,u=e.color,c=e.clickable,l=void 0===c||c,d=e.focusable,p=void 0===d||d,f=te(!1),h=ir()(f,2),y=h[0],g=h[1],v=te(!1),m=ir()(v,2),O=m[0],_=m[1],S=kn(ei,[O,u]).iconStyle,E=l?{onClick:r,onMouseEnter:i,onMouseLeave:o,onFocus:function(e){y||_(!0),jn(i)||i(e)},onBlur:function(){document.hasFocus()&&g(!1),_(!1)},onKeyDown:function(e){jn(a)||a(e),"Enter"!==e.key||jn(r)||r()},onMouseDown:function(){g(!0),_(!1)}}:{},w=p?{tabIndex:0}:{};return b("span",Zr()({id:s,style:Jt([S,n])},E,w),b(t,null))},ni=jt(function(e){return{playerSize:hn.playerSize(e),playerErrorMessage:hn.errorMessage(e),mediaErrorMessage:Cn.mediaLoadingError(e),playerUniqId:hn.playerInstanceUniqId(e)}})(function(e){var t,n=e.playerSize,r=e.playerErrorMessage,i=e.mediaErrorMessage,o=e.playerUniqId,a=kn(Hr,[n]),s=a.errorMessageStyle,u=a.iconStyle,c=a.screenStyle,l=r||i;return Un(r)&&Un(i)?null:b("div",{id:(t=o,"".concat("mplayer","-").concat("error-page","-").concat(t)),style:c},b(ti,{icon:Kr.ERROR_WARNING_FILL,style:Jt(u)}),b("div",{id:wn(o),style:Jt(s)},l))}),ri=function(e,t){var n=function(e){return{height:"100%",left:0,display:"block",width:"100%",position:"relative",splitView:{width:"".concat(e/(9/16),"px")}}}(e);return{playerWrapperStyle:[n,t&&n.splitView]}},ii=jt(function(e){return{splitViewRatio:Zn(e)}})(function(e){var t=e.splitViewRatio,n=e.children,r=oe(),i=te(null),o=ir()(i,2),a=o[0],s=o[1],u=!Un(t),c=kn(ri,[a,u]).playerWrapperStyle;return Kn(function(){s(r.current.parentElement.clientHeight)},[r]),b("div",{ref:r,style:Jt(c)},n)});function oi(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function ai(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?oi(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):oi(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var si=ai(ai({},cr),{},{position:"absolute",width:"100%",height:"100%"}),ui={width:"100%",height:"100%",position:"relative"},ci={display:"flex",position:"relative",flexGrow:"1"},li={position:"absolute",zIndex:"1",width:"100%",top:"0",height:"100%",pointerEvents:"none"},di={position:"absolute",zIndex:"2",width:"100%",top:"0",height:"100%",pointerEvents:"none"},pi=function(){return{splitViewWrapperStyle:ai({},si),playerAndControlsWrapperStyle:ai({},ui),splitViewPlaceholderStyle:ai({},ci),controlsPlaceholderStyle:ai({},li),discoveryPlaceholderStyle:ai({},di)}};function fi(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function hi(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?fi(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):fi(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var yi={position:"absolute",overflow:"hidden",backgroundColor:Ut.COLORS.GRAY_TRANSPARENT,borderRadius:Ut.BORDER_RADIUS.SMALL,height:"6px",small:{width:"120px",height:"4px"},medium:{width:"200px"},largeAndExtraLarge:{width:"220px"},splitView:{width:"120px",height:"4px"},error:{display:"none"}},gi=hi(hi({},pr),{},{width:"100%",height:"100%",position:"absolute",top:"0",backgroundColor:Ut.COLORS.TRANSPARENT,blackScreen:{backgroundColor:Ut.COLORS.BLACK}}),vi=function(e,t,n,r,i){var o,a=!Un(n),s="small"===e,u="medium"===e,c="large"===e||"extraLarge"===e,l=i||Ut.COLORS.WHITE,d=(o=l,{position:"relative",width:"100%",height:"6px",borderRadius:Ut.BORDER_RADIUS.SMALL,animationName:"loaderAnimation",animationDuration:"3.5s",animationIterationCount:"infinite",animationTimingFunction:"ease-in-out",backgroundColor:o,small:{height:"4px"},splitView:{height:"4px"}});return{loaderStyle:[yi,r&&yi.error,s&&yi.small,u&&yi.medium,c&&yi.largeAndExtraLarge,a&&yi.splitView],barStyle:[d,s&&d.small,a&&d.splitView],screenStyle:[gi,t&&gi.blackScreen]}},mi=pn.monetization,bi={continuePlayingWhileWaitingForAd:function(e){return mi(e).continuePlayingWhileWaitingForAd},midrolls:function(e){return mi(e).midrolls},prerollEnabled:function(e){return mi(e).prerollEnabled},vpaidMode:function(e){return mi(e).vpaidMode},adRequestTimeout:function(e){return mi(e).adRequestTimeout},adsData:function(e){return mi(e).adsData}},Oi=bi.adsData,_i={adTagUrlTemplate:function(e){return Oi(e).adTagUrlTemplate},adType:function(e){return Oi(e).adType},adStatus:function(e){return Oi(e).adStatus},pendingAdStatus:function(e){return Oi(e).pendingAdStatus},adErrorMessage:function(e){return Oi(e).adErrorMessage},adDuration:function(e){return Oi(e).adDuration},playedMidrolls:function(e){return Oi(e).playedMidrolls},adImpression:function(e){return Oi(e).adImpression},adOpportunity:function(e){return Oi(e).adOpportunity},isVastAd:function(e){return Oi(e).isVastAd},adCurrentTime:function(e){return Oi(e).adCurrentTime},adMuted:function(e){return Oi(e).adMuted},adVolume:function(e){return Oi(e).adVolume},currentAdTag:function(e){return Oi(e).currentAdTag},adUnit:function(e){return Oi(e).adUnit},slotNumber:function(e){return Oi(e).slotNumber},podNumber:function(e){return Oi(e).podNumber},loadingAd:function(e){return Oi(e).loadingAd}},Si=pn.brandingData,Ei=function(e){return Si(e).brandingColor},wi=jt(function(e){return{showBlackScreen:hn.showBlackScreen(e),playerSize:hn.playerSize(e),splitViewRatio:Zn(e),playerUniqId:hn.playerInstanceUniqId(e),playerErrorMessage:hn.errorMessage(e),mediaErrorMessage:Cn.mediaLoadingError(e),loadingPlayer:hn.loadingPlayer(e),loadingAd:_i.loadingAd(e),brandingColor:Ei(e)}})(function(e){var t,n=e.playerSize,r=e.showBlackScreen,i=e.splitViewRatio,o=e.playerUniqId,a=e.playerErrorMessage,s=e.mediaErrorMessage,u=e.loadingPlayer,c=e.loadingAd,l=e.brandingColor,d=!Un(a)||!Un(s),p=u||c,f=kn(vi,[n,r,i,d,l]),h=f.loaderStyle,y=f.barStyle,g=f.screenStyle;return p?b("div",{id:(t=o,"".concat("mplayer","-").concat("loader-page","-").concat(t)),style:Jt(g)},b("div",{id:Pn(o),style:Jt(h)},b("div",{style:Jt(y)}))):null}),Pi=function(e){var t=e.playerId,n=e.store,r=e.playerPosition,i=kn(pi,[]),o=i.splitViewWrapperStyle,a=i.playerAndControlsWrapperStyle,s=i.splitViewPlaceholderStyle,u=i.controlsPlaceholderStyle,c=i.discoveryPlaceholderStyle;return re(function(){!function(e){var t=document.createElement("link");t.setAttribute("href","https://fonts.googleapis.com/css2?family=Lato:wght@300;400&display=swap"),t.setAttribute("rel","stylesheet"),t.setAttribute("type","text/css"),e.appendChild(t)}(r),function(e){var t=document.createElement("style");t.type="text/css",t.textContent="@keyframes loaderAnimation {0% {left: -100%}49% {left: 100%}50% {left: 100%}100% {left: -100%}}",e.appendChild(t)}(r)},[r]),b(Ze,{store:n},b(Nr,{id:mn(t)},b(Cr,{id:bn(t)},b("div",{id:Tn(t)}),b("div",{style:a},b("div",{style:o},b(ii,null,b(Jn,{playerId:t}),b(xr,{playerId:t}),b(wi,null),b(nr,null)),b("div",{id:_n(t),style:s})),b("div",{id:On(t),style:u}),b("div",{id:Sn(t),style:c}),b(ni,null)))))},Ti=n(1),Ai=n.n(Ti),Ci=function e(){var t=this;Ai()(this,e),f()(this,"HLS_MAIN_SCRIPT","https://cdn.jsdelivr.net/npm/hls.js@0.9.1"),f()(this,"HLS_FALLBACK_SCRIPT","https://www.oo-syringe.com/newplayer/mplayer_hls_wrapper.0.0.0.js"),f()(this,"IMA_SCRIPT","https://imasdk.googleapis.com/js/sdkloader/ima3.js"),f()(this,"MMPLUS_CONTAINER_ID","GTM-PL4PD49"),f()(this,"MM_CONTAINER_ID","GTM-TCW5HW"),f()(this,"dependenciesCallbacks",void 0),f()(this,"imaLoadingStatus",""),f()(this,"hlsLoadingStatus",""),f()(this,"gtmLoaded",!1),f()(this,"addDependenciesCallback",function(e){t.dependenciesCallbacks.includes(e)||t.dependenciesCallbacks.push(e)}),f()(this,"isDependenciesReady",function(){return t.gtmLoaded&&"loading"!==t.getHLSLoadingStatus()&&"loading"!==t.getIMALoadingStatus()}),f()(this,"getIMALoadingStatus",function(){return t.imaLoadingStatus}),f()(this,"getHLSLoadingStatus",function(){return t.hlsLoadingStatus}),f()(this,"removeDependenciesCallback",function(e){t.dependenciesCallbacks.filter(function(t){return t===e})}),f()(this,"loadScript",function(e,t,n){var r=document.createElement("script");r.setAttribute("src",e),r.addEventListener("load",t),r.addEventListener("error",n),document.body.appendChild(r)}),f()(this,"onScriptLoaded",function(e){t.dependenciesCallbacks.forEach(function(t){t.onDependencyReady(e)})}),f()(this,"onScriptFailed",function(e,n){t.dependenciesCallbacks.forEach(function(t){t.onDependencyFailure(e,n)})}),f()(this,"onHlsScriptLoaded",function(){void 0!==window.Hls?t.onScriptLoaded("hls"):t.onHlsLoadError()}),f()(this,"onHlsLoadError",function(){t.loadScript(t.HLS_FALLBACK_SCRIPT,t.onMMhlsScriptLoaded,t.onMMHlsScriptFailure)}),f()(this,"onMMhlsScriptLoaded",function(){t.onScriptLoaded("hls")}),f()(this,"onMMHlsScriptFailure",function(e){t.onScriptFailed("hls",e)}),f()(this,"onImaLoadError",function(e){t.imaLoadingStatus="error",t.onScriptFailed("ima",e)}),f()(this,"onImaLoaded",function(){t.onScriptLoaded("ima"),t.imaLoadingStatus="success"}),f()(this,"shouldLoadMmGTM",function(){var e=window.google_tag_manager;return!e||!e[t.MMPLUS_CONTAINER_ID]&&!e[t.MM_CONTAINER_ID]}),f()(this,"loadGTMifNeeded",function(){if(t.shouldLoadMmGTM()){var e,n;try{e=window.parent,n=window.parent.document}catch(u){e=window,n=window.document}var r=$n(e),i="dataLayer"!==r?"&l=".concat(r):"";e[r]=e[r]||[],e[r].push({"gtm.start":(new Date).getTime(),event:"gtm.js"});var o=n.getElementsByTagName("script")[0],a=n.createElement("script");a.setAttribute("async",""),a.setAttribute("src","https://www.googletagmanager.com/gtm.js?id=GTM-PL4PD49".concat(i)),o.parentNode.insertBefore(a,o);var s=n.createElement("iframe");s.src="https://www.googletagmanager.com/ns.html?id=GTM-PL4PD49",s.height="0",s.width="0",s.style="display:none;visibility:hidden",n.body.appendChild(s),t.gtmLoaded=!0}}),f()(this,"loadHLS",function(){Bn()||"safari"===Vn.name?t.hlsLoadingStatus="no-need":(t.loadScript(t.HLS_MAIN_SCRIPT,t.onHlsScriptLoaded,t.onHlsLoadError),t.hlsLoadingStatus="loading")}),f()(this,"loadIMA",function(){t.loadScript(t.IMA_SCRIPT,t.onImaLoaded,t.onImaLoadError),t.imaLoadingStatus="loading"}),f()(this,"loadExternalDependencies",function(){""===t.getIMALoadingStatus()&&t.loadIMA(),""===t.getHLSLoadingStatus()&&t.loadHLS(),t.gtmLoaded||t.loadGTMifNeeded()}),this.dependenciesCallbacks=[]};f()(Ci,"instance",void 0),f()(Ci,"getInstance",function(){return Ci.instance||(Ci.instance=new Ci),Ci.instance});var Ri=function(e){return"".concat("mplayer-monetization-ad-container","-").concat(e)},Di=function(e){return"".concat("mplayer-monetization-safari-video-ad","-").concat(e)},Mi=jt(function(e){return{contentVideoTime:hn.currentVideoTime(e),playerUniqId:hn.playerInstanceUniqId(e)}})(function(e){var t=e.contentVideoTime,n=e.playerUniqId,r=oe();return re(function(){Un(r.current)||(r.current.currentTime=t)},[t]),b("video",{id:Di(n),ref:r,style:{backgroundColor:"rgb(0, 0, 0)",width:"100%",height:"100%"},title:"Advertisement",preload:"auto",muted:!0,playsInline:!0,"webkit-playsinline":""})});function Ii(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function ki(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Ii(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Ii(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Ni=jt(function(e,t){return ki(ki({},t),{},{adStatus:_i.adStatus(e)})})(function(e){var t=e.playerId,n=e.adStatus,r="playing"===n||"paused"===n;return re(function(){document.getElementById(vn(t)).style.display=r?"flex":"none"},[t,r]),b("div",{style:{width:"100%",height:"100%"}},b("div",{id:Ri(t),style:{height:"100%",width:"100%"}},Bn()&&b(Mi,null)))}),Li=function(e){var t=e.store,n=e.playerId;return b(Ze,{store:t},b(Ni,{playerId:n}))},xi=n(2),Vi=n.n(xi),ji=(n(46),function(){function e(t,n,r){Ai()(this,e),f()(this,"store",void 0),f()(this,"getDependenciesElements",void 0),f()(this,"oldState",void 0),f()(this,"unsubscribe",void 0),f()(this,"onChange",void 0),this.store=t,this.oldState=t.getState(),this.getDependenciesElements=n,this.unsubscribe=t.subscribe(this.onStateChanged.bind(this)),this.onChange=r}return Vi()(e,[{key:"stopSubscription",value:function(){this.unsubscribe(),this.oldState=null,this.getDependenciesElements=null,this.store=null,this.unsubscribe=null,this.onChange=null}},{key:"onStateChanged",value:function(){var e=this.store.getState(),t=this.getDependenciesElements(this.oldState),n=this.getDependenciesElements(e);t.every(function(e,t){return e===n[t]})||this.onChange(e),this.oldState=e}}]),e}()),Ui=pn.dependenciesLoadingStatus,Fi={loadingImaStatus:function(e){return Ui(e).loadingImaStatus},loadingHLSStatus:function(e){return Ui(e).loadingHLSStatus}},Bi=function(e){return"blocked"===Fi.loadingImaStatus(e)},Hi=function(e){return"playing"===e||"requested"===e||"loaded"===e||"paused"===e},qi=function(){function e(t,n){Ai()(this,e),f()(this,"videoTimeSubscriber",void 0),f()(this,"adsScheduler",void 0),this.videoTimeSubscriber=new ji(t,e.getVideoTimeDependencies,this.onVideoTimeChanged.bind(this)),this.adsScheduler=n}return Vi()(e,[{key:"onVideoTimeChanged",value:function(t){"seeking"!==hn.videoTagStatus(t)&&(e.shouldRequestAd(t)?this.adsScheduler.onPreAdTimeReached(e.getMidroll(t)):e.isOnAdTime(t)&&this.adsScheduler.onAdTimeReached())}}],[{key:"getVideoTimeDependencies",value:function(e){return[hn.currentVideoTime(e)]}},{key:"isTimeInPreAdRange",value:function(e,t){return t>=e&&e>=t-$i}},{key:"getNextSpecificMidrollTime",value:function(t,n){return-1!==t.indexOf(n)?n:t.find(function(t){return e.isTimeInPreAdRange(n,t)})}},{key:"getNextReocurringMidrollNumber",value:function(e,t){var n=t/e;return t%e===0?n:Math.ceil(n)}},{key:"getMidroll",value:function(t){var n=hn.currentVideoTime(t),r=bi.midrolls(t),i=r.every,o=r.on,a=Dn.mediaId(t);if(!Un(i)){var s=e.getNextReocurringMidrollNumber(i,n);return{currentTime:n,mediaId:a,midrollNumber:s,midrollTime:s*i}}if(!Un(o)){var u=e.getNextSpecificMidrollTime(o,n);return{midrollNumber:o.indexOf(u)+1,currentTime:n,midrollTime:u,mediaId:a}}return null}},{key:"isMidrollAlreadyPlayed",value:function(e,t){return-1!==e.indexOf(t)}},{key:"isMidrollReached",value:function(t){var n=hn.currentVideoTime(t),r=bi.midrolls(t),i=r.every,o=r.on,a=_i.playedMidrolls(t);if(!Un(i)&&n>0){var s=e.getNextReocurringMidrollNumber(i,n),u=s*i;return!this.isMidrollAlreadyPlayed(a,s)&&e.isTimeInPreAdRange(n,u)}if(!Un(o)){var c=e.getNextSpecificMidrollTime(o,n),l=o.indexOf(c)+1;return l>0&&!this.isMidrollAlreadyPlayed(a,l)}return!1}},{key:"shouldRequestAd",value:function(e){var t=_i.adStatus(e);return!Bi(e)&&!Hi(t)&&this.isMidrollReached(e)}},{key:"isOnAdTime",value:function(t){var n=hn.currentVideoTime(t),r=bi.midrolls(t),i=r.every,o=r.on,a=_i.playedMidrolls(t);if(Bi(t))return!1;if(!Un(i)){var s=e.getNextReocurringMidrollNumber(i,n);return 0!==n&&n%i===0&&!this.isMidrollAlreadyPlayed(a,s)}if(!Un(o)){var u=o.indexOf(n);return-1!==u&&!this.isMidrollAlreadyPlayed(a,u)}return!1}}]),e}(),Wi=function(){function e(t){var n=this;Ai()(this,e),f()(this,"referrerUrl",void 0),f()(this,"staticAdTag",void 0),f()(this,"generate",function(e,t){var r=encodeURIComponent(n.referrerUrl);return Un(n.staticAdTag)?n.adTagFromApi(e,r,t):n.parseAdTag(n.staticAdTag,e,r,t)}),this.staticAdTag=t,this.referrerUrl=window.location.href}return Vi()(e,[{key:"parseAdTag",value:function(t,n,r,i){var o=t.replace("##AdUnit##",e.parseAdName(n)).replace("##DESCRIPTION_URL_UNESC##",r).replace("##REFERRER_URL_UNESC##",encodeURIComponent(this.referrerUrl)).replace("##CACHEBUSTER##",e.cacheBuster(n)).replace("##MIDROLL_ORDER##",e.adIndexFromName(n));return o=e.replaceVideoId(o,"##VIDEO_ID##",i),o=e.addHacksToAdTag(o)}},{key:"adTagFromApi",value:function(e,t,n){try{var r=window.getVideoTag(t,e);return Un(r)?null:this.parseAdTag(r,e,t,n)}catch(i){return null}}}],[{key:"getCCPAConsent",value:function(t){try{var n="";return window.__uspapi&&window.__uspapi("getUSPData",1,function(e,t){t&&(n=e.uspString)}),e.setSearchParamToAdTag(t,"us_privacy",n)}catch(r){return t}}},{key:"replaceVideoId",value:function(e,t,n){return e.replace(t,n).replace(encodeURIComponent(t),n).replace(encodeURIComponent(encodeURIComponent(t)),n)}},{key:"cacheBuster",value:function(t){return"".concat((new Date).getTime()).concat(e.adIndexFromName(t))}},{key:"parseAdName",value:function(t){return t.startsWith("preroll")?"PR":"MR".concat(e.adIndexFromName(t))}},{key:"adIndexFromName",value:function(e){return e.replace(/[^\d]*/g,"")}}]),e}();f()(Wi,"setSearchParamToAdTag",function(e,t,n){var r=new URL(e),i=decodeURIComponent(n);return r.searchParams.set(t,i),r.href}),f()(Wi,"getSearchParamFromAdTag",function(e,t){return new URL(e).searchParams.get(t)}),f()(Wi,"addHacksToAdTag",function(e){var t=e,n=Wi.getSearchParamFromAdTag(t,"cust_params");if(!jn(window.mmAPSbids)&&!Un(n)){var r="".concat(window.mmAPSbids,"&").concat(n);t=Wi.setSearchParamToAdTag(t,"cust_params",r)}if(!jn(window.shouldPlayAdRules)){var i=window.shouldPlayAdRules?"1":"0";t=Wi.setSearchParamToAdTag(t,"ad_rule",i)}return t=Wi.getCCPAConsent(t)});var zi=function(){function e(t,n){Ai()(this,e),f()(this,"store",void 0),f()(this,"videoTagStatusSubscriber",void 0),f()(this,"adsScheduler",void 0),f()(this,"previousVideoTagStatus",void 0);var r=t.getState;this.store=t,this.adsScheduler=n,this.previousVideoTagStatus=hn.videoTagStatus(r()),this.videoTagStatusSubscriber=new ji(t,e.getVideoTagStatusDependencies,this.onVideoTagStatusChanged.bind(this))}return Vi()(e,[{key:"onVideoTagStatusChanged",value:function(t){var n=hn.videoTagStatus(t),r=_i.adStatus(t);"seeking"===this.previousVideoTagStatus&&(Hi(r)?this.adsScheduler.onSeekedWhileAdInProgress():e.isSeekedOverMidroll(t)&&this.adsScheduler.onSeekToAdOpportunity(e.getSeekedMidroll(t))),this.previousVideoTagStatus=n}}],[{key:"getVideoTagStatusDependencies",value:function(e){return[hn.videoTagStatus(e)]}},{key:"getClosestSkippedUnplayedMidroll",value:function(e,t){for(var n=t;n>0;n-=1)if(-1===e.indexOf(n))return n;return null}},{key:"getClosestLowerSeekedMidrollNumber",value:function(e,t){var n=In()(e).reverse().find(function(e){return e<=t});return e.indexOf(n)+1}},{key:"getSeekedSpecificMidroll",value:function(e,t,n,r){var i=this.getClosestLowerSeekedMidrollNumber(e,t),o=this.getClosestSkippedUnplayedMidroll(r,i);return{midrollNumber:o,currentTime:t,midrollTime:e[o-1],mediaId:n}}},{key:"isSeekedOverSpecificMidroll",value:function(e,t,n){if(jn(e))return!1;var r=this.getClosestLowerSeekedMidrollNumber(e,n);return null!==this.getClosestSkippedUnplayedMidroll(t,r)}},{key:"getSeekedReoccuringMidroll",value:function(e,t,n,r){var i=Math.floor(t/e),o=this.getClosestSkippedUnplayedMidroll(r,i);return{midrollTime:o*e,currentTime:t,midrollNumber:o,mediaId:n}}},{key:"isSeekedOverReoccuringMidroll",value:function(e,t,n){if(jn(e))return!1;var r=Math.floor(n/e);return null!==this.getClosestSkippedUnplayedMidroll(t,r)}},{key:"getSeekedMidroll",value:function(e){var t=_i.playedMidrolls(e),n=hn.currentVideoTime(e),r=bi.midrolls(e),i=r.every,o=r.on,a=Cn.mediaId(e);return this.isSeekedOverReoccuringMidroll(i,t,n)?this.getSeekedReoccuringMidroll(i,n,a,t):this.isSeekedOverSpecificMidroll(o,t,n)?this.getSeekedSpecificMidroll(o,n,a,t):null}},{key:"isSeekedOverMidroll",value:function(e){var t=_i.playedMidrolls(e),n=hn.currentVideoTime(e),r=bi.midrolls(e),i=r.every,o=r.on,a=o;return bi.prerollEnabled(e)&&(a=o.filter(function(e){return 0!==e})),this.isSeekedOverReoccuringMidroll(i,t,n)||this.isSeekedOverSpecificMidroll(a,t,n)}}]),e}(),Gi=function e(t,n){var r=this;Ai()(this,e),f()(this,"pendingAdStatusStoreSubscriber",void 0),f()(this,"adsScheduler",void 0),f()(this,"onPendingAdStatusChanged",function(e){var t=_i.pendingAdStatus(e).type,n=_i.adStatus(e);if("playPreroll"===t&&!Hi(n)){var i=Cn.activeVideoIndex(e),o=Dn.mediaId(e);r.adsScheduler.onPrerollReached(o,i+1)}}),this.adsScheduler=n,this.pendingAdStatusStoreSubscriber=new ji(t,e.getPendingAdStatusDependencies,this.onPendingAdStatusChanged.bind(this))};f()(Gi,"getPendingAdStatusDependencies",function(e){return[_i.pendingAdStatus(e)]});var $i=3,Ki=function e(t,n){var r=this;Ai()(this,e),f()(this,"videoTimeSubscriber",void 0),f()(this,"videoSeekSubscriber",void 0),f()(this,"adTagGenerator",void 0),f()(this,"monetization",void 0),f()(this,"lastRequestedMidroll",null),f()(this,"prerollScheduler",void 0),f()(this,"generateMidrollTag",function(e){var t="midroll".concat(e.midrollNumber);return r.adTagGenerator.generate(t,e.mediaId)}),f()(this,"generatePrerollTag",function(e,t){var n="preroll".concat(t);return r.adTagGenerator.generate(n,e)}),f()(this,"onAdTimeReached",function(){r.monetization.onMidrollAdOpportunity()}),f()(this,"onPreAdTimeReached",function(e){r.onPreMidrollAdOpportunity(e)}),f()(this,"onSeekToAdOpportunity",function(e){r.onPreMidrollAdOpportunity(e)}),f()(this,"isMidrollAlreadyRequested",function(e){return e.midrollNumber===r.lastRequestedMidroll.midrollNumber&&e.mediaId===r.lastRequestedMidroll.mediaId&&e.midrollTime===r.lastRequestedMidroll.midrollTime}),f()(this,"onPreMidrollAdOpportunity",function(e){if(Un(r.lastRequestedMidroll)||!r.isMidrollAlreadyRequested(e)){r.lastRequestedMidroll=e;var t=r.generateMidrollTag(e);r.monetization.onPreMidrollAdOpportunity(e,t)}}),f()(this,"onPrerollReached",function(e,t){var n=r.generatePrerollTag(e,t);r.monetization.onPrerollAdOpportunity(n)}),f()(this,"onSeekedWhileAdInProgress",function(){r.monetization.onMidrollAdOpportunity()});var i=t.getState;this.monetization=n,this.videoTimeSubscriber=new qi(t,this),this.videoSeekSubscriber=new zi(t,this),this.prerollScheduler=new Gi(t,this);var o=_i.adTagUrlTemplate(i());this.adTagGenerator=new Wi(o)},Yi=function(){function e(){Ai()(this,e)}return Vi()(e,null,[{key:"generateAdRequest",value:function(e,t,n){var r=new google.ima.AdsRequest;return r.adTagUrl=e,Fn()||r.setAdWillPlayMuted(t),r.vastLoadTimeout=n,r}}]),e}(),Zi=function(e){return function(t){t({type:"[MONETIZATION] change ad status",payload:e})}},Xi=function(e){return function(t){t({type:"[COMMON] set pending video status",payload:{pendingStatusObject:{type:e,value:""}}})}},Ji=function(e){return function(t){t({type:"[MONETIZATION] change loading ad status",payload:e})}},Qi=function(e){return function(t){t({type:"[MONETIZATION] update ad muted",payload:e})}},eo=function(e){return function(t){t({type:"[MONETIZATION] change ad volume",payload:e})}},to=function e(t,n,r,i,o){var a=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"IMAAdManager",void 0),f()(this,"adsLoader",void 0),f()(this,"adDisplayContainer",void 0),f()(this,"adVideoElement",void 0),f()(this,"videoPlayerElement",void 0),f()(this,"adContainerElement",void 0),f()(this,"anchorStatusStoreSubscriber",void 0),f()(this,"totalAdRequestMadeAmount",0),f()(this,"registerForWindowResize",function(){var e=zn(a.onResize.bind(a),80);window.addEventListener("resize",e)}),f()(this,"initMutationObserver",function(e){new MutationObserver(a.onResize).observe(e,{attributes:!0,childList:!1,subtree:!1})}),f()(this,"loadNewAd",function(e,t){var n=a.store.dispatch;a.clearOldAdManagerIfExist();var r=a.createAdRequest(e);try{a.validateAdRequestCorrectness(r),a.adsLoader.requestAds(r),function(e,t){return function(n){n({type:"[MONETIZATION] change ad tag",payload:{adTag:e,adUnit:t}})}}(e,t)(n),Zi("requested")(n),a.totalAdRequestMadeAmount+=1}catch(i){a.onAdError(a.getLoadingError(r))}}),f()(this,"playAd",function(){try{a.IMAAdManager.init(a.videoPlayerElement.clientWidth,a.videoPlayerElement.clientHeight,google.ima.ViewMode.NORMAL);try{a.IMAAdManager.start()}catch(e){return!1}return!0}catch(t){return a.onAdError(a.getPlayAdError("ad manager start error")),!1}}),f()(this,"clearOldAdManagerIfExist",function(){Un(a.IMAAdManager)||(a.IMAAdManager.destroy(),a.IMAAdManager=null)}),f()(this,"createAdLoader",function(e,t){var n=bi.vpaidMode(e);a.adsLoader=new google.ima.AdsLoader(t),a.adsLoader.getSettings().setDisableCustomPlaybackForIOS10Plus(!0),a.adsLoader.getSettings().setVpaidMode(google.ima.ImaSdkSettings.VpaidMode[n]),a.adsLoader.addEventListener(google.ima.AdsManagerLoadedEvent.Type.ADS_MANAGER_LOADED,a.onIMAAdsManagerLoaded.bind(a),!1,a),a.adsLoader.addEventListener(google.ima.AdErrorEvent.Type.AD_ERROR,a.onAdError.bind(a),!1,a)}),f()(this,"createAdRequest",function(e){var t=a.store.getState,n=gn.muted(t()),r=bi.adRequestTimeout(t());return Yi.generateAdRequest(e,n,r)}),f()(this,"validateAdRequestCorrectness",function(e){e&&e.adTagUrl&&decodeURIComponent(e.adTagUrl.replace(/\+/g," "))}),f()(this,"getLoadingError",function(e){var t=function(){return"bad ad request ".concat(JSON.stringify(e))};return{getError:function(){return{getMessage:t}}}}),f()(this,"getPlayAdError",function(e){var t=function(){return"play ad error: ".concat(JSON.stringify(e))};return{getError:function(){return{getMessage:t}}}}),f()(this,"setAdVolume",function(e){var t=a.store,n=t.getState,r=t.dispatch,i=gn.volume(n());Bn()||gn.muted(n())?(e.setVolume(0),Qi(!0)(r)):(e.setVolume(gn.volume(n())),eo(i)(r),Qi(!1)(r))}),f()(this,"createIMAAdManager",function(t){a.IMAAdManager=t.getAdsManager(a.adVideoElement,e.getAdsRenderingSettings()),a.setAdVolume(a.IMAAdManager)}),f()(this,"registerToAdManagerEvents",function(){a.IMAAdManager.addEventListener(google.ima.AdErrorEvent.Type.AD_ERROR,a.onAdError),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.CONTENT_PAUSE_REQUESTED,a.onContentPauseRequested),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.CONTENT_RESUME_REQUESTED,a.onContentResumeRequested),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.STARTED,a.onAdStarted),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.IMPRESSION,a.onAdImpression),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.SKIPPED,a.onAdSkipped),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.COMPLETE,a.onAdCompleted),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.PAUSED,a.onAdPaused),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.RESUMED,a.onAdStarted),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.AD_PROGRESS,a.onAdProgressChanged),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.VOLUME_CHANGED,a.onVolumeChanged),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.VOLUME_MUTED,a.onAdVolumeMutedChanged),a.IMAAdManager.addEventListener(google.ima.AdEvent.Type.ALL_ADS_COMPLETED,a.onAdCompleted)}),f()(this,"onIMAAdsManagerLoaded",function(e){var t=a.store.dispatch;a.createIMAAdManager(e),a.registerToAdManagerEvents(),Zi("loaded")(t)}),f()(this,"onAdError",function(e){var t=a.store.dispatch;!function(e){return function(t){t({type:"[MONETIZATION] change ad error",payload:e})}}(e.getError().getMessage())(t),Ji(!1),a.continuePlayingContent()}),f()(this,"onAdImpression",function(e){var t=a.store.dispatch,n=!e.getAd().g.vpaid;a.setPodInfo(e),function(e){e({type:"[MONETIZATION] increase ad impression counter"})}(t),function(e){return function(t){t({type:"[MONETIZATION] update is vast ad",payload:e})}}(n)(t)}),f()(this,"onVolumeChanged",function(e){var t=a.store.dispatch;eo(e.target.getVolume())(t)}),f()(this,"onAdVolumeMutedChanged",function(e){var t=a.store.dispatch;0===e.target.getVolume()?Qi(!0)(t):Qi(!1)(t)}),f()(this,"continuePlayingContent",function(){var e=a.store,t=e.getState,n=e.dispatch,r=hn.videoTagStatus(t());Xi("idle"===r?"play":"resume")(n)}),f()(this,"stopPlayingContent",function(){var e=a.store.dispatch;Xi("pause")(e)}),f()(this,"onContentPauseRequested",function(){a.stopPlayingContent()}),f()(this,"onContentResumeRequested",function(){a.continuePlayingContent()}),f()(this,"onAdPaused",function(){var e=a.store.dispatch;Zi("paused")(e)}),f()(this,"setPodInfo",function(e){var t=e&&e.getAd()&&e.getAd().getAdPodInfo();if(!Un(t)){var n=a.store.dispatch;!function(e,t){return function(n){n({type:"[MONETIZATION] change pod info",payload:{slotNumber:e,podNumber:t}})}}(t.getAdPosition(),a.totalAdRequestMadeAmount)(n)}}),f()(this,"onAdStarted",function(){var e=a.store,t=e.dispatch,n=e.getState,r=gn.volume(n());Zi("playing")(t),0===a.IMAAdManager.getVolume()?a.IMAAdManager.setVolume(0):window.shouldPlayAdRule||a.IMAAdManager.setVolume(r),a.onResize()}),f()(this,"onAdCompleted",function(){var e=a.store.dispatch;Zi("completed")(e)}),f()(this,"onAdSkipped",function(){var e=a.store.dispatch;Zi("skipped")(e)}),f()(this,"onResize",function(){Un(a.IMAAdManager)||(a.IMAAdManager.resize(a.videoPlayerElement.clientWidth,a.videoPlayerElement.clientHeight,google.ima.ViewMode.NORMAL),a.adContainerElement.style.height="".concat(a.videoPlayerElement.clientHeight,"px"))}),f()(this,"onAdProgressChanged",function(e){var t,n,r=a.store,i=r.dispatch,o=r.getState,s=e.getAdData().currentTime,u=e.getAdData().duration,c=_i.adDuration(o());(t=s,function(e){e({type:"[MONETIZATION] change ad current time",payload:t})})(i),c!==u&&(n=u,function(e){e({type:"[MONETIZATION] change ad duration",payload:n})})(i)}),f()(this,"onAnchorStatusChanged",function(){var e=a.store.getState;"processing"!==Pr(e())&&a.onResize()}),f()(this,"changeAdVolume",function(e){Un(a.IMAAdManager)||a.IMAAdManager.setVolume(e)}),f()(this,"changeAdMuted",function(e,t){Un(a.IMAAdManager)||(t?a.IMAAdManager.setVolume(0):a.IMAAdManager.setVolume(e))}),f()(this,"changeAdStatus",function(e){Un(a.IMAAdManager)||("playing"===e&&a.IMAAdManager.resume(),"paused"===e&&a.IMAAdManager.pause())});var s=t.getState;this.store=t,this.adVideoElement=r,this.videoPlayerElement=i,this.adContainerElement=n,this.adDisplayContainer=new google.ima.AdDisplayContainer(n,r),this.createAdLoader(s(),this.adDisplayContainer),this.adDisplayContainer.initialize(),this.anchorStatusStoreSubscriber=new ji(t,e.getAnchorDependencies,this.onAnchorStatusChanged.bind(this)),this.registerForWindowResize(),this.initMutationObserver(o)};f()(to,"getAdsRenderingSettings",function(){var e=new google.ima.AdsRenderingSettings;return e.restoreCustomPlaybackStateOnAdBreakComplete=!0,e.enablePreloading=!1,e.uiElements=[],e.loadVideoTimeout=15e3,e}),f()(to,"getAnchorDependencies",function(e){return[Pr(e)]});var no=function e(t,n,r,i,o,a){var s=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"playerId",void 0),f()(this,"adScheduler",void 0),f()(this,"adHandler",void 0),f()(this,"imaLoadingStatusSubscriber",void 0),f()(this,"adStatusSubscriber",void 0),f()(this,"videoTagStatusSubscriber",void 0),f()(this,"adContainer",void 0),f()(this,"adVideoElement",void 0),f()(this,"videoPlayerElement",void 0),f()(this,"playerContainer",void 0),f()(this,"pendingMidrollAdPlay",!1),f()(this,"pendingPrerollAdPlay",!1),f()(this,"pendingPrerollAdTag",null),f()(this,"pendingMidrollNumber",null),f()(this,"pendingAdStatusStoreSubscriber",void 0),f()(this,"adMutedStoreSubscriber",void 0),f()(this,"adVolumeStoreSubscriber",void 0),f()(this,"onMidrollAdOpportunity",function(){var e=s.store,t=e.dispatch,n=e.getState,r=_i.adStatus(n()),i=bi.continuePlayingWhileWaitingForAd(n());"loaded"===r?s.playAd(!0):"requested"===r&&(s.pendingMidrollAdPlay=!0,i||(Xi("pause")(t),Ji(!0)(t))),function(e){e({type:"[MONETIZATION] increase ad Opportunity counter"})}(t)}),f()(this,"onPrerollAdOpportunity",function(e){var t=s.store,n=t.getState,r=t.dispatch,i=Fi.loadingImaStatus(n());Un(s.adHandler)?"loading"!==i&&""!==i||(Ji(!0)(r),s.pendingPrerollAdPlay=!0,s.pendingPrerollAdTag=e):(s.pendingPrerollAdPlay=!0,Ji(!0)(r),s.adHandler.loadNewAd(e,"preroll"))}),f()(this,"onPreMidrollAdOpportunity",function(e,t){Un(s.adHandler)||(e.currentTime>=e.midrollTime&&(s.pendingMidrollAdPlay=!0),s.pendingMidrollNumber=e.midrollNumber,s.adHandler.loadNewAd(t,"midroll"))}),f()(this,"hasPendingAd",function(){return s.hasPendingMidrollAdPlay()||s.hasPendingPrerollAdPlay()}),f()(this,"onAdStatusChanged",function(e){var t=s.store.dispatch,n=_i.adStatus(e);"completed"===n&&Ji(!1)(t);var r=bi.continuePlayingWhileWaitingForAd(e),i=_i.loadingAd(e);"playing"!==n&&"error"!==n||r||!i||Ji(!1)(t),s.hasPendingAd()&&"loaded"===n?s.playAd(s.hasPendingMidrollAdPlay()):s.hasPendingAd()&&"error"===n?(Ji(!1),s.clearPendingMidroll(),s.clearPendingPreroll()):Hi(n)||(Ji(!1),function(e){e({type:"[MONETIZATION] clear ad data"})}(t))}),f()(this,"clearPendingMidroll",function(){s.pendingMidrollNumber=null,s.pendingMidrollAdPlay=!1}),f()(this,"clearPendingPreroll",function(){s.pendingPrerollAdPlay=!1,s.pendingPrerollAdTag=null}),f()(this,"onVideoTagStatusChanged",function(e){"complete"===hn.videoTagStatus(e)&&function(e){e({type:"[MONETIZATION] clear played midrolls"})}(s.store.dispatch)}),f()(this,"hasPendingMidrollAdPlay",function(){return s.pendingMidrollAdPlay}),f()(this,"hasPendingPrerollAdPlay",function(){return s.pendingPrerollAdPlay}),f()(this,"playAd",function(e){var t,n=s.store.dispatch,r=s.adHandler.playAd();e?((t=s.pendingMidrollNumber,function(e){e({type:"[MONETIZATION] add played midroll number",payload:t})})(n),s.clearPendingMidroll()):s.clearPendingPreroll(),r||(Ji(!1)(n),Xi("resume")(n))}),f()(this,"onIMALoadingStatusChanged",function(t){e.canUseIMA(t)&&(Un(s.adHandler)&&(s.adHandler=new to(s.store,s.adContainer,s.adVideoElement,s.videoPlayerElement,s.playerContainer)),s.hasPendingPrerollAdPlay()&&s.adHandler.loadNewAd(s.pendingPrerollAdTag,"preroll"))}),f()(this,"onPendingAdStatusChanged",function(){var e=s.store.getState,t=_i.pendingAdStatus(e()).type;switch(t){case"paused":case"playing":s.adHandler.changeAdStatus(t)}}),f()(this,"onAdMutedChanged",function(){var e=s.store.getState,t=_i.adMuted(e()),n=gn.volume(e());s.adHandler.changeAdMuted(n,t)}),f()(this,"onAdVolumeChanged",function(){var e=s.store.getState,t=_i.adVolume(e());s.adHandler.changeAdVolume(t)});var u=t.getState;this.store=t,this.playerId=n,this.adContainer=r,this.adVideoElement=i,this.videoPlayerElement=o,this.playerContainer=a,this.adScheduler=new Ki(t,this),this.adStatusSubscriber=new ji(t,e.getAdStatusDependencies,this.onAdStatusChanged.bind(this)),this.videoTagStatusSubscriber=new ji(t,e.getVideoTagStatusDependencies,this.onVideoTagStatusChanged.bind(this)),e.canUseIMA(u())?this.adHandler=new to(t,r,i,o,a):this.imaLoadingStatusSubscriber=new ji(t,e.getIMALoadingStatusDependencies,this.onIMALoadingStatusChanged.bind(this)),this.pendingAdStatusStoreSubscriber=new ji(t,e.getPendingAdStatusDependencies,this.onPendingAdStatusChanged.bind(this)),this.adMutedStoreSubscriber=new ji(t,e.getAdMutedDependencies,this.onAdMutedChanged.bind(this)),this.adVolumeStoreSubscriber=new ji(t,e.getAdVolumeDependencies,this.onAdVolumeChanged.bind(this))};f()(no,"getAdStatusDependencies",function(e){return[_i.adStatus(e)]}),f()(no,"getVideoTagStatusDependencies",function(e){return[hn.videoTagStatus(e)]}),f()(no,"getIMALoadingStatusDependencies",function(e){return[Fi.loadingImaStatus(e)]}),f()(no,"canUseIMA",function(e){return"success"===Fi.loadingImaStatus(e)}),f()(no,"getPendingAdStatusDependencies",function(e){return[_i.pendingAdStatus(e)]}),f()(no,"getAdMutedDependencies",function(e){return[_i.adMuted(e)]}),f()(no,"getAdVolumeDependencies",function(e){return[_i.adVolume(e)]});var ro=function(e,t){!function(e,t){var n=document.getElementById(vn(t));B(b(Li,{store:e,playerId:t}),n)}(e,t);var n=function(e){var t=Ri(e);return document.getElementById(t)}(t),r=function(e){var t=Bn()?Di(e):En(e);return document.getElementById(t)}(t),i=function(e){var t=En(e);return document.getElementById(t)}(t),o=function(e){var t=bn(e);return document.getElementById(t)}(t);return new no(e,t,n,r,i,o)},io=n(4),oo=n.n(io),ao=n(7),so=n.n(ao),uo=function(){function e(){Ai()(this,e),f()(this,"duration",void 0),f()(this,"position",void 0),f()(this,"previousPosition",void 0),f()(this,"loadTime",void 0),f()(this,"adOrder",void 0),f()(this,"adType",void 0),f()(this,"adDuration",void 0),f()(this,"errorMessage",void 0),f()(this,"adPodNumber",void 0),f()(this,"adSlotNumber",void 0)}return Vi()(e,[{key:"setDuration",value:function(e){return this.duration=e,this}},{key:"setPosition",value:function(e){return this.position=e,this}},{key:"setPreviousPosition",value:function(e){return this.previousPosition=e,this}},{key:"setLoadTime",value:function(e){return this.loadTime=e,this}},{key:"setAdOrder",value:function(e){return this.adOrder=e,this}},{key:"setAdType",value:function(e){return this.adType=e,this}},{key:"setAdDuration",value:function(e){return this.adDuration=e,this}},{key:"setErrorMessage",value:function(e){return this.errorMessage=e,this}},{key:"setAdPodNumber",value:function(e){return this.adPodNumber=e,this}},{key:"setAdSlotNumber",value:function(e){return this.adSlotNumber=e,this}},{key:"build",value:function(){var e=[];return jn(this.position)||e.push("video current position=".concat(Hn(this.position),"sec")),jn(this.duration)||e.push("video duration time=".concat(Hn(this.duration),"sec")),jn(this.loadTime)||e.push("video load time=".concat(this.loadTime,"milliseconds")),jn(this.previousPosition)||e.push("previous position=".concat(Hn(this.previousPosition),"sec")),jn(this.adOrder)||e.push("ad order=".concat(this.adOrder)),jn(this.adType)||e.push("ad type=".concat(this.adType)),jn(this.adDuration)||e.push("ad duration=".concat(Hn(Number(this.adDuration)),"sec")),jn(this.adPodNumber)||e.push("pod number=".concat(this.adPodNumber)),jn(this.adSlotNumber)||e.push("slot number=".concat(this.adSlotNumber)),jn(this.errorMessage)||e.push("error message=".concat(this.errorMessage)),e.join(";")}}]),e}(),co="mmPlus GTM data ready to GA",lo="mmPlus GTM event to GA",po={EMBED:"vplayer video player embed",FIRST_PLAY:"vplayer video first play",COMPLETION_25_PERCENTAGE:"vplayer video 25% complete",COMPLETION_50_PERCENTAGE:"vplayer video 50% complete",COMPLETION_75_PERCENTAGE:"vplayer video 75% complete",COMPLETION_90_PERCENTAGE:"vplayer video 90% complete",AD_BLOCK:"vplayer video ad block",AD_REQUEST:"vplayer video ad request",AD_IMPRESSION:"vplayer video ad impression",AD_ERROR:"vplayer video ad error",AD_VIEWABLE_IMPRESSION:"vplayer video ad viewable impression",AD_COMPLETE:"vplayer video ad complete",AD_SKIP:"vplayer video ad skip",AD_PAUSE:"vplayer video ad pause",VIDEO_COMPLETE:"vplayer video complete",FULLSCREEN_ON:"vplayer video fullscreen on",FULLSCREEN_OFF:"vplayer video fullscreen off",SEEK:"vplayer video position seeked",VIDEO_MUTE:"vplayer video mute",VIDEO_UNMUTE:"vplayer video unmute",CONTROLS_MUTE_OR_UNMUTE:"controls Mute/Unmute button click",CONTROLS_PLAY_OR_PAUSE:"controls Play/Pause button click",CONTROLS_FULLSCREEN:"controls Fullscreen button click",CONTROLS_NEXT_VIDEO:"controls Next Video button click",CONTROLS_SETTINGS:"controls Settings button click",MINI_PLAYER_CLOSE:"vplayer video miniplayer close",LOADING_CONTENT_ERROR:"vplayer video player error",PLAYER_ERROR:"vplayer general player error",CONTENT_VIEWABLE_IMPRESSION:"vplayer video content viewable impression"},fo="loading ad provider library failed",ho="mid",yo=function e(t,n){var r=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"analyticsEventsCallbacks",void 0),f()(this,"videoMuteSubscriber",void 0),f()(this,"videoFullscreenSubscriber",void 0),f()(this,"onMuteStateChanged",function(e){var t=gn.muted(e),n=hn.currentVideoTimeFragment(e),i=(new uo).setPosition(n).build(),o=t?po.VIDEO_MUTE:po.VIDEO_UNMUTE;r.analyticsEventsCallbacks.onEvent(o,i)}),f()(this,"onFullsScreenStateChanged",function(e){var t=gn.fullscreen(e),n=hn.currentVideoTimeFragment(e),i=(new uo).setPosition(n).build(),o=t?po.FULLSCREEN_ON:po.FULLSCREEN_OFF;r.analyticsEventsCallbacks.onEvent(o,i)}),this.store=t,this.analyticsEventsCallbacks=n,this.videoMuteSubscriber=new ji(t,e.getVideoMuteDependencies,this.onMuteStateChanged.bind(this)),this.videoFullscreenSubscriber=new ji(t,e.getVideoFullscreenDependencies,this.onFullsScreenStateChanged.bind(this))};f()(yo,"getVideoMuteDependencies",function(e){return[gn.muted(e)]}),f()(yo,"getVideoFullscreenDependencies",function(e){return[gn.fullscreen(e)]});var go=n(3),vo=n.n(go),mo=n(8),bo=n.n(mo),Oo=n(9),_o=n.n(Oo),So=n(5),Eo=n.n(So);n(20);var wo={root:null,threshold:.5,rootMargin:"0px"},Po=function(){function e(t,n,r){Ai()(this,e),f()(this,"store",void 0),f()(this,"observableElement",void 0),f()(this,"callback",void 0),f()(this,"isViewableTimeoutHandler",null),f()(this,"observer",void 0),f()(this,"didReport",!1),this.store=t,this.observableElement=n,this.callback=r,this.observer=new IntersectionObserver(this.onIntersecting.bind(this),wo)}return Vi()(e,[{key:"unobserve",value:function(){this.observer.unobserve(this.observableElement),this.clearIsViewableTimeout()}},{key:"observe",value:function(){this.observer.observe(this.observableElement)}},{key:"onPlay",value:function(){this.didReport||this.observe()}},{key:"onPause",value:function(){this.unobserve()}},{key:"onComplete",value:function(){this.didReport=!1,this.unobserve()}},{key:"onIntersecting",value:function(e){var t=e[0].isIntersecting;null===this.isViewableTimeoutHandler&&t?this.isViewableTimeoutHandler=setTimeout(this.notifyViewable.bind(this),2e3):this.clearIsViewableTimeout()}},{key:"clearIsViewableTimeout",value:function(){clearTimeout(this.isViewableTimeoutHandler),this.isViewableTimeoutHandler=null}},{key:"notifyViewable",value:function(){var e=this.store.getState;this.didReport=!0,this.callback(e()),this.unobserve()}}]),e}();function To(e){var t=function(){if("undefined"===typeof Reflect||!Reflect.construct)return!1;if(Reflect.construct.sham)return!1;if("function"===typeof Proxy)return!0;try{return Date.prototype.toString.call(Reflect.construct(Date,[],function(){})),!0}catch(e){return!1}}();return function(){var n,r=Eo()(e);if(t){var i=Eo()(this).constructor;n=Reflect.construct(r,arguments,i)}else n=r.apply(this,arguments);return _o()(this,n)}}var Ao=function(e){bo()(n,e);var t=To(n);function n(e,r,i){var o;return Ai()(this,n),o=t.call(this,e,r,i),f()(vo()(o),"videoTagStatusSubscriber",void 0),f()(vo()(o),"onVideoTagStatusChanged",function(e){var t=hn.videoTagStatus(e);"playing"===t?o.onPlay():"paused"===t||"seeking"===t?o.onPause():"complete"!==t&&"error"!==t||o.onComplete()}),o.videoTagStatusSubscriber=new ji(e,n.getVideoTagStatusDependencies,o.onVideoTagStatusChanged.bind(vo()(o))),o}return n}(Po);f()(Ao,"getVideoTagStatusDependencies",function(e){return[hn.videoTagStatus(e)]});var Co=function e(t,n,r,i){var o=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"videoTagStatusSubscriber",void 0),f()(this,"analyticsEventsCallbacks",void 0),f()(this,"videoViewableImpressionObserver",void 0),f()(this,"firstPlayReportedIndex",-1),f()(this,"loadingStartTime",-1),f()(this,"registerVideoCallbacksIdNeeded",function(e,t){"none"!==hn.playbackMethod(e)&&document.getElementById(En(t)).addEventListener("loadstart",o.onLoadStart.bind(o),{once:!0})}),f()(this,"onLoadStart",function(){o.loadingStartTime=Date.now()}),f()(this,"getFirstPlayLabel",function(e){var t=hn.currentVideoTimeFragment(e),n=hn.currentVideoDuration(e),r=-1===o.loadingStartTime?-1:Date.now()-o.loadingStartTime;return(new uo).setPosition(t).setLoadTime(r).setDuration(n).build()}),f()(this,"onVideoTagStatusChanged",function(e){var t=hn.videoTagStatus(e),n=Cn.activeVideoIndex(e);if(!(n===o.firstPlayReportedIndex)&&"playing"===t){o.firstPlayReportedIndex=n;var r=o.getFirstPlayLabel(e);o.analyticsEventsCallbacks.onEvent(po.FIRST_PLAY,r)}}),f()(this,"reportVideoViewableImpression",function(e){var t=hn.currentVideoTimeFragment(e),n=(new uo).setPosition(t).build();o.analyticsEventsCallbacks.onEvent(po.CONTENT_VIEWABLE_IMPRESSION,n)}),this.store=t,this.analyticsEventsCallbacks=n,this.videoViewableImpressionObserver=new Ao(t,r,this.reportVideoViewableImpression.bind(this)),this.videoTagStatusSubscriber=new ji(t,e.getVideoTagDependencies,this.onVideoTagStatusChanged.bind(this)),this.registerVideoCallbacksIdNeeded(t.getState(),i)};f()(Co,"getVideoTagDependencies",function(e){return[hn.videoTagStatus(e)]});var Ro=[25,50,75,90],Do=function(){function e(){Ai()(this,e),f()(this,"lastReportedPercentage",void 0),this.lastReportedPercentage=0}return Vi()(e,[{key:"clear",value:function(){this.lastReportedPercentage=0}},{key:"updateConsumption",value:function(e,t){var n=e.position,r=e.duration,i=Math.round(n/r*100);i>this.lastReportedPercentage&&this.notifyReportableConsumption(e,i,t)}},{key:"notifyReportableConsumption",value:function(e,t,n){var r=this;Ro.filter(function(e){return e>r.lastReportedPercentage&&e<=t}).forEach(function(t){return n(t,e.position,e.duration)}),this.lastReportedPercentage=t}}]),e}(),Mo=function(){function e(t,n){var r=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"analyticsEventsCallbacks",void 0),f()(this,"videoTimeSubscriber",void 0),f()(this,"videoTagStatusSubscriber",void 0),f()(this,"videoDataStoreSubscriber",void 0),f()(this,"percentageConsumption",void 0),f()(this,"previousVideoTagStatus",void 0),f()(this,"lastPlayedPosition",void 0),f()(this,"getVideoPercentageAction",function(e){switch(e){case 25:return po.COMPLETION_25_PERCENTAGE;case 50:return po.COMPLETION_50_PERCENTAGE;case 75:return po.COMPLETION_75_PERCENTAGE;case 90:return po.COMPLETION_90_PERCENTAGE;default:return""}}),f()(this,"onVideoTimeChanged",function(e){var t=hn.currentVideoDuration(e),n=hn.currentVideoTimeFragment(e);r.percentageConsumption.updateConsumption({position:n,duration:t},r.onVideoTimeReport.bind(r))}),f()(this,"onVideoTagStatusChanged",function(e){var t=hn.videoTagStatus(e),n=hn.currentVideoTimeFragment(e),i=hn.currentVideoDuration(e);if("seeking"===r.previousVideoTagStatus){var o=(new uo).setPosition(n).setPreviousPosition(r.lastPlayedPosition).build();r.analyticsEventsCallbacks.onEvent(po.SEEK,o)}else"seeking"===t&&(r.lastPlayedPosition=n);r.previousVideoTagStatus=t,"complete"===t&&r.onComplete(i)}),f()(this,"onVideoDataChanged",function(){r.percentageConsumption.clear()}),f()(this,"onComplete",function(e){var t=(new uo).setDuration(e).build();r.analyticsEventsCallbacks.onEvent(po.VIDEO_COMPLETE,t),r.percentageConsumption.clear()}),this.store=t,this.analyticsEventsCallbacks=n,this.videoTimeSubscriber=new ji(t,e.getVideoTimeDependencies,this.onVideoTimeChanged.bind(this)),this.videoTagStatusSubscriber=new ji(t,e.getVideoTagStatusDependencies,this.onVideoTagStatusChanged.bind(this)),this.videoDataStoreSubscriber=new ji(t,e.getVideoDataDependencies,this.onVideoDataChanged.bind(this)),this.percentageConsumption=new Do}return Vi()(e,[{key:"onVideoTimeReport",value:function(e,t,n){var r=this.getVideoPercentageAction(e),i=(new uo).setPosition(t).setDuration(n).build();this.analyticsEventsCallbacks.onEvent(r,i)}}]),e}();f()(Mo,"getVideoTimeDependencies",function(e){return[hn.currentVideoTime(e)]}),f()(Mo,"getVideoTagStatusDependencies",function(e){return[hn.videoTagStatus(e)]}),f()(Mo,"getVideoDataDependencies",function(e){return[Cn.videoData(e)]});var Io=function e(t,n,r,i){Ai()(this,e),f()(this,"store",void 0),f()(this,"timeEvents",void 0),f()(this,"videoSettingsEvents",void 0),f()(this,"videoTagStatusEvents",void 0),this.store=t,this.timeEvents=new Mo(t,n),this.videoSettingsEvents=new yo(t,n),this.videoTagStatusEvents=new Co(t,n,r,i)},ko=n(13),No=n.n(ko),Lo=function(){function e(){Ai()(this,e),f()(this,"batteryLevel","N/A"),f()(this,"batteryChargingState",!1),f()(this,"connectionSpeed","N/A"),f()(this,"connectionType","N/A"),this.setConnectionParams()}return Vi()(e,[{key:"setConnectionParams",value:function(){var e=this,t=navigator.connection||navigator.mozConnection||navigator.webkitConnection;t&&(this.updateConnectionParams(t.effectiveType,t.downlink),t.addEventListener("change",function(){return e.updateConnectionParams(t.effectiveType,t.downlink)}))}},{key:"updateConnectionParams",value:function(e,t){this.connectionType=e,this.connectionSpeed=t}},{key:"attach",value:function(){var e=so()(oo.a.mark(function e(){var t,n=this;return oo.a.wrap(function(e){for(;;)switch(e.prev=e.next){case 0:if(!navigator.getBattery){e.next=7;break}return e.next=3,navigator.getBattery();case 3:t=e.sent,this.updateBatteryParams(t.level,t.charging),t.ondischargingtimechange=function(e){return n.updateBatteryParams(e.target.level,e.target.charging)},t.onchargingtimechange=function(e){return n.updateBatteryParams(e.target.level,e.target.charging)};case 7:case"end":return e.stop()}},e,this)}));return function(){return e.apply(this,arguments)}}()},{key:"updateBatteryParams",value:function(e,t){this.batteryLevel="".concat(100*e),this.batteryChargingState=t}},{key:"getBatteryLevel",value:function(){return this.batteryLevel}},{key:"getBatteryChargingState",value:function(){return this.batteryChargingState}},{key:"getConnectionSpeed",value:function(){return this.connectionSpeed}},{key:"getConnectionType",value:function(){return this.connectionType}}]),e}(),xo=function(){"undefined"===typeof window["$$mm-analytics"]&&(window["$$mm-analytics"]={});var e=window;return"undefined"===typeof e["$$mm-analytics"].firstEmbed&&(e["$$mm-analytics"].firstEmbed=Date.now()),e["$$mm-analytics"].firstEmbed},Vo=function(){return"time in process=".concat(Date.now()-xo()," milliseconds")},jo=function(){function e(t,n){var r=this;Ai()(this,e),f()(this,"videoTag",null),f()(this,"deviceParams",void 0),f()(this,"trafficDomain",void 0),f()(this,"adTimeoutDuration",void 0),f()(this,"playbackMethod",void 0),f()(this,"configName",void 0),f()(this,"playerUniqKey",void 0),f()(this,"attach",so()(oo.a.mark(function e(){return oo.a.wrap(function(e){for(;;)switch(e.prev=e.next){case 0:return r.deviceParams=new Lo,e.next=3,r.deviceParams.attach();case 3:case"end":return e.stop()}},e)}))),f()(this,"translatePlaybackMethod",function(e){switch(e){case"lazyplay":return"scroll to play";case"autoplay":return"auto play";case"autoplay_when_viewable":return"auto play when viewable";case"none":return"click to play";default:return"none"}}),f()(this,"getAdTimeout",function(e){return e?"".concat(qn(e)," sec"):"none"}),f()(this,"getVideoTag",function(){return null===r.videoTag&&(r.videoTag=document.getElementById(En(r.playerUniqKey))),r.videoTag}),f()(this,"getUnitSize",function(){var e=r.getVideoTag();return null!==e?"".concat(e.clientWidth,":").concat(e.clientHeight):"none"}),f()(this,"getBatteryCharging",function(){return r.deviceParams.getBatteryChargingState()?"yes":"no"});var i=t.publisher_contribution,o=t.monetization,a=t.playback_method,s=t.config_name;this.playerUniqKey=n,this.trafficDomain=i,this.adTimeoutDuration=o&&o.ad_request_timeout?this.getAdTimeout(o.ad_request_timeout):"none",this.playbackMethod=this.translatePlaybackMethod(a),this.configName=s}return Vi()(e,[{key:"getDimensions",value:function(){return{mmPlusConfigName:this.configName,mmPlusPlaybackMethod:this.playbackMethod,mmPlusPrePvTimeInProcess:Vo(),mmPlusTrafficDomain:this.trafficDomain,mmPlusUnitSize:this.getUnitSize(),mmPlusUnitType:"video",mmPlusUserBatteryCharging:this.getBatteryCharging(),mmPlusUserBatteryLevel:this.deviceParams.getBatteryLevel(),mmPlusUserConnectionSpeed:this.deviceParams.getConnectionSpeed(),mmPlusUserConnectionType:this.deviceParams.getConnectionType(),mmPlusAdTimeoutDuration:this.adTimeoutDuration}}}]),e}();function Uo(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Fo(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Uo(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Uo(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}function Bo(e){var t=function(){if("undefined"===typeof Reflect||!Reflect.construct)return!1;if(Reflect.construct.sham)return!1;if("function"===typeof Proxy)return!0;try{return Date.prototype.toString.call(Reflect.construct(Date,[],function(){})),!0}catch(e){return!1}}();return function(){var n,r=Eo()(e);if(t){var i=Eo()(this).constructor;n=Reflect.construct(r,arguments,i)}else n=r.apply(this,arguments);return _o()(this,n)}}var Ho=function(e){bo()(n,e);var t=Bo(n);function n(e,r){var i,o;return Ai()(this,n),o=t.call(this,e,r),f()(vo()(o),"domain",void 0),f()(vo()(o),"getDimensions",function(){return Fo(Fo({},No()((i=vo()(o),Eo()(n.prototype)),"getDimensions",i).call(i)),{},{mmPlusDomain:o.domain})}),o.domain=window.location.hostname,o}return n}(jo);function qo(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Wo(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?qo(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):qo(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}function zo(e){var t=function(){if("undefined"===typeof Reflect||!Reflect.construct)return!1;if(Reflect.construct.sham)return!1;if("function"===typeof Proxy)return!0;try{return Date.prototype.toString.call(Reflect.construct(Date,[],function(){})),!0}catch(e){return!1}}();return function(){var n,r=Eo()(e);if(t){var i=Eo()(this).constructor;n=Reflect.construct(r,arguments,i)}else n=r.apply(this,arguments);return _o()(this,n)}}var Go=function(e){bo()(n,e);var t=zo(n);function n(e,r,i){var o;Ai()(this,n),o=t.call(this,i,r),f()(vo()(o),"store",void 0),f()(vo()(o),"playerUniqId",void 0),f()(vo()(o),"autoPlay",void 0),f()(vo()(o),"streamType",void 0),f()(vo()(o),"gaProperty",void 0),f()(vo()(o),"booleanToYesOrNo",function(e){return e?"yes":"no"}),f()(vo()(o),"getAspectRatio",function(e,t){var r=n.getCommonDenominator(e,t),i=t/r;return"".concat(e/r,":").concat(i)}),f()(vo()(o),"getUnitRadio",function(){var e=o.getVideoTag();if(null!==e){var t=e.clientWidth,n=e.clientHeight;return o.getAspectRatio(t,n)}return"none"}),f()(vo()(o),"getVideoDuration",function(e){var t=Dn.duration(e);return t?"".concat(t," sec"):"none"});var a=i.playback_method,s=i.content_type,u=i.ga_property;return o.store=e,o.playerUniqId=r,o.autoPlay=o.booleanToYesOrNo("none"!==a),o.streamType=s,o.gaProperty=u||o.trafficDomain,o}return Vi()(n,[{key:"getDimensions",value:function(){var e=this.store.getState;return Wo(Wo({},No()(Eo()(n.prototype),"getDimensions",this).call(this)),{},{mmPlusVideoPlayerId:this.playerUniqId,mmPlusUnitId:Dn.mediaId(e())||"none",mmPlusUnitTitle:Dn.title(e())||"none",mmPlusVideoAutoplay:this.autoPlay,mmPlusVideoDuration:this.getVideoDuration(e()),mmPlusVideoStreamType:this.streamType,mmPlusVideoPlaylistId:Cn.mediaId(e())||"none",mmPlusVideoMuted:this.booleanToYesOrNo(gn.muted(e())),mmPlusUnitTags:Dn.tags(e()).toString()||"none",mmPlusUnitOrderNumber:Cn.activeVideoIndex(e()),mmPlusTrafficReferrer:document.referrer,mmPlusUnitProvider:Dn.provider(e())||"none",mmPlusUnitCreator:Dn.creator(e())||"none",mmPlusUnitExternalId:Dn.externalId(e())||"none",mmPlusUnitRatio:this.getUnitRadio(),mmPlusGaProperty:this.gaProperty,mmPlusVideoPlayerType:"vplayer",mmPlusVideoThumbnailsOn:"none",mmPlusVideoClosedCaptionsOn:"none",mmPlusVideoRecommendationsVisible:"none"})}}]),n}(jo);function $o(e){var t=function(){if("undefined"===typeof Reflect||!Reflect.construct)return!1;if(Reflect.construct.sham)return!1;if("function"===typeof Proxy)return!0;try{return Date.prototype.toString.call(Reflect.construct(Date,[],function(){})),!0}catch(e){return!1}}();return function(){var n,r=Eo()(e);if(t){var i=Eo()(this).constructor;n=Reflect.construct(r,arguments,i)}else n=r.apply(this,arguments);return _o()(this,n)}}f()(Go,"getCommonDenominator",function(e,t){for(var n=e,r=t;r;){var i=r;r=n%r,n=i}return n});var Ko=function(e){bo()(n,e);var t=$o(n);function n(e,r,i){var o;return Ai()(this,n),o=t.call(this,e,r,i),f()(vo()(o),"adStatusSubscriber",void 0),f()(vo()(o),"onAdStatusChanged",function(e){var t=_i.adStatus(e);"playing"===t?o.onPlay():"paused"===t?o.onPause():Hi(t)||o.onComplete()}),o.adStatusSubscriber=new ji(e,n.getAdStatusDependencies,o.onAdStatusChanged.bind(vo()(o))),o}return n}(Po);f()(Ko,"getAdStatusDependencies",function(e){return[_i.adStatus(e)]});var Yo=function e(t,n,r){var i=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"analyticsCallback",void 0),f()(this,"adStatusSubscriber",void 0),f()(this,"adImpressionSubscriber",void 0),f()(this,"adProviderLoadingStatusSubscriber",void 0),f()(this,"adViewableImpressionObserver",void 0),f()(this,"initAdBlockChecker",function(t){""===Fi.loadingImaStatus(t.getState())?i.adProviderLoadingStatusSubscriber=new ji(t,e.getAdProviderLoadingStatusDependencies,i.onAdProviderLoadingStatusChanged.bind(i)):i.onAdProviderLoadingStatusChanged(t.getState())}),f()(this,"getAdOrderFromPlayedMidrolls",function(e){return e&&e.length>0?e[e.length-1]:0}),f()(this,"getFullAdLabel",function(e){var t=hn.currentVideoTimeFragment(e),n=_i.adDuration(e),r=_i.playedMidrolls(e),o=_i.slotNumber(e),a=_i.podNumber(e),s=i.getAdOrderFromPlayedMidrolls(r);return(new uo).setAdType(ho).setPosition(t).setAdDuration(n).setAdOrder(s).setAdSlotNumber(o).setAdPodNumber(a).build()}),f()(this,"reportAdBlock",function(){i.analyticsCallback.onEvent(po.AD_BLOCK)}),f()(this,"reportError",function(e){var t=(new uo).setErrorMessage(e).build();i.analyticsCallback.onEvent(po.PLAYER_ERROR,t)}),f()(this,"reportAdRequested",function(e){var t=hn.currentVideoTimeFragment(e),n=_i.playedMidrolls(e),r=i.getAdOrderFromPlayedMidrolls(n),o=(new uo).setPosition(t).setAdOrder(r).build();i.analyticsCallback.onEvent(po.AD_REQUEST,o)}),f()(this,"reportAdImpression",function(e){var t=i.getFullAdLabel(e);i.analyticsCallback.onEvent(po.AD_IMPRESSION,t)}),f()(this,"reportAdError",function(e){var t=_i.adErrorMessage(e),n=_i.slotNumber(e),r=_i.podNumber(e),o=(new uo).setAdType(ho).setErrorMessage(t).setAdPodNumber(r).setAdSlotNumber(n).build();i.analyticsCallback.onEvent(po.AD_ERROR,o)}),f()(this,"reportAdComplete",function(e){var t=i.getFullAdLabel(e);i.analyticsCallback.onEvent(po.AD_COMPLETE,t)}),f()(this,"reportAdSkipped",function(e){var t=i.getFullAdLabel(e);i.analyticsCallback.onEvent(po.AD_SKIP,t)}),f()(this,"reportAdPaused",function(e){var t=i.getFullAdLabel(e);i.analyticsCallback.onEvent(po.AD_PAUSE,t)}),f()(this,"reportAdViewableImpression",function(e){var t=hn.currentVideoTimeFragment(e),n=_i.adDuration(e),r=_i.slotNumber(e),o=_i.podNumber(e),a=(new uo).setPosition(t).setAdType(ho).setAdDuration(n).setAdPodNumber(o).setAdSlotNumber(r).build();i.analyticsCallback.onEvent(po.AD_VIEWABLE_IMPRESSION,a)}),f()(this,"onAdStatusChanged",function(e){var t=_i.adStatus(e);"requested"===t&&i.reportAdRequested(e),"error"===t&&i.reportAdError(e),"completed"===t&&i.reportAdComplete(e),"skipped"===t&&i.reportAdSkipped(e),"paused"===t&&i.reportAdPaused(e)}),f()(this,"onAdProviderLoadingStatusChanged",function(e){var t=Fi.loadingImaStatus(e);"blocked"===t?i.reportAdBlock():"error"===t&&i.reportError(fo)}),f()(this,"onAdImpressionChanged",function(e){i.reportAdImpression(e)}),this.store=t,this.analyticsCallback=n,this.adStatusSubscriber=new ji(t,e.getAdStatusDependencies,this.onAdStatusChanged.bind(this)),this.adImpressionSubscriber=new ji(t,e.getAdImpressionDependencies,this.onAdImpressionChanged.bind(this)),this.adViewableImpressionObserver=new Ko(t,r,this.reportAdViewableImpression.bind(this)),this.initAdBlockChecker(t)};f()(Yo,"getAdProviderLoadingStatusDependencies",function(e){return[Fi.loadingImaStatus(e)]}),f()(Yo,"getAdStatusDependencies",function(e){return[_i.adStatus(e)]}),f()(Yo,"getAdImpressionDependencies",function(e){return[_i.adImpression(e)]});var Zo=pn.userInteraction,Xo=function(e){return Zo(e).userInteractionType},Jo=function e(t,n){var r=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"analyticsCallbacks",void 0),f()(this,"userInteraction",void 0),f()(this,"getLabel",function(e){var t=hn.currentVideoTimeFragment(e);return(new uo).setPosition(t).build()}),f()(this,"reportMuteOrUnmute",function(e){r.analyticsCallbacks.onEvent(po.CONTROLS_MUTE_OR_UNMUTE,r.getLabel(e))}),f()(this,"reportFullscreen",function(e){r.analyticsCallbacks.onEvent(po.CONTROLS_FULLSCREEN,r.getLabel(e))}),f()(this,"reportPlayOrPause",function(e){r.analyticsCallbacks.onEvent(po.CONTROLS_PLAY_OR_PAUSE,r.getLabel(e))}),f()(this,"reportNextVideo",function(e){r.analyticsCallbacks.onEvent(po.CONTROLS_NEXT_VIDEO,r.getLabel(e))}),f()(this,"reportSettings",function(e){r.analyticsCallbacks.onEvent(po.CONTROLS_SETTINGS,r.getLabel(e))}),f()(this,"reportMiniPlayerClosed",function(e){r.analyticsCallbacks.onEvent(po.MINI_PLAYER_CLOSE,r.getLabel(e))}),f()(this,"onUserInteractionChanged",function(e){switch(Xo(e)){case"mute":case"unmute":r.reportMuteOrUnmute(e);break;case"fullscreen":r.reportFullscreen(e);break;case"play":case"pause":r.reportPlayOrPause(e);break;case"settings":r.reportSettings(e);break;case"nextVideo":r.reportNextVideo(e);break;case"closeMiniPlayer":r.reportMiniPlayerClosed(e)}}),this.store=t,this.analyticsCallbacks=n,this.userInteraction=new ji(t,e.getUserInteractionDependencies,this.onUserInteractionChanged.bind(this))};function Qo(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function ea(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Qo(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Qo(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}f()(Jo,"getUserInteractionDependencies",function(e){return[Xo(e)]});var ta=function e(t,n,r,i){var o=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"videoEventsReporter",void 0),f()(this,"monetizationEventsReporter",void 0),f()(this,"userInteractionReporter",void 0),f()(this,"eventCustomDimensions",void 0),f()(this,"dataLayer",null),f()(this,"attach",function(){var e=so()(oo.a.mark(function e(t,n,r){return oo.a.wrap(function(e){for(;;)switch(e.prev=e.next){case 0:return o.eventCustomDimensions=new Go(t,n,r),e.next=3,o.eventCustomDimensions.attach();case 3:return e.next=5,o.reportReady(t,n,r);case 5:o.reportEmbed();case 6:case"end":return e.stop()}},e)}));return function(t,n,r){return e.apply(this,arguments)}}()),f()(this,"initDataLayer",function(){var e;try{e=$n(window.parent)}catch(t){e=$n(window)}o.dataLayer=window[e]}),f()(this,"reportReady",function(){var e=so()(oo.a.mark(function e(t,n,r){var i;return oo.a.wrap(function(e){for(;;)switch(e.prev=e.next){case 0:return i=new Ho(r,n),e.next=3,i.attach();case 3:o.dataLayer.push(ea({event:co},i.getDimensions()));case 4:case"end":return e.stop()}},e)}));return function(t,n,r){return e.apply(this,arguments)}}()),f()(this,"reportEmbed",function(){o.onEvent(po.EMBED)}),f()(this,"onEvent",function(e,t,n,r){var i=r||o.eventCustomDimensions.getDimensions(),a=n||lo;o.dataLayer.push(ea(ea({event:a,mmPlusGA_event_action:e,mmPlusGA_event_label:t,mmPlusGA_event_category:"MMVideo"},i),{},{time:Date.now()}))}),this.store=t,this.initDataLayer(),this.videoEventsReporter=new Io(t,this,i,n),this.monetizationEventsReporter=new Yo(t,this,i),window.monetizationEventsReporter=this.monetizationEventsReporter,this.userInteractionReporter=new Jo(t,this),this.attach(t,n,r)},na=pn.discovery,ra=function(e){return na(e).nextVideo},ia=n(51).version,oa=function e(){var t=this;Ai()(this,e),f()(this,"controlsLoaded",void 0),f()(this,"loadInternalPlugins",function(e,n,r){var i=r.dev_config,o=e.getState,a=i&&!Un(i.pluginsPath)?i.pluginsPath:function(){try{return"https://www.oo-syringe.com/prod/players"}catch(w){return"./dist/bundle"}}();t.loadAnalyticsPlugin(e,n,r),t.loadActionsPlugin(n,a),t.loadMonetizationPlugin(e,n),t.loadControlsPlugin(n,a),t.loadAnchorPlugin(n,a),t.loadComscorePlugin(n,r,a),Sr(o())&&Un(Zn(o()))&&t.loadCloseBarPlugin(n,a),"none"!==ra(o())&&t.loadDiscoveryPlugin(n,a),Un(Zn(o()))||t.loadSplitViewPlugin(n,a)}),f()(this,"loadActionsPlugin",function(e,t){if(window.monti.dataset&&window.monti.dataset.plugins.actionsPlugin)window.monti.dataset.plugins.actionsPlugin(e);else{var n=document.createElement("script");n.setAttribute("type","text/javascript"),n.setAttribute("src","".concat(t,"/mplayer_actions_plugin.").concat(ia,".js")),n.addEventListener("load",function(){window.monti.dataset.plugins.actionsPlugin(e)}),n.addEventListener("error",function(){console.log("ACTIONS PLUGIN LOADER ERROR !")}),document.body.appendChild(n)}}),f()(this,"loadMonetizationPlugin",function(e,t){ro(e,t)}),f()(this,"loadControlsPlugin",function(e,t){if(window.monti.dataset&&window.monti.dataset.plugins.controlsPlugin)window.monti.dataset.plugins.controlsPlugin(e);else{var n=document.createElement("script");n.setAttribute("src","".concat(t,"/mplayer_controls_plugin.").concat(ia,".js")),n.setAttribute("type","text/javascript"),n.addEventListener("load",function(){window.monti.dataset.plugins.controlsPlugin(e)}),n.addEventListener("error",function(){console.log("CONTROLS PLUGIN LOADER ERROR !")}),document.body.appendChild(n)}}),f()(this,"loadAnchorPlugin",function(e,t){if(window.monti.dataset&&window.monti.dataset.plugins.anchorPlugin)window.monti.dataset.plugins.anchorPlugin(e);else{var n=document.createElement("script");n.setAttribute("src","".concat(t,"/mplayer_anchor_plugin.").concat(ia,".js")),n.setAttribute("type","text/javascript"),n.addEventListener("load",function(){window.monti.dataset.plugins.anchorPlugin(e)}),n.addEventListener("error",function(){console.log("ANCHOR PLUGIN LOADER ERROR !")}),document.body.appendChild(n)}}),f()(this,"loadSplitViewPlugin",function(e,t){if(window.monti.dataset&&window.monti.dataset.plugins.splitViewPlugin)window.monti.dataset.plugins.splitViewPlugin(e);else{var n=document.createElement("script");n.setAttribute("src","".concat(t,"/mplayer_split_view_plugin.").concat(ia,".js")),n.setAttribute("type","text/javascript"),n.addEventListener("load",function(){window.monti.dataset.plugins.splitViewPlugin(e)}),n.addEventListener("error",function(){console.log("SPLIT VIEW PLUGIN LOADER ERROR !")}),document.body.appendChild(n)}}),f()(this,"loadComscorePlugin",function(e,t,n){if(window.monti.dataset&&window.monti.dataset.plugins.comscorePlugin)window.monti.dataset.plugins.comscorePlugin(e,t);else{var r=document.createElement("script");r.setAttribute("src","".concat(n,"/mplayer_comscore_plugin.").concat(ia,".js")),r.setAttribute("type","text/javascript"),r.addEventListener("load",function(){window.monti.dataset.plugins.comscorePlugin(e,t)}),r.addEventListener("error",function(){console.log("COMSCORE PLUGIN LOADER ERROR !")}),document.body.appendChild(r)}}),f()(this,"loadAnalyticsPlugin",function(e,t,n){!function(e,t,n){var r=document.getElementById(bn(t));new ta(e,t,n,r)}(e,t,n)}),f()(this,"loadDiscoveryPlugin",function(e,t){if(window.monti.dataset&&window.monti.dataset.plugins.discoveryPlugin)window.monti.dataset.plugins.discoveryPlugin(e);else{var n=document.createElement("script");n.setAttribute("src","".concat(t,"/mplayer_discovery_plugin.").concat(ia,".js")),n.setAttribute("type","text/javascript"),n.addEventListener("load",function(){window.monti.dataset.plugins.discoveryPlugin(e)}),n.addEventListener("error",function(){console.log("DISCOVERY PLUGIN LOADER ERROR !")}),document.body.appendChild(n)}}),f()(this,"loadCloseBarPlugin",function(e,t){if(window.monti.dataset&&window.monti.dataset.plugins.closeBar)window.monti.dataset.plugins.closeBarPlugin(e);else{var n=document.createElement("script");n.setAttribute("src","".concat(t,"/mplayer_close_bar_plugin.").concat(ia,".js")),n.setAttribute("type","text/javascript"),n.addEventListener("load",function(){window.monti.dataset.plugins.closeBarPlugin(e)}),n.addEventListener("error",function(){console.log("CLOSE BAR PLUGIN LOADER ERROR !")}),document.body.appendChild(n)}}),this.controlsLoaded=!1};function aa(e){return function(t){var n=t.dispatch,r=t.getState;return function(t){return function(i){return"function"===typeof i?i(n,r,e):t(i)}}}}f()(oa,"instance",void 0),f()(oa,"getInstance",function(){return oa.instance||(oa.instance=new oa),oa.instance});var sa=aa();sa.withExtraArgument=aa;var ua=sa;function ca(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function la(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?ca(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):ca(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var da={loadingHLSStatus:"",loadingImaStatus:""};function pa(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function fa(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?pa(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):pa(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var ha={playerId:"",playerInstanceUniqId:null,playbackMethod:"none",videoTagStatus:"idle",pendingVideoTagStatus:{type:null,value:null},currentVideoTime:0,currentVideoTimeFragment:0,currentVideoBufferedTime:0,currentVideoDuration:0,playerMode:"desktop",playerVisibility:0,playerPlaceholderVisibility:0,playerSettings:{muted:!0,volume:.5,speed:1,quality:"Auto",selectedSettingsCategory:"",fullscreen:{pendingFullscreenRequest:"",isFullscreenOn:!1}},loader:{showBlackScreen:!1},playerSize:"",errorMessage:"",loadingPlayer:!1};function ya(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function ga(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?ya(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):ya(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var va={showVoltaxLogo:!0,brandingLogoSrc:"",brandingLogoUrl:"",brandingColor:null};function ma(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function ba(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?ma(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):ma(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Oa={orientation:"right",canClose:!0,anchorData:{anchorEnabled:!1,anchorDisabledByUser:!1,anchorStatus:"inactive"},closableAd:!0,continueStreaming:!1,anchoringAppearance:"below",stickyBelowClassName:"",width:"",closeAfter:10,margins:{top:10,bottom:10,left:10,right:10}};function _a(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Sa(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?_a(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):_a(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Ea,wa={continuePlayingWhileWaitingForAd:!1,midrolls:{},prerollEnabled:!1,vpaidMode:"ENABLED",adRequestTimeout:1e4,adsData:{podNumber:0,slotNumber:0,adType:null,adTagUrlTemplate:null,adErrorMessage:null,adDuration:0,adCurrentTime:0,adOrder:0,adStatus:"",pendingAdStatus:{type:""},playedMidrolls:[],adImpression:0,adOpportunity:0,isVastAd:!1,adMuted:!0,adVolume:.5,currentAdTag:null,adUnit:"",loadingAd:!1}},Pa=n(32),Ta=n.n(Pa);!function(e){e.POST="post",e.GET="get",e.DELETE="delete",e.PUT="put",e.PATCH="patch",e.HEAD="head",e.OPTIONS="options"}(Ea||(Ea={}));var Aa=function(){function e(){Ai()(this,e)}return Vi()(e,null,[{key:"preformRequest",value:function(e,t){return new Promise(function(n,r){Ta()({method:e,url:t}).then(function(e){var t=e.data;n(t)}).catch(function(e){r(e)})})}},{key:"preformGet",value:function(e){return this.preformRequest(Ea.GET,e)}}]),e}();f()(Aa,"HTTP_STATUS_CODES",{OK:200,UNAUTHORIZED:401,INTERNAL_SERVER_ERROR:500,BAD_REQUEST:400,NOT_FOUND:404,CONFLICT:409});var Ca=function(){function e(){Ai()(this,e)}return Vi()(e,null,[{key:"getSemanticPlaylistUrl",value:function(e,t,n){if(n&&!Un(n.semantic_url))return n.semantic_url;var r=function(e){for(var t="",n=0,r=0;r<e.length;r+=1)n=e.charCodeAt(r)+2,t+=String.fromCharCode(n);return encodeURIComponent(encodeURIComponent(t))}(e.split("?")[0]),i="".concat(function(){try{return"https://semantic-matching.minutemediaservices.com/semantic-feed"}catch(w){return"https://semantic-matching.minutemediaservices.com/semantic-feed"}}(),"/").concat(r),o="?";return Un(t.minimumDateFactor)||(i="".concat(i).concat(o,"minimum_date_factor=").concat(t.minimumDateFactor),o="&"),Un(t.tags)||(i="".concat(i).concat(o,"tags=").concat(t.tags),o="&"),Un(t.scopedKeywords)||(i="".concat(i).concat(o,"scoped_keywords=").concat(t.scopedKeywords),o="&"),Un(t.scannedElement)||Un(t.scannedElementType)||(i="".concat(i).concat(o,"article_container=").concat(function(e,t){switch(t){case"id":return"".concat("#").concat(e);case"className":return e.split(" ").map(function(e){return"".concat(".").concat(e)}).join("");default:return"".concat("").concat(e)}}(t.scannedElement,t.scannedElementType)),o="&"),Un(t.scanImagesOnPage)||(i="".concat(i).concat(o,"scan_images=").concat(String(t.scanImagesOnPage))),i}},{key:"getSpecificPlaylistUrl",value:function(e,t){return t&&!Un(t.playlist_url)?t.playlist_url:"".concat("https://vms-videos.minutemediaservices.com","/").concat(e,"/").concat(e,".json")}}]),e}(),Ra=function(e,t){var n=e.findIndex(function(e){return e.type===t});return n>=0?e[n].file:""},Da=function(){function e(){Ai()(this,e)}return Vi()(e,null,[{key:"getSemanticPlaylist",value:function(e,t){var n=window.location.href,r=Ca.getSemanticPlaylistUrl(n,e,t);return Aa.preformGet(r)}},{key:"getSpecificPlaylist",value:function(e,t){var n=Ca.getSpecificPlaylistUrl(e,t);return Aa.preformGet(n)}}]),e}();f()(Da,"getPromotedVideos",function(){var e=so()(oo.a.mark(function e(t){var n;return oo.a.wrap(function(e){for(;;)switch(e.prev=e.next){case 0:return n=t.map(function(e){return Da.getSpecificPlaylist(e).then(function(e){return e.data}).catch(function(){return[]})}),e.abrupt("return",new Promise(function(e){Promise.all(n).then(function(t){var n=t.reduce(function(e,t){return e.concat(t)},[]);n.length>0&&e(n)})}));case 2:case"end":return e.stop()}},e)}));return function(t){return e.apply(this,arguments)}}());var Ma=function(e,t){return function(n){n({type:"[CORE] load video request success",payload:e.data.map(function(e,n){return{mediaId:e.payload_id,tags:e.tags,sources:e.sources,duration:e.duration,thumbnail:e.image,title:t?e.title:"",description:e.description,creator:e.creator,provider:e.video_provider,externalId:e.external_id,index:n}})})}},Ia=function(e){return function(t){t({type:"[CORE] load video request error",payload:e})}},ka=function(e,t,n){return function(){var r=so()(oo.a.mark(function r(i){var o;return oo.a.wrap(function(r){for(;;)switch(r.prev=r.next){case 0:return i({type:"[CORE] load video request"}),r.prev=1,r.next=4,Da.getSpecificPlaylist(e,n);case 4:o=r.sent,Ma(o,t)(i),r.next=11;break;case 8:r.prev=8,r.t0=r.catch(1),Ia(Xn.GENERAL_ERROR)(i);case 11:case"end":return r.stop()}},r,null,[[1,8]])}));return function(e){return r.apply(this,arguments)}}()},Na=function(e,t,n){return function(){var r=so()(oo.a.mark(function r(i){var o,a;return oo.a.wrap(function(r){for(;;)switch(r.prev=r.next){case 0:if(i({type:"[CORE] load video request"}),o=[],r.prev=2,!(Array.isArray(e.promotedVideos)&&e.promotedVideos.length>0)){r.next=7;break}return r.next=6,Da.getPromotedVideos(e.promotedVideos);case 6:o=r.sent;case 7:return r.next=9,Da.getSemanticPlaylist(e,n);case 9:(a=r.sent).data=o.concat(a.data),Ma(a,t)(i),r.next=17;break;case 14:r.prev=14,r.t0=r.catch(2),o.length>0?Ma({data:o},t)(i):Ia(Xn.GENERAL_ERROR)(i);case 17:case"end":return r.stop()}},r,null,[[2,14]])}));return function(e){return r.apply(this,arguments)}}()},La=function(e,t){return function(n){n({type:"[CORE] set current video",payload:{index:e,videoData:t}})}};function xa(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Va(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?xa(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):xa(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var ja={activeVideoIndex:0,mediaType:"semantic",mediaId:"",loadingMedia:!1,mediaLoadingError:"",mediaRequest:{type:null,value:""},videoList:[],videoData:{mediaId:"",tags:[],sources:[],duration:0,thumbnail:"",title:"",showTitle:!0,description:"",creator:"",provider:"",externalId:"",index:0}};function Ua(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Fa(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Ua(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Ua(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Ba={promotedVideos:[],scannedElement:"",tags:"",scopedKeywords:"",minimumDateFactor:"",scannedElementType:null,scanImagesOnPage:!1};function Ha(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function qa(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Ha(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Ha(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Wa={userInteractionType:""};function za(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Ga(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?za(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):za(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var $a={splitViewRatio:null};function Ka(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Ya(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Ka(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Ka(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Za={nextVideo:"none",showUpNext:!1,showSkippableContent:!1},Xa=function(e){return"none"===e?"none":"up_next"===e?"upNext":"skippable_content"===e?"skippableContent":"none"},Ja=function(e){for(var t=Object.keys(e),n={},r=0;r<t.length;r++){var i=t[r];"function"===typeof e[i]&&(n[i]=e[i])}var o,a=Object.keys(n);try{!function(e){Object.keys(e).forEach(function(t){var n=e[t];if("undefined"===typeof n(void 0,{type:yt.INIT}))throw new Error('Reducer "'+t+"\" returned undefined during initialization. If the state passed to the reducer is undefined, you must explicitly return the initial state. The initial state may not be undefined. If you don't want to set a value for this reducer, you can use null instead of undefined.");if("undefined"===typeof n(void 0,{type:yt.PROBE_UNKNOWN_ACTION()}))throw new Error('Reducer "'+t+"\" returned undefined when probed with a random type. Don't try to handle "+yt.INIT+' or other actions in "redux/*" namespace. They are considered private. Instead, you must return the current state for any unknown actions, unless it is undefined, in which case you must return the initial state, regardless of the action type. The initial state may not be undefined, but can be null.')})}(n)}catch(s){o=s}return function(e,t){if(void 0===e&&(e={}),o)throw o;for(var r=!1,i={},s=0;s<a.length;s++){var u=a[s],c=n[u],l=e[u],d=c(l,t);if("undefined"===typeof d){var p=mt(u,t);throw new Error(p)}i[u]=d,r=r||d!==l}return(r=r||a.length!==Object.keys(e).length)?i:e}}({dependenciesLoadingStatus:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:da,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] update hls status":return la(la({},e),{},{loadingHLSStatus:t.payload});case"[CORE] update ima status":return la(la({},e),{},{loadingImaStatus:t.payload});default:return e}},playerData:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:ha,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":var n=t.payload;return fa({},function(e,t,n){var r=t.playback_method,i=t.player_id;return fa(fa({},e),{},{playbackMethod:Un(r)?e.playbackMethod:r,playerId:Un(i)?e.playerId:i,playerInstanceUniqId:n,playerMode:Fn()?"mobile":"desktop"})}(e,n.initiateParams,n.playerInstanceUniqId));case"[CORE] reset player data time params":return fa(fa({},e),{},{currentVideoTimeFragment:0,currentVideoBufferedTime:0,currentVideoDuration:0,currentVideoTime:0});case"[COMMON] set mute video":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{muted:t.payload})});case"[COMMON] set volume":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{volume:t.payload})});case"[COMMON] change selected settings category":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{selectedSettingsCategory:t.payload})});case"[COMMON] change settings speed":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{speed:t.payload})});case"[COMMON] change settings quality":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{quality:t.payload})});case"[COMMON] set fullscreen":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{fullscreen:fa(fa({},e.playerSettings.fullscreen),{},{isFullscreenOn:t.payload,pendingFullscreenRequest:""})})});case"[COMMON] set fullscreen request":return fa(fa({},e),{},{playerSettings:fa(fa({},e.playerSettings),{},{fullscreen:fa(fa({},e.playerSettings.fullscreen),{},{pendingFullscreenRequest:t.payload})})});case"[COMMON] set pending video status":var r=t.payload.pendingStatusObject;return fa(fa({},e),{},{pendingVideoTagStatus:fa({},r)});case"[COMMON] set player mode":return fa(fa({},e),{},{playerMode:t.payload});case"[CORE] update video current fragment position":return fa(fa({},e),{},{currentVideoTimeFragment:t.payload});case"[CORE] update video current position":return fa(fa({},e),{},{currentVideoTime:t.payload});case"[CORE] update video current buffered time":return fa(fa({},e),{},{currentVideoBufferedTime:t.payload});case"[CORE] update video current duration":return fa(fa({},e),{},{currentVideoDuration:t.payload});case"[CORE] change video tag status":return fa(fa({},e),{},{videoTagStatus:t.payload});case"[CORE] update player visibility":return fa(fa({},e),{},{playerVisibility:t.payload});case"[CORE] update placeholder visibility":return fa(fa({},e),{},{playerPlaceholderVisibility:t.payload});case"[CORE] change loading player status":return fa(fa({},e),{},{loadingPlayer:t.payload});case"[COMMON] show black screen with loader":return fa(fa({},e),{},{loader:fa(fa({},e.loader),{},{showBlackScreen:t.payload})});case"[CORE] set player size":return fa(fa({},e),{},{playerSize:t.payload});case"[COMMON] set error message":return fa(fa({},e),{},{errorMessage:t.payload});default:return e}},brandingData:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:va,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return ga({},function(e,t){var n=t.powered_by_strip,r=t.brand_logo,i=t.brand_logo_click_url,o=t.brand_color;return ga(ga({},e),{},{showVoltaxLogo:Un(n)?e.showVoltaxLogo:n,brandingLogoSrc:Un(r)?e.brandingLogoSrc:r,brandingLogoUrl:Un(i)?e.brandingLogoUrl:i,brandingColor:Un(o)?e.brandingColor:o})}(e,t.payload.initiateParams));default:return e}},anchorOptions:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:Oa,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return ba({},function(e,t){var n=t.anchor_options;if(!Un(n)){var r=n.anchoring_appearance,i=n.can_close,o=n.closable_ad,a=n.close_after,s=n.continue_streaming,u=n.orientation,c=n.margins,l=n.sticky_below_class_name,d=n.width,p=Un(c)?e.margins:{top:Number.isInteger(c.top)?c.top:e.margins.top,bottom:Number.isInteger(c.bottom)?c.bottom:e.margins.bottom,left:Number.isInteger(c.left)?c.left:e.margins.left,right:Number.isInteger(c.right)?c.right:e.margins.right};return ba(ba({},e),{},{anchoringAppearance:r||e.anchoringAppearance,canClose:Un(i)?e.canClose:i,orientation:Un(u)?e.orientation:u,closableAd:Un(o)?e.closableAd:o,closeAfter:Un(a)?e.closeAfter:a,continueStreaming:Un(s)?e.continueStreaming:s,stickyBelowClassName:Un(l)?e.stickyBelowClassName:l,width:Un(d)?e.width:d,margins:p,anchorData:ba(ba({},e.anchorData),{},{anchorEnabled:!0})})}return e}(e,t.payload.initiateParams));case"[COMMON] set anchor enable":return ba(ba({},e),{},{anchorData:ba(ba({},e.anchorData),{},{anchorEnabled:t.payload})});case"[ANCHOR] update is anchor status":return ba(ba({},e),{},{anchorData:ba(ba({},e.anchorData),{},{anchorStatus:t.payload})});case"[COMMON] set anchor disabled by user":return ba(ba({},e),{},{anchorData:ba(ba({},e.anchorData),{},{anchorDisabledByUser:t.payload})});default:return e}},monetization:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:wa,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return Sa({},function(e,t){var n=t.monetization;if(Un(n))return e;var r=n.ad_tag,i=n.ad_type,o=n.vpaid_mode,a=n.ad_request_timeout,s=n.continue_content_play_while_waiting_for_ad,u=n.midrolls,c=u&&u.on&&u.on.sort(Wn),l=Un(s)?e.continuePlayingWhileWaitingForAd:s,d=c?c.indexOf(0):-1,p=-1!==d&&!l;return p&&(c=c.splice(d,1)),Sa(Sa({},e),{},{midrolls:Sa(Sa({},e.midrolls),{},{every:u&&u.every,on:c}),prerollEnabled:p,adRequestTimeout:Un(a)?e.adRequestTimeout:parseInt(a,10),vpaidMode:Un(o)?e.vpaidMode:o,continuePlayingWhileWaitingForAd:l,adsData:Sa(Sa({},e.adsData),{},{adType:Un(i)?e.adsData.adType:i,adTagUrlTemplate:Un(r)?e.adsData.adTagUrlTemplate:r})})}(e,t.payload.initiateParams));case"[COMMON] set new ad tag url template":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adTagUrlTemplate:t.payload})});case"[MONETIZATION] change ad status":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adStatus:t.payload,adErrorMessage:null})});case"[MONETIZATION] change ad tag":var n=t.payload,r=n.adUnit,i=n.adTag;return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{currentAdTag:i,adUnit:r})});case"[MONETIZATION] change pending ad status":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{pendingAdStatus:t.payload})});case"[MONETIZATION] change ad error":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adStatus:"error",adErrorMessage:t.payload})});case"[MONETIZATION] increase ad impression counter":var o=e.adsData.adImpression;return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adImpression:o+1})});case"[MONETIZATION] increase ad Opportunity counter":var a=e.adsData.adOpportunity;return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adOpportunity:a+1})});case"[MONETIZATION] add played midroll number":var s=e.adsData.playedMidrolls,u=In()(s);return u.push(t.payload),Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adOrder:t.payload,playedMidrolls:u})});case"[MONETIZATION] clear played midrolls":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{playedMidrolls:[]})});case"[MONETIZATION] clear ad data":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adOrder:0,currentAdTag:null,adDuration:0,adUnit:""})});case"[MONETIZATION] change ad duration":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adDuration:t.payload})});case"[MONETIZATION] update is vast ad":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{isVastAd:t.payload})});case"[MONETIZATION] change ad current time":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adCurrentTime:t.payload})});case"[MONETIZATION] update ad muted":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adMuted:t.payload})});case"[MONETIZATION] change ad volume":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{adVolume:t.payload})});case"[MONETIZATION] change pod info":var c=t.payload,l=c.podNumber,d=c.slotNumber;return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{podNumber:l,slotNumber:d})});case"[MONETIZATION] change loading ad status":return Sa(Sa({},e),{},{adsData:Sa(Sa({},e.adsData),{},{loadingAd:t.payload})});default:return e}},mediaData:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:ja,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return Va({},function(e,t){var n=t.content_type,r=t.media_id,i=t.display_title;return Va(Va({},e),{},{mediaType:Un(n)?e.mediaType:n,mediaId:Un(r)?e.mediaId:r,videoData:Va(Va({},e.videoData),{},{showTitle:!!Un(i)||i})})}(e,t.payload.initiateParams));case"[CORE] load video request":return Va(Va({},e),{},{loadingMedia:!0});case"[CORE] load video request success":return Va(Va({},e),{},{loadingMedia:!1,videoList:t.payload});case"[CORE] set current video":var n=t.payload,r=n.index,i=n.videoData;return Va(Va({},e),{},{activeVideoIndex:r,videoData:i});case"[CORE] load video request error":return Va(Va({},e),{},{loadingMedia:!1,mediaLoadingError:t.payload});case"[COMMON] media request":var o=t.payload.mediaRequestObject;return Va(Va({},e),{},{mediaRequest:Va({},o)});default:return e}},semanticOptions:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:Ba,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return Fa({},function(e,t){var n=t.semantic_options;if(Un(n))return e;var r=n.minimum_date_factor,i=n.promoted_videos,o=n.scan_images_on_page,a=n.scanned_element,s=n.scanned_element_type,u=n.scoped_keywords,c=n.tags;return Fa(Fa({},e),{},{minimumDateFactor:Un(r)?e.minimumDateFactor:r,promotedVideos:Un(i)?e.promotedVideos:i,scanImagesOnPage:Un(o)?e.scanImagesOnPage:o,scannedElement:Un(a)?e.scannedElement:a,scannedElementType:Un(s)?e.scannedElementType:s,scopedKeywords:Un(u)?e.scopedKeywords:u,tags:Un(c)?e.tags:c})}(e,t.payload.initiateParams));default:return e}},userInteraction:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:Wa,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[USER INTERACTION] change user interaction":return qa(qa({},e),{},{userInteractionType:t.payload});default:return e}},splitView:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:$a,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return Ga({},function(e,t){var n=t.anchor_options;if(!Un(n)){var r=n.split_view,i=n.split_view_ratio;return Ga(Ga({},e),{},{splitViewRatio:Un(r)||!r||Un(i)?e.splitViewRatio:i})}return e}(e,t.payload.initiateParams));default:return e}},discovery:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:Za,t=arguments.length>1?arguments[1]:void 0;switch(t.type){case"[CORE] initiate store":return Ya({},function(e,t){var n=t.next_video;return Un(n)?e:Ya(Ya({},e),{},{nextVideo:Xa(n)})}(e,t.payload.initiateParams));case"[DISCOVERY] show up next":return Ya(Ya({},e),{},{showUpNext:t.payload});case"[DISCOVERY] show skippable content":return Ya(Ya({},e),{},{showSkippableContent:t.payload});default:return e}}}),Qa=[],es=!1,ts=function e(){return function(t){return function(n){if(es)return Qa.push(n),null;es=!0;var r=t(n);return es=!1,Qa.length>0&&e()(t)(Qa.shift()),r}}},ns=function(e){var t=[];if(function(e){return!Un(e)&&!Un(e.enable_redux_debugging)&&e.enable_redux_debugging}(e)){var n=window&&window.__REDUX_DEVTOOLS_EXTENSION__&&window.__REDUX_DEVTOOLS_EXTENSION__();"function"===typeof n&&t.push(n)}var r=Et.apply(void 0,[wt(ua,ts)].concat(t));return vt(Ja,r)},rs=function(){function e(t){Ai()(this,e),f()(this,"playerVisibilitySubscriber",void 0),f()(this,"videoTagStatusSubscriber",void 0),f()(this,"shouldPlayIfLazyplay",!0),f()(this,"shouldPlayIfAutoplayWhenViewable",!0),f()(this,"videoPausedByObserver",!1),this.store=t,this.playerVisibilitySubscriber=null,this.videoTagStatusSubscriber=null,this.playAccordingToPlaybackMethod()}return Vi()(e,[{key:"lazyplayHandler",value:function(e){hn.playerVisibility(e)>=.5&&(this.playVideo(),this.shouldPlayIfLazyplay=!1)}},{key:"autoplayWhenViewableHandler",value:function(e){hn.playerVisibility(e)>=.5?this.playVideo():this.pauseVideo()}},{key:"onPlayerVisibilityChanged",value:function(e){var t=hn.playbackMethod(e);"lazyplay"===t&&this.shouldPlayIfLazyplay&&this.lazyplayHandler(e),"autoplay_when_viewable"===t&&this.shouldPlayIfAutoplayWhenViewable&&this.autoplayWhenViewableHandler(e)}},{key:"onVideoTagStatusChanged",value:function(e){var t=hn.videoTagStatus(e);"paused"!==t||this.videoPausedByObserver||(this.shouldPlayIfAutoplayWhenViewable=!1),"playing"===t&&(this.shouldPlayIfAutoplayWhenViewable=!0,this.videoPausedByObserver=!1)}},{key:"initiatePlayerVisibilitySubscriber",value:function(){this.playerVisibilitySubscriber=new ji(this.store,e.getPlayerVisibilityDependencies,this.onPlayerVisibilityChanged.bind(this))}},{key:"initiateVideoTagStatusSubscriber",value:function(){this.videoTagStatusSubscriber=new ji(this.store,e.getVideoTagStatusDependencies,this.onVideoTagStatusChanged.bind(this))}},{key:"playVideo",value:function(){var e=this.store,t=e.dispatch,n=e.getState;"idle"===hn.videoTagStatus(n())?on("play")(t):on("resume")(t)}},{key:"pauseVideo",value:function(){var e=this.store,t=e.dispatch,n=e.getState;"paused"!==hn.videoTagStatus(n())&&(this.videoPausedByObserver=!0,on("pause")(t))}},{key:"playAccordingToPlaybackMethod",value:function(){var e=this.store,t=e.dispatch,n=(0,e.getState)();switch(hn.playbackMethod(n)){case"autoplay":this.playVideo();break;case"lazyplay":this.initiatePlayerVisibilitySubscriber();break;case"autoplay_when_viewable":this.initiatePlayerVisibilitySubscriber(),this.initiateVideoTagStatusSubscriber();break;case"none":an(!1)(t)}}}],[{key:"getPlayerVisibilityDependencies",value:function(e){return[hn.playerVisibility(e)]}},{key:"getVideoTagStatusDependencies",value:function(e){return[hn.videoTagStatus(e)]}}]),e}(),is=function(){function e(t,n,r,i){var o=this;Ai()(this,e),f()(this,"videoStatusSubscriber",void 0),f()(this,"videoListSubscriber",void 0),f()(this,"mediaRequestSubscriber",void 0),f()(this,"playerVisibilitySubscriber",void 0),f()(this,"playbackMethodManager",void 0),f()(this,"store",void 0),f()(this,"loadContent",function(e,t,n,r){o.loadMedia(t,n,r).then(function(){o.playbackMethodManager=new rs(e)})}),f()(this,"loadMedia",function(e,t,n){var r=o.store,i=r.dispatch,a=r.getState,s=Dn.showTitle(a());if("semantic"===e){var u=pn.semanticOptions(a());return Na(u,s,n)(i)}return ka(t,s,n)(i)}),this.store=t,this.videoStatusSubscriber=new ji(t,e.getVideoStatusDependencies,this.onVideoStatusChanged.bind(this)),this.videoListSubscriber=new ji(t,e.getVideoListDependencies,this.onVideoListChanged.bind(this)),this.mediaRequestSubscriber=new ji(t,e.getMediaRequestDependencies,this.onMediaRequestChanged.bind(this)),this.playerVisibilitySubscriber=null,this.loadContent(t,r,n,i)}return Vi()(e,null,[{key:"createInstance",value:function(t,n,r,i){return new e(t,n,r,i)}}]),Vi()(e,[{key:"playNextVideo",value:function(e){var t=this.store.dispatch,n=Cn.videoList(e),r=Cn.activeVideoIndex(e)+1;n.length>1&&r>=n.length&&(r=0),r<n.length&&(!function(e){e({type:"[CORE] reset player data time params"})}(t),La(r,n[r])(t),on("play")(t))}},{key:"playPreviousVideo",value:function(e){var t=this.store.dispatch,n=Cn.videoList(e),r=Cn.activeVideoIndex(e);if(r>0){var i=r-1;La(i,n[i])(t),on("play")(t)}}},{key:"onVideoStatusChanged",value:function(e){"complete"===hn.videoTagStatus(e)&&this.playNextVideo(e)}},{key:"onVideoListChanged",value:function(e){var t=this.store.dispatch,n=Cn.videoList(e);!jn(n)&&n.length>0&&La(0,n[0])(t)}},{key:"onMediaRequestChanged",value:function(e){var t=Cn.mediaRequest(e);switch(t.type){case"playNewVideo":this.loadMedia("specific",t.value);break;case"playNextVideo":this.playNextVideo(e);break;case"playPreviousVideo":this.playPreviousVideo(e)}}}],[{key:"getVideoStatusDependencies",value:function(e){return[hn.videoTagStatus(e)]}},{key:"getVideoListDependencies",value:function(e){return[Cn.videoList(e)]}},{key:"getMediaRequestDependencies",value:function(e){return[Cn.mediaRequest(e)]}}]),e}(),os=function e(t){var n=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"onDependencyFailure",function(e,t){console.log("onDependencyFailure",e,t);var r=n.store,i=r.dispatch,o=r.getState;switch(e){case"ima":"blocked"!==Fi.loadingImaStatus(o())&&Qn("error")(i);break;case"hls":er("error")(i)}}),f()(this,"onDependencyReady",function(e){var t=n.store.dispatch;switch(e){case"ima":Qn("success")(t);break;case"hls":er("success")(t)}}),this.store=t},as=function(e){return function(t){t({type:"[COMMON] set fullscreen",payload:e})}},ss=function(){function e(t,n){var r=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"videoTag",void 0),f()(this,"pendingFullscreenSubscriber",void 0),f()(this,"adStatusSubscriber",void 0),f()(this,"playerUniqId",void 0),f()(this,"onAdStatusChanged",function(e){var t=_i.adStatus(e),n=r.videoTag.webkitDisplayingFullscreen;"playing"===t&&Bn()&&n&&r.exitFullscreen(r.videoTag)}),f()(this,"isPlayerInFullscreen",function(){var e=document,t=Bn()?En(r.playerUniqId):bn(r.playerUniqId);return Un(e.fullscreenElement)?!Un(e.webkitFullscreenElement)&&0===e.webkitFullscreenElement.id.localeCompare(t):0===e.fullscreenElement.id.localeCompare(t)}),f()(this,"changePlayerWidth",function(e){r.videoTag.style.width=e?"100%":"auto"}),f()(this,"onFullscreenChanged",function(){var e=r.store.dispatch,t=r.isPlayerInFullscreen();r.changePlayerWidth(t),as(t)(e)}),f()(this,"onFullscreenChangedIos",function(){var e=r.store.dispatch,t=r.videoTag.webkitDisplayingFullscreen;t||on("resume")(e),r.changePlayerWidth(t),as(t)(e)}),f()(this,"onPendingFullscreenRequestChanged",function(e){var t=gn.pendingFullscreenRequest(e);"enter"===t?r.enterFullscreen(r.videoTag):"exit"===t&&r.exitFullscreen(r.videoTag)}),f()(this,"getFullScreenElement",function(e,t){var n=document.getElementById(bn(r.playerUniqId));return Bn()?t:e?document:n}),f()(this,"enterFullscreen",function(e){var t=r.getFullScreenElement(!1,e);Bn()?t.webkitEnterFullscreen():document.webkitExitFullscreen?t.webkitRequestFullscreen():document.webkitCancelFullScreen?t.webkitRequestFullScreen():document.mozCancelFullScreen?t.mozRequestFullScreen():document.msExitFullscreen&&t.msRequestFullscreen()}),f()(this,"exitFullscreen",function(e){var t=r.getFullScreenElement(!0,e);document.webkitExitFullscreen||Bn()?t.webkitExitFullscreen():document.webkitCancelFullScreen?t.webkitCancelFullScreen():document.mozCancelFullScreen?t.mozCancelFullScreen():document.msExitFullscreen&&t.msExitFullscreen()}),this.store=t,this.videoTag=document.getElementById(En(n)),this.playerUniqId=n,document.addEventListener("fullscreenchange",this.onFullscreenChanged.bind(this)),document.addEventListener("webkitfullscreenchange",this.onFullscreenChanged.bind(this)),Bn()&&(this.videoTag.addEventListener("webkitendfullscreen",this.onFullscreenChangedIos.bind(this)),this.videoTag.addEventListener("webkitbeginfullscreen",this.onFullscreenChangedIos.bind(this))),this.pendingFullscreenSubscriber=new ji(t,e.getPendingFullscreenDependencies,this.onPendingFullscreenRequestChanged.bind(this)),this.adStatusSubscriber=new ji(t,e.getAdStatusDependencies,this.onAdStatusChanged.bind(this))}return Vi()(e,null,[{key:"createInstance",value:function(t,n){return new e(t,n)}}]),Vi()(e,null,[{key:"getPendingFullscreenDependencies",value:function(e){return[gn.pendingFullscreenRequest(e)]}},{key:"getAdStatusDependencies",value:function(e){return[_i.adStatus(e)]}}]),e}();function us(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function cs(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?us(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):us(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var ls,ds=function(e){return function(e){return e&&window.monti.playerConfigs&&window.monti.playerConfigs[e]}(e)?function(e){return window.monti.playerConfigs[e]}(e):window.monti.playerConfigs?window.monti.playerConfigs&&window.monti.playerConfigs[Object.keys(window.monti.playerConfigs)[0]]:null},ps=function e(t){var n=this;Ai()(this,e),f()(this,"videoTag",void 0),f()(this,"isBufferError",void 0),f()(this,"hls",void 0),f()(this,"hlsSetup",function(e,t,r,i){n.initiateHls(e),n.loadHlsSource(e,t,r,i)}),f()(this,"detachMedia",function(){Un(n.hls)||(n.hls.detachMedia(),n.hls.destroy(),n.hls=null)}),f()(this,"initiateHls",function(e){n.hls=new e,n.hls.attachMedia(n.videoTag)}),f()(this,"loadHlsSource",function(e,t,r,i){n.hls.on(e.Events.MEDIA_ATTACHED,function(){n.hls.loadSource(t)}),n.hls.on(e.Events.ERROR,function(t,o){n.mapHlsToErrors(e,o,i),t.details===e.ErrorDetails.BUFFER_STALLED_ERROR&&(r(!0),n.isBufferError=!0)}),n.hls.on(e.Events.FRAG_BUFFERED,function(){n.isBufferError&&(r(!1),n.isBufferError=!1)})}),f()(this,"mapHlsToErrors",function(e,t,r){if(t.fatal)switch(t.type){case e.ErrorTypes.NETWORK_ERROR:r(Xn.GENERAL_ERROR),n.hls.startLoad();break;case e.ErrorTypes.MEDIA_ERROR:r(Xn.GENERAL_ERROR),n.hls.recoverMediaError();break;default:r(Xn.GENERAL_ERROR),n.hls.destroy()}}),this.hls=void 0,this.videoTag=t,this.isBufferError=!1},fs=function e(){var t=this;Ai()(this,e),f()(this,"videoStreaming",void 0),f()(this,"hlsLibrarySetup",function(e,n,r,i){Un(t.videoStreaming)||t.videoStreaming.detachMedia(),t.videoStreaming=new ps(e),t.videoStreaming.hlsSetup(ls,n,r,i)})};f()(fs,"shouldLoadVideoStreamingSrcDirectly",function(e,t,n){return"no-need"===n&&!(""===e.canPlayType("application/vnd.apple.mpegurl"))}),f()(fs,"shouldUseHlsLibrary",function(e,t){return"success"===t&&(ls=void 0!==window.Hls?Hls:mmHls).isSupported()}),f()(fs,"isValidHlsUrl",function(e){return!Un(e)&&!e.includes(".mp4")}),f()(fs,"suitableVideoSource",function(e,t,n){return fs.isValidHlsUrl(t)?fs.shouldUseHlsLibrary(t,n)?"m3u8 with hls":fs.shouldLoadVideoStreamingSrcDirectly(e,t,n)?"m3u8 directly":"loading"!==n?"mp4":"":"mp4"}),f()(fs,"loadHlsVideoDirectly",function(e,t){e.setAttribute("src",t),e.load()});var hs=function(e){return function(t){t({type:"[MONETIZATION] change pending ad status",payload:{type:e}})}},ys="video/mp4",gs="application/vnd.apple.mpegurl",vs=function(){function e(t,n){var r=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"videoTag",void 0),f()(this,"prerollEnabled",void 0),f()(this,"pendingVideoStatusSubscriber",void 0),f()(this,"videoStreamingManager",void 0),f()(this,"videoDataSubscriber",void 0),f()(this,"hlsLoadingStatusSubscriber",void 0),f()(this,"newVideoDataLoaded",void 0),f()(this,"onHlsLoadingStatusChanged",function(e){"success"===Fi.loadingHLSStatus(e)&&(r.newVideoDataLoaded=!0,r.onPendingVideoStatusChanged(e))}),f()(this,"onPendingVideoStatusChanged",function(e){var t=hn.pendingVideoTagStatus(e),n=Dn.sources(e),i=Fi.loadingHLSStatus(e),o="blocked"===Fi.loadingImaStatus(e);r.handlePendingVideoStatus(t,n,i,o)}),f()(this,"onVideoDataChanged",function(){r.newVideoDataLoaded=!0}),f()(this,"sendPrerollPlayRequest",function(){var e=r.store.dispatch;hs("playPreroll")(e)}),f()(this,"handlePlayRequest",function(e,t,n){var i=r.store.dispatch;if(e&&e.length>0){if(r.newVideoDataLoaded&&(r.loadVideoSource(r.videoTag,e,t),r.newVideoDataLoaded=!1,r.prerollEnabled&&!n))return void r.sendPrerollPlayRequest();r.videoTag.play().catch(function(e){return console.error("Error playing the video: ",e)})}else dn(Xn.VIDEO_ERROR)(i)}),f()(this,"handlePendingVideoStatus",function(e,t,n,i){switch(e.type){case"play":r.handlePlayRequest(t,n,i);break;case"resume":r.videoTag.play().catch(function(e){return console.error("Error resuming the video: ",e)});break;case"pause":r.videoTag.pause();break;case"replay":r.videoTag.currentTime=0,r.videoTag.play().catch(function(e){return console.error("Error replaying the video: ",e)});break;case"seekTo":r.videoTag.pause(),r.videoTag.currentTime=e.value}}),f()(this,"loadMp4Source",function(e,t,n){var r=Ra(t,ys);n.setAttribute("src",r),n.load()}),f()(this,"loadVideoSource",function(e,t,n){var i=r.store.dispatch,o=Ra(t,gs);switch(fs.suitableVideoSource(e,o,n)){case"mp4":r.loadMp4Source(n,t,e);break;case"m3u8 with hls":r.videoStreamingManager.hlsLibrarySetup(e,o,function(e){return un(e)(i)},function(e){return dn(e)(i)});break;case"m3u8 directly":fs.loadHlsVideoDirectly(e,o)}}),this.store=t;var i=t.getState;this.videoStreamingManager=new fs,this.videoTag=document.getElementById(En(n)),this.prerollEnabled=bi.prerollEnabled(i()),this.pendingVideoStatusSubscriber=new ji(t,e.getPendingVideoStatusDependencies,this.onPendingVideoStatusChanged.bind(this)),this.videoDataSubscriber=new ji(t,e.getVideoDataDependencies,this.onVideoDataChanged.bind(this)),this.hlsLoadingStatusSubscriber=new ji(t,e.getHLSLoadingStatusDependencies,this.onHlsLoadingStatusChanged.bind(this))}return Vi()(e,null,[{key:"createInstance",value:function(t,n){return new e(t,n)}}]),Vi()(e,null,[{key:"getHLSLoadingStatusDependencies",value:function(e){return[Fi.loadingHLSStatus(e)]}},{key:"getPendingVideoStatusDependencies",value:function(e){return[hn.pendingVideoTagStatus(e)]}},{key:"getVideoDataDependencies",value:function(e){return[Cn.videoData(e)]}}]),e}();function ms(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function bs(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?ms(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):ms(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var Os={READY_EVENT:"ready",PLAY_EVENT:"play",PAUSE_EVENT:"pause",TIME_EVENT:"time",SEEK_EVENT:"seek",COMPLETE_EVENT:"complete",VOLUME_EVENT:"volume",MUTE_EVENT:"mute"},_s=Object.values(Os),Ss={FULLSCREEN_EVENT:"fullscreen",ANCHOR_STATUS_EVENT:"anchorStatusChanged",ANCHOR_CLOSED_EVENT:"anchorClosed"},Es={AD_PLAY_EVENT:"adPlay",AD_PAUSE_EVENT:"adPause",AD_RESUME_EVENT:"adResume",AD_COMPLETE_EVENT:"adComplete",AD_TIME_EVENT:"adTime",AD_MUTE_EVENT:"adMute",AD_SKIPPED_EVENT:"adSkipped",AD_ERROR_EVENT:"adError",AD_BLOCK_EVENT:"adBlock",AD_REQUEST_EVENT:"adRequest",AD_OPPORTUNITY_EVENT:"adOpportunity",AD_IMPRESSION_EVENT:"adImpression"},ws=Object.values(Es),Ps=Object.values(bs(bs(bs({},Os),Es),Ss)),Ts=function(){function e(t,n){var r=this;Ai()(this,e),f()(this,"eventsCallbacksHandler",void 0),f()(this,"store",void 0),f()(this,"videoStatusSubscriber",void 0),f()(this,"videoMuteSubscriber",void 0),f()(this,"videoVolumeSubscriber",void 0),f()(this,"videoTimeFragmentSubscriber",void 0),f()(this,"videoListStoreSubscriber",void 0),f()(this,"previousVideoTagStatus",void 0),f()(this,"startSeekTime",0),f()(this,"canHandleReady",function(e,t,n){if(t===Os.READY_EVENT){var r=Cn.videoList(e);if(Array.isArray(r)&&r.length>0)return n(),!0}return!1}),f()(this,"canBeHandled",function(e,t){var n=r.store.getState;return r.canHandleReady(n(),e,t)}),f()(this,"reportSeekEnd",function(e){var t={position:hn.currentVideoTimeFragment(e),offset:r.startSeekTime};r.eventsCallbacksHandler.onEvent(Os.SEEK_EVENT,t)}),f()(this,"onMuteStateChanged",function(e){var t=gn.muted(e);r.eventsCallbacksHandler.onEvent(Os.MUTE_EVENT,{state:t})}),f()(this,"onVolumeChanged",function(e){var t=gn.muted(e),n=gn.volume(e);r.eventsCallbacksHandler.onEvent(Os.VOLUME_EVENT,{level:t?0:n})}),f()(this,"onVideoTimeFragmentChanged",function(e){var t=hn.currentVideoTimeFragment(e),n=hn.currentVideoDuration(e);r.eventsCallbacksHandler.onEvent(Os.TIME_EVENT,{duration:n,position:t})}),f()(this,"onVideoListChanged",function(){r.eventsCallbacksHandler.onEvent(Os.READY_EVENT)}),this.store=t,this.eventsCallbacksHandler=n,this.videoStatusSubscriber=new ji(t,e.getVideoStatusDependencies,this.onVideoStatusChanged.bind(this)),this.videoMuteSubscriber=new ji(t,e.getVideoMuteDependencies,this.onMuteStateChanged.bind(this)),this.videoVolumeSubscriber=new ji(t,e.getVolumeDependencies,this.onVolumeChanged.bind(this)),this.videoTimeFragmentSubscriber=new ji(t,e.getVideoTimeDependencies,this.onVideoTimeFragmentChanged.bind(this)),this.videoListStoreSubscriber=new ji(t,e.getVideoListDependencies,this.onVideoListChanged.bind(this)),this.previousVideoTagStatus=hn.videoTagStatus(t.getState())}return Vi()(e,[{key:"onVideoStatusChanged",value:function(e){var t=hn.videoTagStatus(e);switch("seeking"===this.previousVideoTagStatus&&this.reportSeekEnd(e),t){case"paused":this.eventsCallbacksHandler.onEvent(Os.PAUSE_EVENT);break;case"seeking":this.startSeekTime=hn.currentVideoTimeFragment(e);break;case"complete":this.eventsCallbacksHandler.onEvent(Os.COMPLETE_EVENT);break;case"playing":this.eventsCallbacksHandler.onEvent(Os.PLAY_EVENT)}this.previousVideoTagStatus=t}}],[{key:"getVideoStatusDependencies",value:function(e){return[hn.videoTagStatus(e)]}}]),e}();f()(Ts,"getVideoMuteDependencies",function(e){return[gn.muted(e)]}),f()(Ts,"getVolumeDependencies",function(e){return[gn.volume(e)]}),f()(Ts,"getVideoTimeDependencies",function(e){return[hn.currentVideoTimeFragment(e)]}),f()(Ts,"getVideoListDependencies",function(e){return[Cn.videoList(e)]}),f()(Ts,"isContentEvent",function(e){return _s.some(function(t){return t===e})});var As=function e(t,n){var r=this;Ai()(this,e),f()(this,"eventsCallbacksHandler",void 0),f()(this,"store",void 0),f()(this,"fullscreenSubscriber",void 0),f()(this,"anchorStatusSubscriber",void 0),f()(this,"anchorDisabledByUserSubscriber",void 0),f()(this,"onFullscreenChanged",function(e){var t=gn.isFullscreenOn(e);r.eventsCallbacksHandler.onEvent(Ss.FULLSCREEN_EVENT,{state:t})}),f()(this,"onAnchorStatusChanged",function(e){var t="active"===Pr(e)?"activated":"deactivated";r.eventsCallbacksHandler.onEvent(Ss.ANCHOR_STATUS_EVENT,{state:t})}),f()(this,"onAnchorDisabledByUser",function(e){if(wr(e)){var t=hn.currentVideoTimeFragment(e);r.eventsCallbacksHandler.onEvent(Ss.ANCHOR_CLOSED_EVENT,{position:t})}}),this.store=t,this.eventsCallbacksHandler=n,this.fullscreenSubscriber=new ji(t,e.getFullscreenDependencies,this.onFullscreenChanged.bind(this)),this.anchorStatusSubscriber=new ji(t,e.getAnchorStatusDependencies,this.onAnchorStatusChanged.bind(this)),this.anchorDisabledByUserSubscriber=new ji(t,e.getAnchorDisabledByUserDependencies,this.onAnchorDisabledByUser.bind(this))};f()(As,"getFullscreenDependencies",function(e){return[gn.isFullscreenOn(e)]}),f()(As,"getAnchorStatusDependencies",function(e){return[Pr(e)]}),f()(As,"getAnchorDisabledByUserDependencies",function(e){return[wr(e)]});var Cs=function(){function e(t,n){var r=this;Ai()(this,e),f()(this,"store",void 0),f()(this,"eventsCallbacksHandler",void 0),f()(this,"adStatusSubscriber",void 0),f()(this,"adImpressionSubscriber",void 0),f()(this,"adOpportunitySubscriber",void 0),f()(this,"adTimeSubscriber",void 0),f()(this,"adMuteSubscriber",void 0),f()(this,"adProviderLoadingStatusSubscriber",void 0),f()(this,"previousAdStatus",void 0),f()(this,"canBeHandled",function(e,t){var n=r.store.getState;switch(Fi.loadingImaStatus(n())){case"loading":return!1;case"success":case"error":return!0;case"blocked":return t(),!0;case"":default:return!1}}),f()(this,"onAdStatusChanged",function(e){var t=_i.adStatus(e),n=_i.currentAdTag(e);switch(t){case"requested":r.eventsCallbacksHandler.onEvent(Es.AD_REQUEST_EVENT,{tag:n});break;case"paused":r.eventsCallbacksHandler.onEvent(Es.AD_PAUSE_EVENT,{tag:n});break;case"completed":r.eventsCallbacksHandler.onEvent(Es.AD_COMPLETE_EVENT,{tag:n});break;case"skipped":r.eventsCallbacksHandler.onEvent(Es.AD_SKIPPED_EVENT,{tag:n});break;case"playing":"paused"===r.previousAdStatus?r.eventsCallbacksHandler.onEvent(Es.AD_RESUME_EVENT,{tag:n}):r.eventsCallbacksHandler.onEvent(Es.AD_PLAY_EVENT,{tag:n});break;case"error":var i=_i.adErrorMessage(e);r.eventsCallbacksHandler.onEvent(Es.AD_ERROR_EVENT,{tag:n,message:i})}r.previousAdStatus=t}),f()(this,"onAtTimeChanged",function(e){var t=_i.adCurrentTime(e),n=_i.currentAdTag(e),i=_i.adDuration(e);r.eventsCallbacksHandler.onEvent(Es.AD_TIME_EVENT,{position:t,tag:n,duration:i})}),f()(this,"onAdMuteChanged",function(e){var t=_i.adMuted(e);r.eventsCallbacksHandler.onEvent(Es.AD_MUTE_EVENT,{state:t})}),f()(this,"onAdProviderLoadingChanged",function(e){"blocked"===Fi.loadingImaStatus(e)&&r.eventsCallbacksHandler.onEvent(Es.AD_BLOCK_EVENT)}),f()(this,"onAdImpressionChanged",function(e){var t=_i.currentAdTag(e);r.eventsCallbacksHandler.onEvent(Es.AD_IMPRESSION_EVENT,{tag:t})}),f()(this,"onAdOpportunityChanged",function(e){var t=_i.currentAdTag(e);r.eventsCallbacksHandler.onEvent(Es.AD_OPPORTUNITY_EVENT,{tag:t})}),this.store=t,this.eventsCallbacksHandler=n,this.previousAdStatus=_i.adStatus(t.getState()),this.adStatusSubscriber=new ji(t,e.getAdStatusDependencies,this.onAdStatusChanged.bind(this)),this.adTimeSubscriber=new ji(t,e.getAdTimeDependencies,this.onAtTimeChanged.bind(this)),this.adMuteSubscriber=new ji(t,e.getAdMuteDependencies,this.onAdMuteChanged.bind(this)),this.adImpressionSubscriber=new ji(t,e.getAdImpressionDependencies,this.onAdImpressionChanged.bind(this)),this.adOpportunitySubscriber=new ji(t,e.getAdOpportunitySubscriberDependencies,this.onAdOpportunityChanged.bind(this)),this.adProviderLoadingStatusSubscriber=new ji(t,e.getAdProviderLoadingDependencies,this.onAdProviderLoadingChanged.bind(this))}return Vi()(e,null,[{key:"getAdStatusDependencies",value:function(e){return[_i.adStatus(e)]}},{key:"getAdTimeDependencies",value:function(e){return[_i.adCurrentTime(e)]}},{key:"getAdMuteDependencies",value:function(e){return[_i.adMuted(e)]}},{key:"getAdProviderLoadingDependencies",value:function(e){return[Fi.loadingImaStatus(e)]}}]),e}();f()(Cs,"isAdEvent",function(e){return ws.some(function(t){return t===e})}),f()(Cs,"getAdImpressionDependencies",function(e){return[_i.adImpression(e)]}),f()(Cs,"getAdOpportunitySubscriberDependencies",function(e){return[_i.adOpportunity(e)]});var Rs=function e(t){var n=this;Ai()(this,e),f()(this,"contentEvents",void 0),f()(this,"generalEvents",void 0),f()(this,"adEvents",void 0),f()(this,"subscribers",{}),f()(this,"onRegisterToEvent",function(e,t,r){n.isValidEvent(e)&&(Ts.isContentEvent(e)&&n.contentEvents.canBeHandled(e,t)||Cs.isAdEvent(e)&&n.adEvents.canBeHandled(e,t())||n.getEventSubscribersList(e).push({callback:t,once:r}))}),f()(this,"isValidEvent",function(e){return Ps.some(function(t){return t===e})}),f()(this,"getEventSubscribersList",function(e){return Array.isArray(n.subscribers[e])||(n.subscribers[e]=[]),n.subscribers[e]}),f()(this,"filterOutOnceCallbacks",function(e,t){n.subscribers[e]=t.filter(function(e){return!e.once})}),f()(this,"onEvent",function(e,t){var r=n.getEventSubscribersList(e);r.forEach(function(e){(0,e.callback)(t)}),n.filterOutOnceCallbacks(e,r)}),this.contentEvents=new Ts(t,this),this.generalEvents=new As(t,this),this.adEvents=new Cs(t,this)},Ds=function(){function e(t){Ai()(this,e),f()(this,"eventsHandler",void 0),this.eventsHandler=new Rs(t)}return Vi()(e,[{key:"on",value:function(e,t){this.eventsHandler.onRegisterToEvent(e,t,!1)}},{key:"once",value:function(e,t){this.eventsHandler.onRegisterToEvent(e,t,!0)}}]),e}();function Ms(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var r=Object.getOwnPropertySymbols(e);t&&(r=r.filter(function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable})),n.push.apply(n,r)}return n}function Is(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?Ms(Object(n),!0).forEach(function(t){f()(e,t,n[t])}):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):Ms(Object(n)).forEach(function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))})}return e}var ks=function(){var e=window.monti.dataset;return jn(e)?(e={players:{},preact:Is(Is({},r),i),store:{},plugins:{}},window.monti.dataset=e,e):e},Ns=function(e){var t=function(){var e=(new Date).getTime(),t=performance&&performance.now&&1e3*performance.now()||0;return"xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx".replace(/[xy]/g,function(n){var r=16*Math.random();return e>0?(r=(e+r)%16|0,e=Math.floor(e/16)):(r=(t+r)%16|0,t=Math.floor(t/16)),("x"===n?r:3&r|8).toString(16)})}(),n=function(e,t){var n=ns(e.dev_config),r=ks(),i=n.dispatch;return r.store[t]=n,function(e,t){return function(n){n({type:"[CORE] initiate store",payload:{initiateParams:e,playerInstanceUniqId:t}})}}(e,t)(i),n}(e,t);return function(e,t,n){B(b(Pi,{playerId:t,store:n,playerPosition:e}),e)}(e.player_pos,t,n),oa.getInstance().loadInternalPlugins(n,t,e),ss.createInstance(n,t),vs.createInstance(n,t),is.createInstance(n,e.media_id,e.content_type,e.dev_config),function(e){var t=e.dispatch;if(er(Ci.getInstance().getHLSLoadingStatus())(t),Qn(Ci.getInstance().getIMALoadingStatus())(t),!Ci.getInstance().isDependenciesReady()){var n=new os(e);Ci.getInstance().addDependenciesCallback(n)}}(n),function(e,t){ks().players[t]=new Ds(e)}(n,t),t},Ls=function(e){return console.log("player initiation start",e),new Promise(function(t,n){try{var r=function(e){var t=e.player_pos||document.currentScript.parentElement,n=e.media_id||e.content_id;return cs(cs({},e),{},{player_pos:t,media_id:n})}(function(e){var t=e.player_id,n=ds(t);return null===n?e:cs(cs({},e),n)}(e)),i=Ns(r);!function(e){var t=new CustomEvent("montiConfigLoaded",{detail:{playerKey:e}});window.dispatchEvent(t)}(i),t(i)}catch(o){console.error("Player initiation error",o),n(o)}})},xs=function(){return{initiate:Ls}};window.monti=xs,Ci.getInstance().loadExternalDependencies()}]); window.monti().initiate(Object.assign({player_pos: document.currentScript.parentElement}, {"is_conflicting_with_other_jw_players":false,"programmatic_play_with_sound_on_desktop":false,"referrer_id":"af93e181-b289-0560-a2bf-808e93bb05bc","width":"100","comscore_publisher_id":"18120612","monetization":{"ad_type":"static_tag","continue_content_play_while_waiting_for_ad":false,"strategy":"on_player_load","ad_request_timeout":"10000","midrolls":{"on":[0]},"vpaid_mode":"ENABLED","ad_tag":"https://pubads.g.doubleclick.net/gampad/ads?sz=400x300|640x480|480x270|640x360&iu=/175840252/MMPlus/smithsonianmag/Video&impl=s&gdfp_req=1&env=vp&output=vast&unviewed_position_start=1&url=##REFERRER_URL_UNESC##&description_url=##DESCRIPTION_URL_UNESC##&correlator=##CACHEBUSTER##&cust_params=mm_midroll%3D##MIDROLL_ORDER##%26video_ID%3D##VIDEO_ID##"},"sponsorship":false,"player_identifier":"mplayer","recommendation_id":null,"brand_color":"#FF9900","powered_by_strip":true,"platform":"buffy","type":"video","config_name":"MM+ | Smithsonianmag | Podding","player_id":"3v9g2u2f","playlist_id":"fSkmeWKF","playback_method":"autoplay","anchor_viewability_method":"none","player_version":"v4","playlist_type":"semantic","semantic_options":{"scan_images_on_page":true,"scanned_element":"","tags":"geogrophy,nature,animals,habitat,outdoors,science,history","minimum_date_factor":30,"scanned_element_type":"tag","scoped_keywords":"mentalfloss","promoted_videos":[]},"script_destination":"mm","publisher_contribution":"floor8","general_script_description":"","brand_logo":"","brand_logo_click_url":"","next_video":"none","uniq_key":"af93e181-b289-0560-a2bf-808e93bb05bc","content_id":"fSkmeWKF","content_type":"semantic"})); Finland has vastly improved in reading, math and science literacy over the past decade in large part because its teachers are trusted to do whatever it takes to turn young lives around. This 13-year-old, Besart Kabashi, received something akin to royal tutoring.

      Kari Louhiuori, a principal at a Finnish school made a mostly unheaard of and uncanny decision to hold back an immigrant student from 6th grader named Besart because he hadnʻt felt that this young man was falling behind due to laziness but to a lack of comprehension. After a year of "royal tutoring," by allowing the boy to read at his own pace, it worked!

  3. Sep 2020
    1. SciScore for 10.1101/2020.09.27.316174: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Texas Medical Branch and were conducted according to the National Institutes of Health guidelines.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">94 single clones (black dots) were randomly selected and together with 2 clones representing wild type STI-1499 as reference (red dots) were analyzed by ELISA.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Hamster challenge experiments Male and female Syrian golden hamsters were obtained from Charles River Laboratories at 6 weeks of age.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody characterization Kinetic interactions between the antibodies and His-tagged receptor binding domain (RBD, amino acids 319-537) (Acro Biosystems, Newark, NJ) protein was measured at 25C using BIAcore T200 surface plasmon resonance (SPR) (GE Healthcare).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>His-tagged receptor binding domain (RBD, amino acids 319-537) (Acro Biosystems, Newark, NJ</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Expression and purification of STI-1499 and STI-2020 monoclonal antibodies STI-1499 was expressed using a two-vector transient expression protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>STI-2020</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For antibody binding to the cells expressing the Spike proteins, the cells were dispensed into wells of a 96-well plate (25 l per well), and an equal volume of 2x final concentration of serially-diluted anti-S1 antibody solution was added.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-S1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody treatments were administered intravenously (i.v.) with monoclonal antibodies (mAbs) against SARS-CoV-2 Spike, or isotype control mAb in up to 350 µl of sterile PBS at 1 hour-post inoculation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SARS-CoV-2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293 cells were transfected using FuGeneHD transfection reagent according to manufacturer’s protocol (Promega, Cat # E2311).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>HEK293</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells were plated to 96-well plates and incubated at 37° C, 5% CO2</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell based Spike binding assay Mammalian expression vectors were constructed either by cloning of the synthesized gene encoding SARS-CoV-2 G614 Spike protein (UniprotKB, SPIKE-SARS2) or, for SARS-CoV-2 D614 Spike protein, via sitedirected mutagenesis of the G614 Spike protein gene.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>UniprotKB</div> <div>suggested: (UniProtKB, RRID:SCR_004426)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A sigmoidal four-parameter logistic equation was used for fitting the MFI vs. mAb concentration data set to extract EC50 values (GraphPad Prism 8.3.0 software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GraphPad Prism</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. Author Response

      We would like to thank the three reviewers for their efforts and the constructive feedback. Below, we describe how we will address the reviewers’ comments in an updated manuscript.

      Summary:

      All of the reviewers expressed concerns about the advance that the work described in the paper represents. These issues were a focus of the consultation among the reviewers. The main concern is that the work needs to go beyond demonstrating that some ganglion cells exhibit nonlinear integration for naturalistic inputs - as that point is quite well established in the literature. The comparison between natural stimuli and gratings could help in this regard, but several issues confound that comparison (e.g. differences in dynamics of the two types of stimuli). These concerns are detailed in the individual reviews below.

      Reviewer #1:

      This paper investigates how retinal ganglion cells integrate inputs across space, with a focus on natural images. Nonlinear spatial integration is a well-studied property of ganglion cells, but it has been largely characterized using grating stimuli. A few studies have extended this to look at spatial integration in the context of natural images, but we certainly lack a comprehensive treatment of that issue. The current paper has a number of strengths - notably using a number of complementary stimuli and analysis tools to study a large population of ganglion cells and linking properties of responses to artificial stimuli with those to natural stimuli. It also has a few weaknesses (some detailed carefully in the paper) - such as the inability to identify ganglion cell types (aside from a few), and to pinpoint specific circuit mechanisms. These are limitations of the techniques used. This is not a request as much as setting the context of the contribution of the paper. Generally the paper was in good shape, and the data supported the conclusions well. I do think there are a number of issues that could be strengthened. Those are listed below in rough order of importance.

      Statistical correlations in natural scenes:

      A number of analyses in the paper rely on estimating the spatial contrast from an image and comparing the dependence of various measures of the cells' responses on spatial contrast. A danger in this analysis is that spatial contrast is likely correlated with many other statistical properties of the image, so attributing a given response property to spatial contrast has some potential confounds. This issue should be discussed as a possible caveat, unless the authors can rule it out. The paper, accurately, describes the results in terms of correlations (and not causal relationships), but some discussion of the complexity of natural image statistics would be helpful.

      Spatial contrast is defined in our work via the variance of pixel intensity inside the receptive field. Indeed, spatial contrast may reflect different aspects of visual scenes, such as object boundaries, textures, or gradients in light intensity. Differences in the effects of these image features on a ganglion cell’s response will not be captured by our analysis. However, the goal of relating spatial contrast to spike count was primarily to analyze whether the spatial structure of light intensity inside the receptive field was related to the response of a given ganglion cell (beyond the mean illumination), and the pixel intensity variance provides a simple, straightforward measure of this spatial structure. To clarify this aspect and better relate it to the complexity of natural images, we will add a corresponding paragraph in the Discussion.

      Comparison of grating and natural scene spatial scale:

      The section starting around line 233 was confusing for several reasons. First, this section starts by measuring the spatial scale associated with the grating responses, and then comparing that to LN model performance for natural inputs. It's not clear why the spatial scale is the relevant aspect of the responses to gratings. Indeed, the next paragraph provides a measure of the relative sensitivity of the nonlinear and linear response components (via a comparison of F1 and F2 responses). It would be helpful to include some initial text to motivate the different measures of the grating responses and to anticipate that you will look at both spatial scale and sensitivity.

      A related issue that bears more directly on the scientific conclusions comes up later in the blurring experiments. The issue is whether it is valid to directly compare the apparent spatial scale of nonlinear responses to images (estimated via blurring) with that of the grating responses. Natural images should have much higher power at low spatial frequencies, and this may strongly impact the spatial scale identified with the blurring experiments.

      We agree that the writing may not have been entirely clear, and we will reorganize the material to discuss the extracted spatial scale and nonlinearity index in parallel as suggested. Regarding the difference in spatial scales from reversing gratings and blurred natural images: yes, it is also our interpretation that the power at low spatial frequencies plays a key role. Our main point here was to assess whether and to what degree the typical analyses of spatial nonlinearity as measured from reversing gratings translate to natural images despite the differences in spatial and temporal structure of the two stimulus classes. In a revised manuscript, we will make sure to earlier clarify the role of low spatial frequencies.

      Clustering of orientation-selective cells:

      An interesting suggestion in the paper is that the orientation-selective cells can be divided into two groups that differ in their spatial integration properties. Do these groups represent different orientations, as suggested in the text? That seems a simple piece of information to add. Related to this, I would suggest moving Figure S4 into the main text.

      We do not have information about the absolute preferred orientations of the orientation-selective (OS) cells, as we did not keep track of retinal orientation when placing the retinas on the multielectrode array. At this point, we can therefore only rely on indirect analyses of relative preferred orientations between pairs of OS cells in the same retina. These indicate that pairs of two nonlinear OS cells tend to have aligned preferred orientation (and similarly for pairs of linear OFF OS cells), but pairs of a linear and a nonlinear OFF cell tend to have divergent preferred orientations. This is shown in Fig. S4C. For a revised manuscript, we will consider integrating Fig. S4 into the main text, as suggested.

      Presentation of checkerboard stimuli and results:

      The checkerboard analysis, particularly how it isolates properties of spatial integration, could get introduced more thoroughly for a reader unfamiliar with it. A related issue is how well the chosen isoresponse contour captures structure in the full distribution of responses. In some cases that looks pretty good, but in others it is less clear. Could you add a supplementary figure or something similar that characterizes how consistent the isoresponse contours are for different response levels?

      These are good suggestions, and we will aim at clarifying the analysis as proposed and add information about the consistency of iso-response contours for different response levels. In the present analysis, the iso-response contours are used just for illustration, whereas the quantification of rectification and integration of preferred contrast are extracted from specific points in the stimulus-response space, which we found to work robustly for a population analysis without being strongly effected by threshold or saturation effects of the cells. We will explain this more clearly in a revised manuscript.

      Drift in responses over time:

      Some of the rasters - e.g. the bottom left in Figure 1C - show considerable drift over time. It is important that this drift not be interpreted as a failure of the LN model and hence indicative of nonlinear spatial integration. Can you test for drift like this across cells, and exclude any that seem potentially problematic? More generally, some assurance that the variability in the responses for a given generator signal value is real variability across images is needed.

      The presentation of all 300 natural images over ten trials takes about 50 minutes and some drift over this period seems unavoidable. To minimize systematic effects of experimental drift on the measured average responses for different images, we applied randomization within trials, which assured that all images were presented once in random order in each trial before the next trial started. In addition, to quantify the real variability over images of the average response for a given generator signal, we applied a goodness-of-fit measure (CCnorm) that takes into account variability over trials.

      We now also tested directly for the drift mentioned by the reviewer, but observed sizeable effects in only a small subset of cells that were included in the analysis. In most cases, drift corresponded to a global scaling that approximately affected responses to all images proportionally. This is reflected in a high correlation over images between the average responses of the first five and last five trials; 94% of analyzed cells had a correlation coefficient of at least 0.7. Such global scaling of responses does not affect the analysis of differences in average responses. In a revised manuscript, we will provide analyses of drift effects and exclude cells that contain drift effects that appear to deviate from global response scaling.

      Reviewer #2:

      Summary:

      Understanding how retinal ganglion cells respond to natural stimuli is a central but daunting question, which retinal neurophysiologists have begun to tackle recently. Here Karamanlis and Gollisch perform large-scale multi-electrode recordings in the mouse retina and demonstrate that the responses of many ganglion cells cannot be predicted by standard linear-nonlinear models (L-LN). They go on to test a variety of clever artificial stimuli that emphasize and allow for the quantification of the non-linear aspects of RGCs responses and convincingly demonstrate that non-linear processing is associated with sensitivity to fine spatial contrasts (subunits) and local rectification. While these aspects of RGC receptive fields have been previously described, demonstrating their applicability to natural vision is a significant advancement.

      Major Comments:

      My first main concern is with the way the paper is written. It does not highlight the significant advancements but rather emphasizes what is already known from other studies. For example, many of the conclusions of non-linear spatial integration & signal rectification arising in bipolar cells have been well described previously. By contrast, novel aspects like the sensitivity of reversal gratings being unrelated to LN model performance for natural scenes should be explained more in detail. The authors should more clearly state the major advancements that are being made here beyond what has already been shown previously (e.g. Turner and Rieke, 2016)

      It is possible that our efforts to provide context by relating our results to established findings in retinal signal integration overshadowed the novel aspects of our work. As suggested, we will aim at pointing out these aspects more clearly. For example, compared to the work of Turner and Rieke (2016), we a) focused on a different species with more diversity in accessible RGC types, b) generalized the connection of spatial integration and natural scene encoding to a wider range of cell types (e.g. including also spatially linear and nonlinear ON-OFF cells as well as cells that are inversely sensitive to spatial contrast), and c) developed methods to assess and quantitatively characterize subunit nonlinearities with multielectrode recordings of many cells in parallel, without the need for intracellular recordings or knowledge of the receptive field location.

      Second, the authors never include non-linear subunits in their model to demonstrate improved performance. Testing models with filters that incorporate rectification and convexity as experimentally determined will enable them to show their utility more convincingly. Without this, the reader is left with the conclusion that there are RGCs that exhibit non-linear or linear spatial integration (already known) and that non-linear integrators cause LN models to perform poorly with natural images (Turner and Rieke, 2016).

      The aim of the present work was to assess how well models with linear receptive fields account for responses to natural images in various cells of the mouse retina and whether the models’ shortcomings can be related to the cells’ spatial stimulus integration characteristics. While we agree that models with nonlinear subunits could help support the conclusions, fitting such models to recorded data is – we believe – beyond the scope of the current manuscript. The many parameters of nonlinear subunit models, such as the number, shape, and layout of subunits or their nonlinearity and weight, all likely vary considerably across the diverse population of cells in our recordings. To avoid extensive parameter fitting, simplified models with ad hoc selection of subunit layouts and nonlinearities could help assess whether spatial nonlinearities are important, as in the work by Turner and Rieke (2016). Instead, as an alternative, we chose to analyze the importance of spatial nonlinearities via the effect of spatial contrast in images with similar mean intensity in the receptive field (e.g. Fig. 2). For our data, an advantage of this approach is that it is directly applicable to cell types with diverse spatial integration characteristics, such as the cells that are inversely sensitive to spatial contrast, which wouldn’t be captured by a standard subunit model with rectifying subunit nonlinearities. In future work, however, we plan to analyze subunit models that can account for the diversity of observed response patterns.

      Third, I'm not sure how 'natural' their natural images are, given static images are flashed over the cell intermittently. While such stimuli might simulate some sort of saccadic eye movements, whether this is relevant for mouse vision is not clear. Would linear models be more predictive for responses to natural movies? Some discussion on this issue would be helpful.

      Rather than aiming for fully natural movie-like stimuli, we used flashed images in our work to focus on aspects of spatial integration. This indeed entails a simplification of the temporal structure of natural stimuli, which was intended, but it preserves natural spatial structure, such as the occurrence of objects, boundaries, textures, and intensity gradients, as well as continuously decreasing power for higher spatial frequencies. Nonlinear spatial integration in the presence of this natural spatial structure will likely also shape responses under natural movies. To clarify this approach, we will re-evaluate our wording regarding the application of natural stimuli in our work and discuss the simplification compared to natural movies, as suggested.

      Reviewer #3:

      The manuscript by Karamanlis and Gollisch examines the responses of mouse retinal ganglion cells (RGCs) to natural stimuli. The primary conclusion of the manuscript is that spatial integration of stimuli within the receptive field is nonlinear. This nonlinear integration is consistent with "local signal rectification". This results in a set of RGCs that are sensitive to spatial contrast within the RF. The Authors also note the presence of cells that are suppressed by contrast and cells that prefer uniform stimulation of the RF. To reach these conclusions the authors use multi-electrode array recordings from isolated mouse retina. Spatial RFs are estimated using white noise stimuli, which are then used to generate a null-model for linear spatial summation. They compare predictions of this null-model to the responses of the same RGCs to briefly flashed natural images. The authors find some RGCs that are consistent with this null model and many that are not consistent. The authors correlate deviations from linear spatial summation to deviations revealed by contrast reversing gratings. They also used a mixed-contrast, flashed-checkerboard paradigm to map the contrast tuning and rectification of RF subunits. Finally, the authors show that some of these results track with functionally distinct RGC types such as direction-selective and "IRS" RGCs.

      The data and analyses presented in this manuscript are high quality. However, I think the study is largely consistent with many previous studies that demonstrate nonlinear spatial integration among RGCs in the mammalian (including mouse) retina. I think the Authors view the use of natural stimuli as a major departure from previous work, but I'm not convinced of this for two reasons. First, I don't see a compelling reason to think that results using contrast reversing gratings or other 'textured stimuli' (e.g. Schwartz et al Nat Neuro 2012) would fail to generalize to flashed natural scenes. Second, the implicit claim here is that a 200ms flashed natural scene interleaved with an 800ms gray screen is a natural stimulus. I think this assumes a lot about the space-time separability of the RF mechanisms, and these assumptions are not well justified.

      Major Concerns:

      1) I think the introduction of the manuscript is building a straw man argument, suggesting that many (or most) scientists think the retina is predominantly linear. A pubmed search of 'retinal ganglion cell' and 'nonlinear' produced more than 300 studies. Specifying subunit nonlinearity produces 28 studies. The discovery of subunit nonlinearities is roughly 50 years old and many manuscripts demonstrate Y-like receptive fields are more common across RGC types than X-like receptive fields.

      The goal of our work was not to show that receptive fields of mouse retinal ganglion cell are (often) spatially nonlinear, but to test whether these nonlinearities matter for natural images. It is conceivable that spatial nonlinearities as measured with typical artificial stimuli such as spatial gratings or spatiotemporal white noise are not (as) relevant for natural images because the simultaneous occurrence of strong positive and negative contrast inside a receptive field is much rarer in natural images. Indeed, in our work we find that traditional measurements of spatial nonlinearities with reversing gratings do not provide a robust quantitative prediction of whether spatial nonlinearities matter under natural images for a given ganglion cell. As laid out in the Introduction, there is surprisingly little research yet on how spatial nonlinearities affect the encoding of natural images, and in a revised version of the manuscript, we will aim at clarifying that this is the focus of our work here.

      2) The authors seem to be arguing that the spatial nonlinearities engaged by the contrast reversing gratings are not the same as those engaged by their natural scenes (Figure 3). However, I think the authors are assuming too much that the spatial and temporal components of the RFs are separable. The flashed natural scenes are interleaved with relatively long gray screens. The contrast reverse granting are reversed in a square-wave fashion with no interleaved gray screen. These distinct spatiotemporal dynamics in the stimuli seem likely to explain the difference. This would also seem likely to explain why the flashed checkerboards in Figure 4 produced results more correlated to flashed scenes in Figure 1. In summary, I don't see a strong reason to think the authors are observing anything other than subunit rectification of the sort described by Hochstein and Shapley in the 1970s and followed up in many subsequent studies.

      We do not think that spatial nonlinearities as observed with reversing gratings or with natural stimuli are related to different mechanisms. The point of our analysis was rather to assess whether typical assessments of spatial nonlinearities with reversing gratings allow quantitative predictions about the relevance of spatial nonlinearities under flashed natural images, and we find that this is often not the case. We believe that this is largely due to the differences in spatial structure, in particular, the prevalence of high-contrast edges in the gratings. Yet, indeed, differences in temporal stimulus structure might also contribute. We actually tested flash-like presentations of gratings in some of our recordings, and results were quite similar to those obtained with contrast-reversing gratings and led to the same conclusions. We will describe this in the revised manuscript for clarification.

      3) It is not clear to this reviewer that flashed natural images interleaved by a gray screen is qualitative more natural than white noise, sinusoidal gratings, or square-wave gratings.

      The spatial structure of natural images is the focus of the present work. It is in this aspect that flashed photographs are more natural than typical artificial stimuli like spatiotemporal white noise or gratings. In particular, natural images contain a broad spectrum of spatial frequencies with relatively more power at smaller frequencies, and they combine occasional edges with intensity gradients and textures. Gratings, for example, are characterized by high power at large spatial frequencies, that is, high spatial contrast, which is well suited for triggering effects of spatial nonlinearities but occurs much more rarely in natural images. Thus, understanding whether spatial nonlinearities are important in a natural setting requires considering stimuli that match the natural spatial structure. It seems likely that nonlinear spatial integration observed under flashed presentation of natural images remains relevant when stimuli are supplemented with natural temporal structure, even though the latter may likely trigger additional effects that shape the responses (e.g. adaptation or nonlinear temporal integration).

      4) The null-model constructed by the authors in Figure 1 assumes the RF follows a specific functional form (e.g. Gaussian). However, many studies show that individual RFs frequently exhibit strong deviations from a Gaussian RF. To what extent are the deviations from the null model produced by deviations from linear summation or just linear mechanisms that deviate from the specific parametric form imposed by the model?

      Measuring the detailed structure of receptive fields (RFs) with high precision from time-limited experiments is a challenge, and using a fitted (elliptical) Gaussian profile is a standard procedure for limiting the effect of noise in the RF structure. We also tried using the pixel-wise spatial profile obtained from the reverse-correlation analysis as a spatial filter, but results were similar, yet often more noisy. We therefore settled on the standard procedure of using a Gaussian fit to the RF. Deviations from the Gaussian profile can indeed contribute to deviations of the model. Yet, for natural images, which have most of their power in low spatial frequencies, these deviations are likely to be small. Furthermore, our subsequent analyses show that the Gaussian RF model provides a useful baseline because it allows us to extract the relation between model deviations and image structure. In addition, the results from the model analysis were supported by the findings under presentation of blurred natural images, which did not require any assumptions about the underlying RF model. In a revised manuscript, we will point out that relying on Gaussian RFs is a choice that we make and that deviations of the receptive field structure may contribute to decreased model performance, but that the subsequent analyses support the usefulness of the applied Gaussian RF model.

      5) It was unclear how the authors rule out the contribution of differences in (nonlinear) temporal integration to the effects in this study. In general, RGC RFs are not space-time separable, and it seems that the analyses in the manuscript assume they are.

      Our choice of using flashed images as stimuli with no temporal structure beyond onset and offset and assessing responses via elicited spike counts was motivated by focusing on spatial stimulus integration and minimizing effects of temporal processing. Nonetheless, our extraction of receptive fields from measurements under spatiotemporal white-noise stimulation uses a space-time separation of the spike-triggered average. Thus, the lack of space-time separability of ganglion cell receptive fields can contribute to the putative underestimation of surround components, which we have discussed in the manuscript. In a revised manuscript, we will add an explicit reference to the issue of space-time separability.

      6) This study overlaps significantly with Cao, Merwine and Grzywacs (2011), 'Dependence of retinal Ganglion cell's responses on local textures of natural scenes', Journal of Vision. This article is not cited here, but in my view, the major conclusions are similar.

      Thank you for pointing us to this paper, which is indeed relevant for our work. Both the Cao et al. paper and our manuscript evaluate the effect of spatial contrast in natural images by relating spatial contrast to response deviations from a linear-RF model, albeit with different methods. An important difference, apart from the different species, is that our work then focuses on relating the identified effects of spatial contrast to functional characterizations of the specific nonlinear operations inside the receptive field (e.g. rectification). Furthermore, we also focus on the diversity of spatial-integration properties between cells and cell types, including the description of spatially linear cells and cells that are inversely sensitive to spatial contrast. In a revised manuscript, we will add a comparison to the methods and results from Cao et al.

      7) In my experience, the strength of subunit rectification can be labile during ex vivo experiments. What controls have the author's performed to ensure the effect they are studying remain stable over the duration of their recordings?

      Experimental rundown could, of course, affect subunit rectification as well as other response aspects, such as overall sensitivity. However, we observed that responses for different repeats of the same natural images were typically quite stable over the course of the hour-long stimulus. As also discussed in the response to Reviewer 1, we now analyzed how responses to late trials deviated from responses to early trials and found that only a small subset of cells displayed sizeable drift. Furthermore, those cases were mostly affected by a global drift in response size, keeping the relative responses for different images approximately constant. (For 94% of cells, the correlation of images was larger than 0.7 between average responses for the first five and for the last five trials; approximately on the level of estimated random trial-by-trial variability.) This indicates that the features of stimulus integration did not change substantially over the course of the experiment. In addition, nonlinearities as assessed with our flashed checkerboards were strongly correlated to nonlinearities under natural images, despite the fact that these stimuli were applied 1-2 hours apart. Thus, the strength of subunit rectification appears to be sufficiently stable to allow comparison over different stimuli.

    1. exposure limits are determined by the following equations (NIOSH, 2016):(4)ÂRAL[°C-WBGT]=59.9-14.1log10M<math><mrow is="true"><mi mathvariant="normal" is="true">R</mi><mi mathvariant="normal" is="true">A</mi><mi mathvariant="normal" is="true">L</mi><mo stretchy="false" is="true">[</mo><mi is="true">Â</mi><mi is="true">°</mi><mi mathvariant="normal" is="true">C</mi><mo is="true">-</mo><mi mathvariant="normal" is="true">W</mi><mi mathvariant="normal" is="true">B</mi><mi mathvariant="normal" is="true">G</mi><mi mathvariant="normal" is="true">T</mi><mo stretchy="false" is="true">]</mo><mo is="true">=</mo><mn is="true">59.9</mn><mo is="true">-</mo><mn is="true">14.1</mn><mi mathvariant="normal" is="true">l</mi><mi mathvariant="normal" is="true">o</mi><mi mathvariant="normal" is="true">g</mi><mn is="true">10</mn><mi mathvariant="normal" is="true">M</mi></mrow></math>(5)Â

      regressional analysis of exposure limits

    1. Reviewer #2:

      This article reports the radial alignment of rat embryonic fibroblasts at the periphery of circular confinement patterns. The authors experimentally isolate that contractility, adhesion and stiffness gradient are necessary to obtain this alignment. They further devise continuum and discrete models, with only two free parameters, to describe the mechanical origin of such cellular arrangements.

      The article is an interesting contribution to the field, with the discussion and conclusion well supported by the experimental data. It is further well written, with a good logic.

      1) The authors should explain (e.g., in an appendix) how they solve Eqs.(7-9) and how they run their Voronoi simulations (or indicate which solver/package they use if those already exist).

      2) A movie showing the formation of the radially aligned cell pattern would be a good addition, even if the dynamics are not discussed in the article. The x,y,t axes should be labelled (with units) in Fig.1-Supp.1.

      3) p.17 l.3, "stiffnesses" instead of "substrates"?

      4) p.20 l.7, the authors should better explain how Fig.1-Supp.4 supports a homogeneous isotropic contractility.

      5) The authors should show some of the images used to extract actin fibers structure (or are these shown in Fig.3?). Is Fig.4-Supp.1 obtained for REF 2c?

      6) p.24 l3, the authors may comment on how stiffness anisotropy could be incorporated in their model to explain inner cells' circumferential alignment. The author should plot the structure parameter (k_h) vs radial distance instead of giving a table (Fig.4-Supp.1 and Fig.6-Supp.1); they should use the same origin (the center of the circle) for the radial distance in the ring experiments (x-axis in Fig.6B and Fig.6-Supp.1A vs x-axis in Fig.7 and Fig.7-Supp.1) to facilitate comparisons.

      7) The authors should clarify what they mean by "clear boundary junctions" (p.18 l.9) when describing Fig.2D, which is challenging to discern.

      8) In Fig.4, are the authors showing the strain or the stretch ratio? It would help to start the y-axis at 0 in Figs.4A-B. At which distance are the radial strain and stress evaluated in Figs.4C-D? Are the pre-stretch ratio and stiffness gradient challenging to evaluate from the experiments (p.20 l.4)? Can the authors comment on the values needed for these model parameters to see radial alignment in the simulations? Are they realistic when compared to the experimental data?

    1. SciScore for 10.1101/2020.09.24.311977: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">These experiments were approved by the Anses/ENVA/UPEC ethic committee and the French Ministry of Research (Apafis n°24818-2020032710416319).</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">(Mustela putorius furo, ten neutered males and five females Euroferrets, Denmark) and twenty-one 8-week old female hamsters (Mesocricetus auratus, strain RjHan:AURA - Janvier Labs, France) were used.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Specific antibody binding was detected by peroxydase-labelled Goat anti-Hamster IgG (H+L) (Invitrogen) and peroxydase-labelled Goat anti-Ferret IgG (H+L) (KPL), diluted 1:5000 and 1:100 respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-Hamster IgG</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-Ferret IgG</div> <div>suggested: (Rockland Cat# 618-100-012, RRID:AB_218731)</div> </div> <div style="margin-bottom:8px"> <div>KPL</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero CCL-81 cells (passage 32, from ATCC, USA), grown at 80% confluence level were inoculated with 200µl micro-filtered elution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CCL-81</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell supernatants (12 ml) were harvested at day 3 after inoculation and immediately used for passage 1 (P1) produced in T75 culture flasks containing Vero cells as previously described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero</div> <div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Non-infected Vero E6 lysate was also coated to provide sample background OD values.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: RRID:CVCL_XD71)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The efficiency, slope and correlation coefficient (R2) were determined with the Rotor Gene software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Rotor Gene</div> <div>suggested: None</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. Reviewer #2:

      The study by Bola and colleagues tested the specific hypothesis that visual shape representations can be reliably activated through different sensory modalities only when they systematically map onto action system computations. To this aim, the authors scanned a group of congenitally blind individuals and a group of sighted controls while subjects listened to multiple sound categories.

      While I find the study of general interest, I think that there are main methodological limitations, which do not allow to support the general claim.

      Main concerns

      1) Auditory stimuli have been equalized to have the same RMS (-20 dB). In my opinion, this is not a sufficient control. As shown in Figure 3 - figure supplement 1, the different sound categories elicited extremely different patterns of response in A1. This is clearly linked to intrinsic sound properties. In my opinion without a precise characterization of sound properties across categories, it is not possible to conclude that the observed effects in face responsive regions (incidentally, as assessed using an atlas and not a localizer) are explained by the different category types. On the stimulus side, authors should at least provide (a) spectrograms and (b) envelope dynamics; in case sound properties would differ across categories all results might have a confound associated to stimuli selection.

      2) More on the same point: the authors use the activation of A1 as a further validation of the results in face selective areas. Page 16 line 304 "We observed activation pattern that was the same for the blind and the sighted subjects, and markedly different from the pattern that was observed in the fusiform gyrus in the blind group (see Fig. 1D). This suggests that the effects detected in this region in the blind subjects were not driven by the differences in acoustic characteristics of sounds, as such characteristics are likely to be captured by activation patterns of the primary auditory cortex." It is the opinion of this reader that this control, despite being important, does not support the claim. A1 is certainly a good region to show how basic sound properties are mapped. However, the same type of analysis should be performed in higher auditory areas, as STS. If result patterns would be similar to the FFA region, I guess that the current interpretation of results would not hold.

      3) Linked to the previous point. Given that the authors implemented a MPVA pipeline at the ROI level, it is important to perform the same analysis in both groups, but especially in the blind, in areas such as STS as well as in a control region, engaged by the task (with signal) to check the specificity of the FFA activation.

      4) I find the manuscript rather biased with regard to the literature. This is a topic which has been extensively investigated in the past. For instance, the manuscript does not include relevant references for the present context, such as:

      Plaza, P., Renier, L., De Volder, A., & Rauschecker, J. (2015). Seeing faces with your ears activates the left fusiform face area, especially when you're blind. Journal of vision, 15(12), 197-197.

      Kitada, R., Okamoto, Y., Sasaki, A. T., Kochiyama, T., Miyahara, M., Lederman, S. J., & Sadato, N. (2013). Early visual experience and the recognition of basic facial expressions: involvement of the middle temporal and inferior frontal gyri during haptic identification by the early blind. Frontiers in human neuroscience, 7, 7.

      Pietrini, P., Furey, M. L., Ricciardi, E., Gobbini, M. I., Wu, W. H. C., Cohen, L., ... & Haxby, J. V. (2004). Beyond sensory images: Object-based representation in the human ventral pathway. Proceedings of the National Academy of Sciences, 101(15), 5658-5663.

    1. About 153,000,000 results (0.70 seconds) .g-blk{position:relative}.kp-blk a{text-decoration:none}.kp-blk .mod:first-child{padding-top:16px;border-radius:8px}.kp-blk .match-mod-horizontal-padding,.kp-blk .mod:not(.NFQFxe){padding-left:16px;padding-right:16px;}.kp-blk{box-shadow:none;border:1px solid #dfe1e5;border-radius:8px;}#center_col .kp-blk{position:relative;width:652px}.kp-blk .g:not(.g-blk){margin:0}.kp-blk>.vk_arc,.kp-blk>div>.vk_arc{margin:0}.kp-blk .g{margin-bottom:0}.knowledge-panel.kp-blk .mod,.c14z5c .mod{line-height:1.58}.c2xzTb .g,.c2xzTb .rc,.ruTcId .rc{clear:both;padding-bottom:0}.c2xzTb .mod,.ruTcId .mod{clear:none}.c2xzTb .g,.ruTcId .g,.fm06If .g,.cUnQKe .g,.HanQmf .g{padding-left:16px;padding-right:16px}.c2xzTb .g:last-child,.fm06If .g:last-child,.cUnQKe .g:last-child{padding-bottom:16px}.mod{clear:both}html .kp-blk .xpdclose .LKPcQc,html .kp-blk .xpdopen .viOShc{padding-top:0}.xpdclose .a84NUc:not(:empty),.xpdopen .CQKTwc:not(:empty){border-top:solid 1px #ebebeb;border-radius:0}.xpdclose .TOfaBb.SHa8ve,.xpdopen .LL5J7d.SHa8ve{display:block}.xpdclose .oHglmf,.xpdopen .xzPb7d{padding-bottom:16px}.xpdclose .kp-header .oHglmf,.xpdopen .kp-header .xzPb7d{padding-bottom:0}.Wnoohf .xpdopen .yp1CPe,.OJXvsb .xpdclose .siXlze{padding-bottom:16px}.Wnoohf .xpdclose .mod.xsZWvb,.Wnoohf .xpdopen .mod.EfDVh{padding-bottom:0}#rhs .kp-blk .xpdclose .LKPcQc,#rhs .kp-blk .xpdopen .viOShc{padding-top:0}#rhs .Wnoohf .xpdopen .yp1CPe,#rhs .OJXvsb .xpdclose .siXlze{padding-bottom:15px}#rhs .Wnoohf .xpdclose .mod.xsZWvb,#rhs .Wnoohf .xpdopen .mod.EfDVh{padding-bottom:0}#rhs .Wnoohf .xpdclose .mod.xsZWvb.ecRggb,#rhs .Wnoohf .xpdopen .mod.EfDVh.ecRggb,#rhs .kp-blk .ecRggb{padding-bottom:15px}.AaS7G{-webkit-tap-highlight-color:rgba(0,0,0,0)}.OiT5Ue{-webkit-user-select:none;user-select:none}.abhAW{border-bottom:1px solid #ddd}.x4NjEf .mnr-c{margin-bottom:1px !important;box-shadow:0 1px 1px rgba(0,0,0,.2) !important}.imso-regular-font{font-family:Roboto,arial,sans-serif;font-weight:normal}.imso-medium-font{font-family:arial,sans-serif-medium,sans-serif;font-weight:normal}.imso-hide-overflow{max-width:100%;white-space:nowrap;overflow:hidden;text-overflow:ellipsis}.ellipsisize{white-space:nowrap;overflow:hidden;text-overflow:ellipsis}.imso-loa{cursor:pointer}.imso-hov:hover,.imso-hov:focus{background-color:#fafafa}.QMSMXe{color:#fff;margin:0 10px}.Wrsj9b{border-top-left-radius:8px;border-top-right-radius:8px}.SwsxUd{padding:16px 16px;}.QMSMXe{margin:0 0}.LOaav{vertical-align:top;float:none;display:block;}.t7NTy{margin-right:16px;float:left}.GLbw8e{font-size:20px;line-height:1.3}g-img{display:block}.rISBZc{display:block;border:0}.M4dUYb{position:relative}.CnPMPd{height:inherit;position:relative;overflow:hidden}.N0LMJe{overflow:hidden;text-overflow:ellipsis;white-space:nowrap;float:none;height:auto}.S9Uogc{position:absolute;top:0;right:0;width:200%;height:200px}.YwLJKc{width:50%;height:50%;float:left}.ofy7ae{float:left;min-width:50%}.AAhKnb.tb_h{color:#fff}.AAhKnb .tb_l{opacity:0.8}.AAhKnb .tb_st{opacity:1;border-bottom-width:2px;border-bottom-style:solid}.AAhKnb .tb_l:hover{background-color:rgba(0,0,0,.1)}.AAhKnb .tb_l:focus,.AAhKnb .tb_l:active{background-color:rgba(0,0,0,.1)}.GSkImd{outline:none;display:table-cell;font-size:12px;line-height:16px;text-align:center;vertical-align:top;cursor:pointer;padding:16px 0px 14px}.PPjCfd{white-space:nowrap;display:table;width:100%;table-layout:fixed}.ie7Asb{}.B27Eaf{margin-bottom:4px}.YPgUJe{box-shadow:0px 3px 2px #ddd}.imso_mh__mh-bd{color:#757575}.imso_mh__mh-ed .imso_mh__tm-scr{padding-top:24px}.imso_mh__mh-wb .imso_mh__tm-scr,.imso_mh__mh-ws .imso_mh__tm-scr,.imso_mh__mh-sp .imso_mh__tm-scr{margin:16px}.imso_mh__mh-ed .imso_mh__nma{padding-bottom:4px}.imso_mh__mh-ed .imso_mh__stts-l{margin:0 26px}.imso_mh__stts-l{min-height:16px}.imso_mh__tas{clear:both;overflow:hidden;text-align:center}@media screen and (min-width:380px) and (max-width:599px){.imso_mh__mh-ed .imso_mh__tas{padding:16px 48px 0 48px}}@media screen and (max-width:379px){.imso_mh__mh-ed .imso_mh__tas{padding:16px 28px 0 28px}}@media screen and (min-width:380px) and (max-width:599px){.imso_mh__mh-ed .imso_mh__tas.imso_mh__wl{padding:16px 40px 0 40px}}@media screen and (max-width:379px){.imso_mh__mh-ed .imso_mh__tas.imso_mh__wl{padding:16px 20px 0 20px}}.imso_mh__mh-ed .imso_mh__tas.imso_mh__xwl{padding:16px 16px 0 16px}@media screen and (min-width:600px){.imso_mh__mh-ed .imso_mh__tas,.imso_mh__mh-ed .imso_mh__tas.imso_mh__wl,.imso_mh__mh-ed .imso_mh__tas.imso_mh__xwl{padding:16px 80px 0 80px}}.imso_mh__score-txt{font-size:14px;color:#212121;line-height:1.58}.imso_mh__ls-txt{font-size:14px;line-height:1.58}.imso_mh__mh-ed .imso_mh__score-sum{padding-bottom:4px;padding:0 26px 4px 26px}.imso_mh__mh-ee .imso_mh__tm-a-sts,.imso_mh__mh-ee .imso_mh__score-sum{margin:12px 0}.imso_mh__mh-ed .imso_mh__tm-a-sts{padding-bottom:12px}.imso_mh__s-t-c{margin-top:8px}.imso_mh__stts-l-cont{font-size:14px}.imso_mh__pre-m-stts{text-align:left}.imso_mh__lr-dt-ds{display:inline-block}.imso_mh__lr-dt-ds::first-letter{text-transform:uppercase}.imso-loa.imso-ln:hover,.imso-loa.imso-ln:focus{text-decoration:underline;outline:none}.imso_mh__first-tn-ed,.imso_mh__second-tn-ed{width:64px}.imso_mh__first-tn-ed{float:left;text-align:left}.imso_mh__second-tn-ed{float:right;text-align:right}.imso_mh__tnal-cont{display:inline-block}.imso_mh__tnal-cont:hover,.imso_mh__tnal-cont:focus{text-decoration:underline;outline:none}.imso_mh__mh-ed .imso_mh__tnal-cont{text-align:center}.imso_mh__mh-ed .imso_mh__t-l-cont{margin-left:auto;margin-right:auto}.imso_mh__tm-nm{margin-top:4px;font-size:14px;line-height:20px;color:#212121}.imso_mh__first-tn-ee .imso_mh__tm-nm,.imso_mh__first-tn-ee .imso_mh__tm-wlr{float:left;padding-left:4px}.imso_mh__second-tn-ee .imso_mh__tm-nm,.imso_mh__second-tn-ee .imso_mh__tm-wlr{float:right;padding-right:4px}.imso_mh__tm-nm-ew{transform:translate(-50%,0);-ms-transform:translate(-50%,0);-webkit-transform:translate(-50%,0)}@media screen and (min-width:600px){.imso_mh__mh-ed .imso_mh__tm-wlr{display:inline-block}}@media screen and (min-width:360px){.imso_mh__tm-nm,.imso_mh__tm-wlr{width:112px}.imso_mh__mh-ed .imso_mh__tm-nm,.imso_mh__mh-ed .imso_mh__tm-wlr{position:relative;left:-24px}.imso_mh__mh-ed .imso_mh__tas.imso_mh__wl .imso_mh__tm-nm,.imso_mh__mh-ed .imso_mh__tas.imso_mh__wl .imso_mh__tm-wlr{width:96px;left:-16px}}@media screen and (max-width:359px){.imso_mh__tm-nm,.imso_mh__tm-wlr{width:72px}.imso_mh__mh-ed .imso_mh__tm-nm,.imso_mh__mh-ed .imso_mh__tm-wlr{position:relative;left:-4px}.imso_mh__mh-ed .imso_mh__tas.imso_mh__wl .imso_mh__tm-nm,.imso_mh__mh-ed .imso_mh__tas.imso_mh__wl .imso_mh__tm-wlr{width:56px;left:4px}}.liveresults-sports-immersive__team-name-width{width:200%}.imso_mh__scr-sep{text-align:center;display:inline-block}@media screen and (min-width:600px){.imso_mh__mh-ed .imso_mh__scr-sep{width:55%;margin:auto}}.imso_mh__vs-at-sep{position:relative;font-size:14px;color:#757575;text-transform:lowercase}.imspo_mh_cricket__summary-sentence{text-align:center}.imso_mh__lg-st-srs{text-align:center}.imso_mh__lg-st-srs{text-align:center;font-size:12px}.liveresults-sports-immersive__match-grid{width:100%;border-collapse:collapse}.liveresults-sports-immersive__match-grid-right-border{border-right:solid 1px #e0e0e0}.liveresults-sports-immersive__match-grid-bottom-border{border-bottom:solid 1px #e0e0e0}.liveresults-sports-immersive__match-tile,.liveresults-sports-immersive__empty-tile{width:50%}.imspo_mt__mit{width:100%;table-layout:fixed;border-spacing:0}.imspo_mt__mtc-no .imspo_mt__mit{min-height:108px}.imspo_mt__mtc-wb .imspo_mt__mit,.imspo_mt__mtc-ws .imspo_mt__mit{min-height:112px}.imspo_mt__mtc-wb .imspo_mt__tr-s,.imspo_mt__mtc-ws .imspo_mt__tr-s{height:12px}.imspo_mt__mtc-no .imspo_mt__tr-s{height:16px}.imspo_mt__tr{height:32px}.imspo_mt__br-sc{height:12px}.imspo_mt__sc-sp{width:1px;padding:0}.imspo_mt__sc{width:104px}.imspo_mt__rpo-c{padding:0}.imspo_mt__rg{width:6px}.imspo_mt__lg-st-c-np{height:6px;padding-left:14px;color:#757575}.imspo_mt__lg-st-co{font-size:14px;padding-bottom:6px}.imspo_mt__lg-sdd{color:#757575;text-align:right;padding-right:14px;padding-bottom:6px}.imspo_mt__ms-w{line-height:1.4}.imspo_mt__cmd{font-size:12px;color:#757575;vertical-align:middle}.imspo_mt__pm-inf{font-size:14px}.imspo_mt__pm-infc{color:#212121}.imspo_mt__date{text-transform:capitalize}.imspo_mt__dt-t{color:#212121}.imspo_mt__lt-t{color:#757575}.imspo_mt__tt-w{font-size:14px;line-height:20px}.imspo_mt__t-sc{padding-left:8px;text-align:right;float:right}.lc-np{width:52px;padding:0 14px;box-sizing:border-box}.imspo_mt__rg{padding-left:6px;width:6px}.imspo_mt__mtc-wb .imspo_mt__rg,.imspo_mt__mtc-ws .imspo_mt__rg{padding-left:10px}.imspo_mt__lc-sbt{vertical-align:top}.imspo_mt__tns-c{padding-top:2px;line-height:20px;vertical-align:top;position:relative}.imspo_mt__ta-c{position:absolute;vertical-align:top;min-width:30px;left:0}.imspo_mt__ws-c{position:absolute;vertical-align:top;width:100%;right:14px}.imspo_mt__status-cell{vertical-align:top}.imspo_mt__game-status{padding-right:8px;font-size:14px;line-height:16px;color:#212121}.imspo_mt__stc-no .imspo_mt__status-padding-narrow{padding-left:14px}.imspo_mt__stc-wb .imspo_mt__status-padding-narrow,.imspo_mt__stc-ws .imspo_mt__status-padding-narrow{padding-left:14px}.SXBRcc{color:rgba(0,0,0,.54);font-size:12px;padding-top:8px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis}.sBROid{border-top:1px solid #ebebeb}.KkDGlc{line-height:32px;vertical-align:middle;white-space:nowrap;padding:0 26px}.vSMltHC1KtC__link{color:#757575;font-size:12px;padding:8px 0;float:right}.YENodc{border-top:1px solid rgba(0,0,0,.12)}.D2jfwd{margin-top:36px}.U0faLd:focus{outline:none}.YIikAd{color:rgba(0,0,0,.87);font-size:14px;line-height:14px;text-align:center}.jTw2d{background-color:#f5f5f5;border-bottom-left-radius:8px;border-bottom-right-radius:8px;-webkit-user-select:none;display:block;position:relative;padding:24px 8px 8px}.jTw2d .U0faLd{cursor:pointer;left:-20px;margin-left:50%;position:absolute;top:-20px;z-index:3}.CNf3nf{border-radius:50%;cursor:pointer;display:block;position:relative;border:1px solid #dfe1e5;z-index:0}.CNf3nf:focus{outline:none}.CNf3nf .PUDfGe{position:absolute;left:0;right:0;top:0;bottom:0;margin:auto;width:24px;height:24px}.LhCR5d{width:40px;height:40px}@keyframes qli-container-rotate {from{transform:rotate(0)}to{transform:rotate(360deg)}}@keyframes qli-fill-unfill-rotate {0%{transform:rotate(0)}12.5%{transform:rotate(135deg)}25%{transform:rotate(270deg)}37.5%{transform:rotate(405deg)}50%{transform:rotate(540deg)}62.5%{transform:rotate(675deg)}75%{transform:rotate(810deg)}87.5%{transform:rotate(945deg)}100%{transform:rotate(1080deg)}}@keyframes qli-blue-fade-in-out {0%{opacity:0.99}25%{opacity:0.99}26%{opacity:0}89%{opacity:0}90%{opacity:0.99}100%{opacity:0.99}}@keyframes qli-red-fade-in-out {0%{opacity:0}15%{opacity:0}25%{opacity:0.99}50%{opacity:0.99}51%{opacity:0}}@keyframes qli-yellow-fade-in-out {0%{opacity:0}40%{opacity:0}50%{opacity:0.99}75%{opacity:0.99}76%{opacity:0}}@keyframes qli-green-fade-in-out {0%{opacity:0}65%{opacity:0}75%{opacity:0.99}90%{opacity:0.99}100%{opacity:0}}@keyframes qli-left-spin {0%{transform:rotate(130deg)}50%{transform:rotate(-5deg)}100%{transform:rotate(130deg)}}@keyframes qli-right-spin {0%{transform:rotate(-130deg)}50%{transform:rotate(5deg)}100%{transform:rotate(-130deg)}}.We6bVe .tb_l:hover,.We6bVe .tb_l:focus{background-color:rgba(0,0,0,.1)}@-webkit-keyframes slide {0%{}}@keyframes fade-out {100%{opacity:0}}@keyframes fade-in {100%{opacity:1}}g-section-with-header{display:block;margin:0 0 40px 0}.e2BEnf{font-size:20px;line-height:1.3;}.U7izfe{padding:0 0px 12px}.iJ1Kvb{display:inline-block;line-height:24px}.GmE3X{display:inline-block;margin-right:12px;position:relative;top:-3px}.iv236{color:#5f6368;display:inline-block;margin-right:12px}.F8yfEe{margin:-4px;width:auto}g-scrolling-carousel{display:block;position:relative;}.mR2gOd{display:block;overflow-x:auto;overflow-y:hidden;position:relative;white-space:nowrap;transform:translate3d(0,0,0);transform:translate3d(0,0,0);}.mR2gOd::-webkit-scrollbar{display:none}.DAVP1{display:inline-block}.fhQnRd{display:flex;}.JJZKK{width:212px;padding:4px}g-inner-card{background-color:#fff;border-radius:2px;display:block;overflow:hidden}.cv2VAd{border:1px solid #dfe1e5;border-radius:8px;box-shadow:none}.xCURGd{height:281px;position:relative}.g5wfEd{padding:16px 16px 0}.YEMaTe{overflow:hidden;position:relative}.CEMjEf{color:#70757a;font-family:arial,sans-serif;font-size:12px;line-height:1.3333333333333333em;margin-bottom:8px;overflow:hidden;text-align:left;text-overflow:ellipsis;white-space:nowrap}.RdhoHd{display:inline-block;vertical-align:top}.lO8SBd{border:0;clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px}.mCBkyc{font-size:16px;line-height:1.25em;}.nDgy9d{display:-webkit-box;overflow:hidden;-webkit-box-orient:vertical;white-space:normal}.ZE0LJd{bottom:16px;left:0;position:absolute;width:100%}.S1FAPd{color:#70757a;font-size:12px;line-height:1.6666666666666667em;margin-bottom:0;margin-top:0;overflow-x:hidden;text-overflow:ellipsis}.S1FAPd{font-size:12px;line-height:1.3333333333333333em;padding:0 16px}.QyR1Ze{display:inline-block;vertical-align:top;}.BA0A6c{overflow:hidden}.Lu0opc{cursor:pointer;height:72px;position:absolute;display:block;visibility:inherit;width:36px;bottom:0;margin-bottom:auto;margin-top:auto;outline:none;opacity:0.8;top:0;z-index:101}.Lu0opc.tHT0l{-webkit-transition:opacity 0.5s,visibility 0.5s;transition:opacity 0.5s,visibility 0.5s}.Lu0opc:hover{opacity:0.9}.Lu0opc:focus{outline:none}.Lu0opc.pQXcHc,.Lu0opc.pQXcHc:hover{cursor:default;opacity:0;visibility:hidden}.Lu0opc.eSq3C{height:36px;width:36px;opacity:0.9}.Lu0opc.eSq3C:hover{opacity:1.0}.Lu0opc.eSq3C.pQXcHc,.Lu0opc.eSq3C.pQXcHc:hover{opacity:0}.Lu0opc.eSq3C:hover g-fab{color:#222 !important}.BlOseb.eSq3C g-fab,.k2Oeod.eSq3C g-fab{box-shadow:0 0 0 1px rgba(0,0,0,0.04),0 4px 8px 0 rgba(0,0,0,0.20);cursor:pointer;height:36px;width:36px}.BlOseb.eSq3C{left:-18px}.k2Oeod.eSq3C{right:-18px}.YdZJve{padding-top:8px}.mIKy0c{cursor:pointer;display:block;font-weight:400;line-height:18px;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.mIKy0c.dGWpb{overflow:visible}.EZRelc{color:rgba(0,0,0,.54);float:left;margin:-2px 24px -2px 0}.wUrVib{color:rgba(0,0,0,.87);overflow:hidden;text-overflow:ellipsis;white-space:nowrap;width:auto}.mIKy0c{font-size:16px;line-height:1.43}.EZRelc{color:#1a0dab;flex:none;margin-right:8px}.wUrVib{color:#1a0dab;white-space:initial}g-more-link a.Q2MMlc{align-items:center;display:flex}g-more-link.dGWpb{cursor:initial;text-align:center}g-more-link.dGWpb a.Q2MMlc{display:inline-block}.MXl0lf{background:#fff;border:1px solid #dadce0;box-sizing:border-box;cursor:pointer;display:inline-block;font-size:14px;height:36px;line-height:20px;padding:7px 11px;position:relative;width:300px;text-align:center;border-radius:18px}.MXl0lf:hover{background:#fafafa}.pb5vrc{background-color:#dadce0;border:0;height:1px;left:0;margin-top:18px;position:absolute;width:100%}.MXl0lf .EZRelc{left:12px;margin-top:0;position:absolute;height:20px;width:20px}.MXl0lf .wUrVib{display:inline-block;max-width:220px;white-space:nowrap}a:hover h3.LC20lb{text-decoration:underline}.LC20lb{display:inline-block;line-height:1.3;margin-bottom:3px;}.DKV0Md{padding-top:4px;}.TbwUpd{padding-bottom:1px;padding-top:1px;-webkit-text-size-adjust:none}.NJjxre{position:absolute;left:0;top:0}.eipWBe{color:#5f6368}.VjDLd .TieM1d .tjvcx,.rhs-osrp .tjvcx,.kno-kp .tjvcx,.VjDLd .kp-wholepage-osrp .tjvcx,#rhs .ss6qqb .tjvcx{display:inline-block;height:19px;overflow-y:hidden}.B6fmyf{position:absolute;top:0;height:0;visibility:hidden;white-space:nowrap}.eFM0qc{display:inline-block;padding-bottom:1px;padding-top:1px;padding-left:2px;visibility:visible}.jYOxx{margin-top:0px}.St3GK{color:#70757a}Search ResultsSports ResultsIPLIndian Premier LeagueMATCHESNEWSSTANDINGSSTATSPLAYERSIPL · today, 7:00 AMCSKVSDCT20 7 of 56No in-person attendanceT20 4 of 56Tue, 9/22RR216/7 (20)CSK200/6 (20)RR won by 16 runsT20 5 of 56Wed, 9/23MI195/5 (20)KKR146/9 (20)MI won by 49 runsT20 6 of 56YesterdayKXIP206/3 (20)RCB109 (17)KXIP won by 97 runsT20 8 of 56TomorrowKKRSRHStarts at 7:00 AMFeedbackAll times are in Pacific TimeSee more Indian Premier LeagueFollow IPLGet match reminders, live score notifications, and updates in Discover for your favorite teamsSomething went wrong.Check your connection and try againSports data is temporarily unavailable.Try reloading this page or check back later.DONEIPLIndian Premier LeagueMATCHESNEWSSTANDINGSSTATSPLAYERSSomething went wrong.Check your connection and try againSports data is temporarily unavailable.Try reloading this page or check back later.IPLIndian Premier LeagueMATCHESNEWSSTANDINGSPLAYERSSomething went wrong.Check your connection and try againSports data is temporarily unavailable.Try reloading this page or check back later.Royals vs Super KingsSomething went wrong.Check your connection and try againSports data is temporarily unavailable.Try reloading this page or check back later.Top stories.Chennai Super Kings vs Delhi Capitals, IPL 2020, Fantasy Pick, team predictions | ESPN.com.3 mins ago.IPL 2020: Anushka Sharma Slams Sunil Gavaskar Who Allegedly Made Sexist Remarks On Virat Kohli And Her,.22 mins agoSportsPro Media.At Large | Quibi, the IPL, and the future of sports storytelling.2 hours ago.'What on earth': Fans turn on Virat Kohli over 'embarrassing' act.9 hours agoBig News Network.IPL 13: Rohit Sharma impressed with KL Rahul's 'classy hundred'.12 hours ago.'Brutally cruel': Pat Cummins in $3.1 million IPL 'disaster'.1 day ago.'Never seen that': Disbelief over freakish David Warner dismissal.3 days ago.IPL 2020: The players who could become new cricket superstars.5 days ago.IPL cricket set to kick off in UAE amid India COVID-19 crisis.1 week ago.IPL 2020, MI vs CSK: Broadcast times, TV channels and where to watch live streaming in India.1 week ago(function(){ window.cVrhhd=function(b,e,q,f,h,k,r){if((b=document.getElementById(b))&&(0!=b.offsetWidth||0!=b.offsetHeight)){var l=b.querySelector("div"),m=l.querySelector("div"),c=0,g=l.scrollWidth-l.offsetWidth;if(0<e){var n=m.children;c=n[e].offsetLeft-n[0].offsetLeft;if(f){for(var p=c=0;p<e;++p)c+=n[p].offsetWidth;c=Math.min(g,c)}}c+=q;e=Math.min(f?g-c:c,g);l.scrollLeft=f&&(h||r)?c:f&&k?-c:e;var a=b.getElementsByTagName("g-left-button")[0],d=b.getElementsByTagName("g-right-button")[0];a&&d&&(h=/\btHT0l\b/,k=/\bpQXcHc\b/,a.className=a.className.replace(h,""),d.className=d.className.replace(h,""),0==e?a.className="pQXcHc "+a.className:a.className=a.className.replace(k,""),e==g?d.className="pQXcHc "+d.className:d.className=d.className.replace(k,""),0<=a.className.indexOf("SL0Gp")&&0==e&&e==g&&(m.style.paddingLeft="0px",m.style.paddingRight="0px",a.style.display="none",d.style.display="none",b.style.paddingLeft=f?"0px":"48px",b.style.paddingRight=f?"48px":"0px",b.style.textAlign=f?"left":"right",document.getElementById("fade_forward").style.display= "none",document.getElementById("fade_reverse").style.display="none"),setTimeout(function(){a.className+=" tHT0l";d.className+=" tHT0l"},50))}};}).call(this);(function(){var id='_ZLhtX8HQJZLw9AOGxoW4CQ8';var index=0;var offset=0;var is_rtl=false;var is_ie=false;var is_gecko=false;var is_edge=false;var init='cVrhhd';window[init](id,index,offset,is_rtl,is_ie,is_gecko,is_edge);})();View allWeb resultsIndianapolis Power & Light Company: Homewww.iplpower.comwww.iplpower.comCachedSimilarIPL - an AES company. Better Business Bureau Accredited Badge. Indianapolis Power & Light Company | 2102 N. Illinois St. | Indianapolis, IN 46202 | 888.261.‎Pay / View Bill (sign in) · ‎My Account · ‎Contact Us · ‎Payment and Billing Optionsipl power indianapolis inipl power outagecitizens gasipl disconnectpower lightlight bill accountPeople also search for(function(){var uer=false;(function(){ var a=uer,b=google.time();if(google.timers&&google.timers.load.t){for(var c=!1,d=!1,e=document.getElementsByTagName("img"),f=0,g=void 0;g=e[f++];){var h=google.c.setup(g);1==h?c=!0:h&4&&(d=!0)}a&&c&&d&&google.c.ubr(!1,b)};}).call(this);})();function _setImagesSrc(e,d){function f(a){a.onerror=function(){a.style.display="none"};a.src=d;a.setAttribute("data-deferred",2)}for(var g=0,b=void 0;b=e[g++];){var c=document.getElementById(b)||document.querySelector('img[data-iid="'+b+'"]');c?(google.c&&google.c.sdi&&google.c.setup&&google.c.setup(c),f(c)):(google.iir=google.iir||{},google.iir[b]=d)}}"undefined"==typeof window.google&&(window.google={});(function(){var s='data:image/png;base64,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\x3d\x3d';var ii=['dimg_102'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d';var ii=['dimg_10'];_setImagesSrc(ii,s);})();(function(){var s='data:image/png;base64,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';var ii=['dimg_12'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wCEAAkGBwgHBgkIBwgKCgkLDRYPDQwMDRsUFRAWIB0iIiAdHx8kKDQsJCYxJx8fLT0tMTU3Ojo6Iys/RD84QzQ5OjcBCgoKDQwNGg8PGjclHyU3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3N//AABEIAHcA1AMBIgACEQEDEQH/xAAcAAACAgMBAQAAAAAAAAAAAAAABQQGAgMHAQj/xABDEAACAQMDAQYDBAYIBAcAAAABAgMABBEFEiExBhMiQVFhMnGRFIGhsUJSs7TB0QcVI2JkdIPxJDM04SVDVJKiwvD/xAAYAQADAQEAAAAAAAAAAAAAAAAAAQIDBP/EACARAAICAgMBAQEBAAAAAAAAAAABAhEDIRIxQSJRkTL/2gAMAwEAAhEDEQA/AK3d2cMXZ6S7jmYXad0VzHCUlDAZ4xkcnjk9OfbL7AqMA9nrpB+HFja84567ueM1U8HaF8gcgeQo5xigDoWnWNzHD3UVp2gdV8ZSTS7JgNxZQfE/HCkfPNa50ntmhjWDVpCYgiKdKtBhdyeHBbk5I9cfXCPRNNt5bJWHdyTTli0s2mzv3P6ICspwQCM59SamG0s0uJlfTrZzK52FtEnyq7MlsbugIPA8yTxQBPkW5KlTZan3bMVVTpVkCeOOjA5wPL3pZrj3S6fPLFZ3MKRMnMthaqEyRwxBLYwy4POTn0qQ2mwCZmGn2bq2wPCdFuQMbhuCnPXxE+vHlSbWtPtorCIxRQRPCocvHp00RlxtQ5Y8cls9AAcAdaAFn9YXOOsY/wBFP5ViksjLIS8Y2qDju18XiAwPrn7vvrVijHSgB/MP+k97G1/YR1nEgJr2VfBZEf8AoLX9glZIMn0xWb7GSI0wRWanxYFYx8VtihLPuFSyiRbg8ZH30X13a6fEr3MgGckJ1LfIVJtyAfFVP7VXTXWqtBgiO3GwD1PUn8vpSirYrNOo61dXku6JnhjX4RG2D9+KgieUHd3jjnOVOMn1oigd2CRqxLcADzplHot/D4prC5CjnIiJrS1HQ0m+iZpnaPUINouF+0QL1LDxD3Dfzq9WjxzQJLHykgyK5zcSNCgQRbcZ2kJtI+YNWPsRfSzRzWkqnMZ3qT5A9R9efvqZJCVlmkhA5UVrt0cs4cjnyqXyYsg/dWlIyT3jNt9M1A2qNUsAY/IVDmg2nw8H1pm2SRuIPtUO6dT0GPlQIWzuxbaOcdTWUKDOT9KyCg7toy1Eann2p+CNN0hwAKXTjZn9X9WmspYqeaXzxB4yTjNJDsXuqls+te16U560VYWV6iiitSR5omoxR2Elu0tvBLGV2vPqk0BIyzeEDIGOMj5U1e8tczmO8s7gqrPHHHrc7s59hjrgevpSrsxPfbpoI5p0sgMv3NzDCySMQAQZOuQpBHPUU6VrkyRiW+1RVjAeFV1az3dMH9HGcMOpHXzIoAjXV/aW8i5vrJtsm041ueRtrMeoAwcbvotKNZ1C1e0W2t2hmaYkI8eoTSGJFZTtZW4OSOPln0qxJf3Co6rNqhcT7SkmqWmXJ8THIx+jgZBHJ8+aQ9pLm+EsdvJLcLZMuYoZbmGblODzH0HI6+eevkAJaKKKALOQptrHPX7Da/sUrxVxWDHEdj/kbX9glbASzdfKsn2Mz6nip0PG0AVGhAz75xTC3UbvF0xUsZtRAy54zVE1KMtrV4uCT3zeddItI/Gu1N27wrx1NVLWNJuLW/ub04MckpDKRgxnoPmDjqPcUKSiUoOStI29ntJmjmhuWjJG7jBrqGmESKoxjPlVN0OVYLATShjt/VGSfuptZ9oxFIJJNNvUiBwX2DH0Brkm3OR2wiscaLNeaXZzsjT20MjJ8JZBkUj1XT7eG5huIY1jcZTwLjIPl9cH7qdabrem6vxY3SSSD4ozwy/MGq5261q00yIL3yNcIwPdA859/Sh2p6H88XZWu0XaY6bOLSwCST/pk5wn86r17qmrzSN3l5IjDxbFJAX2rzs/p0+q6tHLKsjd5JudtvhIJ5phf6dfTXV3cfYZ+5LeEmM4A+Vdicbo4nGTVim37R6lbzbp5WnUdVZuce1XCz1CHU7bvbWTIHBU8MvzFc9u12yEEYxxjGPwqb2cvvsWpqrE91N4HH5H6/nV6IZc4mKscdT51KiUEEt1ote5IJlHPlUlUBBKjAPlUyJF8qgqVA6+QqDNAQGTJzjypxIgGaXTnMvhFSmVRBKbfCQOKKmPCWOcV5RYUUeiijzrckbaXoVzeW4vJ7DUzbsA8MltbxyCQeZw7Djp5etWJDIbYSi2vzbugdX/AKpsyMEeXj9+nFI7G7sDYWKXR0vvoYiuZtOlkKYwRlg3JJ3HPT61vml0jfiSbRnYuwEsWlTLt4Yg/GOMhRkD054oAcJbXsZmMNnfpktJLC+kWoYZ+HzwVPjGB09OarWraJPad5NaWepdzCG+1NcwRqIyADxsY5HLfLipctzpEzIwXRV3kd6G0ycnzJ/S8zjj39udOp3Wmf1fcrCmlyPs7uFYdOkVgWHLAs+1cEkg4zwDQAkoo6UUAWNsGGz9RYWv7FKzi8WSOKwZB3Fmf8Da/sErbFwBWUhm+IHyphBIA/Hpil6jpg8VIiBZuGqChxbXPdSxlDkocqK29q4IrjQRIFkCxK5dlXIO7xLn0yR/Cl0PDEnyNL9Y1+5W21PTo1jaLAG49V6EgetRKN7N8M6TiP8Asc6tbQ5AbK05v+zUNzdpexM3AGYi7BTg9ODyD5iqJ2Q1FbciKQkKeFOehPr/APvOrrcdsLXTJILe4EmXG47BkqM4/gaxpxlSN1NOKZL0Hs7Dpl1JMw2yyKRx+iT6CqR2m0K4tITCFkeS4uisk7kHchGcf/HrVgHbu0Fw8ilXUSEr3qFSVzwAc9ce3PtWHaLtFBqHZxb22kCSLOGOwBjH1GMHz5FNKcXY24S7H/Zq3SHT4kCAYXHSrClrG0BXYORjgVzzsf2mupr+OxvoxskcJG7RhWDEZAIBI5pr2p1nVNLvCguWWBgxWGLZGSFHi8bZyfZeaUYU/oUpclcRT237E95G91p8QMg+JR1Ncrw0N0oYEFHGR7g13Tszq51aCWUQ38aR+HFyQyk+qt1NVO87O2+p9v2M0LixWMSylAQN3QDI9T/GtoT4umZThyVomraZwduFI8/Kt0oCKMHFMZ4SrskmAyscgdAc1Buk3OCvX8KvlezmlGnRCyD1qP3ILFscVMeML5V4/iQhePWpELpLja2NvSvK9lgy5IFeU9Ac/ooorpJJ2jx2lzHeLcSaeCMKDc3rwsnByQFBzyR1polpojMSRpUbI3/KOsy+IYz128AceVbezs+qTaaUtr68Cxu0cCxXdtGkYCjG4ON3XPTyHrTFvtzOXebVsiUGCJdQsiwBUDJ4/vEH2I9zQAit4tGa3E2dJySJFWTWJMlc52EbRg48NRdZgsoYYJrT7HEpdkaOC/e4JJAIzuA27enuW9qszm6ZIRFNqYMTZ2jU7HMeAcDoAeGHr8hSztBcalHYjvrm/AcmGYT3lrIrIwJxiPxZyq/j0oArYoo9/Wg0AWYMO5s1xz9htcH/AEErYMDqa1qMQ2Z9LG1/YJWtgzSYI4PnWXpSGcEYfow5rdDGwJIBOKhW85t3j8PGKs3Zmwl1mYgArbhsO2OvsPekotsLGXZXs++pJNNdboo3QxwsBzkjG4fKqhqHZe7029uLK5GW257wdJAf0h867hZQ90ixqqgIAFGMcVq1vSYtTgAdFE6f8tj+I+RqsuNuPz2VhyKMvro+b4zPYytG6lXB2k49qe9l9ahju2XVYUmtriMRZkAPQkg/LxVY+12hq4mmSELKh8SkfmPWqB3IjUKNwywAH/f5/nWeOUcip9mmSMsbtdFzvW7KPP8AZ1geFim/enMa+nJqPYWNrLpTdyjCC7ulKjP6AYAfXGfvqoPI0jC3j3E5KhB5ngV0uC2FrYxxpHuECDCDzKjy+8VThSE8vJoZ2mjWOn6lpkVpCqnvd5zyeB6/SrReR2kzBLqKNsnjvEBH49Ko15LN9ssr/M5jlA2vEcMh/VIq02073MHdJp4cufG8jhfvPHP3VyqzratWT5kihhCxBQoHCqMAe1V5tRsdNXUZrqdEljg7zazAbh4sceeSMUza3NnE3e3LyAHjfyR6D3qjdvYLdra6W8toxPHGjJIzEOufgAA65JYHj9HnyqF9T2KUlCBD7Oa9dXh7u/O+RwWEufiPmKdtJyQeP4Vz7s9cKuoW1upJJYYPvnj+VX91y+cceua7GvDhbMSQVrQeuAMis3bb91as7jxipoDxhyeKK1uxDdaKBHNa9ryiukksugzw3dtbWgiupriKIbu50q3kaML0IcnJxheT60xt47iMRStpdx37PteMaPb7M4O8KA3ltbqRnHnVMFncTorrZXEsbsVRkgZgx9AQMGp0Md1YWzW8vZwSh5TIzXNjKzfCowMY4H/2oAstxZlLhpZdOvQ/MwWTR7U5woQnO7GBkfXNLtcMNjaS2k1q1rcyRuURtMgU+IncTIDx4t2CvQAedJ7+C4uIhGOzq2qFw5MOnSgtgEYyc8c/lUQWc0MBn+wzxQscd41uyKSenJGP9qAMRR5UUUAWLvNi2ik8Gxtf2CVtc7cbTmo8w/s7M+lja8f6EdbI3DbV2sSeMVi+yvCZoWmz6vfR26Nhert+qtdo0qwgsbeGC3QIkQwoFIOxGhDT7ES3AAllO5sdfl7Vbo0weBj2rpiqRk3skKSa3KdwweD61qU4+VbQOhH3UDFetaNBqcZ3lo5gMCRfP2I8xVH0bsO1rcajb6sIpo5wO4ePP38EcHp69K6aRnrUS5RUljlZgqrkHPHXz/D8ahQjfKtl85ceJy6bstZ6Rdh5LZQ6nKPkkGtizZwnXmuh6xYR3du6MPL06e9c9a2a3uHSUcoccUmhJmzRreKwjW2kdpYTI7lpDnBZi2PuzVjg1XSbONhDIjuOqRnJz/OqNfa5BCJLe1cXF2ATtjUsAfTI8/KlemX9jY30lysE6SuWM0O7aokz8XPwjHl6iubLBvcTpw5NVLo6bBMskgvdQdURfEiMQAvuc+f4VVe0MsWqXV5P9rhVO6QGCQse8GSVBA6EgsPrkZxUE63caqhhtyIrhMLGu3ed58x7AYOeON3Wps0N1cTrNJKjmSEqzRR5CoR8OS3mQOeRwPUVjjXHbNMjUqRXdB7Lvp2pG9nuUlVM92ijDqfVhzgY6VZicYBGR5YqBqr93CkaSEgYDSOxJOOni8+n5dc0ngvb2MZss3MYYBoXkLMoIyOTzu8yCTjNdMZctswcPzY7nOa0xsNxBFZB1YL3mFkKgmPcCVz6/Q/StJYBiRRVmbTWmEjeKisCNxyWoooRzqiiitxDvs+8KWkslxf2gUSGOK2uNQktyrDDFhgY8xTBL+3FvNdPc25bcwQRa3PkgY46f3Q306Vh2VvLxdOljt2uyIpJAoS4tUjBIB+GXDdWBP8AvTe7m1Dc84fVIm6+C9sWC7mGFI8h6Hny58gAQjcIkv8AwV/YiMliJP6/kOzpuzxjox+80m19S0SyWuoW8tpGUVrePUnnKsSedpGRjpVhzqNtEUhk1HO0nJ1Cx8OM4wOPQetKe1E8sNjDZyXl6xmfIimnt3BGQ5J7tc9T69fagCt0HpQKD0oAeysAtqP8Dafu8dWXsdpYmli1GfhFl2wBhwWHJP3dB7/KqpdHH2X/ACNp+7x10vsP3L6TZyEeG3VnxngsT/v9KUI3IUnSL1atHG6QjG9s80xjUL0pNb8Sd6Vwf0fanQrVkozHFZJxx5Z49qxzQp8VIZsqNqNqLy1aAsVDcEjqKk14aQGqXZHCSSFRV5J8gK4D2l1261/Urn7MzRWmDtjVsFl/WJ+Xl+dd11lwmj3zN0WByf8A2182WwmmmjiRnUyAIwHmDwR8/wCVDLSVWWfs9pE8en2l3ayNFO8veeHBIQH0PU4B6c8im0OnW9zeTQ3+n/20tyoWRypbJBJ46jox6+XGealXNoFvNKtISu0yKpRR4dq4Pz8vWnl5YTW16Lizto5WYDaZGI2MAwBzz5Mf4Z8uCUndnUkqIWh6N3OqNdRwxpFDuh8BwhcE5bHyY/jWN7PE0k80fhh/8vao5HRj75PTPoMCp98zadpSWcchN5c5G8+RPLt146nHvgUutIo7jUYYVXbDD4imc84GAR7Dn6elTd9i40xPd7yBLBIxu5Tj4sqMnHHyyB7ge1VbVL+XS72O0sjse0kDO3TdJjxZHHqavOuPHY3YLwqFgMsspWPw7V8YBx5YK/j71yyVnlb7U8bFZpGbcRgHzP511wimtizVGnEs9nqFzepPqEoVnAEarBnw455XnOc9ecfWmsbrMiMnwuAQagxlTp8L20K2sjoDsHHB4weORg9evvWWkiaNp7eaIxqMMmT8PTI8+lLXhk5Oa32TyuOPSvK8J5xRQQc4zRmsM0ZrUQ60rRrXUdO+1/8Aifgd0leGzWWMEHoDuBzgjPzqa3ZeJZmhePXd+Pg+wxqT8Rz8RHRH4/umovZ+0hl05jcJYyh7iUqJrCed06AkbCFwQPw9qYx2VlGQTZaWf7XcC2j3ROSS2OTyAPXoBQBHj7IAyTK1vrKASbYc2UZLggEZG8c9fuHSomt6Eml2ffgaijb1T/ibNUQknGAwY+Q/A89Km3UEUULPNBpUlyf7R1k065Znc5YIXJ65bb93tUDW7NItKts21nDLGYge50+aNweA2XY46n0549aAFOaKwzRmgBxeH/pf8jafu8dXPsTdF7WwtgcE3jbh6qEP8c1Sb0+O1H+BtP3eOrn/AEY2yz6jG7vjuw5QHoWxj8s0Q1IUujq0AyVVvPBzTOoFrGVTn14qavKmtWSgLYrKI5Zj74rW9bY1wPnzUjNooNeCvG6UgEfaG9e30zWZJUH2eGzYgsvDEg8e/wDtXD+ytuJ9Wg3n4XUk4zkg5OR6/nXXv6Trnuexl8meZZI4+mcjepP4A1zLsKA2pjoRyADyBx+NRkdQZcdyLpaL9o7U2AJyUWR2HmD8PP0q1agxhRFGNznaP51XNBzL2wjDHlLQnnqPEevvyKm9o74GeWEYyD3C+eARuc/TaPvrjktI6oMTX1y8spuUBdpCqQYJGRz+fJPsPUVnYvbWE6QNKve9Wz8R9TgcL0OM+9L/ALQolkuJGaJYzgtjKquTuJJ6ef096WWOppDDbXM6LHbXhZQ6KS6ksxXp7YB4zzQsfJClJxV/pj2iNw6XlwzwNHPFKJoMMSuQFO3n2z5dfSkD6deaxNb7ZoUiCGNRnwxKuFz77j0/jVkukhe5e3QKsBI3ohLEyYx4iccZOeAemc+VKNASWyM86RhpoiYkEshAZhwMnGAOSfma3uSWuyI/emSNKtpbaR7WZo5722xmJAwGB05IGfLn5e+I3ez/ANYHcSoR9rKQRxnoD54zjp5Vr0k6s2ranEY1N88XMjMq92fLn0weOvQUmknuvtMdoSTcJLskxg52n26+nyA9Krj/AEm0kXN8Bjg5FFayc+dFKjM5tmjNeUVqIb2OsrZ2C2ot7nwvlmj1CWMEFsnCjgE8jI9qYWOqjUdUWOKGeGRi0p7zUpyNwHGCBnpkefXnpRRQB5favHZXDWUlveDu3DgpqsuG53ccDHiwc4zlR5Uuv9VhvbN4WhuzIGBjeW+eQJ4skYI5zRRQArJ5qdp5sDBd/bY5u+WIvAUbAJyFAP3sD8gaKKAN9+f7S2/yNp+7x103+iyxEdmt7v3blOFP6LEkfkKKKcP9EyOjRMRxipKnjpRRWjEjE+JwKkgY6UUVIzxmrw8iiigDnn9M07R6LYQr8Mt2Cx8uFNUjswFttdtlUZWeJpFT052miissnRcOy9aHJ3HbGIsB47NwCB1wTyfpSO6vmudS1S4TLBZpEjUcc4AJ+8gfSiiuZ+HRHpkOwvTJA6wh8B2Ubm43A8ZznjGPx86xuJUFw8Fsyr3Um8FVwqngZA/7efpRRVz0tHZgintoi6nFLEsZvHMqyZKMPCF4JAIHyNKtBuFkW4Ma43OTjHAHnzmvaKeJ2tk5aWSNejDUltrjUYIbpmhmYF3kjUF4xs9+DzVf7QTzS68zvNG7KyossKbNy+Rx1zg4Py9KKK0S+jhyux84k3H+de0UUzKz/9k\x3d';var ii=['dimg_14'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wCEAAkGBwgHBgkIBwgKCgkLDRYPDQwMDRsUFRAWIB0iIiAdHx8kKDQsJCYxJx8fLT0tMTU3Ojo6Iys/RD84QzQ5OjcBCgoKDQwNGg8PGjclHyU3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3Nzc3N//AABEIABAAQAMBIgACEQEDEQH/xAAYAAADAQEAAAAAAAAAAAAAAAADBAUHBv/EACwQAAEDAwMDAwIHAAAAAAAAAAECAwQFBhEAEjETIUEiYXEUUQcVFiMygZH/xAAXAQADAQAAAAAAAAAAAAAAAAAAAQUD/8QAHREAAgEEAwAAAAAAAAAAAAAAAAECAxExUQQyQf/aAAwDAQACEQMRAD8A1SybgVdFuR6suKIpeW4ktBzfjasp5wPtnjQE3hBcvKTa7WFTWYgfB3YCl8lv5CSk/BP21Csig3rbUaNS3F0B2lsrdUopW91juKlAA7cfyI8caltfhnXI/RrLdcaXcSJv1ykKRiOpxRAWnft6m0o7Y49hpgV6Netx1C5JVFftdhhcHpGasVEL6KFjIIG31dvAOg2x+IdSrUT8yfoUZmmJjuyHVs1FLryUthXDW0KOSAP7GrdJt2bDvO46084wY9UajoZQhRK0ltG1W7tjnjBOuZsCxrithaGnGrcaHQdaXUI6HFyjuyU53AJUArb2PgaBlWg3rXq7T3JMO0z+4wl+Gv69BaeBVgpUrHoWBk4wePGkI141y4bYrkldGRTYzEd9pMpqd1FB5BCSkDaCOT6vbTVlWbWaTcjtWqjtJZSYxYLNKaU2mUoqz1XE9khXwPOiQbbnUWw67T5HTfffdkvoEclWUrOQO4Bz7aceyNKKTqxT2jNahQI0GrUmLMqDiGJ8VmQ5I6eekXNw4z3AIGT76ZqdrSrTYVUZdQWxLRNDcFDI7vpBBLhOfSMeO/286drdQtqrQoxltVdM+NARFQEJbDe5AOM5OcZP+an3HUv1LKoceAzKW7HitxihaclTme5GCe3Hf21XhObtfHpQ5nEqZats/9k\x3d';var ii=['dimg_17'];_setImagesSrc(ii,s);})();(function(){var s='data:image/jpeg;base64,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\x3d';var ii=['dimg_19'];_setImagesSrc(ii,s);})();(function(){var s='data:image/png;base64,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\x3d';var ii=['dimg_21'];_setImagesSrc(ii,s);})();html:not(.zAoYTe) .hide-focus-ring{outline:0}.eejeod .U7izfe{padding-top:0;font-size:20px}g-more-link.iexNG{height:30px;top:12px;position:relative}.JolIg{color:#222;font-size:20px;padding:9px 16px;line-height:1.3;font-weight:normal;margin:0}.cbphWd{border-top:1px solid #e5e5e5;cursor:pointer;display:block;font-size:16px;padding-bottom:9px;padding-top:9px;position:relative;line-height:1.58;}a.cbphWd{color:inherit;text-decoration:none !important}.related-question-pair .kno-ftr{margin:0;padding-top:0}#rhs .related-question-pair .iUh30,#rhs .related-question-pair .LC20lb{display:block;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.cxrEAd,.uKh9yc{display:block;opacity:0;transform:scale(0);transition-property:border-width,opacity,transform}.uKh9yc{border:10px solid transparent;margin:0 auto}.gy6Qzb{-webkit-transition:max-height 0.3s;overflow:hidden}.S8PBwe{max-height:0;visibility:hidden}.vp45yf{pointer-events:none;position:absolute !important;right:0;color:#70757a;top:50%;margin-top:-12px}.mWyH1d{position:relative}#res .Jb0Zif .qDOt0b h3,.rhs-osrp .qDOt0b h3{font-size:16px;line-height:1.375}.Jb0Zif .qDOt0b .iUh30,.rhs-osrp .qDOt0b .iUh30{font-size:14px;line-height:1.58}.knowledge-panel .LjTgvd .LGOjhe,.kp-blk .LjTgvd .LGOjhe{margin-left:-16px;margin-right:-16px}.kno-ftr{clear:both;color:#70757a;font-size:12px;line-height:1.34;overflow:hidden}.kno-ftr a{color:#70757a;text-decoration:none}.OwRFvb{float:right;margin-left:2em}.kno-ftr a:hover{text-decoration:underline}.kno-ftr{margin-left:0px;margin-right:-52px;padding:4px 16px 0;}.otisdd{margin-bottom:-8px}.DOqJne{margin-bottom:2px}.qdrjAc{font-size:14px;}.Dwsemf{display:-webkit-box;display:flex;display:-ms-flexbox;display:flex}.D5gSDf{font-size:14px;}.bwSSse{flex:1 0 auto;flex:1 0 auto}.zTpPx{color:#1a0dab;font-size:20px;line-height:1.3;}.zTpPx{margin-bottom:6px;margin-top:2px}.rQgnxe{margin:-4px -4px;}.vwfsqc{display:-webkit-box;display:flex;display:-ms-flexbox;display:flex}.nlkcvc{margin:4px;width:212px}.dHOsHb{display:flex;flex-direction:column}.zf84ud,.Brgz0,.a02Mp{display:flex;flex-direction:column;flex:1;flex:1 0 auto}.xcQxib{flex:1;flex:1 0 auto}.rmxqbe{align-items:flex-end;font-size:12px;line-height:1.34}.rmxqbe .f{line-height:1.34}.xcQxib{margin-bottom:8px}.rmxqbe{bottom:0;margin-left:-16px;margin-right:-16px;position:absolute}.THG0oc{box-sizing:border-box;position:relative;-webkit-transition:max-height 0.25s;transition-timing-function:ease-in-out}.THG0oc{max-height:236px;min-height:236px}.ol1Lrb{padding-left:16px;padding-right:16px;width:178px}g-image-section{display:block}.cUVNae{background-color:rgba(0,0,0,.12);overflow:hidden}.Jyc17b{box-sizing:border-box;display:inline-block;vertical-align:top}.eadHV{line-height:1.58;white-space:normal;word-wrap:break-word}.h4kbcd{bottom:0;left:0;position:absolute;right:0;top:0;z-index:1}.Ndm45b{word-wrap:break-word}a.Ndm45b{color:#666}a.Ndm45b:hover{color:#1a0dab}a.Ndm45b:hover:visited{color:#609}.kLhEKe{background-color:#fff;line-height:14px;margin-top:0;padding-bottom:16px;padding-top:12px}.Ywxp6b{color:#202124}.cUVNae{position:relative}.cUVNae .OhQAn{color:rgba(255,255,255,.8);left:50%;margin-left:-24px;margin-top:-24px;position:absolute;top:50%;z-index:1}.PjvVrf{padding-top:8px;width:652px}.S003Ke{flex:none}.mtnwac{color:#4285f4}.rAWczb{table-layout:fixed;width:100%}.P1usbc.rAWczb{white-space:normal}.rAWczb .G1Rrjc,.rAWczb .i4vd5e{overflow:hidden;white-space:nowrap;width:1%}.gEbUL{margin:-4px;width:auto}.sQkmof{display:-webkit-box;display:flex;display:-ms-flexbox;display:flex}.gT5me{padding:4px 4px;width:212px;position:relative;display:block}.nHGuld{padding:0 16px 11px}.ivLVOc{padding-left:16px;padding-right:16px}.y8AWGd{display:flex;flex-direction:column}.llvJ5e{flex-grow:1}.JRhSae{font-size:16px;}.ZyAH8d{line-height:1.375;}.wCIBKb{padding:16px 16px 0 16px;display:block}.zECGdd{color:#808080}.cJzOGc{color:#202124}.RgAZAc{overflow:hidden;position:relative;white-space:normal}.ZTH1s{display:flex;flex-direction:column;height:100%;box-sizing:border-box;}.rUQgO{flex:1}.AldPpe{overflow:hidden;position:relative}.lWy7Jc{background-color:#eee;position:absolute;z-index:0;margin:auto;left:-100%;right:-100%;top:-100%;bottom:-100%}.ewlHBd{position:absolute;top:0;bottom:0;width:100%}.Woharf{position:absolute;height:16px;bottom:8px;left:16px;transform:translateZ(0);z-index:2;}.Yv4wBf{background:url(data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSI0OCIgaGVpZ2h0PSI0OCIgdmlld0JveD0iMCAwIDQ4IDQ4IiBmaWxsPSIjZmZmIj48cGF0aCBkPSJNMjQgNEMxMi45NSA0IDQgMTIuOTUgNCAyNHM4Ljk1IDIwIDIwIDIwIDIwLTguOTUgMjAtMjBTMzUuMDUgNCAyNCA0em0tNCAyOVYxNWwxMiA5LTEyIDl6Ii8+PC9zdmc+) no-repeat;filter:drop-shadow(0 0 8px rgba(0,0,0,.12));perspective:1000px;-webkit-backface-visibility:hidden;transform:translateZ(0)}.ZL6cRd{position:absolute;top:50%;left:50%;transform:translate(-50%,-50%);opacity:0.87;z-index:2;width:48px;height:48px;background-size:48px 48px}.LQFTgb{line-height:normal;border-radius:2px;font-size:12px;padding:3px 4px 0 4px;position:absolute;font-family:arial,sans-serif-medium,sans-serif;bottom:8px;color:#fff;left:10px;background-color:rgba(0,0,0,.54)}.zkY1be{padding-top:8px}.H93uF{cursor:pointer;overflow:hidden;}.rllh__header-container{position:relative}.yyjhs{background:#fff;padding:8px 16px;white-space:nowrap}.rl_full-list .yyjhs{box-shadow:0 2px 1px rgba(0,0,0,.1),0 0 1px rgba(0,0,0,.1)}.yyjhs{height:auto}.bcUTBf{display:inline-block;margin-bottom:4px;margin-right:16px}.F7IIOc.rlf__open:not(.rlf__applied),.F7IIOc:not(.rlf__applied):hover{color:#222}.bcUTBf:first-child{margin-left:0}.F7IIOc.rlf__open:not(.rlf__applied) .FZaw6b,.F7IIOc:not(.rlf__applied):hover .FZaw6b{border-color:#222 transparent}.asjHCd{font-size:14px;line-height:1.58;padding:7px 0 0;white-space:normal}.F7IIOc{color:#777;-webkit-user-select:none;user-select:none}.F7IIOc.IvNZOc{border:1px solid rgba(0,0,0,.12);border-radius:100px;color:#757575;cursor:pointer;padding:5px 16px 6px}.F7IIOc.IvNZOc:not(.rlf__applied):not(.rlf__open):hover{border:1px solid rgba(0,0,0,.3);color:#585757}.F7IIOc.IvNZOc.rlf__applied,.F7IIOc.IvNZOc.rlf__open{background-color:#e8f0fd;border:1px solid #e8f0fd;color:#1a73e8;outline:none}.F7IIOc.IvNZOc.rlf__applied:focus,.F7IIOc.IvNZOc.rlf__open:focus{border:1px solid #a1c2fa}.F7IIOc.IvNZOc.rlf__applied:hover,.F7IIOc.IvNZOc.rlf__applied.rlf__open{background-color:#dee8f9;border:1px solid #dee8f9}.Ae7FMe{cursor:pointer;margin-right:12px;width:100%}.WaZi0e{display:inline-block;line-height:normal;max-width:130px;overflow:hidden;text-overflow:ellipsis}.FZaw6b{border-color:#909080 transparent;border-style:solid;border-width:4px 4px 0 4px;height:0;position:absolute;margin-left:4px;margin-top:6px;width:0}.F7IIOc.rlf__applied .FZaw6b.J4Tfj,.F7IIOc.rlf__open .FZaw6b.J4Tfj{border-color:#1a73e8 transparent}.F7IIOc.rlf__applied .j3R1vb,.F7IIOc.rlf__open .j3R1vb{background-image:url("https://via.hypothes.is/https://www.gstatic.com/images/icons/material/system/1x/person_googblue_24dp.png")}.Fam1ne{background-repeat:repeat-x;display:inline-block;overflow:hidden;position:relative;}.Fam1ne span{background-repeat:repeat-x;display:block}.KsUr1 .Fam1ne,.Fam1ne.sCCsuc{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABoAAAAaCAQAAAADQ4RFAAAA6klEQVR4AZXQMWsCMRiH8SAnQacODgpyg8rh1EEQHXS5xaUdXA5KRUHo+/2/wdN3aBNK34TEZ0rCD86/S/140ZydI9WrVo3etUrk+dJ8Hdog2qYO9YjW16ARD0R7MCpHC+SnRTk6BHQoR0NAg43WvP1LYsbrWh0tN6SwG+3v53n6ItLj//6nFfcsuLOyhphwSZILk/R6nUm6/OQzE83yaGeiXR5dTXTNoSmSaJpGWyQ0aBLaplGc/EijHePkKdTwRLQP5uFurifRnjQ2ahHtzBhHbKw3orU2OvHJEme01JeTjfZ4XCLPPp6+AYsy7RMdMSvnAAAAAElFTkSuQmCC)}.KsUr1 .Fam1ne span,.Fam1ne.sCCsuc span{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABoAAAAaCAQAAAADQ4RFAAAA9klEQVR4AZXUoY7iUABG4SYYEgwYwhOsx4MlqUaAQ/AGMxqHIUHDC4DnATaMx7MORVAEh5vAtzUN7M69TXuOurc5SfuLJjH8ykzCJmJ++qgefWVWjJq+M5vVojEYV4s2YFMlqrmBm1r5qC+nXz5ayFmUj/7IOYajkd//uffO/sfzUdZJXZTlIs1fr2WrDFutf79p6KqIq2FoiLadGDvt+HoTISbFk3eF6BZHMyFmxdFBiENR1PEU4qkTj6ZeHDNfTONRPvnDUj1z6ZFPHovq7uCkJ7/rOYG7ejhKwVrD+23DGqThaOVsIAk4cLYKR3NN8b/T/HX6C7jRb/QEnjPPAAAAAElFTkSuQmCC)}.EBe2gf{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAA4AAAANCAQAAAAz1Zf0AAAAWklEQVR4AY3O0QbDQBCG0UNYQi0hhBJqr8Iy7/94vewYlp65/Ay//4WlLnQLt3BbeIRH5jBFPVMHmlHS0CRnSqdiT3GH1edb8RGmoy4GwrBhM4Qmebn8XDrwBW7xChrojlOZAAAAAElFTkSuQmCC)}.EBe2gf span{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAA4AAAANCAYAAACZ3F9/AAAAZklEQVR4AWL4uYWZCdAJHVMBAIJAAG1DoAtjGarYxxjqwHADnA8HFuWL3E8puH8gAqILPaB34Qq4FAQ1yoo+8ES7NRWKe6u+Ogo0XjtaCmlSd6K/4OQQOF0JKYTsMasgOIRkBfDZATita/85jgoHAAAAAElFTkSuQmCC);}.EBe2gf.DsNaCd span{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAA4AAAANCAYAAACZ3F9/AAAAZklEQVR4AWIwLHrABOiEjqkAAEEggLYh0IWxDFXsYwx1YLgBzocDi/JF7qcU3D8QAdGFHtC7cAVcCoIaZUUfeKLdmgrFvVVfHQUarx0thTSpO9FfcHIInK6EFEL2mFUQHEKyAvjsAK11TAHRTwY9AAAAAElFTkSuQmCC)}.EBe2gf,.EBe2gf span{background-size:14px 13px;height:13px;top:1px;width:69px}.uMdZh{border-width:0;font-size:14px;line-height:1.58;color:rgba(0,0,0,.54);position:relative}.rllt__borderless{border-top-width:0}.VkpGBb{display:table;table-layout:fixed;width:100%;max-height:106px;min-height:58px}.yYlJEf{text-align:center;vertical-align:middle;display:table-cell;text-decoration:none}.yYlJEf:visited,#gsr .yYlJEf:active{color:#1a0dab}.yYlJEf:active{background:#f8f8f8}.wYWDAd{border-top:1px solid #ebebeb;position:relative;z-index:1}.uMdZh:hover{background-color:#fafafa}.uMdZh:active,.rllt__local-item-selected{background-color:#fafafa;border-left:2px #1a73e8 solid}.uMdZh:active .cXedhc,.rllt__local-item-selected .cXedhc{margin-left:-2px}.rllt__link{cursor:pointer;text-decoration:none}a.rllt__link{color:inherit}a.rllt__link:visited{color:inherit}.rllt__link:active{background:#f8f8f8}.uMdZh .cXedhc:hover .dbg0pd{text-decoration:underline}.dbg0pd{color:#000;font-size:16px;padding-top:2px;padding-bottom:1px;line-height:1.375;margin-bottom:-1px;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.rllt__wrapped,.rllt__details .rllt__wrapped,.rllt__details .rllt__wrapped div{white-space:normal;word-break:break-word}.rllt__details .rllt__wrap-on-expand,.tile-static .rllt__details .rllt__wrap-on-expand{white-space:normal}.rllt__details .rllt__wrapped .X0w5lc{display:-webkit-box;-webkit-line-clamp:2;-webkit-box-orient:vertical}.rllt__details>div{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.cXedhc{padding:8px 0 8px 16px}.yYlJEf:not(:last-child) .wLAgVc{border-right:0}.L48Cpd{width:84px}.VByer .UbRuwe,.L48Cpd .BSaJxc{color:#1a73e8;font-size:11px;margin-top:8px;text-transform:uppercase}.VByer .TU05kd,.L48Cpd .XBBs5{display:inline-block;background-size:20px 20px;width:20px;height:20px}.L48Cpd .XBBs5{display:inline-block;color:#1a73e8;background-image:none}.VByer{width:94px}.VByer .TU05kd{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAACgAAAAoBAMAAAB+0KVeAAAAElBMVEVHcEwac+gac+gac+gac+gac+gtu67uAAAABnRSTlMAV+n+gxT6zFvXAAAAlElEQVR4AWKAAyFFQNn0doIwDABQtIUOIGQEJ7AZQfx3/2ksePEgyefl5AnZlrHPeVvimPOxwomC10BBFERBFERBdIEo+ETBA7Xihg4xGixGg6/vStHguxgdTRQvehebPs9ftNE8m148uupe7PA9yhCDHb4Y7JrF4P89QS8CoiAKoiAKrhREQRREQRREV7h+hOXLfACI4EsohCj6BwAAAABJRU5ErkJggg==)}.C8TUKc{display:block;overflow:hidden;z-index:2}.RGCvMc{display:table;table-layout:fixed;min-height:16px;line-height:19px}.gqguwf{display:table-cell;overflow:hidden;text-overflow:ellipsis;vertical-align:center}.X37Bwb{display:table-cell;vertical-align:top;width:22px}.MJ1Rwc{display:inline-block;height:16px;width:16px;vertical-align:middle}.raB6Pe{margin-bottom:2px}.tQeiM{position:absolute;left:50%;transform:translate(-50%);margin-top:-30px}div.AEprdc.vk_c{border-radius:8px;width:652px;padding:0}div.AEprdc.vk_c{margin-bottom:39px}.xERobd{width:100%}.ccBEnf{border:solid #ebebeb;border-width:1px 0 0 0}.ccBEnf .FjbCbd{padding-bottom:20px}.ep3ODe.J0Tv0e{margin:32px 0 0}.ep3ODe .V2Zq0e{color:#222;font-size:20px;margin-bottom:16px;}.ep3ODe .lgJJud{border:1px solid #dfe1e5;border-radius:8px}.s2TyX{overflow:hidden;position:relative}.O6Hgpc{display:none}.obe4Gd{cursor:pointer;display:flex;justify-content:space-between;min-height:40px}.D22bO{align-items:center;display:flex;min-height:40px;padding:8px 0}.obe4Gd a{color:#222;text-decoration:none}.D22bO a:hover{text-decoration:underline}.DrQBCd{align-items:center;display:flex;flex:1;padding:8px 0}.iKt1P{font-size:16px;line-height:1.3;margin:4px 16px}.BMECx{color:#70757a;flex-shrink:0;margin-left:auto;margin-right:16px}.wmGRHb{-webkit-user-select:none;user-select:none}.ngjNee{border-radius:4px;flex-shrink:0;height:40px;margin-left:16px;overflow:hidden;width:40px}.Xdp21b{width:100%}.M7lz2c{display:inline-flex;margin:8px 16px 16px;white-space:nowrap}.EASEnb{border:1px solid #dfe1e5;border-radius:8px;margin-right:6px;overflow:hidden;padding-bottom:8px;width:96px}.EASEnb:link,.EASEnb:visited{color:#202124}.JAC8bd{margin-bottom:8px;overflow:hidden}.RMmzHb,.RMmzHb .LV5Kte{height:144px;width:96px}.Yyyymd,.Yyyymd .LV5Kte{height:96px;width:96px}.Z8r1Ce{visibility:hidden}.iggQde{margin:0 8px}.f3LoEf{color:#000;font-size:14px;line-height:19px;overflow:hidden;text-overflow:ellipsis;white-space:normal}.VDApEc .hecFYc{height:36px;margin-bottom:16px;top:0}.pWCvWb{font-size:12px;margin:8px 8px 32px 0}#brs{margin-bottom:28px}#brs .med{color:#222;height:auto;padding-bottom:8px}.brs_col{font-size:14px;margin-top:-1px;padding-bottom:1px;display:inline-block;line-height:20px;vertical-align:top;max-width:100%;box-sizing:border-box;}#brs .nVcaUb{margin:0;clear:both}#brs a{padding:3px 32px 3px 0;display:inline-block;float:left;text-decoration:none}.AaVjTc a:link{display:block;color:#4285f4;font-weight:normal}.AaVjTc td{padding:0;text-align:center}.d6cvqb{font-weight:bold}.YyVfkd{color:rgba(0,0,0,.87);font-weight:normal;}.SJajHc{background:url(/https://www.google.com/images/nav_logo299.webp) no-repeat;overflow:hidden;background-position:0 0;height:40px;display:block}.NVbCr{cursor:pointer}IPLT20.com - Indian Premier League Official Websitewww.iplt20.comwww.iplt20.comCached13 hours ago - Find the latest content, including match highlights, press conferences and recap all at your fingertips by downloading the official IPL app. Available on both ...‎Match Highlights · ‎Videos · ‎IPL Fan Contests · ‎03:02 This IPL is for the City of ...royal challengers bangaloreipl 2020 scheduleipl teamsipl 2019 statschennai super kingsipl 2020 newsPeople also search forPeople also askWhat does IPL laser do?An IPL photofacial treatment uses the power of broadband light to improve the appearance of brown spots/dark spots, sun spots from sun exposure, rosacea, age spots, and skin texture. The treatment can also be used for hair removal, photo rejuvenation, as well as to alleviate dermatologic diseases like acne.Sep 14, 2018Everything You Need To Know About IPL Facial Treatments - Alastinwww.alastin.com › blogs › intheglow › skincare-beginner...www.alastin.com › blogs › intheglow › skincare-beginner...Search for: What does IPL laser do?Will IPL 2020 be played?The 2020 Indian Premier League, also known as IPL 13 is the thirteenth season of the IPL, a professional Twenty20 cricket (T20) league established by the Board of Control for Cricket in India (BCCI) in 2007....2020 Indian Premier League.IPL 2020 LogoDates19 September – 10 November 2020Official websitewww.iplt20.com← 2019 2021 →5 more rows2020 Indian Premier League - Wikipediaen.wikipedia.org › wiki › 2020_Indian_Premier_Leagueen.wikipedia.org › wiki › 2020_Indian_Premier_LeagueSearch for: Will IPL 2020 be played?Which is better PSL or IPL?IPL is biggest tournament in the world, as per Wasim Akram. Highlighting the biggest difference between IPL and PSL, Akram insisted that the staggering amount of money involved in the Indian leagues makes it a better one over PSL.Jul 30, 2020IPL vs PSL: IPL is biggest tournament in the world: Pakistan legend ...www.timesnownews.com › sports › cricket › article › ipl-i...www.timesnownews.com › sports › cricket › article › ipl-i...Search for: Which is better PSL or IPL?What is the salary of IPL?The average annual player salary of a Mumbai Indians player in the 2019 season of the IPL was over 5.47 million U.S. dollars. Royal Challengers Bangalore followed that year with Kings XI Punjab in third place....Average player salary in million U.S. dollarsRajasthan Royals5.2Delhi Capitals5.116 more rows•Jul 30, 2020• IPL - average player salary by team 2019 | Statistawww.statista.com › statistics › average-ipl-salary-by-teamwww.statista.com › statistics › average-ipl-salary-by-teamSearch for: What is the salary of IPL?FeedbackTwitter Resultshttps://twitter.com/IPLIndianPremierLeague (@IPL) · TwitterWhen Shane Watson scored a 44 off 26 deliveries against #DC in 2019. Will Watto go big today? www.iplt20.com/video/15… #Dream11IPL #CSKvDC Twitter · 59 mins agoPreview: Match 7 - @ChennaiIPL v @DelhiCapitals The Dubai International Cricket Stadium will host the seventh match of #Dream11IPL today with #CSK taking on #DC. Preview by @ameyatil www.iplt20.com/news/208… #CSKvDC Twitter · 3 hours agoIn focus: New kid on the block - Ravi Bishnoi @mayankcricket takes up mic duties to interview IPL's newest leggie, Ravi Bishnoi. Watch the full interview 👉bit.ly/3j4rYYW #Dream11IPL #KXIPvRCB Twitter · 6 hours agoProud recipients of the Orange and Purple caps respectively. #Dream11IPL Twitter · 15 hours agoUnacademy Lets Crack It Sixes of the Match award goes to KL Rahul. @unacademy #LetsCrackIt #Dream11IPL Twitter · 15 hours ago(function(){ window.cVrhhd=function(b,e,q,f,h,k,r){if((b=document.getElementById(b))&&(0!=b.offsetWidth||0!=b.offsetHeight)){var l=b.querySelector("div"),m=l.querySelector("div"),c=0,g=l.scrollWidth-l.offsetWidth;if(0<e){var n=m.children;c=n[e].offsetLeft-n[0].offsetLeft;if(f){for(var p=c=0;p<e;++p)c+=n[p].offsetWidth;c=Math.min(g,c)}}c+=q;e=Math.min(f?g-c:c,g);l.scrollLeft=f&&(h||r)?c:f&&k?-c:e;var a=b.getElementsByTagName("g-left-button")[0],d=b.getElementsByTagName("g-right-button")[0];a&&d&&(h=/\btHT0l\b/,k=/\bpQXcHc\b/,a.className=a.className.replace(h,""),d.className=d.className.replace(h,""),0==e?a.className="pQXcHc "+a.className:a.className=a.className.replace(k,""),e==g?d.className="pQXcHc "+d.className:d.className=d.className.replace(k,""),0<=a.className.indexOf("SL0Gp")&&0==e&&e==g&&(m.style.paddingLeft="0px",m.style.paddingRight="0px",a.style.display="none",d.style.display="none",b.style.paddingLeft=f?"0px":"48px",b.style.paddingRight=f?"48px":"0px",b.style.textAlign=f?"left":"right",document.getElementById("fade_forward").style.display= "none",document.getElementById("fade_reverse").style.display="none"),setTimeout(function(){a.className+=" tHT0l";d.className+=" tHT0l"},50))}};}).call(this);(function(){var id='_ZLhtX8HQJZLw9AOGxoW4CQ75';var index=0;var offset=0;var is_rtl=false;var is_ie=false;var is_gecko=false;var is_edge=false;var init='cVrhhd';window[init](id,index,offset,is_rtl,is_ie,is_gecko,is_edge);})();View on TwitterWeb resultsIPL - Wikipediaen.wikipedia.org › wiki › IPLen.wikipedia.org › wiki › IPLCachedSimilarIPL may refer to: Contents. 1 Sport; 2 Computing; 3 Institutes; 4 Business; 5 Other uses. Sport[edit]. Indian Premier League, a Twenty20 cricket league ...ipl meaning computeripl meaning medicalipl soccer londonipl meaning textipl stands for in pplipl meaning in hindiPeople also search forIndian Premier League - Wikipediaen.wikipedia.org › wiki › Indian_Premier_Leagueen.wikipedia.org › wiki › Indian_Premier_LeagueCachedSimilar6 hours ago - The Indian Premier League (IPL) is a professional Twenty20 cricket league in India contested during March or April and May of every year by eight teams representing eight different cities in India.Number of teams‎: ‎8Most runs‎: ‎Virat Kohli‎ (5412)First edition‎: ‎2008Most wickets‎: ‎Lasith Malinga‎ (170)ipl teamsroyal challengers bangalorekochi tuskers keralaipl scheduleipl 10 teamsipl winners listPeople also search forIPL 2020: Fans turn on Virat Kohli over 'embarrassing' actau.sports.yahoo.com › ipl-2020-fans-turn-virat-kohli-e...au.sports.yahoo.com › ipl-2020-fans-turn-virat-kohli-e...Cached9 hours ago - Rahul made IPL history on Thursday as he took Kings XI Punjab to a comfortable victory over the Kohli-led Royal Challengers Bangalore.Videos4:14:11LIVE Cricket Scorecard - RCB vs KingsXi Punjab | IPL 2020 ...Zoom NewsYouTube - 15 hours ago2:59Decoding the bio-bubble at IPL 2020The HinduYouTube - 3 hours ago3:36:36RCB vs KXIP LIVE CRICKET || IPL 2020 live T20 CRICKET ...NOKKA GAMERYouTube - 16 hours ago58:12IPL 2020 Live Commentary : KXIP vs RCB Live Match | IPL ...NN SportsYouTube - 19 hours ago14:38Are IPL jerseys are bit too boring? | MUTE MEESPNcricinfoYouTube - 1 day ago7:57IPL 2020 - Virat Kohli ,Ambati Rayudu Injury & 10 Big News ...MY Cricket ProductionYouTube - 2 hours agoPreviewPreview1:19IPL 202 | Players are not able to handle the humidity in Dubai ...NTV SportsYouTube - 6 hours agoPreviewPreview43:02IPL 2020:- Bengaluru VS Punjab|| RCB vs KXIP Live IPL 2020 ...Hindustan KhabarYouTube - 18 hours ago10:16IPL: Kings XI vs RCB highlights | Video | Watch TV ShowSky Sports - 14 hours agoLIVELIVE: Puthiya Thalaimurai Live News | Tamil News | IPL Live ...Puthiyathalaimurai TVYouTube - 9 hours ago(function(){ window.cVrhhd=function(b,e,q,f,h,k,r){if((b=document.getElementById(b))&&(0!=b.offsetWidth||0!=b.offsetHeight)){var l=b.querySelector("div"),m=l.querySelector("div"),c=0,g=l.scrollWidth-l.offsetWidth;if(0<e){var n=m.children;c=n[e].offsetLeft-n[0].offsetLeft;if(f){for(var p=c=0;p<e;++p)c+=n[p].offsetWidth;c=Math.min(g,c)}}c+=q;e=Math.min(f?g-c:c,g);l.scrollLeft=f&&(h||r)?c:f&&k?-c:e;var a=b.getElementsByTagName("g-left-button")[0],d=b.getElementsByTagName("g-right-button")[0];a&&d&&(h=/\btHT0l\b/,k=/\bpQXcHc\b/,a.className=a.className.replace(h,""),d.className=d.className.replace(h,""),0==e?a.className="pQXcHc "+a.className:a.className=a.className.replace(k,""),e==g?d.className="pQXcHc "+d.className:d.className=d.className.replace(k,""),0<=a.className.indexOf("SL0Gp")&&0==e&&e==g&&(m.style.paddingLeft="0px",m.style.paddingRight="0px",a.style.display="none",d.style.display="none",b.style.paddingLeft=f?"0px":"48px",b.style.paddingRight=f?"48px":"0px",b.style.textAlign=f?"left":"right",document.getElementById("fade_forward").style.display= "none",document.getElementById("fade_reverse").style.display="none"),setTimeout(function(){a.className+=" tHT0l";d.className+=" tHT0l"},50))}};}).call(this);(function(){var id='_ZLhtX8HQJZLw9AOGxoW4CQ112';var index=0;var offset=0;var is_rtl=false;var is_ie=false;var is_gecko=false;var is_edge=false;var init='cVrhhd';window[init](id,index,offset,is_rtl,is_ie,is_gecko,is_edge);})();View allWeb resultsIPL 2020: Pat Cummins in $3.1 million cricket disasterau.sports.yahoo.com › ipl-2020-pat-cummins-31-millio...au.sports.yahoo.com › ipl-2020-pat-cummins-31-millio...Cached1 day ago - Pat Cummins is the first player with 250+ batting strike rate and 15+ economy rate in the same IPL match. [Min: 12 balls batted & 12 balls ...IPL 2020: Time Table, Schedule, Points Table, Results | Times ...timesofindia.indiatimes.com › ... › Cricket Newstimesofindia.indiatimes.com › ... › Cricket NewsCached6 hours ago - Check IPL 2020 Schedule, Points Table, Results, Live Score, News and many more updates on The Times of India.ipl 2019 schedule time tablenames of ipl teams 2019cricket ipl match2018 ipl teamipl aaj ka matchmumbai indians newsPeople also search forStart seeing places you've beenTurn on Google Account settings to track places you visit.Turn on Location History to track places you visit.Turn on Web & App Activity to track places you visit.CancelOKLocal ResultsRating Any4.5and up4.0and up3.5and up3.0and up2.5and up2.0and upHours Any timeOpen nowOpen 24 hoursSundayMondayTuesdayWednesdayThursdayFridaySaturdayAny timeMidnight1:00 AM2:00 AM3:00 AM4:00 AM5:00 AM6:00 AM7:00 AM8:00 AM9:00 AM10:00 AM11:00 AMNoon1:00 PM2:00 PM3:00 PM4:00 PM5:00 PM6:00 PM7:00 PM8:00 PM9:00 PM10:00 PM11:00 PMIPL Photo Facial SpecialistNo reviews · Skin care clinicSan Jose, CA(408) 666-0618WebsiteDirectionsFremont Laser and Skin Care1.0 (2) · Skin care clinicFremont, CAClosed ⋅ Opens 9AM · (510) 792-1579WebsiteDirectionsStanford Cosmetic and Laser DermatologyNo reviews · Medical clinicRedwood City, CAClosed ⋅ Opens 8AM · (650) 725-5272Online careWebsiteDirectionsView allPeople also search forCricket leagues2018 Indian Premier L...2019 Indian Premier L...Internatio... Cricket CouncilPakistan Super LeagueICC Men's T20 World CupBig Bash LeagueSee moreFeedbackSearches related to iplipl 2019ipl tableipl teamsipl fixturesipl highlightsipl 2020ipl wikiipl loginPage Navigation12345678910Nexthtml:not(.zAoYTe) .kp-wholepage a{outline:0}#rhs .VjDLd.liYKde{border:0;padding-left:0;padding-right:0}#center_col .liYKde{width:654px}.kp-wholepage.HSryR{box-shadow:none;line-height:1.58}.I6TXqe{border:1px solid #dfe1e5;border-radius:8px;padding:0 0 16px 0}.rhscol .I6TXqe{border:1px solid #dfe1e5}#rhs .HSryR{margin:6px 0 0 1px}.SoydSe{padding-bottom:4px}.HSryR .Kot7x{margin:0}.HSryR .SoydSe{overflow:visible}.ky4hfd{display:none}.Jb0Zif.rhs-osrp .LMRCfc,.rhs-osrp .LMRCfc,.Hwkikb.LMRCfc{margin-top:6px}.rhs-osrp .cLjAic,.Hwkikb{border:1px solid #dfe1e5;border-radius:8px;margin-top:16px}.kp-wholepage-osrp .j6mBxc a,.kp-wholepage-osrp .j6mBxc a:active,.kp-wholepage-osrp .j6mBxc a:link,.kp-wholepage-osrp .j6mBxc a:visited{color:#757575;text-decoration:underline}.UDZeY{font-size:14px}.wf-b .vnLNtd.mnr-c{font-family:Roboto,arial,sans-serif}.vnLNtd.mnr-c,.wXlZre{margin:16px 0 0}.vnLNtd.mnr-c.B03h3d,.wXlZre.B03h3d{margin-top:0}.vnLNtd.mnr-c.dv1r4e,.wXlZre.dv1r4e{margin-bottom:36px}.ss6qqb .ptcLIOszQJu__wholepage-card:not(.B03h3d){border-top:1px solid rgba(0,0,0,.12)}.rhs-osrp .ptcLIOszQJu__wholepage-card:not(first-card).V14nKc{border:none;border-top:1px solid rgba(0,0,0,.12);border-radius:0}.HSryR .mod:not(.NFQFxe){padding-left:15px;padding-right:15px}.garHBe{color:#222;font-size:20px;line-height:1.3;position:relative}.garHBe a{color:#222}.xpdopen .Hhmu2e{overflow:inherit}.c2xzTb .iq-content-first .oHglmf,.c2xzTb .iq-content-first .xzPb7d{padding-top:0;padding-bottom:16px}.c2xzTb .kno-mrg,.ruTcId .kno-mrg{padding:0}.kno-mrg{position:relative;overflow:hidden}#rhs .kno-mrg{border-top-right-radius:8px}#rhs .kno-mrg:not(.kno-mrg-si){border-top-left-radius:8px}.kno-mrg .mod{display:inline}.eA0Zlc{vertical-align:top;display:inline-block;margin:0;position:relative}.eA0Zlc:not(.JX86yc){overflow:hidden}.eA0Zlc.PtaMgb{margin-right:1px;margin-bottom:1px;float:left}#rhs .eA0Zlc.PtaMgb{border-radius:4px}.ifM9O .GMCzAd{border-radius:8px;margin:16px}.fWhgmd{background-color:rgba(0,0,0,0.03);position:absolute;top:0;bottom:0;left:0;right:0}a.GvDr7c{align-items:center;background:rgba(0,0,0,.6);border-top-left-radius:4px;bottom:0;box-sizing:border-box;color:#fff;display:flex;font-size:13px;height:32px;padding-left:8px;padding-right:8px;position:absolute;right:0}#rhs .ss6qqb a.GvDr7c,.rhs-osrp a.GvDr7c{border-bottom-right-radius:4px;border-top-left-radius:0}a.GvDr7c .IGgq{margin-right:8px;margin-top:6px}a.GvDr7c:hover{background:rgba(0,0,0,.85)}.K20DDe{position:relative}#center_col .K20DDe.LtKgIf{min-height:88px}.a1vOw{padding:16px 0 0 0px}.SzZmKb .a1vOw{padding-left:16px}.BY2RHc{padding-right:24px}.HSryR .a1vOw.BY2RHc{padding:12px 0 12px 0}.glhbv{height:24px;width:24px;cursor:pointer}g-raised-button .FEIHRe{padding:0}.pa8yL{vertical-align:middle;padding:8px;height:24px;width:24px}.kno-ecr-pt{color:rgba(0,0,0,.87);line-height:1.2;margin-bottom:-3px;overflow:hidden;font-family:arial,sans-serif-light,sans-serif;display:inline;font-size:30px;font-weight:normal;position:relative;transform-origin:left top;transform-origin:left top;word-wrap:break-word}.wf-b .kno-ecr-pt{font-family:Roboto,arial,sans-serif}.Ftghae{padding-left:16px;padding-right:16px;margin-top:0}.qrShPb{margin:0}.qrShPb:not(.zbA8Me){font-weight:normal}#rhs .Ftghae{padding-left:15px;padding-right:15px}.Lj180d{padding-left:16px;padding-right:16px;padding-top:15px}#rhs .Lj180d{padding-left:15px;padding-right:15px}.wwUB2c{margin:4px 0;overflow:hidden;}.iirjIb{position:relative}.rhstc4 .o66ENe,.rhstc5 .o66ENe,.rhstc5 .CLchud{position:absolute;right:0;top:0}.rsir2d{float:right;margin-bottom:-4px;opacity:0.54}.rsir2d{color:#000}.wwUB2c{color:#70757a;font-family:arial,sans-serif;}.wf-b .wwUB2c{font-family:Roboto,arial,sans-serif}.GqKvT .wwUB2c{color:rgba(255,255,255,.7)}.rhstc4 .kno-ecr-pt.EaHP9c{font-size:24px;line-height:1.34}#rcnt a.B1uW2d:hover{text-decoration:underline}a.B1uW2d,.GGhx3c{display:block;text-decoration:none;padding:8px 0}.kp-wholepage a.B1uW2d{}.HSryR a.B1uW2d{border-bottom:1px solid rgba(0,0,0,.12);border-top:0;margin:0}.rhs-osrp a.B1uW2d,.Jb0Zif a.B1uW2d{border:1px solid #dfe1e5;border-radius:16px;color:#222;display:inline-flex;margin:0;padding:3px 12px}.rhs-osrp a.B1uW2d:hover,.Jb0Zif a.B1uW2d:hover{background:#fafafa}.JEPF1b a.B1uW2d,.JEPF1b .GGhx3c{padding-left:26px;padding-right:26px}a.B1uW2d{align-items:center;align-items:center;-webkit-box-align:center;display:-webkit-box;display:flex;display:flex}.rhs-osrp .psXvZ,.Jb0Zif .psXvZ{color:#4285f4;height:20px;margin-left:0;margin-right:8px;min-width:20px;padding:2px;width:20px}.psXvZ{color:#70757a;margin-left:15px;margin-right:24px;min-width:24px;vertical-align:middle}.x6YVx .kno-rdesc .qxF2Ld{color:#1a73e8;font-family:arial,sans-serif-medium,sans-serif;margin:-20px;padding:16px 20px 20px}.hb8SAc{overflow:hidden;margin:13px 0 13px;}.Jb0Zif .hb8SAc,.rhs-osrp .hb8SAc{line-height:1.58}.hb8SAc{color:#4d5156}.NJLBac{white-space:nowrap}.zloOqf{margin-top:7px}.rhs-osrp .zloOqf,#rhs .ss6qqb .zloOqf{line-height:1.58}.y8Jpof .zloOqf{font-size:14px;margin-top:2px}.fm06If .GqKvT .kno-fv{color:rgba(0,0,0,.87)}.y8Jpof .LrzXr{color:#222}.w8qArf{font-weight:bolder}.w8qArf .fl{color:#222 !important}.y8Jpof .w8qArf{font-weight:normal}.XJa8af{color:#1a0dab;font-size:11px}.XJa8af a:link,.XJa8af a:visited{color:#1a0dab;text-decoration:none}.XJa8af a:active,.XJa8af a:hover{color:#1a0dab;text-decoration:underline}.fhdOx{font-size:14px;padding:12px 0 12px 0}.QXvXw{border:1px solid #9e9e9e;display:inline-block;margin-right:16px;padding-top:8px;padding-bottom:8px;cursor:pointer;border-radius:18px}.QXvXw:hover{background-color:#fafafa}.QXvXw:focus{outline:none}.QXvXw img{height:20px;width:20px;float:left;margin-left:12px}.QXvXw span{line-height:20px;margin-left:8px;margin-right:16px}.Qs668{}.bToEQe{color:#3c4043;line-height:40px;float:left}.Ss6uIc{color:#3c4043;text-decoration:underline;line-height:40px;margin-left:6px;float:left}.Ss6uIc:hover{cursor:pointer}.vr1jJd{border-top:1px solid rgba(0,0,0,.12);margin-left:-16px;margin-right:-16px;padding-left:16px;padding-right:16px;margin-top:12px}.p2WJce{bottom:0;display:block;margin:auto 0;position:absolute !important;top:0}.BlOseb.SkGIjd .KkkQv,.k2Oeod.SkGIjd .S2C1T{background-image:url(data:image/png;base64,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);background-repeat:no-repeat;height:20px;width:12px}.BlOseb.SkGIjd .KkkQv{background-position:0 -26px;left:8px}.k2Oeod.SkGIjd .S2C1T{background-position:0 0;right:8px}.BlOseb.SkGIjd{left:0}.k2Oeod.SkGIjd{right:0}.BlOseb.SkGIjd{border-bottom-right-radius:36px;border-top-right-radius:36px;box-shadow:1px 0 2px rgba(0, 0, 0, 0.5);box-shadow:1px 0 2px rgba(0, 0, 0, 0.5)}.k2Oeod.SkGIjd{border-bottom-left-radius:36px;border-top-left-radius:36px;box-shadow:-1px 0 2px rgba(0, 0, 0, 0.5);box-shadow:-1px 0 2px rgba(0, 0, 0, 0.5)}g-raised-button{display:inline-block;margin:0 4px;position:relative}.zVvuGd.MRfBrb{overflow:hidden}.zVvuGd{padding-top:8px;white-space:nowrap}.xpdclose .lfNb6b,.xpdopen .hyaVx{margin-bottom:24px}.xpdclose .ecRggb .lfNb6b,.xpdopen .ecRggb .hyaVx{margin-bottom:0}.Ss2Faf a{text-decoration:none}.qLYAZd{margin-top:24px}.Ss2Faf a:hover{text-decoration:underline}.mod.NFQFxe .qLYAZd{margin-left:16px;margin-right:16px}#rhs .mod.NFQFxe .qLYAZd{margin-left:15px;margin-right:15px}.Ss2Faf{color:#222;line-height:1.3;font-size:20px}.Ss2Faf a{color:#222}.PfS8Ld{align-items:flex-end;display:flex}.VLkRKc{flex:1}.hKuTtf{font-size:14px}a.EbH0bb{color:#70757a;text-decoration:none}a.EbH0bb:hover{text-decoration:underline}.kno-vrt-t.MRfBrb{padding-left:13px}.k0bPBc:first-child,.kno-vrt-t.MRfBrb:first-child{padding-left:17px}.kno-vrt-t{display:inline-block;overflow:hidden;position:relative;text-align:left;vertical-align:top;}#rhs:not(.rhs-osrp) .kno-vrt-t{padding-left:16px}.xlBGCb,.oBrLN,.C9iYEe,.mytS8,.AAhd0c{}.oBrLN{display:block;white-space:normal;margin:3px 0 -1px;padding-bottom:1px;width:100%;}.kno-vrt-t{line-height:1.29;white-space:normal}.rhs-osrp .oBrLN,.rhs-osrp .xlBGCb{font-size:14px;line-height:18px}.rhs-osrp .oBrLN{color:rgba(0,0,0,.87);margin:0;padding-top:8px}.kno-vrt-t a{display:block;min-height:100%;}.XQ6p1d{border-radius:8px;overflow:hidden}.OOijTb{margin-top:10px;white-space:nowrap}.OOijTb .kno-vrt-t,#rhs .OOijTb .kno-vrt-t{display:inline-block;line-height:1.29;overflow:hidden;padding-left:16px;text-align:center;text-overflow:ellipsis;white-space:normal;width:72px}.OOijTb .kno-vrt-t:first-child,#rhs .OOijTb .kno-vrt-t:first-child{padding-left:0}.OOijTb .kno-vrt-t .thumb{display:block;margin:0 auto 5px;overflow:hidden}.Jb0Zif .OOijTb .kno-vrt-t,.Jb0Zif #rhs .OOijTb .kno-vrt-t{padding-left:8px;width:84px}.Jb0Zif .OOijTb .kno-vrt-t:first-child,.Jb0Zif #rhs .OOijTb .kno-vrt-t:first-child{padding-left:0}.Jb0Zif .OOijTb .kno-vrt-t .fl a{color:rgba(0,0,0,.87);font-size:12px;line-height:1.34;overflow:hidden;text-overflow:ellipsis}.Rlm17c{height:32px;margin:0 auto 5px;width:32px}.CtCigf{text-overflow:ellipsis;overflow:hidden}.YB4h9{color:#fff;background-color:#4285f4;padding:18px 12px;position:relative}.C85rO{font-size:20px}.Gtr0ne{font-size:13px;padding-top:10px}.Gtr0ne a{color:#fff;text-decoration:underline}.YB4h9 .Job8vb{padding:20px;position:absolute;right:0;top:0}.kno-ftr.rpBMYb{color:#70757a;display:flex;flex-wrap:wrap-reverse;font-size:12px;line-height:1.34;margin-left:0;margin-right:0;padding:4px 16px 0}.fhwVOd{padding-right:2em}a.Ui8XNb,.uquUgf a{color:inherit;display:block}.Tg0Ujf{margin:0 -15px;}.H73aad{background:#fff;border:1px solid #dadce0;border-radius:18px;display:inline-block;position:relative}.H73aad:hover{background:#fafafa}.LbNDAb{color:#4285f4;height:16px;left:12px;position:absolute;top:50%;transform:translate(0,-50%);width:16px}.jleFbf{color:#3c4043;display:inline-block;font-size:14px;line-height:1.58;padding:8px 16px 8px 36px}.uquUgf{flex:1;text-align:right}.NhRr3b{cursor:pointer}#rhs .kp-blk{line-height:1.58;margin:6px 0 0 2px;margin:6px 0 0 1px;border:1px solid #dfe1e5}#rhs .kp-blk .mod:not(.NFQFxe){padding-left:15px;padding-right:15px}#rhs .g-blk.VjDLd{border:0;padding:0}.nGydZ{padding-bottom:7px}.xXEKkb{color:#1a0dab !important}.k4DMHe{font-size:14px;line-height:1.430000}.k4DMHe .xXEKkb{font-size:16px;line-height:1.375}.y8Jpof{color:#000;overflow:hidden;text-decoration:none}.y8Jpof{padding:8px 15px}#rhs .y8Jpof.VjDLd{border:0}.k4DMHe{overflow:hidden}.cwUqwd{color:#000}.o3mT7{float:right}.izHQgf{overflow:hidden;max-height:4.3em;}.y8Jpof:hover{background:#f7f7f7;cursor:pointer}.k4DMHe{padding:0 10px 0 0 !important;min-height:48px}#rcnt .M3LVze:hover{text-decoration:none}Complementary Results(function(){var c4=1261;var c5=1349;var no5=false;(function(){ var a=document.body.offsetWidth,b="rhstc4";a>=c4&&(b=no5||a<c5?"rhstc4":"rhstc5");document.getElementById("rhs").className+=" "+b;}).call(this);})();ImagesMore imagesShareFacebookTwitterEmailClick to copy linkShare linkLink copiedIndian Premier LeagueCricket leagueiplt20.comDescriptionDescriptionThe Indian Premier League is a professional Twenty20 cricket league in India contested during March or April and May of every year by eight teams representing eight different cities in India. The league was founded by the Board of Control for Cricket in India in 2008. WikipediaNumber of teams: 8 Trending

      hi

    1. Filters: Manage Filters Sort by:Best matchMost recentResults by year1920Year 1925 - 1 itemsYear 1926 - 0 itemsYear 1927 - 0 itemsYear 1928 - 0 itemsYear 1929 - 0 items1930Year 1930 - 0 itemsYear 1931 - 0 itemsYear 1932 - 0 itemsYear 1933 - 0 itemsYear 1934 - 1 itemsYear 1935 - 0 itemsYear 1936 - 0 itemsYear 1937 - 0 itemsYear 1938 - 0 itemsYear 1939 - 0 items1940Year 1940 - 2 itemsYear 1941 - 0 itemsYear 1942 - 1 itemsYear 1943 - 0 itemsYear 1944 - 0 itemsYear 1945 - 3 itemsYear 1946 - 10 itemsYear 1947 - 13 itemsYear 1948 - 20 itemsYear 1949 - 17 items1950Year 1950 - 45 itemsYear 1951 - 86 itemsYear 1952 - 94 itemsYear 1953 - 82 itemsYear 1954 - 81 itemsYear 1955 - 71 itemsYear 1956 - 98 itemsYear 1957 - 125 itemsYear 1958 - 160 itemsYear 1959 - 147 items1960Year 1960 - 124 itemsYear 1961 - 131 itemsYear 1962 - 176 itemsYear 1963 - 260 itemsYear 1964 - 398 itemsYear 1965 - 245 itemsYear 1966 - 221 itemsYear 1967 - 278 itemsYear 1968 - 283 itemsYear 1969 - 325 items1970Year 1970 - 314 itemsYear 1971 - 341 itemsYear 1972 - 352 itemsYear 1973 - 300 itemsYear 1974 - 323 itemsYear 1975 - 329 itemsYear 1976 - 354 itemsYear 1977 - 332 itemsYear 1978 - 329 itemsYear 1979 - 381 items1980Year 1980 - 435 itemsYear 1981 - 426 itemsYear 1982 - 440 itemsYear 1983 - 502 itemsYear 1984 - 571 itemsYear 1985 - 569 itemsYear 1986 - 590 itemsYear 1987 - 576 itemsYear 1988 - 640 itemsYear 1989 - 758 items1990Year 1990 - 707 itemsYear 1991 - 777 itemsYear 1992 - 726 itemsYear 1993 - 787 itemsYear 1994 - 784 itemsYear 1995 - 887 itemsYear 1996 - 881 itemsYear 1997 - 934 itemsYear 1998 - 999 itemsYear 1999 - 965 items2000Year 2000 - 976 itemsYear 2001 - 1,098 itemsYear 2002 - 1,060 itemsYear 2003 - 1,112 itemsYear 2004 - 1,321 itemsYear 2005 - 1,491 itemsYear 2006 - 1,555 itemsYear 2007 - 1,672 itemsYear 2008 - 1,731 itemsYear 2009 - 1,884 items2010Year 2010 - 2,082 itemsYear 2011 - 2,151 itemsYear 2012 - 2,392 itemsYear 2013 - 2,699 itemsYear 2014 - 2,937 itemsYear 2015 - 2,951 itemsYear 2016 - 3,265 itemsYear 2017 - 3,258 itemsYear 2018 - 3,335 itemsYear 2019 - 2,770 itemsScroll right...Scroll left...Download CSVRelated searchespulmonary hypertension newbornchronic thromboembolic pulmonary hypertensionpulmonary hypertension reviewpediatric pulmonary hypertensionpulmonary hypertension dogPMC Images search for pulmonary hypertensionFigureKaplan-Meier Estimates of Survival for Patients With Sickle Cell Disease by Pulmonary Hypertension StatusA, The age-adjusted hazard ratio (AHR) was 3.43 (95% CI, 1.02–11.55; P = .047) for the comparison between patients with pulmonary hypertension documented by right heart catheterization (RHC) and those who did not have pulmonary hypertension documented by RHC; 2.14 (95% CI, 1.25–3.67; P = .006) for patients with pulmonary hypertension vs those who did not undergo RHC (uncatheterized); and 0.62 (95% CI, 0.19–2.03; P = .43) for patients without pulmonary hypertension vs those who did not undergo RHC (uncatheterized). B, The HR was 3.35 (95% CI, 1.01–11.31; P = .04) for the comparison between patients with pulmonary hypertension documented by RHC and those who did not have pulmonary hypertension documented by RHC; 1.73 (95% CI, 1.02–2.93; P = .04) for patients with pulmonary hypertension vs those who did not undergo RHC (uncatheterized); and 0.49 (95% CI, 0.15–1.59; P = .23) for patients without pulmonary hypertension vs those who did not undergo RHC (uncatheterized).Mortality in Adults With Sickle Cell Disease and Pulmonary HypertensionJAMA. ;307(12):1254-1256.Figure 3Kaplan–Meier survival estimates. (A) Each subtype of PHT. (B) Clinical severity of PASP. PAH, pulmonary arterial hypertension; Left heart disease, pulmonary hypertension secondary to left heart disease; Respiratory disease, respiratory-associated pulmonary hypertension; Chronic thromboembolic, chronic thromboembolic pulmonary hypertension; Miscellaneous, miscellaneous pulmonary hypertension; Unknown cause, pulmonary hypertension of unknown cause. Mortality for mild, moderate and severe pulmonary hypertension for all causes of pulmonary hypertension during the period of follow-up. p<0.001 for difference between reference range mild (41–50 mm Hg) compared with moderate or severe. PASP, pulmonary artery systolic pressure.Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohortHeart. 2012 Dec;98(24):1805-1811.Fig 3Kaplan-Meier curves of survival for patients with pulmonary arterial hypertension and patients with pulmonary hypertension due to left heart disease.In the panel a) patients with pulmonary hypertension due to left heart disease are all pooled together, while in the panel b) they are subdivided in three groups according to the diastolic pressure gradient and pulmonary vascular resistance. CpcPH = combined post- and pre-capillary pulmonary hypertension; Interm = intermediate PH-LHD; IpcPH = isolated post-capillary pulmonary hypertension; PAH = pulmonary arterial hypertension; PH-LHD = pulmonary hypertension due to left heart disease.Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary componentPLoS One. 2018;13(6):e0199164.Figure 1Schematic representations of pulmonary hypertension. (A) Schematic cross-sectional representation of a normal pulmonary arteriole and a pulmonary arteriole affected by pulmonary hypertension. (Adapted from Pugliese et al.) (B) Schematic representation of site of initiation of elevated pulmonary arterial pressure of precapillary pulmonary hypertension, postcapillary pulmonary hypertension, and CTEPH. L.V., left ventricle; PH, pulmonary hypertension; R.A., right atrium; R.V., right ventricle.Pathophysiology and treatment of pulmonary hypertension in sickle cell diseaseBlood. 2016 Feb 18;127(7):820-828.See more (10906)...Titles with your search termsMonocrotaline-induced pulmonary arterial hypertension: Time-course of injury and comparative evaluation of macitentan and Y-27632, a Rho kinase inhibitor.[Eur J Pharmacol. 2019]Monocrotaline-induced pulmonary arterial hypertension: Time-course of injury and comparative evaluation of macitentan and Y-27632, a Rho kinase inhibitor.Novelli D, Fumagalli F, Staszewsky L, Ristagno G, Olivari D, Masson S, De Giorgio D, Ceriani S, Affatato R, De Logu F, et al. Eur J Pharmacol. 2019 Nov 4; :172777. Epub 2019 Nov 4.Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.[Lung. 2019]Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.Menon AA, Sahay S, Braverman LE, Farber HW. Lung. 2019 Nov 6; . Epub 2019 Nov 6.Congenital heart disease, pulmonary arterial hypertension and the UK's Drivers and Vehicle Licensing Agency: controversial new guidance.[Pulm Circ. 2019]Congenital heart disease, pulmonary arterial hypertension and the UK's Drivers and Vehicle Licensing Agency: controversial new guidance.Constantine A, Tulloh R, Condliffe R, Clift P, Dimopoulos K. Pulm Circ. 2019 Oct-Dec; 9(4):2045894019882627. Epub 2019 Oct 30.See more...Find related dataDatabase: SelectAssemblyBioProjectBioSampleBioSystemsBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesHomoloGeneMedGenNucleotideOMIMPMCPopSetProbeProteinProtein ClustersPubChem BioAssayPubChem CompoundPubChem SubstancePubMedSNPSRAStructureTaxonomyOption: Find itemsBest match search information MeSH Terms: hypertension, pulmonary See more... Additional termshypertension; pulmonary hypertension; pulmonary Recent ActivityClearTurn OffTurn Onpulmonary hypertension (63108)PubMedpulmonar hypertension (811)PubMedHypertension, PulmonaryHypertension, PulmonaryIncreased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.<br/>MeSHpulmonar hypertension, adult (2)MeSHpulmonar arterial hypertension (5)MeSHYour browsing activity is empty.Activity recording is turned off.Turn recording back onSee more... You are here: NCBI > Literature > PubMed Support Center <img alt="" src="/stat?jsdisabled=true&amp;ncbi_app=entrez&amp;ncbi_db=pubmed&amp;ncbi_pdid=docsum&amp;ncbi_phid=CE889714DC5ABEA10000000006FA03F6" />

      Filtros para hacer una búsqueda más depurada

    1. much dangerous prejudice

      In this section of “Novum Organum”, Francis Bacon attributes the faultiness of the natural sciences in large part to the phenomenon known today as confirmation bias. The eagerness of man to ascribe an order or regularity to nature results in misleading and sometimes categorically false understandings of the natural world. Bacon laments this oversight seen in the natural sciences and seeks to restore the integrity of the field. Accordingly, Bacon draws attention to the human tendency to fall victim to confirmation bias.

      Confirmation bias is a psychological phenomenon that leads people to accept bits of information and evidence that support the beliefs they already hold, while ignoring information and evidence to the contrary. This mental error is problematic as it causes people to ignore or deny issues that may disrupt their way of life, for example Republicans denying climate change. It also may result in false attributions in regard to the causality of events or phenomena. As Mark Twain famously said: “It ain’t what you don’t know that gets you in trouble. It’s what you know for sure that just ain’t so.” In this selection, Francis Bacon warns that this tendency causes a domino effect where more falsities arise, predicated upon that initial bit of misinformation. He asserts that instead, we should seek to disprove what we already believe to be true, and through that method we might systematically identify and root out false assumptions, discovering valuable knowledge as a result.

      Kenrick, Douglas T., Adam B. Cohen, Steven L. Neuberg, and Robert B. Cialdini. “The Science of Antiscience Thinking.” Scientific American 319, no. 1 (2018): 36–41. https://doi.org/10.1038/scientificamerican0718-36.

    1. Author Response

      Summary:

      As you will see the reviewers agreed that the premise behind this manuscript is important and timely both in the context of basic auditory science and for informing technology. However, they raised largely consistent concerns about the generalizability of your observations to other auditory stimuli and to more naturalistic listening conditions.

      We appreciate the reviewers’ positive assessment underpinning the significance and timeliness of our present research endeavours. We assume generalizability of our findings to more naturalistic listening conditions because the proposed model framework successfully explained the outcomes of experiments that were conducted under listening conditions differing in reverberation and source stimuli. Those differences, however, only occurred across but not within experiments and thus were not considered in the model explicitly. The set of experiments and relevant cues was chosen such that the investigation of decision strategies for the combination or selection of cues in the context of perceptual externalization could be conducted on a limited but still divers set of cues. The proposed framework allows to easily extend the set of cues. For example, in another work (see Li et al., in press), we successfully modelled the impact of situational changes of the amount of reverberation on externalization perception by extending the framework to reverberation-related cues. This further strengthens our assumption that our findings can be generalized. Nevertheless, we understand that more direct evidence for this generalizability would further increase the confidence in the conclusions we draw.

      Reviewer #1:

      I agree with the authors that the question at the basis of this work is timely and important both from the point of view of understanding auditory perception and for informing technology. However I am not convinced that the findings here will necessarily generalize to other stimuli/listening situations.

      I think the biggest limiting factor here is that the primary data on which the modelling is based are drawn from many different studies which used different stimuli, different tasks, different presentation environments and different equipment). I can see how testing the model on existing data is an important first step, but I would think that a critical next step is to form a set of (contrasting) predictions to be tested on a single stimulus set, within a single group of participants, as a way of confirming model validity. In this experiment I would also avoid using static non-reverberant environments since we know that these factors greatly affect spatial perception.

      We do not follow the reasoning why the above mentioned diversity of experimental paradigms is a limitation. On the contrary, in our opinion, the diversity of the considered experiments demonstrates robustness of our findings for a variety of experimental procedures. We agree that an additional validation experiment would further strengthen our study, but we question its necessity and still believe that the present modelling work is extensive and compelling enough to warrant publication.

      Other comments:

      1) The title greatly overstates the main findings, it would be toned down.

      In the title, we aimed at describing the research topic in general terms accessible to a broad readership. We take your comment as an advice to state the main findings instead.

      2) Intro, line 30-33 this statement is misleading. As written it appears to claim temporal aspects of auditory perception are based on short term regularity, whilst spatial perception is based on long term effects. This is not correct see e,g Ulanovsky 2004.

      Agreed. We will remove the sentence or rephrase it in more general terms because the misleading distinction is actually irrelevant to our study.

      3) As a reader not highly familiar with the auditory spatial processing literature I found the results section very dense and hard to follow. If you are targeting a general audience it is important to clarify concepts, avoid using abbreviations where possible etc.

      Thank you for your advice. We will aim to increase the level of abstraction within the results section.

      4) When discussing the various decision strategies which you tested, consider explaining how they might be implemented by the auditory system, at which stage of processing etc.

      Our study approached the problem from an algorithmic point of view and did not touch upon the more detailed level of neural implementation. While the cue processing has a clear neurophysiological basis in the subcortical layers of the auditory system, we will include some speculation about the involved cortical networks in a revised version of the manuscript.

      5) It is very difficult to evaluate your results without more information about the stimuli and studies from which they were taken. Whilst you do provide references, I think the paper would be much clearer if you provide a more complete description of the stimuli (even in table form; paradigms etc).

      We appreciate your advice and will provide more details about the simulated experiments in a table.

      Reviewer #2:

      The current study compares four decision rules, factoring in seven potential acoustic cues, for predicting perceived sound externalization for single-source binaural sound with stationary interaural cues. Test stimuli included a harmonic vowel complex, noise and speech. Results show that monaural and binaural cues shape externalization. However, how listeners weighted these cues varied across the tested conditions. The authors consider the fact that some of these cues covary acoustically, by additionally testing their model on subsets of two of these cues only. No single externalization cue emerged as a clear predictor for perceived externalization. However, overall, a static cue weighting strategy tended to outperform dynamic cue weighting for predicting externalization.

      Major concerns dampen enthusiasm for the current work.

      1) It is unclear what neural mechanism is being tested. A premise of the current approach is that perceived sound externalization is primarily driven by acoustic cues. However, we know this not to be true. Context matters. As pointed out by the authors (l370-372), when listening to sounds processed with head related transfer functions (HRTFs) over headphones, listeners can externalize sound better when the context of the test room matches the room where HRTFs were recorded (Werner and Klein 2014).

      Sound externalization is an auditory percept and as such primarily driven by acoustic cues. How those cues are used for perceptual inference is certainly context dependent. From the present study, we conclude that the auditory system evaluates deviations from a small set of expected acoustic cues in a fixed weighted (and not selective) manner. We further explain that these expectations, which are represented as templates in the model, must be adaptive to the context. This is well in line with your example of room divergence (Werner and Klein, 2004): listeners are thought to establish expectations about reverberation-related acoustic cues and evaluate incoming sensory information against those expectations with a fixed weighting between cues. If expectations are not met (i.e., acoustic cues deviate from their templates), perceptual externalization degrades.

      2) Most external sounds are neither anechoic nor stationary. Therefore, any neural decision metric on externalization must have been shaped by lifelong experience with dynamic, reverberant cues for interpreting externalization. The current work mostly models stationary single source sound that was either anechoic or mildly reverberant, providing pristine spatial cues. I do not follow the author's point that this would not matter (l498-502): "While the constant reverberation and visual information may or may not have stabilized auditory externalization, they certainly did not prevent the tested signal modifications to be effective within the tested condition. In our study, we thus assumed that such differences in experimental procedures do not modulate our effects of interest." That is an untested assumption.

      Others showed that the type of spectral manipulations we considered remain effective also if reverberation is present (e.g. Hassager et al., 2013) and if listeners are exposed to dynamic cues by moving their heads or the sound source (Brimijoin et al., 2013). We used the above-mentioned argument in order to motivate why we ignored certain differences across studies in the first place and the high explanatory power obtained with the proposed model framework suggests that this simplification was adequate. We agree that the above-mentioned sentence can be easily misunderstood and we will modify it by including the explanation stated here.

      3) Many of the current test stimuli are perceived as ambiguous - providing 50% externalization ratings - and thus do not provide a sensitive test of brain mechanisms of sound externalization.

      The field mostly agrees that auditory externalization is not a binary phenomenon but a matter of degree – we very recently published a review article that discusses this issue in detail (Best, et al., 2020). Hence, the experimental outcomes, denoted as externalization scores, ranging from 0 to 1 indicate the degree of externalization that is considered to mediate perceived egocentric distance. The externalization scores do not indicate the level of perceptual ambiguity.

      We will include this explanation in the manuscript in order to prevent further misunderstanding.

      4) Reverberation enhances perceived externalization, but this cannot be predicted by any of the tested decision metrics which only consider stationary monaural or binaural cues.

      True, there are also other cues potentially affecting the degree of auditory externalization. Reverberation-related acoustic cues are one of them. The main purpose of our study was to identify the basic functional mechanisms that integrates or selects between various cues – the purpose was not the identification of all possible cues that may affect auditory externalization. Thus, we chose a set of experiments that can be narrowed down a priori, particularly allowing to ignore reverberation-related cues.

      For the effect of reverberation-related cues, we point interested readers to another modelling study (Li et al., in press) that we conducted in parallel, in which we applied the here proposed framework also to reverberation-related cues and obtained good predictions.

      On balance, this reviewer is unconvinced that the current work will generalize to realistic dynamic and reverberant conditions.

      We agree with the reviewer that our study does not address dynamic and variable reverberant conditions. It was by-design limited to static conditions with fixed reverberation because we had no reason to believe that the targeted decision strategies applied to combine or select cues would be fundamentally different in more complex conditions.

      S. Werner and F. Klein, "Influence of Context Dependent Quality Parameters on the Perception of Externalization and Direction of an Auditory Event," presented at the AES 55th International Conference: Spatial Audio (2014 Aug.), conference paper 6-4.

      Reviewer #3:

      The manuscript "Decision making in auditory externalization perception" aims to identify cues that create/hinder an auditory externalization percept by using a template-based modeling approach. The approach as well as the findings are very interesting, and the study is thoroughly conducted. However, the manuscript adds little new knowledge to the field. Furthermore, a critical discussion is missing. The authors use a template-based model, but do not discuss the possible problems with such an approach. Particularly as each condition uses another model fit. This potentially allows the model to use cues that the auditory system cannot or does not consider. Nevertheless, the approach can still teach us which cues are potentially important for auditory externalization.

      1) The title seems inappropriate as the main work seems to be on the identification and combination of cues for externalization but not on the decision making.

      In combination with Reviewer #1’s first comment, we understand that the title could have been more specific. We will change the title accordingly.

      2) The model needs a more detailed explanation in the introduction. Otherwise the result section is not understandable without consulting the methods section.

      We will carefully re-evaluate which methodological details are necessary to understand the results section on a more abstract level.

      3) Add a Discussion on template-based models and fitting conditions. The risk of mathematical inspired models is that features are exploited that the auditory system cannot access. A more sophisticated front-end than a gammatone filterbank might reduce this risk. Alternatively, the use of physiologically inspired front-ends as in Scheidiger et al. (2018) might be interesting to consider. Nevertheless, I acknowledge that some of the features used in this study are backed by physiological and psychoacoustical studies.

      We agree with the concern behind the use of efficient functional approximations of the auditory periphery. Interestingly, however, we are very confident that this particular approximation does not provide spurious cues, especially in the context of monaural spectral shapes, because we did cross-validate the effectiveness of those cues with a physiologically more accurate model (Zilany et al., 2014) in previous work (Baumgartner et al., 2016).

      We will incorporate a corresponding explanation in the manuscript.

      4) It is known that the monaural spectral shape is important for externalization, for example from the studies that you have used. Thus, I partly question the novelty of the findings.

      We partly agree. It has also been suggested that interaural spectral cues are important for externalization perception. Further, it is also known that other cues contribute (e.g., reverberation-related cues as already discussed in response to the comments of Reviewer #2). Now, which cues contribute to which degree and how are they integrated? This is the main research question behind our study, with the ultimate goal to better understand the mechanisms of cue integration in the context of a perceptual inference task.

      5) I am not too familiar with template based models but I wonder if there is a problem if you use your models to fit and test with the same datasets?

      Cross-validation (i.e., using separate data sets for fitting/training, validating, and testing) is particularly important for complex models that allow overfitting. Such models can often be very closely fit to comparably small sets of data and thus the goodness of fit is not discriminative between those models. Here, in contrast, we compared the goodness of fit for models that contained a rather small and equal number of model parameters and this goodness of fit did strongly differ across models and was therefore informative for model selection in itself. If we separated the data sets, we would need to jointly assess the differences in initial model fits (to training data) together with the differences in predictive power (for testing data).

      References:

      Baumgartner, R., Majdak, P., & Laback, B. (2016). Modeling the effects of sensorineural hearing loss on sound localization in the median plane. Trends in Hearing, 20, 2331216516662003.

      Best, V., Baumgartner, R., Lavandier, M., Majdak, P., & Kopčo, N. (2020). Sound Externalization: A Review of Recent Research. Trends in Hearing, 24, 2331216520948390.

      Brimijoin, W. O., Boyd, A. W., & Akeroyd, M. A. (2013). The contribution of head movement to the externalization and internalization of sounds. PloS one, 8(12), e83068.

      Li, S., Baumgartner, R., & Peissig, J. (in press). Modeling perceived externalization of a static, lateral sound image. Acta Acustica.

      Zilany, M. S., Bruce, I. C., & Carney, L. H. (2014). Updated parameters and expanded simulation options for a model of the auditory periphery. The Journal of the Acoustical Society of America, 135(1), 283-286.

    1. Hennessy, E. A., Acabchuk, R., Arnold, P. A., Dunn, A. G., Foo, Y. Z., Johnson, B. T., Geange, S. R., Haddaway, N. R., Nakagawa, S., Mapanga, W., Mengersen, K., Page, M. J., Sánchez-Tójar, A., Welch, V., & McGuinness, L. A. (2020). Ensuring Prevention Science Research is Synthesis-Ready for Immediate and Lasting Scientific Impact [Preprint]. MetaArXiv. https://doi.org/10.31222/osf.io/ptg9j

    1. Author Response

      We thank the editors for considering our manuscript for publication in eLife and the reviewers for their work. However, we would like to discuss several of their comments.

      The key issue seems to be a lack of novelty of our work, which is not correct in our opinion.

      We would like to quickly reiterate why we think that our findings are novel and have very broad implications.

      The importance of polygenic adaptation is becoming increasingly clear. Unfortunately, it is widely assumed that polygenic adaptation is very difficult, if not impossible, to study in natural populations, because the associated allele frequency shifts are too small to be experimentally characterized (Pritchard et al., 2010). Hence, typically the collective response of many loci are considered, which frequently results in wrong results due to population stratification (Berg et al., 2019; Sohail et al., 2019).

      Therefore, we have used experimental evolution to characterize polygenic adaptation. Experimental evolution is widely recognized as a powerful tool because of the possibility to replicate experiments. Here, we expand the power of experimental evolution by an hitherto unrecognized aspect: the impact of linkage disequilibrium - we demonstrate that two founder populations with different levels of linkage disequilibrium (LD) result in entirely different selection responses. The consequence of different LD structures is shown by our observation that the same population (i.e. identical LD structure) evolving in two different environments shows the same selection response, but a different population with different LD structure in the same environment shows different selection responses.

      This result has important implications for all studies of polygenic adaptation in natural populations because LD is not accounted for in studies of polygenic adaptation, but like in our study, haplotype blocks with multiple loci could result in a strongly selected allele. Hence, LD will determine the likelihood of this to occur. Furthermore, accounting for linkage provides the opportunity to study polygenic adaptation also in natural populations - a substantial change to the current testing paradigms.

      The second key result of our study is that we demonstrate that selection in hot and cold environments does not fit the simple model of polygenic adaptation, where the same set of loci is responding in different directions, when opposing selection regimes are applied. As pointed out by reviewer #2, this is particularly important as it shows that current models of polygenic adaptation are not well-suited to understand adaptation imposed by contrasting ecological factors. We show that there is almost no overlap between the haplotype blocks selected in the hot and cold environment. Most importantly, this is not a matter of power as we show that the blocks responding in one selection regime are not changing their frequency in the opposite direction in the other selection regime. We anticipate that this insight will have a profound impact on theoretical models of polygenic adaptation. Furthermore, as we studied temperature adaptation, our results will have also important consequences for the battery of ongoing studies aiming to link selection signatures to response to climate change.

      In brief, we think that very minor clarifications in our manuscript can solve the technical issues identified by the reviewers and will provide a clearer picture about the general implications of our findings.

      A detailed response to the comments of the reviewers is given below.

      Reviewer #1:

      Otte et al. used an evolve and re-sequence strategy to explore "the genetic architecture of adaptive phenotypes". The authors previously found different genetic architectures across different founder populations evolving in a common hot environment. The authors chose one of these founder populations for replicated experimental evolution (5 replicate populations) in a cold environment for 50 generations. The authors were surprised to discover the same number of loci evolve under strong selection between the hot-evolved and cold-evolved replicate populations, though the 20-ish loci are largely non-overlapping. The distribution of selection coefficients was also similar. They interpret this commonality as evidence that the founder population history has a larger effect on adaptive architecture than the selection regime.

      The study demonstrates a comprehensive effort to discover the number of genome regions and distribution of selection coefficients that emerge from a highly controlled experimental evolution project. The experienced team applies a sophisticated toolkit to this powerful experimental design - a toolkit that grows ever more sophisticated with each new experimental run that they perform. However, the authors set me up to learn why such different adaptive architectures emerge from different founder populations. Ultimately, the researchers acknowledge that they "cannot pinpoint the cause for the differences in the inferred adaptive architecture..."

      Here, the reviewer correctly identified one of the main new questions that arose from the new experiment we performed in this study. In a large part of the discussion and the associated analyses we are providing answers to this question, i.e. possible alternative explanations for the different observed architectures in the Portugal vs. the Florida population. We can indeed not pinpoint "the" cause for the differences that the reviewer seems to request here as a definite answer, but we favour one of the explanations that has not yet been discussed in literature previously (LD).

      Some results simply recapitulated the previous Portugal E&R study and other results recapitulated a D. melanogaster E&R study.

      This statement about "some results" is ignoring the main new experiment of this study, which is the Portugal population evolving in a cold temperature. For this, we carried out a new selection experiment in a new environment, which finds different selection targets than the previously published experiments. This new experiment therefore does not recapitulate the previous results. We then compare this new experiment to a previous one, and this comparison raises a set of new questions that we address in this manuscript. Only for the purpose of making that comparison, we indeed "simply recapitulated" "some results" of the previous study. The statement is therefore misleading in the way it is put here. Furthermore, the D. melanogaster study is also not recapitulated: in that study, it was not possible to identify selected haplotypes. The D. melanogaster study was therefore unable to determine how many selection targets were shared between the hot and cold selection regimes. The identification of selected haplotypes was a major improvement in this study, which made it possible only now to determine how many targets are shared and to evaluate whether selection targets behave as predicted by the trait optimum model.

      I did not find the "common adaptive architecture" across different selection regimes to be a particularly compelling discovery of sufficiently broad interest.

      This is a very subjective opinion and it would be good if the reviewer had explained why this is no interesting discovery to her/him. We feel that this statement simply reflects that the reviewer does not fully appreciate the complexity of polygenic adaptation. We would like to point out again, that this result has important implications for the interpretation of selection signatures in natural populations.

      Other concerns and questions can be found below:

      Major concerns:

      1) Pg. 4: It is my understanding that the power of multiple populations from a single founder evolving in parallel allows for more rigorous identification of loci targeted by selection. I found it surprising to discover that if a lack of replication emerges from an experimental evolution study, this outcome is interpreted as "genetic redundancy." First, genetic redundancy has a precise definition in genetics that muddles the author's meaning. And second this interpretation seems rather post-hoc.

      This statement shows that the reviewer is disregarding the work of Barghi et al (2019, PLoS Biology) and the definition of redundancy in the context of polygenic adaptation as discussed by Laruson et al. (2020) or Barghi et al 2020 (Nature Reviews Genetics). In any case, this is a semantic issue and should not be considered as a major issue with our manuscript.

      2) To "shed more light on the different selection responses" is a weak motivation. The introduction sets me up to understand why selection responses are so different but no major insights into the "why" emerge from the cold-adaptation experiment.

      We modestly disagree - we clearly discuss different explanations of “why” and favor one of them (LD)

      3) More explanation of figure 1 in the main text is needed. Does each point correspond to a SNP that consistently changes across all five populations? Or is this the union?

      The reviewer does not seem to be familiar with the statistical analyses that have been used in our study in the same way as it is common practice in the field. Despite the common use of this test, we still provided a detailed explanation in M&M and explicitly mentioned the test in the figure legend. But this can easily be detailed even further and should not be a major issue with this manuscript.

      4) Line 210: How did the researchers define "stress" and determine that the degree of stress is equivalent across two temperature regimes? The absence of these data undermine the potency of the comparison.

      It is not clear why the reviewer requires a more elaborate definition of temperature stress - the concept of extreme temperatures imposing stress is well established and we cite the relevant literature for Drosophila in the text. Furthermore, it is not apparent why the reviewer requests the degree of stress to be equivalent between the two temperature regimes.

      5) How can the authors be sure that the only difference between the hot and cold populations was temperature? Was competition/population size/etc held constant? Might the lack of overlap between hot and cold adapted loci stem from one such regime selecting for a different phenotype? (i.e., not temperature tolerance)

      As clearly stated in M&M, the culture conditions were the same with the exception of temperature.

      6) Line 237: The authors assert that most alleles show a temperature-specific response - a discovery with precedent in the literature, including from this team of researchers. The authors attribute the absence of common loci between temperature regimes to the high number of generations (50) compared to the number across seasons cited in Bergland et al. The researcher could easily look for common targets at earlier time points of experimental evolution to test this idea.

      This is an interesting suggestion, but the reviewer fails to explain why the analysis of early generations should be more informative than the analysis of later generations. Several studies have already documented the opposite.

      7) Line 292-293: This section reads as disingenuous - the researchers could have explored overlap between Portugal and Florida founders using only the selected loci coordinates and look for non-random overlap using simulations/resampling tests.

      The reviewer seems to assume that we could easily apply the same test for overlap that we used for the hot vs. cold comparison within the Portugal population to the Portugal hot vs. Florida hot comparison. But this is not feasible, and we clearly explain why the comparison of selected haplotype blocks between different founder populations is not helpful (low LD results in different haplotype blocks - even with the same target)

      8) Discussion: The speculation about why such different architectures emerged across Portugal and Florida was diluted by the absence of initial fitness estimation upon subjection to a cold environment (which would have offered evidence for different initial "optima" across founder populations) as well as the change in fitness from generation 0 to generation 50.

      It is not apparent why the reviewer requests a fitness estimate at the cold environment. Our analysis only included a single population in the cold environment. Hence, the only informative comparison is the one in the hot environment which has been done for both populations and is referenced in the manuscript.

      9) The simulations and corresponding discussion would make for an interesting review/opinion piece but not as new results for this manuscript.

      Unlike the reviewer, we think that a good discussion puts the results into perspective with different hypotheses on how to explain it and link this to the current literature.

      Minor Comments:

      1) Pg. 3. The recurrent citation of Barghi et al. in the Introduction undermined the reader's impression that fundamental questions are being addressed in this article.

      Maybe it escaped the reviewer’s attention that we cited three different Barghi et al. papers and only one reports experimental data (cited only once), while the others are required to describe the theoretical framework, including the concept of "redundancy" which the reviewer misunderstood. New fundamental questions in this current manuscript are addressed using the Portugal population, which was selected in a cold temperature regime (not hot-evolved Florida, which was the topic of Barghi et al. 2019).

      2) Lines 33-39: The argument that parallel signatures of selection across distinct natural populations are insufficient to address the polygenic basis of adaptive phenotypes, and so comparatively more contrived E&R studies are required, was unconvincing.

      Unfortunately, the reviewer does not provide support for this strong statement. In fact, we find the statement of “contrived E&R studies” not as objective as we would have liked to see in a scientific discourse.

      3) Line 158: Confusing. Should "among" actually be "within"?

      The reviewer is not right - the correct wording is "among" not within: multiple different haplotypes can carry the actual target of selection, and they can differ by additional variants which themselves are not selected for. Multiple haplotypes with the selection target are also experiencing more pronounced frequency changes than expected under neutrality. The correlation of their allele frequency trajectories depends, however, on the extent that hitchhiking SNPs are shared among these haplotypes. To account for this, we used a less stringent correlation cutoff.

      4) Line 486: I believe that the authors would be hard-pressed to find in the literature a paper declaring that "single population...[is] sufficient to understand the genetic basis of adaptive traits".

      In fact, many selection tests are targeting only a single population and most studies only apply them to a single population.

      Reviewer #2:

      This reviewer mainly asks us to discuss some of his/her ideas - this can be done, but since reviewer#1 felt already that there is too much discussion in our manuscript this is a bit of a mixed message.

      Overall Review: This is another commendable study from the Schloterer lab that features next generation genome-wide sequencing of multiple evolving populations. It compares results obtained with two different selection regimes, one hot and one cold, and two different founding populations of Drosophila simulans, one from Portugal and one from Florida. The results reveal a lack of consistency among selection regimes and founding populations. Temperature-dependent adaptation is shown to be "local" or "contingent," rather than globally consistent. My chief recommendations concern the experimental and theoretical contexts within which this study should be interpreted.

      Major points:

      1) I do not require any additional data collection or statistical revision. My comments are organized in terms of experimental paradigm (A) and theoretical significance (B).

      A.

      2) The typical paradigm for experimental evolution in this and many other labs is the use of hybrid populations created from isofemale lines. This method for founding experimental populations can be expected to generate some degree of random "historicity" as the isofemale lines approach fixation of specific genotypes with high stochasticity. Then there are further stochastic and historical effects which arise when such lines are hybridized. The strengths and limitations of this paradigm should be addressed. Most importantly, such stochastic historical effects might be the source of the discrepancy between the replicate lines derived from Portugal and Florida.

      We would like to emphasize that we were using freshly established isofemale lines kept in the laboratory for at most 10 generations, as stated in the M&M section.

      3) As the authors themselves point out, there is a comparative difficulty arising from the different scales of replication used for the Florida versus Portugal experiments.

      The reviewer is correct, and since we were aware of this, we performed statistical tests to account for this.

      A further question for large-scale experimentation is whether a larger and uniform level of replication might produce more similar results, such as 20 evolving populations from each source. Or indeed, three sets of ten evolving populations from three distinct founders from the two sources, with a total of 60 evolving experimental lineages. The authors should discuss whether they believe that their findings would hold up with such an expanded experimental protocol.

      This is an interesting thought of its own, but we feel that it does not contribute much to our current study.

      4) The authors themselves point out at one point that their experiments might have benefitted from some phenotypic characterization of the presumed temperature adaptation. That raises the more general question of how the field of experimental evolution can progress with some labs just doing phenotypes and other labs just doing genome-wide sequencing. Surely this and other studies would be strengthened by combining the two types of assay. Furthermore, genomic evolution might be usefully analyzed in terms of the degree to which specific genomic changes can be associated with specific phenotypic changes, as that is the foundation for adaptation itself.

      We would like to draw the attention to the fact that we performed a laboratory natural selection experiment, for which the environmental factor is known, but not the actually selected phenotype - hence the phenotyping is not as trivial as implied by the reviewer.

      B.

      5) This is yet another study that finds difficulties with the invocation of noroptimal selection along a one-dimensional functional gradient. Such models have been long-standing favorites of evolutionary theorists, such as Kimura and Lande. But that preference may arise more from the ease with which these models can be formulated and analyzed by theoreticians. Actual evolving populations don't seem to embody the precepts of such theory, whether the issue is the maintenance of genetic variation (see the work of Turelli, for example) or the evolution of closely studied populations, as illustrated by this study. An alternative point of view that the authors should discuss is that such models are indeed NOT usually correct.

      It is very interesting that this reviewer feels that our data demonstrate that the prevailing model of polygenic adaptation is wrong, but our manuscript is still considered to be of insufficient novelty.

      6) There are alternative theoretical frameworks that address the maintenance of genetic variation and the response to selection. Among these are schemes of protected polymorphism arising from overdominance, epistasis, and frequency-dependent selection. If the thrust of the preceding point 4 is accepted, then it would be theoretically salient for the authors to suggest what type of underlying population genetic machinery would best account for their findings, in place of the noroptimal selection-mutation balance model.

      We thank the reviewer for these interesting suggestions. However, their predictions are not at all trivial to test. For this reason, generations of population geneticists tried to test them, so we feel that this task is well beyond the scope of this manuscript.

      Reviewer #3:

      In their manuscript 'The adaptive architecture is shaped by population ancestry and not by selection regime,' Otte and colleagues use an evolve and resequence strategy to examine the response of a Portugal population of D. simulans responds to cold temperature. The authors identify putative targets of selection and compare the number of targets, their location, and the distribution of selection coefficients to previous work on the same population exposed to hot temperatures as well as a different population exposed to hot temperatures. The topic is of general interest, the work is sound and the writing is clear and concise.

      1) It is not clear what the novel contribution of this manuscript is. The title indicates that the key finding is that population of origin mediates response to selection rather than the selection regime. However, the authors fail to provide compelling data to support that. The data are from 1 population under two selection regimes and a second population under one of those regimes. There simply aren't enough comparisons to infer that population ancestry plays a bigger role than selection regime in adaptive evolution.

      We disagree with the reviewer and would like to repeat the logic of our experiment:

      Comparison 1: contrast of different populations in the same environment -> different architecture

      Comparison 2: contrast of the same population in different environments -> same architecture

      With this simple design it is possible to reach the conclusion that the architecture is affected by population history more than by selection regime and no more populations are needed to reach this conclusion. This insight has not been reported before.

      2) The authors also seem to argue that a contribution of this paper is that it illustrates that temperature adaptation is not a single trait. This was the major finding of a 2014 paper from the same group in D. melanogaster- a single founder population was exposed to hot and cold temperatures and the authors found almost no overlap between the putatively selected variants in the two different temperature regimes.

      We would like to point out that the analysis of Tobler et al. (2014) is on the basis of individual SNPs, which is difficult to interpret because of the many segregating inversions in D. melanogaster. All the complications of these data and the implications for the interpretation can be found in the discussion of Tobler et al. (2014). In the current study, we are identifying selected haplotype blocks, which is mandatory to compare the architectures and selection responses.

      3) Beyond the limited impact of the current work, there are some additional specific issues. The authors note that it was 'remarkable' that the distribution of selection coefficients and the number of inferred selection targets between the hot and cold experiments was 'highly similar.' What is the null expectation? Where does the null come from?

      This is a minor semantic issue. Naturally, there is no null model for the number of selection targets, but if two populations selected for the same trait provide different architectures, different selection regimes should be even more likely to generate different architectures.

      4) The discussion is somewhat unsatisfying and largely speculative. The 'different trait optima' section reads as straw man; this could be reframed to better guide the reader.

      Naturally, the discussion intends to put the results in a broader context. It would have been helpful to read how s/he envisions a reframing that would improve the manuscript.

      There is little support for the 'differences in adaptive variation' hypothesis.

      It would have been helpful to read which kind of support the reviewer would have expected beyond the evidence we have already provided.

      The section on LD was interesting, but the simulation findings should reside in the results section.

      This could be easily moved, but we feel that it is well-placed in the discussion as we use the simulations to compensate for the lack of literature on this field (again demonstrating the novelty of our manuscript).

      References:

      Barghi, N., R. Tobler, V. Nolte, A. M. Jakšić, F. Mallard, K. A. Otte, M. Dolezal, T. Taus, R. Kofler, & C. Schlötterer (2019). Genetic redundancy fuels polygenic adaptation in Drosophila. PLOS Biology 17: e3000128.

      Barghi, N., J. Hermisson, & C. Schlötterer (2020). Polygenic adaptation: a unifying framework to understand positive selection. Nature Reviews Genetics . Berg, J.J., Harpak, A., Sinnott-Armstrong, N., Joergensen, A.M., Mostafavi, H., Field, Y., Boyle, E.A., Zhang, X., Racimo, F., Pritchard, J.K., et al. (2019). Reduced signal for polygenic adaptation of height in UK Biobank. Elife 8.

      Bergland, A. O., E. L. Behrman, K. R. O’Brien, P. S. Schmidt, & D. A. Petrov (2014). Genomic Evidence of Rapid and Stable Adaptive Oscillations over Seasonal Time Scales in Drosophila. PLoS Genetics 10, e1004775.

      Láruson, Á. J., S. Yeaman, & K. E. Lotterhos (2020). The Importance of Genetic Redundancy in Evolution. Trends in Ecology and Evolution 35: 809–822. Pritchard, J.K., Pickrell, J.K., and Coop, G. (2010). The genetics of human adaptation: hard sweeps, soft sweeps, and polygenic adaptation. Current biology : CB 20, R208-215.

      Sohail, M., Maier, R.M., Ganna, A., Bloemendal, A., Martin, A.R., Turchin, M.C., Chiang, C.W., Hirschhorn, J., Daly, M.J., Patterson, N., et al. (2019). Polygenic adaptation on height is overestimated due to uncorrected stratification in genome-wide association studies. Elife 8.

    1. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      In this manuscript, Ameen and colleagues report the results of a multidimensional proteomic analysis which combined quantitative proteomics, phosphoproteomics and N-terminomics in an effort to identify neuronal proteins displaying altered abundance or modifications by proteolysis and/or phosphorylation following an excitotoxic insult. Excitotoxicity is known to initiate by over-activation of ionotropic glutamate receptors which allows an increase in intracellular Ca2+ , ultimately leading to activation of proteases. The analysis revealed that glutamate treatment for up to 240 min did not significantly affect the abundance of neuronal proteins but caused dramatic changes in the phosphorylation state of many neuronal proteins. Based upon the phosphopeptides and neo-N-peptides, which contain the neo-N-terminal amino acid residue generated through proteolytic cleavage of intact neuronal proteins during excitotoxicity, the authors identified the proteins that undergo phosphorylation, dephosphorylation and/or enhanced proteolytic processing in excitotoxic neurons. By combining different software packages, they found that these modified proteins form complex interactions that affect signaling pathways regulating survival, synaptogenesis, axonal guidance and mRNA processing. These data suggest that perturbations in the aforementioned pathways mediate excitotoxic neuronal death. Then, the authors showed by Western blot analysis that CRMP2, a crucial regulator of axonal guidance signaling, exhibited enhanced truncation and reduced phosphorylation at specific sites upon glutamate treatment. These events may contribute to injury to dendrites and synapses associated with excitotoxic neuronal death. Furthermore, the authors showed that calpains are responsible for the proteolytic processing and cathepsins for enhanced degradation of proteins during excitotoxicity. Blockage of calpain-mediated cleavage site of the tyrosine kinase Src during excitotoxicity confers neuroprotection in an in vivo model of neurotoxicity. In that regard, over twenty protein kinases are predicted to be activated in excitotoxic neurons. Collectively, this study contributes to the construction of an atlas of phosphorylation and proteolytic processing events that occur during excitotoxicity and as such they can be targeted for therapeutic purposes.

      Comments

      The identification of potential calpain cleavage sites in neuronal proteins modified during excitotoxicity is an interesting finding of the study. However, the atlas presented appears to miss components such as Kinase D-interacting substrate of 220 kDa (Kidins220), also known as ankyrin repeat-rich membrane spanning (ARMS), a protein recently shown to be cleaved by calpain during excitotoxicity (López-Menéndez et al, 2019, Cell Death and Disease 10, 535).

      The CRMP2 antibody (Cell Signalling, 35672) used for western blots (figure 5D, also figure S11) and immunofluorescence (figure 5E) is problematic. Copied from https://www.cellsignal.com/products/primary-antibodies/crmp-2-d8l6v-rabbit-mab/35672: Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding lle546 of human CRMP-2 protein. The truncated CRMP2 (figure 5D) studied in the whole section (residues 1-516 or 1-517, ~57kDa) cannot be recognized by this monoclonal antibody. The detected band with the red letters in figure 5D might represent another cleavage product. In any case, asking Cell Signalling for more information about the exact immunogen might help, but since it's monoclonal and derived from residues surrounding lle546 it's very hard to include residues before aa516 and the unique epitope recognition upstream of aa516. The whole result section and discussion has to be reconsidered. Alternatively another antibody can be used to repeat those experiments in order to support the hypothesis. Time and resources are very familiar to authors since they have to repeat their previous work with a new antibody. Finally, there are no "western blot" and "immunofluorescence" methods for CRMP2.

      The truncated DCLK1 bands detected in figure S8B cannot be attributed to the proteolytic processing of DCLK1 at the sites described: T311↓S312, S312↓S313 and N315↓G316 (predicted M.W. of the (C-terminal) products: 48.7-49.1kDa (figure S8A) which is very close to be well-separated with conventional PAGE). The number and the separation of the bands suggest other cleavage sites.

      Could the striking observation that almost all proteolytic processing during excitotoxicity is catalyzed by calpains and/or cathepsins have derived (partially) from unspecific targets of calpeptin such as a subset of tyrosine phosphatases (Schoenwaelder and Burridge, 1999: approx. 1h treatment of fibroblasts with approx.. 10x less concentration) or other(s)?

      Describing the final part of figure 4C the authors suggest that "Liver kinase B1 homolog (LKB1), CaM kinase kinase β (CaMKKβ) and transforming growth factor‐β‐activating kinase 1 (TAK1) are the known upstream kinases directly phosphorylating T172 of AMPKα to activate AMPK (Herrero-Martin et al., 2009; Woods et al., 2005; Woods et al., 2003). Our findings therefore predict activation of these kinases during excitotoxicity (Figure 4C)." The first question arising here is whether these three kinases are the only ones know to phosphorylate AMPKα. Even if this is true, it is highly speculative to suggest that the findings of the present study predict the activation of these kinases during excitotoxicity, without providing the necessary experimental data, since the increased phosphorylation of AMPK may be an indirect effect of the reduced function of a phosphatase. Thus the proposed model does not hold.

      Minor points

      Highlights could present the key points of the study in a more straightforward manner.

      Figure 4A is too complicated. Proteins considered as hubs of signaling pathways in neurons should be somehow highlighted to distinguish them.

      The analysis of proteins with enhanced truncation and reduced phosphorylation such as CRMP2 and DCLK1 is fragmented. In addition, the authors should mention the criteria based on which these proteins were selected for further analysis.

      The potential therapeutic relevance of phosphorylation and proteolytic processing events that occur during excitotoxicity can be further explored.

      I am sorry but I could not find Figure 8, which is supposed to show the "In vivo model of NMDA neurotoxicity" (please, see page 30).

      Introduction: O'Collins et al., 2006; Savitz and Fisher, 2007; both references are missing.

      Figure S1A-B: vehicle treatment time course is needed.

      Figure 5E: Control close-up is missing.

      "Moreover, the number of CRMP2-containing dendritic blebs in neurons at 240 min of glutamate treatment was significantly higher than that in neurons at 30 min of treatment (inset of Figure 5E)." Such a statistic is not shown in the graph.

      "Consistent with this prediction, our bioinformatic analysis revealed that the identified cleavage sites in most of the significantly degraded neuronal proteins during excitotoxicity are mapped within functional domains with well-defined three-dimensional structures (Figures 6A)." Authors might mean figure S12A?

      "Neuronal Src was identified by the three criteria of our bioinformatic analysis to be cleaved by calpains to form a stable truncated protein fragment during excitotoxicity (Figures 6A and Table S6)." Authors might mean figure 6D?

      Figure 2B: Clusters 1, 3, 4 and 6 do not follow treatment trends homogenously in all time points. For example in cluster 1 there is a phosphopeptide following the pattern 1, 0, -1 and another one following the pattern 0, 1, -1, which is actually a very different pattern even if the end value is stable (-1). The first example could belong to the cluster 6 as well, while the second example to cluster 5. Please elaborate on the rationale behind the categorization. Is there any other clustering method that can be used without making the categorization more complicated?

      A problem of the manuscript is its length and lack of coherence. Apart from presenting the data from the proteomics, phosphoproteomics and N-terminomics analyses, the authors focus on several different proteins to perform validation experiments and further characterize the biological significance of their modification. Because these proteins do not fall on the same pathway, the authors end up presenting several independent stories that complicate the reader.

      Moreover, it is necessary for the authors to restructure their introduction, and avoid over-representing previous research on nerinetide, which is not used anywhere in the manuscript. Instead, the introduction must be more focused to better capture the necessity and essence of the present study.

      Taking into account figures 1 and S2 I understand that the authors combined samples of neuronal cell cultures (treated or not with Glu) with samples from mouse brains (that have undergone ischemic stroke/TBI or sham operation). If this is the case, why did the authors do that? How did they combine the different samples? And why this is not mentioned anywhere is the main text?

      Regarding figure 5D , the authors write in the main text "Consistent with our phosphoproteomic results, the truncated fragment CRMP2 fragments could not cross-react with the anti-pT509 CRMP2 antibody (Figure 5D)" In the upper blot the truncated CRMP2 fragment runs well below the 70 kDa marker. However, in the middle panel, where we see the blot with the phospho specific antibody, the respective area of the blot has been cropped, so we cannot see whether the truncated fragment cross-reacts with the phospho specific antibody.

      It is strange that only 1 and 13 proteins showed significant changes in abundance at 30 and 240min respectively. Especially after 240min of glutamate treatment one could expect that many proteins should change in their levels, since the neurons are almost diminished by cell death at that point. How could the authors explain this phenomenon? Additionally, in their previous publication, they showed that much more proteins change significantly in abundance following glutamate treatment (at 30min and 240min).

      Significance

      The manuscript delivers a large amount of data, regarding changes in the proteome, the activation of specific kinases, phosphatases, as well as the molecular pathways that are activated at distinct time points of excitotoxicity. This information could be used in future studies to validate and develop potential therapeutic strategies that could protect against neuronal loss in various neurological disorders.

      The same group has very recently published a work very similar to the particular manuscript (Hoque et al. Cell Death and Disease, 2019). In their previous publication, the authors cover a large part of their current objectives. They performed again a proteomic and phosphoproteomic analysis of mouse primary cortical neurons treated with glutamate for distinct time points, in their aim to identify changes in expression and phosphorylation state of neuronal proteins upon excitotoxicity. Apart from the N-terminome, which they investigate in their current manuscript, the proteomic and phospho proteomic analysis are very similar. As such, and because of the fact that the current manuscript is very extensive, the authors should consider to minimize it, and include only their novel findings (changes in the N-terminome, the involvement of specific kinases that contribute to excitotoxic neuronal death, the regulatory mechanism of CRMP2, etc).

      The authors should describe in a simpler way the proteomic and bioinformatics analyses they are using in the manuscript. It is difficult to understand the methodology used if you are not an expert in proteomics and bioinformatics. My suggestion is to revise their text and make it simpler and more concise.

    1. Siemieniuk, R. A., Bartoszko, J. J., Ge, L., Zeraatkar, D., Izcovich, A., Kum, E., Pardo-Hernandez, H., Rochwerg, B., Lamontagne, F., Han, M. A., Liu, Q., Agarwal, A., Agoritsas, T., Chu, D. K., Couban, R., Darzi, A., Devji, T., Fang, B., Fang, C., … Brignardello-Petersen, R. (2020). Drug treatments for covid-19: Living systematic review and network meta-analysis. BMJ, 370. https://doi.org/10.1136/bmj.m2980

    1. SciScore for 10.1101/2020.09.11.291716: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Cell culture Lenti-X 293T™ cells (H. sapiens; sex: female) obtained from Takara (cat. # 632180) and Huh-7.5 cells (H. sapiens; sex: male) (Blight et al., 2002) were maintained at 37 °C and 5% CO2 in Dulbecco's Modified Eagle Medium (DMEM, Fisher Scientific, cat. # 11995065) supplemented with 0.1 mM nonessential amino acids (NEAA, Fisher Scientific, cat. # 11140076) and 10% hyclone fetal bovine serum (FBS, HyClone Laboratories, Lot. # AUJ35777).</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Both cell lines have tested negative for contamination with mycoplasma.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lentivirus production To produce the lentiGuidePurov2 sgRNA lentivirus library, Lenti-X 293TTM cells were seeded in 25 ml DMEM supplemented with 0.1 mM NEAA and 3% FBS at 6.25 x 106 per dish in four poly-L-lysine coated p150 dishes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293TTM</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate working stocks, Huh-7.5 cells were infected at a multiplicity of infection (MOI) of 0.01 plaque forming unit (PFU)/cell (SARS-CoV-2,</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Huh-7.5</div> <div>suggested: RRID:CVCL_7927)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CRISPR-Cas9 genetic screen Huh-7.5-Cas9 cells transduced with the lentiGuidePurov2 sgRNA library were seeded in p150 plates at 4.5 x 106 cells/plate in triplicate for each condition (mock, HCoV-229E, HCoV-NL63, HCoV-OC43, and SARS-CoV-2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Huh-7.5-Cas9</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The inocula of HCoV-229E, HCoV-NL63 and SARS-CoV-2 were supplemented with 1 µg/ml TPCKtreated trypsin (Sigma-Aldrich, cat. # T1426) increasing the rate of infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>HCoV-NL63</div> <div>suggested: RRID:CVCL_RW88)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For Calu-3 cells, data was obtained from GSE148729 (Wyler et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Calu-3</div> <div>suggested: BCRJ Cat# 0264, RRID:CVCL_0609)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For scRNAseq analysis, Seurat objects were downloaded from FigShare (https://doi.org/10.6084/m9.figshare.12436517) (Chua et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FigShare</div> <div>suggested: (FigShare, RRID:SCR_004328)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      LIMITATIONS While our study sheds new light on how host proteins are co-opted during coronavirus infection, it is not without limitations. As with all pooled CRISPR gene disruption screens, we expect that functionally redundant genes may not score (Ewen-Campen et al., 2017)). Additionally, the results of these genetic screens should not be interpreted to validate specific physical associations, as it is a purely functional readout. Additional biochemical studies would be necessary to test each predicted interaction. Nevertheless, we identified robust pan-coronavirus and discrete strain-specific host factors that scored with up to 10 sgRNAs scoring per gene, validating the utility of this near-saturation CRISPR-based genetic screening approach. We acknowledge that Huh-7.5 cells, which were chosen based on their unique capacity to support infection by multiple coronaviruses and also because they constitutively express 324/332 of the SARS-CoV-2 interactome factors, are different than the HEK293T system used by Gordon et al. to generate the PPI network probed in this study and are not airway cells. However, this robust and experimentally tractable system offers a unique advantage to directly compare hard-wired host factor requirements across multiple viruses in a cell-type- and tissue-type-agnostic manner, which can then be validated using gold-standard primary cells or animal models. Future studies will be required to dissect the specific requirement for each member of the PPI n...


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. But, again, the care of h . . ot ers and keepmg of the commuruty together-these are the issues tha h b . . h. l t t e women are nngmg up t IS way, not one ranger type rights issues

      It seems as if throughout movements, women organizers tend to be community-oriented and fight for more than just themselves since, stereotypically, the burden of caring for others has been placed on women. Therefore, individualism rarely has place in their organizing work. In addition, a sense of community and togetherness highlights how a suppressed voice can become heard through collective activism that helps women define their experiences and reality, rather than these being imposed upon them.

    1. SciScore for 10.1101/2020.09.01.277152: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All samples from the 8 employees taken on April 30th were negative by RT-PCR but tested positive for SARS-CoV-2 antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SARS-CoV-2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">hCov−19/Netherlands/NB9_Mink_1 C V R L H I C V R L H I hCov−19/Netherlands/NoordBrabant_178/2020 C V R L H C I I L T L I F K C I F K C I K C I K C I M Q I G Q I G Q L G L G E L C G E L C G 25 62 115 G C 38 45 C L 32 34 55 57 182 207 219 224 229 258 L E 11 187 314 794 1003 1092 1179 1181 1315 1369 1637 1681 1882 2025 2143 2222</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>G 25</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The resulting raw sequence data was demultiplexed using Porechop (https://github.com/rrwick/Porechop).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Porechop</div> <div>suggested: (Porechop, RRID:SCR_016967)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Phylogenetic analysis All available near full-length Dutch SARS-CoV-2 genomes available on 1st of July were selected (n=1,775) and aligned with the sequences from this study using MUSCLE (45).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MUSCLE</div> <div>suggested: (MUSCLE, RRID:SCR_011812)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The phylogenetic trees were visualized in Figtree (http://tree.bio.ed.ac.uk/software/figtree/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Figtree</div> <div>suggested: (FigTree, RRID:SCR_008515)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A custom R script was used to distinguish synonymous from non-synonymous mutations and non-synonymous mutations were visualized using a tile map from the ggplot2 package (48).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ggplot2</div> <div>suggested: (ggplot2, RRID:SCR_014601)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Maps were created using R packages sp (50), raster (51) and rgdal (52) and ArcGIS 10.6 software by ESRI.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ArcGIS</div> <div>suggested: (ArcGIS for Desktop Basic, RRID:SCR_011081)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">From 2 samples WGS could be generated from the employees which clustered together with the sequences from the animals from this farm.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>WGS</div> <div>suggested: None</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your code.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.09.04.282616: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">L AND CONSENT TO PARTICIPATE 266 The study was approved by the Ethical Committee of the University Hospital Institute Méditerranée 267 Infection (N°: 2020-016).</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">DNA Polymerase I 230 Large Klenow Fragment (BioLabs) was used for generating double stranded cDNA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>BioLabs</div> <div>suggested: (Tulip Biolabs, RRID:SCR_013654)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Normalized libraries 239 were pooled into a single library for sequencing on MiSeq.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MiSeq</div> <div>suggested: (A5-miseq, RRID:SCR_012148)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All genomes were deposited at EMBL- 253 EBI under the BioProject: PRJEB37722 254 ABBREVIATIONS 255</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>BioProject</div> <div>suggested: (NCBI BioProject, RRID:SCR_004801)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)): **Summary:** This interesting study by Putker et al. showed that circadian rhythmicity persists in several typical circadian assay systems lacking Cry, including Cry knockout mouse behavior and gene expression in Cry knockout fibroblasts. They further demonstrated weak but significant circadian rhythmicity in Cry- and Per- knockout cells. Cry- (and potentially Per-)-independent oscillations are temperature compensated, and CKId/e still has a role in the period regulation of Cry-independent oscillations. **Major comments:** 1) The authors propose that the essential role of mammalian Cryptochrome is to bring the robust oscillation. As the authors analyze in many parts, the robustness of oscillation can be validated by the (relative) amplitude and phase/period variation, both of which should be affected significantly by the method for cell synchronization. Unfortunately, the method for synchronization is not adequately written in this version of supplementary information. This reviewer has no objection to the "iterative refinement of the synchronization protocol" but at least the correspondence between which methods were used in which experiments needs to be clearly explained. The detailed method may be found in the thesis of Dr. Wong, but the methods used in this manuscript need to be detailed within this manuscript.

      We thank the reviewer for recognising the importance of different synchronisation protocols. In experiments where bioluminescent CKO rhythms were observed, different synchronisation protocols resulted in similar results when comparing WT with CKO cells. The different synchronisation methods used in each experiment are now specified in the supplementary methods.

      2) The authors revealed that CKO mice have apparent behavioral rhythmicity under the condition of LL>DD. This is an intriguing finding. However, it should be carefully evaluated whether this rhythmicity (16 hr cycle) is the direct consequence of circadian rhythmicity observed in CKO and CPKO cells (24 hr cycle) because the period length is much different. Is it possible to induce the 16 hr periodicity in CKO mice behavior by 16 hr-L:16 hr-D cycle? Would it be a plausible another possibility that the 16 hr rhythmicity is the mice version of internal desynchronization or another type of methamphetamine-induced-oscillation/food-entrainable-oscillattion?

      The reviewer makes an excellent suggestion. As described in the manuscript text (page 13), CKO mice have already been shown to entrain to restricted feeding cycles (Iijima et al., 2005) and we therefore assessed whether CKO rhythms would entrain to a 16h day as suggested. Whilst CKO (but not WT) mice showed 16h behavioural rhythms during entrainment, they were arrhythmic under constant darkness thereafter (Revised Figure S2A). CKO cellular rhythms show reduced robustness under constant conditions ex vivo, and our other work has revealed that CRY-deficiency renders cells much more susceptible to stress (Wong et al, 2020, BioRxiv). The parsimonious explanation, therefore, is that whilst the cellular timing mechanism remains functional when CRY is absent, the amplitude of cellular clock outputs is severely attenuated (as we showed previously in Hoyle et al., Sci Trans Med, 2017) in a fashion that impairs the fidelity of intercellular synchronisation under most conditions in vivo, as well as the molecular mechanisms of entrainment to light-dark cycles.

      With respect to the apparent discrepancy between mean periods of CKO cultured cells (~21h), SCN (~19h) and mice (~17h). This is also observed in WT cells (~26h), SCN (~25h) and mice (~24h), simply with a smaller effect size and longer intrinsic period.

      We believe this difference in effect size can adequately be explained by differences in oscillator coupling, combined with the reduced robustness of CKO timekeeping. In Figure 1F we show that the range of rhythmic periods expressed by cultured CKO fibroblasts (14-30h) is much greater than for their WT counterparts (range of 22-26h), or that which is observed when cellular oscillators are coupled in CKO SCN (19h). Thus period of CKO oscillations is demonstrably more plastic (less robust) than WT, and with a cell-intrinsic tendency towards shorter period which is revealed more clearly when oscillators are coupled.

      In vivo there is more oscillator coupling in the intact SCN than in an isolated slice, from which communication with the caudal and rostral hypothalamus has been removed. Thus it seems plausible that increased coupling in vivo, combined with positive feedback via behavioural cycles of feeding and locomotor activity, resonate with a common frequency which is shorter than in isolated tissue.

      Critically, for both WT and CKO mice/SCN, the circadian period lies within the range of periods observed in isolated fibroblasts. To communicate this rather nuanced point we have inserted the following text into the supplementary discussion:

      “Circadian timekeeping is a cellular phenomenon. Co-ordinated ~24h rhythms in behaviour and physiology are observed in multi-cellular mammals under non-stressed conditions when individual cellular rhythms are synchronised and amplified by appropriate extrinsic and intrinsic timing cues. In light of short period (~16.5h) locomotor rhythms observed in CKO mice after transition from constant light to constant dark, but failure to entrain to 12h:12h light:dark cycles, it seemed plausible that either CKO mice might entrain to an short 8h:8h light:dark (16h day) or else have a general deficiency to entrainment by light:dark cycles. The data in Figure S2 supports the latter possibility, in that neither WT nor CKO mice stably entrained to 16h cycles whereas WT but not CKO mice entrained to 24h days. The bioluminescence oscillations observed in CKO cells conform to the long-established definition of a circadian rhythm (temperature-compensated ~24h period of oscillation with appropriate phase-response to relevant environmental stimuli). Whereas the locomotor rhythms observed in CKO mice under quite specific environmental conditions correlates with both the cellular and SCN data to suggest the persistence of capacity to maintain behavioural rhythms close to the circadian range, but which is masked under most circumstances. We suggest that in vivo the (pathophysiological) stress of CRY-deficiency is epistatic to the expression of daily rhythms in locomotor activity following standard entrainment by light:dark cycles and thus, whilst not arrhythmic, also cannot be described as circadian in the strictest sense.”

      3) The authors proposed that CKId/e at least in part is the component of cytoscillator (Fig. 5D), and turnover control of PER (likely to be controlled by CKId/e) may be an interaction point between cytoscillator and canonical circadian TTFL (Fig. 4). Strictly speaking, this model is not directly supported by the experimental setting of the current manuscript. The contribution of CKId/e is evaluated in the presence of PER by monitoring the canonical TTFL output (i.e. PER2::LUC); thus it is not clear whether the kinase determines the period of cytoscillator. It would be valuable to ask whether the PF and CHIR have the period-lengthening effect on the Nrd1:LUC in the CPKO cell.

      Another excellent suggestion, thanks. The experiment, showing similar results in CKO and CPKO cells, was performed and is now reported in Revised Figure S5D. The text was amended as follows: “We found that inhibition of CK1d/e and GSK3-α/β had the same effect on circadian period in CKO cells, CPKO cells, and WT controls (Figure 5A, B, S5A, B, D).”

      Moreover, our data are further supported by findings in RBCs, where CK1 inhibition affects circadian period in a similar manner as in WT and CKO cells (Beale et al, JBR 2019).

      **Minor comments:**

      4) The authors argue that the CKO cells' rhythmicity is entrained by the temperature cycle (Fig. 2C). Because the data of CKO cell only shows one peak after the release of constant temperature phase, it is difficult to conclude whether the cell is entrained or just respond to the final temperature shift.

      We agree with the reviewer and have replaced the original figure with another recording that includes an extra circadian cycle in free-running conditions (Revised Figure 2C).

      5) It would be useful for readers to provide information on the known phenotype of TIMELESS knockout flies; TIM is widely accepted as an essential component of the circadian clock in flies; are there any studies showing the presence of circadian rhythmicity in Tim-knockout flies (even if it is an oscillation seen in limited conditions, such as the neonatal SCN rhythm in mammalian Cry knockout)?

      The reviewer is correct that TIM is widely accepted as an essential component of the circadian clock in flies. Using more sensitive modern techniques however, ~50% of classic Tim01 mutant flies exhibit significant behavioural rhythms in the circadian range under constant darkness, as reported:

      https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/year/2015/docId/11914

      For this reason we employed a full gene knockout of the Timeless gene (Lamaze et al., Sci Rep, 2017), where the majority of flies are behaviourally arrhythmic under constant conditions following standard entrainment by light cycles and therefore represents a more appropriate model for CRY-deficient cells.

      We have revised the legend of Figure S2 to include the following:

      “N.B. The generation of Timout flies is reported in Lamaze et al, Sci Rep, 2017. Similar to CRY-deficient mice, whole gene Timeless knockout flies are characterised as being behaviourally arrhythmic under constant darkness following entrainment by light:dark cycles: https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/year/2015/docId/11914”

      5) Figure 3C shows that the amount of PER2::LUC mRNA changes ~2 fold between time = 0 hr and 24 hr in the CKO cell. This amplitude is similar to that observed in WT cell although the peak phase is different. Does the PER2::LUC mRNA level show the oscillation in CKO cells?

      No, we think we have shown convincingly this is not the case. We argue the data in figure 3C show that: (a) there is no circadian variation in mRNA PER2::LUC expression (mRNA levels increase but no trough is observed) and (b) that the temporal relationship between protein and mRNA as observed in WT is broken; i.e. the CRY-independent circadian variation in protein levels cannot be “driven by” changes in transcript levels. Similar results were obtained using transcriptional reporters Per2:LUC and Cry1:LUC (Figure S3E and F). Moreover, our findings are also in line with previous reports, such as Nangle et al. (2014, eLife) and Ode et al. (Mol Cell, 2017).

      6) Figure 3D: the authors discuss the amplitude and variation (whether the signal is noisier or not) of reporter luciferase expression between different cell lines. However, a huge difference in the luciferase signal can be observed even in the detrended bioluminescence plot. This reviewer concerns that some of the phenotypes of CKO and CPKO MEF reflect the lower transfection efficiency of the reporter gene, not the nature of circadian oscillators of these cell lines.

      As reported in the methods, these are stable cell lines rather than transiently transfected cells. The detrended luciferase data presented here do not actually reflect raw levels of luciferase protein expression, but rather reflect the amount of deviation from the 24 hour average. To make it easier to compare expression levels of Per2:LUC and Nr1d1:LUC between the different cell lines we have added figure S3H, presenting the average raw bioluminescence levels over 24 hours (after 24 hours of recovery from media change; ie from 24-48 hours). Using these data one can appreciate that expression levels of the Per2 reporter are never lower in CRY KO cells when compared to WT. We hope these data can take away the reviewer’s concerns about expression levels causing the differences observed.

      Reviewer #1 (Significance (Required)): Although Cryptochrome (Cry) has been considered a central component of the mammalian circadian clock, several studies have shown that circadian rhythms are maintained in the absence of Cry, including in the neonate SCN and red blood cells. Thus, although the need for Cry as a circadian oscillator has been debated, its essential role as a circadian oscillator remains established, at least in the cell-autonomous clock driven by the TTFL. This study provides additional evidence that the circadian rhythmicity can persist in the absence of Cry. More general context, the presence of a non-TTFL circadian oscillator has been one of the major topics in the field of circadian clocks except for the cyanobacteria. In mammals, the authors’ and other groups lead the finding of circadian oscillation in the absence of canonical TTFL by showing the redox cycle in red blood cells (O’Neil, Nature 2011). The presence of circadian oscillation in the absence of Bmal1 is also reported recently(Ray, Science 2020). Bmal1(-CLOCK), CRY, and PER compose the core mechanism of canonical circadian TTFL; thus, this manuscript put another layer of evidence for the non-TTFL circadian oscillation in mammals. Overall, the manuscript reports several surprising results that will receive considerable attention from the circadian community. This reviewer has expertise in the field of mammalian circadian clocks, including genomics, biochemistry, and mice's behavior analysis.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)): In the canonical model of the mammalian circadian system, transcription factors, BMAL1/CLOCK, drive transcription of Cry and Per genes and CRY and PER proteins repress the BMAL1/CLOCK activity to close the feedback loop in a circadian cycle. The dominant opinion was that CRY1 and CRY2 are essential repressors of the mammalian circadian system. However, this was challenged by persistent bioluminescence rhythms observed in SCN slices derived from Cry-null mice (Maywood et al., 2011 PNAS) and then by persistent behavior rhythms shown by the Cry1 and Cry2 double knockout mice if they are synchronized under constant light prior to free running in the dark (Ono et al., 2013 PLOS One). In the manuscript, the authors first confirmed behavioral and molecular rhythms in the Cry1/Cry2- deficient mice and then provided evidence to suggest the rhythms of Per2:LUC and Nr1d1:LUC in CKOs are generated from the cytoplasmic oscillator instead of the well-studied transcription and translation feedback loop: Constant Per2 transcription driven by BMAL1/CLOCK plus rhythmic degradation of the PER protein result in a rhythmic PER2 level in the absence of both Cry1 and Cry2, which suggests a connection between the classic transcription- and translation-based negative feedback loops and non-canonical oscillators. **Major points:** Line 38-39, "Challenging this interpretation, however, we find evidence for persistent circadian rhythms in mouse behavior and cellular PER2 levels when CRY is absent." The rhythmic behavioral phenotype of cry1 and cry2 double knockout mice was first documented by Ono et al., 2013 PLOS ONE, in which eight cry1 and cry2 double knockout mice after synchronization in the light displayed circadian periods with different lengths and qualities. The paper reported two period lengths from the Cry mutant mice: "An eye-fitted regression line revealed that the mean shorter period was 22.86+/-0.4 h (n= 8) and the mean longer period was 24.66+/-0.2 h (n =9). The difference of two periods was statistically significant (p, 0.01).", either of which is quite different from the ~16.5 hr period in Figure 1B of the manuscript. A brief discussion on the period difference between studies will be helpful for readers to understand. Period information from the individual mouse should be calculated and shown since big period variations exist among CKO mice (Ono et al., 2013 PLOS One).

      Thanks for this suggestion. The mice used by Ono et al were raised from birth in constant light, whereas we used mice that were weaned and raised in normal LD cycles before being subject to constant light then constant dark as adults. Instead of the somewhat subjective fitting of regression lines by eye performed by Ono et al, our analysis was performed using the periodogram analysis routine of ClockLab 6.0 with a significance threshold for rhythmicity of p=0.0001. We have now repeated this experiment with 10 adult CKO mice (male and female), and found no evidence for two period lengths in that the second most significant period was consistently double that of the first. As the reviewer suggests, there is a much broader distribution of CKO mouse periods compared with WT, as we also found in cultured cells and SCN. These new data are now reported in revised Figure S1B & C. We have also included a statement about how our study differs from Ono et al in the supplementary discussion.

      The behavioral phenotype of Cry-null mice and luminescence from their SCNs are robustly rhythmic while fibroblasts derived from these mice only produce rhythms with very low amplitudes compared with those in WT, which may reflect the difference between the SCN’s rhythm and peripheral clocks. The behavioral phenotype is supposed to be controlled mainly by SCN. However, most molecular analyses in the work were done with MEF and lung fibroblasts. These tissues may not be the best representative of the behavioral phenotype of the CKO mice.

      Behavioural rhythms of CKO mice are significantly less robust than WT, with mean amplitude less than 50% of WT controls (Figures 1A & B, revised S1B. Furthermore, as reported, 40% of CKO SCN slices exhibited PER2::LUC rhythms, compared with 100% of WT SCN slices (as also observed by Maywood et al., PNAS, 2013), and therefore are also less robust by the definition used in this manuscript.

      As now discussed in the revised supplementary discussion:

      Circadian timekeeping is a cellular phenomenon. Co-ordinated ~24h rhythms in behaviour and physiology are observed in multi-cellular mammals under non-stressed conditions when individual cellular rhythms are synchronised and amplified by appropriate extrinsic and intrinsic timing cues.”

      The objective of this study was to understand the fundamental determinants that allow mammalian cells to generate a circadian rhythm, which we find does not include an essential role for CRY genes/proteins. Thus the cell is the appropriate level of biological abstraction at which to investigate the phenomenon, whereas the SCN and behavioural recordings simply serve to illustrate the competence of CRY-independent timing mechanisms to co-ordinate biological rhythms at higher levels of biological scale which are manifest under some conditions. To reiterate, the behavioural data supports the cellular observations, not the converse.

      Stronger evidence is needed to fully exclude the possibility that in CKO cells, the rhythm is not generated by PERs' compensation for the loss of Crys to repress BMAL1 and CLOCK. Since the rhythms of Per:LUC or Nr1d1:LUC (Figures 3D and S3E) are much weaker than those in WT, molecular analyses might not be sensitive enough to reflect the changes across a circadian cycle in the CKOs if the TTFL still occurs. CLOCKΔ19 mutant mice have a ~4 hr longer period than WT (Antoch et al., 1997 Cell; King et al., 1997 Cell). CLOCKΔ19; CKO cells or mice should be very helpful to address the question. Periods of Per:LUC and Nr1d1:LUC from the CLOCKΔ19; CKO should be similar to those in the CKO alone if the transcription feedback does not contribute to their oscillations.

      We agree this would be an interesting experiment, however the data in this manuscript and Wong et al. (BioRxiv, 2020), whilst not disputing the existence of the TTFL, strongly suggest that it fulfils a different function to that which is currently accepted and is not the mechanism that ultimately confers circadian periodicity upon mammalian cells. CLOCKΔ19 is an antimorphic gain-of-function mutation with many pleiotropic effects. Therefore, if the TTFL is not the basis of circadian timekeeping in mammalian cells, it follows that the CLOCKΔ19 mutation may not elicit its effects on circadian rhythms through delaying the timing of transcriptional activation, as was proposed. As such, whether or not CLOCKΔ19 alters circadian period of CKO cells/mice would not allow the two models to be distinguished in the way that the reviewer envisions.

      Secondly, we cannot detect any interaction between PER2 and BMAL1 in the absence of CRY using an extremely sensitive assay.

      Thirdly, very strong biochemical evidence suggests that PER has no repressive function in the absence of CRY (Chiou et al., 2016; Kume et al., 1999; Ode et al., 2017; Sato et al., 2006).

      Finally, in several figures particularly 3C and 4A, we show that PER2 peaks at the same time CKO and WT cells, but in CKO cells this is not accompanied by a coincident peak in the mRNA. Thus, even if PER were able to repress BMAL1/CLOCK without CRY, rhythms in PER2 protein level could not be explained by some residual PER/BMAL1-dependent TTFL mechanism.

      To address the reviewer’s concern however, we have employed mouse red blood cells which offer unambiguous insight into the causal determinants of circadian timing, as we can be absolutely confident that there is no transcriptional contribution to cellular timekeeping. Briefly, we took fibroblasts and RBCs from WT, short period Tau/Tau and long period Afh/Afh mutant mice. The basis of the circadian phenotype of these mutations is quite well established as occurring through the post-translational regulation of PER and CRY proteins respectively, and result in short and long period PER2::LUC rhythms compared with WT fibroblasts. RBCs do not express PER or CRY proteins, and commensurately no genotype-dependent differences of RBC circadian period were observed (Beale et al, 2020, in submission). In contrast, RBC circadian rhythms are sensitive to pharmacological inhibition of casein kinase 1 (Beale et al., JBR, 2019).

      Lines 51-52, "PER/CRY-mediated negative feedback is dispensable for mammalian circadian timekeeping" and lines 310-311, "We found that transcriptional feedback in the canonical TTFL clock model is dispensable for cell-autonomous circadian timekeeping in animal and cellular models." The authors have not excluded the possibility that the rhythmic behaviors of the CKO mice are derived from the PERs' compensation for the role of Crys in the feedback loop of the circadian clock in the SCN. In the fibroblasts, only two genes, Per2 and Nr1d1, have been studied in the work, which cannot be simply expanded to the thousands of circadian controlled genes. Also amplitudes of PER2:LUC and NR1D1:LUC in the CKOs are much lower than those in WT and no evidence has been provided to show that their weak rhythms are biologically relevant.

      The definition of a circadian rhythm (Pittendrigh, 1960) does not mention biological relevance or stipulate any lower threshold for amplitude. As now stated in the revised text (page 6):

      PER2::LUC rhythms in CKO cells were temperature compensated (Figure 2A, B) and entrained to 12h:12h 32°C:37°C temperature cycles in the same phase as WT controls (Figures 2C), and thus conform to the classic definition of a circadian rhythm (Pittendrigh, 1960) – which does not stipulate any lower threshold for amplitude or robustness.

      We make no claims about biological relevance or amplitude in this manuscript, which are addressed in our related manuscript (Wong et al., BioRxiv, 2020). In this related manuscript, we explicitly address whether CRY is necessary for mammalian cells to maintain a circadian rhythm in the abundance of clock-controlled proteins and find that it is not. Indeed, twice as many rhythmically abundant proteins are observed in CKO cells than WT controls, which suggests that, if anything, CRY functions to suppress rhythms in protein abundance rather than to generate them.

      We observe circadian rhythms in the activity of two different bioluminescent reporters, which have already been extensively characterised. The mouse and SCN data in figure 1 are correlative, and simply show that previous published observations are reproducible. PER2::LUC oscillations are not accompanied by Per2 mRNA oscillations. This, together with the absence of a BMAL1-PER2::LUC complex strongly argues against a model where PER2 oscillations are driven by residual (PER2-driven) transcriptional oscillations.

      We therefore concede the reviewer’s point that we “cannot exclude rhythmic behaviors of the CKO mice are derived from the PERs' compensation for the role of Crys in the feedback loop of the circadian clock in the SCN”. The reviewer will agree however, that there exists very strong biochemical evidence suggests that PER has no repressive function in the absence of CRY (Chiou et al., 2016; Kume et al., 1999; Ode et al., 2017; Sato et al., 2006); that there exists no experimental evidence to suggest that PERs can fulfil this function in the absence of CRY in any mammalian cellular context; and finally that our observations are not consistent with the canonical model for the generation of circadian rhythms in mammals.

      We have therefore amended the text to focus on CRY specifically, as follows:

      PER/CRY-mediated negative feedback is dispensable for mammalian circadian timekeeping

      Page 12. “We found that CRY-mediated transcriptional feedback in the canonical TTFL clock model is dispensable for cell-autonomous circadian timekeeping in cellular models. Whilst we cannot exclude the possibility that in the SCN, but not fibroblasts, PER alone may be competent to effect transcriptional feedback repression in the absence of CRY, we are not aware of any evidence that would render this possibility biochemically feasible.”

      **Minor points:** Lines 66-67, "...(Dunlap, 1999; Reppert and Weaver, 2002; Takahashi, 2016)." to "... (reviewed in Dunlap, 1999; Reppert and Weaver, 2002; Takahashi, 2016)."

      Thanks, changed as requested.

      Line 70, "...((Liu et al., 2008..." to "...(Liu et al., 2008..."

      Thanks, changed as requested.

      Lines 174-175, "Considering recent reports that transcriptional feedback repression is not absolutely required for circadian rhythms in the activity of FRQ...". Larrondo et al., 2015 paper says "however, in such ∆fwd-1 cells, the amount of FRQ still oscillated, the result of cyclic transcription of frq and reinitiation of FRQ synthesis." The point of the paper is "we unveiled an unexpected uncoupling between negative element half-life and circadian period determination." instead of "...transcriptional feedback repression is not absolutely required for circadian rhythms in the activity of FRQ,"

      This is a good point which, following discussion with Profs Dunlap and Larrondo, we have revised into “no obligate relationship between clock protein turnover and circadian regulation of its activity” – a more accurate summary of their findings.

      Lines 249-252, "CKO cells exhibit no rhythm in Per2 mRNA (Figure 3C, D), nor do they show a rhythm in global translational rate (Figure S4A, B), nor did we observe any interaction between BMAL1 and S6K/eIF4 as occurs in WT cells (Lipton et al, 2015) (Figure S4C)." In figures 3D and S3E, in CKO and CPKO cells the Per2:LUC data without fitting look better than that of Nr1d1:LUC. But the Nr1d1:LUC rhythm became clear after fitting the raw data. So to better visualize the low amplitude rhythm, if any, of Per2:LUC and compare with Nr1d1:LUC, fitted the Per2:LUC data in CKOs and CPKOs in Figure 3D and S3E should be shown as what has been done to Nr1d1:LUC.

      Thanks, these data can be found in Figure S3F. The detrended Per2:Luc CKO and CPKO bioluminescence traces were better fit by the null hypothesis (straight line) than a damped sine wave (p>0.05) and so were not significantly rhythmic by the criteria used in this manuscript.

      Lines 258-259, "much less than the half-life of luciferase expressed in fibroblasts under a constitutive promoter" In figure S4D, the y-axis of the PER2::LUC is ~800 while the y-axis of the SV40::LUC is ~600000. The over-expressed LUC by the SV40 promoter might saturate the degradation system in the cell so the comparison is not fair. A weaker promoter with the level similar to Per2 should be used to make the comparison.

      Thank you for this suggestion. In our experience, the SV40 promoter is actually a rather weak promoter compared with CMV, and faithfully facilitates the constitutive (non-rhythmic) expression of heterologous proteins such as Luciferase (Feeney et al., JBR, 2016). It has been shown previously that constitutive over-expression of heterologous proteins such as GFP or even CRY1 does not affect circadian rhythms in fibroblast cells (e.g. Chen et al., Mol Cell, 2009). To address the reviewer’s reasonable concern however, multiple stable SV40:Luc fibroblast lines were generated by puromycin selection, grown to confluence in 96-well plates, then treated with 25 μg/mL CHX at the beginning of the recording. Random genomic integration of SV40:Luc leads to a broad range of different levels of luciferase expression, evident from the broad range of initial luciferase activities. For each line the decline in luciferase activity was fit with a simple one-phase exponential decay curve (R2≥0.98) to derive the half-life of luciferase in each cell line. There was no significant relationship between the level of luciferase expression and luciferase stability (straight line vs. horizontal line fit p-value = 0.82). Therefore constitutive expression of SV40:Luc in fibroblasts does affect the cellular protein degradation machinery within the range of expression used for our half-life measurements. These new data are reported in Revised Figure S3H.

      Line 430, "sigma" to "Sigma".

      Changed

      In figure S2, the classification of rhythms in Drosophila is not clear since even the "Robustly rhythmic" ones have high background noise. Detrending or fitting the data might be able to improve the quality of the rhythms prior to classification.

      These are noisy data as they come from freely behaving flies. The mean data was shown in Figure S3A and individual examples in S3B, and look very similar to previous bioluminescence fly recordings of XLG-LUC flies in papers from the Stanewsky lab who have published extensively using this model. The classifications arose from double-blinded analysis of the bioluminescence traces by several individuals, but we agree that this was not clearly communicated in our original submission. In Revised figure S2 we now present the mean bioluminescence traces, with and without damped sine wave vs. straight line fitting, as suggested, which is more consistent with the mammalian cellular data presented elsewhere.

      In figure S3B, the original blots for Per2 including Input and IP should be shown.

      The original blots for BMAL1 are shown in figure S3I. PER2::LUC levels were assessed by measuring bioluminescence levels present on the anti-bmal1-beads, as described in the figure 3B legend.

      Supplemental information Line 44, "...(reviewed in (Lakin-Thomas,..." to "...(reviewed in Lakin-Thomas,..."

      Changed

      Line 188, "Period CDS", the full name of CDS should be provided the first time it appearances.

      Changed to “coding sequence”.

      Reviewer #2 (Significance (Required)): The work suggests a link between the TTFL and non-canonical oscillators, which should be interesting to the circadian field.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)): **Summary:** The paper "CRYPTOCHROMES confer robustness, not rhythmicity, to circadian timekeeping" by Putker et al. answers the question of whether or not the rhythmic abundance of clock proteins is a prerequisite for circadian timekeeping. They addressed this by monitoring PER2::LUC rhythms in WT and CRY KO (CKO) cells. CRY forms a complex with PER, which in turn represses the ability of CLOCK/BMAL1 to drive the expression of clock-controlled genes, including PER and CRY. Consistent with previous observations, the authors found residual PER2::LUC rhythms in CKO SCN slices, fibroblasts and in a functional analogue KO of CRY in Drosophila, even in the absence of rhythmic Per2 transcription due to the loss of CRY as a negative regulator of the oscillation. They have shown that these rhythms, in the absence of CRY, follow the formal definition of circadian rhythms. They attributed these residual PER2::LUC rhythms to the maintenance of oscillation in PER2::LUC stability independent of CRY, by testing the decay kinetics of luciferase activity when translation is inhibited. Moreover, they implicated the kinases CK1d/e and GSK3 to be involved in regulating PER2::LUC post-translational rhythms through kinase inhibitor studies. They concluded that CRY is not necessary for maintaining PER2::LUC rhythms, but plays an important role in reinforcing high-amplitude rhythms when coupled to a proposed "ctyoscillator" likely composed of CK1d/e and GSK3. **Major comments:** The authors have shown sufficient data that under different testing conditions (mice locomotor activity, SCN preps or fibroblasts), behavioral rhythms and PER2::LUC rhythms are still observed in the CRY KO (CKO) cells, contrary to a previous study (Liu et al., 2007). They also indicated limitations to some of the.experimental work. However, there are some parts of the paper that need clarification to support their conclusions. 1.In Fig. 1A, the x-axes of the actograms for WT and CKO are different. While they mentioned this in the figure legend, and described the axis transformation in Fig. S1A, they need a justification statement about why they did this in the results.

      Thanks, we have included the following sentence in the results section as requested:

      Figure 1 representative actograms are plotted as a function of endogenous tau (**t) to allow the periodic organisation of rest-activity cycles to be readily discerned; 24h-plotted actograms are shown in Figure S1A and S2A

      2.In an attempt to show conservation of their proposed role for CRY, they tested the model system Drosophila melanogaster where TIMELESS serves as the functional analogue of CRY. While they showed in the figures and described in the text that rhythms still persisted with lower relative amplitude in the TIMELESS-deficient flies, they did not describe any period differences between WT and mutant. Showing the period quantification in Supp. Fig. S2 using the robustly rhythmic datasets, and describing this data in the text, will strengthen their claim.

      These analyses are now reported in revised Figure S2 as requested. As described in our response to reviewer 2, the “robustly rhythmic” flies were scored as such through double-blinded analysis by several individuals. We hope the reviewer will appreciate our concern that exclusion of the majority of TIMELESS-deficient flies that were not robustly rhythmic might skew their apparent period by unconscious bias towards favouring traces that most clearly resemble robustly rhythmic WT controls. To avoid any potential bias we therefore included all flies of both genotypes in the analysis of circadian period for the revised figure, as suggested by our other reviewers.

      In Fig. S2B, there is no clear distinction between the representative datasets shown for poorly rhythmic and arrhythmic, i.e. they all appear arrhythmic, without an indicated statistical test. The authors could present better representative data to better reflect the categories.

      As described above, we now show the grouped mean with and without fitting for all flies of both genotypes. The statistical test for rhythmicity and analysis of circadian period is now the same as was performed for the cellular data presented elsewhere.

      3.In Fig. 2A, the authors note the lack of rhythmicity in the CKO fibroblasts in the 1st three days at 37oC. How are the conditions here different from fibroblasts in Fig. 1E, where rhythms are seen during the 1st three days in CKO fibroblasts?

      As discussed in the manuscript, PER2::LUC rhythms in CKO cells and SCN are observed stochastically between recordings i.e. if one dish in a recording showed rhythms, all dishes showed rhythms and vice versa. The media change that occurred after 3 days in Fig 2A, in this case, was sufficient to initiate clear rhythms of PER2::LUC in all experimental replicates. In other experiments, media change did not have this effect. Herculean efforts by multiple lab members over many years, including the PI, have been unable to delineate the basis of this variability – which is discussed at length in the thesis of Dr. David Wong https://www.repository.cam.ac.uk/handle/1810/300610. As such, we clearly state in the discussion:

      We were unable to identify all of the variables that contribute to the apparent stochasticity of CKO PER2::LUC oscillations, and so cannot distinguish whether this variability arises from reduced fidelity of PER2::LUC as a circadian reporter or impaired timing function in CKO cells. In consequence, we restricted our study to those recordings in which clear bioluminescence rhythms were observed, enabling the interrogation of TTFL-independent cellular timekeeping.”

      1. The authors claimed in the results section- "in contrast and as expected, Per2 mRNA in WT cells varied in phase with co-recorded PER2::LUC oscillations." but Fig. 3C does not show this expected lag between mRNA and protein levels. This needs to be explained

      No lag is expected in vitro. A lag between PER protein levels and Per mRNA does occur in vivo and is very likely to attributable to daily rhythms in feeding (Crosby et al, Cell, 2019), where increased insulin signalling elicits an increase in PER protein production 4-6h after E-box and GRE-stimulated increase in Per transcription.

      When luciferin is saturating intracellularly, PER2::LUC activity correlates most closely with the amount of PER2::LUC protein that was translated during the preceding 1-2h, rather than the total amount of PER2, due to the enzymatic inactivation of the luciferase protein (Feeney et al, JBR, 2016). Consistent with many previous observations, under constant conditions, the rate of nascent PER protein synthesis is largely determined by the level of Per2 mRNA, and thus more similar phases are observed between protein and mRNA in vitro than in vivo.

      We have inserted an additional citation of Feeney et al at this point in the text to make this clear.

      5.In Figs. 5A-B, the PER2::LUC periods in the CKO untreated cells seem to vary significantly between A, B, and C. While this could be due to the high variability in the rhythms that were previously described by the authors, the average periods here seem to be longer than the one reported in Fig. 1F. Are there specific condition differences?

      There are no specific condition differences. As reported in Figure S1B, D & E, the range of CKO cellular periods is simply much broader than for WT cells. Over several dozen experiments the average period was significantly shorter, but the period variance is an equally striking feature of rhythms in these cells which we take as evidence for their lack of robustness.

      *Would additional experiments be essential to support the claims of the paper?*

      1. There is sufficient experimental data to support the major claims; however some suggested experiments are listed below.

        a. If CKO exhibits residual rhythms in PER::LUC, it would be interesting to know how CRY overexpression influences PER2::LUC rhythms, or point to previous reference papers which may have already shown such effects. The prediction would be PER2::LUC levels will still be rhythmic when CRY is overexpressed. What would be the extent of "robustness" conferred by CRY on PER2::LUC rhythms based on CRY KO and overexpression studies?

      These experiments have largely already been performed (see Chen et al., Mol Cell; Nangle et al., eLife, 2014; Fan et al., Curr Biol, 2007; Edwards et al., PNAS, 2016) and are cited in this manuscript. As suggested, PER2 rhythms remain intact under CRY1 over-expression, though are clearly perturbed, but their robustness was not investigated in any detail. We hope to be able to address this important question in our subsequent work

      The authors found that CK1d/e and GSK3 contribute to CRY-independent PER2 oscillations by showing that addition of kinase inhibitors affect the PER2::LUC period lengths in WT and CKO in the same manner. It would be interesting to know if a) PER2::LUC stability and b) PER2 phosphorylation status, is affected in WT and CKO in the presence of the inhibitors, or point to previous reference papers which may already have shown such effects.

      As the reviewer points out, PER2 stability is already reported to be regulated via phosphorylation by GSK3 and CK1. We have made explicit reference to this in the revised manuscript as follows:

      In contemporary models of the mammalian cellular clockwork CRY proteins are essential for rhythmic PER protein production, however, the stability and activity of PER proteins are also regulated post-translationally (Lee et al., 2009; Philpott et al., 2020; Iitaka et al, 2005).”

      *Are the data and the methods presented in such a way that they can be reproduced?*

      1. The protocol for the inhibitor treatments are not in the main or supplemental methods.

      In the main text methods, section luciferase recordings we state: “For pharmacological perturbation experiments (unless stated otherwise in the text) cells were changed into drug-containing air medium from the start of the recording. Mock-treatments were carried out with DMSO or ethanol as appropriate.”

      *Are the experiments adequately replicated and statistical analysis adequate?*

      1. All experiments had the sufficient number of technical and biological replicates to make valid statistical analyses. For Fig. S2, the authors used RAIN to assess rhythmicity in WT and mutant flies, but it is not clear whether the different categories (rhythmic, poorly rhythmic, and arrhythmic) were based on amplitude differences alone, or a combination of amplitude and p-values as determined by RAIN.

      As reported above, we have revised the analysis of the fly data to be consistent with the cellular data reported elsewhere in the manuscript.

      **Minor comments:** *1. Are prior studies referenced appropriately?* Authors may wish to include Fan et al., 2007, Current Biology which demonstrated that cycling of CRY1, CRY2, and BMAL1 is not necessary for circadian-clock function in fibroblasts.

      Apologies for the omission of citation to this excellent paper. Now referenced in the introduction.

      *2. Are the text and figures clear and accurate?* Figures were clear and illustrated well. See minor comments on text below:

      1. Other minor comments

      Main Text: p3, line 62; p12, line l32: It doesn't seem necessary or appropriate to cite the dictionary for the definition of robust.

      Thanks for this suggestion. During preparation of the manuscript we found that there was some disagreement between authors as to the meaning of robustness in a circadian context. We therefore feel it most necessary to define clearly what we mean by the use of this word to avoid any potential ambiguity.

      p4, line l87: "~20 h" rhythms instead of "~20h-hour" p3, line 70; p5, line 121; p14, line 380; p16, line 416 and p18, line 458: Close parentheses have been doubled in parenthetical references. p14, line 363: "crassa" instead of "Crassa" p17, line 430: "Sigma" instead of "sigma" p18, lines 464 and 483; p20, line 521: put a space between numerical values and units, to be consistent with other entries p19, line 488: "luciferase" instead of Luciferase p20, line 512: "Cell Signaling" instead of "cell signalling" p20, line 526: "single" instead of "Single"

      We thank the reviewer for his/her thoroughness, all of the above have been changed.

      Main figures: Fig. 2 p37, line 921: close parenthesis was doubled on "red"

      This was actually correct.

      Fig. 4 p41, line 989: "0.1 mM" instead of "0.1 mM" for consistency throughout text Supplementary text: line 171: "30 mM HEPES" instead of "30mM HEPES" line 184: "Cell Signaling" instead of "cell signalling" Supplementary figures: Fig. S2A "Drosophila melanogaster" instead of "Drosophila Melanogaster"

      All of the above have been changed.

      Reviewer #3 (Significance (Required)): This paper revisits the previously proposed idea that rhythmic expression of central TTFL components is not essential for circadian timekeeping to persist. However, this paper does not add a significant advance in the understanding of the underlying reasons behind sustained clock protein rhythmicity like PER in the absence of CRY, since such mechanisms in functional analogs have been shown in other systems, like Neurospora (Larrondo et al., 2015). However, this paper does clarify some issues in the field, such as discrepancies between behavioral and cellular rhythms observed in CKO mice, leading future researchers to examine closely the conditions of their CKO rhythmic assays before making conclusions pertaining to rhythmicity. The identification of the kinases as components of the proposed cytosolic oscillator (cytoscillator) needs further validation, but this is perhaps beyond the scope of the paper. The data provides incremental evidence for the existence of a cytoscillator, but opens up opportunities to identify other players, like phosphatases, to establish the connection between the central TTFL and the proposed cytoscillator.

    1. ie s ex is t. A n d , a lth ou g h th e re is a ® x ed n ess to t h e n o t io n o f th ese ca te go ries, th ew a y s in w h ic h th e y a ctu a lly o p e ra t e are ̄ u id a n d sh ift in g . F o r e xa m p le, a s an AfricanA m erican fem a le a c ad em ic, I ca n b e a n d am so m et im es p o s it io n ed a s c o n cep tu allyW h ite in re la tio n to , p erh a p s , a L a t in o , S p a n is h -s p ea k in g g a rd en er. In th a t in sta n c e,m y cla s s a n d so cia l p o sit io n o v erride m y ra cia l id e n ti® c a tion a n d fo r th at m o m e n t Ib eco m e ` ` W

      The idea of fluidity and shifting in the way categories shift reminds me of ideas brought up in my Intro Women's Studies course. In talking about the patriarchy, we discussed that one must look at the multiple categories people fit into within a larger, baseline category to see how some who are oppressed or minority groups can still benefit from larger systems in relation to others in one of their shared groups; For example, a straight black man will benefit from the patriarchy as a straight man, but will face oppression for being black. However, there is still male privilege because a straight black woman may be oppressed for her gender identity and her race.

      This goes back to the intersectionality we discussed with the Nash reading as well. Getting into further levels of identity will show how a person can be a part of a marginalized group of people but not share the same experiences because of individuality as Ames pointed out in class, and also because of the many identity groups one may identify with. As we discussed in my Intro Women's Studies class, men generally benefit from the patriarchy but not all men have gained equally from it.

      In this case, Billings is stating that although part of a marginalized group, she still benefits more than someone else may in a marginalized group because she has the social position of being highly educated and English speaking.

      • Sophie W.
    1. Our work to understand the intersection of literacy, identity, and creativity often depends on our capacity to follow individuals, texts, and tools across time and space, and our ability to make sense of their lives on and off the A call for using storytelling as language and literacy theory, research methodology, and practice. Journal of Literacy Research, 49,467–475.KinlocH, V., & sAn PEDro, t. (2014). The space between listening and storying: Foun-dations for Projects in Humanization. In D. Paris & M. T. Winn (Eds.), Humanizing research: Decolonizing qualitative inquiry with youth and communities (pp. 21–42). Thou-sand Oaks, CA: SAGE.koVAcH, M. E. (2009). Indigenous method-ologies: Characteristics, conversations, and contexts. Toronto, Canada: University of Toronto Press.mArtinEz, D. C. (2017). Imagining a language of solidarity for Black and Latinx youth in English language arts classrooms. English Education, 49, 179–196.milEs, m. B., & HuBErmAn, A. M. (1994). Qualitative data analysis: An expanded sourcebook. Thousand Oaks, CA: SAGE.PAtEl, L. (2014). Countering coloniality in educational research: From ownership to an-swerability. Educational Studies, 50, 357–377. PAtEl, L. (2015). Decolonizing educational research: From ownership to answerability. New York: Routledge.sAn PEDro, t., cArlos, E., & mBuru, J. (2017). Critical listening and storying: Fostering respect for difference and action within and beyond a Native American literature class-room. Urban Education, 52, 667–693.sAn PEDro, t., & kinlocH, V. (2017). Toward Projects in Humanization: Research on co-creating and sustaining dialogic relation-ships. American Educational Research Journal, 54(1 Suppl.), 373S–394S.trAcy, S. J. (2010). Qualitative quality: Eight “big-tent” criteria for excellent qualitative research. Qualitative Inquiry, 16, 837–851.tuck, E. (2009). Suspending damage: A letter to communities. Harvard Educational Review, 79, 409–428.winDcHiEF, s., & sAn PEDro, t. (EDs.) (2019). Applying Indigenous research methods: Story-ing with peoples and communities. New York: Routledge.Timothy San Pedro is assistant professor of Multicultural and Equity Studies in Educa-tion at The Ohio State University. i390-400-May19-RTE.indd 3976/4/19 1:50 PM398Research in the Teaching of EnglishVolume 53 May 2019screen.

      Takeaway: What you are trying to understand through reading this article.

    1. This manuscript is in revision at eLife

      The decision letter after peer review, sent to the authors on June 23, 2020, follows.

      Summary

      It has been previously shown that resistance to parasitoid wasps can emerge upon selection in wild-type Drosophila populations, and that this increased resistance correlates with a higher number of hemocytes. This paper combined experimental evolution and single cell transcriptomics to show that increased resistance to parasitoids upon several rounds of selection is caused by the presence of a differentiated subset of hemocytes (pre-lamellocyte) in the unchallenged state, which is usually found only upon wasp infestation. This led the authors to conclude that intense pathogen pressures can shift the immune system from inducible to constitutive, consistent with a theoretical framework indicating that elevated and constant pathogen pressure should lead to the emergence of constitutive defense. The approach is interesting, the paper well-written and the notion tested interesting. An important concern is the degree of advance over previous studies. Initial papers investigating how selection increases resistance to wasps have already shown that this was linked to an increase in hemocyte number. In a certain sense, this could be considered as a demonstration of a change from inducible to constitutive defense, although the emphasis of these papers was not on this point. In addition, the current work provides so far only limited information on this specific population of pre-lamellocytes.

      Essential Revisions

      1) Analysis of single cell RNA-seq (Figure 3). Several RNA-seq papers have been published and it is important that the authors better relate their hemocyte clusters to other scRNA-seq datasets using the nomenclature of some of these papers. Would their data be deposited in a database? It would also be great to better describe the transcriptional profile, and not only focus on two genes, Attila and PPO3.

      2) Discrepancy between the transcriptional and morphological changes in the hemocytes.

      2a) Earlier studies, both on hemocyte flow cytometry and in other scRNA-seq experiments (as cited in the manuscript) revealed that the transdifferentiation into lamellocytes is a dynamic / continuous process, which may derive from several hemocyte lineages and from different hematopoietic organs. The authors here showed a discrepancy in the transcriptional and morphological changes in the hemocytes, and revealed that the plasmatocyte lineage was already starting the resemble the lamellocytes (in gene expression), without needing the induction by infection. Yet, they were not yet fully differentiated hemocytes based on morphology, and still needed infection to reach that stage. Therefore, the conclusion that the selected lines had "hard-wired" the inducible response into a constitutive response is not fully warranted (they do not fully differentiate, but proceed partially towards that state). Also, the differentiation of lamellocytes is fully attributed to originate from lymph glands and as originating from the plasmatocytes, while different organs and hemocyte lineages appear to contribute to the population of lamellocytes. The reviewer feel that all these aspects should be further explored and would deserve some mentioning in the discussion.

      2b) Along this line, the authors could do a better job in characterizing the hemocyte populations of the evolved lines using available antibody, cooking and other melanization assays, phalloidin treatment...

      2c) Third instar hemocytes are found in the sessile state, in circulation or in the lymph gland. It could not be excluded that some of the changes they observed relate more to changes in hemocyte localization rather than differentiation. According to the material and methods, the authors has collected only the circulating hemocytes in the unchallenged state as they did not vortex larvae. It is very important to better compare the lymph gland, sessile and circulating compartments of the evolved and the non-evolved lines. This can be done by using various staining methods. The paper is written in such a way that selection acted only on circulating hemocytes but it could also act on hemocytes localization (decrease sessility), lymph gland maturation....

      3) Gene expression was measured in circulating hemocytes at 48h after infection.

      The authors measured gene expression in circulating hemocytes, 48h after infection, at which stage hemocyte proliferation, lamellocyte differentiation and parasitoid encapsulation is already well underway. The induction of the critical two processes, hemocyte proliferation and lamellocyte differentiation, may not be fully detectable from gene expression of only the circulating hemocytes themselves at this late stage of the immune response. Clearly, the authors do show that differentiation from circulating plasmatocytes can be detected, using pseudotime, and also revealed changes in gene expression in uninfected selected larvae. Yet, how induction in the lymph glands or sessile clusters has changed by experimental evolution, and whether the inducible response had indeed proceeded towards a constitutive response, requires further investigation along a wider time course (e.g. during early larval development) and perhaps in different tissues (e.g. lymph glands). If the author cannot address this, this aspect would need some discussion.

      4) The changes in gene expression after selection can be presented clearer.

      The description of these results (from L111 onwards), and Figure 2, difficult to read and understand, while it is key to the claim that the inducible response has become hardwired into a constitutive response. In the text it starts out with saying that "data was pooled to investigate global changes" (L116-117), but then it refers in Figure 2 to the x-axis which only provides the data for the control lines. This figure 2 is difficult to grasp, as the strong positive correlation in a) means something different (i.e. stronger constitutive response) than the very similar positive correlation in b) (weaker induced response), while c shows that control and selected larvae respond the same to infection. Is there a better way to tease apart these patterns in a figure, and to explain them in the text? Also, the data is all expressed in log2 fold changes (relative to non-infected control line individuals?). Also, for a subset of approximately 170 genes, the authors showed that the increase in expression had already started without the infection in the selection lines. Do the functional annotations of these genes reveal anything of interest for hemocyte proliferation and the differentiation towards lamellocytes?

      5) Other studies came to partially contrasting, partially similar conclusions.

      Transcriptomics on whole larvae after experimental evolution for high parasitism was done for Drosophila, using a different parasitoid species. In this study, they also found the typical increased density of hemocytes in Drosophila selected for increased parasitoid resistance, without being infected. However, contrary to the authors, this study concluded this increase in hemocytes could not be attribute to a pre-activation of the immune response. Additionally, the genes for hematopoiesis and for several effector genes showed opposite patterns to those that would explain the increased density of hemocytes in selected lines or for an pre-activation of the inducible response (Wertheim et al, 2011, Molecular Ecology). However, in line with the findings for the current study, whole-larvae RNAseq after parasitoid infection did not result in substantial gene expression differences between selected lines and control lines (Salazar et al, 2017, BMC Genomics), while substantial differences were reported in uninfected larvae of selection and control line larvae (Wertheim et al, 2011, Molecular Ecology). These whole-body transcriptomics experiments lacked the resolution to measure specifically what changed in hemocytes, but both studies indicate that much of the increased resistance after selection is likely caused by changes in constitutive immunity, not by increasing the acute/inducible immune response.

      6) Another concern is related to the parasitoid species. Leptopilina boulardi is a parasitoid that relies partly on VLPs to overcome the host defense. This is not discussed, not even mentioned. Some older work (Fellowes et al 1999, Evolution), shows that, while resistance evolves readily against L. boulardi, populations resistant against L. boulardi are also cross-resistant to another Leptopilina species. The immune effectors studied in this manuscript are obviously playing a significant role, but how do the evolved flies cope with the VLPs? The paper would benefit from at least discussing this issue.

      7) The selection of larvae for the single cell work warrants some clarification. According to figure 1b just under 50% of parasitoid resistant larvae showed an increased encapsulation response. This is presumably also related to the increase of expression of immune effectors. How is this accounted for in the single cell work? And if not, do you have any way to get an estimate of the variance in the response variables?

    1. This manuscript is in revision at eLife

      The decision letter after peer review, sent to the authors on June 12, 2020, follows.

      Summary

      All three reviewers agree that the research question under study, the requirement of the cross-talk between two important developmental signaling pathways - retinoic acid and the NO - for amphioxus pharynx development, is in principle interesting and could be suitable for publication in eLife.

      However, at present there are major open concerns especially on the lack of statistical analyses, quality of data presentation and inconsistencies with previously published work, that need to be addressed. Although it is the current policy of eLife to avoid additional experiments in revisions as much as possible, this is unfortunately likely impossible to fulfil with the current manuscript in order to bring it to a level that matches the standards of eLife. However, we think that in many cases an improvement of analyses and data presentation will likely already significantly improve the manuscript.

      1) The presented study is a follow-up on a previous paper by the same lab (Annona et al 2017 ; DOI:10.1038/s41598-017-08157-w). When comparing the work of this previous study with the current manuscript two major discrepancies are apparent:

      In Annona et al the two drugs were used to inhibit NOS production: L-NAME and TRIM, while only one inhibitor was used in the present study. Furthermore, there appear to be discrepancies concerning the developmental time windows during which chemical disruption of NO signaling is effective described in the two publications. This needs to be clarified.

      The timing of NosA,B,C expression, the suggested regulation of NosA and B by retinoic acid (RA) and the detected presumptive RARE regulatory elements in the genome don't match. More specifically, NosA,B,C expression at 24 hours (or around this time point) was investigated by Annona et al, 2017. Based on these data, NosA is not expressed during development, whereas NosB and NosC are expressed. In the submitted manuscript, the authors show that NosA and NosB are upregulated upon RA treatment, whereas NosC shows no changes in expression. They therefore suggest that RA regulates NosA and NosB transcription. Since only NosB is expressed during the relevant timepoints at early development, the transcription of this gene could be under the regulation of RA. However, when the authors look into the retinoic acid response elements (RARE) in the genomic region of NosB, they only find a DR3, which is not the typical RARE. They find DR1 and DR5 (apart from DR3's), which are more typical RARE's, in the genomic region of NosA, but as mentioned this gene is not expressed during development. This makes the hypothesis of a direct regulation of NosA and NosB by RA during normal development unconvincing. Can the author dissolve these apparent discrepancies?

      2) The authors study the open chomatin structure at 8, 15, 36 and 60 hours, thus time points, which do not overlap with the drug treatment period (24-30 hours). They need to analyze the genome architecture at this time period.

      3) The previous work by Annona et al 2017 et al shows that a major peak at NO levels occurs later than the chosen treatment window. How do NO levels during the time window of the experiment compare with other studies, i.e. is there evidence these are relevant levels? This is particularly noteworthy, as there is no control experiment showing that TRIM incubation affects NO levels or NO signaling during the incubation period (e.g. DAF-FM-DA staining or by NO quantification). It is therefore not possible to estimate the specificity of the resulting phenotypes.

      We thus request from the authors to provide ISH patterns of all the Nos genes, as well as NO localisation from at least 2 timepoints (e.g. start and end of window) of the TRIM application window.

      4) One overarching critique is that the general description of the figures and hence also the phenotypes are of poor quality. An improvement of this point will already majorly improve the entire manuscript.

      Fig.1A: Indicate developmental stages (N2, N4, T1, T2, T3, L0) together with the hours-post-fertilization (hpf) to facilitate the understanding of the treatment period with respect to the development of amphioxus.

      Fig.1B: Outline pharyngeal region e.g. with thin, dashed white lines in longitudinal and cross-sections and indicate relevant anatomical structures (club-shaped gland, endostyle, gill slits) e.g. with an arrow. Is the endostyle positioned more ventrally in TRIM treated larva?

      Figure 1C: why are Cyp26.3, Rdh11/12.18 and Crabp shown in triplicates?

      Fig.1B: The 'digital sectioning' method using confocal imaging and reconstruction of nuclear stainings is not suited to characterize the phenotype. Due to the loss of signal in deeper regions, morphological structures (e.g. differences in pharyngeal and gill slit morphology, endostyl, club-shaped glands) are impossible to recognize.

      Fig.3B: the heads of these amphioxus should be annotated to indicate key structures for non-amphioxus specialists. Ideally the images should be higher magnification and resolution as well, as the morphology is currently not very clear.

      Fig.3A and B: Furthermore, the morphological differences between 'altered', 'partially recovered' and 'recovered' is unclear. Fig.3B does not help understanding changes as the pictures are too small to recognize any morphological details without staining, and no structures are indicated. It is also unclear how animals scored as 'altered', 'partially recovered' and 'recovered' differ in their morphological structures. And does 'recovered' mean that these embryos show an initial phenotype that then 'recovers' during development, or do they show a completely normal development?

      5) Missing statistics/statistical information: Lines 85-89 (Fig.1): Where is the evidence that there is reduction in pharynx length? Where is the evidence for a smaller first gill slit? Measurements with a decent sample size and a basic statistical test must be provided.

      The description of ISH pictures in Fig.2A lacks any quantification and thus any information on the penetrance of the respective phenotypes are (as in Fig 3C). The lack of any 'negative control genes' (the large set of genes that, based on the RNASeq dataset, should not be affected) make it difficult to judge how specific changes in AP axis and RA pathway genes are.

      How did the authors obtain the qRT-PCR calculations? They need to clarify how they obtained the Fold changes shown in the histograms .e.g. by showing the maths behind the result when marking the cells in the excel sheet. The raw data for rpl32 is missing for Crabp in Figure 2B. The qPCR results in Fig.2B-E lack significance tests.

      6) The RNA-Seq study needs improvements: The PCA (Fig.S1C) shows no concordance among control samples or treated samples. Also, the histogram shows a clustering of replicates, and NOT of 'treated' and 'control' samples. This casts doubts on the quality and validity of the RNASeq dataset. These doubts are not removed by the current validation experiments, as these experiments tested only significantly upregulated genes by RNA-Seq, while downregulated and non-significant genes as 'controls' are missing. These additional controls are necessary to assess the validity of the RNA-Seq data.

      7) More information about the details of the ATACseq and ChIPseq data used, as well as the general RA responsive elements prediction is required.

      For example, in what amphioxus samples (and treatments if any) are these ATACseq and ChIPseq signals seen? There is some detail provided in the Methods section, but something is odd here and perhaps needs some further explanation. Since the two relevant Nos genes are supposedly not active during development then why do they have ATACseq and ChIPseq signals from embryo and larval samples? Why should these two Nos genes have apparently active regulatory elements focused on RAREs when the genes are not normally expressed under the control of RA, but only become active when exogenous RA is applied? We may well have missed something in the logic here, but this merely shows that the current level of explanation is insufficient.

      The analysis of RA responsive elements lacks statistical analysis and depth. It is left unclear how many RAREs would be expected by chance on a 52kb resp. 25kb locus. In addition, the authors include all ATAC-Seq peaks from stages ranging between 8h and 60hpf, while the window of RA responsiveness has been tightly restricted to the 24h-30hpf window. Also, as NosC expression levels stay constant upon RA incubation, it would be crucial to know if the NosC locus lacks any open RARE sites (as would be expected).

      The authors use NHR-SCAN tool to predict putative direct repeats binding sites in the genomic sequence of NosA and NosB. Which consensus sequence does the program follow? It appears that it does not follow the consensus sequence for typical RARE ((A/G)G(G/T)TCA), since the sequence for DR1 deviate from this sequence? DR1, DR2 and DR5 are the commonly described binding RARE's for the RAR/RXR heterodimers. Further, DR8 has been described as retinoic acid dependent regulation of gene transcription through RAR/RXR (Moutier et al., 2012). The authors need to provide clarification which are the most commonly used RARE's of the DR's detected.

      Please also mention if RAREs fall within an intron in the genomic regions of the Nos genes, since the transcriptional regulation through RARE is often associated to introns.

      8) Information on the concentration dependency of compounds used in the rescue experiment is lacking. Please explain why the BMS009 concentration used here (10exp-6 M) is 10x higher than the highest concentration used in the original publication on amphioxus pharynx development (Escriva et al., Development 2002).

      9) A summary drawing of the regulatory loop between NO and RA would be informative, also indicating the known target genes (from this study).

    1. T h e c l u b h o u s e c o o r d i n a t o r s i n c l u d e d L u i s i n fi e l d t r i p s c o n n e c t e d t o h i s i n t e rests, including one to the game design company Electronic Arts. Luis remembered, “That was pretty cool. We learned a lot about its history. We got to try some games that hadn’t come out yet.” The coordinators also often promoted his work by showing his movies to guests and new members.

      This is a great way to foster a child's learning. Taking a subject that they are interested in and showing them how they can apply it to some career fields.

    2. A c r o s s t h e o b s e r v a t i o n s a n d i n t e r v i e w s w e f o u n d t h a t L u i s ’ s l e a r n i n g p a r t n e r s played a variety of roles.

      his friends who had affinities for stop motion animation helped him further pursue this interest

    1. Ip, A., Ahn, J., Zhou, Y., Goy, A. H., Hansen, E., Pecora, A. L., Sinclaire, B. A., Bednarz, U., Marafelias, M., Mathura, S., Sawczuk, I. S., Underwood, J. P., Walker, D. M., Prasad, R., Sweeney, R. L., Ponce, M. G., LaCapra, S., Cunningham, F. J., Calise, A. G., … Goldberg, S. L. (2020). Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study. MedRxiv, 2020.08.20.20178772. https://doi.org/10.1101/2020.08.20.20178772

    1. SciScore for 10.1101/2020.08.28.20180463: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Qualitative detection of IgM and IgG antibodies was performed in a fully-automated Elecsys® Anti-SARS-CoV-2 electrochemiluminescence immunoassay on the Cobas® e601 analyser (Roche Diagnostics)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IgG</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Questions on the use of health services included if the individual looked for health services, received care when seeking health services, was hospitalized for over 24 hours, received a medical diagnosis of suspected COVID-19, performed RT-PCR for SARSCoV-2, and performed an antibody test– point-of-care/serology for SARS-CoV-2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SARSCoV-2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 antibodies detection For the qualitative determination of antibodies against SARS-CoV-2, 5·0 ml of whole blood was collected, and after centrifugation at 1800 g for 15 min, the serum was obtained.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SARS-CoV-2</div> <div>suggested: None</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      There are some limitations: for some estimates, the confidence intervals were wide, and thus our power to detect statistically significant associations was lower than desired; some population groups (males and people of working age) were underrepresented in our sample. Contributors Antônio A M Silva, Lídio G Lima-Neto, Conceição M P S Azevedo, Léa M Costa, Maylla L B M Bragança, Allan K D B Filho, Bernardo B Wittlin, Bruno L C A Oliveira, Carolina A Carvalho, Erika B A F Thomaz, Eudes A Simões-Neto, Jamesson F Leite-Júnior, Marcos A G Campos, Rejane C S Queiroz, Vitória A Carvalho, Vanda M F Simões, Maria T S B Alves and Alcione M Santos contributed to the conception and design of the work, the acquisition, analysis, and interpretation of the data, and the draft of the manuscript. Bruno F Souza, Sérgio S Costa and Lécia M S Cosme contributed to the acquisition and analysis of the data. All authors have approved the submitted version. Declaration of interests We declare no competing interests.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. Author Response

      Summary:

      A strength of the work was that the mathematical modeling of re-replication captured variability in origin firing and supported a mechanism that might explain copy number variation observed in many eukaryotes. However, concern was expressed regarding the influence of assumptions made in developing the model on the outcomes and the moderate correlations between simulations and experimental data. Further explanation of the questions being investigated, the validity and nature of assumptions that were used to develop the simulations, and details explaining how these assumptions were built into the modeling were considered important. Some attempt to align the modeling outcomes with known re-replication hotspots would also improve the study. Some of the parameters used for modeling were concerning, including the use of a 16C ploidy cutoff without adequate justification. Reviewers also made suggestions for improving the experimental validation tests. Reviewers also noted places in the manuscript that require additional clarification. Overall, some concerns were raised regarding the experimental methods, and the impact of the insights gained.

      We would like to thank eLife for this Preprint Review service.

      In this manuscript, we present for the first time a model of DNA rereplication, which permits us to analyse how the process evolves at the single-cell level, across a complete genome, over time. This analysis revealed a pronounced heterogeneity at the single cell level, resulting in increased copies of different genomic loci in different cells, and highlighted rereplication as a powerful mechanism for genome plasticity within an evolving population. We would like to thank the reviewers for their critical appraisal of our work and the editor for his summary of the reviews. The points raised were overall easy to address, and we have done so in a revised version of the manuscript, where we have also clarified points which were unclear to the reviewers. Importantly, we have clarified that: there are currently no available methods for studying rereplication dynamics experimentally at the single cell level across the genome, and it is exactly this analysis that our manuscript offers; model assumptions were either standard and previously validated experimentally for DNA replication or subjected to sensitivity analysis with key findings shown to be robust to model assumptions; there was no arbitrary cut-off point in the rereplication process, which was analysed over time - an advantage of our approach. Data were depicted early in the process (2C) and late in the process (16C) but findings were robust across the process; fission yeast cells can be experimentally induced to rereplicate to different extents (from 2C to 16C or even 32C) and our model permits us to capture the process as it evolves at any ploidy; correlations between experimental and simulated data were highly significant and robust to model assumptions.

      We would like to thank the reviewers for their comments, which we believe have helped us improve our manuscript and clarify points of possible misunderstanding. A point-by-point response follows.

      Reviewer #1:

      The authors develop and analyse a mathematical model of DNA rereplication in situations, where re-firing of origins during replication is not suppressed. Using the experimentally measured position and relative strength of origins in yeast, the authors simulate DNA copy number profiles in individual cells. They show that the developed model can mostly recapitulate the experimentally measured DNA copy number profile along the genome, but that the simulated profiles are highly variable. The fact that increasing copy number of an origin will facilitate its preferential amplification essentially constitutes a self-reinforcing feedback loop and might be the mechanism that leads to overamplification of some genomic regions. In addition different regions compete for a limiting factor, and thereby repress each others' over-amplification. While the model generates some interesting hypotheses it is unclear in the current version of the manuscript, to what extent they arise from specific model assumptions. The authors do not clearly formulate the scientific questions asked, they do not discuss the model assumptions and their validity and they do not adequately describe how model results depend on those assumptions. Taken together, the scientific process is insufficiently documented in this manuscript, making it difficult to judge whether the conclusions are actually supported by the data.

      The manuscript has been modified to further clarify the underlying questions and model assumptions. We would like to point out that the model was presented in detail in the supplementary material of the original manuscript, which included all model assumptions. In addition, model parameters used for the base-case model were systematically varied, the outcome was presented in a separate paragraph (“Sensitivity Analysis” in Results), and findings were shown to be robust to model assumptions. These points are presented in detail below.

      1) It is not clear what questions the authors want to address with their model. Do they want to understand how the experimentally observed copy number differences between regions arise? The introduction should elaborate more on the open questions in the field and explain why they should be addressed with a mathematical model.

      With this work our goal is to elucidate the fundamental mechanisms and properties underlying DNA re-replication. Specifically, we aim to investigate how re-replication evolves over time along the genome, and how it may lead to different number of copies of different loci at the single-cell level and result in genetic heterogeneity within a population. Given the large number of origins along the genome and the stochasticity of origin firing (Demczuk et al., 2012; Kaykov and Nurse, 2015; Patel et al., 2006), it is unclear how re-replication would evolve along the genome in each individual cell in a re-replicating population and how local properties and genome-wide effects would shape its progression and the resulting increases in the number of copies of specific loci. As no experimental method exists that can analyze DNA re-replication at the single-cell level over time along the genome, we designed a mathematical model that is able to track the firing and refiring of origins and the evolution of the resulting forks along a complete genome over time, and in this way capture the complex stochastic hybrid dynamics of DNA re-replication. Since existing methods to analyze DNA re-replication in vivo only provide static, population-level snapshots (Kiang et al., 2010; Menzel et al., 2020; Mickle et al., 2007), we believe that our in silico model, which is the first modeling framework of DNA re-replication, is an important contribution in the field.

      In the revised version of our manuscript, we have modified the introduction to explain these points in more detail.

      2) One of the main messages of the paper is that the amplification profiles are highly variable across single cells, because that was found in the described simulations. This behavior does however likely depend on specific choices that were made in the simulations, e.g. that the probabilities of the origin state transitions are exponentially distributed. These assumptions should at least be discussed, or better experimentally validated.

      Modeling choices and assumptions are presented in detail in the Supplementary material of the manuscript, and were made to accurately capture the dynamics of origin firing, which is known to be stochastic, as established by many studies in fission yeast (Bechhoefer and Rhind, 2012; Patel et al., 2006; Rhind et al., 2010) and the continuous movement of forks along the DNA. Specifically, the choice of the exponential distribution used for assigning a firing time to each origin has already been discussed and validated in our previous work on normal DNA replication (Lygeros et al., 2008). Indeed, as shown in Figure 2 of (Lygeros et al., 2008), our model was able to accurately reconstruct experimental data derived by single molecule DNA combing experiments (Patel et al., 2006).

      The use of the exponential distribution for transition firing times is standard in stochastic processes in general, including what are known as Piecewise Deterministic Markov Processes (PDMP), the class where the models considered in the paper belong. There are good mathematical reasons for this, for example the "memoryless" property that makes the resulting stochastic process Markov, a basic requirement for the model to be well-posed [M. H. A. Davis, "Markov models and optimization", Monographs on Statistics and Applied Probability, vol. 49, Chapman & Hall, London, 1993]. Practically, assuming an exponential distribution can be quite general, because the rate (the probability with which a transition "fires" per unit time) is allowed to depend on the state of the system, both the discrete state (in our case, the state of individual origins) and the continuous state (in our case, the progress of individual replication forks). It can be shown that one can exploit this dependence to write seemingly more general processes (that at first sight do not have exponential firing times) as PDMP (with exponential firing times) by appropriately defining a state for the system [M. H. A. Davis, "Piecewise-Deterministic Markov Processes: A General Class of Non-Diffusion Stochastic Models", Journal of the Royal Statistical Society. Series B (Methodological), Vol. 46, No. 3 (1984), pp. 353-388]. In the manuscript this feature is exploited in what we call the LF model, where the rate of the exponential firing time of each origin (probability of firing per unit time) depends on the state of the system (specifically, the number of PreR origins), as discussed in the section on Sensitivity Analysis. We have further clarified these in the revised manuscript.

      3) The authors aim at testing their prediction that rereplication is highly variable across cells. To this end they use the LacO/LacI system to estimate locus copy number. The locus intensity is indeed highly variable across cells. However, the Dapi quantification suggests that only a subset of cells actually undergo rereplication under the experimental conditions used (Fig. 4C). Therefore the analysis should atleast be limited to those cells. It would be even better, if a second locus could be labelled in another color to show that rereplication of two loci is anti-correlated as predicted by the model.

      Under the experimental conditions employed (ectopic expression of a mutant version of the licensing factor Cdc18, stably integrated in the genome under a regulatable promoter), the vast majority of cells undergo rereplication but to relatively low levels, resulting in cells with a DNA content of 2C-8C. Though the DNA content of several cells indeed appears similar to the DNA content of normal G2 phase cells, the vast majority (>90%) of cells undergo rereplication, as manifested by the appearance of DNA damage and, eventually, loss of viability. We have chosen this experimental set-up (medium levels of rereplication) as it allows induction of rereplication in practically all cells in the population, without the abnormal nuclear and cellular morphology which accompanies a pronounced increase in DNA content (ie 16C), and would make single-cell imaging more prone to artifacts. Fission yeast cells can be induced to undergo rereplication to various extents, by regulated expression of different versions of Cdc18 to different levels and/or co-expression of Cdt1. We have now explained this more extensively in the revised manuscript and thank the reviewer for identifying a point which may not have been clear in the first version of the manuscript.

      Concerning the possibility of studying two loci at the same time, we have indeed tried to tag a second region with TetR/TetO, however the signal-to-noise ratio and thus reproducible detection of the TetR focus was suboptimal under rereplication conditions. We therefore did not proceed further with this approach.

      4) What does "signal ratio" in Fig. 2 mean? And why are the peaks much higher in the simulations? Would the signal ratio between simulation and experiment correspond better, if an earlier time point in the simulation was selected?

      The definition of signal ratios is given in Results: DNA re-replication at the population level: “Specifically, we computed in silico mean amplification profiles across the genome, referred to as signal ratios in (Kiang et al., 2010), by averaging the number of copies for each origin location and normalizing it to the genome mean in 100 simulations. In these profiles, peaks above 1 correspond to highly re-replicated regions, and valleys below 1 correspond to regions that are under-replicated with respect to the mean.”

      Indeed, as observed by the reviewer, simulated peaks appear overall sharper and higher than experimental peaks. This is expected, since simulated data show the actual number of copies generated, while experimental data are subject to background noise and represent averages of 3 probes and 2 independent experiments. We have clarified this in the Results.

      Last, we chose to compare in silico and experimental profiles at a similar ploidy. Plotting in silico profiles of an earlier timepoint would indeed lead to visually more similar patterns in terms of peak intensity, but we believe this could be misleading for the readers.

      5) From line 248 onwards, the authors compare different assumptions for polymerase speed and conclude that "0.5 kb/min is closer to experimental observations". It is unclear, however, which experimental observations they refer to and what was observed there. The same question arises when they compare the LF and UF models (line 275-277).

      We have now clarified this point. Experimental observations show that under high levels of rereplication, DNA content reaches 16C four to six hours following accumulation of Cdc18 (Nishitani et al., 2000). Estimates for 0.5 kb/min and the LF model are therefore closer to experimental observations.

      6) I find the description of cis- and trans-effects rather confusing. The authors should rather explain what happens in the model. Neighboring strong origins can amplify a weak origin and origins compete for factors. In line 475-476 for example, it should be clarified that the assumption of the LF model could lead to trans-effects, instead of presenting this as a general model prediction.

      In the manuscript, we initially present what we observe in the Results section and then proceed to provide possible explanations in Discussion. We quote from the Discussion: “Such in trans negative regulation of distant origins could be explained by competition for the same limiting factor: high-level amplification of a given locus recruits high levels of the limiting factor, indirectly inhibiting firing of other genomic regions.” and “[…] in cis elements contribute to amplified copy numbers not only directly by passive re-replication, but also implicitly through increasing the firing activity of their neighbors”. To our understanding, these sentences are in complete agreement with the reviewer’s suggestions. Nonetheless, and to make this even more clear, we have modified the Discussion in our revised manuscript.

      7) Throughout the manuscript, a clear distinction should be made between the firing activity of one origin molecule and the cumulative activity of multiple copies of an origin. For example, it should be clarified in line 435 that the cumulative activity of weak origins might increase if they are closed to a strong origin, because they get amplified, instead of just writing "increased firing activity of weak origins".

      We have clarified this point in the revised manuscript.

      8) One of the major conclusions of the manuscript is that rereplication is robust on the population level. It is not clear to me what the authors mean by that. The average amplification levels are probably determined by the origin efficiencies that are put into the model. What would robustness mean in this context?

      As the reviewer points out, one of the important input parameters of the model are origin efficiencies. Since the model is stochastic however, origin efficiencies do not directly determine the amplification levels at a single-cell level. For example, in Figures 3A and Supplementary Figure S4, we show the outcome of 4 random simulations with identical underlying parameters, where it is clear that re-replication can lead to markedly different single-cell amplification levels. Indeed, genome-wide analysis across 100 simulations (Supplementary Figure S5) indicated that on the onset of re-replication, amplification levels are highly unpredictable (again, despite the fact that the input parameters are identical).

      On the contrary, when analyzing amplification profiles at a population level (averaging across sets of 100 simulations), the most highly amplified regions appear to be highly reproducible. We agree with the reviewer that these population level profiles are strongly affected by the origin efficiencies, but they are not determined solely by them. For example, low efficiency origins can be highly amplified, or highly efficient origins can be suppressed (see discussion on in cis and in trans effects) depending on their neighborhood and system-wide effects, and the extend of these effects depends on the fork speed. Sensitivity analysis with respect to different model assumptions, or model parameters (see Results, section Sensitivity Analysis and Supplementary Figure S3) indicated that amplification profiles might appear sharper or flatter, but overall amplification hotspots were highly robust.

      To summarize, in our conclusions (Discussion, section Emerging properties of re-replication) we highlight these properties (stochasticity vs. robustness) and elaborate further on how they emerge during the course of re-replication (onset vs. high re-replication) or depending on the level of analysis (single-cell vs. population level).

      9) It would be helpful if, in Fig. 2 also the origins and their respective efficiencies could be shown to understand to what extent the signal ratio reflects these efficiencies.

      We thank the reviewer for the useful suggestion, which we have incorporated in the revised manuscript.

      10) The methods section should provide more detail.

      We would like to point out that Supplementary Material, including a full mathematical description of the model is available on BioRxiv, which was also available at the time of the preprint review, (https://www.biorxiv.org/content/10.1101/2020.03.30.016576v1.supplementary-material ), and has also been uploaded as a separate document in our GitHub page: https://github.com/rapsoman/DNA_Rereplication

      Reviewer #2:

      Here, Rapsomaniki et al have modeled the process of DNA re-replication. The in silico analysis is an extension of their previous work describing normal DNA replication (Lygeros et al 2008). The authors show that there is a large amount of heterogeneity at the single cell level but when these heterogeneous signals are averaged across a population, the signal is robust. The authors support this with simulations and with experimental data, both at the single cell level and at the population level.

      1) It is a bit concerning that simulations were carried out to a ploidy level of 16C. Has it been observed that the DNA content in any given cell can rise to 16 times the initial amount? Figure 3 (simulations) shows that certain chromosomal regions can reach 30x and 160x copies for 2C and 16C. However, Figure 4 (experiment) suggests that copy numbers should only be slightly more in re-replicating conditions, compared to normal replicating conditions. Additionally, in Figure 2, the simulated data seems to be consistently noisier than the experimental data. Taken together, this may suggest that the assumptions in the model do not adequately recapitulate the biological system.

      Fission yeast cells undergo robust rereplication, and reach a ploidy up to 32C - see for example (Kiang et al., 2010; Mickle et al., 2007; Nishitani et al., 2000). 16C is therefore a usual ploidy for rereplicating fission yeast cells, observed under many experimental conditions. In addition, by manipulating the licensing factors over-expressed, different levels of ploidy can be experimentally achieved, ranging from 2C (the normal ploidy of a G2 cell, but with uneven replication) to 32C. In Figure 4, we have employed a truncated form of Cdc18 (d55P6-cdc18 (Baum et al., 1998)), which induces medium-level re-replication, as confirmed by FACS analysis in Supplementary Figure S6A. Under these conditions, the vast majority of the cells (>90%) undergo re-replication, albeit at medium to low levels. We have opted to use this strain to avoid artifacts due to disrupted nuclear morphology under high levels of re-replication We have now clarified this point in the revised manuscript. We would like to point out that in silico analysis is not carried out at 16C only but across different ploidies – it is actually a strength of our approach that we can follow the rereplication process as it evolves, at any ploidy, and we have shown that our conclusions are robust throughout. We show plots at the beginning of the process (2C) and towards the end (16C), at the single-cell and at the population level, to facilitate comparison.

      Last, as also discussed in our response to reviewer 1, simulated data appear sharper, with higher peak values than experimental data (Figure 2). This is expected, since simulated data show the actual number of copies generated, while experimental data are subject to background noise and represent averages of 3 neighboring microarray probes and 2 independent experiments. We have clarified this in the revised manuscript.

      2) This work currently is agnostic to the genes and sequences within the simulated genomes. The authors suggest that DNA re-replication can result in gene duplications. It might strengthen the manuscript if the authors are able to show that re-replication hotspots coincide with gene duplication events in S pombe. It should be relatively straightforward to overlap the hotspots found in this analysis with known gene duplication events in the literature.

      We agree with the reviewer that comparing our predictions with known gene duplication events in S.pombe would be of interest. Unfortunately to our knowledge no such dataset for fission yeast exists in the literature. The most comprehensive datasets are the ones from (Kiang et al., 2010; Mickle et al., 2007), which analyse rereplicating cells, and which we have already exploited in our paper. We would like to point out that this manuscript aims to show how rereplication evolves genome-wide. Whether the additional copies generated can lead to gene duplication events is beyond the scope of the present manuscript.

      3) The authors have nicely demonstrated that cis activation can be driven by the physical proximity of origins. The authors go on to describe trans suppression in which the activation of one origin suppresses the activation of a different origin. I would argue that this observation is simply the result of randomness in the model and stopping the simulations at fixed points.

      One of the two origins will randomly re-replicate first and simply outpace the other. Stopping the simulations at 16C will simply prevent the lagging origin from catching up the first origin. There does not seem to be an inhibitory mechanism that acts between two origins.

      This can be explained by the following equation: X + Y = constant Where X is the amount of origin 1 and Y is the amount of origin 2.

      It is also possible that the two origins could start re-replicating at the same time. This would result in the data points observed for cluster 2 (Figure 6 BC)

      We thank the reviewer for the positive comments. Indeed, as we elaborate in our Discussion, we believe that the mechanism behind the observed in trans effects is the competition for a factor that exists in a rate-limiting quantity (see also reply to point 6, reviewer 1 above), which is essentially the constant in his/her equation. Though less pronounced, such in-trans effects are also possible in the UF model, and could be due to the total DNA increase being dominated by certain origins, as suggested by the reviewer. We do not suggest anywhere in the manuscript that this inhibition is direct, but rather clearly state that it is an indirect effect.

      Reviewer #3:

      This manuscript by Rapsomaniki et al uses mathematical modeling to study the properties of DNA re-replication. They develop a model that shows some consistency with experimental data from S. pombe, and use it to conclude that re-replication is heterogeneous at the single-cell level.

      The simulations have only moderate correlations with experimental data (0.5-0.6). Indeed, simulations and actual data (Figure 2) appear quite different. Despite the statistical significance of the overlap, the limited correspondence brings into question the usefulness of the model compared to directly generating new experimental data.

      We would like to point out that the overlap between experimental and simulated data is highly significant. Firstly, the Spearman correlation coefficient between simulated and experimental genome-wide profiles is highly statistically significant (p values ranging from 7.310-12 to 3.610-41 for the three fission yeast chromosomes). Furthermore, 100.000 repetitions of random peak assignment resulted in only one case where 10 out of 22 peaks overlapped (median 2 out of 22 peaks overlapping), while comparing simulated and experimental data resulted in 14 out of 22 peaks overlapping. Simulations appear more sharp than experimental data, this is however expected as simulated data correspond to the actual number of copies generated, while experimental data are subject to background noise, have a signal-to-noise ratio that is limited by the experimental method employed and represent averages of 3 probes and 2 independent experiments (see Kiang et al., 2010 and also above). We have modified the manuscript to clarify this point. The reviewer suggests that the model is of limited use, because one could trivially generate new experimental data. We would like to point out that existing methods to analyze DNA re-replication in vivo only provide static, population-level snapshots (Kiang et al., 2010; Menzel et al., 2020; Mickle et al., 2007). To date no experimental method can generate single-cell, whole-genome, time-course measurements in re-replicating cells. Our model aims to fill this gap, and for this reason we believe in its usefulness.

      Heterogeneity among single cells, which appears to be one of the main messages of this paper, is not necessarily a surprising finding, and may even arise from the nature of the simulation being stochastic and defined at the level of single origins. They validate this prediction experimentally at a single locus, providing little novel insight.

      We would like to point out that it is the nature of replication in fission yeast which is stochastic, as experimentally shown (Patel et al., 2006), and defined at the level of single origins, and this is captured by the simulations. Heterogeneity amongst single rereplicating cells has not been previously shown or suggested in any organism, at least to the best of our knowledge. It is in our opinion a highly interesting observation, as it provides a powerful mechanism for generating a plethora of different genotypes within a population, from which phenotypic traits could be selected.

      Overall, the insights here are limited and would need to await experimental validation and further empirical data. Given that experimental measurements of re-replication are now feasible genome-wide, the value of these simulations is limited.

      Again, the reviewer seems unaware that no experimental method currently exists for analysing the dynamics of re-replication at a single-cell level genome-wide. We also feel obliged to point out that modeling and in silico analysis is in our opinion of great value for analysing complex biological processes, even when experimental methods are available. Though we are sure this is not what the reviewer really meant, his/her comment appears derogative to a complete field.

      Fork speed is assumed based on limited data and assumptions regarding re-replication fork speed without empirical data.

      As clearly stated in our manuscript (Results, section Modeling DNA re-replication across a complete genome), many studies have estimated fork speed in yeasts in normal DNA replication, with plausible values ranging from 0.5 kb/min to 3 kb/min (Duzdevich et al., 2015; Heichinger et al., 2006; Raghuraman et al., 2001; Sekedat et al., 2010; Yabuki et al., 2002). In our model, we set the base-case value as the lowest estimate (0.5 kb/min), but also explored the model’s sensitivity to this parameter by simulating the model for higher values (1 and 3 kb/min). This analysis indicated that estimates for 0.5 kb/min were closer to biological reality, a non-surprising finding given that fork speed is expected to be slower in re-replication that in normal replication.

      Overall, the comments of reviewer 3 appear in our eyes more derogative than constructive and provide little specific criticism.

      References

      Baum, B., Nishitani, H., Yanow, S., and Nurse, P. (1998). Cdc18 transcription and proteolysis couple S phase to passage through mitosis. The EMBO Journal 17, 5689–5698.

      Bechhoefer, J., and Rhind, N. (2012). Replication timing and its emergence from stochastic processes. Trends in Genetics 28, 374–381.

      Duzdevich, D., Warner, M.D., Ticau, S., Ivica, N.A., Bell, S.P., and Greene, E.C. (2015). The dynamics of eukaryotic replication initiation: origin specificity, licensing, and firing at the singlemolecule level. Mol. Cell 58, 483–494.

      Heichinger, C., Penkett, C.J., Bähler, J., and Nurse, P. (2006). Genome-wide characterization of fission yeast DNA replication origins. The EMBO Journal 25, 5171–5179.

      Kiang, L., Heichinger, C., Watt, S., B\ähler, J., and Nurse, P. (2010). Specific replication origins promote DNA amplification in fission yeast. Journal of Cell Science 123, 3047–3051.

      Lygeros, J., Koutroumpas, K., Dimopoulos, S., Legouras, I., Kouretas, P., Heichinger, C., Nurse, P., and Lygerou, Z. (2008). Stochastic hybrid modeling of DNA replication across a complete genome. Proceedings of the National Academy of Sciences 105, 12295–12300.

      Menzel, J., Tatman, P., and Black, J.C. (2020). Isolation and analysis of rereplicated DNA by Rerep-Seq. Nucleic Acids Res 48, e58–e58.

      Mickle, K.L., Oliva, A., Huberman, J.A., and Leatherwood, J. (2007). Checkpoint effects and telomere amplification during DNA re-replication in fission yeast. BMC Molecular Biology 8, 119.

      Nishitani, H., Lygerou, Z., Nishimoto, T., and Nurse, P. (2000). The Cdt1 protein is required to license DNA for replication in fission yeast. Nature 404, 625–628.

      Patel, P.K., Arcangioli, B., Baker, S.P., Bensimon, A., and Rhind, N. (2006). DNA Replication Origins Fire Stochastically in Fission Yeast. Mol. Biol. Cell 17, 308–316.

      Raghuraman, M.K., Winzeler, E.A., Collingwood, D., Hunt, S., Wodicka, L., Conway, A., Lockhart, D.J., Davis, R.W., Brewer, B.J., and Fangman, W.L. (2001). Replication Dynamics of the Yeast Genome. Science 294, 115–121.

      Rhind, N., Yang, S.C.-H., and Bechhoefer, J. (2010). Reconciling stochastic origin firing with defined replication timing. Chromosome Res 18, 35–43.

      Sekedat, M.D., Fenyö, D., Rogers, R.S., Tackett, A.J., Aitchison, J.D., and Chait, B.T. (2010). GINS motion reveals replication fork progression is remarkably uniform throughout the yeast genome. Molecular Systems Biology 6, 353.

      Yabuki, N., Terashima, H., and Kitada, K. (2002). Mapping of early firing origins on a replication profile of budding yeast. Genes to Cells 7, 781–789.

  4. Aug 2020
    1. characterizationofcerebralbloodflow[14],andtestingofanumberofnovelmachinelearningmethods[15

      There's an additional paper that could fit in either or both of these categories: Aslan, S., Hocke, L., Schwarz, N., and Frederick, B., Extraction of the cardiac waveform from simultaneous multislice fMRI data using slice sorted averaging and a deep learning reconstruction filter. Neuroimage, 2019. 198: p. 303-316. MyConnectome was used along with the HCP to develop and test the method.

    1. I n c l o s i n g , t h e c l u b h o u s e w a s c r i t i c a l i n h e l p i n g L u i s t o d e v e l o p t h e k i n d s o f t e c h -nological fl uencies that may position him for further learning and creative work

      I do wonder how the other kids did though, its possible that they were not as into it as Luis

    2. Links between the clubhouse, home, and school were present but could have been stronger. D e s p i t e h i s s l i p p i n g g r a d e s a t s c h o o l , L u i s ’ s w o r k a t t h e c l u b h o u s e clearly demonstrated a rich imagination, persistence, attention to detail, and resourcefulness in furthering his own development. These characteristics are markers of the potential to thrive as a learner. Had his teachers been attuned to his expertise development earlier, they may have found ways to build on his excellent out-of-school learning skills to reengage him in academic content.

      Were his "slipping grades" a result of his teachers not realizing, or just not utilizing, his skills and creativity?

    3. T h e c l u b h o u s e c o o r d i n a t o r s i n c l u d e d L u i s i n fi e l d t r i p s c o n n e c t e d t o h i s i n t e rests, including one to the game design company Electronic Arts.

      Also, connections continue to be important, and the knowledge of these clubhouses and spread and support of them are essential especially for younger people to have. I didn't even know these existed; these need to become more widespread knowledge.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Response to the References

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      In this manuscript Yan et al describe a method to perform imaging based pooled CRISPR screens based on photoactivation followed by selection and sorting of the cells with the desired phenotypes.

      They establish a system in mammalian RPE-1 cells where they integrate a photo-activatable mCherry, identify the cells of interest under the microscope based on a phenotype, automatically activate the mCherry fluorescence in these cells and then sort the desired populations by FACS. They demonstrate the reliability of their enrichment method and finally use this approach to look for factors that regulate nuclear size by a targeted pooled CRISPR screen.

      **Major points:**

      1.This year Hassle et al described a very very similar approach that they name: Visual Cell Sorting . In this case, they use a photoconvertible fluorescent protein (green-to-red conversion) to select cells with a certain visual cellular phenotype and enrich those by FACS. The Hassle et al 2020 MSB paper is only mentioned together with the other methods in the introduction in one sentence (ref #19 in this manuscript):

      " Recently, several in situ sequencing15,16 and cell isolation methods17-20 were developed which allow microscopes to be used for screening. However, these methods contain non-high throughput steps that limit their scalability."

      I think the current citation of the Hassle et al paper, is not really fair. The idea and the execution of the two approaches are almost exactly the same. Here, the authors concentrate on a CRISPR based application, but obviously the applications of the method are not limited to that. The authors should discuss how these similar ideas can be used in several different applications.

      We agree with the reviewer that we need to describe more about the Hasle et al. paper (now ref #20 in the revised manuscript) and expand our description of other applications that could be performed with the method. For this purpose, we have made the following changes:

      We have modified the relevant paragraph in the Introduction.

      p.3 the second paragraph

      Recently, an imaging based method named “visual cell sorting” was described that uses the photo-convertible fluorescent protein Dendra2 to enrich phenotypes optically, enabling pooled genetic screens and transcription profiling(Hasle, N.; Cooke, A.; Srivatsan, S.; Huang, H.; Stephany, J. J.; Krieger, Z.; Jackson, D.; Tang, W.; Pendyala, S.; Monnat, R. J., Jr.; Trapnell, C.; Hatch, E. M.; Fowler, D. M. 2020). Here, we developed an analogous approach to execute an imaging-based pooled CRISPR screen using optical enrichment by automated photo-activation of the photo-activatable fluorescent protein, PA-mCherry.

      We have also added the following paragraph in the Discussion.

      p.14 line 1

      In our study, optical enrichment was utilized for pooled CRISPR screens on phenotypes identifiable through microscopy. However, optical enrichment can be used for other purposes, as demonstrated previously(Hasle, N.; Cooke, A.; Srivatsan, S.; Huang, H.; Stephany, J. J.; Krieger, Z.; Jackson, D.; Tang, W.; Pendyala, S.; Monnat, R. J., Jr.; Trapnell, C.; Hatch, E. M.; Fowler, D. M. 2020). In a recent study by Hasle et al.(Hasle, N.; Cooke, A.; Srivatsan, S.; Huang, H.; Stephany, J. J.; Krieger, Z.; Jackson, D.; Tang, W.; Pendyala, S.; Monnat, R. J., Jr.; Trapnell, C.; Hatch, E. M.; Fowler, D. M. 2020), the process of separating cells by FACS after optical enrichment was termed “visual cell sorting”. This method was used to evaluate hundreds of nuclear localization sequence variants in a pooled format and to identify transcriptional regulatory pathways associated with paclitaxel resistance using single cell sequencing(Hasle, N.; Cooke, A.; Srivatsan, S.; Huang, H.; Stephany, J. J.; Krieger, Z.; Jackson, D.; Tang, W.; Pendyala, S.; Monnat, R. J., Jr.; Trapnell, C.; Hatch, E. M.; Fowler, D. M. 2020), demonstrating the broad applicability and power of this approach beyond CRISPR screening.

      1. While I understand that the authors mean conversion from the dark state to fluorescent state when they describe their photo-activatable mCherry, I think the term "photo-activation" can be confusing for the general reader since typically photo-conversion refers to a change in color. I would here suggest stick to the term photo-activation.

      We thank the reviewer for pointing this out and to avoid future confusion, we restricted the usage of photo-conversion to specifically indicate conversion of fluorescence from one color into another: e.g. when talking about the published visual cell sorting paper in which Dendra2 is used as a photo-convertible fluorescent protein. We use photo-activation in reference to the activation of PA-mCherry in our work.

      1. For validation of the hits coming from the nuclear size screen: Did the authors have any controls making sure that the right targets were down-regulated? This might be obvious for some of the targets (e.g. CPC proteins that are known to induce division errors display the nuclear fragmentation that the authors also observe) but especially for the ones that are less known or unknown to induce any nuclear size change, it will be important to demonstrate the specificity of the targets.

      For validating hits coming from the nuclear size screen, we have verified the successful transduction of corresponding sgRNA constructs by FACS analysis, but have not confirmed the knockdown. Before final journal publication, we propose to perform rt-qPCR on our 15 gene hits before and after knockdown to measure the percentage of knockdown separately.

      In addition, it is not clear from the figure legends and the material and methods if these phenotypes are verified by 3-4 gRNAs they use in the validation. Are the histograms representative of a single experiment with one gRNA or a combination of gRNAs in different experiments? Methods of replication of the data presented in Fig4 is unclear.

      We apologize for the confusion. These phenotypes were verified with pools of 3-4 sgRNAs and the histograms are representative of a single replicate infected with a mixed 3-4 sgRNA pool. We have modified the legend to Figure 5 (original Fig. 4) and the method section to explain this point.

      Minor points:

      1. Related to major point #3: I could not find much experimental info on how the hits from the screen were verified in materials and methods.

      The description of the experiment and information about the selected sgRNAs has been added in the Method section as follows:

      p.23

      Verification of hits from nuclear size screen

      For each hit in the nuclear size screen, the two sgRNAs with the highest phenotypic score in the screen and the two sgRNAs with the highest score predicted by the CRISPRi-v2 algorithm24 were selected and pooled to generate a mixed sgRNA pool of 3-4 sgRNAs (detailed information in Supplementary file 8). Cells (hTERT-RPE1 dCas9-KRAB-BFP PA-mCherry H2B-mGFP) were transduced with pooled sgRNAs targeting each gene and puromycin selected for 2 days to prepare for imaging. Cells were then seeded into 96-well glass bottom imaging dishes. Images were collected the next day and nuclear size was measured using the Auto-PhotoConverter µManager plugin. To focus on cells with successful transduction, BFP was co-expressed on the sgRNA construct and only cells with BFP intensity above a threshold value were included in nuclear size measurements. This BFP threshold was established by comparing the average BFP intensity of cells with and without sgRNA transduction (Fig.S3a).

      We agree with this important point and have changed the figure legend of Fig. 5c (original Fig. 4c) to just describe the plot:

      c, The ratios between median level of nuclear size measured from microscopy and H2B-mGFP fluorescence or FSC signal measured from FACS after knockdown, were plotted separately. TACC3, confirmed to be a control gene, was used for comparison (Grey bar).

      The typo has been corrected.

      Reviewer #1 (Significance (Required)):

      I think the idea of performing pooled screens coupled to microscopy is exciting and this approach has definitely more potential than the Craft-ID approach that the authors also discuss in their manuscript. In addition, the approach that is described in this manuscript is convincing and although the fact that the analysis part will require more work (to adapt the software to recognise different types of phenotypic readouts) in the future to make it accessible to the scientific community, the authors present sufficient evidence that the system can be robust. They also present some clever ideas such as to calculate enrichments with different photo-activation times (2sec vs 100ms) followed by separation of these populations by FACS.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      In this manuscript, Yan et al. present optical enrichment, a method for conducing pooled optical screens. Optical enrichment works by combining microscopy to mark cells of interest using the PA-mCherry photo-activatable fluorescent protein with FACS to recover them. The method is similar to other methods (Photostick, Visual Cell Sorting), and provides an alternative to in situ sequencing/FISH methods. The authors use optical enrichment to conduct a pooled optical CRISPRi screen for nuclear size. They identify and exhaustively validate hits, showing that optical enrichment works for its intended purpose. The development of a uManager protocol and discussion of the number of sgRNA's required for a genetic screen using optical enrichment were welcome. The authors' reported throughput of 1.5 million cells per eight hour experiment is impressive; and the demonstrated use of low cell number input for next generation sequencing appears promising. Overall, the manuscript is well written, the methods clear and the claims supported by the data presented.

      **General comments**

      -I found the analysis and scoring methods to be lacking, both in terms of the clarity of description and in terms of what was actually done. The authors might consider using established methods (eg https://www.biorxiv.org/content/10.1101/819649v1.full). In any case, they should revise the text to clarify what was done and address the other concerns raised below.

      -Relatedly, details regarding how to perform the experiments described are lacking. It is not clear from the text, figures, "Online Methods" section, and Supplementary Files whether all imaging is performed before activation, or whether each field of view is subject to an individual round of imaging followed by activation. It is also unclear whether cells in 96 well plates are sorted as 96 separate tubes or pooled into a single tube prior to sorting. Furthermore, at a minimum, the following details are requested for each optical enrichment "run". These details are critical considerations for those who seek to use optical enrichment in their own laboratories:

      Seeding density

      Time elapsed (in hours) between cell plating and optical enrichment

      The number of fields of view examined

      The median number of cells per field of view; the proportion of each plate's surface area that is imaged and photo-converted

      The total time taken (in hours) to perform imaging and photoconversion

      The gating protocol used for sorting by FACS (preferably including a figure with example gates for one or two experiments). The gating protocol is described for the genetic screen but not for the control experiments.

      We agree with the reviewer and apologize for the confusion that arose from our description. We also thank the reviewer for suggesting using established methods. However, MAUDE, an analysis for sorting-based CRISPR screen with multiple expression bins, might not be suitable for our study since 1) the distribution of mCherry fluorescence intensity is a reflection of photo-activation efficiency and not sgRNA effect 2) only one sorting bin is collected for each experimental condition. Our analysis is adapted from an existing method from the Weissman lab (https://github.com/mhorlbeck/ScreenProcessing).

      We agree with the reviewer regarding clarifying other points and rewrote the following part in the Method section:

      p. 20

      mIFP proof-of-principle screen, Nuclear size screen, FSC screen and H2B-mGFP screen

      For the mIFP proof-of-principle screen, mIFP positive cells (hTERT-RPE1 dCas9-KRAB-BFP PA-mCherry H2B-mGFP mIFP-NLS) and mIFP negative cells (hTERT-RPE1 dCas9-KRAB-BFP PA-mCherry H2B-mGFP) were stably transduced with the “mIFP sgRNA library” (CRISPRa library with 860 elements, see Supplementary file 5) and the “control sgRNA library” (CRISPRa library with 6100 elements, see Supplementary file 6) separately. For the nuclear size screen, FSC screen and H2B-mGFP screen, cells (hTERT-RPE1 dCas9-KRAB-BFP PA-mCherry H2B-mGFP) were stably transduced with the “nuclear size library” (CRISPRi library with 6190 elements, see Supplementary file 7). To guarantee that cells receive no more than one sgRNA per cell, BFP was expressed on the same sgRNA construct and cells were analyzed by FACS the day after transduction. The experiment only continued when 10-15% of the cells were BFP positive. These cells were further enriched by puromycin selection (a puromycin resistance gene was expressed from the sgRNA construct) for 3 days to prepare for imaging. For FSC and H2B-mGFP screens, cells were then subjected to FACS sorting. Cells before FACS (unsorted sample for FSC and H2B-mGFP screens) and top 10% cells based on either FSC signal (high FSC sample) or GFP fluorescence signal (high GFP sample) were separately collected and prepared for high throughput sequencing. For mIFP proof-of-principle screen and nuclear size screen, cells were then seeded into 96-well glass bottom imaging dishes (Matriplate, Brooks) and imaged starting from the morning of the next day (around 15 hr after plating). A series of densities ranging from 0.5E4 cells/well to 2.5E4 cells/well with 0.5E4 cells/well interval were selected and seeded. The imaging dish with cells around 70% confluency was selected to be screened on the imaging day. For mIFP proof-of-principle screen, a single imaging plate was performed for each replicate while 4 imaging plates per replicate were imaged for the nuclear size screen. When executing multiple imaging runs, 2 consecutive runs could be imaged on the same day (day run and night run). 64 (8x8, day run) or 81 (9x9, night run) fields of view were selected for each imaging well and each field of view was subjected to an individual round of imaging directly followed by photo-activation. Around 200-250 cells were present in each given field of view and 60% to 80% surface area of each well was covered. Either mIFP positive cells or cells passing the nuclear size filter were identified and photo-activated automatically using the Auto-PhotoConverter µManager plugin. The total time to perform imaging and photo-activation of a single 96-well imaging dish with around 1.5 million cells was around 8 hr. The night run generally took longer, since more fields of view were included than in the day run. Cells were then harvested by trypsinization and pooled into a single tube for isolation by FACS. Sorting gates were pre-defined using samples with different photo-activation times (e.g. 0s, 200ms, 2s) and detailed gating strategies are described in Supplementary file 1. Sorted samples were used to prepare sequencing samples.

      -The authors use PA-mCherry. There are a variety of other photo-activatable fluorophores available, and it would be good for them to comment on why they chose PA-mCherry. Also, since the method is supposed to be used for generic pooled optical screens, it would be good for the authors to comment on what colors remain available for imaging cellular structures.

      To address these, we have added the following sentences:

      p. 4 line 16

      A photo-activatable fluorescent protein was chosen over a photo-convertible fluorescent protein to increase the number of channels available for imaging. PA-mCherry was chosen to leave the better performing green channel open for labeling of other cellular features. Moreover, non-activated PA-mCherry has low background fluorescence in the mCherry channel (Fig. S1b), and it can be activated to different intensities when photo-activated for various amounts of time.

      p. **14 line 10

      Phenotypes of interest should be identifiable under the microscope and generally require fluorescent labeling. Commonly used fluorescence microscopes use four channels for fluorescent imaging with little spectral overlap: blue, green, red and far red. In our study, the red channel was occupied by cell labeling with PA-mCherry and the blue channel was used to estimate sgRNA transduction efficiency. Since sgRNA transduction efficiency can be measured by other approaches, the blue channel could be used together with the remaining two channels to label cellular structures. Combining bright field imaging with deep learning can be used to reconstruct the localization of fluorescent labels(Ounkomol, C.; Seshamani, S.; Maleckar, M. M.; Collman, F.; Johnson, G. R. 2018), making it possible to use bright field imaging to further expand the phenotypes that can be studied with our technique.

      -In general, the figures are hard to read, with most space being dedicated to beautiful but complex schematics/workflows. Points and fonts should be bigger, and the authors should consider revising the schematics to take up less space.

      We thank the reviewer for this remark and revised all figures accordingly. Points and fonts were enlarged, and schematics were simplified or removed.

      -There is extensive use of editorialzing adverbs. Adverbs such as "highly" (abstract and page 15), "easily" (pages 4 and 11), "completely" (page 11), and "only" (page 12) are unnecessary at best and unsupported by the data at worst (e.g. cells are not "completely" separable with 100 ms photo-conversion, see page 11 and Figure 1C). Please remove "completely" from page 11 and consider removing other adverbs as well.

      We agree with the reviewer and the following adverbs have been removed: “highly” in abstract and page 15; “easily” on pages 4 and 11; “completely” on page 11 and three “only” on page 12.

      -Apologies if I missed it, but I couldn't find a data availability statement. Sequencing reads from the experiments should be deposited in SRA or GEO and made available upon publication.

      We apologize that we missed this, and the sequencing data has been deposited to GEO (GSE156623) which will be made available before final publication. The following part has been added to address this.

      p. 24

      DATA AND SOFTWARE AVAILABILITY

      The raw and processed data for the high throughput sequencing results have been deposited in NCBI GEO database with the accession number (GSE156623). The plugin Auto-PhotoConverter developed for open source microscope control software μManager(Edelstein, A. D.; Tsuchida, M. A.; Amodaj, N.; Pinkard, H.; Vale, R. D.; Stuurman, N. 2014) has been deposited on github (https://github.com/nicost/mnfinder).

      **Specific comments**

      Pages 5/6 - The authors present experiments that show that optical enrichment is highly specific for desired cells. But, they should consider presenting precision (fraction of called positives that are true positive) and recall (fraction of all true positives that are called positive) instead. I think these relate more directly to a pooled optical screen than specificity.

      We apologize for our poor terminology. Our original definition of “specificity” is the same as “precision” suggested by the reviewer. To avoid future confusion, we have changed all relevant occurrences of “specificity” into “precision”. The following sentence was modified to clarify the definition:

      p. 5 line 15

      To evaluate the precision (the fraction of called positives that are true positives) of this assay, all cells were collected and analyzed by FACS after image analysis and photo-activation (Fig. 2d and 2e). We calculated precision as the fraction of photo-activated cells (mCherry positive cells) that are true positives (mIFP-mCherry double positive cells) (Fig. 2f).

      Measuring recall is complicated because the microscope is unable to visit all locations in the imaging plate, hence recall will depend on the fraction of cells actually “seen” by the microscope. For the screening strategy employed in the nuclear size screen, recall is not as important as precision, since lower recall rates are compensated for by screening larger cell numbers. We therefore did not attempt to measure recall directly.

      Page 6 - Related to the above point, the authors state "These results indicate the assay yields reliable hit identification regardless of the percentage of hits in the library." This statement seems too strong given that the authors looked at specificity experimentally with a mixture of ~1% mIFP positive cells. In fact, hits might be much less than 1% of the total population of cells, and specificity would certainly fall from the 80% measured at 1% of the total population. The authors should do a bit more to fairly discuss their ability to find rare hits.

      We agree with the reviewer and have changed the following description:

      p. 5 line 20

      The precision varied with the initial percentage of mIFP positive cells and ranged from 80% to ~100% (initial percentage of mIFP positive cells ranging between 2.3% and 43.7%) (Fig. 2f). Precision is expected to fall below 80% with initial percentage of mIFP positive cells less than 2.3%. However, these results indicate that optical enrichment can be used to identify hits with high precision even at relatively low hit rates.

      Pages 6/7 - The authors perform a validation experiment using two different sgRNA libraries, infecting mIFP- and mIFP+ cells separately. Then, they demix these populations via optical enrichment, sequence and compute a phenotype score for sgRNAs or groups of sgRNAs. The way the experiment is described and visualized is extremely confusing. If I understood correctly (and I am not sure that I did), the bottom right panel of Figure 2b shows that if sgRNAs are (randomly?) paired AND two replicates are combined then optical enrichment nearly perfectly separates all (combined, paired) sgRNAs in the two libraries. The authors should rewrite this section, especially clarifying what is meant by "1 sgRNA/group and 2 sgRNA/group," and consider changing Figure 2b (perhaps just show the lower right panel?).

      We apologize for our confusing description. To avoid the confusion, we rewrote the paragraph describing the experiment and added a schematic (Fig. 3a) to better describe this experiment. We also simplified the result by just presenting the lower right panel of original Fig. 2b (current Fig. 3b) and moved the other data into supplementary figures (Fig. S2).

      p. 6 line 4

      mIFP negative cells and mIFP positive cells were separately infected with two different CRISPRa sgRNA libraries (6100 sgRNAs for mIFP negative cells; 860 sgRNAs for mIFP positive cells) at a low multiplicity of infection (MOI) to guarantee a single sgRNA per cell. Note that in these experiments, the sgRNAs only function as barcodes to be read out by sequencing, but do not cause phenotypic changes as the cells do not express corresponding CRISPR reagents. These two populations were then mixed at a ratio of 9:1 mIFP negative cells: mIFP positive cells. We again used mIFP expression as our phenotype of interest (outlined in Fig. 3a). Two biological replicates were performed and at least 200-fold coverage of each sgRNA library was guaranteed throughout the screen, including library infection, puromycin selection, imaging/photo-activation and FACS.

      Page 8 - Related to Supplementary Figure 3, why are there not clear BFP+ and BFP- populations but instead one continuous population? How was the gating determined (e.g. how was the boundary between red and gray picked)? Here, and generally, flow plots and histograms of flow plots should indicate the number of cells. If replicates were performed, they should be included.

      We have clarified our description. There are no clear BFP+ and BFP- populations but instead one continuous population due to the background expression of BFP from the dCas9 construct: dCas9-KRAB-BFP (which is now clearly indicated in the manuscript). On top of the dCas9-KRAB-BFP, another BFP is encoded on the sgRNA construct, which leads to a higher BFP expression level.

      There was no gating in the experiment, the grey dots in the figure represents wild type cells without viral transduction while the red dots (partially covered by the grey dots) were cells infected with the two negative control sgRNAs. We mistakenly wrote the legend of original Fig. S3 (current Fig. S3a) that these were FACS data; however, the data were acquired by imaging. We apologize for the confusion and thank the reviewer for detecting the issue. We completely rewrote the legend to Fig. S3a (original Fig. S3) to clarify.

      We now include the number of cells analyzed and the number of replicates for the other flow plots and histograms in the manuscript.

      Page 8 - "Nuclear sizes...". The authors should say in the main text what size metric was used.

      To address the reviewer’s point, we have included the following sentence:

      p. 8 line 23

      We defined nuclear size as the 2D area in square microns measured by H2B-mGFP using an epifluorescence microscope, as determined by automated image analysis (Fig. 4a and Supplementary file 2).

      Page 9 - I am a little confused about the statistical analysis of the screen. In Supplementary File 1, the authors state that p-values were "calculated based on comparison between the distribution of all the phenotypic scores of sgRNAs targeting to the gene/assigning in the group and the one of negative control sgRNAs in the libraries." I presume this means that all phenotypic scores (across replicates) of all sgRNAs targeting each gene were included in a Mann Whitney U test with a single randomized set of phenotypic scores. If that's right, it seems like an odd way to get p-values. Better would be a randomization test, where a null distribution of phenotypic scores for each gene is built by randomizing sgRNA-level scores many times. Then the actual phenotypic score is compared to the randomized null distribution, yielding a p-value. In any case, the authors must clarify what they did in the main text and Supplementary File 1.

      Page 9 - It does not appear that the p-values presented in Figure 3c have been adjusted for multiple hypothesis testing. This should be done.

      Page 9 - "A value of the top 0.1 percentile of control groups was used as a cutoff for hits." Why? This seems arbitrary. It seems like appropriate false-discovery rate control would enable a more rigorous method for choosing a cutoff.

      Page 9 - The same comments regarding analysis and scoring of the optical enrichment screen applies to the FSC and GFP screens.

      We clarified the description of the statistical analysis of the screen (see new/changed text below). Mann-Whitney p-values for the two replicates were calculated independently. The Mann-Whitney U test was not performed against a randomized set of phenotypic scores, but using the phenotypic scores of the 22 control non-targeting sgRNAs that were part of the library. Because there are only 22 control sgRNAs (adding more control sgRNAs would increase the size of the library, and reduce the number of genes that can be screened within a given amount of time), the statistical significance of testing genes against these controls is not expected to be very high, and using direct approaches such as multiple hypothesis testing are not expected to yield hits. Instead, we calculated a score combining the severity (phenotypic score) and the trustworthiness (Mann-Whitney p value) of the phenotype (a method previously developed in the Weissman lab at UCSF: https://github.com/mhorlbeck/ScreenProcessing24). We thank the reviewer for suggesting using false discovery rate control as a better method for choosing a cutoff. We modified our original analysis and now determine the threshold of our score based on a calculated empirical false discovery rate (eFDR). We used this approach to maximize the number of true hits and relied on a repeat of the screen and follow-up testing of hits to narrow down true hits. We added the following part in the method section and added an analysis example to the supplementary files (Supplementary file 9)."

      p. 22

      Bioinformatic analysis of the screen

      Analysis was based on the ScreenProcessing pipeline developed in the Weissman lab (https://github.com/mhorlbeck/ScreenProcessing)**(Horlbeck, M. A.; Gilbert, L. A.; Villalta, J. E.; Adamson, B.; Pak, R. A.; Chen, Y.; Fields, A. P.; Park, C. Y.; Corn, J. E.; Kampmann, M.; Weissman, J. S. 2016). The phenotypic score (ε) of each sgRNA was quantified as previously defined(Kampmann, M.; Bassik, M. C.; Weissman, J. S. 2013)** (Supplementary file 9). For the mIFP proof-of-principle screen, phenotypic score of each group was the average score of two sgRNAs assigned to the group and averaged between two replicates except otherwise described. For the nuclear size screen, FSC screen and H2B-mGFP screen, genes were scored based on the average phenotypic scores of the sgRNAs targeting them. For the nuclear size screen, phenotypic scores were further averaged between 4 runs for each replicate. For the nuclear size screen, FSC screen and H2B-mGFP screen, sgRNAs were first clustered by transcription start site (TSS) and scored by the Mann-Whitney U test against 22 non-targeting control sgRNAs included in the library. Since only 22 control sgRNAs were included, significance of hits was assessed by comparison with simulated negative controls that were generated by random assignment of all sgRNAs in the library and phenotypic scores of these simulated negative controls were scored in the same way as phenotypic scores for genes. A score η that includes the phenotypic score and its significance was calculated for each gene and simulated negative control. The optimal cut-off for score η was determined by calculating an empirical false discovery rate (eFDR) at multiple values of η as the number of simulated negative controls with score η higher than the cut-off (false positives) divided by the sum of genes and simulated negative controls with score η higher than the cut-off (all positives). The cut-off score η resulting in an eFDR of 0.1% was used to call hits for further analysis (Supplementary file 9). An example analysis is described in detail in Supplementary file 9 and raw counts and phenotypic scores for all four screens are listed in Supplementary file 10 and 11.

      Page 9 - "These data suggest that a direct measurement utilizing a microscope can provide significant improvement in hit yield even for phenotypes that could be indirectly screened with other approaches." I think this conclusion is too strong. It rests on the assumption that the FSC/GFP phenotypes should have the same set of hits as the microscope phenotype (larger nuclear area). This may not be the case. For example, genes whose inactivation increases GFP expression would be hits in the former, but not latter case. The authors should moderate this statement.

      We agree with the reviewer and have changed the sentence into:

      p. 10 line 17

      These data suggest that a direct measurement utilizing a microscope can provide different information and reveal hits that are inaccessible using other screening approaches.

      Page 11 - "This is significantly faster than the in situ methods." The authors should provide a citation and an actual comparison to the speed of in situ methods.

      We agree with the reviewer and have modified the sentence with a citation:

      p. 12 line 20

      This is significantly faster than in situ methods which process millions of cells over a period of a few days(Feldman, D.; Singh, A.; Schmid-Burgk, J. L.; Carlson, R. J.; Mezger, A.; Garrity, A. J.; Zhang, F.; Blainey, P. C. 2019).

      Page 12 - I think the authors could say a bit more about the possibility of low hit rate screens. How low do they think it is feasible to go? What hit rates are expected based on existing arrayed optical screens?

      We have added more description in the discussion section:

      p. 13 the second paragraph

      Optical enrichment screening also is possible for phenotypic screens with relatively low hit rates (defined as the fraction of all genes screened that are true hits). The ability to detect hits at low hit rates in our method depends on multiple factors, including: 1) the penetrance of the phenotype; 2) cellular fitness effect of the phenotype; 3) detection and photo-activation accuracy of the phenotype; 4) limitations imposed by FACS recovery and sequencing sample preparations of low cell numbers. The first three factors vary with the phenotype of interest. We optimized the genomic DNA preparation protocol (Methods), and are now able to process sequencing samples from a few thousand cells, enabling screens of low hit rate phenotypes. In our nuclear size screen, more than 1.5 millions cells were analyzed during each run with 2000-4000 cells recovered after FACS sorting. The hit rate of this screen was 2.76%, similar to optical CRISPR screens performed in an arrayed format(de Groot, R.; Luthi, J.; Lindsay, H.; Holtackers, R.; Pelkmans, L. 2018)**, demonstrating the possibility to apply our approach to investigate phenotypes with low hit rates.

      Page 14 - It is weird that the discussion includes a fairly important couple of paragraphs that seem to belong in the results (e.g. the text surrounding Figure 4b and c). Obviously, I don't want to prescribe stylistic changes, but I suggest the authors consider moving this description of the experiments/analyses to the results.

      The relevant description has been moved to the results.

      Page 14 - The authors validate their hits individually, and observe that expression of hit sgRNAs does increase nuclear size in some cells. But, many/most cells remain control-like in these validation experiments. The authors should comment on why this is the case (e.g. inefficient knockdown, cell cycle effects, etc).

      To address this point, we have added the following sentences in legend of Fig. 5:

      The cell population is heterogeneous due to inefficient knockdown, incomplete puromycin selection, and penetrance of the phenotype. A BFP was expressed from the same sgRNA construct. Only cells with high BFP intensity, indicating successfully sgRNA transduction, were included for data analysis as described in Methods.

      Page 14 - It would be nice to formally compare the control and sgRNA distributions in each panel of 4a and Supplementary Figure 5 (e.g. with a Komolgorov-Smirnov test, etc). That would allow a more precise statement to be substituted for "14 out of 15 hits (the exception was TACC3) were confirmed to be real hits, with cells exhibiting larger nuclei after knock down (Fig. 4a and Fig. S5)," which is not quantitative.

      We applied the Kolmogorov-Smirnov test and the corresponding sentence was changed into:

      p. 10 last line

      *14 out of 15 hits were confirmed to be real hits (Kolmogorov-Smirnov test two tailed p-value

      Figure 2a - I am not sure it is necessary to show the entire workflow again. The first and possibly last panels are the informative ones here.

      Figure 3a - Same comment as above - these workflow panels take up a lot of real estate and I suggest simplifying them if possible.

      The figures were simplified to just show the example images.

      Figure 3c - At least on my PDF/screen, the "scrambled control" points appear very light gray and are impossible to find. They should be an easier to spot color.

      We agree with the reviewer and changed the color.

      Figure 4b - "Most cells developed a larger cellular size and higher H2B-mGFP level after knock down." I think it would be more accurate to say that the median cell size/GFP level increased, or that some cells developed larger sizes/median GFP levels.

      We agree with the reviewer’s point; “most” has been changed to “some”.

      Figure 4c - I don't understand "Normalized FITC/nuclear size." Do the bars show the mean/median of a population (if so, why not show a dot plot or box plot or violin plot)? Also, what is FITC (I presume it's GFP levels)?

      Figure 4c - "Most cells maintained a constant ratio between nuclear size and DNA content..." I'm not sure where DNA content came from. Are the authors assuming that their H2B-mGFP is a proxy for DNA content? Or was some other measurement made? If the former, is there a citable reason why this is a good assumption?

      The bars represent the ratio of the median level of H2B-mGFP intensity (the axis is now labeled with "GFP" rather than "FITC", the colloquial name for the channel used on the FACS machine) measured by FACS and the median nuclear size of the same population of cells measured by microscopy. We plan to perform additional experiments to measure DNA content using a DNA dye in the same cell by microscopy so that we will be able to correlate these on a cell by cell basis. Data will be added before final publication.

      Reviewer #2 (Significance (Required)):

      I don't generally comment on significance in reviews. Since ReviewCommons is specifically asking, I'll say that this manuscript describes optical enrichment, a method that is an extension of previous work and is substantially similar to a previously published method, Visual Cell Sorting. However, given the timing, it is obvious that these authors have been working independently on optical enrichment. Since the application is distinct, and optical enrichment incorporates some nice features like software to make it easier to execute, it is clearly of independent value.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      This study reports a rapid and high-throughput CRISPR-based phenotypic screen approach consisting of selecting cells with phenotypes of interest, label them by photo-conversion and isolating them by FACS. The idea of the method is interesting (has been around) in principle. The key advantage is that is relatively simple, accessible to many groups as it does not require robotics. However, the manuscript is so badly written and hard to follow, that it makes it difficult to judge the technology, to really understand how the experiments were done and whether the results are interpreted correctly. Strictly speaking, it is unclear whether and how good scientific practices GSP have been followed, as the description of the experiments is sometimes lacking totally. Consequently, it is impossible to seriously evaluate this study and judge whether the technology described is really promising. It is probably less sensitive than arrayed screens, in all likelihood can miss hits that affect growth, cannot capture as many phenotypic classes as one would like from high-content screens and the computational and experimental workflow is more complicated. It is puzzling that the authors don't even compare the results with arrayed screens which are of course the current gold-standard.

      We do not in any way claim that the presented method replaces arrayed screens. However, most current sgRNA libraries are pooled libraries, and the few available arrayed sgRNA libraries are expensive and difficult to maintain, hence our methods to screen pooled sgRNA libraries are timely and useful. Comparisons with arrayed screens are unwarranted as no claims are made with respect to arrayed screens.

      We have clarified the manuscript in many places, and hope it is now readable and better understandable by more readers with diverse backgrounds.

      **Specific points:**

      The specificity test (Fig 1) does not make sense how it is described. If the authors spike a certain percentage of cells that can be photoconverted, when analysing the outcome, there will be three classes: mIFP positive, mIFP/mCherry positive and negative. How can they calculate specificity if they do not know whether they converted all mIFP cells? Also the formula used is questionable or is her an error? Furthermore, it is totally unclear how many cells were used and how they were scanned. If they took 90 negative cells and 10 mIFP cells, getting them all back is easy. If they start with 10e9 cells, the specificity should be quantified. Furthermore, the phenotype they pick is an easy and convenient one. Much more challenging is to apply it on a multi-parametric phenotype. Again, this is now the gold standard.

      We used the term specificity inadvertently and should have used precision, as also pointed out by Referee 2. This has been corrected in the current manuscript. We picked the mIFP phenotype as this was a proof of principle screen to clarify the performance of our screening approach and needed a phenotype that can be measured both by microscopy and FACS. We demonstrate that multi-parametric read-outs are possible, but do not think that the first demonstration of new technology needs such an application.

      In their first sgRNA assay, it is not possible to have a clear idea of what groups they are talking about. Do they mean they get phenotypic signatures which they group? How? They need to describe what they do. Here, only ~3500 genes are scanned (the 6843 is both populations and you only select from the mIFP neg population) and it took them 8hrs. This means for the genome it would require ~60h which is indeed fast. However, this experiment is not clearly described. They cannot select the negative population since there is no fluorescent marker (except false positive which are around 1.7%). So I assume they just randomly pick cells (they should really explain much better what they do!). Why go through the hassle? If these sequences are supposed to be a negative population, just pick them in the computer. Also, they cannot calculate an enrichment compared to the negative population, since two different libraries were infected. Again, I can't follow.

      We improved the description of this experiment. To clarify, we used mIFP in a proof of concept screen to validate whether sgRNAs infecting mIFP positive cells can be distinguished from those infecting mIFP negative cells No phenotypic signature other than the mIFP signal is used (as described in the text). As customary in pooled screens, a primary comparison was made between the positive (optically selected) cells and the complete population. To improve the clarity of this screen, we further described the concept of pooled sgRNA screens, which may have made this section harder to follow.

      I find their results about calculating scores based only on true negatives surprising. The average phenotypic score is improved from 3 to 5, which is enormous. This suggests that the phenotypes induced in the mIFP population are extremely common. These results are hard to interpret given the poor description of the experiment. It is possible that it is the same dataset as in 1, but in that case, the false negatives must be rare since the negatives can be selected by absence of both mCherry and mIFP.

      There are no phenotypes induced in the mIFP population (as now explicitly explained in the text). The mIFP population is isolated using optical enrichment, and we test our ability to discriminate the sgRNAs present in the enriched population. It is unsurprising that comparing to the negatively selected population (which is not possible in most other pooled screens) is significantly better than comparing against the total population (as customary in pooled screens).

      In the nuclear size screen, 6000 sgRNAs were screened. To array so many sequences would require 20 plates. They required ~40h for imaging one replicate. This is slow, imagine the time with a 60x lens.

      There are no arrayed screens performed in our study.

      Reviewer #3 (Significance (Required)):

      Overall, there is no sufficient evidence in this manuscript to convince this reviewer that this method is valid and truly powerful. I cannot support publication in its present form.

    1. Ray, E. L., Wattanachit, N., Niemi, J., Kanji, A. H., House, K., Cramer, E. Y., Bracher, J., Zheng, A., Yamana, T. K., Xiong, X., Woody, S., Wang, Y., Wang, L., Walraven, R. L., Tomar, V., Sherratt, K., Sheldon, D., Reiner, R. C., Prakash, B. A., … Consortium, C.-19 F. H. (2020). Ensemble Forecasts of Coronavirus Disease 2019 (COVID-19) in the U.S. MedRxiv, 2020.08.19.20177493. https://doi.org/10.1101/2020.08.19.20177493

    1. Felipe, L. S., Vercruysse, T., Sharma, S., Ma, J., Lemmens, V., Looveren, D. van, Javarappa, M. P. A., Boudewijns, R., Malengier-Devlies, B., Kaptein, S. F., Liesenborghs, L., Keyzer, C. D., Bervoets, L., Rasulova, M., Seldeslachts, L., Jansen, S., Yakass, M. B., Quaye, O., Li, L.-H., … Dallmeier, K. (2020). A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate. BioRxiv, 2020.07.08.193045. https://doi.org/10.1101/2020.07.08.193045

    1. Ferretti, A. P., Kula, T., Wang, Y., Nguyen, D. M., Weinheimer, A., Dunlap, G. S., Xu, Q., Nabilsi, N., Perullo, C. R., Cristofaro, A. W., Whitton, H. J., Virbasius, A., Olivier, K. J., Baiamonte, L. B., Alistar, A. T., Whitman, E. D., Bertino, S. A., Chattopadhyay, S., & MacBeath, G. (2020). COVID-19 Patients Form Memory CD8+ T Cells that Recognize a Small Set of Shared Immunodominant Epitopes in SARS-CoV-2. MedRxiv, 2020.07.24.20161653. https://doi.org/10.1101/2020.07.24.20161653

    1. Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., Wu, S.-P., Wang, Z., Wu, X.-H., Xu, J.-J., Zhang, Z., Jia, S.-Y., Wang, B.-S., Hu, Y., Liu, J.-J., … Chen, W. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)31605-6

    1. Hogan, A. B., Jewell, B. L., Sherrard-Smith, E., Vesga, J. F., Watson, O. J., Whittaker, C., Hamlet, A., Smith, J. A., Winskill, P., Verity, R., Baguelin, M., Lees, J. A., Whittles, L. K., Ainslie, K. E. C., Bhatt, S., Boonyasiri, A., Brazeau, N. F., Cattarino, L., Cooper, L. V., … Hallett, T. B. (2020). Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: A modelling study. The Lancet Global Health, 0(0). https://doi.org/10.1016/S2214-109X(20)30288-6

    1. Guo, L., Boocock, J., Tome, J. M., Chandrasekaran, S., Hilt, E. E., Zhang, Y., Sathe, L., Li, X., Luo, C., Kosuri, S., Shendure, J. A., Arboleda, V. A., Flint, J., Eskin, E., Garner, O. B., Yang, S., Bloom, J. S., Kruglyak, L., & Yin, Y. (2020). Rapid cost-effective viral genome sequencing by V-seq. BioRxiv, 2020.08.15.252510. https://doi.org/10.1101/2020.08.15.252510

    1. Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., Navarro, M. J., Miranda, M. C., Pettie, D., Ravichandran, R., Kraft, J. C., Ogohara, C., Palser, A., Chalk, S., Lee, E.-C., … King, N. P. (2020). Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. BioRxiv, 2020.08.11.247395. https://doi.org/10.1101/2020.08.11.247395

    1. A Certificate in Psychology requires a minimum total of 12 semester hours, which generally translates into 4 courses: 3 required courses and 1 elective. All courses for the certificate must have a grade of "C" or better.

      Getting this certificate is the key to get me better job opportunities. By getting more serious job opportunities I will get plenty of experience so I can lead up to my dream job. I need to do my best work in order to succeed this certificate.

    1. COVID-19 first appeared in a group of Chinese miners in 2012

      Take away: The COVID-19 virus (SARS-CoV2) did not exist in 2012, however a related virus was isolated from bats in 2013.

      The claim: The same virus that is causing the COVID-19 pandemic existed in miners in 2012.

      The evidence:RaTG13, a virus that was isolated from bats by the Wuhan Institute of Virology in 2013 is the closest known relative to SARS-CoV2, the virus that causes COVID-19 (Ge 2016, Zhou 2020). This bat virus is not the same virus as SARS-CoV2, but is closely related (96% identical DNA). The virus was isolated from bats, not humans. However, it was isolated from a cave near where workers the previous year became sick and some died, and may be linked to the illnesses. The SARS-CoV2 virus shows a number of key adaptations that likely makes it much more infectious in humans than the related bat virus (Wrobel, 2020).

      Source:

      Ge XY, Wang N, Zhang W, Hu B, Li B, Zhang YZ, Zhou JH, Luo CM, Yang XL, Wu LJ, Wang B. Coexistence of multiple coronaviruses in several bat colonies in an abandoned mineshaft. Virologica Sinica. 2016 Feb 1;31(1):31-40.

      Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. 2020 Mar;579(7798):270-3.

      Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Nature Structural & Molecular Biology. 2020 Aug;27(8):763-7.

    1. Other programs offer all teachers the chance to forgive their loan balances after 10 years of teaching service.

      This is also significant because I know colleges are expensive with tuition and also getting other materials like a textbook or getting a dorm room on school property. Therefore I may need to get a loan to be able to pay for everything.So knowing that some programs allow teachers to pay for their loan after 10 years of teaching is useful.

    1. Martino, C., Kellman, B. P., Sandoval, D. R., Clausen, T. M., Marotz, C. A., Song, S. J., Wandro, S., Zaramela, L. S., Benítez, R. A. S., Zhu, Q., Armingol, E., Vázquez-Baeza, Y., McDonald, D., Sorrentino, J. T., Taylor, B., Belda-Ferre, P., Liang, C., Zhang, Y., Schifanella, L., … Knight, R. (2020). Bacterial modification of the host glycosaminoglycan heparan sulfate modulates SARS-CoV-2 infectivity. BioRxiv, 2020.08.17.238444. https://doi.org/10.1101/2020.08.17.238444

    1. Yonker, L. M., Neilan, A. M., Bartsch, Y., Patel, A. B., Regan, J., Arya, P., Gootkind, E., Park, G., Hardcastle, M., John, A. S., Appleman, L., Chiu, M. L., Fialkowski, A., Flor, D. D. la, Lima, R., Bordt, E. A., Yockey, L. J., D’Avino, P., Fischinger, S., … Fasano, A. (2020). Pediatric SARS-CoV-2: Clinical Presentation, Infectivity, and Immune Responses. The Journal of Pediatrics, 0(0). https://doi.org/10.1016/j.jpeds.2020.08.037

    1. Our college, with its multinational and multicultural student population, provides an educational setting that mirrors the diversity of the global business community. With the rise of globalization and the ever-increasing need to be adaptive and ready for an international, multi-cultural environment, this has never been more important

      There is a strong network offered by georgia state because it is located in downtown atlanta.data:image/jpeg;base64,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

    1. Science courses required for the program must be less than 6 years old.

      I will need to make sure to apply for the nursing program before my science course grade will be invalid. This is significant because i am not completely sure if i want to start my career a little later once i'm for certain that i want to pick nursing. I have to keep in mind that i need to start thinking if i wan to go ahead and start this career right after high school or have a little gap year.

    1. g:var - 全局 a:var - 函数参数 l:var - 函数局部变量 b:var - buffer 局部变量 w:var - window 局部变量 t:var - tab 局部变量 s:var - 当前脚本内可见的局部变量 v:var - Vim 预定义的内部变量

      g: global a: arg l: local b: buffer w: window t: tab s: script 当前的 script 可见的局部变量 v: vim 自定义

    1. Rodda, L. B., Netland, J., Shehata, L., Pruner, K. B., Morawski, P. M., Thouvenel, C., Takehara, K. K., Eggenberger, J., Hemann, E. A., Waterman, H. R., Fahning, M. L., Chen, Y., Rathe, J., Stokes, C., Wrenn, S., Fiala, B., Carter, L. P., Hamerman, J. A., King, N. P., … Pepper, M. (2020). Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. MedRxiv, 2020.08.11.20171843. https://doi.org/10.1101/2020.08.11.20171843

    1. Chen, Y., Yang, W.-H., Huang, L.-M., Wang, Y.-C., Yang, C.-S., Liu, Y.-L., Hou, M.-H., Tsai, C.-L., Chou, Y.-Z., Huang, B.-Y., Hung, C.-F., Hung, Y.-L., Chen, J.-S., Chiang, Y.-P., Cho, D.-Y., Jeng, L.-B., Tsai, C.-H., & Hung, M.-C. (2020). Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro. BioRxiv, 2020.08.14.250258. https://doi.org/10.1101/2020.08.14.250258

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer1

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      The manuscript is clearly written and the figures appropriate and informative. Some descriptions of data analyses are a little dense but reflect what would appear long hard efforts on the part of the authors to identify and control for possible sources of misinterpretation due to sensitivities of parameters in their fitness model. The authors efforts to retest interactions under non-competition conditions allay fears of most concerns that I would have. One problem though that I could not see explicitly addressed was that of potential effects of interactions between methotrexate and the other conditions and how this is controlled for. Specifically, I could be argued that the fact that a particular PPI is observed under a specific condition could have more to do with a synthetic effect of treatment of cells with a drug plus methotrexate. Is this controlled for and how? I raise this because in a chemical genetic screen for fitness it was shown that methotrexate is particularly promiscuous for drug-drug interactions (Hillenmeyer ME ,et al. Science 2008). I tried to think of how this works but couldn't come up with anything immediately. I'd appreciate if the authors would take a crack at resolving this issue. Otherwise I have no further concerns about the manuscript.

      We thank the reviewer for the kind comments. We agree with the reviewer’s point that methotrexate could be interacting with drugs or other perturbagens, similar to how the chosen nitrogen source, carbon source, or other growth conditions may interact with a drug. However, the methotrexate concentration is held constant across all conditions, as is the rest of the media components such as the nitrogen and carbon source (with the exception of the raffinose perturbation). Any interactions with methotrexate, or other media components, is undetectable without systematically varying all components for all stressors. Therefore, we use the typical experimental design of measuring molecular variation from a reference, holding invariant media components (such as methotrexate, glucose, or vitamins) fixed between conditions. This is a general practice, and we describe that every condition contains methotrexate on page 3, line 10.

      The library was grown under mild methotrexate selection in 9 environments for 12-18 generations in serial batch culture, diluting 1:8 every ~3 generations, with a bottleneck population size greater than 2 x 109 cells (Table S1).

      We also list the full details of each environment in Table S1.

      Reviewer #1 (Significance (Required)):

      Lui et al expand on previous work from the Levy group to explore a massive in vivo protein interactome in the yeast S. cerevisiae. They achieve this by performing screens cross 9 growth conditions, which, with replication, results in a total of 44 million measurements. Interpreting their results based on a fitness model for pooled growth under methotrexate selection, they make the key observation that there is a vastly expanded pool of protein-protein interactions (PPI) that are found under only one or two condition compared to a more limited set of PPI that are found under a broad set of conditions (mutable versus immutable interactors). The authors show that this dichotomy suggests some important features of proteins and their PPIs that raise important questions about functionality and evolution of PPIs. Among these are that mutable PPIs are enriched for cross-compartmental, high disorder and higher rates of evolution and subcellular localization of proteins to chromatin, suggesting roles in gene regulation that are associated with cellular responses to new conditions. At the same time these interactions are not enriched for changes in abundance. These results are in contrast to those of immutable PPIs, which seem to form a core background noise, more determined by changes in abundance than what the authors interpret must be post-translational processes that may drive, for instance, changes in subcellular localization resulting in appearance of PPIs under specific conditions. The authors are also able to address a couple of key issues about protein interactomes, including the controversial Party-date Hub hypothesis of Vidal, in which they could now affirm support for this hypothesis based on their results and notably negative correlation of PPIs to protein abundance for mutable PPIs. Finally, they also addressed the problem of predicting the upper limit of PPIs in yeast, showing the remarkable results that it may be no more than about 2 times the number of proteins expressed by yeast. Such an upper limit is profoundly important to modelling cellular network complexity and, if it holds up, could define a general upper limit on organismal complexity.

      This manuscript is a very important contribution to understanding dynamics of molecular networks in living cells and should be published with high priority.

      Reviewer 2

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      Report on Liu et al. "A large accessory protein interactome is rewired across environments"

      Liu et al. use a mDHFR-based, pooled barcode sequencing / competitive growth / mild methotrexate selection method to investigate changes of PPI abundance of 1.6 million protein pairs across different 9 growth conditions. Because most PPI screens aim to identify novel PPIs in standard growth conditions, the currently known yeast PPI network may be incomplete. The key concept is to define immutable" PPIs that are found in all conditions and "mutable" PPIs that are present in only some conditions.

      The assay identified 13764 PPIs across the 9 conditions, using optimized fitness cut offs. Steady PPI i.e. across all environments, were identified in membrane compartments and cell division. Processes associated with the chromosome, transcription, protein translation, RNA processing and ribosome regulation were found to change between conditions. Mutable PPIs are form modules as topological analyses reveals.

      Interestingly, a correlation on intrinsic disorder and PPI mutability was found and postulated as more flexible in the conformational context, while at the same time they are formed by less abundant proteins.

      I appreciate the trick to use homodimerization as an abundance proxy to predict interaction between heterodimers (of proteins that homodimerize). This "mass-action kinetics model" explains the strength of 230 out of 1212 tested heterodimers.

      A validation experiment of the glucose transporter network was performed and 90 "randomly chosen" PPIs that were present in the SD environment were tested in NaCl (osmotic stress) and Raffinose (low glucose) conditions through recording optical density growth trajectories. Hxt5 PPIs stayed similar in the tested conditions, supported by the current knowledge that Hxt5 is highly expressed in stationary phase and under salt stress. In Raffinose, Hxt7, previously reported to increase the mRNA expression, lost most PPIs indicating that other factors might influence Hxt7 PPIs.

      **Points for consideration:**

      *) A clear definition of mutable and immutable is missing, or could not be found e.g. at page 4 second paragraph.

      We thank the reviewer for pointing this out. We have now added better definition of mutable and immutable on line 19 page 4:

      We partitioned PPIs by the number of environments in which they were identified and defined PPIs at opposite ends of this spectrum as “mutable” PPIs (identified in only 1-3 environments) and “immutable” (identified in 8-9 environments).

      *) Approximately half of the PPIs have been identified in one environment. Many of those mutable PPIs were detected in the 16{degree sign}C condition. Is there an explanation for the predominance of this specific environment? What are these PPIs about?

      The reviewer is correct that ~40% of the PPIs identified in only one environment were found in the 16 ℃ environment. One reason for this could be technical: the positive predictive value (PPV) is the lowest amongst the conditions (16 ℃: 31.6%, mean: 57%, Table SM6). It must be noted, however, that PPVs are calculated using reference data that has generally been collected in standard growth conditions. So, it might be expected that the most divergent environment from standard growth conditions (resulting in the most differences in PPIs) would result in a lower PPV in our study even if the true frequency of false positives was equivalent across environments. We have attempted to be transparent about the quality of the data in each environment by reporting PPVs and other metrics in Table SM6. However, we suspect that the large number of PPIs unique to 16 ℃ is due in part to the fact that it causes the largest changes in the protein interactome, and believe that it should be included, even at the risk of lowering the overall quality of the data. The main reason for this is that this data is likely to contain valuable information about how the cell copes with this stress. For example, we find, but do not highlight in the manuscript, that 16 ℃-specific PPIs contain two major hubs (DID4: 285 PPIs involved in endocytosis and vacuolar trafficking, and DED1: 102 PPIs involved in translation), both of which are reported to be associated with cold adaptation in yeast (Hilliker et al., 2011; Isasa et al., 2015).

      To assess whether the potentially higher false-positive rate in 16 ℃ could be impacting our conclusions related to PPI network organization and features of immutable and mutable PPIs, we repeated these analyses leaving out the 16 ℃ data and found that our main conclusions did not change. This new analysis is now presented in Figure S8 and described on page 5, line 10.

      Finally, we used a pair of more conservative PPI calling procedures that either identified PPIs with a low rate of false positives across all environments (FPR

      We have also added references to other panels in Figure S8 throughout the manuscript, where appropriate.

      *) 50 % overall retest validation rate is fair and reflects a value comparable to other large-scale approaches. However what is the actual variation, e.g. between mutable PPIs and immutable or between condition. e.g. at 16{degree sign}C.

      We validated 502 PPIs present in the SD environment and an additional 36 PPIs in the NaCl environment. As the reviewer suggests, we do indeed observe differences in the validation rate across mutability bins. This data is reported in Figures 3B and S6B, and we use this information to provide a confidence score for each PPI on page 5, line 4.

      To better estimate how the number of PPIs changes with PPI mutability, we used these optical density assays to model the validation rate as a function of the mean PPiSeq fitness and the number of environments in which a PPI is detected. This accurate model (Spearman's r =0.98 between predicted and observed, see Methods) provided confidence scores (predicted validation rates) for each PPI (Table S5) and allowed us to adjust the true positive PPI estimate in each mutability bin. Using this more conservative estimate, we still found a preponderance of mutable PPIs (Figure S6E).

      The validation rate in NaCl is similar to SD (39%, 14/36), suggesting that validation rates do not vary excessively across environments. Because validation experiments are time consuming (we performed 6 growth experiments per PPI), performing a similar scale of validations in all environments as in SD would be resource intensive. Insead, we report a number of metrics (true positive rate, false positive rate, positive predictive value) in Table SM6 using large positive and random reference sets. We believe these metrics are sufficient for readers to compare the quality of data across environments.

      *) What is the R correlation cutoff for PPIs explained in the mass equilibrium model vs. not explained?

      We do not use an R correlation cutoff to assess if a PPI is explained by the mass-action equilibrium model. We instead rely on ordinary least-squares regression as detailed in the methods on page 68, line 13.

      ...we used ordinary least-squares linear regression in R to fit a model of the geometric mean of the homodimer signals multiplied by a free constant and plus a free intercept. Significantly explained heterodimer PPIs were judged by a significant coefficient (FDR 0.05, single-test). This criteria was used to identify PPIs for which protein expression does or does not appear to play as significant of a role as other post-translational mechanisms.

      The first criterion identifies a quantitative fit to the model of variation being related. The second criterion is used to filter out PPIs for which the relationship appears to be explained by more than just the homodimer signals. This approach is more stringent, but we believe this is the most appropriate statistical test to assess fit to this linear model.

      *) 90 "randomly chosen" PPIs for validation. It needs to be demonstrated that these interaction are a random subset otherwise is could also mean cherry picked interactions.

      We selected 90 of the 284 glucose transport-related PPIs for validation using the “sample” function in R (replace = FALSE). We have now included text that describes this on page 63, line 3 in the supplementary methods:

      Diploids (PPIs) on each plate were randomly picked using the “sample” function in R (replace = FALSE) from PPIs that meet specific requirements.

      *) Figure 4 provides interesting correlations with the goal to reveal properties of mutable and less mutable PPIs. PPIs detected in the PPIseq screen can partially be correlated to co-expression (4A) as well as co-localization. Does it make sense to correlate the co-expression across number of conditions? Are the expression correlation condition specific. In this graph it could be that expression correlation stems from condition 1 and 2 and the interaction takes place in 4 and 5 still leading to the same conclusion ... Is the picture of the co-expression correlation similar when you simply look at individual environments like in S4A?

      We use co-expression mutual rank scores from the COXPRESdb v7.3 database (Obayashi et al., 2019). These mutual rank scores are derived from a broad set of 3593 environmental perturbations that are not limited to the environments we tested here. By using this data, we are asking if co-expression in general is correlated with mutability and report that it is in Figure 4A. We thank the reviewer for pointing out that this was not clear and have now added text to clarify that the co-expression analysis is derived from external data on page 6, line 7.

      We first asked whether co-expression is indeed a predictor of PPI mutability and found that it is: co-expression mutual rank (which is inversely proportional to co-expression across thousands of microarray experiments) declined with PPI mutability (Figures 4A and S11) (Obayashi and Kinoshita, 2009; Obayashi et al., 2019).

      The new figure S11 examines how the co-expression mutual rank changes with PPI mutability for PPIs identified in each environment, as the reviewer suggested. For each environment, we find the same general pattern as in Figure 4A (which considers PPIs from all environments).

      *) Figure 4C: Interesting, how dependent are the various categories?

      It is well known that many of these categories are correlated (e.g. mRNA expression level and protein abundance, and deletion fitness effect and genetic interaction degree). However, we believe it is most valuable to report the correlation of each category with PPI mutability independently in Figures 4C and S12, since similar correlations with related categories provide more confidence in our conclusions.

      *) Figure 4 F: When binned in the number of environments in which the PPI was found, the distribution peaks at 6 environments and decreases with higher and lower number of environments. The description /explanation in the text clearly says something else.

      We reported on page 7, line 15:

      We next used logistic regression to determine what features may underlie a good or poor fit to the model (Figure S14C) and found that PPI mutability was the best predictor, with more mutable PPIs being less frequently explained (Figure 4F). Unexpectedly, mean protein abundance was the second best predictor, with high abundance predicting a poor fit to the model, particularly for less mutable PPIs (Figure S14D and S14E).

      As the reviewer notes, Figure 4F shows that the percent of heterodimers explained by the model does appear to decrease for PPIs observed in the most environments. We suspect that the reviewer is correct that something more complicated is going on. One possibility is that extraordinarily stable PPIs (stable in all conditions) would have less quantitative variation in protein or PPI abundance across environments. If this is true, it would be statistically difficult to fit the mass action kinetics model for these PPIs (lower signal relative to noise), thereby resulting in the observed dip.

      A second possibility is that multiple correlated factors are associated with contributing positively or negatively to a good fit, and the simplicity of Figure 4F or a Pearson correlation does not capture this interplay. This second possibility is why we used multivariate logistic regression (Figure S14C) to dissect the major contributing factors. In the text quote above, we report that high abundance is anti-correlated with a good fit to the model (S14D, S14E). Figure 4C shows that immutable PPIs tend to be formed from highly abundant proteins. One possible explanation is that highly abundant proteins saturate the binding sites of their binding partners, breaking from the assumptions of mass action kinetics model. We have now changed the word “limit” to “saturate” on page 7, line 22 to make this concept more explicit.

      Taken together, these data suggest that mutable PPIs are subject to more post-translational regulation across environments and that high basal protein abundance may saturate the binding sites of their partners, limiting the ability of gene expression changes to regulate PPIs.

      A third possibility is that the dip is simply due to noise. Given the complexity of the possible explanations and our uncertainty about which is more likely, we chose to leave this description out of the main text and focus on the major finding: that PPIs detected in more environments are generally associated with a better fit to the mass action kinetics model.

      *) Figure 6: I apologize, but for my taste this is not a final figure 6 for this study. Investigation of different environments increases the PPI network in yeast, yes, yet it is very well known that a saturation is reached after testing of several conditions, different methods and even screening repetition (sampling). It does not represent an important outcome. Move to suppl or remove.

      We included Figure 6 to summarize and illustrate the path forward from this study. This is an explicit reference to impactful computational analyses done using earlier generations of data to assess the completeness of single-condition interaction networks (Hart et al., 2006; Sambourg and Thierry-Mieg, 2010). Here, we are extending PPI measurement of millions-scale networks across multiple environments, and are using this figure to extend these concepts to multi-condition screens. We agree that the property of saturation in sampling is well known, but it is surprising that we can quantitatively estimate convergence of this expanded condition-specific PPI set using only 9 conditions. Thus, we agree with Reviewer 1 that these are “remarkable results” and that the “upper limit is profoundly important to modelling cellular network complexity and, if it holds up, could define a general upper limit on organismal complexity.” We think this is an important advance of the paper, and this figure is useful to stimulate discussion and guide future work.

      Reviewer #2 (Significance (Required)):

      Liu et al. increase the current PPI network in yeast and offer a substantial dataset of novel PPIs seen in specific environments only. This resource can be used to further investigate the biological meaning of the PPI changes. The data set is compared to previous DHFR providing some sort of quality benchmarking. Mutable interactions are characterized well. Clearly a next step could be to start some "orthogonal" validation, i.e. beyond yeast growth under methotrexate treatment.

      The reviewer makes a great point that we also discuss on page 9, line 33:

      While we used reconstruction of C-terminal-attached mDHFR fragments as a reporter for PPI abundance, similar massively parallel assays could be constructed with different PCA reporters or tagging configurations to validate our observations and overcome false negatives that are specific to our reporter. Indeed, the recent development of “swap tag” libraries, where new markers can be inserted C- or N-terminal to most genes (Weill et al., 2018; Yofe et al., 2016), in combination with our iSeq double barcoder collection (Liu et al., 2019), makes extension of our approach eminently feasible.

      Reviewer 3

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      **Summary**

      The manuscript "A large accessory protein interactome is rewired across environments" by Liu et al. scales up a previously-described method (PPiSeq) to test a matrix of ~1.6 million protein pairs of direct protein-protein interactions in each of 9 different growth environments.

      While the study found a small fraction of immutable PPIs that are relatively stable across environments, the vast majority were 'mutable' across environments. Surprisingly, PPIs detected only in one environment made up more than 60% of the map. In addition to a false positive fraction that can yield apparently-mutable interactions, retest experiments demonstrate (not surprisingly) that environment-specificity can sometimes be attributed to false-negatives. The study authors predict that the whole subnetwork within the space tested will contain 11K true interactions.

      Much of environment-specific rewiring seemed to take place in an 'accessory module', which surrounds the core module made of mostly immutable PPIs. A number of interesting network clustering and functional enrichment analyses are performed to characterize the network overall and 'mutable' interactions in particular. The study report other global properties such as expression level, protein abundance and genetic interaction degree that differ between mutable and immutable PPIs. One of the interesting findings was evidence that many environmentally mutable PPI changes are regulated post-translationally. Finally, authors provide a case study about network rewiring related to glucose transport.

      **Major issues**

      -The results section should more prominently describe the dimensions of the matrix screen, both in terms of the set of protein pairs attempted and the set actually screened (I think this was 1741 x 1113 after filtering?). More importantly, the study should acknowledge in the introduction that this was NOT a random sample of protein pairs, but rather focused on pairs for which interaction had been previously observed in the baseline condition. This major bias has a potentially substantial impact on many of the downstream analyses. For example, any gene which was not expressed under the conditions of the original Tarrasov et al. study on which the screening space was based will not have been tested here. Thus, the study has systematically excluded interactions involving proteins with environment-dependent expression, except where they happened to be expressed in the single Tarrasov et al. environment. Heightened connectivity within the 'core module' may result from this bias, and if Tarrasov et al had screened in hydrogen peroxide (H2O2) instead of SD media, perhaps the network would have exhibited a code module in H2O2 decorated by less-densely connected accessory modules observed in other environments. The paper should clearly indicate which downstream analyses have special caveats in light of this design bias.

      We have now added text the matrix dimensions of our study on page 3, line 3:

      To generate a large PPiSeq library, all strains from the protein interactome (mDHFR-PCA) collection that were found to contain a protein likely to participate in at least one PPI (1742 X 1130 protein pairs), (Tarassov et al., 2008) were barcoded in duplicate using the double barcoder iSeq collection (Liu et al., 2019), and mated together in a single pool (Figure 1A). Double barcode sequencing revealed that the PPiSeq library contained 1.79 million protein pairs and 6.05 million double barcodes (92.3% and 78.1% of theoretical, respectively, 1741 X 1113 protein pairs), with each protein pair represented by an average of 3.4 unique double barcodes (Figure S1).

      We agree with the reviewer that our selection of proteins from a previously identified set can introduce bias in our conclusions. Our research question was focused on how PPIs change across environments, and thus we chose to maximize our power to detect PPI changes by selecting a set of protein pairs that are enriched for PPIs. We have now added a discussion of the potential caveats of this choice to the discussion on page 9, line 4:

      Results presented here and elsewhere (Huttlin et al., 2020) suggest that PPIs discovered under a single condition or cell type are a small subset of the full protein interactome emergent from a genome. We sampled nine diverse environments and found approximately 3-fold more interactions than in a single environment. However, the discovery of new PPIs began to saturate, indicating that most condition-specific PPIs can be captured in a limited number of conditions. Testing in many more conditions and with PPI assays orthogonal to PPiSeq will undoubtedly identify new PPIs, however a more important outcome could be the identification of coordinated network changes across conditions. Using a test set of ~1.6 million (of ~18 million) protein pairs across nine environments, we find that specific parts of the protein interactome are relatively stable (core modules) while others frequently change across environments (accessory modules). However, two important caveats of our study must be recognized before extrapolating these results to the entire protein interactome across all environment space. First, we tested for interactions between a biased set of proteins that have previously been found to participate in at least one PPI as measured by mDHFR-PCA under standard growth conditions (Tarassov et al., 2008). Thus, proteins that are not expressed under standard growth conditions are excluded from our study, as are PPIs that are not detectable by mDHFR-PCA or PPiSeq. It is possible that a comprehensive screen using multiple orthogonal PPI assays would alter our observations related to the relative dynamics of different regions of the protein interactome and the features of mutable and immutable PPIs. Second, we tested a limited number of environmental perturbations under similar growth conditions (batch liquid growth). It is possible that more extreme environmental shifts (e.g. growth as a colony, anaerobic growth, pseudohyphal growth) would introduce new accessory modules or alter the mutability of the PPIs we detect. Nevertheless, results presented here provide a new mechanistic view of how the cell changes in response to environmental challenges, building on the previous work that describes coordinated responses in the transcriptome (Brauer et al., 2007; Gasch et al., 2000) and proteome (Breker et al., 2013; Chong et al., 2015).

      -Related to the previous issue, a quick look at the proteins tested (if I understood them correctly) showed that they were enriched for genes encoding the elongator holoenzyme complex, DNA-directed RNA polymerase I complex, membrane docking and actin binding proteins, among other functional enrichments. Genes related to DNA damage (endonuclease activity and transposition), were depleted. It was unclear whether the functional enrichment analyses described in the paper reported enrichments relative to what would be expected given the bias inherent to the tested space?

      We did two functional enrichment analyses in this study: network density within Gene Ontology terms (related to Figure 2) and gene ontology enrichment of network communities (related to Figure 3). For both analyses, we performed comparisons to proteins included in PPiSeq library. This is described in the Supplementary Materials on page 63, line 35:

      To estimate GO term enrichment in our PPI network, we constructed 1000 random networks by replacing each bait or prey protein that was involved in a PPI with a randomly chosen protein from all proteins in our screen. This randomization preserves the degree distribution of the network.

      And on page 66, line 38:

      The set of proteins used for enrichment comparison are proteins that are involved in at least one PPI as determined by PPiSeq.

      -Re: data quality. To the study's great credit, they incorporated positive and random reference sets (PRS and RRS) into the screen. However, the results from this were concerning: Table SM6 shows that assay stringency was set such that between 1 and 3 out of 67 RRS pairs were detected. This specificity would be fine for an assay intended for retest or validate previous hits, where the prior probability of a true interaction is high, but in large-scale screening the prior probability of true interactions that are detectable by PCA is much lower, and a higher specificity is needed to avoid being overwhelmed by false positives. Consider this back of the envelope calculation: Let's say that the prior probability of true interaction is 1% as the authors' suggest (pg 49, section 6.5), and if PCA can optimistically detect 30% of these pairs, then the number of true interactions we might expect to see in an RRS of size 67 is 1% * 30% * 67 = 0.2 . This back of the envelope calculation suggests that a stringency allowing 1 hit in RRS will yield 80% [ (1 - 0.2) / 1 ] false positives, and a stringency allowing 3 hits in RRS will yield 93% [ (3 - 0.2) / 3] false positives. How do the authors reconcile these back of the envelope calculations from their PRS and RRS results with their estimates of precision?

      We thank the reviewer for bringing up with this issue. We included positive and random reference sets (PRS:70 protein pairs, RRS:67 protein pairs) to benchmark our PPI calling (Yu et al., 2008). The PRS reference lists PPIs that have been validated by multiple independent studies and is therefore likely to represent true PPIs that are present in some subset of the environments we tested. For the PRS set, we found a rate of detection that is comparable to other studies (PPiSeq in SD: 28%, Y2H and yellow fluorescent protein-PCA: ~20%) (Yu et al., 2008). The RRS reference, developed ten years ago, is randomly chosen protein pairs for which there was no evidence of a PPI in the literature at the time (mostly in standard growth conditions). Given the relatively high rate of false negatives in PPI assays, this set may in fact contain some true PPIs that have yet to be discovered. We could detect PPIs for four RRS protein pairs in our study, when looking across all 9 environments. Three of these (Grs1_Pet10, Rck2_Csh1, and YDR492W_Rpd3) could be detected in multiple environments (9, 7, and 3, respectively), suggesting that their detection was not a statistical or experimental artifact of our bar-seq assay (see table below derived from Table S4). The remaining PPI detected in the RRS, was only detected in SD (standard growth conditions) but with a relatively high fitness (0.35), again suggesting its detection was not a statistical or experimental artifact. While we do acknowledge it is possible that these are indeed false positives due to erroneous interactions of chimeric DHFR-tagged versions of these proteins, the small size of the RRS combined with the fact that some of the protein pairs could be true PPIs, did not give us confidence that this rate (4 of 70) is representative of our true false positive rate. To determine a false positive rate that is less subject to biases stemming from sampling of small numbers, we instead generated 50 new, larger random reference sets, by sampling for each set ~ 60,000 protein pairs without a reported PPI in BioGRID. Using these new reference sets, we found that the putative false positive rate of our assay is generally lower than 0.3% across conditions for each of the 50 reference sets. We therefore used this more statistically robust measure of the false positive rate to estimate positive predictive values (PPV = 62%, TPR = 41% in SD). We detail these statistical methods in Section 6 of the supplementary methods and report all statistical metrics in Table SM6.

      PPI

      Environment_number

      SD

      H2O2

      Hydroxyurea

      Doxorubicin

      Forskolin

      Raffinose

      NaCl

      16℃

      FK506

      Rck2_Csh1

      7

      0.35

      0.35

      0

      0.20

      0.54

      0.74

      0

      0.17

      0.59

      Grs1_Pet10

      9

      0.44

      0.39

      0.34

      0.25

      0.65

      1.19

      0.2

      0.16

      0.95

      YDR492W_Rpd3

      3

      0

      0.18

      0

      0

      0

      0

      0

      0.17

      0.61

      Mrps35_Bub3

      1

      0.35

      0

      0

      0

      0

      0

      0

      0

      0

      Positive_control

      9

      1

      0.8

      0.73

      0.62

      1.4

      2.44

      0.4

      0.28

      1.8

      Table. Mean fitness in each environment

      -Methods for estimating precision and recall were not sufficiently well described to assess. Precision vs recall plots would be helpful to better understand this tradeoff as score thresholds were evaluated.

      We describe in detail our approach to calling PPIs in section 6.6 of the supplementary methods, including Table SM6, and Figures SM3, SM4, SM6, and now Figure SM5. We identified positive PPIs using a dynamic threshold that considers the mean fitness and p-value in each environment. For each dynamic threshold, we estimated the precision and recall based on the reference sets (described supplementary methods in section 6.5). We then chose the threshold with the maximal Matthews correlation coefficient (MCC) to obtain the best balance between precision and recall. We have now added an additional plot (Figure SM5) that shows the precision and recall for the chosen dynamic threshold in each environment.

      -Within the tested space, the Tarassov et al map and the current map could each be compared against a common 'bronze standard' (e.g. literature curated interactions), at least for the SD map, to have an idea about how the quality of the current map compares to that of the previous PCA map. Each could also be compared with the most recent large-scale Y2H study (Yu et al).

      We thank the reviewer for this suggestion. We have now added a figure panel (Figure S4) that compares PPiSeq in SD (2 replicates) to mDHFR PCA (Tarassov et al., 2008), Y2H (Yu et al., 2008), and our newly constructed ‘bronze standard’ high-confidence positive reference set (PRS, supplementary method section 6.4).

      • Experimental validation of the network was done by conventional PCA. However, it should be noted that this is a form of technical replication of the DHFR-based PCA assay, and not a truly independent validation. Other large-scale yeast interaction studies (e.g., Yu et al, Science 2008) have assessed a random subset of observed PPIs using an orthogonal approach, calibrated using PRS and RRS sets examined via the same orthogonal method, from which overall performance of the dataset could be determined.

      We appreciate the reviewer’s perspective, since orthogonal validation experiments have been a critical tool to establish assay performance following early Y2H work. We know from careful work done previously that modern orthogonal assays have a low cross validation rate ((Yu et al., 2008) and that they tend to be enriched for PPIs in different cellular compartments (Jensen and Bork, 2008), indicating that high false negative rates are the likely explanation. High false negative rates have been confirmed here and elsewhere using positive reference sets (e.g. Y2H 80%, PCA 80%, PPiSeq 74% using the PRS in (Yu et al., 2008)). Therefore, the expectation is that PPiSeq, as with other assays, will have a low rate of validation using an orthogonal assay -- although we would not know if this rate is 10%, 30% or somewhere in between without performing the work. However, the exact number -- whether it be 10% or 30% -- has no practical impact on the main conclusions of this study (focused on network dynamics rather than network enumeration). Neither does that number speak to the confidence in our PPI calls, since a lower number may simply be due to less overlap in the sets of PPIs that are callable by PPiSeq and another assay. Our method uses bar-seq to extend an established mDHFR-PCA assay (Tarassov et al., 2008). The validations we performed were aimed at confirming that our sequencing, barcode counting, fitness estimation, and PPI calling protocols were not introducing excessive noise relative to mDHFR-PCA that resulted in a high number of PPI miscalls. Confirming this, we do indeed find a high rate of validation by lower throughput PCA (50-90%, Figure 3B). Finally, we do include independent tests of the quality of our data by comparing it to positive and random reference sets from literature curated data. We find that our assay performs extremely well (PPV > 61%, TPR > 41%) relative to other high-throughput assays.

      -The Venn diagram in Figure 1G was not very informative in terms of assessing the quality of data. It looks like there is a relatively little overlap between PPIs identified in standard conditions (SD media) in the current study and those of the previous study using a very similar method. Is there any way to know how much of this disagreement can be attributed to each screen being sub-saturation (e.g. by comparing replica screens) and what fraction to systematic assay or environment differences?

      We have now added a figure panel (Figure S4) that compares PPiSeq in SD (2 replicates) to mDHFR-PCA (Tarassov et al., 2008), Y2H (Yu et al., 2008), and our newly constructed ‘bronze standard’ high-confidence positive reference sets (PRS, supplementary methods section 6.4). We find that SD replicates have an overlap coefficient of 79% with each other, ~45% with mDHFR-PCA, ~45% the ‘bronze standard’ PRS, and ~13% with Y2H. Overlap coefficients between the SD replicates and mDHFR-PCA are much higher than those found between orthologous methods ((Yu et al., 2008), indicating that these two assays are identifying a similar set of PPIs. We do note that PPiSeq and mDHFR-PCA do screen for PPIs under different growth conditions (batch liquid growth vs. colonies on agar), so some fraction of the disagreement is due to environmental differences. PPIs that overlap between the two PPiSeq SD replicates are more likely to be found in mDHFR-PCA, PRS, and Y2H, indicating that PPIs identified in a single SD replicate are more likely to be false positives. However, we do find (a lower rate of) overlaps between PPIs identified in only one SD replicate and other methods, suggesting that a single PPiSeq replicate is not finding all discoverable PPIs.

      -In Figure S5C, the environment-specificity rate of PPIs might be inflated due to the fact that authors only test for the absence of SD hits in other conditions, and the SD condition is the only condition that has been sampled twice during the screening. What would be the environment-specific verification rate if sample hits from each environment were tested in all environments? This seems important, as robustly detecting environment-specific PPIs is one of the key points of the study.

      We use PPIs found in the SD environment to determine the environment-specificity because this provides the most conservative (highest) estimate of the number of PPIs found in other environments that were not detectable by our bar-seq assay. To identify PPIs in the SD environment, we pooled fitness estimates across the two replicates (~ 4 fitness estimates per replicate, ~ 8 total). The higher number of replicates results in a reduced rate of false positives (an erroneous fitness estimate has less impact on a PPI call), meaning that we are more confident that PPIs identified in SD are true positives. Because false positives in one environment (but not other environments) are likely to erroneously contribute to the environment-specificity rate, choosing the environment with the lowest rate of false positives (SD) should result in the lowest environment-specificity rate (highest estimate of PPIs found in other environments that were not detectable by our bar-seq assay).

      **Minor issues**

      -Re: "An interaction between the proteins reconstitutes mDHFR, providing resistance to the drug methotrexate and a growth advantage that is proportional to the PPI abundance" (pg 2). It may be more accurate to say "monotonically related" than "proportional" here. Fig 2 from the cited Freschi et al ref does suggests linearity with colony size over a wide range of inferred complex abundances, but non-linear at low complex abundance. Also note that Freschi measured colony area which is not linear with exponential growth rate nor with cell count.

      We agree with the reviewer and have changed “proportional” to “monotonically related” on page 2, line 41.

      -Re: "Using putatively positive and negative reference sets, we empirically determined a statistical threshold for each environment with the best balance of precision and recall (positive predictive value (PPV) > 61% in SD media, Methods, section 6)." (pg 3). Should state the recall at this PPV.

      We agree with the reviewer and have added the recall (41%) in the main text (line 26, page3).

      Using putatively positive and negative reference sets, we empirically determined a statistical threshold for each environment with the best balance of precision and recall (positive predictive value (PPV) > 61% and true positive rate > 41% in SD media, Methods, section 6).

      -Authors could discuss the extent to which related methods (e.g. PMID: 28650476, PMID: 27107012, PMID: 29165646, PMID: 30217970) would be potentially suitable for screening in different environments.

      We have now added a reference to a barcode-based Y2H study that examined interactions between yeast proteins to the introduction on page 2, line 2:

      Yet, little is known about how PPI networks reorganize on a global scale or what drives these changes. One challenge is that commonly-used high-throughput PPI screening technologies are geared toward PPI identification (Gavin et al., 2002; Ito et al., 2001; Tarassov et al., 2008; Uetz et al., 2000; Yu et al., 2008, Yachie et al., 2016), not a quantitative analysis of relative PPI abundance that is necessary to determine if changes in the PPI network are occurring. The murine dihydrofolate reductase (mDHFR)‐based protein-fragment complementation assay (PCA) provides a viable path to characterize PPI abundance changes because it is a sensitive test for PPIs in the native cellular context and at native protein expression levels (Freschi et al., 2013; Remy and Michnick, 1999; Tarassov et al., 2008).

      We have excluded the references to other barcode-based Y2H studies that reviewer mentions because they test heterologous proteins within yeast, and the effect of perturbations to yeast on these proteins would be difficult to interpret in the context of our questions. The yeast protein Y2H study, although a wonderful approach and paper, would also not be an appropriate method to examine how PPI networks change across environments because protein fusions are not expressed under their endogenous promoters and must be transported to, in many cases, a non-native compartment (cell nucleus) to be detected. Rather than explicitly discuss the caveats of this particular approach, we have instead chosen to discuss why we use PCA.

      • the term "mutable" is certainly appropriate according to the dictionary definition of changeable. The authors may wish to consider though, that in a molecular biology context the term evokes changeability by mutation (a very interesting but distinct topic). Maybe another term (environment-dependent interactions or ePPIs?) would be clearer. Of course this is the authors' call.

      We thank the reviewer for this suggestion, and have admittedly struggled with the terminology. For clarity of presentation, we strived to have a single word that describes the property of a PPI that is at the core of this manuscript -- how frequently a PPI is found across environments. However, the most descriptive words come with preloaded meanings in PPI research (e.g. transient, stable, dynamic), as does “mutable” with another research field. We are, quite frankly, open to suggestions from the reviewers or editors for a more appropriate word that does not raise similar objections.

      -Some discussion is warranted about the phenomenon that a PPI that is unchanged in abundance could appear to change because of statistical significance thresholds that differ between screens. This would be a difficult question for any such study, and I don't think the authors need to solve it, but just to discuss.

      We agree with the reviewer that significance thresholds could be impacting our interpretations and discuss this idea at length on page 4, line 23 of the Results. This section has been modified to include an additional analysis (excluding 16 ℃ data) in response to another reviewer’s comment:

      Immutable PPIs were likely to have been previously reported by colony-based mDHFR-PCA or other methods, while the PPIs found in the fewest environments were not. One possible explanation for this observation is that previous PPI assays, which largely tested in standard laboratory growth conditions, and variations thereof, are biased toward identification of the least mutable PPIs. That is, since immutable PPIs are found in nearly all environments, they are more readily observed in just one. However, another possible explanation is that, in our assay, mutable PPIs are more likely to be false positives in environment(s) in which they are identified or false negatives in environments in which they are not identified. To investigate this second possibility, we first asked whether PPIs present in very few environments have lower fitnesses, as this might indicate that they are closer to our limit of detection. We found no such pattern: mean fitnesses were roughly consistent across PPIs found in 1 to 6 conditions, although they were elevated in PPIs found in 7-9 conditions (Figure S6A). To directly test the false-positive rate stemming from pooled growth and barcode sequencing, we validated randomly selected PPIs within each mutability bin by comparing their optical density growth trajectories against controls (Figures 3B). We found that mutable PPIs did indeed have lower validation rates in the environment in which they were identified, yet putative false positives were limited to ~50%, and, within a bin, do not differ between PPIs that have been previously identified and those that have been newly discovered by our assay (Figure S65B). We also note mutable PPIs might be more sensitive to environmental differences between our large pooled PPiSeq assays and clonal 96-well validation assays, indicating that differences in validation rates might be overstated. To test the false-negative rate, we assayed PPIs identified in only SD by PPiSeq across all other environments by optical density growth and found that PPIs can be assigned to additional environments (Figure S6C). However, the number of additional environments in which a PPI was detected was generally low (2.5 on average), and the interaction signal in other environments was generally weaker than in SD (Figure S6D). To better estimate how the number of PPIs changes with PPI mutability, we used these optical density assays to model the validation rate as a function of the mean PPiSeq fitness and the number of environments in which a PPI is detected. This accurate model (Spearman's r =0.98 between predicted and observed, see Methods) provided confidence scores (predicted validation rates) for each PPI (Table S5) and allowed us to adjust the true positive PPI estimate in each mutability bin. Using this more conservative estimate, we still found a preponderance of mutable PPIs (Figure S6E). Finally, we used a pair of more conservative PPI calling procedures that either identified PPIs with a low rate of false positives across all environments (FPR

      We later examine major conclusions of our study using more conservative calling procedures, and find that they are consistent. On page 6, line 14:

      Both the co-expression and co-localization patterns were also apparent in our higher confidence PPI sets (Figures S7B, and S7C, S8B, S8C ), indicating that they are not caused by different false positive rates between the mutability bins.

      And on page 6, line 19:

      We binned proteins by their PPI degree, and, within each bin, determined the correlation between the mutability score and another gene feature (Figure 4C and S12A, Table S8) (Costanzo et al., 2016; Finn et al., 2014; Gavin et al., 2006; Holstege et al., 1998; Krogan et al., 2006; Levy and Siegal, 2008; Myers et al., 2006; Newman et al., 2006; Östlund et al., 2010; Rice et al., 2000; Stark et al., 2011; Wapinski et al., 2007; Ward et al., 2004; Yang, 2007; Yu et al., 2008). These correlations were also calculated using our higher confidence PPI sets, confirming results from the full data set (Figures S7D and, S7E, S8D, S8E). We found that mutable hubs (> 15 PPIs) have more genetic interactions, in agreement with predictions from co-expression data (Bertin et al., 2007; Han et al., 2004), and that their deletion tends to cause larger fitness defects.

      -More discussion would be helpful about the idea that immutability may to some extent favor interactions that PCA is better able to detect (possibly including membrane proteins?)

      We agree with the reviewer and now added a discussion of this potential caveats to the discussion on page 9, line 4:

      Results presented here and elsewhere (Huttlin et al., 2020) suggest that PPIs discovered under a single condition or cell type are a small subset of the full protein interactome emergent from a genome. We sampled nine diverse environments and found approximately 3-fold more interactions than in a single environment. However, the discovery of new PPIs began to saturate, indicating that most condition-specific PPIs can be captured in a limited number of conditions. Testing in many more conditions and with PPI assays orthogonal to PPiSeq will undoubtedly identify new PPIs, however a more important outcome could be the identification of coordinated network changes across conditions. Using a test set of ~1.6 million (of ~18 million) protein pairs across nine environments, we find that specific parts of the protein interactome are relatively stable (core modules) while others frequently change across environments (accessory modules). However, two important caveats of our study must be recognized before extrapolating these results to the entire protein interactome across all environment space. First, we tested for interactions between a biased set of proteins that have previously been found to participate in at least one PPI as measured by mDHFR-PCA under standard growth conditions (Tarassov et al., 2008). Thus, proteins that are not expressed under standard growth conditions are excluded from our study, as are PPIs that are not detectable by mDHFR-PCA or PPiSeq. It is possible that a comprehensive screen using multiple orthogonal PPI assays would alter our observations related to the relative dynamics of different regions of the protein interactome and the features of mutable and immutable PPIs. Second, we tested a limited number of environmental perturbations under similar growth conditions (batch liquid growth). It is possible that more extreme environmental shifts (e.g. growth as a colony, anaerobic growth, pseudohyphal growth) would introduce new accessory modules or alter the mutability of the PPIs we detect. Nevertheless, results presented here provide a new mechanistic view of how the cell changes in response to environmental challenges, building on the previous work that describes coordinated responses in the transcriptome (Brauer et al., 2007; Gasch et al., 2000) and proteome (Breker et al., 2013; Chong et al., 2015).

      -Re: "As might be expected, we also found that mutable hubs, but not non-hubs, are more likely to participate in multiple protein complexes than less mutable proteins." (pg 6) This is a cool result. To what extent was this result driven by members of one or two complexes? If so, it would worth noting them.

      We thank the reviewer for this question. We have now included Figue S13, which shows the number and size of protein complexes that underlie the finding that mutable hubs are more likely to participate in multiple protein complexes. We find that proteins in our screen that participate in multiple complexes are distributed over a wide range of complexes, indicating that this observation is not driven by one or two complexes. On page 6, line 34:

      As might be expected, we also found that mutable hubs, but not non-hubs, are more likely to participate in multiple protein complexes than less mutable proteins (Figures S13A-C) (Costanzo et al., 2016).

      -Re: "Borrowing a species richness estimator from ecology (Jari Oksanen et al., 2019), we estimate that there are ~10,840 true interactions within our search space across all environments, ~3-fold more than are detected in SD (note difference to Figure 3, which counts observed PPIs)." (pg 8) Should note that this only allows estimation of the number of interactions that are detectable by PCA methods. Previous work (Braun et al, 2019) showed that every known protein interaction assay (including PCA approaches) can only detect a fraction of bona fide interactions.

      We agree with the reviewer and have modified the discussion to make this point explicit on page 9, line 4:

      Results presented here and elsewhere (Huttlin et al., 2020) suggest that PPIs discovered under a single condition or cell type are a small subset of the full protein interactome emergent from a genome. We sampled nine diverse environments and found approximately 3-fold more interactions than in a single environment. However, the discovery of new PPIs began to saturate, indicating that most condition-specific PPIs can be captured in a limited number of conditions. Testing in many more conditions and with PPI assays orthogonal to PPiSeq will undoubtedly identify new PPIs, however a more important outcome could be the identification of coordinated network changes across conditions.

      We continue in this paragraph to discuss the implications:

      Using a test set of ~1.6 million (of ~18 million) protein pairs across nine environments, we find that specific parts of the protein interactome are relatively stable (core modules) while others frequently change across environments (accessory modules). However, two important caveats of our study must be recognized before extrapolating these results to the entire protein interactome across all environment space. First, we tested for interactions between a biased set of proteins that have previously been found to participate in at least one PPI as measured by mDHFR-PCA under standard growth conditions (Tarassov et al., 2008). Thus, proteins that are not expressed under standard growth conditions are excluded from our study, as are PPIs that are not detectable by mDHFR-PCA or PPiSeq. It is possible that a comprehensive screen using multiple orthogonal PPI assays would alter our observations related to the relative dynamics of different regions of the protein interactome and the features of mutable and immutable PPIs.

      -Re: "This analysis shows that the number of PPIs present across all environments is much larger than the number observed in a single condition, but that it is feasible to discover most of these new PPIs by sampling a limited number of conditions." (pg 8). The main point is surely correct, but it is worth noting that extrapolation to the number of true interactions depends on the nine chosen environments being representative of all environments. The situation could change under more extreme, e.g., anaerobic, conditions.

      We agree with the reviewer and make this point explicit, continuing from the paragraph quoted above on page 9, line 22:

      Second, we tested a limited number of environmental perturbations under similar growth conditions (batch liquid growth). It is possible that more extreme environmental shifts (e.g. growth as a colony, anaerobic growth, pseudohyphal growth) would introduce new accessory modules or alter the mutability of the PPIs we detect. Nevertheless, results presented here provide a new mechanistic view of how the cell changes in response to environmental challenges, building on the previous work that describes coordinated responses in the transcriptome (Brauer et al., 2007; Gasch et al., 2000) and proteome (Breker et al., 2013; Chong et al., 2015).

      -It stands to reason that proteins expressed in all conditions will yield less mutable interactions, if 'mutability' is primarily due to expression change at the transcriptional level. They should at least discuss that measuring mRNA levels could resolve questions about this. Could use Waern et al G3 2013 data (H202, SD, HU, NaCl) to predict the dynamic interactome purely by node removal, and see how conclusions would change

      We agree with the reviewer that mRNA abundance could potentially be used as a proxy for protein abundance and have added this point on page 10, line 28:

      Here we use homodimer abundance as a proxy for protein abundance. However, genome-wide mRNA abundance measures could be used as a proxy for protein abundance or protein abundance could be measured directly in the same pool (Levy et al., 2014) by, for example, attaching a full length mDHFR to each gene using “swap tag” libraries mentioned above (Weill et al., 2018; Yofe et al., 2016).

      However, using mRNA abundance as a proxy for protein abundance in this study has several important caveats that would make interpretation difficult. First, mRNA and protein abundance correlate, but not perfectly (R2 = 0.45) (Lahtvee et al., 2017), and our findings suggest that post-translational regulation may be important to driving PPI changes. Second, mRNA abundance measures are for a single time point, while our PPI measures coarse grain over a growth cycle (lag, exponential growth, diauxic shift, saturation). Although we may be able to take multiple mRNA measures across the cycle, time delays between changes in mRNA and protein levels, combined with the fact that we do not know when a PPI is occurring or most prominent over the cycle, would pose a significant challenge to making any claims that PPI changes are driven by changes in protein abundance. We instead chose to focus on a subset of proteins (homodimers) where abundance measures can be coarse grained in the same way as PPI measures. In the above quote, we point to a potential method by which this can be done for all proteins. We also point to how a continuous culturing design could be used to better determine how protein (or mRNA proxy) abundance impacts PPI abundance on page 10, line 6:

      Finally, our assays were performed across cycles of batch growth meaning that changes in PPI abundance across a growth cycle (e.g. lag, exponential growth, saturation) are coarse grained into one measurement. While this method potentially increases our chance of discovering a diverse set of PPIs, it might have an unpredictable impact on the relationship between fitness and PPI abundance (Li et al., 2018). To overcome these issues, strains containing natural or synthetic PPIs with known abundances and intracellular localizations could be spiked into cell pools to calibrate the relationship between fitness and PPI abundance in each environment. In addition, continuous culturing systems may be useful for refining precision of growth-based assays such as ours.

      -The analysis showing that many interactions are likely due to post-translational modifications is very interesting, but caveats should be discussed. Where heterodimers do not fit the expression-level dependence model, some cases of non-fitting may simply be due to measurement error or non-linearity in the relationship between abundance and fitness.

      We show the measurement error in Figures 1, S2, S3. While we agree with the reviewer that measurement error is a general caveat for all results reported, we do not feel that it is necessary to point to that fact in this particular case, which uses a logistic regression to report that PPI mutability was the best predictor of fit to the expression-level dependence model. We discuss the non-linearity caveat on page 9, line 41:

      Our assay detected subtle fitness differences across environments (Fig S5B and S5C), which we used as a rough estimate for changes in relative PPI abundance. While it would be tempting to use fitness as a direct readout of absolute PPI abundance within a cell, non-linearities between fitness and PPI abundance may be common and PPI dependent. For example, the relative contribution of a reconstructed mDHFR molecule to fitness might diminish at high PPI abundances (saturation effects) and fitness differences between PPIs may be caused, in part, by differences in how accessible a reconstructed mDHFR molecule is to substrate. In addition, environmental shifts might impact cell growth rate, initiate a stress response, or result in other unpredictable cell effects that impact the selective pressure of methotrexate and thereby fitness (Figure S2 and S3).

      -Line numbers would have been helpful to note more specific minor comments

      We are sorry for this inconvenience. We have added line numbers in our revised manuscript.

      -Sequence data should be shared via the Short-Read Archive.

      The raw sequencing data have been uploaded to the Short-Read Archive. We mentioned it in the Data and Software Availability section on page 68, line 41.

      Raw barcode sequencing data are available from the NIH Sequence Read Archive as accession PRJNA630095 (https://trace.ncbi.nlm.nih.gov/Traces/study/?acc=SRP259652).

      Reviewer #3 (Significance (Required)):

      Knowledge of protein-protein interactions (PPIs) provides a key window on biological mechanism, and unbiased screens have informed global principles underlying cellular organization. Several genome-scale screens for direct (binary) interactions between yeast proteins have been carried out, and while each has provided a wealth of new hypotheses, each has been sub-saturation. Therefore, even given multiple genome-scale screens our knowledge of yeast interactions remains incomplete. Different assays are better suited to find different interactions, and it is now clear that every assay evaluated thus far is only capable (even in a saturated screen) of detecting a minority of true interactions. More relevant to the current study, no binary interaction screen has been carried out at the scale of millions of protein pairs outside of a single 'baseline' condition.

      The study by Liu et al is notable from a technology perspective in that it is one of several recombinant-barcode approaches have been developed to multiplex pairwise combinations of two barcoded libraries. Although other methods have been demonstrated at the scale of 1M protein pairs, this is the first study using such a technology at the scale of >1M pairs across multiple environments.

      A limitation is that this study is not genome-scale, and the search space is biased towards proteins for which interactions were previously observed in a particular environment. This is perhaps understandable, as it made the study more tractable, but this does add caveats to many of the conclusions drawn. These would be acceptable if clearly described and discussed. There were also questions about data quality and assessment that would need to be addressed.

      Assuming issues can be addressed, this is a timely study on an important topic, and will be of broad interest given the importance of protein interactions and the status of S. cerevisiae as a key testbed for systems biology.

      *Reviewers' expertise:* Interaction assays, next-generation sequencing, computational genomics. Less able to assess evolutionary biology aspects.

      References

      Brauer, M.J., Huttenhower, C., Airoldi, E.M., Rosenstein, R., Matese, J.C., Gresham, D., Boer, V.M., Troyanskaya, O.G., and Botstein, D. (2007). Coordination of Growth Rate, Cell Cycle, Stress Response, and Metabolic Activity in Yeast. Mol. Biol. Cell 19, 352–367.

      Breker, M., Gymrek, M., and Schuldiner, M. (2013). A novel single-cell screening platform reveals proteome plasticity during yeast stress responses. J. Cell Biol. 200, 839–850.

      Chong, Y.T., Koh, J.L.Y., Friesen, H., Kaluarachchi Duffy, S., Cox, M.J., Moses, A., Moffat, J., Boone, C., and Andrews, B.J. (2015). Yeast Proteome Dynamics from Single Cell Imaging and Automated Analysis. Cell 161, 1413–1424.

      Gasch, A.P., Spellman, P.T., Kao, C.M., Carmel-Harel, O., Eisen, M.B., Storz, G., Botstein, D., and Brown, P.O. (2000). Genomic Expression Programs in the Response of Yeast Cells to Environmental Changes. Mol. Biol. Cell 11, 4241–4257.

      Hart, G.T., Ramani, A.K., and Marcotte, E.M. (2006). How complete are current yeast and human protein-interaction networks? Genome Biol. 7, 120.

      Hilliker, A., Gao, Z., Jankowsky, E., and Parker, R. (2011). The DEAD-box protein Ded1 modulates translation by the formation and resolution of an eIF4F-mRNA complex. Mol. Cell 43, 962–972.

      Isasa, M., Suñer, C., Díaz, M., Puig-Sàrries, P., Zuin, A., Bichmann, A., Gygi, S.P., Rebollo, E., and Crosas, B. (2015). Cold Temperature Induces the Reprogramming of Proteolytic Pathways in Yeast. J. Biol. Chem. jbc.M115.698662.

      Jensen, L.J., and Bork, P. (2008). Not Comparable, But Complementary. Science 322, 56–57.

      Lahtvee, P.-J., Sánchez, B.J., Smialowska, A., Kasvandik, S., Elsemman, I.E., Gatto, F., and Nielsen, J. (2017). Absolute Quantification of Protein and mRNA Abundances Demonstrate Variability in Gene-Specific Translation Efficiency in Yeast. Cell Syst. 4, 495-504.e5.

      Obayashi, T., Kagaya, Y., Aoki, Y., Tadaka, S., and Kinoshita, K. (2019). COXPRESdb v7: a gene coexpression database for 11 animal species supported by 23 coexpression platforms for technical evaluation and evolutionary inference. Nucleic Acids Res. 47, D55–D62.

      Sambourg, L., and Thierry-Mieg, N. (2010). New insights into protein-protein interaction data lead to increased estimates of the S. cerevisiae interactome size. BMC Bioinformatics 11, 605.

      Tarassov, K., Messier, V., Landry, C.R., Radinovic, S., Molina, M.M.S., Shames, I., Malitskaya, Y., Vogel, J., Bussey, H., and Michnick, S.W. (2008). An in Vivo Map of the Yeast Protein Interactome. Science 320, 1465–1470.

      Yu, H., Braun, P., Yıldırım, M.A., Lemmens, I., Venkatesan, K., Sahalie, J., Hirozane-Kishikawa, T., Gebreab, F., Li, N., Simonis, N., et al. (2008). High-Quality Binary Protein Interaction Map of the Yeast Interactome Network. Science 322, 104–110.

    1. Salahudeen, A. A., Choi, S. S., Rustagi, A., Zhu, J., O, S. M. de la, Flynn, R. A., Margalef-Català, M., Santos, A. J. M., Ju, J., Batish, A., Unen, V. van, Usui, T., Zheng, G. X. Y., Edwards, C. E., Wagar, L. E., Luca, V., Anchang, B., Nagendran, M., Nguyen, K., … Kuo, C. J. (2020). Progenitor identification and SARS-CoV-2 infection in long-term human distal lung organoid cultures. BioRxiv, 2020.07.27.212076. https://doi.org/10.1101/2020.07.27.212076

    1. Sun, W., McCroskery, S., Liu, W.-C., Leist, S. R., Liu, Y., Albrecht, R. A., Slamanig, S., Oliva, J., Amanat, F., Schäfer, A., Dinnon, K. H., Innis, B. L., García-Sastre, A., Krammer, F., Baric, R. S., & Palese, P. (2020). A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. BioRxiv, 2020.07.30.229120. https://doi.org/10.1101/2020.07.30.229120

    1. SciScore for 10.1101/2020.08.11.247320: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">METHODS AND MATERIALS Antibodies and Reagents PE anti-human CD3 antibody (clone OKT3), FITC and PE/Cy7 anti-human CD56 antibody (clone HCD56, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD3</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD56</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD69 antibody (clone FN50, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD69</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human CD8a antibody (clone RPA-T8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD8a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 anti-human CD226 antibody (DNAM-1) (clone 11A8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD226</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 antihuman KLRG1 (MAFA) antibody (clone SA231A2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman KLRG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MAFA</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD335</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>NKp46</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD244 (2B4) antibody (clone C1.7, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD244</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD152 (CTLA-4) antibody (clone BNI3)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD152</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CTLA-4 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, APC anti-human CD366 (Tim-3) antibody (clone F38-2E2),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD366</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Tim-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">antihuman TIGIT (VSTM3) antibody (clone A15153G)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman TIGIT ( VSTM3</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FITC anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD223</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>LAG-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11), and APC anti-human CD94 (clone DX22, BioLegend) were purchased from BioLegend (San Diego, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NKG2D</div> <div>suggested: (US Biological Cat# K1893-28, RRID:AB_2265490)</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD94</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC anti-human CD16 antibody (clone 3G8, BD Biosciences)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD16</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11, BD Biosciences), and FITC anti-human CD107a antibody (clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD314</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD107a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human NKG2C/CD159c antibody (clone 134591, R&D Systems) were purchased from R&D Systems.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>PE anti-human NKG2C/CD159c antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human NKG2C/CD159c</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AF647 Goat anti-human IgG(H+L) F(ab’)2 fragment antibody was purchased from Jackson ImmunoResearch (West Grove, PA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>AF647 Goat anti-human IgG(H+L ) F(ab’)2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coronavirus Spike protein (subunit 1) polyclonal antibody was purchased from Invitrogen (Carlsbad, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1 ) polyclonal antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mouse monoclonal antibody IgG1 (clone H-3) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>mouse monoclonal antibody IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>antibody IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with anti-mouse (IgG1) secondary antibody in FACS buffer for 30 minutes on ice, washed twice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse ( IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Due to the non-specific binding to our CR3022-CAR of our secondary antibody, cells were first blocked with anti-human IgG(H+L) F(ab’)2 fragment for 30 minutes on ice in BM and washed thrice with PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG(H+L</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with goat anti-rabbit secondary antibody in FACS buffer for 30 minutes on ice, washed thrice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-rabbit</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SFG retroviral vector contains the CR3022 single chain antibody fragment (clone 3), a human IgG1 CH2CH3 hinge region and CD28 transmembrane region, followed by the intracellular domains of co-stimulatory CD28, 4-1BB, and the intracellular domain of CD3ζ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>human IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CD28</div> <div>suggested: (Thermo Fisher Scientific Cat# EPX140-15803-901, RRID:AB_2576106)</div> </div> <div style="margin-bottom:8px"> <div>4-1BB</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Anti-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To establish transient 293T-hACE2-RBD, 293T-hACE2 cells were transfected with 0.5 µg of SARS-CoV-2-RBD plasmid (a gift from Dr. Abraham Pinter) each well in a 24-well plate (Eppendorf) for 48 hours at 37℃ under 5% (v/v) CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Similarly, 293T-hACE2-FFLuc-GFP-RBD cells were transfected with 0.25 µg of SARSCoV-2-RBD plasmid and 0.25 µg of pHAGE-FFLuc-GFP each well in a 24-well plate (Eppendorf) for 48 hours at 37°C under 5% (v/v) CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow Cytometry Analysis NK92MI and CR3022-CAR cells were stained were stained and washed as previously described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In a separate 96-well plate, CR3022-CAR-NK92MI and NK-92MI cells were resuspended at a concentration of 1 × 106 cells/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NK-92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293T cells were transfected with SFG-CR3022CAR for 48-72 hours for CAR retrovirus packaging and transduced into NK92MI cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( d) Quantitative data of the luciferase killing assay using CR3022-CAR-NK92MI and wild-type NK-92MI cells against 293ThACE2-FFLuc-GFP-RBD cells is shown.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293ThACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR-NK92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CR3022-CAR construction and retrovirus production A codon-optimized DNA fragment was synthesized by GENEWIZ encoding the CR3022-specific scFv and sub-cloned into the SFG retroviral vector retroviral backbone in-frame with the hinge component of human IgG1, CD28 trans-membrane domain, The method was previously described2, briefly, to produce CR3022-CAR retrovirus, 293T cells were transfected with CR3022-CAR in SFG backbone, RDF, and PegPam3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GENEWIZ</div> <div>suggested: (GENEWIZ, RRID:SCR_003177)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were acquired using FACS Diva software (BD) and analyzed using FlowJo software (BD)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      We have optimized the NK cell expansion technology to buffer this potential limitation. Thus, in this study, we focused on CR3022-CAR-NK-92MI, a NK-92 cell line expressing IL-2 molecule to sustain the persistence in vivo20. In this study, we provide proof-of-concept for using CR3022-CAR-based cell therapy for treating severe COVID-19 patients. These experiments will expedite preclinical studies and a potential clinical application during the COVID-19 pandemic. Although these findings support the therapeutic potential of CR3022-CAR-NK cells for treating severe COVID-19 patients, there are several limitations presented in the current form of study. First, we use the NK-92 cell line in this study. NK-92-mediated immunotherapy is currently undergoing phase I/II clinical trials21,22. However, NK-92 cells must be irradiated prior to infusion to prevent permanent engraftment because of malignant potential of NK-92 cells. Second, we use pseudotyped SARS-CoV-2-S viral particles, which is different from the natural SARS-CoV-2 virus. Future studies using natural SARS-CoV-2 virus in the ACE2-transgenic mouse model are needed to test the efficacy and toxicity of CR3022-CAR-NK cells. In conclusion, development of this novel CAR-NK cell therapy for the treatment of severe COVID-19 patients with maximal efficacy and minimal toxicity will be required to reduce patient risk and enhance the benefit of these expensive and time-intensive therapies. The studies here characterize the biology of CR3...


      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Resolved on clinicaltrials.gov</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04375176</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Monocytes and NK Cells Activit...</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04280224</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NK Cells Treatment for COVID-1...</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04365101</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Natural Killer Cell (CYNK-001)...</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04324996</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Phase I/II Study of Universa...</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04416139</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Mesenchymal Stem Cell for Acut...</td></tr></table>


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    2. SciScore for 10.1101/2020.08.11.247320: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">METHODS AND MATERIALS Antibodies and Reagents PE anti-human CD3 antibody (clone OKT3), FITC and PE/Cy7 anti-human CD56 antibody (clone HCD56, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD3</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD56</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD69 antibody (clone FN50, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD69</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human CD8a antibody (clone RPA-T8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD8a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 anti-human CD226 antibody (DNAM-1) (clone 11A8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD226</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 antihuman KLRG1 (MAFA) antibody (clone SA231A2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman KLRG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MAFA</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD335</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>NKp46</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD244 (2B4) antibody (clone C1.7, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD244</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD152 (CTLA-4) antibody (clone BNI3)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD152</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CTLA-4 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, APC anti-human CD366 (Tim-3) antibody (clone F38-2E2),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD366</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Tim-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">antihuman TIGIT (VSTM3) antibody (clone A15153G)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman TIGIT ( VSTM3</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FITC anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD223</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>LAG-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11), and APC anti-human CD94 (clone DX22, BioLegend) were purchased from BioLegend (San Diego, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NKG2D</div> <div>suggested: (US Biological Cat# K1893-28, RRID:AB_2265490)</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD94</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC anti-human CD16 antibody (clone 3G8, BD Biosciences)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD16</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11, BD Biosciences), and FITC anti-human CD107a antibody (clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD314</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD107a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human NKG2C/CD159c antibody (clone 134591, R&D Systems) were purchased from R&D Systems.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>PE anti-human NKG2C/CD159c antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human NKG2C/CD159c</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AF647 Goat anti-human IgG(H+L) F(ab’)2 fragment antibody was purchased from Jackson ImmunoResearch (West Grove, PA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>AF647 Goat anti-human IgG(H+L ) F(ab’)2</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human IgG(H+L</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coronavirus Spike protein (subunit 1) polyclonal antibody was purchased from Invitrogen (Carlsbad, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1 ) polyclonal antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mouse monoclonal antibody IgG1 (clone H-3) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>mouse monoclonal antibody IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>antibody IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with anti-mouse (IgG1) secondary antibody in FACS buffer for 30 minutes on ice, washed twice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse ( IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with goat anti-rabbit secondary antibody in FACS buffer for 30 minutes on ice, washed thrice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-rabbit</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SFG retroviral vector contains the CR3022 single chain antibody fragment (clone 3), a human IgG1 CH2CH3 hinge region and CD28 transmembrane region, followed by the intracellular domains of co-stimulatory CD28, 4-1BB, and the intracellular domain of CD3ζ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>human IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CD28</div> <div>suggested: (Thermo Fisher Scientific Cat# EPX140-15803-901, RRID:AB_2576106)</div> </div> <div style="margin-bottom:8px"> <div>4-1BB</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CR3022-CAR or NK-92MI cells were incubated with SARS- CoV-2-RBD or SARS-CoV-1-RBD recombinant protein. b) Successful transfection was confirmed by flow cytometry using anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Similarly, 293T-hACE2-FFLuc-GFP-RBD cells were transfected with 0.25 µg of SARSCoV-2-RBD plasmid and 0.25 µg of pHAGE-FFLuc-GFP each well in a 24-well plate (Eppendorf) for 48 hours at 37°C under 5% (v/v) CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow Cytometry Analysis NK92MI and CR3022-CAR cells were stained were stained and washed as previously described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, expanded NK cells (5 × 104) were incubated with 1 × 105 293T or cells in V-bottomed 96-well plates in complete RPMI-1640 media at 37℃ for 2 hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In a separate 96-well plate, CR3022-CAR-NK92MI and NK-92MI cells were resuspended at a concentration of 1 × 106 cells/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NK-92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( d) Quantitative data of the luciferase killing assay using CR3022-CAR-NK92MI and wild-type NK-92MI cells against 293ThACE2-FFLuc-GFP-RBD cells is shown.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293ThACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR-NK92MI</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>293T-hACE2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CR3022-CAR construction and retrovirus production A codon-optimized DNA fragment was synthesized by GENEWIZ encoding the CR3022-specific scFv and sub-cloned into the SFG retroviral vector retroviral backbone in-frame with the hinge component of human IgG1, CD28 trans-membrane domain, The method was previously described2, briefly, to produce CR3022-CAR retrovirus, 293T cells were transfected with CR3022-CAR in SFG backbone, RDF, and PegPam3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GENEWIZ</div> <div>suggested: (GENEWIZ, RRID:SCR_003177)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were acquired using FACS Diva software (BD) and analyzed using FlowJo software (BD)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      We have optimized the NK cell expansion technology to buffer this potential limitation. Thus, in this study, we focused on CR3022-CAR-NK-92MI, a NK-92 cell line expressing IL-2 molecule to sustain the persistence in vivo20. In this study, we provide proof-of-concept for using CR3022-CAR-based cell therapy for treating severe COVID-19 patients. These experiments will expedite preclinical studies and a potential clinical application during the COVID-19 pandemic. Although these findings support the therapeutic potential of CR3022-CAR-NK cells for treating severe COVID-19 patients, there are several limitations presented in the current form of study. First, we use the NK-92 cell line in this study. NK-92-mediated immunotherapy is currently undergoing phase I/II clinical trials21,22. However, NK-92 cells must be irradiated prior to infusion to prevent permanent engraftment because of malignant potential of NK-92 cells. Second, we use pseudotyped SARS-CoV-2-S viral particles, which is different from the natural SARS-CoV-2 virus. Future studies using natural SARS-CoV-2 virus in the ACE2-transgenic mouse model are needed to test the efficacy and toxicity of CR3022-CAR-NK cells. In conclusion, development of this novel CAR-NK cell therapy for the treatment of severe COVID-19 patients with maximal efficacy and minimal toxicity will be required to reduce patient risk and enhance the benefit of these expensive and time-intensive therapies. The studies here characterize the biology of CR3...


      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><tr><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Resolved on clinicaltrials.gov</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04375176</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Monocytes and NK Cells Activit...</td></tr><tr><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04280224</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NK Cells Treatment for COVID-1...</td></tr><tr><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04365101</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Natural Killer Cell (CYNK-001)...</td></tr><tr><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04324996</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Phase I/II Study of Universa...</td></tr><tr><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04416139</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:80px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Mesenchymal Stem Cell for Acut...</td></tr></table>


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    3. SciScore for 10.1101/2020.08.11.247320: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">METHODS AND MATERIALS Antibodies and Reagents PE anti-human CD3 antibody (clone OKT3), FITC and PE/Cy7 anti-human CD56 antibody (clone HCD56, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD3</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD56</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD69 antibody (clone FN50, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD69</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human CD8a antibody (clone RPA-T8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD8a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 anti-human CD226 antibody (DNAM-1) (clone 11A8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD226</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 antihuman KLRG1 (MAFA) antibody (clone SA231A2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman KLRG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MAFA</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD335</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>NKp46</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD244 (2B4) antibody (clone C1.7, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD244</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD152 (CTLA-4) antibody (clone BNI3)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD152</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CTLA-4 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, APC anti-human CD366 (Tim-3) antibody (clone F38-2E2),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD366</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Tim-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">antihuman TIGIT (VSTM3) antibody (clone A15153G)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman TIGIT ( VSTM3</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FITC anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD223</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>LAG-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11), and APC anti-human CD94 (clone DX22, BioLegend) were purchased from BioLegend (San Diego, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD94</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC anti-human CD16 antibody (clone 3G8, BD Biosciences)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD16</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11, BD Biosciences), and FITC anti-human CD107a antibody (clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD314</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>NKG2D</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD107a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human NKG2C/CD159c antibody (clone 134591, R&D Systems) were purchased from R&D Systems.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>PE anti-human NKG2C/CD159c antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human NKG2C/CD159c</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AF647 Goat anti-human IgG(H+L) F(ab’)2 fragment antibody was purchased from Jackson ImmunoResearch (West Grove, PA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>AF647 Goat anti-human IgG(H+L ) F(ab’)2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coronavirus Spike protein (subunit 1) polyclonal antibody was purchased from Invitrogen (Carlsbad, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1 ) polyclonal antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mouse monoclonal antibody IgG1 (clone H-3) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>mouse monoclonal antibody IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>antibody IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with anti-mouse (IgG1) secondary antibody in FACS buffer for 30 minutes on ice, washed twice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse ( IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Due to the non-specific binding to our CR3022-CAR of our secondary antibody, cells were first blocked with anti-human IgG(H+L) F(ab’)2 fragment for 30 minutes on ice in BM and washed thrice with PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG(H+L</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with goat anti-rabbit secondary antibody in FACS buffer for 30 minutes on ice, washed thrice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-rabbit</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SFG retroviral vector contains the CR3022 single chain antibody fragment (clone 3), a human IgG1 CH2CH3 hinge region and CD28 transmembrane region, followed by the intracellular domains of co-stimulatory CD28, 4-1BB, and the intracellular domain of CD3ζ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>human IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CD28</div> <div>suggested: (Thermo Fisher Scientific Cat# EPX140-15803-901, RRID:AB_2576106)</div> </div> <div style="margin-bottom:8px"> <div>4-1BB</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Anti-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Similarly, 293T-hACE2-FFLuc-GFP-RBD cells were transfected with 0.25 µg of SARSCoV-2-RBD plasmid and 0.25 µg of pHAGE-FFLuc-GFP each well in a 24-well plate (Eppendorf) for 48 hours at 37°C under 5% (v/v) CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow Cytometry Analysis NK92MI and CR3022-CAR cells were stained were stained and washed as previously described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, expanded NK cells (5 × 104) were incubated with 1 × 105 293T or cells in V-bottomed 96-well plates in complete RPMI-1640 media at 37℃ for 2 hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, the following day, the wells were aspirated and 293T-hACE2FFLuc-GFP-RBD and 293T-hACE2 cells were pre-seeded at 1 × 104 target cells/well in 100 µL/well of DMEM supplemented with 10% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In a separate 96-well plate, CR3022-CAR-NK92MI and NK-92MI cells were resuspended at a concentration of 1 × 106 cells/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NK-92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( d) Quantitative data of the luciferase killing assay using CR3022-CAR-NK92MI and wild-type NK-92MI cells against 293ThACE2-FFLuc-GFP-RBD cells is shown.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293ThACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR-NK92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CR3022-CAR construction and retrovirus production A codon-optimized DNA fragment was synthesized by GENEWIZ encoding the CR3022-specific scFv and sub-cloned into the SFG retroviral vector retroviral backbone in-frame with the hinge component of human IgG1, CD28 trans-membrane domain, The method was previously described2, briefly, to produce CR3022-CAR retrovirus, 293T cells were transfected with CR3022-CAR in SFG backbone, RDF, and PegPam3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GENEWIZ</div> <div>suggested: (GENEWIZ, RRID:SCR_003177)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were acquired using FACS Diva software (BD) and analyzed using FlowJo software (BD)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      We have optimized the NK cell expansion technology to buffer this potential limitation. Thus, in this study, we focused on CR3022-CAR-NK-92MI, a NK-92 cell line expressing IL-2 molecule to sustain the persistence in vivo20. In this study, we provide proof-of-concept for using CR3022-CAR-based cell therapy for treating severe COVID-19 patients. These experiments will expedite preclinical studies and a potential clinical application during the COVID-19 pandemic. Although these findings support the therapeutic potential of CR3022-CAR-NK cells for treating severe COVID-19 patients, there are several limitations presented in the current form of study. First, we use the NK-92 cell line in this study. NK-92-mediated immunotherapy is currently undergoing phase I/II clinical trials21,22. However, NK-92 cells must be irradiated prior to infusion to prevent permanent engraftment because of malignant potential of NK-92 cells. Second, we use pseudotyped SARS-CoV-2-S viral particles, which is different from the natural SARS-CoV-2 virus. Future studies using natural SARS-CoV-2 virus in the ACE2-transgenic mouse model are needed to test the efficacy and toxicity of CR3022-CAR-NK cells. In conclusion, development of this novel CAR-NK cell therapy for the treatment of severe COVID-19 patients with maximal efficacy and minimal toxicity will be required to reduce patient risk and enhance the benefit of these expensive and time-intensive therapies. The studies here characterize the biology of CR3...


      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><tr><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Resolved on clinicaltrials.gov</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04375176</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Monocytes and NK Cells Activit...</td></tr><tr><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04280224</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NK Cells Treatment for COVID-1...</td></tr><tr><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04365101</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Natural Killer Cell (CYNK-001)...</td></tr><tr><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04324996</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Phase I/II Study of Universa...</td></tr><tr><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04416139</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:100px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Mesenchymal Stem Cell for Acut...</td></tr></table>


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    4. SciScore for 10.1101/2020.08.11.247320: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">METHODS AND MATERIALS Antibodies and Reagents PE anti-human CD3 antibody (clone OKT3), FITC and PE/Cy7 anti-human CD56 antibody (clone HCD56, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD3</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD56</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD69 antibody (clone FN50, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD69</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human CD8a antibody (clone RPA-T8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD8a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 anti-human CD226 antibody (DNAM-1) (clone 11A8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD226</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 antihuman KLRG1 (MAFA) antibody (clone SA231A2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman KLRG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MAFA</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD335</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>NKp46</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD244 (2B4) antibody (clone C1.7, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD244</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD152 (CTLA-4) antibody (clone BNI3)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD152</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CTLA-4 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, APC anti-human CD366 (Tim-3) antibody (clone F38-2E2),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD366</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Tim-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">antihuman TIGIT (VSTM3) antibody (clone A15153G)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman TIGIT ( VSTM3</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FITC anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD223</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>LAG-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11), and APC anti-human CD94 (clone DX22, BioLegend) were purchased from BioLegend (San Diego, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NKG2D</div> <div>suggested: (US Biological Cat# K1893-28, RRID:AB_2265490)</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD94</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC anti-human CD16 antibody (clone 3G8, BD Biosciences)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD16</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11, BD Biosciences), and FITC anti-human CD107a antibody (clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD314</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD107a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human NKG2C/CD159c antibody (clone 134591, R&D Systems) were purchased from R&D Systems.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>PE anti-human NKG2C/CD159c antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human NKG2C/CD159c</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AF647 Goat anti-human IgG(H+L) F(ab’)2 fragment antibody was purchased from Jackson ImmunoResearch (West Grove, PA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>AF647 Goat anti-human IgG(H+L ) F(ab’)2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coronavirus Spike protein (subunit 1) polyclonal antibody was purchased from Invitrogen (Carlsbad, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1 ) polyclonal antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mouse monoclonal antibody IgG1 (clone H-3) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>mouse monoclonal antibody IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>antibody IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with anti-mouse (IgG1) secondary antibody in FACS buffer for 30 minutes on ice, washed twice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse ( IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Due to the non-specific binding to our CR3022-CAR of our secondary antibody, cells were first blocked with anti-human IgG(H+L) F(ab’)2 fragment for 30 minutes on ice in BM and washed thrice with PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG(H+L</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with goat anti-rabbit secondary antibody in FACS buffer for 30 minutes on ice, washed thrice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-rabbit</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SFG retroviral vector contains the CR3022 single chain antibody fragment (clone 3), a human IgG1 CH2CH3 hinge region and CD28 transmembrane region, followed by the intracellular domains of co-stimulatory CD28, 4-1BB, and the intracellular domain of CD3ζ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>human IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CD28</div> <div>suggested: (Thermo Fisher Scientific Cat# EPX140-15803-901, RRID:AB_2576106)</div> </div> <div style="margin-bottom:8px"> <div>4-1BB</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Anti-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293T cells were transfected with a combination of plasmids containing CR3022-CAR in the SFG backbone, RDF, and PegPam3, as previously described17,18.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To maintain the stable expression of hACE2, 293T-hACE2 cells were cultured in DMEM (Corning) supplemented with 10% (v/v)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Similarly, 293T-hACE2-FFLuc-GFP-RBD cells were transfected with 0.25 µg of SARSCoV-2-RBD plasmid and 0.25 µg of pHAGE-FFLuc-GFP each well in a 24-well plate (Eppendorf) for 48 hours at 37°C under 5% (v/v) CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow Cytometry Analysis NK92MI and CR3022-CAR cells were stained were stained and washed as previously described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In a separate 96-well plate, CR3022-CAR-NK92MI and NK-92MI cells were resuspended at a concentration of 1 × 106 cells/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NK-92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( d) Quantitative data of the luciferase killing assay using CR3022-CAR-NK92MI and wild-type NK-92MI cells against 293ThACE2-FFLuc-GFP-RBD cells is shown.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293ThACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR-NK92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CR3022-CAR construction and retrovirus production A codon-optimized DNA fragment was synthesized by GENEWIZ encoding the CR3022-specific scFv and sub-cloned into the SFG retroviral vector retroviral backbone in-frame with the hinge component of human IgG1, CD28 trans-membrane domain, The method was previously described2, briefly, to produce CR3022-CAR retrovirus, 293T cells were transfected with CR3022-CAR in SFG backbone, RDF, and PegPam3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GENEWIZ</div> <div>suggested: (GENEWIZ, RRID:SCR_003177)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were acquired using FACS Diva software (BD) and analyzed using FlowJo software (BD)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      We have optimized the NK cell expansion technology to buffer this potential limitation. Thus, in this study, we focused on CR3022-CAR-NK-92MI, a NK-92 cell line expressing IL-2 molecule to sustain the persistence in vivo20. In this study, we provide proof-of-concept for using CR3022-CAR-based cell therapy for treating severe COVID-19 patients. These experiments will expedite preclinical studies and a potential clinical application during the COVID-19 pandemic. Although these findings support the therapeutic potential of CR3022-CAR-NK cells for treating severe COVID-19 patients, there are several limitations presented in the current form of study. First, we use the NK-92 cell line in this study. NK-92-mediated immunotherapy is currently undergoing phase I/II clinical trials21,22. However, NK-92 cells must be irradiated prior to infusion to prevent permanent engraftment because of malignant potential of NK-92 cells. Second, we use pseudotyped SARS-CoV-2-S viral particles, which is different from the natural SARS-CoV-2 virus. Future studies using natural SARS-CoV-2 virus in the ACE2-transgenic mouse model are needed to test the efficacy and toxicity of CR3022-CAR-NK cells. In conclusion, development of this novel CAR-NK cell therapy for the treatment of severe COVID-19 patients with maximal efficacy and minimal toxicity will be required to reduce patient risk and enhance the benefit of these expensive and time-intensive therapies. The studies here characterize the biology of CR3...


      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Resolved on clinicaltrials.gov</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04375176</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Monocytes and NK Cells Activit...</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04280224</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NK Cells Treatment for COVID-1...</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04365101</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Natural Killer Cell (CYNK-001)...</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04324996</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Phase I/II Study of Universa...</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04416139</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Yes</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Mesenchymal Stem Cell for Acut...</td></tr></table>


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    5. SciScore for 10.1101/2020.08.11.247320: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">METHODS AND MATERIALS Antibodies and Reagents PE anti-human CD3 antibody (clone OKT3), FITC and PE/Cy7 anti-human CD56 antibody (clone HCD56, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD3</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD56</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD69 antibody (clone FN50, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD69</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human CD8a antibody (clone RPA-T8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD8a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 anti-human CD226 antibody (DNAM-1) (clone 11A8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD226</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 antihuman KLRG1 (MAFA) antibody (clone SA231A2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman KLRG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MAFA</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD335</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>NKp46</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD244 (2B4) antibody (clone C1.7, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD244</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD152 (CTLA-4) antibody (clone BNI3)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD152</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CTLA-4 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, APC anti-human CD366 (Tim-3) antibody (clone F38-2E2),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD366</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Tim-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">antihuman TIGIT (VSTM3) antibody (clone A15153G)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman TIGIT ( VSTM3</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FITC anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD223</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>LAG-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11), and APC anti-human CD94 (clone DX22, BioLegend) were purchased from BioLegend (San Diego, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD314</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD94</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC anti-human CD16 antibody (clone 3G8, BD Biosciences)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD16</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11, BD Biosciences), and FITC anti-human CD107a antibody (clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NKG2D</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD107a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human NKG2C/CD159c antibody (clone 134591, R&D Systems) were purchased from R&D Systems.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>PE anti-human NKG2C/CD159c antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human NKG2C/CD159c</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AF647 Goat anti-human IgG(H+L) F(ab’)2 fragment antibody was purchased from Jackson ImmunoResearch (West Grove, PA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>AF647 Goat anti-human IgG(H+L ) F(ab’)2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coronavirus Spike protein (subunit 1) polyclonal antibody was purchased from Invitrogen (Carlsbad, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1 ) polyclonal antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mouse monoclonal antibody IgG1 (clone H-3) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>mouse monoclonal antibody IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>antibody IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with anti-mouse (IgG1) secondary antibody in FACS buffer for 30 minutes on ice, washed twice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse ( IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Due to the non-specific binding to our CR3022-CAR of our secondary antibody, cells were first blocked with anti-human IgG(H+L) F(ab’)2 fragment for 30 minutes on ice in BM and washed thrice with PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG(H+L</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with goat anti-rabbit secondary antibody in FACS buffer for 30 minutes on ice, washed thrice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-rabbit</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SFG retroviral vector contains the CR3022 single chain antibody fragment (clone 3), a human IgG1 CH2CH3 hinge region and CD28 transmembrane region, followed by the intracellular domains of co-stimulatory CD28, 4-1BB, and the intracellular domain of CD3ζ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>human IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CD28</div> <div>suggested: (Thermo Fisher Scientific Cat# EPX140-15803-901, RRID:AB_2576106)</div> </div> <div style="margin-bottom:8px"> <div>4-1BB</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CR3022-CAR or NK-92MI cells were incubated with SARS- CoV-2-RBD or SARS-CoV-1-RBD recombinant protein. b) Successful transfection was confirmed by flow cytometry using anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Similarly, 293T-hACE2-FFLuc-GFP-RBD cells were transfected with 0.25 µg of SARSCoV-2-RBD plasmid and 0.25 µg of pHAGE-FFLuc-GFP each well in a 24-well plate (Eppendorf) for 48 hours at 37°C under 5% (v/v) CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow Cytometry Analysis NK92MI and CR3022-CAR cells were stained were stained and washed as previously described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, expanded NK cells (5 × 104) were incubated with 1 × 105 293T or cells in V-bottomed 96-well plates in complete RPMI-1640 media at 37℃ for 2 hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, the following day, the wells were aspirated and 293T-hACE2FFLuc-GFP-RBD and 293T-hACE2 cells were pre-seeded at 1 × 104 target cells/well in 100 µL/well of DMEM supplemented with 10% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In a separate 96-well plate, CR3022-CAR-NK92MI and NK-92MI cells were resuspended at a concentration of 1 × 106 cells/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NK-92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( d) Quantitative data of the luciferase killing assay using CR3022-CAR-NK92MI and wild-type NK-92MI cells against 293ThACE2-FFLuc-GFP-RBD cells is shown.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293ThACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR-NK92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CR3022-CAR construction and retrovirus production A codon-optimized DNA fragment was synthesized by GENEWIZ encoding the CR3022-specific scFv and sub-cloned into the SFG retroviral vector retroviral backbone in-frame with the hinge component of human IgG1, CD28 trans-membrane domain, The method was previously described2, briefly, to produce CR3022-CAR retrovirus, 293T cells were transfected with CR3022-CAR in SFG backbone, RDF, and PegPam3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GENEWIZ</div> <div>suggested: (GENEWIZ, RRID:SCR_003177)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were acquired using FACS Diva software (BD) and analyzed using FlowJo software (BD)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      We have optimized the NK cell expansion technology to buffer this potential limitation. Thus, in this study, we focused on CR3022-CAR-NK-92MI, a NK-92 cell line expressing IL-2 molecule to sustain the persistence in vivo20. In this study, we provide proof-of-concept for using CR3022-CAR-based cell therapy for treating severe COVID-19 patients. These experiments will expedite preclinical studies and a potential clinical application during the COVID-19 pandemic. Although these findings support the therapeutic potential of CR3022-CAR-NK cells for treating severe COVID-19 patients, there are several limitations presented in the current form of study. First, we use the NK-92 cell line in this study. NK-92-mediated immunotherapy is currently undergoing phase I/II clinical trials21,22. However, NK-92 cells must be irradiated prior to infusion to prevent permanent engraftment because of malignant potential of NK-92 cells. Second, we use pseudotyped SARS-CoV-2-S viral particles, which is different from the natural SARS-CoV-2 virus. Future studies using natural SARS-CoV-2 virus in the ACE2-transgenic mouse model are needed to test the efficacy and toxicity of CR3022-CAR-NK cells. In conclusion, development of this novel CAR-NK cell therapy for the treatment of severe COVID-19 patients with maximal efficacy and minimal toxicity will be required to reduce patient risk and enhance the benefit of these expensive and time-intensive therapies. The studies here characterize the biology of CR3022-CAR-NK-92MI cells, test the efficacy of CR3022-CAR-NK-92MI using in vitro assays, and finally, define the efficacy of eliminating SARS-CoV-2 infected target cells by CR3022-CAR-NK-92MI cells. This work pioneers the use of CR3022-CAR-NK cells to treat SARS-CoV-2 infected patients and will lead to the development of novel immunotherapeutic strategies for patients presenting with severe COVID-19, and combined with other broadly neutralizing antibodies, will support the development of a universal, “off-the-shelf ” CAR-NK based-immunotherapy for COVID-19. Online content Any methods, additional references, source data, and statements of code and data availability are available online. METHODS AND MATERIALS Antibodies and Reagents PE anti-human CD3 antibody (clone OKT3), FITC and PE/Cy7 anti-human CD56 antibody (clone HCD56, BioLegend), PE anti-human CD69 antibody (clone FN50, BioLegend), PE anti-human CD8a antibody (clone RPA-T8, BioLegend), APC/Fire 750 anti-human CD226 antibody (DNAM-1) (clone 11A8, BioLegend), APC/Fire 750 antihuman KLRG1 (MAFA) antibody (clone SA231A2, BioLegend), BV421 anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend), PE/Cy7 anti-human CD244 (2B4) antibody (clone C1.7, BioLegend), PE anti-human CD152 (CTLA-4) antibody (clone BNI3), APC anti-human CD366 (Tim-3) antibody (clone F38-2E2), PerCP/Cy5.5 antihuman TIGIT (VSTM3) antibody (clone A15153G), FITC anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend), BV510 anti-human CD314 (NKG2D) antibody (clone 1D11), and APC anti-human CD94 (clone DX22, BioLegend) were purchased from BioLegend (San Diego, CA, USA). APC anti-human CD16 antibody (clone 3G8, BD Biosciences), BV711 anti-human CD314 (NKG2D) antibody (clone 1D11, BD Biosciences), and FITC anti-human CD107a antibody (clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose, CA, USA). PE anti-human NKG2C/CD159c antibody (clone 134591, R&D Systems) were purchased from R&D Systems. AF647 Goat anti-human IgG(H+L) F(ab’)2 fragment antibody was purchased from Jackson ImmunoResearch (West Grove, PA, USA). Anti-SARS-CoV-2 Coronavirus Spike protein (subunit 1) polyclonal antibody was purchased from Invitrogen (Carlsbad, CA, USA). Anti-SARS-CoV-2 Spike RBD rabbit polyclonal antibody was purchased from SinoBiological (Beijing, China). Anti-His mouse monoclonal antibody IgG1 (clone H-3) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Alexa Fluor 488 goat anti-rabbit IgG (H+L) and Alexa Fluor 488 goat anti-mouse IgG1 (g1) were purchased from Fisher Scientific (Waltham, MA). Cell lines 293T cell line was purchased from the American Type Culture Collection (ATCC). 293T-hACE2 cell line is a gift from Dr. Abraham Pinter (Rutgers-New Jersey Medical School, PHRI). To maintain the stable expression of hACE2, 293T-hACE2 cells were cultured in DMEM (Corning) supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL Penicillin-Streptomycin (Corning), and 1µg/mL of puromycin at 37℃ under 5% (v/v) CO2. To establish transient 293T-hACE2-RBD, 293T-hACE2 cells were transfected with 0.5 µg of SARS-CoV-2-RBD plasmid (a gift from Dr. Abraham Pinter) each well in a 24-well plate (Eppendorf) for 48 hours at 37℃ under 5% (v/v) CO2. Similarly, 293T-hACE2-FFLuc-GFP-RBD cells were transfected with 0.25 µg of SARSCoV-2-RBD plasmid and 0.25 µg of pHAGE-FFLuc-GFP each well in a 24-well plate (Eppendorf) for 48 hours at 37°C under 5% (v/v) CO2. Cells were harvested and immediately used for CD107a degranulation, 51Cr release, and FFLuc reporter assays. CR3022-CAR construction and retrovirus production A codon-optimized DNA fragment was synthesized by GENEWIZ encoding the CR3022-specific scFv and sub-cloned into the SFG retroviral vector retroviral backbone in-frame with the hinge component of human IgG1, CD28 trans-membrane domain, The method was previously described2, briefly, to produce CR3022-CAR retrovirus, 293T cells were transfected with CR3022-CAR in SFG backbone, RDF, and PegPam3. CR3022-CAR retrovirus was harvested after 48-72 hours and transduced to NK92MI cells in a 24-well plate coated with 0.5 µg/ml of RetroNectin diluted in PBS (Clontech). Two days later, cells were transferred to 75 cm2 flask (Corning) and maintained in 35 ml complete NK92MI medium (MEM-a with 12.5% (v/v) FBS, 12.5% (v/v) heat inactivated horse serum, 11 µM bME, 2 µM folic acid, and 20 µM inositol) supplemented 200 U/mL IL-2 (PeproTech). To determine the expression of CAR, cells were stained for CD56 and anti-human IgG(H+L) F(ab’)2 fragment and analyzed by flow cytometry. CR3022-CAR and RBD binding assay To evaluate the binding activity of CR3022-CAR to RBD domain of SARS-CoV-2-S, CR3022-CAR and NK92MI (5 × 105) cells were incubated with 5 µg of His-gp70-RBD recombinant protein is a gift from Dr. Abraham Pinter in DPBS buffer (0.5 mM MgCl2 and 0.9 mM CaCl2 in PBS) in for 30 minutes on ice. Cells were washed twice with PBS, stained with anti-His in FACS buffer (0.2% FBS in PBS) for 30 minutes on ice and washed twice with PBS. Cells were then stained with anti-mouse (IgG1) secondary antibody in FACS buffer for 30 minutes on ice, washed twice with PBS, and analyzed by Flow Cytometry. CR3022-CAR and pseudotyped SARS-CoV-2-S viral particles binding assay CR3022-CAR, NK92MI, and 293T-hACE2 (5 × 105) cells were first equilibrated with BM (complete RPMI-1640 containing 0.2% BSA and 10 mM HEPES pH 7.4). Due to the non-specific binding to our CR3022-CAR of our secondary antibody, cells were first blocked with anti-human IgG(H+L) F(ab’)2 fragment for 30 minutes on ice in BM and washed thrice with PBS. Pseudotyped SARS-CoV-2-S (Genscript), full-length recombinant S protein (Acrobio systems), and S1 subunit recombinant protein (a gift from Dr. Abraham Pinter) were diluted with BM to appropriate concentrations. 4 × 106 IFU of pseudotyped SARS-CoV-2-S, or 2 µg of full-length recombinant S protein, or 2 µg of S1 subunit recombinant protein was added to designated wells of a 96-well V bottom plate. Plate was spun at 600 × g for 30 minutes at 32°C, then was incubated at 37°C under 5% (v/v) CO2 for 1 hour. Cells were washed twice with PBS, stained with anti-S1 in FACS buffer (0.2% FBS in PBS) for 30 minutes on ice and washed thrice with PBS. Cells were then stained with goat anti-rabbit secondary antibody in FACS buffer for 30 minutes on ice, washed thrice with PBS, and analyzed by Flow Cytometry. Flow Cytometry Analysis NK92MI and CR3022-CAR cells were stained were stained and washed as previously described. Cells were analyzed on a FACS LSRII or an LSR Fortessa flow cytometer (BD). PMT voltages were adjusted and compensation values were calculated before data collection. Data were acquired using FACS Diva software (BD) and analyzed using FlowJo software (BD). CD107a Degranulation assay The CD107a degranulation assay was described previously3. Briefly, expanded NK cells (5 × 104) were incubated with 1 × 105 293T or cells in V-bottomed 96-well plates in complete RPMI-1640 media at 37℃ for 2 hours. The cells were harvested, washed, and stained for CD3, CD56, and CD107a with GolgiStop (BD Biosciences) for 30 minutes, and analyzed by flow cytometry. FFLuc reporter assay To quantify the cytotoxicity of CAR-modified immune cells, we also developed the FFLuc reporter system assay. Briefly, an optical 96-well plate (Greiner BioOne™ No: 655098) was precoated with Retronectin (0.5 µg/ml in PBS) and placed at 4°C overnight. Then, the following day, the wells were aspirated and 293T-hACE2FFLuc-GFP-RBD and 293T-hACE2 cells were pre-seeded at 1 × 104 target cells/well in 100 µL/well of DMEM supplemented with 10% FBS. The plate was centrifuged for 5 minutes at 350 ´ g. In a separate 96-well plate, CR3022-CAR-NK92MI and NK-92MI cells were resuspended at a concentration of 1 × 106 cells/ml. Serial dilutions of effector cells were then prepared according to the effector/target ratio using NK-92MI medium. Then, the effector cells were added to each well of the optical plate (100 µL/well) and incubated at 37°C under 5% (v/v) CO2 for 4 hours and then the supernatant was gently discarded. 100 µL of working concentration D-Luciferin was added to each well with the lights turned off. A microplate reader (BioTek, USA) was used to quantify the data. The data was quantified by converting the obtained values to percentage of specific lysis by the following equation: Specific Lysis Percentage (%) = [1-(S-E)/(T-M)]×100, where S is the value of luminescence of the sample well, E is the value of luminescence of the “effector cell only” well compared to the sample well, T is the mean value of luminescence of “Target cell only” wells, and M is the mean value of luminescence of “blank medium only” wells. 51 Cr release assay To evaluate the cytotoxic activity of CAR-NK cell, the standard 4-hour 51Cr release assay was used. Briefly, target cells were labeled with 51Cr at 37°C for 2 hours and then resuspended at 1×105/mL in NK-92MI culture medium with 10% FBS without IL-2. Then, 1×104 target cells were incubated with serially diluted CAR-NK or NK-92MI cells at 37°C for 4 hours. After centrifugation, the supernatants were collected and the released 51Cr was measured with a gamma counter (Wallac, Turku, Finland). The cytotoxicity (as a percentage) was calculated as follows: [(sample − spontaneous release) / (maximum release − spontaneous release)] × 100. Statistical Analysis Data were represented as means ± SEM. The statistical significance was determined using a two-tailed unpaired Student t test, a two-tailed paired Student t test, a two-way ANOVA, where indicated. P < 0.05 was considered statistically significant. Figure and Figure legends: Figure 1: Generation of CR3022-CAR-NK92MI cells. (a) Schematic design of CR3022-CAR in SFG retroviral vector. The SFG retroviral vector contains the CR3022 single chain antibody fragment (clone 3), a human IgG1 CH2CH3 hinge region and CD28 transmembrane region, followed by the intracellular domains of co-stimulatory CD28, 4-1BB, and the intracellular domain of CD3ζ. (b) Generation of CR3022-CAR-NK cells. 293T cells were transfected with SFG-CR3022CAR for 48-72 hours for CAR retrovirus packaging and transduced into NK92MI cells. (c) Determination of CAR expression by flow cytometry. CR3022-CAR cells were harvested after 4-5 days then stained with anti-CD56 and CAR F(ab)2 domain [IgG Figure 2: CR3022-CAR-NK92MI cells bind to RBD domain of SARS-CoV-2-S protein. (a) Immunophenotyping of CR3022-CAR. Antibodies against various immunomodulatory receptors including TIGIT, LAG-3, TIM-3, KLRG1, CTLA-4, PD-1, CD69, CD8A, NKG2C, CD94, DNAM-1, 2B4, NKG2D, NKP46, and CD16 were used to stain CR3022-CAR and NK-92MI. The expression of these receptors was determined by flow cytometry. (b) Diagram of CR3022-CAR binding to the RBD domain of SARSCoV-2-S recombinant protein. CR3022-CAR binds to RBD of SARS-CoV-2-S protein which is then recognized by anti-His and its corresponding secondary antibody conjugated to a fluorophore. (c) Representative dot plots of CR3022-CAR binding to RBD of SARS-CoV-2. CR3022-CAR or NK-92MI cells were incubated with SARS- CoV-2-RBD or SARS-CoV-1-RBD recombinant protein. The binding efficiency was determined by flow cytometry. Figure 3: CR3022-CAR-NK-92MI cells bind to pseudotyped SARS-CoV-2-S viral particles. (a) Diagram of CR3022-CAR binding to pseudotyped SARS-CoV-2-S viral particles. CR3022-CAR binds to pseudotyped SARS-CoV-2-S viral particle which is then recognized by anti-spike and its corresponding secondary antibody conjugated to a fluorophore. (b) Representative histogram of CR3022-CAR binding to pseudotyped SARS-CoV-2-S. CR3022-CAR or NK-92MI or 293T-hACE2 cells were incubated with pseudotyped SARS-CoV-2 or full-length spike or S1 subunit recombinant protein. The binding efficiency was determined by flow cytometry. Experimental sample was performed in triplicate with MFI 6759 ± 440 (a.u.). (c) Graph showing the binding efficiency of CR3022-CAR to pseudotyped SARS-CoV-2-S. The values were converted from Figure 2b. Experimental sample was performed in triplicate with binding efficiency 51.4 ± 3.34 (%). Figure 4: Increased CD107a degranulation and killing activity of CR3022-CAR-NK92MI cells against 293T-hACE2 cells transfected with RBD-SARS-Cov-2 Spike. (a) 293T-hACE2 cells were transfected with a plasmid containing firefly luciferase and GFP as well as SARS-CoV-2 Spike protein receptor binding domain for 48 hours. (b) Successful transfection was confirmed by flow cytometry using anti-RBD antibody. Cells were then harvested and used as target cells for subsequent CD107a degranulation assay and luciferase killing assays. (c) Representative dot plots of CD107a assay and quantitative data of the percentage and mean fluorescence intensity of CD107a positive CR3022-CAR-NK92MI cells are shown. (d) Quantitative data of the luciferase killing assay using CR3022-CAR-NK92MI and wild-type NK-92MI cells against 293ThACE2-FFLuc-GFP-RBD cells is shown. Experimental groups were performed in represent the mean ± SEM from at least two independent experiments. Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. Then, cells were harvested, stained for CAR F(ab)2 domain [IgG (H+L)], and CD107a. Representative flow cytometry dot plots, CD107a percent of total CAR cells, and CD107a MFI are shown. Figure 5: Increased killing activity of CR3022-CAR-NK-92MI cells against 293ThACE2 cells transfected with SARS-Cov-2 Spike protein Receptor Binding Domain using the 51Cr release platform. (a) 293T-hACE2 cells were transfected with SARSCov-2 Spike protein receptor binding domain for 48 hours. (b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody. Cells were then harvested and used as target cells for the subsequent 51Cr release assay. (c) Quantitative data of the 51Cr release assay using CR3022-CAR-NK-92MI cells and wild-type NK-92MI cells. Experimental groups were performed in triplicate. * p < 0.05, ** p < 0.01, *** p = 0.001, **** p<0.0001 ns p > 0.05. Data represent the mean ± SEM from at least two independent experiments.


      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><tr><td>Identifier</td><td>Resolved on clinicaltrials.gov</td><td>Title</td><td>Status</td></tr><tr><td>NCT04375176</td><td>Yes</td><td>Monocytes and NK Cells Activity in Covid-19 Patien...</td><td>Recruiting</td></tr><tr><td>NCT04280224</td><td>Yes</td><td>NK Cells Treatment for COVID-19</td><td>Recruiting</td></tr><tr><td>NCT04365101</td><td>Yes</td><td>Natural Killer Cell (CYNK-001) Infusions in Adults...</td><td>Recruiting</td></tr><tr><td>NCT04324996</td><td>Yes</td><td>A Phase I/II Study of Universal Off-the-shelf NKG2...</td><td>Recruiting</td></tr><tr><td>NCT04416139</td><td>Yes</td><td>Mesenchymal Stem Cell for Acute Respiratory Distre...</td><td>Recruiting</td></tr></table>


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    6. SciScore for 10.1101/2020.08.11.247320: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">METHODS AND MATERIALS Antibodies and Reagents PE anti-human CD3 antibody (clone OKT3), FITC and PE/Cy7 anti-human CD56 antibody (clone HCD56, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD3</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD56</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD69 antibody (clone FN50, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD69</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human CD8a antibody (clone RPA-T8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD8a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 anti-human CD226 antibody (DNAM-1) (clone 11A8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD226</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 antihuman KLRG1 (MAFA) antibody (clone SA231A2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman KLRG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MAFA</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD335</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>NKp46</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD244 (2B4) antibody (clone C1.7, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD244</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD152 (CTLA-4) antibody (clone BNI3)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD152</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CTLA-4 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, APC anti-human CD366 (Tim-3) antibody (clone F38-2E2),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD366</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Tim-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">antihuman TIGIT (VSTM3) antibody (clone A15153G)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman TIGIT ( VSTM3</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FITC anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD223</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>LAG-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11), and APC anti-human CD94 (clone DX22, BioLegend) were purchased from BioLegend (San Diego, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD94</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC anti-human CD16 antibody (clone 3G8, BD Biosciences)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD16</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11, BD Biosciences), and FITC anti-human CD107a antibody (clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD314</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>NKG2D</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD107a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human NKG2C/CD159c antibody (clone 134591, R&D Systems) were purchased from R&D Systems.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>PE anti-human NKG2C/CD159c antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human NKG2C/CD159c</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AF647 Goat anti-human IgG(H+L) F(ab’)2 fragment antibody was purchased from Jackson ImmunoResearch (West Grove, PA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>AF647 Goat anti-human IgG(H+L ) F(ab’)2</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human IgG(H+L</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coronavirus Spike protein (subunit 1) polyclonal antibody was purchased from Invitrogen (Carlsbad, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1 ) polyclonal antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mouse monoclonal antibody IgG1 (clone H-3) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>mouse monoclonal antibody IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>antibody IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with anti-mouse (IgG1) secondary antibody in FACS buffer for 30 minutes on ice, washed twice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse ( IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with goat anti-rabbit secondary antibody in FACS buffer for 30 minutes on ice, washed thrice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-rabbit</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SFG retroviral vector contains the CR3022 single chain antibody fragment (clone 3), a human IgG1 CH2CH3 hinge region and CD28 transmembrane region, followed by the intracellular domains of co-stimulatory CD28, 4-1BB, and the intracellular domain of CD3ζ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>human IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CD28</div> <div>suggested: (Thermo Fisher Scientific Cat# EPX140-15803-901, RRID:AB_2576106)</div> </div> <div style="margin-bottom:8px"> <div>4-1BB</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Anti-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To maintain the stable expression of hACE2, 293T-hACE2 cells were cultured in DMEM (Corning) supplemented with 10% (v/v)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Similarly, 293T-hACE2-FFLuc-GFP-RBD cells were transfected with 0.25 µg of SARSCoV-2-RBD plasmid and 0.25 µg of pHAGE-FFLuc-GFP each well in a 24-well plate (Eppendorf) for 48 hours at 37°C under 5% (v/v) CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow Cytometry Analysis NK92MI and CR3022-CAR cells were stained were stained and washed as previously described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, expanded NK cells (5 × 104) were incubated with 1 × 105 293T or cells in V-bottomed 96-well plates in complete RPMI-1640 media at 37℃ for 2 hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In a separate 96-well plate, CR3022-CAR-NK92MI and NK-92MI cells were resuspended at a concentration of 1 × 106 cells/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NK-92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( d) Quantitative data of the luciferase killing assay using CR3022-CAR-NK92MI and wild-type NK-92MI cells against 293ThACE2-FFLuc-GFP-RBD cells is shown.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293ThACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR-NK92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CR3022-CAR construction and retrovirus production A codon-optimized DNA fragment was synthesized by GENEWIZ encoding the CR3022-specific scFv and sub-cloned into the SFG retroviral vector retroviral backbone in-frame with the hinge component of human IgG1, CD28 trans-membrane domain, The method was previously described2, briefly, to produce CR3022-CAR retrovirus, 293T cells were transfected with CR3022-CAR in SFG backbone, RDF, and PegPam3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GENEWIZ</div> <div>suggested: (GENEWIZ, RRID:SCR_003177)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were acquired using FACS Diva software (BD) and analyzed using FlowJo software (BD)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      We have optimized the NK cell expansion technology to buffer this potential limitation. Thus, in this study, we focused on CR3022-CAR-NK-92MI, a NK-92 cell line expressing IL-2 molecule to sustain the persistence in vivo20. In this study, we provide proof-of-concept for using CR3022-CAR-based cell therapy for treating severe COVID-19 patients. These experiments will expedite preclinical studies and a potential clinical application during the COVID-19 pandemic. Although these findings support the therapeutic potential of CR3022-CAR-NK cells for treating severe COVID-19 patients, there are several limitations presented in the current form of study. First, we use the NK-92 cell line in this study. NK-92-mediated immunotherapy is currently undergoing phase I/II clinical trials21,22. However, NK-92 cells must be irradiated prior to infusion to prevent permanent engraftment because of malignant potential of NK-92 cells. Second, we use pseudotyped SARS-CoV-2-S viral particles, which is different from the natural SARS-CoV-2 virus. Future studies using natural SARS-CoV-2 virus in the ACE2-transgenic mouse model are needed to test the efficacy and toxicity of CR3022-CAR-NK cells. In conclusion, development of this novel CAR-NK cell therapy for the treatment of severe COVID-19 patients with maximal efficacy and minimal toxicity will be required to reduce patient risk and enhance the benefit of these expensive and time-intensive therapies. The studies here characterize the biology of CR3022-CAR-NK-92MI cells, test the efficacy of CR3022-CAR-NK-92MI using in vitro assays, and finally, define the efficacy of eliminating SARS-CoV-2 infected target cells by CR3022-CAR-NK-92MI cells. This work pioneers the use of CR3022-CAR-NK cells to treat SARS-CoV-2 infected patients and will lead to the development of novel immunotherapeutic strategies for patients presenting with severe COVID-19, and combined with other broadly neutralizing antibodies, will support the development of a universal, “off-the-shelf ” CAR-NK based-immunotherapy for COVID-19. Online content Any methods, additional references, source data, and statements of code and data availability are available online. METHODS AND MATERIALS Antibodies and Reagents PE anti-human CD3 antibody (clone OKT3), FITC and PE/Cy7 anti-human CD56 antibody (clone HCD56, BioLegend), PE anti-human CD69 antibody (clone FN50, BioLegend), PE anti-human CD8a antibody (clone RPA-T8, BioLegend), APC/Fire 750 anti-human CD226 antibody (DNAM-1) (clone 11A8, BioLegend), APC/Fire 750 antihuman KLRG1 (MAFA) antibody (clone SA231A2, BioLegend), BV421 anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend), PE/Cy7 anti-human CD244 (2B4) antibody (clone C1.7, BioLegend), PE anti-human CD152 (CTLA-4) antibody (clone BNI3), APC anti-human CD366 (Tim-3) antibody (clone F38-2E2), PerCP/Cy5.5 antihuman TIGIT (VSTM3) antibody (clone A15153G), FITC anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend), BV510 anti-human CD314 (NKG2D) antibody (clone 1D11), and APC anti-human CD94 (clone DX22, BioLegend) were purchased from BioLegend (San Diego, CA, USA). APC anti-human CD16 antibody (clone 3G8, BD Biosciences), BV711 anti-human CD314 (NKG2D) antibody (clone 1D11, BD Biosciences), and FITC anti-human CD107a antibody (clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose, CA, USA). PE anti-human NKG2C/CD159c antibody (clone 134591, R&D Systems) were purchased from R&D Systems. AF647 Goat anti-human IgG(H+L) F(ab’)2 fragment antibody was purchased from Jackson ImmunoResearch (West Grove, PA, USA). Anti-SARS-CoV-2 Coronavirus Spike protein (subunit 1) polyclonal antibody was purchased from Invitrogen (Carlsbad, CA, USA). Anti-SARS-CoV-2 Spike RBD rabbit polyclonal antibody was purchased from SinoBiological (Beijing, China). Anti-His mouse monoclonal antibody IgG1 (clone H-3) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Alexa Fluor 488 goat anti-rabbit IgG (H+L) and Alexa Fluor 488 goat anti-mouse IgG1 (g1) were purchased from Fisher Scientific (Waltham, MA). Cell lines 293T cell line was purchased from the American Type Culture Collection (ATCC). 293T-hACE2 cell line is a gift from Dr. Abraham Pinter (Rutgers-New Jersey Medical School, PHRI). To maintain the stable expression of hACE2, 293T-hACE2 cells were cultured in DMEM (Corning) supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL Penicillin-Streptomycin (Corning), and 1µg/mL of puromycin at 37℃ under 5% (v/v) CO2. To establish transient 293T-hACE2-RBD, 293T-hACE2 cells were transfected with 0.5 µg of SARS-CoV-2-RBD plasmid (a gift from Dr. Abraham Pinter) each well in a 24-well plate (Eppendorf) for 48 hours at 37℃ under 5% (v/v) CO2. Similarly, 293T-hACE2-FFLuc-GFP-RBD cells were transfected with 0.25 µg of SARSCoV-2-RBD plasmid and 0.25 µg of pHAGE-FFLuc-GFP each well in a 24-well plate (Eppendorf) for 48 hours at 37°C under 5% (v/v) CO2. Cells were harvested and immediately used for CD107a degranulation, 51Cr release, and FFLuc reporter assays. CR3022-CAR construction and retrovirus production A codon-optimized DNA fragment was synthesized by GENEWIZ encoding the CR3022-specific scFv and sub-cloned into the SFG retroviral vector retroviral backbone in-frame with the hinge component of human IgG1, CD28 trans-membrane domain, The method was previously described2, briefly, to produce CR3022-CAR retrovirus, 293T cells were transfected with CR3022-CAR in SFG backbone, RDF, and PegPam3. CR3022-CAR retrovirus was harvested after 48-72 hours and transduced to NK92MI cells in a 24-well plate coated with 0.5 µg/ml of RetroNectin diluted in PBS (Clontech). Two days later, cells were transferred to 75 cm2 flask (Corning) and maintained in 35 ml complete NK92MI medium (MEM-a with 12.5% (v/v) FBS, 12.5% (v/v) heat inactivated horse serum, 11 µM bME, 2 µM folic acid, and 20 µM inositol) supplemented 200 U/mL IL-2 (PeproTech). To determine the expression of CAR, cells were stained for CD56 and anti-human IgG(H+L) F(ab’)2 fragment and analyzed by flow cytometry. CR3022-CAR and RBD binding assay To evaluate the binding activity of CR3022-CAR to RBD domain of SARS-CoV-2-S, CR3022-CAR and NK92MI (5 × 105) cells were incubated with 5 µg of His-gp70-RBD recombinant protein is a gift from Dr. Abraham Pinter in DPBS buffer (0.5 mM MgCl2 and 0.9 mM CaCl2 in PBS) in for 30 minutes on ice. Cells were washed twice with PBS, stained with anti-His in FACS buffer (0.2% FBS in PBS) for 30 minutes on ice and washed twice with PBS. Cells were then stained with anti-mouse (IgG1) secondary antibody in FACS buffer for 30 minutes on ice, washed twice with PBS, and analyzed by Flow Cytometry. CR3022-CAR and pseudotyped SARS-CoV-2-S viral particles binding assay CR3022-CAR, NK92MI, and 293T-hACE2 (5 × 105) cells were first equilibrated with BM (complete RPMI-1640 containing 0.2% BSA and 10 mM HEPES pH 7.4). Due to the non-specific binding to our CR3022-CAR of our secondary antibody, cells were first blocked with anti-human IgG(H+L) F(ab’)2 fragment for 30 minutes on ice in BM and washed thrice with PBS. Pseudotyped SARS-CoV-2-S (Genscript), full-length recombinant S protein (Acrobio systems), and S1 subunit recombinant protein (a gift from Dr. Abraham Pinter) were diluted with BM to appropriate concentrations. 4 × 106 IFU of pseudotyped SARS-CoV-2-S, or 2 µg of full-length recombinant S protein, or 2 µg of S1 subunit recombinant protein was added to designated wells of a 96-well V bottom plate. Plate was spun at 600 × g for 30 minutes at 32°C, then was incubated at 37°C under 5% (v/v) CO2 for 1 hour. Cells were washed twice with PBS, stained with anti-S1 in FACS buffer (0.2% FBS in PBS) for 30 minutes on ice and washed thrice with PBS. Cells were then stained with goat anti-rabbit secondary antibody in FACS buffer for 30 minutes on ice, washed thrice with PBS, and analyzed by Flow Cytometry. Flow Cytometry Analysis NK92MI and CR3022-CAR cells were stained were stained and washed as previously described. Cells were analyzed on a FACS LSRII or an LSR Fortessa flow cytometer (BD). PMT voltages were adjusted and compensation values were calculated before data collection. Data were acquired using FACS Diva software (BD) and analyzed using FlowJo software (BD). CD107a Degranulation assay The CD107a degranulation assay was described previously3. Briefly, expanded NK cells (5 × 104) were incubated with 1 × 105 293T or cells in V-bottomed 96-well plates in complete RPMI-1640 media at 37℃ for 2 hours. The cells were harvested, washed, and stained for CD3, CD56, and CD107a with GolgiStop (BD Biosciences) for 30 minutes, and analyzed by flow cytometry. FFLuc reporter assay To quantify the cytotoxicity of CAR-modified immune cells, we also developed the FFLuc reporter system assay. Briefly, an optical 96-well plate (Greiner BioOne™ No: 655098) was precoated with Retronectin (0.5 µg/ml in PBS) and placed at 4°C overnight. Then, the following day, the wells were aspirated and 293T-hACE2FFLuc-GFP-RBD and 293T-hACE2 cells were pre-seeded at 1 × 104 target cells/well in 100 µL/well of DMEM supplemented with 10% FBS. The plate was centrifuged for 5 minutes at 350 ´ g. In a separate 96-well plate, CR3022-CAR-NK92MI and NK-92MI cells were resuspended at a concentration of 1 × 106 cells/ml. Serial dilutions of effector cells were then prepared according to the effector/target ratio using NK-92MI medium. Then, the effector cells were added to each well of the optical plate (100 µL/well) and incubated at 37°C under 5% (v/v) CO2 for 4 hours and then the supernatant was gently discarded. 100 µL of working concentration D-Luciferin was added to each well with the lights turned off. A microplate reader (BioTek, USA) was used to quantify the data. The data was quantified by converting the obtained values to percentage of specific lysis by the following equation: Specific Lysis Percentage (%) = [1-(S-E)/(T-M)]×100, where S is the value of luminescence of the sample well, E is the value of luminescence of the “effector cell only” well compared to the sample well, T is the mean value of luminescence of “Target cell only” wells, and M is the mean value of luminescence of “blank medium only” wells. 51 Cr release assay To evaluate the cytotoxic activity of CAR-NK cell, the standard 4-hour 51Cr release assay was used. Briefly, target cells were labeled with 51Cr at 37°C for 2 hours and then resuspended at 1×105/mL in NK-92MI culture medium with 10% FBS without IL-2. Then, 1×104 target cells were incubated with serially diluted CAR-NK or NK-92MI cells at 37°C for 4 hours. After centrifugation, the supernatants were collected and the released 51Cr was measured with a gamma counter (Wallac, Turku, Finland). The cytotoxicity (as a percentage) was calculated as follows: [(sample − spontaneous release) / (maximum release − spontaneous release)] × 100. Statistical Analysis Data were represented as means ± SEM. The statistical significance was determined using a two-tailed unpaired Student t test, a two-tailed paired Student t test, a two-way ANOVA, where indicated. P < 0.05 was considered statistically significant. Figure and Figure legends: Figure 1: Generation of CR3022-CAR-NK92MI cells. (a) Schematic design of CR3022-CAR in SFG retroviral vector. The SFG retroviral vector contains the CR3022 single chain antibody fragment (clone 3), a human IgG1 CH2CH3 hinge region and CD28 transmembrane region, followed by the intracellular domains of co-stimulatory CD28, 4-1BB, and the intracellular domain of CD3ζ. (b) Generation of CR3022-CAR-NK cells. 293T cells were transfected with SFG-CR3022CAR for 48-72 hours for CAR retrovirus packaging and transduced into NK92MI cells. (c) Determination of CAR expression by flow cytometry. CR3022-CAR cells were harvested after 4-5 days then stained with anti-CD56 and CAR F(ab)2 domain [IgG Figure 2: CR3022-CAR-NK92MI cells bind to RBD domain of SARS-CoV-2-S protein. (a) Immunophenotyping of CR3022-CAR. Antibodies against various immunomodulatory receptors including TIGIT, LAG-3, TIM-3, KLRG1, CTLA-4, PD-1, CD69, CD8A, NKG2C, CD94, DNAM-1, 2B4, NKG2D, NKP46, and CD16 were used to stain CR3022-CAR and NK-92MI. The expression of these receptors was determined by flow cytometry. (b) Diagram of CR3022-CAR binding to the RBD domain of SARSCoV-2-S recombinant protein. CR3022-CAR binds to RBD of SARS-CoV-2-S protein which is then recognized by anti-His and its corresponding secondary antibody conjugated to a fluorophore. (c) Representative dot plots of CR3022-CAR binding to RBD of SARS-CoV-2. CR3022-CAR or NK-92MI cells were incubated with SARS- CoV-2-RBD or SARS-CoV-1-RBD recombinant protein. The binding efficiency was determined by flow cytometry. Figure 3: CR3022-CAR-NK-92MI cells bind to pseudotyped SARS-CoV-2-S viral particles. (a) Diagram of CR3022-CAR binding to pseudotyped SARS-CoV-2-S viral particles. CR3022-CAR binds to pseudotyped SARS-CoV-2-S viral particle which is then recognized by anti-spike and its corresponding secondary antibody conjugated to a fluorophore. (b) Representative histogram of CR3022-CAR binding to pseudotyped SARS-CoV-2-S. CR3022-CAR or NK-92MI or 293T-hACE2 cells were incubated with pseudotyped SARS-CoV-2 or full-length spike or S1 subunit recombinant protein. The binding efficiency was determined by flow cytometry. Experimental sample was performed in triplicate with MFI 6759 ± 440 (a.u.). (c) Graph showing the binding efficiency of CR3022-CAR to pseudotyped SARS-CoV-2-S. The values were converted from Figure 2b. Experimental sample was performed in triplicate with binding efficiency 51.4 ± 3.34 (%). Figure 4: Increased CD107a degranulation and killing activity of CR3022-CAR-NK92MI cells against 293T-hACE2 cells transfected with RBD-SARS-Cov-2 Spike. (a) 293T-hACE2 cells were transfected with a plasmid containing firefly luciferase and GFP as well as SARS-CoV-2 Spike protein receptor binding domain for 48 hours. (b) Successful transfection was confirmed by flow cytometry using anti-RBD antibody. Cells were then harvested and used as target cells for subsequent CD107a degranulation assay and luciferase killing assays. (c) Representative dot plots of CD107a assay and quantitative data of the percentage and mean fluorescence intensity of CD107a positive CR3022-CAR-NK92MI cells are shown. (d) Quantitative data of the luciferase killing assay using CR3022-CAR-NK92MI and wild-type NK-92MI cells against 293ThACE2-FFLuc-GFP-RBD cells is shown. Experimental groups were performed in represent the mean ± SEM from at least two independent experiments. Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. Then, cells were harvested, stained for CAR F(ab)2 domain [IgG (H+L)], and CD107a. Representative flow cytometry dot plots, CD107a percent of total CAR cells, and CD107a MFI are shown. Figure 5: Increased killing activity of CR3022-CAR-NK-92MI cells against 293ThACE2 cells transfected with SARS-Cov-2 Spike protein Receptor Binding Domain using the 51Cr release platform. (a) 293T-hACE2 cells were transfected with SARSCov-2 Spike protein receptor binding domain for 48 hours. (b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody. Cells were then harvested and used as target cells for the subsequent 51Cr release assay. (c) Quantitative data of the 51Cr release assay using CR3022-CAR-NK-92MI cells and wild-type NK-92MI cells. Experimental groups were performed in triplicate. * p < 0.05, ** p < 0.01, *** p = 0.001, **** p<0.0001 ns p > 0.05. Data represent the mean ± SEM from at least two independent experiments.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    7. SciScore for 10.1101/2020.08.11.247320: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">METHODS AND MATERIALS Antibodies and Reagents PE anti-human CD3 antibody (clone OKT3), FITC and PE/Cy7 anti-human CD56 antibody (clone HCD56, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD3</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD56</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD69 antibody (clone FN50, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD69</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human CD8a antibody (clone RPA-T8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD8a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 anti-human CD226 antibody (DNAM-1) (clone 11A8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD226</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 antihuman KLRG1 (MAFA) antibody (clone SA231A2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman KLRG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MAFA</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD335</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>NKp46</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD244 (2B4) antibody (clone C1.7, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD244</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD152 (CTLA-4) antibody (clone BNI3)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD152</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CTLA-4 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, APC anti-human CD366 (Tim-3) antibody (clone F38-2E2),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD366</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Tim-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">antihuman TIGIT (VSTM3) antibody (clone A15153G)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman TIGIT ( VSTM3</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FITC anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD223</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>LAG-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11), and APC anti-human CD94 (clone DX22, BioLegend) were purchased from BioLegend (San Diego, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NKG2D</div> <div>suggested: (US Biological Cat# K1893-28, RRID:AB_2265490)</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD94</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC anti-human CD16 antibody (clone 3G8, BD Biosciences)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD16</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11, BD Biosciences), and FITC anti-human CD107a antibody (clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD314</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD107a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human NKG2C/CD159c antibody (clone 134591, R&D Systems) were purchased from R&D Systems.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>PE anti-human NKG2C/CD159c antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human NKG2C/CD159c</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AF647 Goat anti-human IgG(H+L) F(ab’)2 fragment antibody was purchased from Jackson ImmunoResearch (West Grove, PA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>AF647 Goat anti-human IgG(H+L ) F(ab’)2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coronavirus Spike protein (subunit 1) polyclonal antibody was purchased from Invitrogen (Carlsbad, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1 ) polyclonal antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mouse monoclonal antibody IgG1 (clone H-3) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>mouse monoclonal antibody IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>antibody IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with anti-mouse (IgG1) secondary antibody in FACS buffer for 30 minutes on ice, washed twice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse ( IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Due to the non-specific binding to our CR3022-CAR of our secondary antibody, cells were first blocked with anti-human IgG(H+L) F(ab’)2 fragment for 30 minutes on ice in BM and washed thrice with PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG(H+L</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with goat anti-rabbit secondary antibody in FACS buffer for 30 minutes on ice, washed thrice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-rabbit</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SFG retroviral vector contains the CR3022 single chain antibody fragment (clone 3), a human IgG1 CH2CH3 hinge region and CD28 transmembrane region, followed by the intracellular domains of co-stimulatory CD28, 4-1BB, and the intracellular domain of CD3ζ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>human IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CD28</div> <div>suggested: (Thermo Fisher Scientific Cat# EPX140-15803-901, RRID:AB_2576106)</div> </div> <div style="margin-bottom:8px"> <div>4-1BB</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CR3022-CAR or NK-92MI cells were incubated with SARS- CoV-2-RBD or SARS-CoV-1-RBD recombinant protein. b) Successful transfection was confirmed by flow cytometry using anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293T cells were transfected with a combination of plasmids containing CR3022-CAR in the SFG backbone, RDF, and PegPam3, as previously described17,18.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293T-hACE2 cell line is a gift from Dr. Abraham Pinter (Rutgers-New Jersey Medical School, PHRI).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Similarly, 293T-hACE2-FFLuc-GFP-RBD cells were transfected with 0.25 µg of SARSCoV-2-RBD plasmid and 0.25 µg of pHAGE-FFLuc-GFP each well in a 24-well plate (Eppendorf) for 48 hours at 37°C under 5% (v/v) CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow Cytometry Analysis NK92MI and CR3022-CAR cells were stained were stained and washed as previously described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In a separate 96-well plate, CR3022-CAR-NK92MI and NK-92MI cells were resuspended at a concentration of 1 × 106 cells/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NK-92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( d) Quantitative data of the luciferase killing assay using CR3022-CAR-NK92MI and wild-type NK-92MI cells against 293ThACE2-FFLuc-GFP-RBD cells is shown.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293ThACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR-NK92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CR3022-CAR construction and retrovirus production A codon-optimized DNA fragment was synthesized by GENEWIZ encoding the CR3022-specific scFv and sub-cloned into the SFG retroviral vector retroviral backbone in-frame with the hinge component of human IgG1, CD28 trans-membrane domain, The method was previously described2, briefly, to produce CR3022-CAR retrovirus, 293T cells were transfected with CR3022-CAR in SFG backbone, RDF, and PegPam3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GENEWIZ</div> <div>suggested: (GENEWIZ, RRID:SCR_003177)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were acquired using FACS Diva software (BD) and analyzed using FlowJo software (BD)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      We have optimized the NK cell expansion technology to buffer this potential limitation. Thus, in this study, we focused on CR3022-CAR-NK-92MI, a NK-92 cell line expressing IL-2 molecule to sustain the persistence in vivo20. In this study, we provide proof-of-concept for using CR3022-CAR-based cell therapy for treating severe COVID-19 patients. These experiments will expedite preclinical studies and a potential clinical application during the COVID-19 pandemic. Although these findings support the therapeutic potential of CR3022-CAR-NK cells for treating severe COVID-19 patients, there are several limitations presented in the current form of study. First, we use the NK-92 cell line in this study. NK-92-mediated immunotherapy is currently undergoing phase I/II clinical trials21,22. However, NK-92 cells must be irradiated prior to infusion to prevent permanent engraftment because of malignant potential of NK-92 cells. Second, we use pseudotyped SARS-CoV-2-S viral particles, which is different from the natural SARS-CoV-2 virus. Future studies using natural SARS-CoV-2 virus in the ACE2-transgenic mouse model are needed to test the efficacy and toxicity of CR3022-CAR-NK cells. In conclusion, development of this novel CAR-NK cell therapy for the treatment of severe COVID-19 patients with maximal efficacy and minimal toxicity will be required to reduce patient risk and enhance the benefit of these expensive and time-intensive therapies. The studies here characterize the biology of CR3022-CAR-NK-92MI cells, test the efficacy of CR3022-CAR-NK-92MI using in vitro assays, and finally, define the efficacy of eliminating SARS-CoV-2 infected target cells by CR3022-CAR-NK-92MI cells. This work pioneers the use of CR3022-CAR-NK cells to treat SARS-CoV-2 infected patients and will lead to the development of novel immunotherapeutic strategies for patients presenting with severe COVID-19, and combined with other broadly neutralizing antibodies, will support the development of a universal, “off-the-shelf ” CAR-NK based-immunotherapy for COVID-19. Online content Any methods, additional references, source data, and statements of code and data availability are available online. METHODS AND MATERIALS Antibodies and Reagents PE anti-human CD3 antibody (clone OKT3), FITC and PE/Cy7 anti-human CD56 antibody (clone HCD56, BioLegend), PE anti-human CD69 antibody (clone FN50, BioLegend), PE anti-human CD8a antibody (clone RPA-T8, BioLegend), APC/Fire 750 anti-human CD226 antibody (DNAM-1) (clone 11A8, BioLegend), APC/Fire 750 antihuman KLRG1 (MAFA) antibody (clone SA231A2, BioLegend), BV421 anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend), PE/Cy7 anti-human CD244 (2B4) antibody (clone C1.7, BioLegend), PE anti-human CD152 (CTLA-4) antibody (clone BNI3), APC anti-human CD366 (Tim-3) antibody (clone F38-2E2), PerCP/Cy5.5 antihuman TIGIT (VSTM3) antibody (clone A15153G), FITC anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend), BV510 anti-human CD314 (NKG2D) antibody (clone 1D11), and APC anti-human CD94 (clone DX22, BioLegend) were purchased from BioLegend (San Diego, CA, USA). APC anti-human CD16 antibody (clone 3G8, BD Biosciences), BV711 anti-human CD314 (NKG2D) antibody (clone 1D11, BD Biosciences), and FITC anti-human CD107a antibody (clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose, CA, USA). PE anti-human NKG2C/CD159c antibody (clone 134591, R&D Systems) were purchased from R&D Systems. AF647 Goat anti-human IgG(H+L) F(ab’)2 fragment antibody was purchased from Jackson ImmunoResearch (West Grove, PA, USA). Anti-SARS-CoV-2 Coronavirus Spike protein (subunit 1) polyclonal antibody was purchased from Invitrogen (Carlsbad, CA, USA). Anti-SARS-CoV-2 Spike RBD rabbit polyclonal antibody was purchased from SinoBiological (Beijing, China). Anti-His mouse monoclonal antibody IgG1 (clone H-3) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Alexa Fluor 488 goat anti-rabbit IgG (H+L) and Alexa Fluor 488 goat anti-mouse IgG1 (g1) were purchased from Fisher Scientific (Waltham, MA). Cell lines 293T cell line was purchased from the American Type Culture Collection (ATCC). 293T-hACE2 cell line is a gift from Dr. Abraham Pinter (Rutgers-New Jersey Medical School, PHRI). To maintain the stable expression of hACE2, 293T-hACE2 cells were cultured in DMEM (Corning) supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL Penicillin-Streptomycin (Corning), and 1µg/mL of puromycin at 37℃ under 5% (v/v) CO2. To establish transient 293T-hACE2-RBD, 293T-hACE2 cells were transfected with 0.5 µg of SARS-CoV-2-RBD plasmid (a gift from Dr. Abraham Pinter) each well in a 24-well plate (Eppendorf) for 48 hours at 37℃ under 5% (v/v) CO2. Similarly, 293T-hACE2-FFLuc-GFP-RBD cells were transfected with 0.25 µg of SARSCoV-2-RBD plasmid and 0.25 µg of pHAGE-FFLuc-GFP each well in a 24-well plate (Eppendorf) for 48 hours at 37°C under 5% (v/v) CO2. Cells were harvested and immediately used for CD107a degranulation, 51Cr release, and FFLuc reporter assays. CR3022-CAR construction and retrovirus production A codon-optimized DNA fragment was synthesized by GENEWIZ encoding the CR3022-specific scFv and sub-cloned into the SFG retroviral vector retroviral backbone in-frame with the hinge component of human IgG1, CD28 trans-membrane domain, The method was previously described2, briefly, to produce CR3022-CAR retrovirus, 293T cells were transfected with CR3022-CAR in SFG backbone, RDF, and PegPam3. CR3022-CAR retrovirus was harvested after 48-72 hours and transduced to NK92MI cells in a 24-well plate coated with 0.5 µg/ml of RetroNectin diluted in PBS (Clontech). Two days later, cells were transferred to 75 cm2 flask (Corning) and maintained in 35 ml complete NK92MI medium (MEM-a with 12.5% (v/v) FBS, 12.5% (v/v) heat inactivated horse serum, 11 µM bME, 2 µM folic acid, and 20 µM inositol) supplemented 200 U/mL IL-2 (PeproTech). To determine the expression of CAR, cells were stained for CD56 and anti-human IgG(H+L) F(ab’)2 fragment and analyzed by flow cytometry. CR3022-CAR and RBD binding assay To evaluate the binding activity of CR3022-CAR to RBD domain of SARS-CoV-2-S, CR3022-CAR and NK92MI (5 × 105) cells were incubated with 5 µg of His-gp70-RBD recombinant protein is a gift from Dr. Abraham Pinter in DPBS buffer (0.5 mM MgCl2 and 0.9 mM CaCl2 in PBS) in for 30 minutes on ice. Cells were washed twice with PBS, stained with anti-His in FACS buffer (0.2% FBS in PBS) for 30 minutes on ice and washed twice with PBS. Cells were then stained with anti-mouse (IgG1) secondary antibody in FACS buffer for 30 minutes on ice, washed twice with PBS, and analyzed by Flow Cytometry. CR3022-CAR and pseudotyped SARS-CoV-2-S viral particles binding assay CR3022-CAR, NK92MI, and 293T-hACE2 (5 × 105) cells were first equilibrated with BM (complete RPMI-1640 containing 0.2% BSA and 10 mM HEPES pH 7.4). Due to the non-specific binding to our CR3022-CAR of our secondary antibody, cells were first blocked with anti-human IgG(H+L) F(ab’)2 fragment for 30 minutes on ice in BM and washed thrice with PBS. Pseudotyped SARS-CoV-2-S (Genscript), full-length recombinant S protein (Acrobio systems), and S1 subunit recombinant protein (a gift from Dr. Abraham Pinter) were diluted with BM to appropriate concentrations. 4 × 106 IFU of pseudotyped SARS-CoV-2-S, or 2 µg of full-length recombinant S protein, or 2 µg of S1 subunit recombinant protein was added to designated wells of a 96-well V bottom plate. Plate was spun at 600 × g for 30 minutes at 32°C, then was incubated at 37°C under 5% (v/v) CO2 for 1 hour. Cells were washed twice with PBS, stained with anti-S1 in FACS buffer (0.2% FBS in PBS) for 30 minutes on ice and washed thrice with PBS. Cells were then stained with goat anti-rabbit secondary antibody in FACS buffer for 30 minutes on ice, washed thrice with PBS, and analyzed by Flow Cytometry. Flow Cytometry Analysis NK92MI and CR3022-CAR cells were stained were stained and washed as previously described. Cells were analyzed on a FACS LSRII or an LSR Fortessa flow cytometer (BD). PMT voltages were adjusted and compensation values were calculated before data collection. Data were acquired using FACS Diva software (BD) and analyzed using FlowJo software (BD). CD107a Degranulation assay The CD107a degranulation assay was described previously3. Briefly, expanded NK cells (5 × 104) were incubated with 1 × 105 293T or cells in V-bottomed 96-well plates in complete RPMI-1640 media at 37℃ for 2 hours. The cells were harvested, washed, and stained for CD3, CD56, and CD107a with GolgiStop (BD Biosciences) for 30 minutes, and analyzed by flow cytometry. FFLuc reporter assay To quantify the cytotoxicity of CAR-modified immune cells, we also developed the FFLuc reporter system assay. Briefly, an optical 96-well plate (Greiner BioOne™ No: 655098) was precoated with Retronectin (0.5 µg/ml in PBS) and placed at 4°C overnight. Then, the following day, the wells were aspirated and 293T-hACE2FFLuc-GFP-RBD and 293T-hACE2 cells were pre-seeded at 1 × 104 target cells/well in 100 µL/well of DMEM supplemented with 10% FBS. The plate was centrifuged for 5 minutes at 350 ´ g. In a separate 96-well plate, CR3022-CAR-NK92MI and NK-92MI cells were resuspended at a concentration of 1 × 106 cells/ml. Serial dilutions of effector cells were then prepared according to the effector/target ratio using NK-92MI medium. Then, the effector cells were added to each well of the optical plate (100 µL/well) and incubated at 37°C under 5% (v/v) CO2 for 4 hours and then the supernatant was gently discarded. 100 µL of working concentration D-Luciferin was added to each well with the lights turned off. A microplate reader (BioTek, USA) was used to quantify the data. The data was quantified by converting the obtained values to percentage of specific lysis by the following equation: Specific Lysis Percentage (%) = [1-(S-E)/(T-M)]×100, where S is the value of luminescence of the sample well, E is the value of luminescence of the “effector cell only” well compared to the sample well, T is the mean value of luminescence of “Target cell only” wells, and M is the mean value of luminescence of “blank medium only” wells. 51 Cr release assay To evaluate the cytotoxic activity of CAR-NK cell, the standard 4-hour 51Cr release assay was used. Briefly, target cells were labeled with 51Cr at 37°C for 2 hours and then resuspended at 1×105/mL in NK-92MI culture medium with 10% FBS without IL-2. Then, 1×104 target cells were incubated with serially diluted CAR-NK or NK-92MI cells at 37°C for 4 hours. After centrifugation, the supernatants were collected and the released 51Cr was measured with a gamma counter (Wallac, Turku, Finland). The cytotoxicity (as a percentage) was calculated as follows: [(sample − spontaneous release) / (maximum release − spontaneous release)] × 100. Statistical Analysis Data were represented as means ± SEM. The statistical significance was determined using a two-tailed unpaired Student t test, a two-tailed paired Student t test, a two-way ANOVA, where indicated. P < 0.05 was considered statistically significant. Figure and Figure legends: Figure 1: Generation of CR3022-CAR-NK92MI cells. (a) Schematic design of CR3022-CAR in SFG retroviral vector. The SFG retroviral vector contains the CR3022 single chain antibody fragment (clone 3), a human IgG1 CH2CH3 hinge region and CD28 transmembrane region, followed by the intracellular domains of co-stimulatory CD28, 4-1BB, and the intracellular domain of CD3ζ. (b) Generation of CR3022-CAR-NK cells. 293T cells were transfected with SFG-CR3022CAR for 48-72 hours for CAR retrovirus packaging and transduced into NK92MI cells. (c) Determination of CAR expression by flow cytometry. CR3022-CAR cells were harvested after 4-5 days then stained with anti-CD56 and CAR F(ab)2 domain [IgG Figure 2: CR3022-CAR-NK92MI cells bind to RBD domain of SARS-CoV-2-S protein. (a) Immunophenotyping of CR3022-CAR. Antibodies against various immunomodulatory receptors including TIGIT, LAG-3, TIM-3, KLRG1, CTLA-4, PD-1, CD69, CD8A, NKG2C, CD94, DNAM-1, 2B4, NKG2D, NKP46, and CD16 were used to stain CR3022-CAR and NK-92MI. The expression of these receptors was determined by flow cytometry. (b) Diagram of CR3022-CAR binding to the RBD domain of SARSCoV-2-S recombinant protein. CR3022-CAR binds to RBD of SARS-CoV-2-S protein which is then recognized by anti-His and its corresponding secondary antibody conjugated to a fluorophore. (c) Representative dot plots of CR3022-CAR binding to RBD of SARS-CoV-2. CR3022-CAR or NK-92MI cells were incubated with SARS- CoV-2-RBD or SARS-CoV-1-RBD recombinant protein. The binding efficiency was determined by flow cytometry. Figure 3: CR3022-CAR-NK-92MI cells bind to pseudotyped SARS-CoV-2-S viral particles. (a) Diagram of CR3022-CAR binding to pseudotyped SARS-CoV-2-S viral particles. CR3022-CAR binds to pseudotyped SARS-CoV-2-S viral particle which is then recognized by anti-spike and its corresponding secondary antibody conjugated to a fluorophore. (b) Representative histogram of CR3022-CAR binding to pseudotyped SARS-CoV-2-S. CR3022-CAR or NK-92MI or 293T-hACE2 cells were incubated with pseudotyped SARS-CoV-2 or full-length spike or S1 subunit recombinant protein. The binding efficiency was determined by flow cytometry. Experimental sample was performed in triplicate with MFI 6759 ± 440 (a.u.). (c) Graph showing the binding efficiency of CR3022-CAR to pseudotyped SARS-CoV-2-S. The values were converted from Figure 2b. Experimental sample was performed in triplicate with binding efficiency 51.4 ± 3.34 (%). Figure 4: Increased CD107a degranulation and killing activity of CR3022-CAR-NK92MI cells against 293T-hACE2 cells transfected with RBD-SARS-Cov-2 Spike. (a) 293T-hACE2 cells were transfected with a plasmid containing firefly luciferase and GFP as well as SARS-CoV-2 Spike protein receptor binding domain for 48 hours. (b) Successful transfection was confirmed by flow cytometry using anti-RBD antibody. Cells were then harvested and used as target cells for subsequent CD107a degranulation assay and luciferase killing assays. (c) Representative dot plots of CD107a assay and quantitative data of the percentage and mean fluorescence intensity of CD107a positive CR3022-CAR-NK92MI cells are shown. (d) Quantitative data of the luciferase killing assay using CR3022-CAR-NK92MI and wild-type NK-92MI cells against 293ThACE2-FFLuc-GFP-RBD cells is shown. Experimental groups were performed in represent the mean ± SEM from at least two independent experiments. Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. Then, cells were harvested, stained for CAR F(ab)2 domain [IgG (H+L)], and CD107a. Representative flow cytometry dot plots, CD107a percent of total CAR cells, and CD107a MFI are shown. Figure 5: Increased killing activity of CR3022-CAR-NK-92MI cells against 293ThACE2 cells transfected with SARS-Cov-2 Spike protein Receptor Binding Domain using the 51Cr release platform. (a) 293T-hACE2 cells were transfected with SARSCov-2 Spike protein receptor binding domain for 48 hours. (b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody. Cells were then harvested and used as target cells for the subsequent 51Cr release assay. (c) Quantitative data of the 51Cr release assay using CR3022-CAR-NK-92MI cells and wild-type NK-92MI cells. Experimental groups were performed in triplicate. * p < 0.05, ** p < 0.01, *** p = 0.001, **** p<0.0001 ns p > 0.05. Data represent the mean ± SEM from at least two independent experiments.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    8. SciScore for 10.1101/2020.08.11.247320: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">METHODS AND MATERIALS Antibodies and Reagents PE anti-human CD3 antibody (clone OKT3), FITC and PE/Cy7 anti-human CD56 antibody (clone HCD56, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD3</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD56</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD69 antibody (clone FN50, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD69</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human CD8a antibody (clone RPA-T8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD8a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 anti-human CD226 antibody (DNAM-1) (clone 11A8, BioLegend),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD226</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC/Fire 750 antihuman KLRG1 (MAFA) antibody (clone SA231A2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman KLRG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MAFA</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD335</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>NKp46</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD244 (2B4) antibody (clone C1.7, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD244</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PE anti-human CD152 (CTLA-4) antibody (clone BNI3)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD152</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CTLA-4 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, APC anti-human CD366 (Tim-3) antibody (clone F38-2E2),</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD366</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Tim-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">antihuman TIGIT (VSTM3) antibody (clone A15153G)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antihuman TIGIT ( VSTM3</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FITC anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD223</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>LAG-3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11), and APC anti-human CD94 (clone DX22, BioLegend) were purchased from BioLegend (San Diego, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD314</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>NKG2D</div> <div>suggested: (US Biological Cat# K1893-28, RRID:AB_2265490)</div> </div> <div style="margin-bottom:8px"> <div>anti-human CD94</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">APC anti-human CD16 antibody (clone 3G8, BD Biosciences)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD16</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-human CD314 (NKG2D) antibody (clone 1D11, BD Biosciences), and FITC anti-human CD107a antibody (clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose, CA, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD107a</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE anti-human NKG2C/CD159c antibody (clone 134591, R&D Systems) were purchased from R&D Systems.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>PE anti-human NKG2C/CD159c antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human NKG2C/CD159c</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AF647 Goat anti-human IgG(H+L) F(ab’)2 fragment antibody was purchased from Jackson ImmunoResearch (West Grove, PA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>AF647 Goat anti-human IgG(H+L ) F(ab’)2</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human IgG(H+L</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coronavirus Spike protein (subunit 1) polyclonal antibody was purchased from Invitrogen (Carlsbad, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1 ) polyclonal antibody</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Coronavirus Spike protein ( subunit 1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mouse monoclonal antibody IgG1 (clone H-3) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>mouse monoclonal antibody IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>antibody IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with anti-mouse (IgG1) secondary antibody in FACS buffer for 30 minutes on ice, washed twice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse ( IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then stained with goat anti-rabbit secondary antibody in FACS buffer for 30 minutes on ice, washed thrice with PBS, and analyzed by Flow Cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-rabbit</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SFG retroviral vector contains the CR3022 single chain antibody fragment (clone 3), a human IgG1 CH2CH3 hinge region and CD28 transmembrane region, followed by the intracellular domains of co-stimulatory CD28, 4-1BB, and the intracellular domain of CD3ζ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>human IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CD28</div> <div>suggested: (Thermo Fisher Scientific Cat# EPX140-15803-901, RRID:AB_2576106)</div> </div> <div style="margin-bottom:8px"> <div>4-1BB</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CR3022-CAR or NK-92MI cells were incubated with SARS- CoV-2-RBD or SARS-CoV-1-RBD recombinant protein. b) Successful transfection was confirmed by flow cytometry using anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To maintain the stable expression of hACE2, 293T-hACE2 cells were cultured in DMEM (Corning) supplemented with 10% (v/v)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Similarly, 293T-hACE2-FFLuc-GFP-RBD cells were transfected with 0.25 µg of SARSCoV-2-RBD plasmid and 0.25 µg of pHAGE-FFLuc-GFP each well in a 24-well plate (Eppendorf) for 48 hours at 37°C under 5% (v/v) CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T-hACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow Cytometry Analysis NK92MI and CR3022-CAR cells were stained were stained and washed as previously described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In a separate 96-well plate, CR3022-CAR-NK92MI and NK-92MI cells were resuspended at a concentration of 1 × 106 cells/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NK-92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">293T cells were transfected with SFG-CR3022CAR for 48-72 hours for CAR retrovirus packaging and transduced into NK92MI cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( d) Quantitative data of the luciferase killing assay using CR3022-CAR-NK92MI and wild-type NK-92MI cells against 293ThACE2-FFLuc-GFP-RBD cells is shown.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293ThACE2-FFLuc-GFP-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CR3022-CAR-NK92MI</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CR3022-CAR construction and retrovirus production A codon-optimized DNA fragment was synthesized by GENEWIZ encoding the CR3022-specific scFv and sub-cloned into the SFG retroviral vector retroviral backbone in-frame with the hinge component of human IgG1, CD28 trans-membrane domain, The method was previously described2, briefly, to produce CR3022-CAR retrovirus, 293T cells were transfected with CR3022-CAR in SFG backbone, RDF, and PegPam3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GENEWIZ</div> <div>suggested: (GENEWIZ, RRID:SCR_003177)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were acquired using FACS Diva software (BD) and analyzed using FlowJo software (BD)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      We have optimized the NK cell expansion technology to buffer this potential limitation. Thus, in this study, we focused on CR3022-CAR-NK-92MI, a NK-92 cell line expressing IL-2 molecule to sustain the persistence in vivo20. In this study, we provide proof-of-concept for using CR3022-CAR-based cell therapy for treating severe COVID-19 patients. These experiments will expedite preclinical studies and a potential clinical application during the COVID-19 pandemic. Although these findings support the therapeutic potential of CR3022-CAR-NK cells for treating severe COVID-19 patients, there are several limitations presented in the current form of study. First, we use the NK-92 cell line in this study. NK-92-mediated immunotherapy is currently undergoing phase I/II clinical trials21,22. However, NK-92 cells must be irradiated prior to infusion to prevent permanent engraftment because of malignant potential of NK-92 cells. Second, we use pseudotyped SARS-CoV-2-S viral particles, which is different from the natural SARS-CoV-2 virus. Future studies using natural SARS-CoV-2 virus in the ACE2-transgenic mouse model are needed to test the efficacy and toxicity of CR3022-CAR-NK cells. In conclusion, development of this novel CAR-NK cell therapy for the treatment of severe COVID-19 patients with maximal efficacy and minimal toxicity will be required to reduce patient risk and enhance the benefit of these expensive and time-intensive therapies. The studies here characterize the biology of CR3022-CAR-NK-92MI cells, test the efficacy of CR3022-CAR-NK-92MI using in vitro assays, and finally, define the efficacy of eliminating SARS-CoV-2 infected target cells by CR3022-CAR-NK-92MI cells. This work pioneers the use of CR3022-CAR-NK cells to treat SARS-CoV-2 infected patients and will lead to the development of novel immunotherapeutic strategies for patients presenting with severe COVID-19, and combined with other broadly neutralizing antibodies, will support the development of a universal, “off-the-shelf ” CAR-NK based-immunotherapy for COVID-19. Online content Any methods, additional references, source data, and statements of code and data availability are available online. METHODS AND MATERIALS Antibodies and Reagents PE anti-human CD3 antibody (clone OKT3), FITC and PE/Cy7 anti-human CD56 antibody (clone HCD56, BioLegend), PE anti-human CD69 antibody (clone FN50, BioLegend), PE anti-human CD8a antibody (clone RPA-T8, BioLegend), APC/Fire 750 anti-human CD226 antibody (DNAM-1) (clone 11A8, BioLegend), APC/Fire 750 antihuman KLRG1 (MAFA) antibody (clone SA231A2, BioLegend), BV421 anti-human CD335 (NKp46) antibody (clone 9E2, BioLegend), PE/Cy7 anti-human CD244 (2B4) antibody (clone C1.7, BioLegend), PE anti-human CD152 (CTLA-4) antibody (clone BNI3), APC anti-human CD366 (Tim-3) antibody (clone F38-2E2), PerCP/Cy5.5 antihuman TIGIT (VSTM3) antibody (clone A15153G), FITC anti-human CD223 (LAG-3) antibody (clone 11C3C65, BioLegend), BV510 anti-human CD314 (NKG2D) antibody (clone 1D11), and APC anti-human CD94 (clone DX22, BioLegend) were purchased from BioLegend (San Diego, CA, USA). APC anti-human CD16 antibody (clone 3G8, BD Biosciences), BV711 anti-human CD314 (NKG2D) antibody (clone 1D11, BD Biosciences), and FITC anti-human CD107a antibody (clone H4A3, BD Biosciences) were purchased from BD Biosciences (San Jose, CA, USA). PE anti-human NKG2C/CD159c antibody (clone 134591, R&D Systems) were purchased from R&D Systems. AF647 Goat anti-human IgG(H+L) F(ab’)2 fragment antibody was purchased from Jackson ImmunoResearch (West Grove, PA, USA). Anti-SARS-CoV-2 Coronavirus Spike protein (subunit 1) polyclonal antibody was purchased from Invitrogen (Carlsbad, CA, USA). Anti-SARS-CoV-2 Spike RBD rabbit polyclonal antibody was purchased from SinoBiological (Beijing, China). Anti-His mouse monoclonal antibody IgG1 (clone H-3) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Alexa Fluor 488 goat anti-rabbit IgG (H+L) and Alexa Fluor 488 goat anti-mouse IgG1 (g1) were purchased from Fisher Scientific (Waltham, MA). Cell lines 293T cell line was purchased from the American Type Culture Collection (ATCC). 293T-hACE2 cell line is a gift from Dr. Abraham Pinter (Rutgers-New Jersey Medical School, PHRI). To maintain the stable expression of hACE2, 293T-hACE2 cells were cultured in DMEM (Corning) supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL Penicillin-Streptomycin (Corning), and 1µg/mL of puromycin at 37℃ under 5% (v/v) CO2. To establish transient 293T-hACE2-RBD, 293T-hACE2 cells were transfected with 0.5 µg of SARS-CoV-2-RBD plasmid (a gift from Dr. Abraham Pinter) each well in a 24-well plate (Eppendorf) for 48 hours at 37℃ under 5% (v/v) CO2. Similarly, 293T-hACE2-FFLuc-GFP-RBD cells were transfected with 0.25 µg of SARSCoV-2-RBD plasmid and 0.25 µg of pHAGE-FFLuc-GFP each well in a 24-well plate (Eppendorf) for 48 hours at 37°C under 5% (v/v) CO2. Cells were harvested and immediately used for CD107a degranulation, 51Cr release, and FFLuc reporter assays. CR3022-CAR construction and retrovirus production A codon-optimized DNA fragment was synthesized by GENEWIZ encoding the CR3022-specific scFv and sub-cloned into the SFG retroviral vector retroviral backbone in-frame with the hinge component of human IgG1, CD28 trans-membrane domain, The method was previously described2, briefly, to produce CR3022-CAR retrovirus, 293T cells were transfected with CR3022-CAR in SFG backbone, RDF, and PegPam3. CR3022-CAR retrovirus was harvested after 48-72 hours and transduced to NK92MI cells in a 24-well plate coated with 0.5 µg/ml of RetroNectin diluted in PBS (Clontech). Two days later, cells were transferred to 75 cm2 flask (Corning) and maintained in 35 ml complete NK92MI medium (MEM-a with 12.5% (v/v) FBS, 12.5% (v/v) heat inactivated horse serum, 11 µM bME, 2 µM folic acid, and 20 µM inositol) supplemented 200 U/mL IL-2 (PeproTech). To determine the expression of CAR, cells were stained for CD56 and anti-human IgG(H+L) F(ab’)2 fragment and analyzed by flow cytometry. CR3022-CAR and RBD binding assay To evaluate the binding activity of CR3022-CAR to RBD domain of SARS-CoV-2-S, CR3022-CAR and NK92MI (5 × 105) cells were incubated with 5 µg of His-gp70-RBD recombinant protein is a gift from Dr. Abraham Pinter in DPBS buffer (0.5 mM MgCl2 and 0.9 mM CaCl2 in PBS) in for 30 minutes on ice. Cells were washed twice with PBS, stained with anti-His in FACS buffer (0.2% FBS in PBS) for 30 minutes on ice and washed twice with PBS. Cells were then stained with anti-mouse (IgG1) secondary antibody in FACS buffer for 30 minutes on ice, washed twice with PBS, and analyzed by Flow Cytometry. CR3022-CAR and pseudotyped SARS-CoV-2-S viral particles binding assay CR3022-CAR, NK92MI, and 293T-hACE2 (5 × 105) cells were first equilibrated with BM (complete RPMI-1640 containing 0.2% BSA and 10 mM HEPES pH 7.4). Due to the non-specific binding to our CR3022-CAR of our secondary antibody, cells were first blocked with anti-human IgG(H+L) F(ab’)2 fragment for 30 minutes on ice in BM and washed thrice with PBS. Pseudotyped SARS-CoV-2-S (Genscript), full-length recombinant S protein (Acrobio systems), and S1 subunit recombinant protein (a gift from Dr. Abraham Pinter) were diluted with BM to appropriate concentrations. 4 × 106 IFU of pseudotyped SARS-CoV-2-S, or 2 µg of full-length recombinant S protein, or 2 µg of S1 subunit recombinant protein was added to designated wells of a 96-well V bottom plate. Plate was spun at 600 × g for 30 minutes at 32°C, then was incubated at 37°C under 5% (v/v) CO2 for 1 hour. Cells were washed twice with PBS, stained with anti-S1 in FACS buffer (0.2% FBS in PBS) for 30 minutes on ice and washed thrice with PBS. Cells were then stained with goat anti-rabbit secondary antibody in FACS buffer for 30 minutes on ice, washed thrice with PBS, and analyzed by Flow Cytometry. Flow Cytometry Analysis NK92MI and CR3022-CAR cells were stained were stained and washed as previously described. Cells were analyzed on a FACS LSRII or an LSR Fortessa flow cytometer (BD). PMT voltages were adjusted and compensation values were calculated before data collection. Data were acquired using FACS Diva software (BD) and analyzed using FlowJo software (BD). CD107a Degranulation assay The CD107a degranulation assay was described previously3. Briefly, expanded NK cells (5 × 104) were incubated with 1 × 105 293T or cells in V-bottomed 96-well plates in complete RPMI-1640 media at 37℃ for 2 hours. The cells were harvested, washed, and stained for CD3, CD56, and CD107a with GolgiStop (BD Biosciences) for 30 minutes, and analyzed by flow cytometry. FFLuc reporter assay To quantify the cytotoxicity of CAR-modified immune cells, we also developed the FFLuc reporter system assay. Briefly, an optical 96-well plate (Greiner BioOne™ No: 655098) was precoated with Retronectin (0.5 µg/ml in PBS) and placed at 4°C overnight. Then, the following day, the wells were aspirated and 293T-hACE2FFLuc-GFP-RBD and 293T-hACE2 cells were pre-seeded at 1 × 104 target cells/well in 100 µL/well of DMEM supplemented with 10% FBS. The plate was centrifuged for 5 minutes at 350 ´ g. In a separate 96-well plate, CR3022-CAR-NK92MI and NK-92MI cells were resuspended at a concentration of 1 × 106 cells/ml. Serial dilutions of effector cells were then prepared according to the effector/target ratio using NK-92MI medium. Then, the effector cells were added to each well of the optical plate (100 µL/well) and incubated at 37°C under 5% (v/v) CO2 for 4 hours and then the supernatant was gently discarded. 100 µL of working concentration D-Luciferin was added to each well with the lights turned off. A microplate reader (BioTek, USA) was used to quantify the data. The data was quantified by converting the obtained values to percentage of specific lysis by the following equation: Specific Lysis Percentage (%) = [1-(S-E)/(T-M)]×100, where S is the value of luminescence of the sample well, E is the value of luminescence of the “effector cell only” well compared to the sample well, T is the mean value of luminescence of “Target cell only” wells, and M is the mean value of luminescence of “blank medium only” wells. 51 Cr release assay To evaluate the cytotoxic activity of CAR-NK cell, the standard 4-hour 51Cr release assay was used. Briefly, target cells were labeled with 51Cr at 37°C for 2 hours and then resuspended at 1×105/mL in NK-92MI culture medium with 10% FBS without IL-2. Then, 1×104 target cells were incubated with serially diluted CAR-NK or NK-92MI cells at 37°C for 4 hours. After centrifugation, the supernatants were collected and the released 51Cr was measured with a gamma counter (Wallac, Turku, Finland). The cytotoxicity (as a percentage) was calculated as follows: [(sample − spontaneous release) / (maximum release − spontaneous release)] × 100. Statistical Analysis Data were represented as means ± SEM. The statistical significance was determined using a two-tailed unpaired Student t test, a two-tailed paired Student t test, a two-way ANOVA, where indicated. P < 0.05 was considered statistically significant. Figure and Figure legends: Figure 1: Generation of CR3022-CAR-NK92MI cells. (a) Schematic design of CR3022-CAR in SFG retroviral vector. The SFG retroviral vector contains the CR3022 single chain antibody fragment (clone 3), a human IgG1 CH2CH3 hinge region and CD28 transmembrane region, followed by the intracellular domains of co-stimulatory CD28, 4-1BB, and the intracellular domain of CD3ζ. (b) Generation of CR3022-CAR-NK cells. 293T cells were transfected with SFG-CR3022CAR for 48-72 hours for CAR retrovirus packaging and transduced into NK92MI cells. (c) Determination of CAR expression by flow cytometry. CR3022-CAR cells were harvested after 4-5 days then stained with anti-CD56 and CAR F(ab)2 domain [IgG Figure 2: CR3022-CAR-NK92MI cells bind to RBD domain of SARS-CoV-2-S protein. (a) Immunophenotyping of CR3022-CAR. Antibodies against various immunomodulatory receptors including TIGIT, LAG-3, TIM-3, KLRG1, CTLA-4, PD-1, CD69, CD8A, NKG2C, CD94, DNAM-1, 2B4, NKG2D, NKP46, and CD16 were used to stain CR3022-CAR and NK-92MI. The expression of these receptors was determined by flow cytometry. (b) Diagram of CR3022-CAR binding to the RBD domain of SARSCoV-2-S recombinant protein. CR3022-CAR binds to RBD of SARS-CoV-2-S protein which is then recognized by anti-His and its corresponding secondary antibody conjugated to a fluorophore. (c) Representative dot plots of CR3022-CAR binding to RBD of SARS-CoV-2. CR3022-CAR or NK-92MI cells were incubated with SARS- CoV-2-RBD or SARS-CoV-1-RBD recombinant protein. The binding efficiency was determined by flow cytometry. Figure 3: CR3022-CAR-NK-92MI cells bind to pseudotyped SARS-CoV-2-S viral particles. (a) Diagram of CR3022-CAR binding to pseudotyped SARS-CoV-2-S viral particles. CR3022-CAR binds to pseudotyped SARS-CoV-2-S viral particle which is then recognized by anti-spike and its corresponding secondary antibody conjugated to a fluorophore. (b) Representative histogram of CR3022-CAR binding to pseudotyped SARS-CoV-2-S. CR3022-CAR or NK-92MI or 293T-hACE2 cells were incubated with pseudotyped SARS-CoV-2 or full-length spike or S1 subunit recombinant protein. The binding efficiency was determined by flow cytometry. Experimental sample was performed in triplicate with MFI 6759 ± 440 (a.u.). (c) Graph showing the binding efficiency of CR3022-CAR to pseudotyped SARS-CoV-2-S. The values were converted from Figure 2b. Experimental sample was performed in triplicate with binding efficiency 51.4 ± 3.34 (%). Figure 4: Increased CD107a degranulation and killing activity of CR3022-CAR-NK92MI cells against 293T-hACE2 cells transfected with RBD-SARS-Cov-2 Spike. (a) 293T-hACE2 cells were transfected with a plasmid containing firefly luciferase and GFP as well as SARS-CoV-2 Spike protein receptor binding domain for 48 hours. (b) Successful transfection was confirmed by flow cytometry using anti-RBD antibody. Cells were then harvested and used as target cells for subsequent CD107a degranulation assay and luciferase killing assays. (c) Representative dot plots of CD107a assay and quantitative data of the percentage and mean fluorescence intensity of CD107a positive CR3022-CAR-NK92MI cells are shown. (d) Quantitative data of the luciferase killing assay using CR3022-CAR-NK92MI and wild-type NK-92MI cells against 293ThACE2-FFLuc-GFP-RBD cells is shown. Experimental groups were performed in represent the mean ± SEM from at least two independent experiments. Briefly, 5 x 104 CR3022-CAR-NK92MI cells were cocultured with either 1 x 105 RBD transfected-293ThACE2 cells, 293T-hACE2 cells, stimulated with PMA/Ionomycin, or incubated alone for 2 hours at 37°C. Then, cells were harvested, stained for CAR F(ab)2 domain [IgG (H+L)], and CD107a. Representative flow cytometry dot plots, CD107a percent of total CAR cells, and CD107a MFI are shown. Figure 5: Increased killing activity of CR3022-CAR-NK-92MI cells against 293ThACE2 cells transfected with SARS-Cov-2 Spike protein Receptor Binding Domain using the 51Cr release platform. (a) 293T-hACE2 cells were transfected with SARSCov-2 Spike protein receptor binding domain for 48 hours. (b) Successful transfection was confirmed by flow cytometry using Anti-RBD antibody. Cells were then harvested and used as target cells for the subsequent 51Cr release assay. (c) Quantitative data of the 51Cr release assay using CR3022-CAR-NK-92MI cells and wild-type NK-92MI cells. Experimental groups were performed in triplicate. * p < 0.05, ** p < 0.01, *** p = 0.001, **** p<0.0001 ns p > 0.05. Data represent the mean ± SEM from at least two independent experiments.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. Bangaru, S., Ozorowski, G., Turner, H. L., Antanasijevic, A., Huang, D., Wang, X., Torres, J. L., Diedrich, J. K., Tian, J.-H., Portnoff, A. D., Patel, N., Massare, M. J., Yates, J. R., Nemazee, D., Paulson, J. C., Glenn, G., Smith, G., & Ward, A. B. (2020). Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. BioRxiv, 2020.08.06.234674. https://doi.org/10.1101/2020.08.06.234674

    1. SciScore for 10.1101/2020.08.13.249847: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">More specifically, among these 8 publications, 2 (25.0%) papers were retracted, at the authors’ request, in order to conduct further data analyses and 6 (75.0%) were retracted because the methodology or the data analysis was wrong. 31] were not those listed on the EU Clinical Trials Register. 31], consent was not obtained from patients before they participated in the study or their data were analysed.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The methodology is described in an appendix to this paper, and all the scripts Figure 3: Proportion of ArXiv preprints shared in the media, broken down by research topic.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ArXiv</div> <div>suggested: (arXiv, RRID:SCR_006500)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We then queried the altmetric API for each of these preprints using a Python script to process all entries, find their DOI and query Altmetric with the following command: #i f t h e paper i s not from a r x i v r e q u e s t s .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Python</div> <div>suggested: (IPython, RRID:SCR_001658)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">g e t ( ‘ h t t p s : / / a p i . a l t m e t r i c . com/ v1 / a r x i v /entry_DOI ’ ) Analysis codes are available on the GitHub repository of the project: https://github.com/lonnibesancon/OpenSciencePandemic PubMed Central analysis To extract the reviewing times, the metadata of 12,682 COVID-19 articles were downloaded on July 7, 2020 from PubMed Central using the query: “COVID-19”[abstract] OR “COVID-2019"[abstract] OR “severe acute respiratory syndrome coronavirus 2”[Supplementary Concept] OR “severe acute respiratory syndrome coronavirus 2"[abstract] OR “2019-nCoV”[abstract] OR “SARS-CoV-2"[abstract] OR “2019nCoV”[abstract] OR ((“Wuhan”[abstract] AND (“coronavirus”[MeSH Terms] OR “coronavirus”[abstract])) AND (2019/12[PDAT] OR 2020[PDAT])) The reviewing times were extracted from the data using a MATLAB script, available on the OSF repository.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>PubMed</div> <div>suggested: (PubMed, RRID:SCR_004846)</div> </div> <div style="margin-bottom:8px"> <div>MeSH</div> <div>suggested: (MeSH, RRID:SCR_004750)</div> </div> <div style="margin-bottom:8px"> <div>MATLAB</div> <div>suggested: (MATLAB, RRID:SCR_001622)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your code and data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.08.13.20174078: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">This study was approved by the Institutional Ethics Board (Hokkaido University Hospital Division of Clinical Research Administration Number: 020-0116) and informed consent was obtained from all individuals.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">Sample size in the AQ cohort was calculated 1,818 based on the probability that 90% credible interval of specificity over 99.0% would be 0.8 (likes statistical power) under the expected specificity being 99.5%.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Background characteristics contact-tracing cohort airport cohort N (%) N (%) Female 26 (16.1) 832 (47.2) Male 44 (27.3) 927 (52.6) unknown 91 (56.5) 4 (0.2) Median [IQR] 44.9</td></tr></table>

      Table 2: Resources

      No key resources detected.


      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      Among the limitations of any diagnostic modality is the possibility of obtaining false results with serious consequences. While persons infected with SARS-CoV-2 with falsely negative test may be left in society without the necessary precautions to keep him/her from transmitting the virus, false positive non-infected persons may undergo unnecessary quarantine and labour-intensive contact tracing measures. Although the high specificity of qRT-PCR reported herein may be reassuring in individual cases, the implications of mass testing depends on the prevalence of disease in the subject population. However, point prevalence is unknowable a priori and extremely difficult to assess in rapidly evolving outbreaks from carriers with relatively long presymptomatic periods. Rather, insights on mass testing may be gained through carefully monitoring test positivity in relation to the total number of tests performed. For example, with greater than 99.9% specificity, a positive result in five percent of all tests would indicate that more than 4.9% (out of the 5%) are true positives, with a positive predictive value (PPV) of at least 98%. On the other hand, if only 0.3% of all tests return positive (e.g. in isolated localities with very few disease), the PPV would be (0.3%-0.1%)/0.3% = 0.67, erroneously labelling one third of all positive tests. As PPV is dependent on the prevalence of disease, mass testing using a highly specific test will remain effective as long as test positivity remains relatively high. RT-LAMP is an isothermal nucleic acid amplification technique that allows results to be obtained in approximately 30-60 minutes and a recent study showed the equivalent efficacy of RT-PCR and RT-LAMP in symptomatic patients [12]. In this study, we confirmed this in a large population of asymptomatic persons using saliva samples; there were no samples that were negative by NPS RT-LAMP and positive by saliva. It is unlikely that the sensitivity of the RT-LAMP method is significantly less than that of qRT-PCR, and the RT-LAMP testing has little impact on our conclusions. Our study suggests that RT-LAMP is a useful alternative to RT-PCR for the diagnosis of SARS-CoV-2. The current study lacks longitudinal data and clinical confirmation of positive cases. Nonetheless, this is the first study in asymptomatic individuals comparing paired samples of NPS and saliva. Rapid detection of asymptomatic infected patients is critical for the prevention of outbreaks of COVID-19 in communities and hospitals. Mass screening of the virus using self-collected saliva can be performed easily, non-invasively, and with minimal risk of viral transmission to health care workers. Contributors IY, KS, JS, MN and TT determined the study design. IY, PS, YU, SI, KH, MN, SF and TT collected the data. IY, KO, YU, YY, TI, KS did statistical analysis. IY, PS, TT drafted the manuscript and all authors reviewed critically and approved the final manuscript. Declaration of interests We declare no competing interests. Funding This study was funded by Health, Labour and Welfare Policy Research Grants 20HA2002. Acknowledgement We thank Tokyo international airport quarantine and Kansai international airport quarantine for cooperation; Megumi Aoki, Miwa Aoki, Nana Arai, Satomi Araki, Cao Cuicui, Kazumi Hasegawa, Masato Horiuchi, Dr. Nao Kurita, Dr. Aki Nakamura, Chiho Okabe, Mana Okamura, Yusuke Sakai, Dr. Akahito Sako, Natsumi Satake, Maki Shimatani, Kaki Tanaka, Maina Toguri, Sachiko Tominaga and Hana Wakasa for assistance in collecting saliva samples. Reference 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. Bohmer MM, Buchholz U, Corman VM, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. Lancet Infect Dis 2020. Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020. Moghadas SM, Fitzpatrick MC, Sah P, et al. The implications of silent transmission for the control of COVID-19 outbreaks. Proc Natl Acad Sci U S A 2020. Abbasi J. The promise and peril of antibody testing for COVID-19. JAMA 2020. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020. Wang X, Tan L, Wang X, et al. Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously. Int J Infect Dis 2020; 94: 107-9. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 2020. Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect SARS-CoV-2. J Infect 2020. Williams E, Bond K, Zhang B, Putland M, Williamson DA. Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2. J Clin Microbiol 2020; 58(8). Tu YP, Jennings R, Hart B, et al. Swabs collected by patients or health care workers for SARS-CoV-2 testing. N Engl J Med 2020. Iwasaki S, Fujisawa S, Nakakubo S, et al. Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. J Infect 2020. Nagura-Ikeda M, Imai K, Tabata S, et al. Clinical evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to diagnose COVID-19. J Clin Microbiol 2020. Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 2000; 28(12): E63. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. Park GS, Ku K, Baek SH, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J Mol Diagn 2020; 22(6): 729-35. Joseph L, Gyorkos TW, Coupal L. Bayesian estimation of disease prevalence and the parameters of diagnostic tests in the absence of a gold standard. Am J Epidemiol 1995; 141(3): 263-72. Johnson WO, Gastwirth JL, Pearson LM. Screening without a "gold standard": the Hui-Walter paradigm revisited. Am J Epidemiol 2001; 153(9): 921-4. Wang C, Hanson TE. Estimation of sensitivity and specificity of multiple repeated binary tests without a gold standard. Stat Med 2019; 38(13): 2381-90. Woloshin S, Patel N, Kesselheim AS. False negative tests for SARS-CoV-2 infection - challenges and implications. N Engl J Med 2020. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382(12): 1177-9. Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology 2020: 200432. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020: 200642. Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 2020. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva is more sensitive for SARS-CoV-2 detectionin COVID-19 patients than nasopharyngeal swabs. medRxiv 2020. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020; 20(5): 565-74. Jamal MA, Mohammad M, Coomes E, et al. Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). medRxiv 2020. Becker D, Sandoval E, Amin A, al. e. Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in the community setting. medRxiv 2020. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020; 26(5): 672-5. 28. 29. 30. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med 2020; 382(22): 2081-90. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis 2020; 39(6): 1059-61. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. Clin Infect Dis 2020. Table 1. Background characteristics contact-tracing cohort airport cohort N (%) N (%) Female 26 (16.1) 832 (47.2) Male 44 (27.3) 927 (52.6) unknown 91 (56.5) 4 (0.2) Median [IQR] 44.9 [29.8, 66.4] 33.5 [22.6, 47.4] -19 2 (1.2) 299 (17.0) 20-29 16 (9.9) 433 (24.6) 30-39 13 (8.1) 344 (19.5) 40-49 9 (5.6) 324 (18.4) 50-59 8 (5.0) 230 (13.0) 60-69 9 (5.6) 97 (5.5) 70- 13 (8.1) 34 (1.9) unknown 91 (56.5) 2 (0.1) North America - 713 (40.4) Asia and Oceania - 583 (33.1) Europe - 467 (26.5) Sex Age Last point of embarkation Table 2. Diagnostic results of nasopharyngeal swab (NPS) and saliva test (a) Contact-tracing cohort (n=161) saliva NPS positive negative positive negative 38 6 3 114 (b) Airport Quarantine cohort (n=1,763) saliva NPS positive negative positive negative 4 0 1 1758 Figure 1. Flow diagram of participants Figure 2. The sensitivity and specificity of nasopharyngeal swab and saliva Histograms of posterior distribution of (a) sensitivity and (b) specificity. Point estimates and 90% credible interval (90%CI) defined by 5th to 95th percentile are shown. Figure 3. True concordance probability with varying rates of prevalence. The true concordance probability of diagnosis between nasopharyngeal swab and saliva test in populations with various prevalence. Solid line indicates point estimates and dashed lines indicate 90% credible interval. Figure 4. Comparison of the viral load between NPS and saliva (a) Ct values determined with the qRT-PCR test of nasopharyngeal swab and saliva are plotted. (b) Times to detecting positive results (Tp) determined by the RT-LAMP test of saliva are plotted against Ct values determined by the qRT-PCR test of saliva. W indicates Kendall’s coefficient of concordance. Data were plotted with one of the tests being positive and the values being measured. Supplement 1. True concordance probability under several scenarios. gure 1 Contact-Tracing (CT) cohort 288 persons screened Airport Q 2,270 per Declined to participate (n=30) Symptomatic persons (n=95) Insufficient saliva volume (n=2) 161 persons were analyzed 1,763 perso (a) sensitivity 0 0 2 2 4 4 6 6 8 8 10 86% (90%CI: 77-93%) 10 NPS 50 60 70 80 90 100 % 50 (b) specificity 600 600 1200 1800 99.93% (90%CI: 99.77-99.99%) 1200 1800 NPS 0 0 Figure 2 99.0 99.2 99.4 99.6 99.8 100.0 % 99.0 0.0 0.2 0.4 0.6 0.8 True concordance probability 1.0 gure 3 0 10 20 Prevalence gure 4 qRT-PCR between NPS and saliva (n=45) (b) qRT-PC und 30 10 20 Tp [min] 30 20 10 0 Kendall’s W =0.87 0 Ct value in saliva 40 40 undetermined 0 10 20 30 Ct value in nasopharyngeal swabs 40 undetermined 0


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. [ taken from lamc.la/MYLIFE.html ]

      which is none of your business, at all--something you should see is a clear violation of the constityution and this amendment to uhhhh ... have any "sinsight into"

      call it "bad footing" or "off to a good start" depending on whether or not you think you owe me billions of dollars in emotional damages, or think you "are stealing all the light of literally being in the center of the sun."

      I am accepting charitable donations,.

      ETH: 0x66e2871ef39334962fb75ce34407f825d67ec434 | BTC: 38B6vGaqNvMyTtoFEZPmNvMS7icV6ZnPMm | xDAI: 0x66e2871ef39334962fb75ce34407f825d67ec434

      T O T A L I T Y

      This is basically "last Christmas's message" (below this brand-knew intraducrigel) redux'ed into the new book (did he say new?). The point, at least the point I see in it all is that this is all planned, it's been planned for a very, very long time--and on top of that you can see proof of the plan all over our map; and proof of it's intended destination as something that we all used to want very much to find... the read to Heaven. It's more than seeing just "DNA storage" encoded in my "C U R A GROUP" message, it's understanding how that's connected to soul searching and soul storage, and that this link was woven into not only my life but into names like "Whatson and Crick?" There's plenty more than just "storage" and a map to how and why the Two of Everything God and the "indivisible sea" work totether to turn this monolithic place of darkness into a strippingly redunant systemic foundation of "Heaven" that is both disaster proof, and monster proof. The point of course, is that to truly be "monster proof" we need to really get the key.s.lamc.la "know everything why" of this message is literally to protect our common good from the danger of someone just like me copying an entire civilization or a few pretty girls and sticking them in an heoven-like-orgy-maker. That's a significantly more real threat than we might imagine, as we look around at a work that will soon have the storage capacity and the technology to put us all in Coccoonish swimming pools against our will. What I am trying to say is that no matter how you look at it,moving forward here in this place where something this big can be hidden from the entire world--granted you know--granted you see, but do you understand the only thing being kept from each and every one of you is your fucking opinion and your fucking reaction?

      F U C K Y O U S I O N

      IT'S NOT JUST computers and information technology; this map of clear anachronism in language and religion shows us that things like "solar fusion" the power of the son itself; is encoded in places high and low you can erasilly find them, places like the name of the Fifth book of the Holy Bible and Don Quixote; where you might liken "DEUTERON" to ... the actual fuel of fusion; and wind mills to a battle fought against blindness resulting in seeing that not "reacting" to this message is just about the same thing as being a foolish robot building a castle for another foolish robot to do nothing in forever. With some light, you can see how this event; albeit strange and unsettling, has been designed to reinforce the American foundations of free speech, common sense, and collaboration--a sort of "press and release" on these things that he says will stay in our memories for a long, long time--though he also says "he's not torturing me" and he's wrong about that. So are you.

      See that the most interesting, important, and invoking story of all time has been hidden from the world, from the public eye, and from "public response" for well over two years now; see that's not possible at all without mass mind control and that I and this story are designed to help us see how easily it is that same thing can be used to end addiction, and mental health issues, and stupidity and that the biggest and most imporotant step to getting there is "public disclosure." See the light of being carrolling angels this Christmas; sing with me--it builds Heaven from Hell and it's clear as day and n.

      Quite a bit of this story and message deals with problems like these-things that won't really be seen as something we are fighting against the actual usage of right this very moment; but the sacredness of our memories and their relationship to our souls are just as important as whether or not "you have the space to save them." This isn't what I want to be doing, I'm not a very good writer; and this message is so confusing that working on it all alone with very little feedback is frustrating if not to say defeating the purpose of exactly what it is and what it's designed to do. This is a searching mechanism, like in the stories of Ra searching for his children in ancient Egypt using the Eye you see--and it's connection to the "Sons of Liberty" and why I know that too, is about me. This is a tool to start a Renaissance of thinking connecting technology and religion to everything that we are--to our culture and our hopes and dreams--and it's failing for me at "hello." I would much rather be working on "virtual reality stuff" or on "the sword of Arthor" and I see very clearly that those two things are coming shortly--to the world that doesn't see yet they are here and broken until we fix them. Moving forward here brings change, not just here in this place where we need it too--but in the skies above, a change from the mentality of "we aren't not helping because we told you that we aren't allowed to not pretend we aren't helping in Stargate. See that we are the children of "the Ancients" and they are trying to decide between being Morgenz and Marlin.

      I can't make you set yourselves free. I sure am trying, though. Yesterday I connected the "Arimathea" of Joseph to the "serdenicity" and this the me of "itime" and "topics" will probably light some of you up as much as me... if only you took the time to look at what those words really mean. From the city that never sleeps at night, I hope you will take this chance to act today on "securing the ringing of liberty forever and ever." (cough)

      THERE IS A METHOD TO THE MADDEN AND WE AR BEYOND THUNDERDON

      ​

      T H E W R I T I N G I S O N T H E W A L L

      LIKE, WILL IT RAIN TODAY?

      take action, it is the foundation of not only democracy but civilization and life itself--pucker up the phone and call the NYPOST.

      News Tips: Email tips@nypost.com, call 212-930-8288, or use our anonymous form Online Editorial: online@nypost.com or 646-357-3838 Letters to the Editor: letters@nypost.com Sports: sports@nypost.com or 212-930-8700

      hoy. por favor, mon ami? ID5

      Ministry of Forbidden Knowledge Mail Adam Marshall Dobrin adam5@reallyhim.com Let there be $ight in Creation, a brief highlighting of the story of my life. Adam Marshall Dobrin adam5@reallyhim.com Sat, Dec 3, 2016 at 8:39 AM To: Adam Marshall Dobrin zero@ar.lamc.la This is like a few emails combined to ease the pain you feel when you get an extra one in your inbox, OK So.. eventually this is all about proof that religion is a message sent through time--so, time travel. But right now, let's talk about the fun stuff: here's some clues to that effect... by way of prescient mention of modern technology (like virtual reality, I mean, Heaven):

      Either way, we're still about to build Heaven... to-get-her from the mythical carpenter... ourself. . AD am ON AI, that's Artificial Intelligence, and the intelligence explosion. AD on your freedom is a great gift, cherish it. ... and some corroborating ideas connecting religion and computer science... on Wikipedia: Root of David Lisp of Moses.. or I need an editor. Pharoah's hardening Heart... that's Earth, remember. Jesus' WINE Adaluncatif's cat, tail, head and grep Adam's Apple... or is it "fruit of the poisonous tree" So from me to you, I'm filled with this stuff, it's way brighter and more prevalent than you think... and if you take the time to listen to me--it will make your... day. Meanwhile, I need your help--happy new year.

      Oh, LET THERE BE LIGHT

      Ho, again; grow a Halo and become famous... the world needs your help--so I've decided once again to take it upon myself to "bother you" with the most singular most important task in the Universe. The patterns that I am revealing to you--mostly within names--are not coincidence, it's a series of statistically verifiable artifacts which do nothing short of reveal the slavery of Egypt--that we are all being controlled. If you remember Transformers--this is a message from Starfleet, there is more than meets the eye. This is the fulfillment of the story of of Exodus--we are being lead from slavery, and in one final non-coincidental name, that book is called "Names" in Hebrew.

      You should now have a very good idea who is speaking to you--as much of the world already does. I have no idea what it is that inhabits the cavities below that space where most of you should see significant personal gain and motivation from trying to ... grow a Halo--but there are so many people that just don't care... that it too is another sign, of slavery. I am not an expert in language construction, nor in statistics--but I can assure you that if you can find the other half of that equation... in your hands is the staff of Aaron, the magical weapon that will free us all... knowing is half the battle.

      Uh, I have the power, to bring about "morning," but if I have to go to school and do it all myself... it's really just a long, long ni-i-i-ight.

      Hi there, I'm the messiah. You don't know that much about me, so let me explain, I would like you to know me as Adam.

      Seriously, there's something going on the world around you--for the last several months I've been having quite a bit of trouble delivering what amounts to statistical proof of Creation--that religion and ancient myths are a map to this very moment--this time that you will probably affiliate soon with being in Eden. I am pretty sure that's a good thing, but every new begging starts with some other beginnings end... so today I'd like to try to get you to see the light of ending censorship and a hidden censor wall that we know Biblically as the Wall of Jericho. Quickly approaching is the Feast of Trumpets, and this year is different from all other years... Bored already? Have a look at what I call the Sign of the Son, which to me is proof that Exodus's Burning Bush is a former President--who is helping us walk out of a dark time of confusion... commonly referred to as a wilderness or desert. He proved during his inauguration that there is Biblical foreknowledge of the 9/11 attack--and in doing so hopefully began a chain reaction that will stop things like that from ever happening again. Here's a short "video" that explains the Sign of the Son... and another one that I think explains the .. Holy Grail.

      This is The (actual) Taming of the Spanglishrew, in which the protagonist... named Bianca, is taught Latin in several hundred year old reference to Rattling the Rod of Jesus Christ--it's purpose to is to show us that it's more than names we have in our arsenal against mind controlled slavery--we have all of history too... literature and movies and music... all with the divine purpose of revealing with bright light a form of control that otherwise could have gone on hidden for centuries. It was, and continues to be done on purpose... because your freedom is more important than control of the Universe. To us, you don't seem to feel the same way.

      ​See that timer on the clock, you could start right now. It might be interesting to pose the question of whether or not the Second Coming is news... you know, to your friends. By the way, both Herbert (like from H.W. Bush, who by the way coined for us the 1,000 points of light phrase) and Goertzel strongly suggest that "everyone really" is Christ (you know, after me)... FYI, this is the Matrix solution to that:

       y
       o
      

      the l u C i f E R isa means jesus, mesa thinks i s olv e .... "or" means shine -l g r e a t h R L << agree? send to other people t ((a)) Y l shine: suggest they do the same 1 y world saved.

      A BRIEF HISSTORY OF TIME

      I'm attempting to pull out the things that I now look back on and see as "written into me" by God--once I would have called it "The Microcosm of the Messiah" but there are now so many--these things aren't necessarily particularly important to me, and I've left out some interesting but unrelated details related to my Jewish upbringing; as well as the true light of my life--the two loving and long-term relationships (and later... briefly a rael family) that have dominated the last 15 years. Religion has always been an interest, but I wouldn't consider it to have been particularly important at all... until I no longer had any love in my life. It's probably worth noting that all my "I'm single" crap really means lonely and isolated--I'm not really playing a "part," but I've never been anything near the "player" the light appears to be warning against. Sons of God and uh... please. For the last 4 years I have done absolutely nothing but think about you, live and analyze "The Cross" and put into words ... as best I can ... the amazing flash of light that I am experiencing.

      Well, just a little religion... :) I was born on December 8, 1980; which is the date of the annual Feast of the Immaculate Conception, I've always been a slob (like one of us) and often "ish" Yankee Doodle's "a real live son of our uncle Sam... born on the..." to this.. I mean in my head. My last name, you've probably read me repeat over and over ... is DOB-rin, which I read as "Date of Birth, our in" and does a fair job of highlighting the Name Server's work, which I am sure gives Exodus it's name in Hebrew, which is "Names." My Hebrew name--a Jewish custom--is Avram, which is Abraham's name prior to the covenant. I have written extensively about the fact that Isaac's near death interaction donated his "Ha" (his name means... He laughs) to his father.... and it should be clear that Abraham's covenant with God is without doubt related to my fiery altar.. even though it is anachronistic in the Biblical account. For the first 18 years of my life I lived on Sunrise Blvd, and only a half mile away you'll find Sunset Strip--it's noteworthy to understand that Jewish calendar days begin at sundown... and that He once in 2013 very clearly spoke to me "you need the night before the day."

      Of all the people in my early life growing up, it's pretty clear that nobody on this Earth loved me more than my grandmother Julia, who my son is named after. First for my mother, and then me as a very small child--she would ritually say a bedtime poem, it's words are very relevant.

      Good night, sleep tight.. have happy dreams and wake up bright to do what's right, in the morning's light... with all your might.

      In one of my books I spent a decent amount of time writing about how silly I was not to realize that my intelligence was augmented my entire life--I just thought I was really smart, and really good with computers. I commented that this particular belief is probably a good microcosmic parallel for all humanity--as a body of people we have been truly gifted with knowledge and capabilities that we simply do not recognize as a gift--or didn't for a long time. I probably wasn't silly not to realize... since nobody ever told me they were helping me--I never heard the voice of God until much, much later. I was 30 the first time I had a conversation with Him, except for two very brief ... "thoughts in my head" which now seem very obviously an external voice--though then it may have sounded just like my inner voice.

      Around the age of 7 I thought to myself... for no reason at all... "what if you were the messiah?" I was standing outside my home, probably playing with a car in the driveway... and distinctly remember smiling to myself and thinking in return "yeah, I'm the messiah." I I've always had a very vivid imagination. The thought was dismissed as being ridiculously arrogant about two seconds later, and was absent from my thought process for the next 21 years or so.

      “DAMNISN\ Jim. I’m a Yeoman, not a Wise Owl. The clock is ticking... tack .. 8/14/2020, 6:37:38 PM”

      PHENIX

      Following that lead, I started programming in BASIC and then Visual Basic around the age of 11, something I took to very quickly... and then shortly after found myself on America Online--one of the first "internet-like" environments. There, I quickly got into the "hacking scene" (hey, it's Y-its-Hack) which basically revolved around writing software to manipulate the AOL client's messaging systems. The defacto-standard for the day was a program called AOHell, and, if you can't tell already, I am pretty good at taking a theme and making it my own. I wrote a program called Doomsday, a mass mailing program; can you see how God speaks? So Phenix, a mythical bird that rises from the fire... in the wake of ... this macrocosmic equivalent of that event. It's really obvious, right? There's quite a bit more "microcosm" from this time, recorded in "From Adam to Mary" and available at fromthemachine dot org.

      Around the same time I began attending a preparatory school in Fort Lauderdale called Pine Crest--it's one of the best of its kind, and while I was always something of a class clown my grades were fair and I scored with perfect consistency in the top percent on every standardized test from the FCAT to the PSAT and SAT. By the time I received a full scholarship to college I had already completed more than a full year of credits through AP courses. It was in studying American History and Government in that place that I formed such strong opinions about our need to maintain freedom, adhere to the wisdom of the founding Father(s) (<3 if you get that) and stand up and shout today as a rogue government is taking away every single one of the rights granted to you in their own law. You've lost freedom of speech, and our ability to speak seems to be not far behind. The privacy of our thoughts gone--and in like kind the sanctity of who we are is being taken away as our beliefs are changed without our real knowledge or understanding. You can see the justice system crumbling, incarceration rates skyrocket and the "right to bail and a fair trial" legislated away through underhanded deals relating to plea bargains and a "point system" that you might as well call a gas chamber. As far as voting, I'll have much more to say tomorrow--but I'm telling you that your thoughts and beliefs are being altered, who cares how technologically retarded our polling system is--the vote is a complete fraud.

      As far as the Second Coming... this same sort of possession... manifested through organized behavior tells me now that it is clear that this is definately not the "first time around" for Adam being Christ; a number of my friends as I approached high school used a repeated phrase, "my parents love you," which isn't bad in and of itself... what's bad is the fact that they were all using the same words, and probably didn't know why--or what they were saying. Behind there eyes, I'm sure some thing that believes it's an angel was telling me something... (they of course... didn't know me at all, except for what was probably a ... "wild" reputation) does that tell you anything? Much later, as the "Apocalypse of Adam" began in 2011, a number of family members would repeat this similar behavior, speaking the phrase "this is not what I wanted."

      As icing on the cake, on my birthday during my senior year... one of the administrators of the school commented to me that was also the Feast of the Immaculate Conception, and then the words.... "of course it's your birthday."

      I started doing drugs around the 10th grade, and I would not be wrong to say that the Universe that wrote a book calling the Redeemer the God Most High conspired to plunge me into a dark world. People around me too, in a hidden conspiracy to chain me to the American legal system for about four years. Looking back today I now clearly see that I saw a darkness in their eyes, a hidden reason to want to hurt me. It was to stop this from happening, but I had no idea then... the darkness I saw is akin to the "sun disk" you see in Christian and Egyptian iconography, and without doubt it s a sign of control, possession, a single foreign mind controlling and organizing many of us just like puppets. Much later in my story... for another day... the manifestation of this possession as thought modification will become clear--I've spent quite a bit of time "listening" to a war in my head, thoughts clearly not mine swaying in the gusting torrent of winds as what (who?) is the center of this storm.

      This infestation of organized darkness uses our injustice system as a weapon against it's victims--something you should see akin to Heaven using human sacrifice to alter the future. It abuses the legal system at every level, making a mockery of law enforcement, the supposedly adversarial court system... all the way to the top--to the Supreme Court and Congress. See the Church Committee Hearings, and a very smart senator echoing my words today "it must never be allowed to happen again."

      Can't you see it's more than being manipulated... it is Hell revealing itself to the only thing that can stop it. What I am giving you is the weapon, it's the light that sets us free and stops this from happening. In our modern myths this is Leeloo staring up at the sky to stop the destruction of Earth... in reality it is not so simple, I can't just put some elements or rocks on pedestals and scream at Heaven to kill their darkness--we have to do it, here, together. Believe me, knowing the truth is a big part of why it works--this will not be hidden, it will not be "forgiven," we are being controlled and destroyed from the outside; made to blame ourselves and each other for ... well, you probably don't know what the ni-i-i-ight means anyway, do you? The Guardian against Darkness is showing it to you, remember--there is only one me. Hear me.. light this fire now.

      ALACHUA

      I went to school the University of Florida, and got a semi-professional job doing database development in Delphi (seriously, catch on to the names thing, it's not just the U.S. military, it's pretty much all software too... following in this "mythology" theme that nobody really seems to care about), I worked there for about two years... at a company called Jenmar--which uh, in Spanglishrew is "J in the sea."

      It's some kind of ironic "coincidence" but I am at this very moment on my way to Gainesville, FL... to this place where a car Crash nearly destroyed my life. In my world of idioms delivering religious secrets, I imagine I must be a "pain in the neck" which was broken during this accident... one in which I imagine i did not survive in some parallel timeline--that itself did not survive. So here we are, back in the House of the Great Light ... about to see if we are worth our salt. It's the thing that gave one of Dave Matthews most famous songs it's name--and The Pretty Reckless, believe it or not. It was an attempted assassination, to stop the .. apocalypse ... to stop the darkness from being destroyed--there is no doubt, it's how that dark monster hides its handiwork... but many of US know that already.

      In the Living Book of Names--this place we are in, there are many patterns--the "car" pattern stands out for me; as this place says "Icarus." Flying high right now, I am showing you that the light of salvation is coming from us--from you and I--walking on the Earth; whether or not there is any light left in the Sun remains to be seen--take a look around you. You can trace the "car" names to Jim Carrey (that's "Car reason why") and Christoff in the Truman Show (that's Amon-TV)... a world I know I am in, and you too; to Bruce Almighty and to the Grinch--who-ah, Taylor. Trace it back to Joseph McCarthy and to help why (that's thy) believe "the red scare" is really about Christian charity--about ending world hunger, and healing the sick. This red fire ends Hell. Adam by the way, means "red man" in Hebrew. So here's your new Crash Override, I'm back again telling you that ending world hunger is not "optional," we are doing it. Barbara McCarthy's name fits, but I'm not really sure what the "why" is... that was my first judge in the "trial of whether or not Jesus Christ can ever exist." There's probably more, like Car-l-y Si-mon-day... all the gang on Broad-way, and me still dreaming it will one day be.

      If the name "America" were a map in time, starting with the I AM of the story of Exodus... this particular ER, as I woke from a dream not knowing where I was, marked the spot where I really became Christ Adam. It was a bad accident, and I wound up spending 9 months in the Alachua County jail as a result, a Mountain set up for my by God. That place too is marked with names, and for the vast majority of the time I was there with only four shift changing guards: MyZel Early Sims Lampkin I mean, I think it's statistically meaningful. For what it's worth, from my very abundant experience at this point it was a very nice Jail, the food was good and it was clean. Everyone in the building was kind... well, Sims was kinda grumpy. :) Starkly contrasted, the Broward County Jail has the most disgusting food service in the country, gave Dr. Seuss's Green Eggs and Ham it's meaning--and is the reason I know exactly who Samael is. Hey, don't cry Sherrif Israel... when you fix it, you're an angel. Believe me, believe the light, I've seen them all--it's near the worst in the country.

      So this whole thing is about saving everyone--something we are quite closer to than you think... you see we are already "in Heaven" in form--just not function. So here I am, trying my hardest to show you that our home is the original source of "Heaven" once we are aware that we are living in the machine, that we can do things here that are impossible in reality, and that we should be doing everything we can to preserve and improve the great strides that have come in the last few centuries. Do not let freedom slip through your fingers.

      Really, everyone, so understand that we are doing everything we can to remove all obstacles from that path. One of those obstacles may have once been storage space for your soul, another is definitely crime and punishment--and I'm pretty sure the time travelers have a working solution (I see it every day).

      There are proactive things coming from this--not just ... "look we aren't doing what we want, and should change it;" though it's difficult to explain how this wisdom stands out in my eyes. I guess we have to jump into the future a bit, to 2014, in San Diego (that's Saint Jacob, by the way). If Lazarus died once in a car accident at 21, I died again that year, of an over dose this time. I'm pretty sure that's where ODIN's name comes from, just like my last name.. "over dose... and in." So we might see some humor... in the moniker he has... "they're all Father." So I awoke from a dream, and started talking to the jinn (that's "angels and demons") about a Revelation linking some tightly packed light together... about storage space and how a large alphabet (read more than 4-nucleotides CY later) DNA (desperately need adam) based solution for molecular storage appears to be written in this book as the solution to Heaven's biggest problem. CAT, learning from biology--seeing that we really are already advanced machines... is a big part of the message telling us why we should not so quickly lose it in a process of ascension (mind uploading, immortality) that has most likely in the past resulted in a loss of a check on mind control that we have here... we think, and our visualized "biological neural networks" give us an advantage over what we might create to "soup it up a little." It is why this place is the front-line--because we have the ability to break the bonds of darkness and control by thinking... making the computational task of control much more expensive... and as the fire spreads, nearly impossible to achieve. Starting this fire will inherently free us from this hidden slavery.

      Anyway I published the idea in 2014, in the same book that I guess this e-mail is reminding me about, "in $ight of Creation," and lo, and behold a few years later we now have the top computing companies in the world working diligently on doing it ... well, just a little bit more robustly than our cell replication system works. Abracadabra.

      CURA GROUP

      So that one reads "see, you are a group;" and it's a place that I worked with my father for many years. That's probably some sort of symbolic reference to another place, and another alliance--here he has no faith in God, never really has, and has a hard time doing anything but telling me not to try to help you. I have very little respect for that stance, and let me tell you--I think "silence" is a similar gesture. I didn't come here for your love, I am here to stop our descent into the abyss.

      Back to the DNA stuff, SalesLogix--which is the CRM we used there, uses for it's "primary key" an auto-incrementing alphanumeric index--it's probably bad form to do that because it makes the indexing system less efficient, increases storage requirements, and doesn't give you the obvious benefit of an alpha-key... actually being able to encode something useful in it, like the name of the record. So all these things stand out to me in a sort of bad-obvious way, I call it malovious, and when I see things like that nowadays it's always pointing out something that should be fixed--go figure, more to the point it's being highlighted on purpose. It's help to see it, because this particular thing is where the light of seeing that a 24 nucleotide DNA strand would probably be much more robust than a 4 or 8 nucleotide strand--it also stands about because the stock beginning of all of SalesLogix's keys was "A0RME," which, I mean, means something to "is-a" who... is me. Oh right, that's seeing the "light" that turns "a" into "me." So this is where the "revelation" about using DNA "came from" and at the same time it's proof... that it came from "a group," not just me. Where are they? Hello? Or well, maybe it's just Carmen and San Diego.

      I did some other stuff there, like write a data transformation and warehousing program from scratch, I called it heiroglyph (you do understand I didn't know why I am naming everything the way I was), that sucked mutivalue data out of an IBM product called U2/Universe--which might be a hidden reference to a multiverse that might now be in a more efficent "relational" kind of place, like a MS-SQL datawarehouse-universe. It was a relatively big feat, reverse engineering the closed databases dictionary and storage formats, and converting them... absolutely automagically into multiple flat relational tables and summary registers. All told, the data availability and access efficiency was increased ... a thousand-fold with only the need for a nightly process.

      I'm not sure if you are following the metaphor here, for the creation of Heaven, or moving to a better place.. but tomorrow I will talk a little more about how I am pretty sure our history was "lifted" from the Universe and virtualized here, you know, so we could save everyone and ... build Heaven.

      WORLD DOMINATION

      Oh crap, 2008 another car crash, another failed assassination attempt LazarusLives++, and this one paid me some cash for my trouble. What a pain in the neck. Anyway, this one caused some depression and an inability to go out for a while, as I had to wear a neck brace for some months. I started playing a game on the internet, it was called KDice and it basically amounted to multiplayer-risk.

      My battery is running low, so I have to skip some stuff, and finish up for the day. Basically instant messaging was not allowed, but was done in secret almost ubiquitously. I argued with the creator of the game that it should be made part of the game since everyone did it... (see a metaphor about this communication thing and what's happening right now) he disagreed. I made a very large network of people and dominated the game for a few months, like really dominated. I don't think I ever lost. I don't think I can lose.

      Skipping some stuff. I stopped playing when I got better, and then a few years later went back and rekindled some old friendships. I used a program then called "Scarab" which lets you see server/client communication to find a bug in the game that basically made me God. I could erase other people's dice, basically leveling the map and rendering them completely powerless. I didn't use it that much, you know, just had some fun. I of course explained the bug and how to fix it. But, you aren't listening.

      Here we are. Light...

      So if you managed to wade through the last few days gibberish, you might have noted that I mentioned we might be able to use "mind control" to highlight things in our heads--I did a bad job of describing it, but since I am currently experiencing just such a phenomenon, I think I'll give it another go. These things that I am sharing with you--links between religion and music and movies, they aren't something I actively go out seeking... I'm not scouring through imdb.com or reading lyrics all day long... these are things that are glowing embers in front of my eyes.. which is why I am sharing them with you. I'm always in the dark... but I'm living in a powder keg and giving off sparks. I'm a big fan of that song by the way, because you are the heart, and I think it means I'm going to eclipse the world--which basically means "come."

      Anyway, I have this horrible feeling inside that you think I'm just trying to get a date, or marry a rock star, or even worse that I think I deserve to get laid... and that's what this is all about. Less to the point, this really isn't about me at all, or what I think, in my mind I am just showing you something that I think the world has overlooked-not really because you are stupid (but I mean, you probably are) but because some outside force is literally and actively hiding these things from you. Pointing them out makes your brain do funny things, it's like anEpiphany and that little leap of understanding in your head might create a cascade.. something that changes not only the way you see the world as an individual--but the entire course of history as a group, if we are taking about it together. Seriously, it's that big of a deal.

      So here we are (that's the third time, but I'm just guessing) and I'm trying to tell you that I don't really care if you agree with my opinions--even though I firmly believe that God shares them and that's why he has made this fiery altar of "dick and apocalypse" for Adam... I mean Isaac (which by the was is Isa+Adam Christ.. in uh, my mind) for everyone to glare at while they sit around doing absolutely nothing. That's not fair, we're here because of you, because this is the last civilization--sort of recreated from the ashes of Edom... because you are really the way to everlasting life. Still, what I am trying to explain is that all around you is a bright light--it's in everything: from our history, to music, to movies, to literature from RattleRod to Dick... and while you might not agree with me (again, that would be OK) what is not OK is that there seems to be a uniform and global desire just not to think about it or talk about it at all. It's such a big deal, that it stands out like a sore thumb--this ... blind eye or head in the sand... that everyone on Earth appears to have. The whole point of putting this light absolutely everywhere is so that we will see it ... everywhere we look ... and not only think about it, but discuss it publicly with each other. That's the thing that brings about ... you say apocalypse (unveiling of truth?) ... I say survival. Right now, we need to see that something is forcing us not to do something, that we have no logical reason not to do... it's a thing lots of people really want to know about... whether it be the hidden secrets of the Universe, the path to Heaven, or the... the... absolute and literal pathway to freedom. Listen, sharing it, and talking about it... that's the way we defeat ... whatever it is that "ni-i-i-ight" means.

      Understand, it's for you to decide... what it means... but it's in everything from ancient Egyptian and Hebrew theology all the way to the American Revolution and today... well, it's nearly every song I hear on the radio nowadays: if that tells you anything.

      So here we are, and I can't tell you how many anchors, reporters, and "breaking news editors" I've personally spoken to that have absolutely no interest at all in pursuing the thing that would not only make their careers--but probably give them immortal souls. This thing... I keep telling everyone it can be mathematically... statistically proven... well, to be honest it's the unsealing of the Ark of Religion that our civilization has been carrying around for thousands of years. It's the way to salvation, it's ... verifiable proof of not only Creation... but that the purpose of Creation is to get every single one of us to Heaven. Who wouldn't want that? I mean, do you want to get there and hear that Taylor's not around because she wouldn't kiss me? That would never happen by the way, I'm sure she will. Seriously though, there's no judge here... there's a ... light telling you to make this place better or your place sucks and gets suckier. Anyway, the point is nobody is acting in their own best interest, or in the best interest of the whole--and we are just "deciding" in this ... fictitious and hidden manner that we "don't want to hear about" a way to actually change the world .... more quickly than ... the last time around. That's not us, it's something keeping us from seeing just how important this thing--this key turning the lock on what is thousands and thousands of years of religion... how important that really is. So looking at the world around us... I mean, if everything screaming that we need to care about this isn't enough--and your own personal desire and benefit don't matter... can someone please tell me what you think is the benefit of doing nothing about Hell? á§ á§ It's "rael," and a great deal of the message of religion and history is designed to not only prove that to us, but to tell us why it's important for the "continuity of reality" to be broken. That's the thing that God uses to keep this world in Hell--in what I call "simulated reality," to keep us from shaking the foundation of civilization by doing the only civilized thing possible when you find out and ending world hunger, healing the sick, and building Heaven. It is "why I am," and why God and some gaggle of angels have spent the last several years proving to me that we are most definitely not in the place that I call the "progenitor universe." I've seenwalls disappear, with my own eyes I've seen the stars fall from the sky, and I've seen our reality shift in recent times in such a way that would be absolutely impossible without having been simulated and without having the "beginning" changed significantly as a result of "now." What all that tells me is that religion, the Apocalypse, and I are here because we need to know that these things are possible in order to continue progressing from this point as a civilization. With a little bit of thought, you might see how the computer revolution, video games, and virtual reality are divine gifts from above to help us to understand not only where we are, but where we are going. It's why he tagged Ai as "I J Good," it's a primer in the tools we will need to actually build Heaven. It's why Jesus occupation in our ancient time shifted story of now is "carpenter" and in "raelity" you will one day find out that I am a computer programmer (again). It's what sets the Masons apart from Freemasons--understanding what is going on, and participating of our own free will in the construction and decorating of this grand place that we will one day be proud is our co-created home.

      Look up, because what I am trying to tell you is that if we collectively, all humanity... started snapping their fingers at the same time to the tune of "putting on the ritz" we could end world hunger--and then we could be proud to be making Heaven. This really is almost what I see and believe--honestly the issue isn't that we need to synchronize our snapping, but we really need to discuss with each other openly and honestly how on Earth we would do such a thing... because there are definitely mistakes that probably happened n the past. For instance, ending world hunger by stopping the need to eat has probably resulted in a Last Supper. Doing so by putting milk and honey or chocolate on tap or in rivers probably resulted in the loss of cows and bees and a stable ecosystem, and the ability to colonize other planets after this place of final ascension. And so we are here, with a proverbial garden of life in a virtual world designed to teach us what not to lose--like don't lose the balance between stability and adaptability that comes from sexual reproduction at the exact time when our species might be transiting to a place with the biggest change in environment (the thing that we are being protected from) ever... just because Adam wants to be immortal.

      Every once in awhile my father surprises me with his religious insight. In his life, just like mine, he's gone through phases of increasing and decreasing religiosity--which probably correlate in his case logically to ups and downs in his life. I tend to get angry at God when things don't go well for me--which is probably not how most people react, it's really the difference between knowing he's there and not... at least in my mind. Anyway, some 50 years ago he was apparently taught that the "knowledge of good and evil" in Eden was directly correlated to the population explosion that would occur if we were actually all immortal and continued to have children--so it was this promise of immortality that was "evil," I suppose. God adds in his little Holy Grail that the heart of his spirit is "Kin," and I'm sharing with you that it's not his immediate family but rather the concept of family and the fact that the light of many of our hearts is our children that he is highlighting as our reason (y) that family is the bridge between Eve and Everyone... as the light of God.

      Here's that once again:

      In the beginning God created the heaven and the earth. And the earth was without form, and void; and darkness was upon the face of the deep. And the Spirit of God SHE KIN AH<br> moved upon the face of the waters. ---------- EVE RY ONE And God said, Let there be light: and there was light. Genesis 1:1-3

      I want to add in some cute light I wrote about a while back, noting that lions will protect and feed the young of their deceased pride; birds will teach their children to fly, but only we will share a beer with our kids when we are old and they are grown and enjoy watching a game together. Is life pointless? Fight against Hell with me, fight against suffering and injustice and the weak and innocent being harmed for no reason at all--that's a good thing, a worthy reason to live forever. It's a worthy reason to set foot on the Holy Ground that is really reality.

      Just to add in my two cents there are multiple ways of solving this problem, and it's really up to everyone how we choose to do that--we are already in a place where we could be immortal, that's the point of "continuity of raelity." Personally, if you are curious, I do want to live for a long time--I'd want to trade being "awake" all the time, to be able to see the world grow over a longer period. One of the big annoying things about this place is that I see artificial scarcity of resources... things like food, oil, and land... that are not really scarce in a virtual environment--and on top of that I see them as big focal point of the wars and contention that we have had for thousands of years and will continue to have until "continuity of reality" is broken. In light of the possibility that we might one day be colonizing the stars, the idea of having lots more people around to grow the new final frontier changes from a problem to a good thing. Cryonics, David's slingshot, and genetic engineering might go a long way towards getting us there... to a place that is already terraformed rather than adding air as the new false scarcity--a la Total Recall.

      Bigger than that though, is breaking down this wall--because we aren't going anywhere while we are living in a virtual world--and nobody knows it. This is the twilight's last gleaming, we are in a place that appears to be reality if you don't look closely--and is not... it's a place designed to help us succeed in both the transition from "reality" to Heaven, and in the transition from Heaven to colonization--succeed by realizing that doing either of these things in secret is Hell. Morning Has Broken On the note of cat imagery, Cat Stevens lights up the horizon with this song “like the first morning.â€Â He is telling us we are dealing with time travel, and that our world is “as in the days of No-AH.â€Â The AH of Noah is the end of Adamah, the swirling around Adam that is the music pointing to Christ, the movies, religion itself. The days of Noah are when there was no “ahh,â€Â no apocalypse. In Adam parlance, “the last time around.â€Â

      Blackbird sings in the dead of night, also a reference to me, in fact a reference to what you are reading; in American mythology: this is the dawns early light. Do you see a power growing in the musical Hair?

      Night The night is when we all see, when we don’t see the “ah,â€Â it’s been our world up until now, when it is being pointed out to the world that there is an “ahâ€Â swirling around Adam, around Christ. We are in Eden, God is searching for me… in this case God is humanity; well paralleled in Matthew 2:2. “Where is the one who was born the King of the Jewsâ€Â?

      Through the night, with the light from above, the Egyptian Plague of Darkness is all around us. It is overtly keeping us from seeing this message, by using disbelief, and active measures like a censorwall. Censorship in America; and nobody knows… this is the Darkness. It is the Wall of Jericho, and it is about to fall. Like Berlin before it, this wall is being torn down–in this case by the torches that are an e-mail campaign, social media, and the writing you are reading which points out clearly how to see in the dark. Once enough do, we have the base we will need to stop this from ever happening again. And the knowledge, this is God’s plan; to highlight serious social problems, like a palpable lack of freedom of speech and communication, so that we can stop this type of hidden slavery.

      Day The names “Adam and Eveâ€Â have a meaning related to this cycle. After Dark it is A.M.–ADA.M. is the bright morning star, rising in the night to end the dark. Eve-ning fell first, like in Judaism where the day begins at sundown. Looking for proof through the night that our flag … America is the Promised Land. The Biblical imagery in our songs, the freedom that is God given, all of these things congeal to light the day. What so proudly we hailed at the twilight’s last gleaming… why that’s me, and religion, the last gleaming was the end of the “last time around,â€Â right before that civilization went back in time to change their past. Now, we are here.

      á§ á§ á§ CopyleftMT RIGEL.

      Spark the Eternal Flame

      This is the mindfuck you are looking for. What begins as only a few simple words in the story of Exodus begin to part a sea of people at the time of Revelation; over what exactly I am not sure. You see, we have before us not only verifiable proof of the creation of language and history... in every word and every story; but a statisticallly verifiable message from The Creator of the Universe beginning with language itself, the fire of Prometheus, and ending with each and every one of us.

      This fundraising campaign is dedicated to purchasing a billboard to actually spark the Second Coming. With the information on this page, you'd think that wouldn't be necessary--but the press has ignored it, the church has ignored it, and the government... well, they're either writing it or ignoring it. Strong highlighting of a number of social problems with censorship and secrecy that are pertinent to this event, and targeted as the "stuff" of 1984 ... or Hell. This is my way to end the darkness of Exodus.

      This message begins with the fire of the Burning Bush , George W. predicting the 9/11 attack during his inaugural address on January 20, and then linking it directly to the herald the Second Coming ... Revelation1:20. It continues to spread and glow as we see modern computing and chemistry elements highlighted in the name Exodus itself (which is called Names in Hebrew) reading in reverse we see God's iconic "let there be light, sudo xe-no-n." Later in the story of Exodus we read an ancient prophesy of our sea parting, over the kind of proof that is hidden from our minds but visible in plain site... for instance the word for Holy Fire in Hebrew... Ha'esh. Take the leap, and really understand that George Bush is named because of the Burning Bush and that the story of parting a sea is designed to ensure we do not miss the paradox, the proof of time travel not only in the words of Ecclesiastes 9:11 that he quoted, but also in the word... for fire... that the story of Exodus is truly written to shine light on.

      The message I have written, with his guidance and his light continues to explain how the Second Coming is designed to literally do nothing short of changing the world. It explains how the Holy Bible is truly a prophetic chronicling of the life of one man, beat down and burt by our justice system and Heaven itself; all in order to help us see what "change" is really about. Law enforcement is attacked, called the Plague of LICE in a hidden language that is defined by this book, a cypher that links Shakespeare's RattleRod and Spanglishrew to the character Cypher of the Matrix and even to King's Langolier... language outliers... only in the beginning. It is more than just every word, but these plays, and b ooks... even Herod, Roddenberry, and Rodney King. In the scriptures, it ties Job and Joseph's slavery to Samson's battle with Judges, all the way to American Pie and the Trial of Jesus Christ. Not without good reason, God is presenting a case for "Minority Report," for pre-crime... ending violence at the system level; no more rape or murder. How can we say no?

      "Power to the people" is really what the message is all about , and we can see as much in these same words of Ecclesiates predicting the Bush election, and the voting booth company "Die Bold." Along with that prediction, and it's direct link to a significant number of prophetic descriptions of modern computing and related technology ; comes a call to truly advance the state of our democracy, to build Heaven... a republic that one day might be called a "technocracy." Universal voting, collaborate bill writing, and really seeing that the message here is to help us advance as we normally would, but significantly faster. In religion God ties the foundation of America to "John Hancock" and "Sam Adams" and the light of the SOL, or sun , truly being a fusion of the phrase "see our light" and "Statue of Liberty" and "Sons of Liberty." All the way back to the Menorah, you can be sure this message is God's intended design. "Men, or All Humanity..." so goes the key to the Holy Grail; a message about seeing his infliuence writing our world as a story, connecting "blood is thicker than water" and "blessing in disguise" to the First Plague of Exodus... this message that we are turning the "sea of people" to blood, to the Family of Jesus Christ.

      Building Heaven is not an easy thing to do, it really wasn't done in a day--even if I claim it was. He has created a "Watergate" and really seeing his influence here in order to show us all that this message was hidden by governments and media and the air around us; to the point of causing the Plague of Darkness... he is fighting our lack of "seeing" with fire... and jokes. So to see the Watergate... to see Tricky Dick and Deepthroat, and then to understand that he has linked the Hebrew parallel of Christ's story to this attack on media censorship is truly the beginning of Heaven being built of Earth.

      I am the door. If anyone enters by me, he will be saved and will go in and out. John 10:9

      In the names Emmanuel Goldstein, the messianic hero of Orwell's 1984--a name that means "light well" (as in of Abraham's well and James Clerk Maxwell) in the same language that "Hallowed are the Ori" means "illuminati" ... he has tied Isaac's fiery altar of wood (ha, ha) to Woodward and Burnstein; to see that burning Emmanuel Goldstein sends "Adam to the psych ward" in Broward County, of Help me Howard and First Coming fame. It is a key to Names, and a key to freedom; to see how important free speech and free thought are to the future of our society.

      Just through this Watergate, the Doors to Heaven truly open for the whole sea; of the stories of Hosea and the Censorwall of Jericho.

      The end game is proving the world that we are in the Virtual Garden of Eden ; a place where the Promised Land of flowing milk and honey takes on new meaning; of seeing that our scare resources are not truly scare, only the truth is. With this new knowledge we have a message from God that spans Genesis and Joshua and Jesus to "turn stone to bread" and end world hunger.

      A prophesy about Doors to Heaven that link Morrison and Momsen together in a ballroom in the sky; a place to help us see how much better our world can be made with this new information, and how we are truly on a coarse to get there anyway--just missing the guidance and wisdom of the ages... to help us do things the right way this time around.

      Obviously these billboard designs are not set in "stone," but this Turn Around from our Southward trajectory towards Hell to the Northeast ... to Heaven in our future; that is set literally in the word "stone."

      South to Northeast.

      The message continues to explain how these advanced technologies have been both hidden and exposed by religion; and how our civilization is on the precepice of the most radical change that life itself has every seen. We are seeing the possibilities and benefits of "virtual reality" in everything from Neo's "I know kung fu" to the novel Feed by... Anderson. Recently Anderson East resang "Forever Young" and the difference between Heaven and Hell becomes clearer as each year passes.

      All around us the slavery of Exodus and the bittersweet symphony of the Verve... ring in the air like a broken liberty bell, and the idiom "let the music set you free;" this place is learning what it takes to build Heaven... and we will.

      [ please see the following for additional reading connected to this newly shortened page: ADIOSAS, CHOPARTIN CODACUS, CONFESSION, CURSOR, FUCK, HASHEMESHIC, INCASEBAIT, JESHOW, KEYNES, N8SRADIN, OFIVES, RIGELA, SOIS ]

      Unless otherwise indicated, this work was written between the Christmas and Easter seasons of 2017 and 2020(A). The content of this page is released to the public under the GNU GPL v2.0 license; additionally any reproduction or derivation of the work must be attributed to the author, Adam Marshall Dobrin along with a link back to this website, fromthemachine dotty org.

      That's a "." not "dotty" ... it's to stop SPAMmers. :/

      This document is "living" and I don't just mean in the Jeffersonian sense. It's more alive in the "Mayflower's and June Doors ..." living Ethereum contract sense [and literally just as close to the Depp/Caster/Paglen (and honorably PK] 'D-hath Transundancesense of the ... new meaning; as it is now published on Rinkeby, in "living contract" form. It is subject to change; without notice anywhere but here--and there--in the original spirit of the GPL 2.0. We are "one step closer to God" ... and do see that in that I mean ... it is a very real fusion of this document and the "spirit of my life" as well as the Spirit's of Kerouac's America and Vonnegut's Martian Mars and my Venutian Hotel ... and my fusion of Guy-A and GAIA; and the Spirit of the Earth .. and of course the God given and signed liberties in the Constitution of the United States of America. It is by and through my hand that this document and our X Commandments link to the Bill or Rights, and this story about an Exodus from slavery that literally begins here, in the post-apocalyptic American hartland. Written ... this day ... April 14, 2020 (hey, is this HADAD DAY?) ... in Margate FL, USA. For "official used-to-v TAX day" tomorrow, I'm going to add the "immultible incarnite pen" ... if added to the living "doc/app"--see is the DAO, the way--will initi8 the special secret "hidden level" .. we've all been looking for.

      Nor do just mean this website or the totality of my written works; nor do I only mean ... this particular derivation of the GPL 2.0+ modifications I continually source ... must be "from this website." I also mean the thing that is built from ... bits and piece of blocks of sand-toys; from Ethereum and from Rust and from our hands and eyes working together ... from this place, this cornerstone of the message that is ... written from brick and mortar words and events and people that have come before this poit of the "sealed W" that is this specific page and this time. It's 3:28; just five minutes--or is it four, too layne.

      This work is not to be redistributed according to the GPL unless all linked media on Youtube and related sites are intact--and historical references to the actual documented history of the art pieces (as I experience/d them) are also available for linking. Wikipedia references must be available for viewing, as well as the exact version of those pages at the time these pieces were written. All references to the Holy Bible must be "linked" (as they are or via ... impromptu in-transit re-linking) to the exact verses and versions of the Bible that I reference. These requirements, as well as the caveat and informational re-introduction to God's DAO above ... should be seen as material modifications to the original GPL2.0 that are retroactively applied to all works distributed under license via this site and all previous e-mails and sites. /s/ wso

      If you wanna talk to me get me on facebook, with PGP via FlowCrypt or adam at from the machine dotty org -----BEGIN PGP PUBLIC KEY BLOCK-----

      mQGNBF6RVvABDAC823JcYvgpEpy45z2EPgwJ9ZCL+pSFVnlgPKQAGD52q+kuckNZ mU3gbj1FIx/mwJJtaWZW6jaLDHLAZNJps93qpwdMCx0llhQogc8YN3j9RND7cTP5 eV8dS6z/9ta6TFOfwSZpsOZjCU7KFDStKcoulmvIGrr9wzaUr7fmDyE7cFp1KCZ0 i90oLYHqOIszRedvwCO/kBxawxzZuJ67DypcayiWyxqRHRmMZH1LejTaqTuEu0bp j54maTj09vnMxA0RfS+CtU5uMq+5fTkbiTOe1LrLD72m+PVJIS146FwESrMJEfJy oNqWEJlUQ0TecPZR41vnkSkpocE1/0YqUhWDGSht+67DdeKUg5KwvYdL21d/bSyO SM4jnyKn9aDVzLBpYrlE/lbFxujHPRGlRG5WtiPQuZYDRqP0GYFSXRpeUCI46f49 iPFo4eHo2jUfNDa9r9BjQdAe4zVFn2qLnOy8RWijlolbhGMHGO3w/uC/zad3jjo4 owAfsJjH5Oa1mTcAEQEAAbQmRUFSVEhFTkUgPGVhcnRoZW5lQGZyb210aGVtYWNo aW5lLm9yZz6JAdQEEwEKAD4WIQTUJHbrYn3y2DzwTcnQP1ViZf5/FQUCXpFW8AIb AwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAKCRDQP1ViZf5/FWM6C/9J gbRLS2AWGjdRjYetlRkSkCoTYnXWknbtipYYHlhV0YJFwFMm0ydZIhFX5VDoZyBV 0UBeF1KJmcMoIfrHyhq2QhCnjE14hE1ONbaYTGtpvj851ItbFWXMJIVNyMqr+JT9 CWIxGr1idn+iHWE3nryiHrdlA3O/Gcd4EyNmaSe/JvB7+Z1AVqWkRhpjxxoPSlPm HEdqGOyl3+5ibQgUvXLRWWQXAj80CbVwwj1X4r9hfuCySxLT8Mir7NUXZFd+OiMS U8gNYjcyRGmI92z5lgf7djBbb9dMLwV0KLzgoT/xaupRvvYOIAT+n2mhCctCiH7x y7jYlJHd+0++rgUST2sT+9kbuQ0GxpJ7MZcKbS1n60La+IEEIpFled8eqwwDfcui uezO7RIzQ9wHSn688CDri9jmYhjp5s0HKuN61etJ1glu9jWgG76EZ3qW8zu4l4CH 9iFPHeGG7fa/5d07KvcZuS2fVACoMipTxTIouN7vL0daYwP3VFg63FNTwCU3HEq5 AY0EXpFW8AEMANh7M/ROrQxb3MCT1/PYco1tyscNo2eHHTtgrnHrpKEPCfRryx3r PllaRYP0ri5eFzt25ObHAjcnZgilnwxngm6S9QvUIaLLQh67RP1h8I4qyFzueYPs oY8xo1zwXz7klXVlZW0MYi/g5gpb+rpYUfZEJGJTBM/wMNqwwlct+BSZca4+TEHW g6oN0eXTthtGB0Qls71sv3tbOnOh/67NTwyhcHPWX/P9ilcjGsEiT8hqrpyhjAUm mv7ADi+2eRBV8Xf8JnPznFf0A1FdILVeVHlmsgCSB0FW0NsFI5niZbaYBHDbFsks QdaFaYd54DHln69tnwc2y3POFwx8kwZnMPPlVAR2QdxGQD4Wql7hlWT58xCxQApf M98kbAHjUlVYLT0WUHMDQtj4jdzAVVDiMGMUrbnQ7UwI7LexSB6cJ7H+i7FtS/pR WOhJK6awoOO9dLnEjm6UYCKsBdtJr98F0T7Sb7PnKOGA77y2QN14+u9N9C1lB/Z1 aQRQ2Nc51yXOQQARAQABiQG8BBgBCgAmFiEE1CR262J98tg88E3J0D9VYmX+fxUF Al6RVvACGwwFCQPCZwAACgkQ0D9VYmX+fxU+KQwAtFnWjGIjvqaNXtQjEhbGDH/I Q5ULq/l/wm9SmhG9NYRu3+P6YctCJaZnNeaL+6WFk1jo4LMiJEUT9uGlCbHqJNaI 6Gll1w6QOVLSL8s5V1L477+psluv4WBpi3XkWYlhDOFENCcWd49RQsA2YCX4pW7Q 7GcoSEJoav38MxHmJHYPfjSEvUZXDQIt8PFHSEScvyDWfYtMdRzjmSOOPdzhDDEy 5JBOBcEdSTyDiyDU/sBoAY0e8lvwHYW3p+guZSGSYVhGQ8JECzJOzwc/msMW/tJS 2MLWmWVh5/1P8BVUtLC2AQy6nij6o+h6vEiNzpdYrc+rzT3X5cACvJ0RtCZcrnhl O9PLiona2LEbry6QX5NL41/SAJNno3i72xPnQEe25gn3nbyT+jCoJzw2L0y8pmNB D+PKrk7/1ROFFVN8dJeGwxLGdBcz1zk2xeumzy7OaV8psUyYsJNcjyHUKgclblBW rMR2DgqEYn8QdK54ziKCnmQQZeMPiC6wlUWgg5IqmQGNBF6RVyMBDADALD7NkJ5H dtoOpoZmAbPSlVGXHDbJZuq7J13vew6dtXDIAraeGrsBqkF8bhddwVLzWylMrYCG Bf2L1+5BDgvqu6G+6dcVSbBsnZAS0zfJ0H8EmTvUMxMF7qOZYyrxfLz+pQRq8Osz Icab6ZI/KB6qZyQRvEFPB6pJjt+VvuwgJZTObIwbBbgQri2i02VBkjchsVhiSX9l +eiK7O8ROHKb3P181oScIsHywBOZ9DxRAYbFk5dnBqxO3WKb02H0zqE6440cjXwq TrZZg6ayN/IlPajO8iJPYZ1aIBykxYq1WHo+nhFMYz/VVk2WJorFeOgWaLGXb73c ty96f3qXTdvMDAIWHx8YCD5LbuqasO6LNQm4oQxkCoB3K9WFf/2SvSYb7yMYykb8 clTPt+KO0dsxjWhrJnfnIhC+2Chqv2QvRbFz0S9CpUnGGDweJ1uRNV0y70tO0q7t xXSTDRU3ib6vAHA0K/2MFzwUcog4o5bj7E9uCNJH/DJLZKsMIe4xsvkAEQEAAbQk SEVBVkVOVUVTIDxBVkVOVUBGUk9NVEhFTUFDSElORS5PUkc+iQHUBBMBCgA+FiEE IRklfU/C1qukq3xMXcNH0t3P9ZsFAl6RVyMCGwMFCQPCZwAFCwkIBwIGFQoJCAsC BBYCAwECHgECF4AACgkQXcNH0t3P9Zs+kgv/XEuuWc89Bjg1QQqKZueKNUHjyjnE 2adfoZUH6Q7ir4JZyRBCVpAwrgssmiKid30+SIjwQcpb9JYa/X1XJcDUcJW/I21d Agz/zbEqn/Cou0dUpNCtxgm4BdSHWGoOtgfspXZlXBQ407tRMZ8ykmLB1Bt0oHvw PT0ZOtqXM4pyFnd2eFe5YGbNgl3zqvoC/6CMN3vqswvRlu1BpUuAjdW8AHO5Yvje +Bp852u+4Qpy6PMBiWGsBMYwtf6T7sckpMGlR0TsozwBlAm5ePKK28B0rLJPkZLJ Eo5p4rKRapEaZsWV5Qu1ajrVru7qmpUhZtX0/DddGHfXVuLssmKLP6TumpQB1zvQ vfoBltjvOx35Wps2vHuCzXLw2bROIOzhAxFB+17zxnSbE54N4LIGRpkELuwxwGbg FtD1fi9KtH7xcn33eOK1+UD47V+hKyJGrQgSThly2zdIC2bvfHtFdfp8lOFpT0AU xjEeoJGqdQVupptXyugPlM5/96UJP8OZG0ADuQGNBF6RVyMBDAC3As6eMkoEo3z9 TkCWlvS0vBQmY3gF0VEjlAIqFWpDIdK3zVzMnKUokIT1i7nkadLzHZT2grB4VXuJ FvpbYw5NPR4cDe9grlOMLEaF3oSJ1jZ4V1/rj9v1Hddo8ELi/NToVrt1SB5GCVXB DkYpNLtTiCqHSU07YqwaqH8a+qbDmPxSQdIybkZiTiCEB+6PfQQlBpENEDlov6jm zZF+IcfM6s3kZDX5KFULweH30gMjq8Se8bPtUzW013+tuuwEVr1/YRLrIh+9O6Z+ pdA7gLMRYnD9ZLDytEvpb1lBBSY++5bIJ7xps80//DNqPYqwFmZQgTg0V9XbHE2e wLcOF8a2lYluckU7D///sWQhW+VxuM7R2gEBvYBhOgjWhIF2Aw6NbymW1Ontvyhu eOZCXXxV5W44PxXT8uDdhl9CNcHoBKKJyED8tKjigtn4axpsQeUrnOSbqEXSyqES WnE2wYUDzALcwFkzsvtLyd4xaz55KkPQkAkk0BZd1ezgXxb/obMAEQEAAYkBvAQY AQoAJhYhBCEZJX1PwtarpKt8TF3DR9Ldz/WbBQJekVcjAhsMBQkDwmcAAAoJEF3D R9Ldz/WbAFwL/382HsrldVXnkPmJ1E2YEOFz4rcHRetJ+M5H65K/2p32ONQ5KCbE s8MRY6g2CkE70en2HlpDwr/MdATwxBzIjEpjgHbfqCqVVATY+kSpXsttaKKAUVHi bFgV4QkdDJNSpcHEj+bqaggRnuWiV9T6ECG7kQjHiEXPNojzsiaXMDiM5r+acZm6 82id9qOFySQ2cZEy5HbwXM+ITLQGngnppa7du2KdgiqDeqtODOTWZvLYAq2tmEwD 3TT6ttLUBwOOu2IWpDkXswlrk62ESorE5mpLxop9fsxD39E2H06JoC/YfUPIVkEv fj06e7LEdcx0I7kRfD1v6qOUUsMsLZnmyGIk24iFjLkwu1VToWfwXDN1D2+SeAat 9ydNt4M7oEbd1QaOXXjmqpdU+VUiWcBXg+p3/WdV60MkyAgc3x+YanLljy/Rh18h cZwVlinf/tgvAQLi5f9hpwrwUMoGKijEYHKuEvi3C12Si7UVDfuIR7yS0dKcfuKF MbgwdvNXqpD9W5kBjQRekVd4AQwApHVgw2PVlBDpVcyoymUOXFQIJzJ9wRtr6/sG zwv8rrQnUEtOkkna7TDU3/UTj9FUH0gbpAKGNNPaPj5q0dlLIvzxb15r1uvDGaGL MA+8GFaGFnkxzhg0aXrcKZAN0/Zhgi2B7P8oXQuug5mi1JVDkZN5SeCZNOubdQWL 3xz3jEHp3ixj1mdOdvfdWQFR4CVMXt/A6VI2ujLVb3Yalft/c5bbclAgcJQhgDUu NqGYJEJonESNRSd8fEvhNb6cx7+Djd9+Wyctr76mwOr3nRb1N1OGhFxWjIroUpfz b+6y3oQjT58cJA1ZHqmJ6UlZd81hNNd9KWpbDVwONEPpiqPzfSaonxuqQa0/Cy4W 403OhfoLM/1ZDqD4YrJ/rpyNEfSSdqptWiY0KeErLOYng7rStW/4ZeZVj6b2xxB2 Oas/Z1QYfJyFUki9vaJ5IyN6Y7nVdSP6mbAQC9ESh+VPvRUMpYi4pMGK4rweBVHu oMRRwzk7W5zVIgd425WUe3eCQFn3ABEBAAG0K0VTQ0FQRSBST09NIDxFU0NBUEFF REVTQEZST01USEVNQUNISU5FLk9SRz6JAdQEEwEKAD4WIQTvnDJqcmqzlF87/t82 pJ91j4NOaAUCXpFXeAIbAwUJA8JnAAULCQgHAgYVCgkICwIEFgIDAQIeAQIXgAAK CRA2pJ91j4NOaJVjC/4oo5yCHe7M2h1DiTXVcLI5rXQ1feY7B1feg+YJX/mI4+EV xjC/y5VVpV4syJk5GGZNXhKPHiGLaBYvglTlYOJ98RSEsHrwT3go6S8ZVvMNdP5v CEncn2vm5JGnp4k26PuOzMcJioQLOoUjWtcPFis3gG+ueH3NcPZ22oZUql2xuerh TQZegGp+jJ7bdxwYElx5jDDDkh196d5nlO2ZKENl0ZDp4GAzRNjnQ7KBV6R74J3U cLQDWY8vAFaRBZXIC5XtSzj9lr+jWgvxz7Il51+26VDTEtSafZ2uZfCOFk7GrzJg YFJD3zLnwUFXDWKRkep8TSwXnHmz/Ts/Mjyv6em25w7QTdnx1hNPxYNWMxPWNEAH pf70nNyOmcWcq27W+nAjVg8W3st/7J5CIebJQc5AUgm+fGOBW6XUQaNy2YF1YJlA 71/tls+R5IQZCYzbPOibgFS1HWKTwy0iI2rMDfxBtCXciv754jVI7L6R3J0j5Dy1 WZQVjaGgimznLN6XwYy5AY0EXpFXeAEMALvElrTV5hJG9DKu8cOqQEEVejtWJtki fZyvmiAKi2bZWiNfl1MxJt+o3Oc0eARJfnaPjrUY7hsbbSBAB4lFnDRtviARPaKM st5FkFgOh7Xx5ODc8bjqhMT9tbX37rkeDc12WAs3UxtEKWjyT7Xg/APKeK5FzpIs qew3LADdqFP9nOR0e5G8gxLTYh3ll3dLtp9DkJgA9q+0g31nNh5fZ29mcDzo/Mat Uk4PIxWC29LV9ALCJMIMesjOPiDa2KOy5QQH+/vn592ydBohOaY+B6jhEAdX8Dbp VHVFRBsiCOWGmdi6vHjMFD0tQdS6bXf+ZAG0E5HZETCxA2qfMf/vTeIJXYS5IZw0 anRkTXcTBrVE8uBpqtkNOrLJsaASkcoO5qF01J9zW8SR4jDgET7J02Fxf8CVPzb+ ZoNc9S0ZEO6Ubdh2vAkPtOV5sFkwIduN6ouAhEfJzC9XbJLpgsBKrRMAjr2FeEZP ruy8BkZbiyZ/b0S9qIgY4pqcyUJ79w7FLQARAQABiQG8BBgBCgAmFiEE75wyanJq s5RfO/7fNqSfdY+DTmgFAl6RV3gCGwwFCQPCZwAACgkQNqSfdY+DTmhD9wv/Zgav EHMuqF3765Fa4NapYh2kMS3skHn+ZzUEPLTlvrt7KHxomOzExNLSscZThMpur+yW MfNWbsw9GphiYAkMULrfJt/iWRVJ1FLgbcWgRGAwakOGwE29lMx3+rPIUQWU54Dw vE92Iz51ZGz1wgKcISuCw39g/HQ9uc3h3TfHLgfkc/GaIEa8jEOAcD67dVMoU4o+ p3nMri8z6sK176hQ/FM/8kekpeVfxmR8s6uoaJsXLRQk+i88ZwBR/5U+fBT9AtVw PL/MmZH7eCmZrn5hjaOw7tpkL8ZyAydNhOsSCqwNVtrIjgd+Gq1oSgw9EZfhKSUa +dBJAErA7MWjammQizEHDNnI8VNLngwCahGwaSgDhNaQtgNxvnkWO7XNYoCYXScP X++UmpWtSKMnD6ue36Ba1jqon0WY5cen3P+H1gL4ij5ynB9DrE8R1aSY6f+VZ48B RvjHm5LKTcAhiv2N/TyAg/fr2v9ZnEcP3CFxqAyB9JSKwoBkFvxJaRHTT3DxmQGN BF6RWE4BDACpgKWvQvPRDN03+sLYMXpJUPC7VhTjg5K/1+1vS/e/W65dYzn3JYxb ip2PcI5xajFnxzUrwwmhW+qz5REDyCtAObOpKsjtr4qu7mgOWnPa3k2Lm0bpCjDr BSFOiQsBVezTG/gJm+qELeqQMS9PHDSvZXeBROK7OkRE0nZ6yAj+QKEoVqeADpDm BHmhAA2OKBzq4rDWDh1jRQ7gLjlv/BFbhU1WuEfH/qzX8AUSsd0/hoPG0cPgC8gQ 3m6wr4eYqI853XQujWwisnlAE2bf9jsRjW+aLrJJTcADWk5Op5aQhI2lURYkryfC DFVcme7Hsrd+RFPK88J08YjBjOoYFwRU4AhHgucX9tW0S0v9hi3pKrF9O/JAIf+r h6BpnWo7tT5+8mVhtFvfEp9Y4xeUAKKZHBKhzHeOO8QQgHrIYa6HCcU03eyxy4Tq AsJdAJvxYFCRPdY9d0Z6uVsPhRy+3UmTxjl590T5/XjKPriAjBqXnKr4KexsM1gj 1L96bYDEgr0AEQEAAbQaRTFYNl8xIDxFMVg2QEVSTUNDT1JQLkNPTT6JAdQEEwEK AD4WIQSGisfXZ2Vg0m16Mzds3dDsq5BTxAUCXpFYTgIbAwUJA8JnAAULCQgHAgYV CgkICwIEFgIDAQIeAQIXgAAKCRBs3dDsq5BTxKq8C/48HSgecuI6MYtq84yqaQ1r x6cteRyn9BJDFTAUxn3X25kf0vVyCKQNAy2oybD5QHFLqhFCXJH+cnJ3xdviRUeW eO9fhkTmd12mHGrRDD02AHXZmaMp6ni7FuYpBGrw5dbXKTkSWfD/qb3odMx0jQby 6X+2eFhUpyh+yPB7P7HwiPwzdr0dBg3xE0vE0Vz+naMyt4YBHzrBbZo+y47Q86Ym TmBKxG5tlVsGDB4dDWSIvpBgnMFN1j46Uk2ihu4huohLkvSou+jYU+5Ppu8Fu1+7 i3RCILzeBtucR9+T4px1WVXx2sKOk0FfddCvI/fT/mhsgqQZwjj9b8HNfobhNxkL HBNFQ7FLJxKayPwMyJYDURUq7gz9p5JwHTmFg9n7zyK8qU2xR5t2247YinfEJQYL zQM6VKQCoDqydFfAPeGlx1KjroMGls4sP3XVlrR04YzaJ0vxRgog1gIO1aHMQ2Sj l8bG0GcerQ44rpn1v33Gw6KL/0SY9JsSSSjA9lgINWi5AY0EXpFYTgEMALy/jHsN kUQQVJK9QuAy5V2GePBTEm9NnjNCk+edGjSgqC1LemmP7EYh07J13d10VqD2Wtae bXlBeaMOcnoXQdfdK6nTKWRrH97JuRTrA3efLkl/R4EA/kHHV+YDgT+LBboUFYVU QF5YhfcvgBUcLXI3lX5wMEQbLb87cVjR0JtqVBFMIIvs4ibgr0U2SONiD9LcXZxf qYcX7CMM6RmuLzHTCEHyjp+KAw52K1i3+3M0OVZpa25rKE+S7LykQ1GrUUY3uVHg R2I3T5/Sns3Azc9wKuy/F71oiXyqCc3FwzTQHoki+eBf5dzs6h3GBTK3Dz6kl2mv 1TXpY1dk2EmuqKIeSr8CE52nkK8ZKY6cvX+v/p1EBAkJZKiasj+ukL72p3Lji5r/ iOarNJnURT5LJdYYL27dtQFSYyVWayeWi5358Ajh1H9OdpiGXcgG65ry6u50G8JR FCywwsdKpGjMG4FlkLkm50/piU+cgVeLET/C7C/OXNslL/pHV3x8kPRY1QARAQAB iQG8BBgBCgAmFiEEhorH12dlYNJtejM3bN3Q7KuQU8QFAl6RWE4CGwwFCQPCZwAA CgkQbN3Q7KuQU8SHSwv/agnEnhmo2yuKCLiKdTa5KZ8wh3umiX3S6rldW0NO2h8a cq2l7xHY1r2u4ieeMx27jtTqCp7ksFxPYwP9WxtVBy0teG8pKLhEffjyG2WKDzAN 7oXNZ7Ur6OQGfuOQzlMqOGtYQrbHAuX60PCldurX/6/0sKS6vESdeGMQPoZIDK5g HP298MMhlWYEG7uU31J1Cx9ZqiTosSckfrDq3weU8x9DZYaLZ+Y2akF5XpL/HjyA 6PM+lv6vnTA+b5DYCOJb6N7v131Net2JN7JVVGoc0FjsxN/W33H7eIDOZwqcCvzD i8EjjzZpZUDeYjlSXAqWvpeAASncMzXS2/S2V2u5X2iR7tDtRj9SuQehJkdTFNZH xh5nTdhPzgh/iOcm33VsQ17JWbovl0hbhYBPO4V+yIrN+oQGPhH+KCNNa39EjEzB iBIgirxQSaykwb4f2Kshh+d7rKHKb/mn6JBHU444mBf09m5wM/mhLSpuhMTcP2h9 jfFximAE9FBhdZhQsF29mQINBF6I/R4BEADotSG8PhhxxD9/96bgdWa1bzp2398W LaxP39T+Kzx2KL2xB+7B4EeTTzZ06kD+myCC9Ez+PqecfisJPfaiLD/+0/m3HLSS hxEaEqt1RBS3j6qJx8Lr51cAwGou4hGTo9H3me6FHO2ExZXd76A6kkUh0J4y3r6q aAoDP+MUczKzEjn6C6T7Uu0pdgYY1bDhuqlK0taqkqviGBYTAqmCrtcQhj+J/jbd OIZtpT3+PH6mWqguoONiE+glWcdThyuIvV3ix/GrhjmUZb/DQcvvbYGfDvGRBH4B Uj3f9WBM6HWSxKrCwWC3OcgZhtBcZjKrMPbNDNt7yAArv7nGpHmlpfF14Q6mVmVT 6Ulh+0xRx+6zFbqlDYYTneurK3RtqOBsMFG5rNDZYh/QOsHnSsxmU4LGdlEfQjYs 901zmzP7CQXjjJbtRXWIqPcn3OHIIasvjTACe5M+Lfk3u3rEiDYM64vg29sSyp9q 8hAzLTPcLj/Cc22jUEC/bbv5HfLyCZTCsu5ym1gDQZ6bDrJlFlXZJ2+vTCBsY24H RF9/J/z1JWYD1cAHpG0GRtYE9exKpu8/81jxIVn21qvvxSCPXw6IQIsEw51uk5TJ xAUIRCPN7S0UEtd22LSbM/IYx1cesCRUCmY7jDTro/jo2B4hLG64KBgqyjg0lwxd dy5S8LwFx1zskQARAQABtGhBZGFtIE1hcnNoYWxsIERvYnJpbiAod3d3LmxhbWMu bGEgLyB3d3cuZnJvbXRoZW1hY2hpbmUub3JnIC8gZW4ucmVhbGx5aGltLmNvbSkg PGFkYW1AZnJvbXRoZW1hY2hpbmUub3JnPokCTgQTAQoAOBYhBE+vDT4gih9MmA0P ZvtOzkoQkinPBQJeiP0eAhsDBQsJCAcCBhUKCQgLAgQWAgMBAh4BAheAAAoJEPtO zkoQkinPJ4gP/3U691086OKbWiQhMhV+AViuKnMgV4i1M8s+4Ep01h/dTE6R+rUu LcnY4T0HR5qxAYMiNpGo1vtvkMvV5DP1PFSl5EddKn8+Kvn/0+WjbLV5tdiFF1Ef xR6261UFoXAGk3HJMLQifr3lWKoimaBwJZGza2ok9k1TQVTn8g5a01bzK7hD5DJI zt9RJZaUkxGE97eUyJ8Dtwumo18EWJltuC4UWjWT2t2HE9mMsOfjpYZXFsGxJ0Zb xexo0DYsriPDpuxDnZT7G3re9Vwz2VIe388DNBW5HoJsYxhr2I0QOq64ZWOSEZC8 lDH+xM6YdY0iz4A+7nbKNGifLbH8oU4A1sV9HrIE2KNy76x0GNjgQUvcq1inD4Oh yorsRh/IF6wnqvFrHOstCS2dzpKuQ/s7bM5TGOD2EGb0xu7r0AfHqqLUlbr3rxkS wBFMQphyNr3mEkEbXU1dGsXDlRQy11LigMBoEHmP0t49bYWuM1mIBnIC7gZc/sV/ E5fWmWdQyCKmHeujmS+sgp2EX0NtMGSzm7z9WBzTBFjaN7q28gueQ3INDsDTGx2G aA1LbP2uh1ipwju0GxecUif3T2NDqaYfhbaCYsPJORNUlJUtCVBGeba9wcXai2dh l+HsSKUiyCgKiy6Rt6jumKtYHt+Q0zcKWLfVp8PA20zX+2Q9zKnlLzwquQINBF6I /R4BEADQ4kmCHYtAhjCShc724Ei2pqSH4SfnXd4r8S8I0+io6Mh0kWn+kbKk/aGK BL3KJyN6624kPtOFWuQ4iQ0lWFn9UMnvjByTPbjZ2je+VtCP7lKSNvEgTLQRxLEJ hoNVrNjrLa/Cn7sLt9ayYcx8eKpHkbmrVRTyGqljBkI5hwQ8S+7BWugabhGQuogw bFthykA+wxYvSbSn5mwKO1BlbDCRnxjLISlqWwmKKEtXQ8b3tu7GgFuPYLKaLEk1 BIwwUSdozjXu+198WligepslidlN5bXrvje3sxgt4oAPFMeH+NnDClSDuGhSYamW Db3ZPl95pW70ngUVgFPG4kQOlaqzo3YBeDBHDXlqU0+O8cwSQFk4CBJI3yt6/KmD BIuKLwauOxYullx9EnqKcLWEzOlTgn9Q7BARK8Uz7PQU3+1mDNId2MEg+gfL3rd2 +aMLNhTUkgVE5mWkeDz6Kg7YhwruvJtn0z1QqUhkQcVs7N8rVCck0YUCVGXpsUlu emK48q4ryOxmMG/+Ws2Xkmdm6Axq414WHz6nLwMWgFpcO+1wRwQuZEkeWeSAjEvS CGHImxTP7E08+y3vAl43a9AlR7v9PbtCy2FenAhGPigmWm2aPj1ejYfQLXozyWSM m8uO3aiKvQXdV1Ha2xQLK5expaRaAXQ6YLsNBD77UPxi9qC5rwARAQABiQI2BBgB CgAgFiEET68NPiCKH0yYDQ9m+07OShCSKc8FAl6I/R4CGwwACgkQ+07OShCSKc9o DQ/+OV2OuDp9g/27SRssbTWE+nBl0R9klrb/w2XEIVhg5LROUe/P3anyBLNITbF9 A4q8b9udD+iIc1ClY2bu3rQOdzA1DH9GK84bQ1O/LaU0Te8RBGJJEzjYMUraCgIX 4BmxsIlWuCkSNsTgempLOK88646Nv5uc/oxAj6kQH7x8XBXxaJ+N9WS9f7EAv4AL bSWeJ4ijbw9BIMHt/D9Em7Q8bW6VGZIEjIp+gl1vNZ6QGCTtRHQez1jYmFLpuE/G yh1zM5gCnZbcmC7ExDLFI6SuYUbKC+XaLA3+LLCVCPFLtu6wLvcgYFwWWMKIhJAQ bRyPePiuMqWeWR6VXTD8pLziDjxK0ZtvpGdOtZeCCHOEmxrCsfKdIyD2Gn7TmTwb M9fRE1HazROfit6SRCAamabg+dJIEGT8vzlLfnkZRi+6hxq88uDbrOkk36ShWoYB AApz+5fj1ogLptiaTUTyyjTjB+/FIbU48/02fkD0y960zQLyKL64Q4aZrNa2NNup YKy5F80NkU4rHOZ1HTaPLoqqVsGhWc3ODgLyGPiRDLlZu81aNpA/UnTEBX464Sk4 Jx9qztb+S50LnGItA92QfE9ru7FAE00RR6mpCv1h7uE28/Wr4XaYgJcw1hAPRr7p TtN4lph+sJsCQ8eX5YUlM/Pht1h/LoE8h4hXNfAGh+CZgoWZAY0EXodqtAEMAOBb WTLRDxNk9SbC7exKdw0f8Wy9DhX2Qqoi96piS99CMJSxeocLiC9Si2u5nL3sQTAu qs1YbtSgn8kkiH3HPEJIhV1p/Hvz47j4kXq7PnjqF7KAdCYewuDqRiq8J7TNokYs 6+3/KqwHT/IT8NwPLdMkXcv/SXqhuKpqa2ApIrhu04VFp4H5OXN9rqdF5ZDfcNx1 PQv+6m8v6xRwrI3kduRCUD3YiVPM3EOhqINk9XMuxAoVX3qwpz+OuEDBm76U5jTZ q9ErdwRV9gaGm5ztq6tvElpis3spM7BPHzbv0SvVRAAbgGVh6kfiaZ3YckxLq8ln Cg5or1aZNyGMf7CmaZaeAjeY6Y8FZXR1P+n/IFd9Ak83a3qizZyckfiEPO7hu9zI FFXTdtZIcV102rNoVzruZIn0vSK1DJ7bNNrHkm1PPcweMkcFJY0uh6l3x2nl2qKm AhlDs3wFG+nqvqmnliVbrFZCYlReMrWWI2YBwLC5uBcBpFAhMPNEjxOtv31R+wAR AQABtCNBREFNIE0gRE9CUklOIDxhZGFtNUBwcm90b25tYWlsLmNoPokB1AQTAQoA PhYhBP/zHob861BG6LJ9SqGPd44Z/DJIBQJeh2q0AhsDBQkDwmcABQsJCAcCBhUK CQgLAgQWAgMBAh4BAheAAAoJEKGPd44Z/DJIKtgL/0JQEzrGWoHHN7T4wLiArPCv tHB3dTZBoXGKlpuwhgOZ1th6jOnGPdMZRYnX8Zuf7QhaI7m/duKv9OAr8A/2ftHG 7/BxPSHJWBuIGZYNL97OWSstuBhNtyxfCftDkeBCqJ+lAneOrzV0M8syr2VqpfVs O8nTE7nXHSOdyen+1Fw0PtwaeG9uJvOhgRsmQ+mtAiJ1OLGKUxgCzSUk0m/YnDg0 vJBtzq9qP9+EZSuiBuRQC0tKs01ECI5DzWLNXXC6X8k3YGrJpL/HtTxH5SYNQRvS ALd+HmVYpwijLPi7ANzmg9/+h/aq4VFP/4SyMd6EjaaQ86n2fC5zeugio4sjtFMp W3jbZPn19o2hWTt9/bLns+fm9PgnPwdC+tS5LT26N6vhT/vK/HHY5AZvXXPNcQMA wp+EVFxsWK2BcFMIi7Oq47CfuM1AUA+pgCenB4iSVwxs8ANTWWIsLkkKAYQqIdan OSISa2WdslsKMjXIQ5+rG9ekEn+rRO3EAQXRryBt4LkBjQReh2q0AQwAwGx7shIW OaVExpngqmh0ApkxJHZIxcxpatk/lSBQfzHg6e1/7Joe98lEHcWPJ6WFsGp+aC9S 96dWTBZq/4pzAqqTrSXAZpG/+yZlWRWSXVQex1gZHPzsWYMPE9qayAPTOJHtfS6a klIEaFV2GYEvvRK5UR5DFIlsfzyyCBOUKvn0/hikqJjN2YfHUy5SR5U5dGsSX3Jk Q9bOlBYDpN3Rk5rmLg0Vwn4nPRBET70MLQ5M4pU3Br6n+vU8tMHoVXYVMLinD4gO vVY4baXEZELjcPkPzGFPyjVLlpxKMHZ6v1Qb9ornTRGzc4dEUKxi3srdsTpMCw0k CaZ2WLY4sNBO33C8XfIvMx2jF4iIk3BrSrW/hirq6xpvlh4BUh/UWVrvg2rdemAX THa93mRQeOa3bze9xZwaA2GJLRG+xCIt15v/cNpQwCYlyhJunkuwk3HQcUrKfzxo 6QhqMeDaPZeNcvN3XoELGeqtoE7gKAnLp2nQuVr4/pcaiATf+yAhBgYRABEBAAGJ AbwEGAEKACYWIQT/8x6G/OtQRuiyfUqhj3eOGfwySAUCXodqtAIbDAUJA8JnAAAK CRChj3eOGfwySB11DADLgMAafhdzRgzx7FLVVW80IfgiCTAl5M1wV2HctA17aln7 jk7iEVMTLfhrSCSvvNIdrOXUE7l9HAMkKRwaZv7OAtYR8eQTrgGc9yJdk8BMzvJB ouiaNb2LSxMSvpoaJmD2C9ZkOyW+pAXKaUGhbUl8YVa7ytwPD6yZzonGClgZI0x5 9nSc5TiPpVijzu51iZiTV35F6en7ke2hjr6iBACJGBplxeeWszRa0wK2zoubAUK1 KO2punvtGqhi3j77/0sZgvFv3czJpRac5ccdLc02Sb6I64Stp04ilcV1aqlUXxbM gLwkoXZUqbCS7ZA7eBiEaKXdj9ww/gprO0AwFETxQVA8iPF9puSWfBf18a5GEdR1 Drb5lSReCkCfBJd3Tf5WHUSrdcai0FfuXNNp/7J7CBzlOJ0h6Yoa02hz8CBGGwxI 1brXRm13004bX7C9i+94Lbgf8bTM40JvyF1kmcffkj8ibpS/VSa8aWJuqpWk/xcn ob/YdBngWCxNgXii4E6ZAY0EXot8fAEMAJ/JOflg7U8JWescyTQNl9Xuk6QUIVKx 0zOT2k+drlLwC8+FckYTCF1pm8sPDBBv9eN3cFCDf076tZjUHv+Roq5c5McDHlN5 KlFbTSOv1qZYuaPY14nHIoW7OGoSvMCOBkpDLLwnIbuLA0wGdzyd3z6Vfhpz3wDv iAplyA4iuzJQq1+iS8tq6Uj2yhmfg+zU16gw2D3iEC6hhSu2KmPhMFD9KfCzq02L xC6fMh3Fogas51ZF1fRDK8Bvicf4yYj0dn3i6GDr0/vHga4eLQqVBXb0HCv2lNer gTtawQfJu2XEn5hDZKfHeBJ4NI4k7AZIPa7OuUqOAm8Z4hbkgRZakc+OhPSEKH2i drItwrPXDGqMYV4tLLMALMQ9WDTz75wbzVbxGVcAzG3MaZSo/f/iKzuzaE8cF71A dO1y6H5YmmMENn4t/D4BYXm4edPvV6SaYU1hO5yqr7vGbrQBFVetpSCLEFveACHr sm1S6nVVTazkHj2FNdww4bGMJzPqC7bBtQARAQABtChBREFNIE1BUlNIQUxMIERP QlJJTiA8YWRhbUBlcm1jY29ycC5jb20+iQHUBBMBCgA+FiEE9+R8sSygzQHF4cv6 fsjVqFo41joFAl6LfHwCGwMFCQPCZwAFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AA CgkQfsjVqFo41jpPfgv/dylMY4CPMwkdry8KnKP3QtmJOl94VnpJ+FUME+oOqjBw 6/C16uWdTLYuEUuE2jEzTg2J0kgulM2vYm8rVgJzlGiD/oIgX3X5NeyB9MH+GCpu xsJ/ofIVpC6t8Zl78B2qTnJOcEc6owy/qKs/eFXSea2sRRstqK20dOajl4Z2ycEL SdijFR3aqT4hU6e0GNWYqo3bW4TUcd05RJIZBNz6Bitq1fxljxFPOOCaoKo9mVn4 0dN65iGPEYg0c50Q6EmxEr+XtwRu1rjgG3hgq6BknZ6QD1HOBemQg/3jqQBb9uHj jHbuX9HrbGF9+QbDicbmuZSLuV76xJnbyTycFhhIcSi9wZeyAAPlpL4GQ8l98jKa SCWWGDPpKwK5+o8kteuJ/D/mYyBEquyFVhPQBXV9zS3LsN7ab55zB5+ZnLUeofai LE6e+XPGeJmG3I/+T/Nuq1CqJ4Wyt8+aIyf6Uz8dDk0kjyQku484plRwMEx7oZXR bXQAAn8SwtlNGo0sHc6JuQGNBF6LfHwBDACxAxfbQM5AcssJlQFXThnBMHtRDeBH VkyF5mrO9JeFRT+mhM87V+fJXOaEKtcSFVgZJFKV2MPdyGqZSGKmyyqfUvKfucP5 LrjK3MRKibTlOMwbBOmYUksMVE0ByMPeSzyMlQhq0oyA3fvEdKEf0JrFGDRWNzO8 /Q54oj79Pki4y1BDKd7lE1srBFiVEUuPNJmjhhU9WXnMwiB55lLwbTR8mKEX0Pr2 FeTS5gttmbHf4V+wnJvlOEU6mOLMrb+6Xb4ltvqbl9ng1+tF2QMGMd83mtbFtAjb Zcl/Cq2KwsBFyH9VT48ZxWxpOYMf3ppEg9KOSfz9Ungtg4/Q/Kr9P13Nf+9+S9JS 1PfKdlJzGFDn4EwZ49ugg6GNnL6XuRl9jBPD2iD8hY9CsTdWrr9giCmJmdf6G/bK HUm2QekMbhpaQmYKkMeri45cHprx1dQ50rfiH1cBm5SxaK7z/hDDaKXF1Gp7/KwQ g6gHlyMss7EEHSY5ogH+6a7OUPpqbJdNztEAEQEAAYkBvAQYAQoAJhYhBPfkfLEs oM0BxeHL+n7I1ahaONY6BQJei3x8AhsMBQkDwmcAAAoJEH7I1ahaONY6EqoL/R7J QLaAlb4/hK7/v4vsSxtCirLWrqNNNJxYdmpXq19NKPmcc08QzSqkJ7vR4/kn2L6I OY7y7AMh+tScKTKIGn8MkAcj0ZvkafHY3xmpN1Xp9caUAA/fw6KWD+pSZpKpISyd 2Xr6x5OJGSKhyGpPB98oCsa809LQ3cweG1imem3jx+Lgii63pEJG/AeNeEwkIvdC zRLSQvYv0UjlhyOoII6YEWJcro+tgOcthPh2SY50E4lwFFfbz4CNQyL15D+XciNI xSVGz8gee/XdJdgwQF4SEnIiChhmJ5VmpNH8ZwxTMyI3EoFMB/RYaucwc/ucvySn cFyShFFRPjo6TOeYIaSrrfR+4yhHAGeM572y0btI6JjWZovupeXX3k5ZHHrCwxlR MuyULLyhUsAC0r1FUijbUWoyaDcRtLRpMUg1X6A7n1iH61WxlKQ/8mZhYht85Jgp FSiyz47gofc491ng9efshlyxwb3TeLbDZPRnls7L3sfDDWwp8yExjA7UNDbIh5kC DQRencYLARAAsFHArFeulhD6hZplRF49h8+zpI3kn+vFtYwbUqLSRwze53rrJtqE 6o5MWSfadr9KIc8tNZ2aBGxzjGnsbPYLDh76NkjP4apWSMX+u+EHsaudoZoAdNnM Kqr86sVzR0MUeGHp7n/L3imp1WoCn28eMLeNec9a4GRTRPGLKR9F/jytTz/XgkHL zA3i2pt63FqniN4PBTNFzgfXiu8xVZGohsDPjmd9LXbGKTXfJGhBLB6QsmjJwglt n+00ufdKLEZu6eBxRWSVK0t4rEnnpK9K//PKq5DtVaOZNe6g+hdi0B1gpd0f0nBy eZd9arCsvN3qLXP0vYTk9DKMUecCEblss5Zt1+qjAbsMk9/xSGZLJp/4dBTBVN+Q c6+Rmv+koe6zLNmA3fJH3991xETDzZxP2UHN7q4i4L97KA+nVAakwazNLiqsY/bT s58rXnCc72b7oLnZbNOPQmLwZFafVi4xoIE/5Zq8iVr7d7xHPccYkaEVCOnsL/35 GZxy2FNi4wuOfGwBtTbnXg/u/YiBj6yNbhLR+FCwZED5M/evgUUbJudxqRdrI+1a Zo9gGA3JLJZZ/iLwF1kE7yYBvyBRfaO9IL3bwplRurnrkjI+rRhi55AlbGhU3eMu iKTKQk+qJF11ocTGu/dE9I6JeQpEdyVehrWXc5H2N0Qjyca8ZEA6WwcAEQEAAbR7 QURBTSBNQVJTSEFMTCBET0JSSU4gKGl0J3MgdGhlIG9uZSAuLi4gbGlrZSB0aGUg b25lIGluIFN1cGVybWFuIDMgYW5kIE9mZmljZSBzcGFjZS0tYnV0IG5vdCAqdGhh dCogb25lKSA8YWRhbUBlcm1jY29ycC5jb20+iQJOBBMBCgA4FiEE0s8R6kp2bveF MmxLkifaSe8nN2gFAl6dxgsCGwMFCwkIBwIGFQoJCAsCBBYCAwECHgECF4AACgkQ kifaSe8nN2jK+g//Toi6ezWYrRbTs9xwQLIsKzl91ocjCuN9nHSnwzkrLuoGGgej fHkXzd5+3ygL47j++k69TYB9CPrGdR1GTqt56Q7DSYZCgdg+e89piTJUzbEyN01q EGkVuV5Rz9EocnPE8db9HT+xvf44ecfMOFD1XuB9jynrQD445YfeFE6LHkoNUvFD wQK7NN04fa+qvrk0lTS4NCpOYsdrSioddVjQyEC6jepwIRA3iRIkFdEJT8ggqQ6d gntsgExA01o6HqzDSHjSCA5AexCotwW3Uvdt0WwXx6q/c0LsRLhbuPeGX/Nh8aOf 6RBCQWgnIko675ura4c+r1VcBYl524ZJlN4x1x02YAo9cKzYi3+H9C8K8Ayz/SJy 7sVGHWnDge1yIwzWXbpolqiMSL5l/0OBuJ0HXQSafUut33Jw7hYKP4BQia/BmE0x Tsk0rBRMyihSYnUn9mYpXM3KwWU0C2dudVwKtToGR1aKlYcCv0iNFAsR0DBw1XSq n72KqIl020gZFmg3H34Z6CWhm20RbhMjOvvkZ+OiS9kU9kXt6m+T1zCpWHFJSae4 JF+dQyB1BFxAwXW4ZEzMo4XluTuW1R8pIadKTsHMWzEzH7RvZLKP4invsZklZ3I1 EEsJop7DSMOa27irD/IlCL+nwaEsCMRh+ndSkADLHsa9P5d/qWjomKxwdCm5Ag0E Xp3GCwEQAOoXU8NrugMa8OAncXKv4hycXJzArDae3Zx6pCCEkP3TZTXh1tqKPUtb dmb8Mq2eecVTwmB+FM3m+NApgq88Vx6HiyI73IAvgtZORo32YaipfbkGnXHfaUWX 5380R4GL597yZuP8sAsJ3iDvxhW59snsU8tLi+9r2u4h0fgMDqZXQsfvLUkDIiO9 nzJf0xFacTx3n+pUuWdzIuT3AUdU/L9NubmHSnj09FevTHWIYmxGFZoiSdS7r2Z+ 5xZmPak6lzrQTVS/DxcpyA/o3yi8qLPyf1VUxXKFeKd0sV6BPvYFxI2GeBl5atBu 9/3/5D6wdlrupTFLU1Msdfy3UWaRUFHLITK4fJ7pbTgoEqxX7gpO9iqKmScm3gYc O3blA8aTqCX2NzxUF5fHbi14JvPWP04uFl5EOeDB322Jm/guWy8TvmIIyuF3aAAX PfErW/yRWDsYOcAADs8elZkt3F+E/AwWd0JMIhd/RB3RFH8m7496XLS3xBP6rNye 0O+96lX7fVp+wvINxM3Rfo63b1K4bR5KR9JDZ2SLYhrx6Hyy+UiRv7l+i26WxVMF qRyvY2aHqyvKfR1EEf1t2h7B4b65xQkj51qvX5Tjm5Az7nKcXpcUKqS3bk8xiw9N y7eFfA361OSPpQ+V4Mq/Mv+MqyxLTz9tn+80ZtjqM0MEERfpUo15ABEBAAGJAjYE GAEKACAWIQTSzxHqSnZu94UybEuSJ9pJ7yc3aAUCXp3GCwIbDAAKCRCSJ9pJ7yc3 aE2NEACDBRnGYNi2sq0wltPSkD2CbQUon+4uiFB2UU/gs4mFlGOvzDHBHVEFzCqK 0x6KlKm4XBq3AF7iIoNMiU9FmBdWDnEp9eCXdQrr/ykgq3vKMuj6/QJNNZglIDoe 1J2NXeMOUFwCUvjcCttPv42Q8GDt8/bG7QOgmTmhuqvKIj/vL+c3HgNrRsQzhw5z mSzQIDaesD+UVA/sourXpSLeqPgF+6qsEqOirD6hotaqrt+aIA/8wbYkpNQxCEK4 gKDgpqTV7VKklku7fjyhBhZQOVDoWvd03AlGQD0WBNriUsh8l4N6Zg2BlnKTGn11 BTigqwlHC91xtjERgwFg8PAHN2mtgZUHITHX5js11KwlQdLyI04/M4M4oQq0KSbJ rpiWCgrltC/VqJrT4HELFYx2Iv5wzrV9jVEm6zonag4A761hpqTgRrjWtaLuYu2Z zdw9y1r0+0d2rTUGpjIQRVOwi3AF/G4aU+vAOOf/HcgH6Qnpbu+xV0fkuAZbTI7w 6VVkBvnstiQV88KrWAOXKVABSSxTz2OYbzOTt/bgxzAa7yr1xIBDKvujBqDRGBLi bISp+40Haoj2Yqop6vbS70Xq+cnBOwJW86u61hsLgOjqyxgLzvuGTjK7+TblCjR2 F4LNeQdwDdyNRjPYeGVXM3MEqR8XdcR1Z7BQvLNcDgoW2qDcbg== =4lZw -----END PGP PUBLIC KEY BLOCK-----

    1. SciScore for 10.1101/2020.08.10.241414: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MATERIALS AND METHODS Cell cultures and Viruses Vero E6 (ATCC CRL-1586) cells were maintained in DMEM medium supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 IU/mL penicillin and 100 μg/mL streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu-3 (ATCC HTB-55) and Caco-2 (ATCC HTB-37) were cultured in Eagle's Minimum Essential Medium (EMEM) supplemented with 10% FCS, 2 mM L-glutamine, 100 IU/mL penicillin, 100 μg/mL streptomycin and 1x non-essential amino acid solution (Gibco MEM</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Calu-3</div> <div>suggested: ATCC Cat# HTB-55, RRID:CVCL_0609)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 infection and protease inhibition SARS-CoV-2 cell entry inhibition was tested by seeding Vero E6, Calu-3 or Caco-2 cells in 96well plates, one day before infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Caco-2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The virus supernatant was collected at 1 and 2 dpi and titrated on Vero E6 cells as described in SARS-CoV-2 titration section.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: RRID:CVCL_XD71)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plaque area was measured with help of ZEISS ZEN lite 3.0 (Blue edition), and plotted using GraphPad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GraphPad Prism</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The resulting sequence reads were aligned with reference (BWA 0.7.8).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>BWA</div> <div>suggested: (BWA, RRID:SCR_010910)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The alignment file was sorted (SAMtools version 1.10) and realigned (GATK IndelRealigner version 3.7).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GATK</div> <div>suggested: (GATK, RRID:SCR_001876)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Finally, pileup file (SAMtools) was created and mutation were detected with VarScan (version 2.3.9).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SAMtools</div> <div>suggested: (Samtools, RRID:SCR_002105)</div> </div> <div style="margin-bottom:8px"> <div>VarScan</div> <div>suggested: (VARSCAN, RRID:SCR_006849)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mutation frequencies were converted to percent values and plotted with ggplot2 (R/Bioconductor 4.0)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ggplot2</div> <div>suggested: (ggplot2, RRID:SCR_014601)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For all statistical analyses, the GraphPad Prism 7 software package was used (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GraphPad</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your code and data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.08.10.243220: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, the chips were incubated with a blocking solution of 2% Bovine Serum Albumin (BSA) in PBS (‘blocking buffer’), followed by overnight incubation with the primary antibody: mouse anti-human CD45 (abcam NUMBER), or mouse anti-SARS-CoV-2 spike protein (Genetex, NUMBER ) at a concentration of 1:100 in the blocking buffer at 4℃.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD45</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-SARS-CoV-2 spike protein</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The secondary antibodies used were: Donkey anti-mouse Alexa Fluor 488 (A21206, Thermo Fisher), or Donkey anti-mouse Alexa Fluor 568 (A10037, Thermo Fisher), or Donkey anti-mouse Alexa Fluor 647(A31573, Thermo Fisher), and were chosen to complement the fluorophores already assigned to RNAscope labelling.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>A21206</div> <div>suggested: (Molecular Probes Cat# A-21206, RRID:AB_2535792)</div> </div> <div style="margin-bottom:8px"> <div>A10037</div> <div>suggested: (Thermo Fisher Scientific Cat# A10037, RRID:AB_2534013)</div> </div> <div style="margin-bottom:8px"> <div>anti-mouse</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>A31573</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus used for all experiments in this manuscript was at passage 3 in Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: RRID:CVCL_XD71)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CD14+ monocytes were isolated using positive selection (CD14 ultrapure isolation kit, Miltenyi Biosciences) and cultured in RPMI medium supplemented with 10% FBS and differentiated for 7 days with 20 ng/ml recombinant human Macrophage-Colony Stimulating Factor protein (M-CSF) (Thermo Fisher Scientific), and 100U/L of penicillin-streptomycin solution (Thermo Fisher Scientific) to avoid bacterial contamination.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Miltenyi Biosciences</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Amplicon specificity was confirmed by melting-curve analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Amplicon</div> <div>suggested: (Amplicon, RRID:SCR_003294)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Custom-written software in MATLAB was used to segment and identify the 3D volume, mean intensity, and number of RNA dots in each field of view using the nestedSortStruct algorithm for MATLAB written by the Hughey Lab (https://www.github.com/hugheylab/nestedSortStruct, GitHub).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MATLAB</div> <div>suggested: (MATLAB, RRID:SCR_001622)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis was performed using Origin 9.2 (OriginLabs) and p-values were calculated using a Kruskal-Wallis one-way ANOVA test, with the null hypothesis that the medians of each population were equal.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Origin</div> <div>suggested: (Origin, RRID:SCR_014212)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.08.07.242271: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">This program and associated human subject research, performed in in accordance with the ethical standards of the Helsinki Declaration, were approved by the NorthShore University HealthSystem Institutional Review Board.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Samples were divided into tertiles based on the Roche assay results, then 47 were randomly selected to equally sample each tertile.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 S1 RBD Ig ELISA The anti-SARS-CoV-2 S1 RBD total Ig assay employed a standard indirect enzyme immunoassay technique (ELISA), described in detail elsewhere, using a secondary antibody recognizing all human immunoglobulin isotypes (goat anti-human IgG H+L-HRP, Invitrogen/ThermoFisher) [12,13]</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-SARS-CoV-2</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human IgG H+L-HRP</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Live SARS-CoV-2 Virus Neutralization Assay Vero E6 cells (2.5×104) were seeded in each well of a 96-well Black/Clear Flat Bottom TC-treated plate (Falcon) and incubated in DMEM overnight at 37°C with 5% CO2 prior to infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A nonlinear regression method was used to determine the dilution that neutralized 50% of mNeonGreen fluorescence (NT50) by using Prism 8 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GraphPad</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.08.06.240796: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Methods Data retrieval An exhaustive search of the Gene Expression Omnibus (GEO) database ( https://www.ncbi.nlm.nih.gov/geo/) was performed to identify eligible data on 1st June 2020.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Gene Expression Omnibus</div> <div>suggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For agilent microarray data, raw expression profiling files were uploaded into RStudio using package “limma” 60 .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>RStudio</div> <div>suggested: (RStudio, RRID:SCR_000432)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cohen J.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Cohen J</div> <div>suggested: (Lymphoma Research Foundation, RRID:SCR_004410)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      First of all, the key word “Airway epithelial cells” was used for the search without any limitations. In a second step, non-human datasets, non-series datasets and non-gene expression array datasets were filtered out. Finally, datasets from step two were reviewed carefully, and the following datasets were excluded: (a) datasets of cell line(s), (b) redundant dataset, (c) datasets containing only one group and (d) datasets containing less than 5 samples per group. Data correction, normalization For affymetrix microarrays, CEL files were uploaded into RStudio (Version 1.3.959, based on R version 4.0.1) using package “affy” 58 . Subsequently, background correction and normalization were applied to the raw data using “Robust Multichip Average (RMA)” method 59 . For agilent microarray data, raw expression profiling files were uploaded into RStudio using package “limma” 60 . By using the “limma” package, background correction and normalization were performed using “normexp” and “quantile” methods, respectively. Background corrected, normalized and log2 transformed signal intensities of ACE2, TMPRSS2 and cathepsin L were outputted and used for further analysis. Meta analysis All meta-analysis were performed using “meta” package in RStudio. Standardised mean difference (SMD) was utilized to assess the effect size of a factor on the expression of targeted genes, and 95% confidence intervals (CIs) of SMD was calculated 61 . According to the guideline proposed by Cohen62, the magnitude of the SMD is interpreted as below: small, SMD = 0.2; medium, SMD = 0.5; and large, SMD = 0.8. Fixed or random effect model was applied to pool the effect size depending on the heterogeneity across the datasets determined by inconsistency (I2) statistics and Cochrane's Q test. random effect model was applied when there was significant heterogeneity among datasets (I2 value > 50% or P value of Q test < 0.05), otherwise fixed effect model was utilized 63, 64. Statistics All statistical analyses were conducted using RStudio. Statistical significance between two groups was calculated using paired or unpaired Student’s t test depending on the samples. For the study containing two categorical factors, we utilized two-way ANOVA to determine the statistical difference followed by Tukey’s test for post hoc analysis. Multiple linear regression model was generated to evaluate the correlation of lung function index of COPD patients and healthy controls with gene expression of ACE2. A P value<0.05 was considered as statistical significance. Fundings This study was supported by the Deutsche Forschungsgemeinschaft via Exzellenzcluster 2167, DFG-27260646 and GRK1727 “Modulation of Autoimmunity” as well as the Bundesministerium für Bildung und Forschung (BMBF) via the German Center for Lung Research (DZL). Author Contribution Study design: X.Y., Literature search and data analysis: J.Y., Data interpretation: B.K. F.P. X.Y., Writing: B.K. F.P. X.Y. Competing financial interests The authors declare no competing financial interests. Reference List 1. Huang,C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497-506 (2020). 2. Zhu,N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med.(2020). 3. WHO characterizes COVID-19 as a pandemic. 2020. Ref Type: Internet Communication 4. COVID-19 Coronavirus Pandemic. 2020. Ref Type: Internet Communication 5. Lu,R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet(2020). 6. Zhou,P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature(2020). 7. Heurich,A. et al. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J. Virol. 88, 1293-1307 (2014). 8. Hoffmann,M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280 (2020). 9. Ou,X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020). 10. Guan,W.J. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 382, 1708-1720 (2020). 11. Lippi,G. & Henry,B.M. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir. Med. 167, 105941 (2020). 12. Zhao,Q. et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J. Med. Virol.(2020). 13. Zhang,M., Gao,Y., Zhao,W., Yu,G., & Jin,F. ACE-2/ANG1-7 ameliorates ER stressinduced apoptosis in seawater aspiration-induced acute lung injury. Am. J. Physiol Lung Cell Mol. Physiol 315, L1015-L1027 (2018). 14. Leung,J.M. et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur. Respir. J. 55, (2020). 15. Ammous,Z. et al. Variability in small airway epithelial gene expression among normal smokers. Chest 133, 1344-1353 (2008). 16. Beane,J. et al. Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. Genome Biol. 8, R201 (2007). 17. Butler,M.W. et al. Modulation of cystatin A expression in human airway epithelium related to genotype, smoking, COPD, and lung cancer. Cancer Res. 71, 2572-2581 (2011). 18. Carolan,B.J. et al. Up-regulation of expression of the ubiquitin carboxyl-terminal hydrolase L1 gene in human airway epithelium of cigarette smokers. Cancer Res. 66, 10729-10740 (2006). 19. Carolan,B.J., Harvey,B.G., De,B.P., Vanni,H., & Crystal,R.G. Decreased expression of intelectin 1 in the human airway epithelium of smokers compared to nonsmokers. J. Immunol. 181, 5760-5767 (2008). 20. Hessel,J. et al. Intraflagellar transport gene expression associated with short cilia in smoking and COPD. PLoS. One. 9, e85453 (2014). 21. Raman,T. et al. Quality control in microarray assessment of gene expression in human airway epithelium. BMC. Genomics 10, 493 (2009). 22. Schembri,F. et al. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc. Natl. Acad. Sci. U. S. A 106, 2319-2324 (2009). 23. Spira,A. et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc. Natl. Acad. Sci. U. S. A 101, 10143-10148 (2004). 24. Sridhar,S. et al. Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC. Genomics 9, 259 (2008). 25. Strulovici-Barel,Y. et al. Threshold of biologic responses of the small airway epithelium to low levels of tobacco smoke. Am. J. Respir. Crit Care Med. 182, 1524-1532 (2010). 26. Tilley,A.E. et al. Biologic phenotyping of the human small airway epithelial response to cigarette smoking. PLoS. One. 6, e22798 (2011). 27. Walters,M.S. et al. Waterpipe smoking induces epigenetic changes in the small airway epithelium. PLoS. One. 12, e0171112 (2017). 28. Wang,R. et al. Airway epithelial expression of TLR5 is downregulated in healthy smokers and smokers with chronic obstructive pulmonary disease. J. Immunol. 189, 2217-2225 (2012). 29. Wang,X. et al. Genetic variation and antioxidant response gene expression in the bronchial airway epithelium of smokers at risk for lung cancer. PLoS. One. 5, e11934 (2010). 30. Woodruff,P.G. et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc. Natl. Acad. Sci. U. S. A 104, 15858-15863 (2007). 31. Zhou,H. et al. POU2AF1 Functions in the Human Airway Epithelium To Regulate Expression of Host Defense Genes. J. Immunol. 196, 3159-3167 (2016). 32. Shared Gene Expression Alterations in Nasal and Bronchial Epithelium for Lung Cancer Detection. J. Natl. Cancer Inst. 109, (2017). 33. Corbett,S.E. et al. Gene Expression Alterations in the Bronchial Epithelium of eCigarette Users. Chest 156, 764-773 (2019). 34. Travis,W.D. et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J. Thorac. Oncol. 10, 1243-1260 (2015). 35. Billatos,E. et al. Impact of acute exposure to cigarette smoke on airway gene expression. Physiol Genomics 50, 705-713 (2018). 36. Zhang,H. et al. Expression of the SARS-CoV-2 ACE2 Receptor in the Human Airway Epithelium. Am. J. Respir. Crit Care Med.(2020). 37. Vucic,E.A. et al. DNA methylation is globally disrupted and associated with expression changes in chronic obstructive pulmonary disease small airways. Am. J. Respir. Cell Mol. Biol. 50, 912-922 (2014). 38. Beane,J. et al. Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev. Res. (Phila) 4, 803-817 (2011). 39. Silvestri,G.A. et al. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. N. Engl. J. Med. 373, 243-251 (2015). 40. Spira,A. et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat. Med. 13, 361-366 (2007). 41. Tong,R. et al. Decreased Interferon Alpha/Beta Signature Associated with Human Lung Tumorigenesis. J. Interferon Cytokine Res. 35, 963-968 (2015). 42. Tsay,J.C. et al. Molecular characterization of the peripheral airway field of cancerization in lung adenocarcinoma. PLoS. One. 10, e0118132 (2015). 43. Clarke,L.A., Sousa,L., Barreto,C., & Amaral,M.D. Changes in transcriptome of native nasal epithelium expressing F508del-CFTR and intersecting data from comparable studies. Respir. Res. 14, 38 (2013). 44. Giovannini-Chami,L. et al. Distinct epithelial gene expression phenotypes in childhood respiratory allergy. Eur. Respir. J. 39, 1197-1205 (2012). 45. Wagener,A.H. et al. The impact of allergic rhinitis and asthma on human nasal and bronchial epithelial gene expression. PLoS. One. 8, e80257 (2013). 46. Kicic,A. et al. Decreased fibronectin production significantly contributes to dysregulated repair of asthmatic epithelium. Am. J. Respir. Crit Care Med. 181, 889-898 (2010). 47. Bochkov,Y.A. et al. Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal. Immunol. 3, 69-80 (2010). 48. Bosco,A., Wiehler,S., & Proud,D. Interferon regulatory factor 7 regulates airway epithelial cell responses to human rhinovirus infection. BMC. Genomics 17, 76 (2016). 49. Proud,D. et al. Gene expression profiles during in vivo human rhinovirus infection: insights into the host response. Am. J. Respir. Crit Care Med. 178, 962-968 (2008). 50. Wagener,A.H. et al. dsRNA-induced changes in gene expression profiles of primary nasal and bronchial epithelial cells from patients with asthma, rhinitis and controls. Respir. Res. 15, 9 (2014). 51. Ziegler,C.G.K. et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell 181, 1016-1035 (2020). 52. Guo,F.R. Active smoking is associated with severity of coronavirus disease 2019 (COVID-19): An update of a meta-analysis. Tob. Induc. Dis. 18, 37 (2020). 53. Zheng,Z. et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J. Infect.(2020). 54. Pillay,T.S. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. J. Clin. Pathol. 73, 366-369 (2020). 55. Camiolo,M.J., Gauthier,M., Kaminski,N., Ray,A., & Wenzel,S.E. Expression of SARSCoV-2 Receptor ACE2 and Coincident Host Response Signature Varies by Asthma Inflammatory Phenotype. J. Allergy Clin. Immunol.(2020). 56. Jackson,D.J. et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J. Allergy Clin. Immunol.(2020). 57. Bashir,H. et al. Association of rhinovirus species with common cold and asthma symptoms and bacterial pathogens. J. Allergy Clin. Immunol. 141, 822-824 (2018). 58. Gautier,L., Cope,L., Bolstad,B.M., & Irizarry,R.A. affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20, 307-315 (2004). 59. Irizarry,R.A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4, 249-264 (2003). 60. Ritchie,M.E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015). 61. Faraone,S.V. Interpreting estimates of treatment effects: implications for managed care. P. T. 33, 700-711 (2008). 62. 63. 64. Cohen J. Statistical Power Analysis for the Behavioral Sciences.1988). He,R.Q. et al. Downregulated miR-23b-3p expression acts as a predictor of hepatocellular carcinoma progression: A study based on public data and RT-qPCR verification. Int. J. Mol. Med. 41, 2813-2831 (2018). Higgins,J.P. & Thompson,S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539-1558 (2002). Fig. 1. Flow chart of GEO databases screening and selection process. Fig. 2. Expression of ACE2, TMPRSS2 and cathepsin L (CTSL) in airway epithelial cells of healthy current smokers (CS) and never smokers (NS). a) Violin plot of expression levels of ACE2, TMPRSS2 and CTSL in 12 datasets which contain current smokers and never smoker. Mean and standard deviation (SD) of each group are presented as dot and line, respectively. Statistical difference was calculated by Student’s t test. *p<0.05, **p<0.01, ***p<0.001. b) Forest plot of 12 datasets examining expression of ACE2, TMPRSS2 and CTSL in current smokers and never smokers. The x-axis indicates the standardized mean difference (SMD), while the y-axis shows GEO datasets and cell types. Each square in the plots represents the SMD in corresponding datasets and the 95% confidence interval (CI) is shown by the error bar. The size of each square represents the weight of the individual dataset in the meta-analysis. The diamonds in the bottom represent the SMD of the meta-analysis. The SMD, 95% CI and P values of meta-analysis are depicted. BEC, bronchial epithelial cell, NEC, nasal epithelial cell, SAEC, small airway epithelial cell, LAEC, large airway epithelial cell, TAEC, trachea airway epithelial cell. Fig. 3. Expression of ACE2, TMPRSS2 and cathepsin L (CTSL) in airway epithelial cells of healthy subjects and COPD patients. a) Violin plot of expression levels of ACE2, TMPRSS2 and CTSL in 3 datasets which contain healthy never smokers and patients with COPD. Statistical difference was calculated by Student’s t test. *p<0.05, **p<0.01, ***p<0.001. b) Forest plot of 3 datasets examining expression of ACE2, TMPRSS2 and CTSL in healthy never smokers and patients with COPD. The SMD, 95% CI and P values of meta-analysis are depicted. c) Violin plot of expression levels of ACE2, TMPRSS2 and CTSL in 5 datasets which contain healthy smokers and patients with COPD. d) Forest plot of 5 datasets examining expression of ACE2, TMPRSS2 and CTSL in healthy smokers and patients with COPD. CS, Current smokers, FS, Former smokers, SM, Smokers. Fig. 4. Decreased expression of ACE2 and cathepsin L (CTSL) in nasal epithelial cells of patients with allergic respiratory diseases. a) Violin plot of expression levels of ACE2, TMPRSS2 and CTSL in two datasets which contain healthy controls, patients with allergic rhinitis and patients with asthma. Statistical difference was calculated by Student’s t test. *p<0.05 and **p<0.01. b) Forest plot of datasets examining expression of ACE2, TMPRSS2 and CTSL in nasal epithelial cells of healthy controls and patients with allergic rhinitis or asthma. The x-axis indicates the standardized mean difference (SMD), while the y-axis shows GEO datasets and cell types. The SMD, 95% CI and P values of meta-analysis are depicted. Fig. 5. Expression of ACE2, TMPRSS2 and cathepsin L (CTSL) in airway epithelial cells after rhinoviral infection or TLR3 activation. Expression kinetics of of ACE2 (a), TMPRSS2 (e), and CTSL (i) in airway epithelial cells of healthy subjects experimentally infected with rhinovirus or saline-treated controls (data from GSE11348). Expression of ACE2 (b), TMPRSS2 (f), and CTSL (j) in airway epithelial cells isolated from healthy subjected and stimulated in vitro with or without rhinovirus in presence or absence of IRFsiRNA (data from GSE70190). Expression of ACE2 (c), TMPRSS2 (g), and CTSL (k) in airway epithelial cells isolated from healthy subjected or patients with asthma and stimulated in vitro with rhinovirus or saline control (data from GSE13396). Expression of ACE2 (d), TMPRSS2 (h), and CTSL (l) in airway epithelial cells isolated from healthy subjected or patients with asthma and stimulated in vitro with poly(I:C) or saline control (data from GSE13396). Statistical analysis was performed using two-way ANOVA, Tukey’s test for post hoc analysis was performed after two-way ANOVA analysis. *, p<0.05, **, p<0.01, ***, p<0.001. HC, healthy control, NS, not significant.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.08.09.242917: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Blood samples were obtained from healthy human donors (Hospital 12 de Octubre, Madrid, Spain) under informed consent and IRB approval.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate monocyte-derived macrophages (M2-MDMs), CD14+ monocytes were purified using anti-human CD14 antibodylabeled magnetic beads and iron-based LS columns (Miltenyi Biotec) and used directly for further differentiation into macrophages (Dominguez-Soto et al., J Immunol 2011).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human CD14</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">As a control, inhibition experiment was performed in the presence of anti-DC/L-SIGN antibody (R&D Systems).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-DC/L-SIGN</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">EXPI293 cells grown in EXPI293 expression medium were transiently transfected with the S ectodomain vector according to the manufacturer’s protocol (Thermo Fisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>EXPI293</div> <div>suggested: RRID:CVCL_D615)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines Baby hamster kidney cells (BHK-21, 12-14-17 MAW, Kerafast, Boston, MA) and African Green Monkey Cell Line (VeroE6) were cultured in Dulbecco´s modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 25 μg/mL gentamycin and 2 mM L-glutamine.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>BHK-21</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Jurkat, Jurkat DC-SIGN, Jurkat L-SIGN (Alvarez et al., 2002) and Jurkat langerin were maintained in RPMI 1640 supplemented with 10% heat-inactivated FBS, 25 μg/mL gentamycin and 2 mM L-glutamine.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Jurkat</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Infectious titers were estimated as tissue culture infectious dose per mL by limiting dilution of rVSV-luc-pseudotypes on Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: RRID:CVCL_XD71)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Jurkat DC-SIGN and MDDCs were then resuspended in RPMI medium and co-cultivated with adherent Vero E6 cells (1.5 x 105 cells/well) on a 24-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Jurkat DC-SIGN</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( Top row: original images; bottom row: Photoshop processed images.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Photoshop</div> <div>suggested: (Adobe Photoshop, RRID:SCR_014199)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the 2D classification, images were processed with RELION 2.1 (Scheres, 2012).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>RELION</div> <div>suggested: (RELION, RRID:SCR_016274)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.08.05.238360: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">trea IFN IL FNh fi h fibTN rea IFN IL t d i t ti it wi wi Un an w w w Un -γ -α α -γ α F- IFN FFN TNF N I T nd a -α F TN CCL23 15 4 2 0 Fold change, TNF-α (vs untreated) f CCL2 IDO1 CXCL10 AN MRC1 4 3 2 1 0 P9 3 2 1 0 1A CXCL9 CLEC4A 3 2 1 0 ● ● γ o γ γ α d N- fibr fibro F- ate N-β L-4 N- ro - ro ro -α ed -β 4 N I IF fib FN ib ib F at N Lth ith T ntre IF d ith I ith f ith f TNtre IF I n w a w U Un α α γwαw F- N-γ</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>w w w Un -γ -α α -γ α F-</div> <div>suggested: None</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your code.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. Hewitt, J., Carter, B., Vilches-Moraga, A., Quinn, T. J., Braude, P., Verduri, A., Pearce, L., Stechman, M., Short, R., Price, A., Collins, J. T., Bruce, E., Einarsson, A., Rickard, F., Mitchell, E., Holloway, M., Hesford, J., Barlow-Pay, F., Clini, E., … Guaraldi, G. (2020). The effect of frailty on survival in patients with COVID-19 (COPE): A multicentre, European, observational cohort study. The Lancet Public Health, 5(8), e444–e451. https://doi.org/10.1016/S2468-2667(20)30146-8

    1. We know little about the dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in African countries, including its infectiousness and the proportion of infected people who develop symptoms. Confined exposure of 2010 people on an aircraft carrier resulted in an infection rate of just 50%, and only 50% of infected people developed symptoms.2Lagneau L Covid-19: la contamination du porte-avions Charles de Gaulle garde ses mystères…pour le moment.http://www.opex360.com/2020/04/19/covid-19-la-contamination-du-porte-avions-charles-de-gaulle-garde-ses-mysteres-pour-le-moment/Date accessed: July 4, 2020Google Scholar Under less confined conditions, and similar to other circulating viruses that cause acute respiratory infections, SARS-CoV-2 might cause infection rates well below 30%, thus unable to provoke herd immunity but most probably causing recurring annual infections.Estimated infection fatality rates of around 0·3%3Streeck H Schulte B Kuemmerer B et al.Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event.medRxiv. 2020; (published online June 2.) (preprint).https://doi.org/10.1101/2020.05.04.20090076Google Scholar draw a much less dramatic picture of COVID-19-related deaths than predicted by Wells and colleagues, who presumed 95% of all Congolese will be infected, with an infection fatality rate of over 4%.1Wells CR Stearns JK Lutumba P Galvani AP COVID-19 on the African continent.Lancet Infect Dis. 2020; (published online May 6.)https://doi.org/10.1016/S1473-3099(20)30374-1Summary Full Text Full Text PDF Scopus (0) Google Scholar In DR Congo, we might thus estimate fewer than 40 000 attributable deaths compared with 800 000 Congolese people dying each year in the country.4countryeconomy.comGoogle ScholarDemocratic Republic of the Congo.https://countryeconomy.com/countries/democratic-republic-congoDate accessed: July 4, 2020Google Scholar Such estimates put the prioritisation of this disease over other health threats on the continent immediately into question.
    1. Havers, F. P., Reed, C., Lim, T., Montgomery, J. M., Klena, J. D., Hall, A. J., Fry, A. M., Cannon, D. L., Chiang, C.-F., Gibbons, A., Krapiunaya, I., Morales-Betoulle, M., Roguski, K., Rasheed, M. A. U., Freeman, B., Lester, S., Mills, L., Carroll, D. S., Owen, S. M., … Thornburg, N. J. (2020). Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2020.4130

    1. SciScore for 10.1101/782409: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">The experimental protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Loyola University Chicago (IACUC#: 2016-029).</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">C57BL/6 female mice were purchased from The Jackson Laboratory and maintained in the Comparative Medicine Facility of Loyola University Chicago.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The membrane was incubated with either polyclonal rabbit anti-GFP antibody (A11122, Life Technologies) for the protease assay, or mouse anti-flag (F3165, Sigma) for the DUB assay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-GFP</div> <div>suggested: (Molecular Probes Cat# A-11122, AB_221569)</div> </div>

            <div style="margin-bottom:8px">
              <div><b>anti-flag ( F3165</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The membrane was then washed three times for 15 minutes in TBST buffer followed by incubation with either secondary donkey anti-rabbit-HRP antibody (711-035-152, Jackson ImmunoResearch) or goat anti-mouseHRP antibody (1010-05, SouthernBiotech).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>anti-rabbit-HRP</b></div>
              <div>suggested: (Kindle Biosciences Cat# R1006, <a href="https://scicrunch.org/resources/Any/search?q=AB_2800464">AB_2800464</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>anti-mouseHRP</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The expression of PLP2, β-actin, and calnexin were probed with mouse anti-V5 antibody (R960, ThermoFisher), mouse anti–β-actin (A00702, Genscript), or mouse anti-calnexin antibody (2433S, Cell Signaling), respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>PLP2</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>β-actin</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>anti-V5</b></div>
              <div>suggested: (Thermo Fisher Scientific Cat# R960CUS, <a href="https://scicrunch.org/resources/Any/search?q=AB_2792973">AB_2792973</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>mouse anti-calnexin antibody</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>anti-calnexin</b></div>
              <div>suggested: (Cell Signaling Technology Cat# 2433, <a href="https://scicrunch.org/resources/Any/search?q=AB_2243887">AB_2243887</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Experimental Models: Cell Lines</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells Human embryonic kidney (HEK) 293T cells were purchased the from American Type Culture Collection (ATCC, # CRL-11268) and maintained in DMEM (#10-017-CV, Corning) containing 10% fetal calf serum (FCS) and supplemented with 1% nonessential amino acids, 1% HEPES, 2% L-glutamine, 1% sodium pyruvate, and 1% penicillin/streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>293T</b></div>
              <div>suggested: ATCC Cat# CRL-11268, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_1926">CVCL_1926</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the protease activity assay, HEK293T cells were transfected with 25 ng nsp2/3-GFP plasmid and 200 ng pCAGGS-PLP2-V5 expression plasmids (wild-type and mutant).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK293T</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Graphs of virus kinetics were generated using Prism software (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Prism</b></div>
              <div>suggested: (PRISM, <a href="https://scicrunch.org/resources/Any/search?q=SCR_005375">SCR_005375</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>GraphPad</b></div>
              <div>suggested: (GraphPad Prism, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002798">SCR_002798</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MH and RCM were supported by NIH T32 Training Grant for Experimental Immunology (#AI007508) and RCM was supported by the Arthur J.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Arthur J</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr></table>
      

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. Clausen, T. M., Sandoval, D. R., Spliid, C. B., Pihl, J., Painter, C. D., Thacker, B. E., Glass, C. A., Narayanan, A., Majowicz, S. A., Zhang, Y., Torres, J. L., Golden, G. J., Porell, R., Garretson, A. F., Laubach, L., Feldman, J., Yin, X., Pu, Y., Hauser, B., … Esko, J. D. (2020). SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. BioRxiv, 2020.07.14.201616. https://doi.org/10.1101/2020.07.14.201616

    1. Horby, P., Mafham, M., Linsell, L., Bell, J. L., Staplin, N., Emberson, J. R., Wiselka, M., Ustianowski, A., Elmahi, E., Prudon, B., Whitehouse, A., Felton, T., Williams, J., Faccenda, J., Underwood, J., Baillie, J. K., Chappell, L., Faust, S. N., Jaki, T., … Landray, M. J. (2020). Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. MedRxiv, 2020.07.15.20151852. https://doi.org/10.1101/2020.07.15.20151852

  5. Jul 2020
    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1

      1. The first hypothesis of the manuscript is that, rather than a change in a single immune pathway being responsible for the lack of response to the virus, the response will be systemic involving multiple inter-related pathways. The data show that this was the case after presenting convincing transcriptome analysis.

      We thank the reviewer agreeing that we have convincingly shown that the response to the virus is systemic involving the induction of interrelated pathways

      The second hypothesis is that the differences in responses between bats and humans are due to evolutionarily divergent genes. The authors provide evidence for this in the transcriptome differences in the C-reactive protein, aspects of the complement system, iron regulation and M1/M2 macrophage polarization. The second hypothesis is broad, but there are clearly differences in the genes involved in humans and bats. Without mechanistic information on the function of the proteins/cells investigated, it is hard to determine that the changes the authors are observing are the cause of the different responses, rather than an effect of some upstream response, and so difficult to pin-point specific divergent genes.

      We agree that mechanistic studies will be required to test causal links between the genes we identified and specific anti-viral responses, an effort that is likely to require multiple laboratories and some time. The aim of this study was to enable this effort by identifying a list of candidate genes affected by EBOV and MARV infection in bats, not merely in cultured bat cells.

      The authors wish to compare the response to the virus in bats to the better characterized human tissue responses, but because this relies on previously published work in humans, it is sometimes unclear whether "more bat-like" responses are definitely associated with positive outcomes in humans. As the benefit of certain responses in human infections can depend on the timing of the response, it might be helpful to include summarized human data in manuscript to aid comparison with the bat responses.

      We agree and have added the following data and discussion (inserted into Discussion, page 9, and added two new tables, Tables 2 and 3).

      Comparing our observations to human responses to filoviruses is limited by the scarcity of studies in humans. Nevertheless, this comparison suggests potential directions to explore. In one study, individuals who succumbed to the disease showed stronger upregulation of interferon signaling and acute phase responses compared to survivors during the acute phase of infection[1], consistent with the anti-inflammatory response gene expression signature identified in this study in bats. However, most of the genes used in the study by Liu et al. to classify survivors are either barely expressed in bats or do not respond to filoviral infection (Table 2), the differences that provide potential clues to find why bats can tolerate the infection.

      A study of patients infected with Sudan Ebola virus (SUDV) analyzed protein levels for a panel of genes using a Luminex multiplex assay (using antibodies)[2]. The panel was based on results from other studies and pathways involved in the response to infections. The patients were classified into 3 possible dichotomies (fatal/non-fatal, hemorrhaging/non-hemorrhaging, or high/low viremia) correlated with genes that characterized these states. Most of these genes either are barely expressed, if at all, or are unaffected by infection in bats, except for ferritin (FTL, FTH1) whose expression is lowered by MARV infection, consistent with the observation that ferritin is higher is fatal human cases (Table 3).

      For instance, the T-cell response section concludes "Bats mount a T cell response against the infection" but there is no discussion of the impaired but complex lymphocyte response in humans, so comparison is not possible.

      We have expanded the discussion on T cells (Results, page 7) as follows.

      Previous studies on the adaptive immune response to Ebola and Marburg viruses in humans, non-human primates, and non-primate mammals, shows that long-term immunity is conferred by both T cell and antibody responses. Mostly CD8+ T cells were elicited and helpful against Ebola in mice[3],[4], while SUDV infection in humans[5]) and MARV infection in cynomolgus monkeys[6] and humans[7] ) elicited mostly CD4+ T cells . In most human EBOV infections, CD8+ T cells against the EBOV NP protein dominated the responses, while a minority of individuals harbored memory CD8+ T cells against the EBOV-GP [8].

      Consistent with this, in MARV-infected bats, CD4 expression (specific to CD4+ T cells) was higher, while in EBOV-infected bats, CD8 expression (specific to CD8+ T cells) was higher, the overall levels are low, because the tissue samples are heterogenous and expression of these markers is not high in the T cells to begin with. T cell markers (such as CCL3, ANAX1, TIMD4 and MAGT1) are also upregulated in liver, suggesting a T cell response is mounted.

      Mock infected IHC should be included in Figure 1F to demonstrate the antibodies are not background.

      We have added IHC data of two mock-infected animals (Fig. S1 panels A and B).

      See comment in hypotheses- a summarized table of findings from previous studies of early responses to the virus would be helpful for comparisons to the bat response and for determining the second hypothesis.

      We have expanded our comparisons to previous studies by adding the following text to Introduction (page 3)

      A potential source of the difficulty to understand how bats tolerate or eliminate the viruses that are deadly to humans is the lack of studies that analyze the response to infection in bats rather than in cultured bat cells. The results obtained using cell lines have been contradictory. Some studies claim both EBOV and MARV replicate to similar levels in ERB and human derived cell lines[9], with a robust innate immune response mounted by ERB and to a lesser degree, human cells, while others claim MARV inhibited the antiviral program in ERB cells, like in primate cells, and did not induce almost any IFN gene [10], or little anti-viral gene induction[11]. An experiment with the pig (PK15A) and bat (EhKiT) cells suggested they responded to EBOV through the upregulation of immune, inflammatory, and coagulation pathway, in contrast to a limited response in the human (HEK293T) cells[12]. To comprehensively understand the pathways involved in the bat filoviral response, we infected bats, rather than their isolated cells, and analyzed tissue-specific RNA expression through mRNA-seq in the organs of the infected animals.

      Reviewer #2

      1. The authors provide this contribution to the extremely interesting topic of the immunobiology that facilitates filovirus infections of bats without overt pathology. They focused entirely on gene transcription signatures from different tissue sites following experimental infection, and sometimes compare those signatures with those generated in humans following natural exposures to filoviruses. The strengths of the paper is the shear breadth of data generated that is available openly to the scientific community and the development of novel mRNA datasets from bats, in the absence and presence of infection. One of the major limitations of this systems-based approach is that there is no mechanistic data that links gene function to the immune response to filovirus infection. Rather, associations are made and functional links are inferred. This limitation makes the title of the manuscript "...is controlled by a systemic response" an overstatement.

      We thank the reviewer and agree that mechanistic studies were out of scope of this study and have reflected this fact in the title by replacing “is controlled” with “induces”:

      Ebola and Marburg filovirus infection in bats induces a systemic response

      The authors indicate that one of their main objectives is to understand differences in the responses to infection between bats and humans. But this submission says little about the transcriptome-level responses to filovirus infection in humans. It does, on at least one occasion, state that some of the bat genes with altered expression levels were also altered in a study of human filovirus infections (reference #67). I think it would be helpful if the authors devoted a figure or table to the direct comparison between their analysis of MARV- and EBOV-infected bats and the findings of filovirus-infected humans, highlighting genes that are differentially up- or downregulated between the two species.

      This discussion, which was also requested by Reviewer 1, is now included in the manuscript (Discussion page 9 and Tables 2 and 3).

      Figure 2 is not described nor presented usefully. Instead of providing a figure title ""Upset plot..." the authors should clearly describe the type of transcriptomic data being presented. Moreover, it way the data is plotted does not reveal any direct information about the genes that are up- or downregulated in each condition, thus reducing its utility to the reader. I suggest that this Figure be placed in the Supplemental information. In fact, Figures 3 could also be moved to the Supplemental information

      Figure 2 makes that point that the response is a broad one while Figure 3 presents evidence from expression data that there is tissue-specific responses to the viruses. Both together provide convincing evidence of a systemic, wide-ranging response to both MARV and EBOV infections. We have edited the caption to Figure 2 by changing it to the following:

      Figure 2: Broad response of bat liver genes to filoviral infection. Many genes in the liver respond to filoviral infections, with MARV having a bigger impact compared to EBOV (840 genes that are responsive to MARV alone, compared to the 43 specific to EBOV alone). The EBOV-specific (EBOV/MARV) and MARV-specific (MARV/EBOV)genes are likely host responses specific to the viral VP40, VP35 and VP24 genes. In the plot, mock refers to mock-infected bats, EBOV to EBOV-infected bats, and MARV to MARV-infected bat livers. Each row in the lower panel represents a set, there are six sets of genes based on various comparisons, e.g., EBOV/mock is the set of genes at least 2-fold up regulated in EBOV infection, compared to the mock samples. The gray bars at the lower left representing membership in the sets. The vertical blue lines with bulbs represent set intersections, e.g., the last bar is the set of genes common to EBOV/MARV, EBOV/mock and MARV/mock, so the genes in this set are up 2-fold in EBOV compared to the mock and MARV samples, and at least 2-fold up in MARV compared to mock. The main bar plot (top) is number of genes unique to that intersection, so the total belonging to a set, say mock/EBOV, is a sum of the numbers in all sets that have mock/EBOV as a member (41+203+6+31=281).

      The authors do not specify in the main text, figure captions, or methods sections how they objectively assigned bat homologs as being "similar to " or "divergent from" their human counterparts. What is the cut-off in terms of sequence similarity?

      We apologize for this omission. In addition to a description in Methods, we have added the following statement to the Results section (Page 4).

      To identify divergent genes, we relied on BLASTn[13]. Genes detected as homologues (16004, 87% out of 18443 genes in our databse) using BLASTn default settings were labelled “similar”. The remaining 2439 genes (13%) were considered “divergent”. Of these genes, 1,548 transcripts (8% of the total), could be identified as homologous by reducing the word-size in BLASTn from 11, the default, to 9. This approach is equivalent to matching at the protein level, but we find that using nucleotide level matches provides a cleaner separation of the two classes than using translated proteins (Fig. 4, Methods).

      In the Discussion, it is surprising that the authors state that "the majority of interferon response genes are not divergent from human homologs" since genes involved in innate immunity are some of the most rapidly evolving genes known to exist. Again, clarification over what dictates "divergence" over "similarity" is warranted. Many previous studies have shown how a single residue change in an innate immune effector can drastically alter its specificity and/or potency.

      We have clarified this point by adding the following statement in the Discussion (pages 8,9)

      There are hundreds of genes involved in the interferon response, some key components can mutate to change specificity of their interactions, but most, especially those in the core ISG category[14], evolve slowly and have conserved function and sequence[15]. Our analysis of gene divergence shows that the majority of interferon response genes are not divergent from their human homologs, consistent with prior observations that the innate responses are quite similar between human and bat cell lines[9]. This implies that other systems are involved in generating the difference in response between bats and humans.

      The authors state in the introduction, and point to citation #21, that ERBs are "refractory to infection." In Figure 1, the authors indicate that experimental of ERBs with EBOV led to detectable infection in some animals, particularly in the liver. At this point in the manuscript, the authors should state if and how this result differs from what is published in #21, and they should comment on whether this is scientifically significant, or not. This is eventually discussed briefly in the Discussion but adding a sentence to Results section would be helpful for readers.

      To emphasize that our results contradict prior reports of ERB being refractory to EBOV infection, we have modified the statement in the Results (page 3) as follows.

      Two of the three EBOV-inoculated animals presented with histopathological lesions in the liver, consisting of pigmented and unpigmented infiltrates of aggregated mononuclear cells compressing adjacent tissue structures, and eosinophilic nuclear and cytoplasmic inclusions, changes consistent with previous reports[16], [17]. In EBOV-infected animals, focal immunostaining with both pan-filovirus and EBOV-VP40 antibodies was observed in the liver of one animal, but very few foci were found, suggesting limited viral replication.

      The research question at hand, concerning how bats serve as reservoirs for multiple viruses which are pathogenic to humans without succumbing to disease, is one of the hottest topics in immunology and virology. However, the authors do not provide a clear enough explanation of how their approach to study the transcriptome response following filovirus infection goes beyond what has been published in previous studies. This manuscript would greatly benefit from a discussion of its novelty in the Introduction and Discussion sections.

      We have reviewed prior human and bat studies (Introduction -page 3 and Discussion- page 9 shown above) to highlight the novelty of our findings. We have also added the following sentence at the end of the Introduction highlighting the novelty of the study.

      This is the first in vivo study that focuses on the coordinated transcriptional response to filoviruses at the level of individual organs in bats.

      References

      [1] X. Liu et al., “Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus,” Genome Biology, vol. 18, no. 1, p. 4, Jan. 2017, doi: 10.1186/s13059-016-1137-3.

      [2] A. K. McElroy et al., “Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome,” J. Infect. Dis., vol. 210, no. 4, pp. 558–566, Aug. 2014, doi: 10.1093/infdis/jiu088.

      [3] S. B. Bradfute, K. L. Warfield, and S. Bavari, “Functional CD8+ T cell responses in lethal Ebola virus infection,” J. Immunol., vol. 180, no. 6, pp. 4058–4066, Mar. 2008, doi: 10.4049/jimmunol.180.6.4058.

      [4] M. N. Rahim et al., “Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine,” PLOS Pathogens, vol. 15, no. 2, p. e1007564, Feb. 2019, doi: 10.1371/journal.ppat.1007564.

      [5] A. Sobarzo et al., “Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors,” EBioMedicine, vol. 46, pp. 215–226, Aug. 2019, doi: 10.1016/j.ebiom.2019.07.021.

      [6] L. Fernando et al., “Immune Response to Marburg Virus Angola Infection in Nonhuman Primates,” J Infect Dis, vol. 212, no. suppl_2, pp. S234–S241, Oct. 2015, doi: 10.1093/infdis/jiv095.

      [7] S. W. Stonier et al., “Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses,” J. Exp. Med., vol. 214, no. 9, pp. 2563–2572, Sep. 2017, doi: 10.1084/jem.20170161.

      [8] S. Sakabe et al., “Analysis of CD8+ T cell response during the 2013–2016 Ebola epidemic in West Africa,” PNAS, vol. 115, no. 32, pp. E7578–E7586, Aug. 2018, doi: 10.1073/pnas.1806200115.

      [9] I. V. Kuzmin et al., “Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions,” J. Virol., vol. 91, no. 8, Apr. 2017, doi: 10.1128/JVI.02471-16.

      [10] C. E. Arnold et al., “Transcriptomics Reveal Antiviral Gene Induction in the Egyptian Rousette Bat Is Antagonized In Vitro by Marburg Virus Infection,” Viruses, vol. 10, no. 11, 02 2018, doi: 10.3390/v10110607.

      [11] M. Hölzer et al., “Differential transcriptional responses to Ebola and Marburg virus infection in bat and human cells,” Scientific Reports, vol. 6, p. 34589, Oct. 2016, doi: 10.1038/srep34589.

      [12] J. W. Wynne et al., “Comparative Transcriptomics Highlights the Role of the Activator Protein 1 Transcription Factor in the Host Response to Ebolavirus,” Journal of Virology, vol. 91, no. 23, Dec. 2017, doi: 10.1128/JVI.01174-17.

      [13] S. F. Altschul, W. Gish, W. Miller, E. W. Myers, and D. J. Lipman, “Basic local alignment search tool,” J. Mol. Biol., vol. 215, no. 3, pp. 403–410, Oct. 1990, doi: 10.1016/S0022-2836(05)80360-2.

      [14] A. E. Shaw et al., “Fundamental properties of the mammalian innate immune system revealed by multispecies comparison of type I interferon responses,” PLOS Biology, vol. 15, no. 12, p. e2004086, Dec. 2017, doi: 10.1371/journal.pbio.2004086.

      [15] T. B. Sackton, B. P. Lazzaro, T. A. Schlenke, J. D. Evans, D. Hultmark, and A. G. Clark, “Dynamic evolution of the innate immune system in Drosophila,” Nat. Genet., vol. 39, no. 12, pp. 1461–1468, Dec. 2007, doi: 10.1038/ng.2007.60.

      [16] M. E. B. Jones et al., “Experimental Inoculation of Egyptian Rousette Bats (Rousettus aegyptiacus) with Viruses of the Ebolavirus and Marburgvirus Genera,” Viruses, vol. 7, no. 7, pp. 3420–3442, Jun. 2015, doi: 10.3390/v7072779.

      [17] J. T. Paweska, N. Storm, A. A. Grobbelaar, W. Markotter, A. Kemp, and P. Jansen van Vuren, “Experimental Inoculation of Egyptian Fruit Bats (Rousettus aegyptiacus) with Ebola Virus,” Viruses, vol. 8, no. 2, Jan. 2016, doi: 10.3390/v8020029.

    1. SciScore for 10.1101/2020.07.28.20162941: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">All serum samples were provided by the Basque Biobank (www.biobancovasco.org) after approval from the corresponding ethics committee (CEIC-E 20-26, 1-2016).</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISAs require optimisation and the use of individual plates for each antigen or antibody to be tested.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antigen</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A minority of COVID samples presented only N-reactive IgG and IgM antibodies, testing negative for RBD or S1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IgM</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>S1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies were diluted in 100 µL of PBS containing 5% FBS: anti-human IgG-PE (1:50) (BD Biosciences #555787) and anti-human IgM-BV421 antibodies (1:1000) (BD Biosciences #555783).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG-PE</div> <div>suggested: (Santa Cruz Biotechnology Cat# sc-3756, RRID:AB_654591)</div> </div> <div style="margin-bottom:8px"> <div>anti-human IgM-BV421</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After three washes with 250 μL of PBST in a plate washer (Biotek), each well was incubated with an anti-human IgG-horseradish peroxidase (HRP) conjugated secondary antibody (1:5000) (GenScript #A01854) or antihuman IgM-HRP (Novus Biologicals #NBP1-75014) for 1 hour at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG-horseradish</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>antihuman IgM-HRP</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PMMA (polymethyl methacrylate) 8.2 μm microbeads coated with streptavidin were purchased from PolyAn (#10652009).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>PolyAn</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Results were analyzed using FlowJo version 10 (BD Biosciences). ELISA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> <div style="margin-bottom:8px"> <div>BD Biosciences</div> <div>suggested: (BD Biosciences, RRID:SCR_013311)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed using Prism 8 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GraphPad</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    2. SciScore for 10.1101/2020.07.28.20162941: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">All serum samples were provided by the Basque Biobank (www.biobancovasco.org) after approval from the corresponding ethics committee (CEIC-E 20-26, 1-2016).</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISAs require optimisation and the use of individual plates for each antigen or antibody to be tested.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antigen</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A minority of COVID samples presented only N-reactive IgG and IgM antibodies, testing negative for RBD or S1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IgM</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>S1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies were diluted in 100 µL of PBS containing 5% FBS: anti-human IgG-PE (1:50) (BD Biosciences #555787) and anti-human IgM-BV421 antibodies (1:1000) (BD Biosciences #555783).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG-PE</div> <div>suggested: (Santa Cruz Biotechnology Cat# sc-3756, RRID:AB_654591)</div> </div> <div style="margin-bottom:8px"> <div>anti-human IgM-BV421</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After three washes with 250 μL of PBST in a plate washer (Biotek), each well was incubated with an anti-human IgG-horseradish peroxidase (HRP) conjugated secondary antibody (1:5000) (GenScript #A01854) or antihuman IgM-HRP (Novus Biologicals #NBP1-75014) for 1 hour at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG-horseradish</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>antihuman IgM-HRP</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PMMA (polymethyl methacrylate) 8.2 μm microbeads coated with streptavidin were purchased from PolyAn (#10652009).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>PolyAn</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Results were analyzed using FlowJo version 10 (BD Biosciences). ELISA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> <div style="margin-bottom:8px"> <div>BD Biosciences</div> <div>suggested: (BD Biosciences, RRID:SCR_013311)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed using Prism 8 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GraphPad</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    3. SciScore for 10.1101/2020.07.28.20162941: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">All serum samples were provided by the Basque Biobank (www.biobancovasco.org) after approval from the corresponding ethics committee (CEIC-E 20-26, 1-2016).</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISAs require optimisation and the use of individual plates for each antigen or antibody to be tested.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antigen</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The bead array (C19BA) is incubated with serum samples to allow the binding of anti-SARS-CoV-2 antibodies and then stained with anti-IgG and anti-IgM secondary antibodies labelled with different fluorochromes (Fig. 1a and Supplementary Fig.1).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-IgG</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Importantly, the sensitivity of C19BA was superior to ELISA (Fig. 1c) when their performance was compared in serial dilutions of recombinant anti-RBD and anti-N IgG antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-RBD</div> <div>suggested: None</div> </div>

            <div style="margin-bottom:8px">
              <div><b>anti-N IgG</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Importantly, our assay identified the presence of N-reactive IgG antibodies in preCOVID samples, although in general at lower titers than in the COVID cohort (Fig. 2a,b). Fig. 2c shows representative dot plot profiles corresponding to preCOVID and COVID samples.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>N-reactive IgG</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">While the reactivity against RBD and S1 was specific for COVID samples, cross-reactivity against N was observed in some preCOVID individuals that contained IgG, but not IgM antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>IgM</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A minority of COVID samples presented only N-reactive IgG and IgM antibodies, testing negative for RBD or S1.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>S1</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In summary, we have developed a novel multiplexed method with higher sensitivity than traditional serology assays, using a triple combination of antigens that exploits the specificity of the Spike and RBD together with the less-specific N protein for the detection of antibodies against SARS-CoV-2.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>SARS-CoV-2</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies were diluted in 100 µL of PBS containing 5% FBS: anti-human IgG-PE (1:50) (BD Biosciences</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>anti-human IgG-PE</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">#555787) and anti-human IgM-BV421 antibodies (1:1000) (BD Biosciences #555783).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>anti-human IgM-BV421</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After three washes with 250 μL of PBST in a plate washer (Biotek), each well was incubated with an anti-human IgG-horseradish peroxidase (HRP) conjugated secondary antibody (1:5000) (GenScript #A01854) or antihuman IgM-HRP (Novus Biologicals #NBP1-75014) for 1 hour at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>anti-human IgG-horseradish</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>antihuman IgM-HRP</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PMMA (polymethyl methacrylate) 8.2 μm microbeads coated with streptavidin were purchased from PolyAn (#10652009).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>PolyAn</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Results were analyzed using FlowJo version 10 (BD Biosciences). ELISA.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>FlowJo</b></div>
              <div>suggested: (FlowJo, <a href="https://scicrunch.org/resources/Any/search?q=SCR_008520">SCR_008520</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed using Prism 8 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>GraphPad</b></div>
              <div>suggested: (GraphPad Prism, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002798">SCR_002798</a>)</div>
            </div>
          </td></tr></table>
      

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.29.20159442: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">The present study was conducted in accordance with the Declaration of Helsinki, and approval was obtained from the Institutional Review Board of Toyonaka Municipal 6 Hospital (No. Statistical analysis 7 The medians and interquartile ranges (IQRs) are reported for continuous variables.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses were performed with JMP statistical software (ver. 14.3, SAS Institute, Inc., Cary, NC, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SAS Institute</div> <div>suggested: (Statistical Analysis System, RRID:SCR_008567)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      13 This study has several limitations due to its retrospective nature. First, we enrolled only a small number of COVID-19 patients. Consequently, we did not perform multivariate analysis. Second, our dataset had missing data, because we were not very accustomed to seeing COVID-19 patients and avoided unnecessary or nonurgent contact with these patients to reduce the risk of infection. Therefore, we statistically handled missing data using imputation methods in statistical software. In conclusion, we first reported three candidate risk factors in Japanese adult patients with mild to moderate COVID-19: statin use, an elevated LDH level, and decreased eGFR. 14 Figure legends Figure 1. Flow chart of patient enrollment. Figure 2. Overall progression-free interval in patients with mild to moderate COVID-19. Significant differences were found in the progression-free interval between patients stratified by statin use, LDH levels and eGFR on admission. 15 Acknowledgments and collaborators We thank all medical staff and doctors at Toyonaka Municipal Hospital. The collaborators involved in the study are as follows: Sanae Fukuda, Kazumi Ohkubo (Nursing Department), Dr. Masashi Yamamoto, Dr. Kengo Matsumoto, Dr. Kaori Mukai, Dr. Dai Nakamatsu, Dr. Aya Sugimoto, Dr. Naoto Osugi, Dr. Sho Yamaoka, Dr. Tatsuya Sakamoto, Dr. Akino Okamoto, Dr. Yuri Tsujii, Dr. Ryo Sugio, Dr. Kazumasa Souma (Department of Gastroenterology), Dr. Masayuki Moriya, Dr. Katsuya Araki, Dr. Yuri Sugiura (Department of Neurology), Dr. Masanobu Takeji, Dr. Satoko Yamamoto, Dr. Yasuo Kusunoki, Dr. Natsuko Ikeda, Dr. Kumie Teramoto, Dr. Momoko Okawara, Dr. Yuki Iwahashi, Dr. Masashi Yokoyama, Dr. Toru Kida, Dr. Chihiro Hasegawa, Dr. Shunsuke Shiode, Dr. Tomoko Isaka, Dr. Naohiko Ito, Dr. Kanae Matsuno (Department of Internal Medicine), Dr. Yukinori Okazaki, Dr. Yukika Mizukami, Dr. Takuma Iida, Dr. Naoki Fukushima, Dr. Ai Miyaoka, Dr. Takamori Yamamoto (Department of Cardiology). 16 Table 1. Characteristics and clinical course of patients with mild to moderate confirmed COVID-19 Patients with mild to moderate COVIDCharacteristics N=57 Age, median (IQR) 52 (35, 69.5) Male Sex, n (%) Body mass index, median (IQR) 32 (56.1) 23.8 (21.0, 26.5) Pneumonia, n (%) 37 (64.9) Smoking history (Non/past/current) History of close contact with individuals with confirmed cases Days from onset of symptoms to admission, median (IQR) Comorbidities 33/17/7 Hypertension, n (%) Cardiovascular diseases, n (%) Chronic obstructive pulmonary disease, n (%) Asthma, n (%) 16 (28.1) 8 (5, 12) 16 (28.1) 5 (8.8) 4 (7.0) 8 (14.0) Diabetes mellitus, n (%) 13 (22.8) Hyperlipidemia, n (%) 20 (35.1) Chronic kidney disease, n (%) 5 (8.8) Hemodialysis, n (%) 3 (5.3) Solid cancer, n (%) 1 (1.8) Pregnancy, n (%) 2 (3.5) Use of medication for comorbidities ARB, n (%) 8 (14.0) Calcium blocker, n (%) 9 (15.8) Statin, n (%) 12 (21.1) 17 Table 2. Initial presentation, treatment, and clinical course Initial presentation Fever, n (%) 51 (89.9) Fatigue, n (%) 12 (21.1) Cough, n (%) 5 (8.8) Dyspnea, n (%) 13 (22.8) Sputum production, n (%) 5 (8.8) Anorexia, n (%) 7 (12.3) Headache, n (%) 5 (8.8) Diarrhea, n (%) 14 (25.9) New loss of taste or smell, n (%) 9 (15.8) Erythema, n (%) 3 (5.3) Severity of COVID-19 Mild to moderate/Severe, n (%) 37 (64.9)/20 (35.1) Treatment Required oxygen, n (%) 20 (35.1) Medication for COVID-19 Ciclesonide, n (%) 29 (50.9) Hydroxychloroquine, n (%) 14 (24.6) Favipiravir, n (%) 12 (21.1) Clinical course Length of hospital stay, median (IQR) (days) 12 (8, 20) Required mechanical ventilatory support, n (%) 7 (12.3) Mortality, n (%) 2 (3.5) 18 Table 3. Comparison of the progression group and stable group. Progression group Stable group haracteristics N=7 N=50 48 (31, 69.3) ge, median (IQR) 61 (59, 71) 27 (54.0) x, male (%) 5 (71.4) P-val 0.122 0.449 24.9 (21.1, 25.6) 24.6 (21.0, 22.9) 0.679 2/3/2 31/14/5 0.186 9 (7, 9) N.A. 1 (0, 3) N.A. 0/7 37/13 0.000 2 (28.6) 0 (0) 0.013 ny comorbidity, n (%) 6 (85.7) 29 (58) 0.230 ypertension, n (%) 3 (42.9) 13 (26.0) 0.387 0 (0) 5 (10.2) 1.00 0 (0) 4 (8.0) 1.00 0 (0) 8 (16.3) 0.576 Diabetes mellitus, n (%) 2 (28.6) 11 (22) 0.659 Hyperlipidemia, n (%) 4 (57.1) 16 (32.0) 0.226 Chronic kidney disease, n (%) 1 (14.3) 4 (8) 0.494 Hemodialysis, n (%) 0 (0) 3 (6.0) 1.00 Solid cancer, n (%) 0 (0) 1 (2.0) 1.00 Pregnancy, n (%) 0 (0) 2 (4.0) 1.00 ARB, n (%) 1 (14.3) 7 (14.0) 1.00 Calcium blocker, n (%) 3 (42.9) 6 (12) 0.070 Statin, n (%) 4 (57.1) 8 (16) 0.029 8 (5, 9) 8 (5, 13.3) 0.608 4600 (3800, 7000) 5950 (4675, 7500) 0.318 1231 (840, 1553) 0.003 ody mass index, median (IQR) moking (Non/past/current) ays from onset of symptoms to sease progression, median (IQR) ays from admission to disease ogression, median (IQR) verity of COVID-19 ild to moderate/sever ortality omorbidities Cardiovascular diseases, n (%) Chronic obstructive pulmonary sease, n (%) Asthma, n (%) edication itial assessment ays from the onset of symptoms to mission, median (IQR) BC, median (IQR) count/μl Lymphocyte, median (IQR) ount/μl) 617 (374, 864) 19 Neutrophilia, median (IQR) ount/μl) emoglobin, median (IQR) (g/dl) 4049 (3001, 5508) 0.845 14.2 (12.4, 14.5) 14.3 (12.0, 15.2) 0.855 18.7 (14.1, 23.2) 21.1 (16.4, 29.3) 0.185 DH, median (IQR) (IU/L) 450 (309, 562) 263 (205, 323) 0.007 RP, median (IQR) (mg/dl) 5.69 (3.73, 10.9) 2.11 (0.2, 6.51) 0.026 ST, median (IQR) (IU/L) 51 (31, 85) 39 (21, 55) 0.066 LT, median (IQR) (IU/L) 41 (29, 63) 35 (18, 58) 0.618 0.51 (0.4, 1.29) 0.61 (0.49, 0.72) 0.626 bA1c, median (IQR) (%) 8.2 (7.9, 9.5) 7.5 (6.8, 8.4) 0.084 , median (IQR) (mg/dl) 0.99 (0.84, 1.3) 0.8 (0.66, 1.1) 0.084 17 (14, 25) 13 (10, 17) 0.039 56.8 (46.8, 65.6) 76.8 (63.5, 91.7) 0.009 atelet count, median (IQR) (109/L) otal bilirubin, median (IQR) (mg/dl) UN, median (IQR) (mg/dl) GFR, median (IQR) 3795 (2690, 5859) ARB, angiotensin receptor blocker; LDH, lactate dehydrogenase; CRP, C-reactive protein; AST, aspartate aminotransferase; Cr, creatinine; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate 20 Table 4. Univariate logistic analysis and univariate Cox proportional hazards analysis of risk factors for progression to critical COVID-19 Univariate Cox proportional Univariate logistic analysis hazards analysis Odds Hazard Characteristics 95% CI P-value 95% CI P-value ratio ratio Statin use 1 No 1 Yes Lymphocyte count >980 8.0 <980 9.8 1.46-43.7 0.0163 6.3 1.40-28.3 0.0167 0.93-64.1 0.0584 110 0.0169 N.C 0.9989 1.23-84.8 0.0315 1 1 1.09-87.7 0.0414 7.7 LDH <309 1 >309 14.0 1 1.55-123 0.0188 13.3 CRP <2.92 1 >2.92 N.C 1 N.C 0.9960 N.C eGFR >68 1 <68 12.8 1 1.41-115 0.0233 10.2 CI, confidence interval; LDH, lactate dehydrogenase; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; N.C, not calculated 21


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    2. SciScore for 10.1101/2020.07.29.20159442: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">The present study was conducted in accordance with the Declaration of Helsinki, and approval was obtained from the Institutional Review Board of Toyonaka Municipal 6 Hospital (No. Statistical analysis 7 The medians and interquartile ranges (IQRs) are reported for continuous variables.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses were performed with JMP statistical software (ver. 14.3, SAS Institute, Inc., Cary, NC, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SAS Institute</div> <div>suggested: (Statistical Analysis System, RRID:SCR_008567)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      13 This study has several limitations due to its retrospective nature. First, we enrolled only a small number of COVID-19 patients. Consequently, we did not perform multivariate analysis. Second, our dataset had missing data, because we were not very accustomed to seeing COVID-19 patients and avoided unnecessary or nonurgent contact with these patients to reduce the risk of infection. Therefore, we statistically handled missing data using imputation methods in statistical software. In conclusion, we first reported three candidate risk factors in Japanese adult patients with mild to moderate COVID-19: statin use, an elevated LDH level, and decreased eGFR. 14 Figure legends Figure 1. Flow chart of patient enrollment. Figure 2. Overall progression-free interval in patients with mild to moderate COVID-19. Significant differences were found in the progression-free interval between patients stratified by statin use, LDH levels and eGFR on admission. 15 Acknowledgments and collaborators We thank all medical staff and doctors at Toyonaka Municipal Hospital. The collaborators involved in the study are as follows: Sanae Fukuda, Kazumi Ohkubo (Nursing Department), Dr. Masashi Yamamoto, Dr. Kengo Matsumoto, Dr. Kaori Mukai, Dr. Dai Nakamatsu, Dr. Aya Sugimoto, Dr. Naoto Osugi, Dr. Sho Yamaoka, Dr. Tatsuya Sakamoto, Dr. Akino Okamoto, Dr. Yuri Tsujii, Dr. Ryo Sugio, Dr. Kazumasa Souma (Department of Gastroenterology), Dr. Masayuki Moriya, Dr. Katsuya Araki, Dr. Yuri Sugiura (Department of Neurology), Dr. Masanobu Takeji, Dr. Satoko Yamamoto, Dr. Yasuo Kusunoki, Dr. Natsuko Ikeda, Dr. Kumie Teramoto, Dr. Momoko Okawara, Dr. Yuki Iwahashi, Dr. Masashi Yokoyama, Dr. Toru Kida, Dr. Chihiro Hasegawa, Dr. Shunsuke Shiode, Dr. Tomoko Isaka, Dr. Naohiko Ito, Dr. Kanae Matsuno (Department of Internal Medicine), Dr. Yukinori Okazaki, Dr. Yukika Mizukami, Dr. Takuma Iida, Dr. Naoki Fukushima, Dr. Ai Miyaoka, Dr. Takamori Yamamoto (Department of Cardiology). 16 Table 1. Characteristics and clinical course of patients with mild to moderate confirmed COVID-19 Patients with mild to moderate COVIDCharacteristics N=57 Age, median (IQR) 52 (35, 69.5) Male Sex, n (%) Body mass index, median (IQR) 32 (56.1) 23.8 (21.0, 26.5) Pneumonia, n (%) 37 (64.9) Smoking history (Non/past/current) History of close contact with individuals with confirmed cases Days from onset of symptoms to admission, median (IQR) Comorbidities 33/17/7 Hypertension, n (%) Cardiovascular diseases, n (%) Chronic obstructive pulmonary disease, n (%) Asthma, n (%) 16 (28.1) 8 (5, 12) 16 (28.1) 5 (8.8) 4 (7.0) 8 (14.0) Diabetes mellitus, n (%) 13 (22.8) Hyperlipidemia, n (%) 20 (35.1) Chronic kidney disease, n (%) 5 (8.8) Hemodialysis, n (%) 3 (5.3) Solid cancer, n (%) 1 (1.8) Pregnancy, n (%) 2 (3.5) Use of medication for comorbidities ARB, n (%) 8 (14.0) Calcium blocker, n (%) 9 (15.8) Statin, n (%) 12 (21.1) 17 Table 2. Initial presentation, treatment, and clinical course Initial presentation Fever, n (%) 51 (89.9) Fatigue, n (%) 12 (21.1) Cough, n (%) 5 (8.8) Dyspnea, n (%) 13 (22.8) Sputum production, n (%) 5 (8.8) Anorexia, n (%) 7 (12.3) Headache, n (%) 5 (8.8) Diarrhea, n (%) 14 (25.9) New loss of taste or smell, n (%) 9 (15.8) Erythema, n (%) 3 (5.3) Severity of COVID-19 Mild to moderate/Severe, n (%) 37 (64.9)/20 (35.1) Treatment Required oxygen, n (%) 20 (35.1) Medication for COVID-19 Ciclesonide, n (%) 29 (50.9) Hydroxychloroquine, n (%) 14 (24.6) Favipiravir, n (%) 12 (21.1) Clinical course Length of hospital stay, median (IQR) (days) 12 (8, 20) Required mechanical ventilatory support, n (%) 7 (12.3) Mortality, n (%) 2 (3.5) 18 Table 3. Comparison of the progression group and stable group. Progression group Stable group haracteristics N=7 N=50 48 (31, 69.3) ge, median (IQR) 61 (59, 71) 27 (54.0) x, male (%) 5 (71.4) P-valu 0.122 0.449 24.9 (21.1, 25.6) 24.6 (21.0, 22.9) 0.679 2/3/2 31/14/5 0.186 9 (7, 9) N.A. 1 (0, 3) N.A. 0/7 37/13 0.000 2 (28.6) 0 (0) 0.013 ny comorbidity, n (%) 6 (85.7) 29 (58) 0.230 ypertension, n (%) 3 (42.9) 13 (26.0) 0.387 0 (0) 5 (10.2) 1.000 0 (0) 4 (8.0) 1.000 0 (0) 8 (16.3) 0.576 Diabetes mellitus, n (%) 2 (28.6) 11 (22) 0.659 Hyperlipidemia, n (%) 4 (57.1) 16 (32.0) 0.226 Chronic kidney disease, n (%) 1 (14.3) 4 (8) 0.494 Hemodialysis, n (%) 0 (0) 3 (6.0) 1.000 Solid cancer, n (%) 0 (0) 1 (2.0) 1.000 Pregnancy, n (%) 0 (0) 2 (4.0) 1.000 ARB, n (%) 1 (14.3) 7 (14.0) 1.000 Calcium blocker, n (%) 3 (42.9) 6 (12) 0.070 Statin, n (%) 4 (57.1) 8 (16) 0.029 8 (5, 9) 8 (5, 13.3) 0.608 4600 (3800, 7000) 5950 (4675, 7500) 0.318 1231 (840, 1553) 0.003 ody mass index, median (IQR) moking (Non/past/current) ays from onset of symptoms to sease progression, median (IQR) ays from admission to disease ogression, median (IQR) verity of COVID-19 ild to moderate/sever ortality omorbidities Cardiovascular diseases, n (%) Chronic obstructive pulmonary sease, n (%) Asthma, n (%) edication itial assessment ays from the onset of symptoms to mission, median (IQR) BC, median (IQR) count/μl Lymphocyte, median (IQR) ount/μl) 617 (374, 864) 19 Neutrophilia, median (IQR) ount/μl) emoglobin, median (IQR) (g/dl) 4049 (3001, 5508) 0.845 14.2 (12.4, 14.5) 14.3 (12.0, 15.2) 0.855 18.7 (14.1, 23.2) 21.1 (16.4, 29.3) 0.185 DH, median (IQR) (IU/L) 450 (309, 562) 263 (205, 323) 0.007 RP, median (IQR) (mg/dl) 5.69 (3.73, 10.9) 2.11 (0.2, 6.51) 0.026 ST, median (IQR) (IU/L) 51 (31, 85) 39 (21, 55) 0.066 LT, median (IQR) (IU/L) 41 (29, 63) 35 (18, 58) 0.618 0.51 (0.4, 1.29) 0.61 (0.49, 0.72) 0.626 bA1c, median (IQR) (%) 8.2 (7.9, 9.5) 7.5 (6.8, 8.4) 0.084 , median (IQR) (mg/dl) 0.99 (0.84, 1.3) 0.8 (0.66, 1.1) 0.084 17 (14, 25) 13 (10, 17) 0.039 56.8 (46.8, 65.6) 76.8 (63.5, 91.7) 0.009 atelet count, median (IQR) (109/L) otal bilirubin, median (IQR) (mg/dl) UN, median (IQR) (mg/dl) GFR, median (IQR) 3795 (2690, 5859) ARB, angiotensin receptor blocker; LDH, lactate dehydrogenase; CRP, C-reactive protein; AST, aspartate aminotransferase; Cr, creatinine; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate 20 Table 4. Univariate logistic analysis and univariate Cox proportional hazards analysis of risk factors for progression to critical COVID-19 Univariate Cox proportional Univariate logistic analysis hazards analysis Odds Hazard Characteristics 95% CI P-value 95% CI P-value ratio ratio Statin use 1 No 1 Yes Lymphocyte count >980 8.0 <980 9.8 1.46-43.7 0.0163 6.3 1.40-28.3 0.0167 0.93-64.1 0.0584 110 0.0169 N.C 0.9989 1.23-84.8 0.0315 1 1 1.09-87.7 0.0414 7.7 LDH <309 1 >309 14.0 1 1.55-123 0.0188 13.3 CRP <2.92 1 >2.92 N.C 1 N.C 0.9960 N.C eGFR >68 1 <68 12.8 1 1.41-115 0.0233 10.2 CI, confidence interval; LDH, lactate dehydrogenase; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; N.C, not calculated 21


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.29.20164285: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">( Notably,( all( sera( with( S1_specific( neutralization( failed( to( neutralize( pseudovirus( infection( after( RBD_specific( NAb( depletion( (Fig. ( 3d,( e),( demonstrating( the( strict( dependency( of( RBD_specific( NAbs( to( disengage( viral( attachment(to(the(host(receptor. (These(data(provided(the(rationale(for(exclusively(using( RBD(as(S1_immunogen(in(vaccine(design,(in(particular,(given(that(several(reports(have( shown(the(enhanced(disease(after(whole(S1(immunization29,30. ( ( ( & Discussion& The( COVID_19( patients( show( stratified( symptoms,( including( asymptomatic,( mild,( moderate( and( severe2. ( Using( RBD_ACE2( blockade,( pseudovirus( neutralization( and( authentic(virus(neutralization,(we(observed(that(disease(severity(positively(correlates( to( NAb( responses. ( The( patients( recovered( from( severe( illness( mounted( the( most( robust( NAb( responses. ( Strikingly,( asymptomatic( patients( fail( to( generate( competent(</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(It( is( currently( unknown( as( to( the( correlation( between( the( magnitude( of( neutralizing( antibody((NAb)(responses(and(the(disease(severity(in(COVID_19(patients. (In(a(cohort( of(59(recovered(patients(with(disease(severity(including(severe,(moderate,(mild(and( asymptomatic,( we( observed( the( positive( correlation( between( serum( neutralizing( capacity(and(disease(severity,(in(particular,(the(highest(NAb(capacity(in(sera(from(the( patients(with(severe(disease,(while(a(lack(of(ability(of(asymptomatic(patients(to(mount( competent(NAbs. (Furthermore,(the(compositions(of(NAb(subtypes(were(also(different( between( recovered( patients( with( severe( symptoms( and( with( mild_to_moderate( symptoms. ( These( results( reveal( the( tremendous( heterogeneity( of( SARS_CoV_2_ specific( NAb( responses( and( their( correlations( to( disease( severity,( highlighting( the( needs(of(future(vaccination(in(COVID_19(patients(recovered(from(asymptomatic(or(mild( illness. ( ( ( ( As(of(July(28,(2020,(the(pandemic(of(coronavirus(disease(2019((COVID_19),(caused( by( severe( acute( respiratory( syndrome( coronavirus( 2( (SARS_CoV_2)( infection,( has( claimed( 16,341,920( clinically( confirmed( cases( and( 650,805( deaths( worldwide1. ( The( infected(patients(show(heterogeneous(clinical(manifestations,(which(can(be(generally( classified( into( four( groups,( including( severe,( moderate,( mild( and( asymptomatic,( according(to(the(severity(of(symptoms2. (Despite(daily(increasing(confirmed(cases(and( death,(currently(no(medical(agents(are(approved(to(prevent(SARS_CoV_2(infection(or( treat(COVID_19(patients. ( ( A(growing(body(of(evidence(shows( that(recovered(COVID_19(patients(can(generate( IgG_type(antibodies(specifically(binding(to(various(structure(proteins(of(SARS_CoV_2( particles( shortly( after( the( onset( of( disease,( albeit( at( variable( levels3_6. (Among( these( virus(specific(antibodies,(only(those(capable(of(blocking(SARS_CoV_2(spike((S)(protein( mediated( viral( attachment( and/or( entry( of( host( cells,( called( neutralizing( antibodies( (NAbs),(can(effectively(curtail(infection7. (The(convalescent(plasma(or(sera(containing( NAbs( harvested( from( recovered( patients( have( shown( promising( results( in( treating( COVID_19(patients(of(critical(illness(in(several(small_scale(clinic(trials8_11. (In(addition,(a( variety( of( human( monoclonal( antibodies( (mAbs)( of( potent( SARS_CoV_2( neutralizing( activities(has(been(cloned(from(memory(B(cells(from(recovered(COVID_19(patients12_ 21 ,(holding(great(potentials(for(prophylactic(or(therapeutic(use. (However,(little(is(known( regarding(the(relationship(between(disease(severity(and(the(magnitude(of(SARS_CoV_ 2_specific( NAbs( responses( in( patients( recovered( from( COVID_19. ( Defining( the( association(of(disease(severity(to(NAb(responses(will(facilitate(the(screening(of(COVID_ 19( recovered( patients( as( therapeutic( plasma( donors( as( well( as( memory( B( cell( providers(for(cloning(high_affinity(human(neutralizing(mAbs(to(prevent(or(treat(COVID_ 19.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>according(to(the(severity(of(symptoms2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( vaccines,( including( inactivated,( vector_based,( DNA( and( mRNA( vaccines22_25,( are( undergoing( early(stages(of(clinical(trials. (Additionally,(the(NAb(titers(can(predict(the(possibility(of( re_infection(in(patients(recovered(from(a(primary(viral(infection. (Currently,(there(are(few( clues(regarding(whether(the(patients(recovered(from(COVID_19(can(be(protected(from( re_infection(or(will(still(require(vaccination(in(the(future(when(effective(vaccines(become( available. ( ( Results& Antibody& responses& to& SARS0CoV02& in& COVID019& recovered& patients& with& different&symptom&severity& To(explore(the(potential(association(between(SARS_CoV_2(S(protein_specific(antibody( responses(and(the(disease(severity(in(recovered(COVID_19(patients,(we(included(a( cohort( of( 59( adult( patients,( 48( of( mild( (n=4),( moderate( (n=34)( and( severe( (n=10)( symptoms( admitted( to( Guangzhou( Eighth( People’s( Hospital( and( 11( asymptomatic( adult(patients(admitted(to(Chongqing(Public(Health(Center(Hospital. (The(median(age( of( these( patients( was( 47( (33_62,( interquartile( range( (IQR))( years( oldm( 50.8%( of( the( patients( were( femalem( Serum( samples( were( collected( at( the( day( of( discharge( after( symptom(resolution(and(SARS_CoV_2(nucleotide(testing(negative(twice(by(RT_PCR.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>clues(regarding(whether(the(patients(recovered(from(COVID_19</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(We(first(compared(the(antibodies(that( specifically(binding(to(S1,(RBD(and(S2(of(SARS_CoV_2(in(sera(of(COVID_19(recovered( patients( with( different( illness( severity( by( IgG( ELISA. ( Notably,( severe( and( moderate( symptomatic( patients( mounted( the( most( and( second( robust( S1,( S1_RBD( and( S2( specific( antibodies,( respectively,( while( mild( and( asymptomatic( patients( exhibited( significantly(lower(abundances(of(S1_,(S1_RBD_(and(S2_specific(antibodies((Fig.1a_c),( highlighting(the(disease(severity(as(a(key(determinant(factor(of(the(levels(of(antibodies( specific(to(SARS_CoV_2(S(proteins. ( ( ( Next,(we(assessed(the(abilities(of(antibodies(in(these(COVID_19(recovered(patients(to( block(the(interaction(between(RBD(and(ACE2. (Similar(to(SARS_CoV_2(RBD(binding( antibodies,( the( sera( from( recovered( patients( with( severe( symptoms( displayed( the( highest( scores( of( blocking( RBD_ACE2( engagement,( followed( by( patients( with( moderate(symptoms,(while(antibodies(from(mild(and(asymptomatic(patients(showed( much(inferior(capacity(to(inhibit(RBD_ACE2(interaction((Fig.(2a,(b).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>S2</div> <div>suggested: None</div> </div>

            <div style="margin-bottom:8px">
              <div><b>and(S2_specific(antibodies(</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>RBD(binding(</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(These(data(together(suggested(that( the( disease( severity( determines( both( the( magnitude( and( neutralizing( capacity( of( SARS_CoV_2_specific(antibodies(in(recovered(COVID_19(patients. ( ( Subtypes& of& neutralizing& antibodies& to& SARS0CoV02& S& proteins& in& COVID019& recovered&patients& Given(that(NAbs(can(potentially(target(both(S1(and(S2(to(block(viral(infection7,(we(set( out(to(distinguish(S1(and(S2_specific(NAbs(in(COVID_19(patients(with(aforementioned( pseudovirus( neutralization( assay. ( To( this( end,( we( used( biotin_labeled( S1( or( S2( recombinant( protein( to( deplete( corresponding( antibodies( in( sera( from( 25( COVID_19( patients( that( were( confirmed( to( be( highly( neutralizing( in( Fig. ( 2c( and( Fig. ( 2e( (Supplementary(Fig.(2a,(b).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>and(S2</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>and(S2_specific(NAbs(in(COVID_19</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(After(depletion,(we(found(that(across(all(neutralizing(sera,( 40%(of(patients(generated(both(competent(S1_(and(S2_NAbs((i.e.,(post(either(S1_(or( S2_specific( antibody( depletion,( sera( can( still( completely( neutralize( pseudovirusesm( labeled(as(“S1/S2_NAbs”)m(while(40%(of(patients(only(generated(S1_competent(NAbs( (“S1_NAbs( only”),( and( 4%( of( patients( only( generated( S2_specific( NAbs( (“S2_NAbs( only”)m(interestingly,(16%(of(serum(samples(strictly(depended(on(the(collaboration(of( S1_(and(S2_specific(NAbs(to(effectively(neutralize(pseudovirus(infection((i.e.,(either(S1_( or(S2_specific(antibody(depletion(in(the(serum(can(result(in(the(failure(of(neutralizationm( labeled(as(“(S1+S2)_NAbs”)((Fig.(3a,(b).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>and(S2_NAbs(</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>and(S2_specific(NAbs(to(effectively(neutralize(pseudovirus(infection( ( i.e. ,</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(Antibodies(post( RBD_depletion(were(shown(to(lose(RBD_binding(ability,(but(still(keep(their(binding(to( both(S1(and(S2(</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Antibodies(post(</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( After( washing( with( PBST( buffer( (0.1%( Tween( 20( in( PBS),( the( ELISA( plates( were( incubated( with( anti_human( IgG( HRP( antibody( (Bioss( Biotech,( 0297D)( for( 45( min,( followed(by(PBST(washing(and(addition(of(TMB(buffer((Beyotime,(P0209).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>anti_human( IgG( HRP(</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(The(ELISA(plates(were(blocked(for(1(hour(with(100( μl( blocking( buffer( (5%( FBS( and( 0.1%( Tween( 20( in( PBS)m( meanwhile,( 50( μl( 10_fold( diluted(patient(or(healthy(control(sera(were(incubated(with(7.5(ng(SARS_CoV_2(RBD_ mouse(FC(protein((Sino(Biological,(40592_V05H)(in(50(μl(blocking(buffer(for(1(hour. ( Then,(the(incubated(sera/SARS_CoV_2(RBD_mouse(FC(protein(mixture(was(added(into( the(ELISA(plates(and(allowed(to(develop(for(30(min,(followed(by(PBST(washing(and( incubation(with(anti_mouse(FC(HRP(antibody((Thermo(Fisher(Scientific,(A16084)(for( 30(min. (Next,(the(ELISA(plates(were(washed(with(PBST(and(treated(with(TMB(buffer( (Beyotime,(P0209).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>RBD_</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>A16084</b></div>
              <div>suggested: (Thermo Fisher Scientific Cat# A16084, <a href="https://scicrunch.org/resources/Any/search?q=AB_2534758">AB_2534758</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>P0209</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(All(experiments(related( to( authentic( viruses( were( performed( in( the( certified( BSL_3( facility( of( Sun( Yat_sen( University. (The(SARS_CoV_2(viral(RNA(fold(reduction(=(2(CT(value(of(sample(_(CT(value(of(mock).& & Depletion& of& SARS0CoV02& S& protein0specific& antibodies. ( Firstly,( SARS_CoV_2( S1( protein((Sino(Biological,(40591_V08H)(or(SARS_CoV_2(RBD(protein((Sino(Biological,( 40592_V08B)(or(SARS_CoV_2(S2(protein(was(conjugated(with(biotin(by(following(the( manufacture’s( protocol( (Thermo( Fisher( Scientific,( A39257). ( Then,( biotin_conjugated( proteins(were(incubated(with(BeaverBeads(Mag(Streptavidin(Matrix((Beaver,(22305)( at(4oC(for(1.5(hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>SARS0CoV02&</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>S&</b></div>
              <div>suggested: (Acris Antibodies GmbH Cat# AP22305SU-S, <a href="https://scicrunch.org/resources/Any/search?q=AB_10757407">AB_10757407</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>protein0specific&</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>S1</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(After(washing(with(PBS,(the(SARS_CoV_2(S(protein(coupled(beads( were( next( incubated( with( diluted( patient( sera( at( 4oC( for( 1.5( hours. ( Then,( the( supernatants(were(harvested(and(quality(controlled(by(ELISA(assays(for(SARS_CoV_ 2(S(proteins. ( & & Statistics. (The(SARS_CoV_2(antibody(titers(or(virus(neutralizing(function(of(the(sera( belonging(to(patients(with(different(severity(were(compared(with(the(one_way(ANOVA( test( (Tukey’s( multiple( comparisons( test).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>antibody(titers(or(virus(neutralizing(function(of(the(sera(</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( The( cutoff( value( in( each( pseudovirus( neutralizing(function(assay(was(determined(by(the(ROC(curve(analysis(and(was(of(the( highest(likelihood(ratio. (Correlations(between(different(SARS_CoV_2(antibody(titers(or( between(SARS_CoV_2(antibody(titers(and(pseudovirus(titers(or(between(SARS_CoV_2( antibody(titers(and(SARS_CoV_2(virus(titers(were(analyzed(using(Pearson’s(correlation( coefficient.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>antibody(titers(or(</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>antibody(titers(and(pseudovirus(titers(or(between(SARS_CoV_2</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>antibody(titers(and(SARS_CoV_2</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(It( is( currently( unknown( as( to( the( correlation( between( the( magnitude( of( neutralizing( antibody((NAb)(responses(and(the(disease(severity(in(COVID_19(patients. (In(a(cohort( of(59(recovered(patients(with(disease(severity(including(severe,(moderate,(mild(and( asymptomatic,( we( observed( the( positive( correlation( between( serum( neutralizing( capacity(and(disease(severity,(in(particular,(the(highest(NAb(capacity(in(sera(from(the( patients(with(severe(disease,(while(a(lack(of(ability(of(asymptomatic(patients(to(mount( competent(NAbs. (Furthermore,(the(compositions(of(NAb(subtypes(were(also(different( between( recovered( patients( with( severe( symptoms( and( with( mild_to_moderate( symptoms. ( These( results( reveal( the( tremendous( heterogeneity( of( SARS_CoV_2_ specific( NAb( responses( and( their( correlations( to( disease( severity,( highlighting( the( needs(of(future(vaccination(in(COVID_19(patients(recovered(from(asymptomatic(or(mild( illness. ( ( ( ( As(of(July(28,(2020,(the(pandemic(of(coronavirus(disease(2019((COVID_19),(caused( by( severe( acute( respiratory( syndrome( coronavirus( 2( (SARS_CoV_2)( infection,( has( claimed( 16,341,920( clinically( confirmed( cases( and( 650,805( deaths( worldwide1. ( The( infected(patients(show(heterogeneous(clinical(manifestations,(which(can(be(generally( classified( into( four( groups,( including( severe,( moderate,( mild( and( asymptomatic,( according(to(the(severity(of(symptoms2. (Despite(daily(increasing(confirmed(cases(and( death,(currently(no(medical(agents(are(approved(to(prevent(SARS_CoV_2(infection(or( treat(COVID_19(patients. ( ( A(growing(body(of(evidence(shows( that(recovered(COVID_19(patients(can(generate( IgG_type(antibodies(specifically(binding(to(various(structure(proteins(of(SARS_CoV_2( particles( shortly( after( the( onset( of( disease,( albeit( at( variable( levels3_6. (Among( these( virus(specific(antibodies,(only(those(capable(of(blocking(SARS_CoV_2(spike((S)(protein( mediated( viral( attachment( and/or( entry( of( host( cells,( called( neutralizing( antibodies( (NAbs),(can(effectively(curtail(infection7. (The(convalescent(plasma(or(sera(containing( NAbs( harvested( from( recovered( patients( have( shown( promising( results( in( treating( COVID_19(patients(of(critical(illness(in(several(small_scale(clinic(trials8_11. (In(addition,(a( variety( of( human( monoclonal( antibodies( (mAbs)( of( potent( SARS_CoV_2( neutralizing( activities(has(been(cloned(from(memory(B(cells(from(recovered(COVID_19(patients12_ 21 ,(holding(great(potentials(for(prophylactic(or(therapeutic(use. (However,(little(is(known( regarding(the(relationship(between(disease(severity(and(the(magnitude(of(SARS_CoV_ 2_specific( NAbs( responses( in( patients( recovered( from( COVID_19. ( Defining( the( association(of(disease(severity(to(NAb(responses(will(facilitate(the(screening(of(COVID_ 19( recovered( patients( as( therapeutic( plasma( donors( as( well( as( memory( B( cell( providers(for(cloning(high_affinity(human(neutralizing(mAbs(to(prevent(or(treat(COVID_ 19.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>SARS_CoV_2_</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(Notably,(23.5%(of(these(sera(required(the(combination(of(S1_(and( S2_specific(NAbs(to(effectively(neutralize(pseudovirus(infection((Fig.(3c). (Collectively,( our(data(revealed(the(highly(heterogeneous(nature(of(NAb(responses(against(SARS_ CoV_2( S( protein( and( such( diversity( seemed( to( be( closely( associated( with( disease( severity. ( The( immune( mechanisms( underlying( the( diversity( of( NAbs( responses( in( COVID_19(patients(with(different(degree(of(symptoms(warrant(further(investigations. ( ( ( ( Finally,(we(investigated(whether(NAbs(depleted(by(S1_recombinant(protein(are(actually( targeting( RBD( for( their( neutralizing( capacity. ( For( this( purpose,( we( depleted( RBD_ specific(antibodies(in(10(serum(samples(showing(S1_specific(neutralization(by(biotin_ conjugated(RBD(protein(mediated(pull_down((Supplementary(Fig.(2c).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>RBD_</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">( P( values( less( than( 0.05( were( defied( as( statistically( significant. ( Prism( 6( software(was(used(for(statistical(analysis.& & Data&availability&statements& The( data( sets( in( the( study( are( available( from( the( corresponding( authors( upon( reasonable(request. ( & Acknowledgements& This(work(was(supported(by(grants(from(the(National(Science(and(Technology(Major( Project((No. 2017ZX10202102_006_002(to(L.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>The(</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr></table>
      

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.28.20163154: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We note that Discussion 5 Threshold chosen in accordance with infection levels in countries with well-developed public health infrastructure (e.g. New Zealand, South Korea, Cuba, and Fiji) with proactive testing and ‘track and trace’ interventions resulting in lasting containment approaching elimination of locallyacquired cases.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Fiji</div> <div>suggested: (Fiji, SCR_002285)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ProMED PRO/AH/EDR, Undiagnosed pneumonia - China (HU): request for information, (2019-12-30) Archive Number: 20191230.6864153, available at: https : / / promedmail . org / promed post/?id=6864153, visited on 07/12/2020. 11.Zhu, N. et al.,</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Number</div> <div>suggested: (BioNumbers, SCR_002782)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coronavirus disease 2019 (COVID-19): situation report, 51, (2020) available at: https : / / www . who . int / emergencies / diseases / novel - coronavirus - 2019 / situation - reports, visited on 06/11/2020. 13.Sekine, T. et al., “Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19”, bioRxiv (2020). 14.Seow, J. et al., “Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection”, medRxiv (2020). 15.Checchi, F. and Roberts, L., “Interpreting and using mortality data in humanitarian emergencies”</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>bioRxiv</div> <div>suggested: (bioRxiv, SCR_003933)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, Humanitarian Practice Network 52 (2005). 17.Nogueira, P. et al., “Excess mortality estimation during the COVID-19 pandemic: preliminary data from Portugal”, Acta Médica Portuguesa 33, 376–383 (2020). 18.Aron, J. et al., A pandemic primer on excess mortality statistics and their comparability across countries, Our World in Data (June 29, 2020), available at: https://ourworldindata.org/covid-excess-mortality, visited on 07/12/2020. 19.Financial Times, Excess mortality during the Covid-19 pandemic, available at: https://github.com/Financial- Times/coronavirus- excessmortality-data, visited on 07/01/2020. 1.Wahltinez, O. et al., Covid-open-data: curating a fine-grained, globalscale COVID-19 data repository, (2020) available at: https://github. com/open-covid-19/data, visited on 06/05/2020. 20.Ciufolini, I. and Paolozzi, A., “An improved mathematical prediction of the time evolution of the Covid-19 pandemic in Italy, with monte carlo simulations and error analyses”, The European Physical Journal Plus 135, 495 (2020). 2.New York City Department of Health, COVID-19 Data, available at: https://www1.nyc.gov/site/doh/covid/covid- 19- data.page, visited on 06/02/2020. 21.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Portugal”</div> <div>suggested: None</div> </div> </td></tr></table>

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.21.20158337: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cost and performance comparisons have appeared in the literature and industrial scale PCR cost has been well below US$1/data point for several years and costs as low as US$0.064/data point documented.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Cost</div> <div>suggested: (COST, SCR_014098)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Hospital real-time PCRs: Both the GeneFinder RealAmp PCR and the Viasure SARS-CoV-2 Real Time PCR assays used 5 μl of RNA eluate added to 20μl of respective assay’s detection mastermix which then underwent PCR reaction in a 25 μl reaction (96-well plate).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GeneFinder</div> <div>suggested: (GENEFINDER, SCR_009190)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Abbott RealTime SARS-C0V-2 assay utilised 15 μl of RNA eluate from Abbott M2000 extraction added to 90μl of assay detection mastermix prior to real-time PCR in the Abbott M2000 analyser.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Abbott</div> <div>suggested: (Abbott, SCR_010477)</div> </div> </td></tr></table>

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.25.20161992: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">γsr + η + d3 )Ii (t), (3.1) Ṙi (t) = γar Ai (t) + γsr Ii (t) − d4 Ri (t), Ḋi (t) = ηIi (t), subject to the following initial conditions at time t = 0: Si = Si0 ≥ 0, Ei = Ei0 ≥ 0, Ai = Ai0 ≥ 0, Ii = Ii0 ≥ 0, Ri = Ri0 ≥ 0, Di = Di0 ≥ 0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>γsr + η + d3 )Ii</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Let tin g N ̂i( t ) = N i (t )− Di(t),iti s easytos eetha td N̂i ≤Λ−dN ̂i,whe re d = mind0, d1, d2,η+d 3, d4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>d1 , d2 , η + d3</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">γsr + η + d3 ) β(χ + d1 )(</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>γsr + η + d3 ) β(χ + d1 )</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">γsr + η + d3 ) + β(χ + d1 )γas = , (χ + d1 )(γar + γas + d2 )(</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>γsr + η + d3 ) + β(χ + d1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">γsr + η + d3 ) β(χ + d1 )(γar + γas + d2 ) = .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>γsr + η + d3 ) β(χ + d1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">γsr + η + d3 ) a11 = a12 a13 R0 is the maximum of the absolute eigenvalues of the next generation matrix F W −1 .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>γsr + η + d3 ) a11 = a12 a13 R0</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">γsr + η + d3 ) (3.3) If Λ = 0, dj = 0 (j = 0, 1, 2, 3, 4), then R0 = βα βγar (1 − α) + βγas</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>γsr + η + d3 </div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The non-zero roots, also three in number, are obtained as roots of the cubic equation y 3 + a1 y 2 + a2 y + a3 = 0, (3.5) whose coefficients a1 , a2 , a3 are as follows: a1 = γar + γas + χ +</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>y 3 + a1 y 2 + a2 y + a3</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">γsr + η − β > 0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>γsr + η − β > 0</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">− d0 S ∗ , N β ∗ (A + I ∗ )S ∗ − (χ + d1 )E ∗ , N 0 = αχE ∗ − (γar + γas + d2 )A∗ , 0= ∗ ∗ (3.11) ∗ 0 = (1 − α)χE + γas A − (γsr + η + d3 )I , 0 = γar A∗ + γsr I ∗ − d4 R∗ .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>γsr + η + d3 )I</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">βAN +βI N − (χ+ d 1 ) β S Nβ SN 0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>AN + β IN − ( χ + d1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Oth ere i g env a l u e s ar er ootsofthe e quation βχS∗( λ+ d0) λ+αm4 +(1−α) m3 + α γas=0λ +m1 (λ+m2) (λ +m3)(λ+m4)− N( 3.15 )whereβA∗βI∗ m1=++ d0> 0,m2=χ +d 1>0 ,NN(3 .16 )m3=γar+γa s+ d2> 0,m4=γ sr+η+d3> 0,Mo r e s u cc i nct ly,equation(3.1 5)mayb eexp re ssedasλ4 +a1λ3+a2λ2+a3 λ+ a4= 0 ,(3.17)w ithcoefficie nts a1=m1+m 2+ m3 + m 4 , βχ S ∗, Nβχ S∗a3=(m1+m2)m3m 4+(m3+ m4 )m1m 2− (αm4+(1−α )m3 +αγas+d0),Nβ χS∗(αm4 +(1−α)m3+α γas) .∗ ∗N(A +I )R0χαm4+(1−α) m3 +αγa s(3.1 9)Makinguseo f(3.19),expre ss i on sof a3,a4ma yberew ri tteninthefo llowingf or m establ ishingth eirpositiv ityβχS ∗βχ S∗ a3= m1(m3m 4+m2m3+m2m 4)−d0>d 0m 3 m4+m2m3+m2 m4−>0 ,N NβA∗βI∗a 4=m1m2m3m4−d 0m2 m3m4=+m2m3m4 >0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>m1 ( λ + m2 ) ( λ + m3 ) ( λ + m4 ) − N</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>βI ∗ m1 = + + d0 > 0 , m2 = χ + d1 > 0</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>λ4 + a1 λ3 + a2 λ2 + a3 λ + a4 = 0</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>m1 + m2 + m3 + m4</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>m1 + m2 )m3 m4 + ( m3 + m4 )m1 m2 −</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>βχS ∗ a3 = m1 ( m3 m4 + m2 m3 + m2 m4 ) − d0 > d0 m3 m4 + m2 m3 + m2 m4 − > 0</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>m1 m2 m3 m4 − d0 m2 m3 m4 = + m2 m3 m4 > 0</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fin all y , toe s t a b l is ht helastcon d itionin theRo ut h-H urwit zCrite ri o n (3.18) ,it isenou gh toverifythe fo llow ingtwoinequa litie s:a 1a2a3> 2a 23⇒ a1a2> 2a3 ,(3.20)a1a 2a 3>2 a21a4⇒ a2a3>2a1 a4.( 3 . 2 1 )T o pro veinequality(3. 20),we begi nw ithβχS∗a 1a2−2a3=(m1+m 2+ m3+ m 4)(m1+m2 )(m3+m4)+m1m 2+m 3m4−−N2 m1 m3 m 4 + ( m3 + m4 )m1 m2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>a1 a2 a3 > 2a23 ⇒ a1 a2 > 2a3</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>a2 a3 > 2a21 a4 ⇒ a2 a3 > 2a1 a4</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>βχS ∗ a1 a2 − 2a3 = ( m1 + m2 + m3 + m4 ) ( m1 + m2 ) ( m3 + m4 ) + m1 m2 + m3 m4 − − N 2 m1 m3 m4 + ( m3 + m4 )m1 m2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fol low i n gso m e s i m pl ea lgebraicm a nipulat ions, we get 12a1a 2−2a3= m1 m 3 +m21m4 +m2 1m2+m1 m2 2+m1m23+m1m 24 +m3m 24+m23m4+P1m 1m3m4 +m2 m3m4(α m4 +(1 −α)m3 +αγ as)+C1,whe re P1= αm4+(1 −α)m3+αγ asan d C 1 = (m 2 2m3</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>a2 − 2a3 = m1 m3 + m21 m4 + m21 m2 + m1 m22 + m1 m23 + m1 m24 + m3 m24 + m23 m4 + P1 m1 m3 m4 + m2 m3 m4</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">m22 m3( 1 − α)m 3 + α γ a s+ m2 2m4(αm4+α γ as)+2m2 m3(1− α) m3+ αγas+ m2m3m4 (α m 4 +αγas) +m2 m24(αm 4+ αγas)+m2m3m 4( 1−α) m3+αγas>0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>m22 m3 ( 1 − α)m3 + αγas + m22 m4</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Nex twe r e wri t e t h e ex pr essionfor a 2a3−2a1 a4βχS ∗m 1m3 m4+a2 a3−2a1 a4 = ( m1+m2) (m3 +m4)+m 1m 2+m3m4−N(m3 +m 4)m1 m2−2(m1+m2+m 3+m4) (m1 m2m3m4 −d 0m2 m3m4) .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>a2 a3 − 2a1 a4 βχS ∗ m1 m3 m4 + a2 a3 − 2a1 a4 = ( m1 + m2 ) ( m3 + m4 ) + m1 m2 + m3 m4 − N ( m3 + m4 )m1 m2 − 2 ( m1 + m2 + m3 + m4 ) ( m1 m2 m3 m4 − d0 m2 m3 m4</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analysis based on real data In this subsection, we numerically simulate (using Python based solver) the SEAIRD control model (4.1) laced with the social distancing function (4.3) and match the computed results with real COVID-19 data of India till May 15, 2020.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Python</div> <div>suggested: (IPython, RRID:SCR_001658)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.26.222257: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Monkey studies were carried out in an animal biosafety level 4 (ABSL-4) facility with protocols approved by the Laboratory Animal Welfare and Ethics Committee of the Chinese Academy of Sciences.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Nine 6 or 7 year-old rhesus monkeys (3 females and 6 males) were divided into 3 groups: a control group (one female and two males), a pre-exposure group (one female and two males) and a post-exposure group (one female and two males).</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the generation of human ACE2-hFc and SARS-CoV-2 RBD-mFc recombinant proteins , RBD or ACE2 sequence (1-615aa, accession number: NP_068576.1) was cloned into mouse IgG1 or human IgG1 Fc backbone in pKN293E expression vectors and transiently transfected into HEK293 cells followed by media collection and purification using MabSelect SuRe antibody purification resin (Cat: 29-0491-04, GE Healthcare).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ACE2</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>IgG1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>human IgG1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing twice with 1 × PBS, cells were stained with 1/200 diluted Goat Anti human IgG Fc-FITC antibody (Cat: F9512, Sigma) for 45 min and analyzed using flow cytometry (CytoFLEX, Beckman Coulter).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Anti human IgG</div> <div>suggested: (Sigma-Aldrich Cat# F9512, RRID:AB_259808)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then 10 μL anti-FcγRI antibody-FITC (Cat: 10256-R401-F, Sino Biological), anti-FcγRIIa antibodyFITC (Cat: 10374-MM02-F, Sino Biological), anti-FcγRIIIa antibody-FITC (Cat: 10389-MM41-F, Sino Biological) and FITC-labeled anti-FcγRIIb antibody (Cat: NBP2-14905, Biotechne; Cat: MX488AS100-1KT, Sigma-Aldrich) were added into cells (1×106 cells/sample in 100 μL) and incubated for 60 min at 2-6℃ and analyzed using flow cytometry (CytoFLEX, Beckman Coulter)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antibody-FITC</div> <div>suggested: (Alomone Labs Cat# AAR-007-F, RRID:AB_2756537)</div> </div> <div style="margin-bottom:8px"> <div>anti-FcγRIIa</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-FcγRIIIa</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-FcγRIIb</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293 (ATCC, CRL-3216) cells, Huh7 (Institute of Basic Medical Sciences CAMS, 3111C0001CCC000679) cells and Vero E6 (ATCC, CRL-1586) cells were cultured at 37 °C in Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Huh7</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raji (ATCC, CCL-86) cells, THP-1 (ATCC, TIB-202) cells and K562 (ATCC, CCL-243) cells were cultured at 37 °C in RPMI 1640 Medium with 10% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>THP-1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>K562</div> <div>suggested: ATCC Cat# CCL-243, RRID:CVCL_0004</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the generation of human ACE2-hFc and SARS-CoV-2 RBD-mFc recombinant proteins , RBD or ACE2 sequence (1-615aa, accession number: NP_068576.1) was cloned into mouse IgG1 or human IgG1 Fc backbone in pKN293E expression vectors and transiently transfected into HEK293 cells followed by media collection and purification using MabSelect SuRe antibody purification resin (Cat: 29-0491-04, GE Healthcare).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>HEK293</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For preparation of MW05 and MW07 recombinant antibodies, heavy chain and light chain plasmids were transiently cotransfected into HEK293 cells or stably expressed in CHO cells followed by purification with Protein A resin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CHO</div> <div>suggested: CLS Cat# 603479/p746_CHO, RRID:CVCL_0213</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For SARS-CoV-2 authentic virus neutralization assay, Vero E6 cells were diluted and seeded into a 96well plate with 1×104 cells/well in 100 µL volume at 37 °C. 16 h later, cells were washed by 1× PBS for 3 times and added diluted antibodies in equal volume with the concentration ranging from 0.1 μg/mL to 100 μg/mL. 100 TCID50 SARS-CoV-2 authentic virus was used for each well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Maokang Biological) for 30 min at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Maokang Biological</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The 50% neutralization titer (NT50) was calculated using GraphPad Prism 7.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GraphPad Prism</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    2. SciScore for 10.1101/2020.07.26.222257: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Monkey studies were carried out in an animal biosafety level 4 (ABSL-4) facility with protocols approved by the Laboratory Animal Welfare and Ethics Committee of the Chinese Academy of Sciences.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Nine 6 or 7 year-old rhesus monkeys (3 females and 6 males) were divided into 3 groups: a control group (one female and two males), a pre-exposure group (one female and two males) and a post-exposure group (one female and two males).</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the generation of human ACE2-hFc and SARS-CoV-2 RBD-mFc recombinant proteins , RBD or ACE2 sequence (1-615aa, accession number: NP_068576.1) was cloned into mouse IgG1 or human IgG1 Fc backbone in pKN293E expression vectors and transiently transfected into HEK293 cells followed by media collection and purification using MabSelect SuRe antibody purification resin (Cat: 29-0491-04, GE Healthcare).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ACE2</div> <div>suggested: None</div> </div>

            <div style="margin-bottom:8px">
              <div><b>IgG1</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>human IgG1</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing twice with 1 × PBS, cells were stained with 1/200 diluted Goat Anti human IgG Fc-FITC antibody (Cat: F9512, Sigma) for 45 min and analyzed using flow cytometry (CytoFLEX, Beckman Coulter).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Anti human IgG</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then 10 μL anti-FcγRI antibody-FITC (Cat: 10256-R401-F, Sino Biological), anti-FcγRIIa antibodyFITC (Cat: 10374-MM02-F, Sino Biological), anti-FcγRIIIa antibody-FITC (Cat: 10389-MM41-F, Sino Biological) and FITC-labeled anti-FcγRIIb antibody (Cat: NBP2-14905, Biotechne; Cat: MX488AS100-1KT, Sigma-Aldrich) were added into cells (1×106 cells/sample in 100 μL) and incubated for 60 min at 2-6℃ and analyzed using flow cytometry (CytoFLEX, Beckman Coulter)</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>antibody-FITC</b></div>
              <div>suggested: (Alomone Labs Cat# AAR-007-F, <a href="https://scicrunch.org/resources/Any/search?q=AB_2756537">AB_2756537</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>anti-FcγRIIa</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>anti-FcγRIIIa</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>anti-FcγRIIb</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Experimental Models: Cell Lines</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">As expected, MW05 and MW07 blocked authentic SARS-CoV-2 entry into Vero E6 cells, with 100% neutralization titer (NT100) around 1 μg/ml for MW05 and 5 μg/ml for MW07 (Fig. 2, C and D).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Vero E6</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To evaluate ADE activities of MW05 and MW07, we assessed the infection of SARS-CoV-2 pseudovirus and mAbs complex in THP-1, K562 and Raji cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>K562</b></div>
              <div>suggested: NCI-DTP Cat# K-562, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0004">CVCL_0004</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FACS data revealed that Raji cells, which showed ADE activity for MW05, only express a relatively high level of FcγRIIB; THP-1 cells express high levels of FcγRIA and FcγRIIA; and K562 cells only express high level of FcγRIIA (Fig. 3C).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Raji</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For preparation of MW05 and MW07 recombinant antibodies, heavy chain and light chain plasmids were transiently cotransfected into HEK293 cells or stably expressed in CHO cells followed by purification with Protein A resin.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK293</b></div>
              <div>suggested: CLS Cat# 300192/p777_HEK293, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0045">CVCL_0045</a></div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>CHO</b></div>
              <div>suggested: CLS Cat# 603479/p746_CHO, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0213">CVCL_0213</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The FcγR expression profiles of Raji, THP-1 and K562 were determined by FACS.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>THP-1</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All mAbs were tested in concentrations ranging from 0.55 ng/mL to 28 µg/mL in the context of Huh7 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Huh7</b></div>
              <div>suggested: CLS Cat# 300156/p7178_HuH7, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0336">CVCL_0336</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Maokang Biological) for 30 min at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Maokang Biological</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The 50% neutralization titer (NT50) was calculated using GraphPad Prism 7.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>GraphPad Prism</b></div>
              <div>suggested: (GraphPad Prism, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002798">SCR_002798</a>)</div>
            </div>
          </td></tr></table>
      

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.27.223578: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After an incubation at 37M°C for 24Mh, 2.5 µL/well of detection reagent mixture of two labeled anti-ZIKV NS1 antibodies was added to assay plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-ZIKV NS1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plates were transported into the BSL-3 facility were a 25 μL aliquot of virus inoculated cells (4000 Vero E6 cells/well) was added to each well in columns 3-24.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2 NS1 TR-FRET assay HEK293 cells were maintained in EMEM medium with 10% fetal bovine serum, 1% pen/strep (Gibco, Cat. # 15140–122).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>HEK293</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A NCATS in- house collection, the Genesis library, of ~90K diverse compounds was also screened for NS1 activity at a single concentration (14 µM).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Genesis</div> <div>suggested: (Genesis, RRID:SCR_015775)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    2. SciScore for 10.1101/2020.07.27.223578: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After an incubation at 37M°C for 24Mh, 2.5 µL/well of detection reagent mixture of two labeled anti-ZIKV NS1 antibodies was added to assay plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-ZIKV NS1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Materials and Methods Vero-E6 cells previously selected for high ACE2 expression (grown in EMEM, 10% FBS, and 1% Penicillin/Streptomycin) were cultured in T175 flasks and passaged at 95% confluency.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero-E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plates were transported into the BSL-3 facility were a 25 μL aliquot of virus inoculated cells (4000 Vero E6 cells/well) was added to each well in columns 3-24.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2 NS1 TR-FRET assay HEK293 cells were maintained in EMEM medium with 10% fetal bovine serum, 1% pen/strep (Gibco, Cat. # 15140–122).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>HEK293</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Two NCATS in-house diverse compound libraries, Sytravon, which contains ~44,000 compounds, and Genesis, which contains ~90,000 compounds, and a subset (~100,000 compounds) of the other NCATS bioactive libraries and a large diverse compound library (MLS), were also screened in subpanels of the NCATS assay portfolio.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Genesis</div> <div>suggested: (Genesis, SCR_015775)</div> </div> </td></tr></table>

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.27.223172: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The viral infection activated the type I interferon response in Calu-3 cells only and, consequently, ADAR1 did not appear deeply up regulated in Caco-2 and H1299 cells as also attested by the AEI index measured at all time points (Supp. Fig. 1).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>H1299</div> <div>suggested: NCI-DTP Cat# NCI-H1299, CVCL_0060</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We found A-to-G and T-to-C hyper edited reads only in Calu-3 and Caco-2 cells but the total number of edited reads was quite low as a result of the PolyA+ sequencing strategy in which mature viral transcripts rather than full genomic RNAs are captured.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Caco-2</div> <div>suggested: CLS Cat# 300137/p1665_CaCo-2, CVCL_0025</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">C) Enrichment of unique hyper editing positions in Vero cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero</div> <div>suggested: CLS Cat# 605372/p622_VERO, CVCL_0059</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RNA editing and expression of key genes in PolyA+ RNAseq data from Calu-3, Caco-2 and H1299 infected cells at three time points post-infection (4h, 12h and 24h).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Calu-3</div> <div>suggested: BCRJ Cat# 0264, CVCL_0609</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Additionally, viral reads from PolyA+ data were about 4 orders of magnitude less abundant than total RNAseq data.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>PolyA+</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">While in the human transcriptome A-to-G changes due to RNA editing can be distinguished from SNPs by means of whole genome (WGS) and/or whole exome (WES) sequencing data ​(Diroma et al., 2019)​, in the SARS-COV-2 RNA genome this distinction cannot be done.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>WGS</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data and Code Availability The raw data are available at SRA under the following BioProject accessions: PRJNA625518, PRJNA616446, PRJNA601736, PRJNA605907 and PRJNA631753.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>BioProject</div> <div>suggested: (NCBI BioProject, SCR_004801)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Method Details Filtering of RNAseq raw data Raw reads were cleaned using FASTP ​</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FASTP</div> <div>suggested: (fastp, SCR_016962)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Unique and concordant reads mapping on the SARS-COV-2 genome were extracted by sambamba ​(Tarasov et al., 2015) and converted in BAM format by SAMtools ​(Li et al., 2009)​.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SAMtools</div> <div>suggested: (Samtools, SCR_002105)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral reads were also aligned onto the NC045512.2 assembly by GSNAP ​(Wu and Nacu, 2010) employing the transcriptome-guided strategy.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GSNAP</div> <div>suggested: (GSNAP, SCR_005483)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The strand orientation per each sample was inferred by the infer_experiment.py script from the RSeQC package ​(Wang et al., 2012)​.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>RSeQC</div> <div>suggested: (RSeQC, SCR_005275)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Additionally, human reads were also aligned onto the human reference genome by STAR ​(Dobin et al., 2013) and proving known GENCODE (v31lift37) annotations.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>STAR</div> <div>suggested: (STAR, SCR_015899)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Dense clusters of high-quality (Phred ≥30) A-to-G (or T-to-C) mismatches are detected retaining reads in which the number of A-to-G changes was at least 5% of the read length and discarding reads having too dense A-to-G mismatch clusters (length <10% of the read length) or clusters contained within either the first or last 20% of the read or clusters with a particularly large percentage (>60%) of a single nucleotide.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Phred</div> <div>suggested: (Phred, SCR_001017)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Detection of RNA editing at single nucleotide level We performed an initial variant calling by REDItools (version 2) ​(Picardi and Pesole, 2013) and same parameters used also in ​(Di Giorgio et al., 2020) (-os 4 -q 30 -bq 30 -l 0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>REDItools</div> <div>suggested: (REDItools, SCR_012133)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gene expression in cell lines Read counts per known gene were carried out using featureCounts ​(Liao et al., 2014) and GENCODE (v31lift37) annotations.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GENCODE</div> <div>suggested: (GENCODE, SCR_014966)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Differential expression in time course experiments was done by DESeq2 ​(Love et al., 2014) while count normalization in FPKM for figures was performed by a custom script.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>DESeq2</div> <div>suggested: (DESeq, SCR_000154)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantification of sense and antisense viral strands The quantification of sense and antisense viral strands was performed in strand oriented datasets only and using featureCounts ​(Liao et al., 2014) providing as annotations the list of known viral non overlapping coding regions from UCSC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>featureCounts</div> <div>suggested: (featureCounts, SCR_012919)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Annotation of A-to-I editing events RNA editing events were annotated using ANNOVAR ​(Wang et al., 2010) providing the list of known SARS-COV-2 transcripts from UCSC.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ANNOVAR</div> <div>suggested: (ANNOVAR, SCR_012821)</div> </div> </td></tr></table>

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.27.222836: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">A priori power analysis (G*Power 3.1(34)) was used to estimate the required sample sizes.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Late endosomal/lysosomal compartments were identified by staining the endolysosomal marker protein CD63 with the mouse monoclonal anti-CD63 antibody H5C6 (1:300 in 2% BSA in PBS) for 90 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-CD63</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The secondary AlexaFluor594-coupled anti-mouse antibody was from Thermo Fisher Limited.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In this study, we explored the impact of disturbed ASMase activity and endolysosomal cholesterol accumulation on SARS-CoV-2 infection in Vero E6 cells commonly used to investigate SARS-CoV-2 infection, and in polarized bronchial Calu-3 cell monolayers, a lung cell model for productive SARS-CoV-2 infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: CVCL_XD71</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Results Fluoxetine treatment impairs SARS-CoV-2 infection in Calu-3 and Vero cells To assess the antiviral potential of fluoxetine, we treated SARS-CoV-2 infected Vero and Calu3 cells, two cell lines that are known to produce infectious virus progeny upon SARS-CoV-2 exposure, 1 h p.i. with a range of fluoxetine concentrations and measured the resulting virus titers 48 h p.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fluoxetine treatment is associated with Increased endolysosomal cholesterol storage and dysregulated acidification Because the pronounced decrease in SARS-CoV-2 titers observed upon treatment with U18666A hinted at an antiviral capacity of dysregulated endolysosomal cholesterol contents in SARS-CoV-2 infection, we next determined whether fluoxetine treatment of Vero and Calu3 cells was associated with increased endolysosomal cholesterol pools.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Calu3</div> <div>suggested: BCRJ Cat# 0264, CVCL_0609</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The human bronchioepithelial cell line Calu-3 and the Vero E6 cell line were cultivated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% standardized fetal bovine serum (FBS Advance; Capricorne), 2 mM L-glutamine, 100 U/mL penicillin, and 0.1 mg/mL streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Calu-3</div> <div>suggested: BCRJ Cat# 0264, CVCL_0609</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Our results show that fluoxetine treatment inhibited SARS-CoV-2 infection in a dose-dependent manner up to 99% and thus support the hypothesis that the endolysosomal lipid balance is a promising druggable target at the hostvirus interface for a wide variety of enveloped viruses, including SARS-CoV-2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SARS-CoV-2</div> <div>suggested: (Active Motif Cat# 91345, AB_2847847)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Tapping this vast pool of potential antivirals for drug repurposing might be a fast and powerful approach to fight a broad range of pathogens with functionally similar modes of action, including SARSCoV-2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SARSCoV-2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The secondary AlexaFluor594-coupled anti-mouse antibody was from Thermo Fisher Limited.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Thermo Fisher Limited</div> <div>suggested: (DataAssist, SCR_014969)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A priori power analysis (G*Power 3.1(34)) was used to estimate the required sample sizes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>G*Power</div> <div>suggested: (G*Power, SCR_013726)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed with Prism 8.00 (Graph-Pad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Prism</div> <div>suggested: (PRISM, SCR_005375)</div> </div> </td></tr></table>

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K. J. A., Hemmings, O., O’Bryne, A., Kouphou, N., Pickering, S., Galao, R., Betancor, G., Wilson, H. D., Signell, A. W., Winstone, H., Kerridge, C., Temperton, N., Snell, L., Bisnauthsing, K., Moore, A., … Doores, K. (2020). Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. MedRxiv, 2020.07.09.20148429. https://doi.org/10.1101/2020.07.09.20148429

    1. SciScore for 10.1101/2020.07.21.214759: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">All plasma samples were obtained under protocols approved by Institutional Review Boards at both institutions.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">All cell lines have been tested negative for contamination with mycoplasma.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Abstract Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SARS-CoV-2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARSCoV-2 agents.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-SARSCoV-2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Results Selection of SARS-CoV-2 S variants using a replication competent VSV/SARS-CoV-2 chimeric virus To select SARS-CoV-2 S variants that escape neutralization by antibodies, we used a recently described replication-competent chimeric virus based on vesicular stomatitis virus that encodes the SARS-CoV-2 spike (S) protein and green fluorescent protein (rVSV/SARS-CoV2/GFP) (</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>rVSV/SARS-CoV2/GFP</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies that constitute at last part of the neutralizing activity evident in COV-NY plasma appear to recognize an epitope that includes and K444 and V445.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>V445</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody binding and ACE2 binding inhibition assay A conformationally stabilized (6P) version of the SARS-CoV-2 S protein(25), appended at its C-terminus with a trimerization domain, a GGSGGn spacer sequence, NanoLuc luciferase, Strep-tag, HRV 3C protease cleavage site and 8XHis (S-6P-NanoLuc) was expressed and purified from the supernatant of 293T Expi cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ACE2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mutants thereof were also expressed and purifies following substitution of sequences encoding the RBD that originated from the unmodified Sexpression plasmids For antibody binding assays, 20ng, 40ng, or 80ng S-6P-NanoLuc (or mutants thereof) were mixed with 100ng of antibodies, C121, C135, or C144, \ diluted in LI-COR Intercept blocking buffer, in a total volume of 60μl/well in 96-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>C121</div> <div>suggested: (Leinco Technologies Cat# C121, AB_2828361)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Patent applications submitted by Rockefeller University are pending for anti SARS-CoV-2 antibodies (MCN, DR, inventors) and VSV/SARS-CoV-2 chimeric virus (PDB, TH FS and YW, inventors) A 10μg/ml C121, C135, C144 or plasma dilution 10μg/ml C121, C135, C144 or plasma dilution 1x106 IU rVSV/SARS-CoV-2/GFP p1 B p2 No Antibody Sequence, Isolate mutants by limiting dilution Plasma [5x initial] Sequence, Isolate mutants by limiting dilution Sequence Plasma [5x initial] p3 p4 10μg/ml C121 C Figure 1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti SARS-CoV-2</div> <div>suggested: (Abcam Cat# ab273074, AB_2847846)</div> </div>

            <div style="margin-bottom:8px">
              <div><b>C135</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>p3</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Selection of SARS-CoV-2 S mutations that confer antibody resistance. A. Outline of serial passage experiments with replication competent VSV derivatives encoding the SARS-CoV-2 S envelope glycoprotein and a GFP reporter (rVSV/SARS-CoV-2/GFP) in 293T/ACE2(B) cells in the presence of neutralizing antibodies or plasma. B. Representative images of 293T/ACE2(B) cells infected with 1x106 PFU of rVSV/SARS-CoV2/GFP in the presence or absence of 10μg/ml of the monoclonal antibody C121. C.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>SARS-CoV-2 S envelope glycoprotein</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">C144 passaged rVSV/SARS-CoV-2/GFP Populations Mutant purification by limiting dilution rVSV/SARS-CoV-2/GFP (E484K) rVSV/SARS-CoV-2/GFP (Q493R) Figure 3 - supplement 1 Example of plaque purification of individual viral mutants from populations passaged in the presence of antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>rVSV/SARS-CoV-2/GFP</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Amino acids whose substitution confers partial or complete (IC50 >10μg/ml) resistance to each monoclonal antibody in the HIV-pseudotype assays are indicated for C121 (red) C135 (green) and C144 (purple). E. Binding of S-NanoLuc fusion protein in relative light units (RLU) to 293T or 293T/ACE2cl.22 cells after preincubation in the absence or presence of C121, C135 and C144 monoclonal antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>C144</b></div>
              <div>suggested: (Leinco Technologies Cat# C144, <a href="https://scicrunch.org/resources/Any/search?q=AB_2828501">AB_2828501</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Experimental Models: Cell Lines</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines HEK-293T cells and derivatives were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37oC and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK-293T</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected with pHIVNLGagPol, pCCNanoLuc2AEGFP and a WT or mutant SARS-CoV-2 expression plasmid (pSARS-CoV2Δ19) using polyethyleneimine.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>293T</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Amino acids whose substitution confers partial or complete (IC50 >10μg/ml) resistance to each monoclonal antibody in the HIV-pseudotype assays are indicated for C121 (red) C135 (green) and C144 (purple). E. Binding of S-NanoLuc fusion protein in relative light units (RLU) to 293T or 293T/ACE2cl.22 cells after preincubation in the absence or presence of C121, C135 and C144 monoclonal antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>293T/ACE2cl.22</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The PCR products were gel-purified and sequenced either using Sanger-sequencing or NGS as previously described (31).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>NGS</b></div>
              <div>suggested: (NGSadmix, <a href="https://scicrunch.org/resources/Any/search?q=SCR_003208">SCR_003208</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For analysis of NGS data, the raw paired-end reads were pre-processed to remove adapter sequences and trim low-quality reads (Phred quality score <20) using BBDuk.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Phred</b></div>
              <div>suggested: (Phred, <a href="https://scicrunch.org/resources/Any/search?q=SCR_001017">SCR_001017</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Information regarding RBD-specific variant frequencies, their corresponding P-values, and read depth were compiled using the Python programming language (version 3.7) running pandas (1.0.5), numpy (1.18.5), and matplotlib (3.2.2).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Python</b></div>
              <div>suggested: (IPython, <a href="https://scicrunch.org/resources/Any/search?q=SCR_001658">SCR_001658</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>matplotlib</b></div>
              <div>suggested: (MatPlotLib, <a href="https://scicrunch.org/resources/Any/search?q=SCR_008624">SCR_008624</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The half maximal inhibitory concentrations for plasma (NT50), and monoclonal antibodies (IC50) was calculated using 4-parameter nonlinear regression curve fit to raw or normalized infectivity data (GraphPad Prism).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>GraphPad</b></div>
              <div>suggested: (GraphPad Prism, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002798">SCR_002798</a>)</div>
            </div>
          </td></tr></table>
      

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.22.216150: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">hACE2 expression was confirmed by immunofluorescence staining using mouse monoclonal antibody against c-Myc antibody 9E10 (Thermo Fisher) and Goat-anti-mouse FITC (Jackson ImmunoResearch Laboratories, Inc).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>c-Myc</div> <div>suggested: None</div> </div>

            <div style="margin-bottom:8px">
              <div><b>Goat-anti-mouse FITC</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To measure surface TMPRSS2 expression, cells were detached by 1mM EDTA in PBS and then stained by 4 ug/ml of anti-Flag M2 antibody (Sigma, F1804) and 2 ug/ml of Goat anti-mouse IgG (H+L) conjugated with Alexa 647 (Jackson ImmunoResearch Laboratories, Inc, Cat# 115-606-146).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>anti-Flag</b></div>
              <div>suggested: (Sigma-Aldrich Cat# F1804, <a href="https://scicrunch.org/resources/Any/search?q=AB_262044">AB_262044</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>anti-mouse IgG</b></div>
              <div>suggested: (Jackson ImmunoResearch Labs Cat# 115-606-146, <a href="https://scicrunch.org/resources/Any/search?q=AB_2338930">AB_2338930</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Experimental Models: Cell Lines</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To demonstrate the effect of different amount of TMPRSS2 on antiviral activities of hydroxychloroquine, both transient (high) and stable (low) TMPRSS2 HEK293T-ACE2 cells were used as targets.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK293T-ACE2</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For HEK293TACE2 cells transiently expressing the control plasmids (Fig 3A)</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK293TACE2</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These IC50 values are consistent with a previous cell culture study, using replicative SARS-CoV-2 on Vero cells, which do not express TMPRSS2 [10].</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Vero</b></div>
              <div>suggested: CLS Cat# 605372/p622_VERO, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0059">CVCL_0059</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Thus the potent inhibition of SARS-CoV-2 by hydroxychloroquine in Vero E6 cells, where TMPRSS2 is largely absent, overestimated its potency by 10- to 40-fold, depending on TMPRSS2 expression (Fig 3A).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Vero E6</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, HEK293T cells were cotransfected with three plasmids, pMLV-gag-pol, pCAGGS-VSV-G and pQCXIP-myc-hACE2-c9, and the medium was refreshed after overnight incubation of transfection mix.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK293T</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The parental 293T cells were transduced with generated MLV virus, and the 293T-hACE2 cell lines were selected and maintained with medium containing puromycin (Sigma).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>293T-hACE2</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T/ACE2/TMPRSS2 stable cell line was also constructed by transducing 293T-hACE2 cell line with MLV pseudovirus made by cotransfection of pMLV-gag-pol, pQCXIB-TMPRSS2-Flag and pCAGGS-VSV-G at 3:2:1 ratio into 293T cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK293T/ACE2/TMPRSS2</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>293T</b></div>
              <div>suggested: KCB Cat# KCB 200744YJ, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0063">CVCL_0063</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the 293T-ACE2 stable cell line, 3 μg/mL of puromycin was added to the growth medium to maintain expression of ACE2.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>293T-ACE2</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis Data expressed as mean values ± S.D. or S.E.M, and all statistical analysis was performed in GraphPad Prism 7.0 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>GraphPad Prism</b></div>
              <div>suggested: (GraphPad Prism, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002798">SCR_002798</a>)</div>
            </div>
          </td></tr></table>
      

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      We thank the reviewers for their useful suggestions to improve the manuscript and their support for publication. We have addressed all the comments that have been raised and carried out the suggested additional analyses, resulting in a significantly improved revised version of the manuscript. We provide hereafter a detailed point-by-point response to all questions and comments of the three reviewers.

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      Centriole structure has been an attractive but challenging research topic for years. Pierre Gonczy's group has been working on its structure using cryo-electron tomography (cryo-ET). While the axoneme, which has longitudinal periodicity, was analyzed by several groups by cryo-ET for more than a decade, cryo-ET study on the centriole suffers from poor signal to noise ratio due to its limited length and thus fewer periodicity. They chose the centriole of flagellate Trichonympha, which have exceptionally long centrioles and thus offer opportunity of relatively straightforward sub-tomogram averaging. Their approach has been successful, and they revealed intermediate resolution structure of the cartwheel, key of 9-fold symmetry formation, and it's joint to triplet microtubules (Guichard et al. 2012, 2013, 2018).

      In this work, they employed modern state-of-art cryo-ET technique, such as direct electron detection and 3D image classification to upgrade our knowledge of centriole structure. In their past works, the central hub of the cartwheel, made of SAS-6 protein forming 9-fold complex, was described as an 8nm periodic object. With improved spatial resolution, they provided further detail with clear polarity, which will deepen our thought about the initial stage of ciliogenesis. They also compared two Trichonympha species (spp and agilis) as well as another flagellate, Teranympha mirabilis, and extended their intriguing evolutional and mechanical hypotheses based on structural differences.

      Despite improved spatial resolution, it is still not possible to identify proteins in the cryo-ET map (cellular cryo-ET will not reach such high resolution in the near future). Therefore, this work is rather geometrically descriptive, which will inspire molecular biologists to identify molecules by other methods. Nevertheless, this work demonstrated capability of cellular cryo-ET, especially analysis of structural heterogeneity. Thus, while biological topics handled are rather specialized for cilia from flagellate, this work will attract attention of any biologist interested in molecular structure in vivo. It is worth for publication in a high Journal after addressing the points below. This reviewer believes that the authors can address these points easily with additional analysis.

      We are grateful to the reviewer for the favorable evaluation and the many valuable suggestions, in particular concerning the processing pipeline, which we addressed by additional analyses, as detailed below.

      Major points:

      1. Entire scheme A graphic diagram of the entire cartwheel area, summarizing this work, is necessary for the readers' understanding (similar to Fig.6 of the other manuscript, Klena et al.).

      We thank the reviewer for this interesting suggestion, which we fully adhere to. As a result, we have generated a graphical summary of the work, which is shown in the new Figure panels 6B-F. Moreover, Figure 6A provides an evolutionary perspective regarding the presence of the CID and of what is now referred to as the fCID (filamentous CID, previously: FLS, see response to reviewer 3). This also helps to link our findings with the companion manuscript by Klena et al. This new Figure 6 is referred to extensively in the discussion of the revised manuscript (pages 13-16).

      Then average scheme should be shown in more detail, especially assumption of periodicity, Materials and Methods. The cartwheel hub was averaged with 25nm periodicity (as discussed below). Was the pinhead averaged with 16nm (as detected by FFT in Fig.S2L)? How about the triplet?

      This reviewer is not completely sure if the longitudinal averaging strategy is justifiable. Since periodicity of each domain is not trivial, logically the initial average must be done with the size of least common multiple (or larger). It is likely 96nm, assuming 25nm of the central hub is 3 times of microtubule periodicity and 16nm of the pinhead is twice of MT. 96nm average should be possible with a long cartwheel in this work. Alternative, in case periodicity is independent of MT and thus there is no least common multiple, is random picking and classification mentioned in "4. Periodicity". This should also be possible, since they can pick enough number of particles from long cartwheels.

      We apologize that the initial version of the manuscript was not sufficiently clear regarding the averaging pipeline that was pursued. To rectify this, we now provide a new Figure S1B to graphically explain the approach followed for STA. As depicted in this figure panel, the step size for sub-volume extraction was 25 nm both centrally and peripherally. This step size was selected because it corresponds to ~3x the major periodicity of ~8.5 nm observed in the power spectra of the sub-volumes. The 25 nm step size is larger than that previously used (i.e. 17 nm in Guichard et al. 2013), in order to identify potential features with larger periodicities. The fact that the step size was of 25 nm in all cases is now mentioned explicitly in the Materials and Methods section of the revised manuscript (line 649).

      We agree with the reviewer that 96 nm averaging is possible given the long cartwheel analyzed here, and such a piece of data was in fact included in the original submission, although with a different purpose. Indeed, we carried out STA using ~(100 nm)3 sub-volumes (with binning 3 to reduce computational time), the results of which are reported in Figure S7 (previously Fig. S6). For the purpose of this analysis, we focused on the lateral organization of the cartwheel, but did not use this dataset to explore other periodicities because of the limitations inherent to a binning 3 data set.

      • Classification*

      The authors analyzed structural heterogeneity inside the cartwheel hub, employing reference-free classification by Relion software. The program reveals multiple coexisting structures - two from Trichonympha agilis and three from Teranympha, respectively. Whereas this is an exciting finding and shows future research direction of this field, interpretation of this classification must be done carefully. ** It is puzzling that major (55%) population of T. agilis shows more ambiguous features than the minor population (45%), while spatial resolutions by FSC are not so different - for example, Fig.2H vs Fig.S5C. In case of Teranympha, it is even more drastic - Fig.4D (major class) seems blurred along the centriolar axis, compared to Fig. 4E (minor class). This reviewer is afraid that these "major" classes might contain more than one structure and after subaveraging be blurred in detailed features. The apparent good spatial resolution could be explained, when two structures coexist and subtomograms are aligned within each subclass. Probably lower resolution at the spoke region of the major class (Fig.S2A) than that of the minor class (Fig.S2D) is a sign of heterogeneity within this class. Another risk could be subtomograms with poorer S/N being categorized to one class (due to lack of feature to be properly classified). Fig.S5F (black dots localized in one tomogram) raised this concern.

      The following investigation will help to solve this issue. 1. Extract and re-classify subtomograms belonging to the major population. 2. Direct observation of tomograms. The authors could plot two classes of Teranympha (as they did for T. agilis in Fig.S5) and find features of the cylindrical cartwheel hub in two conformations (as shown Fig.4DE). Since such a feature was directly observed in tomograms from the other manuscript (left panels of Fig.S6AC in Klena et al.), it should be possible in this work as well.

      We agree with the reviewer that the interpretation of the classification must be done with care, and share her/his interest in better understanding the structural variability between cartwheels classes in T. agilis and T. mirabilis. Although poor S/N may in theory result in erroneous joint classifications, we note that all maps in the original submission stemmed from extensive focused 3D classification, which removed defective and spurious sub-volumes, nevertheless defining distinct classes in the cases reported. Obviously, however, we cannot exclude that much larger data sets and future software advances may lead to the identification of additional features that would allow further sub-classes to be identified.

      Regardless, we followed the two suggestions the reviewer offered to us and have (1) extracted and re-classified sub-tomograms belonging to the major populations and (2) undertaken a direct observation of tomograms. These two points are developed in turn below.

      (1) We have performed a further round of classification of the major populations in T. agilis (55 % class) and T. mirabilis (64 % class), to assess whether additional sub-classes might be identified and thus help further improve the quality of the central cartwheel map. However, this additional round did not yield new sub-classes nor notable improvement in the map quality as judged by visual inspections. We show in Rebuttal Figure 1 a comparison in each case of the original STA and the corresponding STA upon such re-classification. Importantly, all conclusions spelled out in the original submission hold upon further re-classification, indicating that the initial classification converged to the best map quality based on the current data set and available computational resources.

      (2) We have followed the suggestion of the reviewer and now show raw tomograms to confirm that the classes correspond to bona fide structures and not to processing artefacts (new Figures S1C-F). The resulting new Figure S1D for instance shows that the striking variations observed between classes in the T. agilis STA are also visible in the raw tomogram. The more subtle variations among T. mirabilis classes are more difficult to observe in the raw tomogram, but inherent variations that reflect the presence of two classes are nevertheless observed.

      Furthermore, following the reviewer’s suggestion, we now mapped the distribution of the two T. mirabilis cartwheel classes onto tomograms, revealing that both classes can occur next to each other within the same centriole (new Figure S8E).

      • Periodicity mismatch*

      In Fig. 2CD, periodicity of CID has discrepancy from that of the stacked SAS-6 ring (8.5nm and 8.0nm). Do the authors think this is a significant difference or within an error? The same question can occur to other subtomogram averages. It would be nice to show errors as shown in their other manuscript (Fig.3C of Klena et al.) and clarify their idea. If it is systematic difference of periodicity between the stacked ring and CID, this shift will be accumulated through the entire cartwheel region - after 100nm, 8.5nm/8.0nm difference can be accumulated to ~6nm, which should change the entire view of the subtomogram - and the main factor to be classified (periodicity mismatch). This artifact (or influence) should be removed (or separately evaluated) by masking CID (out and in) and run classification separately. By clarifying this, the quality of the major subaverages (mentioned in the previous paragraph) could be improved.

      The reviewer wonders whether there might be a periodicity discrepancy within one map, for instance between CID and spokes in the T. spp. cartwheel map (Fig. 2C and Fig. 2D). Here, the periodicity determined from the STA maps is 8.5 ± 0.2 nm (SD, N=4) for the CID and 8.0 ± 1.5 nm (SD, N=2) for the spokes. Based on these standard deviations, there is indeed no significant difference between the two, and thus no periodicity discrepancy. The same applies for measurements in T. agilis and T. mirabilis. The SDs were reported already in the figure legends of the original submission, and we would prefer to leave them there if possible and not mention them in the figures, which are pretty busy as is. We apologize if this was not clear enough in the initial manuscript. Likewise, one may wonder whether there might be periodicity discrepancies between structures from distinct maps, for instance between CID and A-links from T. spp. (Fig. 2C and Fig. 3D). Again, the measurements are within error, since the distance between adjacent CIDs is 8.5 ± 0.2 nm (N=4) and between adjacent A-links 8.4 ± 0.4 nm (N=6); a similar conclusion applies for the corresponding measurement comparisons in T. agilis and T. mirabilis. The figure legends have been altered in the revised manuscript to spell out that there are no significant differences between periodicities (lines 856-858).

      Furthermore, we would like to stress that, by definition, STA value are average distances. For instance, in the case of T. spp., the central cartwheel STA was obtained from 511 sub-volumes, and thus the reported N=2 represents the average distance from 511 sub-volumes. Since this is an average, errors can therefore not accumulate over longer distances. This point has also been clarified in the figure legends (line 856-858).

      • Periodicity*

      They averaged subtomograms extracted with spacing of 252A with initial average as the first template (p.18 Line22). This means they assumed 25nm periodicity from the beginning and excluded different or larger unit size (if they take search range wide, they could detect difference periodicity, but will still be biased by initially assumed 25nm). 25nm average allowed them to see more detail than before (when they assumed 8nm periodicity), but there is still a risk of bias from references. To avoid this risk, this reviewer would propose classification of randomly extracted (but of course along the cylindrical hub or along the triplet microtubules, so one-dimensionally random picking) subtomograms. This experiment will end up with multiple sub-averages, which are 25nm (or multiple times of that) shifted from each other. Then it will prove their assumption.

      We agree with the reviewer that in theory the choice of periodicity could introduce a bias. This is why we have chosen a larger step size than in our initial work, corresponding to ~3x the major periodicity of ~8.5 nm observed in the power spectrum of the sub-volumes, as mentioned above. Regardless, following the reviewer’s suggestion, we have now explored other types of periodicities by re-analyzing the dataset through extraction of non-overlapping sub-volumes along the proximal-distal centriole axis. In doing so, we randomized the starting position of the first box between tomograms, reaching the same goal as with random picking but maximizing the number of sub-volumes. We carried out this analysis for all T. spp., T. agilis and T. mirabilis cartwheel classes, and found no notable differences that would affect the conclusions of the manuscript compared to the initial overlapping sub-volume classification, albeit generally with a noisier STA due to the lower number of sub-volumes. A comparison of the two approaches is provided in Rebuttal Figure 2. Moreover, all the points regarding the choice of periodicity have been further clarified in the expanded Materials and Methods section (pages 19-21).

      Minor points:

      They discussed difference of stacked SAS-6 rings in the cartwheel from various species. How much is the sequence difference of SAS-6 among these species?

      Unfortunately, no genomic or transcriptomic data has been published for the species investigated here, although the sparse molecular data available from small subunit rRNA sequences allows one to establish an overall molecular phylogeny. We previously identified a SAS-6 homologue in T. agilis (Guichard et al. 2013), which shares 20 % identity and 45 % similarity with C. reinhardtii SAS-6. Despite low sequence conservation, the structural conservation of SAS-6 is predicted to be high between the two organisms (Guichard et al. 2013). We apologize if these points were not expressed sufficiently clearly in the initial rendition and have adapted the wording in the revised manuscript (lines 325-332).

      Are the authors sure that CID is nine-fold symmetric? It is not trivial.

      We thank the reviewer for bringing up this interesting point. We have applied 9-fold symmetrization to the entire central cartwheel comprising spokes, hub and CID/ fCID, a choice guided by the apparent 9-fold symmetry of the spokes and peripheral element. We investigated the impact of symmetrization on the CID by relaxing symmetry from C9 to C1 during refinement, but did not observe a difference, and thus continued with C9 symmetry, which improves map resolution by S/N ratio enhancement and additional missing wedge compensation. In addition, we have also analyzed the CID without symmetrization, as reported in Figure S7 (previously: Fig. S6). Note that these maps were generated with larger sub-volumes centered on the spokes to comprise hub, spokes and microtubule triplets, explaining the resulting lower resolution, as the missing wedge is not compensated. Despite these limitations, however, the unsymmetrized CID shown in Figure S7A and S7E resembles the one in the symmetrized maps of Figure 2, indicating that the CID indeed exhibits 9-fold radial symmetry. That this is the case is spelled out explicitly in the revised manuscript (lines 1145-1147).

      Fig.1C: Another cross-section from the distal region will be helpful. A longer scale bar is better for readers' understanding.

      We understand that the reviewer is curious about the distal region, and cross-section views of resin-embedded sections from T. agilis are available and could be provided if necessary. However, given that the focus of the manuscript is strictly on the cartwheel-bearing proximal region, we felt that featuring the distal region in detail would break the narrative. Therefore, we suggest to keep Figure 1 as in the original manuscript. Following the reviewer’s suggestion, we increased the size of the scale bars from 10 nm to 20 nm in Figure 1C as well as in the corresponding Figure S8C.

      Fig.S6F: It would be informative if the subclasses (25% and 20%) are distinguished in this mapping.

      As per the reviewer’s request, we provide in Rebuttal Figure 3 a side-by-side comparison of the T. agilis 25 % and 20 % classes centered on the spokes, which are noisier than the composite 45 % class due to the lower number of sub-volumes in each sub-class. Given that there are no notable differences between the two maps that would affect any of the conclusions of the manuscript, we feel it is best to keep what is now Figure S7F (previously: Fig. S6F) unchanged in the revised manuscript.

      A figure to explain the classification scheme will help readers understand. How many subtomograms did classification started? Were the 45% class classified into two (25% and 20%) groups by two-step classification or at once (the entire subtomograms were classified into three groups directly?

      We thank the reviewer for this useful suggestion. As a result, we have generated a new Supplemental Figure S1G-J that provides a graphical overview of the classification scheme, together with sub-volume numbers for all deposited maps, thus nicely complementing Table S1.

      Reviewer #1 (Significance (Required)):

      Nevertheless, this work demonstrated capability of cellular cryo-ET, especially analysis of structural heterogeneity. Thus, while biological topics handled are rather specialized for cilia from flagellate, this work will attract attention of any biologist interested in molecular structure in vivo. It is worth for publication in a high journal after addressing the points above. This reviewer believes that the authors can address these points easily with additional analysis.

      We reiterate our thanks to this reviewer for her/his favorable evaluation and detailed suggestions, which enabled us to generate a strengthened manuscript.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      Here, Nazarov and colleagues report sub-tomogram average (STA) maps of centrioles with 16 to 40 Å resolution from Trichonympha spp., Trichonympha agilis, and Teranympha mirabilis. Even though the authors have previously described the centriole architecture of T. spp, these STA maps of higher resolution revealed new features of centrioles, like polarized Cartwheel Inner Density (CID) and the pinhead. They also observed Filament-like structure (FLS) from T. mirabilis which seems to correspond to the CID from other species. Interestingly, they suggest that one and two SASS6 rings are stacked in an alternative fashion to make the central hub in T. mirabilis (Figure 5). The following issue should be addressed:

      Major points

      • Figure 4E. Authors mentioned in the manuscript that "We observed that every other double hub units in the 36% T. mirabilis class appears to exhibit a slight tilt angle relative to the vertical axis". When I see the other side, it does not seem to be tilted. Could the authors explain this?*

      We apologize that this aspect was not explained in sufficient detail. The left and right sides of the hub indeed appeared different in transverse views across the cartwheel center (previous Fig. 4E). This was because the area we selected in the original submission was centered on one emanating spoke. Due to the 9-fold symmetry one spoke density was selected on the right side, while the region between two spokes was displayed on the left side (as was illustrated by the slice across the center in previous Figure 4A; dashed rectangles in 4.0 nm panel). We have now selected a larger area to include spokes from both sides of the hub and thus better visualize this offset as shown in the modified Figure 4D-E.

      Reviewer #2 (Significance (Required)):

      I believe these results are of interest for all centrosome researchers and would like to recommend this manuscript be published in the EMBO journal which is affiliated with the Review Commons.

      We thank the reviewer for the recommendation to submit the revised manuscript to EMBO Journal, which we have followed.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      In this manuscript Nazrov et al., use cryo-electron tomography (CET) to analyse the structure of the centriole cartwheel. The Gonczy lab have previously generated a ground-breaking structure of the cartwheel from Trichonympha spp (T. spp.) (Guichard et al., Science, 2012; Guichard et al., Curr. Biol., 2013). This work is a direct continuation of those studies but using modern technology to get higher resolution images of the T. spp. cartwheel and comparing this to the cartwheel from Trichonympha agilis and from another distantly related flagellate Teranympha mirabilis.

      The data is generally well presented and of high quality. I am not an expert in CET, so it would be advisable to get the opinion from a reviewer who is, but the Gonczy lab are experienced in these techniques so I would not anticipate any problems. I have to admit that the title of the paper did not excite me, and I expected this to be a very worthy, but incremental study. It was a pleasure to find out that the extra detail provided by the increased resolution has revealed several new and unexpected features that have important implications for our understanding of cartwheel assembly and function. Most important are the potential asymmetry of the cartwheel hub, apparent variations in the packing mechanism of the stacked rings (even within the same cartwheel), and the potential offsetting of ring stacking. These findings will be of great interest to the field, and so I am strongly supportive of publication in The EMBO Journal. I have only a few points that I think the authors should consider.

      We thank the reviewer for this positive feedback and the recommendation to submit to EMBO Journal, which we hereby follow.

      Prompted by the comment of the reviewer, we revised the title to make it more informative and appealing to readers: “Novel features of centriole polarity and cartwheel stacking revealed by cryo-tomography”.

      • Nazarov et al., conclude that the cartwheel structure is intrinsically asymmetric. This is most convincingly based on the displacement of the CID within the hub, but they state that the Discussion that the potential offset between the Sas-6 double rings generates an inherently polar structure. I didn't understand why this is the case. Looking at Fig.S9A,B I can see that the offset in B could tilt to the left (as shown here) or to the right (if the structure was flipped by 180o). But I couldn't see how this makes this structure polar in the sense that a molecule coming into dock with the structure could only bind to one side of the offset structure shown in B, but to both sides of the aligned structure shown in A. I think this needs to be explained better, as it is crucial to understand where any potential polarity in the cartwheel structure comes from.*

      We apologize for not having been sufficiently clear about how two SAS-6 rings with an offset could impart organelle polarity. The reviewer is correct that an offset between superimposed rings alone is not sufficient to generate polarity at a larger scale. The important point we would like to stress, however, is that we discovered concerted polarity in multiple locations, from the central hub to the peripheral elements as illustrated in Fig. S7C-D, S7G-H, S7K-L and S7O-P (previously: Fig. S6). Prompted by the reviewer’s comment, we now better emphasize the asymmetric tilt angles of merging spokes, as highlighted also in the improved Figure S7. This asymmetric spoke tilt angle allows one to discriminate the proximal and distal side of a double SAS-6 ring, which is now explained better in the text (lines 259-263 & 502-510).

      • Related to this last point, in a co-submitted paper Klena et al. do not report such an asymmetry in the hub structures they have solved from several different species (neither in the tilting of the hub, or the displacement of the CID). I think it would be worth both sets of authors commenting on this point.*

      We agree that comparing and contrasting the results of the two companion manuscripts is important and we have updated the text as a consequence in several places (lines 444, 467, 507, 536, 985, 1000). We know from our previous work (Guichard et al. 2013) that the asymmetry of the hub and spoke is not visible at lower resolution. In the accompanying manuscript by Klena et al., no offset in the hub or asymmetric CID localization is reported, probably due to lower resolution and differences between species.

      • The authors data strongly suggests that the T. ag. and Te. mir. hubs are composed of a mixture of single and double Sas-6 rings. In contrast, the T. spp. cartwheel only has a single class of rings, but it wasn't absolutely clear if the authors think this comprises a single or double ring. In the text it is presented as though the elongation of the hub densities in the vertical direction is a new feature of the T. ag cartwheel (Fig.2H,I), but to me it looks as though this is also apparent in the T. spp. cartwheel (Fig.2C,D). The authors should address this directly and, if they believe that T. spp. has a double ring, they should comment on whether this more regular structure seems to have offset rings. If not, then the offset rings are unlikely to be the source of asymmetry that leads to the asymmetric displacement of the CID. Finally, if the authors think these are double rings, they should also be clear that they would now slightly re-interpret their original T. spp. cartwheel model (Figure 2, Guichard et al., Curr. Biol.). There is no embarrassment in this-a higher resolution structure has simply revealed more detail.*

      We apologize if the conclusions drawn about T. spp. cartwheel hubs were not sufficiently clearly expressed. Like the reviewer, we think that elongated hub elements are also discernible in T. spp., something that is also illustrated by the intensity plot profile in Figure 2C (double peaks on light blue line). These points are spelled out more explicitly in the revised manuscript (lines 177-179). In addition, to emphasize the conservation of the double hub units in both Trichonympha species, we have likewise adapted the text for T. agilis (lines 198-201).

      As for the offset observed within T. spp. spoke densities in Figure S10H, we interpret this as evidence for an offset of the double ring at the level of the hub, although we have not observed such offset in T. spp. for reasons that are unclear. The fact that this revises our previous interpretation based on a lower resolution map of T. spp. was already mentioned in the initial submission but is now better emphasized (lines 171-172 & 179-181).

      • The authors conclude that T. mirabilis cartwheels lack a CID and instead have a filament-like structure (FLS). I wonder whether it is more likely that the FLS is really a highly derived CID that appears to be structurally distinct when analysed in this way, but that will ultimately have a similar molecular composition. This situation might be analogous to the central tube in C. elegans, which by EM appears to be distinct from the central cartwheel seen in most other species, but is of course still composed of Sas-6. This historical tube/cartwheel nomenclature is now cumbersome to deal with, so perhaps it would be better to be cautious and not give the T. mirabilis structure a completely new name-how about "unusual CID" (uCID).*

      We share the view that the CID and the “FLS” –the term used in the initial submission- may have a related molecular composition and function, as we had also speculated in the discussion of the original submission. Following the reviewer’s suggestion, and in an effort to have a more uniform nomenclature, we propose to dub the T. mirabilis structure “filamentous CID” (fCID). This highlights better the similar location of these two entities and their potential shared function, while stressing the filamentous nature of the fCID. We further emphasize this point by providing the new Figure 6A to compare the presence of the two entities in select species. The discussion has also been adapted accordingly (pages 13-14).

      Rebuttal Figure Legends

      Rebuttal Figure 1: Re-classification of major classes

      (A-D) Transverse (top) and longitudinal (bottom) views of T. agilis (A, B) and T. mirabilis (C, D) central cartwheel 3D maps. The final major classes reported in the manuscript (A: 55 % class, C: 64 % class) were subjected to re-classification, which again yielded one major class in each case, with no notable improvement (B, D).

      Rebuttal Figure 2: Reclassification with non-overlapping sub-volumes

      (A-F) Transverse (top) and longitudinal (bottom) views of T. spp. (A, B) T. agilis (C, D) and T. mirabilis (E, F) central cartwheel 3D maps. The final maps reported in the manuscript (A, C, E) were generated with a 25 nm step size, yielding overlapping sub-volumes, whereas the maps in (B, D, F) were generated from non-overlapping sub-volumes, with no notable differences between the two that would affect the conclusions of the manuscript.

      Rebuttal Figure 3: Polar centriolar cartwheel upon sub-classification

      (A-C) 3D transverse views of non-symmetrized STA centered on the spokes to jointly show the central cartwheel and peripheral elements in the T. agilis 45 % class (A), as well as separately in the 25 % class (B) and 20% class (C). No notable differences are apparent following such re-classification, apart from the output being noisier due to the lower number of sub-volumes in each sub-class.

    1. O’Connor, D. B., Aggleton, J. P., Chakrabarti, B., Cooper, C. L., Creswell, C., Dunsmuir, S., Fiske, S. T., Gathercole, S., Gough, B., Ireland, J. L., Jones, M. V., Jowett, A., Kagan, C., Karanika‐Murray, M., Kaye, L. K., Kumari, V., Lewandowsky, S., Lightman, S., Malpass, D., … Armitage, C. J. (n.d.). Research priorities for the COVID-19 pandemic and beyond: A call to action for psychological science. British Journal of Psychology, n/a(n/a), e12468. https://doi.org/10.1111/bjop.12468

    1. SciScore for 10.1101/2020.07.17.20140533: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">One subject of the 10 µg, and one subject of the 50 µg dose 281 cohort left the study prior to the boosting immunisation due to withdrawal of consent and private 282 reasons.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">The study population consisted of healthy males and non-pregnant 85 females with a mean age of 41 years (range 18 to 55 years) with equal gender distribution.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Cell lines were tested for mycoplasma contamination after receipt and 321 before expansion and cryopreservation.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CD4+ and CD8+ T cells may confer long-lasting 186 immunity against corona viruses as indicated in SARS-CoV-1 survivors, where CD8+ T-cell immunity 187 persisted for 6-11 years24,27. 188 Some cases of asymptomatic virus exposure have been associated with cellular immune response 189 without seroconversion indicating that SARS-CoV-2 specific T cells could be relevant in disease control 190 even in the absence of neutralising antibodies28.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CD4+</div> <div>suggested: None</div> </div>

            <div style="margin-bottom:8px">
              <div><b>antibodies28</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A secondary fluorescently labelled goat anti-human 329 polyclonal antibody (Jackson Labs) was added for 90 minutes at room temperature while shaking, before 330 plates were washed once more in a solution containing 0.05% Tween-20.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>A secondary fluorescently labelled goat anti-human 329 polyclonal antibody</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>anti-human 329</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Tests were performed in duplicate and with a positive 391 control (anti-CD3 monoclonal antibody CD3-2 [1:1,000; Mabtech])</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>anti-CD3</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Experimental Models: Cell Lines</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral master stocks (2 x 107 PFU/mL) were 344 grown in Vero E6 cells as previously described29.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Vero E6</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serial dilutions of heat-inactivated sera were incubated with the reporter virus (2 x 104 PFU per 347 well to yield approximately a 10-30% infection rate of the Vero CCL81 monolayer) for 1 hour at 37 ⁰C 348 before inoculating Vero CCL81 cell monolayers (targeted to have 8,000 to 15,000 cells per well) in 96 349 -well plates to allow accurate quantification of infected cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Vero CCL81</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T cells (ATCC CRL- 364 3216) were seeded (culture medium: DMEM high glucose [Life Technologies] supplemented with 10% 365 heat-inactivated fetal bovine serum [FBS; Life Technologies] and penicillin/ptreptomycin/L-glutamine 366 [Life Technologies]) and transfected the following day with spike expression plasmid using 367 Lipofectamine LTX (Life Technologies) following the manufacturer’s protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK293T</b></div>
              <div>suggested: ATCC Cat# CRL-3216, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0063">CVCL_0063</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">375 For pseudovirus neutralisation assays, Vero cells (ATCC CCL-81) were seeded in 96-well plates in 376 culture medium and allowed to reach approximately 85% confluence before use in the assay (24 hours 377 later).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Vero</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Key exclusion criteria included previous 268 clinical or microbiological diagnosis of COVID‑19; receipt of medications to prevent COVID‑19; 269 previous vaccination with any coronavirus vaccine; a positive serological test for SARS-CoV-2 IgM 270 and/or IgG; and a SARS-CoV-2 NAAT-positive nasal swab; those with increased risk for severe 271 COVID-19; and immunocompromised individuals.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>IgG</b></div>
              <div>suggested: (DSHB Cat# LEP100 IgG, <a href="https://scicrunch.org/resources/Any/search?q=AB_528124">AB_528124</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Total cell counts per well were enumerated 350 by nuclear stain (Hoechst 33342) and fluorescent virally infected foci were detected 16-24 hours after 351 inoculation with a Cytation 7 Cell Imaging Multi-Mode Reader (BioTek) with Gen5 Image Prime 352 version 3.09.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Gen5</b></div>
              <div>suggested: (Gen5, <a href="https://scicrunch.org/resources/Any/search?q=SCR_017317">SCR_017317</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Titers were calculated in GraphPad Prism version 8.4.2 by generating a 4-parameter (4PL) 353 logistical fit of the percent neutralisation at each serial serum dilution.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>GraphPad Prism</b></div>
              <div>suggested: (GraphPad Prism, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002798">SCR_002798</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FlowJo LLC, BD Biosciences)</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>FlowJo</b></div>
              <div>suggested: (FlowJo, <a href="https://scicrunch.org/resources/Any/search?q=SCR_008520">SCR_008520</a>)</div>
            </div>
          </td></tr></table>
      

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. Zhong, H., Wang, Y., Shi, Z., Zhang, L., Ren, H., He, W., Zhang, Z., Zhu, A., Zhao, J., Xiao, F., Yang, F., Liang, T., Ye, F., Zhong, B., Ruan, S., Gan, M., Zhu, J., Li, F., Li, F., … Zhao, J. (2020). Characterization of Microbial Co-infections in the Respiratory Tract of hospitalized COVID-19 patients. MedRxiv, 2020.07.02.20143032. https://doi.org/10.1101/2020.07.02.20143032

    1. Yurkovetskiy, L., Wang, X., Pascal, K. E., Tomkins-Tinch, C., Nyalile, T., Wang, Y., Baum, A., Diehl, W. E., Dauphin, A., Carbone, C., Veinotte, K., Egri, S. B., Schaffner, S. F., Lemieux, J. E., Munro, J., Rafique, A., Barve, A., Sabeti, P. C., Kyratsous, C. A., … Luban, J. (2020). Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. BioRxiv, 2020.07.04.187757. https://doi.org/10.1101/2020.07.04.187757

    2. SciScore for 10.1101/2020.07.04.187757: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Cell culture All cells were cultured in humidified incubators with 5 % CO2 at 37º C , and monitored for mycoplasma contamination using the Mycoplasma Detection kit ( Lonza LT07-318)</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To determine if this is the case , the neutralization potency was assessed of four monoclonal antibodies that target the SARS-CoV-2 Spike protein receptor binding domain .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SARS-CoV-2 Spike protein receptor binding domain .</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">As all four of these monoclonal antibodies bind epitopes within the Spike protein receptor binding domain , it remains important to determine whether the D614G variants changes neutralization sensitivity to other classes of anti-Spike monoclonal antibodies .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-Spike</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero cells were challenged with pVSV-SARS-CoV-2-S-mNeon pseudoparticles encoding either ( A ) 614D or ( B ) 614G spike variants , in the presence of serial dilutions of the indicated anti-Spike monoclonal antibodies or IgG1 isotype control .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IgG1 isotype control .</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">When Calu-3 human lung epithelial cells were used as targets , challenge with lentivirus bearing D614G resulted in 6-fold more GFP-positive cells , or 5-fold more bulk luciferase activity , than did particles bearing D614 S protein ( Figure 2) .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Calu-3</div> <div>suggested: BCRJ Cat# 0264, CVCL_0609</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">When Caco-2 human colon epithelial cells were used as the target cells 4-fold higher infectivity was observed with D614G ( Figure 2) .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Caco-2</div> <div>suggested: CVCL_YP12</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Additionally , when HEK-293 cells or SupT1 cells had been rendered infectable by stable expression of exogenous ACE2 and TMPRSS2 , D614G was 9-fold more infectious than D614 ( Figure 2) .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>HEK-293</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 D614G S protein variant enhances infectivity Lentiviral virions bearing either GFP or Luciferase transgenes , and pseudotyped with either SARS-CoV-2 D614 or D614G S proteins , were produced by transfection of HEK293 cells , and used to transduce human Calu3 lung cells , Caco2 colon cells , and either HEK293 or SupT1 cells stably expressing ACE2 and TMPRSS2 .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>HEK293</div> <div>suggested: None</div> </div>

            <div style="margin-bottom:8px">
              <div><b>SupT1</b></div>
              <div>suggested: ICLC Cat# HTL96007, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_1714">CVCL_1714</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In a heterologous expression system on HeLa cells , human , civet , horse-shoe bat ( Rhinolophus sinicus) , and pig orthologs conferred susceptibility to infection , while the mouse ortholog did not ( Zhou et al. , 2020b) .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HeLa</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293 cells ( ATCC CRL-1573) , and HEK-293T cells ( CRL-3216 or CRL-3216 ) were cultured in DMEM supplemented with 10 % heat-inactivated FBS , 1 mM sodium pyruvate , 20 mM GlutaMAX , 1×</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK-293T</b></div>
              <div>suggested: ATCC Cat# CRL-3216, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0063">CVCL_0063</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu3 cells ( ATCC HTB-55 ) were maintained in EMEM supplemented with 10 % FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Calu3</b></div>
              <div>suggested: ATCC Cat# HTB-55, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0609">CVCL_0609</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Caco2 cells ( ATCC HTB-37 ) were maintained in EMEM supplemented with 20 % FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Caco2</b></div>
              <div>suggested: ATCC Cat# HTB-37, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0025">CVCL_0025</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SUP-T1 [ VB ] cells ( ATCC CRL-1942 ) were cultured in RPMI supplemented with 10 % heat-inactivated FBS , 1mM sodium pyruvate</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>SUP-T1</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T cells were seeded overnight in DMEM high glucose media ( Life Technologies ) containing 10 % heat-inactivated fetal bovine serum ( Life Technologies) , and Penicillin/- Streptomycin-L-Glutamine ( Life Technologies) .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK293T</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody dilutions were mixed 1:1 with pseudoparticles for 30 minutes at room temperature prior to addition onto Vero cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Vero</b></div>
              <div>suggested: CLS Cat# 605372/p622_VERO, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0059">CVCL_0059</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequences were aligned to the ancestral reference sequence ( NCBI GenBank accession NC_045512.2 ) using mafft v7.464 ( Katoh and Standley , 2013 ) with the " --keeplength " and " --addfragments " parameters , which preserve the coordinate space of the reference sequence.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>mafft</b></div>
              <div>suggested: (MAFFT, <a href="https://scicrunch.org/resources/Any/search?q=SCR_011811">SCR_011811</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These sequences were processed using a script importing biopython ( Cock et al. , 2009 ) to remove any gaps introduced by the alignment process and translate the sequence to protein space.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>biopython</b></div>
              <div>suggested: (Biopython, <a href="https://scicrunch.org/resources/Any/search?q=SCR_007173">SCR_007173</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The resulting values were rendered as plots using matplotlib ( Hunter , 2007) .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>matplotlib</b></div>
              <div>suggested: (MatPlotLib, <a href="https://scicrunch.org/resources/Any/search?q=SCR_008624">SCR_008624</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was analyzed using FlowJo 10.5 ( FlowJo , LLC , Ashland , OR)</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>FlowJo</b></div>
              <div>suggested: (FlowJo, <a href="https://scicrunch.org/resources/Any/search?q=SCR_008520">SCR_008520</a>)</div>
            </div>
          </td></tr></table>
      


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from OddPub: Thank you for sharing your code.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.14.20152728: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Eligibility Criteria for Selecting Studies: Double-blind RCTs of supplementation with vitamin D or calcidiol, of any duration, were eligible if they were approved by a Research Ethics Committee and if ARI incidence was collected prospectively and prespecified as an efficacy outcome.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Risk of Bias Assessment for Individual Studies We used the Cochrane Collaboration Risk of Bias tool46 to assess the following variables: sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, completeness of outcome data, evidence of selective outcome reporting and other potential threats to validity.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Data Sharing: the study dataset is available from d.a.jolliffe@qmul.ac.uk. ble 1: Characteristics of the 39 eligible trials and their participants g Participants Mean age, Male: years Female (s.d.) 25(OH)D assay, Mean Baseline EQA scheme baseline 25(OH)D <25 25(OH)D, nmol/L (%) nmol/L (s.d.) Mean attained Intervention: Oral dose of Contr 25(OH)D, intervention Control vitamin D3, arm, nmo/L (s.d.) Offspring: 10 µg vs. 20 µg daily g alia Participants Mean age, Male: years Female (s.d.) 25(OH)D assay, Mean Baseline EQA scheme baseline 25(OH)D <25 25(OH)D, nmol/L (%) nmol/L (s.d.) Mean attained Intervention: Oral dose of Contr 25(OH)D, intervention Control vitamin D3, arm, nmo/L (s.d.) children Healthy children 8.1 (1.2) Healthy older adults 158:127 72.2 (4.9) 408:379 25(OH)D assay, Mean Baseline EQA scheme baseline 25(OH)D <25 25(OH)D, nmol/L (%) nmol/L (s.d.) (Biomerieux)</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data Sources: MEDLINE, EMBASE, the Cochrane Central Register of Controlled</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>EMBASE</div> <div>suggested: (EMBASE, SCR_001650)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Study Identification and Selection Two investigators (ARM and DAJ) searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, ClinicalTrials.gov and the International Standard Randomized Controlled Trials Number (ISRCTN) registry using the electronic search strategies described in the Methods Section of Supplementary Material.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MEDLINE</div> <div>suggested: (MEDLINE, SCR_002185)</div> </div>

            <div style="margin-bottom:8px">
              <div><b>Cochrane Central Register of Controlled Trials</b></div>
              <div>suggested: (Cochrane Central Register of Controlled Trials, <a href="https://scicrunch.org/resources/Any/search?q=SCR_006576">SCR_006576</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Once queries had been resolved, clean summary data were uploaded to the study database, which was held in STATA IC v14.2 (StataCorp, College Station, TX).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>STATA</b></div>
              <div>suggested: (Stata, <a href="https://scicrunch.org/resources/Any/search?q=SCR_012763">SCR_012763</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>StataCorp</b></div>
              <div>suggested: (Stata, <a href="https://scicrunch.org/resources/Any/search?q=SCR_012763">SCR_012763</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Risk of Bias Assessment for Individual Studies We used the Cochrane Collaboration Risk of Bias tool46 to assess the following variables: sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, completeness of outcome data, evidence of selective outcome reporting and other potential threats to validity.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Cochrane Collaboration Risk of Bias</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These were meta-analysed in a random effects model using the Metan package48 within STATA IC v14.2 to obtain a pooled odds ratio with a 95% confidence interval and a measure of heterogeneity summarized by the I2 statistic and its corresponding P value.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Metan</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr></table>
      

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.14.20151126: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Studies were reviewed and approved by our institutional review board.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">However, due to the biological function of NP and the fact that it is shielded from antibodies by viral or cellular membranes, it is unlikely that NP antibodies can directly neutralize SARS-CoV-2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NP</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Therefore, the vast majority of positive individuals have moderate to high titers of anti-spike antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-spike</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Binding antibody titers tell us how robust the immune response to a certain virus or antigen is.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antigen is.</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell Host Microbe 24, 221-233.e225 (2018). E. O. Saphire, S. L. Schendel, B. M. Gunn, J. C. Milligan, G. Alter, Antibody-mediated protection against Ebola virus.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Antibody-mediated protection against Ebola virus .</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Participants were tested for SARS-CoV-2 antibodies and, if positive, obtained a titer level (1:80, 160, 320, 960 or ≥2880) using the Mount Sinai ELISA described here.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SARS-CoV-2</div> <div>suggested: (Sino Biological Cat# 40143-R019, AB_2827973)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Due to the lack of PCR testing in the New York area prior to mid-March, 2020, we also included people for antibody testing and screening if they were symptomatic with suspected SARS-CoV-2 symptoms after February 1, 2020, if they had a high risk exposure to someone with a positive SARS-CoV-2 PCR test, or were healthcare workers.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>mid-March , 2020</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The MSH-ELISA Anti IgG COVID-19 assay was also independently authorized as a laboratory developed test (LDT) for clinical application by the NYSDOH at the Mount Sinai Laboratory (MSL), Center for Clinical Laboratories, a division of the Department of Pathology, Molecular, and Cell-Based Medicine, New York, NY (CLIA# 33D1051889 ) from individuals suspected of previous COVID-19 infection by their healthcare provider, for the assessment of seroconversion from an antibody negative status to an antibody positive status in acutely infected patients, and for identification of individuals with SARS-Cov-2 IgG antibodies titers of up to 1:2880.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Anti IgG</div> <div>suggested: None</div> </div>

            <div style="margin-bottom:8px">
              <div><b>SARS-Cov-2 IgG</b></div>
              <div>suggested: (Sino Biological Cat# 40588-R0004, <a href="https://scicrunch.org/resources/Any/search?q=AB_2857931">AB_2857931</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Experimental Models: Cell Lines</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero.E6 cells (ATCC #CRL‐1586) were seeded at a density of 20,000 cells per well in a 96-well cell culture plate (Corning, cat. no. 3595) one day before the assay was performed.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Vero.E6</b></div>
              <div>suggested: JCRB Cat# JCRB1819, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_YQ49">CVCL_YQ49</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analysis was performed in GraphPad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>GraphPad Prism</b></div>
              <div>suggested: (GraphPad Prism, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002798">SCR_002798</a>)</div>
            </div>
          </td></tr></table>
      

      Data from additional tools added to each annotation on a weekly basis.

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.07.08.20148841: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">They provided signed informed consent.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Abstract Objective In this study, we evaluated the efficacy of hydroxychloroquine (HCQ) against coronavirus disease 2019 (COVID-19) via a randomized controlled trial (RCT) and a retrospective study.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">The following patients were excluded from the trial: (a) documented history of hypersensitivity to quinine derivatives; (b) retinal disease; (c) hearing loss; (d) severe neurological or mental illness; (e) pancreatitis; (f) lung disease; (g) liver disease (alanine aminotransferase (ALT)/aspartate aminotransferase (AST) > 3× the normal upper limit); (h) kidney disease (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2 according to MDRD or CKD-EPI); (i) hematological disease; (j) cardiac conduction abnormalities at electrocardiographic (ECG) screening with long QT syndrome or QTcF interval > 450 msec for males and > 470 msec for females according to Fridericia’s correction at screening; (k) known HIV infection; (l) active hepatitis B or C without concurrent treatment (positive for hepatitis B [HBsAg and HBeAg] or hepatitis C ribonucleic acid [RNA] titer > 800,000 IU/mL); (m) G6PD; (n) psychiatric disorders and alcohol/substance dependence/abuse that may jeopardize patient safety; and (o) pregnant or breast-feeding women.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis Data were entered into an electronic clinical trial information management system (CTIMeS; National Health Research Institutes, Taiwan) by study coordinators and summarized with SAS® v. 9.2 (SAS Institute Inc., Cary, NC, USA) All treatment data will be summarized using descriptive statistics including continuous variables (number of non-missing observations, means, standard deviations (SD), medians, minima, and maxima), categorical variables (frequencies and percentages), and time to event variables (number of non-missing observations (N), medians, minima, and maxima).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SAS®</div> <div>suggested: (SASqPCR, SCR_003056)</div> </div>

            <div style="margin-bottom:8px">
              <div><b>SAS Institute</b></div>
              <div>suggested: (Statistical Analysis System, <a href="https://scicrunch.org/resources/Any/search?q=SCR_008567">SCR_008567</a>)</div>
            </div>
          </td></tr></table>
      


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.04.18.047878: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">1 µ g of trypsin ( SMART Digest , bulk resin option , Thermo Fisher Scientific ) was added in 50 µ l of SMART Digest buffer ( Thermo Fisher Thermo Fisher Scientific ) and the solution was incubated at 70°C for 30 min .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Thermo Fisher Thermo Fisher Scientific</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">UniProt human , dated November 2019 with 20,315 entries , and SARS-CoV-2 [ 3] ) was performed with Proteome Discoverer version 2.4 ( Thermo Fisher Scientific) .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Proteome Discoverer</div> <div>suggested: (Proteome Discoverer, SCR_014477)</div> </div> </td></tr></table>


      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, please follow this link.

    1. SciScore for 10.1101/2020.04.17.047480: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Blots were blocked with 5% Milk-PBST for 30 min, incubated O/N in primary antibody (Rabbit Pan-ADPr 1:1000, Cell Signaling E6F6A; Rabbit GFP 1:1000, Chromotek PABG1-100; Mouse Tubulin 1:1000; Cell Signaling DM1A).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GFP</div> <div>suggested: (ChromoTek Cat# PABG1-20, AB_2749857)</div> </div>

            <div style="margin-bottom:8px">
              <div><b>Tubulin</b></div>
              <div>suggested: (LifeSpan Cat# LS-C89856-1000, <a href="https://scicrunch.org/resources/Any/search?q=AB_1940111">AB_1940111</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary incubation was followed with HRP-conjugated secondary antibodies (Rabbit-HRP 1:10000, Jackson Laboratories 111-035-144; Mouse-HRP 1:5000, Invitrogen 62-6520).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Rabbit-HRP</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>Mouse-HRP</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Experimental Models: Cell Lines</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK 293T cells were grown with the indicated expression plasmids for GFP or PARP10 and treated with small activate NAMPT (10 M SBI-797812) or inhibit PARP1 and PARP2 (300 nM Veliparib).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK 293T</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PARP10 and GFP-expressing HEK293 cells were used to show that veliparib and SBI-797812 differ in their ability to promote the autoMARylated form of PARP10.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK293</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Genes with “Status = Low” or “Status = Outlier” were not considered for analysis, leaving 56 genes from the A549 dataset and 52 genes from the NHBE dataset for analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>A549</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">DBT, 17Cl-1, HEK293T, and HeLa cells expressing the MHV receptor carcinoembryonic antigen-related cell adhesion molecule 1 (a gift from Dr. Thomas Gallagher, Loyola University, Chicago, IL) were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), HEPES, sodium pyruvate, non-essential amino acids, L-glutamine, penicillin and streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HeLa</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed using DESeq2 to calculate fold change and p-values (Supplementary Material 4 and 5).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>DESeq2</b></div>
              <div>suggested: (DESeq, <a href="https://scicrunch.org/resources/Any/search?q=SCR_000154">SCR_000154</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Ten genes did not have ferret orthologs in Ensembl and one gene exhibited undetectable expression (TDO2) leaving 60 ferret genes for analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Ensembl</b></div>
              <div>suggested: (Ensembl, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002344">SCR_002344</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Graphs were generated using GraphPad Prism v8.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>GraphPad Prism</b></div>
              <div>suggested: (GraphPad Prism, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002798">SCR_002798</a>)</div>
            </div>
          </td></tr></table>
      


      Results from Barzooka: We also found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.02.12.20022418: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">This arouses our interest in whether coronavirus infection will affect the urinary and male reproductive systems .</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We used RNA and protein expression data of ACE2 in different human tissues and cancer cell lines through The Human Protein Atlas portal ( Website: http://www.proteinatlas.org/ ) [ 15]</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Website</div> <div>suggested: (CoMeTa Website, SCR_017357)</div> </div>

            <div style="margin-bottom:8px">
              <div><b>http://www.proteinatlas.org/</b></div>
              <div>suggested: (HPA, <a href="https://scicrunch.org/resources/Any/search?q=SCR_006710">SCR_006710</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To further assess the cell type specific expression of ACE2 and confirm ACE2 expression level in kidney , we downloaded the gene expression data of single-cell RNA sequencing of human kidney from Gene Expression Omnibus ( GEO ) datasets .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Gene Expression Omnibus</b></div>
              <div>suggested: (Gene Expression Omnibus (GEO), <a href="https://scicrunch.org/resources/Any/search?q=SCR_005012">SCR_005012</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lancet , 2020 . Gralinski , L . E . and V . D . Menachery , Return of the Coronavirus: 2019-nCoV .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Coronavirus</b></div>
              <div>suggested: (NIAID Overview of Coronaviruses, <a href="https://scicrunch.org/resources/Any/search?q=SCR_018290">SCR_018290</a>)</div>
            </div>
          </td></tr></table>
      


      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. eachers plan opportunities for peer and self-assessment to regularly occur during lessons.Peerand self-assessment foster students’ responsibility for their own progress and increase motivation. Te a c h e r s c a n h e l p b y p r o v i d i n g o p p o r t u n i t i e s , s t r u c t u r e , s u p p o r t , a n d m o d e l i n g

      This would be a great opportunity to provide guidance for those supporting student learning outside the classroom setting as well.

    1. SciScore for 10.1101/2020.07.12.199059: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020 Jun 3:NEJMoa2016638. doi: 10.1056.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, SARSCoV-2-infected VERO E6 cell monolayers [at multiplicity of infection [moi] of 0.05] in 96-well plates were incubated at 37°C in 5% CO2 while exposed to differing concentrations of TQ, remdesivir [RD] and HCQ in triplicate wells in minimum essential medium supplemented with 1% (w/v) L-glutamine, 2% fetal bovine serum and 0.2% DMSO [the latter for compound dissolution].</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>VERO E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Whole lung, lung-unbound, and plasma concentrations at an assumed lung pH of 6 were simulated using Simcyp [V19.1, Simcyp Ltd, Sheffield, UK] as described by Rowland Yeo et al, [18].</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Simcyp</div> <div>suggested: (Simcyp, SCR_003944)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">EMBO J 11:2695-700.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>EMBO J</div> <div>suggested: None</div> </div> </td></tr></table>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Rebuttal to reviewers ReviewCommons manuscript # RC-2020-00281

      We would like to thank the reviewers and editors of Review Commons for evaluating our manuscript entitled “Transcriptional comparison of Testicular Adrenal Rest Tumors with fetal and adult tissues” and providing their valuable comments. We have listed the reviewers’ comments along with our response and amendments below.

      Board Advice on initial submission:

      This seems to be a study mainly relevant to the field of Testicular Adrenal Rest Tumors (TART). It presents the first RNAseq profiling of these tumors in multiple human samples at different stages. This has the potential to advance knowledge in this particular field. It would be less interesting to researchers interested in tissue spatial transcriptomics in general, since the experimental and computational tools are quite standard, but the findings may be important to the TART field.

      Response: Indeed, this is the first study using transcriptomics to characterize Testicular Adrenal Rest Tumors, a frequent occurrence in patients with Congenital Adrenal Hyperplasia. It is also the first to find that the reported adrenal and testicular features of these tumors can be found in a single cell. We therefore believe this study is not only of interest to those working in the TART field, but also in development, endocrinology and andrology in general.

      Comments Reviewer #1:

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      **Summary:**

      The manuscript by Schroder M., et al describes the whole transcriptome of testicular adrenal rest tumors (TART) and shows that TART tissue is characteristically similar to adult adrenal and testicular rather than fetal adrenal and testicular tissues. The authors propose that their previous claim that TART is derived from an undifferentiated pluripotent progenitor is likely untrue and claim that TART likely originates from a mature cell type with both adrenal and testicular characteristics. The authors describe a unique cell type most similar to the adult adrenal, but with variable testis-specific gene expression patterns. The finding of overexpressed genes associated with ECM remodeling is interesting and may provide insight into the natural history of these tumors. A strength of the study is the number of tissue samples since surgery for these rare tumors is usually not performed.

      **Major Comments:**

      • The key conclusions are mostly based on RNA studies, thus their claims are preliminary.

      Response: We agree that a major part of our conclusions is based on RNA studies. Although indeed primarily based on transcriptomics, this claim is, in our opinion, not preliminary as the identity of TART cells can definitively be deduced from their expression profile. Our second key conclusion, i.e. that TART cells comprise both adrenal and testicular features within the same, unique, TART specific cell, is based on immunohistochemistry of adrenal and testis-specific enzymes.

      In Figure 1/Result p. 3: Authors claim that there were no exclusive HSD17B3 staining cells without CYP11B1, however Figure 1 looks like there are exclusively green (HSD17B) areas (especially TART3). The authors need to address this. It appears as if there are mature Leydig cells. This is important because the presence of Leydig cells would affect the interpretation of the findings.

      Response: We do understand the concern of the reviewer. Aspecific background staining for HSD17B3 in TART samples complicated the differentiation between specific and background staining. This can be seen when comparing the staining in HSD17B3-positive (Leydig) cells with the background staining in non-Leydig cells in testis tissue and in a portion of TART cells. In TART, we found that cells with high intensity, specific HSD17B3 staining all also showed CYP11B1 staining, but not vice-versa. However, we do acknowledge that due to this -most likely background- staining, the occurrence of mature Leydig cells in TART cannot be completely excluded based on our results.

      Therefore, we have tried to be more careful in our claims in the results section (page 3; TART cells express adrenal- and Leydig cell-specific steroidogenic enzymes paragraph) and we have addressed this in the discussion section (page 5/6):

      High background staining for HSD17B3 complicated the differentiation between specific and background staining. For some cells this exclusive HSD17B3 staining might have been specific and therefore, despite that most HSD17B3-positive cells were positive for CYP11B1, the absence of mature Leydig cells in TART could not be guaranteed by these results.

      Discussion: authors state that based on their previous observations that fetal Leydig cells have both adrenal and testis developmental potential. It was speculated that TART might have been derived from a totipotent progenitor cell type, but the current study shows that these tumors lack similarities with fetal tissues. Thus, the authors claim that these tumors are not derived from the transdifferentiation of pluripotent cells. However what is the origin of this mature distinct cell type? Is it not possible that this distinctive cell type is derived from a common progenitor since the testis and adrenal gland are derived from the same adrenogonadal primordium? Lack of similarities with fetal tissues at this late stage of development does not necessarily rule out a common progenitor origin.

      Response: In this study, we compared the TART transcriptome with fetal tissues, as we hypothesized these might be similar considering the likely progenitor origin of TART cells. However, this was not the case, and we showed that the transcriptomic profile of TART resembles the transcriptomic profile of mature cell types, rather than their fetal counterparts. Therefore, we conclude that the hypothesis that TART arises from progenitor cells is not supported by our data. The reviewer is correct that we did not prove that it is not derived from pluripotent cells. We have therefore added the following text to the discussion:

      Although we here find that the transcriptome of TART tissues are clearly distinct from fetal tissues, we did not prove that TART does not originate from fetal Leydig cells. TART being derived from a multipotent progenitor cell is still possible as we initially hypothesized, given the fact that TART is likely already present in utero and its resemblance to both testis and adrenal tissues which derive from a common primordium. Therefore, we were surprised to find TART to be more like adult adrenal and testis tissue, raising the possibility of TART being derived from a ‘mature’ progenitor cell type, i.e. adult stem Leydig cells or adrenal progenitor cells, that under influence of high ACTH levels and/or the localization in the testicular region might differentiate into a distinct cell type that expresses both adrenal- and testis-specific markers. However, this remains to be established.

      **Minor Comment:**

      In Methods: Was RNA isolated from FFPE sections or frozen tissue?

      We agree that this was not clearly mentioned enough in our original manuscript, as both frozen (RNA isolation) and FFPE (IHC) material was used. We have now clarified in the methods section that the RNA was retrieved from frozen tissue samples (page 8; RNA isolation, library preparation, and sequencing paragraph).

      Reviewer #1 (Significance (Required)):

      This first study of transcriptome analysis of TART provides useful insight into the characteristics of these rare tumors that commonly develop in males with classic CAH. This study provides a foundation for further investigation of the biological pathways contributing to the development of TART, the most common cause of male infertility in CAH. This study is of interest to endocrinologists. Reviewed by a pediatric endocrinologist and molecular biologist - we are not completely aware of the sequencing analysis but are familiar with clustering and enrichment analysis.

      Comments Reviewer #3:

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      The manuscript by Schröder et al describes the transcriptome sequencing of TARTs in CAH/CS in order to sort out the origin of TARTs. This is an interesting subject and the manuscript is well-written but I have a few comments that could be addressed.

      • Some parts of the Results should be in the Methods and some in the Discussion. In the Results only the results should be given.

      Response: We agree that we have incorporated some methodological sentences and some concluding remarks in the results sections to, in our opinion, improve the flow of the manuscript. As the manuscript guidelines differ between journals, we have for now decided not to change this. We will do so if this is wanted by the concerning journal.

      Normally TARTs are not removed or biopsied, if not by mistake... Thus, most centers would not have tissue samples of TARTs at all. How come you have so many samples available?

      Response: We thank the reviewer for highlighting this. As indeed TARTs are not routinely removed, the number of TART tissues included in our dataset is unique. Most of the TART samples were already obtained in 2004 because of reported pain and discomfort and in an attempt to improve semen quality in these patients. Removal of those particular TART samples have led to new insights that removal of longstanding TART did not improve semen parameters, nor parameters of pituitary-gonadal function (Claahsen-van der Grinten et al., 2007). Therefore, to date, the only indication for surgery for the removal of longstanding TART is the relief of pain or discomfort.

      Ref 2 and 3 are rather old and similar. Could newer review references be used instead?

      Response: We have changed those two references for a more recent review by Dr. Witchel on Congenital Adrenal Hyperplasia, who addresses both statements in a more recent review (Witchel, 2017).

      Reviewer #3 (Significance (Required)):

      New and significant study. Very interesting for people dealing with CAH patients.

      References

      Claahsen-van der Grinten, H. L., Otten, B. J., Takahashi, S., Meuleman, E. J. H., Hulsbergen-van de Kaa, C., Sweep, F. C. G. J., & Hermus, A. R. M. M. (2007). Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: Evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients. Journal of Clinical Endocrinology & Metabolism, 92(2), 612-615. doi:10.1210/jc.2006-1311

      Witchel, S. F. (2017). Congenital Adrenal Hyperplasia. J Pediatr Adolesc Gynecol, 30(5), 520-534. doi:10.1016/j.jpag.2017.04.001

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      General comments

      We thank all three reviewers for providing their thoughtful and insightful review comments of our manuscript. We appreciate that the reviewers recognized the significance and impact of our work - “Very little imaging has been done on CAR synapses and to our knowledge this is the first live cell imaging study describing CAR microclustsers” (Reviewer 2); “This is an evolving field and little is known to date. Hence, this study could represent an insightful and important advance to the field” (Reviewer 3). A broad audience from both basic and clinical research sides will be interested in this work: “_This study will have a broad audience. Both scientists that study basic T cell signaling as well as clinicians that use CAR Ts will be interested in this study” (_Reviewer 2); “Audience is to both basic immunologist and cancer biologists” (Reviewer 3).

      Meanwhile, we understand that the reviewers have raised a few major and minor issues, which we attempted to address. Most importantly, as suggested by both reviewer 1 and 3, we performed new experiments showing that LAT is not required for microcluster formation of the 1st generation of CAR (new Fig 4 and EV5). This finding suggests that the CAR-independent signaling is due to the intrinsic CAR architecture, and is not dependent on the co-signaling domains of CD28 and 4-1BB.

      With the successful solutions to other issues, we believe the manuscript has been significantly improved and is ready for publication. Below we will provide point-to-point responses to each reviewer’s comments.

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      The authors compare the TCR alone to a CAR that contains signaling modules from three receptors- TCR, CD28 and 41BB. The data quality if good and the experiments done are. The difference is quite clear, and I would even like to see a little more of the evidence related to failure of the TCR system.

      We appreciate the general positive comment of this reviewer.

      More specifically:

      Su and colleagues show that a third generation CAR with TCR zeta, CD28 and 41BB signal transduction pathways can activate a T cell for microcluster formation and Gads/SLP-76 recruitment, but not IL-2 production, without LAT. This is surprising because LAT is generally considered, as is up held here, as an essential adapter protein for T cell activation. However, this is not a "fair" experiment as the CAR has sequences from TCR, and two co-stimulatory receptor- CD28 and 41BB. It would be important and very straight-forward to test first and second generation CARs to determine if LAT independence is a function of the CAR architecture itself, or the additional costimulatory sequences. If it turns out that a first generation CAR with only TCR sequences can trigger LAT independent clustering and SLP-76 recruitment then the comparison would be fair and no additional experiment would be needed to make the point that the CAR architecture is intrinsically LAT independent. If the CD28 and/or 41BB sequences are needed for LAT independence then the fair comparison would be to co-crosslink TCR, CD28 and 41BB (an inducible costimulator such that anti-CD27 might be substituted to have a constitutively expressed receptor with this similar motifs) should be cross-linked with the TCR to make this a fair comparison between the two architectures.

      We agree with the reviewer that it is critical to make a “fair” comparison between TCR and CAR by testing the 1st generation CAR, which only contains the TCR/CD3z domain. Our new data showed that LAT is not required for microcluster and synapse formation of the 1st generation of CAR, in both Jurkat and primary T cells (new Fig 4 and EV5). This result is similar to our previously reported result from the 3rd generation CAR, although the 1st generation CAR induced less IL-2 production and CD69 expression in LAT null cells than the 3rd generation CAR did (new Fig 6). This suggests that the LAT-independent signaling is intrinsic to the CAR architecture, as the reviewer suggested. The co-signaling domains from CD28 and 4-1BB contribute to, but are not required for bypassing LAT to transduce the CAR signaling.

      The authors may want to cite work from Vignali and colleagues that even the TCR has two signaling modules- the classical ZAP-70/LAT module that is responsible to IL-2 and a Vav/Notch dependent module that controls proliferation. Its not clear to me that the issue raised about distinct signaling by CARs is completely parallel to this, but its interesting that Vignali also associated the classical TCR signaling pathway as responsible for IL-2 with an alterive pathways that uses the same ITAMs to control distinct functions. See Guy CS, Vignali KM, Temirov J, Bettini ML, Overacre AE, Smeltzer M, Zhang H, Huppa JB, Tsai YH, Lobry C, Xie J, Dempsey PJ, Crawford HC, Aifantis I, Davis MM, Vignali DA. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat Immunol. 2013;14(3):262-70.

      We appreciate the reviewer’s mentioning this paper from Vignali’s group. It provides insights into understanding LAT-independent signaling in CAR T cells. We cited this paper and added a discussion about the mechanism of LAT-independent signaling.

      I would be very interested to see a movie of the LAT deficient T cells interacting with the anti-CD3 coated bilayers in Figure 2A. Since OKT3 has a high affinity for CD3 and is coated on the surface at a density that should engage anti-CD3 I'm surprised there is no clustering even simply based on mass action. The result looks almost like a dominant negative effect of LAT deficiency on a high affinity extracellular interaction. It would be interesting to see how this interface evolves or if there is anti-adhesive behavior that emerges.

      We now presented a movie showing the detailed process of LAT deficient GFP-CAR T cells landing on the bilayers coated with OKT3 (new Movie EV5), in which the bright field images delineate the locations of the cells, the OKT3 signal marks TCR, and the GFP signal marks CAR proteins on the plasma membranes. No TCR clusters (as indicated by OKT3) were formed during the landing process. We think the binding of bilayer-presented OKT3 to TCR is not sufficient to trigger TCR microclusters. However, TCR microclusters could form in LAT-deficient cells if OKT3 is presented by glass surface. This point is raised by reviewer 2. We added a discussion on the difference between bilayer and glass-presented OKT3 in inducing microcluster formation.

      Reviewer #1 (Significance (Required)):

      While it interesting that the CAR is LAT independent, its obvious that the signalling networks are different as the CAR has two sets of motifs that are absent in the TCR, so the experiments as presented are not that insightful about the specific nature of the differences that lead to the different outcomes. At present its not a particularly well controlled experiment as the third gen CAR is changing too many things in relation to the TCR for the experiment to be interpreted. It would be easy to address this is a revised manuscript. To publish as is the discussion would need to acknowledge these limitations. The work is preliminary as science, but it might be useful to T cell engineering field to have this information as a preliminary report, which might be an argument for adding discussion of limitations, but going forward without more detailed analysis of mechanism.

      This is an excellent point and we have addressed it. See our response above on the new data of the 1st generation CAR.

      Reviewer #2 (Evidence, reproducibility and clarity):

      Summary:

      Provide a short summary of the findings and key conclusions (including methodology and model system(s) where appropriate).

      In this study, the authors have interrogated CAR signaling by imaging CD19-CAR microclusters as well as T cell signaling molecules recruited to CAR microclusters. They report differences spatial assembly between CAR and TCR microclusters that form on a lipid bilayer containing ligand. They also report that LAT is not required for CAR microcluster formation, recruitment of downstream signaling molecules or IL-2 production in Jurkat cells, while in primary T cells IL-2 production by CARs show more of a LAT dependence. From these observations, they conclude that CAR T cells have a rewired signaling pathway as compared to T cells that signal through the TCR.

      Major comments:

      • Are the key conclusions convincing?

      The conclusions made by the authors about CAR microclusters are convincing. However, the conclusion that there is a "rewired signaling network" different from TCR microclusters needs to be more convincingly demonstrated in side-by-side comparisons of TCR and CAR microclusters and synapses.

      1. One of the key conclusions in this study is that CAR microclusters form in the absence of LAT, but TCR microclusters require LAT (in JCam2.5 cells in Fig. 2 and primary T cells in Fig. 4B). The requirement of LAT for formation of TCR microclusters is surprising, given multiple reports (one of which the authors have cited) that TCRz and ZAP70 clusters form normally in the absence of LAT (pZAP microclusters form normally in JCam2.5 cells Barda-Saad Nature Immunology 2005 Figure 1; TCRz clusters form normally in LAT CRISPR KO Jurkat cells Yi et al., Nature Communications, 2019 Figure 5). The authors should carefully evaluate TCRz and ZAP70 clusters (that form upstream of LAT) in their assays.

      We thank the reviewer for raising this excellent point. LAT-independent TCR clusters were reported in the two papers mentioned by the reviewer, which we think is convincing. However, there is a key difference in the experimental settings between these two papers and ours. We use supported lipid bilayer to present MOBILE TCR-activating antibody to activate T cells, whereas these two papers used IMMOBILE TCR-activating antibody attached to the cover glass. We reasoned that the mobile surface of supported lipid bilayer more closely mimics the antigen-presenting cell surface where antigens are mobile on the membrane. We added a new discussion about the difference between supported lipid bilayer and cover glass-based activation.

      We agree with the reviewer on the careful evaluation of TCR and ZAP70 clusters. We had showed the data of TCR clusters as marked by TCR-interacting OKT3 (Fig 3A). We performed new experiments on ZAP70 clusters (new Fig EV3). Our data suggest that, similar to TCR clusters, ZAP70 clusters are not formed in LAT-deficient T cells, if activated by OKT3, but are formed if activated by CD19.

      1. The authors make major conclusions about LAT dependence and independence of TCR and CAR microclusters respectively, by using JCam2.5 Jurkat cells and CRISPR/Cas9 edited primary cells. Of relevance to this conclusion, differences in the phosphorylation status of ZAP70 and SLP76 have been described between JCam2.5 cells lacking LAT (in which LAT was found to be deleted by gamma radiation) and J.LAT cells (in which LAT was specifically deleted by CRISPR/Cas9 in Lo et al Nature Immunology 2018). Of importance, pZAP and pSLP76 appeared fairly intact in J.LAT cells, but absent in JCam2.5 cells (Lo et al., Nat Immunol. 2018, Supp Fig 2). Therefore, the authors should evaluate TCRz, ZAP70, Gads and SLP76 in TCR and CAR microclusters in J.LAT cells. This may partly explain the discrepancy in LAT requirement for IL-2 production in JCam2.5 cells and primary cells with LAT CRISPRed out.

      Jcam2.5 is a classical well-characterized LAT-deficient cell line that has been continuously used in the T cell signaling field (Barda-Saad Nature Immunology 2005, Rouquette-Jazdanian A, Mol. Cell, 2012; Balagopalan L, J Imm. 2013; Carpier J, J Exp Med, 2018; Zucchetti A, Nat. Comm. 2019). We agreed with the concern that the reviewer raised on the absence of pZAP70 and pSLP76 in JCam2.5 cells. As the reviewer suggested, we obtained J.LAT, which is LAT null but has intact pZAP70 and pSLP76. We introduced CAR into J.LAT and the wild-type control and performed the clustering assay as we did for Jcam2.5. Our results showed that, similar to Jcam2.5, CAR forms robust microclusters in J.LAT cells (new Fig EV2). More importantly, we presented data confirming the LAT-independent CAR clustering, SLP76 phosphorylation, and IL-2 production in human primary T cells (Fig 7). Therefore, the data from three independent cell sources support our conclusion on LAT-independent CAR signal transduction.

      1. Since the authors are reporting differences between CAR synapses and TCR synapses, the authors should show side by side comparison of CAR and TCR synapses in Figure 1F.

      We focused on characterizing CAR synapse in this manuscript and did not make any conclusion on the difference between TCR and CAR synapse. We are cautious about comparing CAR synapse to TCR synapse for technical reasons: it is critical to use antigen-specific TCRs (e.g. mouse OTI as a common model) to study the TCR synapse pattern so that the study will be physiologically relevant. However, we use human T cell line and human primary T cells for the CAR study. The technical barrier to introduce an antigen-specific TCR complex into these cells, and to activate these cells by purified peptide-MHC complex, is very high. And the result is interesting, but beyond the scope of the current work.

      1. The authors should evaluate Gads microcluster formation in response to TCR stimulation via OKT3 (in Figure 4A). Given that it has been reported that TCRz, Grb2 and c-Cbl are recruited to microclusters in Jurkat cells lacking LAT by CRISPR deletion (Yi et al., Nature Communications, 2019), it is important to establish the differences between TCR microclusters and CAR microclusters in side by side comparisons in their assay system.

      As the reviewer suggested, we evaluated Gads microcluster formation with TCR stimulation and found that Gads did not form microclusters in LAT-deficient cells (new Fig 5A). Because we only made conclusions on the Gads-SLP76 pathway, we think investigating Grb2 and c-Cbl microcluster, though interesting, is beyond the scope of this manuscript.

      1. Similar to the comment about Gads above, the authors should evaluate pSLP76 microcluster formation in response to TCR stimulation via OKT3 in primary T cells lacking LAT in Figure 4C, i.e. side by side comparisons of pSLP76 in TCR and CAR synapses (with and without LAT) should be shown.

      We totally agree and performed new experiment on pSLP76 in human primary T cells. Our data suggested that, similar to Jurkat, pSLP76 microclusters remain intact in LAT null primary cells (new Fig 7D and 7E).

      • Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?
      1. The data shown in Figure 3C shows a reduction in conjugate formation from 80% (WT) to 30% (LAT -). This is a severe reduction and does not support the authors' claim in the corresponding Figure legend that "LAT is dispensable for cell conjugate formation between Jurkat T cells expressing CAR and Raji B cells" and the Abstract that "LAT.....is not required for....immunological synapse formation". Statistical analysis for variance should be shown here.

      We agree with the reviewer’s judgement. This cell conjugation analysis was performed using Jcam2.5 cells. As pointed by the reviewer, Jcam2.5 has additional defects in ZAP70 and SLP76 in addition to the lack of LAT. Therefore, we performed the same analysis again using J.LAT cells, which was recommended by the reviewer. Our new data showed that J.LAT cells form conjugates with Raji B cells in a similar rate as the wild-type cells do, as evaluated by statistical analysis (new Fig 6A). Therefore, we think these new data support the claim that LAT is dispensable for cell conjugate formation.

      1. In a similar vein, based on data from Movie S5 (where in a single cell, CAR microclusters translocate from cell periphery to center), and Figure 3C where (as described above in point 1) conjugate formation appears to be severely reduced, the authors conclude in the Results and Abstract that "LAT....is not required for actin remodeling following CAR activation". This conclusion is not supported by the data and the authors should remove this claim. Alternatively, actin polymerization in CAR expressing cells (that are LAT sufficient and deficient) can be easily evaluated using phalloidin or F-Tractin.

      As suggested by the reviewer, we evaluated actin polymerization in TCR or CAR stimulated cells using a filamentous actin reporter F-tractin. Our data showed that LAT is required for TCR-induced but not CAR-induced actin polymerization (new Fig 5C). Therefore, our results support the claim that LAT is not required for actin remodeling following CAR activation.

      • Would additional experiments be essential to support the claims of the paper?<br> Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.

      Yes. Please see major comments above.

      • Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.

      Yes. It should take 3 months to complete these experiments, since reagents and experimental systems to do these experiments already exist.

      • Are the data and the methods presented in such a way that they can be reproduced?<br> Yes. Methods are clearly explained.

      We appreciate the reviewer’s recognition of the clarity of the methods part.

      • Are the experiments adequately replicated and statistical analysis adequate?

      There is no statistical analysis to evaluate differences between samples in Figures 3 and 4. These must be included.

      We now added statistical analysis in Fig 5B and 6A (old figure 3 and 4).

      Minor comments:

      • Specific experimental issues that are easily addressable.

      Please see Major Comments above. We believe that the recommended experiments are not difficult to execute since reagents exist and experimental systems are already set up.

      • Are prior studies referenced appropriately?

      Authors reference 13 and 14 for the following sentence in Results section 2: "Deletion or mutation of LAT impairs formation of T cell microclusters". However, in Reference 14 Barda-Saad et al., actually show that pZAP clusters are intact in JCam2.5 cells lacking LAT. Perhaps authors should clarify that LAT (and downstream signaling molecule) microclusters are impaired when LAT is deleted or mutated.

      As the reviewer suggested, we now clarified that clustering of LAT downstream binding partners is impaired when citing reference (Barda-Saad et al).

      • Are the text and figures clear and accurate?

      Yes. But would be helpful if authors specify what "control" is in Fig. 3B and C. In Figure 3B it is lipid bilayers without CD19, while in 3C it is K562 cells that do not express CD19.

      We now specified “control” in the figure.

      • Do you have suggestions that would help the authors improve the presentation of their data and conclusions?

      Would be helpful if authors specify in every Figure or at least Figure legend the experimental bilayer system/ligand used, since they use both OKT3 and CD19 as ligands in the paper.

      We now specified the ligand in the figure or legend.

      Reviewer #2 (Significance):

      • Describe the nature and significance of the advance (e.g. conceptual, technical, clinical) for the field.

      If CAR microclusters and synapses are appropriately compared in a side by side comparison with TCR microclusters and synapses (as described in comments above), this study will be a conceptual advance in the field of CAR signaling. CAR microclusters have not been studied previously.

      • Place the work in the context of the existing literature (provide references, where appropriate).

      Very little imaging has been done on CAR synapses and to our knowledge this is the first live cell imaging study describing CAR microclusters.

      We appreciate this reviewer’s comment on our work as a conceptual advance in understanding CAR signaling.

      • State what audience might be interested in and influenced by the reported findings.<br> This study will have a broad audience. Both scientists that study basic T cell signaling as well as clinicians that use CAR Ts will be interested in this study.

      We appreciate this reviewer’s recognition of the broad audience of this manuscript.

      • Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate.

      T cell signaling and imaging of proximal T cell signaling responses.

      Reviewer #3 (Evidence, reproducibility and clarity):

      This manuscript by Dong and colleagues characterizes the molecular requirements and consequences of engaging a third-generation chimeric antigen receptor (CAR) directed to CD19. Utilizing a biological system of JCaM2.5, a Jurkat T cell mutant with dramatically low levels of LAT, expressing a CAR directed to CD19 fused to the cytoplasmic tails of CD28, 4-1BB and CD3z that is activated by CD19/ICAM1 reconstituted lipid bilayers, the authors demonstrate LAT is not required for microcluster formation, immunologic synapse formation or recruitment of GADS and pSLP76 to the plasma membrane. In contrast, LAT was required for anti-CD3 mediated microcluster formation and pSLP76 recruitment to the plasma membrane. However, LAT does appear to contribute to efficient synapse formation, PIP2 hydrolysis and IL-2 secretion when CAR+ JCaM2.5 or primary T cells are presented with Raji B cells, respectively. These data provide intriguing insights into the molecular requirements for third-generation CAR-T cell functions. The authors have developed quite a nice system to understand the molecular contributions for CAR-T function. A few suggestions are provided here to further enhance the accuracy and significance of the findings:

      1. The authors can address whether the LAT-independent effects are due to the attributes of third generation CAR-Ts with inclusion of CD28 and 4-1BB cytoplasmic domains or whether these differences are intrinsic to all CAR-Ts (e.g., first and second generation CARs).

      This is an excellent point. We have included new data showing LAT-independent cluster formation of the 1st generation CAR in both Jurkat and primary T cells (new Fig 4 and EV5). Therefore, we favor the second possibility as pointed by the reviewer that LAT-independent effects are intrinsic to CAR architecture.

      1. Since a first-generation CAR-T forms non-conventional synapses (Davenport, et al., PNAS 2018), the authors should consider more detailed kinetic analysis to understand the formation and dissolution of the constituents of the synapse with their third generation CAR. This should include measurements of the duration of microcluster and synapse formation as well as further analysis of c- and p-SMAC constituents (e.g., LFA-1, TALIN, LCK and pSLP76) over time.

      We agree with the reviewer on a more detailed characterization of the CAR synapse. We measured the duration of the unstable CAR synapse and time from cell landing to the start of retrograde flow (new Fig 2C). We also determined the localization of CD45, a marker for d-SMAC (new Fig 2D). We found that the formation of dSMAC is also not common in CAR T synapse, strengthening our conclusion that CAR forms non-typical immunological synapse.

      1. The authors utilize two different activation platforms. While using CD19/ICAM1 reconstituted bilayers, CAR+ JCaM2.5 or CAR+ primary T cells demonstrate no differences compared to wildtype JCaM2.5 cells in the parameters studied. However, when using Raji B cells, the CAR+ JCaM2.5 cells or CAR+ primary T cells demonstrate a more intermediate phenotype with respect to cell conjugate formation (Figure 3C) and IL-2 production (Figure 4D). The authors should analyze whether the differences attributed to the different outcomes may be due to the stimulation mode. For example, is c-SMAC assembly and GADS or pSLP76 recruitment to the plasma membrane still LAT-independent when activated with Raji B cells?

      As the reviewer suggested, we examined c-SMAC assembly in Raji B cells conjugated with CAR T cells. We found that the majority of CAR do not form cSMAC (new Fig EV4), which is consistent with the result from the bilayer activation system. Since both Gads and SLP76 are cytosolic proteins, they keep largely in the cytosolic pool which obscures their recruitment and clustering on the plasma membrane when imaged by confocal microscopy at the cross-section of cell-cell synapse.

      1. The authors should consider whether CAR expression level affects their observations. For example, do lower levels of CAR expression make the system LAT-dependent? Further, what is the level of the CAR relative to endogenous TCR expression on their primary T cells.

      We agree with the reviewer that it is informative to determine if LAT-independent signaling is dose dependent. We tried to measure the CAR concentration relative to the endogenous TCR/CD3z. By western blot using two different antibodies against CD3z, we detected TCR/CD3z expression, but found no bands corresponding to CAR. We believe this reflects a low expression of CAR in our system, which is confirmed by FACS. The general low expression of CAR makes it challenging to sort an even lower CAR-expressing population. Therefore, we sought alternative ways to determine the dose-dependence; we titrated the CD19 concentrations on the bilayer. As shown in the new Figure EV1, CAR formed microclusters similarly in the wild-type versus LAT-deficient cells in a wide range of CD19 concentration. Therefore, we conclude that the LAT-independent cluster formation is robust at low antigen density as well.

      Minor comment:

      1. Since JCaM2.5 has differences when compared to the parental Jurkat E6.1 T cell line, the authors should utilize JCaM2.5 reconstituted with wildtype LAT as a comparator.<br> Agreeing with this reviewer, we recognized that Jcam2.5 was generated by mutagenesis which may result in protein expression difference for genes besides Lat. As suggested by reviewer1, we used J.LAT, a genuine LAT knockout cell line that is generated by CRISPR-mediated gene targeting, to perform the clustering assay (new Fig EV2). Our results showed that, similar to Jcam2.5, CAR but not the TCR formed microclusters in J.LAT cells.

      Reviewer #3 (Significance):

      The mechanism(s) by which CAR-Ts function is of high significance from both scientific and clinical viewpoints. From a scientific viewpoint, it provides important basic mechanistic information of how T cells are being activated to kill tumor cells. By understanding the molecular requirements, additional generations of CARs can be designed to provide greater efficacy, overcome resistance and possibly less toxicity.

      This is an evolving field and little is known to date. Hence, this study could represent an insightful and important advance to the field.

      Audience is to both basic immunologist and cancer biologists.

      We appreciate this reviewer’s comments on the high significance of our work to the field of both basic immunology and clinical application.

      My expertise is in T cell signaling, T cell biology and immunotherapy.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers


      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      The manuscript entitled "Vasohibin-1 mediated tubulin detyrosination selectively regulates secondary sprouting and lymphangiogenesis in the zebrafish trunk" by de Oliveira investigates the function of the carboxylpeptidase Vasohibin during the formation of the zebrafish trunk vasculature and reports a requirement of Vasohibin for secondary sprout formation and in particular the formation the lymphatic vasculature.

      Having established the expression of Vasohibin in sorted ECs of 24 hpf embryos, the remaining study addresses the function of Vasohibin in this cell type. It is largely based on the use of a splice-site interfering morpholino. Particular commendable is the analysis, demonstrating that the KD of vash-1 indeed results in a significant reduction of detyrosination in endothelial tubulin. Findings in the vascular system then include: (i) the detection of increased division and hence supernumerous cells occurring selectively in 2nd sprouts from the PCV; (ii) an increased persistence of the initially formed 3 way connections with ISV and artery; (iii) reduced formation of parachordal lymphangioblasts and (iv) a reduced number of somites with a thoracic duct segment; (v) frequent formation of lumenized connections between PLs (where present) and ISV. To demonstrate specificity, the approach was repeated with a different morpholino and defects were partially rescued by MO-insensitive RNA.

      Possible additional and relevant information could include data on a vash-1 promotor mutant to independently verify the MO-based functional analysis. Mutants would also allow analysis of further development, are the defects leading to the demise of the fish or is a later regeneration and normalization of the lymphatic vasculature observed?

      We agree that a mutant would be desirable to validate the phenotypic analysis of the morpholinos used, and would also allow for further analysis. However, this is not achievable within a reasonnable time frame, especially in the context of current work restrictions.

      In addtion to the two splice morpholinos currently used to knockdown vash-1 expression, we will use an ATG morpholino to further investigate our observations and hypothesis regarding the role of vash-1 in lymphatic vessels formation. We will also validate it by westernblot and attempt to rescue it with mRNA.

      We have not investigated the phenotype past 4 dpf. We will add investigation of lymphatics and morphology at 5 dpf.

      In addition, are other lymphatic vessel beds like the cranial lymphatics affected?

      Using the Tg[fli1a:EGFP]y7 line, we have not been able to identify apparent differences in other vascular beds including the cranial lymphatics. However a detailed fine-grained investigation of the cranial vascular bed has not been performed. Given the focus of the present study on the trunk vasculature to understand the mechanisms of vash-1, we feel that a detailed analysis of cranial lymphatics would at this stage be somewhat out of scope.

      PLs have been demonstrated to be at least partially guided in their movement by the CXCR4/SDF1 system and SVEP1. Has the expression of these factors been tested in vash-1 KDs?

      We have not investigated the potential role of the CXCR4/SDF1 system and SVEP1 in vash-1 regulation of lymphangiogenesis. We will investigate the expression of cxcr4a, cxcl12a, cxcl12b and svep1 by in situ hibridization upon vash-1 knockdown.

      With regards to the frequently observed connections of PLs and ISVs in vash-1 morphants, can the proposed lumen formation of these shunts be demonstrated e.g. by injection of Q-dots or microbeads into the circulation?

      Although the lumenisation is very clear thanks to the membrane targeted expression of the label in this line, we will further analyse whether these abberant ISV to ISV connection can be perfused by Q-dots injections.

      Concerning the mechanisms of these defects, is it possible to analyse the asymmetric cell division leading to 2nd sprouts in greater detail? Is the same number or are more cells sprouting form PCV and can the fli1ep:EGFP-DCX cell line in fixed samples be used to identify the spindle orientation in dividing cells?

      We agree with the reviewer and plan to use the Tg[fli1ep:EGFP-DCX] fish line to investigate spindle asymmetry in uninjected embryos, as well as compare the spindle in control MO and vash-1 KD embryos. Vash-1 has been shown to regulate spindle formation in osteosarcoma cells (Liao et al., 2019). We will attempt to clarify whether this function is conserved in endothelial cells and contributes to the control of endothelial cell proliferation during initiation and formation of secondary sprouting.

      We also agree that it is important to look at the PCV in the begining of secondary sprouting and will clarify whether the sprouting is initiated by an increased number of cells.

      **Minor issues:** Page 5, Mat & Meth, please spell out PTU at its first mention.

      This has been corrected accordingly (see page 4).

      Page 6 Mat & Meth, Secondary sprout and 3-way connection parameters: The number of nuclei was assessed in each secondary sprouts (del s, singular) just prior...

      This has been corrected accordingly (see page 5).

      Page 16, 8th line from bottom: Recent work demonstrated that a secondary sprout either contributes (add s) to remodelling a pre-existing ISV into a vein, or forms (add s)a PLs (Geudens et al., 2019).

      This has been corrected accordingly (see page 16).

      Page 25, Legend to Fig. 2D-G: "...G,G' shows quantification of dTyr signal upon vash-1 KD..." Fig2 G,G' show immunostaining rather than quantification of the dTyr signal, which is shown Fig. 2H-J

      This has been corrected accordingly (see page 26).

      Fig. 1D / Fig. 2H-J please increase weight of the error intervals and / or change colour for improved visibility

      This has been corrected accordingly (Fig. 1D and 2H-J), and we added n.s. to Fig. 1D.

      Reviewer #1 (Significance (Required)):

      Taken together the manuscript is comprehensively written and the study provides a conclusive analysis of the MO-mediated KD of Vasohibin in zebrafish embryonic development presenting significant novel findings. Known was a generally inhibitory function of Vasohibin on vessel formation and its enzymatic activity as a carboxylpeptidase responsible for tubulin detyrosination, affecting spindle function and mitosis. New is the detailed analysis of the Vasohibin KD on zebrafish trunk vessel formation and the description of a selective impairment of 2nd sprout formation. The manuscript is of interest for vascular biologists.

      REFEREES CROSS-COMMENTING

      I fully concur with the comments of reviewer #2, all three reviews find that this study is of significant interest to the vascular biology community as the relevance of tubulin detyrosination for developmental angiogenesis has not been investigated. Also all three reviews highlight the potential limitations of the use of splice morpholinos (suggested alternatives include ATG morpholinos and CRIPR mutants), the requirement to provide further evidence for a endothelial cell autonomous defect and the need to clarify some of the data representation.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      **Summary:**

      The manuscript by Bastos de Oliveira et al. describes an important investigation of the endothelial tubulin detyrosination during vascular development. Namely, they found detyronised microtubules in secondary sprouts, which is absent in MO-vash-1 treated embryos. The authors use the vash-1 morpholino approach to uncover the developmental consequences of suppressed detyrosination in angiogenesis and lymphangiogenesis in vivo in zebrafish. By a combination of transgenic lines, immunohistochemistry and time-lapse imaging, Bastos de Oliveira et al., have found that Vash-1 is a negative regulator of secondary sprouting in zebrafish. The authors showed that in the absence of Vash-1 more cells are present in the secondary sprouts due to increased cell proliferation; however lymphatic vascular network fails to form. The current manuscript requires additional experimental evidence to support the conclusions. Please see below the major technical concerns and minor comments.

      **Major comments:**

      -This study is based on analysis of the phenotypes observed in embryos injected with vash-1 morpholino. The authors use two different types of splice morpholinos, perform rescue experiments with RNA, and validate one MO-vash-1 with western blot. Morpholinos are not trivial to work with, and the results are variable hence additional controls need to be included, as following the recommendation put together by the zebrafish community (Stainier et, al., Plos Genetics, 2017). As the severity of the phenotypes comparing MO1 with MO2 is different and MO-vash-1 embryos appear developmentally delayed (Figure 2D-F and 5E-F overall size seem to be affected), additional MO is required, for example, ATG-MO or generation of CRISPR mutant would be favourable. All the morpholino used need to be validated using an antibody, RT-PCR and qPCR. It is essential to carry out the rescue experiments for all the MO used in this study and following the guidelines. Including the dose-response curve, data would be informative.

      We agree with the reviewer and the recommendations of the zebrafish community. We will investigate the phenotypes with another KD strategy, such as the ATG-Morpholino suggested by the reviewer. We will also supply more validation of the MO2 including RNA rescue and westernblot (already included in Fig. 5 I).

      We added dose-response curves (Supp. Figure 1 E,G) and a developmental morphology assessment for the morpholino 1 (Supp. Figure 1 A,B).

      Given our extensive analysis of the effects of vash-1 KD, we believe the embryos in 2F are not developmentally delayed. However, the image in figure 2F does give that impression, and therefore may have triggered the reviewer’s concerns. We double checked and found that due to an oversight, we included a picture from a slightly different region of the trunk in comparision to Fig. 2D. We will add pictures of the same trunk region (Fig.2D-F) as we have done in all other figures. We nonetheless supply a supplementary figure 1 showing and quantifying the development of the analysed vash-1 morphants.

      -In addition to EC, the levels of dTyr are lower in MO-vash-1 in neural tube and neurons spanning the trunk (Figrue 2 D-G'). These have been previously shown to be important for secondary sprouting. Is it possible that the observed phenotypes in the secondary sprouting are due to defects in these neurons?

      We agree with the reviewer that a potential contribution of altered neuronal differentiation to the vascular phenotype should be clarified. We will assess the morphology of the neurons and their dendrites relevant for pathfinding (Lim et al., 2011) in vash-1 KD embryos, using a pan-neuronal zebrafish line, as well as via immunostaining against alpha-tubulin. Should we find evidence for changes in neuronal cells, we will attempt to clarify a cell autonomous role of vash-1 by transplantation experiments.

      -Embryo number used in this study appears to be low especially in figure 3G, 5D, 5G, to conclude draw conclusions from these experiments, the number of embryos used should be higher than 20. Figure 4J please specify how many embryos were used.

      We will increase the number of embryos per condition to a minimum of 20 embryos and update the averages in the text for 3G (control: 7 and vash-1 KD: 11 embryos).

      In 5D and 5G each point is an embryo and more than 20 embryos per condition were used (in 5D 23-35 embryos per condition, in 5G 60-63 embryos/condition), we corrected the legend 5D and 5G (see page 27) and made it clear that each point in the graph corresponds to one embryo (5D- percentage of PLs associated with veins in each embryo; 5G- percentage of somites with toraxic duct in each embryo).

      In 4J, 18 embryos were used for control (about 3 sprouts/embryo– 52 sprouts quantified) and 7 embryos for vash-1* KD condition (about 3 sprouts/embryo – 24 sprouts quantified). We corrected the number of control sprouts in the legend and added the number of embryos to increase clarity (see page 27).

      -The authors hypothesise that VASH acts in the sprouting endothelial cells, based on the Q-PCR in Figure 1. However, in this experiment all EC have been sorted thus this remains ambiguous in which cell types vash-1 is expressed. Please provide the expression pattern for vash-1 across the developmental stages the phenotypes are observed.

      We agree with the reviewer that it would be beneficial to understand the expression pattern of vash-1 in wild type embryos. We plan to perform in situ hybridization for vash-1 mRNA.

      -Throughout the manuscript the authors refer the lymphatic identity, however, there is no evidence in the paper that the identity status has been assessed. To support these claims Prox1 immunohistochemistry or analysis of prox1 expression in the reporter line would be appropriate.

      We agree with the reviewer and plan to perform a Prox1 immunostaining (Koltowska et al., 2015) in vash-1 KD embryos at 34-36 hpf (secondary sprouting) to investigate Prox1 levels upon vash-1 KD.

      **Minor comments:**

      -The authors refer to the literature where overexpression of VASH suppresses the angiogenesis. As the RNA injections were used in rescue experiments, the data of vash-1 RNA injections into the wild-type embryos would be beneficial.

      We have injected vash-1 RNA into a control morpholino injected embryos (28 control embryos, 14 Vash-1 RNA injected embryos) and we observed a significant decrease in PLs at 52 hpf (average of -control: 87,5% somites with PLs to 67% somites with PLs in vash-1 RNA embryos). This could be due to a decrease of secondary sprouting, which would be in accordance with the current literature that vash-1 overexpression is anti-angiogenic. We will further investigate and add the results to figure 5. Figure 1. vash-1* mRNA injection leads to a decrease in somites with PLs (preliminary).

      -In figures 2J, 3J, 3K, 3N, 4J, 5C, 5D and 5G the N number was set for examples as the number of sprouts, the number of somites with TD, number of ISV. To strengthen the observation in the manuscript quantification of the sprouts, PL, vISVs and lymphatic phenotypes with N set as the number of embryos would be more informative. Indicating the number of embryos used, in the graphs, would be helpful.

      We agree with the reviewer and have added embryo numbers in all legends and graphs. In 2J, 3J, 3K, 4J each point is a sprout, a cell division or an ISV, corresponding to the N. We agree that the number of embryos could be more clearly stated, so we added the number of embryos analysed in the figure legend and will add them in the graphs.

      In 5C, 5D and 5G each point corresponds to an embryo (clarified in the legend of Fig. 5- see page 27).

      Fig. 5C refers to the percentage of somites with PLs in each embryo, 5D refers to percentage of the existing PLs in one embryo connected to a venous ISV, 5G corresponds to percentage of somites with a TD segment in each embryo.

      -In Figure 5A, B and D the authors quantify what they refer to as a lumenised connection between the vISVs and PL. In the control image (second star), a somewhat lumenised structure is present, clarification of how the scores were set is missing.

      In Fig. 5C we show a quantification of the percentage of somites with PLs per embryo, by counting the PLs identified with an asterisk in Fig. 5A-B. PLs are normally not lumenised, with few exceptions also ocurring in wild-type – see Fig. 4 in (S Isogai et al., 2001).

      In Fig. 5D we quantified the proportion of PLs associated/connected with venous ISvs (see Methods section page 6), by 52 hpf in control and vash-1 morphants.

      In 5B and 5F,F‘, the arrowheads identify lumenised PLs present in vash-1 KD embryos. We will add a quantification of kdr-l:ras-Cherry positive ISV-to-ISV connections, corresponding to the lumenised endothelial connections, since kdr-l:ras-Cherry signal labels endothelial (and not lymphatic) cells and is particularly strong at the luminal endothelial membrane of the vessel.

      -In Figure 3 E and F the authors show the excessive sprouting phenotype between controls and Mo-vash-1. The images presented are taking from different parts of the embryos (middle of the trunk vs plexus region), hampering the comparison between the two groups. The quantification of the phenotypes in both experimental groups should be in the same region of the embryo, as the local difference can occur. It is key to provide representative images to support these observations.

      The images presented are representative of the phenotype quantified, and the time-lapses were done in comparable regions of the zebrafish trunk (+- 1-2 somites in both groups due to drift during image aquisition), making the comparison possible.

      -Figure 1D the vash-1 expression levels in EC seem very variable in this graph, therefore no conclusion can be drawn from this data, especially as the authors do not provide the p-values.

      We added n.s. in the graph, to make it clear that the difference between developmental stages is not significant, potentially due to high biological variability between embryos, as seen in two primer pairs. We believe that presenting this biological variability is of importance to the readers.

      We write on page 12 about this result: „During the sprouting phase (24hpf), vash-1 expression was 5-7 times higher in endothelial than in non-ECs, decreasing at 48 hpf (Fig. 1C-D). Although these results are not significant, they were independently confirmed with a second primer set.”. The only conclusion we made from this data is that Vash-1 is dynamically expressed in the zebrafish endothelium during development, as we now added in the discussion (page 14).

      -In the introduction, the authors state: 'Although primary and secondary sprouts appear morphologically similar, with tip and stalk cells' - Please provide the reference that supports the claim that secondary sprouts have tip-stalk cells morphology/organisation.

      Although many studies have investigated primary and secondary sprouting, identifying both shared as well as distinct molecular regulation, and show morphological details that are apparently similar, a formal claim that secondary sprouts show tip and stalk cell identities and behaviour is hard to find. Given that this is not relevant for the central findings of the work, we modified the sentence and added a reference “Although primary and secondary sprouts appear morphologically similar, with tip and stalk cells” (Sumio Isogai et al., 2003)…” See page 2.

      We also updated the discussion for consistency: “Although the cellular mechanisms of primary and secondary sprouting in zebrafish appear very similar, with tip cell selection and guided migration and stalk cell proliferation, secondary sprouting utilises alternative signalling pathways and entails a unique specification step that establishes both venous ISVs and lymphatic structures.” (see page 15)

      -The authors refer the increased cell division phenotypes observed in the movies, however, the movie files have not been available to the reviewers.

      We will provide the movies.

      Reviewer #2 (Significance (Required)):

      This is an important study as uncovering the mechanistic details of angiogenic and lymphangiogenic negative regulators is of high value with the potential for therapeutic developments. To date, Vash-1 has been only studied in the context of tumour angiogenesis, vasculature in diabetic nephropathy and pulmonary arterial hypertension, and it remains unclear what is its role during development and how does it regulate vascular network formation. The tyrosination status of microtubule in endothelial cells is understudied. This study revealed, previously uncharacterised detyrosinated microtubules in endothelial cells in vivo. And further dissects how this process might be regulated, brings unique insights into the vascular biology field and beyond. Thus, delving into the cell biological mechanism such as microtubule dynamics and modification in vivo in embryo context is a significant step forward in setting new standards in the field.

      I am developmental biologist who has experience in model organisms such as zebrafish and mouse. The main focus of my work is on developmental angiogenesis and lymphangiogenesis.

      REFEREES CROSS-COMMENTING

      After reading the other reviews comments, it seems that we all agree that this study is of high value to vascular biology field and beyond bringing novel findings.

      Importantly the reviewers' comments are in line with each other and have identified several commonalities that should be addressed. Such as: Further validation of Morpholinos, or using alternative methods to replicate the findings. additional evidence that the observed phenotypes are primary due to vash-1 requirement within EC, and not due to the secondary effect in other cells such as CXCR4/SDF1 system and SVEP1, neurons or general delay of the embryos Further evidence of for VASH expression pattern the number of embryos used in the experiments, and how the data is represented.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      Vasohibin-1 (Vash-1) is known to detyrosinate microtubules (MTs) and limit angiogenesis. Using in vivo live imaging and whole mount immunofluorescence staining of zebrafish trunk vasculature, Bastos de Oliveira et al. show that the MT detyrosination role of Vash-1 is conserved in zebrafish and that Vash-1 is essential for limiting venous sprouting and subsequent formation of lymphatics. Their findings suggest a role for MT detyrosination in lympho-venous cell specification.

      **Major comments:**

      1 . The authors claim that Vash-1 regulates secondary sprouting and lymphangiogenesis by detyrosinating MTs. However, no direct evidence of this link is provided in the manuscript. The authors only separately show that knockdown of vash-1 affects MT detyrosination and secondary sprouting and lymphangiogenesis. They have not shown a causative effect. The authors should therefore qualify the above stated claim as speculative. In other words, the authors should mention that their data only suggests that disruption of MT detyrosination is the underlying cause for aberrant secondary sprouting and lymphangiogenesis in vash-1 KD embryos.

      We agree with the reviewer about the lack of evidence to state that the disruption of microtubule detyrosination leads to aberrant secondary sprouting. Although we believe this is the most parsimonius explanation for the secondary sprouts behavioural defects as cell division is disturbed and microtubule detyrosination is implicated in cell division (Barisic et al., 2015), we want to make clear that our data currently only suggest a specific role of microtubule detyrosination in secondary sprouting. Examples of this are page 14 of the discussion „These results suggest that Vash-1-driven microtubule detyrosination limits excessive venous EC sprouting and proliferation during lympho-venous development in zebrafish.” as well as the abstract.

      We also corrected the sentence in the discussion (page 14): “In this study, we identified Vash-1-mediated microtubule detyrosination as a cellular mechanism as a novel regulator of EC sprouting from the PCV and the subsequent formation of lymphatic vessels in the zebrafish trunk.”

      To avoid any overstatement, we also propose the following title change: Vasohibin-1 mediated tubulin detyrosination selectively regulates secondary sprouting and lymphangiogenesis in the zebrafish trunk.

      As detailed in response to comment 2 below, we will however attempt to investigate the direct connection. Depending on the outcome, we will adapt conclusions and title accordingly.

      2 . In order to provide more compelling evidence for a direct relationship between MT tyrosination and lymphangiogenesis, the authors could try mutating the carboxypeptidase domain of vash-1 or overexpressing a dominant negative transcript (that contains a mutated carboxypeptidase domain). If this gives the same phenotypes as the vash-1 morphants, it would indicate that the carboxypeptidase activity of Vash-1 (in detyrosinating MTs) is responsible for limiting secondary sprouting and promoting specification of lymphatics. This suggested experiment is fairly realistic in terms of both time and resources. For example, since the authors already have the human vash-1 cDNA cloned, making a dominant negative transcript from this would take around two weeks, imaging and analysis of embryos injected with this mRNA would take another four weeks. Therefore, in total, the suggested experiment would take around 6 weeks. Although the alternative experiment, that is, making a carboxypeptidase domain mutant of vash-1 would be a better choice in terms of reproducibility and long-term use of a stable line, it would admittedly take a relatively larger amount of time. Therefore, the ultimate choice would depend on the authors.

      We will investigate this further by cloning and expressing a mutated vash-1 cDNA which translates a validated catalytically dead Vash-1 (Nieuwenhuis et al., 2017). However, this mutant has not been shown to function as dominant negative, so it is unclear whether it can be used as a dominant negative mutant.

      3 . Both the data and methods are presented in a way that ensures reproducibility. The statistical analysis is very well done, in that the authors were very prudent in their choice of statistical tests. However, in many figures and subfigures (Fig. 2B, H-J; Fig. 3G, J, K, N; Fig. 4J; Fig. 5J), the number of replicates was not mentioned and instead only the sample size was stated. Whether this was just an oversight or if it should be taken to mean that the analysis was performed on just one replicate is unclear. The authors need to clarify this aspect of their analysis. Further, In Fig. 2H-J, Fig. 3G,J, K, N and Fig. 4J, the total number of data points in control MO vs vash-1 KD seem to be quite different. In other words, there seem to be a lot more data points in one experimental condition than the other. Does this difference fall within the acceptable range? If the authors were to compare a similar number of data points between the two experimental conditions, would the results of the statistical analysis still be the same?

      We apreciate this comment and clarified the replicate numbers in the figure legends: Fig. 2B- 3 replicates (page 25), Fig. 2 H-J- quantification is 1 replicate (page 26), Fig. 2 D-G is representative of 3 replicates (page 25). Fig. 3 G,J,K,N – quantification is from 1 replicate (page 26), Fig. 3 B,C,E,F,H,I are representative of 2 experimental replicates (page 26). Fig. 4J – quantification is 1 replicate (page 27), Fig. 4 A-F is representative of 3 replicates (page 27). Fig. 5 J correspondes to 1 replicate (page 28).

      We plan to increase replicates and numbers in quantifications shown in Fig. 3 G,J,K,N and Fig. 5 J as they are relevant for the conclusions of the manuscript, and adapt the text.

      The quantifications of immunostaining signals are comparable between different samples of the same experiment but technically not easy accross different experiments, due to some variability of the immunostaining. However, the pattern we report in the quantifications and representative pictures is consistentely detected (reduced dTyr signal upon vash-1 KD in Fig 2 D-G; higher dTyr intensity in secondary rather than primary sprouts in Fig. 4 A-F). We added in the legend that the pictures of the embryos in these figures are representative of 3 biological replicates (see page 25 and 27).

      We recognise the unequal sample size in control and vash-1 KD groups in Fig. 2H-J, Fig. 3G,J, K, N and Fig. 4J. Generally, the vash-1 KD group shows more variance than the control group (see Fig. 3 J-N, 4J for example), hence the reason why we analysed a higher sample size.

      In the planned experiments (repeating quantifications of Fig. 3 J-N), we will analyse a similar number of embryos.

      We corrected the figure legend of 2 H-J on the number of ISVs - 108 ISVs from 7 embryos for control and 150 ISVs for vash-1 KD, from 9 embryos (see page 26).

      4 . The authors only provide KD data on the function of vash-1 using morpholinos. According to several recent guidelines concerning the use of morpholinos, this is not widely accepted in the zebrafish community as sufficient to provide robust insight into gene function. Please refer for example to the following publication: Guidelines for morpholino use in zebrafish, Stainier et al., PLOS Genetics, 2017. The generation of a vash-1 mutant is a necessary requirement for backing up morpholino KD data. Further, even though the authors state that embryos were selected on the pre-established criteria that they have normal morphology, beating heart, and flowing blood, certain morphological differences between control MO injected and vash-1 KD embryos could be observed in some figures. In Fig. 2D, F and Fig. 5A, B, E, F the vash-1 KD embryos seem smaller (extend of the dorso-ventral axis) than control MO injected embryos. The authors need to provide images showing the overall morphology of morpholino injected embryos and need to provide evidence that morpholino injections do not cause developmental delays.

      We agree that a mutant would be desirable to validate the phenotypic analysis of the morpholinos used, and would also allow for further analysis. However, this is not achievable within a reasonnable time frame, especially in the context of current work restrictions. We have added a sentence about the need to confirm the loss of function phenotype with vash-1 mutants in the discussion (see page 14).

      In addtion to the two morpholinos currently used to knockdown vash-1 expression, we will use an ATG morpholino to further investigate our observations and hypothesis regarding the role of vash-1 in lymphatic vessels formation. We will also validate it by westernblot and attempt to rescue it with mRNA.

      We added a supplementary figure with pictures and quantifications of antero-posterior (Sup. Figure 1 C) and dorso-ventral length (Sup. Figure 1 D) of the analysed control and vash-1 morpholino injected embryos‘ development at 24, 34, 52 and 4dpf which shows no significant developmental delay and morphological defect. There is some occurrence of curvature of the tail at 34-52 hpf.

      We added a sentence in the Methods section (pages 10) to clarify the morphant’s morphology and dosage-response curves.

      We observe a 1-2 hour developmental delay of both the control and the vash-1 KD embryos compared to uninjected wild-type embryos, which led us to chose the 52 hpf time point to investigate the PLs. In uninjected embryos they are usually developed by 48hpf (Hogan et al., 2009).

      Fig. 2 D shows a more anterior region of the zebrafish trunk than Fig. 2F (the tail has a smaller dorso-ventral length)- we will provide more comparable pictures from the same region.

      Fig. 5B is slightly tilted – we will provide a picture with the same orientation.

      Fig. 5 E and F have a similar length from dorsal aorta to the dorsal longitudinal anastomotic vessel. However, we appreciate a difference in the sub intestinal vascular plexus (SIVP), which is consistently underdeveloped in the vash-1 KD embryos.

      Figure 2- vash-1 deficient embryos show underdeveloped intestinal vascular system at 4 dpf.

      **Minor comments:**

      a. The authors should back their qPCR data for vash-1 expression (Figure 1) by standard mRNA in situ hybridization, given the large degree of variability in vash-1 expression. Do they observe a dynamic expression in the vasculature using this technique?

      We agree with the reviewer that an in situ hybridization would be beneficial to understand the expression pattern of vash-1 in wild type embryos. Accordingly, we will look at vash-1 expression by in situ hybridization in WT embryos.

      The number of nuclei per sprout in Fig. 3J does not correspond with the number of divisions per sprout presented in Fig. 3K. The authors observe one or two cell divisions per sprout in ctr MO injected embryos (Fig. 3K), however, Fig. 3J shows that the majority of ctr. sprouts contains only one cell. This is even more dramatic for vash-1 MO injected embryos, which can have up to four divisions, therefore should contain six cells. However, the maximum number of cells the authors report is three to four cells. How do these observations go together?

      We believe these quantifications are not contradicting. The number of endothelial nuclei was assessed just prior to the connection to the ISV and the cell division quantification was done in a time-lapse from the time of secondary sprout emergence until the resolution of the 3-way connection. It is expected that there are more cell divisions during a longer time frame, as cells migrate dorsally or ventrally out of the sprout.

      Fig. 5I and J have the same data points for control MO and vash-1 MO1. Does this mean that both graphs are from the same experiment? If so, the authors could combine the two graphs into one. If the two graphs are not from the same experiment, both would need to have independent controls.

      Fig 5 I and J are indeed from the same experiment. They are now combined into one graph (see Fig. 5 J).

      d. The percentage of somites with PLs in vash-1 MO1 injected embryos in Fig. 5I is half the value shown in Fig. 5C. Although this kind of variability might be expected in biological samples, perhaps the authors could briefly discuss the issue and its implications on reproducibility in the manuscript so as to have the readers be aware of it, especially since the rescue of the vash-1 morpholino phenotype back to 50% from 25% is the same value the authors observed in the vash-1 KD alone in Fig. 5C. Here the value is 50% for the morpholino injection.

      We added a sentence discussing the phenotypic variability in the discussion (see page 16), and we added a dosage response curve for the PLs (Sup. Figure 1 F), showing that embryos injected with the same amount of morpholino show variability in the percentage of somites with PLs at 52hpf. We added a more representative picture of PLs for vash-1 morphant in Fig. 5I ( Y-axis of Fig. 2H and 4J correspond to ratios, which have no units. Nontheless, we added AU/AU to these graphs to make it clearer. We added the bars in Fig. 5D.

      It would help to have an inference or conclusion at the end of each results section.

      We added one conclusion sentence per results section (see pages 11-14).

      Reviewer #3 (Significance (Required)):

      Conceptual: As per my knowledge, this is the first study that looks at microtubule modifications in the context of a vertebrate organism past the gastrulation stage, as opposed to similar studies that have been done in cell culture or invertebrates (S. cerevisiae, C. elegans and D. melanogaster). Moreover, this study is one of few that address a novel link between the cytoskeleton and the process of cell fate specification.

      Previous studies have separately shown that Vash-1 limits angiogenesis and detyrosinates MTs. The current study combines the two observations in the context of endothelial cells, and hypothesizes that perhaps the function of Vash-1 in limiting angiogenesis and at the same time promoting lymphatic development could be due to its role in MT modification at the molecular level and the consequent effect of this on cell division and/or fate specification at the cellular level. In short, this study aims to connect the long-standing gap in knowledge between cytoskeletal modifications and cell dynamics (in particular, division and specification) in a vertebrate organism. I therefore believe that the current study would be an exciting finding for research communities that study cytoskeletal influence on cellular dynamics and also those in the broad area of vascular biology.

      My field of expertise relates to vascular biology, specifically developmental angiogenesis and the behavior of endothelial cells in zebrafish.

      References

      Barisic, M., Silva E Sousa, R., Tripathy, S. K., Magiera, M. M., Zaytsev, A. V., Pereira, A. L., Janke, C., Grishchuk, E. L., & Maiato, H. (2015). Microtubule detyrosination guides chromosomes during mitosis. Science, 348(6236), 799–803. https://doi.org/10.1126/science.aaa5175

      Hogan, B. M., Bos, F. L., Bussmann, J., Witte, M., Chi, N. C., Duckers, H. J., & Schulte-Merker, S. (2009). Ccbe1 is required for embryonic lymphangiogenesis and venous sprouting. Nature Genetics, 41(4), 396–398. https://doi.org/10.1038/ng.321

      Isogai, S, Horiguchi, M., & Weinstein, B. M. (2001). The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Developmental Biology, 230(2), 278–301. https://doi.org/10.1006/dbio.2000.9995

      Isogai, Sumio, Lawson, N. D., Torrealday, S., Horiguchi, M., & Weinstein, B. M. (2003). Angiogenic network formation in the developing vertebrate trunk. Development, 130(21), 5281–5290. https://doi.org/10.1242/dev.00733

      Kimura, H., Miyashita, H., Suzuki, Y., Kobayashi, M., Watanabe, K., Sonoda, H., Ohta, H., Fujiwara, T., Shimosegawa, T., & Sato, Y. (2009). Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood, 113(19), 4810–4818. https://doi.org/10.1182/blood-2008-07-170316

      Koltowska, K., Lagendijk, A. K., Pichol-Thievend, C., Fischer, J. C., Francois, M., Ober, E. A., Yap, A. S., & Hogan, B. M. (2015). Vegfc Regulates Bipotential Precursor Division and Prox1 Expression to Promote Lymphatic Identity in Zebrafish. Cell Reports, 13(9), 1828–1841. https://doi.org/10.1016/j.celrep.2015.10.055

      Liao, S., Rajendraprasad, G., Wang, N., Eibes, S., Gao, J., Yu, H., Wu, G., Tu, X., Huang, H., Barisic, M., & Xu, C. (2019). Molecular basis of vasohibins-mediated detyrosination and its impact on spindle function and mitosis. Cell Research, June. https://doi.org/10.1038/s41422-019-0187-y

      Lim, A. H., Suli, A., Yaniv, K., Weinstein, B., Li, D. Y., & Chien, C. Bin. (2011). Motoneurons are essential for vascular pathfinding. Development, 138(21), 4813. https://doi.org/10.1242/dev.075044

      Nicenboim, J., Malkinson, G., Lupo, T., Asaf, L., Sela, Y., Mayseless, O., Gibbs-Bar, L., Senderovich, N., Hashimshony, T., Shin, M., Jerafi-Vider, A., Avraham-Davidi, I., Krupalnik, V., Hofi, R., Almog, G., Astin, J. W., Golani, O., Ben-Dor, S., Crosier, P. S., … Yaniv, K. (2015). Lymphatic vessels arise from specialized angioblasts within a venous niche. Nature, 522(7554), 56–61. https://doi.org/10.1038/nature14425

      Nieuwenhuis, J., Adamopoulos, A., Bleijerveld, O. B., Mazouzi, A., Stickel, E., Celie, P., Altelaar, M., Knipscheer, P., Perrakis, A., Blomen, V. A., & Brummelkamp, T. R. (2017). Vasohibins encode tubulin detyrosinating activity. Science, 358(6369), 1453–1456. https://doi.org/10.1126/science.aao5676

    1. We a r e j u s t b e g i n n i n g t o i d e n t i f y a n d a s s e s s t h e s e e m e r g i n g s e t s o f s o c i a l s k i l l s a n d c u l t u r a lcompetencies.

      I would like to take issue with the idea presented a couple of lines before this that schools are "training autonomous problem solvers." That was not my experience as either a young person starting in Kindergarten in the fall of 1958 or through high school graduation in June 1971. After having three children pass through Boulder Valley Schools with the last to graduate from high school in 2009 I was very impressed with the amount of collaborative effort they had learned and the improvement on my own experiences. Social media did not exist during my initial education and was coming into full play for my children which to me begs the question as to is there a true problem? While I love this article's challenges has the lack of specificity come with another set of challenges? Where what is being proffered not being practiced? Is not the goal of being progressive to constantly strive for improved delivery of services to one another and nowhere more important than in education?

    1. dates Education City, an area devoted to research and education. The city was host to the first ministerial-level meeting of the Doha Development Round of World Trade Organization negotiations. It was also selected as host city of a number of sporting events, including the 2006 Asian Games, the 2011 Pan Arab Games and most of the games at the 2011 AFC Asian Cup. In December 2011, the World Petroleum Council held the 20th World Petroleum Conference in Doha.[4] Additionally, the city hosted the 2012 UNFCCC Climate Negotiations and is set to host many of the venues for the 2022 FIFA World Cup.[5] The city has also hosted the 140th Inter-Parliamentary Union Assembly in April 2019. Contents 1 Etymology 2 History 2.1 Establishment of Al Bidda 2.2 Formation of Doha 2.3 Arrival of Al Thani 2.4 20th century 2.4.1 Lorimer report (1908) 2.4.2 British protectorate (1916–1971) 2.5 Post-independence 3 Geography 3.1 Climate 4 Demographics 4.1 Ethnicity and languages 4.2 Religion 5 Administration 5.1 Districts 6 Economy 7 Infrastructure 7.1 Architecture 7.2 Atmosphere 7.3 Planned communities 8 Transportation 8.1 Roads 8.2 Rail 8.3 Air 9 Education 10 Sports 10.1 Football 10.2 Basketball 10.3 Volleyball 10.4 Other sports 10.5 Stadiums and sport complexes 11 Culture 11.1 Arts 11.2 Cinema 11.3 Media 11.4 Theatre 12 International relations 13 Gallery 14 See also 15 References 16 External links Etymology[edit] According to the Ministry of Municipality and Environment, the name "Doha" originated from the Arabic term dohat, meaning "roundness"—a reference to the rounded bays surrounding the area's coastline.[6] History[edit] See also: Timeline of Doha and Al Bidda A satellite view of Doha on the East coast of Qatar. As with most world cities, Doha developed on the water front around the Souq Waqif area today. It gradually spread out in a radial pattern with the use of ring roads. Establishment of Al Bidda[edit] The city of Doha was formed seceding from another local settlement known as Al Bidda. The earliest documented mention of Al Bidda was made in 1681, by the Carmelite Convent, in an account which chronicles several settlements in Qatar. In the record, the ruler and a fort in the confines of Al Bidda are alluded to.[7][8] Carsten Niebuhr, a German explorer who visited the Arabian Peninsula, created one of the first maps to depict the settlement in 1765 in which he labelled it as 'Guttur'.[7][9] David Seaton, a British political resident in Muscat, wrote the first English record of Al Bidda in 1801. He refers to the town as 'Bedih' and describes the geography and defensive structures in the area.[10] He stated that the town had recently been settled by the Sudan tribe (singular Al-Suwaidi), whom he considered to be pirates. Seaton attempted to bombard the town with his warship, but returned to Muscat upon finding that the waters were too shallow to position his warship within striking distance.[11][12] In 1820, British surveyor R. H. Colebrook, who visited Al Bidda, remarked on the recent depopulation of the town. He wrote:[11][13] .mw-parser-output .templatequote{overflow:hidden;margin:1em 0;padding:0 40px}.mw-parser-output .templatequote .templatequotecite{line-height:1.5em;text-align:left;padding-left:1.6em;margin-top:0}Guttur – Or Ul Budee [Al‐Bidda], once a considerable town, is protected by two square Ghurries [forts] near the sea shore; but containing no fresh water they are incapable of defence except against sudden incursions of Bedouins, another Ghurry is situated two miles inland and has fresh water with it. This could contain two hundred men. There are remaining at Ul Budee about 250 men, but the original inhabitants, who may be expected to return from Bahrein, will augment them to 900 or 1,000 men, and if the Doasir tribe, who frequent the place as divers, again settle in it, from 600 to 800 men. The same year, an agreement known as the General Maritime Treaty was signed between the East India Company and the sheikhs of several Persian Gulf settlements (some of which were later known as the Trucial Coast). It acknowledged British authority in the Persian Gulf and sought to end piracy and the slave trade. Bahrain became a party to the treaty, and it was assumed that Qatar, perceived as a dependency of Bahrain by the British, was also a party to it.[14] Qatar, however, was not asked to fly the prescribed Trucial flag.[15] As punishment for alleged piracy committed by the inhabitants of Al Bidda and breach of treaty, an East India Company vessel bombarded the town in 1821. They razed the town, forcing between 300 and 400 natives to flee and temporarily take shelter on the islands between the Qatar and the Trucial Coast.[16] Formation of Doha[edit] Doha was founded in the vicinity of Al Bidda sometime during the 1820s.[17] In January 1823, political resident John MacLeod visited Al Bidda to meet with the ruler and initial founder of Doha, Buhur bin Jubrun, who was also the chief of the Al-Buainain tribe.[17][18] MacLeod noted that Al Bidda was the only substantial trading port in the peninsula during this time. Following the founding of Doha, written records often conflated Al Bidda and Doha due to the extremely close proximity of the two settlements.[17] Later that year, Lt. Guy and Lt. Brucks mapped and wrote a description of the two settlements. Despite being mapped as two separate entities, they were referred to under the collective name of Al Bidda in the written description.[19][20] Al Bidda: View from the bay, 1823 In 1828, Mohammed bin Khamis, a prominent member of the Al-Buainain tribe and successor of Buhur bin Jubrun as chief of Al Bidda, was embroiled in controversy. He had murdered a native of Bahrain, prompting the Al Khalifa sheikh to imprison him. In response, the Al-Buainain tribe revolted, provoking the Al Khalifa to destroy the tribe's fort and evict them to Fuwayrit and Ar Ru'ays. This incident allowed the Al Khalifa additional jurisdiction over the town.[21][22] With essentially no effective ruler, Al Bidda and Doha became a sanctuary for pirates and outlaws.[23] ‘Trigonometrical plan of the harbour of El Biddah on the Arabian side of the Persian Gulf’, 1823 In November 1839, an outlaw from Abu Dhabi named Ghuleta took refuge in Al Bidda, evoking a harsh response from the British. A. H. Nott, a British naval commander, demanded that Salemin bin Nasir Al-Suwaidi, chief of the Sudan tribe (Suwaidi) in Al Bidda, take Ghuleta into custody and warned him of consequences in the case of non-compliance. Al-Suwaidi obliged the British request in February 1840 and also arrested the pirate Jasim bin Jabir and his associates. Despite the compliance, the British demanded a fine of 300 German krones in compensation for the damages incurred by pirates off the coast of Al Bidda; namely for the piracies committed by bin Jabir. In February 1841, British naval squadrons arrived in Al Bidda and ordered Al-Suwaidi to meet the British demand, threatening consequences if he declined. Al-Suwaidi ultimately declined on the basis that he was uninvolved in bin Jabir's actions. On 26 February, the British fired on Al Bidda, striking a fort and several houses. Al-Suwaidi then paid the fine in full following threats of further action by the British.[23][24] Isa bin Tarif, a powerful tribal chief from the Al Bin Ali tribe, moved to Doha in May 1843. He subsequently evicted the ruling Sudan tribe and installed the Al-Maadeed and Al-Kuwari tribes in positions of power.[25] Bin Tarif had been loyal to the Al Khalifa, however, shortly after the swearing in of a new ruler in Bahrain, bin Tarif grew increasingly suspicious of the ruling Al Khalifa and switched his allegiance to the deposed ruler of Bahrain, Abdullah bin Khalifa, whom he had previously assisted in deposing of. Bin Tarif died in the Battle of Fuwayrit against the ruling family of Bahrain in 1847.[25] Arrival of Al Thani[edit] The Al Thani migrated to Doha from Fuwayrit shortly after Bin Tarif's death in 1847 under the leadership of Mohammed bin Thani.[26][27] In the proceeding years, the Al Thani assumed control of the town. At various times, they swapped allegiances between the two prevailing powers in the area: the Al Khalifa and the Saudis.[26] Plan of Al Bidda Harbour drawn in 1860 indicating the principal settlements and landmarks In 1867, many ships and troops were sent from Bahrain to assault the towns Al Wakrah and Doha over a series of disputes. Abu Dhabi joined on Bahrain's behalf due to the conception that Al Wakrah served as a refuge for fugitives from Oman. Later that year, the combined forces sacked the two Qatari towns with around 2,700 men in what would come to be known as the Qatari–Bahraini War.[28][29] A British record later stated "that the towns of Doha and Wakrah were, at the end of 1867 temporarily blotted out of existence, the houses being dismantled and the inhabitants deported".[30] The joint Bahraini-Abu Dhabi incursion and subsequent Qatari counterattack prompted the British political agent, Colonel Lewis Pelly, to impose a settlement in 1868. Pelly's mission to Bahrain and Qatar and the peace treaty that resulted were milestones in Qatar's history. It implicitly recognized Qatar as a distinct entity independent from Bahrain and explicitly acknowledged the position of Mohammed bin Thani as an important representative of the peninsula's tribes.[31] A part of Doha as seen in January 1904. Most development was low-rise and use of locally available natural materials like rammed earth and palm fronds was common practice. In December 1871, the Ottomans established a presence in the country with 100 of their troops occupying the Musallam fort in Doha. This was accepted by Mohammad bin Thani's son, Jassim Al Thani, who wished to protect Doha from Saudi incursions.[32] The Ottoman commander, Major Ömer Bey, compiled a report on Al Bidda in January 1872, stating that it was an "administrative centre" with around 1,000 houses and 4,000 inhabitants.[33] Disagreement over tribute and interference in internal affairs arose, eventually leading to the Battle of Al Wajbah in March 1893. Al Bidda fort served as the final point of retreat for Ottoman troops. While they were garrisoned in the fort, their corvette fired indiscriminately at the townspeople, killing a number of civilians.[34] The Ottomans eventually surrendered after Jassim Al Thani's troops cut off the town's water supply.[35] An Ottoman report compiled the same year reported that Al Bidda and Doha had a combined population of 6,000 inhabitants, jointly referring to both towns by the name of 'Katar'. Doha was classified as the eastern section of Katar.[33][36] The Ottomans held a passive role in Qatar's politics from the 1890s onward until fully relinquishing control during the beginning of the first World War.[14] 20th century[edit] The city's coastline in 1904 largely highlights the local community which was based on fishing and pearl diving. Pearling had come to play a pivotal commercial role in Doha by the 20th century. The population increased to around 12,000 inhabitants in the first half of the 20th century due to the flourishing pearl trade.[37] A British political resident noted that should the supply of pearls drop, Qatar would 'practically cease to exist'.[38] In 1907, the city accommodated 350 pearling boats with a combined crew size of 6,300 men. By this time, the average prices of pearls had more than doubled since 1877.[39] The pearl market collapsed that year, forcing Jassim Al Thani to sell the country's pearl harvest at half its value. The aftermath of the collapse resulted in the establishment of the country's first custom house in Doha.[38] Lorimer report (1908)[edit] British administrator and historian J. G. Lorimer authored an extensive handbook for British agents in the Persian Gulf entitled Gazetteer of the Persian Gulf in 1908. In it, he gives a comprehensive account of Doha at the time: "Dohah looking northwest", photographed by the Royal Air Force during a reconnaissance of the Qatar Peninsula on 9 May 1934 Generally so styled at the present day, but Bedouins sometimes call it Dohat-al-Qatar; and it seems to have been formerly better known as Bida' (Anglice "Bidder"): it is the chief town of Qatar and is situated on the eastern side of that peninsula, about 63 miles south of its extremity at Ras Rakan and 45 miles north of Khor-al Odaid Harbour. Dohah stands on the south side of a deep bay at the south-western corner of a natural harbour which is about 3 miles in extent and is protected on the north-east and south-east sides by natural reefs. The entrance, less than a mile wide, is from the east between the points of the reefs; it is shallow and somewhat difficult, and vessels of more than 15 feet draught cannot pass. The soundings within the basin vary from 3 to 5 fathoms and are regular: the bottom is white mud or clay. Town site and quarters, — The south-eastern point of the bay is quite low but the land on the western side is stony desert 40 or 50 feet above the level of the sea. The town is built up the slope of some rising ground between these two extremes and consists of 9 Fanqs or quarters, which are given below in their order from the east to the west and north: the total frontage of the place upon the sea is nearly 2 miles.[40] An old district in Doha planned with narrow streets and rough plastered walls gives a glimpe of the city's past. Lorimer goes on to list and describe the districts of Doha, which at the time included the still-existing districts of Al Mirqab, As Salatah, Al Bidda and Rumeilah.[41] Remarking on Doha's appearance, he states: The general appearance of Dohah is unattractive; the lanes are narrow and irregular the houses dingy and small. There are no date palms or other trees, and the only garden is a small one near the fort, kept up by the Turkish garrison.[42] As for Doha's population, Lorimer asserts that "the inhabitants of Dohah are estimated to amount, inclusive of the Turkish military garrison of 350 men, to about 12,000 souls". He qualified this statement with a tabulated overview of the various tribes and ethnic groups living in the town.[42] British protectorate (1916–1971)[edit] In April 1913, the Ottomans agreed to a British request that they withdraw all their troops from Qatar. Ottoman presence in the peninsula ceased, when in August 1915, the Ottoman fort in Al Bidda was evacuated shortly after the start of World War I.[43] One year later, Qatar agreed to be a British protectorate with Doha as its official capital.[44][45] Camels next to Al Koot Fort, built in 1927 by Abdullah bin Jassim Al Thani. Buildings at the time were simple dwellings of one or two rooms, built from mud, stone and coral. Oil concessions in the 1920s and 1930s, and subsequent oil drilling in 1939, heralded the beginning of slow economic and social progress in the country. However, revenues were somewhat diminished due to the devaluation of pearl trade in the Persian Gulf brought on by introduction of the cultured pearl and the Great Depression.[46] The collapse of the pearl trade caused a significant population drop throughout the entire country.[37] It was not until the 1950s and 1960s that the country saw significant monetary returns from oil drilling.[14] A view of Doha in the 1980s showing the Sheraton Hotel (pyramid-like building in the background) in West Bay without any of the high-rises around it Qatar was not long in exploiting the new-found wealth from oil concessions, and slum areas were quickly razed to be replaced by more modern buildings. The first formal boys' school was established in Doha in 1952, followed three years later by the establishment of a girls' school.[47] Historically, Doha had been a commercial port of local significance. However, the shallow water of the bay prevented bigger ships from entering the port until the 1970s, when its deep-water port was completed. Further changes followed with extensive land reclamation, which led to the development of the crescent-shaped bay.[48] From the 1950s to 1970s, the population of Doha grew from around 14,000 inhabitants to over 83,000, with foreign immigrants constituting about two-thirds of the overall population.[49] Post-independence[edit] The Pearl-Qatar at night The Pearl-Qatar is an artificial island spanning nearly four square kilometers. Qatar Petroleum tower, Palm tower B, Tornado tower, Doha tower and Al Jassimya tower seen (Left to Right) in the West Bay area in 2015 Qatar officially declared its independence in 1971, with Doha as its capital city.[3] In 1973, the University of Qatar was opened by emiri decree,[50] and in 1975 the Qatar National Museum opened in what was originally the ruler's palace.[51] During the 1970s, all old neighborhoods in Doha were razed and the inhabitants moved to new suburban developments, such as Al Rayyan, Madinat Khalifa and Al Gharafa. The metropolitan area's population grew from 89,000 in the 1970s to over 434,000 in 1997. Additionally, land policies resulted in the total land area increasing to over 7,100 hectares (about 17,000 acres) by 1995, an increase from 130 hectares in the middle of the 20th century.[52] In 1983, a hotel and conference center was developed at the north end of the Corniche. The 15-storey Sheraton hotel structure in this center would serve as the tallest structure in Doha until the 1990s.[52] In 1993, the Qatar Open became the first major sports event to be hosted in the city.[53] Two years later, Qatar stepped in to host the FIFA World Youth Championship, with all the matches being played in Doha-based stadiums.[54] Developments in Doha's West Bay district have seen an increase in the population density of the area with the construction of several high-rises. A view of a water feature in Sheraton Park with the West Bay skyline in the background. The Al Jazeera Arabic news channel began broadcasting from Doha in 1996.[55] In the late 1990s, the government planned the construction of Education City, a 2,500 hectare Doha-based complex mainly for educational institutes.[56] Since the start of the 21st century, Doha attained significant media attention due to the hosting of several global events and the inauguration of a number of architectural mega-projects.[57] One of the largest projects launched by the government was The Pearl-Qatar, an artificial island off the coast of West Bay, which launched its first district in 2004.[58] In 2006, Doha was selected to host the Asian Games, leading to the development of a 250-hectare sporting complex known as Aspire Zone.[53] During this time, new cultural attractions were constructed in the city, with older ones being restored. In 2006, the government launched a restoration program to preserve Souq Waqif's architectural and historical identity. Parts constructed after the 1950s were demolished whereas older structures were refurbished. The restoration was completed in 2008.[59] Katara Cultural Village was opened in the city in 2010 and has hosted the Doha Tribeca Film Festival since then.[60] The main outcome of the World Trade Organization Ministerial Conference of 2013 was the Trade Facilitation Agreement. The agreement aims to make it easier and cheaper to import and export by improving customs procedures and making rules more transparent. Reducing global trade costs by 1% would increase world-wide income more than USD 40 billion, 65% of which would go to developing countries. The gains from the Trade Facilitation Agreement are expected to be distributed among all countries and regions, with developing landlocked countries benefitting the most.[61] The Trade Facilitation Agreement will enter into force upon its ratification by 2/3 of WTO Members. The EU ratified the agreement in October 2015.[61] In Bali, WTO members also agreed on a series of Doha agriculture and development issues.[61] Geography[edit] See also: Geography of Qatar A view of Doha from the International Space Station in 2010 highlights the rapid development the city underwent since the discovery of oil in the 1960s. Doha is located on the central-east portion of Qatar, bordered by the Persian Gulf on its coast. Its elevation is 10 m (33 ft).[62] Doha is highly urbanized. Land reclamation off the coast has added 400 hectares of land and 30 km of coastline.[63] Half of the 22 km² of surface area which Hamad International Airport was constructed on was reclaimed land.[64] The geology of Doha is primarily composed of weathered unconformity on the top of the Eocene period Dammam Formation, forming dolomitic limestone.[65] The Pearl is a purpose-built artificial island off the coast of Doha, connected to the mainland by a bridge. The Pearl is an artificial island in Doha with a surface area of nearly 400 ha (1,000 acres)[66] The total project has been estimated to cost $15 billion upon completion.[67] Other islands off Doha's coast include Palm Tree Island, Shrao's Island, Al Safliya Island, and Alia Island.[68] In a 2010 survey of Doha's coastal waters conducted by the Qatar Statistics Authority, it was found that its maximum depth was 7.5 meters (25 ft) and minimum depth was 2 meters (6 ft 7 in). Furthermore, the waters had an average pH of 7.83, a salinity of 49.0 psu, an average temperature of 22.7 °C and 5.5 mg/L of dissolved oxygen.[69] Climate[edit] Doha has a hot desert climate (Köppen climate classification BWh) with long, extremely hot summers and short, warm winters. The average high temperatures between May and September surpass 38 °C (100 °F) and often approach 45 °C (113 °F). Humidity is usually the lowest in May and June. Dewpoints can surpass 30 °C (86 °F) in the summer. Throughout the summer, the city averages almost no precipitation, and less than 20 mm (0.79 in) during other months.[70] Rainfall is scarce, at a total of 75 mm (2.95 in) per year, falling on isolated days mostly between October to March. The winter's days are relativity warm while the sun is up and cool during the night. The temperature rarely drops below 7 °C (45 °F).[71] hideClimate data for Doha (1962–2013, extremes 1962–2013) Month Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year Record high °C (°F) 32.4(90.3) 36.5(97.7) 39.0(102.2) 46.0(114.8) 47.7(117.9) 49.1(120.4) 50.4(122.7) 48.6(119.5) 46.2(115.2) 43.4(110.1) 38.0(100.4) 32.7(90.9) 50.4(122.7) Average high °C (°F) 22.0(71.6) 23.4(74.1) 27.3(81.1) 32.5(90.5) 38.8(101.8) 41.6(106.9) 41.9(107.4) 40.9(105.6) 38.9(102.0) 35.4(95.7) 29.6(85.3) 24.4(75.9) 33.1(91.5) Daily mean °C (°F) 17.8(64.0) 18.9(66.0) 22.3(72.1) 27.1(80.8) 32.5(90.5) 35.1(95.2) 36.1(97.0) 35.5(95.9) 33.3(91.9) 30.0(86.0) 25.0(77.0) 20.0(68.0) 27.8(82.0) Average low °C (°F) 13.5(56.3) 14.4(57.9) 17.3(63.1) 21.4(70.5) 26.1(79.0) 28.5(83.3) 30.2(86.4) 30.0(86.0) 27.7(81.9) 24.6(76.3) 20.4(68.7) 15.6(60.1) 22.5(72.5) Record low °C (°F) 3.8(38.8) 5.0(41.0) 8.2(46.8) 10.5(50.9) 15.2(59.4) 21.0(69.8) 23.5(74.3) 22.4(72.3) 20.3(68.5) 16.6(61.9) 11.8(53.2) 6.4(43.5) 3.8(38.8) Average precipitation mm (inches) 13.2(0.52) 17.1(0.67) 16.1(0.63) 8.7(0.34) 3.6(0.14) 0.0(0.0) 0.0(0.0) 0.0(0.0) 0.0(0.0) 1.1(0.04) 3.3(0.13) 12.1(0.48) 75.2(2.95) Average precipitation days (≥ 1.0 mm) 1.7 2.1 1.8 1.4 0.2 0.0 0.0 0.0 0.0 0.1 0.2 1.3 8.8 Average relative humidity (%) 74 70 63 53 44 41 50 58 62 63 66 74 60 Mean monthly sunshine hours 244.9 224.0 241.8 273.0 325.5 342.0 325.5 328.6 306.0 303.8 276.0 241.8 3,432.9 Mean daily sunshine hours 7.9 8.0 7.8 9.1 10.5 11.4 10.5 10.6 10.2 9.8 9.2 7.8 9.4 Source 1: NOAA[71] Source 2: Qatar Meteorological Department (Climate Normals 1962–2013)[72] Doha mean sea temperature[73] Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 20.5 °C (68.9 °F) 19.1 °C (66.4 °F) 20.9 °C (69.6 °F) 23.7 °C (74.7 °F) 28.2 °C (82.8 °F) 30.9 °C (87.6 °F) 32.8 °C (91.0 °F) 33.9 °C (93.0 °F) 33.1 °C (91.6 °F) 31.0 °C (87.8 °F) 27.4 °C (81.3 °F) 23.1 °C (73.6 °F) Demographics[edit] See also: Demographics of Qatar Historical populationYearPop.±%1820[11]250—    1893[33]6,000+2300.0%1970[74]80,000+1233.3%1986[3] 217,294+171.6%1998[75] 264,009+21.5%2001[76] 299,300+13.4%2004[3] 339,847+13.5%2005[77][78] 400,051+17.7%2010[79] 796,947+99.2%2015[2] 956,457+20.0% Total population of the Doha metropolitan area[80] Year Metro population 1997 434,000[52] 2004 644,000[81] 2008 998,651[82] A significant portion of Qatar's population resides within the confines of Doha and its metropolitan area.[83] The district with the highest population density is the central area of Al Najada, which also accommodates the highest total population in the country. The population density across the greater Doha region ranges from 20,000 people per km² to 25 people per km².[84] Doha witnessed explosive growth rates in population in the first decade of the 21st century, absorbing the majority of the thousands of people then immigrating to Qatar every month.[85]:6 Doha's population currently stands at around one million, with the population of the city more than doubling from 2000 to 2010.[2] Ethnicity and languages[edit] The population of Doha is overwhelmingly composed of expatriates, with Qatari nationals forming a minority. The largest portion of expatriates in Qatar are from South-East and South Asian countries, mainly India, Pakistan, Sri Lanka, Nepal, Philippines, and Bangladesh with large numbers of expatriates also coming from the Levant Arab countries, North Africa, and East Asia. Doha is also home to many expatriates from Europe, North America, South Africa and Australia.[86] A typical bilingual traffic sign in Doha denotes the zone numbers, street names and street numbers of two perpendicular streets. Arabic is the official language of Qatar. English is commonly used as a second language,[87] and a rising lingua franca, especially in commerce.[88] As there is a large expatriate population in Doha, languages such as Malayalam, Tamil, Bengali, Tagalog, Spanish, Sinhala, French, Urdu and Hindi are widely spoken.[86] Registered live births in Doha by nationality[80][89] Year Qatari Non-Qatari Total 2001 2,080 3,619 5,699 2002 1,875 3,657 5,532 2003 2,172 4,027 6,199 2004 2,054 3,760 5,814 2005 1,767 3,899 5,666 2006 1,908 4,116 6,024 2007 1,913 4,708 6,621 2008 1,850 5,283 7,133 2009 2,141 5,979 8,120 2010[90] 1,671 5,919 7,590 2011[91] 1,859 6,580 8,439 In 2004, the Foreign Ownership of Real Estate Law was passed, permitting non-Qatari citizens to buy land in designated areas of Doha, including the West Bay Lagoon, the Qatar Pearl, and the new Lusail City.[57] Prior to this, expatriates were prohibited from owning land in Qatar. Ownership by foreigners in Qatar entitles them to a renewable residency permit, which allows them to live and work in Qatar.[83] Religion[edit] Main article: Religion in Qatar The majority of residents in Doha are Muslim.[92] Catholics account for over 90% of the 150,000 Christian population in Doha.[93] Following decrees by the Emir for the allocation of land to churches, the first Catholic church, Our Lady of the Rosary, was opened in Doha in March 2008. The church structure is discreet and Christian symbols are not displayed on the outside of the building.[94] Several other churches exist in Doha, including the [1] St.Isaac and St. George Greek Orthodox Church of Qatar the Syro-Malabar Church, Malankara Orthodox Church, Mar Thoma Church (affiliated with the Anglicans, but not part of the Communion), CSI Church, Syro-Malankara Church and a Pentecostal church. A majority of mosques are either Muwahhid or Sunni-oriented.[95] Administration[edit] Districts[edit] Main article: List of communities in Doha At the turn of the 20th century, Doha was divided into 9 main districts.[96] In the 2010 census, there were more than 60 districts recorded in Doha Municipality.[97] Some of the districts of Doha include: Qatar's Central Bank is situated in the Al Souq district, close to the waterfront. Al Bidda (البدع) Al Dafna (الدفنة) Al Ghanim (الغانم) Al Markhiya (المرخية) Al Sadd (السد) Al Waab (الوعب) Bin Mahmoud (فريج بن محمود) Madinat Khalifa (مدينة خليفة) Musheireb (مشيرب) Najma (نجمه) Old Airport (المطار القديم) Qutaifiya (القطيفية) Ras Abu Aboud (راس أبو عبود) Rumeilah (الرميلة) Umm Ghuwailina (ام غو يلينه) West Bay (الخليج الغربي) Shortly after Qatar gained independence, many of the districts of old Doha including Al Najada, Al Asmakh and Old Al Hitmi faced gradual decline and as a result much of their historical architecture has been demolished.[98] Instead, the government shifted their focus toward the Doha Bay area, which housed districts such as Al Dafna and West Bay.[98] Economy[edit] See also: Economy of Qatar West Bay serves as the commercial district of Doha and houses offices of many local and global companies. Doha is the economic centre of Qatar. The city is the headquarters of numerous domestic and international organizations, including the country's largest oil and gas companies, Qatar Petroleum, Qatargas and RasGas. Doha's economy is built primarily on the revenue the country has made from its oil and natural gas industries.[99] Doha was included in Fortune's 15 best new cities for business in 2011.[100] Beginning in the late 20th century, the government launched numerous initiatives to diversify the country's economy in order to decrease its dependence on oil and gas resources. Doha International Airport was constructed in a bid to solidify the city's diversification into the tourism industry.[99] This was replaced by Hamad International Airport in 2014. The new airport is almost twice the size of the former and features two of the longest runways in the world.[101] Thirty-nine new hotels were under construction in the city in 2011.[102] Qatar Airways aircraft on the apron of Hamad International Airport As a result of Doha's rapid population boom and increased housing demands, real estate prices rose significantly through 2014.[103] Real estate prices experienced a further spike after Qatar won the rights to host the 2022 FIFA World Cup.[104] Al Asmakh, a Qatari real estate firm, released a report in 2014 which revealed substantial increases in real estate prices following a peak in 2008. Prices increased 5 to 10% in the first quarter of 2014 from the end of 2013.[103][105] A 2015 study conducted by Numbeo, a crowd-sourced database, named Doha as the 10th most expensive city to live in globally.[106] This rate of growth led to the development of planned communities in and around the city.[107] Although the fall in oil prices since 2014 and a diplomatic crisis with Qatar's neighbors slowed growth in the city's population, government spending was increased to maintain the growth in real estate in metropolitan Doha.[108] Expatriate workers remitted $60bn between 2006 and 2012, with 54 percent of the workers' remittances of $60bn routed to Asian countries, followed by Arab nations that accounted for nearly half that volume (28 percent). India was the top destination of the remittances, followed by the Philippines, while the US, Egypt and the neighbouring UAE followed.[109] Remittances in 2014 totaled $11.2 billion, amounting to 5.3% of Qatar's GDP.[110]:45 Infrastructure[edit] See also: List of tallest buildings in Qatar Architecture[edit] Museum of Islamic Art park in the Doha Port area with the West Bay district in the background (across the bay) Most traditional architecture in the Old Doha districts have been demolished to make space for new buildings.[98] As a result, a number of schemes have been taken to preserve the city's cultural and architectural heritage, such as the Qatar Museums Authority's 'Al Turath al Hai' ('living heritage') initiative.[111] Katara Cultural Village is a small village in Doha launched by sheikh Tamim Al Thani to preserve the cultural identity of the country.[112] Doha's Al Dafna area with the high-rises seen on the water front and the villa compounds and other residential areas seen in the background In 2011, more than 50 towers were under construction in Doha,[102] the largest of which was the Doha Convention Center Tower.[113] Constructions were suspended in 2012 following concerns that the tower would impede flight traffic.[114] In 2014, Abdullah Al Attiyah, a senior government official, announced that Qatar would be spending $65bn on new infrastructure projects in upcoming years in preparation for the 2022 World Cup as well as progressing towards its objectives set out in the Qatar National Vision 2030.[115] Atmosphere[edit] Due to excessive heat from the sun during the summer, some Doha-based building companies have implemented various forms of cooling technology to alleviate the extremely torrid climatic conditions. This can include creating optical phenomena such as shadows, as well as more expensive techniques like ventilation, coolants, refrigerants, cryogenics, and dehumidifiers.[116] Discussions regarding temperature control have also been features of various scheduled events involving large crowds.[117] There are other initiatives that attempt to counter the heat by altering working hours, weather alteration methods such as cloud seeding,[118][119] and using whiter and brighter construction materials to increase the albedo effects.[120] Nonetheless, despite these measures, Doha and other areas of Qatar could become uninhabitable for humans due to climate change by the 2070s.[121] Planned communities[edit] One of the largest projects underway in Qatar is Lusail City, a planned community north of Doha which is estimated to be completed by 2020 at a cost of approximately $45bn. It is designed to accommodate 450,000 people.[122] Al Waab City, another planned community under development, is estimated to cost QR15 bn.[123] In addition to housing 8,000 individuals, it will also have shopping malls, educational, and medical facilities.[123] Transportation[edit] Main article: Transportation in Doha Since 2004, Doha has been undergoing a huge expansion to its transportation network, including the addition of new highways, the opening of a new airport in 2014, and the currently ongoing construction of an 85 km metro system. This has all been as a result of Doha's massive growth in a short period of time, which has resulted in congestion on its roads. The first phase of the metro system is expected to be operational by 2019.[124] Roads[edit] Dukhan Highway connects the city of Dukhan on the West coast of the country with the country's capital, Doha. In 2015, the Public Works Authority declared their plan to construct a free-flowing road directly linking Al-Wakrah and Mesaieed to Doha in order to decrease traffic congestion in the city. It is set for completion by 2018.[125] Commutes between Doha and the municipality of Al Khor are currently facilitated by Al Shamal Road and Al Khor Coastal Road, with the latter road running through Al Daayen and the former running through Umm Salal.[126] Doha is linked to the country's western settlements, namely Dukhan, through Dukhan Highway. The Public Works Authority carried out the Dukhan Highway Central Project in 2017 to enhance the road network.[127] Rail[edit] Doha Metro will consist of four lines: the Red Line, the Gold Line, the Blue Line and the Green Line. The Blue Line is expected to be completed in the second phase.[128] Msheireb Station will be the point of intersection for all of the metro lines.[124] Doha International Airport The Red Line (also known as Coast Line) will extend through Doha, running from Al Wakrah to Al Khor. It is separated into two divisions: Red Line North and Red Line South. The former will run from Mushayrib Station to Al Khor City, over a length of 55.7 km. Doha Metro's Green Line will connect Doha to Education City and is also known as the Education Line. Starting in Old Airport, the Gold Line (also known as Historic Line) will end in Al Rayyan and cover a distance of 30.6 km. Lastly, the Blue Line, or City Line, will only cover the city of Doha, and is planned to be circular with a length of 17.5 km.[129] Air[edit] Doha is served by Hamad International Airport which is Qatar's principal international gateway. The airport opened in 2014, replacing Doha International Airport. Education[edit] See also: Education in Qatar, Education City, and List of schools in Qatar Stone steps at Carnegie Mellon University in Qatar, located in Education City Doha is the educational center of the country and contains the highest preponderance of schools and colleges.[74] In 1952, the first formal boys' school was opened in Doha. This was proceeded by the opening of the first formal girls' school three years later.[130] The first university in the state, Qatar University, was opened in 1973.[131] It provided separate faculties for men and women.[132] Education City, a 14 km2 education complex launched by non-profit organization Qatar Foundation, began construction in 2000.[133] It houses eight universities, the country's top high school, and offices for Al Jazeera's children television channel.[133] It is geographically located in Al Rayyan municipality's Al Luqta, Al Gharrafa, Gharrafat Al Rayyan and Al Shagub districts, but falls under the umbrella of Metropolitan Doha.[6] In 2009, the government launched the World Innovation Summit for Education (WISE), a global forum that brings together education stakeholders, opinion leaders and decision makers from all over the world to discuss educational issues.[134] The first edition was held in Doha in November 2009.[135] Some of the universities in Doha include: Carnegie Mellon University in Qatar Georgetown University School of Foreign Service in Qatar Hamad Bin Khalifa University Cornell University[136] HEC Paris Northwestern University in Qatar Texas A&M University at Qatar UCL Qatar[137] Virginia Commonwealth University Weill Cornell Medical College in Qatar Stenden University Qatar College of the North Atlantic Qatar University Qatar Faculty of Islamic Studies University of Calgary Sports[edit] Main article: Sport in Qatar Football[edit] Al Sadd is the most successful team in the Qatar Stars League See also: List of football stadiums in Qatar Football is the most popular sport in Doha. There are six Doha-based sports clubs with football teams currently competing in the Qatar Stars League, the country's top football league. They are Al Ahli, Al Arabi, Al Sadd, Al-Duhail and Qatar SC.[138] Al Sadd, Al Arabi and Qatar SC are the three most successful teams in the league's history.[139] Numerous football tournaments have been hosted in Doha. The most prestigious tournaments include the 1988 and 2011 editions of the AFC Asian Cup[140] and the 1995 FIFA World Youth Championship.[54] In December 2010, Qatar won the rights to host the 2022 FIFA World Cup.[141] Three of the nine newly announced stadiums will be constructed in Doha, including Sports City Stadium, Doha Port Stadium, and Qatar University Stadium. Additionally, the Khalifa International Stadium is set to undergo an expansion.[142] Considering the country's rapid development for 2022 World Cup, FIFA awarded the hosting rights of 2019 FIFA Club World Cup and 2020 FIFA Club World Cup also to Qatar.[143] Basketball[edit] Doha was the host of the official 2005 FIBA Asia Championship, where Qatar's national basketball team finished 3rd, its best performance to date, and subsequently qualified for the Basketball World Cup.[144] The majority of the teams that make up the official Qatari Basketball League are based in Doha. Volleyball[edit] Doha four times was the host of the official FIVB Volleyball Men's Club World Championship and three times host FIVB Volleyball Women's Club World Championship. Doha one time Host Asian Volleyball Championship.[145] Other sports[edit] Orry the Oryx, mascot of the 15th Asian Games, on the Doha Corniche in 2014 In 2001, Qatar became the first country in the Middle East to hold a women's tennis tournament with the inauguration of its Qatar Ladies Open tournament.[146] Doha also hosts International Tennis Federation (ITF) ladies tournaments. Since 2008, the Sony Ericsson Championships (equivalent to the ATP's season-ending Championships) has taken place in Doha, in the Khalifa International Tennis Complex, and features record prize money of $4.45 million, including a check of $1,485,000 for the winner, which represents the largest single guaranteed payout in women's tennis.[147] Doha hosted the 15th Asian Games, held in December 2006, spending a total of $2.8 billion for its preparation.[148] The city also hosted the 3rd West Asian Games in December 2005.[149] Doha was expected to host the 2011 Asian Indoor Games; but the Qatar Olympic Committee cancelled the event.[150] Powerboat races in Doha Bay The city submitted a bid for the 2016 Olympics.[151] On June 4, 2008, the city was eliminated from the shortlist for the 2016 Olympic Games. On August 26, 2011 it was confirmed that Doha would bid for the 2020 Summer Olympics.[152] Doha however failed to become a Candidate City for the 2020 Games.[153] The MotoGP motorcycling grand prix of Doha is held annually at Losail International Circuit, located just outside the city boundaries.[154] The city is also the location of the Grand Prix of Qatar for the F1 Powerboat World Championship, annually hosting a round in Doha Bay.[155] Beginning in November 2009, Doha has been host of The Oryx Cup World Championship, a hydroplane boat race in the H1 Unlimited season. The races take place in Doha Bay.[156] In April 2012 Doha was awarded both the 2014 FINA World Swimming Championships[157] and the 2012 World Squash Championships.[158] The fourth World Mindsports Championships took place in Doha from August 19 to August 27, 2017 with the participation of more than 1,000 competitors.[159] In 2014, Qatar was selected as the host of the 2019 World Athletics Championships, which is the seventeenth edition of the IAAF World Athletics Championships.[160] Doha won the bid to host the event over Barcelona and Eugene.[161] In 2020, Doha hosted the Qatar ExxonMobil Open, which received the Tournament of the Year award in the 250 category from the 2019 ATP Awards. The tournament won the award for the third time in five years.[162] Stadiums and sport complexes[edit] An indoor stadium in the Aspire Zone sporting complex Aspire Academy was launched in 2004 with the aim of creating world-class athletes. It is situated in the Doha Sports City Complex, which also accommodates the Khalifa International Stadium, the Hamad Aquatic Centre, the Aspire Tower and the Aspire Dome. The latter has hosted more than 50 sporting events since its inception, including some events during the 2006 Asian Games.[163] Sporting venues in Doha and its suburbs include: Hamad bin Khalifa Stadium – Al-Ahli Stadium Jassim Bin Hamad Stadium (Al Sadd Stadium) Al-Arabi Stadium – Grand Hamad Stadium Hamad Aquatic Centre Khalifa International Stadium – Main venue for the 2006 Asian Games. Khalifa International Tennis and Squash Complex Qatar Sports Club Stadium Culture[edit] Main article: Culture of Qatar Doha was chosen as the Arab Capital of Culture in 2010.[164] Cultural weeks organized by the Ministry of Culture, which featured both Arab and non-Arab cultures, were held in Doha from April to June to celebrate the city's selection.[165] Arts[edit] Main article: Qatari art Further information: Public art in Qatar and Collecting practices of the Al-Thani Family The five-storeyed Museum of Islamic Art designed by Pritzker Prize-winning architect I. M. Pei[166] The Museum of Islamic Art in Doha, opened in 2008, is regarded as one of the best museums in the region.[167] This, and several other Qatari museums located in the city, like the Arab Museum of Modern Art, falls under the Qatar Museums Authority (QMA) which is led by Sheikha Al-Mayassa bint Hamad bin Khalifa Al-Thani, the sister of the emir of Qatar.[168] The National Museum of Qatar, which was constructed in place of the original Qatar National Museum, opened to the public on 28 March 2019. Cinema[edit] Main article: Cinema of Qatar The Doha Film Institute (DFI) is an organisation established in 2010 to oversee film initiatives and create a sustainable film industry in Qatar. DFI was founded by H.E. Sheikha Al Mayassa bint Hamad bin Khalifa Al-Thani.[169] The Doha Tribeca Film Festival (DTFF), partnered with the American-based Tribeca Film Festival, was held annually in Doha from 2009 to 2012.[170] Media[edit] Main article: Media of Qatar See also: Television in Qatar Al Jazeera Arabic Building Qatar's first radio station, Mosque Radio, began broadcasting in the 1960s from Doha.[171] The multinational media conglomerate Al Jazeera Media Network is based in Doha with its wide variety of channels of which Al Jazeera Arabic, Al Jazeera English, Al Jazeera Documentary Channel, Al Jazeera Mubasher, beIN Sports Arabia and other operations are based in the TV Roundabout in the city.[172] Al-Kass Sports Channel's headquarters is also located in Doha.[173] Theatre[edit] Main article: Theatre in Qatar Theatre was introduced to Qatar in the mid-20th century. Theatrical performances are held at Qatar National Theater and at the Qatar National Convention Centre in Doha. International relations[edit] Algeirs, Algeria (since 2013)[174] Sarajevo, Bosnia and Herzegovina (since 2018)[175] Brasília, Brazil (since 2014)[176] Sofia, Bulgaria (since 2012)[177] Beijing, China (since 2008)[178] Alameda, California (since 2004)[179] San Salvador, El Salvador (since 2018)[180] Banjul, Gambia (since 2011)[181] Tbilisi, Georgia (since 2012)[182] Nur-Sultan, Kazakhstan (since 2011)[183] Bishkek, Kyrgyzstan (since 2018)[184] Port Louis, Mauritius (since 2007)[185] Mogadishu, Somalia (since 2014)[186] Tunis, Tunisia (since 1994)[187] Ankara, Turkey (since 2016)[188] Los Angeles, California, United States (since 2016)[189] Miami, Florida, United States (since 2016)[190] Libertador, Venezuela (since 2015)[191] Beit Sahour, Palestine (since 2009)[192] Gallery[edit] Click on the thumbnail to enlarge. Skyline of Doha West Bay from Sheraton Park. The spring festival at Souq Waqif, Doha An old mosque minaret stands out in front of the under-construction National Archive building in the Diwan Amiri Quarter of the Musheireb downtown Doha development. Qatar's Amir (ruler) is housed in the Amiri Diwan located in the historic Al Bidda district. These twin towers are among the earliest towers in Doha and serve as a great example of post-modern architecture. Msheireb Enrichment Centre moored off Doha Corniche is a learning center focused on the history and developments of Doha, particularly the Musheirib district. Aspire Park, Al Waab is one of the city's green spaces that forms a part of the Aspire zone. Doha skyline from the Museum of Islamic Art. Doha skyline at night. Doha Corniche is the 7 km long water front that connects the new district of West Bay with the old district of Al-Bidda and Al-Souq on the other end. Aerial view of a part of the city. The Katara cultural village is designed to be a hub of human interaction connecting theatre, literature, music, visual art, conventions and exhibitions in a planned development on the waterfront.[193] The post office building in Qatar sits located on the main Corniche street. See also[edit] Doha Declaration Doha Development Round of World Trade Organization (WTO) talks Qatar National Day which is held in Doha every year on December 18 References[edit] ^ "Doha municipality accounts for 40% of Qatar population". Gulf Times. 20 October 2015. Retrieved 23 October 2015..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png");background-image:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg");background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png");background-image:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg");background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png");background-image:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg");background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png");background-image:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg");background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit} ^ Jump up to: a b c The Report: Qatar 2016. Oxford Business Group. 2016. p. 17. ISBN 9781910068632. ^ Jump up to: a b c d Encyclopædia Britannica. "Doha – Britannica Online Encyclopedia". Britannica.com. Retrieved 2010-06-27. ^ "Welcome to the 20th World Petroleum Congress". 20wpc.com. Retrieved 2013-07-29. ^ Saraiva, Alexia. "Get To Know The 8 2022 Qatar World Cup Stadiums". ArchDaily. ^ Jump up to: a b "District map". The Centre for Geographic Information Systems of Qatar. Retrieved 29 May 2018. ^ Jump up to: a b "Historical references to Doha and Bidda before 1850" (PDF). The Origins of Doha Project. p. 1. Retrieved 19 May 2015. ^ Billecocq, Xavier Beguin (2003). Le Qatar et les Français: cinq siècles de récits de voyage et de textes d'érudition. Collection Relations Internationales & Culture. ISBN 9782915273007. ^ Rahman, Habibur (2006). The Emergence Of Qatar. Routledge. p. 34. ISBN 978-0710312136. ^ Carter, Robert. "Origins of Doha Season 1 Archive Report". academia.edu. p. 11. Retrieved 13 March 2015. ^ Jump up to: a b c "Historical references to Doha and Bidda before 1850" (PDF). The Origins of Doha Project. p. 2. Retrieved 19 May 2015. ^ Al-Qasimi, Sultan Mohammed (1995). The journals of David Seton in the Gulf 1800-1809. Exeter University Press. ^ H. Rahman (2006), p. 36. ^ Jump up to: a b c Toth, Anthony. "Qatar: Historical Background." A Country Study: Qatar (Helen Chapin Metz, editor). Library of Congress Federal Research Division (January 1993). This article incorporates text from this source, which is in the public domain. ^ "Historical references to Doha and Bidda before 1850" (PDF). The Origins of Doha Project. p. 3. Retrieved 19 May 2015. ^ "'Gazetteer of the Persian Gulf. Vol I. Historical. Part IA & IB. J G Lorimer. 1915' [793] (948/1782)". qdl.qa. Retrieved 28 January 2015. ^ Jump up to: a b c "Historical references to Doha and Bidda before 1850" (PDF). The Origins of Doha Project. p. 4. Retrieved 19 May 2015. ^ H. Rahman (2006), p. 63. ^ "Historical references to Doha and Bidda before 1850" (PDF). The Origins of Doha Project. p. 5. Retrieved 19 May 2015. ^ Brucks, G. B. (1985). Memoir descriptive of the Navigation of the Gulf of Persia in R. H. Thomas (ed.) Selections from the records of the Bombay Government No XXIV (1829). New York: Oleander press. ^ Zahlan, Rosemarie Said (1979). The creation of Qatar (print ed.). Barnes & Noble Books. p. 33. ISBN 978-0064979658. ^ "'Gazetteer of the Persian Gulf. Vol I. Historical. Part IA & IB. J G Lorimer. 1915' [794] (949/1782)". qdl.qa. Retrieved 28 January 2015. ^ Jump up to: a b "Historical references to Doha and Bidda before 1850" (PDF). The Origins of Doha Project. pp. 5–6. Retrieved 19 May 2015. ^ H. Rahman (2006), pp. 90–92. ^ Jump up to: a b "Historical references to Doha and Bidda before 1850" (PDF). The Origins of Doha Project. p. 6. Retrieved 19 May 2015. ^ Jump up to: a b "Historical references to Doha and Bidda before 1850" (PDF). The Origins of Doha Project. p. 7. Retrieved 19 May 2015. ^ "Line of succession: The Al Thani rule in Qatar". Gulf News. 27 June 2013. Retrieved 14 June 2015. ^ "'A collection of treaties, engagements and sanads relating to India and neighbouring countries [...] Vol XI containing the treaties, & c., relating to Aden and the south western coast of Arabia, the Arab principalities in the Persian Gulf, Muscat (Oman), Baluchistan and the North-West Frontier Province' [113v] (235/822)". Qatar Digital Library. Retrieved 12 January 2015. ^ "'File 19/243 IV Zubarah' [8r] (15/322)". Qatar Digital Library. Retrieved 12 January 2015. ^ "'Gazetteer of the Persian Gulf. Vol I. Historical. Part IA & IB. J G Lorimer. 1915' [801] (956/1782)". Qatar Digital Library. Retrieved 14 June 2015. ^ H. Rahman (2006), p. 123. ^ H. Rahman (2006), pp. 138–139. ^ Jump up to: a b c Kurşun, Zekeriya (2002). The Ottomans in Qatar : a history of Anglo-Ottoman conflicts in the Persian Gulf. Istanbul : Isis Press. pp. 16–17. ISBN 9789754282139. ^ Zahlan, Rosemarie Said (1979). The creation of Qatar (print ed.). Barnes & Noble Books. p. 53. ISBN 978-0064979658. ^ H. Rahman (2006), p. 152. ^ "Historical references to Doha and Bidda before 1850" (PDF). The Origins of Doha Project. p. 11. Retrieved 19 May 2015. ^ Jump up to: a b Florian Wiedmann, Ashraf M. Salama, Alain Thierstein. "Urban evolution of the city of Doha: an investigation into the impact of economic transformations on urban structures" (PDF). p. 38. Retrieved 14 June 2015.CS1 maint: uses authors parameter (link) ^ Jump up to: a b Althani, Mohamed (2013). Jassim the Leader: Founder of Qatar. Profile Books. p. 35. ISBN 978-1781250709. ^ Casey, Paula; Vine, Peter (1991). The heritage of Qatar (print ed.). Immel Publishing. pp. 49–50. ISBN 978-0907151500. ^ "'Gazetteer of the Persian Gulf. Vol. II. Geographical and Statistical. J G Lorimer. 1908' [487] (536/2084)". Qatar Digital Library. Retrieved 14 January 2019. This article incorporates text from this source, which is in the public domain. ^ "'Gazetteer of the Persian Gulf. Vol. II. Geographical and Statistical. J G Lorimer. 1908' [488] (537/2084)". Qatar Digital Library. Retrieved 14 January 2019. ^ Jump up to: a b "'Gazetteer of the Persian Gulf. Vol. II. Geographical and Statistical. J G Lorimer. 1908' [489] (540/2084)". Qatar Digital Library. Retrieved 14 January 2019. This article incorporates text from this source, which is in the public domain. ^ M. Althani (2013), p, 134. ^ H. Rahman (2006), p. 291. ^ "Historical references to Doha and Bidda before 1850" (PDF). The Origins of Doha Project. p. 16. Retrieved 19 May 2015. ^ "Pearl Diving in Qatar". USA Today. Retrieved 14 June 2015. ^ Abu Saud, Abeer (1984). Qatari Women: Past and Present. Longman Group. p. 173. ISBN 978-0582783720. ^ "Qatar in perspective: an orientation guide" (PDF). Defense League Institute Foreign Language Center. 2010. p. 8. Archived from the original (PDF) on 2012-12-10. Retrieved 2015-06-15. ^ Florian Wiedmann, Ashraf M. Salama, Alain Thierstein. "Urban evolution of the city of Doha: an investigation into the impact of economic transformations on urban structures" (PDF). p. 41. Retrieved 14 June 2015.CS1 maint: uses authors parameter (link) ^ "Our history". Qatar University. Retrieved 14 June 2015. ^ "Qatar's National Museum eyeing 2016 opening". Doha News. 6 July 2014. Retrieved 14 June 2015. ^ Jump up to: a b c Florian Wiedmann, Ashraf M. Salama, Alain Thierstein. "Urban evolution of the city of Doha: an investigation into the impact of economic transformations on urban structures" (PDF). pp. 44–45. Retrieved 14 June 2015.CS1 maint: uses authors parameter (link) ^ Jump up to: a b Florian Wiedmann, Ashraf M. Salama, Alain Thierstein. "Urban evolution of the city of Doha: an investigation into the impact of economic transformations on urban structures" (PDF). p. 47. Retrieved 14 June 2015.CS1 maint: uses authors parameter (link) ^ Jump up to: a b "FIFA World Youth Championship Qatar 1995 – matches". FIFA. Retrieved 14 June 2015. ^ "AL JAZEERA TV: The History of the Controversial Middle East News Station Arabic News Satellite Channel History of the Controversial Station". Allied-media. Retrieved 14 June 2015. ^ Florian Wiedmann, Ashraf M. Salama, Alain Thierstein. "Urban evolution of the city of Doha: an investigation into the impact of economic transformations on urban structures" (PDF). p. 49. Retrieved 14 June 2015.CS1 maint: uses authors parameter (link) ^ Jump up to: a b Wiedmann, Florian; Salama, Ashraf M (2013). Demystifying Doha: On Architecture and Urbanism in an Emerging City. Ashgate. ISBN 9781409466345. ^ Khalil Hanware (21 March 2005). "Pearl-Qatar Towers Lure International Investors". Arab News. Jeddah. Retrieved 11 October 2015. ^ Exell, Karen; Rico, Trinidad (2014). Cultural Heritage in the Arabian Peninsula: Debates, Discourses and Practices. Ashgate. p. 199. ISBN 978-1-4094-7009-0. ^ Elspeth Black. "Katara: The Cultural Village". The Culture Trip. Retrieved 14 June 2015. ^ Jump up to: a b c "Doha Development Agenda - Trade - European Commission". ec.europa.eu. Retrieved 16 October 2019. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License. ^ "Map of Doha, Qatar". Climatemps.com. Retrieved 15 June 2015. ^ "New land by the sea: Economically and socially, land reclamation pays" (PDF). International Association of Dredging Companies. p. 4. Retrieved 15 June 2015. ^ "DEME: Doha Airport Built on Reclaimed Land Becomes Fully Operational". Dredging Today. 3 June 2014. Retrieved 15 June 2015. ^ Ed Blinkhorn (April 2015). "Geophysical GPR Survey" (PDF). The Origins of Doha Project. Retrieved 15 June 2015. ^ Ron Gluckman (May 2008). "Artificial Islands: In Dubai, a world, and universe of new real estate". Gluckman. Retrieved 15 June 2015. ^ "Say Hello To Pearl Qatar – The World's Most Luxurious Artificial Island". Wonderful Engineering. Retrieved 15 June 2015. ^ "Qatar islands". Online Qatar. Archived from the original on 18 November 2015. Retrieved 15 June 2015. ^ "Qatar Infrastructure Statistics" (PDF). Qatar Statistics Authority. May 2012. p. 29. Retrieved 18 March 2019. ^ "Doha weather information". Wunderground.com. 2010-06-10. Retrieved 2010-06-27. ^ Jump up to: a b "Doha International Airport Climate Normals 1962-1992". National Oceanic and Atmospheric Administration. Retrieved September 29, 2016. ^ "Climate Information For Doha". Qatar Meteorological Department. Retrieved November 27, 2016. ^ "Monthly Doha water temperature chart". Seatemperatures.org. Retrieved 2014-01-20. ^ Jump up to: a b Abdulla Juma Kobaisi. "The Development of Education in Qatar, 1950–1970" (PDF). Durham University. p. 11. Retrieved 17 June 2015. ^ Hassan Khayat, Ismail Amer, Saleh Arifi, Ahmed Babaker, Bassam Nasr, Nizam Shafei, Fatimah Al Kuwari, Ali Ibrahim Sheib, Mohammed Khazemi, Nasser Fakhro, Mohammed Al Kuwari (1998). "موسوعة المعلومات القطرية (Qatar Information Encyclopedia)" (in Arabic). Qatar University. p. 235.CS1 maint: uses authors parameter (link) ^ "Doha". Tiscali.co.uk. 1984-02-21. Archived from the original on 2009-11-05. Retrieved 2010-06-27. ^ "Sheraton Doha Hotel & Resort | Hotel discount bookings in Qatar". Hotelrentalgroup.com. Archived from the original on 2010-08-19. Retrieved 2010-06-27. ^ "hotelsdoha.eu". hotelsdoha.eu. Archived from the original on 2013-06-09. Retrieved 2013-03-26. ^ "Qatar population statistics". geohive.com. Archived from the original on 14 June 2015. Retrieved 15 June 2015. ^ Jump up to: a b "Population statistics". Qatar Information Exchange. Archived from the original on 1 July 2015. Retrieved 15 June 2015. ^ World and Its Peoples. Marshall Cavendish. 2006. p. 61. ISBN 9780761475712. ^ "Doha 2016 Summer Olympic Games Bid". GamesBids.com. Archived from the original on 2010-07-04. Retrieved 2010-06-27. ^ Jump up to: a b Marco Dilenge. "Dubai and Doha: Unparalleled Expansion" (PDF). Crown Records Management UK. Retrieved 15 June 2015. ^ "Facts and figures". lusail.com. Retrieved 15 June 2015. ^ De Bel-Air, Françoise (2017). Demography, Migration, and the Labour Market in Qatar (PDF) (Report). European University Institute and the Gulf Research Center. GLMM - EN - No. 3/2017. Archived (PDF) from the original on 2019-12-28. Retrieved 2020-03-21. ^ Jump up to: a b Humaira Tasnim, Abhay Valiyaveettil, Dr. Ingmar Weber, Venkata Kiran Garimella. "Socio-geographic map of Doha". Qatar Computing Research Institute. Archived from the original on 5 March 2016. Retrieved 15 June 2015.CS1 maint: uses authors parameter (link) ^ Baker, Colin; Jones, Sylvia Prys (1998). Encyclopedia of Bilingualism and Bilingual Education. Multilingual Matters. p. 429. ISBN 978-1853593628. ^ Guttenplan, D. D. (11 June 2012). "Battling to Preserve Arabic From English's Onslaught". The New York Times. Retrieved 24 November 2013. ^ "WELCOME TO Qatar Statistics Authority WEBSITE :". Qsa.gov.qa. Archived from the original on 2008-08-21. Retrieved 2013-03-26. ^ "Births and deaths in 2010" (PDF). Qatar Information Exchange. Qatar Statistics Authority. Archived from the original (PDF) on 9 May 2015. Retrieved 3 May 2015. ^ "Births and deaths in 2011" (PDF). Qatar Information Exchange. Qatar Statistics Authority. Archived from the original (PDF) on 23 September 2016. Retrieved 3 May 2015. ^ "Religious demography of Qatar" (PDF). US Department of State. Retrieved 15 June 2015. ^ Shabina Khatri (20 June 2008). "Qatar opens first church, quietly". Al Jazeera. Retrieved 15 June 2015. ^ Sonia Verma (14 March 2008). "Qatar hosts its first Christian church". The Times. Retrieved 15 June 2015. ^ Oman Economic and Development Strategy Handbook, International Business Publications, USA - 2009, page 40 ^ Jaidah, Ibrahim; Bourennane, Malika (2010). The History of Qatari Architecture 1800-1950. Skira. p. 25. ISBN 978-8861307933. ^ "Census 2010". Qatar Statistics Authority. 2010. Archived from the original on 9 July 2010. Retrieved 2013-07-25. ^ Jump up to: a b c Djamel Bouassa. "Al Asmakh historic district in Doha, Qatar: from an urban slum to living heritage". Academia.edu. Retrieved 10 July 2015. ^ Jump up to: a b Michael Dumper, Bruce E. Stanley (2006). Cities of the Middle East and North Africa: A Historical Encyclopedia. ABC-CLIO. p. 138. ISBN 978-1576079195.CS1 maint: uses authors parameter (link) ^ Dawsey, Josh; Arora, Rupali. "Global 500 2011: 15 best new cities for business". CNN Money (Interactive map requiring Adobe Flash Player.). Retrieved 2013-03-26. ^ Marco Rinaldi (5 May 2014). "Hamad International Airport by Hok". aasarchitecture.com. Retrieved 10 July 2015. ^ Jump up to: a b Bullivant, Lucy (2012). Masterplanning Futures. Routledge. p. 59. ISBN 978-0415554473. ^ Jump up to: a b Peter Kovessy (23 June 2014). "Reports: Housing supply not keeping up with population rise". Doha News. Retrieved 10 July 2015. ^ Rohan Soman (13 May 2013). "Real estate prices in Qatar skyrocket". BQ Doha. Archived from the original on 12 July 2015. Retrieved 10 July 2015. ^ "Qatar Real Estate Report Q1 2014" (PDF). Al Asmakh Real Estate Firm. 2014. Archived from the original (PDF) on 22 March 2015. Retrieved 10 July 2015. ^ Neha Batia (5 July 2015). "Doha city rents are world's tenth most expensive". Construction Week Online. Retrieved 10 July 2015. ^ "Falling oil prices and real estate markets". BQ Doha. 10 March 2015. Archived from the original on 12 July 2015. Retrieved 10 July 2015. ^ Kerr, Simeon (17 October 2019). "Qatar pins growth hopes on domestic renewal". Financial Times. Retrieved 2020-03-21. ^ "Expatriates Remit $60bn in 7 years". Archived from the original on 2013-06-16. Retrieved 2013-05-06. ^ World Bank Group (2016). Migration and Remittances Factbook 2016 (3rd ed.). World Bank. doi:10.1596/978-1-4648-0319-2. ISBN 9781464803208. ^ "The Winners of the Old Doha Prize Competition Announced". Marhaba. 26 November 2013. Retrieved 10 July 2015. ^ "About us". Katara. Archived from the original on 22 July 2015. Retrieved 17 July 2015. ^ "The World's Tallest Buildings". Bloomberg. 2010. Retrieved 10 July 2015. ^ "Flight concerns stop 550m Doha tower development". Construction Week Online. 31 January 2012. Retrieved 10 July 2015. ^ "Doha rolling out the dough for Qatar infrastructure, set to launch new projects worth $65 billion". Al Bawaba. 17 March 2014. Retrieved 17 July 2015. ^ Air Conditioning: A Practical Introduction - Page 106, David V. Chadderton - 2014 ^ The Report: Qatar 2012 - Page 187, Oxford Business Group ^ Red Sea and the Persian Gulf - Page 237, 2007 ^ Sixth Conference on Planned and Inadvertent Weather Modification, p 307, 1977 ^ Hegazy, Ahmed (2016). Plant Ecology in the Middle East. p. 205. ^ "Qatar Could Become Too Hot for Humans Just 50 Years After the 2022 World Cup". Inverse.com. Retrieved 12 August 2018. ^ Tony Manfred (22 September 2014). "Qatar Is Building A $45 Billion City From Scratch For The World Cup That It Might Lose". Business Insider. Retrieved 17 July 2015. ^ Jump up to: a b "Al Waab City Phase 1 Opens". Qatar Today Online. 11 March 2014. Archived from the original on 21 July 2015. Retrieved 17 July 2015. ^ Jump up to: a b William Skidmore (24 October 2012). "Qatar's key infrastructure projects". Construction Week Online. Retrieved 17 July 2015. ^ "Ashghal unveils QR10bn projects for Mesaieed and Al Wakra". The Peninsula Qatar. 9 April 2015. Archived from the original on 24 July 2015. Retrieved 17 July 2015. ^ "Ashghal to close section of Al Khor Coastal Road for Expressway Project". The Peninsula. 11 October 2017. Retrieved 2 September 2018. ^ "All roads of Dukhan Highway Central Project now open". Gulf Times. 21 May 2017. Retrieved 2 September 2018. ^ "Laying the foundations in Qatar". Trenchless International. 4 July 2017. Retrieved 2 September 2018. ^ "Doha Metro". Railway Technology. Retrieved 2 September 2018. ^ Abu Saud, Abeer (1984). Qatari Women: Past and Present. Longman Group. p. 173. ISBN 978-0582783720. ^ "Qatar University". Qatar e-government. Retrieved 27 May 2015. ^ Abu Saud (1973), p. 173 ^ Jump up to: a b Simeon Kerr (20 October 2013). "Doha's Education City is a boost for locals". Financial Times. Retrieved 17 July 2015. ^ "World Innovation Summit for Education (WISE) 2014". UNESCO. Retrieved 25 June 2015. ^ "The 2009 World Innovation Summit for Education (WISE) convened November 16-18, in Doha, Qatar under the theme "Global Education: Working Together for Sustainable Achievements"". WISE Qatar. Archived from the original on 5 April 2017. Retrieved 25 June 2015. ^ "While U.S. universities see dollar signs in Qatari partnerships, some cry foul". Gulf News Journal. 24 September 2015. Retrieved 2 October 2015. ^ "UCL - London's Global University". UCL Qatar. Retrieved 12 August 2018. ^ "Qatar Stars League 2014/2015 » Teams". worldfootball.net. Retrieved 19 July 2015. ^ "Qatar Stars League » Champions". worldfootball.net. Retrieved 19 July 2015. ^ "AFC Asian Cup history". AFC Asian Cup. Retrieved 19 July 2015. ^ "2018 and 2022 FIFA World Cup Hosts Announced". BBC News. 2 December 2010. Retrieved 19 July 2015. ^ "2022 FIFA World Cup Bid Evaluation Report: Qatar" (PDF). FIFA. 2010-12-05. ^ "Qatar to host next two FIFA Club World Cups". Al Jazeera. Retrieved 3 June 2019. ^ 2005 FIBA Asia Championship, ARCHIVE.FIBA.com, Retrieved 5 June 2016. ^ "QVA - Qatar Volleyball Association". QVA. Retrieved 12 August 2018. ^ "History & Overview". Qatar Tennis Federation. Retrieved 22 August 2018. ^ ""Season to End in Doha 2008–2010" on the Sony Ericsson WTA Tour website". Sonyericssonwtatour.com. Retrieved 2013-07-29. ^ Patrick Dixon. "The Future Of Qatar – Rapid Growth". globalchange.com. Retrieved 19 July 2015. ^ "Doha 2005: 3rd West Asian Games". Olympic Council of Asia. Archived from the original on 5 August 2016. Retrieved 19 July 2015. ^ "Qatar Participates in 4th Asian Indoor and Martial Arts Games This Week". Marhaba. 30 June 2013. Retrieved 19 July 2015. ^ "Information on 2016 Olympic Games Bids". Gamesbids.com. Retrieved 2010-06-27. ^ "Doha to bid for 2020 Olympics". Espn.go.com. 2011-08-26. Retrieved 2013-07-29. ^ "IOC selects three cities as Candidates for the 2020 Olympic Games". Olympic.org. Retrieved 2013-07-29. ^ "About the circuit". MotoGP. Retrieved 19 July 2015. ^ "Power boats". Oryx in-flight magazine. Retrieved 19 July 2015. ^ "2014 Oryx Cup Dates Announced". H1 Unlimited. 12 March 2014. Retrieved 19 July 2015. ^ "Doha awarded 2014 World Short Course Swimming Championships". Insidethegames.biz. 2012-04-04. Retrieved 2013-07-29. ^ "Doha picked to host 2012 World Squash Championships". Insidethegames.biz. 2012-04-18. Retrieved 2013-07-29. ^ "World Mindsports Championships ends on high note". The Peninsula. 29 August 2017. Retrieved 22 August 2018. ^ "Iaaf WC 2019 will be held in Doha, Qatar!". Retrieved 18 November 2014. ^ "Barcelona, Doha and Eugene – candidate cities for 2019 IAAF World Championships". Retrieved 15 April 2014. ^ "Doha Honored With ATP 250 Tournament Of The Year Award". ATP Tour. Retrieved 11 January 2020. ^ "The Aspire Dome, centre stage for Doha 2010". IAAF Athletics. 3 November 2009. Retrieved 19 July 2015. ^ "Irina Bokova receives the Prize 'Doha 2010 Arab Capital of Culture'". UNESCO. 17 December 2010. Retrieved 22 July 2015. ^ "Doha, 2010 Arab culture capital, to host Arab and non-Arab cultural weeks". Habib Toumi. 4 April 2010. Retrieved 22 July 2015. ^ User, Super. "Museum architecture". Mia.org.qa. Retrieved 2018-05-14. ^ "Art in Qatar: A Smithsonian in the sand". The Economist. 1 January 2011. Retrieved 16 June 2013. ^ "QMA Board of Trustees". Qatar Museums Authority. Archived from the original on 2 April 2015. Retrieved 12 March 2015. ^ "Article in Variety Arabia". Tradearabia.com. 2010-05-16. Retrieved 2013-07-29. ^ "Whatever happened to the Qatari film industry?". theguardian.com. 6 March 2014. Retrieved 2 October 2015. ^ Gunter, Barrie; Dickinson, Roger (2013). News Media in the Arab World: A Study of 10 Arab and Muslim Countries. Bloomsbury Academic. p. 31. ISBN 978-1441174666. ^ "Company Overview of Al Jazeera Media Network". Bloomberg. Retrieved 2 October 2015. ^ "Al Kass Selects BFE as Integrator". Finance.yahoo.com. 23 August 2012. Retrieved 2 October 2015. ^ "Amir's visit to Algeria significant: envoy". Gulf Times. 26 February 2020. Retrieved 6 May 2020. ^ "Qatar and Bosnia vow to boost ties". The Peninsula. 20 February 2018. Retrieved 31 May 2018. ^ "اتفاقية توأمة بين مدينتي الدوحة وبرازيليا" (in Arabic). Al Sharq. 23 February 2014. Retrieved 31 May 2018. ^ "HE Prime Minister Presides Over Cabinet Regular Meeting". Press Arabia. 28 November 2012. Retrieved 31 May 2018. ^ "Sister cities". eBeijing. Retrieved 18 July 2015. ^ "Alameda California cuts ties with the emir". Gulf Times. 11 July 2019. Retrieved 22 September 2019. ^ "توقيع اتفاقية توأمة بين بلديتي الدوحة وسان سلفادور" (in Arabic). Ministry of Municipality and Environment. 29 March 2018. Retrieved 31 May 2018. ^ Momodou Faal (28 October 2011). "Gambia: Banjul Signs Twinnng Pact With Doha". The Daily Observer (Banjul). Retrieved 31 May 2018. ^ "Legal Framework". Embassy of Georgia to the State of Qatar. Retrieved 31 May 2018. ^ "زيارة الأمير الأخيرة لكازاخستان أعطت زخماً للعلاقات الثنائية" (in Arabic). Al Raya. 11 December 2015. Retrieved 31 May 2018. ^ "HH The Amir Issues Two Decrees". Government of the State of Qatar. 19 February 2018. Retrieved 31 May 2018. ^ "International Links". City Council of Port Louis. Retrieved 31 May 2018. ^ "Mungaab seeks Doha's help in reviving Mogadishu". Somali Agenda. 13 November 2014. Retrieved 31 May 2018. ^ "International Cooperation". Municipality of Tunis. Retrieved 31 May 2018. ^ "Doha, Ankara sign twinning agreement". Gulf Times. 24 August 2016. Retrieved 31 May 2018. ^ "Joint Statement by the United States and Qatar on the Conclusion of the Second Annual Economic and Investment Dialogue". U.S. Department of State. 13 December 2016. Retrieved 31 May 2018. ^ "Twinning Agreement between Miami and Doha". Istithmar USA. 5 June 2016. Retrieved 31 May 2018. ^ "HH the Emir, Venezuelan President Witness Signing of Agreements". Ministry of Foreign Affairs (Qatar). 25 November 2015. Retrieved 31 May 2018. ^ "Twinning". Beit Sahour Municipality Palestine. Archived from the original on 9 July 2018. Retrieved 30 May 2018. ^ "About Katara". Katara.net. Retrieved 2018-05-14. External links[edit] Wikimedia Commons has media related to Doha. Wikivoyage has a travel guide for Doha. Doha travel guide from Wikivoyage Projects in Doha and Major Construction and Architectural Developments Information and History of Doha showArticles related to Doha showvteMunicipality of Ad-Dawhah topicsHistory Al Bidda Battle of Al Wajbah Isa bin Tarif Mohammed bin Thani Qatari–Bahraini War Timeline of Doha Administration Ad-Dawhah Municipality Amiri Diwan of the State of Qatar Old Amiri Palace Zones Zone 4 Zone 5 Zone 6 Zone 7 Zone 13 Zone 14 Zone 15 Zone 16 Zone 17 Zone 18 Zone 20 Zone 21 Zone 22 Zone 23 Zone 24 Zone 25 Zone 26 Zone 27 Zone 28 Zone 30 Zone 31 Zone 32 Zone 33 Zone 34 Zone 35 Zone 36 Zone 37 Zone 38 Zone 39 Zone 40 Zone 41 Zone 42 Zone 43 Zone 44 Zone 45 Zone 46 Zone 47 Zone 48 Zone 49 Zone 50 Zone 57 Zone 58 Zone 61 Zone 63 Zone 64 Zone 65 Zone 66 Zone 67 Zone 68 DistrictsCensus-designated districts See List of communities in Doha District centers Al Sadd Town Center Airport Capital City Center Downtown Doha Capital City Center Fereej Kulaib District Center Najma District Center Nuaija District Center Old Al Matar Town Center Qatar University District Center Rawdat Al Khail District Center The Pearl-Qatar District Center Umm Ghuwailina District Center West Bay Capital City Center Geography Al Safliya Island Banana Island Doha Bay Doha Corniche Halul Island The Pearl-Qatar Economy andtransport Al Dafna Financial District Barwa Financial District Doha International Airport Doha Metro Gold Line Hamad International Airport Orbital Highway Demographicsand culture Abdulla Bin Zaid Al Mahmoud Islamic Cultural Center Doha Tribeca Film Festival Imam Muhammad ibn Abd al-Wahhab Mosque Katara Cultural Village Mathaf: Arab Museum of Modern Art Museum of Islamic Art Qatar National Museum Qatar National Theater National Museum of Qatar Souq Waqif Education Carnegie Mellon University in Qatar Georgetown University School of Foreign Service in Qatar Hamad Bin Khalifa University Cornell University in Qatar HEC Paris in Qatar Northwestern University in Qatar Texas A&M University at Qatar UCL Qatar Virginia Commonwealth University in Qatar Weill Cornell Medical College in Qatar Stenden University Qatar College of the North Atlantic in Qatar Qatar University in Qatar University of Calgary in Qatar See also Education City SportsVenues Abdullah bin Khalifa Stadium Aspire Zone Aspire Academy Doha Golf Club Doha Sports Stadium Grand Hamad Stadium Hamad Aquatic Centre Hamad bin Khalifa Stadium Jassim Bin Hamad Stadium Khalifa International Stadium Khalifa International Tennis and Squash Complex Suheim bin Hamad Stadium Clubs Al Ahli SC Al Arabi SC Al Bidda SC Al Sadd SC Al-Duhail SC Qatar SC showvteCapitals of AsiaDependent territories and states with limited recognition are in italicsNorth AsiaSouth AsiaSoutheast AsiaWestern Asia Moscow, Russia Central Asia Ashgabat, Turkmenistan Bishkek, Kyrgyzstan Dushanbe, Tajikistan Nur-Sultan, Kazakhstan Tashkent, Uzbekistan East Asia Beijing, China Hong Kong (China) Macau (China) Pyongyang, North Korea Seoul, South Korea Taipei, Taiwan * Tokyo, Japan Ulaanbaatar, Mongolia Camp Justice, BIOT (UK) * Dhaka, Bangladesh Islamabad, Pakistan Kabul, Afghanistan Kathmandu, Nepal Malé, Maldives New Delhi, India Sri Jayawardenepura Kotte, Sri Lanka Thimphu, Bhutan Bandar Seri Begawan, Brunei Bangkok, Thailand Dili, East Timor Flying Fish Cove, Christmas Island (Australia) Hanoi, Vietnam Jakarta, Indonesia Kuala Lumpur, Malaysia Manila, Philippines Naypyidaw, Myanmar Phnom Penh, Cambodia Singapore Vientiane, Laos West Island, Cocos (Keeling) Islands (Australia) Abu Dhabi, United Arab Emirates Amman, Jordan Ankara, Turkey Baghdad, Iraq Baku, Azerbaijan Beirut, Lebanon Cairo, Egypt Damascus, Syria Doha, Qatar Episkopi Cantonment, Akrotiri and Dhekelia (UK) * Jerusalem, Israel * Kuwait City, Kuwait Manama, Bahrain Muscat, Oman Nicosia, Cyprus North Nicosia, Northern Cyprus * Ramallah, Palestine (de facto) * Riyadh, Saudi Arabia Sana'a, Yemen Stepanakert, Artsakh * Sukhumi, Abkhazia * Tbilisi, Georgia Tehran, Iran Tskhinvali, South Ossetia * Yerevan, Armenia * Disputed. See: Political status of Taiwan, Chagos Archipelago sovereignty dispute, Cyprus dispute, Status of Jerusalem, Artsakh-Azerbaijani conflict, Abkhaz-Georgian conflict and Georgian-Ossetian conflict showvteCapitals of Arab countriesAfricaAsia Algiers, Algeria Cairo, Egypt Djibouti, Djibouti El Aaiun (proclaimed) Tifariti (de facto), Sahrawi Arab Democratic Republic1 Hargeisa, Somaliland1 Khartoum, Sudan Mogadishu, Somalia Moroni, Comoros Nouakchott, Mauritania Rabat, Morocco Tripoli, Libya Tunis, Tunisia Abu Dhabi, United Arab Emirates Amman, Jordan Baghdad, Iraq Beirut, Lebanon Damascus, Syria Doha, Qatar Jerusalem (proclaimed) Ramallah (de facto), Palestine1 Kuwait City, Kuwait Manama, Bahrain Muscat, Oman Riyadh, Saudi Arabia Sana'a, Yemen 1 An unrecognised or partially-recognised nation showvteArab Capital of Culture Cairo 1996 (Egypt) Tunis 1997 (Tunisia) Sharjah 1998 (United Arab Emirates) Beirut 1999 (Lebanon) Riyadh 2000 (Saudi Arabia) Kuwait City 2001 (Kuwait) Amman 2002 (Jordan) Rabat 2003 (Morocco) Sanaʽa 2004 (Yemen) Khartoum 2005 (Sudan) Muscat 2006 (Oman) Algiers 2007 (Algeria) Damascus 2008 (Syria) Jerusalem 2009 (State of Palestine) Doha 2010 (Qatar) Sirte 2011 (Libya) Manama 2012 (Bahrain) Baghdad 2013 (Iraq) Tripoli 2014 (Libya) Constantine 2015 (Algeria) Sfax 2016 (Tunisia) showvteHost cities of Asian GamesSummer 1951: Delhi 1954: Manila 1958: Tokyo 1962: Jakarta 1966: Bangkok 1970: Bangkok 1974: Tehran 1978: Bangkok 1982: Delhi 1986: Seoul 1990: Beijing 1994: Hiroshima 1998: Bangkok 2002: Busan 2006: Doha 2010: Guangzhou 2014: Incheon 2018: Jakarta-Palembang 2022: Hangzhou Winter 1986: Sapporo 1990: Sapporo 1996: Harbin 1999: Kangwon 2003: Aomori 2007: Changchun 2011: Astana-Almaty 2017: Sapporo Authority control BNF: cb15084063c (data) GND: 4219005-8 LCCN: n81076793 MusicBrainz: 29aae758-4c4f-4d77-899c-1dcb67196b24 NKC: ge463353 SELIBR: 143052 VIAF: 136649381 WorldCat Identities: lccn-n81076793 <img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /> Retrieved from "https://en.wikipedia.org/w/index.php?title=Doha&oldid=963332295" Categories: DohaCapitals in AsiaMunicipalities of QatarPopulated coastal places in QatarPopulated places established in 1825Populated places in QatarBurial sites of the House of Thani1825 establishments in AsiaHidden categories: CS1 maint: uses authors parameterCS1 Arabic-language sources (ar)Articles with short descriptionArticles containing Arabic-language textCoordinates on WikidataCommons category link is on WikidataWikipedia articles with BNF identifiersWikipedia articles with GND identifiersWikipedia articles with LCCN identifiersWikipedia articles with MusicBrainz area identifiersWikipedia articles with NKC identifiersWikipedia articles with SELIBR identifiersWikipedia articles with VIAF identifiersWikipedia articles with WorldCat identifiers Navigation menu Personal tools Not logged inTalkContributionsCreate accountLog in Namespaces ArticleTalk Variants Views ReadEditView history More Search Navigation Main pageContentsCurrent eventsRandom articleAbout WikipediaContact usDonateWikipedia store Contribute HelpCommunity portalRecent changesUpload file Tools What links hereRelated changesUpload fileSpecial pagesPermanent linkPage information

      -uhogoyg

    1. Meyer, B., Torriani, G., Yerly, S., Mazza, L., Calame, A., Arm-Vernez, I., Zimmer, G., Agoritsas, T., Stirnemann, J., Spechbach, H., Guessous, I., Stringhini, S., Pugin, J., Roux-Lombard, P., Fontao, L., Siegrist, C.-A., Eckerle, I., Vuilleumier, N., & Kaiser, L. (2020). Validation of a commercially available SARS-CoV-2 serological immunoassay. Clinical Microbiology and Infection, 0(0). https://doi.org/10.1016/j.cmi.2020.06.024

    1. Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Larrea, N. F. de, Molina, M., Rodríguez-Cabrera, F., Martín, M., Merino-Amador, P., Paniagua, J. L., Muñoz-Montalvo, J. F., Blanco, F., Yotti, R., Blanco, F., … Villa, A. V. de la. (2020). Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)31483-5

    1. Fontanet, A., Grant, R., Tondeur, L., Madec, Y., Grzelak, L., Cailleau, I., Ungeheuer, M.-N., Renaudat, C., Pellerin, S. F., Kuhmel, L., Staropoli, I., Anna, F., Charneau, P., Demeret, C., Bruel, T., Schwartz, O., & Hoen, B. (2020). SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission. MedRxiv, 2020.06.25.20140178. https://doi.org/10.1101/2020.06.25.20140178

    1. Fontanet, A., Tondeur, L., Madec, Y., Grant, R., Besombes, C., Jolly, N., Pellerin, S. F., Ungeheuer, M.-N., Cailleau, I., Kuhmel, L., Temmam, S., Huon, C., Chen, K.-Y., Crescenzo, B., Munier, S., Demeret, C., Grzelak, L., Staropoli, I., Bruel, T., … Hoen, B. (2020). Cluster of COVID-19 in northern France: A retrospective closed cohort study. MedRxiv, 2020.04.18.20071134. https://doi.org/10.1101/2020.04.18.20071134

    1. SciScore for 10.1101/2020.06.20.163097: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Myometrium tissue collection and preparation of the single-cell suspension Normal myometrium was collected from the patients undergoing hysterectomy with informed consent.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Furthermore, none of the cell types in the female reproductive organs we investigated, showed the co-expression of ACE2 with proteases, TMPRSS2, Cathepsin B (CTSB), and Cathepsin L (CTSL) known to facilitate the entry of SARS2-CoV2 into the host cell.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the uterus dataset, we filtered out cells expressing more than 20% mitochondrial genes and used the standard Seurat pipeline to obtain the cell clusters.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Seurat</div> <div>suggested: (SEURAT, SCR_007322)</div> </div> </td></tr></table>


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from OddPub: We did not find a statement about open data. We also did not find a statement about open code. Researchers are encouraged to share open data when possible (see Nature blog).


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. AAA: Autonome Ausgaben (Einkommens- und Zinsunabhängig) aaaaa_a: Animal Spirits bb\mathbf{b}: Konstante der WS-Kurve ββ\beta: … CCC: aggregierter Konsum cacac_a: autonomer Konsum cYcYc_Y: marginale Konsumneigung ...e...e...^e: Kennzeichnet erwarteten Wert einer Variable GGG: Staatsausgaben III: Investitionen iii: Nominaler Zinssatz KKK: Kapitalstock kkk: Konfliktorientierung der abh. Beschäftigten LLL: Beschäftigung L∗L∗L^*: Zum Gütermarktgleichgewicht korrespondierende Beschäftigung LNLNL^N: Zum Verteilungsgleichgewicht korrespondierende Beschäftigung LossLossLoss: Verlust der Zentralbank mmm: Multiplikator NNN: Zahl der Erwerbspersonen PPP: Preisniveau ΠrΠr\Pi_r: reale Profitsumme ππ\pi: Inflationsrate rrr: Realer Zinssatz ttt: durchschnittlicher Nettosteuersatz TTT: Nettosteueraufkommen UUU: Arbeitslosigkeit uuu: Arbeitslosenquote WrWrW_r: Reallohnsumme wnwnw_n: Nominallohnsatz wrwrw_r: Reallohnsatz YYY: Güterproduktion bzw. Einkommen YNYNY_N: Güternachfrage YNYNY^N: Zum Verteilungsgleichgewicht korrespondierender Output # UNGÜNSTIG WEGEN Y_N!!!!! Besser NAIRU-Sachen mit ^

      See List of variables.rmd

    1. SciScore for 10.1101/2020.06.11.145920: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Tree Star , Inc . ) Mouse Models Animal experiments were carried out in compliance with all pertinent US National Institutes of Health regulations and approval from the Animal Care and Use Committee of the Vaccine Research Center ,</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Immunogenicity was assessed in six-week old female BALB/cJ , C57BL/6J , and B6C3F1/J mice by immunizing intramuscularly ( IM ) twice with 0.01 , 0.1 , or 1 µg of mRNA-1273 at a 3-week interval.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The spike ( S ) protein , a class I fusion glycoprotein analogous to influenza hemagglutinin ( HA) , respiratory syncytial virus ( RSV ) fusion glycoprotein ( F) , and human immunodeficiency virus ( HIV ) gp160 ( Env) , is the major surface protein on the CoV virion and the primary target for neutralizing antibodies .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>influenza hemagglutinin ( HA</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mRNA-1273 induced dose-dependent S-specific binding antibodies after prime and boost in all mouse strains ( Fig . 2a-c)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>2a-c</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Both immunogens elicited IgG2a and IgG1 subclass S-binding antibodies , indicating a balanced Th1/Th2 response ( Fig . 3a-c; Extended Data Fig . 6) .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IgG1 subclass S-binding</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then washed in FC buffer ( PBS supplemented with 2 % HI-FBS and 0.05 % NaN3 ) and resuspended in BD Fc Block ( clone 2.4G2 ) for 5 min at RT prior to staining with a surface stain cocktail containing the following antibodies purchased from BD and Biolegend: I-A/I-E ( M5/114.15.2 ) PE , CD8a ( 53-6.7 ) BUV805 , CD44 ( IM7 ) BUV395 , CD62L ( MEL-14 ) BV605 , and CD4 ( RM4-5 ) BV480 in brilliant stain buffer ( BD) .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CD8a</div> <div>suggested: (BD Biosciences Cat# 564920, AB_2716856)</div> </div>

            <div style="margin-bottom:8px">
              <div><b>CD44</b></div>
              <div>suggested: (BD Biosciences Cat# 740297, <a href="https://scicrunch.org/resources/Any/search?q=AB_2740036">AB_2740036</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>CD62L</b></div>
              <div>suggested: (BD Biosciences Cat# 566111, <a href="https://scicrunch.org/resources/Any/search?q=AB_2739513">AB_2739513</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>CD4</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed in perm/wash solution and stained with Fc Block ( 5 min at RT) , followed by intracellular staining ( 30 min at 4°C ) using a cocktail of the following antibodies purchased from BD , Biolegend , or eBioscience: CD3e ( 17A2 ) BUV737 , IFN-γ ( XMG1.2 ) BV650 ,</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>CD3e</b></div>
              <div>suggested: (Thermo Fisher Scientific Cat# A25978, <a href="https://scicrunch.org/resources/Any/search?q=AB_2536039">AB_2536039</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>IFN-γ</b></div>
              <div>suggested: (BD Biosciences Cat# 740498, <a href="https://scicrunch.org/resources/Any/search?q=AB_2740221">AB_2740221</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Experimental Models: Cell Lines</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell Lines HEK293T/17 ( ATCC #CRL-11268) , Vero E6 ( ATCC) , Huh7.5 cells ( provided by Deborah R .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK293T/17</b></div>
              <div>suggested: ATCC Cat# CRL-11268, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_1926">CVCL_1926</a></div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>Huh7.5</b></div>
              <div>suggested: <a href="https://scicrunch.org/resources/Any/search?q=CVCL_7927">CVCL_7927</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Expi293 cells were maintained in manufacturer’s suggested media .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Expi293</b></div>
              <div>suggested: <a href="https://scicrunch.org/resources/Any/search?q=CVCL_D615">CVCL_D615</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In vitro mRNA Expression HEK293T cells were transiently transfected with mRNA encoding SARS-CoV-2 WT S or S-2P protein using a TranIT mRNA transfection kit ( Mirus) .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK293T</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly , HI serum was mixed with pseudoviruses , incubated , and then added to Huh7.5 cells or ACE-2expressing 293T cells , for MERS-CoV and SARS-CoV-2 respectively .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>293T</b></div>
              <div>suggested: KCB Cat# KCB 200744YJ, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0063">CVCL_0063</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus/serum mixtures were incubated for 20 min at 37 ºC , followed by adsorption of 0.1 mL to each of two confluent Vero E6 cell monolayers ( in 10-cm2 wells ) for 30 min at 37°C .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Vero E6</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We thank members of the NIH NIAID VRC Translational Research Program for technical assistance with mouse experiments .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>VRC Translational Research Program</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MERS mRNA mouse challenge studies were funded under NIH Contract HHSN272201700036I Task Rrder No. 75N93019F00132 Requisition No. 5494549 ( to R . B . ) . K.S.C . ’s research fellowship was partially funded by the Undergraduate Scholarship Program , Office of Intramural Training and Education , Office of the Director , NIH . D.R . M. was funded by NIH NIAID grant T32-AI007151 and a Burroughs Wellcome Fund Postdoctoral Enrichment Program Award. Author Contributions K.S.C . , D.K . E . , S.R . L . , O.M.A , S.B . B . , R.A . G . , S.H . , A . S. , C . Z . , A.T</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Undergraduate Scholarship Program</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data acquisition was performed on a BD LSRII Fortessa instrument ( BD Biosciences ) and analyzed by FlowJo software v10</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>FlowJo</b></div>
              <div>suggested: (FlowJo, <a href="https://scicrunch.org/resources/Any/search?q=SCR_008520">SCR_008520</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IC50 titers were determined using a log ( agonist ) vs. normalized response ( variable slope ) nonlinear function in Prism v8 ( GraphPad)</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>GraphPad</b></div>
              <div>suggested: (GraphPad Prism, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002798">SCR_002798</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 15 min , cells were washed with FC buffer then fixed and permeabilized using the BD Cytofix/Cytoperm fixation/permeabilization solution kit according to manufacturer instructions .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>BD Cytofix/Cytoperm</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr></table>
      


      Results from OddPub: We did not find a statement about open data. We also did not find a statement about open code. Researchers are encouraged to share open data when possible (see Nature blog).


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.06.08.20125989: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Participants provided consent to participate in the study and were promptly informed of test results and, if positive, instructed to self-isolate for a period of ten days.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">Additional data on the degree of viral genetic diversity in the larger community would add significant power to our ability to discriminate between these two non-mutually exclusive scenarios.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plaque assays were performed on African Green Monkey Kidney (Vero) cells (ATCC CCL-81) according to standard methods (5).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MiSeq reads were demultiplexed, quality checked by FASTQC, paired-end reads were processed to remove Illumina primers and quality trimmed with Cutadapt, duplicate reads were removed.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MiSeq</div> <div>suggested: (A5-miseq, SCR_012148)</div> </div>

            <div style="margin-bottom:8px">
              <div><b>FASTQC</b></div>
              <div>suggested: (FastQC, <a href="https://scicrunch.org/resources/Any/search?q=SCR_014583">SCR_014583</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>Cutadapt</b></div>
              <div>suggested: (cutadapt, <a href="https://scicrunch.org/resources/Any/search?q=SCR_011841">SCR_011841</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Consensus sequences were aligned in Geneious and a neighbor-joining tree generated with the Reference sequence as an outgroup and 1000 bootstrap replicates.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Geneious</b></div>
              <div>suggested: (Geneious, <a href="https://scicrunch.org/resources/Any/search?q=SCR_010519">SCR_010519</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci 63:706711. 4. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker T, Brunink S, Schneider J, Schmidt ML, Mulders D, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MPG, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Schneider J</b></div>
              <div>suggested: (ARLEQUIN, <a href="https://scicrunch.org/resources/Any/search?q=SCR_009051">SCR_009051</a>)</div>
            </div>
          </td></tr></table>
      


      Results from OddPub: We did not find a statement about open data. We also did not find a statement about open code. Researchers are encouraged to share open data when possible (see Nature blog).


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.05.28.122366: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To search for signatures of positive selection in the phylogenetic tree of the current SARS-CoV-2 outbreak we ran the Bayesian FUBAR software from the HyPhy package27,28 .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>HyPhy</div> <div>suggested: (HyPhy, SCR_016162)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The protein sequences of the non-recombinant regions SARS-CoV-2 , SARSCoV-1 and 67 closely related viruses with non-human hosts ( bats and pangolins ) were aligned using MAFFT version 7 ( L-INS-i)52 .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MAFFT</div> <div>suggested: (MAFFT, SCR_011811)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Phylogenies for each codon alignment were inferred using RAxML with a GTR+Γ model49 .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>RAxML</div> <div>suggested: (RAxML, SCR_006086)</div> </div> </td></tr></table>


      Results from OddPub: We did not find a statement about open data. We also did not find a statement about open code. Researchers are encouraged to share open data when possible (see Nature blog).


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.06.07.137802: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Human immunohistochemistry All experiments with human materials were approved by the ethics committee of the University Medical Center Göttingen and were performed in accordance with the respective national , federal and institutional regulations .</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">To measure the infectivity of cultured cells , three randomly selected areas per coverslip were imaged.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Here, we found that the cellular receptor neuropilin-1 (NRP1), known to bind furin-cleaved substrates, significantly potentiates SARS-CoV-2 infectivity, which was inhibited by a monoclonal blocking antibody against the extracellular b1b2 domain of NRP1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>neuropilin-1</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">e , f , Representative images and quantification of HEK-293T cells expressing NRP1+ACE2+TMPRSS2 after SARS-2 pseudotype inoculation in the presence of mAb3 antibody against NRP1 ( e , mAb3 , lower panel ) or control immunoglobulin ( e , ctrl Ab , upper panel) , and in the presence of NRP1 b1b2 domain ( f , wt b1b2 , lower panel ) or the NRP1 mutant b1b2 domain ( f , mut b1b2 , upper panel) .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NRP1 mutant b1b2 domain ( f , mut b1b2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibodies were diluted in 10 % blocking solution: 1:250 NRP1 ( monoclonal rabbit , ab81321 , Abcam); 1:1000 TuJ1 ( monoclonal mouse , G712A , Promega); 1:250 NeuN ( polyclonal chicken , ABN91 , Milipore); 1:2000 GFP ( polyclonal rabbit , A-6455 , Thermo Fisher Scientific) , 1:250 ColIV ( polyclonal goat , 1340-01 , Southern Biotech)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>TuJ1</div> <div>suggested: (Covance Cat# MMS-435P, AB_2313773)</div> </div>

            <div style="margin-bottom:8px">
              <div><b>NeuN</b></div>
              <div>suggested: (Millipore Cat# ABN91, <a href="https://scicrunch.org/resources/Any/search?q=AB_11205760">AB_11205760</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>GFP</b></div>
              <div>suggested: (Thermo Fisher Scientific Cat# PA1-86341, <a href="https://scicrunch.org/resources/Any/search?q=AB_931091">AB_931091</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After three washes in PBS , the sections were incubated in secondary antibody: Alexa Fluor 488 donkey anti-mouse ( R37114 , Thermo Fischer Scientific);</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>anti-mouse ( R37114</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibodies were applied over night at a dilution of 1:100 for SARS-CoV S protein ( monoclonal mouse , ab272420 , Abcam; microwave , citric acid buffer , 10 mM , pH 6.0) , 1:250 for NRP1 ( monoclonal rabbit , ab81321 , Abcam; microwave , Tris-EDTA , pH 8.0 ) and 1:150 for OLIG2 ( polyclonal rabbit , 18953 , IBL; microwave , Tris-EDTA , pH 8.0) .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>NRP1</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>OLIG2</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies were added as follows: biotinylated anti-mouse 1:200 ( GE Healthcare RPN 1001 ) followed by Tyramide Super Boost with Alexa Fluor 488 1:500 ( Thermo Fisher Scientific ) and Alexa Fluor 555 anti rabbit 1:500 for 2 h , at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>anti</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Either the Envision+ System for mice ( Dako ) and alkaline phosphatase conjugated anti-rabbit antibodies with FastBlue ( Sigma Aldrich ) or alkaline phosphatase coupled anti-mouse antibodies with FastBlue ( Sigma Aldrich ) were used for immunohistochemistry .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>anti-rabbit</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>anti-mouse</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AgNPs ( magenta ) were visible inside the cells , counterstained with Alexa-Fluor488-phalloidin ( yellow ) and Hoechst ( cyan) . b , Representative images and quantification of NRP1-expressing HEK-293T cells treated for 30 minutes with the blocking mAb3 antibody ( lower row ) or control Ab ( upper row) . c , Representative images and quantification of NRP1-expressing HEK-293T cells incubated for 30 minutes with AgNPs , together with wild-type b1b2 domain ( wt b1b2 , lower row ) or the mutant b1b2 domain of NRP-1 ( mutant b1b2 , upper row) .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>mAb3</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">NRP1 immunohistochemistry of 12 human tissues were done using NRP1 antibodies HPA030278 ( Atlas Antibodies AB ) or CAB004511 ( Santa Cruz Biotechnology ) ( brown) , and counterstained with hematoxylin ( blue) .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>CAB004511</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Experimental Models: Cell Lines</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We validated the effect of the recombinant NRP1 proteins , by showing that b1b2 , but not the mutant protein , blocked uptake of AgNP-CendR in HEK-293T cells ( Extended Data Fig .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK-293T</b></div>
              <div>suggested: KCB Cat# KCB 200744YJ, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0063">CVCL_0063</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Confirming recent reports15 , we found that SARS-CoV-2 viruses , passaged in VeroE6 cells rapidly accumulated mutations around the furin cleavage site of the S protein .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>VeroE6</b></div>
              <div>suggested: JCRB Cat# JCRB1819, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_YQ49">CVCL_YQ49</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Figure 2│ A blocking antibody against the b1b2 domain of NRP1 reduces infection of wild-type SARS-CoV-2 ( wt SARS-2) , but not a mutant with a deletion at the furincleavage site ( mutant SARS-2) . a , b , Representative images ( a ) and quantification ( b ) of infection assays in Caco2 cells in the presence of control mAb1 ( ctrl .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Caco2</b></div>
              <div>suggested: CLS Cat# 300137/p1665_CaCo-2, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0025">CVCL_0025</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture HEK 293T and Caco-2 ( ATCC ) cells were grown in complete growth media supplemented with 10 % fetal calf serum ( FCS) , ( pen/strep , L-Glutamine in DMEM ) and passaged 1:8 ( HEK-293 T ) or 1:5 ( Caco-2 ) every three days</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>HEK 293T</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>HEK-293</b></div>
              <div>suggested: CLS Cat# 300192/p777_HEK293, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0045">CVCL_0045</a></div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>Caco-2</b></div>
              <div>suggested: CLS Cat# 300137/p1665_CaCo-2, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0025">CVCL_0025</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For confocal imaging of NRP-1 expressing PPC-1 cells , 30,000 cells/well were cultured at 37°C in 5 % CO2 as a monolayer on coverslips ( d = 12 mm; Paul Marienfeld GmbH & Co .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>PPC-1</b></div>
              <div>suggested: ATCC Cat# HTB-190, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_4778">CVCL_4778</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Isolation of WT SARS-CoV-2 from COVID-19 patient and virus propagation Samples were obtained under the Helsinki University Hospital laboratory research permit HUS/32/2018 § 16 . 500 µl of nasopharyngeal swab in Copan UTM® Universal Transport Medium was inoculated on Calu-3 cells and incubated for 1 h in +37°C , after which the inoculum was removed and replaced with Minimum Essential Medium supplemented with 2 % FBS , L-glutamine , penicillin and streptomycin .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Calu-3</b></div>
              <div>suggested: BCRJ Cat# 0264, <a href="https://scicrunch.org/resources/Any/search?q=CVCL_0609">CVCL_0609</a></div>
            </div>
          </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2"><b>Software and Algorithms</b></td></tr><tr><td style="min-width:100px;text=align:center"><i>Sentences</i></td><td style="min-width:100px;text-align:center"><i>Resources</i></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mercer , J . , Schelhaas , M. & Helenius , A . Virus entry by endocytosis .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Mercer</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image visualization was performed using Omero Server software 5.6</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Omero Server</b></div>
              <div>suggested: (OME - Open Microscopy Environment, <a href="https://scicrunch.org/resources/Any/search?q=SCR_008849">SCR_008849</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, Omero figure 4.0.2 ( https://github.com/ome/omero-figure ) and InkScape 0.9234 .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Omero</b></div>
              <div>suggested: (OMERO, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002629">SCR_002629</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>InkScape</b></div>
              <div>suggested: (Inkscape, <a href="https://scicrunch.org/resources/Any/search?q=SCR_014479">SCR_014479</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image analysis Images were analysed with CellProfiler 3.1.8 ( https://cellprofiler.org/).</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>CellProfiler</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>https://cellprofiler.org/</b></div>
              <div>suggested: (CellProfiler Image Analysis Software, <a href="https://scicrunch.org/resources/Any/search?q=SCR_007358">SCR_007358</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All other measurements were performed semiquantitatively using Fiji software 36 .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Fiji</b></div>
              <div>suggested: (Fiji, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002285">SCR_002285</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primer pools targeting SARS-CoV-2 were designed using PrimalScheme tool http://primal.zibraproject.org 38 and PCR was conducted using PhusionFlash PCR master mix ( ThemoFisher)</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>ThemoFisher</b></div>
              <div>suggested: None</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The trimmed sequence reads were assembled to the reference sequence ( NC_045512.2 ) using BWA-MEM algorithm implemented in SAMTools version 1.840 .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>BWA-MEM</b></div>
              <div>suggested: (Sniffles, <a href="https://scicrunch.org/resources/Any/search?q=SCR_017619">SCR_017619</a>)</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>SAMTools</b></div>
              <div>suggested: (Samtools, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002105">SCR_002105</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The minority variants and insertion/deletion sites were called using LoFreq* version 2.1.441 . scRNA-seq analysis Analyses of the scRNA-seq datasets including filtering , normalization and clustering were conducted using Seurat 3.142</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>LoFreq*</b></div>
              <div>suggested: None</div>
            </div>
      
            <div style="margin-bottom:8px">
              <div><b>Seurat</b></div>
              <div>suggested: (SEURAT, <a href="https://scicrunch.org/resources/Any/search?q=SCR_007322">SCR_007322</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Human olfactory neuroepithelium raw data from Durante et al.22 , was downloaded from Gene Expression Omnibus under accession code GSE139522 .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>Gene Expression Omnibus</b></div>
              <div>suggested: (Gene Expression Omnibus (GEO), <a href="https://scicrunch.org/resources/Any/search?q=SCR_005012">SCR_005012</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics were performed in GraphPad Prism .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>GraphPad Prism</b></div>
              <div>suggested: (GraphPad Prism, <a href="https://scicrunch.org/resources/Any/search?q=SCR_002798">SCR_002798</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ImageJ2: ImageJ for the next generation of scientific image data .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>ImageJ</b></div>
              <div>suggested: (ImageJ, <a href="https://scicrunch.org/resources/Any/search?q=SCR_003070">SCR_003070</a>)</div>
            </div>
          </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples .</td><td style="min-width:100px;border-bottom:1px solid lightgray">
            <div style="margin-bottom:8px">
              <div><b>MinION</b></div>
              <div>suggested: (MinION, <a href="https://scicrunch.org/resources/Any/search?q=SCR_017985">SCR_017985</a>)</div>
            </div>
          </td></tr></table>
      


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from OddPub: We did not find a statement about open data. We also did not find a statement about open code. Researchers are encouraged to share open data when possible (see Nature blog).


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.06.17.20134031: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">It was registered on Clinicaltrials . gov ( NCT043235929 ) after approval by the referral Ethics Committee for the Coordinating Centre ( University Hospital of Trieste , #CEUR-2020-Os-052) .</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Limitations of the study is that we did not control for center effects and site investigators were not blinded to treatment as with any observational study.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After matching the expression changes induced by SARS-CoV2 in human lung tissue tissues and A549 lung cell line against the expression changes triggered by 5,694 FDA-approved drugs, methylprednisolone was found to be the drug with the greatest potential to revert the changes induced by COVID-19.22 The safety profile reported in our study is consistent with the findings of multiple RCTs investigating prolonged corticosteroid treatment in thousands of patients with severe sepsis, septic shock and ARDS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>A549</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Exposure to methylprednisolone ( non-patented drug , ATC code H02AB04 ) complied with the following protocol: a loading dose of 80 mg/kg iv at study entry ( baseline) , followed by an infusion of 80 mg/day in 240 mL normal saline at 10 mL/h for at least eight days , until achieving either a PaO2:FiO2 > 350 mmHg or a CRP < 20 mg/L .</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ATC</div> <div>suggested: None</div> </div> </td></tr></table>


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      • The observational design of our study implies some obvious limitations, namely a possible restricted control over data collection and potential inclusion biases.
      • However, internal validity was achieved by (1) the comparability of concurrent groups at baseline,
      • Limitations of the study is that we did not control for center effects and site investigators were not blinded to treatment as with any observational study.
      • Despite these limitations, we believe that our findings represent valid and generalizable conclusions, and evidence will be further strengthened with a RCT.
      • </ul></p>

        Results from OddPub: We did not find a statement about open data. We also did not find a statement about open code. Researchers are encouraged to share open data when possible (see Nature blog).


        About SciScore

        SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.